PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	ELSADR, W; CAPPS, L				ELSADR, W; CAPPS, L			THE CHALLENGE OF MINORITY RECRUITMENT IN CLINICAL-TRIALS FOR AIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PLACEBO-CONTROLLED TRIAL; RANDOMIZED TRIAL; DOUBLE-BLIND; PENTAMIDINE; ZIDOVUDINE; INFECTION; EFFICACY; THERAPY		COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032	Columbia University	ELSADR, W (corresponding author), HARLEM HOSP MED CTR,DIV INFECT DIS,ROOM 3107,506 LENOX AVE,NEW YORK,NY 10037, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI095029] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-95029] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOZZETTE SA, 1990, NEW ENGL J MED, V323, P1451, DOI 10.1056/NEJM199011223232104; BURKE DS, 1987, NEW ENGL J MED, V317, P131, DOI 10.1056/NEJM198707163170302; CONTE JE, 1990, ANN INTERN MED, V113, P203, DOI 10.7326/0003-4819-113-3-203; EASTERBROOK PJ, 1991, JAMA-J AM MED ASSOC, V266, P2713, DOI 10.1001/jama.266.19.2713; FAUCI AS, 1989, ACAD MED, V64, P115, DOI 10.1097/00001888-198903000-00002; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GAGNON S, 1990, NEW ENGL J MED, V323, P1444, DOI 10.1056/NEJM199011223232103; HAMILTON JD, IN PRESS N ENGL J ME; HOO GWS, 1990, ANN INTERN MED, V113, P195, DOI 10.7326/0003-4819-113-3-195; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; KINGSLEY LA, 1991, AM J EPIDEMIOL, V134, P331, DOI 10.1093/oxfordjournals.aje.a116094; LAGAKOS S, 1991, JAMA-J AM MED ASSOC, V266, P2709, DOI 10.1001/jama.266.19.2709; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; LEVINE RJ, 1986, ETHICS REGULATIONS C, P67; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; MOSER M, 1982, CLIN PHARMACOL THER, V32, P307, DOI 10.1038/clpt.1982.165; NOVICK LF, 1991, AM J PUBLIC HEALTH, V81, P15, DOI 10.2105/AJPH.81.Suppl.15; SMITH WM, 1964, ANN INTERN MED, V61, P829, DOI 10.7326/0003-4819-61-5-829; SVENSSON CK, 1989, JAMA-J AM MED ASSOC, V261, P263, DOI 10.1001/jama.261.2.263; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WALLE T, 1985, CLIN PHARMACOL THER, V38, P509, DOI 10.1038/clpt.1985.216; 1970, JAMA-J AM MED ASSOC, V213, P1143; 1990, MMWR, V39, P81; 1982, BR J CLIN PHARM, V14, P97; 1979, JAMA-J AM MED ASSOC, V242, P2562	26	122	122	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					954	957		10.1001/jama.267.7.954	http://dx.doi.org/10.1001/jama.267.7.954			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1734108				2022-12-01	WOS:A1992HD15500029
J	GOODWIN, FK				GOODWIN, FK			BEHAVIORAL STRESS REACTIVITY RELATED TO ARTHRITIS SUSCEPTIBILITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							STERNBERG EM, 1992, BRAIN RES, V570, P54, DOI 10.1016/0006-8993(92)90563-O	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					910	910						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1310338				2022-12-01	WOS:A1992HD15500004
J	GOODWIN, FK				GOODWIN, FK			NEED TO LOSE WEIGHT AGAIN - OH RATS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							FRASER C, 1991, J BIOL CHEM, V266, P24053	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					910	910						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1310338				2022-12-01	WOS:A1992HD15500003
J	LONDON, SJ; CONNOLLY, JL; SCHNITT, SJ; COLDITZ, GA				LONDON, SJ; CONNOLLY, JL; SCHNITT, SJ; COLDITZ, GA			A PROSPECTIVE-STUDY OF BENIGN BREAST DISEASE AND THE RISK OF BREAST-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LESIONS; WOMEN	Objective. - To examine the relation between proliferative benign breast disease with and without atypical hyperplasia and the subsequent risk of breast cancer. Design. - Case-control study nested within a prospective cohort study. Median follow-up after breast biopsy was 8 years (25th to 75th percentile, 5 to 14 years). Participants. - Selected from a prospective cohort of 121 700 US registered nurses followed up from 1976 to 1986. Cases were women with breast cancer who had a prior biopsy for benign breast disease. Controls were randomly selected and matched on year of biopsy and year of birth from among women in the cohort who had a benign breast biopsy but who did not develop breast cancer. Included in the analysis were 121 cases and 488 controls. Main Outcome Measure. - Development of breast cancer. Results. - Slides from the first benign breast biopsy were reviewed by two breast pathologists blinded to the outcome, The multiply adjusted relative risks (RRs) for breast cancer, relative to women with no proliferative disease, were 1.6 for proliferative disease without atypia (95% confidence interval [Cl], 1.0 to 2.5) and 3.7 for atypical hyperplasia (95% Cl, 2.1 to 6.8). Breast cancer risk was more strongly associated with atypical hyperplasia among premenopausal women (RR = 5.9; 95% Cl, 2.9 to 13.2) than postmenopausal women (RR = 2.3; 95% CI, 0.9 to 5.9), but the association of breast cancer risk with proliferative disease without atypia did not differ across menopausal status. Conclusion. - These results confirm the marked increase in breast cancer risk among women with atypical hyperplasia, particularly in premenopausal women, and suggest that these women should be encouraged to undergo frequent breast cancer screening.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, CHANNING LAB, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	LONDON, SJ (corresponding author), UNIV SO CALIF, SCH MED, DEPT PREVENT MED, 1420 SAN PABLO ST, PMB B306, LOS ANGELES, CA 90033 USA.		Colditz, Graham/A-3963-2009; London, Stephanie/C-3734-2019	Colditz, Graham/0000-0002-7307-0291; London, Stephanie/0000-0003-4911-5290	NCI NIH HHS [CA 46475, CA 40356, CA 09001] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356, R01CA046475] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1986, Arch Pathol Lab Med, V110, P171; BLACK MM, 1972, CANCER, V29, P338, DOI 10.1002/1097-0142(197202)29:2&lt;338::AID-CNCR2820290212&gt;3.0.CO;2-U; BRESLOW NE, 1980, INT AGENCY RES CANCE, V32; CARTER CL, 1988, AM J EPIDEMIOL, V128, P467, DOI 10.1093/oxfordjournals.aje.a114995; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; DONNELLY PK, 1975, MAYO CLIN PROC, V50, P650; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; DUPONT WD, 1989, HUM PATHOL, V20, P723, DOI 10.1016/0046-8177(89)90063-4; FOOTE FW, 1945, ANN SURG, V121, P197, DOI 10.1097/00000658-194502000-00009; HUTCHINSON WB, 1980, J NATL CANCER I, V65, P13; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; KODLIN D, 1977, CANCER, V39, P2603, DOI 10.1002/1097-0142(197706)39:6<2603::AID-CNCR2820390645>3.0.CO;2-T; PAGE DL, 1985, CANCER, V55, P2698, DOI 10.1002/1097-0142(19850601)55:11<2698::AID-CNCR2820551127>3.0.CO;2-A; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105	14	372	383	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					941	944		10.1001/jama.267.7.941	http://dx.doi.org/10.1001/jama.267.7.941			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1734106				2022-12-01	WOS:A1992HD15500026
J	NOVACK, AH				NOVACK, AH			ANTIMICROBIAL TREATMENT OF THE UMBILICAL-CORD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							BACTERIAL-COLONIZATION; CARE REGIMENS				NOVACK, AH (corresponding author), UNIV WASHINGTON,SEATTLE,WA 98195, USA.							BARRETT FF, 1979, J PEDIATR-US, V94, P796, DOI 10.1016/S0022-3476(79)80159-6; BOWEN TJ, 1982, J PEDIATR-US, V101, P932, DOI 10.1016/S0022-3476(82)80013-9; GLADSTONE IM, 1988, CLIN PEDIATR, V27, P127, DOI 10.1177/000992288802700302; SPECK WT, 1980, CHEMOTHERAPY, V26, P372, DOI 10.1159/000237929; SPECK WT, 1977, AM J DIS CHILD, V131, P1005, DOI 10.1001/archpedi.1977.02120220071012	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					1008	1008						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1734090				2022-12-01	WOS:A1992HD15500038
J	WILSON, WC; SMEDIRA, NG; FINK, C; MCDOWELL, JA; LUCE, JM				WILSON, WC; SMEDIRA, NG; FINK, C; MCDOWELL, JA; LUCE, JM			ORDERING AND ADMINISTRATION OF SEDATIVES AND ANALGESICS DURING THE WITHHOLDING AND WITHDRAWAL OF LIFE-SUPPORT FROM CRITICALLY ILL PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIAZEPAM; MIDAZOLAM; DECISION	Objective. - To determine why and how sedatives and analgesics are ordered and administered during the withholding and withdrawal of life support from critically ill patients. Design. - Prospective case series. Setting. - Medical-surgical intensive care units at a county hospital and a university hospital. Patients. - Consecutive 1-year sample of 22 patients from whom life support was withheld or withdrawn in one intensive care unit at a county hospital and a random sample of 22 similar patients in the intensive care unit in the university hospital over the same period. Main Outcome Measures. - Physicians and nurses were interviewed to determine their reasons for ordering and administering drugs, and medical records were reviewed to document amounts of drugs ordered and administered. Results. - Drugs were given to 75% of patients during withholding and withdrawal of life support. Patients who did not receive medication were comatose and considered incapable of benefiting from sedation and analgesia. The median time until death following the initiation of the withholding or withdrawal of life support was 3.5 hours in the patients who received drugs and 1.3 hours in those patients who did not (P, not significant). Physicians ordered drugs to decrease pain in 88% of patients, to decrease anxiety in 85%, to decrease air hunger in 76%, to comfort families in 82%, and to hasten death in 39%; in no instance was hastening death the only reason cited. The amounts of benzodiazepines and opiates averaged 2.2 mg/h of diazepam and 3.3 mg/h of morphine sulfate in the 24 hours before withholding and withdrawal of life support and 9.8 mg/h and 11.2 mg/h in the 24 hours thereafter (P < .025 and P < .001, respectively). Conclusions. - Large doses of sedatives and analgesics were ordered primarily to relieve pain and suffering during the withholding and withdrawal of life support, and death was not hastened by drug administration.	SAN FRANCISCO GEN HOSP,ROOM 5K1,1001 POTRERO AVE,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT NURSING,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SOCIAL WORK,SAN FRANCISCO,CA 94143	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								ANGELL M, 1982, NEW ENGL J MED, V306, P98, DOI 10.1056/NEJM198201143060210; BERGGREN L, 1987, ACTA ANAESTH SCAND, V31, P667, DOI 10.1111/j.1399-6576.1987.tb02643.x; CLOUSER KD, 1977, ANN INTERN MED, V87, P622, DOI 10.7326/0003-4819-87-5-622; FLAKE JW, 1985, ANESTH ANALG, V64, P897; FORRESTER A, 1980, ANESTHESIOLOGY, V53, P494; GEORGE KA, 1977, BRIT J CLIN PHARMACO, V4, P45, DOI 10.1111/j.1365-2125.1977.tb00665.x; GREENBLATT DJ, 1981, BR J PHARM S, V11, pS2; HAMMOND J, 1989, CRIT CARE MED, V17, P136, DOI 10.1097/00003246-198902000-00006; JAFFE JH, 1981, PHARM BASIS THERAPEU; JONSEN AR, 1983, ANN INTERN MED, V99, P261, DOI 10.7326/0003-4819-99-2-261; JONSEN AR, 1986, CLIN ETHICS, P120; KEATS AS, 1985, ANNU REV PHARMACOL, V25, P41, DOI 10.1146/annurev.pa.25.040185.000353; LUCE JM, 1988, CHEST, V94, P621, DOI 10.1378/chest.94.3.621; PORRO GB, 1988, GASTROINTEST ENDOSC, V34, P252, DOI 10.1016/S0016-5107(88)71323-1; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; SCHNEIDERMAN LJ, 1988, NEW ENGL J MED, V318, P984, DOI 10.1056/NEJM198804143181509; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WEIL MH, 1988, CRIT CARE MED, V16, P636, DOI 10.1097/00003246-198806000-00015; WHITE PF, 1988, PLAST RECONSTR SURG, V81, P703, DOI 10.1097/00006534-198805000-00009; ZAWACKI B, 1989, CRIT CARE MED, V17, P198; 1986, AM REV RESPIR DIS, V134, P1327	22	170	170	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					949	953						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1370853				2022-12-01	WOS:A1992HD15500028
J	WRIGHT, JW				WRIGHT, JW			PERSISTENT TYMPANIC MEMBRANE PERFORATION FROM VENTILATION TUBES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											WRIGHT, JW (corresponding author), EAR INST INDIANA,INDIANAPOLIS,IN 46256, USA.							TOS M, 1990, OTOLARYNGOLOGY, pCH22	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					1008	1008						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1734091				2022-12-01	WOS:A1992HD15500039
J	YIP, R; SCANLON, K; TROWBRIDGE, F				YIP, R; SCANLON, K; TROWBRIDGE, F			IMPROVING GROWTH STATUS OF ASIAN REFUGEE CHILDREN IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRESCHOOL-CHILDREN; PHYSICAL GROWTH; BIRTH-WEIGHT; HEIGHT	Objective. - To analyze the trend and pattern of the nutrition status of Southeast Asian refugee children and other low-income children in the United States. Design. - Descriptive analysis of the growth data from the Pediatric Nutrition Surveillance System of the Centers for Disease Control, Atlanta, Ga, from 1980 through 1989. Subjects. - Children under 5 years of age from low-income families enrolled in public health clinics in 12 selected states. Measurements and Main Results. - Asian refugee children experienced a progressive and significant decline in the prevalence of low birth weight, low height-for-age, and low weight-for-age, while these nutritional indexes remained stable for low-income white, black, and Hispanic children. By 1989, the growth status of Asian children was near that of other ethnic groups. Conclusions. - The marked improvement of growth status among Asian refugee children over a short period suggests that the poor growth status often observed among recently immigrated Asian children is primarily related to nutritional and health factors, rather than genetic factors. In assessing the growth of Asian or immigrant children, it would be helpful to take their family and early childhood background into account.			YIP, R (corresponding author), CTR DIS CONTROL,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,DIV NUTR,MAIL STOP K-26,ATLANTA,GA 30333, USA.							BALDWIN LM, 1988, AM J DIS CHILD, V142, P526, DOI 10.1001/archpedi.1988.02150050064033; BINKIN NJ, 1988, PEDIATRICS, V82, P828; DAVIES DP, 1988, LINEAR GROWTH RETARD, P75; DEWEY KG, 1986, AM J PUBLIC HEALTH, V76, P806, DOI 10.2105/AJPH.76.7.806; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P736, DOI 10.1093/ajcn/46.5.736; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P749, DOI 10.1093/ajcn/46.5.749; Eveleth P.B., 1976, WORLDWIDE VARIATION, V8; GAYLE HD, 1988, PUBLIC HEALTH REP, V103, P143; GRAITCEN PL, 1988, LANCET, V2, P297; HABICHT JP, 1974, LANCET, V1, P611; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; KELLER W, 1988, LINEAR GROWTH RETARD, P17; LI DK, 1990, AM J PUBLIC HEALTH, V80, P685, DOI 10.2105/AJPH.80.6.685; MIETTINEN OS, 1985, THEORETICAL EPIDEMIO, P198; OLNESS K, 1984, AM J DIS CHILD, V138, P544, DOI 10.1001/archpedi.1984.02140440028006; PECK RE, 1981, AM J PUBLIC HEALTH, V71, P1144, DOI 10.2105/AJPH.71.10.1144; ROUJIA C, 1989, J TROP PEDIATRICS, V35, P255, DOI 10.1093/tropej/35.5.255; SCHUMACHER LB, 1987, PEDIATRICS, V80, P861; YIP R, 1987, JAMA-J AM MED ASSOC, V258, P1619, DOI 10.1001/jama.258.12.1619; YIP R, 1991, PEDIATRICS, V87, P688; YIP R, 1989, 14TH P INT C NUTR SE; 1979, MMWR, V28, P386; 1983, CDC838295 US DEP HLT	23	43	43	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					937	940		10.1001/jama.267.7.937	http://dx.doi.org/10.1001/jama.267.7.937			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1734105				2022-12-01	WOS:A1992HD15500025
J	AOUN, H				AOUN, H			FROM THE EYE OF THE STORM, WITH THE EYES OF A PHYSICIAN	ANNALS OF INTERNAL MEDICINE			English	Note						ACQUIRED IMMUNODEFICIENCY SYNDROME; PHYSICIAN-PATIENT RELATIONS; EDUCATION, MEDICAL; SOCIAL SUPPORT; ETHICS, MEDICAL		A physician acquires a terrible disease and, as a patient, is confronted with aspects of medical care that contribute to the suffering rather than the healing. As a result of these experiences, his views on what constitutes a good physician become simpler. A good physician cares for his patients and works toward preserving their dignity and independence. The issue is raised of whether current medical education can be effective in producing that caring physician, for it is particularly in caring for patients with catastrophic or incurable illnesses that the role of the physician is more, not less, important.										AOUN H, 1989, NEW ENGL J MED, V321, P693, DOI 10.1056/NEJM198909073211020; AOUN H, 1991, NEW ENGL J MED, V324, P265, DOI 10.1056/NEJM199101243240412; Harrison TR, 1950, PRINCIPLES INTERNAL; NATELSON BH, 1990, TOMORROWS DOCTORS PA; Peabody FW, 1927, J AMER MED ASSOC, V88, P0877, DOI 10.1001/jama.1927.02680380001001; RABIN D, 1982, NEW ENGL J MED, V307, P506, DOI 10.1056/NEJM198208193070827; RABIN R, 1985, 6 PARTS LOVE ONE FAM; TOSTESON DC, 1990, NEW ENGL J MED, V322, P234, DOI 10.1056/NEJM199001253220405	8	23	23	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					335	338		10.7326/0003-4819-116-4-335	http://dx.doi.org/10.7326/0003-4819-116-4-335			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	11651175				2022-12-01	WOS:A1992HD54600012
J	BAMFORD, J				BAMFORD, J			CLINICAL EXAMINATION IN DIAGNOSIS AND SUBCLASSIFICATION OF STROKE	LANCET			English	Article							LACUNAR INFARCTION; NATURAL-HISTORY; DATA-BANK; DESIGN; PROJECT				BAMFORD, J (corresponding author), ST JAMES UNIV HOSP, DEPT NEUROL, BECKETT ST, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND.		Bamford, John/ABE-6218-2021					ALLEN CMC, 1983, Q J MED, V52, P515; Aring CD, 1935, ARCH INTERN MED, V56, P435, DOI 10.1001/archinte.1935.00170010023002; BAMFORD J, 1987, STROKE, V18, P545, DOI 10.1161/01.STR.18.3.545; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BAMFORD JM, 1988, STROKE, V19, P1074, DOI 10.1161/01.STR.19.9.1074; BOGOUSSLAVSKY J, 1988, STROKE, V19, P1083, DOI 10.1161/01.STR.19.9.1083; GENT M, 1988, STROKE, V19, P1203, DOI 10.1161/01.STR.19.10.1203; HARRISON MJG, 1980, POSTGRAD MED J, V56, P629, DOI 10.1136/pgmj.56.659.629; HOROWITZ SH, 1991, STROKE, V22, P1245, DOI 10.1161/01.STR.22.10.1245; KAPPELLE LJ, 1988, STROKE, V19, P1093, DOI 10.1161/01.STR.19.9.1093; KUNITZ SC, 1984, STROKE, V15, P740, DOI 10.1161/01.STR.15.4.740; LODDER J, 1990, STROKE, V21, P375, DOI 10.1161/01.STR.21.3.375; MOHR JP, 1986, STROKE PATHOPHYSIOLO, P281; POUNGVARIN N, 1991, BRIT MED J, V302, P1565, DOI 10.1136/bmj.302.6792.1565; PRICE TR, 1986, STROKE PATHOPHYSIOLO, P1060; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; SACCO SE, 1991, STROKE, V22, P1236, DOI 10.1161/01.STR.22.10.1236; SANDERCOCK P, 1985, BRIT MED J, V290, P193, DOI 10.1136/bmj.290.6463.193; STERMAN AB, 1987, STROKE, V18, P524, DOI 10.1161/01.STR.18.2.524; TURNEY TM, 1984, STROKE, V15, P790, DOI 10.1161/01.STR.15.5.790; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WHISNANT JP, 1990, STROKE, V21, P707, DOI 10.1161/01.STR.21.5.707; 1989, STROKE BETTER MANAGE	23	56	57	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 15	1992	339	8790					400	402		10.1016/0140-6736(92)90085-H	http://dx.doi.org/10.1016/0140-6736(92)90085-H			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346666				2022-12-01	WOS:A1992HD65900010
J	DEBONO, DP; SAMANI, NJ; SPYT, TJ; HARTSHORNE, T; THRUSH, AJ; EVANS, DH				DEBONO, DP; SAMANI, NJ; SPYT, TJ; HARTSHORNE, T; THRUSH, AJ; EVANS, DH			TRANSCUTANEOUS ULTRASOUND MEASUREMENT OF BLOOD-FLOW IN INTERNAL MAMMARY ARTERY TO CORONARY-ARTERY GRAFTS	LANCET			English	Article								Transcutaneous doppler ultrasound was used to examine internal-mammary-artery (IMA) blood-flow in 26 patients with IMA coronary bypass grafts. The ungrafted right IMA could be seen in all of 19 patients, the grafted left IMA in 16 of 26, and the grafted right IMA in 3 of 7. The velocity profile recorded from the proximal part of the grafted IMA is distinct from that of an ungrafted artery, with a systolic peak which reflects graft capacitance in the face of high intramyocardial resistance, and a diastolic peak which represents graft conductance when intramyocardial resistance is low. Total graft blood-flow can be estimated from the mean velocity and the measured vessel diameter, resting flows ranged from 22 to 79 ml/min. In recently grafted patients, resting graft blood-flow correlated with myocardial "run-off" estimated from preoperative arteriograms; graft blood-flow increased appropriately with exercise. This simple, non-invasive technique to measure IMA graft blood-flow may find applications for routine postoperative follow-up of patients with IMA grafts and for studies on the physiology and pharmacology of coronary artery blood-flow.	UNIV LEICESTER,DEPT CARDIOL,LEICESTER LE1 7RH,ENGLAND; UNIV LEICESTER,DEPT SURG,LEICESTER LE1 7RH,ENGLAND; UNIV LEICESTER,DEPT MED PHYS,LEICESTER LE1 7RH,ENGLAND	University of Leicester; University of Leicester; University of Leicester								BARNER HB, 1982, ANN THORAC SURG, V34, P408, DOI 10.1016/S0003-4975(10)61402-6; BRANDT PWT, 1977, CLIN RADIOL, V28, P261; CANVER CC, 1991, J VASC SURG, V13, P294, DOI 10.1016/0741-5214(91)90222-G; Evans DH, 1989, DOPPLER ULTRASOUND P, P233; LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101; MILLS NL, 1989, J THORAC CARDIOV SUR, V98, P73; SONS H, 1989, European Heart Journal, V10, P304	7	77	79	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1992	339	8790					379	381		10.1016/0140-6736(92)90076-F	http://dx.doi.org/10.1016/0140-6736(92)90076-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346657				2022-12-01	WOS:A1992HD65900001
J	FAYAD, IM; HIRSCHHORN, N; ABUZIKRY, M; KAMEL, M				FAYAD, IM; HIRSCHHORN, N; ABUZIKRY, M; KAMEL, M			HYPERNATREMIA SURVEILLANCE DURING A NATIONAL DIARRHEAL DISEASES CONTROL PROJECT IN EGYPT	LANCET			English	Article							ORAL REHYDRATION SOLUTION; INFANTILE DIARRHEA; CHILDREN	The nationwide introduction of oral rehydration therapy to Egypt has led to improvement in diarrhoea case management and a fall in infant and child mortality. With the wider use of oral rehydration solution (ORS) prepared from packets, the incidence of hypernatraemia (serum sodium > 150 mmol/l) in inpatients with dehydration seen at Abu El-Reeche Hospital, Cairo, increased between 1980 and 1984. Systematic surveillance of hypernatraemia in the outpatient rehydration unit began in late 1984, and we report trends in hypernatraemia and analyses of key variables affecting its incidence in dehydrated children. In 1980, 17 of 100 children sampled had hypernatraemia and 2 had severe hypernatraemia (ie, serum sodium > 165 mmol/l). The frequency in inpatients peaked at 49% of 222 children in 1984 (19% with severe hypernatraemia). Between 1 986 and 1 989, at least 1 000 dehydrated outpatients were surveyed each year; by 1989 the incidence of hypernatraemia had fallen to around 10% (2% severe hypernatraemia). The rise and decline coincided with increasing use of ORS and then increasing ability of mothers to mix the solution correctly. Hypernatraemia was positively related to the quantity of ORS taken, severity of dehydration, nutritional status, and the cooler season, and negatively related to age and duration of diarrhoea. Explanations for our findings include improved use of ORS and better case-management. Good practice promoted through the mass media has facilitated these changes, if the standard of ORS use is not maintained, there may be a case for reducing the sodium content of ORS.	JOHN SNOW INC, BOSTON, MA USA; MINIST HLTH CAIRO, NATL CONTROL DIARRHEAL DIS PROJECT, CAIRO, EGYPT	Egyptian Knowledge Bank (EKB); Ministry of Health & Population - Egypt	FAYAD, IM (corresponding author), UNIV CAIRO, CHILDRENS HOSP, ABU EL REECHE HOSP, FAC MED, GASTROENTERITIS UNIT, CAIRO, EGYPT.							BLACK RE, 1984, PEDIATRICS, V73, P799; CLEARY TG, 1981, J PEDIATR-US, V99, P739, DOI 10.1016/S0022-3476(81)80397-6; ELMOUGI M, 1989, J TROP PEDIATRICS, V35, P230, DOI 10.1093/tropej/35.5.230; ELRAFIE M, 1990, LANCET, V335, P334; FARTHING MJG, 1988, DRUGS, V36, P80, DOI 10.2165/00003495-198800364-00011; FORTIN J, 1978, J TROP PED ENV CH H, V24, P110, DOI 10.1093/tropej/24.3.110; HELMY N, 1988, J PEDIATR GASTR NUTR, V7, P417, DOI 10.1097/00005176-198805000-00018; HIRSCHHORN N, 1980, AM J CLIN NUTR, V33, P637, DOI 10.1093/ajcn/33.3.637; PANETH N, 1980, AM J DIS CHILD, V134, P785, DOI 10.1001/archpedi.1980.02130200053017; PIZARRO D, 1984, J PEDIATR-US, V104, P316, DOI 10.1016/S0022-3476(84)81023-9; SANTOSHAM M, 1990, J PEDIATR-US, V116, P868, DOI 10.1016/S0022-3476(05)80642-0; 1988, LANCET, V2, P145; 1977, B WORLD HEALTH ORGAN, V55, P87	13	19	19	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 15	1992	339	8790					389	393		10.1016/0140-6736(92)90079-I	http://dx.doi.org/10.1016/0140-6736(92)90079-I			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346660				2022-12-01	WOS:A1992HD65900004
J	FRIEDLAND, IR; KLUGMAN, KP				FRIEDLAND, IR; KLUGMAN, KP			FAILURE OF CHLORAMPHENICOL THERAPY IN PENICILLIN-RESISTANT PNEUMOCOCCAL MENINGITIS	LANCET			English	Article							ANTIBIOTICS; ORGANISM	First-line therapy for meningitis is often penicillin plus chloramphenicol. Penicillin-resistant Streptococcus pneumoniae (PRSP) infections are increasing world wide, but the efficacy of chloramphenicol for PRSP meningitis is unknown. We therefore prospectively assessed children with pneumococcal meningitis treated with penicillin plus chloramphenicol over 27 months to compare outcome of penicillin-susceptible S pneumoniae (PSSP) meningitis with that of PRSP meningitis. 68 children with pneumococcal meningitis who survived 24 hours were evaluated, of whom 25 had chloramphenicol-susceptible PRSP meningitis that was treated initially with chloramphenicol. 20 (80%) of these 25 children had an unsatisfactory outcome (death, serious neurological deficit, or poor clinical response). By contrast, 14 (33%) of 43 children with PSSP meningitis (treated with benzylpenicillin) had an adverse outcome (p < 0.001). Despite similar zone sizes on antibiotic disc testing (indicating chloramphenicol susceptibility) the chloramphenicol minimum bactericidal concentrations (MBCs) of PRSP isolates were significantly higher than those of PSSP isolates. The higher chloramphenicol MBCs resulted in borderline cerebrospinal-fluid bactericidal activity in many cases of PRSP meningitis and frequent treatment failure. Current definitions of chloramphenicol susceptibility of S pneumoniae may be inappropriate for management of pneumococcal meningitis. We suggest that chloramphenicol should not be used for the management of PRSP meningitis, alternative agents, such as third-generation cephalosporins, are more appropriate.	S AFRICAN INST MED RES,MRC,EMERGENT PATHOGEN RES UNIT,JOHANNESBURG 2000,SOUTH AFRICA; BARAGWANATH HOSP,DEPT PAEDIAT,JOHANNESBURG 2013,SOUTH AFRICA; BARAGWANATH HOSP,DEPT CLIN MICROBIOL,JOHANNESBURG 2013,SOUTH AFRICA; UNIV WITWATERSRAND,JOHANNESBURG 2001,SOUTH AFRICA	University of Witwatersrand								CAPUTO GM, 1983, ANN INTERN MED, V98, P416, DOI 10.7326/0003-4819-98-3-416_2; Facklam RR, 1985, MANUAL CLIN MICROBIO, V4th, P154; FRIEDLAND IR, 1991, PEDIATR INFECT DIS J, V10, P705, DOI 10.1097/00006454-199109000-00018; IZER PV, 1978, PEDIATRICS, V61, P157; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; MCCRACKEN GH, 1985, ANTIMICROB AGENTS CH, V27, P141, DOI 10.1128/AAC.27.2.141; MOELLERING RC, 1989, J ANTIMICROB CHEMOTH, V24, P1; NARAQI S, 1974, J PEDIATR-US, V85, P671, DOI 10.1016/S0022-3476(74)80513-5; PAREDES A, 1976, PEDIATRICS, V58, P378; VILADRICH PF, 1991, ANTIMICROB AGENTS CH, V35, P2467, DOI 10.1128/AAC.35.12.2467; VILADRICH PF, 1988, AM J MED, V84, P839, DOI 10.1016/0002-9343(88)90061-7; WONG UK, 1991, PEDIATR INFECT DIS J, V10, P122; 1990, NCCLS M7A2 NAT COMM	13	150	154	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1992	339	8790					405	408		10.1016/0140-6736(92)90087-J	http://dx.doi.org/10.1016/0140-6736(92)90087-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346668				2022-12-01	WOS:A1992HD65900012
J	GALVE, E; ORDI, J; BARQUINERO, J; EVANGELISTA, A; VILARDELL, M; SOLERSOLER, J				GALVE, E; ORDI, J; BARQUINERO, J; EVANGELISTA, A; VILARDELL, M; SOLERSOLER, J			VALVULAR HEART-DISEASE IN THE PRIMARY ANTIPHOSPHOLIPID SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						HEART VALVE DISEASE; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; CARDIOLIPINS; LUPUS ERYTHEMATOSUS, SYSTEMIC	SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTICARDIOLIPIN ANTIBODIES; THROMBOCYTOPENIC PURPURA; MITRAL REGURGITATION; ANTICOAGULANT; ASSOCIATION; NECROPSY; PATTERNS; PATIENT	Objective: To determine the prevalence of cardiac valvular involvement in patients with the primary antiphospholipid syndrome. Design: Cross-sectional study with evaluation of case patients and control patients by Doppler echocardiography. The mean follow-up for case patients was 21 months. Setting: University-based tertiary medical center. Patients: Twenty-eight consecutive patients who were diagnosed with the primary antiphospholipid syndrome during a 10-year period; 28 age- and sex-matched healthy controls. Measurements and Main Results: Ten patients (36%; 95% Cl, 19% to 56%) with the primary antiphospholipid syndrome had cardiac valvular involvement: Four patients had mitral valve involvement; four patients, aortic valve involvement; and two patients, both mitral and aortic valve involvement; no patients had tricuspid or pulmonary valve disease. Eight of 10 patients had a regurgitant murmur. None of the control patients had valvular disease. The mean mitral valve thickness in patients with mitral valve involvement was 7.0 +/- 1.6 mm, compared with 2.7 +/- 0.8 mm in patients with normal valves and 3.2 +/- 0.9 mm in the control group. The mean aortic valve thickness in patients with aortic valve involvement was 3.8 +/- 0.5 mm compared with 1.4 +/- 0.3 mm in patients with normal valves and 1.4 +/- 0.5 mm in the control group. Stenotic lesions were not found. Regurgitation was severe in two patients (one required surgery), moderate in three patients, and mild in three patients. Conclusions: Valvular involvement is frequently found in patients with the primary antiphospholipid syndrome. The lesions are left-sided, causing regurgitation that may be clinically important.			GALVE, E (corresponding author), HOSP GEN UNIV VALL HEBRON, DEPT MED, SERV CARDIOL, PASEO VALL HEBRON S-N, E-08035 BARCELONA, SPAIN.		Barquinero, Jordi/F-6979-2011	Barquinero, Jordi/0000-0002-1677-9851				ANDERSON D, 1987, J RHEUMATOL, V14, P839; ARROYO R A, 1989, Arthritis and Rheumatism, V32, pS73; ASHERSON RA, 1989, MEDICINE, V68, P366, DOI 10.1097/00005792-198911000-00004; BULKLEY BH, 1975, AM J MED, V58, P243, DOI 10.1016/0002-9343(75)90575-6; CANOSO RT, 1987, BRIT J HAEMATOL, V65, P495, DOI 10.1111/j.1365-2141.1987.tb04157.x; CHARTASH EK, 1989, AM J MED, V86, P407, DOI 10.1016/0002-9343(89)90337-9; CONLEY CL, 1952, J CLIN INVEST, V31, P621; DALTON JG, 1985, STROKE, V16, P512, DOI 10.1161/01.STR.16.3.512; DELEZE M, 1988, J RHEUMATOL, V15, P611; EVANGELISTA A, 1989, European Heart Journal, V10, P404; EXNER T, 1978, BRIT J HAEMATOL, V40, P143, DOI 10.1111/j.1365-2141.1978.tb03648.x; FORD PM, 1988, J RHEUMATOL, V15, P597; GALVE E, 1988, NEW ENGL J MED, V319, P817, DOI 10.1056/NEJM198809293191302; GALVE E, 1989, NEW ENGL J MED, V320, P740; HARRIS EN, 1987, BRIT J RHEUMATOL, V26, P324; HARRIS EN, 1985, BRIT J HAEMATOL, V59, P231, DOI 10.1111/j.1365-2141.1985.tb02989.x; HUGHES GRV, 1986, J RHEUMATOL, V13, P486; HUGHES GRV, 1985, CLIN EXP RHEUMATOL, V3, P285; KEANE A, 1987, BRIT J RHEUMATOL, V26, P346; KHAMASHTA MA, 1990, LANCET, V335, P1541, DOI 10.1016/0140-6736(90)91373-I; KOCHENOUR NK, 1987, OBSTET GYNECOL, V69, P460; KOZLOWSKI CL, 1987, POSTGRAD MED J, V63, P793, DOI 10.1136/pgmj.63.743.793; LOIZOU S, 1985, CLIN EXP IMMUNOL, V62, P738; MALIA RG, 1988, CLIN EXP IMMUNOL, V73, P456; MURPHY JJ, 1989, BRIT HEART J, V62, P61; NANDA NN, 1989, ATLAS COLOR DOPPLER; NIHOYANNOPOULOS P, 1990, CIRCULATION, V82, P369, DOI 10.1161/01.CIR.82.2.369; OROURKE RA, 1990, CIRCULATION, V82, P636, DOI 10.1161/01.CIR.82.2.636; PONSLLADO G, 1986, AM J CARDIOL, V57, P806, DOI 10.1016/0002-9149(86)90618-1; POPE JM, 1991, AM J MED, V90, P299, DOI 10.1016/0002-9343(91)90569-J; ROUGET JP, 1983, ANN MED INTERNE, V134, P111; SALVARANI C, 1989, CLIN EXP RHEUMATOL, V7, P329; SCHLEIDER MA, 1976, BLOOD, V48, P499; SONTHEIMER RD, 1987, ARCH DERMATOL, V123, P590, DOI 10.1001/archderm.123.5.590; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; THIAGARAJAN P, 1986, BLOOD, V68, P869; TIRRI G, 1990, CLIN EXP RHEMATOL, V8, P215; VAARALA O, 1986, CLIN IMMUNOL IMMUNOP, V41, P8, DOI 10.1016/0090-1229(86)90046-2	38	162	168	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					293	298		10.7326/0003-4819-116-4-293	http://dx.doi.org/10.7326/0003-4819-116-4-293			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	1733383				2022-12-01	WOS:A1992HD54600004
J	HENDRA, TJ; MARSHALL, AJ				HENDRA, TJ; MARSHALL, AJ			INCREASED PRESCRIPTION OF THROMBOLYTIC TREATMENT TO ELDERLY PATIENTS WITH SUSPECTED ACUTE MYOCARDIAL-INFARCTION ASSOCIATED WITH AUDIT	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTRAVENOUS STREPTOKINASE; THERAPY; MORTALITY	Objectives - To assess prescription of thrombolytic treatment to elderly patients with suspected acute myocardial infarction and the incidence of side effects. Design - Retrospective analysis of prescriptions during five months (first audit) followed by prospective analysis of uptake of treatment during five months after interventions in clinical management; prospective assessment of adverse events during thrombolytic treatment. Setting - Coronary care unit of large district general hospital. Patients - 110 patients aged greater-than-or-equal-to 65 with subsequently proved acute myocardial infarction admitted in first audit and 119 admitted in the second. Main outcome measures - Site of infarct, prescription of thrombolysis treatment, reasons for nonprescription, complications. Results - Before intervention thrombolytic treatment was prescribed to 13/110 (12%) patients with subsequently confirmed myocardial infarction and after intervention to 55/119 (46%) patients (p < 0.01). In the first audit no patients with angina received thrombolytic treatment whereas 13/79 (16%) were treated in the second audit. Increased prescription of thrombolytic treatment in the second audit was associated with significantly fewer exclusions owing to dyspepsia (p < 0.05) and unstated or unsatisfactory reasons (p < 0.01) Streptokinase infusions were completed uneventfully in 75% (48/64) and 77% (10/13) of patients with infarction and angina respectively. Side effects of treatment were more common in patients with inferior than with anterior infarcts (16/42 (30%) v 3/24 (13%), p < 0.05). Conclusions - Low rates of prescription of thrombolytic treatment to elderly patients with suspected acute myocardial infarction were identified and corrected. Streptokinase treatment was associated with transient arrhythmias or hypotension in about a third of these patients with infarcts, particularly those with electrocardiographic changes in inferior leads.	DERRIFORD HOSP, DEPT CARDIOL, PLYMOUTH PL6 8DH, ENGLAND	Derriford Hospital								ALDRICH MS, 1985, JAMA-J AM MED ASSOC, V253, P1777, DOI 10.1001/jama.253.12.1777; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; BURRELL CJ, 1990, BMJ-BRIT MED J, V300, P237, DOI 10.1136/bmj.300.6719.237; GRINES CL, 1990, J AM COLL CARDIOL, V16, P223, DOI 10.1016/0735-1097(90)90482-5; KENNEDY JW, 1990, ANN INTERN MED, V113, P907, DOI 10.7326/0003-4819-113-12-907; LEW AS, 1987, AM J CARDIOL, V59, P1, DOI 10.1016/S0002-9149(87)80059-0; LEW AS, 1985, CIRCULATION, V72, P1321, DOI 10.1161/01.CIR.72.6.1321; MIDGETTE AS, 1990, ANN INTERN MED, V113, P961, DOI 10.7326/0003-4819-113-12-961; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; MURRAY N, 1987, BRIT HEART J, V57, P144; PETCH MC, 1990, BMJ-BRIT MED J, V300, P483, DOI 10.1136/bmj.300.6723.483; SHAW C, 1990, MED AUDIT HOSPITAL H; SLEIGHT P, 1990, EUR HEART J, V11, P1; SMITH LDR, 1990, POSTGRAD MED J, V66, P263, DOI 10.1136/pgmj.66.774.263; TIMMIS AD, 1990, BMJ-BRIT MED J, V301, P941, DOI 10.1136/bmj.301.6758.941; WILCOX RG, 1988, LANCET, V2, P525; 1976, PUBLIC HLTH EUROPE, V5	18	22	22	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 15	1992	304	6824					423	425		10.1136/bmj.304.6824.423	http://dx.doi.org/10.1136/bmj.304.6824.423			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE389	1547391	Green Published, Bronze			2022-12-01	WOS:A1992HE38900022
J	LANDI, G				LANDI, G			CLINICAL-DIAGNOSIS OF TRANSIENT ISCHEMIC ATTACKS	LANCET			English	Article							ISCHEMIC ATTACKS; INTEROBSERVER AGREEMENT; STROKE; RELIABILITY; COMMUNITY; RIND				LANDI, G (corresponding author), OSPED POLICLIN, NEUROL CLIN, VIA F SFORZA 35, I-20122 MILAN, ITALY.							BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; CALANCHINI PR, 1977, JAMA-J AM MED ASSOC, V238, P2029, DOI 10.1001/jama.238.19.2029; CAPLAN LR, 1983, STROKE, V14, P431, DOI 10.1161/01.STR.14.3.431; DENNIS M, 1990, J NEUROL, V237, P257, DOI 10.1007/BF00314630; DENNIS MS, 1989, STROKE, V20, P1494, DOI 10.1161/01.STR.20.11.1494; DENNIS MS, 1989, LANCET, V1, P185; FISHER CM, 1986, STROKE, V17, P1033, DOI 10.1161/01.STR.17.5.1033; FISHER CM, 1982, NEUROLOGY, V32, P871, DOI 10.1212/WNL.32.8.871; HANKEY GJ, 1991, LANCET, V337, P335, DOI 10.1016/0140-6736(91)90953-M; HODGES JR, 1990, BRAIN, V113, P639, DOI 10.1093/brain/113.3.639; KAPPELLE LJ, 1991, ANCET, V337, P339; KOUDSTAAL PJ, 1986, STROKE, V17, P723, DOI 10.1161/01.STR.17.4.723; KRAAIJEVELD CL, 1984, STROKE, V15, P723, DOI 10.1161/01.STR.15.4.723; LANDI G, IN PRESS CEREBROVASC; LARSEN BH, 1990, J NEUROL NEUROSUR PS, V53, P1029, DOI 10.1136/jnnp.53.12.1029; LEE H, 1990, NEUROLOGY, V40, P165, DOI 10.1212/WNL.40.1.165; MEISSNER I, 1986, NEUROLOGY, V36, P1029, DOI 10.1212/WNL.36.8.1029; PORTENOY RK, 1984, STROKE, V15, P1009, DOI 10.1161/01.STR.15.6.1009; SHINAR D, 1987, ARCH NEUROL-CHICAGO, V44, P149, DOI 10.1001/archneur.1987.00520140021012; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TOMASELLO F, 1982, STROKE, V13, P32, DOI 10.1161/01.STR.13.1.32; WAXMAN SG, 1983, STROKE, V14, P433, DOI 10.1161/01.STR.14.3.433; WIEBERS DO, 1982, NEUROLOGY, V32, P459, DOI 10.1212/WNL.32.5.459; YANAGIHARA T, 1985, ANN NEUROL, V18, P244, DOI 10.1002/ana.410180212	24	39	41	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 15	1992	339	8790					402	405		10.1016/0140-6736(92)90086-I	http://dx.doi.org/10.1016/0140-6736(92)90086-I			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346667				2022-12-01	WOS:A1992HD65900011
J	LINDAN, CP; ALLEN, S; SERUFILIRA, A; LIFSON, AR; VANDEPERRE, P; CHENRUNDLE, A; BATUNGWANAYO, J; NSENGUMUREMYI, F; BOGAERTS, J; HULLEY, S				LINDAN, CP; ALLEN, S; SERUFILIRA, A; LIFSON, AR; VANDEPERRE, P; CHENRUNDLE, A; BATUNGWANAYO, J; NSENGUMUREMYI, F; BOGAERTS, J; HULLEY, S			PREDICTORS OF MORTALITY AMONG HIV-INFECTED WOMEN IN KIGALI, RWANDA	ANNALS OF INTERNAL MEDICINE			English	Article						RWANDA; AFRICA; HUMAN IMMUNODEFICIENCY VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME; SEXUALLY TRANSMITTED DISEASES; PREGNANCY COMPLICATIONS, INFECTIOUS; WOMENS HEALTH SERVICES	HUMAN-IMMUNODEFICIENCY-VIRUS; CLINICAL CASE-DEFINITION; SUB-SAHARAN AFRICA; NUTRITIONAL-STATUS; LATENCY PERIOD; HOMOSEXUAL MEN; SURVIVAL-TIME; BISEXUAL MEN; RISK-FACTORS; AIDS	Objective: To better characterize the natural history of disease due to human immunodeficiency virus (HIV) infection in African women. Design: Prospective cohort study over a 2-year follow-up period. Participants: A total of 460 HIV-seropositive women and a comparison cohort of HIV-seronegative women recruited from prenatal and pediatric clinics in Kigali, Rwanda in 1988. Measurements: Clinical signs and symptoms of HIV disease, AIDS, and mortality. Main Results: Follow-up data at 2 years were available for 93% of women who were still alive. At enrollment, many seropositive women reported symptoms listed in the World Health Organization (WHO) clinical case definition of AIDS, but these were nonspecific and often improved over time. The 2-year mortality among HIV-infected women by Kaplan-Meier survival analysis was 7% (95% Cl, 5% to 10%) overall, and 21% (Cl, 8% to 34%) for the 40 women who fulfilled the WHO case definition of AIDS at entry. In comparison, the 2-year mortality in women not infected with HIV was only 0.3% (Cl, 0% to 7%). Independent baseline predictors of mortality in seropositive women by Cox proportional hazards modeling were, in order of descending risk factor prevalence: a body mass index of 21 kg/m2 or less (relative hazard, 2.3; Cl, 1.1 to 4.8), low income (relative hazard, 2.3; Cl, 1.1 to 4.5), an erythrocyte sedimentation rate exceeding 60 mm/h (relative hazard, 4.9; Cl, 2.2 to 10.9), chronic diarrhea (relative hazard, 2.6; Cl, 1.1 to 5.7), a history of herpes zoster (relative hazard 5.3; Cl, 2.5 to 11.4), and oral candida (relative hazard, 7.3; Cl, 1.6 to 33.3). Human immunodeficiency virus disease was the cause of death in 38 of the 39 HIV-positive women who died, but only 25 met the WHO definition of AIDS before death. Conclusions: Human immunodeficiency virus disease now accounts for 90% of all deaths among child-bearing urban Rwandan women. Many symptomatic seropositive patients may show some clinical improvement and should not be denied routine medical care. Easily diagnosed signs and symptoms and inexpensive laboratory tests can be used in Africa to identify those patients with a particularly good or bad prognosis.	PROJET SAN FRANCISCO, KIGALI, RWANDA; UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL & BIOSTAT, SAN FRANCISCO, CA 94131 USA; RWANDAN NATL AIDS PROGRAM, KIGALI, RWANDA; CTR HOSP KIGALI, KIGALI, RWANDA; MINIST HLTH KIGALI, KIGALI, RWANDA	University of California System; University of California San Francisco	LINDAN, CP (corresponding author), UNIV CALIF SAN FRANCISCO, CTR AIDS PREVENT STUDIES, 74 NEW MONTGOMERY ST, SUITE 600, SAN FRANCISCO, CA 94105 USA.		Van de Perre, Philippe/B-9692-2008	Van de Perre, Philippe/0000-0002-3912-0427	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [MH42459] Funding Source: Medline; PHS HHS [A123980] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; ALLEN S, 1991, J INFECT DIS, V164, P67, DOI 10.1093/infdis/164.1.67; ANZALA A, 1991, 6 INT C AIDS FLOR, P103; BECHERER PR, 1990, AM J HEMATOL, V34, P204, DOI 10.1002/ajh.2830340310; BLAXHULT A, 1990, AIDS, V4, P125, DOI 10.1097/00002030-199002000-00005; CARAEL M, 1988, AIDS, V2, P201; CARSWELL JW, 1988, BRIT MED BULL, V44, P183, DOI 10.1093/oxfordjournals.bmb.a072240; CHIN J, 1989, B WORLD HEALTH ORGAN, V67, P1; CHLEBOWSKI RT, 1989, AM J GASTROENTEROL, V84, P1288; COLEBUNDERS R, 1987, LANCET, V1, P492; COLEBUNDERS RL, 1989, J INFECT DIS, V160, P902, DOI 10.1093/infdis/160.5.902; DARBY SC, 1990, STAT MED, V9, P681, DOI 10.1002/sim.4780090615; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; DECOCK KM, 1991, BMJ-BRIT MED J, V303, P1185, DOI 10.1136/bmj.303.6811.1185; GILKS CF, 1991, BRIT MED J, V303, P1189, DOI 10.1136/bmj.303.6811.1189; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; GOODGAME RW, 1990, NEW ENGL J MED, V323, P383, DOI 10.1056/NEJM199008093230605; HASSIG SE, 1990, AIDS, V4, P883, DOI 10.1097/00002030-199009000-00009; HEBERT JR, 1988, MED HYPOTHESES, V27, P51, DOI 10.1016/0306-9877(88)90083-7; HEBERT JR, 1990, J SUBST ABUSE TREAT, V7, P161; HESSOL NA, 1990, J ACQ IMMUN DEF SYND, V3, P1078; HIRA SK, 1990, J ACQ IMMUN DEF SYND, V3, P87; HUNTER SS, 1990, SOC SCI MED, V31, P681, DOI 10.1016/0277-9536(90)90250-V; LANGE JMA, 1989, AIDS, V3, pS153, DOI 10.1097/00002030-198901001-00023; LEFRERE JJ, 1988, AIDS, V2, P63, DOI 10.1097/00002030-198802000-00013; LEFRERE JJ, 1989, AIDS, V3, P603, DOI 10.1097/00002030-198909000-00008; LUCAS SB, 1990, T ROY SOC TROP MED H, V84, P34, DOI 10.1016/0035-9203(90)90453-L; LUCAS SB, 1987, ADV MED, V23, P102; MAMUN KZ, 1989, AIDS, V3, P323, DOI 10.1097/00002030-198905000-00017; MBAGA JM, 1990, E AFR MED J, V67, P95; MCLEOD DT, 1989, T ROY SOC TROP MED H, V83, P694, DOI 10.1016/0035-9203(89)90400-8; MCLEOD DT, 1990, RESP MED, V84, P225, DOI 10.1016/S0954-6111(08)80039-X; MELBYE M, 1987, LANCET, V1, P728; MELBYE M, 1986, LANCET, V2, P1113; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; MULLER O, 1990, LANCET, V335, P236, DOI 10.1016/0140-6736(90)90339-7; MURRAY HW, 1989, AM J MED, V86, P533, DOI 10.1016/0002-9343(89)90380-X; NELSON JA, 1990, AIDS, V4, P1, DOI 10.1097/00002030-199001000-00001; NGALY B, 1990, J ACQ IMMUN DEF SYND, V3, P430; NGALY B, 1988, J ACQ IMMUN DEF SYND, V1, P551; PALLANGYO KJ, 1987, LANCET, V2, P972; PHAIR J, 1991, 6 INT C AIDS FLOR; PIOT P, 1988, SCIENCE, V239, P573, DOI 10.1126/science.3277271; QUINN TC, 1987, JAMA-J AM MED ASSOC, V257, P2617, DOI 10.1001/jama.257.19.2617; ROWLEY JT, 1990, AIDS, V4, P47, DOI 10.1097/00002030-199001000-00007; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SCHECHTER MT, 1989, AIDS, V3, P347, DOI 10.1097/00002030-198906000-00002; VANDEPERRE P, 1989, LANCET, V1, P941; VANDEPERRE P, 1987, AIDS, V1, P207; VANGRIENSVEN GJP, 1990, AM J EPIDEMIOL, V132, P203; WENGER JD, 1988, J GEN INTERN MED, V3, P464, DOI 10.1007/BF02595923; WIDYWIRSKI R, 1988, JAMA-J AM MED ASSOC, V260, P3286, DOI 10.1001/jama.260.22.3286; 1989, DRAFT REPORT INFORMA; 1987, MMWR S, V36, pS3; 1986, WEEKLY EPIDEMIOL REC, V61, P69; REPORTED AIDS CASES	56	139	140	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					320	328		10.7326/0003-4819-116-4-320	http://dx.doi.org/10.7326/0003-4819-116-4-320			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	1733389				2022-12-01	WOS:A1992HD54600010
J	LOPEZ, A; MIRANDA, P; TEJADA, E; FISHBEIN, DB				LOPEZ, A; MIRANDA, P; TEJADA, E; FISHBEIN, DB			OUTBREAK OF HUMAN RABIES IN THE PERUVIAN JUNGLE	LANCET			English	Article								Transmission of rabies to man by vampire bats has been known for 60 years but there have been few reports of the features of rabies transmitted in this way. These aspects of the disease were investigated during an outbreak in Peru in early 1990. Between Jan 1 and April 30, 1990, 29 (5%) of 636 residents of the two rural communities in the Amazon Jungle in Peru acquired an illness characterised by hydrophobia, fever, and headache and died shortly thereafter. A census in one of the two towns revealed that the proportion affected was significantly higher for 5-14 year olds (17%) than for other age-groups (p < 10(-5)). Interviews conducted with 23 of the patients or their families revealed that 22 (96%) had a history of bat bite, compared with 66 (22%) of 301 community members who remained healthy (p < 10(-6)). A rabies virus strain identical to those isolated from vampire bats (Desmodus rotundus) was isolated from the brain of the only person on whom necropsy could be done. Because of the extreme isolation of this and other communities affected by bat-transmitted rabies, preventive measures should be directed at decreasing the risk of nocturnal exposure to bats by bat proofing dwellings or use of mosquito nets and at prompt wound care. Rabies pre-exposure or postexposure vaccination is clearly indicated, but may not be feasible in these isolated populations.	CTR DIS CONTROL, EPIDEMIOL PROGRAM OFF,DIV FIELD EPIDEMIOL, INT BRANCH,MAILSTOP C08, ATLANTA, GA 30333 USA; MINIST SALUD, PROGRAMA ENTRENAMIENTO & EPIDEMIOL CAMPO, OFICIANA GEN EPIDEMIOL, LIMA, PERU; CTR DIS CONTROL, NATL CTR INFECT DIS, DIV VIRAL & RICKETTSIAL DIS, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								Acha P N, 1967, Bull Off Int Epizoot, V67, P343; ARELLANOSOTA C, 1988, REV INFECT DIS, V10, pS707; Carini A, 1911, ANN I PASTEUR PARIS, V25, P843; Dean A. G., 1990, EPI INFO VERSION 5 W; GOLDWASSER RA, 1958, P SOC EXP BIOL MED, V98, P219, DOI 10.3181/00379727-98-23996; GUT H. JAMES, 1959, JOUR MAMMAL, V40, P534, DOI 10.2307/1376270; Hurst EW, 1931, LANCET, V2, P622; Hurst EW, 1932, J PATHOL BACTERIOL, V35, P301, DOI 10.1002/path.1700350302; Johnson H. N., 1971, Rabies. Proceedings of working conference on rabies, Tokyo, 1970., P237; LORD R D, 1975, Journal of Wildlife Diseases, V11, P210; MALAGAALBA A, 1954, AM J PUBLIC HEALTH, V44, P909, DOI 10.2105/AJPH.44.7.909; MCCARTHY TJ, 1989, AM J TROP MED HYG, V40, P320, DOI 10.4269/ajtmh.1989.40.320; NEHAUL BBG, 1955, AM J TROP MED HYG, V4, P550, DOI 10.4269/ajtmh.1955.4.550; NEHAUL BBG, 1965, AM J TROP MED HYG, V14, P295, DOI 10.4269/ajtmh.1965.14.295; SMITH JS, 1989, ADV VIRUS RES, V36, P215; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; VERLINDE JD, 1975, TROP GEOGR MED, V27, P137; WATERMAN J A, 1959, Caribb Med J, V21, P46; 1983, MMWR, V32, P494; 1987, WHORABIES89199	20	46	55	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 15	1992	339	8790					408	411						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346669				2022-12-01	WOS:A1992HD65900013
J	MARTELL, JV; SEITZ, RS; HARADA, JK; KOBAYASHI, J; SASAKI, VK; WONG, C				MARTELL, JV; SEITZ, RS; HARADA, JK; KOBAYASHI, J; SASAKI, VK; WONG, C			HOSPITALIZATION IN AN URBAN HOMELESS POPULATION - THE HONOLULU URBAN HOMELESS PROJECT	ANNALS OF INTERNAL MEDICINE			English	Article						HOMELESS PERSONS; HOSPITALIZATION; HOSPITALS, PSYCHIATRIC; COSTS AND COST ANALYSIS; SUBSTANCE ABUSE	MENTAL-HEALTH	Objective: To determine the rate and estimate the cost of hospitalization in a defined urban homeless population. Design: Retrospective chart review. Setting: Kalihi-Palama Health Clinic Health Care for the Homeless Project, Hawaii State Hospital, and seven acute care hospitals in Honolulu, Hawaii. Patients: A total of 1751 homeless clients contacted between 1 December 1988 and 30 November 1990. Measurements and Main Results: A total of 1751 individuals were studied for an aggregate of 871.3 person-years. Five hundred sixty-four hospitalizations were identified: ninety-two to the state psychiatric hospital and 472 to acute care hospitals. The age- and sex-adjusted hospitalization rate for acute care hospitals was 542/1000 person-years (compared with the state rate of 96/1000 person-years). Homeless persons were admitted to acute care hospitals for 4766 days compared with a predicted 640 days. The age- and sex-adjusted rate of admission to the state psychiatric hospital was 105/1000 person-years (compared with the state rate of 0.8/1000 person-years). Homeless persons were admitted to the state psychiatric hospital for 3837 days compared with a predicted 139 days. Conclusions: Homeless individuals in this study were hospitalized in acute care and psychiatric hospitals far more frequently than were members of the general population.	UNIV HAWAII, JOHN A BURNS SCH MED, OFF STUDENT AFFAIRS, HONOLULU, HI 96822 USA	University of Hawaii System								BAHR HM, 1971, PUBLIC OPIN QUART, V35, P374, DOI 10.1086/267922; BASSUK EL, 1984, SCI AM, V251, P40, DOI 10.1038/scientificamerican0784-40; BORLAND A, 1989, HOSP COMMUNITY PSYCH, V40, P369; Bowdler J E, 1989, Nurse Pract, V14, P50; BOWDLER JE, 1989, NURSE PRACTITIONER, V14, P47; BOWDLER JE, 1989, NURSE PRACT, V14, P50; BREAKEY WR, 1989, JAMA-J AM MED ASSOC, V262, P1352, DOI 10.1001/jama.262.10.1352; BRICKNER PW, 1972, ANN INTERN MED, V77, P565, DOI 10.7326/0003-4819-77-4-565; BRICKNER PW, 1986, ANN INTERN MED, V104, P405, DOI 10.7326/0003-4819-104-3-405; CHRIST WR, 1989, SOC WORK HEALTH CARE, V14, P33, DOI 10.1300/J010v14n01_03; COHEN CI, 1988, J GERONTOL, V43, pS121, DOI 10.1093/geronj/43.4.S121; FISCHER PJ, 1986, AM J PUBLIC HEALTH, V76, P519, DOI 10.2105/AJPH.76.5.519; GELBERG L, 1989, JAMA-J AM MED ASSOC, V262, P1973, DOI 10.1001/jama.262.14.1973; LAMB HR, 1986, JAMA-J AM MED ASSOC, V256, P498, DOI 10.1001/jama.256.4.498; MARWICK C, 1985, JAMA-J AM MED ASSOC, V253, P1232, DOI 10.1001/jama.253.9.1232; MARWICK C, 1985, JAMA-J AM MED ASSOC, V253, P3217, DOI 10.1001/jama.253.22.3217; MORRIS W, 1989, WESTERN J MED, V151, P472; ROBERTSON MJ, 1986, AM J PUBLIC HEALTH, V76, P561, DOI 10.2105/AJPH.76.5.561; ROPERS RH, 1987, SOC SCI MED, V24, P669, DOI 10.1016/0277-9536(87)90310-8; ROSSI PH, 1987, SCIENCE, V235, P1336, DOI 10.1126/science.2950592; TORREY EF, 1990, HOSP COMMUNITY PSYCH, V41, P526; WLODARCZYK D, 1988, WESTERN J MED, V148, P717; 1990, DHHS901232 US DEP HL, P184; 1990, HOSPITAL STATISTICS, P62; 1990, STATE HAWAII DATA BO, P37	25	65	65	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					299	303		10.7326/0003-4819-116-4-299	http://dx.doi.org/10.7326/0003-4819-116-4-299			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	1733384				2022-12-01	WOS:A1992HD54600005
J	MOUKARZEL, AA; SONG, MK; BUCHMAN, AL; VARGAS, J; GUSS, W; MCDIARMID, S; REYEN, L; AMENT, ME				MOUKARZEL, AA; SONG, MK; BUCHMAN, AL; VARGAS, J; GUSS, W; MCDIARMID, S; REYEN, L; AMENT, ME			EXCESSIVE CHROMIUM INTAKE IN CHILDREN RECEIVING TOTAL PARENTERAL-NUTRITION	LANCET			English	Article							MILD PERIPHERAL NEUROPATHY; GLUCOSE-TOLERANCE; DEFICIENCY; SUPPLEMENTATION; SUFFICIENCY; VITAMINS; INFANTS; INSULIN; BLOOD; SERUM	Various expert bodies have recommended that the daily parental intake of chromium in children receiving total parenteral nutrition (TPN) should be 0.20-mu-g/kg. To test whether this-recommendation is appropriate, we assessed chromium intake, serum chromium concentrations, and renal function in 15 children receiving TPN. The median duration of TPN use was 9.5 (range 1.3-14) years. The children's glomerular filtration rate (GFR), measured by plasma clearance of indium-111-DTPA was lower than that of non-TPN controls (70 [SD 17) vs 110 [10] ml/min per 1.73 m2). The daily chromium intake averaged 0.15 (0.09) mu-g/kg daily but the serum chromium concentration was 20 (4 to 42) times higher than that of the controls (2.1 [1.2] vs 0.10 [0.03] mu-g/l; p < 0.0001). GFR was significantly inversely correlated with serum chromium concentration (r = -0.60, p < 0.02), daily chromium intake (r = -0.69, p <0.01), cumulative parenteral chromium intake (r = -0.72, p < 0.01), and TPN duration (r = -0.52, p < 0.05). We discontinued chromium supplementation of TPN solutions and reassessed the children a year later. Contaminating chromium concentrations were 1.0-1.8-mu-g/l in TPN solutions and 0.9-mu-g/l in fat emulsions. Drinking water contained 4.3-5.7-mu-g/l. Thus, the chromium intake without supplementation was only 0.05 (0.01) mu-g/kg daily. The mean serum chromium concentration fell to 0.50 (0.30) mu-g/l but was still significantly higher than that in the controls (p < 0.01). The GFR did not change significantly (65 [14] ml/min per 1.73 m2). No patient has shown signs of chromium deficiency. Although our patients were receiving less than the recommended chromium intake during supplementation, their high serum concentrations suggested excessive intake. The recommended parenteral chromium intake for children should be lowered.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,DIV PEDIAT GASTROENTEROL & NUTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								ANDERSON RA, 1989, SCI TOTAL ENVIRON, V86, P75, DOI 10.1016/0048-9697(89)90196-4; BROWN RO, 1986, DIGEST DIS SCI, V31, P661, DOI 10.1007/BF01318699; BYRNE WJ, 1979, SURG GYNECOL OBSTET, V149, P593; CASEY CE, 1984, BRIT J NUTR, V52, P73, DOI 10.1079/BJN19840072; CHASSON AL, 1961, AM J CLIN PATHOL, V35, P83, DOI 10.1093/ajcp/35.1_ts.83; ESPINAL J, 1987, NATURE, V328, P574, DOI 10.1038/328574a0; EVANS GW, 1973, BIOCHEM BIOPH RES CO, V50, P718, DOI 10.1016/0006-291X(73)91303-X; FREUND H, 1979, JAMA-J AM MED ASSOC, V241, P496, DOI 10.1001/jama.241.5.496; GHISOLFI J, 1984, JOURNEES PARISIENNES, P97; GREENE HL, 1988, AM J CLIN NUTR, V48, P1324; GURSON CT, 1971, AM J CLIN NUTR, V24, P1313; HAMBRIDGE KM, 1989, TXB GASTROENTEROLOGY, P398; HOPKINS LL, 1968, AM J CLIN NUTR, V21, P203, DOI 10.1093/ajcn/21.3.203; ITO Y, 1990, JPEN-PARENTER ENTER, V14, P610, DOI 10.1177/0148607190014006610; JEEJEEBHOY KN, 1977, AM J CLIN NUTR, V30, P531; KIEN CL, 1986, JPEN-PARENTER ENTER, V10, P662, DOI 10.1177/0148607186010006662; KUMPULAINEN J, 1980, AM J CLIN NUTR, V33, P2299, DOI 10.1093/ajcn/33.11.2299; MCDIARMID SV, 1990, TRANSPLANTATION, V49, P81, DOI 10.1097/00007890-199001000-00018; MERTZ W, 1969, PHYSIOL REV, V49, P163, DOI 10.1152/physrev.1969.49.2.163; MOORE MC, 1986, PEDIATRICS, V77, P530; RIALES R, 1981, AM J CLIN NUTR, V34, P2670, DOI 10.1093/ajcn/34.12.2670; SCHERMAIER AJ, 1985, CLIN CHIM ACTA, V152, P123, DOI 10.1016/0009-8981(85)90183-4; SCHROEDER HA, 1966, J NUTR, V88, P439, DOI 10.1093/jn/88.4.439; SCHWARZ K, 1959, ARCH BIOCHEM BIOPHYS, V85, P292, DOI 10.1016/0003-9861(59)90479-5; 1989, FOOD NUTRITION BOARD, P242; 1988, CHROMIUM ENV HLTH CR, P61; 1979, DIABETES, V28, P1039; 1979, JAMA-J AM MED ASSOC, V241, P2051	28	70	70	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1992	339	8790					385	388		10.1016/0140-6736(92)90078-H	http://dx.doi.org/10.1016/0140-6736(92)90078-H			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346659				2022-12-01	WOS:A1992HD65900003
J	MURCH, SH; BRAEGGER, CP; SESSA, WC; MACDONALD, TT				MURCH, SH; BRAEGGER, CP; SESSA, WC; MACDONALD, TT			HIGH ENDOTHELIN-1 IMMUNOREACTIVITY IN CROHNS-DISEASE AND ULCERATIVE-COLITIS	LANCET			English	Article							CELLS; REJECTION	Both immunological hypersensitivity and vascular abnormalities have been implicated in the pathogenesis of inflammatory bowel disease. In an attempt to link the two hypotheses, we sought evidence of local production of endothelin-1, a potent vasoconstrictor, in patients with Crohn's disease and ulcerative colitis. An immunohistochemical method was used to detect endothelin-1 in tissue samples from sixteen Crohn's disease patients, nine ulcerative colitis patients, and thirteen controls. In the controls, positively staining cells were infrequent in both lamina propria (mean 0.9% of total cells, 95% confidence interval 0.1-1.7%) and submucosa (2.3%, 0.4-4.1%). The percentage of endothelin-immunoreactive cells was significantly higher in the two disease groups than in the controls. Among the Crohn's disease patients, there were more immunoreactive cells in the submucosa than in the lamina propria (19.1%, 15.2-22.1% vs 12.3%, 8.1-16.5%, p < 0.001), whereas the converse was true for the ulcerative colitis group (8.6%, 1.1-16.1% vs 24.4%, 14.1-34.6%, p < 0.001). Immunoreactive macrophage aggregates around submucosal blood vessels were common in samples from Crohn's disease patients. Endothelin concentrations, measured by radioimmunoassay, in supernatants of homogenised tissue samples were significantly higher in Crohn's disease and ulcerative colitis than in controls. We suggest that local endothelin production by inflammatory cells may contribute to vasculitis in chronic inflammatory bowel disease by inducing intestinal ischaemia through vasoconstriction.	ST BARTHOLOMEWS HOSP, WILLIAM HARVEY RES INST, LONDON EC1A 7BE, ENGLAND	University of London; Queen Mary University London	MURCH, SH (corresponding author), ST BARTHOLOMEWS HOSP, COLL MED, DEPT PAEDIAT GASTROENTEROL, LONDON EC1A 7BE, ENGLAND.		Sessa, William C/B-6844-2011; Braegger, Christian Peter/ABC-9884-2021	Sessa, William C/0000-0001-5759-1938; Braegger, Christian/0000-0001-8069-9875	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMBROSIO G, 1991, J CLIN INVEST, V87, P2056, DOI 10.1172/JCI115236; BANERJEE AK, 1990, GASTROENTEROLOGY, V99, P1190, DOI 10.1016/0016-5085(90)90654-J; BUNCHMAN TE, 1991, J CLIN INVEST, V88, P310, DOI 10.1172/JCI115293; CHOY MY, 1990, GUT, V31, P1365, DOI 10.1136/gut.31.12.1365; EBINA T, 1990, JPN J CANCER RES, V81, P1307, DOI 10.1111/j.1349-7006.1990.tb02695.x; EHRENREICH H, 1990, J EXP MED, V172, P1741, DOI 10.1084/jem.172.6.1741; GASSEL AM, 1990, AM J CLIN PATHOL, V94, P274, DOI 10.1093/ajcp/94.3.274; HALSTENSEN TS, 1990, GASTROENTEROLOGY, V98, P1264, DOI 10.1016/0016-5085(90)90343-Y; HIOKI Y, 1991, BIOCHEM BIOPH RES CO, V174, P446, DOI 10.1016/0006-291X(91)91436-G; INAGAKI H, 1991, GASTROENTEROLOGY, V101, P47, DOI 10.1016/0016-5085(91)90458-W; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISAACSON PG, 1983, PRACTICAL APPLICATIO, P249; KAUFMAN DB, 1990, J EXP MED, V172, P291, DOI 10.1084/jem.172.1.291; KEICHO N, 1991, CELL IMMUNOL, V132, P285, DOI 10.1016/0008-8749(91)90028-A; LEHR HA, 1991, J CLIN INVEST, V87, P2036, DOI 10.1172/JCI115233; MACDONALD TT, 1990, CLIN EXP IMMUNOL, V81, P301; MURCH SH, 1991, GUT, V32, P913, DOI 10.1136/gut.32.8.913; OKADA K, 1990, BIOCHEM BIOPH RES CO, V171, P1192, DOI 10.1016/0006-291X(90)90811-Z; SANDERSON IR, 1987, ARCH DIS CHILD, V62, P123, DOI 10.1136/adc.62.2.123; SAWAMURA T, 1990, BIOCHEM BIOPH RES CO, V168, P1230, DOI 10.1016/0006-291X(90)91160-T; SESSA WC, 1991, BIOCHEM BIOPH RES CO, V174, P613, DOI 10.1016/0006-291X(91)91461-K; SESSA WC, IN PRESS J CARDIOVAS; SPRINGALL DR, 1991, LANCET, V337, P697, DOI 10.1016/0140-6736(91)90279-X; VANE JR, 1990, NEW ENGL J MED, V323, P27; VICAUT E, 1991, J CLIN INVEST, V87, P1537, DOI 10.1172/JCI115165; WAKEFIELD AJ, 1989, LANCET, V2, P1057; WAKEFIELD AJ, 1991, GASTROENTEROLOGY, V100, P1279; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOSHIZAWA T, 1989, NEUROSCI LETT, V102, P179, DOI 10.1016/0304-3940(89)90075-X; YOSHIZUMI M, 1990, BIOCHEM BIOPH RES CO, V166, P324, DOI 10.1016/0006-291X(90)91948-R	30	132	139	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 15	1992	339	8790					381	385		10.1016/0140-6736(92)90077-G	http://dx.doi.org/10.1016/0140-6736(92)90077-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346658				2022-12-01	WOS:A1992HD65900002
J	NEEDLEMAN, SW; SORACE, J; POUSSINROSILLO, H				NEEDLEMAN, SW; SORACE, J; POUSSINROSILLO, H			LOW-DOSE SPLENIC IRRADIATION IN THE TREATMENT OF AUTOIMMUNE THROMBOCYTOPENIA IN HIV-INFECTED PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Note						PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; HUMAN IMMUNODEFICIENCY VIRUS; PREDNISONE; THROMBOCYTOPENIA; RADIOTHERAPY; SPLENECTOMY	RISK	Autoimmune thrombocytopenic purpura (AITP) can complicate the course of human immunodeficiency virus type-1 (HIV)-infected patients. Treatment of these patients with prednisone is problematic because the drug is immunosuppressive. Other modalities are available, but patients often must have splenectomy, which yields effective long-term control comparable to that seen in AITP that is not associated with HIV infection. Splenectomy, however, exposes the patient to substantial perioperative morbidity and mortality. We reasoned that low-dose splenic irradiation may be an effective alternative to splenectomy and obviate the invasive complications of surgery. We present three patients who had splenic irradiation instead of splenectomy and tolerated it well. Howell-Jolly bodies did not appear at any time after the radiation, and durable remission of the AITP was achieved. We conclude that low-dose splenic irradiation may be a safe and effective alternative to splenectomy in HIV-infected patients who suffer from AITP, and that it should be studied further.	UNIV MARYLAND HOSP, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	NEEDLEMAN, SW (corresponding author), BALTIMORE DEPT VET AFFAIRS MED CTR, MED SERV 111, 3900 LOCH RAVEN BLVD, BALTIMORE, MD 21218 USA.							ABOULAFIA DM, 1991, HEMATOL ONCOL CLIN N, V5, P195, DOI 10.1016/S0889-8588(18)30436-2; KARPATKIN S, 1990, HEMATOL ONCOL CLIN N, V4, P193, DOI 10.1016/S0889-8588(18)30513-6; PIROFSKY B, 1975, CLIN HAEMATOL, V4, P167; ROBINETTE CD, 1977, LANCET, V2, P127; SAVONA S, 1985, ANN INTERN MED, V102, P737, DOI 10.7326/0003-4819-102-6-737; SHAFER RW, 1985, LANCET, V1, P934; STRICKER RB, 1985, NEW ENGL J MED, V313, P1375, DOI 10.1056/NEJM198511283132202; WALSH CM, 1984, NEW ENGL J MED, V311, P635, DOI 10.1056/NEJM198409063111004; WOLF BC, 1989, DISORDERS SPLEEN, P39; YU JR, 1986, J CLIN INVEST, V77, P1756, DOI 10.1172/JCI112498	10	11	11	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					310	311		10.7326/0003-4819-116-4-310	http://dx.doi.org/10.7326/0003-4819-116-4-310			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	1733386				2022-12-01	WOS:A1992HD54600007
J	RING, EJ; LAKE, JR; ROBERTS, JP; GORDON, RL; LABERGE, JM; READ, AE; STERNECK, MR; ASCHER, NL				RING, EJ; LAKE, JR; ROBERTS, JP; GORDON, RL; LABERGE, JM; READ, AE; STERNECK, MR; ASCHER, NL			USING TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNTS TO CONTROL VARICEAL BLEEDING BEFORE LIVER-TRANSPLANTATION	ANNALS OF INTERNAL MEDICINE			English	Article						PORTOSYSTEMIC SHUNT, SURGICAL; LIVER TRANSPLANTATION; ESOPHAGEAL AND GASTRIC VARICES; HEMORRHAGE, GASTROINTESTINAL; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT	PORTACAVAL-SHUNT; ENDOSCOPIC SCLEROTHERAPY; HEMORRHAGE; STENTS; MANAGEMENT	Objective: To determine the safety and efficacy of transjugular intrahepatic portosystemic shunts (TIPS) in controlling bleeding from esophageal varices in patients awaiting liver transplantation. Design: Prospective, uncontrolled trial. Setting: University medical center with an active liver transplant program. Patients: Thirteen patients referred for liver transplantation with either active variceal hemorrhage or recurrent variceal hemorrhage despite sclerotherapy; four patients had been previously treated with surgical portosystemic shunts. Intervention: An intrahepatic portosystemic shunt created via a transjugular approach to the hepatic veins using expandable, flexible metallic stents. Measurements: Portal pressures before and after the creation of the shunt, the direction of portal blood flow at differing diameters of the shunts, procedure-related complications, and outcome in terms of survival, liver transplantation, and recurrent variceal bleeding. Main Results: The transjugular intrahepatic portosystemic shunt was placed successfully in 13 patients, and bleeding was controlled acutely in all 13. After the procedure, the mean portal pressure decreased from 34 +/- 8.9 cm H2O to 22.4 +/- 5.4 cm H2O (P < 0.001). No complications were associated with the procedure; however, two patients died of causes unrelated to the procedure. Seven patients subsequently underwent liver transplantation and are doing well, and three patients are being managed conservatively. Bleeding recurred in one patient 102 days after the procedure secondary to shunt occlusion caused by neointimal proliferation. Conclusion: Placement of a transjugular intrahepatic portosystemic shunt is apparently safe and effective therapy for variceal hemorrhage in patients referred for liver transplantation.			RING, EJ (corresponding author), UNIV CALIF SAN FRANCISCO, BOX 0628, SAN FRANCISCO, CA 94143 USA.			Lake, John/0000-0002-4332-0528				CELLO JP, 1984, NEW ENGL J MED, V311, P1589, DOI 10.1056/NEJM198412203112501; COLAPINTO RF, 1982, CAN MED ASSOC J, V126, P267; CRASS RA, 1989, AM J SURG, V157, P476, DOI 10.1016/0002-9610(89)90638-7; DEFRANCHIS R, 1988, NEW ENGL J MED, V319, P983; IWATSUKI S, 1988, SURGERY, V104, P697; PALMAZ JC, 1986, AM J ROENTGENOL, V147, P1251, DOI 10.2214/ajr.147.6.1251; PALMAZ JC, 1985, AM J ROENTGENOL, V145, P821, DOI 10.2214/ajr.145.4.821; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; RICHTER GM, 1990, RADIOLOGY, V174, P1027, DOI 10.1148/radiology.174.3.174-3-1027; ROBERTS JP, 1991, TRANSPLANTATION, V52, P160, DOI 10.1097/00007890-199107000-00036; ROSCH J, 1987, RADIOLOGY, V162, P481; ROSCH J, 1969, RADIOLOGY, V92, P1112; RYPINS EB, 1990, SURG CLIN N AM, V70, P395; SARFEH IJ, 1986, SURGERY, V100, P52; TURRION VS, 1991, TRANSPLANT P, V23, P1570; WARREN WD, 1986, ANN SURG, V203, P454, DOI 10.1097/00000658-198605000-00002; ZEMEL G, 1991, JAMA-J AM MED ASSOC, V266, P390, DOI 10.1001/jama.266.3.390	17	230	229	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					304	309		10.7326/0003-4819-116-4-304	http://dx.doi.org/10.7326/0003-4819-116-4-304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	1733385				2022-12-01	WOS:A1992HD54600006
J	SALT, A; NOBLEJAMIESON, G; BARNES, ND; MOWAT, AP; ROLLES, K; JAMIESON, N; JOHNSTON, P; FRIEND, P; CALNE, RY				SALT, A; NOBLEJAMIESON, G; BARNES, ND; MOWAT, AP; ROLLES, K; JAMIESON, N; JOHNSTON, P; FRIEND, P; CALNE, RY			LIVER-TRANSPLANTATION IN 100 CHILDREN - CAMBRIDGE AND KINGS-COLLEGE-HOSPITAL SERIES	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CYTOMEGALO-VIRUS DISEASE; BILIARY ATRESIA; EXPERIENCE; REJECTION; GRAFT; THROMBOSIS; DEFICIENCY; SURGERY; KIDNEY; DONOR	Objective - To review the results of the Addenbrooke's and King's College Hospital children's liver transplantation programme. Design - Retrospective analysis of the first 100 children to receive liver grafts at Addenbrooke's Hospital, Cambridge, from December 1983 to March 1990. Setting - Addenbrooke's Hospital, Cambridge, and King's College Hospital, London. Subjects - 153 children assessed for liver transplantation, of whom 22 died before a donor became available and 31 were considered unsuitable. 100 children received grafts, of whom 27 had second grafts. Results - One year actuarial patient survival was 71%, with 57% one year graft survival. In the last two years survival rates had improved considerably, with 86% of patients and 63% of grafts surviving for at least one year. Sixty five children were alive 12 to 86 months after transplantation; 63 were well and leading normal active lives and 56 had entirely normal liver function. Children's growth and development were essentially normal, with many showing remarkable catch up growth. Conclusions - Liver transplantation offers children with terminal liver disease a high chance of a return to full quality life and normal development. Improved surgical and medical care have progressively improved survival. The timing of transplantation is critical but has been constrained particularly by the availability of donors and resources.	ADDENBROOKES HOSP, DEPT PAEDIAT, CAMBRIDGE CB2 2QQ, ENGLAND; UNIV LONDON KINGS COLL HOSP, PAEDIAT HEPATOL, LONDON SE5 8RX, ENGLAND; ADDENBROOKES HOSP, DEPT SURG, CAMBRIDGE CB2 2QQ, ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			Friend, Peter/AAH-6512-2019					ANDREWS WS, 1989, J PEDIATR SURG, V24, P77, DOI 10.1016/S0022-3468(89)80306-9; BISMUTH H, 1984, SURGERY, V95, P367; BROELSCH CE, 1988, TRANSPLANTATION, V45, P519, DOI 10.1097/00007890-198803000-00003; CALNE R, 1987, LIVER TRANSPLANTATIO; CALNE RY, 1976, ANN SURG, V184, P605, DOI 10.1097/00000658-197611000-00012; COULDEN RA, 1990, LANCET, V336, P273, DOI 10.1016/0140-6736(90)91804-J; DEHEMPTINNE B, 1987, TRANSPLANT P, V19, P3317; FOEGH ML, 1990, TRANSPL P, V22, P119; GARTNER JC, 1984, PEDIATRICS, V74, P140; HARPER PL, 1988, LANCET, V2, P924; HUBSCHER SG, 1991, TRANSPL P, V23, P1415; KALAYOGLU M, 1989, J PEDIATR SURG, V24, P70, DOI 10.1016/S0022-3468(89)80305-7; MAZZAFERRO V, 1989, TRANSPLANTATION, V47, P971, DOI 10.1097/00007890-198906000-00011; MCDONALD JA, 1989, TRANSPLANT P, V21, P3792; MIELIVERGANI G, 1989, LANCET, V1, P421; NOBLEJAMIESON G, 1990, ARCH DIS CHILD, V65, P1217, DOI 10.1136/adc.65.11.1217; OGUMA S, 1989, HEPATOLOGY, V9, P204, DOI 10.1002/hep.1840090207; OHI R, 1990, J PEDIATR SURG, V25, P442, DOI 10.1016/0022-3468(90)90390-U; OTTE JB, 1987, TRANSPLANT P, V19, P3289; PETT S, 1987, TRANSPLANT P, V19, P3256; ROLLES K, 1984, HEPATOLOGY, V4, pS50, DOI 10.1002/hep.1840040715; SALMELA K, 1990, TRANSPLANT P, V22, P238; SALT A, 1990, J CLIN PATHOL, V43, P63, DOI 10.1136/jcp.43.1.63; SAMUEL D, 1989, TRANSPLANT P, V21, P2225; SNYDMAN DR, 1987, NEW ENGL J MED, V317, P1049, DOI 10.1056/NEJM198710223171703; SOKAL EM, 1990, J PEDIATR-US, V117, P205, DOI 10.1016/S0022-3476(05)80531-1; STARZL TE, 1989, LANCET, V2, P1000; STARZL TE, 1979, PEDIATRICS, V63, P825; STARZL TE, 1968, ANN SURG, V168, P392, DOI 10.1097/00000658-196809000-00009; STRATTA RJ, 1989, ARCH SURG-CHICAGO, V124, P1443; WEIMAR W, 1990, TRANSPLANT P, V22, P229; 1984, HEPATOLOGY S, V4, P107	32	57	57	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 15	1992	304	6824					416	421		10.1136/bmj.304.6824.416	http://dx.doi.org/10.1136/bmj.304.6824.416			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE389	1547389	Green Published, Bronze			2022-12-01	WOS:A1992HE38900019
J	TABAR, L; FAGERBERG, G; DAY, NE; DUFFY, SW; KITCHIN, RM				TABAR, L; FAGERBERG, G; DAY, NE; DUFFY, SW; KITCHIN, RM			BREAST-CANCER-TREATMENT AND NATURAL-HISTORY - NEW INSIGHTS FROM RESULTS OF SCREENING	LANCET			English	Editorial Material							COMPARING TOTAL MASTECTOMY; TRIAL		MRC,BIOSTAT UNIT,CAMBRIDGE,ENGLAND; LINKOPING UNIV HOSP,DEPT DIAGNOST RADIOL,S-58185 LINKOPING,SWEDEN	MRC Biostatistics Unit; Linkoping University	TABAR, L (corresponding author), CENT HOSP FALUN,DEPT MAMMOG,S-79182 FALUN,SWEDEN.		Tabar, Laszlo Kornel/AGT-3287-2022					CHITTOOR SR, 1991, AM FAM PHYSICIAN, V44, P453; DUFFY SW, 1991, BRIT J CANCER, V64, P1133, DOI 10.1038/bjc.1991.477; FISHER B, 1991, LANCET, V338, P327, DOI 10.1016/0140-6736(91)90475-5; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; FISHER B, 1980, CANCER RES, V40, P3863; FISHER ER, 1988, CONTROVERSIES BREAST, P151; MEYER JS, 1991, INT J CANCER, V47, P213, DOI 10.1002/ijc.2910470209; ROSNER D, 1990, CANCER, V66, P199, DOI 10.1002/1097-0142(19900715)66:2<199::AID-CNCR2820660202>3.0.CO;2-L; TABAR L, 1989, J EPIDEMIOL COMMUN H, V43, P107, DOI 10.1136/jech.43.2.107; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; TABAR L, IN PRESS RADIOL CLIN; TUBIANA M, 1991, BREAST CANCER RES TR, V18, P125, DOI 10.1007/BF01990028; 1992, LANCET, V339, P71	14	139	140	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1992	339	8790					412	414		10.1016/0140-6736(92)90090-P	http://dx.doi.org/10.1016/0140-6736(92)90090-P			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346670				2022-12-01	WOS:A1992HD65900014
J	TEANBY, D				TEANBY, D			UNDERREPORTING OF PEDESTRIAN ROAD ACCIDENTS	BRITISH MEDICAL JOURNAL			English	Article								Road accidents to pedestrians caused 1706 deaths and 58 374 injuries in Great Britain during 1989.(1) These figures and other data used for road planning and safety campaigns are derived from accident data supplied by the police. I assessed the completeness of police recording by comparing their figures on accidents to pedestrians with data from a regional database of trauma care.			TEANBY, D (corresponding author), WARRINGTON GEN HOSP,MERSEY REG TRAUMA SURVEY,WARRINGTON WA5 1QG,ENGLAND.							BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; 1990, ROAD ACCIDENTS GREAT, P47	2	7	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1992	304	6824					422	422		10.1136/bmj.304.6824.422	http://dx.doi.org/10.1136/bmj.304.6824.422			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE389	1637379	Green Published, Bronze			2022-12-01	WOS:A1992HE38900021
J	UCHIGATA, Y; KUWATA, S; TOKUNAGA, K; EGUCHI, Y; TAKAYAMAHASUMI, S; MIYAMOTO, M; OMORI, Y; JUJI, T; HIRATA, Y				UCHIGATA, Y; KUWATA, S; TOKUNAGA, K; EGUCHI, Y; TAKAYAMAHASUMI, S; MIYAMOTO, M; OMORI, Y; JUJI, T; HIRATA, Y			STRONG ASSOCIATION OF INSULIN AUTOIMMUNE SYNDROME WITH HLA-DR4	LANCET			English	Note								Insulin autoimmune syndrome is characterised by spontaneous hypoglycaemia without evidence of exogenous insulin administration, a high serum concentration of total immunoreactive insulin, and the presence of insulin autoantibodies in high titre. HLA typing of 27 patients with insulin autoimmune syndrome showed that all had DR4, which was present in only 43% of 51 healthy controls (odds ratio 72.1, p < 2 x l0(-6), and 19 (70%) of the patients were positive for the allelic combination, Cw4, Bw62, and DR4. Analysis of the nucleotide sequences of the DRB1, DQA1, and DQB1 genes showed that all the patients had DRB1*0406, DQA1*0301, and DQB1*0302, compared with only 14% of the controls (odds ratio 281, p < 1 x 10(-10)). We conclude that the development of insulin autoimmune syndrome is associated with a strong genetic predisposition.	UNIV TOKYO,FAC MED,DEPT TRANSFUS MED & IMMUNOHEMATOL,TOKYO 113,JAPAN	University of Tokyo	UCHIGATA, Y (corresponding author), TOKYO WOMENS MED COLL,CTR DIABET,8-1 KAWADA CHO,SHINJUKU KU,TOKYO 162,JAPAN.							BRONSTEIN I, 1989, NATURE, V338, P599, DOI 10.1038/338599a0; EGUCHI Y, 1989, Journal of the Japan Diabetes Society, V32, P887; HIRATA Y, 1983, LANCET, V2, P1037; Hirata Y., 1987, HYPOGLYCEMIA, P105; Hirata Y, 1970, J JPN DIABET SOC, V13, P312; PALMER JP, 1987, DIABETES METAB REV, V3, P1005, DOI 10.1002/dmr.5610030409; TOKUNAGA K, 1985, IMMUNOGENETICS, V22, P359, DOI 10.1007/BF00430919; WILKIN TJ, 1987, HYPOGLYCEMIA, P119; ZIEGLER R, 1991, DIABETES, V40, P709, DOI 10.2337/diabetes.40.6.709	9	83	96	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1992	339	8790					393	394		10.1016/0140-6736(92)90080-M	http://dx.doi.org/10.1016/0140-6736(92)90080-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346661				2022-12-01	WOS:A1992HD65900005
J	WELLS, VD; WONG, ES; MURRAY, BE; COUDRON, PE; WILLIAMS, DS; MARKOWITZ, SM				WELLS, VD; WONG, ES; MURRAY, BE; COUDRON, PE; WILLIAMS, DS; MARKOWITZ, SM			INFECTIONS DUE TO BETA-LACTAMASE-PRODUCING, HIGH-LEVEL GENTAMICIN-RESISTANT ENTEROCOCCUS-FAECALIS	ANNALS OF INTERNAL MEDICINE			English	Article						ENTEROCOCCUS-FAECALIS; BETA-LACTAMASES; DRUG RESISTANCE, MICROBIAL; GENTAMICINS; CROSS INFECTION; DISEASE OUTBREAKS; COMMUNICABLE DISEASE CONTROL	STREPTOCOCCUS-FAECALIS; ENDOCARDITIS; STRAINS	Objective: To investigate the risk factors, clinical features, molecular epidemiology, and treatment outcomes associated with an outbreak of infections due to beta-lactamase-producing, high-level gentamicin-resistant Enterococcus faecalis. Design: Case-control and molecular genetics study. Setting: Tertiary care Veterans Affairs hospital. Patients: Sixty-five patients infected or colonized with beta-lactamase-producing high-level gentamicin-resistant E. faecalis (case patients) were matched and compared with 65 randomly selected patients infected or colonized with beta-lactamase-negative, gentamicin-susceptible E. faecalis. Measurements and Main Results: During the 20-month study period, 124 of 1506 isolates (8.2%) of E. faecalis from 70 patients were found to produce beta-lactamase. Univariate analysis showed older age, higher APACHE II score, nosocomial acquisition, recent surgical procedure, total parenteral nutrition, and antibiotic treatment to be significantly associated with the acquisition of beta-lactamase-producing, high-level gentamicin-resistant E. faecalis. A multivariate analysis, done using stepwise multiple logistic regressions, showed that only two variables remained significant: an APACHE II score > 6 (odds ratio, 9.5; 95% Cl, 4.4 to 20.3) and antibiotic treatment (odds ratio, 10.2; Cl, 4.5 to 23.2). The mortality rate for case patients was 7.7% (5 of 65 patients; Cl, 1.2% to 14.2%); no control patient died. Of 23 infections occurring in case patients, 13 were treated with "inappropriate" antibiotics (regimens that included a beta-lactamase-unstable antibiotic); 2 patients improved and 11 had complete resolution of disease. "Appropriate" treatments (regimens that included a beta-lactamase-stable antibiotic) were used in 10 patients; 5 of 10 infections were fatal. Restriction enzyme digests of total chromosomal DNA showed nearly identical patterns for selected isolates of beta-lactamase-producing, high-level gentamicin-resistant E. faecalis, suggesting dissemination through the hospital of a single strain of E. faecalis. Conclusions: Fatal infections were observed despite treatment with beta-lactamase-stable antibiotics. The risk for infection or colonization with beta-lactamase-producing, high-level gentamicin-resistant E. faecalis was strongly associated with severe underlying disease (acute physiology and chronic health evaluation [APACHE] II score, > 6) and previous antibiotic treatment. These results may be useful in targeting high-risk patients for infection-control interventions.	DEPT VET AFFAIRS MED CTR, INFECT DIS SECT 111C, 1201 BROAD ROCK BLVD, RICHMOND, VA 23249 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DIV INFECT DIS, RICHMOND, VA 23298 USA; UNIV TEXAS, HLTH SCI CTR, PROGRAM INFECT DIS & CLIN MICROBIOL, HOUSTON, TX 77225 USA	Hunter Holmes McGuire Veterinary Affairs Medical Center; Virginia Commonwealth University; University of Texas System; University of Texas Health Science Center Houston								[Anonymous], 1982, EPIDEMIOLOGIC RES; BUSH LM, 1988, ANTIMICROB AGENTS CH, V32, P877, DOI 10.1128/AAC.32.6.877; DOUGHERTY SH, 1983, ARCH SURG-CHICAGO, V118, P232; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; HOFFMANN SA, 1987, ANN INTERN MED, V106, P757, DOI 10.7326/0003-4819-106-5-757; Hosmer D, 2013, APPL LOGISTIC REGRES; INGERMAN M, 1987, J INFECT DIS, V155, P1226, DOI 10.1093/infdis/155.6.1226; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MARKOWITZ SM, 1991, ANTIMICROB AGENTS CH, V35, P1075, DOI 10.1128/AAC.35.6.1075; MURRAY BE, 1986, ANTIMICROB AGENTS CH, V30, P861, DOI 10.1128/AAC.30.6.861; MURRAY BE, 1990, J CLIN MICROBIOL, V28, P2059, DOI 10.1128/JCM.28.9.2059-2063.1990; MURRAY BE, 1983, J CLIN INVEST, V72, P1168, DOI 10.1172/JCI111042; PATTERSON JE, 1988, ANTIMICROB AGENTS CH, V32, P122, DOI 10.1128/AAC.32.1.122; PATTERSON JE, 1990, ANTIMICROB AGENTS CH, V34, P302, DOI 10.1128/AAC.34.2.302; PATTERSON JE, 1989, ANTIMICROB AGENTS CH, V33, P251, DOI 10.1128/AAC.33.2.251; PATTERSON JE, 1988, J INFECT DIS, V158, P1144, DOI 10.1093/infdis/158.5.1144; RHINEHART E, 1990, NEW ENGL J MED, V323, P1814, DOI 10.1056/NEJM199012273232606; ZERVOS MJ, 1986, J INFECT DIS, V153, P1075, DOI 10.1093/infdis/153.6.1075; 1983, MMWR S455, V32, P155; 1985, PROC IML VERSION 5	20	83	85	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					285	292		10.7326/0003-4819-116-4-285	http://dx.doi.org/10.7326/0003-4819-116-4-285			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	1733382				2022-12-01	WOS:A1992HD54600003
J	ETTEHADIEH, E; SANGHERA, JS; PELECH, SL; HESSBIENZ, D; WATTS, J; SHASTRI, N; AEBERSOLD, R				ETTEHADIEH, E; SANGHERA, JS; PELECH, SL; HESSBIENZ, D; WATTS, J; SHASTRI, N; AEBERSOLD, R			TYROSYL PHOSPHORYLATION AND ACTIVATION OF MAP KINASES BY P56LCK	SCIENCE			English	Article							SERINE-THREONINE KINASE; CELL-CYCLE CONTROL; PROTEIN-KINASE; LYMPHOCYTES-T; CD4 RECEPTOR; CYTOPLASMIC DOMAINS; INSULIN; STIMULATION; MATURATION; COMPLEXES	T cell signaling via the CD4 surface antigen is mediated by the associated tyrosyl protein kinase p56lck. The 42-kilodalton mitogen-activated protein (MAP) kinase (p42mapk) was tyrosyl-phosphorylated and activated after treatment of the murine T lymphoma cell line 171CD4+, which expresses CD4, with antibody to CD3. Treatment of the CD4-deficient cell line 171 with the same antibody did not result in phosphorylation or activation of p42mapk. Purified p56lck both tyrosyl-phosphorylated and stimulated the seryl-threonyl phosphotransferase activity of purified p44mpk, a MAP kinase isoform from sea star oocytes. A synthetic peptide modeled after the putative regulatory phosphorylation site in murine p42mapk (Tyr185) was phosphorylated by p56lck with a similar V(max), but a fivefold lower Michaelis constant (K(m)) than a peptide containing the Tyr394 autophosphorylation site from p56lck. MAP kinases may participate in protein kinase cascades that link Src family protein-tyrosyl kinases to seryl-threonyl kinases such as those encoded by rsk and raf, which are putative substrates of MAP kinases.	UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER V6T 1Z3, BC, CANADA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; UNIV BRITISH COLUMBIA, DEPT BIOCHEM, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT MED, VANCOUVER V6T 1Z3, BC, CANADA	University of British Columbia; University of California System; University of California Berkeley; University of British Columbia; University of British Columbia					PHS HHS [R126604] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHN NG, 1991, J BIOL CHEM, V256, P11487; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDERSON P, 1988, J IMMUNOL, V140, P1732; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAREST D, IN PRESS; CHUCK RS, 1990, P NATL ACAD SCI USA, V87, P5021, DOI 10.1073/pnas.87.13.5021; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTH Y, 1991, EMBO J, V10, P2661; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; HOSHI M, 1988, J BIOL CHEM, V263, P5396; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; NEL AE, 1991, J IMMUNOL, V147, P1933; NEL AE, 1990, J IMMUNOL, V145, P971; NEL AE, 1990, J IMMUNOL, V144, P2683; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; PELECH SL, 1988, DEV BIOL, V130, P28, DOI 10.1016/0012-1606(88)90410-1; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROBEY E, 1990, CELL, V60, P697, DOI 10.1016/0092-8674(90)90082-P; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RUDD CE, 1989, IMMUNOL REV, V111, P225, DOI 10.1111/j.1600-065X.1989.tb00548.x; SANGHERA J, UNPUB; SANGHERA JS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P153, DOI 10.1016/0167-4889(91)90078-C; SANGHERA JS, 1991, J BIOL CHEM, V266, P6700; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WATTS JD, 1992, IN PRESS J BIOL CHEM	48	138	141	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 14	1992	255	5046					853	855		10.1126/science.1311128	http://dx.doi.org/10.1126/science.1311128			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD548	1311128				2022-12-01	WOS:A1992HD54800039
J	KAINZ, M; ROBERTS, J				KAINZ, M; ROBERTS, J			STRUCTURE OF TRANSCRIPTION ELONGATION COMPLEXES INVIVO	SCIENCE			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; TERNARY COMPLEXES; PROMOTER DNA; ANTITERMINATION; INITIATION; METHYLATION; MECHANISM; PROTEIN	The opening of duplex DNA in the elongation phase of transcription by Escherichia coli RNA polymerase in vivo was detected at a regulatory site where a prolonged pause in transcription occurs. Single-stranded DNA in the transcription bubble was identified by its reactivity with potassium permanganate (KMnO4). The elongation structure in vivo was similar to that of transcription complexes made in vitro with some differences. The observed reactivity to KMnO4 of the DNA template strand was consistent with the existence of an RNA-DNA hybrid of about 12 nucleotides.			KAINZ, M (corresponding author), CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,BIOTECHNOL BLDG,ITHACA,NY 14853, USA.				NIGMS NIH HHS [GM 21941] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021941, R37GM021941] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARAK S, 1987, CELL, V50, P885; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; GUO HC, 1991, J BACTERIOL, V173, P1554, DOI 10.1128/jb.173.4.1554-1560.1991; HANNA MM, 1983, P NATL ACAD SCI-BIOL, V80, P4238, DOI 10.1073/pnas.80.14.4238; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; KAINZ M, UNPUB; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SHI YB, 1988, J MOL BIOL, V199, P277, DOI 10.1016/0022-2836(88)90314-2; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; WAGNER LA, 1990, NUCLEIC ACIDS RES, V18, P3529, DOI 10.1093/nar/18.12.3529; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; YANG X, 1988, THESIS CORNELL U; YANG XJ, 1989, J MOL BIOL, V210, P453, DOI 10.1016/0022-2836(89)90122-8; YANG XJ, 1987, GENE DEV, V1, P217, DOI 10.1101/gad.1.3.217	22	90	90	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1992	255	5046					838	841		10.1126/science.1536008	http://dx.doi.org/10.1126/science.1536008			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD548	1536008				2022-12-01	WOS:A1992HD54800034
J	MARAHRENS, Y; STILLMAN, B				MARAHRENS, Y; STILLMAN, B			A YEAST CHROMOSOMAL ORIGIN OF DNA-REPLICATION DEFINED BY MULTIPLE FUNCTIONAL ELEMENTS	SCIENCE			English	Article							RIBOSOMAL-PROTEIN GENES; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATOR; CONSENSUS SEQUENCE; BINDING PROTEIN; SILENCER; ARS; PURIFICATION; PLASMIDS; INITIATION	Although it has been demonstrated that discrete origins of DNA replication exist in eukaryotic cellular chromosomes, the detailed organization of a eukaryotic cellular origin remains to bc determined. Linker substitution mutations were constructed across the entire Saccharomyces cerevisiae chromosomal origin, ARS1. Functional studies of these mutants revealed one essential clement (A), which includes a match to the ARS consensus sequence, and three additional elements (B1, B2, and B3), which collectively are also essential for origin function. These four elements arranged exactly as in ARS1, but surrounded by completely unrelated sequence, functioned as an efficient origin. Element B3 is the binding site for the transcription factor-origin binding protein ABF1. Other transcription factor binding sites substitute for the B3 element and a trans-acting transcriptional activation domain is required. The multipartite nature of a chromosomal replication origin and the role of transcriptional activators in its function present a striking similarity to the organization of eukaryotic promoters.	SUNY STONY BROOK, GRAD PROGRAM MOLEC & CELLULAR BIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	MARAHRENS, Y (corresponding author), COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA.			Stillman, Bruce/0000-0002-9453-4091	NIAID NIH HHS [AI20460] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020460, R37AI020460] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; BARU M, 1991, J VIROL, V65, P3496, DOI 10.1128/JVI.65.7.3496-3503.1991; BENNETTCOOK ER, 1991, EMBO J, V10, P959, DOI 10.1002/j.1460-2075.1991.tb08030.x; BOUTON AH, 1986, MOL CELL BIOL, V6, P2354, DOI 10.1128/MCB.6.7.2354; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BROACH JR, 1982, COLD SPRING HARB SYM, V47, P1165, DOI 10.1101/SQB.1983.047.01.132; BUCHMAN AR, 1990, MOL CELL BIOL, V10, P887, DOI 10.1128/MCB.10.3.887; CELNIKER SE, 1984, MOL CELL BIOL, V4, P2455, DOI 10.1128/MCB.4.11.2455; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; DANI GM, 1983, P NATL ACAD SCI-BIOL, V80, P3406, DOI 10.1073/pnas.80.11.3406; DELLASETA F, 1990, MOL CELL BIOL, V10, P2437, DOI 10.1128/MCB.10.5.2437; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DEVILLIERS J, 1984, NATURE, V312, P242, DOI 10.1038/312242a0; DIFFLEY JFX, 1990, TRENDS GENET, V6, P427, DOI 10.1016/0168-9525(90)90305-P; DIFFLEY JFX, 1989, SCIENCE, V246, P1034, DOI 10.1126/science.2511628; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; DORSMAN JC, 1989, NUCLEIC ACIDS RES, V17, P4917, DOI 10.1093/nar/17.13.4917; DUBEY DD, 1991, MOL CELL BIOL, V11, P5346, DOI 10.1128/MCB.11.10.5346; EISENBERG S, 1988, P NATL ACAD SCI USA, V85, P743, DOI 10.1073/pnas.85.3.743; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; FANGMAN WL, 1983, CELL, V32, P831, DOI 10.1016/0092-8674(83)90069-7; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; FITZGERALDHAYES M, 1982, CELL, V29, P235, DOI 10.1016/0092-8674(82)90108-8; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; HALFTER H, 1989, EMBO J, V8, P3029, DOI 10.1002/j.1460-2075.1989.tb08453.x; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; HOFMANN JFX, 1991, CELL, V64, P951, DOI 10.1016/0092-8674(91)90319-T; HOLMES SG, 1989, MOL CELL BIOL, V9, P5464, DOI 10.1128/MCB.9.12.5464; HSIAO CL, 1979, P NATL ACAD SCI USA, V76, P3829, DOI 10.1073/pnas.76.8.3829; HUBERMAN JA, 1988, NUCLEIC ACIDS RES, V16, P6373, DOI 10.1093/nar/16.14.6373; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; KUNO K, 1990, GENE, V95, P73, DOI 10.1016/0378-1119(90)90415-N; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LOHR D, 1988, BIOCHEMISTRY-US, V27, P3961, DOI 10.1021/bi00411a011; LONG CM, 1985, MOL CELL BIOL, V5, P3124, DOI 10.1128/MCB.5.11.3124; MARAHRENS Y, UNPUB; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MCNALLY FJ, 1991, MOL CELL BIOL, V11, P5648, DOI 10.1128/MCB.11.11.5648; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MURRAY AW, 1983, NATURE, V305, P189, DOI 10.1038/305189a0; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; ORRWEAVER TL, 1989, EMBO J, V8, P4153, DOI 10.1002/j.1460-2075.1989.tb08600.x; PALZKILL TG, 1988, CELL, V53, P441, DOI 10.1016/0092-8674(88)90164-X; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; SHORE D, 1987, EMBO J, V6, P461, DOI 10.1002/j.1460-2075.1987.tb04776.x; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; SNYDER M, 1986, NATURE, V324, P87, DOI 10.1038/324087a0; SRIENC F, 1985, MOL CELL BIOL, V5, P1676, DOI 10.1128/MCB.5.7.1676; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; SWEDER KS, 1988, J BIOL CHEM, V263, P17270; THOMA F, 1984, J MOL BIOL, V177, P715, DOI 10.1016/0022-2836(84)90046-9; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; UMEK RM, 1988, CELL, V52, P559, DOI 10.1016/0092-8674(88)90469-2; VANHOUTEN JV, 1990, MOL CELL BIOL, V10, P3917, DOI 10.1128/MCB.10.8.3917; WALKER SS, 1991, NUCLEIC ACIDS RES, V19, P6255, DOI 10.1093/nar/19.22.6255; WALKER SS, 1990, P NATL ACAD SCI USA, V87, P4665, DOI 10.1073/pnas.87.12.4665; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S	70	507	515	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 14	1992	255	5046					817	823		10.1126/science.1536007	http://dx.doi.org/10.1126/science.1536007			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD548	1536007				2022-12-01	WOS:A1992HD54800028
J	RISCH, N				RISCH, N			GENETIC-LINKAGE - INTERPRETING LOD SCORES	SCIENCE			English	Editorial Material							FAMILIAL ALZHEIMERS-DISEASE; BREAST-CANCER; ONSET		YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510	Yale University	RISCH, N (corresponding author), YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06510, USA.				NHGRI NIH HHS [HG00348] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000348] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; BISHOP DT, 1988, GENET EPIDEMIOL, V5, P151, DOI 10.1002/gepi.1370050303; CLAUS EB, 1991, AM J HUM GENET, V48, P232; CLERGETDARPOUX F, 1986, BIOMETRICS, V42, P393, DOI 10.2307/2531059; ELSTON RC, 1975, ANN HUM GENET, V38, P341, DOI 10.1111/j.1469-1809.1975.tb00619.x; FAJANS SS, 1990, DIABETES CARE, V13, P49, DOI 10.2337/diacare.13.1.49; GOATE AM, 1989, LANCET, V1, P352; GREENBERG DA, 1989, GENET EPIDEMIOL, V6, P259, DOI 10.1002/gepi.1370060145; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HALL JM, 1989, AM J HUM GENET, V44, P577; MORTON NE, 1955, AM J HUM GENET, V7, P277; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P1; OTT J, 1985, ANAL HUMAN GENETIC L; RISCH N, 1990, GENET EPIDEMIOL, V7, P3, DOI 10.1002/gepi.1370070103; RISCH N, 1990, AM J HUM GENET, V46, P222; RISCH N, 1991, AM J HUM GENET, V48, P1058; RISCH N, IN PRESS HUM HERED; SCHELLENBERG GD, 1988, SCIENCE, V241, P1507, DOI 10.1126/science.3420406; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; STGEORGEHYSLOP PH, 1990, NATURE, V347, P194, DOI 10.1038/347194a0; TATTERSALL RB, 1975, DIABETES, V24, P44, DOI 10.2337/diabetes.24.1.44; WILLIAMS W R, 1984, Genetic Epidemiology, V1, P7, DOI 10.1002/gepi.1370010104	22	65	83	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1992	255	5046					803	804		10.1126/science.1536004	http://dx.doi.org/10.1126/science.1536004			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD548	1536004				2022-12-01	WOS:A1992HD54800025
J	SHAM, JSK; CLEEMANN, L; MORAD, M				SHAM, JSK; CLEEMANN, L; MORAD, M			GATING OF THE CARDIAC CA2+ RELEASE CHANNEL - THE ROLE OF NA+ CURRENT AND NA+-CA2+ EXCHANGE	SCIENCE			English	Article							SODIUM-CALCIUM EXCHANGE; SARCOPLASMIC-RETICULUM; GUINEA-PIG; ACTIVATES CONTRACTION; VENTRICULAR MYOCYTES; CA-2+ RELEASE; PURKINJE-CELL; HEART-MUSCLE; VOLTAGE; INACTIVATION	In cardiac myocytes, calcium influx through the calcium channel is the primary pathway for triggering calcium release. Recently it has been suggested that the calcium-induced calcium release mechanism can also be activated indirectly by the sodium current, which elevates the sodium concentration under the cell membrane, thereby favoring the entry of "trigger" calcium via the sodium-calcium exchanger. To test this hypothesis, sodium current was suppressed by reducing the external sodium concentration or applying tetrodotoxin. At potentials positive to -30 millivolts, calcium release was unaffected. A small calcium release at more negative potentials could be attributed to partial activation of calcium channels, because it was unaltered by replacement of sodium with lithium and was blocked by cadmium. Thus, sodium influx or its accumulation does not initiate calcium release. In addition, sodium-calcium exchange-related calcium release at potentials positive to +80 millivolts has slower kinetics than calcium channel-induced release. Therefore, only the calcium channel gates the fast release of calcium from the sarcoplasmic reticulum in the range of the action potential.	UNIV PENN, DEPT PHYSIOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania				Sham, James/0000-0002-3571-8712	NHLBI NIH HHS [HL-16152, HL-07400] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016152] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADRIAN RH, 1973, J PHYSIOL-LONDON, V235, P103, DOI 10.1113/jphysiol.1973.sp010380; Baker P F, 1972, Prog Biophys Mol Biol, V24, P177, DOI 10.1016/0079-6107(72)90007-7; BERS DM, 1990, AM J PHYSIOL, V258, pC944, DOI 10.1152/ajpcell.1990.258.5.C944; BEUCKELMANN DJ, 1989, J PHYSIOL-LONDON, V414, P499, DOI 10.1113/jphysiol.1989.sp017700; BEUCKELMANN DJ, 1988, J PHYSIOL-LONDON, V405, P233, DOI 10.1113/jphysiol.1988.sp017331; BROWN AM, 1981, J PHYSIOL-LONDON, V318, P455; CALLEWAERT G, 1988, P NATL ACAD SCI USA, V85, P2009, DOI 10.1073/pnas.85.6.2009; CLEEMANN L, 1991, J PHYSIOL-LONDON, V432, P283, DOI 10.1113/jphysiol.1991.sp018385; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FABIATO A, 1985, J GEN PHYSIOL, V85, P291, DOI 10.1085/jgp.85.2.291; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; HILLE B, 1972, J GEN PHYSIOL, V59, P637, DOI 10.1085/jgp.59.6.637; JOHNSON EA, 1991, SCIENCE, V251, P1370, DOI 10.1126/science.1848371; KIMURA J, 1987, J PHYSIOL-LONDON, V384, P199, DOI 10.1113/jphysiol.1987.sp016450; LANSMAN JB, 1986, J GEN PHYSIOL, V88, P321, DOI 10.1085/jgp.88.3.321; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LEDERER WJ, 1990, SCIENCE, V248, P283, DOI 10.1126/science.2326638; MITRA R, 1985, AM J PHYSIOL, V249, P1056, DOI 10.1152/ajpheart.1985.249.5.H1056; MORAD M, 1983, NATURE, V304, P635, DOI 10.1038/304635a0; NABAUER M, 1990, AM J PHYSIOL, V258, pC189, DOI 10.1152/ajpcell.1990.258.1.C189; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; NIGGLI E, 1990, SCIENCE, V250, P565, DOI 10.1126/science.2173135; NILIUS B, 1988, J PHYSIOL-LONDON, V399, P537; PEACHEY LD, 1973, STRUCTURE FUNCTION M, V3, P1; VALDEOLMILLOS M, 1989, PFLUG ARCH EUR J PHY, V413, P676, DOI 10.1007/BF00581820	26	149	154	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 14	1992	255	5046					850	853		10.1126/science.1311127	http://dx.doi.org/10.1126/science.1311127			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD548	1311127				2022-12-01	WOS:A1992HD54800038
J	SWAIN, A; COFFIN, JM				SWAIN, A; COFFIN, JM			MECHANISM OF TRANSDUCTION BY RETROVIRUSES	SCIENCE			English	Article							SINGLE REPLICATION CYCLE; ROUS-SARCOMA VIRUS; MUTATIONAL HOTSPOTS; BROAD-SPECTRUM; SHUTTLE VECTOR; ONCOGENE; RNA; POLYADENYLATION; HYPERMUTATIONS; SEQUENCE	Retroviruses can capture cellular sequences and express them as oncogenes. Capture has been proposed to be a consequence of the inefficiency of polyadenylation of the viral genome that allows the packaging of cellular sequences flanking the integrated provirus in virions; after transfer into virions, these sequences could be incorporated into the viral genome by illegitimate recombination during reverse transcription. As a test for this hypothesis, a tissue culture system was developed that mimics the transduction process and allows the analysis and quantitation of capture events in a single step. In this model transduction of sequences adjacent to a provirus depends on the formation of readthrough transcripts and their transmission in virions and leads to various recombinant structures whose formation is independent of sequence similarity at the crossover site. Thus, all events in the transduction process can be attributed to the action of reverse transcriptase on readthrough transcripts without involving deletions of cellular DNA.	TUFTS UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,136 HARRISON AVE,BOSTON,MA 02111	Tufts University					NCI NIH HHS [R35 CA 44385] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044385] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; DOGGETT DL, 1989, J VIROL, V63, P2108, DOI 10.1128/JVI.63.5.2108-2117.1989; Frohman MA, 1990, PCR PROTOCOLS GUIDE, P28; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; GOLDFARB MP, 1981, J VIROL, V38, P136, DOI 10.1128/JVI.38.1.136-150.1981; HERMAN SA, 1986, J VIROL, V60, P497, DOI 10.1128/JVI.60.2.497-505.1986; HERMAN SA, 1987, SCIENCE, V236, P845, DOI 10.1126/science.3033828; HUANG CC, 1986, CELL, V44, P935, DOI 10.1016/0092-8674(86)90016-4; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Maniatis T., 1982, MOL CLONING; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6024, DOI 10.1073/pnas.87.16.6024; RAINES MA, 1988, J VIROL, V62, P2437, DOI 10.1128/JVI.62.7.2437-2443.1988; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SEALY L, 1983, VIROLOGY, V130, P155, DOI 10.1016/0042-6822(83)90125-3; SKOLNIKDAVID H, 1987, GENE DEV, V1, P672, DOI 10.1101/gad.1.7.672; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; SWAIN A, 1989, J VIROL, V63, P3301, DOI 10.1128/JVI.63.8.3301-3306.1989; SWANSTROM R, 1983, P NATL ACAD SCI-BIOL, V80, P2519, DOI 10.1073/pnas.80.9.2519; Weiss R, 1985, RNA TUMOR VIRUSES	22	118	120	3	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1992	255	5046					841	845		10.1126/science.1371365	http://dx.doi.org/10.1126/science.1371365			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD548	1371365				2022-12-01	WOS:A1992HD54800035
J	VONHIPPEL, PH; YAGER, TD				VONHIPPEL, PH; YAGER, TD			THE ELONGATION-TERMINATION DECISION IN TRANSCRIPTION	SCIENCE			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; TERNARY COMPLEXES; CHAIN ELONGATION; FACTOR-RHO; KINETICS	At any template position, the decision to extend the transcript by one residue or to release the nascent RNA represents a kinetic competition between elongation and termination pathways. This competition is discussed in terms of alternative Eyring transition state barriers; changes in termination efficiency correspond to small changes in the relative heights of these barriers. Elongation complexes are stable at nonterminator positions; a model is presented to explain the destabilization of these complexes at intrinsic termination sites. Functionally analogous effects can operate at rho-dependent terminators. Mechanisms for modulation of termination efficiency by regulatory proteins are described.	UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon	VONHIPPEL, PH (corresponding author), UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403, USA.			von Hippel, Peter H./0000-0003-2512-8097	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015792, R37GM015792, R01GM029158] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-15792, GM-29158] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS C, 1985, J BIOL CHEM, V260, P5826; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; GILL SC, 1990, BIOPHYS CHEM, V37, P239; JIN D, IN PRESS P NATL ACAD; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; MORGAN WD, 1983, J BIOL CHEM, V258, P9565; RHODES G, 1974, J BIOL CHEM, V249, P6675; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; VONHIPPEL PH, 1991, P NATL ACAD SCI USA, V88, P2307, DOI 10.1073/pnas.88.6.2307; WHELAN WL, UNPUB; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YAGER TD, 1987, CELLULAR MOL BIOL, P1241; YAGER TD, UNPUB; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301	15	85	85	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1992	255	5046					809	812		10.1126/science.1536005	http://dx.doi.org/10.1126/science.1536005			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD548	1536005				2022-12-01	WOS:A1992HD54800026
J	ADAMS, MD; DUBNICK, M; KERLAVAGE, AR; MORENO, R; KELLEY, JM; UTTERBACK, TR; NAGLE, JW; FIELDS, C; VENTER, JC				ADAMS, MD; DUBNICK, M; KERLAVAGE, AR; MORENO, R; KELLEY, JM; UTTERBACK, TR; NAGLE, JW; FIELDS, C; VENTER, JC			SEQUENCE IDENTIFICATION OF 2,375 HUMAN BRAIN GENES	NATURE			English	Article							CDNA CLONING; PROTEIN	WE recently described a new approach for the rapid characterization of expressed genes by partial DNA sequencing to generate 'expressed sequence tags' 1. From a set of 600 human brain complementary DNA clones, 348 were informative nuclear-encoded messenger RNAs. We have now partially sequenced 2,672 new, independent cDNA clones isolated from four human brain cDNA libraries to generate 2,375 expressed sequence tags to nuclear-encoded genes. These sequences, together with 348 brain expressed sequence tags from our previous study, comprise more than 2,500 new human genes and 870,769 base pairs of DNA sequence. These data represent an approximate doubling of the number of human genes identified by DNA sequencing and may represent as many as 5% of the genes in the human genome.	NINCDS,RECEPTOR BIOCHEM & MOLEC BIOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)				Kerlavage, Anthony/0000-0002-3954-9653; Fields, Chris/0000-0002-4812-0744				ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARKER WC, 1991, NUCLEIC ACIDS RES, V19, P2231, DOI 10.1093/nar/19.suppl.2231; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CASERO RA, 1991, J BIOL CHEM, V266, P810; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FANNING TG, 1987, BIOCHIM BIOPHYS ACTA, V910, P203, DOI 10.1016/0167-4781(87)90112-6; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; GALAU G, 1977, ARCH BIOCHEM BIOPHYS, V197, P584; HOOG C, 1991, NUCLEIC ACIDS RES, V19, P6123, DOI 10.1093/nar/19.22.6123; KAMHOLZ J, 1986, P NATL ACAD SCI USA, V83, P4962, DOI 10.1073/pnas.83.13.4962; MCKUSICK VA, 1991, FASEB J, V5, P12, DOI 10.1096/fasebj.5.1.1991580; PAULSON KE, 1985, NATURE, V316, P3259; RAO Y, 1990, NATURE, V345, P163, DOI 10.1038/345163a0; RUBENSTEIN J, NUCLEIC ACIDS RES, V18, P4833; SCHMID CW, 1982, SCIENCE, V216, P1065, DOI 10.1126/science.6281889; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V	19	742	823	2	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					632	634		10.1038/355632a0	http://dx.doi.org/10.1038/355632a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1538749				2022-12-01	WOS:A1992HD54700053
J	ATTAYA, M; JAMESON, S; MARTINEZ, CK; HERMEL, E; ALDRICH, C; FORMAN, J; LINDAHL, KF; BEVAN, MJ; MONACO, JJ				ATTAYA, M; JAMESON, S; MARTINEZ, CK; HERMEL, E; ALDRICH, C; FORMAN, J; LINDAHL, KF; BEVAN, MJ; MONACO, JJ			HAM-2 CORRECTS THE CLASS-I ANTIGEN-PROCESSING DEFECT IN RMA-S CELLS	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCLONAL-ANTIBODIES; VIRAL PEPTIDES; LYMPHOCYTES-T; MHC; MOLECULES; REGION; GENE; DETERMINANT; EXPRESSION	THE murine major histocompatibility complex (MHC) contains two genes (Ham-1 and Ham-2) that encode members of a super-family of ATP-dependent transport proteins 1,2. These genes are believed to mediate the transport of peptide antigen from the cytoplasm into the lumen of the endoplasmic reticulum for binding by MHC class I molecules. Evidence for such a function has come from the rescue of class I surface expression by a cloned copy of the human homologue of Ham-1, PSF-1, in a human cell line that is defective in antigen processing 3. A mutant murine cell line, RMA-S, has an identical antigen-processing-defective phenotype 4,5. Here we show that expression of a cloned copy of the Ham-2 gene in RMA-S cells results in recovery of the ability to process and present class I-restricted antigens to cytotoxic T lymphocytes, and in partial recovery of class I surface expression. Processing defects for classical (H-2 K and D) and non-classical (Qa1 and HMT) class I molecules are corrected by Ham-2. These data indicate that both MHC-linked transporter genes are probably required for class I antigen processing, and that the functional transporter in this pathway may consist of a Ham-1/Ham-2 heterodimer.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL & IMMUNOL,RICHMOND,VA 23298; UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235; UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,GRAD IMMUNOL PROGRAM,DALLAS,TX 75235	Virginia Commonwealth University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Jameson, Stephen C/D-9892-2013	Jameson, Stephen C/0000-0001-9137-1146				ALDRICH CJ, 1988, IMMUNOGENETICS, V28, P334, DOI 10.1007/BF00364232; CARBONE FR, 1988, J EXP MED, V167, P1767, DOI 10.1084/jem.167.6.1767; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CHO SG, 1991, P NATL ACAD SCI USA, V88, P5197, DOI 10.1073/pnas.88.12.5197; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; HERMEL E, 1991, INT IMMUNOL, V3, P407, DOI 10.1093/intimm/3.4.407; HOSKEN NA, 1989, J IMMUNOL, V142, P1079; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; HOSKEN NA, IN PRESS J EXP MED; JONES B, 1981, NATURE, V292, P547, DOI 10.1038/292547a0; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Kohler G., 1981, IMMUNE SYSTEM, V2, P202; LEMKE H, 1979, IMMUNOL REV, V47, P175, DOI 10.1111/j.1600-065X.1979.tb00293.x; LINDAHL KF, 1986, J EXP MED, V163, P334, DOI 10.1084/jem.163.2.334; LINDAHL KF, 1991, ANNU REV IMMUNOL, V9, P351, DOI 10.1146/annurev.iy.09.040191.002031; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MONACO J, IN PRESS J IMMUN RES; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; NIKOLICZUGIC J, 1990, EUR J IMMUNOL, V20, P2431, DOI 10.1002/eji.1830201111; OZATO K, 1980, J IMMUNOL, V125, P2473; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; ROCK KL, 1991, CELL, V65, P611, DOI 10.1016/0092-8674(91)90093-E; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P4200, DOI 10.1073/pnas.88.10.4200; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TADA N, 1980, IMMUNOGENETICS, V11, P441, DOI 10.1007/BF01567813; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0	31	295	301	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					647	649		10.1038/355647a0	http://dx.doi.org/10.1038/355647a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1538753				2022-12-01	WOS:A1992HD54700059
J	BALDWIN, CT; HOTH, CF; AMOS, JA; DASILVA, EO; MILUNSKY, A				BALDWIN, CT; HOTH, CF; AMOS, JA; DASILVA, EO; MILUNSKY, A			AN EXONIC MUTATION IN THE HUP2 PAIRED DOMAIN GENE CAUSES WAARDENBURG SYNDROME	NATURE			English	Article							SYNDROME TYPE-I; MOUSE; DNA; BOX	HERE We report the identification and characterization of a gene defect causing Waardenburg's syndrome with hearing loss in a large Brazilian family. This demonstrates a mutation causing Waardenburg's syndrome as well as a mutation causing a form of congenital deafness. The mutation was found in the HuP2 gene, a member of the paired domain family of proteins that bind DNA and regulate gene expression 1. The mutation occurred in 100% of the cases with the disease in this family and was absent in a random sample of 50 unrelated control subjects. Identification of the Waardenburg's syndrome gene and future characterization of its gene product is likely to increase our understanding of the pathogenesis of this disorder and may allow prevention of deafness of this type.	BOSTON UNIV, SCH MED, CTR HUMAN GENET, 80 E CONCORD ST, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02118 USA; FED UNIV PUERNAMBUCO, INST MATERNOINFANTIL PERNAMBUCO, RECIFE, PE, BRAZIL; FED UNIV PUERNAMBUCO, DEPT GENET, RECIFE, PE, BRAZIL	Boston University; Boston University				Milunsky, Aubrey/0000-0003-2114-4823; Baldwin, Clinton/0000-0002-3275-9463				ASHER JH, 1990, J MED GENET, V27, P618, DOI 10.1136/jmg.27.10.618; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BOPP D, 1989, EMBO J, V8, P3447, DOI 10.1002/j.1460-2075.1989.tb08509.x; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; DASILVA EO, 1991, AM J MED GENET, V40, P65, DOI 10.1002/ajmg.1320400113; EPSTEIN D, 1991, CELL, V67, P1; FOY C, 1990, AM J HUM GENET, V46, P1017; GANGULY A, 1991, J BIOL CHEM, V266, P12035; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HAGEMAN MJ, 1977, AM J HUM GENET, V29, P468; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; ISHIKIRIYAMA S, 1989, AM J MED GENET, V33, P505, DOI 10.1002/ajmg.1320330419; PROCKOP DJ, 1990, ADV HUM GENET, V19, P105; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALKI RK, 1966, SCIENCE, V80, P222; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; Tsui LC, 1991, CURR OPIN GENET DEV, V1, P4, DOI 10.1016/0959-437X(91)80032-H; WAARDENBURG PJ, 1951, AM J HUM GENET, V3, P195; WHITE MB, 1990, NATURE, V344, P665, DOI 10.1038/344665a0; White R, 1991, CURR OPIN GENET DEV, V1, P15, DOI 10.1016/0959-437X(91)80034-J	22	428	434	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 13	1992	355	6361					637	638		10.1038/355637a0	http://dx.doi.org/10.1038/355637a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1347149				2022-12-01	WOS:A1992HD54700055
J	BIRD, H				BIRD, H			AN AFFAIR OF THE HEART	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1992	326	7					487	488		10.1056/NEJM199202133260712	http://dx.doi.org/10.1056/NEJM199202133260712			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD164	1732777				2022-12-01	WOS:A1992HD16400012
J	GRIFFITH, JP; GRIFFITH, DL; RAYMENT, I; MURAKAMI, WT; CASPAR, DLD				GRIFFITH, JP; GRIFFITH, DL; RAYMENT, I; MURAKAMI, WT; CASPAR, DLD			INSIDE POLYOMAVIRUS AT 25-A RESOLUTION	NATURE			English	Article							SIMIAN VIRUS-40; MINICHROMOSOMES; INVITRO; VP1	EMPTY capsids and complete virions of polyomavirus crystallize isomorphously 1. Here we use difference Fourier analysis of X-ray diffraction data at 25-angstrom resolution from these crystals to obtain an electron-density map of the inside of the virion. The polyomavirus capsid is built from 72 pentamers of VP1 that form three different types of connections in the T = 7d icosahedral surface lattice 2. Self-assembly of purified recombinant VP1 into capsid-like aggregates 3,4 has shown that switching of the bonding specificity to form the unanticipated 5 non-equivalent connections is an inherent property of the VP1 pentamers. Our map of the inside of the virion displays 72 prongs of electron density extending from the core into the axial cavities of the VP1 pentamers. We identify these prongs with the VP2 and VP3 molecules, which may function to guide the assembly of the highly ordered capsid on the nucleohistone core. The atomic structure of the closely related simian virus-40 capsid has been determined from the high-resolution diffraction data 6. Our polyomavirus map, calculated using all the low-resolution diffraction data, shows no indication of regular order inside the spherical core.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254; BRANDEIS UNIV,GRAD DEPT BIOCHEM,WALTHAM,MA 02254	Brandeis University; Brandeis University			rayment, ivan/A-2720-2008	rayment, ivan/0000-0001-9279-7835				ADOLPH KW, 1979, SCIENCE, V203, P1117, DOI 10.1126/science.218286; AMBROSE C, 1987, NUCLEIC ACIDS RES, V15, P3703, DOI 10.1093/nar/15.9.3703; BAKER TS, 1988, P NATL ACAD SCI USA, V85, P422, DOI 10.1073/pnas.85.2.422; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; CLEVER J, 1991, VIROLOGY, V181, P78, DOI 10.1016/0042-6822(91)90472-N; COLE CN, 1977, J VIROL, V24, P277, DOI 10.1128/JVI.24.1.277-294.1977; DUBOCHET J, 1986, EMBO J, V5, P519, DOI 10.1002/j.1460-2075.1986.tb04241.x; GHARAKHANIAN E, 1988, P NATL ACAD SCI USA, V85, P6607, DOI 10.1073/pnas.85.18.6607; KRAUZEWICZ N, 1990, J VIROL, V64, P4414, DOI 10.1128/JVI.64.9.4414-4420.1990; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; LIN W, 1984, J VIROL, V50, P363, DOI 10.1128/JVI.50.2.363-371.1984; MONTROSS L, 1991, J VIROL, V65, P4991, DOI 10.1128/JVI.65.9.4991-4998.1991; RAYMENT I, 1983, ACTA CRYSTALLOGR B, V39, P505, DOI 10.1107/S0108768183002785; RAYMENT I, 1983, ACTA CRYSTALLOGR A, V39, P102, DOI 10.1107/S0108767383000197; RAYMENT I, 1982, NATURE, V295, P110, DOI 10.1038/295110a0; SALUNKE DM, 1989, BIOPHYS J, V56, P887, DOI 10.1016/S0006-3495(89)82735-3; SALUNKE DM, 1986, CELL, V46, P895, DOI 10.1016/0092-8674(86)90071-1; Tooze J., 1981, COLD SPRING HARB MON, Vsecond	18	89	93	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					652	654		10.1038/355652a0	http://dx.doi.org/10.1038/355652a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1311415				2022-12-01	WOS:A1992HD54700061
J	JUKES, TH				JUKES, TH			TODAYS NON-ORWELLIAN ANIMAL FARM	NATURE			English	Editorial Material											JUKES, TH (corresponding author), UNIV CALIF BERKELEY,DEPT INTEGRAT BIOL,BERKELEY,CA 94720, USA.							LASLEY FA, 1988, US BROILER IND; Lepkovsky S, 1935, Science, V82, P326, DOI 10.1126/science.82.2127.326; POND WG, 1983, SCI AM, V249, P96; SINGER P, 1991, NATURE, V353, P613, DOI 10.1038/353613a0	4	4	4	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					582	582		10.1038/355582a0	http://dx.doi.org/10.1038/355582a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1538742				2022-12-01	WOS:A1992HD54700018
J	KELLY, A; POWIS, SH; KERR, LA; MOCKRIDGE, I; ELLIOTT, T; BASTIN, J; UCHANSKAZIEGLER, B; ZIEGLER, A; TROWSDALE, J; TOWNSEND, A				KELLY, A; POWIS, SH; KERR, LA; MOCKRIDGE, I; ELLIOTT, T; BASTIN, J; UCHANSKAZIEGLER, B; ZIEGLER, A; TROWSDALE, J; TOWNSEND, A			ASSEMBLY AND FUNCTION OF THE 2 ABC TRANSPORTER PROTEINS ENCODED IN THE HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX	NATURE			English	Article							TOXIC LYMPHOCYTES-T; CLASS-II REGION; HLA-B ANTIGENS; MONOCLONAL-ANTIBODY; INFLUENZA NUCLEOPROTEIN; MULTIDRUG RESISTANCE; MOLECULAR ANALYSIS; CYSTIC-FIBROSIS; HEAVY-CHAINS; MHC	PRESENTATION Of Cytoplasmic antigens to class I-restricted cytotoxic T cells implied the existence of a specialized peptide transporter 1-3 (reviewed in ref. 4). For most class I heavy chains, association with peptides of the appropriate length is required for stable assembly with beta-2-microglobulin 5-11. Mutant cells RMA-S (ref. 12) and .174/T2 (refs 13, 14) neither assemble stable class I molecules nor present intracellular antigens, and we have suggested that they have lost a function required for the transport of short peptides from the cytosol to the endoplasmic reticulum 5-7. The genetic defect in .174 has been localized to a large deletion in the class II region of the major histocompatibility complex 6,15,16, within which two genes (RING4 and RING11) have been identified that code for 'ABC' (ATP-binding cassette) transporters 15,17-21. We report here that the protein products of these two genes assemble to form a complex. Defects in either protein result in the formation of unstable class I molecules and loss of presentation of intracellular antigens. The molecular defect in a new mutant, BM36.1, is shown to be in the ATP-binding domain of the RING11/PSF2 protein. This is in contrast to the mutant .134 (ref. 15), which lacks the RING4/PSF1 protein.	JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND; FREE UNIV BERLIN,KLINIKUM RUDOLF VIRCHOW,INST EXPTL ONKOL & TRANSPLANTAT MED,W-1000 BERLIN 19,GERMANY	University of Oxford; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	KELLY, A (corresponding author), IMPERIAL CANC RES FUND,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.			Townsend, Alain/0000-0002-3702-0107				BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; ERLICH H, 1986, HUM IMMUNOL, V16, P205, DOI 10.1016/0198-8859(86)90049-2; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; GOULD K, 1989, J EXP MED, V170, P1051, DOI 10.1084/jem.170.3.1051; HAYNES BF, 1982, HUM IMMUNOL, V4, P273, DOI 10.1016/0198-8859(82)90001-5; HIGGINS CF, 1990, PHILOS T R SOC B, V326, P353, DOI 10.1098/rstb.1990.0017; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LJUNGGREN HG, 1989, J IMMUNOL, V142, P2911; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; PARHAM P, 1979, J IMMUNOL, V123, P342; POWIS SH, IN PRESS P NATN ACAD; RADKA SF, 1982, J IMMUNOL, V128, P2804; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; SMITH MEF, 1989, P NATL ACAD SCI USA, V86, P5557, DOI 10.1073/pnas.86.14.5557; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SPRING B, 1985, IMMUNOGENETICS, V21, P277, DOI 10.1007/BF00375380; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VOLZ A, IN PRESS CYTOGENET C; WHITTON JL, 1989, J EXP MED, V170, P1033, DOI 10.1084/jem.170.3.1033; ZIEGLER A, 1985, IMMUNOBIOLOGY, V169, P455, DOI 10.1016/S0171-2985(85)80001-2	33	403	407	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					641	644		10.1038/355641a0	http://dx.doi.org/10.1038/355641a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1538751				2022-12-01	WOS:A1992HD54700057
J	LOMBARDI, V; PIAZZESI, G; LINARI, M				LOMBARDI, V; PIAZZESI, G; LINARI, M			RAPID REGENERATION OF THE ACTIN MYOSIN POWER STROKE IN CONTRACTING MUSCLE	NATURE			English	Article							STRIATED-MUSCLE; FIBERS; LENGTH; REFLECTIONS; DIFFRACTION; STIFFNESS; TENSION	AT the molecular level, muscle contraction is the result of cyclic interaction between myosin crossbridges, which extend from the thick filament, and the thin filament, which consists mainly of actin. The energy for work done by a single crossbridge during a cycle of attachment, generation of force, shortening and detachment is believed to be coupled to the hydrolysis of one molecule of ATP 1,2. The distance the actin filament slides relative to the myosin filament in one crossbridge cycle has been estimated as 12 nm by step-length perturbation studies on single fibres from frog muscle 3,4. The 'mechanical' power stroke of the attached crossbridge can therefore be defined as 12-nm shortening with a force profile like that shown by the quick recovery of force following a length perturbation. According to this definition, power strokes cannot be repeated faster than the overall ATPase rate. Here, however, we show that the power stroke can be regenerated much faster than expected from the ATPase rate. This contradiction can be resolved if, in the shortening muscle, the free energy of ATP hydrolysis is used in several actin-myosin interactions consisting of elementary power strokes each of 5-10 nm.			LOMBARDI, V (corresponding author), UNIV FLORENCE,DIPARTIMENTO SCI FISIOL,VIALE GB MORGAGNI 63,I-50134 FLORENCE,ITALY.			LINARI, MARCO/0000-0001-6512-4897				CECCHI G, 1987, PFLUG ARCH EUR J PHY, V409, P39, DOI 10.1007/BF00584747; Cecchi G, 1976, Boll Soc Ital Biol Sper, V52, P733; CECCHI G, 1983, J PHYSIOL-LONDON, V345, pP146; FORD LE, 1977, J PHYSIOL-LONDON, V269, P441, DOI 10.1113/jphysiol.1977.sp011911; FORD LE, 1981, J PHYSIOL-LONDON, V311, P219, DOI 10.1113/jphysiol.1981.sp013582; GOLMAN YE, 1977, J PHYSIOL-LONDON, V269, pP55; HOMSHER E, 1984, CONTRACTILE MECH MUS, P865; HUXLEY AF, 1981, J PHYSIOL-LONDON, V317, pP12; HUXLEY AF, 1980, J PHYSIOL-LONDON, V305, pP15; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1983, J MOL BIOL, V169, P469, DOI 10.1016/S0022-2836(83)80062-X; HUXLEY HE, 1980, NATURE, V284, P140, DOI 10.1038/284140a0; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; KUSHMERICK MJ, 1969, PROC R SOC SER B-BIO, V174, P315, DOI 10.1098/rspb.1969.0096; LOMBARDI V, 1990, J PHYSIOL-LONDON, V431, P141, DOI 10.1113/jphysiol.1990.sp018324; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P617; MATSUBARA I, 1975, NATURE, V255, P728, DOI 10.1038/255728a0; PIAZZESI G, 1992, J PHYSIOL-LONDON, V445, P659, DOI 10.1113/jphysiol.1992.sp018945; Woledge RC., 1985, ENERGETIC ASPECTS MU; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0	20	183	185	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					638	641		10.1038/355638a0	http://dx.doi.org/10.1038/355638a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1538750				2022-12-01	WOS:A1992HD54700056
J	MEDORI, R; TRITSCHLER, HJ; LEBLANC, A; VILLARE, F; MANETTO, V; CHEN, HY; XUE, R; LEAL, S; MONTAGNA, P; CORTELLI, P; TINUPER, P; AVONI, P; MOCHI, M; BARUZZI, A; HAUW, JJ; OTT, J; LUGARESI, E; AUTILIOGAMBETTI, L; GAMBETTI, P				MEDORI, R; TRITSCHLER, HJ; LEBLANC, A; VILLARE, F; MANETTO, V; CHEN, HY; XUE, R; LEAL, S; MONTAGNA, P; CORTELLI, P; TINUPER, P; AVONI, P; MOCHI, M; BARUZZI, A; HAUW, JJ; OTT, J; LUGARESI, E; AUTILIOGAMBETTI, L; GAMBETTI, P			FATAL FAMILIAL INSOMNIA, A PRION DISEASE WITH A MUTATION AT CODON-178 OF THE PRION PROTEIN GENE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CREUTZFELDT-JAKOB DISEASE; SCRAPIE PRION	Background. We previously described two members of a family affected by an apparently genetically determined fatal disease characterized clinically by progressive insomnia, dysautonomia, and motor signs and characterized pathologically by severe atrophy of the anterior ventral and mediodorsal thalamic nuclei. Five other family members who died of this disease, which we termed "fatal familial insomnia," had broader neuropathologic changes suggesting that fatal familial insomnia could be a prion disease. Methods. We used antibodies to prion protein (PrP) to perform dot and Western blot analyses, with and without proteinase K, on brain tissue obtained at autopsy from two patients with fatal familial insomnia, three patients with sporadic Creutzfeldt-Jakob disease, and six control subjects. The coding region of the PrP gene was amplified and sequenced in the samples from the two patients with fatal familial insomnia. Restriction-enzyme analysis was carried out with amplified PrP DNA from 33 members of the kindred. Results. Protease-resistant PrP was found in both patients with fatal familial insomnia, but the size and number of protease-resistant fragments differed from those in Creutzfeldt-Jakob disease. In the family with fatal familial insomnia, all 4 affected members and 11 of the 29 unaffected members had a point mutation in PrP codon 178 that results in the substitution of asparagine for aspartic acid and elimination of the Tth111 I restriction site. Linkage analysis showed a close relation between the point mutation and the disease (maximal lod score, 3.4 when theta was zero). Conclusions. Fatal familial insomnia is a prion disease with a mutation in codon 178 of the PrP gene, but the disease phenotype seems to differ from that of previously described kindreds with the same point mutation.	CASE WESTERN RESERVE UNIV,INST PATHOL,DIV NEUROPATHOL,2085 ADELBERT RD,CLEVELAND,OH 44106; COLUMBIA UNIV,DEPT PSYCHIAT,NEW YORK,NY 10027; NEUROL INST,BOLOGNA,ITALY; HOP LA PITIE SALPETRIERE,NEUROL CLIN,F-75651 PARIS 13,FRANCE; HOP LA PITIE SALPETRIERE,LAB NEUROPATHOL R ESCOUROLLE,F-75651 PARIS 13,FRANCE	Case Western Reserve University; Columbia University; IRCCS Istituto delle Scienze Neurologiche di Bologna (ISNB); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite			Avoni, Patrizia/AAC-1879-2020; Tinuper, Paolo/AAB-7760-2020; Cortelli, Pietro/K-6063-2016	tinuper, paolo/0000-0002-0588-3063; Cortelli, Pietro/0000-0002-3633-8818; AVONI, PATRIZIA/0000-0003-0719-6803	NHGRI NIH HHS [R01 HG000008, UM1 HG006493] Funding Source: Medline; NIA NIH HHS [AG-08992, AG-08012] Funding Source: Medline; NINDS NIH HHS [NS-14509] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [UM1HG006493, R01HG000008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014509] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG008012, R35AG008992] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAKER HF, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92953-Y; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BROWN P, 1991, LANCET, V337, P1019, DOI 10.1016/0140-6736(91)92670-W; FRIEDE RL, 1964, ARCH NEUROL-CHICAGO, V10, P181, DOI 10.1001/archneur.1964.00460140067009; GOLDFARB LG, 1991, LANCET, V337, P425, DOI 10.1016/0140-6736(91)91198-4; GOLDFARB LG, 1992, ANN NEUROL, V31, P274, DOI 10.1002/ana.410310308; GOLDGABER D, 1989, EXP NEUROL, V106, P204, DOI 10.1016/0014-4886(89)90095-2; GUIDON G, 1978, THESIS U RENNES RENN; HALTIA M, 1979, Journal of the Neurological Sciences, V42, P381, DOI 10.1016/0022-510X(79)90171-0; HIRAI T, 1989, BRAIN RES REV, V14, P1, DOI 10.1016/0165-0173(89)90007-6; HSIAO KK, 1991, NEUROLOGY, V41, P681, DOI 10.1212/WNL.41.5.681; KITAMOTO T, 1988, AM J PATHOL, V131, P435; KITAMOTO T, 1991, BRAIN RES, V545, P319, DOI 10.1016/0006-8993(91)91306-L; KOVANEN J, 1988, ACTA NEUROL SCAND, V77, P474, DOI 10.1111/j.1600-0404.1988.tb05943.x; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LUGARESI E, 1986, NEW ENGL J MED, V315, P997, DOI 10.1056/NEJM198610163151605; MANETTO V, IN PRESS NEUROLOGY; Maniatis T., 1982, MOL CLONING; MASTERS CL, 1981, BRAIN, V104, P535, DOI 10.1093/brain/104.3.535; MAY WW, 1968, ARCH NEUROL-CHICAGO, V19, P137, DOI 10.1001/archneur.1968.00480020023002; NIETO A, 1991, LANCET, V337, P622, DOI 10.1016/0140-6736(91)91696-R; OWEN F, 1990, MOL BRAIN RES, V7, P273, DOI 10.1016/0169-328X(90)90038-F; OWEN F, 1991, EXP NEUROL, V112, P240, DOI 10.1016/0014-4886(91)90075-N; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; WEXLER NS, 1991, ANNU REV NEUROSCI, V14, P503, DOI 10.1146/annurev.neuro.14.1.503	27	497	544	1	48	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1992	326	7					444	449		10.1056/NEJM199202133260704	http://dx.doi.org/10.1056/NEJM199202133260704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD164	1346338	Green Accepted			2022-12-01	WOS:A1992HD16400004
J	SPIES, T; CERUNDOLO, V; COLONNA, M; CRESSWELL, P; TOWNSEND, A; DEMARS, R				SPIES, T; CERUNDOLO, V; COLONNA, M; CRESSWELL, P; TOWNSEND, A; DEMARS, R			PRESENTATION OF VIRAL-ANTIGEN BY MHC CLASS-I MOLECULES IS DEPENDENT ON A PUTATIVE PEPTIDE TRANSPORTER HETERODIMER	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; TOXIC LYMPHOCYTES-T; HLA-B ANTIGENS; ASSOCIATION; PROTEIN; RECOGNITION; PATHWAY; INVITRO; REGION; CELLS	MAJOR histocompatibility complex (MHC) class I molecules present peptides derived from the endogenous protein pool to cytotoxic T lymphocytes, which can thus recognize intracellular antigen 1-3 . This pathway may depend on a transporter (PSF1) (refs 4-6) to mediate entry of the cytosolic peptides into a pre-Golgi compartment where they bind to class I heavy chains and promote their stable assembly with beta-2-microglobulin 7-12. There is, however, only indirect support for this function of PSF1 (ref. 6). Here we show that PSF1 is necessary for the efficient assembly of class I molecules and enables them to present a peptide epitope derived from endogenously synthesized viral antigen. Immunochemical and genetic data demonstrate that the PSF1 polypeptide is associated with a complementary transporter chain, which is polymorphic and is encoded by the PSF2 gene 13, which is closely linked to PSF1.	JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND; IST NAZL RIC CANC,I-16132 GENOA,ITALY; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510; UNIV WISCONSIN,GENET LAB,MADISON,WI 53706	University of Oxford; University of Genoa; IRCCS AOU San Martino IST; Yale University; University of Wisconsin System; University of Wisconsin Madison	SPIES, T (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,44 BINNEY ST,BOSTON,MA 02115, USA.			Townsend, Alain/0000-0002-3702-0107; Cerundolo, Vincenzo/0000-0003-0040-3793; Colonna, Marco/0000-0001-5222-4987				ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.biochem.59.1.253; BRODSKY FM, 1979, IMMUNOL REV, V47, P3, DOI 10.1111/j.1600-065X.1979.tb00288.x; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; HYDE SC, 1990, NATURE, V346, P263; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; LEACH R, 1986, P NATL ACAD SCI USA, V83, P3909, DOI 10.1073/pnas.83.11.3909; LJUNGGREN HG, 1990, NATURE, V346, P478; MARKS MS, 1990, J CELL BIOL, V111, P839, DOI 10.1083/jcb.111.3.839; MELLINS E, 1991, J EXP MED, V174, P1607, DOI 10.1084/jem.174.6.1607; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SWEETSER MT, 1989, NATURE, V342, P180, DOI 10.1038/342180a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; WALKER BD, 1989, P NATL ACAD SCI USA, V86, P9514, DOI 10.1073/pnas.86.23.9514; WAYS JP, 1986, J IMMUNOL, V137, P217; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266	28	330	331	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					644	646		10.1038/355644a0	http://dx.doi.org/10.1038/355644a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1538752				2022-12-01	WOS:A1992HD54700058
J	TASSABEHJI, M; READ, AP; NEWTON, VE; HARRIS, R; BALLING, R; GRUSS, P; STRACHAN, T				TASSABEHJI, M; READ, AP; NEWTON, VE; HARRIS, R; BALLING, R; GRUSS, P; STRACHAN, T			WAARDENBURG SYNDROME PATIENTS HAVE MUTATIONS IN THE HUMAN HOMOLOG OF THE PAX-3 PAIRED BOX GENE	NATURE			English	Article							CONSERVATION; DOMAIN; MOUSE	WAARDENBURG'S syndrome (WS) is an autosomal dominant combination of deafness and pigmentary disturbances, probably caused by defective function of the embryonic neural crest 1,2. We have mapped one gene for WS to the distal part of chromosome 2 (ref. 3). On the basis of their homologous chromosomal location, their close linkage to an alkaline phosphatase gene, and their related phenotype, we suggested that WS and the mouse mutant Splotch 4,5 might be homologous. Splotch is caused by mutation in the mouse Pax-3 gene 6,7. This gene is one of a family of eight Pax genes known in mice which are involved in regulating embryonic development; each contains a highly conserved transcription control sequence, the paired box 8. Here we show that some families with WS have mutations in the human homologue 9 of Pax-3. Mutations in a related gene, Pax-6, which, like Pax-3, has both a paired box and a paired-type homeobox sequence, cause the Small-eye mutation in mice 10 and aniridia in man 11. Thus mutations in the Pax genes are important causes of human developmental defects.	UNIV MANCHESTER,ST MARYS HOSP,DEPT MED GENET,MANCHESTER M13 0JH,LANCS,ENGLAND; MAX PLANCK INST IMMUNBIOL,W-7800 FREIBURG,GERMANY; UNIV MANCHESTER,CTR AUDIOL,MANCHESTER M13 9PL,LANCS,ENGLAND; MAX PLANCK INST BIOPHYS CHEM,W-3400 GOTTINGEN,GERMANY	University of Manchester; Max Planck Society; University of Manchester; Max Planck Society			Balling, Rudi/E-9680-2010	Balling, Rudi/0000-0003-2902-5650	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARIAS S, 1971, Birth Defects Original Article Series, V7, P87; ASHER JH, 1990, J MED GENET, V27, P618, DOI 10.1136/jmg.27.10.618; AUERBACH R, 1954, J EXP ZOOL, V127, P305, DOI 10.1002/jez.1401270206; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; COLLIER S, 1989, EMBO J, V8, P1393, DOI 10.1002/j.1460-2075.1989.tb03520.x; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; EPSTEIN DJ, 1991, GENOMICS, V10, P89, DOI 10.1016/0888-7543(91)90488-Z; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FOY C, 1990, AM J HUM GENET, V46, P1017; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; KEEN J, 1991, TRENDS GENET, V7, P5; STEEL KP, 1983, ARCH OTOLARYNGOL, V109, P22; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; WAARDENBURG PJ, 1951, AM J HUM GENET, V3, P195; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4	18	590	601	2	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					635	636		10.1038/355635a0	http://dx.doi.org/10.1038/355635a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1347148				2022-12-01	WOS:A1992HD54700054
J	YEW, N; MELLINI, ML; VANDEWOUDE, GF				YEW, N; MELLINI, ML; VANDEWOUDE, GF			MEIOTIC INITIATION BY THE MOS PROTEIN IN XENOPUS	NATURE			English	Article							ONCOGENE PRODUCT; CELL-CYCLE; CYTOPLASMIC FACTOR; OOCYTE MATURATION; KINASE-ACTIVITY; EGGS	WHEN fully grown Xenopus oocytes are stimulated by progesterone, a period of protein synthesis is necessary for maturation 1. Synthesis of the mos proto-oncogene product, pp39mos, is necessary for the activation of M-phase promoting factor (MPF) in meiosis I (ref. 2). On the basis that mos is translated de novo on hormonal stimulation of Xenopus oocytes 3 and that injecting mos RNA into oocytes induces their maturation 3,4, we have proposed that the mos protein is a candidate initiator of oocyte maturation, needed to trigger the conversion of precursor MPF into its active form 1-3. To determine whether mos is the only protein required for initiating maturation, we have produced a soluble, active recombinant mos protein and injected it into Xenopus oocytes. We report here that in the absence of protein synthesis that mos protein efficiently induces germinal vesicle breakdown and the activation of MPF. The oocytes, however, do not proceed into meiosis II. Thus, the mos protein fulfills the requirements of an initiator protein, but the synthesis of one or more additional proteins may be necessary to complete oocyte maturation.	NCI,FREDERICK CANC RES & DEV CTR,PRI DYNCORP INC,PROT ISOLAT LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	YEW, N (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,PRI DYNCORP INC,ABL,BASIC RES PROGRAM,POB B,FREDERICK,MD 21702, USA.							ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; FELIX MA, 1989, EMBO J, V8, P3059, DOI 10.1002/j.1460-2075.1989.tb08457.x; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MINSHULL J, 1991, J CELL BIOL, V114, P767, DOI 10.1083/jcb.114.4.767; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SMITH LD, 1989, DEVELOPMENT, V107, P685; WALLACE RA, 1978, P NATL ACAD SCI USA, V75, P5534, DOI 10.1073/pnas.75.11.5534; WASSERMAN WJ, 1975, EXP CELL RES, V91, P381, DOI 10.1016/0014-4827(75)90118-4; WASSERMAN WJ, 1982, DEV BIOL, V89, P152, DOI 10.1016/0012-1606(82)90303-7; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604	23	223	223	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					649	652		10.1038/355649a0	http://dx.doi.org/10.1038/355649a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1531698				2022-12-01	WOS:A1992HD54700060
J	ZAMORE, PD; PATTON, JG; GREEN, MR				ZAMORE, PD; PATTON, JG; GREEN, MR			CLONING AND DOMAIN-STRUCTURE OF THE MAMMALIAN SPLICING FACTOR U2AF	NATURE			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; DROSOPHILA-MELANOGASTER; SNRNP BINDING; 70K PROTEIN; RNA; GENE; PURIFICATION; EXPRESSION; INTRONS; IDENTIFICATION	A complementary DNA clone encoding the large subunit of the essential mammalian pre-messenger RNA splicing component U2 snRNP auxiliary factor (U2AF65) has been isolated and expressed in vitro. It contains two functional domains: a sequence-specific RNA-binding region composed of three ribonucleoprotein-consensus sequence domains, and an arginine/serine-rich motif necessary for splicing but not for binding to pre-mRNA.	HARVARD UNIV, SCH MED, MOLEC & CELLULAR PHYSIOL LAB, BOSTON, MA 02115 USA; UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA	Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester	ZAMORE, PD (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA.		Zamore, Phillip D/A-8941-2013	Zamore, Phillip/0000-0002-4505-9618				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BARABINO SML, 1990, CELL, V63, P293, DOI 10.1016/0092-8674(90)90162-8; BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; ETZERODT M, 1988, EMBO J, V7, P4311, DOI 10.1002/j.1460-2075.1988.tb03330.x; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAMER A, 1991, EMBO J, V10, P1503, DOI 10.1002/j.1460-2075.1991.tb07670.x; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MANCEBO R, 1990, MOL CELL BIOL, V10, P2492, DOI 10.1128/MCB.10.6.2492; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; QUERY CC, 1987, CELL, V51, P211, DOI 10.1016/0092-8674(87)90148-6; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; VOELKER RA, 1991, MOL CELL BIOL, V11, P894, DOI 10.1128/MCB.11.2.894; ZAMORE PD, 1990, NATURE, V348, P485, DOI 10.1038/348485a0; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZILLMANN M, 1988, MOL CELL BIOL, V8, P814, DOI 10.1128/MCB.8.2.814	39	499	507	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 13	1992	355	6361					609	614		10.1038/355609a0	http://dx.doi.org/10.1038/355609a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1538748				2022-12-01	WOS:A1992HD54700043
J	GROVER, SA; ABRAHAMOWICZ, M; JOSEPH, L; BREWER, C; COUPAL, L; SUISSA, S				GROVER, SA; ABRAHAMOWICZ, M; JOSEPH, L; BREWER, C; COUPAL, L; SUISSA, S			THE BENEFITS OF TREATING HYPERLIPIDEMIA TO PREVENT CORONARY HEART-DISEASE - ESTIMATING CHANGES IN LIFE EXPECTANCY AND MORBIDITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; COST-EFFECTIVENESS; CHOLESTEROL; MEN; HYPERCHOLESTEROLEMIA; GEMFIBROZIL; THERAPY; TRIAL	Objective. - To evaluate the lifetime benefits of reducing total serum cholesterol levels to prevent coronary heart disease (CHD). Design. - We developed a CHD primary prevention computer model to estimate the benefits associated with lifelong risk factor modification. We validated the model by comparing the computer estimates with the observed results of three primary CHD prevention trials. Patients. - Men and women age 35 to 65 years who are free of CHD, with total serum cholesterol levels ranging from 5.2 to 7.8 mmol/L (200 to 300 mg/dL), with or without additional CHD risk factors. Interventions. - Serum cholesterol reduction through dietary modification or diet and medications. Main Outcome Measures. - Changes in life expectancy and the delay of symptomatic CHD. Results. - The computer forecasts for CHD end points closely matched the observed results of the Lipid Research Clinics Trial, the Helsinki Heart Study, and MRFIT. We then applied the computer model to low-risk and high-risk men and women with total serum cholesterol levels between 5.2 and 7.8 mmol/L (200 and 300 mg/dL) and estimated that, after reducing serum cholesterol levels 5% to 33%, the average life expectancy would increase by 0.03 to 3.16 years. We also forecast that the average onset of symptomatic CHD would be delayed among these patient groups by 0.06 to 4.98 years. Conclusion. - We conclude that this computer model accurately estimates the results of clinical trials and can be used to forecast the changes in life expectancy and morbidity (the development of CHD) associated with specific CHD risk reduction interventions. The wide variation surrounding these estimates underscores the need to better define which groups of individuals will gain the most from cholesterol reduction.	MCGILL UNIV, DEPT MED, MONTREAL H3A 2T5, QUEBEC, CANADA; MCGILL UNIV, DEPT EPIDEMIOL & BIOSTAT, MONTREAL H3A 2T5, QUEBEC, CANADA; CTR CARDIOVASC RISK ASSESSMENT, MONTREAL, QUEBEC, CANADA; MONTREAL GEN HOSP, DIV GEN INTERNAL MED, MONTREAL H3G 1A4, QUEBEC, CANADA	McGill University; McGill University; McGill University	GROVER, SA (corresponding author), MONTREAL GEN HOSP, DIV CLIN EPIDEMIOL, 1650 CEDAR AVE, MONTREAL H3G 1A4, QUEBEC, CANADA.			Coupal, Louis/0000-0003-0828-9665; Abrahamowicz, Michal/0000-0002-3172-3952				ABBOTT RD, 1987, US DHEW NIH872284 PU; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; BERWICK DM, 1980, CHOLESTEROL CHILDREN, P301; BRETT AS, 1989, NEW ENGL J MED, V321, P676, DOI 10.1056/NEJM198909073211009; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GARBER AM, 1989, ANN INTERN MED, V110, P622, DOI 10.7326/0003-4819-110-8-622; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GORDON T, 1982, AM HEART J, V103, P1031, DOI 10.1016/0002-8703(82)90567-1; GORDON T, 1971, FRAMINGHAM STUDY EPI; GROVER SA, 1991, CAN MED ASSOC J, V144, P161; HJERMANN I, 1981, LANCET, V2, P1303; KANNEL WB, 1988, NIH882969 NAT HEART; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; KJELSBERG MO, 1990, JAMA-J AM MED ASSOC, V263, P1795; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; LEWIS B, 1987, EUR HEART J, V8, P77; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NAYLOR CD, 1990, J CLIN EPIDEMIOL, V43, P607; OLIVER MF, 1986, CIRCULATION, V73, P1, DOI 10.1161/01.CIR.73.1.1; OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SHURTLEFF D, 1974, US DHEW NIH74599 PUB; TAYLOR WC, 1987, ANN INTERN MED, V106, P605, DOI 10.7326/0003-4819-106-4-605; TSEVAT J, 1991, CIRCULATION, V83, P1194, DOI 10.1161/01.CIR.83.4.1194; VEGA GL, 1989, JAMA-J AM MED ASSOC, V262, P3148; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; WILSON PWF, 1989, JAMA-J AM MED ASSOC, V262, P41, DOI 10.1001/jama.262.1.41; [No title captured]; 1981, HLTH CANADIANS REPOR; 1973, CORONARY RISK HDB ES; 1989, LIFE TABLES CANADA P; 1987, LANCET, V1, P377	36	80	80	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					816	822						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732653				2022-12-01	WOS:A1992HC48400026
J	NIGHTINGALE, SL				NIGHTINGALE, SL			MORATORIUM ON SILICONE GEL BREAST IMPLANTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					787	787						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732641				2022-12-01	WOS:A1992HC48400005
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW LABELING AND PATIENT PACKAGE INSERT FOR TRIAZOLAM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					787	787						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732641				2022-12-01	WOS:A1992HC48400006
J	SCHLENKER, TL; BAIN, C; BAUGHMAN, AL; HADLER, SC				SCHLENKER, TL; BAIN, C; BAUGHMAN, AL; HADLER, SC			MEASLES HERD-IMMUNITY - THE ASSOCIATION OF ATTACK RATES WITH IMMUNIZATION RATES IN PRESCHOOL-CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES	Objective. - To examine the association between incidence of measles and immunization coverage among preschool-age children. Design. - An ecological study in which measles incidence was compared with immunization coverage among census tracts. The independent effects of race and population density were controlled for. Setting. - A recent measles outbreak in Milwaukee, Wis. immunization coverage data were estimated from a retrospective, school-based survey of Milwaukee grade school students. Patients. - One thousand eleven persons (less-than-or-equal-to 17 years) who had confirmed measles from September 1989 through June 1990. Main Outcome Measures. - Confirmed measles cases grouped by census tract, corresponding census tract preoutbreak immunization coverage, racial breakdown, and population density. Results. - Census tracts stratified into four levels, with mean immunization rates of 50.4%, 60.2%, 69.9%, and 81.0%, had respective median attack rates of 11.6, 5.0, 1.7, and 0.0 cases per 1000 persons (P < .01). The association between immunization coverage and measles attack rate remained significant even after controlling for race and population density. Conclusions. - Modest improvements in low levels of immunization coverage among 2-year-olds confer substantial protection against measles outbreaks. Coverage of 80% or less may be sufficient to prevent sustained measles outbreaks in an urban community.	CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV IMMUNIZAT,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV IMMUNIZAT,DATA MANAGEMENT BRANCH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	SCHLENKER, TL (corresponding author), MILWAUKEE HLTH DEPT,841 N BROADWAY,MILWAUKEE,WI 53202, USA.							BASS JW, 1987, PEDIATR INFECT DIS J, V6, P141, DOI 10.1097/00006454-198702000-00001; EMERSON JD, 1983, UNDERSTANDING ROBUST, P33; FOX JP, 1971, AM J EPIDEMIOL, V94, P179, DOI 10.1093/oxfordjournals.aje.a121310; Hedrich AW, 1933, AM J HYG, V17, P613, DOI 10.1093/oxfordjournals.aje.a117929; HERSH BS, 1991, AM J PUBLIC HEALTH, V81, P360, DOI 10.2105/AJPH.81.3.360; Hollander M., 1973, NONPARAMETRIC STAT M, P114; INMAN RL, 1979, TECHNOMETRICS, V21, P499; KLEINBAUM DG, 1988, APPL REGRESSION ANAL, P314; MARKOWITZ LE, 1989, NEW ENGL J MED, V320, P75, DOI 10.1056/NEJM198901123200202; MARKOWITZ LE, 1990, PEDIATR INFECT DIS J, V9, P101, DOI 10.1097/00006454-199002000-00008; MASSEY DS, 1989, DEMOGRAPHY, V26, P373, DOI 10.2307/2061599; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; Schlenker T, 1990, Wis Med J, V89, P403; SENCER DJ, 1967, PUBLIC HEALTH REP, V82, P253, DOI 10.2307/4592985; THACKER SB, 1991, AM J EPIDEMIOL, V133, P517, DOI 10.1093/oxfordjournals.aje.a115923; 1987, MMWR, V36, P45; 1990, MMWR, V39, P317; 1991, MEASLES EPIDEMIC PRO; 1985, PHC802243 US DEP COM; 1989, MMWR, V38, P1; 1990, MMWR, V39, P353; 1991, MMWR, V40, P93; 1991, MMWR, V40, P36	23	68	68	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					823	826		10.1001/jama.267.6.823	http://dx.doi.org/10.1001/jama.267.6.823			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732654				2022-12-01	WOS:A1992HC48400027
J	SCHOR, JD; LEVKOFF, SE; LIPSITZ, LA; REILLY, CH; CLEARY, PD; ROWE, JW; EVANS, DA				SCHOR, JD; LEVKOFF, SE; LIPSITZ, LA; REILLY, CH; CLEARY, PD; ROWE, JW; EVANS, DA			RISK-FACTORS FOR DELIRIUM IN HOSPITALIZED ELDERLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE CONFUSIONAL STATES; BACTERIAL-MENINGITIS; DEMENTIA; AGE	Objective. - To determine risk factors for delirium in elderly hospitalized patients. Design. - Cohort analytic study. Using a reliable and valid instrument for detection of delirium, we prospectively followed up a cohort of elderly patients admitted to an acute care hospital. Using standardized criteria, we collected risk factor data from patient medical records. Setting. - General medical and surgical wards of a tertiary-care hospital. Patients. - Patients (n = 325) were 65 years of age or older, from either a geographically defined community or a long-term-care institution. We studied those patients (n = 291) not delirious on first evaluation. Fifty-seven patients or their families refused participation. Main Outcome Measures. - Incidence of delirium and risk factors calculated as adjusted odds ratios (ORs). Main Results. - Delirium developed in 91 patients. By stepwise logistic regression, the independent risk factors for in-hospital delirium included prior cognitive impairment (OR, 8.97; 95% confidence interval [Cl], 3.99 to 20.14), age over 80 years (OR, 5.22; 95% Cl, 2.60 to 10.46), fracture on admission (OR, 6.57; 95% Cl, 2.23 to 19.33), symptomatic infection (OR, 2.96; 95% Cl, 1.42 to 6.15), and male sex (OR, 2.40; 95% Cl, 1.19 to 4.84). Among medication groups, only neuroleptic use (OR, 4.48; 95% Cl, 1.82 to 10.45) and narcotic use (OR, 2.54; 955 Cl, 1.24 to 5.18) were independently associated with delirium. Anticholinergic use was not associated with delirium. Conclusions. - Delirium in hospitalized patients is most closely associated with factors already present on admission such as prior cognitive impairment, advanced age, and fracture. In the hospital, use of neuroleptics and narcotics and the presence of infection are less strongly associated with this syndrome.	HEBREW REHABIL CTR AGED, BOSTON, MA USA; RUSH PRESBYTERIAN ST LUKES MED CTR, CTR RES HLTH & AGING, CHICAGO, IL 60612 USA; HARVARD UNIV, SCH MED, DIV AGING, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; MT SINAI MED CTR, NEW YORK, NY 10029 USA	Rush University; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Icahn School of Medicine at Mount Sinai			Cleary, Paul/AAF-7048-2019					ALBERT MS, IN PRESS J GERIATR P; BERGMANN K, 1974, Age and Ageing, V3, P174, DOI 10.1093/ageing/3.3.174; BERNSTEIN S, 1967, NEW ENGL J MED, V277, P638, DOI 10.1056/NEJM196709212771206; BILBERT VE, 1968, METABOLISM, V17, P943; BOHR V, 1983, J INFECTION, V7, P21, DOI 10.1016/S0163-4453(83)90894-0; BRIZER DA, 1982, AM J PSYCHIAT, V139, P1343; DINARELLO CA, 1984, NEW ENGL J MED, V311, P1413; DJOKOVIC JL, 1979, JAMA-J AM MED ASSOC, V242, P2301, DOI 10.1001/jama.242.21.2301; DRACHMAN DA, 1974, ARCH NEUROL-CHICAGO, V30, P113, DOI 10.1001/archneur.1974.00490320001001; ENGEL G L, 1959, J Chronic Dis, V9, P260, DOI 10.1016/0021-9681(59)90165-1; ERKINJUNTTI T, 1986, ARCH INTERN MED, V146, P1923, DOI 10.1001/archinte.146.10.1923; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; GILLICK MR, 1982, SOC SCI MED, V16, P1033, DOI 10.1016/0277-9536(82)90175-7; GORSE GJ, 1984, ARCH INTERN MED, V144, P1603, DOI 10.1001/archinte.144.8.1603; GREENFIELD S, 1988, JAMA-J AM MED ASSOC, V260, P2253, DOI 10.1001/jama.260.15.2253; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; Hodkinson H M, 1973, J R Coll Physicians Lond, V7, P305; JOHNSON JC, 1990, J GERONTOL, V45, pM113, DOI 10.1093/geronj/45.3.M113; KADLECOVA O, 1974, J HYG EPID MICROB IM, V18, P472; LEVKOFF SE, IN PRESS ARCH INTERN; LIPOWSKI ZJ, 1989, NEW ENGL J MED, V320, P578; LIPOWSKI ZJ, 1987, JAMA-J AM MED ASSOC, V258, P1789, DOI 10.1001/jama.258.13.1789; LIPOWSKI ZJ, 1983, AM J PSYCHIAT, V140, P1426; LIPOWSKI ZJ, 1990, DELIRIUM ACUTE CONFU, P229; NORMAN DC, 1983, J AM GERIATR SOC, V31, P677, DOI 10.1111/j.1532-5415.1983.tb04154.x; SEYMOUR DG, 1980, AGE AGEING, V9, P137, DOI 10.1093/ageing/9.3.137; SIESJO BK, 1976, CRIT CARE MED, V4, P283, DOI 10.1097/00003246-197611000-00001; SIMON ALEXANDER, 1963, PSYCHIAT RES REPTS, V16, P8; SUNDERLAND T, 1987, ARCH GEN PSYCHIAT, V44, P418; SUNDERLAND T, 1988, BRAIN RES REV, V13, P371, DOI 10.1016/0165-0173(88)90013-6; THOMAS RI, 1988, ARCH GEN PSYCHIAT, V45, P937; VERGHESE A, 1983, MEDICINE, V62, P271, DOI 10.1097/00005792-198309000-00002; VERGHESE A, 1985, AM J MED, V79, P370, DOI 10.1016/0002-9343(85)90316-X; 1987, DIAGNOSTIC STATISTIC, P100	34	344	351	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					827	831		10.1001/jama.267.6.827	http://dx.doi.org/10.1001/jama.267.6.827			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732655				2022-12-01	WOS:A1992HC48400028
J	SEPKOWITZ, KA; BROWN, AE; TELZAK, EE; GOTTLIEB, S; ARMSTRONG, D				SEPKOWITZ, KA; BROWN, AE; TELZAK, EE; GOTTLIEB, S; ARMSTRONG, D			PNEUMOCYSTIS-CARINII PNEUMONIA AMONG PATIENTS WITHOUT AIDS AT A CANCER HOSPITAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; INFECTIOUS COMPLICATIONS; MARROW TRANSPLANTATION; LYMPHOCYTIC-LEUKEMIA; NEOPLASTIC DISEASES; THERAPY; CHILDREN; CHEMOPROPHYLAXIS; CYCLOSPORINE; DIAGNOSIS	Objectives. - To determine the predisposing factors, attack rate by underlying disease, and outcome of Pneumocystis carinii pneumonia among patients without the acquired immunodeficiency syndrome (AIDS) at a cancer center. Data Source. - Twelve-year retrospective review from a tertiary-care cancer center. Study Selection. - One hundred forty patients, constituting 142 cases, with morphologically proved P carinii pneumonia. Data Synthesis. - Hematologic malignancy (47%) (including lymphoma [27%] and leukemia [18%]), solid tumor (31%), or bone marrow transplantation (18%) was the underlying condition in the majority of cases. Twenty-five cases (18%) were diagnosed at autopsy. All but seven patients had previously established predisposing factors for P carinii pneumonia, including corticosteroid use in 87%. The attack rate for hospitalized patients with primary or metastatic brain tumor increased during the 12-year interval. The attack rates for hospitalized patients with hematologic neoplasm or bone marrow transplantation were stable. The overall mortality rate did not change during the period reviewed, Conclusions. - Despite the availability of effective prophylaxis, P carinii pneumonia continues to occur among patients with neoplastic disease. In addition to patients with certain hematologic neoplasms, those with primary or metastatic brain neoplasm who receive corticosteroids are at risk for the development of P carinii pneumonia and should receive P carinii pneumonia prophylaxis.			SEPKOWITZ, KA (corresponding author), CORNELL UNIV,MED CTR,COLL MED,MEM SLOAN KETTERING CANC CTR,INFECT DIS SERV,1275 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027669] Funding Source: NIH RePORTER; NIAID NIH HHS [5 UO1 AI27669-04] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENOUSAN T, 1990, LANCET, P1066; BRAZINSKY JH, 1969, J AMER MED ASSOC, V209, P1527, DOI 10.1001/jama.209.10.1527; BROWNE MJ, 1986, ANN INTERN MED, V104, P338, DOI 10.7326/0003-4819-104-3-338; BURKE BA, 1973, MEDICINE, V52, P23, DOI 10.1097/00005792-197301000-00002; CAPITANI.MA, 1966, AMER J ROENTGENOL RA, V97, P174, DOI 10.2214/ajr.97.1.174; CHAVE JP, 1991, AIDS, V5, P927, DOI 10.1097/00002030-199108000-00002; CHUSID MJ, 1978, PEDIATRICS, V62, P1031; FOSSIECK BE, 1980, CHEST, V78, P721, DOI 10.1378/chest.78.5.721; FRANSON TR, 1987, ARCH SURG-CHICAGO, V122, P1034; GAJDUSEK DC, 1957, PEDIATRICS, V19, P543; GIRON JA, 1982, LANCET, V2, P46; GLATT AE, 1990, ARCH INTERN MED, V150, P271, DOI 10.1001/archinte.150.2.271; GOESCH TR, 1991, LANCET, P627; GRYZAN S, 1988, AM REV RESPIR DIS, V137, P1268, DOI 10.1164/ajrccm/137.6.1268; HARDY AM, 1984, J INFECT DIS, V149, P143, DOI 10.1093/infdis/149.2.143; HARDY R, 1987, J NATL MED ASSOC, V79, P1205; HARON E, 1988, LANCET, V2, P904; HENSON JW, 1991, ARCH NEUROL-CHICAGO, V48, P406, DOI 10.1001/archneur.1991.00530160074017; HIGGINS RM, 1989, TRANSPLANTATION, V47, P558, DOI 10.1097/00007890-198903000-00032; HUGHES WT, 1978, JOHNS HOPKINS MED J, V143, P184; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; HUGHES WT, 1984, J INFECT DIS, V150, P305, DOI 10.1093/infdis/150.2.305-a; HUGHES WT, 1977, NEW ENGL J MED, V297, P1381, DOI 10.1056/NEJM197712222972505; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; HUGHES WT, 1975, CANCER, V36, P2004, DOI 10.1002/cncr.2820360912; HUGHES WT, 1974, AM J DIS CHILD, V128, P44, DOI 10.1001/archpedi.1974.02110260046008; HUGHES WT, 1973, J PEDIATR-US, V82, P404, DOI 10.1016/S0022-3476(73)80113-1; HUGHES WT, 1982, J INFECT DIS, V145, P767, DOI 10.1093/infdis/145.2.767; HUGHES WT, 1987, PNEUMOCYSTIS CARINII; IVADY G, 1967, LANCET, V1, P616; JACOBS JL, 1991, NEW ENGL J MED, V324, P246, DOI 10.1056/NEJM199101243240407; KOUIDES PA, 1988, BRIT J HAEMATOL, V70, P383, DOI 10.1111/j.1365-2141.1988.tb02500.x; KOVACS JA, 1984, ANN INTERN MED, V100, P663, DOI 10.7326/0003-4819-100-5-663; KRITZ A, 1991, NEW ENGL J MED, V325, P661; LECLAIR RA, 1969, AM REV RESPIR DIS, V99, P542; LEFF RL, 1990, ANN INTERN MED, V112, P716, DOI 10.7326/0003-4819-112-9-716_1; LUNA MA, 1989, SEMIN DIAGN PATHOL, V6, P262; LUNA MA, 1972, TEX REP BIOL MED, V30, P41; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MASUR H, 1989, ANN INTERN MED, V111, P813, DOI 10.7326/0003-4819-111-10-813; MASUR H, 1988, ANN INTERN MED, V109, P755, DOI 10.7326/0003-4819-109-9-755; MEYERS JD, 1982, REV INFECT DIS, V4, P1119; MILLIGAN DW, 1987, LANCET, V1, P867; MURRAY JF, 1990, AM REV RESPIR DIS, V141, P1582, DOI 10.1164/ajrccm/141.6.1582; NATALE RB, 1981, CANCER, V47, P2933, DOI 10.1002/1097-0142(19810615)47:12&lt;2933::AID-CNCR2820471233&gt;3.0.CO;2-G; PERERA DR, 1970, J AMER MED ASSOC, V214, P1074, DOI 10.1001/jama.214.6.1074; PETERS SG, 1987, AM J MED, V82, P73, DOI 10.1016/0002-9343(87)90380-9; RAO CP, 1983, J PEDIATR-US, V103, P410, DOI 10.1016/S0022-3476(83)80415-6; ROSEN P, 1972, AM J MED, V53, P428, DOI 10.1016/0002-9343(72)90138-6; ROSEN PP, 1975, AM J MED, V58, P794, DOI 10.1016/0002-9343(75)90634-8; RUEBUSH TK, 1978, AM J DIS CHILD, V132, P143, DOI 10.1001/archpedi.1978.02120270041009; RUSKIN J, 1967, J AMER MED ASSOC, V202, P1070, DOI 10.1001/jama.202.12.1070; SANTIAGODELPIN EA, 1988, TRANSPLANT P, V20, P462; SCHILLING PJ, 1990, NEW ENGL J MED, V323, P833, DOI 10.1056/NEJM199009203231216; SEDAGHATIAN MR, 1972, CANCER-AM CANCER SOC, V29, P772, DOI 10.1002/1097-0142(197203)29:3<772::AID-CNCR2820290333>3.0.CO;2-K; SELIK RM, 1987, AIDS, V1, P175; SINGER C, 1979, AM J MED, V66, P110, DOI 10.1016/0002-9343(79)90490-X; SINGER C, 1975, ANN INTERN MED, V82, P772, DOI 10.7326/0003-4819-82-6-722; TALSETH T, 1988, TRANSPLANT P, V20, P400; VOGEL CL, 1968, ANN INTERN MED, V68, P97, DOI 10.7326/0003-4819-68-1-97; WALLIS PJW, 1989, ANN RHEUM DIS, V48, P247, DOI 10.1136/ard.48.3.247; WALZER PD, 1974, ANN INTERN MED, V80, P83, DOI 10.7326/0003-4819-80-1-83; WALZER PD, 1977, SCIENCE, V197, P177, DOI 10.1126/science.301657; WALZER PD, 1991, NEW ENGL J MED, V324, P263, DOI 10.1056/NEJM199101243240411; WALZER PD, 1973, J PEDIATR-US, V82, P416, DOI 10.1016/S0022-3476(73)80114-3; WATANABE JM, 1965, J AMER MED ASSOC, V193, P685, DOI 10.1001/jama.1965.03090080047017; WINSTON DJ, 1979, MEDICINE, V58, P1, DOI 10.1097/00005792-197901000-00001	67	232	239	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					832	837		10.1001/jama.267.6.832	http://dx.doi.org/10.1001/jama.267.6.832			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732656				2022-12-01	WOS:A1992HC48400029
J	ZENILMAN, JM; ERICKSON, B; FOX, R; REICHART, CA; HOOK, EW				ZENILMAN, JM; ERICKSON, B; FOX, R; REICHART, CA; HOOK, EW			EFFECT OF HIV POSTTEST COUNSELING ON STD INCIDENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							SEXUALLY-TRANSMITTED DISEASES; VIRUS-INFECTION; CLINICS; AIDS; MEN	Objective. - To evaluate the effectiveness of human immunodeficiency virus (HIV) testing and posttest counseling in reducing subsequent high-risk behavior. Methods. - The incidence of sexually transmitted diseases (STDs) in the Baltimore, Md, public STD clinic population after HIV testing and counseling was determined by chart review and was compared in two groups, 868 HIV-seropositive patients and 1104 HIV-seronegative patients, matched by age, sex, and month in which HIV test was conducted. Patients were observed for incident STDs at intervals of 6 through 23 months. Patients with incident STDs were classified hierarchically after being notified of the HIV test result and receiving posttest counseling. Results. - Of HIV-seropositive patients, 615 (71%) returned for their test results and received posttest counseling; 694 HIV-seronegative patients (63%) returned. Of all those who returned for results and posttest counseling, 60 (9.7%) of 615 HIV-seropositive patients and 61 (8.8%) of 694 HIV-seronegative patients were diagnosed at least once with definite STD (syphilis, gonorrhea, or trichomoniasis) (P, not significant). Twenty-four HIV-seropositive patients (3.9%) and 71 HIV-seronegative patients (10.2%) returned with probable STD (nongonococcal urethritis or pelvic inflammatory disease) (P < .001). Nine HIV-seropositive patients (1.5%) and 23 HIV-seronegative patients (3.3%) returned having had an STD-infected sexual partner (P < .03). Age, sexual orientation, and drug use behavior did not predict return with STD. Conclusions. - Both HIV-seropositive and HIV-seronegative patients showed high rates of repeat STDs after posttest counseling, an important public health challenge in creating effective high-risk behavior prevention strategies.	JOHNS HOPKINS UNIV,SCH MED,DIV INFECT DIS,BALTIMORE,MD 21205; BALTIMORE CITY DEPT HLTH,BALTIMORE,MD	Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027727, R01AI029508] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29508, AI27727] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ERICKSON B, 1990, SEX TRANSM DIS, V17, P194, DOI 10.1097/00007435-199010000-00009; HANDSFIELD HH, 1990, SEX TRANSM DIS, V17, P211, DOI 10.1097/00007435-199010000-00011; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; HOLMBERG SD, 1988, JAMA-J AM MED ASSOC, V259, P1048, DOI 10.1001/jama.259.7.1048; HOLMES KK, 1990, AM J PUBLIC HEALTH, V80, P858, DOI 10.2105/AJPH.80.7.858; KREISS JK, 1986, NEW ENGL J MED, V314, P414, DOI 10.1056/NEJM198602133140704; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; QUINN TC, 1988, NEW ENGL J MED, V318, P197, DOI 10.1056/NEJM198801283180401; REICHART CA, 1990, SEX TRANSM DIS, V17, P147, DOI 10.1097/00007435-199007000-00007; STAMM WE, 1988, JAMA-J AM MED ASSOC, V260, P1429, DOI 10.1001/jama.260.10.1429; 1991, HIV AIDS SURVEILLANC, P1; 1989, MMWR SS8, V38, P1	12	72	72	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					843	845		10.1001/jama.267.6.843	http://dx.doi.org/10.1001/jama.267.6.843			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732658				2022-12-01	WOS:A1992HC48400031
J	ARMSTRONG, AM; MOLYNEUX, E				ARMSTRONG, AM; MOLYNEUX, E			GLASS INJURIES TO CHILDREN	BRITISH MEDICAL JOURNAL			English	Article									ROYAL LIVERPOOL CHILDRENS HOSP,DEPT ACCIDENT & EMERGENCY,LIVERPOOL L12 2AP,ENGLAND	Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital								BAKER MD, 1990, AM J DIS CHILD, V144, P87, DOI 10.1001/archpedi.1990.02150250097042; BELL D, 1984, ARCH DIS CHILD, V59, P672, DOI 10.1136/adc.59.7.672; HAYES M, 1991, CHILD SAFETY REV, P4	3	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1992	304	6823					360	360		10.1136/bmj.304.6823.360	http://dx.doi.org/10.1136/bmj.304.6823.360			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD387	1540735	Bronze, Green Published			2022-12-01	WOS:A1992HD38700026
J	DOUGLAS, NJ; THOMAS, S; JAN, MA				DOUGLAS, NJ; THOMAS, S; JAN, MA			CLINICAL-VALUE OF POLYSOMNOGRAPHY	LANCET			English	Article							HYPOPNEA SYNDROME; SLEEP	Polysomnography is used increasingly to investigate patients with possible sleep apnoea/hypopnoea syndrome (SAHS), but it has not been assessed critically. We thus examined prospectively the value of electrophysiological and respiratory monitoring in 200 consecutive adults (163 men, 37 women; mean [SD] age 50 [13] years) having polysomnography. At polysomnography, 91 patients had SAHS (> 15 apnoeas + hypopnoeas [A + H] per h asleep) and 11 had periodic limb-movement disorder. Recording sleep electrophysiologically was of no diagnostic value and SAHS could be as accurately defined by A + H per time in bed as by A + H per time asleep. 66% of patients with SAHS could be diagnosed with oximetry alone, but many of the undiagnosed patients had moderately severe SAHS and benefited from treatment. Neurophysiological sleep recording is unnecessary and oximetry alone is of limited value in the overnight in investigation of patients suspected of having SAHS.			DOUGLAS, NJ (corresponding author), CITY HOSP EDINBURGH,DEPT MED,RESP MED UNIT,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND.		Douglas, Neil/B-1491-2013					CHESHIRE K, IN PRESS ARCH INTERN; COOPER BG, 1991, THORAX, V46, P586, DOI 10.1136/thx.46.8.586; CROCKER BD, 1990, AM REV RESPIR DIS, V142, P14, DOI 10.1164/ajrccm/142.1.14; DOUGLAS NJ, 1979, LANCET, V1, P1; GOULD GA, 1988, AM REV RESPIR DIS, V137, P895, DOI 10.1164/ajrccm/137.4.895; Guilleminault C., 1978, SLEEP APNEAS SYNDROM, V1, P1; HAPONIK EF, 1984, AM J MED, V77, P671, DOI 10.1016/0002-9343(84)90361-9; MARTIN RJ, 1985, SLEEP, V8, P371, DOI 10.1093/sleep/8.4.371; MCAVOY RD, 1988, GUIDELINES RESPIRATO; PARSONS M, 1986, Q J MED, V58, P295; Phillipson E.A., 1989, AM REV RESPIR DIS, V139, P559, DOI 10.1164/ajrccm/139.2.559; Rechtschaffen A, 1969, MANUAL STANDARDIZED, V26, P644; STRADLING J, 1989, J AMBULATORY MONIT, V2, P197; STRADLING JR, 1991, THORAX, V46, P85, DOI 10.1136/thx.46.2.85; VINER S, 1991, ANN INTERN MED, V115, P356, DOI 10.7326/0003-4819-115-5-356; WHYTE KF, 1989, Q J MED, V72, P659; WHYTE KF, IN PRESS SLEEP; 1990, BTS NEWS, V5, P7; 1990, INT CLASSIFICATION S, P65	19	273	279	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1992	339	8789					347	350		10.1016/0140-6736(92)91660-Z	http://dx.doi.org/10.1016/0140-6736(92)91660-Z			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346422				2022-12-01	WOS:A1992HC77100017
J	EDWARDS, IR; COULTER, DM; MACINTOSH, D				EDWARDS, IR; COULTER, DM; MACINTOSH, D			INTESTINAL EFFECTS OF CAPTOPRIL	BRITISH MEDICAL JOURNAL			English	Article									UNIV OTAGO,SCH MED,NATL TOXICOL GRP,DUNEDIN,NEW ZEALAND	University of Otago								BHASKAR RM, 1984, PEPTIDES, V5, P291; CHONG EKS, 1973, J PHARM PHARMACOL, V25, P170, DOI 10.1111/j.2042-7158.1973.tb10614.x; LEVENS NR, 1985, AM J PHYSIOL, V249, pG3, DOI 10.1152/ajpgi.1985.249.1.G3; PICARELLI ZP, 1954, CIRC RES, V2, P354, DOI 10.1161/01.RES.2.4.354; WALUS KM, 1981, DIGEST DIS SCI, V26, P1069, DOI 10.1007/BF01295970	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1992	304	6823					359	360		10.1136/bmj.304.6823.359	http://dx.doi.org/10.1136/bmj.304.6823.359			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD387	1540734	Green Published, Bronze			2022-12-01	WOS:A1992HD38700025
J	GOLDSMITH, R; YARBOUGH, PO; REYES, GR; FRY, KE; GABOR, KA; KAMEL, M; ZAKARIA, S; AMER, S; GAFFAR, Y				GOLDSMITH, R; YARBOUGH, PO; REYES, GR; FRY, KE; GABOR, KA; KAMEL, M; ZAKARIA, S; AMER, S; GAFFAR, Y			ENZYME-LINKED-IMMUNOSORBENT-ASSAY FOR DIAGNOSIS OF ACUTE SPORADIC HEPATITIS-E IN EGYPTIAN CHILDREN	LANCET			English	Article							NON-B-HEPATITIS; TRANSMITTED NON-A; VIRUS-LIKE PARTICLES; CYNOMOLGUS MACAQUES; POST-TRANSFUSION; EPIDEMIC; ETIOLOGY; TRANSMISSION; RECOVERY	Hepatitis E virus (HEV) is thought to be a cause of enterically transmitted non-A, non-B (ET-NANB) hepatitis. Waterborne epidemics have been recorded in many developing countries, mainly affecting young-to-middle-aged adults; sporadic infection and overt illness in children are rare. However, a convenient and sensitive diagnostic test for HEV infection is not yet available. We now report the use of a solid-phase enzyme-linked immunoassay (ELISA) that detects IgM and IgG antibody to HEV. In a prospective study of endemic acute hepatitis during 1986 in rural Benha, Egypt, 15 (42%) of 36 children with NANB hepatitis (from whom convalescent-phase sera were available every 3 months to 9 or 12 months) were positive for anti-HEV-IgG by ELISA. Of 20 sera from healthy Benha children (controls), 5 (25%) were also positive for anti-HEV-IgG. When evaluated for anti-HEV-IgM, 6 of the 15 IgG-positive children, but none of the controls, were IgM positive and were thus regarded as having confirmed acute HEV infections. These 6 cases together with 2 presumptive cases (IgM negative, IgG seroconversion from positive to negative) presented sporadically over 9 months. This ELISA is a convenient method for the diagnosis of HEV infection; we have shown that the disease is present in Egypt, that it can occur endemically as sporadic cases, and that children do have overt infection.	GENELABS INC,DEPT MOLEC VIROL,REDWOOD CITY,CA; BENHA UNIV,DEPT PEDIAT,BENHA,EGYPT; UNIV CAIRO,DEPT CLIN PATHOL,CAIRO,EGYPT; UNIV CAIRO,DEPT TROP MED,CAIRO,EGYPT; AIN SHAMS UNIV,DEPT MED,CAIRO,EGYPT	Egyptian Knowledge Bank (EKB); Benha University; Egyptian Knowledge Bank (EKB); Cairo University; Egyptian Knowledge Bank (EKB); Cairo University; Egyptian Knowledge Bank (EKB); Ain Shams University	GOLDSMITH, R (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143, USA.							ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1989, NEW ENGL J MED, V321, P1538, DOI 10.1056/NEJM198911303212208; ALTER MJ, 1989, ANN INTERN MED, V110, P583, DOI 10.7326/0003-4819-110-8-583; ARANKALLE VA, 1988, LANCET, V1, P550; ARANKALLE VA, 1988, LANCET, V2, P1199; BALAYAN MS, 1983, INTERVIROLOGY, V20, P23, DOI 10.1159/000149370; BRADLEY DW, 1990, BRIT MED BULL, V46, P442, DOI 10.1093/oxfordjournals.bmb.a072409; BRADLEY DW, 1987, P NATL ACAD SCI USA, V84, P6277, DOI 10.1073/pnas.84.17.6277; BRADLEY DW, 1986, SEMIN LIVER DIS, V6, P56, DOI 10.1055/s-2008-1040794; DECOCK KM, 1987, ANN INTERN MED, V106, P227, DOI 10.7326/0003-4819-106-2-227; KHUROO MS, 1980, AM J MED, V68, P818, DOI 10.1016/0002-9343(80)90200-4; KRAWCZYNSKI K, 1989, J INFECT DIS, V159, P1042, DOI 10.1093/infdis/159.6.1042; PANDA SK, 1989, HEPATOLOGY, V10, P466, DOI 10.1002/hep.1840100411; PURCELL RH, 1988, VIRAL HEPATITIS LIVE, P131; SKIDMORE SJ, 1991, LANCET, V337, P1541, DOI 10.1016/0140-6736(91)93227-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SREENIVASAN MA, 1984, J GEN VIROL, V65, P1005, DOI 10.1099/0022-1317-65-5-1005; TABOR E, 1985, LANCET, V1, P743; VELAZQUEZ O, 1990, JAMA-J AM MED ASSOC, V263, P3281, DOI 10.1001/jama.263.24.3281; WONG DC, 1980, LANCET, V2, P876; YARBOUGH PO, 1991, J VIROL, V65, P5790, DOI 10.1128/JVI.65.11.5790-5797.1991; ZAKARIA S, 1988, TROP GEOGR MED, V40, P285; ZUCKERMAN AJ, 1990, BRIT MED J, V300, P1475, DOI 10.1136/bmj.300.6738.1475; 1990, LANCET, P1158	24	192	204	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1992	339	8789					328	331		10.1016/0140-6736(92)91647-Q	http://dx.doi.org/10.1016/0140-6736(92)91647-Q			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346411				2022-12-01	WOS:A1992HC77100004
J	HADDAD, J; DENY, P; MUNZGOTHEIL, C; AMBROSINI, JC; TRINCHET, JC; PATERON, D; MAL, F; CALLARD, P; BEAUGRAND, M				HADDAD, J; DENY, P; MUNZGOTHEIL, C; AMBROSINI, JC; TRINCHET, JC; PATERON, D; MAL, F; CALLARD, P; BEAUGRAND, M			LYMPHOCYTIC SIALADENITIS OF SJOGRENS-SYNDROME ASSOCIATED WITH CHRONIC HEPATITIS-C VIRUS LIVER-DISEASE	LANCET			English	Article							SALIVARY-GLAND BIOPSIES	Viral infection has often been suggested as a possible cause of Sjogren's syndrome or chronic lymphocytic sialadenitis, and Epstein-Barr virus has been found in the salivary glands of patients with this condition. After we had noted Sjogren's syndrome in several patients infected with hepatitis C virus (HCV), a virus also excreted in saliva, we set up a prospective study to investigate the association of chronic lymphocytic sialadenitis, with or without symptoms, to chronic HCV liver disease. The histological appearances of labial salivary glands in patients with proven HCV hepatitis or cirrhosis were compared with those in dead controls. Histological changes characteristic of Sjogren's syndrome were significantly more common in HCV-infected patients (16 of 28, 57%) compared with controls (1 of 20, 5%). Focal lymphocytic sialadenitis characteristic of Sjogren's syndrome (though only 10 patients had xerostomia and none complained of xerophthalmia) appears to be common in patients with chronic HCV liver disease; if this association is confirmed, identification of the underlying mechanism may improve our understanding of both disorders.	HOP JEAN VERDIER, DEPT HEPATOGASTROENTEROL, SERV HEPATOGASTROENTEROL, AVE 14 JUILLET, F-93143 BONDY, FRANCE; HOP AVICENNE, DEPT MICROBIOL, BOBIGNY, FRANCE; HOP JEAN VERDIER, DEPT PATHOL, F-93140 BONDY, FRANCE; HOP JEAN VERDIER, DEPT ORAL MED, F-93140 BONDY, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP			Deny, Paul/C-6099-2011					ABE K, 1987, J INFECT DIS, V155, P1078, DOI 10.1093/infdis/155.5.1078; BLOCH KJ, 1965, MEDICINE, V44, P187, DOI 10.1097/00005792-196505000-00001; CHISHOLM DM, 1968, J CLIN PATHOL, V21, P656, DOI 10.1136/jcp.21.5.656; DUSHEIKO GM, 1990, LANCET, V336, P503, DOI 10.1016/0140-6736(90)92049-N; FLESCHER E, 1991, AM J MED, V90, P283, DOI 10.1016/0002-9343(91)80006-8; FOX RI, 1986, J IMMUNOL, V137, P3162; GOLDING PL, 1970, BRIT MED J, V4, P340, DOI 10.1136/bmj.4.5731.340; GREENSPAN JS, 1974, ORAL SURG ORAL MED O, V37, P217, DOI 10.1016/0030-4220(74)90417-4; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KOJIMA A, 1980, Experimental Animals (Tokyo), V29, P409; MAGRIN S, 1991, J HEPATOL, V13, P56, DOI 10.1016/0168-8278(91)90864-8; MARIETTE X, 1991, AM J MED, V90, P286, DOI 10.1016/0002-9343(91)80007-9; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MISHIRO S, 1990, LANCET, V336, P1400, DOI 10.1016/0140-6736(90)93101-T; Moutsopoulos H. M., 1987, SJOGRENS SYNDROME CL, P258; SCOTT J, 1980, J BIOL BUCCALE, V8, P187; TAKAMATSU K, 1990, LANCET, V336, P1515, DOI 10.1016/0140-6736(90)93229-I; TODROS L, 1991, J HEPATOL, V13, P128, DOI 10.1016/0168-8278(91)90874-B; VENTO S, 1989, LANCET, V2, P926	19	479	487	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 8	1992	339	8789					321	323		10.1016/0140-6736(92)91645-O	http://dx.doi.org/10.1016/0140-6736(92)91645-O			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346409	Green Published			2022-12-01	WOS:A1992HC77100002
J	JONES, KP; BAIN, DJG; MIDDLETON, M; MULLEE, MA				JONES, KP; BAIN, DJG; MIDDLETON, M; MULLEE, MA			CORRELATES OF ASTHMA MORBIDITY IN PRIMARY CARE	BRITISH MEDICAL JOURNAL			English	Article							PRESSURIZED AEROSOL INHALERS; PEAK EXPIRATORY FLOW; GENERAL-PRACTICE; INTERNATIONAL TRENDS; MANAGEMENT; MORTALITY; PATIENT; PREVALENCE; EDUCATION; CHILDREN	Objectives - To explore the morbidity of patients diagnosed as asthmatic in general practice, to examine the determinants of this morbidity, and to derive a simple morbidity screening tool for use in primary care. Design - Patient interviews, lung function measurements, and data extraction from general practice case notes. Subjects - 300 asthmatic patients aged 5 to 65 years randomly selected from the repeat prescribing registers of three general practices in the Southampton area. Main outcome measures - Reported morbidity using a calculated index based on three questions (Are you in a wheezy or asthmatic condition at least once per week; Have you had time off work or school in the past year because of your asthma; Do you suffer from attacks of wheezing during the night?); mean forced expiratory volume in one second and mean peak expiratory flow (over a seven day period); diurnal variation in peak flow; and the relation of the morbidity index to lung function. Results - Mean forced expiratory volume in one second was 67% predicted (SD 18.4), mean peak expiratory flow was 80% predicted (SD 18.9), and mean diurnal variation was 10% (SD 7.7). 76 subjects were classified as having low morbidity, 95 medium, and 125 high. The morbidity index was significantly associated with forced expiratory volume in one second, mean peak expiratory flow rate, and diurnal variation (p < 0.05); it was not significantly associated with inhaler technique or use of prophylaxis. Conclusions - There was a large burden of persisting morbidity across all ages of patients diagnosed as asthmatic in the three well resourced practices studied. The use of the morbidity index may help to target the asthmatic patients needing more attention by concentrating on those reporting medium to high morbidity.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,SOUTHAMPTON S09 4XY,ENGLAND	University of Southampton	JONES, KP (corresponding author), UNIV SOUTHAMPTON,ALDERMOOR HLTH CTR,FAC MED,PRIMARY MED CARE GRP,SOUTHAMPTON SO1 6SY,ENGLAND.							ALLEN SC, 1986, BRIT J DIS CHEST, V80, P45, DOI 10.1016/0007-0971(86)90008-2; ANDERSON HR, 1990, THORAX, V45, P431, DOI 10.1136/thx.45.6.431; BEASLEY R, 1989, THORAX, V44, P200, DOI 10.1136/thx.44.3.200; BOSANQUET N, 1988, BRIT MED J, V296, P1576, DOI 10.1136/bmj.296.6636.1576; BURNEY PGJ, 1986, LANCET, V2, P323; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; CHARLTON I, 1990, BRIT MED J, V301, P1355, DOI 10.1136/bmj.301.6765.1355; CROMPTON GK, 1982, EUR J RESPIR DIS, V63, P101; EVANS R, 1987, CHEST S, V91, P65; GELLERT AR, 1990, BRIT J GEN PRACT, V40, P197; GONAWARDENA KA, 1987, THORAX, V42, P689; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; HIGGINS BG, 1989, AM REV RESPIR DIS, V140, P1368, DOI 10.1164/ajrccm/140.5.1368; HILTON S, 1982, J ROY SOC MED, V75, P625; HILTON S, 1990, BRIT J GEN PRACT, V40, P505; HILTON S, 1986, LANCET, V1, P26; HOLGATE ST, 1988, Q J MED, V66, P5; HORN CR, 1989, RESP MED, V83, P71, DOI 10.1016/S0954-6111(89)80063-0; HORSLEY MG, 1988, J CLIN PHARM THER, V13, P139, DOI 10.1111/j.1365-2710.1988.tb00170.x; JACKSON R, 1988, CHEST, V94, P914, DOI 10.1378/chest.94.5.914; JENKINSON D, 1988, BRIT MED J, V297, P267, DOI 10.1136/bmj.297.6643.267; JONES K, 1989, J ROY COLL GEN PRACT, V39, P254; Jones K, 1989, UPDATE, V38, P1399; JONES KP, 1990, BRIT MED J, V300, P1629, DOI 10.1136/bmj.300.6740.1629; MAO Y, 1987, CAN MED ASSOC J, V137, P620; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; NEVILLE R, 1990, PRACTITIONER, V234, P417; NORUSIS MJ, 1983, SPSSX INTRO STATISTI; NORUSIS MJ, 1989, SPSS GUIDE DATA ANAL; PEDERSEN S, 1986, ALLERGY, V41, P118, DOI 10.1111/j.1398-9995.1986.tb00287.x; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; STRUNK RC, 1987, J ALLERGY CLIN IMMUN, V80, P455, DOI 10.1016/0091-6749(87)90073-X; TURNERWARWICK M, 1989, J ROY COLL GEN PRACT, V39, P239; WHITE PT, 1989, J ROY COLL GEN PRACT, V39, P182; 1989, LANCET, V2, P199; 1982, BMJ, V285, P1251	36	53	53	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1992	304	6823					361	364		10.1136/bmj.304.6823.361	http://dx.doi.org/10.1136/bmj.304.6823.361			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD387	1540736	Bronze, Green Published			2022-12-01	WOS:A1992HD38700027
J	SCHOUTEN, EG; DEKKER, JM; POOL, J; KOK, FJ; SIMOONS, ML				SCHOUTEN, EG; DEKKER, JM; POOL, J; KOK, FJ; SIMOONS, ML			WELL SHAPED ST SEGMENT AND RISK OF CARDIOVASCULAR MORTALITY	BRITISH MEDICAL JOURNAL			English	Article							SUDDEN-DEATH; MEN; ELECTROCARDIOGRAM; PROGNOSIS	Objective - To investigate the prognostic value of frequently occurring slight variations in the ST segment for cardiovascular mortality in healthy subjects. Design - Follow up study of mortality in relation to variations in ST segment level in a cohort over the 28 years from 1953 to 1981. A case-cohort sampling design was applied to limit the number of electrocardiograms that had to be coded by hand. Setting - General health examination carried out in 1953 of civil servants in Amsterdam and assessment of subsequent mortality. Subjects - Apparently healthy civil servants aged 40 to 65 years: 1583 men and 1508 women. Main outcome measures - Relative risk of variations in ST segment level for mortality from all causes, cardiovascular disease, and coronary heart disease. Results - In men the multivariate relative risks of 15 year mortality from cardiovascular disease and coronary heart disease of slight ST elevation at 80 ms past the J point (compared with isoelectric ST segment) were 0.5 (95% confidence interval 0.3 to 0.9) and 0.4 (0.2 to 0.8), respectively. As expected, ST segment depression (> 0.25 mm) was associated with increased risk: 1.9 (1.1 to 3.0) and 2.2 (1.2 to 3.9), respectively. In women associations were weaker. The full 28 year period showed a similar pattern of somewhat weaker associations for men; among women, however, no predictive value was apparent. Conclusion - These results are empirical evidence for the intuitive opinion among doctors that a curved, upward sloping ST segment, resulting in slight ST elevation at 80 ms, indicates low risk compared with the isoelectric flat, stretched ST segment.	ERASMUS UNIV,CTR THORAX,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam	SCHOUTEN, EG (corresponding author), AGR UNIV WAGENINGEN,DEPT EPIDEMIOL & PUBL HLTH,POB 238,6700 AE WAGENINGEN,NETHERLANDS.							BLACKBURN H, 1970, Circulation Research Supplement, V41, P154; BRUCE RA, 1988, CIRCULATION, V77, P897, DOI 10.1161/01.CIR.77.4.897; BRUCE RA, 1978, HEART ARTERIES VEINS; ELLESTAD MH, 1980, STRESS TESTING PRINC, P95; FORTUIN NJ, 1979, AM J MED, V49, P459; GREENLAND S, 1986, STAT MED, V5, P579, DOI 10.1002/sim.4780050605; KAGAN A, 1989, AM J EPIDEMIOL, V130, P268, DOI 10.1093/oxfordjournals.aje.a115333; KREGER BE, 1987, AM HEART J, V113, P377, DOI 10.1016/0002-8703(87)90281-X; LIAO YL, 1988, J AM COLL CARDIOL, V12, P1494, DOI 10.1016/S0735-1097(88)80016-0; Miettinen O.S., 1985, THEORETICAL EPIDEMIO; MIETTINEN OS, 1985, J CHRON DIS, V38, P543, DOI 10.1016/0021-9681(85)90039-6; MIETTINEN OS, 1982, SCAND J WORK ENV H S, V1, P7; OSTRANDER LD, 1970, AM J CARDIOL, V25, P325, DOI 10.1016/S0002-9149(70)80010-8; Prineas R.J., 1982, MINNESOTA CODE MANUA; QUYYUMI AA, 1983, BRIT HEART J, V50, P460; RABKIN SW, 1982, BRIT HEART J, V47, P546; Reunanen A, 1978, Adv Cardiol, V21, P310; ROSE G, 1978, BRIT HEART J, V40, P636; VANDENBROUCKE JP, 1984, AM J EPIDEMIOL, V119, P742, DOI 10.1093/oxfordjournals.aje.a113795; VANDERHEIDE RM, 1959, THESIS U AMSTERDAM; 1977, MANUAL INT STATISTIC, V1	21	13	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1992	304	6823					356	359		10.1136/bmj.304.6823.356	http://dx.doi.org/10.1136/bmj.304.6823.356			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD387	1540733	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992HD38700024
J	WALSH, KP; SREERAM, N; FRANKS, R; ARNOLD, R				WALSH, KP; SREERAM, N; FRANKS, R; ARNOLD, R			BALLOON DILATATION OF THE ARTERIAL DUCT IN CONGENITAL HEART-DISEASE	LANCET			English	Note							INTERRUPTED AORTIC-ARCH; PROSTAGLANDIN-E1	The systemic circulation of newborn infants with congenital left-heart obstruction is supplied from the right ventricle via a patent arterial duct between the pulmonary artery and descending aorta. The duct closes during the first few days of life, but infusion of prostaglandin E2 can prevent closure in some cases. We report four newborn infants (aged 3-8 days) with intractable heart failure due to severe obstruction of the left heart in the presence of a closing arterial duct. Infusion of prostaglandin E2 did not improve their clinical condition. Cardiac catheterisation and balloon dilatation of their arterial ducts resulted in a dramatic improvement in the babies' clinical condition; during subsequent surgical repair of the infants' hearts, the arterial ducts were found to be widely patent. Balloon dilatation gives immediate and sustained wide patency of the arterial duct in infants who do not respond adequately to prostaglandin E2.			WALSH, KP (corresponding author), ROYAL LIVERPOOL CHILDRENS HOSP,HEART CLIN,LIVERPOOL L12 2AP,ENGLAND.							COLLINSNAKAI RL, 1976, J PEDIATR-US, V88, P959, DOI 10.1016/S0022-3476(76)81049-9; FREED MD, 1981, CIRCULATION, V64, P899, DOI 10.1161/01.CIR.64.5.899; LANG P, 1977, J PEDIATR-US, V91, P805, DOI 10.1016/S0022-3476(77)81047-0; RADFORD DJ, 1976, LANCET, V2, P95	4	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1992	339	8789					331	332		10.1016/0140-6736(92)91648-R	http://dx.doi.org/10.1016/0140-6736(92)91648-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346412				2022-12-01	WOS:A1992HC77100005
J	BENGAL, E; RANSONE, L; SCHARFMANN, R; DWARKI, VJ; TAPSCOTT, SJ; WEINTRAUB, H; VERMA, IM				BENGAL, E; RANSONE, L; SCHARFMANN, R; DWARKI, VJ; TAPSCOTT, SJ; WEINTRAUB, H; VERMA, IM			FUNCTIONAL ANTAGONISM BETWEEN C-JUN AND MYOD PROTEINS - A DIRECT PHYSICAL ASSOCIATION	CELL			English	Article							LEUCINE ZIPPER DOMAIN; DNA-BINDING PROTEINS; MYOGENIC DIFFERENTIATION; GLUCOCORTICOID RECEPTOR; AUTO-REGULATION; FOS; CELLS; MYC; ENHANCER; ELEMENT	The product of the proto-oncogene Jun inhibits myogenesis. Constitutive expression of Jun in myoblasts interferes with the expression and the function of MyoD protein. In transient transfection assays Jun inhibits transactivation of the MyoD promoter, the muscle creatine kinase enhancer, and a reporter gene linked to MyoD DNA-binding sites. Conversely, MyoD suppresses the transactivation by Jun of genes linked to an AP-1 site. We demonstrate that both in vivo and in vitro MyoD and Jun proteins physically interact. Mutational analysis suggests that this interaction occurs via the leucine zipper domain of Jun and the helix-loop-helix region of MyoD.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Fred Hutchinson Cancer Center	BENGAL, E (corresponding author), SALK INST,MOLEC BIOL & VIROL LAB,POB 85800,SAN DIEGO,CA 92186, USA.		scharfmann, raphael/L-3296-2017	Scharfmann, Raphael/0000-0001-7619-337X	NATIONAL CANCER INSTITUTE [F32CA008585] Funding Source: NIH RePORTER; NCI NIH HHS [CA 08585-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOLTZER H, 1975, P NATL ACAD SCI USA, V72, P4051, DOI 10.1073/pnas.72.10.4051; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JONAT G, 1990, CELL, V62, P1189; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; RANSONE LJ, 1990, MOL CELL BIOL, V10, P4565, DOI 10.1128/MCB.10.9.4565; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHARFMANN R, 1991, P NATL ACAD SCI USA, V88, P4626, DOI 10.1073/pnas.88.11.4626; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; SU HY, 1991, ONCOGENE, V6, P1759; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	44	409	411	1	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					507	519		10.1016/0092-8674(92)90187-H	http://dx.doi.org/10.1016/0092-8674(92)90187-H			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1310896				2022-12-01	WOS:A1992HD39800011
J	BOLKER, M; URBAN, M; KAHMANN, R				BOLKER, M; URBAN, M; KAHMANN, R			THE A MATING TYPE LOCUS OF U-MAYDIS SPECIFIES CELL SIGNALING COMPONENTS	CELL			English	Article							YEAST RHODOSPORIDIUM-TORULOIDES; CONJUGATION TUBE FORMATION; USTILAGO-MAYDIS; SACCHAROMYCES-CEREVISIAE; TREMELLA-MESENTERICA; RHODOTORUCINE-A; SEXUAL-DIFFERENTIATION; NEUROSPORA-CRASSA; FISSION YEAST; B-LOCUS	The a mating type locus of the phytopathogenic fungus U. maydis controls fusion of haploid cells and filamentous growth of the dikaryotic mycelium. The a locus exists in two alleles, termed a1 and a2, which are defined by nonhomologous DNA regions comprising 4.5 kb for a1 and 8 kb for a2, flanked by identical sequences. Based on functional assays, mutants, and sequencing, we demonstrate that the mating type in each allele is determined by a set of two genes. One encodes a precursor for a lipopeptide mating factor, and the other specifies the receptor for the pheromone secreted by cells of opposite mating type. Thus, U. maydis employs a novel strategy to determine its mating type by providing the primary determinants of cell-cell recognition directly from the mating type locus.			BOLKER, M (corresponding author), INST GENBIOL FORSCH BERLIN GMBH, IHNESTR 63, W-1000 BERLIN 33, GERMANY.		Urban, Martin/G-6004-2010	Urban, Martin/0000-0003-2440-4352; Bolker, Michael/0000-0002-7366-3855				ABE K, 1975, J BACTERIOL, V122, P710, DOI 10.1128/JB.122.2.710-718.1975; AKADA R, 1989, ARCH MICROBIOL, V152, P484, DOI 10.1007/BF00446934; AKADA R, 1989, MOL CELL BIOL, V9, P3491, DOI 10.1128/MCB.9.8.3491; ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; BANUETT F, 1989, P NATL ACAD SCI USA, V86, P5878, DOI 10.1073/pnas.86.15.5878; BETZ R, 1987, J BIOL CHEM, V262, P546; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; CHRISTENSEN JJ, 1963, AM PHYTOPATHOL SOC M, V2; DAY PR, 1971, P NATL ACAD SCI USA, V68, P533, DOI 10.1073/pnas.68.3.533; DAY PR, 1971, NATURE-NEW BIOL, V231, P19, DOI 10.1038/newbio231019a0; EGEL R, 1990, TRENDS GENET, V6, P369, DOI 10.1016/0168-9525(90)90279-F; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROELIGER EH, 1991, GENE, V100, P113, DOI 10.1016/0378-1119(91)90356-G; FUJINO M, 1980, NATURWISSENSCHAFTEN, V67, P406, DOI 10.1007/BF00405487; Gething M, 1985, PROTEIN TRANSPORT SE, P103; GILLISSEN B, 1992, IN PRESS CELL, V68; GLASS NL, 1990, P NATL ACAD SCI USA, V87, P4912, DOI 10.1073/pnas.87.13.4912; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HOLLIDAY R, 1961, GENET RES, V2, P231, DOI 10.1017/S0016672300000720; Holliday R., 1974, HDB GENETICS, P575, DOI 10.1007/978-1-4899-1710-2_31; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ISHIBASHI Y, 1984, BIOCHEMISTRY-US, V23, P1399, DOI 10.1021/bi00302a010; KAMIYA Y, 1978, BIOCHEM BIOPH RES CO, V83, P1077, DOI 10.1016/0006-291X(78)91505-X; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KOHLER K, 1991, METHOD ENZYMOL, V194, P393; KRONSTAD JW, 1987, CELL, V50, P369, DOI 10.1016/0092-8674(87)90491-0; KRONSTAD JW, 1990, GENE DEV, V4, P1384, DOI 10.1101/gad.4.8.1384; KRONSTAD JW, 1989, P NATL ACAD SCI USA, V86, P978, DOI 10.1073/pnas.86.3.978; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cb.07.110191.003411; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; NAG DK, 1988, GENE, V64, P135, DOI 10.1016/0378-1119(88)90487-8; NAKAYAMA N, 1987, EMBO J, V6, P249, DOI 10.1002/j.1460-2075.1987.tb04746.x; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; PARKER RC, 1977, P NATL ACAD SCI USA, V74, P851, DOI 10.1073/pnas.74.3.851; PUHALLA JE, 1970, GENET RES, V16, P229, DOI 10.1017/S0016672300002457; PUHALLA JE, 1968, GENETICS, V60, P461; PUHALLA JE, 1969, PHYTOPATHOLOGY, V59, P1771; ROWELL JB, 1955, PHYTOPATHOLOGY, V45, P370; ROWELL JB, 1954, PHYTOPATHOLOGY, V44, P356; SAKAGAMI Y, 1979, AGR BIOL CHEM TOKYO, V43, P2643, DOI 10.1080/00021369.1979.10863880; SAKAGAMI Y, 1981, SCIENCE, V212, P1525, DOI 10.1126/science.212.4502.1525; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ B, 1990, CELL, V60, P295, DOI 10.1016/0092-8674(90)90744-Y; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STABEN C, 1990, P NATL ACAD SCI USA, V87, P4917, DOI 10.1073/pnas.87.13.4917; TSUKUDA T, 1988, MOL CELL BIOL, V8, P3703, DOI 10.1128/MCB.8.9.3703; WANG J, 1988, P NATL ACAD SCI USA, V85, P865, DOI 10.1073/pnas.85.3.865; [No title captured]	50	310	317	4	25	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1992	68	3					441	450		10.1016/0092-8674(92)90182-C	http://dx.doi.org/10.1016/0092-8674(92)90182-C			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1310895	hybrid			2022-12-01	WOS:A1992HD39800006
J	BRITTIS, PA; CANNING, DR; SILVER, J				BRITTIS, PA; CANNING, DR; SILVER, J			CHONDROITIN SULFATE AS A REGULATOR OF NEURONAL PATTERNING IN THE RETINA	SCIENCE			English	Article							OPTIC AXONS; PROTEOGLYCANS; GROWTH; INVITRO; CULTURE; INVIVO; NERVE; CELLS	Highly sulfated proteoglycans are correlated with axon boundaries in the developing central nervous system which suggests that these molecules affect neural pattern formation. In the developing mammalian retina, gradual regression of chondroitin sulfate may help control the onset of ganglion cell differentiation and initial direction of their axons. Changes induced by the removal of chondroitin sulfate from intact retinas in culture confirm the function of chondroitin sulfate in retinal histogenesis.			BRITTIS, PA (corresponding author), CASE WESTERN RESERVE UNIV,DEPT NEUROSCI,CLEVELAND,OH 44106, USA.							CARBONETTO S, 1983, J NEUROSCI, V3, P2324; COHEN J, 1986, NATURE, V322, P465, DOI 10.1038/322465a0; COLE GJ, 1991, NEURON, V7, P1007, DOI 10.1016/0896-6273(91)90345-Z; GOLDBERG S, 1977, EXP EYE RES, V25, P399, DOI 10.1016/0014-4835(77)90107-5; HALFTER W, 1987, J NEUROSCI, V7, P3712; HALFTER W, 1985, J COMP NEUROL, V232, P466, DOI 10.1002/cne.902320405; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; HINDS JW, 1974, DEV BIOL, V37, P381, DOI 10.1016/0012-1606(74)90156-0; LEE MK, 1990, CELL MOTIL CYTOSKEL, V17, P118, DOI 10.1002/cm.970170207; MANN I, 1969, DEV HUMAN EYE; MARGOLIS RU, 1975, BIOCHEMISTRY-US, V14, P85, DOI 10.1021/bi00672a014; MORRIS JE, 1987, ARCH BIOCHEM BIOPHYS, V258, P206, DOI 10.1016/0003-9861(87)90337-7; NEWGREEN DF, 1986, CELL TISSUE RES, V244, P299; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Sidman RL, 1961, STRUCTURE EYE, P487; SILVER J, 1979, DEV BIOL, V68, P175, DOI 10.1016/0012-1606(79)90252-5; SILVER J, 1984, DEV BIOL, V106, P485, DOI 10.1016/0012-1606(84)90248-3; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; THRELKELD A, 1989, DEV BIOL, V132, P559, DOI 10.1016/0012-1606(89)90251-0; WATANABE M, 1991, J NEUROBIOL, V22, P85, DOI 10.1002/neu.480220109; ZAREMBA S, 1990, J NEUROSCI, V10, P2985	21	389	397	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1992	255	5045					733	736		10.1126/science.1738848	http://dx.doi.org/10.1126/science.1738848			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC506	1738848				2022-12-01	WOS:A1992HC50600044
J	BROWN, DA; ROSE, JK				BROWN, DA; ROSE, JK			SORTING OF GPI-ANCHORED PROTEINS TO GLYCOLIPID-ENRICHED MEMBRANE SUBDOMAINS DURING TRANSPORT TO THE APICAL CELL-SURFACE	CELL			English	Article							POLARIZED EPITHELIAL-CELLS; VESICULAR STOMATITIS-VIRUS; GLYCOSYL-PHOSPHATIDYLINOSITOL; PLASMA-MEMBRANE; TRYPANOSOMA-BRUCEI; MDCK CELLS; INTRACELLULAR-TRANSPORT; CHOLERA-TOXIN; ORGANIZATION; GLYCOPROTEINS	We show that a protein with a glycosylphosphatidyl inositol (GPI) anchor can be recovered from lysates of epithelial cells in a low density, detergent-insoluble form. Under these conditions, the protein is associated with detergent-resistant sheets and vesicles that contain other GPI-anchored proteins and are enriched in glycosphingolipids, but do not contain a basolateral marker protein. The protein is recovered in this complex only after it has been transported to the Golgi complex, suggesting that protein-sphingolipid microdomains form in the Golgi apparatus and plasma membrane and supporting the model proposed by Simons and colleagues for sorting of certain membrane proteins to the apical surface after intracellular association with glycosphingolipids.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510	Yale University; Yale University					NCI NIH HHS [CA46128] Funding Source: Medline; PHS HHS [A124345] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APGAR JR, 1986, J CELL BIOL, V103, P351, DOI 10.1083/jcb.103.2.351; ARIGA T, 1988, BIOCHEMISTRY-US, V27, P52, DOI 10.1021/bi00401a010; BERGER J, 1987, P NATL ACAD SCI USA, V84, P4885, DOI 10.1073/pnas.84.14.4885; BOOTHROYD JC, 1981, NUCLEIC ACIDS RES, V9, P4735, DOI 10.1093/nar/9.18.4735; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CAPLAN MJ, 1987, NATURE, V329, P632, DOI 10.1038/329632a0; CROSS GAM, 1987, CELL, V48, P179, DOI 10.1016/0092-8674(87)90419-3; DAVIES AA, 1984, BIOCHEM J, V219, P301, DOI 10.1042/bj2190301; DOERING TL, 1990, J BIOL CHEM, V265, P611; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; FEY EG, 1984, J CELL BIOL, V98, P1973, DOI 10.1083/jcb.98.6.1973; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GONZALEZ A, 1987, P NATL ACAD SCI USA, V84, P3738, DOI 10.1073/pnas.84.11.3738; GOTTLIEB TA, 1986, P NATL ACAD SCI USA, V83, P2100, DOI 10.1073/pnas.83.7.2100; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; HAGMANN J, 1982, BIOCHIM BIOPHYS ACTA, V720, P181, DOI 10.1016/0167-4889(82)90010-6; HANSSON GC, 1986, EMBO J, V5, P483, DOI 10.1002/j.1460-2075.1986.tb04237.x; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HOESSLI D, 1985, EXP CELL RES, V156, P239, DOI 10.1016/0014-4827(85)90278-2; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; KELLY RB, 1990, CELL, V61, P5, DOI 10.1016/0092-8674(90)90206-T; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.bi.54.070185.003215; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LETARTEMUIRHEAD M, 1974, BIOCHEM J, V143, P51, DOI 10.1042/bj1430051; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MACALA LJ, 1983, J LIPID RES, V24, P1243; McRoberts J. A., 1981, FUNCTIONALLY DIFFERE, P117; MENON AK, 1988, J BIOL CHEM, V263, P1970; MESCHER MF, 1981, NATURE, V289, P139, DOI 10.1038/289139a0; MESCHER MF, 1986, ADV EXP MED, V184, P387; NELSON WJ, 1987, J CELL BIOL, V104, P1527, DOI 10.1083/jcb.104.6.1527; NELSON WJ, 1986, J CELL BIOL, V103, P1751, DOI 10.1083/jcb.103.5.1751; NICHOLS GE, 1988, J LIPID RES, V29, P1205; PUDDINGTON L, 1987, P NATL ACAD SCI USA, V84, P2756; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROSE JK, 1983, CELL, V34, P513, DOI 10.1016/0092-8674(83)90384-7; ROSE JK, 1982, CELL, V30, P753, DOI 10.1016/0092-8674(82)90280-X; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; STREULI CH, 1981, EXP CELL RES, V136, P247, DOI 10.1016/0014-4827(81)90002-1; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; THIELE HG, 1986, IMMUNOLOGY, V59, P195; THOMPSON TE, 1985, ANNU REV BIOPHYS BIO, V14, P361, DOI 10.1146/annurev.biophys.14.1.361; VAN MEER G, 1982, EMBO J, V1, P847, DOI 10.1002/j.1460-2075.1982.tb01258.x; VITETTA ES, 1973, EUR J IMMUNOL, V3, P446, DOI 10.1002/eji.1830030714; YU J, 1973, Journal of Supramolecular Structure, V1, P233, DOI 10.1002/jss.400010308	54	2574	2627	2	156	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					533	544		10.1016/0092-8674(92)90189-J	http://dx.doi.org/10.1016/0092-8674(92)90189-J			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1531449				2022-12-01	WOS:A1992HD39800013
J	DEVER, TE; FENG, L; WEK, RC; CIGAN, AM; DONAHUE, TF; HINNEBUSCH, AG				DEVER, TE; FENG, L; WEK, RC; CIGAN, AM; DONAHUE, TF; HINNEBUSCH, AG			PHOSPHORYLATION OF INITIATION FACTOR-2-ALPHA BY PROTEIN-KINASE GCN2 MEDIATES GENE-SPECIFIC TRANSLATIONAL CONTROL OF GCN4 IN YEAST	CELL			English	Article							AMINO-ACID BIOSYNTHESIS; DOUBLE-STRANDED-RNA; POLYPEPTIDE-CHAIN INITIATION; SACCHAROMYCES-CEREVISIAE; ALPHA-SUBUNIT; FACTOR-II; MESSENGER-RNA; FACTOR EIF-2; START-SITE; EXPRESSION	We show that phosphorylation of the a subunit of eukaryotic translation initiation factor 2 (eIF-2) by the protein kinase GCN2 mediates translational control of the yeast transcriptional activator GCN4. In vitro, GCN2 specifically phosphorylates the alpha-subunit of rabbit or yeast eIF-2. In vivo, phosphorylation of eIF-2-alpha increases in response to amino acid starvation, which is dependent on GCN2. Substitution of Ser-51 with alanine eliminates phosphorylation of eIF-2-alpha by GCN2 in vivo and in vitro and abolishes increased expression of GCN4 and amino acid biosynthetic genes under its control in amino acid-starved cells. The Asp-51 substitution mimics the phosphorylated state and derepresses GCN4 in the absence of GCN2. Thus, an established mechanism for regulating total protein synthesis in mammalian cells mediates gene-specific translational control in yeast.	INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA	Indiana University System; Indiana University Bloomington	DEVER, TE (corresponding author), NICHHD, MOLEC GENET LOWER EUKARYOTES SECT, BETHESDA, MD 20892 USA.		Dever, Thomas/GSE-0966-2022	Dever, Thomas/0000-0001-7120-9678	NIGMS NIH HHS [GM32263] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032263] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTILHOVALAVICIUS B, 1990, GENETICS, V124, P483; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CIGAN AM, 1991, MOL CELL BIOL, V11, P3217, DOI 10.1128/MCB.11.6.3217; CIGAN AM, 1988, SCIENCE, V242, P93, DOI 10.1126/science.3051379; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; CLEMENS MJ, 1987, J BIOL CHEM, V262, P767; COLTHURST DR, 1987, EUR J BIOCHEM, V166, P357, DOI 10.1111/j.1432-1033.1987.tb13523.x; DAVIES MV, 1989, P NATL ACAD SCI USA, V86, P9163, DOI 10.1073/pnas.86.23.9163; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; ERNST H, 1987, J BIOL CHEM, V262, P1206; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; FOIANI M, 1991, MOL CELL BIOL, V11, P3203, DOI 10.1128/MCB.11.6.3203; HANNIG EM, 1990, GENETICS, V126, P549; HARLOW E, 1988, ANTIBODIES LABORATOR; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; HINNEBUSCH AG, 1983, P NATL ACAD SCI-BIOL, V80, P5374, DOI 10.1073/pnas.80.17.5374; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEVIN D, 1978, P NATL ACAD SCI USA, V75, P1121, DOI 10.1073/pnas.75.3.1121; LONDON IM, 1987, ENZYMES, V18, P359; LUCCHINI G, 1984, MOL CELL BIOL, V4, P1326, DOI 10.1128/MCB.4.7.1326; MAURIDES PA, 1989, ANAL BIOCHEM, V183, P144, DOI 10.1016/0003-2697(89)90182-6; MESSENGUY F, 1976, EUR J BIOCHEM, V67, P335, DOI 10.1111/j.1432-1033.1976.tb10696.x; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MOEHLE CM, 1991, MOL CELL BIOL, V11, P2723, DOI 10.1128/MCB.11.5.2723; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.bi.54.070185.005333; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; NIEDERBERGER P, 1986, CURR GENET, V10, P657, DOI 10.1007/BF00410913; NIEDERBERGER P, 1983, J GEN MICROBIOL, V129, P2571; PATHAK VK, 1988, MOL CELL BIOL, V8, P993, DOI 10.1128/MCB.8.2.993; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; ROUSSOU I, 1988, MOL CELL BIOL, V8, P2132, DOI 10.1128/MCB.8.5.2132; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; SIEKIERKA J, 1984, P NATL ACAD SCI-BIOL, V81, P352, DOI 10.1073/pnas.81.2.352; SIKORSKI RS, 1989, GENETICS, V122, P19; TZAMARIAS D, 1989, CELL, V57, P947, DOI 10.1016/0092-8674(89)90333-4; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WEK RC, 1990, MOL CELL BIOL, V10, P2820, DOI 10.1128/MCB.10.6.2820; WILLIAMS NP, 1989, P NATL ACAD SCI USA, V86, P7515, DOI 10.1073/pnas.86.19.7515; WOLFNER M, 1975, J MOL BIOL, V96, P273, DOI 10.1016/0022-2836(75)90348-4; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479; [No title captured]	47	593	606	2	26	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1992	68	3					585	596		10.1016/0092-8674(92)90193-G	http://dx.doi.org/10.1016/0092-8674(92)90193-G			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1739968				2022-12-01	WOS:A1992HD39800017
J	DEWAEGH, SM; LEE, VMY; BRADY, ST				DEWAEGH, SM; LEE, VMY; BRADY, ST			LOCAL MODULATION OF NEUROFILAMENT PHOSPHORYLATION, AXONAL CALIBER, AND SLOW AXONAL-TRANSPORT BY MYELINATING SCHWANN-CELLS	CELL			English	Article							HEREDITARY HYPERTROPHIC NEUROPATHY; MONOCLONAL-ANTIBODIES DISTINGUISH; MOTOR NEURON DISEASE; TREMBLER MOUSE; MAMMALIAN NEUROFILAMENTS; CYTOSKELETAL PROTEINS; STRUCTURAL PROTEINS; GENE-EXPRESSION; GANGLION-CELLS; SCIATIC-NERVE	Studies in Trembler and control mice demonstrated that myelinating Schwann cells exert a profound influence on axons. Extensive contacts between myelin and axons have been considered structural. However, demyelination decreases neurofilament phosphorylation, slow axonal transport, and axonal diameter, as well as significantly increasing neurofilament density. In control sciatic nerves with grafted Trembler nerve segments, these changes were spatially restricted: they were confined to axon segments without normal myelination. Adjacent regions of the same axons had normal diameters, neurofilament phosphorylation, cytoskeletal organization, and axonal transport rates. Close intercellular contacts between myelinating Schwann cells and axons modulate a kinase-phosphatase system acting on neurofilaments and possibly other substrates. Myelination by Schwann cells sculpts the axon-altering functional architecture, electrical properties, and neuronal morphologies.	UNIV PENN,SCH MED,DEPT PATHOL,MED LAB,PHILADELPHIA,PA 19104	University of Pennsylvania	DEWAEGH, SM (corresponding author), UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023320, R01NS018616, R56NS023868, R01NS023868] Funding Source: NIH RePORTER; NINDS NIH HHS [NS23868, NS23320, NS18616] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGUAYO AJ, 1977, NATURE, V265, P73, DOI 10.1038/265073a0; BERTHOLD CH, 1982, AXOPLASMIC TRANSPORT, P40; BIZZI A, 1986, ACTA NEUROPATHOL, V71, P154, DOI 10.1007/BF00687978; Brady ST, 1982, AXOPLASMIC TRANSPORT, P206; BREEN KC, 1988, FEBS LETT, V241, P213, DOI 10.1016/0014-5793(88)81064-0; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARDEN MJ, 1987, NEUROCHEM PATHOL, V7, P189; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; CARDEN MJ, 1986, NEUROCHEM PATHOL, V5, P15; CZOSNEK H, 1980, J CELL BIOL, V85, P726, DOI 10.1083/jcb.85.3.726; DEWAEGH S, 1990, J NEUROSCI, V10, P1855; FRIEDE RL, 1970, ANAT REC, V167, P379, DOI 10.1002/ar.1091670402; GOLDSTEIN ME, 1987, J NEUROSCI, V7, P1586; Griffin JW, 1988, INTRINSIC DETERMINAN, P403; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HISANAGA S, 1988, J MOL BIOL, V202, P297, DOI 10.1016/0022-2836(88)90459-7; HOFFMAN PN, 1984, J CELL BIOL, V99, P705, DOI 10.1083/jcb.99.2.705; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; HOFFMAN PN, 1985, J NEUROSCI, V5, P2920; HOFFMAN PN, 1985, J CELL BIOL, V101, P1332, DOI 10.1083/jcb.101.4.1332; JOHNSON GVW, 1988, BRAIN RES, V456, P95, DOI 10.1016/0006-8993(88)90350-2; JONES SM, 1982, J BIOL CHEM, V257, P9902; JULIEN JP, 1982, J BIOL CHEM, V257, P467; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lasec R, 1988, INTRINSIC DETERMINAN, P1; LASEK RJ, 1983, COLD SPRING HARB SYM, V48, P731, DOI 10.1101/SQB.1983.048.01.076; LEE VMY, 1986, J NEUROSCI, V6, P2179; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P7384, DOI 10.1073/pnas.85.19.7384; LEE VMY, 1987, J NEUROSCI, V7, P3474; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; LEWIS SE, 1988, J CELL BIOL, V107, P2689, DOI 10.1083/jcb.107.6.2689; LIEM RKH, 1982, BIOCHEMISTRY-US, V21, P3221, DOI 10.1021/bi00256a029; LOW PA, 1976, J NEUROL SCI, V30, P343, DOI 10.1016/0022-510X(76)90139-8; LOW PA, 1976, J NEUROL SCI, V30, P327, DOI 10.1016/0022-510X(76)90138-6; LOW PA, 1975, J NEUROL SCI, V26, P565, DOI 10.1016/0022-510X(75)90057-X; MCQUARRIE IG, 1986, J NEUROSCI, V6, P1593; MEDORI R, 1988, J NEUROSCI, V8, P1814; MEDORI R, 1988, NEUROLOGY, V38, P59; MONACO S, 1989, NEUROPATHOLOGY, V48, P26; NIXON RA, 1986, J BIOL CHEM, V261, P6298; OBLINGER MM, 1988, J NEUROSCI, V8, P1747; OBLINGER MM, 1987, J NEUROSCI, V7, P453; PAGGI P, 1987, J NEUROSCI, V7, P2397; PARHAD I, 1987, AXONAL TRANSPORT, P473; PRICE RL, 1988, J NEUROCYTOL, V17, P55, DOI 10.1007/BF01735377; ROOTS BI, 1983, SCIENCE, V221, P971, DOI 10.1126/science.6192501; SCHMIDT ML, 1987, LAB INVEST, V56, P282; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; SZARO BG, 1990, J COMP NEUROL, V302, P220, DOI 10.1002/cne.903020204; TASHIRO T, 1987, AXONAL TRANSPORT, P201; TOYOSHIMA I, 1989, J NEUROL SCI, V89, P269, DOI 10.1016/0022-510X(89)90028-2; TRAPP BD, 1990, ANN NY ACAD SCI, V605, P29, DOI 10.1111/j.1749-6632.1990.tb42378.x; WATSON DF, 1989, J NEUROCHEM, V53, P1818, DOI 10.1111/j.1471-4159.1989.tb09248.x; WILLARD M, 1983, CELL, V35, P551, DOI 10.1016/0092-8674(83)90189-7; WONG J, 1987, METAB BRAIN DIS, V2, P291, DOI 10.1007/BF00999699	55	649	652	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					451	463		10.1016/0092-8674(92)90183-D	http://dx.doi.org/10.1016/0092-8674(92)90183-D			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1371237				2022-12-01	WOS:A1992HD39800007
J	DURKOP, H; LATZA, U; HUMMEL, M; EITELBACH, F; SEED, B; STEIN, H				DURKOP, H; LATZA, U; HUMMEL, M; EITELBACH, F; SEED, B; STEIN, H			MOLECULAR-CLONING AND EXPRESSION OF A NEW MEMBER OF THE NERVE GROWTH-FACTOR RECEPTOR FAMILY THAT IS CHARACTERISTIC FOR HODGKINS-DISEASE	CELL			English	Article							TUMOR-NECROSIS-FACTOR; STERNBERG-REED CELLS; MONOCLONAL-ANTIBODY; POINT MUTATIONS; LYMPHOID-CELLS; KI-1 ANTIGEN; PROTEIN; LINES; TRANSLOCATION; EFFICIENCY	In man, Hodgkin's disease (HD) represents the most frequent lymphoma entity whose pathogenesis is still unknown. In order to contribute to the characterization of the molecular mechanisms of this disease, cDNAs coding for the HD characteristic antigen CD30 were cloned from expression libraries of the human HUT-102 cell line using the monoclonal antibodies Ki-1 and Ber-H2. The open reading frame of the cDNA that can be translated from two mRNA species of 2.6 kb, and 3.8 kb, respectively, predicts a 595 amino acid protein with leader, extracellular, single transmembrane, and intracellular domains. When expressed in COS-1 cells, the cDNA presented properties comparable to native CD30 antigen. The CD30 extracellular domain proved to be homologous to members of the nerve growth factor receptor superfamily. Six cysteine-rich motifs could be recognized within the putative ligand-binding domain.	FREE UNIV BERLIN,KLINIKUM STEGLITZ,INST PATHOL,W-1000 BERLIN 45,GERMANY; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114	Free University of Berlin; Harvard University; Massachusetts General Hospital								ANDREESEN R, 1984, BLOOD, V63, P1299; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BARDWELL VJ, 1991, CELL, V65, P125, DOI 10.1016/0092-8674(91)90414-T; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOYLSTON AW, 1985, EUR J IMMUNOL, V15, P738, DOI 10.1002/eji.1830150719; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DIEHL V, 1982, CANCER TREAT REP, V66, P615; DIEHL V, 1981, J CANCER RES CLIN, V101, P111, DOI 10.1007/BF00405072; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ESCHENFELDT WH, 1987, METHOD ENZYMOL, V152, P335; FROESE P, 1987, J IMMUNOL, V139, P2081; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GUEBLER U, 1983, GENE, V25, P263; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSEN H, 1990, RES IMMUNOL, V141, P13, DOI 10.1016/0923-2494(90)90098-J; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HOWARD ST, 1991, VIROLOGY, V180, P633, DOI 10.1016/0042-6822(91)90077-O; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JONES DB, 1985, HEMATOL ONCOL, V3, P133, DOI 10.1002/hon.2900030205; KAMESAKI H, 1986, BLOOD, V68, P285; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; MATSUI M, 1990, ONCOGENE, V5, P249; MCMICHAEL AJ, 1987, LEUKOCYTE TYPING 3; MORGAN R, 1989, BLOOD, V73, P2155; NAWROCKI JF, 1988, J IMMUNOL, V141, P672; OTSU M, 1987, MOL CELL BIOL, V7, P708, DOI 10.1128/MCB.7.2.708; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RAGSDALE C, 1991, NATURE, V350, P660, DOI 10.1038/350660a0; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAADT M, 1980, INT J CANCER, V26, P723, DOI 10.1002/ijc.2910260605; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; SCHWARTING R, 1989, BLOOD, V74, P1678; SCHWARTING R, 1989, LEUCOCYTE TYPING 4, P419; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; STEIN H, 1982, INT J CANCER, V30, P445, DOI 10.1002/ijc.2910300411; STEIN H, 1985, BLOOD, V66, P848; STEIN H, 1989, CANCER RES, V117, P15; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SWAN D, 1972, P NATL ACAD SCI USA, V69, P1408; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VONHEINJE G, 1985, NUCLEIC ACIDS RES, V14, P483	63	605	650	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					421	427		10.1016/0092-8674(92)90180-K	http://dx.doi.org/10.1016/0092-8674(92)90180-K			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1310894				2022-12-01	WOS:A1992HD39800004
J	ESTUS, S; GOLDE, TE; KUNISHITA, T; BLADES, D; LOWERY, D; EISEN, M; USIAK, M; QU, XM; TABIRA, T; GREENBERG, BD; YOUNKIN, SG				ESTUS, S; GOLDE, TE; KUNISHITA, T; BLADES, D; LOWERY, D; EISEN, M; USIAK, M; QU, XM; TABIRA, T; GREENBERG, BD; YOUNKIN, SG			POTENTIALLY AMYLOIDOGENIC, CARBOXYL-TERMINAL DERIVATIVES OF THE AMYLOID PROTEIN-PRECURSOR	SCIENCE			English	Article							ALZHEIMERS-DISEASE; SOLUBLE DERIVATIVES; IDENTIFICATION; PHOSPHORYLATION; BIOGENESIS; SULFATE; PEPTIDE	The 39- to 43-amino acid amyloid beta-protein (beta-AP), which is deposited as amyloid in Alzheimer's disease, is encoded as an internal peptide that begins 99 residues from the carboxyl terminus of a 695- to 770-amino acid glycoprotein referred to as the amyloid beta-protein precursor (beta-APP). To clarify the processing that produces amyloid, carboxyl-terminal derivatives of the beta-APP were analyzed. This analysis showed that the beta-APP is normally processed into a complex set of 8- to 12-kilodalton carboxyl-terminal derivatives. The two largest derivatives in human brain have the entire beta-AP at or near their amino terminus and are likely to be intermediates in the pathway leading to amyloid deposition.	NATL INST NEUROSCI,KODAIRA,TOKYO 187,JAPAN; UPJOHN CO,KALAMAZOO,MI 49001	National Center for Neurology & Psychiatry - Japan; Pfizer	ESTUS, S (corresponding author), CASE WESTERN RESERVE UNIV,INST PATHOL,DIV NEUROPATHOL,CLEVELAND,OH 44106, USA.			Lowery, David/0000-0001-5111-4719	NIA NIH HHS [AG06656, AG08012, AG08992] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG006656, P50AG008012, R35AG008992] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GANDY S, 1988, P NATL ACAD SCI USA, V85, P6218, DOI 10.1073/pnas.85.16.6218; HAMBOR JE, 1988, P NATL ACAD SCI USA, V85, P4010, DOI 10.1073/pnas.85.11.4010; HARLOW E, 1988, ANTIBODIES LABORATOR; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PALMERT MR, 1989, BIOCHEM BIOPH RES CO, V165, P182, DOI 10.1016/0006-291X(89)91052-8; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WOLF D, 1990, EMBO J, V9, P2079, DOI 10.1002/j.1460-2075.1990.tb07375.x; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201	18	410	437	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1992	255	5045					726	728		10.1126/science.1738846	http://dx.doi.org/10.1126/science.1738846			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC506	1738846				2022-12-01	WOS:A1992HC50600041
J	FRANGIONI, JV; BEAHM, PH; SHIFRIN, V; JOST, CA; NEEL, BG				FRANGIONI, JV; BEAHM, PH; SHIFRIN, V; JOST, CA; NEEL, BG			THE NONTRANSMEMBRANE TYROSINE PHOSPHATASE PTP-1B LOCALIZES TO THE ENDOPLASMIC-RETICULUM VIA ITS 35 AMINO-ACID C-TERMINAL SEQUENCE	CELL			English	Article							HUMAN-PLACENTA; PROTEIN-KINASE; SIGNAL TRANSDUCTION; PLASMA-MEMBRANE; KIDNEY-CELLS; EXPRESSION; RECEPTOR; GENE; PURIFICATION; ANTIBODIES	We report the first intracellular characterization of an endogenous nontransmembrane protein tyrosine phosphatase (PTP). Using affinity-purified polyclonal antibodies, we have identified PTP-1B as a 50 kd serine phosphoprotein in immunoprecipitation and immunoblotting assays. Surprisingly, indirect immunofluorescence experiments indicate that PTP-1B is localized predominantly i n the endoplasmic reticulum (ER). Subcellular fractionation is consistent with this localization and establishes that PTP-IB is tightly associated with microsomal membranes, with its phosphatase domain oriented towards the cytoplasm. The C-terminal 35 amino acids of PTP-1B are both necessary and sufficient for targeting to the ER. The finding of a tyrosine phosphatase on the ER suggests new possibilities for cellular events controlled by tyrosine phosphorylation.			FRANGIONI, JV (corresponding author), BETH ISRAEL HOSP, MOLEC MED UNIT, BOSTON, MA 02215 USA.				NCI NIH HHS [R01-CA-49152] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049152] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUDIGIER Y, 1988, J BIOL CHEM, V263, P16352; Ausubel FM., 1988, CURRENT PROTOCOLS MO; AVRUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334, DOI 10.1016/0005-2736(71)90331-2; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BOLEN JB, 1989, TRENDS BIOCHEM SCI, V14, P404, DOI 10.1016/0968-0004(89)90288-0; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CRIMAUDO C, 1987, EMBO J, V6, P75, DOI 10.1002/j.1460-2075.1987.tb04721.x; DAILEY HA, 1981, J BIOL CHEM, V256, P3951; DEUTSCHER MP, 1990, METHOD ENZYMOL, V182, P220; DEUTSCHER MP, 1990, METHOD ENZYMOL, V182, P62; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GEORGE SK, 1991, BIOCHIM BIOPHYS ACTA, V1061, P26, DOI 10.1016/0005-2736(91)90264-9; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HARLOW E, 1988, ANTIBODIES LABORATOR; HORTSCH M, 1985, J BIOL CHEM, V260, P9137; HORTSCH M, 1986, J CELL BIOL, V103, P241, DOI 10.1083/jcb.103.1.241; HOWELL KE, 1989, TRENDS BIOCHEM SCI, V14, P44, DOI 10.1016/0968-0004(89)90040-6; KAETZEL CS, 1987, BIOCHEM J, V241, P39, DOI 10.1042/bj2410039; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LEE C, 1988, CELL, V54, P37, DOI 10.1016/0092-8674(88)90177-8; LONBERG N, 1983, P NATL ACAD SCI-BIOL, V80, P3661, DOI 10.1073/pnas.80.12.3661; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NIGAM SK, 1989, J BIOL CHEM, V264, P16927; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIGEL MB, 1983, METHOD ENZYMOL, V93, P3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; SPATZ L, 1971, P NATL ACAD SCI USA, V68, P1042, DOI 10.1073/pnas.68.5.1042; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TAPPIA PS, 1991, BIOCHEM J, V278, P69, DOI 10.1042/bj2780069; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0	55	546	561	0	15	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1992	68	3					545	560		10.1016/0092-8674(92)90190-N	http://dx.doi.org/10.1016/0092-8674(92)90190-N			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1739967				2022-12-01	WOS:A1992HD39800014
J	GOLDE, TE; ESTUS, S; YOUNKIN, LH; SELKOE, DJ; YOUNKIN, SG				GOLDE, TE; ESTUS, S; YOUNKIN, LH; SELKOE, DJ; YOUNKIN, SG			PROCESSING OF THE AMYLOID PROTEIN-PRECURSOR TO POTENTIALLY AMYLOIDOGENIC DERIVATIVES	SCIENCE			English	Article							ALZHEIMERS-DISEASE	The approximately 120-kilodalton amyloid beta-protein precursor (beta-APP) is processed into a complex set of 8- to 12-kilodalton carboxyl-terminal derivatives that includes potentially amyloidogenic forms with the approximate 4-kilodalton amyloid beta-protein (beta-AP) at or near their amino terminus. In order to determine if these derivatives are processed in a secretory pathway or by the endosomal-lysosomal system, (i) deletion mutants that produce the normal set of carboxyl-terminal derivatives and shortened secreted derivatives were analyzed and (ii) the effect of inhibitors of endosomal-lysosomal processing was examined. In the secretory pathway, cleavage of the beta-APP occurs at a single site within the beta-AP to generate one secreted derivative and one nonamyloidogenic carboxyl-terminal fragment, whereas, in the endosomal-lysosomal system, a complex set of carboxyl-terminal derivatives is produced that includes the potentially amyloidogenic forms.	HARVARD UNIV,SCH MED,DEPT NEUROL NEUROSCI,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	GOLDE, TE (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,INST PATHOL,DIV NEUROPATHOL,CLEVELAND,OH 44106, USA.							BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; CATALDO AM, 1990, BRAIN RES, V513, P181, DOI 10.1016/0006-8993(90)90456-L; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLE GM, 1991, NEUROBIOL AGING, V12, P85, DOI 10.1016/0197-4580(91)90046-M; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; COLE GM, 1990, MOL BIOL GENETICS AL, P113; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; ESTUS S, 1992, SCIENCE, V248, P492; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; KAWAI M, IN PRESS AM J PATHOL; LUCOTTE G, 1991, NATURE, V351, P530, DOI 10.1038/351530b0; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865	17	704	727	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1992	255	5045					728	730		10.1126/science.1738847	http://dx.doi.org/10.1126/science.1738847			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC506	1738847				2022-12-01	WOS:A1992HC50600042
J	HUANG, YY; COLINO, A; SELIG, DK; MALENKA, RC				HUANG, YY; COLINO, A; SELIG, DK; MALENKA, RC			THE INFLUENCE OF PRIOR SYNAPTIC ACTIVITY ON THE INDUCTION OF LONG-TERM POTENTIATION	SCIENCE			English	Article							TRANSMISSION; HIPPOCAMPUS; STIMULATION; AFFERENTS; VOLLEYS	Long-term potentiation (LTP) is an extensively studied model of synaptic plasticity, in part because it is a plausible biological correlate for the Hebbian synaptic modification that forms the basis for theoretical models of neural development, learning, and memory. Although these models must incorporate algorithms that constrain synaptic weight changes, physiological evidence for such mechanisms is limited. Examination of LTP in area CA1 of the hippocampus revealed that the threshold for LTP induction was not fixed but could be strongly influenced by the recent history of synaptic activity. This effect was transient, synapse-specific, and dependent on postsynaptic N-methyl-D-aspartate (NMDA) receptor activation. These results suggest that the threshold for LTP induction may be continually adjusted according to the recent history of NMDA receptor activation and provide a physiological mechanism by which LTP can be transiently inhibited.	UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Colino, Asuncion/H-6970-2017	Colino, Asuncion/0000-0002-7061-9197	NIMH NIH HHS [MH45334, MH00942] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH045334] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABRAHAM WC, 1986, NEUROSCI LETT, V70, P217, DOI 10.1016/0304-3940(86)90466-0; BEAR MF, 1987, SCIENCE, V237, P42, DOI 10.1126/science.3037696; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BROWN TH, 1990, ANNU REV NEUROSCI, V13, P475, DOI 10.1146/annurev.ne.13.030190.002355; COAN EJ, 1989, NEUROSCI LETT, V105, P205, DOI 10.1016/0304-3940(89)90038-4; COLINO A, 1992, J NEUROSCI, V12, P180; FUJII S, 1991, BRAIN RES, V555, P112, DOI 10.1016/0006-8993(91)90867-U; Gluck M. A., 1990, NEUROSCIENCE CONNECT; HEBB DO, 1949, ORG BEHAVIOR; KAUER JA, 1988, NATURE, V334, P250, DOI 10.1038/334250a0; LARSON J, 1986, SCIENCE, V232, P985, DOI 10.1126/science.3704635; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; NICOLL RA, 1981, J NEUROSCI METH, V4, P153, DOI 10.1016/0165-0270(81)90049-2; WINSON J, 1986, SCIENCE, V234, P985, DOI 10.1126/science.3775372; YANG XD, 1991, P NATL ACAD SCI USA, V88, P4299, DOI 10.1073/pnas.88.10.4299	18	332	334	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1992	255	5045					730	733		10.1126/science.1346729	http://dx.doi.org/10.1126/science.1346729			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC506	1346729				2022-12-01	WOS:A1992HC50600043
J	KOCKS, C; GOUIN, E; TABOURET, M; BERCHE, P; OHAYON, H; COSSART, P				KOCKS, C; GOUIN, E; TABOURET, M; BERCHE, P; OHAYON, H; COSSART, P			L-MONOCYTOGENES-INDUCED ACTIN ASSEMBLY REQUIRES THE ACTA GENE-PRODUCT, A SURFACE PROTEIN	CELL			English	Article							CELL-LINE CACO-2; LISTERIA-MONOCYTOGENES; SHIGELLA-FLEXNERI; INTRACELLULAR GROWTH; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; F-ACTIN; SPREAD; IDENTIFICATION; PLASMID	The intracellular pathogenic bacterium L. monocytogenes can spread directly from cell to cell without leaving the cytoplasm. The mechanism of this movement, generated through bacterially induced actin polymerization, is not understood. By analyzing an avirulent Tn917-lac mutant defective for actin polymerization, we have identified a bacterial component involved in this process. The transposon had inserted in actA, the second gene of an operon. Gene disruption of downstream genes and transformation of the mutant strain with actA showed that the actA gene encodes a surface protein necessary for bacterially induced actin assembly. Our results indicate that it is a 610 amino acid protein with an apparent molecular weight of 90 kd.	INST PASTEUR,CENT MICROSCOPIE ELECTR STN,F-75724 PARIS 15,FRANCE; UNIV PARIS 05,MICROBIOL LAB,F-75730 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite	KOCKS, C (corresponding author), INST PASTEUR,GENET MOLEC LISTERIA LAB,25 & 28 RUE DR ROUX,F-75724 PARIS 15,FRANCE.			TABOURET, Marc/0000-0003-0499-2804				BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BRYAN J, 1989, J BIOL CHEM, V264, P13873; COSSART P, 1989, MOL BIOL MED, V6, P463; COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; DABIRI GA, 1990, P NATL ACAD SCI USA, V87, P6068, DOI 10.1073/pnas.87.16.6068; DERYCKE J, 1989, J CLIN MICROBIOL, V27, P983, DOI 10.1128/JCM.27.5.983-988.1989; DOMANN E, 1991, INFECT IMMUN, V59, P65, DOI 10.1128/IAI.59.1.65-72.1991; FUZI M, 1962, NATURE, V13, P195; GAILLARD JL, 1987, INFECT IMMUN, V55, P2822, DOI 10.1128/IAI.55.11.2822-2829.1987; GRAY ML, 1966, BACTERIOL REV, V30, P309, DOI 10.1128/MMBR.30.2.309-382.1966; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HAVELL EA, 1986, INFECT IMMUN, V54, P787, DOI 10.1128/IAI.54.3.787-792.1986; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; INGALLS HM, 1986, P NATL ACAD SCI USA, V83, P4779, DOI 10.1073/pnas.83.13.4779; KADURUGAMUWA JL, 1991, INFECT IMMUN, V59, P3463, DOI 10.1128/IAI.59.10.3463-3471.1991; KUHN M, 1990, INFECT IMMUN, V58, P3477, DOI 10.1128/IAI.58.11.3477-3486.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETT MC, 1989, J BACTERIOL, V171, P353, DOI 10.1128/jb.171.1.353-359.1989; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LU X, 1989, Nucleic Acids Research, V17, P442, DOI 10.1093/nar/17.1.442; LUCAS RD, 1989, LETT APPL MICROBIOL, V9, P215, DOI 10.1111/j.1472-765X.1989.tb00329.x; MAKINO S, 1986, CELL, V46, P551, DOI 10.1016/0092-8674(86)90880-9; MENGAUD J, 1991, MOL MICROBIOL, V5, P2273, DOI 10.1111/j.1365-2958.1991.tb02158.x; MENGAUD J, 1989, INFECT IMMUN, V57, P3695, DOI 10.1128/IAI.57.12.3695-3701.1989; MENGAUD J, 1991, INFECT IMMUN, V59, P1043, DOI 10.1128/IAI.59.3.1043-1049.1991; MICHEL E, 1990, MOL MICROBIOL, V4, P2167, DOI 10.1111/j.1365-2958.1990.tb00578.x; MOULDER JW, 1985, MICROBIOL REV, V49, P298, DOI 10.1128/MMBR.49.3.298-337.1985; MOUNIER J, 1990, INFECT IMMUN, V58, P1048, DOI 10.1128/IAI.58.4.1048-1058.1990; OAKS EV, 1985, INFECT IMMUN, V48, P124, DOI 10.1128/IAI.48.1.124-129.1985; PAL T, 1989, INFECT IMMUN, V57, P477; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETIT MA, 1990, J BACTERIOL, V172, P6736, DOI 10.1128/jb.172.12.6736-6740.1990; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; PRICE GJ, 1987, BIOCHEM J, V245, P595, DOI 10.1042/bj2450595; RACZ P, 1970, ACTA MICROBIOL HUNG, V17, P221; Sambrook J., 1989, MOL CLONING LAB MANU; SHAW JH, 1985, J BACTERIOL, V164, P782, DOI 10.1128/JB.164.2.782-796.1985; SULLIVAN M, 1984, GENE, V29, P24; SUN AN, 1990, INFECT IMMUN, V58, P3770, DOI 10.1128/IAI.58.11.3770-3778.1990; TILNEY LG, 1990, J CELL BIOL, V111, P2979, DOI 10.1083/jcb.111.6.2979; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; Vandekerckhove J, 1990, CURR OPIN CELL BIOL, V2, P41, DOI 10.1016/S0955-0674(05)80029-8; VICENTE MF, 1985, FEMS MICROBIOL LETT, V30, P77; WEST RR, 1991, J BIOL CHEM, V266, P21886; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0	48	653	689	0	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					521	531		10.1016/0092-8674(92)90188-I	http://dx.doi.org/10.1016/0092-8674(92)90188-I			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1739966				2022-12-01	WOS:A1992HD39800012
J	PETERSON, CL; HERSKOWITZ, I				PETERSON, CL; HERSKOWITZ, I			CHARACTERIZATION OF THE YEAST SWI1, SWI2, AND SWI3 GENES, WHICH ENCODE A GLOBAL ACTIVATOR OF TRANSCRIPTION	CELL			English	Article							RNA POLYMERASE-II; MATING-TYPE LOCUS; SACCHAROMYCES-CEREVISIAE; HO-GENE; BINDING-PROTEIN; DNA-BINDING; ALCOHOL-DEHYDROGENASE; MESSENGER-RNA; EXPRESSION; SUBUNIT	The yeast SWI1, SWI2 (SNF2), and SWI3 genes are required for transcription of HO and INO1 genes. We show that they are also required for transcription of ADH1, ADH2, SUC2, GAL1, and GAL10 and for function of simple UAS elements with binding sites for yeast GAL4 or Drosophila ftz proteins. SWI3 encodes a 99 kd nuclear protein containing a large, highly acidic N-terminal domain. SWI1 is identical to ADR6, which encodes a positive regulator of ADH1 and ADH2. Transcription of HO also requires SNF5 and SNF6. These and other observations suggest that SWI1, SWI2, SWI3, SNF5, and SNF6 may be components of a large multi-subunit complex. We propose that these products perform a general role in transcription by assisting gene-specific regulatory proteins.			PETERSON, CL (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.				NCI NIH HHS [CA09270-16] Funding Source: Medline; NIAID NIH HHS [AI8738] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMS E, 1986, MOL CELL BIOL, V6, P3643, DOI 10.1128/MCB.6.11.3643; ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; DENIS CL, 1981, J MOL BIOL, V148, P355, DOI 10.1016/0022-2836(81)90181-9; ESTRUCH F, 1990, MOL CELL BIOL, V10, P2544, DOI 10.1128/MCB.10.6.2544; FITZPATRICK VD, 1989, NATURE, V337, P666, DOI 10.1038/337666a0; GINIGER E, 1988, P NATL ACAD SCI USA, V85, P382, DOI 10.1073/pnas.85.2.382; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HAPPEL AM, 1991, GENETICS, V128, P69; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; JENSEN R, 1983, P NATL ACAD SCI-BIOL, V80, P3035, DOI 10.1073/pnas.80.10.3035; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KEMPHUES KJ, 1982, CELL, V31, P655, DOI 10.1016/0092-8674(82)90321-X; KEMPHUES KJ, 1983, GENETICS, V105, P345; KLIED D, 1981, SCIENCE, V214, P1125; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; Miller JH., 1972, EXPT MOL GENETICS; NASMYTH K, 1985, CELL, V42, P213, DOI 10.1016/S0092-8674(85)80117-3; NEIGEBORN L, 1984, GENETICS, V108, P845; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; OHARA PJ, 1988, NUCLEIC ACIDS RES, V16, P10153, DOI 10.1093/nar/16.21.10153; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; RUSSELL DW, 1986, MOL CELL BIOL, V6, P4281, DOI 10.1128/MCB.6.12.4281; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SNYDER M, 1989, J CELL BIOL, V108, P1419, DOI 10.1083/jcb.108.4.1419; SPRAGUE GF, 1983, CELL, V32, P409, DOI 10.1016/0092-8674(83)90460-9; STEINBERG RA, 1981, J BIOL CHEM, V256, P731; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STERN M, 1985, THESIS U CALIFORNIA; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STJOHN TP, 1981, J MOL BIOL, V152, P285, DOI 10.1016/0022-2836(81)90244-8; TAGUCHI AKW, 1987, GENETICS, V116, P523; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353	45	507	518	0	24	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1992	68	3					573	583		10.1016/0092-8674(92)90192-F	http://dx.doi.org/10.1016/0092-8674(92)90192-F			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1339306				2022-12-01	WOS:A1992HD39800016
J	SCHMIDT, HHHW; WARNER, TD; ISHII, K; SHENG, H; MURAD, F				SCHMIDT, HHHW; WARNER, TD; ISHII, K; SHENG, H; MURAD, F			INSULIN-SECRETION FROM PANCREATIC B-CELLS CAUSED BY L-ARGININE DERIVED NITROGEN-OXIDES	SCIENCE			English	Article							NITRIC-OXIDE; DIABETES-MELLITUS; RELEASE; CALMODULIN; CALCIUM; ISLETS; LIVER; RATS	L-Arginine causes insulin release from pancreatic B cells. Data from three model systems support the hypothesis that L-arginine-derived nitrogen oxides (NOs) mediate insulin release stimulated by L-arginine in the presence of D-glucose and by the hypoglycemic drug tolbutamide. The formation of NO in pancreatic B cells was detected both chemically and by the NO-induced accumulation of guanosine 3',5'-monophosphate. N(G)-substituted L-arginine analogs inhibited the release of both insulin and NO. Protein immunoblot and histochemical analysis with antiserum to type I NO synthase suggest that the formation of NO in pancreatic B cells is catalyzed by an NADPH- (reduced form of nicotinamide adenine dinucleotide phosphate), Ca2+/calmodulin-dependent type I NO synthase of about 150 kilodaltons.	UNIV SHIZUOKA,SCH PHARMACEUT SCI,DEPT PHARMACOL,SHIZUOKA 422,JAPAN; ABBOTT LABS,ABBOTT PK,IL 60064	University of Shizuoka; Abbott Laboratories	SCHMIDT, HHHW (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT PHARMACOL,CHICAGO,IL 60611, USA.		Warner, Timothy D/A-1980-2009; Schmidt, Harald HHW/B-1549-2008	Warner, Timothy D/0000-0003-3988-4408; Schmidt, Harald HHW/0000-0003-0419-5549	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028474] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030787] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 28474] Funding Source: Medline; NIDDK NIH HHS [DK 30787] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BJAALAND T, 1988, BIOCHEM SOC T, V16, P1017, DOI 10.1042/bst0161017; BJAALAND T, 1990, DIABETOLOGIA, V32, pA467; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; FLOYD JC, 1966, J CLIN INVEST, V45, P1487, DOI 10.1172/JCI105456; FORSTERMANN U, 1990, MOL PHARMACOL, V38, P7; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; GAGLIARDINO JJ, 1980, BIOCHEM J, V192, P919, DOI 10.1042/bj1920919; GANDA OP, 1984, DIABETES, V33, P516, DOI 10.2337/diabetes.33.6.516; GROSS SS, 1990, BIOCHEM BIOPH RES CO, V170, P96, DOI 10.1016/0006-291X(90)91245-N; HELLMAN B, 1971, ENDOCRINOLOGY, V89, P1432, DOI 10.1210/endo-89-6-1432; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; HUGHES SJ, 1990, BIOCHEM J, V267, P227, DOI 10.1042/bj2670227; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; ISHII K, 1990, EUR J PHARMACOL, V176, P219; KAMATA K, 1989, BRIT J PHARMACOL, V97, P614, DOI 10.1111/j.1476-5381.1989.tb11993.x; KIMURA H, 1975, J BIOL CHEM, V250, P8016; LAYCHOCK SG, 1991, ENDOCRINOLOGY, V129, P3043, DOI 10.1210/endo-129-6-3043; LAYCHOCK SG, 1981, ENDOCRINOLOGY, V108, P1197, DOI 10.1210/endo-108-4-1197; LUHESHI GN, 1990, BRIT J PHARMACOL, V101, P411, DOI 10.1111/j.1476-5381.1990.tb12723.x; MANN GE, 1990, NITRIC OXIDE L ARGIN, P331; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MULLOY AL, 1982, HORM METAB RES, V14, P471, DOI 10.1055/s-2007-1019050; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PANTEN U, 1975, P115; PANTEN U, 1973, N-S ARCH PHARMACOL, V276, P55, DOI 10.1007/BF00500778; SCHMIDT H, UNPUB; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1988, EUR J PHARMACOL, V154, P213, DOI 10.1016/0014-2999(88)90101-X; SENER A, 1990, ENDOCRINOLOGY, V127, P107, DOI 10.1210/endo-127-1-107; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; VERSPOHL EJ, 1989, N-S ARCH PHARMACOL, V339, P348; WARD WK, 1984, J CLIN INVEST, V74, P1318, DOI 10.1172/JCI111542; WOLLHEIM CB, 1975, J BIOL CHEM, V250, P1354	33	394	403	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1992	255	5045					721	723		10.1126/science.1371193	http://dx.doi.org/10.1126/science.1371193			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC506	1371193				2022-12-01	WOS:A1992HC50600039
J	STEIN, D; NUSSLEINVOLHARD, C				STEIN, D; NUSSLEINVOLHARD, C			MULTIPLE EXTRACELLULAR ACTIVITIES IN DROSOPHILA EGG PERIVITELLINE FLUID ARE REQUIRED FOR ESTABLISHMENT OF EMBRYONIC DORSAL-VENTRAL POLARITY	CELL			English	Article							FEMALE STERILE MUTATIONS; DNA-BINDING SUBUNIT; TOLL GENE-PRODUCT; NF-KAPPA-B; SERINE PROTEASE; REL ONCOGENE; TRANSMEMBRANE PROTEIN; NUCLEAR-LOCALIZATION; DORSOVENTRAL PATTERN; MELANOGASTER	Twelve maternal effect genes (the dorsal group and cactus) are required for the establishment of the embryonic dorsal-ventral axis in the Drosophila embryo. Embryonic dorsal-ventral polarity is defined within the perivitelline compartment surrounding the embryo by the ventral formation of a ligand for the Toll receptor. Here, by transplantation of perivitelline fluid we demonstrate the presence of three separate activities present in the perivitelline fluid that can restore dorsal-ventral polarity to mutant easter, snake, and spatzle embryos, respectively. These activities are not capable of defining the polarity of the dorsal-ventral axis; instead they restore structures according to the intrinsic dorsal-ventral polarity of the mutant embryos. They appear to be involved in the ventral formation of a ligand for the Toll protein. This process requires serine proteolytic activity; the infection of serine protease inhibitors into the perivitelline space of wild-type embryos results in the formation of dorsalized embryos.			STEIN, D (corresponding author), MAX PLANCK ENTWICKLUNGSBIOL,SPEMANNSTR 35,W-7400 TUBINGEN,GERMANY.							ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ANDERSON KV, 1984, PATTERN FORMATION, P269; ANDERSON KV, 1986, GAMETOGENESIS EARLY, P177; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; DOYLE HJ, 1986, NATURE, V323, P76, DOI 10.1038/323076a0; ERDELYI M, 1989, GENETICS, V122, P111; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; IP YT, 1991, CELL, V64, P439; JIN YS, 1990, CELL, V60, P873, DOI 10.1016/0092-8674(90)90100-S; KEITH FJ, 1990, EMBO J, V9, P4299, DOI 10.1002/j.1460-2075.1990.tb07878.x; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KONRAD KD, 1988, ROUX ARCH DEV BIOL, V197, P75, DOI 10.1007/BF00375930; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LINDSLEY D, 1987, DROS INF SERV, V65; LINDSLEY D, 1990, DROS INF SERV, V68; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; N?sslein-Volhard C., 1979, DETERMINANTS SPATIAL, P185; NUSSLEINVOLHARD C, 1980, NATURE, V283, P474, DOI 10.1038/283474a0; Poulson D. F., 1950, BIOL DROSOPHILA, P168; RICE TB, 1973, THESIS YALE U NEW HA; Roberts D.B., 1986, P1; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROTH S, 1991, DEVELOPMENT, V112, P371; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; RUSHLOW C, 1987, NATURE, V330, P583, DOI 10.1038/330583a0; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SCHUPBACH T, 1989, GENETICS, V121, P101; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SEIFERT E, 1987, ROUX ARCH DEV BIOL, V196, P78, DOI 10.1007/BF00402028; Sonnenblick B., 1950, BIOL DROSOPHILA; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; Tearle R., 1987, DROSOPHILA INFORMATI, V66, P209; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wieschaus E., 1986, P199; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	53	104	105	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					429	440		10.1016/0092-8674(92)90181-B	http://dx.doi.org/10.1016/0092-8674(92)90181-B			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1739964				2022-12-01	WOS:A1992HD39800005
J	STERN, LJ; WILEY, DC				STERN, LJ; WILEY, DC			THE HUMAN CLASS-II MHC PROTEIN HLA-DR1 ASSEMBLES AS EMPTY ALPHA-BETA-HETERODIMERS IN THE ABSENCE OF ANTIGENIC PEPTIDE	CELL			English	Article							B-CELL LINE; ENDOPLASMIC-RETICULUM; INVARIANT CHAIN; HISTOCOMPATIBILITY ANTIGENS; ENDOGENOUS ANTIGEN; T-CELLS; HLA-DR; MOLECULES; BINDING; IA	We have produced the human class II histocompatibility protein, HLA-DRI, as a soluble, secreted glycoprotein in insect cells infected with baculoviruses carrying truncated alpha and beta-subunit genes. The peptide-binding site is empty, and the empty molecules are fully competent to bind antigenic peptide. We used the empty molecules to measure an intrinsic rate for peptide association, and to investigate the role of peptide in stabilizing the class II structure. Peptide binding kinetics for the empty molecule are only 10-fold faster than for peptide exchange into an occupied site, suggesting that a conformational change may accompany peptide binding. The native alpha-beta-heterodimer assembles in the absence of antigenic peptide, but peptide binding stabilizes the empty heterodimer against aggregation and against SDS-induced denaturation.	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute	STERN, LJ (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.							BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; BUSCH R, 1990, J IMMUNOL METHODS, V134, P1, DOI 10.1016/0022-1759(90)90107-7; BUUS S, 1988, SCIENCE, V242, P1045, DOI 10.1126/science.3194755; BUUS S, 1987, IMMUNOL REV, V98, P115, DOI 10.1111/j.1600-065X.1987.tb00522.x; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CEPPELLINI R, 1989, NATURE, V339, P392, DOI 10.1038/339392a0; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; CRESSWELL P, 1987, CRIT REV IMMUNOL, V7, P31; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P6167, DOI 10.1021/bi00239a013; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DORNMAIR K, 1989, COLD SH Q B, V54, P409; DORNMAIR K, 1990, P NATL ACAD SCI USA, V87, P4134, DOI 10.1073/pnas.87.11.4134; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GORGA JC, 1991, RES IMMUNOL, V142, P401, DOI 10.1016/0923-2494(91)90038-K; GORGA JC, 1986, CELL IMMUNOL, V103, P160, DOI 10.1016/0008-8749(86)90077-8; GORGA JC, 1987, J BIOL CHEM, V262, P16087; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HARDING CV, 1990, P NATL ACAD SCI USA, V87, P5553, DOI 10.1073/pnas.87.14.5553; HARLOW E, 1988, ANTIBODIES LABORATOR; HOFMANN T, 1988, BIOCHEMISTRY-US, V27, P1140, DOI 10.1021/bi00404a010; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; JARVIS DL, 1989, MOL CELL BIOL, V9, P214, DOI 10.1128/MCB.9.1.214; JENSEN PE, 1991, J EXP MED, V174, P1111, DOI 10.1084/jem.174.5.1111; JENSEN PE, 1990, J EXP MED, V171, P1779, DOI 10.1084/jem.171.5.1779; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; NYGARD NR, 1991, J EXP MED, V174, P243, DOI 10.1084/jem.174.1.243; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; ORTIZNAVARRETE V, 1991, P NATL ACAD SCI USA, V88, P3594, DOI 10.1073/pnas.88.9.3594; OSULLIVAN D, 1990, J IMMUNOL, V145, P1799; ROCHE PA, 1990, J IMMUNOL, V144, P1849; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SHACKELFORD DA, 1983, J IMMUNOL, V130, P274; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SUMMERS MD, 1988, TEXAS AGR EXPT STATI, V1555; TAMPE R, 1991, P NATL ACAD SCI USA, V88, P4661, DOI 10.1073/pnas.88.11.4661; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TIJSSEN P, 1985, LABORATORY TECHNIQUE, V15; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TRAUNECKER A, 1989, IMMUNOL TODAY, V10, P29, DOI 10.1016/0167-5699(89)90062-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANBLEEK GM, 1990, NATURE, V348, P213; WATTS TH, 1986, P NATL ACAD SCI USA, V83, P9660, DOI 10.1073/pnas.83.24.9660; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J	69	299	330	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					465	477		10.1016/0092-8674(92)90184-E	http://dx.doi.org/10.1016/0092-8674(92)90184-E			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1371238				2022-12-01	WOS:A1992HD39800008
J	TREACY, MN; NEILSON, LI; TURNER, EE; HE, X; ROSENFELD, MG				TREACY, MN; NEILSON, LI; TURNER, EE; HE, X; ROSENFELD, MG			TWIN OF I-POU - A 2 AMINO-ACID DIFFERENCE IN THE I-POU HOMEODOMAIN DISTINGUISHES AN ACTIVATOR FROM AN INHIBITOR OF TRANSCRIPTION	CELL			English	Article							DNA-BINDING DOMAIN; MAMMALIAN-CELLS; DROSOPHILA-MELANOGASTER; CAENORHABDITIS-ELEGANS; NEGATIVE REGULATOR; CELLULAR PROTEINS; GENE-EXPRESSION; STEROID BINDING; LEUCINE ZIPPER; C-ELEGANS	I-POU, a POU domain nuclear protein that lacks two conserved basic amino acids of the POU homeodomain is coexpressed in the developing Drosophila nervous system with a second POU domain transcription factor, Cf1-a. I-POU does not bind to DNA but forms a POU domain-mediated, high affinity heterodimer with Cf1-a, inhibiting its ability to bind and activate the dopa decarboxylase gene. The I-POU/Cf1-a dimerization interface encompasses only the N-terminal basic region and helices 1 and 2 of the POU homeodomains with precise amino acid and alpha-helical requirements. twin of I-POU, an alternatively spliced transcript of the I-POU gene, encodes a protein containing the two basic amino acid residues absent in I-POU. Twin of I-POU is incapable of dimerizing with Cf1-a, but can act as a positive transcription factor on targets distinct from those regulated by Cf1-a. These findings suggest that the I-POU genomic locus simultaneously generates both a specific activator and inhibitor of gene transcription, capable of modulating two distinct regulatory programs during neural development.	UNIV CALIF SAN DIEGO, SCH MED, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, DEPT BIOL, LA JOLLA, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	TREACY, MN (corresponding author), UNIV CALIF SAN DIEGO, SCH MED, EUKARYOT REGULATORY BIOL PROGRAM, LA JOLLA, CA 92093 USA.		Turner, Eric e/K-3556-2015	Turner, Eric e/0000-0001-5499-6788				AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; AKAM M, 1987, DEVELOPMENT, V101, P1; ALONSO MC, 1988, EMBO J, V7, P2585, DOI 10.1002/j.1460-2075.1988.tb03108.x; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERMINGHAM JR, 1988, EMBO J, V7, P3211, DOI 10.1002/j.1460-2075.1988.tb03188.x; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; BUSTURIA A, 1990, EMBO J, V9, P3551, DOI 10.1002/j.1460-2075.1990.tb07565.x; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ELSHOLTZ HP, 1990, GENE DEV, V4, P43, DOI 10.1101/gad.4.1.43; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GROYER A, 1987, NATURE, V328, P624, DOI 10.1038/328624a0; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JOHNSON WA, 1990, NATURE, V343, P467, DOI 10.1038/343467a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MCKNIGHT JLC, 1987, P NATL ACAD SCI USA, V84, P7061, DOI 10.1073/pnas.84.20.7061; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OCONNOR MB, 1988, EMBO J, V7, P435, DOI 10.1002/j.1460-2075.1988.tb02831.x; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PRATT WB, 1988, J BIOL CHEM, V263, P267; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STRUHL K, 1991, NEURON, V7, P177, DOI 10.1016/0896-6273(91)90256-Y; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VERRIJZER CP, 1990, EMBO J, V9, P1883, DOI 10.1002/j.1460-2075.1990.tb08314.x; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	83	107	108	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1992	68	3					491	505		10.1016/0092-8674(92)90186-G	http://dx.doi.org/10.1016/0092-8674(92)90186-G			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1346754				2022-12-01	WOS:A1992HD39800010
J	ASLANIDIS, C; JANSEN, G; AMEMIYA, C; SHUTLER, G; MAHADEVAN, M; TSILFIDIS, C; CHEN, C; ALLEMAN, J; WORMSKAMP, NGM; VOOIJS, M; BUXTON, J; JOHNSON, K; SMEETS, HJM; LENNON, GG; CARRANO, AV; KORNELUK, RG; WIERINGA, B; DEJONG, PJ				ASLANIDIS, C; JANSEN, G; AMEMIYA, C; SHUTLER, G; MAHADEVAN, M; TSILFIDIS, C; CHEN, C; ALLEMAN, J; WORMSKAMP, NGM; VOOIJS, M; BUXTON, J; JOHNSON, K; SMEETS, HJM; LENNON, GG; CARRANO, AV; KORNELUK, RG; WIERINGA, B; DEJONG, PJ			CLONING OF THE ESSENTIAL MYOTONIC-DYSTROPHY REGION AND MAPPING OF THE PUTATIVE DEFECT	NATURE			English	Article							VECTORS; DNA	MYOTONIC dystrophy is a common dominant disorder (global incidence of 1:8,000) with variable onset and a protean nature of symptoms mainly involving progressive muscle wasting, myotonia and cataracts 1. To define the molecular defect, we have cloned the essential region of chromosome 19q13.3, including proximal and distal markers 2-7 in a 700-kilobase contig formed by overlapping cosmids and yeast artificial chromosomes (YACs). The central part of the contig bridges an area of about 350 kilobases between two new flanking crossover borders 4,5. This segment has been extensively characterized through the isolation of five YAC clones and the subsequent subcloning in cosmids from which a detailed EcoRI, HindIII, MluI and NotI restriction map has been derived. Two genomic probes and two homologous complementary DNA probes were isolated using the cosmids. These probes are all situated within approximately 10 kilobases of genomic DNA and detect an unstable genomic segment in myotonic dystrophy patients. The length variation in this segment shows similarities to the instability seen at the fragile X locus 8. The physical map location and the genetic characteristics of the length polymorphism is compatible with a direct role in the pathogenesis of myotonic dystrophy.	UNIV CALIF LAWRENCE LIVERMORE NATL LAB,CTR HUMAN GENOME,DIV BIOMED SCI,L-452,LIVERMORE,CA 94550; CATHOLIC UNIV NIJMEGEN,FAC MED SCI,DEPT CELL BIOL & HISTOL,6500 HB NIJMEGEN,NETHERLANDS; CATHOLIC UNIV NIJMEGEN,FAC MED SCI,DEPT HUMAN GENET,6500 HB NIJMEGEN,NETHERLANDS; CHILDRENS HOSP EASTERN ONTARIO,DIV GENET,OTTAWA K1H 8L1,ONTARIO,CANADA; UNIV OTTAWA,DEPT MICROBIOL & IMMUNOL,OTTAWA K1N 6N5,ONTARIO,CANADA; CHARING CROSS & WESTMINSTER MED SCH,DEPT ANAT,LONDON W6 8RF,ENGLAND	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; Radboud University Nijmegen; Radboud University Nijmegen; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Imperial College London			Vooijs, Marc/K-3522-2019; Lennon, Greg/T-4717-2019; Buxton, Jessica/L-9849-2019; Jansen, Gert/HCI-8852-2022; Wieringa, Berend/A-5346-2011; Buxton, Jessica L/I-4033-2014	Wieringa, Berend/0000-0001-9192-8020; Buxton, Jessica L/0000-0002-0918-9335; Jansen, Gert/0000-0002-7524-171X; johnson, keith/0000-0002-8578-5921				BRANSCOMB E, 1990, GENOMICS, V8, P351, DOI 10.1016/0888-7543(90)90293-4; BROOK JD, 1991, J MED GENET, V28, P84, DOI 10.1136/jmg.28.2.84; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; BUXTON J, IN PRESS GENOMICS; CARRANO AV, 1989, GENOMICS, V4, P129, DOI 10.1016/0888-7543(89)90291-7; DEJONG PJ, 1989, CYTOGENET CELL GENET, V51, P985; GRIGGS RC, 1989, NEUROLOGY, V39, P420, DOI 10.1212/WNL.39.3.420; HARLEY HG, 1991, AM J HUM GENET, V49, P68; Harper P.S., 1989, MYOTONIC DYSTROPHY; HERMENS R, 1991, NUCLEIC ACIDS RES, V19, P1726, DOI 10.1093/nar/19.7.1726; JANSEN G, IN PRESS GENOMICS; JOHNSON K, 1990, AM J HUM GENET, V46, P1073; KORNELUK RG, 1991, NUCLEIC ACIDS RES, V19, P1157, DOI 10.1093/nar/19.5.1157; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LENNON GG, IN PRESS HUM MOL GEN; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; SHUTLER, 1991, GENOMICS, V9, P500; SHUTLER G, IN PRESS NUCLEIC ACI; SHUTLER G, IN PRESS GENOMICS; SMEETS HJM, 1991, GENOMICS, V9, P257, DOI 10.1016/0888-7543(91)90250-I; TSILFIDIS C, 1991, AM J HUM GENET, V49, P961; TSILFIDIS C, 1991, NUCLEIC ACIDS RES, V19, P1157, DOI 10.1093/nar/19.5.1157-a; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	25	476	486	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					548	551		10.1038/355548a0	http://dx.doi.org/10.1038/355548a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1346925				2022-12-01	WOS:A1992HC52600060
J	BOCK, LC; GRIFFIN, LC; LATHAM, JA; VERMAAS, EH; TOOLE, JJ				BOCK, LC; GRIFFIN, LC; LATHAM, JA; VERMAAS, EH; TOOLE, JJ			SELECTION OF SINGLE-STRANDED-DNA MOLECULES THAT BIND AND INHIBIT HUMAN THROMBIN	NATURE			English	Article							HUMAN ALPHA-THROMBIN; PROTEIN; RNA; SEQUENCES; INVITRO; LIGANDS; GENOME	APTAMERS 1 are double-stranded DNA or single-stranded RNA molecules that bind specific molecular targets. Large randomly generated populations can be enriched in aptamers by in vitro selection and polymerase chain reaction 1-11. But so far single-stranded DNA has not been investigated for aptamer properties, nor has a target protein been considered that does not interact physiologically with nucleic acid. Here we describe the isolation of single-stranded DNA aptamers to the protease thrombin of the blood coagulation cascade and report binding affinities in the range 25-200 nM. Sequence data from 32 thrombin aptamers, selected from a pool of DNA containing 60 nucleotides of random sequence, displayed a highly conserved 14-17-base region. Several of these aptamers at nanomolar concentrations inhibited thrombin-catalysed fibrin-clot formation in vitro using either purified fibrinogen or human plasma.	GILEAD SCI INC,346 LAKESIDE DR,FOSTER CITY,CA 94404	Gilead Sciences								BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; GREEN R, 1990, NATURE, V347, P467; HULTMAN T, 1988, NUCLEOS NUCLEOT, V7, P629, DOI 10.1080/07328318808056299; JOYCE GF, 1989, GENE, V82, P83, DOI 10.1016/0378-1119(89)90033-4; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1989, NUCLEIC ACIDS RES, V17, P3645, DOI 10.1093/nar/17.10.3645; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121	15	2012	2299	30	1166	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					564	566		10.1038/355564a0	http://dx.doi.org/10.1038/355564a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1741036				2022-12-01	WOS:A1992HC52600065
J	CHISAKA, O; MUSCI, TS; CAPECCHI, MR				CHISAKA, O; MUSCI, TS; CAPECCHI, MR			DEVELOPMENTAL DEFECTS OF THE EAR, CRANIAL NERVES AND HINDBRAIN RESULTING FROM TARGETED DISRUPTION OF THE MOUSE HOMEOBOX GENE HOX-1.6	NATURE			English	Article							STEM-CELLS; EXPRESSION; EMBRYO; MURINE; GENOME; CHICK	Gene targeting in mouse embryo-derived stem cells has been used to generate mice with a disruption in the homeobox gene Hox-1.6 Mice heterozygous at the Hox-1.6 locus appear normal, whereas Hox-1.6-/Hox-1.6- mice die at or shortly after birth. These homozygotes exhibit profound defects in the formation of the external, middle and inner ears as well as in specific hindbrain nuclei, and in cranial nerves and ganglia. The affected tissues lie within a narrow region along the anteroposterior axis of the mouse but are of diverse embryonic origin. The set of defects associated with the disruption of Hox-1.6 is distinct from and nonoverlapping with that of the closely linked Hox-1.5 gene. But both mutations cause loss, rather than homeotic transformation, of tissues and structures.			CHISAKA, O (corresponding author), UNIV UTAH,SCH MED,HOWARD HUGHES MED INST,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.							ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; AKAM M, 1987, DEVELOPMENT, V101, P1; ALTMAN J, 1982, ADV ANAT EMBRYOL CEL, V74, P1; BARON A, 1987, EMBO J, V6, P2977, DOI 10.1002/j.1460-2075.1987.tb02603.x; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DEOL MS, 1980, MORPHOGENESIS MALFOR, P243; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; HUNT P, 1991, DEVELOPMENT, V112, P43; INGHAM PN, 1989, NATURE, V335, P25; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; LE DOUARIN N., 2011, DEV CELL BIOL SERIES, V2nd, DOI [10.1017/cbo9780511897948, DOI 10.1017/CBO9780511897948]; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; LUMSDEN A, IN PRESS DEVELOPMENT; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; NODEN DM, 1988, DEVELOPMENT, V103, P121; NODEN DM, 1986, J CRAN GENET DEV BIO, P15; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Van de Water T R, 1980, Birth Defects Orig Artic Ser, V16, P147; VANDEWATER TR, 1980, MORPHOGENESIS MALFOR, P5	30	480	499	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					516	520		10.1038/355516a0	http://dx.doi.org/10.1038/355516a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1346922				2022-12-01	WOS:A1992HC52600047
J	CRIQUI, MH; LANGER, RD; FRONEK, A; FEIGELSON, HS; KLAUBER, MR; MCCANN, TJ; BROWNER, D				CRIQUI, MH; LANGER, RD; FRONEK, A; FEIGELSON, HS; KLAUBER, MR; MCCANN, TJ; BROWNER, D			MORTALITY OVER A PERIOD OF 10 YEARS IN PATIENTS WITH PERIPHERAL ARTERIAL-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERMITTENT CLAUDICATION; RISK-FACTORS; DEFINED POPULATION; PREVALENCE; REGRESSION; CESSATION; SMOKING; FATE; MEN	Background. Previous investigators have observed a doubling of the mortality rate among patients with intermittent claudication, and we have reported a fourfold increase in the overall mortality rate among subjects with large-vessel peripheral arterial disease, as diagnosed by noninvasive testing. In this study, we investigated the association of large-vessel peripheral arterial disease with rates of mortality from all cardiovascular diseases and from coronary heart disease. Methods. We examined 565 men and women (average age, 66 years) for the presence of large-vessel peripheral arterial disease by means of two noninvasive techniques measurement of segmental blood pressure and determination of flow velocity by Doppler ultrasound. We identified 67 subjects with the disease (11.9 percent), whom we followed prospectively for 10 years. Results. Twenty-one of the 34 men (61.8 percent) and 11 of the 33 women (33.3 percent) with large-vessel peripheral arterial disease died during follow-up, as compared with 31 of the 183 men (16.9 percent) and 26 of the 225 women (11.6 percent) without evidence of peripheral arterial disease. After multivariate adjustment for age, sex, and other risk factors for cardiovascular disease, the relative risk of dying among subjects with large-vessel peripheral arterial disease as compared with those with no evidence of such disease was 3.1 (95 percent confidence interval, 1.9 to 4.9) for deaths from all causes, 5.9 (95 percent confidence interval, 3.0 to 11.4) for all deaths from cardiovascular disease, and 6.6 (95 percent confidence interval, 2.9 to 14.9) for deaths from coronary heart disease. The relative risk of death from causes other than cardiovascular disease was not significantly increased among the subjects with large-vessel peripheral arterial disease. After the exclusion of subjects who had a history of cardiovascular disease at base line, the relative risks among those with large-vessel peripheral arterial disease remained significantly elevated. Additional analyses revealed a 15-fold increase in rates of mortality due to cardiovascular disease and coronary heart disease among subjects with large-vessel peripheral arterial disease that was both severe and symptomatic. Conclusions. Patients with large-vessel peripheral arterial disease have a high risk of death from cardiovascular causes.	UNIV CALIF SAN DIEGO,SCH MED,DEPT COMMUNITY & FAMILY MED,DIV HLTH CARE SCI,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,DIV CARDIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,DEPT SURG,DIV GEN SURG,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	CRIQUI, MH (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT COMMUNITY & FAMILY MED,DIV EPIDEMIOL 0607,LA JOLLA,CA 92093, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042973, R01HL022255] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 22255, HL 42973] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; COX DR, 1972, J R STAT SOC B, V34, P187; CRIQUI MH, 1985, CIRCULATION, V72, P768, DOI 10.1161/01.CIR.72.4.768; CRIQUI MH, 1990, CIRCULATION, V82, P2246, DOI 10.1161/01.CIR.82.6.2246; CRIQUI MH, 1989, AM J EPIDEMIOL, V129, P1110, DOI 10.1093/oxfordjournals.aje.a115233; CRIQUI MH, 1985, CIRCULATION, V71, P516, DOI 10.1161/01.CIR.71.3.516; CRIQUI MH, 1985, CIRCULATION, V71, P510, DOI 10.1161/01.CIR.71.3.510; DORMANDY J, 1989, J CARDIOVASC SURG, V30, P50; FRONEK A, 1973, AM J SURG, V126, P205, DOI 10.1016/S0002-9610(73)80154-0; FRONEK A, 1976, CIRCULATION, V53, P957, DOI 10.1161/01.CIR.53.6.957; FRONEK A, 1989, NONINVASIVE DIAGNOST, P88; HERMANSON B, 1988, NEW ENGL J MED, V319, P1365, DOI 10.1056/NEJM198811243192101; HUGHSON WG, 1978, BRIT MED J, V1, P1377, DOI 10.1136/bmj.1.6124.1377; JELNES R, 1986, BRIT MED J, V293, P1137, DOI 10.1136/bmj.293.6555.1137; JONASON T, 1987, ACTA MED SCAND, V221, P253; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; PEABODY CN, 1974, ARCH SURG-CHICAGO, V109, P693; REUNANEN A, 1982, ACTA MED SCAND, V211, P249; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; SMITH GD, 1990, CIRCULATION, V82, P1925, DOI 10.1161/01.CIR.82.6.1925; STRANDNESS DE, 1969, PERIPHERAL ARTERIAL; WINSOR T, 1950, AM J MED SCI, V220, P117, DOI 10.1097/00000441-195008000-00001; 1970, JAMA-J AM MED ASSOC, V213, P1143; 1975, DHEW NIH75628 PUBL, V1; 1989, DHHS PHS891260 DEP H; 1979, JAMA-J AM MED ASSOC, V242, P2562; 1967, JAMA-J AM MED ASSOC, V202, P1028; 1984, JAMA-J AM MED ASSOC, V251, P351; 1979, CIRCULATION, V60, P427	30	1929	2011	1	44	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 6	1992	326	6					381	386		10.1056/NEJM199202063260605	http://dx.doi.org/10.1056/NEJM199202063260605			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC386	1729621				2022-12-01	WOS:A1992HC38600005
J	CUNNINGHAM, CW; BLACKSTONE, NW; BUSS, LW				CUNNINGHAM, CW; BLACKSTONE, NW; BUSS, LW			EVOLUTION OF KING CRABS FROM HERMIT-CRAB ANCESTORS	NATURE			English	Article							DNA; PHYLOGENY; SIZE	KING crabs (Family Lithodidae) are among the world's largest arthropods, having a crab-like morphology and a strongly calcified exoskeleton 1-6. The hermit crabs, by contrast, have depended on gastropod shells for protection for over 150 million years 5,7. Shell living has constrained the morphological evolution of hermit crabs by requiring a decalcified asymmetrical abdomen capable of coiling into gastropod shells and by preventing crabs from growing past the size of the largest available shells 1-6. Whereas reduction in shell-living and acquisition of a crab-like morphology (carcinization) has taken place independently in several hermit crab lineages, and most dramatically in king crabs 1-6, the rate at which this process has occurred was entirely unknown 2,7. We present molecular evidence that king crabs are not only descended from hermit crabs, but are nested within the hermit crab genus Pagurus. We estimate that loss of the shell-living habit and the complete carcinization of king crabs has taken between 13 and 25 million years.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511; YALE UNIV,DEPT GEOL & GEOPHYS,NEW HAVEN,CT 06511	Yale University; Yale University			Cunningham, Clifford/B-9807-2014	Cunningham, Clifford/0000-0002-5434-5122				ALBERCH P, 1979, PALEOBIOLOGY, V5, P296, DOI 10.1017/S0094837300006588; BLACKSTONE NW, 1986, BIOL BULL, V171, P379, DOI 10.2307/1541680; BLACKSTONE NW, 1989, J ZOOL, V217, P477, DOI 10.1111/j.1469-7998.1989.tb02503.x; BLACKSTONE NW, 1985, THESIS YALE U; Borradaile L. A., 1916, Nat Hist Rep Zool, VNo.3; CUNNINGHAM CW, 1991, EVOLUTION, V46, P1301; Felsenstein J., 1990, PHYLIP MANUAL VERSIO; GLAESSNER MF, 1969, ARTHROPODA, V4, pR400; Hart JFL, 1982, BC PROV MUS HDB, V40; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; Hillis David M., 1990, P502; Kafanov A. I., 1984, CANADIAN TRANSLATION, V5052, P1; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; MACDONALD J. D., 1957, PROC ZOOL SOC LONDON, V128, P209; MARTIN AP, 1990, MOL BIOL EVOL, V7, P485; MARTIN JW, 1986, J CRUSTACEAN BIOL, V6, P576, DOI 10.2307/1548195; McLaughlin P. A., 1974, ZOOL VERHANDEL LEIDE, V130, P1; MCLAUGHLIN PA, 1983, J CRUSTACEAN BIOL, V3, P608, DOI 10.2307/1547956; Palumbi S.R., 1991, SIMPLE FOOLS GUIDE P; PIKE R. B., 1960, PUBBL STAZ ZOOL NAPOLI, V31, P493; REESE ES, 1968, SCIENCE, V161, P385, DOI 10.1126/science.161.3839.385; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEVCIC Z, 1971, SYST ZOOL, V20, P331, DOI 10.2307/2412345; SWOFFORD DL, 1991, PAUP VERSION 3 0Q; Vermeij G.J, 1987, EVOLUTION ESCALATION; VERMEIJ GJ, 1991, SCIENCE, V253, P1099, DOI 10.1126/science.253.5024.1099; Williams A.B., 1984, SHRIMPS LOBSTERS CRA; Wolff T., 1961, Galathea Report, V4, P11	29	219	225	5	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					539	542		10.1038/355539a0	http://dx.doi.org/10.1038/355539a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1741031				2022-12-01	WOS:A1992HC52600056
J	FORTINI, ME; SIMON, MA; RUBIN, GM				FORTINI, ME; SIMON, MA; RUBIN, GM			SIGNALING BY THE SEVENLESS PROTEIN TYROSINE KINASE IS MIMICKED BY RAS1 ACTIVATION	NATURE			English	Article							DEVELOPING DROSOPHILA EYE; ELEGANS VULVAR INDUCTION; CELL FATE; GENE; MELANOGASTER; RECEPTOR; EXPRESSION; ENCODES; SEQUENCE; DOMAIN	CELL-FATE specification of R7 photoreceptors in the developing Drosophila eye depends on an inductive signal from neighbouring R8 cells. Mutations in three genes, sevenless (sev), bride-of-sevenless (boss) and seven-in-absentia (sina) cause the R7 precursor to become a non-neural cone cell 1-3. The sev gene encodes a receptor protein tyrosine kinase (Sev) localized on the R7 surface, activated by a boss-encoded ligand presented by R8 (refs 4-6). The sina gene encodes a nuclear factor required in R7 (ref. 3). Reduction in the dosage of the Ras1 gene impairs Sev-mediated signalling, suggesting that activation of Ras1 may be an important consequence of Sev activation 7. We report here that Ras1 activation may account for all of the signalling action of Sev; an activated Ras1Val12 protein rescues the normal R7 precursor from transformation into a cone cell in sev and boss null mutants and induces the formation of supernumerary R7 cells. Similar activation of the Drosophila Ras2 protein does not produce these effects, demonstrating Ras protein specificity.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley				Rubin, Gerald/0000-0001-8762-8703				AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BIER E, 1988, SCIENCE, V240, P913, DOI 10.1126/science.3129785; BISHOP JG, 1988, GENE DEV, V2, P567, DOI 10.1101/gad.2.5.567; BOWTELL DDL, 1989, P NATL ACAD SCI USA, V86, P6245, DOI 10.1073/pnas.86.16.6245; BOWTELL DDL, 1991, P NATL ACAD SCI USA, V88, P6853, DOI 10.1073/pnas.88.15.6853; BOWTELL DDL, 1988, GENE DEV, V2, P620, DOI 10.1101/gad.2.6.620; BROCK HW, 1987, GENE, V51, P129, DOI 10.1016/0378-1119(87)90301-5; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; Dietrich W, 1909, Z WISS ZOOL ABT A, V92, P465; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; Maniatis T., 1982, MOL CLONING; MOZER B, 1985, MOL CELL BIOL, V5, P885, DOI 10.1128/MCB.5.4.885; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	31	283	284	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					559	561		10.1038/355559a0	http://dx.doi.org/10.1038/355559a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1311054				2022-12-01	WOS:A1992HC52600063
J	GLIMCHER, PW; SPARKS, DL				GLIMCHER, PW; SPARKS, DL			MOVEMENT SELECTION IN ADVANCE OF ACTION IN THE SUPERIOR COLLICULUS	NATURE			English	Article							EYE-MOVEMENTS; BEHAVING MONKEY; DISCRIMINATION; NEURONS	THE primate superior colliculus contains a map of saccadic eye movements 1,2. Saccades are high-velocity eye movements to selected targets in the visual field, but little is known about the neural mechanisms responsible for target selection or the related problem of choosing a particular movement from the oculomotor repertoire. Two classes of neurons have been described in the superior colliculus which show bursts of activity before the saccade: discrete bursters display a vigorous pre-saccadic burst and prelude bursters 3 show low-frequency activity as a prelude to burst onset. We have designed experiments to test whether prelude activity is related to saccade selection. Our tasks use a cue to specify which of two physically identical visual stimuli is the goal of an impending saccade. This cue is spatially and temporally isolated from the potential targets as well as from visual cues signalling movement initiation. Our results show that prelude activity occurs shortly after information is available for correct saccade selection and, more importantly, the activity is predictive of saccade choice. The results thus suggest that the superior colliculus participates in the process of saccade selection.			GLIMCHER, PW (corresponding author), UNIV PENN,DEPT PSYCHOL,PHILADELPHIA,PA 19104, USA.			Glimcher, Paul/0000-0001-7872-3856				BOCH RA, 1989, J NEUROPHYSIOL, V61, P1064, DOI 10.1152/jn.1989.61.5.1064; FUCHS AF, 1966, J APPL PHYSIOL, V21, P1068, DOI 10.1152/jappl.1966.21.3.1068; FUNAHASHI S, 1991, J NEUROPHYSIOL, V65, P1464, DOI 10.1152/jn.1991.65.6.1464; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GOLDBERG ME, 1972, J NEUROPHYSIOL, V35, P560, DOI 10.1152/jn.1972.35.4.560; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; MAYS LE, 1980, SCIENCE, V208, P1163, DOI 10.1126/science.6769161; OTTES FP, 1985, VISION RES, V25, P849, DOI 10.1016/0042-6989(85)90193-2; OTTES FP, 1987, EXP BRAIN RES, V66, P465, DOI 10.1007/BF00270679; SPARKS DL, 1978, BRAIN RES, V156, P1, DOI 10.1016/0006-8993(78)90075-6; SPARKS DL, 1987, J NEUROPHYSIOL, V58, P300, DOI 10.1152/jn.1987.58.2.300; SPARKS DL, 1976, BRAIN RES, V113, P21, DOI 10.1016/0006-8993(76)90003-2; WURTZ RH, 1972, J NEUROPHYSIOL, V35, P575, DOI 10.1152/jn.1972.35.4.575	13	229	231	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					542	545		10.1038/355542a0	http://dx.doi.org/10.1038/355542a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1741032				2022-12-01	WOS:A1992HC52600057
J	HARLEY, HG; BROOK, JD; RUNDLE, SA; CROW, S; REARDON, W; BUCKLER, AJ; HARPER, PS; HOUSMAN, DE; SHAW, DJ				HARLEY, HG; BROOK, JD; RUNDLE, SA; CROW, S; REARDON, W; BUCKLER, AJ; HARPER, PS; HOUSMAN, DE; SHAW, DJ			EXPANSION OF AN UNSTABLE DNA REGION AND PHENOTYPIC VARIATION IN MYOTONIC-DYSTROPHY	NATURE			English	Article							GENE	MYOTONIC dystrophy is the commonest adult form of muscular dystrophy, with an estimated incidence of 1 per 7,500, although this is likely to be an underestimate because of the difficulty of detecting minimally affected individuals. It is a multisystem autosomal dominant disorder of unknown biochemical basis 1. No case of new mutation has been proven. We have isolated a human genomic clone that detects novel restriction fragments specific to individuals with myotonic dystrophy. A two-allele EcoRI polymorphism is seen in normal individuals, but in most affected individuals one of the normal alleles is replaced by a larger fragment, which Varies in length both between unrelated affected individuals and within families. The unstable nature of this region may explain the characteristic variation in severity and age at onset of the disease. A second polymorphism at this locus is in almost complete linkage disequilibrium with myotonic dystrophy, strongly supporting our earlier results which indicated that most cases are descended from one original mutation 2.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	HARLEY, HG (corresponding author), UNIV WALES COLL MED,INST MED GENET,HEATH PK,CARDIFF CF4 6EJ,WALES.			Brook, John David/0000-0002-5946-6740	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; FU YH, 1991, CELL, V67, P1; HARLEY HG, 1991, AM J HUM GENET, V49, P68; HARLEY HG, 1991, HUM GENET, V87, P73, DOI 10.1007/BF01213096; Harper P.S., 1989, MYOTONIC DYSTROPHY; HARPER PS, 1972, LANCET, V2, P53; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; JANSEN G, 1991, AM J HUM GENET, V49, P82; JOHNSON K, 1990, AM J HUM GENET, V46, P1073; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PENROSE LS, 1948, ANN EUGENIC, V14, P125; RICHARDS RI, 1991, J MED GENET, V28, P818, DOI 10.1136/jmg.28.12.818; Sambrook J., 1989, MOL CLONING LAB MANU; SHUTLER, 1991, GENOMICS, V9, P500; SMEETS HJM, 1991, GENOMICS, V9, P257, DOI 10.1016/0888-7543(91)90250-I; SUTHERLAND GR, 1991, LANCET, V338, P289, DOI 10.1016/0140-6736(91)90426-P; THIBAULT MC, IN PRESS CYTOGENET C; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; YULE GU, 1968, INTRO THEORY STATIST	24	694	714	1	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					545	546		10.1038/355545a0	http://dx.doi.org/10.1038/355545a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1346923				2022-12-01	WOS:A1992HC52600058
J	HUNTER, CP; WOOD, WB				HUNTER, CP; WOOD, WB			EVIDENCE FROM MOSAIC ANALYSIS OF THE MASCULINIZING GENE HER-1 FOR CELL-INTERACTIONS IN C-ELEGANS SEX DETERMINATION	NATURE			English	Article							CAENORHABDITIS-ELEGANS; DOSAGE COMPENSATION; POLARITY GENE; DROSOPHILA; HERMAPHRODITE; INHIBITOR; LINEAGES; NEMATODE; EVENTS	SEX in Caenorhabditis elegans is determined by a regulatory cascade of seven interacting autosomal genes controlled by three X-linked genes in response to the X chromosome-to-autosome (X/A) ratio 1,2. XX animals (high X/A) develop as self-fertile hermaphrodites, and XO animals (low X/A) develop as males. The activity of the first gene in the sex-determining cascade, her-1, is required for male sexual development 3. XO her-1 loss-of-function mutants develop as self-fertile hermaphrodites, whereas XX her-1 gain-of-function mutants develop as masculinized intersexes 4. By genetic mosaic analysis using a fused free duplication linking her-1 to a cell-autonomous marker gene, we show here that her-1 expression in a sexually dimorphic cell is neither necessary nor sufficient for that cell to adopt a male fate. Our results suggest that her-1 is expressed in many, possibly all, cells and that its gene product can function non-autonomously through cell interactions to determine male sexual development.	UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder								AUBERGER P, 1989, CELL, V58, P631, DOI 10.1016/0092-8674(89)90098-6; Cigarroa FG, 1989, GROWTH FACTORS, V1, P179, DOI 10.3109/08977198909029127; DONIACH T, 1986, GENETICS, V114, P53; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HERMAN RK, 1976, GENETICS, V83, P91; HODGKIN J, 1984, Journal of Embryology and Experimental Morphology, V83, P103; HODGKIN J, 1980, GENETICS, V96, P649; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; HODGKIN J, 1987, ANNU REV GENET, V21, P133, DOI 10.1146/annurev.ge.21.120187.001025; Hodgkin J., 1988, NEMATODE CAENORHABDI, P243; HUNTER CP, 1990, CELL, V63, P1193, DOI 10.1016/0092-8674(90)90415-B; HUNTER CP, 1990, THESIS U COLORADO; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; MCLAREN A, 1988, TRENDS GENET, V4, P153, DOI 10.1016/0168-9525(88)90020-0; MEYER BJ, 1988, TRENDS GENET, V4, P337, DOI 10.1016/0168-9525(88)90053-4; MOHLER J, 1988, GENETICS, V120, P1061; OBRIEN SJ, 1990, GENETIC MAPS, V5; OKKEMA PG, 1991, EMBO J, V10, P171, DOI 10.1002/j.1460-2075.1991.tb07933.x; PATEK CE, 1991, DEVELOPMENT, V113, P311; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; ROSENBLUTH RE, 1985, GENETICS, V109, P493; SCHAUER IE, 1990, DEVELOPMENT, V110, P1303; SCHEDIN P, 1988, THESIS U COLORADO; SCHEDIN P, 1991, DEVELOPMENT, V112, P833; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TRENT C, 1991, MECH DEVELOP, V34, P43, DOI 10.1016/0925-4773(91)90090-S; TRENT C, 1988, GENETICS, V120, P145; VILLENEUVE AM, 1990, GENETICS, V124, P91; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	32	74	80	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					551	555		10.1038/355551a0	http://dx.doi.org/10.1038/355551a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1741033				2022-12-01	WOS:A1992HC52600061
J	KHABBAZ, RF; ONORATO, IM; CANNON, RO; HARTLEY, TM; ROBERTS, B; HOSEIN, B; KAPLAN, JE				KHABBAZ, RF; ONORATO, IM; CANNON, RO; HARTLEY, TM; ROBERTS, B; HOSEIN, B; KAPLAN, JE			SEROPREVALENCE OF HTLV-I AND HTLV-II AMONG INTRAVENOUS-DRUG-USERS AND PERSONS IN CLINICS FOR SEXUALLY-TRANSMITTED DISEASES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS TYPE-I; UNITED-STATES; INFECTION; TRANSMISSION; ABUSERS; PREVALENCE; AIDS; MEN	Background. The human T-cell lymphotropic virus Type I (HTLV-I) is associated with adult T-cell leukemia and myelopathy, whereas HTLV-II infection has uncertain clinical consequences. We assessed the seroprevalence of these retroviruses among intravenous drug users and among patients seen at clinics for sexually transmitted diseases (STD clinics). Methods. We used serum samples that were collected in eight cities in 1988 and 1989 during surveys of human immunodeficiency virus infection among intravenous drug users entering treatment and persons seen in STD clinics. The serum samples were tested for antibodies to HTLV, and positive specimens were tested further by a synthetic peptide-based enzyme-linked immunosorbent assay to differentiate between HTLV-I and HTLV-II. Results. Among 3217 intravenous drug users in 29 drug-treatment centers, the median seroprevalence rates of HTLV varied widely according to city (range, 0.4 percent in Atlanta to 17.6 percent in Los Angeles). Seroprevalence increased sharply with age, to 32 percent in persons over 44 years of age. HTLV infection was more common among blacks (15.5 percent) and Hispanics (10.7 percent) than among whites (4.1 percent), and it was strongly associated with a history of heroin injection (P less-than-or-equal-to 0.001). Among 5264 patients in 24 STD clinics, the median rates of HTLV infection were much lower (range, 0.1 percent in Atlanta and Newark to 2.0 percent in Los Angeles). Again, this infection was more common among intravenous drug users (7.6 percent) than among non-drug users (0.7 percent). Eighty-four percent of the seropositive samples from drug-treatment centers and 69 percent of those from STD clinics were due to HTLV-II infection (P = 0.03). Conclusions. HTLV infection is common among intravenous drug users and is primarily caused by HTLV-II. Among patients seen at STD clinics, HTLV is strongly associated with intravenous drug use, but the retrovirus is also prevalent among non-drug users.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV STD HIV PREVENT,ATLANTA,GA 30333; UNITED BIOMED INC,LAKE SUCCESS,NY	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	KHABBAZ, RF (corresponding author), CTR DIS CONTROL,RETROVIRUS DIS BRANCH,DIV VIRAL & RICKETTSIAL DIS,MS-A32,ATLANTA,GA 30333, USA.							BIGGAR RJ, 1991, J INFECT DIS, V163, P57, DOI 10.1093/infdis/163.1.57; BLATTNER WA, 1990, HUMAN RETROVIROLOGY : HTLV, P251; CANTOR KP, 1991, J ACQ IMMUN DEF SYND, V4, P460; HARTLEY TM, 1990, J CLIN MICROBIOL, V28, P646, DOI 10.1128/JCM.28.4.646-650.1990; HARTLEY TM, 1990, J CLIN MICROBIOL, V28, P1491; HASELTINE WA, 1985, CURR TOP MICROBIOL, V115, P177; HJELLE B, 1990, BLOOD, V76, P450; KHABBAZ RF, 1990, J INFECT DIS, V162, P241, DOI 10.1093/infdis/162.1.241; KHABBAZ RF, 1991, J INFECT DIS, V163, P252, DOI 10.1093/infdis/163.2.252; KHABBAZ RF, 1990, JAMA-J AM MED ASSOC, V263, P60, DOI 10.1001/jama.263.1.60; KWOK S, 1990, AIDS RES HUM RETROV, V6, P561, DOI 10.1089/aid.1990.6.561; LAIRMORE MD, 1989, BLOOD, V74, P2596; LAIRMORE MD, 1990, P NATL ACAD SCI USA, V87, P8840, DOI 10.1073/pnas.87.22.8840; LAL RB, 1991, J CLIN MICROBIOL, V29, P2253, DOI 10.1128/JCM.29.10.2253-2258.1991; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; LEE HH, 1991, LANCET, V337, P1435, DOI 10.1016/0140-6736(91)93126-T; MANNS A, 1988, NEW ENGL J MED, V319, P516, DOI 10.1056/NEJM198808253190811; MURPHY EL, 1989, ANN INTERN MED, V111, P555, DOI 10.7326/0003-4819-111-7-555; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; PAGE JB, 1990, LANCET, V335, P1439, DOI 10.1016/0140-6736(90)91456-K; PAPPAIOANOU M, 1990, PUBLIC HEALTH REP, V105, P113; ROBERTGUROFF M, 1986, JAMA-J AM MED ASSOC, V255, P3133, DOI 10.1001/jama.255.22.3133; WEISS SH, 1987, 3RD P INT C AIDS WAS, P211; 1990, MMWR, V39, P921; 1990, NATIONAL HIV SEROPRE; 1988, MMWR, V37, P736; 1990, MMWR, V39, P915; 1988, MMWR, V37, P745; 1989, MMWR S7, V38, P1	30	167	167	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 6	1992	326	6					375	380		10.1056/NEJM199202063260604	http://dx.doi.org/10.1056/NEJM199202063260604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC386	1729620	Bronze			2022-12-01	WOS:A1992HC38600004
J	SIGURGEIRSSON, B; LINDELOF, B; EDHAG, O; ALLANDER, E				SIGURGEIRSSON, B; LINDELOF, B; EDHAG, O; ALLANDER, E			RISK OF CANCER IN PATIENTS WITH DERMATOMYOSITIS OR POLYMYOSITIS - A POPULATION-BASED STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MALIGNANCY; DISEASE	Background. An association between polymyositis and cancer was first proposed in 1916, but the existence of the association has been disputed. An association between dermatomyositis and cancer is better accepted, but its magnitude is not known. Methods. We undertook a study to provide accurate estimates of the risk of cancer in patients with dermatomyositis or polymyositis. We studied the incidence of cancer and the rate of mortality from cancer in a population-based cohort of 788 patients with dermatomyositis or polymyositis in Sweden from 1963 through 1983. The results were compared with those for the general population. Results. Among the 396 patients with polymyositis, 42 cancers were diagnosed at the same time or after polymyositis was diagnosed in 37 patients (9 percent). The relative risk of cancer was 1.8 (95 percent confidence interval, 1.1 to 2.7) in the male patients and 1.7 (95 percent confidence interval, 1.0 to 2.5) in the female patients. Eighty-four males and 85 females died, and in 24 of these cases (14 percent) cancer was the principal cause of death. The mortality ratio (the rate of mortality from cancer in these patients as compared with that in the general population) was 0.90 (95 percent confidence interval, 0.6 to 1.4). Among the 392 patients with dermatomyositis, 61 cancers were diagnosed at the same time or after dermatomyositis was diagnosed in 59 patients (15 percent). The relative risk of cancer was 2.4 (95 percent confidence interval, 1.6 to 3.6) in the male patients and 3.4 (95 percent confidence interval, 2.4 to 4.7) in the female patients. Fifty-seven males and 110 females died, and in 67 of these cases (40 percent) cancer was the principal cause of death (mortality ratio, 3.8; 95 percent confidence interval, 2.9 to 4.8). Conclusions. The risk of cancer is increased in patients with polymyositis or dermatomyositis. In patients with dermatomyositis there is also a higher rate of mortality from cancer.	HUDDINGE HOSP,DEPT SOCIAL MED,S-14186 HUDDINGE,SWEDEN; NATL BOARD HLTH & WELF,STOCKHOLM,SWEDEN	National Board of Health & Welfare	SIGURGEIRSSON, B (corresponding author), KAROLINSKA HOSP,DEPT DERMATOL,S-10401 STOCKHOLM 60,SWEDEN.		Sigurgeirsson, Bárður/B-6130-2011; Sigurgeirsson, Bardur/AAP-7755-2020	Sigurgeirsson, Bardur/0000-0002-9733-9742				BASSETSEGUIN N, 1990, ARCH DERMATOL, V126, P633, DOI 10.1001/archderm.126.5.633; BOHAN A, 1975, NEW ENGL J MED, V292, P403, DOI 10.1056/NEJM197502202920807; BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; BOHAN A, 1977, MEDICINE, V56, P255, DOI 10.1097/00005792-197707000-00001; BONNETBLANC JM, 1990, DERMATOLOGICA, V180, P212, DOI 10.1159/000248032; CALLEN JP, 1980, ARCH DERMATOL, V116, P295, DOI 10.1001/archderm.116.3.295; CARO I, 1989, MED CLIN N AM, V73, P1181; COX NH, 1990, ARCH DERMATOL, V126, P61, DOI 10.1001/archderm.126.1.61; FROME EL, 1985, AM J EPIDEMIOL, V121, P309, DOI 10.1093/oxfordjournals.aje.a114001; Goh C L, 1983, Ann Acad Med Singap, V12, P6; HENRIKSSON KG, 1982, ACTA NEUROL SCAND, V65, P280, DOI 10.1111/j.1600-0404.1982.tb03087.x; HIDANO A, 1986, Journal of Dermatology (Tokyo), V13, P233; HOFFMAN GS, 1983, AM J MED, V75, P433, DOI 10.1016/0002-9343(83)90344-3; LAKHANPAL S, 1986, MAYO CLIN PROC, V61, P645, DOI 10.1016/S0025-6196(12)62030-8; MANCHUL LA, 1985, ARCH INTERN MED, V145, P1835, DOI 10.1001/archinte.145.10.1835; MATTSSON B, 1984, THESIS KAROLINSKA I; RICHARDSON JB, 1989, MED CLIN N AM, V73, P1211, DOI 10.1016/S0025-7125(16)30629-0; SIGURGEIRSSON B, 1991, COMPUT METH PROG BIO, V35, P193, DOI 10.1016/0169-2607(91)90121-9; Stertz G., 1916, BERL KLIN WOCHENSCHR, V53, P489; TYMMS KE, 1985, J RHEUMATOL, V12, P1140; VESTERAGER L, 1980, CLIN EXP DERMATOL, V5, P31, DOI 10.1111/j.1365-2230.1980.tb01661.x; 1960, CANCER INCIDENCE SWE; 1964, CAUSES DEATH SWEDEN	23	551	574	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 6	1992	326	6					363	367		10.1056/NEJM199202063260602	http://dx.doi.org/10.1056/NEJM199202063260602			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC386	1729618	Bronze			2022-12-01	WOS:A1992HC38600002
J	SIXMA, TK; PRONK, SE; KALK, KH; VANZANTEN, BAM; BERGHUIS, AM; HOL, WGJ				SIXMA, TK; PRONK, SE; KALK, KH; VANZANTEN, BAM; BERGHUIS, AM; HOL, WGJ			LACTOSE BINDING TO HEAT-LABILE ENTEROTOXIN REVEALED BY X-RAY CRYSTALLOGRAPHY	NATURE			English	Article							TOXIN B-SUBUNIT; CHOLERA-TOXIN; ESCHERICHIA-COLI; BACTERIAL TOXINS; GANGLIOSIDE GM1; RECEPTOR; PROTEINS; MEMBRANE; ASSOCIATION; REFINEMENT	RECOGNITION of the oligosaccharide portion of ganglioside G(M1) in membranes of target cells by the heat-labile enterotoxin from Escherichia coli is the crucial first step in its pathogenesis, as it is for the closely related cholera toxin 1-3. These toxins have five B subunits, which are essential for G(M1) binding, and a single A subunit, which needs to be nicked by proteolysis and reduced, yielding an A1-'enzyme' and an A2-'linker' peptide. A1 is translocated across the membrane of intestinal epithelial cells, possibly after endocytosis 4,5, upon which it ADP-ribosylates the G protein G(s-alpha) (reviewed in refs 2, 3, 6). The mechanism of binding and translocation of these toxins has been extensively investigated 1,2,7-20, but how the protein is orientated on binding is still not clear 10-12,18. Knowing the precise arrangement of the ganglioside binding sites of the toxins will be useful for designing drugs against the diarrhoeal diseases caused by organisms secreting these toxins and in the development of oral vaccines against them 21,22. We present here the three-dimensional structure of the E. coli heat-labile enterotoxin complexed with lactose. This reveals the location of the binding site of the terminal galactose of G(M1), which is consistent with toxin binding to the target cell with its A1 fragment pointing away from the membrane. A small helix is identified at the carboxy terminus of A2 which emerges through the central pore of the B subunits and probably comes into contact with the membrane upon binding, whereas the A1 subunit is flexible with respect to the B pentamer.			SIXMA, TK (corresponding author), UNIV GRONINGEN, BIOSON RES INST, DEPT CHEM, NIJENBORGH 16, 9747 AG GRONINGEN, NETHERLANDS.		Berghuis, Albert M/A-6495-2008	Berghuis, Albert/0000-0002-2663-025X; Sixma, Titia K/0000-0001-6180-0632				ARNONE A, 1971, J BIOL CHEM, V246, P2302; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CLEMENTS JD, 1979, INFECT IMMUN, V24, P760, DOI 10.1128/IAI.24.3.760-769.1979; DEAIZPURUA HJ, 1988, J EXP MED, V167, P440, DOI 10.1084/jem.167.2.440; DEWOLF MJS, 1981, J BIOL CHEM, V256, P5489; DWYER JD, 1982, BIOCHEMISTRY-US, V21, P3227, DOI 10.1021/bi00256a030; EIDELS L, 1983, MICROBIOL REV, V47, P596, DOI 10.1128/MMBR.47.4.596-620.1983; FINKELSTEIN RA, 1988, IMMUNOCHEMICAL MOL G, P85; FUKUTA S, 1988, INFECT IMMUN, V56, P1748, DOI 10.1128/IAI.56.7.1748-1753.1988; GOINS B, 1988, BIOCHEMISTRY-US, V27, P2046, DOI 10.1021/bi00406a035; GRIFFITHS SL, 1986, BIOCHEM J, V238, P313, DOI 10.1042/bj2380313; HOLMGREN J, 1982, INFECT IMMUN, V38, P424, DOI 10.1128/IAI.38.2.424-433.1982; JANICOT M, 1991, J BIOL CHEM, V266, P12858; LEONG J, 1985, INFECT IMMUN, V48, P73, DOI 10.1128/IAI.48.1.73-77.1985; LESK AM, 1985, METHOD ENZYMOL, V115, P381; LUDWIG DS, 1985, J BIOL CHEM, V260, P2528; MCDANIEL RV, 1986, BIOPHYS J, V49, P94, DOI 10.1016/S0006-3495(86)83606-2; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; PELHAM HRB, 1989, EMBO J, V8, P3171, DOI 10.1002/j.1460-2075.1989.tb08475.x; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; PRONK SE, 1985, J BIOL CHEM, V260, P3580; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RIBI HO, 1988, SCIENCE, V239, P1272, DOI 10.1126/science.3344432; RUTENBER E, 1991, PROTEINS, V10, P260, DOI 10.1002/prot.340100310; SANCHEZ J, 1988, GENE, V64, P265, DOI 10.1016/0378-1119(88)90341-1; SATTLER J, 1977, H-S Z PHYSIOL CHEM, V358, P159, DOI 10.1515/bchm2.1977.358.1.159; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SUREWICZ WK, 1990, BIOCHEMISTRY-US, V29, P8106, DOI 10.1021/bi00487a017; SVENNERHOLM AM, 1982, LANCET, V1, P305; TOMASI M, 1981, J BIOL CHEM, V256, P1177; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TSUJI T, 1985, J BIOL CHEM, V260, P8552; VANHEYNINGEN S, 1983, CURR TOP MEMBR TRANS, V18, P445; VYAS NK, 1991, J BIOL CHEM, V266, P5226; WISNIESKI BJ, 1981, NATURE, V289, P319, DOI 10.1038/289319a0	36	185	192	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 6	1992	355	6360					561	564		10.1038/355561a0	http://dx.doi.org/10.1038/355561a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1741035				2022-12-01	WOS:A1992HC52600064
J	BULLOCK, KD; REED, RJ; GRANT, I				BULLOCK, KD; REED, RJ; GRANT, I			REDUCED MORTALITY RISK IN ALCOHOLICS WHO ACHIEVE LONG-TERM ABSTINENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATIONAL-DEATH-INDEX; FOLLOW-UP; 1ST ADMISSION; LATE 30S; MEN; SUICIDE	Objectives. - To determine if alcoholic men who achieved stable abstinence experienced fewer deaths than those who relapsed and to develop a model predictive of premature mortality. Design. - A cohort of alcoholic men recruited into a prospective study of neurocognitive effects of alcoholism was followed up from 1 through 11 years. A demographically equated group of nonalcoholic men was also followed up, Alcoholics were classified as stable abstainers or relapsers. Setting. - Alcoholics were patients or ex-patients from a Department of Veterans Affairs Alcoholism Treatment Program and/or members of local chapters of Alcoholics Anonymous. Participants. - There were 234 alcoholic men who met the Diagnostic and Statistical Manual of Mental Disorders, Third Edition, criteria for alcohol dependence. Follow-up status regarding relapse and mortality was obtained for 199 alcoholic subjects (85%). Of these, 1 01 had relapsed and 98 had abstained. Ninety-eight nonalcoholic controls equated for age, education, and sex also participated. Mortality status was obtained for 92 subjects in this group (94%). Exclusions. - Major medical and psychiatric illness and history of nonalcoholic drug abuse. Main Outcome Measure. - Death during a follow-up period of 1 through 11 years. Death was ascertained through the National Death index, the California State Department of Health and Vital Statistics, the State Department of Motor Vehicles, and through personal contact with informants. relatives, and significant others of the subjects. Results. - There were 19 deaths among relapsed alcoholics compared with the expected number of 3.83 (99% confidence interval (CI), 9.64 to 33.38). Among abstinent alcoholics there were four deaths (expected = 3.21; 99% CI, 0.67 to 12.59). The standardized mortality ratio for relapsed alcoholics was 4.96, which significantly exceeded the expected ratio (P < .001), whereas the standardized mortality ratio for abstinent alcoholics (1.25) was indistinguishable from the expected. Cox proportional hazards analysis was used to determine if any of several demographic, medical, cognitive, or drinking history variables (in addition to relapse) helped predict mortality among alcoholics. Only relapse was significantly related to increased mortality (chi-2 = 9. 15, P = .003). Conclusions. - Alcoholic men who achieve stable abstinence do not differ from nonalcoholic men in mortality experience; however, alcoholics who relapse die at a rate 4.96 times that of an age-, sex-, and race-matched representative sample from the US Bureau of the Census.	DEPT VET AFFAIRS MED CTR,PSYCHIAT SERV 116,3350 LA JOLLA VILLAGE DR,SAN DIEGO,CA 92161; VET AFFAIRS MED CTR,RES SERV,SAN DIEGO,CA; UNIV CALIF SAN DIEGO,SCH MED,DEPT PSYCHIAT,LA JOLLA,CA 92093	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego								ADAMS KM, 1980, AM J PSYCHIAT, V137, P928; ADAMS KM, 1981, AM J PSYCHIAT, V138, P445; BERGLUND M, 1985, ALCOHOL CLIN EXP RES, V9, P153, DOI 10.1111/j.1530-0277.1985.tb05541.x; BERGLUND M, 1984, ARCH GEN PSYCHIAT, V41, P888; BERGLUND M, 1984, ACTA PSYCHIAT SCAND, V70, P407, DOI 10.1111/j.1600-0447.1984.tb01228.x; BERGLUND M, 1985, ACTA PSYCHIAT SCAND, V71, P141, DOI 10.1111/j.1600-0447.1985.tb01264.x; COMBSORME T, 1985, J STUD ALCOHOL, V46, P443, DOI 10.15288/jsa.1985.46.443; COX DR, 1972, J R STAT SOC B, V34, P187; de Lint J, 1975, Can Med Assoc J, V113, P385; DIXON WJ, 1988, BMDP STATISTICAL SOF; EDLAVITCH SA, 1988, AM J EPIDEMIOL, V127, P1164, DOI 10.1093/oxfordjournals.aje.a114910; EDWARDS G, 1978, J STUD ALCOHOL, V39, P1607, DOI 10.15288/jsa.1978.39.1607; GORWITZ R, 1966, PUBLIC HLTH REP, V81, P1095; GRANT I, 1984, ARCH GEN PSYCHIAT, V41, P710; GRANT I, 1978, ARCH GEN PSYCHIAT, V35, P1063; GRANT I, 1979, AM J PSYCHIAT, V136, P1263; IMAIZUMI Y, 1986, ALCOHOL ALCOHOLISM, V21, P159; KINNEY EL, 1989, ANGIOLOGY, V40, P270, DOI 10.1177/000331978904000405; Lachar D., 1974, MMPI CLIN ASSESSMENT; LEE ET, 1980, STATISTICAL METHODS; LINDBERG S, 1988, BRIT J ADDICT, V83, P1193; MACKENZIE A, 1986, INT J ADDICT, V21, P865, DOI 10.3109/10826088609027400; MACMAHON B, 1983, AM J PUBLIC HEALTH, V78, P1247; MURPHY GE, 1979, ARCH GEN PSYCHIAT, V36, P65; NICHOLLS P, 1974, Q J STUD ALCOHOL, V35, P841; Pell S, 1973, J Occup Med, V15, P120; Reitan R.M., 1974, CLIN NEUROPSYCHOLOGY; ROGOT E, 1983, AM J PUBLIC HEALTH, V73, P1265, DOI 10.2105/AJPH.73.11.1265; SCHMIDT E, 1970, BR J ADDICT, V64, P327; SCHMIDT W, 1972, Q J STUD ALCOHOL, V33, P171; SCHUCKIT MA, 1974, Q J STUD ALCOHOL, V35, P856; SMITH EM, 1983, ALCOHOL CLIN EXP RES, V7, P237, DOI 10.1111/j.1530-0277.1983.tb05449.x; TAYLOR JR, 1983, J STUD ALCOHOL, V44, P17, DOI 10.15288/jsa.1983.44.17; TAYLOR JR, 1983, BIOL ALCOHOL, V6, P17; THORARINSSON AA, 1979, J STUD ALCOHOL, V40, P704, DOI 10.15288/jsa.1979.40.704; VAILLANT GE, 1983, NATURAL HIST ALCOHOL, P161; WENTWORTH DN, 1983, AM J PUBLIC HEALTH, V73, P1270, DOI 10.2105/AJPH.73.11.1270; 1987, DIAGNOSTIC STATISTIC; 1987, CURRENT POPULATION P, V25; 1980, MORTALITY, V2, P7; 1984, TECHNICAL APPENDIX A, V2	41	39	39	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1992	267	5					668	672		10.1001/jama.267.5.668	http://dx.doi.org/10.1001/jama.267.5.668			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HB354	1731133				2022-12-01	WOS:A1992HB35400023
J	SPACH, DH; STAPLETON, AE; STAMM, WE				SPACH, DH; STAPLETON, AE; STAMM, WE			LACK OF CIRCUMCISION INCREASES THE RISK OF URINARY-TRACT INFECTION IN YOUNG MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FIMBRIATED ESCHERICHIA-COLI; DECREASED INCIDENCE; MALE INFANTS; DIAGNOSIS; PYELONEPHRITIS; URETHRITIS; WOMEN	Objective. - To determine whether lack of circumcision increases the risk of urinary tract infection (UTI) in adult men. Design and Setting. - Retrospective case-control study (1987-1990) at a sexually transmitted disease clinic in Seattle, Wash. Patients. - Twenty-six men (median age, 30 years) who had microbiologically confirmed symptomatic UTIs (cases) compared with 52 men (median age, 32 years) who had urinary symptoms but negative urine cultures (controls). Main Outcome Measure. - Circumcision status among bacteriuric and nonbacteriuric men. Results. - The bacteriuric and nonbacteriuric groups were similar in age, race, sexual activity, and sexual preference. Eight (31%) of the 26 bacteriuric men were uncircumcised compared with 6 (12%) of the 52 nonbacteriuric men (P =.037; odds ratio, 3.4; 95% confidence interval, 1.0 to 11.2). Among 19 patients infected with gram-negative bacilli, 8 (42%) of 19 were uncircumcised vs 6 (12%) of 52 nonbacteriuric men (P = .004; odds ratio, 5.6; 95% confidence interval, 1.6 to 19.4). Escherichia coli was the most common urinary isolate (15 of 26 isolates), and the majority of E coli strains possessed urovirulence determinants, including mannose-resistant hemagglutination (10 of 14 isolates), F fimbriae (11 of 14 isolates), P fimbriae (6 of 14 isolates), hemolysin (10 of 14 isolates), and aerobactin (8 of 14 isolates). Although all 26 bacteriuric men had urethral cultures negative for Chlamydia trachomatis and Neisseria gonorrhoeae, Gram-stained urethral smears showed evidence of urethritis in 17 (68%) of 25 men. Conclusions. - (1) Lack of circumcision increases the risk of UTI in young adult men. (2) The majority of these infections result from urovirulent strains of E coli. (3) Clinically, these infections often produce urethritis as well as UTI.	UNIV WASHINGTON,MED CTR,DIV INFECT DIS,SEATTLE,WA 98195; UNIV WASHINGTON,MED CTR,DEPT MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Stapleton, Ann E/N-2428-2015	Stapleton, Ann E/0000-0003-0130-8659	NIDDK NIH HHS [DK 40045] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040045] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNES RC, 1986, LANCET, V1, P171; BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; BOWIE WR, 1978, SEX TRANSM DIS, V5, P39, DOI 10.1097/00007435-197804000-00001; BURBIGE KA, 1984, J UROLOGY, V132, P541, DOI 10.1016/S0022-5347(17)49727-8; DEPINHO AMF, 1990, 6TH INT C AIDS SAN F, P209; FIHN SD, 1988, J INFECT DIS, V157, P196, DOI 10.1093/infdis/157.1.196; GINSBURG CM, 1982, PEDIATRICS, V69, P409; HERZOG LW, 1989, AM J DIS CHILD, V143, P348, DOI 10.1001/archpedi.1989.02150150106026; JACOBSON SH, 1985, J INFECT DIS, V152, P426, DOI 10.1093/infdis/152.2.426; JOHNSON JR, 1987, J INFECT DIS, V156, P225, DOI 10.1093/infdis/156.1.225; KALLENIUS G, 1981, LANCET, V2, P1369; KIELY B, 1984, IRISH MED J, V77, P384; LIPSKY BA, 1987, J INFECT DIS, V155, P847, DOI 10.1093/infdis/155.5.847; LIPSKY BA, 1989, ANN INTERN MED, V110, P138, DOI 10.7326/0003-4819-110-2-138; Maniatis T., 1982, MOL CLONING; SCHWATZ SL, 1978, J INFECT DIS, V138, P445; STAMM WE, 1983, J CLIN MICROBIOL, V17, P666, DOI 10.1128/JCM.17.4.666-668.1983; STAMM WE, 1982, NEW ENGL J MED, V307, P463, DOI 10.1056/NEJM198208193070802; STAPLETON A, 1991, J INFECT DIS, V163, P773, DOI 10.1093/infdis/163.4.773; VAISANEN V, 1981, LANCET, V2, P1366; VAISANENRHEN V, 1984, INFECT IMMUN, V43, P149; VANBUREN M, 1990, 30TH INT C ANT AG CH, P106; WISWELL TE, 1985, PEDIATRICS, V75, P901; WISWELL TE, 1986, PEDIATRICS, V78, P96	24	88	89	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1992	267	5					679	681		10.1001/jama.267.5.679	http://dx.doi.org/10.1001/jama.267.5.679			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB354	1472171				2022-12-01	WOS:A1992HB35400025
J	WALSH, DC; HINGSON, RW; MERRIGAN, DM; LEVENSON, SM; COFFMAN, GA; HEEREN, T; CUPPLES, LA				WALSH, DC; HINGSON, RW; MERRIGAN, DM; LEVENSON, SM; COFFMAN, GA; HEEREN, T; CUPPLES, LA			THE IMPACT OF A PHYSICIANS WARNING ON RECOVERY AFTER ALCOHOLISM-TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ABUSE; PREVALENCE; DRINKING; IDENTIFICATION; INTERVENTION; RECOGNITION	Objective. - To study whether alcoholic workers had seen physicians during the year they were identified by their company, whether they recalled physicians' warnings about drinking, and whether such warnings affected outcomes 2 years later. Design. - Workers were interviewed at intake and 2 years later: subgroups who did and did not see physicians and who did and did not recall warnings were compared. Setting. - A company-union employee assistance program. Participants. - Two hundred problem drinkers, newly identified on the job, predominantly male, blue-collar workers. Outcomes. - Drinking, drunkenness, average daily alcohol consumption, and impairment score. Results. - Among the 200 participants, 74% saw physicians in the index year; only 22% recalled warnings. Recall of a warning was associated with liver disease' continued drinking while ill, supervisors' job warnings, older age, and marijuana use. Two years later, those warned were more likely to be abstaining, and sober, and were less impaired. Conclusions. - Recalling a physician's warning at intake into alcoholism treatment was associated with better prognosis 2 years later. However, among this group of employees whose drinking was serious enough to be identified on the job, fewer than a quarter recalled physicians' warnings, even though more than three quarters had seen physicians in the year preceding intake.	BOSTON UNIV,SCH PUBL HLTH,DEPT SOCIAL & BEHAV SCI,BOSTON,MA 02215; BOSTON UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL & BIOSTAT,BOSTON,MA 02215	Boston University; Boston University	WALSH, DC (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH & SOCIAL BEHAV,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.			Heeren, Timothy/0000-0001-5643-3559; Levenson, Suzette/0000-0002-1979-2373; Coffman, Gerald/0000-0002-0044-6219	NIAAA NIH HHS [R01 AA06461] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006461] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Armor D. J., 1976, ALCOHOLISM TREATMENT; BELL J, 1988, MED J AUSTRALIA, V149, P351, DOI 10.5694/j.1326-5377.1988.tb120666.x; BERESFORD TP, 1988, PREV MED, V17, P653, DOI 10.1016/0091-7435(88)90058-8; BOWEN OR, 1988, JAMA-J AM MED ASSOC, V260, P2267, DOI 10.1001/jama.260.15.2267; BUSH B, 1987, AM J MED, V82, P231, DOI 10.1016/0002-9343(87)90061-1; CLARK WD, 1981, AM J MED, V71, P275, DOI 10.1016/0002-9343(81)90129-7; CLEARY PD, 1988, AM J MED, V85, P466; CYR MG, 1988, JAMA-J AM MED ASSOC, V259, P51, DOI 10.1001/jama.259.1.51; GREEN J R, 1965, Med J Aust, V1, P465; HINGSON R, 1982, J STUD ALCOHOL, V43, P273, DOI 10.15288/jsa.1982.43.273; KAMEROW DB, 1986, JAMA-J AM MED ASSOC, V255, P2054, DOI 10.1001/jama.255.15.2054; KISSIN B, 1977, TREATMENT REHABILITA, P53; KRISTENSON H, 1983, ALCOHOL CLIN EXP RES, V7, P203, DOI 10.1111/j.1530-0277.1983.tb05441.x; LEWIS DC, 1983, B NEW YORK ACAD MED, V59, P181; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; MULFORD HA, 1977, J STUD ALCOHOL, V38, P21; PRICE J, 1988, MED J AUSTRALIA, V149, P345, DOI 10.5694/j.1326-5377.1988.tb120663.x; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROHMAN ME, 1987, AM J DRUG ALCOHOL AB, V131, P199; ROLLNICK S, 1987, AUST DRUG ALCOHOL RE, V6, P341; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SHERIN KM, 1982, J FAM PRACTICE, V15, P1091; SKINNER HA, 1984, ANN INTERN MED, V101, P847, DOI 10.7326/0003-4819-101-6-847; TRICE HM, 1973, ALCOHOLISM PROGR RES, P359; WALLACE P, 1988, BRIT MED J, V297, P663, DOI 10.1136/bmj.297.6649.663; WALSH DC, 1991, NEW ENGL J MED, V325, P775, DOI 10.1056/NEJM199109123251105; WEST LJ, 1984, ANN INTERN MED, V100, P405, DOI 10.7326/0003-4819-100-3-405; 1980, DIAGNOSTIC STATISTIC; 1987, PHS6TH ALC DRUG AB M	29	42	42	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1992	267	5					663	667		10.1001/jama.267.5.663	http://dx.doi.org/10.1001/jama.267.5.663			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HB354	1731132				2022-12-01	WOS:A1992HB35400022
J	BEWLEY, S; BEWLEY, TH				BEWLEY, S; BEWLEY, TH			DRUG-DEPENDENCE WITH ESTROGEN REPLACEMENT THERAPY	LANCET			English	Editorial Material							ESTRADIOL IMPLANTS; ESTROGEN DEFICIENCY; HORMONE IMPLANTS; SYMPTOMS; WOMEN	Dependence on some drugs can be hard to recognise. Hormone replacement therapy (HRT) has been widely prescribed only in the past two decades, and the indications for treatment and the risk/benefit ratio are still disputed. Oestrogens are psychoactive: they lift mood, can be given by injection, and their use has powerful psychological effects. Reports of women with supraphysiological oestradiol concentrations may represent tolerance and withdrawal. Dependence on substances occurring naturally in the body has been reported before. We propose that HRT dependence occurs.	ST GEORGE HOSP,SCH MED,DEPT ADDICT BEHAV,LONDON SW17,ENGLAND	St Georges University London	BEWLEY, S (corresponding author), UNIV COLL HOSP LONDON,DEPT OBSTET & GYNAECOL,LONDON WC1E 6HX,ENGLAND.			bewley, susan/0000-0001-8064-652X				APPLEBY L, 1991, PROGR OBSTETRICS GYN, V9, P289; BRINCAT M, 1984, LANCET, V1, P16; BROWER KJ, 1991, BRIT J ADDICT, V86, P759; CAMPBELL S, 1977, CLIN OBSTET GYNAECOL, V4, P31; GANGAR K, 1989, BRIT MED J, V299, P601, DOI 10.1136/bmj.299.6699.601-a; GANGAR K, 1991, BRIT J OBSTET GYNAEC, V98, P607, DOI 10.1111/j.1471-0528.1991.tb10383.x; GANGAR KF, 1990, BRIT MED J, V300, P436, DOI 10.1136/bmj.300.6722.436; GARNETT T, 1990, BRIT J OBSTET GYNAEC, V97, P917, DOI 10.1111/j.1471-0528.1990.tb02447.x; GINSBURG J, 1991, BRIT MED J, V302, P1601; LADER M, 1981, AUST NZ J PSYCHIAT, V15, P1, DOI 10.3109/00048678109159402; Magos AL, 1984, PROGR OBSTETRICS GYN, V4, P334; MONTGOMERY JC, 1987, LANCET, V1, P297; NOTT PN, 1976, BRIT J PSYCHIAT, V128, P379, DOI 10.1192/bjp.128.4.379; SHERWIN BB, 1985, PSYCHONEUROENDOCRINO, V10, P325, DOI 10.1016/0306-4530(85)90009-5; STUDD J, 1989, BRIT MED J, V299, P1400, DOI 10.1136/bmj.299.6712.1400-b; STUDD J, 1991, BRIT J OBSTET GYNAEC, V5, P502; WILKES HC, 1991, BRIT MED J, V302, P1317, DOI 10.1136/bmj.302.6788.1317; 1987, DIAGNOSTIC STATISTIC, P167; 1990, MENTAL BEHAVIOURAL D, P54; 1988, HLTH CONSEQUENCES SM, V4, P177	20	19	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1992	339	8788					290	291		10.1016/0140-6736(92)91344-8	http://dx.doi.org/10.1016/0140-6736(92)91344-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB529	1346294				2022-12-01	WOS:A1992HB52900016
J	BRADLEY, CP				BRADLEY, CP			UNCOMFORTABLE PRESCRIBING DECISIONS - A CRITICAL INCIDENT STUDY	BRITISH MEDICAL JOURNAL			English	Article								Objective - To explore the discomfort experienced by general practitioners in relation to decisions about whether or not to prescribe. Design - Focused interviews of general practitioners about prescribing decisions that made them uncomfortable. Analysis based on the critical incident technique. Setting - One family practitioner committee area in the north of England. Respondents - 69 principals and five trainee general practitioners. Main outcome measures - Drugs and clinical problems associated with prescribing discomfort. Reasons given by doctors for making the prescribing decisions they did and reasons for feeling uncomfortable. Results - Antibiotics, tranquillisers, hypnotics, and symptomatic remedies were most often associated with discomfort, but any prescribeable item could be associated with discomfort. Respiratory diseases, musculoskeletal problems, and anxiety were most often associated with discomfort, but again any condition could be associated. The main reasons given for the decisions made were patient expectation, clinical appropriateness, factors related to the doctor-patient relationship, and precedents. The main reasons given for feeling uncomfortable were concern about drug toxicity, failure to live up to the general practitioner's own expectations, concern about the appropriateness of treatment, and ignorance or uncertainty. Conclusions - Many considerations, including medical, social, and logistic ones, influence the decision to prescribe in general practice. The final action taken depends on a complex interaction of these disparate influences.			BRADLEY, CP (corresponding author), UNIV MANCHESTER,RUSHOLME HLTH CTR,DEPT GEN PRACTICE,MANCHESTER M14 5NP,ENGLAND.			Bradley, Colin/0000-0002-3595-9567				BRADLEY CP, 1991, FAM PRACT, V8, P276, DOI 10.1093/fampra/8.3.276; BRADLEY CP, IN PRESS FAM PRACT; BRADLEY CP, 1990, THESIS U DUBLIN; FLANAGAN JC, 1954, PSYCHOL BULL, V51, P327, DOI 10.1037/h0061470; Glaser B. G., 1978, THEORETICAL SENSITIV; HARRIS CM, 1980, BRIT MED J, V281, P57; HEMMINKI E, 1975, MED CARE, V13, P150, DOI 10.1097/00005650-197502000-00006; HOWIE JGR, 1976, BRIT MED J, V2, P1061, DOI 10.1136/bmj.2.6043.1061; PARISH PA, 1973, ROY SOC HEALTH J, V93, P213, DOI 10.1177/146642407309300414; 1986, 1981 1982 MORBIDITY; 1989, HLTH PERSONAL SOCIAL; 1987, BMA GUIDE LIVING RIS	12	145	146	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1992	304	6822					294	296		10.1136/bmj.304.6822.294	http://dx.doi.org/10.1136/bmj.304.6822.294			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC708	1739831	Green Published, Bronze			2022-12-01	WOS:A1992HC70800024
J	FLACK, MR; OLDFIELD, EH; CUTLER, GB; ZWEIG, MH; MALLEY, JD; CHROUSOS, GP; LORIAUX, DL; NIEMAN, LK				FLACK, MR; OLDFIELD, EH; CUTLER, GB; ZWEIG, MH; MALLEY, JD; CHROUSOS, GP; LORIAUX, DL; NIEMAN, LK			URINE FREE CORTISOL IN THE HIGH-DOSE DEXAMETHASONE SUPPRESSION TEST FOR THE DIFFERENTIAL-DIAGNOSIS OF THE CUSHING SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						DIAGNOSIS, DIFFERENTIAL; CUSHING SYNDROME; PITUITARY DISEASE; DEXAMETHASONE; HYDROCORTISONE	LABORATORY TESTS; UPDATE	Objective: To develop criteria for interpreting the high-dose dexamethasone suppression test using urine free cortisol as an end point for the differential diagnosis of the Cushing syndrome. Design: Retrospective review. Setting: Inpatient research ward. Patients: Patients (118) with surgically confirmed causes of the Cushing syndrome: 94 with pituitary disease, 14 with primary adrenal disease, and 10 with ectopic adrenocorticotropic hormone (ACTH) secretion. Main Outcome Measures: The sensitivity, specificity, and diagnostic accuracy were determined for the high-dose dexamethasone suppression test using urine free cortisol and using 17-hydroxysteroid excretion. For each analysis, patients with pituitary disease were considered to be "diseased" and patients with nonpituitary disease were considered to be "non-diseased". The level of suppression that gave 100% specificity was determined for each steroid. Results: The accuracy of urine free cortisol when used as an end point in the high-dose dexamethasone suppression test was equivalent to that of 17-hydroxysteroid excretion. At all levels of sensitivity and specificity, however, the degree of suppression of urine free cortisol used for the diagnosis of pituitary disease was greater than that of 17-hydroxysteroid excretion. The likelihood ratios for pituitary disease based on urine free cortisol suppression of > 50%, of > 80%, and of > 90% were 4.2, 10.1, and "infinite," respectively. Suppression of urine free cortisol greater than 90% or suppression of 17-hydroxysteroid excretion greater than 64% was associated with 100% specificity. When these criteria were combined, the percentage of correct predictions (102 of 118 [86%; 95% Cl, 78% to 92%]) was higher than that obtained using either steroid alone (89 of 118 [75%; Cl, 65% to 83%]) (P = 0.009) and higher than that obtained using the traditional criterion of 50% suppression for 17-hydroxysteroid excretion (95 of 118 [80%; Cl, 71% to 87%]) (P = 0.016). Conclusions: In the high-dose dexamethasone suppression test, the degree of suppression of urine free cortisol used for the diagnosis of pituitary disease is greater than that traditionally used for 17-hydroxysteroid excretion. The diagnostic performance of the test is improved by measuring both urine free cortisol and 17-hydroxysteroid excretion and by requiring greater suppression of both steroids.			FLACK, MR (corresponding author), NICHHD, DEV ENDOCRINOL BRANCH, BLD 10, ROOM 10N262, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.							BEARDWELL CG, 1968, J ENDOCRINOL, V42, P79, DOI 10.1677/joe.0.0420079; BEISEL WR, 1964, J CLIN ENDOCR METAB, V24, P887, DOI 10.1210/jcem-24-9-887; BORUSHEK S, 1964, CLIN CHEM, V10, P41; BROWN RD, 1973, J CLIN ENDOCR METAB, V36, P445; BROWNLEE KA, 1965, STATISTICAL THEORY M, P262; BURKE CW, 1973, Q J MED, V42, P175; CARPENTER PC, 1986, MAYO CLIN PROC, V61, P49, DOI 10.1016/S0025-6196(12)61398-6; COPE CL, 1959, BR MED J        1128, P1117; CRAPO L, 1979, METABOLISM, V28, P955, DOI 10.1016/0026-0495(79)90097-0; EDDY RL, 1973, AM J MED, V55, P621, DOI 10.1016/0002-9343(73)90184-8; FORMAN DT, 1978, MANUAL PROCEDURES SE, P135; GOLD EM, 1979, ANN INTERN MED, V90, P829, DOI 10.7326/0003-4819-90-5-829; HANKIN ME, 1977, CLIN ENDOCRINOL, V6, P185, DOI 10.1111/j.1365-2265.1977.tb03314.x; KAYE TB, 1990, ANN INTERN MED, V112, P434, DOI 10.7326/0003-4819-76-3-112-6-434; LEINUNG MC, 1990, MAYO CLIN PROC, V65, P1314, DOI 10.1016/S0025-6196(12)62142-9; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; LORIAUX DL, 1986, CLIN ENDOCRINOL, P167; MARTIN MM, 1966, J CLIN ENDOCR METAB, V26, P257, DOI 10.1210/jcem-26-3-257; MORRISON DF, 1984, MULTIVARIATE STATIST, P34; MURPHY BEP, 1968, J CLIN ENDOCR METAB, V28, P343, DOI 10.1210/jcem-28-3-343; NICHOLS T, 1968, AM J MED, V45, P116, DOI 10.1016/0002-9343(68)90013-2; NIEMAN LK, 1986, ANN INTERN MED, V105, P862, DOI 10.7326/0003-4819-105-6-862; OLDFIELD EH, 1985, NEW ENGL J MED, V312, P1457; SHEELER LR, 1988, CLEV CLIN J MED, V55, P329, DOI 10.3949/ccjm.55.4.329; SILBER RH, 1950, J BIOL CHEM, V185, P923; SILBER RH, 1954, J BIOL CHEM, V21, P262; SINDLER BH, 1983, AM J MED, V74, P657, DOI 10.1016/0002-9343(83)91024-0; STREETEN DHP, 1984, ENDOCR REV, V5, P371, DOI 10.1210/edrv-5-3-371; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; YOUNG DS, 1975, CLIN CHEM, V21, pD1; 1983, CAN MED ASSOC J, V129, P947	31	128	137	2	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1992	116	3					211	217		10.7326/0003-4819-116-3-211	http://dx.doi.org/10.7326/0003-4819-116-3-211			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB356	1728204				2022-12-01	WOS:A1992HB35600006
J	GODLEE, F				GODLEE, F			HEALTH AND THE ENVIRONMENT - ENVIRONMENTAL RADIATION - A CAUSE FOR CONCERN	BRITISH MEDICAL JOURNAL			English	Article							X-RAYS; NUCLEAR INSTALLATIONS; MORTALITY; CANCER; EMPLOYEES; LEUKEMIA											BEEBE GW, 1978, RADIAT RES, V75, P136; BERAL V, 1985, BRIT MED J, V291, P440, DOI 10.1136/bmj.291.6493.440; BERAL V, 1988, BRIT MED J, V297, P757, DOI 10.1136/bmj.297.6651.757; BOWIE C, 1991, LANCET, V337, P409, DOI 10.1016/0140-6736(91)91177-V; BRANSBYZACHARY MAP, 1989, BRIT MED J, V298, P1294, DOI 10.1136/bmj.298.6683.1294; Caufield Catherine, 1989, MULTIPLE EXPOSURES C; COOKMOZAFFARI P, 1989, LANCET, V2, P1145; COOKMOZAFFARI P, 1987, STUDIES MED POPULATI, V51; FORMAN D, 1987, NATURE, V329, P499, DOI 10.1038/329499a0; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; ISHIMARU T, 1981, RERF1181 RAD EFF RES; KENDALL GM, 1992, BRIT MED J, V304, P220, DOI 10.1136/bmj.304.6821.220; KINLEN LJ, 1990, LANCET, V336, P577, DOI 10.1016/0140-6736(90)93389-7; KINLEN LJ, 1991, BRIT MED J, V303, P1357, DOI 10.1136/bmj.303.6814.1357; MODAN B, 1974, LANCET, V1, P277; MODAN B, 1977, THERAPEUTIC RADIOLOG, V123, P741; NOMURA T, 1982, NATURE, V296, P575, DOI 10.1038/296575a0; RON E, 1980, J NATL CANCER I, V65, P7; ROSCOE RJ, 1989, JAMA-J AM MED ASSOC, V262, P629, DOI 10.1001/jama.262.5.629; SHIMIZU Y, 1987, RAD EFFECTS RES F TE, V12, P1; SMITH PG, 1982, BRIT MED J, V284, P449, DOI 10.1136/bmj.284.6314.449; STAPHER FK, 1988, NRPBR215 NAT RAD PRO; STEWART A, 1970, LANCET, V1, P1185; Sumner D, 1990, Med War, V6, P112, DOI 10.1080/07488009008408915; SUMNER DJ, 1991, RAD RISKS EVALUATION; URQUHART JD, 1991, BRIT MED J, V302, P687, DOI 10.1136/bmj.302.6778.687; WALL BF, 1980, NRPBR105; WING S, 1991, JAMA-J AM MED ASSOC, V265, P1397, DOI 10.1001/jama.265.11.1397; YOSHIMOTO Y, 1990, JAMA-J AM MED ASSOC, V264, P596, DOI 10.1001/jama.264.5.596; YOSHIMOTO Y, 1990, RERF490 RAD EFF RES; 1991, DOCUMENTS NATIONAL R; 1988, HLTH RISKS RADON OTH; 1988, 2ND REPORT INVESTIGA; 1990, RECOMMENDATIONS ICRP; 1984, RADIOLOGICAL PROTECT, V57, P11; 1987, ICRP PUBLICATION 50, V17; 1990, REPORT ROYAL COLLEGE, P1; 1989, LIVING RAD; 1990, PATIENT DOSE REDUCTI, V1; 1990, HOUSEHOLDERS GUIDE R; 1986, REPORT HLTH MINISTER; 1984, INVESTIGATION POSSIB; 1990, DOCUMENTS NATIONAL R, P1; 1989, 3RD REPORT REPORT IN; 1978, RECOMMENDATIONS ICRP, P1	45	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1992	304	6822					299	304		10.1136/bmj.304.6822.299	http://dx.doi.org/10.1136/bmj.304.6822.299			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC708	1739833	Green Published, Bronze			2022-12-01	WOS:A1992HC70800026
J	GRUNDY, CE; ROBINSON, J; GUTHRIE, KA; GORDON, AG; HAY, DM				GRUNDY, CE; ROBINSON, J; GUTHRIE, KA; GORDON, AG; HAY, DM			ESTABLISHMENT OF PREGNANCY AFTER REMOVAL OF SPERM ANTIBODIES INVITRO	BRITISH MEDICAL JOURNAL			English	Article									PRINCESS ROYAL HOSP,HULL,ENGLAND		GRUNDY, CE (corresponding author), UNIV HULL,DEPT APPL BIOL,HULL HU6 7RX,N HUMBERSIDE,ENGLAND.							BRONSON R, 1984, FERTIL STERIL, V42, P171; CLARKE GN, 1985, AM J REPROD IM MIC, V8, P62; GRUNDY CE, 1991, HUM REPROD, V6, P593, DOI 10.1093/oxfordjournals.humrep.a137385; HAAS GG, 1987, FERTIL STERIL, V47, P295; HAAS GG, 1988, J ANDROL, V9, P190	5	11	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1992	304	6822					292	293		10.1136/bmj.304.6822.292-a	http://dx.doi.org/10.1136/bmj.304.6822.292-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC708	1739830	Green Published, Bronze			2022-12-01	WOS:A1992HC70800023
J	LAUER, MS; LEVY, D; ANDERSON, KM; PLEHN, JF				LAUER, MS; LEVY, D; ANDERSON, KM; PLEHN, JF			IS THERE A RELATIONSHIP BETWEEN EXERCISE SYSTOLIC BLOOD-PRESSURE RESPONSE AND LEFT-VENTRICULAR MASS - THE FRAMINGHAM HEART-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						BLOOD PRESSURE; EXERCISE TEST; ECHOCARDIOGRAPHY; HEART ENLARGEMENT; VENTRICULAR FUNCTION, LEFT	RISK-FACTORS; HYPERTROPHY; DISEASE; ECHOCARDIOGRAPHY; HYPERTENSION; SIZE; AGE; MEN	Objective: To assess the association between an exaggerated exercise systolic blood pressure response and the occurrence of left ventricular hypertrophy in healthy, normotensive individuals. Design: Cross-sectional survey using M-mode echocardiography to measure left ventricular mass and to detect left ventricular hypertrophy. Setting: The Framingham Heart Study. Subjects: Eight-hundred sixty men and 1118 women were studied who were free of cardiovascular or pulmonary disease, who were not taking any antihypertensive or cardiovascular medications, and who successfully achieved at least 90% of their age-predicted maximum heart rate during a monitored exercise treadmill test. All subjects had normal baseline and exercise electrocardiograms. Measurements and Main Results: Men with a peak exercise systolic blood pressure of 210 or more and women with a peak exercise systolic blood pressure of 190 or more were considered to have an "exaggerated" blood pressure response; 122 men and 67 women met these criteria. Subjects with an exaggerated exercise systolic blood pressure response had 10% higher left ventricular mass than those with a normal exercise systolic blood pressure response (in men: 115 +/- 25 compared with 105 +/- 24 g/m, P < 0.001; in women: 86 +/- 22 compared with 73 +/- 16 g/m, P < 0.001); they also had a higher prevalence of left ventricular hypertrophy (in men: odds ratio, 1.34, 95% Cl, 1.00 to 1.80; in women: odds ratio, 2.12, Cl, 1.48 to 3.03). After adjusting for age, resting systolic blood pressure, and body mass index, however, subjects with an exaggerated exercise systolic blood pressure response had only 5% higher left ventricular mass (in men: 111 +/- 2.1 compared with 106 +/- 0.8 g/m, P = 0.02; in women: 80 +/- 1.8 compared with 74 +/- 0.4 g/m, P = 0.002), and they no longer had a statistically increased prevalence of left ventricular hypertrophy (in men: odds ratio, 1.21, Cl, 0.87 to 1.67; in women: odds ratio, 1.30, Cl, 0.84 to 2.01). Conclusions: The apparent relation between exercise systolic blood pressure response and left ventricular mass is confounded by age, resting systolic blood pressure, and body mass; the degree of confounding is such that the biologic significance of this relationship should be questioned.	FRAMINGHAM HEART DIS EPIDEMIOL STUDY, 5 THURBER ST, FRAMINGHAM, MA 01701 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA	Framingham Heart Study; Harvard University; Beth Israel Deaconess Medical Center			Levy, Daniel/ABB-2752-2021; Lauer, Michael S/L-9656-2013; Levy, Daniel/ABF-6873-2021	Lauer, Michael S/0000-0002-9217-8177; Levy, Daniel/0000-0003-1843-8724	NHLBI NIH HHS [N01-HC-38038, HL07374] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007374] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRUCE RA, 1973, AM HEART J, V85, P546, DOI 10.1016/0002-8703(73)90502-4; DANNENBERG AL, 1989, AM J CARDIOL, V64, P1066, DOI 10.1016/0002-9149(89)90816-3; Dawber, 1959, J CHRON DIS, V10, P186, DOI 10.1016/0021-9681(59)90002-5; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; DEVEREUX RB, 1990, ANN INTERN MED, V112, P157, DOI 10.7326/0003-4819-112-3-157; DLIN RA, 1983, AM HEART J, V106, P316, DOI 10.1016/0002-8703(83)90198-9; DOUGLAS PS, 1986, AM J CARDIOL, V58, P805, DOI 10.1016/0002-9149(86)90358-9; ELLESTAD MH, 1986, STRESS TESTING PRINC, P472; FAGARD R, 1991, HYPERTENSION, V17, P574, DOI 10.1161/01.HYP.17.4.574; FEIGENBAUM H, 1981, ECHOCARDIOGR-J CARD, P51; GARDIN JM, 1987, HYPERTENSION, V9, P36; GOTTDIENER JS, 1990, ANN INTERN MED, V112, P161, DOI 10.7326/0003-4819-112-3-161; HAMMOND IW, 1986, J AM COLL CARDIOL, V7, P639, DOI 10.1016/S0735-1097(86)80476-4; Kannel W B, 1978, Ann N Y Acad Sci, V304, P128, DOI 10.1111/j.1749-6632.1978.tb25585.x; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; MACMAHON SW, 1986, NEW ENGL J MED, V314, P334, DOI 10.1056/NEJM198602063140602; REN JF, 1985, J AM COLL CARDIOL, V5, P1224, DOI 10.1016/S0735-1097(85)80029-2; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SAVAGE DD, 1990, AM J CARDIOL, V65, P371, DOI 10.1016/0002-9149(90)90304-J; SAVAGE DD, 1979, CIRCULATION, V59, P623, DOI 10.1161/01.CIR.59.4.623; SAVAGE DD, 1987, HYPERTENSION, V9, P40; SHEFFIELD LT, 1988, HEART DISEASE TXB CA, P237; SHEFFIELD LT, 1988, HEART DISEASE TXB CA, P227; VANDENBOSSCHE JL, 1984, J AM COLL CARDIOL, V4, P1195, DOI 10.1016/S0735-1097(84)80138-2; WILSON NV, 1981, PREV MED, V10, P62, DOI 10.1016/0091-7435(81)90006-2	31	144	153	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1992	116	3					203	210		10.7326/0003-4819-116-3-203	http://dx.doi.org/10.7326/0003-4819-116-3-203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB356	1530806				2022-12-01	WOS:A1992HB35600005
J	LUCAS, A; MORLEY, R; COLE, TJ; LISTER, G; LEESONPAYNE, C				LUCAS, A; MORLEY, R; COLE, TJ; LISTER, G; LEESONPAYNE, C			BREAST-MILK AND SUBSEQUENT INTELLIGENCE QUOTIENT IN CHILDREN BORN PRETERM	LANCET			English	Article							BIRTH-WEIGHT INFANTS; MOTHERS CHOICE; DIET	There is considerable controversy over whether nutrition in early life has a long-term influence on neurodevelopment. We have shown previously that, in preterm infants, mother's choice to provide breast milk was associated with higher developmental scores at 18 months. We now report data on intelligence quotient (IQ) in the same children seen at 7 1/2-8 years. IQ was assessed in 300 children with an abbreviated version of the Weschler Intelligence Scale for Children (revised Anglicised). Children who had consumed mother's milk in the early weeks of life had a significantly higher IQ at 7 1/2-8 years than did those who received no maternal milk. An 8.3 point advantage (over half a standard deviation) in IQ remained even after adjustment for differences between groups in mother's education and social class (p < 0.0001). This advantage was associated with being fed mother's milk by tube rather than with the process of breastfeeding. There was a dose-response relation between the proportion of mother's milk in the diet and subsequent IQ. Children whose mothers chose to provide milk but failed to do so had the same IQ as those whose mothers elected not to provide breast milk. Although these results could be explained by differences between groups in parenting skills or genetic potential (even after adjustment for social and educational factors), our data point to a beneficial effect of human milk on neurodevelopment.	UNIV CAMBRIDGE,DEPT PAEDIAT,CAMBRIDGE,ENGLAND; NORFOLK & NORWICH HOSP,DEPT COMMUNITY CHILD HLTH,NORWICH NR1 3SR,NORFOLK,ENGLAND; JESSOP HOSP WOMEN,DEPT PAEDIAT,SHEFFIELD S3 7RE,S YORKSHIRE,ENGLAND	University of Cambridge; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital	LUCAS, A (corresponding author), MRC,DUNN NUTR UNIT,DOWNHAMS LANE,MILTON RD,CAMBRIDGE CB4 1XJ,ENGLAND.		Cole, Tim J/B-7883-2008	Cole, Tim J/0000-0001-5711-8200				BROAD B, 1972, NZ MED J, V76, P28; LUCAS A, 1989, ARCH DIS CHILD, V64, P1570, DOI 10.1136/adc.64.11.1570; LUCAS A, 1984, ARCH DIS CHILD, V59, P722, DOI 10.1136/adc.59.8.722; LUCAS A, 1990, LANCET, V335, P1477, DOI 10.1016/0140-6736(90)93026-L; LUCAS A, 1988, ARCH DIS CHILD, V63, P48, DOI 10.1136/adc.63.1.48; McNemar Q, 1974, J CONSULT CLIN PSYCH, V42, P145, DOI DOI 10.1037/H0035842; MORLEY R, 1988, ARCH DIS CHILD, V63, P1382, DOI 10.1136/adc.63.11.1382; POLLOCK JI, 1989, ARCH DIS CHILD, V64, P763, DOI 10.1136/adc.64.5.763; READ LC, 1988, FETAL NEONATAL GROWT, P131; RODGERS B, 1978, DEV MED CHILD NEUROL, V20, P421, DOI 10.1111/j.1469-8749.1978.tb15242.x; Rogerson BCF, 1939, J MENT SCI, V85, P1163, DOI 10.1192/bjp.85.359.1163; SACK J, 1980, HUMAN MILK ITS BIOL, P56; SILVA PA, 1978, AUST PAEDIATR J, V14, P265; TAYLOR B, 1977, NEW ZEAL MED J, V85, P235; [No title captured]; 1974, ANGLICIZED REVISED E; [No title captured]	17	824	860	2	100	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1992	339	8788					261	264		10.1016/0140-6736(92)91329-7	http://dx.doi.org/10.1016/0140-6736(92)91329-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB529	1346280				2022-12-01	WOS:A1992HB52900002
J	MERTZ, GJ; BENEDETTI, J; ASHLEY, R; SELKE, SA; COREY, L				MERTZ, GJ; BENEDETTI, J; ASHLEY, R; SELKE, SA; COREY, L			RISK-FACTORS FOR THE SEXUAL TRANSMISSION OF GENITAL HERPES	ANNALS OF INTERNAL MEDICINE			English	Article						HERPES GENITALIS; HERPESVIRUS-HOMINIS; SEXUALLY TRANSMITTED DISEASES, VIRAL; ANTIBODIES, VIRAL; PREGNANCY COMPLICATIONS, INFECTIOUS	SIMPLEX VIRUS-INFECTIONS; DOUBLE-BLIND; ORAL ACYCLOVIR; TYPE-2; ACQUISITION; SUPPRESSION; ANTIBODIES; GONORRHEA; PARTNER; TRIAL	Objective: To determine the risk of sexual transmission of genital herpes simplex virus (HSV) in heterosexual couples. Design: Prospective study of couples who were participants in a clinical trial. Each source partner had symptomatic, recurrent genital HSV, and each susceptible partner was without serologic or clinical evidence of genital herpes. Couples were followed for a median of 334 days. Setting: Two university-based research clinics. Patients: One hundred forty-four heterosexual couples were studied out of an initial enrollment of 214 couples. Main Outcome Measures: Development of culture-proven HSV infection or type-specific antibodies in the susceptible partner. Main Results: Transmission occurred in 14 (9.7%) couples, including 11 (16.9%) of 65 couples with male and 3 (3.8%) of 79 with female source partners (P = 0.05). The annual rate of acquisition was higher (31.8%) in susceptible, female partners who lacked antibodies to either HSV type 1 or 2 at entry compared with females with HSV type 1 antibodies at entry (9.1%). Couples avoiding transmission of HSV reported fewer days with genital lesions in source partners. Detailed histories were available at the time of transmission in 13 couples. In nine couples, transmission occurred when the source partner was reported to be asymptomatic and in four, it resulted from sexual contact at the time of prodrome (1 case) or within hours before lesions were first noticed by the source partner (3 cases). Conclusions: Despite clear recognition of genital herpes in source partners, there was substantial risk for transmission; in 70% of patients, transmission appeared to result from sexual contact during periods of asymptomatic viral shedding. The risk for acquisition of HSV was higher in women than men, and previous HSV type 1 infection appeared to reduce the risk for acquisition of HSV type 2 infection among women.	UNIV NEW MEXICO, DEPT MED, ALBUQUERQUE, NM 87131 USA; UNIV WASHINGTON, PACIFIC MED CTR,DEPT LAB MED,ROOM 9301, 1200 12TH AVE S, SEATTLE, WA 98144 USA	University of New Mexico; University of Washington; University of Washington Seattle			Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NIAID NIH HHS [AI-30731, AI-20381] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020381, P01AI030731] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHLEY R, 1987, J VIROL, V61, P264, DOI 10.1128/JVI.61.2.264-268.1987; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BERNSTEIN DI, 1985, J MED VIROL, V15, P251, DOI 10.1002/jmv.1890150306; BREINIG MK, 1990, J INFECT DIS, V162, P299, DOI 10.1093/infdis/162.2.299; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; DOUGLAS JM, 1984, NEW ENGL J MED, V310, P1551, DOI 10.1056/NEJM198406143102402; Handsfield H.H., 1990, PRINCIPLES PRACTICE, P1613; HOLMES KK, 1970, AM J EPIDEMIOL, V91, P170, DOI 10.1093/oxfordjournals.aje.a121125; HOOPER RR, 1978, AM J EPIDEMIOL, V108, P136, DOI 10.1093/oxfordjournals.aje.a112597; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1988, JAMA-J AM MED ASSOC, V260, P201, DOI 10.1001/jama.260.2.201; MERTZ GJ, 1990, J INFECT DIS, V161, P653, DOI 10.1093/infdis/161.4.653; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; PETERSON E, 1983, J CLIN MICROBIOL, V17, P92, DOI 10.1128/JCM.17.1.92-96.1983; ROONEY JF, 1986, NEW ENGL J MED, V314, P1561, DOI 10.1056/NEJM198606123142407; STRAUS SE, 1989, SEX TRANSM DIS, V16, P107; THIN RNT, 1971, BRIT J VENER DIS, V47, P27; WENTWORTH BB, 1973, HEALTH LAB SCI, V10, P75; WHITLEY R, 1991, NEW ENGL J MED, V324, P450, DOI 10.1056/NEJM199102143240704; WHITLEY R, 1991, NEW ENGL J MED, V324, P444, DOI 10.1056/NEJM199102143240703; YEAGER AS, 1984, PEDIATRICS, V73, P188	22	385	395	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1992	116	3					197	202		10.7326/0003-4819-116-3-197	http://dx.doi.org/10.7326/0003-4819-116-3-197			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB356	1309413				2022-12-01	WOS:A1992HB35600004
J	MICHEL, G; RITTER, A; GERKEN, G; ZUMBUSCHENFELDE, KHM; DECKER, R; MANNS, MP				MICHEL, G; RITTER, A; GERKEN, G; ZUMBUSCHENFELDE, KHM; DECKER, R; MANNS, MP			ANTI-GOR AND HEPATITIS-C VIRUS IN AUTOIMMUNE LIVER-DISEASES	LANCET			English	Article							AUTOANTIBODIES; ANTIBODIES	Anti-GOR is an autoantibody found in hepatitis C virus (HCV) infection. We have studied the specificity of this antibody for HCV infection in various groups of autoimmune liver diseases. Anti-HCV was detected by a second generation HCV enzyme-linked immunosorbent assay in 14 of 29 patients with liver-kidney-microsomal (LKM-1) -antibody-positive autoimmune hepatitis type 2 and in all 6 control patients with HCV-RNA-positive chronic hepatitis C. Anti-HCV was not found in those with antinuclear-antibody-positive autoimmune hepatitis type 1 (10 patients), with soluble-liver-protein-antibody-positive autoimmune hepatitis type 3 (8), with primary biliary cirrhosis (9), with systemic lupus erythematosus (SLE) (10), or in healthy controls (13). Anti-GOR was detected in 11 of 14 patients with autoimmune hepatitis type 2 who were all positive for anti-HCV but only in 1 of 15 LKM-1 patients who were negative for anti-HCV. We did not find anti-GOR in any other group of autoimmune liver disease, SLE, or control sera, but this antibody was detected in 3 of 6 patients with chronic hepatitis C. Autoimmune hepatitis type 2 patients who were anti-GOR positive and anti-HCV positive were less likely to be female, were older (p < 0.001), and had lower LKM-1 antibody titres (p < 0.001), lower disease activity, and responded less effectively to immuno- suppression than did those who were anti-HCV negative/anti-GOR negative. The findings show that anti-GOR reflects HCV-specific autoimmunity. HCV seems to induce autoimmunity to both GOR (an HCV-specific autoepitope) and LKM-1 (an epitope that is also recognised by autoimmune hepatitis sera of a different cause). Anti-GOR and LKM-1 antibodies contribute to a better differentiation of chronic hepatitis, a finding that has therapeutic implications.	MED HSCH HANNOVER,ZENTRUM INNERE MED,DEPT GASTROENTEROL & HEPATOL,KONSTANTY GUTSCHOW STR 8,W-3000 HANNOVER 61,GERMANY; ABBOTT LABS,EUROPEAN RES & DEV,WIESBADEN,GERMANY; UNIV MAINZ,DEPT MED 1,W-6500 MAINZ,GERMANY	Hannover Medical School; Johannes Gutenberg University of Mainz								ESTEBAN JI, 1989, LANCET, V2, P294; FUSCONI M, 1990, LANCET, V336, P823, DOI 10.1016/0140-6736(90)93297-3; HOMBERG JC, 1987, HEPATOLOGY, V7, P1333, DOI 10.1002/hep.1840070626; LENZI M, 1991, LANCET, V338, P277, DOI 10.1016/0140-6736(91)90418-O; MANNS M, 1989, J HEPATOL, V9, P272, DOI 10.1016/0168-8278(89)90063-9; MANNS MP, 1989, J CLIN INVEST, V83, P1066, DOI 10.1172/JCI113949; MANNS MP, 1991, J CLIN INVEST, V88, P1370, DOI 10.1172/JCI115443; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MISHIRO S, 1990, LANCET, V336, P1400, DOI 10.1016/0140-6736(90)93101-T; VENTO S, 1989, LANCET, V2, P926; ZANGER UM, 1988, P NATL ACAD SCI USA, V85, P8256, DOI 10.1073/pnas.85.21.8256	11	193	192	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1992	339	8788					267	269		10.1016/0140-6736(92)91332-3	http://dx.doi.org/10.1016/0140-6736(92)91332-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB529	1346282				2022-12-01	WOS:A1992HB52900004
J	PERGOLIZZI, RG; ERSTER, SH; GOONEWARDENA, P; BROWN, WT				PERGOLIZZI, RG; ERSTER, SH; GOONEWARDENA, P; BROWN, WT			DETECTION OF FULL FRAGILE-X MUTATION	LANCET			English	Note								In fragile X syndrome, the most common inherited cause of mental deficiency, the underlying mutation is a large increase in the number of CGG repeats in a gene on chromosome X. We have developed a polymerase chain reaction (PCR) method to amplify across the full mutation in affected individuals. In this report, a fragile X family including a positive prenatally diagnosed fetus was analysed by PCR, and the results are consistent with direct genomic Southern blot analysis. Genetic screening of at-risk populations for fragile X can now be achieved by PCR rapidly, inexpensively, and on small samples.	CORNELL UNIV,N SHORE UNIV HOSP,COLL MED,DEPT RES,MANHASSET,NY 11030; CORNELL UNIV,N SHORE UNIV HOSP,COLL MED,DEPT PEDIAT,MANHASSET,NY 11030	Cornell University; Northwell Health; North Shore University Hospital; Cornell University; Northwell Health; North Shore University Hospital			Brown, William/GXN-2777-2022					BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BROWN WT, 1990, AM J HUM GENET, V47, P175; DOBKIN CS, 1991, LANCET, V338, P957; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LATIMER LJP, 1991, J BIOL CHEM, V266, P13849; NAKAHORI Y, 1991, NUCLEIC ACIDS RES, V19, P4355, DOI 10.1093/nar/19.16.4355; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PIERETTI M, 1991, CELL, V66, P1; TEMPLE IK, 1990, LANCET, V336, P1131, DOI 10.1016/0140-6736(90)92608-K; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H	10	78	81	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1992	339	8788					271	272		10.1016/0140-6736(92)91334-5	http://dx.doi.org/10.1016/0140-6736(92)91334-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB529	1346284				2022-12-01	WOS:A1992HB52900006
J	PISON, G; AABY, P; KNUDSEN, K				PISON, G; AABY, P; KNUDSEN, K			INCREASED RISK OF DEATH FROM MEASLES IN CHILDREN WITH A SIBLING OF OPPOSITE SEX IN SENEGAL	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; TRANSMISSION; INFECTION; EXPOSURE; PATTERN; AREA	Objective - To examine whether contracting measles from a sibling of the opposite sex affects mortality. Design - Prospective registration during 15-20 years of all births and deaths, including 243 measles related deaths. Measles infection was not registered; however, as in fatal cases measles was probably contracted from a maternal sibling the risk of dying during measles outbreaks was examined in families with two boys, two girls, or a boy and a girl. Setting - 31 small villages in two rural areas of eastern Senegal. Subjects - 766 children living in families with two children aged under 10 years during outbreaks of measles, 107 (14%) of whom died of measles. Main outcome measure - Deaths from measles, size of village, age and sex of maternal siblings. Results - The interval between outbreaks in the same village was greater than 10 years. The risk of dying of measles was significantly related to age, increasing with the age difference between siblings and decreasing with the size of village. In a multiple logistic regression analysis adjusting for these background factors, children in families with a boy and a girl had a significantly higher mortality than children in families with two boys or two girls (odds ratio = 1.81, 95% confidence interval 1.17 to 2.82). The increase in risk was the same for boys and girls in families with two children one of whom was a boy and one a girl. Conclusion - Cross sexual transmission may be an important determinant of severity of measles infection.	MUSEUM NATL HIST NAT,ANTHROPOL BIOL LAB,F-75231 PARIS 05,FRANCE; STATENS SERUM INST,DEPT EPIDEMIOL,DK-2300 COPENHAGEN,DENMARK; UNIV COPENHAGEN,STAT RES UNIT,DK-1168 COPENHAGEN,DENMARK	Museum National d'Histoire Naturelle (MNHN); Statens Serum Institut; University of Copenhagen				Aaby, Peter/0000-0001-8331-1389				AABY P, 1991, J INFECTION, V22, P287, DOI 10.1016/S0163-4453(05)80014-3; AABY P, 1989, DAN MED BULL, V36, P93; AABY P, 1990, J INFECT DIS, V161, P171, DOI 10.1093/infdis/161.2.171; AABY P, 1991, INT J EPIDEMIOL, V20, P504, DOI 10.1093/ije/20.2.504; AABY P, 1984, REV INFECT DIS, V6, P239; AABY P, 1990, BRIT MED J, V301, P143, DOI 10.1136/bmj.301.6744.143; AABY P, 1986, REV INFECT DIS, V8, P138; AABY P, IN PRESS ANN TROP PA; BABBOTT FL, 1954, AM J MED SCI, V228, P334; BHUIYA A, 1987, SOC SCI MED, V24, P439, DOI 10.1016/0277-9536(87)90217-6; FARGUES P, 1988, DOUZE ANS MORTALITE; GARENNE M, 1990, J INFECT DIS, V161, P1088, DOI 10.1093/infdis/161.6.1088; McCullagh P., 1983, GEN LINEAR MODELS, DOI [10.1007/978-1-4899-3244-0, DOI 10.1007/978-1-4899-3244-0]; MCGREGOR I A, 1964, West Afr Med J, V13, P251; MONASTIRI H, 1961, Tunis Med, V39, P179; PISON G, 1988, REV INFECT DIS, V10, P468; PISON G, 1985, POP STUD-J DEMOG, V39, P387, DOI 10.1080/0032472031000141586; PISON G, 1982, DYNAMIQUE UNE POPULA	18	20	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1992	304	6822					284	287		10.1136/bmj.304.6822.284	http://dx.doi.org/10.1136/bmj.304.6822.284			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC708	1739828	Bronze, Green Published			2022-12-01	WOS:A1992HC70800020
J	HILLIS, DM; BULL, JJ; WHITE, ME; BADGETT, MR; MOLINEUX, IJ				HILLIS, DM; BULL, JJ; WHITE, ME; BADGETT, MR; MOLINEUX, IJ			EXPERIMENTAL PHYLOGENETICS - GENERATION OF A KNOWN PHYLOGENY	SCIENCE			English	Article							PARSIMONY	Although methods of phylogenetic estimation are used routinely in comparative biology, direct tests of these methods are hampered by the lack of known phylogenies. Here a system based on serial propagation of bacteriophage T7 in the presence of a mutagen was used to create the first completely known phylogeny. Restriction-site maps of the terminal lineages were used to infer the evolutionary history of the experimental lines for comparison to the known history and actual ancestors. The five methods used to reconstruct branching pattern all predicted the correct topology but varied in their predictions of branch lengths; one method also predicts ancestral restriction maps and was found to bc greater than 98 percent accurate.	UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712	University of Texas System; University of Texas Austin	HILLIS, DM (corresponding author), UNIV TEXAS,DEPT ZOOL,AUSTIN,TX 78712, USA.		Hillis, David M/B-4278-2008; Hillis, David/L-5421-2019					ATCHLEY WR, 1991, SCIENCE, V254, P554, DOI 10.1126/science.1948030; Brooks D.R., 1991, PHYLOGENY ECOLOGY BE; CAVALLISFORZA LL, 1967, AM J HUM GENET, V19, P233, DOI 10.2307/2406616; Cochran W.G, 1957, STAT METHODS, V6th ed; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; FITCH WM, 1985, SCIENCE, V228, P1169, DOI 10.1126/science.4001935; FITCH WM, 1987, MOL MORPHOLOGY EVOLU, P203; Harvey P.H., 1991, COMP METHOD EVOLUTIO; HUELSENBECK JP, 1991, SYST ZOOL, V40, P257, DOI 10.2307/2992321; LAKE JA, 1987, MOL BIOL EVOL, V4, P167; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Shennan SJ., 2009, INNOVATIONS CULTURAL, P53; SOKAL ROBERT R., 1958, UNIV KANSAS SCI BULL, V38, P1409; STUDIER FW, 1980, CELLS BEHAVIOR VIEW, P72; Swofford David L., 1990, P411; SWOFFORD DL, 1990, PHYLOGENETIC ANAL US; WHITE ME, 1991, 4TH P INT C SYST EV, P935; [No title captured]	21	214	215	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1992	255	5044					589	592		10.1126/science.1736360	http://dx.doi.org/10.1126/science.1736360			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB531	1736360				2022-12-01	WOS:A1992HB53100040
J	SCHULTZ, JE; KLUMPP, S; BENZ, R; SCHURHOFFGOETERS, WJC; SCHMID, A				SCHULTZ, JE; KLUMPP, S; BENZ, R; SCHURHOFFGOETERS, WJC; SCHMID, A			REGULATION OF ADENYLYL CYCLASE FROM PARAMECIUM BY AN INTRINSIC POTASSIUM CONDUCTANCE	SCIENCE			English	Article							EXCITABLE CILIARY MEMBRANE; DEPENDENT CALCIUM CHANNELS; CYCLIC-AMP LEVELS; GUANYLATE-CYCLASE; TETRAURELIA INVIVO; IONIC REGULATION; PROTEINS; PURIFICATION; SEPARATION; MUTATION	Hyperpolarization of the cell membrane of Paramecium stimulates adenosine 3',5'monophosphate (cAMP) formation. Manipulations of the K+ resting conductance of the ciliate by adaptation in different buffers affected excitability of the cAMP generating system. Blockade of K+ channels inhibited hyperpolarization-stimulated cAMP formation. A mutant of Paramecium that is unable to control its K+ resting conductance had a defect in cAMP formation. Purified adenylyl cyclase, when incorporated into an artificial lipid bilayer membrane, revealed properties of a voltage-independent K+ channel. This indicates that the adenylyl cyclase of Paramecium has a secondary function as carrier of the K+ resting conductance. A hyperpolarization-activated K+ efflux appears to directly regulate adenylyl cyclase activity in vivo.	UNIV WURZBURG, INST BIOTECHNOL, W-8700 WURZBURG, GERMANY	University of Wurzburg	SCHULTZ, JE (corresponding author), UNIV TUBINGEN, INST PHARMAZEUT, MORGENSTELLE 8, W-7400 TUBINGEN 1, GERMANY.			Benz, Roland/0000-0002-9510-9265				BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1988, ANNU REV MICROBIOL, V42, P359, DOI 10.1146/annurev.mi.42.100188.002043; BOHEIM G, 1982, TRANSPORT BIOMEMBRAN, P87; BONINI NM, 1986, CELL MOTIL CYTOSKEL, V6, P2256; DELAAGE MA, 1978, MOL BIOL PHARM CYCLI, P155; DELGADO R, 1991, P NATL ACAD SCI USA, V88, P557, DOI 10.1073/pnas.88.2.557; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; EHRLICH BE, 1984, SCIENCE, V225, P427, DOI 10.1126/science.6330895; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; HINRICHSEN RD, 1984, J PHYSIOL-LONDON, V351, P397, DOI 10.1113/jphysiol.1984.sp015252; KLUMPP S, 1984, FEBS LETT, V171, P95, DOI 10.1016/0014-5793(84)80466-4; KLUMPP S, UNPUB; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; MACHEMER H, 1989, J PROTOZOOL, V36, P463, DOI 10.1111/j.1550-7408.1989.tb01082.x; Machemer H., 1988, P185; MACHEMERROHNISCH S, 1989, EUR J PROTISTOL, V25, P45, DOI 10.1016/S0932-4739(89)80077-X; MAJIMA T, 1980, BIOPHYS CHEM, V11, P101, DOI 10.1016/0301-4622(80)85012-5; Naitoh Y., 1982, P1; OKA T, 1986, J EXP BIOL, V126, P111; PFEUFFER E, 1985, EMBO J, V4, P3675, DOI 10.1002/j.1460-2075.1985.tb04134.x; PFEUFFER T, 1988, CURR TOP CELL REGUL, V29, P129; PRESTON RR, 1991, ANNU REV PHYSIOL, V53, P309, DOI 10.1146/annurev.ph.53.030191.001521; PRESTON RR, 1990, J MEMBRANE BIOL, V115, P61, DOI 10.1007/BF01869106; RICHARD EA, 1985, J NEUROGENET, V2, P239, DOI 10.3109/01677068509102321; SCHONEFELD U, 1986, J PROTOZOOL, V33, P222, DOI 10.1111/j.1550-7408.1986.tb05595.x; SCHRAMM M, 1984, SCIENCE, V225, P1350, DOI 10.1126/science.6147897; SCHULTZ JE, 1984, FEBS LETT, V167, P113, DOI 10.1016/0014-5793(84)80843-1; SCHULTZ JE, 1991, METHOD ENZYMOL, V195, P466; SIAMI Y, 1990, J MEMBRANE BIOL, V112, P79; SIAMI Y, 1987, ANNU REV GENET, V21, P47; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; Sonneborn T. M., 1970, Methods Cell Physiol., V4, P241, DOI 10.1016/S0091-679X(08)61758-6; THIELE J, 1982, EUR J CELL BIOL, V28, P3; YELLEN G, 1987, ANNU REV BIOPHYS BIO, V16, P227	35	138	139	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 31	1992	255	5044					600	603		10.1126/science.1371017	http://dx.doi.org/10.1126/science.1371017			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB531	1371017				2022-12-01	WOS:A1992HB53100044
J	TASAYCO, ML; CAREY, J				TASAYCO, ML; CAREY, J			ORDERED SELF-ASSEMBLY OF POLYPEPTIDE FRAGMENTS TO FORM NATIVE-LIKE DIMERIC TRP REPRESSOR	SCIENCE			English	Article							ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; DNA-BINDING; TROPONIN-C; NMR; APOREPRESSOR; RESOLUTION; INTERMEDIATE	Subdomain-size proteolytic fragments of Escherichia coli trp repressor have been produced that assemble in defined order to regenerate fully native dimers. By characterization of the secondary and tertiary structures of isolated and recombined fragments, the structure of assembly intermediates can be correlated with the kinetic folding pathway of the intact repressor deduced from spectroscopic measurement of folding rates. The nativelike structure of these intermediates provides further evidence that protein folding pathways reflect the stabilities of secondary structural units and assemblies found in the native state. The proteolytic method should be generally useful in adding structural detail to spectroscopically determined folding mechanisms.	PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544	Princeton University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043558, R01GM043558] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARROWSMITH CH, 1990, BIOCHEMISTRY-US, V29, P6332, DOI 10.1021/bi00479a002; ARROWSMITH CH, 1989, BIOCHEMISTRY-US, V28, P3875, DOI 10.1021/bi00435a037; ARROWSMITH CH, 1991, J AM CHEM SOC, V113, P4020, DOI 10.1021/ja00010a070; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; CAREY J, 1989, J BIOL CHEM, V264, P1941; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; GITTELMAN MS, 1990, BIOCHEMISTRY-US, V29, P7011, DOI 10.1021/bi00482a009; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HYDE EI, 1989, EUR J BIOCHEM, V183, P545, DOI 10.1111/j.1432-1033.1989.tb21083.x; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KELLEY RL, 1985, P NATL ACAD SCI USA, V82, P483, DOI 10.1073/pnas.82.2.483; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.bi.59.070190.003215; LAWSON CL, 1988, PROTEINS, V3, P18, DOI 10.1002/prot.340030103; LESK AM, 1981, P NATL ACAD SCI-BIOL, V78, P4304, DOI 10.1073/pnas.78.7.4304; MMULVEY RS, 1974, BIOCHEMISTRY-US, V13, P782; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SCHEVITZ RW, 1985, NATURE, V317, P782, DOI 10.1038/317782a0; STALEY JP, 1990, NATURE, V344, P685, DOI 10.1038/344685a0; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; Taniuchi H, 1986, Methods Enzymol, V131, P185; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0	27	96	96	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1992	255	5044					594	597		10.1126/science.1736361	http://dx.doi.org/10.1126/science.1736361			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB531	1736361				2022-12-01	WOS:A1992HB53100042
J	WITHKA, JM; SWAMINATHAN, S; SRINIVASAN, J; BEVERIDGE, DL; BOLTON, PH				WITHKA, JM; SWAMINATHAN, S; SRINIVASAN, J; BEVERIDGE, DL; BOLTON, PH			TOWARD A DYNAMIC STRUCTURE OF DNA - COMPARISON OF THEORETICAL AND EXPERIMENTAL NOE INTENSITIES	SCIENCE			English	Article							DOUBLE HELIX; MOLECULAR-DYNAMICS; IMINO PROTONS; BASE-PAIR; KINETICS; EXCHANGE; D(CGCGAATTCGCG); SEQUENCE; GEOMETRY	Comparisons of experimental and calculated interproton nuclear Overhauser effect (NOE) buildup curves for duplex d(CGCGAATTCGCG)2 have been made. The calculated NOEs are based on molecular dynamics simulations including counterions and water and on the single-structure canonical A, B, and crystal forms. The calculated NOE effects include consideration of the motions of individual interproton vectors and the anisotropic tumbling of the DNA. The effects due to inclusion of anisotropic tumbling are much larger than those due to the local motion, and both improve the agreement between calculated and experimental results. The predictions based on the dynamical models agree significantly better with experiment than those based on either of the canonical forms or the crystal structure.			WITHKA, JM (corresponding author), WESLEYAN UNIV, DEPT CHEM, MIDDLETOWN, CT 06459 USA.				NIGMS NIH HHS [GM-37909, 1T32 GM-08271] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037909, R37GM037909, T32GM008271] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLTON PH, 1990, PROG NUCL MAG RES SP, V22, P423, DOI 10.1016/0079-6565(90)80006-4; CLORE GM, 1989, CRIT REV BIOCHEM MOL, V24, P479, DOI 10.3109/10409238909086962; DICKERSON RE, 1981, J MOL BIOL, V149, P761, DOI 10.1016/0022-2836(81)90357-0; DICKERSON RE, 1990, STRUCTURE METHOD, V3; EIMER W, 1990, BIOCHEMISTRY-US, V29, P799, DOI 10.1021/bi00455a030; GESSNER RV, 1989, J BIOL CHEM, V264, P7921; GOCHIN M, 1990, BIOCHEMISTRY-US, V29, P11172, DOI 10.1021/bi00503a004; GONZALEZ C, 1991, J MAGN RESON, V91, P659, DOI 10.1016/0022-2364(91)90397-C; HARE DR, 1983, J MOL BIOL, V171, P319, DOI 10.1016/0022-2836(83)90096-7; KONING TMG, 1991, BIOCHEMISTRY-US, V30, P3787, DOI 10.1021/bi00229a028; McCammon A. J., 1986, DYNAMICS PROTEINS NU; MOE JG, 1990, NUCLEIC ACIDS RES, V18, P821, DOI 10.1093/nar/18.4.821; NERDAL W, 1989, BIOCHEMISTRY-US, V28, P10008, DOI 10.1021/bi00452a020; PARDI A, 1982, BIOCHEMISTRY-US, V21, P6567, DOI 10.1021/bi00268a038; PARDI A, 1982, BIOCHEMISTRY-US, V21, P4686, DOI 10.1021/bi00262a026; RAVISHANKER G, 1989, J BIOMOL STRUCT DYN, V6, P669, DOI 10.1080/07391102.1989.10507729; Saenger W., 1983, PRINCIPLES NUCL ACID; SRINIVASAN J, 1990, BIOPHYS J, V58, P533, DOI 10.1016/S0006-3495(90)82397-3; SWAMINATHAN S, 1991, J AM CHEM SOC, V113, P5027, DOI 10.1021/ja00013a043; Van Gunsteren W F, 1986, Ann N Y Acad Sci, V482, P287; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; WITHKA JM, 1991, BIOCHEMISTRY-US, V30, P9931, DOI 10.1021/bi00105a017; WITHKA JM, 1991, J AM CHEM SOC, V113, P5041, DOI 10.1021/ja00013a044; WITHKA JM, 1990, J MAGN RESON, V89, P386, DOI 10.1016/0022-2364(90)90246-6; WITHKA JM, 1991, P NATO ADV RES WORKS, P409; WITHKA JM, UNPUB; Wuthrich K., 1986, NMR PROTEINS NUCL AC	27	61	61	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 31	1992	255	5044					597	599		10.1126/science.1736362	http://dx.doi.org/10.1126/science.1736362			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB531	1736362				2022-12-01	WOS:A1992HB53100043
J	ASO, T; VASAVADA, HA; KAWAGUCHI, T; GERMINO, FJ; GANGULY, S; KITAJIMA, S; WEISSMAN, SM; YASUKOCHI, Y				ASO, T; VASAVADA, HA; KAWAGUCHI, T; GERMINO, FJ; GANGULY, S; KITAJIMA, S; WEISSMAN, SM; YASUKOCHI, Y			CHARACTERIZATION OF CDNA FOR THE LARGE SUBUNIT OF THE TRANSCRIPTION INITIATION-FACTOR TFIIF	NATURE			English	Article							RNA POLYMERASE-II; ACTIVATOR; SEQUENCES; GENE	AT least six chromatographically resolvable general transcription factors may participate in accurate initiation by RNA polymerase II in HeLa cell-derived systems 1-3. TFIIF (also termed FC, RAP30/74 and beta/gamma) can bind directly to RNA polymerase II in solution 4-6 and decrease the affinity of RNA polymerase II for nonspecific DNA 7. From studies on the kinetics of transcription initiation 1, on the composition of transcription initiation complexes fractionated by acrylamide gel electrophoresis 8, and on template competition experiments 9, TFIIF is known to act at an intermediate stage in initiation complex formation. It acts after TFIID firmly associates with DNA, but coincidentally with or immediately after RNA polymerase II binding to DNA, and before the recruitment of factor TFIIE. TFIIF may 6 or may not 4,5 have DNA helicase activity. The small subunit (RAP30) of TFIIF has been cloned 6 and shows some amino-acid sequence homology to bacterial-sigma-factors. We have partially sequenced the RAP74 protein from purified HeLa cells, cloned its complementary DNA and shown that its translation product can interact with RAP30 in vitro as well as in vivo. The cDNA predicts an amino-acid sequence that lacks obvious DNA or RNA helicase motifs. It has regions rich in charged amino acids, including segments containing a higher content of acidic amino acids than are found in strong transcriptional activators such as VP16 (ref. 10).	YALE UNIV,SCH MED,DEPT GENET,333 CEDAR ST,NEW HAVEN,CT 06510; TOKYO MED & DENT UNIV,MED RES INST,DEPT MED,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,MED RES INST,DEPT MOLEC GENET,BUNKYO KU,TOKYO 113,JAPAN	Yale University; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)								BURTOWSKI S, 1989, CELL, V56, P549; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY RC, 1990, J BIOL CHEM, V265, P7559; FLORES O, 1990, J BIOL CHEM, V265, P5629; GANGULY S, 1989, P NATL ACAD SCI USA, V86, P5247, DOI 10.1073/pnas.86.14.5247; HORIKOSHI M, 1991, NUCLEIC ACIDS RES, V19, P5436, DOI 10.1093/nar/19.19.5436; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; KITAJIMA S, 1990, NUCLEIC ACIDS RES, V18, P4843, DOI 10.1093/nar/18.16.4843; KITAJIMA S, 1989, P NATL ACAD SCI USA, V86, P6106, DOI 10.1073/pnas.86.16.6106; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9159; SWAROOP A, 1988, NUCLEIC ACIDS RES, V16, P8739, DOI 10.1093/nar/16.17.8739; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VASAVADA H, IN PRESS P NATN ACAD	19	73	74	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					461	464		10.1038/355461a0	http://dx.doi.org/10.1038/355461a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1734283				2022-12-01	WOS:A1992HB53000074
J	FINKELSTEIN, A; KOSTRUB, CF; LI, J; CHAVEZ, DP; WANG, BQ; FANG, SM; GREENBLATT, J; BURTON, ZF				FINKELSTEIN, A; KOSTRUB, CF; LI, J; CHAVEZ, DP; WANG, BQ; FANG, SM; GREENBLATT, J; BURTON, ZF			A CDNA-ENCODING RAP74, A GENERAL INITIATION-FACTOR FOR TRANSCRIPTION BY RNA POLYMERASE-II	NATURE			English	Article							ACCURATE INITIATION; PROTEINS; BINDING; PROMOTER	RAP30/74 (also known as TFIIF (refs 1, 2), beta-gamma (ref. 3) and FC (ref. 4)) is one of several general factors required for initiation by RNA polymerase II (reviewed in refs 5-7). The small RAP30 subunit of RAP30/74 binds directly to polymerase and appears structurally and functionally homologous to bacterial sigma factors in their RNA polymerase-binding region 8-10. RAP30/74 or recombinant RAP30 suppresses nonspecific binding of RNA polymerase II to DNA (refs 10, 11) and is required for RNA polymerase II to assemble stably into a preinitiation complex containing promoter DNA and the general factors TFIID, TFIIA and TFIIB (refs 2, 12, 13); both RAP30 and RAP74 are physical components of the preinitiation complex 2. A complementary DNA encoding human RAP30 has been isolated 8, and here we report the isolation of a cDNA encoding human RAP74. RAP30 and RAP74 produced in Escherichia coli can be used in place of natural human RAP30/74 to direct accurate transcription initiation by RNA polymerase II in vitro.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; MICHIGAN STATE UNIV,AGR EXPT STN,E LANSING,MI 48824; UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5G 1L6,ONTARIO,CANADA	Michigan State University; Michigan State University; Michigan State University AgBioResearch; University of Toronto; University of Toronto								BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; BURTON ZF, 1986, EMBO J, V5, P2923, DOI 10.1002/j.1460-2075.1986.tb04588.x; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1988, J BIOL CHEM, V263, P10812; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KATAJIMA S, NUCLEIC ACIDS RES, V18, P4843; KILLEEN MT, IN PRESS MOL CELL BI; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; MERMELSTEIN FH, 1989, BIOCHIM BIOPHYS ACTA, V1009, P1, DOI 10.1016/0167-4781(89)90071-7; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PETERSON MG, 1991, NATURE, V354, P369; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SOPTA M, 1985, J BIOL CHEM, V260, P353; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0	28	91	92	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					464	467		10.1038/355464a0	http://dx.doi.org/10.1038/355464a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1734284				2022-12-01	WOS:A1992HB53000075
J	KLIEWER, SA; UMESONO, K; MANGELSDORF, DJ; EVANS, RM				KLIEWER, SA; UMESONO, K; MANGELSDORF, DJ; EVANS, RM			RETINOID X-RECEPTOR INTERACTS WITH NUCLEAR RECEPTORS IN RETINOIC ACID, THYROID-HORMONE AND VITAMIN-D3 SIGNALING	NATURE			English	Article							RESPONSE ELEMENT; BETA-GENE; IDENTIFICATION; BINDING; COMPLEXES; SEQUENCE; PROTEIN	CELLULAR responsiveness to retinoic acid and its metabolites is conferred through two structurally and pharmacologically distinct 1 families of receptors: the retinoic acid receptors (RAR) 2,3 and the retinoid X receptors (RXR) 1. Here we report that the transcriptional activity of RAR and RXR can be reciprocally modulated by direct interactions between the two proteins. RAR and RXR have a high degree of cooperativity in binding to target DNA, consistent with previous reports indicating that the binding of either RAR or RXR to their cognate response elements is enhanced by factors present in nuclear extracts 4,5. RXR also interacts directly with and enhances the binding of nuclear receptors conferring responsiveness to vitamin D3 and thyroid hormone T3; the DNA-binding activities of these receptors are also stimulated by the presence of nuclear extracts 6-9. Together these data indicate that RXR has a central role in multiple hormonal signalling pathways.	HOWARD HUGHES MED INST,LA JOLLA,CA 92037	Howard Hughes Medical Institute	KLIEWER, SA (corresponding author), SALK INST BIOL STUDIES,LA JOLLA,CA 92037, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965; Mangelsdorf, David/0000-0002-4355-0796	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y	21	1357	1386	1	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					446	449		10.1038/355446a0	http://dx.doi.org/10.1038/355446a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1310351	Green Accepted			2022-12-01	WOS:A1992HB53000069
J	MEISEL, A; BICKLE, TA; KRUGER, DH; SCHROEDER, C				MEISEL, A; BICKLE, TA; KRUGER, DH; SCHROEDER, C			TYPE-III RESTRICTION ENZYMES NEED 2 INVERSELY ORIENTED RECOGNITION SITES FOR DNA CLEAVAGE	NATURE			English	Article							BACTERIOPHAGE-T7 DNA; ESCHERICHIA-COLI; ENDONUCLEASE	TYPE III restriction/modification enzymes recognize short, non-palindromic sequences that can be methylated on only one strand, with the paradoxical consequence that during replication of what is in effect hemimethylated DNA totally unmodified sites arise 1. Why the unmodified sites are not subject to suicidal restriction was not clear. Here we show that restriction requires two unmodified recognition sites that can be separated by different distances but which must be in inverse orientation. All of the unmodified sites in newly replicated DNA are of course in the same orientation, which explains why they are not restricted. This result may be of relevance to other manifestations of anisotropy in double-stranded DNA, such as genetic imprinting 2.	UNIV BASEL,BIOZENTRUM,DEPT MICROBIOL,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND; HUMBOLDT UNIV BERLIN,SCH MED CHARITE,INST VIROL,O-1040 BERLIN,GERMANY	University of Basel; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin				Meisel, Andreas/0000-0001-7233-5342				BICKLE TA, 1983, NUCLEASES, P85; HADI SM, 1979, J MOL BIOL, V134, P655, DOI 10.1016/0022-2836(79)90372-3; HADI SM, 1983, J MOL BIOL, V165, P19, DOI 10.1016/S0022-2836(83)80240-X; KLAR AJS, 1987, NATURE, V326, P466, DOI 10.1038/326466a0; KUGER DH, 1990, NUCLEIC ACID METHYLA, P113; MEISEL A, 1991, NUCLEIC ACIDS RES, V19, P3997, DOI 10.1093/nar/19.14.3997; REISER J, 1977, J BIOL CHEM, V252, P451; Sambrook J., 1989, MOL CLONING LAB MANU; SCHROEDER C, 1986, GENE, V45, P77, DOI 10.1016/0378-1119(86)90134-4; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; VANWEZENBEEK PMGF, 1980, GENE, V11, P129, DOI 10.1016/0378-1119(80)90093-1	12	123	127	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					467	469		10.1038/355467a0	http://dx.doi.org/10.1038/355467a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1734285				2022-12-01	WOS:A1992HB53000076
J	MIZUNO, K; SATOMURA, K; MIYAMOTO, A; ARAKAWA, K; SHIBUYA, T; ARAI, T; KURITA, A; NAKAMURA, H; AMBROSE, JA				MIZUNO, K; SATOMURA, K; MIYAMOTO, A; ARAKAWA, K; SHIBUYA, T; ARAI, T; KURITA, A; NAKAMURA, H; AMBROSE, JA			ANGIOSCOPIC EVALUATION OF CORONARY-ARTERY THROMBI IN ACUTE CORONARY SYNDROMES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNSTABLE ANGINA-PECTORIS; PLACEBO-CONTROLLED TRIAL; TISSUE PLASMINOGEN-ACTIVATOR; ANGIOGRAPHIC MORPHOLOGY; INTRACORONARY THROMBUS; THROMBOLYTIC THERAPY; DOUBLE-BLIND; PATHOGENESIS; INFARCTION; DISEASE	Background. Disruption of an atherosclerotic plaque in a coronary artery followed by the formation of a thrombus is believed to be the cause of both unstable angina and acute myocardial infarction. Although thrombolytic therapy is efficacious in patients with acute myocardial infarction, for unknown reasons it is far less effective in patients with unstable angina. We postulated that there might be differences in the composition of the coronary-artery thrombi in unstable angina and acute myocardial infarction. Methods. To investigate the appearance of coronary-artery thrombi, we performed percutaneous transluminal coronary angioscopy in 15 patients with unstable angina and 16 with acute myocardial infarction. Angioscopy was performed within 48 hours after an episode of pain at rest in the patients with unstable angina and within 8 hours of onset in those with acute myocardial infarction. per Results. Angioscopy revealed coronary thrombi in all but two patients (one in each group). Of the 29 patients with thrombi, those with unstable angina were frequently observed to have grayish-white thrombi (10 of 14, 71 percent), but none were seen in the 15 patients with acute myocardial infarction (P < 0.01). By contrast, reddish thrombi were observed in all 15 patients with acute myocardial infarction who had thrombi, but in only 4 of the 14 patients with unstable angina and thrombi (P < 0.01). As assessed by coronary angiography, occlusive thrombi occurred frequently in patients with acute myocardial infarction (13 of 16 patients) but were not seen in any of the 15 patients with unstable angina (P < 0.01). Conclusions. Coronary-artery thrombi play an important part in the pathogenesis of unstable angina and acute myocardial infarction. However, the appearance of the thrombi is different in the two conditions, possibly reflecting differences in the composition or age of the thrombi or the presence or absence of blood flow in the artery. This difference may account for the contrasting results of thrombolytic therapy.	NATL DEF MED COLL,DEPT MED ENGN,TOKOROZAWA,SAITAMA 359,JAPAN; CUNY MT SINAI SCH MED,DEPT MED,DIV CARDIOL,NEW YORK,NY 10029	National Defense Medical College - Japan; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	MIZUNO, K (corresponding author), NATL DEF MED COLL,DEPT INTERNAL MED 1,3-2 NAMIKI,TOKOROZAWA,SAITAMA 359,JAPAN.							AMBROSE JA, 1985, J AM COLL CARDIOL, V5, P609, DOI 10.1016/S0735-1097(85)80384-3; AMBROSE JA, 1987, J AM COLL CARDIOL, V9, P1156, DOI 10.1016/S0735-1097(87)80321-2; AMBROSE JA, 1985, J AM COLL CARDIOL, V6, P1233, DOI 10.1016/S0735-1097(85)80207-2; AMBROSE JA, 1989, J AM COLL CARDIOL, V13, P1661; ANDERSON JR, 1985, MUIRS TXB PATHOLOGY, P1012; BALSANO F, 1990, CIRCULATION, V82, P17, DOI 10.1161/01.CIR.82.1.17; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; CAPONE G, 1985, AM J CARDIOL, V56, P403, DOI 10.1016/0002-9149(85)90875-6; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; DEZWAAN C, 1988, J AM COLL CARDIOL, V12, P301, DOI 10.1016/0735-1097(88)90398-1; FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; FORRESTER JS, 1987, CIRCULATION, V75, P505, DOI 10.1161/01.CIR.75.3.505; FREEMAN MR, 1989, CIRCULATION, V80, P17, DOI 10.1161/01.CIR.80.1.17; FUSTER V, 1988, CIRCULATION, V77, P1213, DOI 10.1161/01.CIR.77.6.1213; GOLD HK, 1987, CIRCULATION, V75, P1192, DOI 10.1161/01.CIR.75.6.1192; GOTOH K, 1988, CIRCULATION, V77, P526, DOI 10.1161/01.CIR.77.3.526; HOLMES DR, 1981, BRIT HEART J, V45, P411; KRUSKAL JB, 1987, NEW ENGL J MED, V317, P1361, DOI 10.1056/NEJM198711263172201; MIZUNO K, 1989, J AM COLL CARDIOL, V13, P363, DOI 10.1016/0735-1097(89)90513-5; MIZUNO K, 1991, LANCET, V337, P809, DOI 10.1016/0140-6736(91)92514-3; Neri Serneri G G, 1990, Lancet, V335, P615, DOI 10.1016/0140-6736(90)90407-V; NERISERNERI GG, 1990, LANCET, V335, P868; NICKLAS JM, 1989, J AM COLL CARDIOL, V13, P434, DOI 10.1016/0735-1097(89)90524-X; PASTERNAK RC, 1988, HEART DISEASE TXB CA, V2, P1222; RAMEE SR, 1991, J AM COLL CARDIOL, V17, P100, DOI 10.1016/0735-1097(91)90710-Q; REHR R, 1989, J AM COLL CARDIOL, V14, P1429, DOI 10.1016/0735-1097(89)90376-8; SHERMAN CT, 1986, NEW ENGL J MED, V315, P913, DOI 10.1056/NEJM198610093151501; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; THEROUX P, 1987, CIRCULATION, V75, P156, DOI 10.1161/01.CIR.75.1.156; TOPOL EJ, 1988, AM J CARDIOL, V62, P368, DOI 10.1016/0002-9149(88)90960-5; UCHIDA Y, 1986, AM HEART J, V112, P691, DOI 10.1016/0002-8703(86)90462-X; VETROVEC GW, 1981, AM HEART J, V102, P1201; WILLIAMS DO, 1990, CIRCULATION, V82, P376, DOI 10.1161/01.CIR.82.2.376; YANAGIDA S, 1989, CIRCULATION S2, V80, P376	35	462	470	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1992	326	5					287	291		10.1056/NEJM199201303260502	http://dx.doi.org/10.1056/NEJM199201303260502			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA991	1728732				2022-12-01	WOS:A1992HA99100002
J	ROBINSON, DS; HAMID, Q; YING, S; TSICOPOULOS, A; BARKANS, J; BENTLEY, AM; CORRIGAN, C; DURHAM, SR; KAY, AB				ROBINSON, DS; HAMID, Q; YING, S; TSICOPOULOS, A; BARKANS, J; BENTLEY, AM; CORRIGAN, C; DURHAM, SR; KAY, AB			PREDOMINANT TH2-LIKE BRONCHOALVEOLAR LYMPHOCYTE-T POPULATION IN ATOPIC ASTHMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN EOSINOPHILS; PULMONARY SARCOIDOSIS; HUMAN INTERLEUKIN-5; BRONCHIAL BIOPSIES; IMMUNE REGULATION; CELL CLONE; TH2 CLONES; IFN-GAMMA; RELEASE; RNA	Background. In atopic asthma, activated T helper lymphocytes are present in bronchial-biopsy specimens and bronchoalveolar-lavage (BAL) fluid, and their production of cytokines may be important in the pathogenesis of this disorder. Different patterns of cytokine release are characteristic of certain subgroups of T helper cells, termed T(H1) and T(H2), the former mediating delayed-type hypersensitivity and the latter mediating IgE synthesis and eosinophilia. The pattern of cytokine production in atopic asthma is unknown. Methods. We assessed cells obtained by BAL in subjects with mild atopic asthma and in normal control subjects for the expression of messenger RNA (mRNA) for interleukin-2, 3, 4, and 5, granulocyte-macrophage colony-stimulating factor (GM-CSF), and interferon gamma by in situ hybridization with P-32-labeled complementary RNA. Localization of mRNA to BAL T cells was assessed by simultaneous in situ hybridization and immunofluorescence and by in situ hybridization after immunomagnetic enrichment or depletion of T cells. Results. As compared with the control subjects, the subjects with asthma had more BAL cells per 1000 cells that were positive for mRNA for interleukin-2 (P < 0.05), 3 (P < 0.01), 4 (P < 0.001), and 5 (P < 0.001) and GM-CSF (P < 0.001). There was no significant difference between the two groups in the number of cells expressing mRNA for interferon gamma. In the subjects with asthma, mRNA for interleukin-4 and 5 was expressed predominantly by T lymphocytes. Conclusions. Atopic asthma is associated with activation in the bronchi of the interleukin-3, 4, and 5 and GM-CSF gene cluster, a pattern compatible with predominant activation of the T(H2)-like T-cell population.	NATL HEART & LUNG INST,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND	Imperial College London			Tsicopoulos, Anne/C-2260-2019	Tsicopoulos, Anne/0000-0002-1579-2763; Bentley, Andrew/0000-0002-6883-9246; Corrigan, Chris/0000-0002-0706-6534				AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BEVERLEY PCL, 1990, IMMUNOL TODAY, V11, P203, DOI 10.1016/0167-5699(90)90083-L; BOTTOMLY K, 1988, IMMUNOL TODAY, V9, P268, DOI 10.1016/0167-5699(88)91308-4; CHANG TL, 1990, J IMMUNOL, V145, P2803; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; CORRIGAN CJ, 1988, LANCET, V1, P1129; DELPOZO V, 1990, J IMMUNOL, V144, P3117; DELPRETE G, 1988, J IMMUNOL, V140, P4193; FONG TAT, 1989, J IMMUNOL, V143, P2887; FOX CH, 1989, J INFECT DIS, V159, P467, DOI 10.1093/infdis/159.3.467; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; GAJEWSKI TF, 1990, J IMMUNOL, V144, P4110; GIAID A, 1989, HISTOCHEMISTRY, V93, P191, DOI 10.1007/BF00315974; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HIRAI K, 1990, J EXP MED, V172, P1525, DOI 10.1084/jem.172.5.1525; HOWELL CJ, 1989, AM REV RESPIR DIS, V140, P1340, DOI 10.1164/ajrccm/140.5.1340; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; LEA T, 1985, SCAND J IMMUNOL, V22, P207, DOI 10.1111/j.1365-3083.1985.tb01873.x; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MOQBEL R, 1991, J EXP MED, V174, P749, DOI 10.1084/jem.174.3.749; MOSMANN TR, 1987, IMMUNOL TODAY, V8, P223, DOI 10.1016/0167-5699(87)90171-X; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; ROBINSON BWS, 1985, J CLIN INVEST, V75, P1488, DOI 10.1172/JCI111852; ROBINSON DS, 1991, 3RD INT C BRONCH LAV; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; SALTINI C, 1986, J CLIN INVEST, V77, P1962, DOI 10.1172/JCI112525; STREET NE, 1990, J IMMUNOL, V144, P1629; SWAIN SL, 1990, J IMMUNOL, V145, P3796; WALKER C, 1991, J IMMUNOL, V146, P1829; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; WONG DTW, 1990, J EXP MED, V172, P673, DOI 10.1084/jem.172.3.673	38	2523	2603	3	150	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1992	326	5					298	304		10.1056/NEJM199201303260504	http://dx.doi.org/10.1056/NEJM199201303260504			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA991	1530827				2022-12-01	WOS:A1992HA99100004
J	RONDEAU, JM; TETEFAVIER, F; PODJARNY, A; REYMANN, JM; BARTH, P; BIELLMANN, JF; MORAS, D				RONDEAU, JM; TETEFAVIER, F; PODJARNY, A; REYMANN, JM; BARTH, P; BIELLMANN, JF; MORAS, D			NOVEL NADPH-BINDING DOMAIN REVEALED BY THE CRYSTAL-STRUCTURE OF ALDOSE REDUCTASE	NATURE			English	Article							X-RAY; PROTEIN; EVOLUTION; MUSCLE; CDNAS; FORMS; GENE	ALDOSE reductase is the first enzyme in the polyol pathway and catalyses the NADPH-dependent reduction Of D-glucose to D-sorbitol. Under normal physiological conditions aldose reductase participates in osmoregulation 1, but under hyperglycaemic conditions it contributes to the onset and development of severe complications in diabetes 2. Here we present the crystal structure of pig lens aldose reductase refined to an R-factor of 0.232 at 2.5-angstrom resolution. It exhibits a single domain folded in an eight-stranded parallel alpha/beta-barrel, similar to that in triose phosphate isomerase 3 and a score of other enzymes. Hence, aldose reductase does not possess the expected canonical dinucleotide-binding domain 4. Crystallographic analysis of the binding of 2'-monophosphoadenosine-5'-diphosphoribose, which competitively inhibits NADPH binding reveals that it binds into a cleft located at the C-terminal end of the strands of the alpha/beta-barrel. This represents a new type of binding for nicotinamide adenine dinucleotide coenzymes.	CNRS,INST BIOL MOLEC & CELLULAIRE,CRISTALLOG BIOL LAB,15 RUE R DESCARTES,F-67084 STRASBOURG,FRANCE; BIOSTRUCT SA,ALGORITHMES,F-67400 ILLKIRCH GRAFFENS,FRANCE; UNIV STRASBOURG 1,INST CHIM,CHIM ORGAN BIOL LAB,F-67008 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Favier, Frederique/B-3090-2013	Favier, Frederique/0000-0003-3249-997X; Podjarny, Alberto/0000-0002-7685-1077				ANDERSON S, 1985, SCIENCE, V230, P144, DOI 10.1126/science.230.4722.144; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURG MB, 1988, KIDNEY INT, V33, P635, DOI 10.1038/ki.1988.46; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; CHUNG S, 1989, J BIOL CHEM, V264, P14775; DELCORSO A, 1990, ARCH BIOCHEM BIOPHYS, V283, P512, DOI 10.1016/0003-9861(90)90675-O; DELCORSO A, 1989, ARCH BIOCHEM BIOPHYS, V270, P604, DOI 10.1016/0003-9861(89)90543-2; DVORNIK D, 1987, ALDOSE REDUCTASE INH; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; FUJII Y, 1990, J BIOL CHEM, V266, P9914; GRIMSHAW CE, 1989, BIOCHEMISTRY-US, V28, P5343, DOI 10.1021/bi00439a006; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; LINDQVIST Y, 1991, J BIOL CHEM, V266, P3198; Nishimura C, 1989, Prog Clin Biol Res, V290, P211; OECHSNER U, 1988, FEBS LETT, V238, P123, DOI 10.1016/0014-5793(88)80240-0; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; RONDEAU JM, 1987, J MOL BIOL, V195, P945, DOI 10.1016/0022-2836(87)90498-0; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SCHADE SZ, 1990, J BIOL CHEM, V265, P3628; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; VANDERJAGT DL, 1990, J BIOL CHEM, V265, P20982; WATANABE K, 1988, P NATL ACAD SCI USA, V85, P11, DOI 10.1073/pnas.85.1.11; Wermuth B, 1985, Prog Clin Biol Res, V174, P209; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WIERENGA RK, 1983, J MOL BIOL, V167, P725, DOI 10.1016/S0022-2836(83)80106-5; WINTERS CJ, 1990, BIOCHEMISTRY-US, V29, P1080, DOI 10.1021/bi00456a034	30	192	199	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					469	472		10.1038/355469a0	http://dx.doi.org/10.1038/355469a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1734286				2022-12-01	WOS:A1992HB53000077
J	SEPPALA, H; NISSINEN, A; JARVINEN, H; HUOVINEN, S; HENRIKSSON, T; HERVA, E; HOLM, SE; JAHKOLA, M; KATILA, ML; KLAUKKA, T; KONTIAINEN, S; LIIMATAINEN, O; OINONEN, S; PASSIMETSOMAA, L; HUOVINEN, P				SEPPALA, H; NISSINEN, A; JARVINEN, H; HUOVINEN, S; HENRIKSSON, T; HERVA, E; HOLM, SE; JAHKOLA, M; KATILA, ML; KLAUKKA, T; KONTIAINEN, S; LIIMATAINEN, O; OINONEN, S; PASSIMETSOMAA, L; HUOVINEN, P			RESISTANCE TO ERYTHROMYCIN IN GROUP-A STREPTOCOCCI	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BETA-HEMOLYTIC STREPTOCOCCI; PYOGENES; LINCOSAMIDES; PHARYNGITIS; ANTIBIOTICS; INFECTIONS; PENICILLIN; MACROLIDES; PATTERN; ADULTS	Background. The use of erythromycin in Finland nearly tripled from 1979 to 1989. In 1988, we observed an unusually high frequency of resistance to erythromycin in group A streptococci in one geographic region. Because routine testing does not detect the sensitivity of these organisms to antibiotics, we initiated a national study to evaluate the extent of this resistance. Methods. We studied 272 isolates of group A streptococci obtained from blood cultures from 1988 through 1990. In 1990 we collected from six regional laboratories 3087 consecutive isolates from throat swabs and 1349 isolates from pus samples. Resistance was indicated by growth on blood agar containing 2-mu-g of erythromycin per milliliter after incubation in 5 percent carbon dioxide. We also evaluated the clinical importance of erythromycin resistance in a retrospective study of consecutive patients with pharyngitis. Results. The frequency of resistance to erythromycin in group A streptococci from blood cultures increased from 4 percent in 1988 to 24 percent in 1990. From January to December 1990, the frequency of resistance in isolates from throat swabs increased from 7 percent to 20 percent, and resistance in isolates from pus increased from 11 percent to 31 percent. In four communities within 50 km of each other, the frequency of erythromycin resistance ranged from 2 to 5 percent to 26 to 44 percent. Several distinct DNA restriction profiles and serotypes were found among resistant isolates from the same area, suggesting a multiclonal origin. The treatment of pharyngitis with erythromycin failed in 9 of 19 patients infected with erythromycin-resistant group A streptococci, as compared with 1 of 26 patients with erythromycin-susceptible isolates (47 percent vs. 4 percent, P = 0.008). Conclusions. In Finland since 1988 there has been a rapid and substantial increase in resistance to erythromycin in group A streptococci. The extent of this resistance is particularly serious since there are only a few alternative antibiotics available for peroral treatment of group A streptococcal infections.	NATL INST PUBL HLTH, OULU REG INST, OULU, FINLAND; NATL INST PUBL HLTH, DEPT BACTERIOL, OULU, FINLAND; UMEA UNIV, DEPT CLIN MICROBIOL, S-90187 UMEA, SWEDEN; HLTH CTR, Pargas, FINLAND; HLTH CTR, POYTYA, FINLAND; KUOPIO UNIV HOSP, DEPT CLIN MICROBIOL, KUOPIO, FINLAND; AURORA HOSP, SF-00250 HELSINKI, FINLAND; TAMPERE UNIV HOSP, TAMPERE, FINLAND; SEINAJOKI CENT HOSP, SEINAJOKI, FINLAND; SOCIAL INSURANCE INST, SOCIAL SECUR RES INST, HELSINKI, FINLAND	Umea University; Kuopio University Hospital; University of Eastern Finland; Tampere University; Tampere University Hospital; Seinajoki Central Hospital	SEPPALA, H (corresponding author), NATL INST PUBL HLTH, ANTIMICROBIAL RES UNIT, POB 57, SF-20521 TURKU, FINLAND.		Huovinen, Pentti/C-1917-2009					[Anonymous], 1991, LANCET, V337, P651; BORZANI M, 1989, J CHEMOTHERAPY, V1, P35, DOI 10.1080/1120009X.1989.11738861; CLEARY PP, 1988, J INFECT DIS, V158, P1317, DOI 10.1093/infdis/158.6.1317; COL NF, 1987, REV INFECT DIS, V9, pS232; DIXON JMS, 1974, J INFECT DIS, V130, P351, DOI 10.1093/infdis/130.4.351; Fernandes P. B., 1987, Antimicrobic Newsletter, V4, P25, DOI 10.1016/0738-1751(87)90002-5; GRAYSTON JT, 1990, J INFECT DIS, V161, P618, DOI 10.1093/infdis/161.4.618; GUNN BA, 1977, J CLIN MICROBIOL, V5, P650; HOLMSTROM L, 1990, SCAND J INFECT DIS, V22, P179, DOI 10.3109/00365549009037900; HORAUD T, 1985, J ANTIMICROB CHEMOTH, V16, P111, DOI 10.1093/jac/16.suppl_A.111; HUOVINEN P, 1989, ANN INTERN MED, V110, P612, DOI 10.7326/0003-4819-110-8-612; ISTRE GR, 1981, ANTIMICROB AGENTS CH, V20, P244, DOI 10.1128/AAC.20.2.244; JARVINEN H, 1989, LANCET, V1, P1022; KAPLAN EL, 1991, EUR J CLIN MICROBIOL, V10, P55, DOI 10.1007/BF01964407; KOMAROFF AL, 1983, SCIENCE, V222, P927, DOI 10.1126/science.6415813; MAKELA PH, 1989, FINN MED J, V44, P419; MALMBORG AS, 1986, J ANTIMICROB CHEMOTH, V18, P293, DOI 10.1093/jac/18.3.293; MARTIN PR, 1990, SCAND J INFECT DIS, V22, P421, DOI 10.3109/00365549009027073; MARUYAMA S, 1979, AM J DIS CHILD, V133, P1143, DOI 10.1001/archpedi.1979.02130110051007; MAXTED WR, 1972, STREPTOCOCCI STREPTO, P256; MIYAMOTO Y, 1978, ANTIMICROB AGENTS CH, V13, P399, DOI 10.1128/AAC.13.3.399; PHILLIPS G, 1990, J ANTIMICROB CHEMOTH, V25, P723, DOI 10.1093/jac/25.4.723; SCOTT RJD, 1989, EPIDEMIOL INFECT, V102, P85, DOI 10.1017/S095026880002971X; SKJOLD SA, 1987, J INFECT DIS, V155, P1145, DOI 10.1093/infdis/155.6.1145; SPENCER RC, 1989, LANCET, V1, P168; STINGEMORE N, 1989, MED J AUSTRALIA, V150, P626, DOI 10.5694/j.1326-5377.1989.tb136725.x; TRALLERO EP, 1989, LANCET, V2, P444; WEISBLUM B, 1985, J ANTIMICROB CHEMOTH, V16, P63, DOI 10.1093/jac/16.suppl_A.63; WITTLER RR, 1990, AM J DIS CHILD, V144, P587, DOI 10.1001/archpedi.1990.02150290081033; ZACKRISSON G, 1988, SCAND J INFECT DIS, V20, P419, DOI 10.3109/00365548809032478; 1990, NLN PUBLICATION, V30; 1990, FINNISH STATISTICS M; 1982, NLN PUBLICATION, V8; 1986, NLN PUBLICATION, V14; 1990, ANTIMICROBIAL SUSCEP, V10	35	295	298	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1992	326	5					292	297		10.1056/NEJM199201303260503	http://dx.doi.org/10.1056/NEJM199201303260503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA991	1728733				2022-12-01	WOS:A1992HA99100003
J	WARNER, KE; GOLDENHAR, LM; MCLAUGHLIN, CG				WARNER, KE; GOLDENHAR, LM; MCLAUGHLIN, CG			CIGARETTE ADVERTISING AND MAGAZINE COVERAGE OF THE HAZARDS OF SMOKING - A STATISTICAL-ANALYSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH; BAN	Background. Health professionals have charged that magazines that depend on revenues from cigarette advertising are less likely to publish articles on the dangers of smoking for fear of off ending cigarette manufacturers. Special concern has focused on magazines directed to women. Restricted coverage of smoking hazards could lead readers to underestimate the risks of smoking in relation to other health risks. Methods. Using logistic-regression analysis of a sample of 99 U.S. magazines published during 25 years (1959 through 1969 and 1973 through 1986), we analyzed the probability that the magazines would publish articles on the risks of smoking in relation to whether they carried advertisements for cigarettes and in relation to the proportion of their advertising revenues derived from cigarette advertisements. We controlled for other factors that might influence coverage. Results. The probability of publishing an article on the risks of smoking in a given year was 11.9 percent for magazines that did not carry cigarette advertisements, as compared with 8.3 percent for those that did publish such advertisements (adjusted odds ratio, 0.73; 95 percent confidence interval, 0.42 to 1.30). For women's magazines alone, the probabilities were 11.7 percent and 5.0 percent, respectively (adjusted odds ratio, 0.13; 95 percent confidence interval, 0.02 to 0.69). When the proportion of revenues derived from cigarette advertising was the independent variable, the probability of publishing an article on the risks of smoking in a given year was reduced by 38 percent (95 percent confidence interval, 18 percent to 55 percent) for magazines with the average proportion of total advertising revenues derived from cigarette advertising for the entire sample of magazines (6 percent) as compared with magazines with no cigarette advertising. This relation was particularly strong in the case of women's magazines. An increase of 1 percent in the share of advertising revenue derived from cigarette advertisements decreased the probability of covering the risks of smoking by three times as much as in other magazines. Conclusions. This study provides strong statistical evidence that cigarette advertising in magazines is associated with diminished coverage of the hazards of smoking. This is particularly true for magazines directed to women.			WARNER, KE (corresponding author), UNIV MICHIGAN,SCH PUBL HLTH,DEPT PUBL HLTH POLICY & ADM,1420 WASHINGTON HTS,ANN ARBOR,MI 48109, USA.			Warner, Kenneth/0000-0002-8214-1776	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004091] Funding Source: NIH RePORTER; NIDA NIH HHS [R01-DA04091] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AMOS A, 1991, LANCET, V337, P93, DOI 10.1016/0140-6736(91)90747-D; Bagdikian B., 1983, MEDIA MONOPOLY; BLUM A, 1986, WASHINGTON POST 0518, pF1; DALE KC, 1982, ACHS NEWS VIEWS, V3, P8; DOUGHERTY PH, 1988, NY TIMES        0406, P1; EMERY CE, 1986, PROVIDENCE J B  0423, pA1; ENGLANDER TJ, 1986, US TOBACCO CAND 0402, P46; GREENE W, 1990, ECONOMETRIC ANAL, P482; JACOBSON B, 1985, SMAOKE GETS YOUR EYE; KESSLER L, 1989, JOURNALISM QUART, V66, P316, DOI 10.1177/107769908906600207; MYERS ML, 1981, STAFF REPORT CIGARET; Seldes George, 1938, LORDS PRESS; SMITH RC, 1978, COLUMBIA JOURNAL REV, V16, P29; WARNER K E, 1989, Journal of Public Health Policy, V10, P32, DOI 10.2307/3342942; WARNER KE, 1979, POLICY ANAL, V5, P435; WARNER KE, 1985, NEW ENGL J MED, V312, P384, DOI 10.1056/NEJM198502073120627; WARNER KE, 1959, IN PRESS TOB CONTROL; Whelan E M, 1981, J Public Health Policy, V2, P28, DOI 10.2307/3342095; 1989, DHHS CDC898411 DEP H; 1964, DHEW PHS1103 PUBL, V1103; 1990, MMWR, V39, P261	21	59	60	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1992	326	5					305	309		10.1056/NEJM199201303260505	http://dx.doi.org/10.1056/NEJM199201303260505			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HA991	1728734				2022-12-01	WOS:A1992HA99100005
J	ZANETTI, M				ZANETTI, M			ANTIGENIZED ANTIBODIES	NATURE			English	Article							RESHAPING HUMAN-ANTIBODIES; 3-DIMENSIONAL STRUCTURE; INTERNAL IMAGE; PROTEIN; PEPTIDE; EPITOPE; MUTAGENESIS; MOLECULES; VACCINES; LIBRARY		UNIV CALIF SAN DIEGO,CTR CANC,SAN DIEGO,CA 92103	University of California System; University of California San Diego	ZANETTI, M (corresponding author), UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92103, USA.							ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; ATASSI MZ, 1980, MOL CELL BIOCHEM, V32, P21; BILLETTA R, 1991, P NATL ACAD SCI USA, V88, P4713, DOI 10.1073/pnas.88.11.4713; BRUCK C, 1986, P NATL ACAD SCI USA, V83, P6578, DOI 10.1073/pnas.83.17.6578; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; CO MS, 1991, P NATL ACAD SCI USA, V88, P2869, DOI 10.1073/pnas.88.7.2869; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; GEYSEN HM, 1985, IMMUNOL TODAY, V6, P364, DOI 10.1016/0167-5699(85)90096-9; HOFFMAN SL, 1991, SCIENCE, V252, P520, DOI 10.1126/science.2020852; JENNINGS PA, 1989, PROTEIN ENG, V2, P365, DOI 10.1093/protein/2.5.365; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; KABAT EA, 1987, PROTEINS IMMUNOLOGIC; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUWAJIMA G, 1988, BIO-TECHNOL, V6, P1080, DOI 10.1038/nbt0988-1080; LERNER RA, 1983, SCI AM, V248, P66, DOI 10.1038/scientificamerican0283-66; NEWMARK P, 1983, NATURE, V305, P9, DOI 10.1038/305009a0; NEWTON SMC, 1989, SCIENCE, V244, P70, DOI 10.1126/science.2468182; NOVOTNY J, 1975, NATURE, V258, P641, DOI 10.1038/258641a0; OLLIER P, 1985, EMBO J, V4, P3681, DOI 10.1002/j.1460-2075.1985.tb04135.x; REIDHAAROLSON JF, 1988, SCIENCE, V241, P53, DOI 10.1126/science.3388019; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; RUTGERS T, 1988, BIO-TECHNOL, V6, P1065, DOI 10.1038/nbt0988-1065; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SOLLAZZO M, 1990, PROTEIN ENG, V4, P215, DOI 10.1093/protein/4.2.215; SPANGLER BD, 1991, J IMMUNOL, V146, P1591; TEMPEST PR, 1991, BIO-TECHNOL, V9, P266, DOI 10.1038/nbt0391-266; VAN CV, 1988, J EXP, V167, P1841; VERHOEYEN M, 1988, SCIENCE, V239, P1534, DOI 10.1126/science.2451287; ZANETTI M, 1991, ANTIIDOTYPIC VACCINE, P123	30	44	64	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					476	477		10.1038/355476a0	http://dx.doi.org/10.1038/355476a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1370860				2022-12-01	WOS:A1992HB53000079
J	ZHANG, XK; HOFFMANN, B; TRAN, PBV; GRAUPNER, G; PFAHL, M				ZHANG, XK; HOFFMANN, B; TRAN, PBV; GRAUPNER, G; PFAHL, M			RETINOID X-RECEPTOR IS AN AUXILIARY PROTEIN FOR THYROID-HORMONE AND RETINOIC ACID RECEPTORS	NATURE			English	Article							RESPONSE ELEMENT; HUMAN TESTIS; BINDING; GENE; IDENTIFICATION; SUPERFAMILY; ENHANCE	THYROID hormones and retinoic acid function through nuclear receptors that belong to the steroid/thyroid-hormone receptor superfamily (reviewed in refs 1-4). Thyroid hormone receptors (TRs) and retinoic acid receptors (RARs) require auxiliary nuclear proteins for efficient DNA binding 5-10. Here we report that retinoid X receptors RXR-alpha (ref. 11) is one of these nuclear proteins. RXR-alpha interacts both with TRs and with RARs, forming heterodimers in solution that strongly interact with a variety of T3/retinoic acid response elements. Transfection experiments show that RXR-alpha can greatly enhance the transcriptional activity of TR and RAR at low retinoic acid concentrations that do not significantly activate RXR-alpha itself. Thus, RXR-alpha enhances the transcriptional activity of other receptors and its own ligand sensitivity by heterodimer formation. Our studies reveal a new subclass of receptors and a regulatory pathway controlling nuclear receptor activities by heterodimer formation.	LA JOLLA CANC RES FDN,CTR CANC,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute								BEDO G, 1989, NATURE, V339, P231, DOI 10.1038/339231a0; BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HERMANN T, 1991, CELL REGUL, V2, P565, DOI 10.1091/mbc.2.7.565; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HUSHMAN M, 1991, MOL CELL BIOL, V11, P4097; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LEHMANN JM, 1991, NUCLEIC ACIDS RES, V19, P573, DOI 10.1093/nar/19.3.573; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MILLAN JL, 1986, J BIOL CHEM, V261, P3112; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; PFAHL M, 1990, METHOD ENZYMOL, V153, P256; PFAHL M, 1992, RETINOIDS NORMAL DEV, P51; ROSEN ED, 1991, MOL CELL ENDOCRINOL, V78, pC83, DOI 10.1016/0303-7207(91)90175-R; SCHUELER PA, 1990, MOL ENDOCRINOL, V4, P227, DOI 10.1210/mend-4-2-227; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; ZHANG X, 1991, MOL ENDOCRINOL, V5, P1909, DOI 10.1210/mend-5-12-1909; ZHANG XK, 1991, NEW BIOL, V3, P1	29	934	968	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					441	446		10.1038/355441a0	http://dx.doi.org/10.1038/355441a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1310350				2022-12-01	WOS:A1992HB53000068
J	ALEDORT, LM; HILGARTNER, MW; PIKE, MC; GJERSET, GF; KOERPER, MA; LIAN, EYC; LUSHER, JM; MOSLEY, JW				ALEDORT, LM; HILGARTNER, MW; PIKE, MC; GJERSET, GF; KOERPER, MA; LIAN, EYC; LUSHER, JM; MOSLEY, JW			VARIABILITY IN SERIAL CD4 COUNTS AND RELATION TO PROGRESSION OF HIV-I INFECTION TO AIDS IN HEMOPHILIC PATIENTS	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; EDINBURGH HEMOPHILIAC COHORT; CONTROLLED TRIAL; QUALITY-CONTROL; ZIDOVUDINE; FOLLOW; TYPE-1; RISK; AZT	Objective - To examine the CD4 count and its near term changes relative to progression to AIDS within 30 months and to subsequent CD4 counts. Design - Longitudinal clinical and laboratory study. Setting - Haemophilia treatment centres in six large American cities. Patients - 555 people with congenital clotting disorders who were infected with HIV, initially without AIDS, and seen at follow up for 6-30 months in 1986-9. Main outcome measures - Absolute CD4 counts and incidence of AIDS. Results - Outset CD4 count and age were independently related to progression to AIDS (p < 0.0001 and p < 0.005 respectively). Patients with CD4 counts of 0.30-0.49 X 10(9) cells/l had an age adjusted risk of AIDS within 30 months of only 9% that of patients with counts < 0.20 X 10(9)/l. Children under 10 years old had only 16% of the CD4 adjusted risk of AIDS of people aged greater-than-or-equal-to 45 years. Analysis of 149 patients' CD4 counts at the beginning and end of two successive six month intervals showed an average decrease of 11% in each six months regardless of the outset count (greater-than-or-equal-to 0.20 X 10(9)/l). For individual patients the decrease in the second six month period was unaffected by the decrease in the first six month period. Conclusions - Antiviral treatment of asymptomatic people, particularly children, with CD4 counts greater-than-or-equal-to 0.3 X 10(9)/l is questionable if predicated on near term progression to AIDS. Because of individual CD4 count variability and the low rate of progression to AIDS near term declines in individual CD4 counts are a poor index for identifying people who will rapidly progress to AIDS.	MT SINAI MED CTR,MED,NEW YORK,NY 10029; CORNELL UNIV,MED CTR,NEW YORK HOSP,NEW YORK,NY 10021; UNIV SO CALIF,DEPT PREVENT MED,LOS ANGELES,CA 90089; PUGET SOUND BLOOD CTR,MED,SEATTLE,WA 98104; UNIV CALIF SAN FRANCISCO,MED,SAN FRANCISCO,CA 94143; WAYNE STATE UNIV,PAEDIAT,DETROIT,MI 48202; UNIV MIAMI,MED,MIAMI,FL 33152	Icahn School of Medicine at Mount Sinai; Cornell University; NewYork-Presbyterian Hospital; University of Southern California; Puget Sound Blood Center; University of California System; University of California San Francisco; Wayne State University; University of Miami					DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB097074, N01HB047003] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HB-4-7003, N01-HB-9-7074] Funding Source: Medline	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN BL, 1990, NEW ENGL J MED, V323, P755; COX DR, 1972, J R STAT SOC B, V34, P187; CUTHBERT RJG, 1990, BMJ-BRIT MED J, V301, P956, DOI 10.1136/bmj.301.6758.956; DARBY SC, 1989, BRIT MED J, V298, P1064, DOI 10.1136/bmj.298.6680.1064; DETRUCHIS P, 1991, LANCET, V337, P1109, DOI 10.1016/0140-6736(91)91766-N; EDWARDS VM, 1989, AM J CLIN PATHOL, V91, P75, DOI 10.1093/ajcp/91.1.75; EYSTER ME, 1987, ANN INTERN MED, V107, P1, DOI 10.7326/0003-4819-107-1-1; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FRIEDLAND GH, 1990, NEW ENGL J MED, V322, P1000, DOI 10.1056/NEJM199004053221409; Goedert James J., 1990, Annals of Epidemiology, V1, P129, DOI 10.1016/1047-2797(90)90004-C; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HAMILTON JD, 1990, NEW ENGL J MED, V323, P754, DOI 10.1056/NEJM199009133231112; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPLAN JE, 1988, JAMA-J AM MED ASSOC, V260, P2694, DOI 10.1001/jama.260.18.2694; KLEINBAUM DG, 1988, APPLIED REGRESSION A; LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; MEDLEY GF, 1988, PROC R SOC SER B-BIO, V233, P367, DOI 10.1098/rspb.1988.0026; MOSS AR, 1990, J ACQ IMMUN DEF SYND, V3, pS69; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; OSMOND DH, 1991, AIDS, V5, P505, DOI 10.1097/00002030-199105000-00005; PARKER JW, 1990, CLIN IMMUNOL IMMUNOP, V55, P187, DOI 10.1016/0090-1229(90)90097-A; PHILLIPS AN, 1991, LANCET, V337, P389; PIZZO PA, 1990, J INFECT DIS, V161, P316, DOI 10.1093/infdis/161.2.316; RAGNI MV, 1990, J ACQ IMMUN DEF SYND, V3, P708; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; SIMMONDS P, 1988, BRIT MED J, V296, P593, DOI 10.1136/bmj.296.6622.593; THOMAS DG, 1977, COMPUT BIOMED RES, V10, P373, DOI 10.1016/0010-4809(77)90006-4; Vermund Sten H., 1990, Annals of Epidemiology, V1, P141, DOI 10.1016/1047-2797(90)90005-D; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1987, MMWR, V36, P3	31	35	35	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1992	304	6821					212	216		10.1136/bmj.304.6821.212	http://dx.doi.org/10.1136/bmj.304.6821.212			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA980	1346752	Green Published, Bronze			2022-12-01	WOS:A1992HA98000022
J	HOGERZEIL, HV; BATTERSBY, A; SRDANOVIC, V; STJERNSTROM, NE				HOGERZEIL, HV; BATTERSBY, A; SRDANOVIC, V; STJERNSTROM, NE			STABILITY OF ESSENTIAL DRUGS DURING SHIPMENT TO THE TROPICS	BRITISH MEDICAL JOURNAL			English	Article							SOLID-PHASE; DECOMPOSITION; DEGRADATION; KINETICS	Objective - To determine whether present methods of international transport of essential drugs by sea adversely affect their quality. Design - Controlled longitudinal study of drug shipments sent by sea from Unicef in Copenhagen to Lagos; to Mombasa and by land to Kampala; and to Bangkok. 11 essential drugs were stored in four locations on board the ships. Setting - Main shipping routes from Unicef, Copenhagen, to tropical countries. Main outcome measures - Temperature and relative humidity in the test packs during the journey. Amount of active ingredient in the drugs before and after shipment. Results - Temperatures recorded within the test packs range from -3.5-degrees-C to 42.4-degrees-C and were 3-12-degrees-C higher than the ambient temperature. Relative humidity within the packs ranged from 20% to 88%. Differences between the locations on board were negligible. Ergometrine injection, methylergometrine injection, and retinol capsules lost 1.5-5.8% of their activity. Ampoules of ergometrine showed a large variation in the amount of active ingredient after shipment, with three of 80 samples having concentrations 60% below those stated. Ampicillin, benzylpenicillin, phenoxymethylpenicillin, and tetracycline were not affected by transport. Conclusions - Drugs were exposed to a much higher temperature and humidity than is recommended by the manufacturer, especially in tropical harbours and during inland transport. Except for ergometrine and methylergometrine the transport would not affect clinical effectiveness.	UNICEF,DIV SUPPLY,DK-2100 COPENHAGEN,DENMARK; MED PROD AGCY,CHEM LABS,S-75125 UPPSALA,SWEDEN	Medical Products Agency	HOGERZEIL, HV (corresponding author), WHO,ACT PROGRAMME ESSENTIAL DRUGS,CH-1211 GENEVA 27,SWITZERLAND.							Abu Reid I, 1990, INT PHARM J, V4, P6; ALKER GJA, 1988, LANCET, V2, P393; [Anonymous], 1986, WHOPHARM86529; BECKER G, 1983, PHARM ZEITUNG, V15, P794; HOGERZEIL HV, 1991, LANCET, V338, P754, DOI 10.1016/0140-6736(91)91470-F; HOGERZEIL HV, 1991, WHODAP911; LONGLAND PW, 1987, PHARM J, P147; PAWELCZYK E, 1980, POL J PHARMACOL PHAR, V32, P47; PAWELCZYK E, 1980, POL J PHARMACOL PHAR, V32, P55; PIKAL MJ, 1977, J PHARM SCI, V66, P1312, DOI 10.1002/jps.2600660927; SMALLENBROEK H, 1983, STABILITY DRUGS TROP; YORK P, 1977, PHARMAZIE, V32, P101; 1990, WHOMCH907; 1990, ESSENTIAL DRUGS PRIC; 1990, WHO TECH REP SER, V790	15	38	39	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1992	304	6821					210	212		10.1136/bmj.304.6821.210	http://dx.doi.org/10.1136/bmj.304.6821.210			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA980	1739795	Green Published, Bronze			2022-12-01	WOS:A1992HA98000021
J	KENDALL, GM; MUIRHEAD, CR; MACGIBBON, BH; OHAGAN, JA; CONQUEST, AJ; GOODILL, AA; BUTLAND, BK; FELL, TP; JACKSON, DA; WEBB, MA; HAYLOCK, RGE; THOMAS, JM; SILK, TJ				KENDALL, GM; MUIRHEAD, CR; MACGIBBON, BH; OHAGAN, JA; CONQUEST, AJ; GOODILL, AA; BUTLAND, BK; FELL, TP; JACKSON, DA; WEBB, MA; HAYLOCK, RGE; THOMAS, JM; SILK, TJ			MORTALITY AND OCCUPATIONAL EXPOSURE TO RADIATION - 1ST ANALYSIS OF THE NATIONAL-REGISTRY-FOR-RADIATION-WORKERS	BRITISH MEDICAL JOURNAL			English	Article							EMPLOYEES; PROGRAM; COHORT; CANCER; PLANT; RISK	Objective - To study cause specific mortality of radiation workers with particular reference to associations between fatal neoplasms and level of exposure to radiation. Design - Cohort study. Setting - United Kingdom. Subjects - 95 217 radiation workers at major sites of the nuclear industry. Main outcome measure - Cause of death. Results - Most standardised mortality ratios were below 100: 83 unlagged, 85 with a 10 year lag for all causes; 84 unlagged, 86 lagged for all cancers; and 80 for all known other causes, indicating a "healthy worker effect." The deficit of lung cancer (75 unlagged, 76 lagged) was significant at the 0.1% level. Standardised mortality ratios were significantly raised (214 unlagged, 303 lagged) for thyroid cancer, but there was no evidence for any trend with external recorded radiation dose. Dose of external radiation and mortality from all cancers were weakly correlated (p = 0.10), and multiple myeloma was more strongly correlated (p = 0.06); for leukaemia, excluding chronic lymphatic, the trend was significant (p = 0.03; all tests one tailed). The central estimates of lifetime risk derived from these data were 10.0% per Sv (90% confidence interval < 0 to 24%) for all cancers and 0.76% per Sv (0.07 to 2.4%) for leukaemia (excluding chronic lymphatic leukaemia). These are, respectively, 2.5 times and 1.9 times the risk estimates recommended by the International Commission on Radiological Protection, but 90% confidence intervals are large and the commission's risk factors fall well within the range. The positive trend with dose for all cancers, from which the risk estimate was derived, was not significant. The positive association between leukaemia (except chronic lymphatic leukaemia) was significant and robust in subsidiary analyses. This study showed no association between radiation exposure and prostatic cancer. Conclusion - There is evidence for an association between radiation exposure and mortality from cancer, in particular leukaemia (excluding chronic lymphatic leukaemia) and multiple myeloma, although mortality from these diseases in the study population overall was below that in the general population. The central estimates of risk from this study lie above the most recent estimates of the International Commission on Radiological Protection for leukaemia (excluding chronic lymphatic leukaemia) and for all malignancies. However, the commission's risk estimates are well within the 90% confidence intervals from this study. Analysis of States indicated lower risk estimates than the commission recommends, and when the American data are combined with our analysis the overall risks are close to those estimated by the commission. This first analysis of the National Registry for Radiation Workers does not provide sufficient evidence to justify a revision in risk estimates for radiological protection purposes.			KENDALL, GM (corresponding author), NATL RADIOL PROTECT BOARD,DIDCOT OX11 0RQ,OXON,ENGLAND.			Butland, Barbara/0000-0001-9952-3108; Muirhead, Colin/0000-0001-5394-1267				[Anonymous], 1990, HLTH EFFECTS EXPOSUR; BARRY SF, 1986, BRIT J IND MED, V43, P572; BERAL V, 1985, BRIT MED J, V291, P440, DOI 10.1136/bmj.291.6493.440; BERAL V, 1988, BRIT MED J, V297, P757, DOI 10.1136/bmj.297.6651.757; BINKS K, 1989, RADIATION PROTECTION - THEORY AND PRACTICE, P49; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; Cox DR, 1974, THEORETICAL STATISTI; DARBY SC, 1981, J R STAT SOC A STAT, V144, P298, DOI 10.2307/2981797; DARBY SC, 1981, NRPBR116; FOX AJ, 1976, BRIT J PREV SOC MED, V30, P225; GILBERT E S, 1990, Radiation Research, V124, P348; GILBERT ES, 1989, RADIAT RES, V120, P19, DOI 10.2307/3577633; GODWIN P, 1975, NATURE, V255, P517; KENDALL GM, 1992, NRPBR251; MUIRHEAD CR, 1991, RADIAT PROT DOSIM, V36, P321; SHIMIZU Y, 1990, RADIAT RES, V121, P120, DOI 10.2307/3577495; SMITH PG, 1986, BRIT MED J, V293, P845, DOI 10.1136/bmj.293.6551.845; 1971, DECENNIAL SUPPLEMENT; 1978, DS1 OFF POP CENS SUR; 1986, DS6 OFF POP CENS SUR; 1991, ICR PUBLICATION, V60, P1	21	152	161	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1992	304	6821					220	225		10.1136/bmj.304.6821.220	http://dx.doi.org/10.1136/bmj.304.6821.220			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA980	1739796	Green Published, Bronze			2022-12-01	WOS:A1992HA98000024
J	SHAH, M; FOREMAN, DM; FERGUSON, MWJ				SHAH, M; FOREMAN, DM; FERGUSON, MWJ			CONTROL OF SCARRING IN ADULT WOUNDS BY NEUTRALIZING ANTIBODY TO TRANSFORMING GROWTH-FACTOR-BETA	LANCET			English	Note								Adult wounds heal with scar-tissue formation, whereas fetal wounds heal without scarring and with a lesser inflammatory and cytokine response. We injected the margins of healing dermal wounds in adult rats with neutralising antibody (NA) to transforming growth factor-beta (TGF-beta). All control wounds (irrelevant antibody, or TGF-beta, or no injection) healed with scarring, whereas the NA-treated wounds healed without scar-tissue formation; NA-treated wounds had fewer macrophages and blood vessels, lower collagen and fibronectin contents, but identical tensile strength and more normal dermal architecture than the other wounds. Early manipulation of the concentrations of selected cytokines may be a new approach to the control of scarring.	UNIV MANCHESTER, SCH BIOL SCI, DEPT CELL & STRUCT BIOL, STOPFORD BLDG, MANCHESTER M13 9PT, LANCS, ENGLAND	University of Manchester								BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; KRUMMEL TM, 1988, J PEDIATR SURG, V23, P647, DOI 10.1016/S0022-3468(88)80638-9; KSANDER GA, 1989, ANNU REP MED CHEM, V24, P223; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; McCartney-Francis N, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011007; MCGRATH MH, 1990, CLIN PLAST SURG, V17, P421; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009-8981(67)90167-2; WHITBY DJ, 1991, DEV BIOL, V147, P207, DOI 10.1016/S0012-1606(05)80018-1; WHITBY DJ, 1991, DEVELOPMENT, V112, P651	10	517	570	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 25	1992	339	8787					213	214		10.1016/0140-6736(92)90009-R	http://dx.doi.org/10.1016/0140-6736(92)90009-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA589	1346175				2022-12-01	WOS:A1992HA58900006
J	WALKER, A				WALKER, A			HEALTH AND THE ENVIRONMENT - SWIMMING - THE HAZARDS OF TAKING A DIP	BRITISH MEDICAL JOURNAL			English	Article											WALKER, A (corresponding author), ST MARYS HOSP,DEPT PAEDIAT,LONDON W2 1NY,ENGLAND.							BALARAJAN R, 1991, BRIT MED J, V303, P144; CABELLI VJ, 1982, AM J EPIDEMIOL, V115, P606, DOI 10.1093/oxfordjournals.aje.a113342; DUNLOP JM, 1991, BRIT MED J, V302, P671, DOI 10.1136/bmj.302.6778.671; HALL C, 1990, RUNNING WATER; MORRIS J, 1991, WATER B, V465, P7; PIKE EB, 1991, 2736MP WAT RES CTR D; PIKE EB, 1990, 2518MP WAT RES CTR D; WHEELER D, 1990, LAB PRACT, V39, P19; 1959, J HYGIENE, V57, P435; 1990, POLLUTION BEACHES 4T; 1991, WATER INFORMATION WA; 1991, BATHING WATER QUALIT; 1990, TOXIC BLUE GREEN ALG	13	9	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1992	304	6821					242	245		10.1136/bmj.304.6821.242	http://dx.doi.org/10.1136/bmj.304.6821.242			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA980	1739802	Green Published, Bronze			2022-12-01	WOS:A1992HA98000031
J	BAIER, H; BONHOEFFER, F				BAIER, H; BONHOEFFER, F			AXON GUIDANCE BY GRADIENTS OF A TARGET-DERIVED COMPONENT	SCIENCE			English	Article							RETINAL AXONS; RETINOTECTAL MAP; TECTAL MEMBRANES; GROWTH; NEURITES; XENOPUS; REGENERATION; PROJECTION; AVOIDANCE; ADHESION	Spatial gradients of axon guiding molecules have long been suspected to provide positional and directional cues for retinal ganglion cell axons growing within the optic tectum. With the identification of a guiding activity from tectal cell membranes, it has become possible to investigate the potential physiological significance of molecular gradients for retinal growth cone behavior in vitro. A subset of retinal growth cones, those from the temporal half, were highly sensitive to small concentration changes of the guiding component. The degree of response was correlated with the strength of the gradient. These findings demonstrate that the neural growth cone can read gradients of surface-associated information.			BAIER, H (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL,PHYS BIOL LAB,SPEMANNSTR 35,W-7400 TUBINGEN,GERMANY.							ADLER J, 1976, SCI AM, V234, P40, DOI 10.1038/scientificamerican0476-40; BONHOEFFER F, 1982, EMBO J, V1, P427, DOI 10.1002/j.1460-2075.1982.tb01186.x; BONHOEFFER F, 1984, TRENDS NEUROSCI, V7, P378, DOI 10.1016/S0166-2236(84)80060-0; DAVIES JA, 1990, NEURON, V2, P11; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cellbio.4.1.649; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; FRASER SE, 1980, DEV BIOL, V79, P453, DOI 10.1016/0012-1606(80)90130-X; FUJISAWA H, 1987, J COMP NEUROL, V260, P127, DOI 10.1002/cne.902600110; GIERER A, 1983, PROC R SOC SER B-BIO, V218, P77, DOI 10.1098/rspb.1983.0027; GIERER A, 1987, DEVELOPMENT, V101, P479; GUNDERSEN RW, 1980, J CELL BIOL, V87, P546, DOI 10.1083/jcb.87.3.546; HALFTER W, 1981, NATURE, V292, P67, DOI 10.1038/292067a0; HARRIS WA, 1989, NATURE, V339, P218, DOI 10.1038/339218a0; HEACOCK AM, 1977, SCIENCE, V198, P64, DOI 10.1126/science.897684; HEFNER CD, 1990, SCIENCE, V247, P217; HOLT CE, 1983, NATURE, V301, P150, DOI 10.1038/301150a0; LETOURNEAU PC, 1983, TRENDS NEUROSCI, V6, P451, DOI 10.1016/0166-2236(83)90217-5; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; MCLOON SC, 1991, J NEUROSCI, V11, P1470; MCNAB RM, 1972, P NATL ACAD SCI USA, V69, P2509; OROURKE NA, 1986, DEV BIOL, V114, P265, DOI 10.1016/0012-1606(86)90191-0; SCHWAB ME, 1990, TRENDS NEUROSCI, V13, P452, DOI 10.1016/0166-2236(90)90098-U; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; STAHL B, 1990, COLD SPRING HARB SYM, V55, P351; STAHL B, 1990, NEURON, V5, P735, DOI 10.1016/0896-6273(90)90227-7; STUERMER CAO, 1988, J COMP NEUROL, V267, P55, DOI 10.1002/cne.902670105; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; WALTER J, 1987, DEVELOPMENT, V101, P685; WALTER J, 1990, J PHYSIOL-PARIS, V84, P104; WALTER J, 1987, DEVELOPMENT, V101, P909; WALTER J, 1990, TRENDS NEUROSCI, V13, P447, DOI 10.1016/0166-2236(90)90097-T	32	269	272	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					472	475		10.1126/science.1734526	http://dx.doi.org/10.1126/science.1734526			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1734526				2022-12-01	WOS:A1992HA59000044
J	CHIN, KV; UEDA, K; PASTAN, I; GOTTESMAN, MM				CHIN, KV; UEDA, K; PASTAN, I; GOTTESMAN, MM			MODULATION OF ACTIVITY OF THE PROMOTER OF THE HUMAN MDR1 GENE BY RAS AND P53	SCIENCE			English	Article							MULTIDRUG-RESISTANCE GENE; P-GLYCOPROTEIN; HUMAN-TUMORS; CELLS; EXPRESSION; TISSUES; PROTEIN; LIVER; DNA; TRANSFORMATION	Drug resistance in human cancer is associated with overexpression of the multidrug resistance (MDR1) gene, which confers cross-resistance to hydrophobic natural product cytotoxic drugs. Expression of the MDR1 gene can occur de novo in human cancers in the absence of drug treatment. The promoter of the human MDR1 gene was shown to be a target for the c-Ha-Ras-1 oncogene and the p53 tumor suppressor gene products, both of which are associated with tumor progression. The stimulatory effect of c-Ha-Ras-1 was not specific for the MDR1 promoter alone, whereas a mutant p53 specifically stimulated the MDR1 promoter and wild-type p53 exerted specific repression. These results imply that the MDR1 gene could be activated during tumor progression associated with mutations in Ras and p53.	NCI,CELL BIOL LAB,BLDG 37,ROOM 1B22,BETHESDA,MD 20892; KYOTO UNIV,DEPT AGR CHEM,KYOTO 606,JAPAN; NCI,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kyoto University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Chin, Khew-Voon/F-2670-2013; pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270; Ueda, Kazumitsu/0000-0003-2980-6078				ARCECI RJ, 1990, MOL REPROD DEV, V25, P101, DOI 10.1002/mrd.1080250202; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BURT RK, 1988, CARCINOGENESIS, V9, P2329, DOI 10.1093/carcin/9.12.2329; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIN KJ, UNPUB; CHIN KV, 1990, J BIOL CHEM, V265, P221; CHIN KV, 1990, CELL GROWTH DIFFER, V1, P361; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FAIRCHILD CR, 1987, P NATL ACAD SCI USA, V84, P7701, DOI 10.1073/pnas.84.21.7701; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GEISER AG, 1991, MOL CELL BIOL, V11, P84, DOI 10.1128/MCB.11.1.84; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GORMAN CM, 1982, MOL CELL BIOL, V2, P10144; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; KEDAR PS, 1990, MOL CELL BIOL, V10, P3852, DOI 10.1128/MCB.10.7.3852; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P666; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; THORGEIRSSON SS, 1987, SCIENCE, V236, P1120, DOI 10.1126/science.3576227; UEDA K, 1987, J BIOL CHEM, V262, P17432; UEDA K, 1989, JPN J CANCER RES, V80, P1127, DOI 10.1111/j.1349-7006.1989.tb02269.x	43	806	840	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					459	462		10.1126/science.1346476	http://dx.doi.org/10.1126/science.1346476			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1346476				2022-12-01	WOS:A1992HA59000039
J	ELBRECHT, A; SMITH, RG				ELBRECHT, A; SMITH, RG			AROMATASE ENZYME-ACTIVITY AND SEX DETERMINATION IN CHICKENS	SCIENCE			English	Article							MULLERIAN INHIBITING SUBSTANCE; DETERMINING REGION; ESTROGEN; OVARY; CHROMOSOME; ANDROGEN; EMBRYO; GENE	During development, the genotype of the zygote determines the nature of the gonad, which then determines the male or female phenotype. The molecular events underlying this process are just beginning to be defined. A single treatment of chicken embryos with an aromatase inhibitor (which blocks the synthesis of estrogen from testosterone) at a stage when their gonads were bipotential caused genetic females to develop a permanent male phenotype. These sex-reversed females developed bilateral testes that were capable of complete spermatogenesis and had the physical appearance and behavior of normal males. This result identifies aromatase as a key developmental switch in the sex determination of chickens.			ELBRECHT, A (corresponding author), MERCK SHARP & DOHME LTD,DEPT ANIM BIOCHEM & MOLEC BIOL,RAHWAY,NJ 07065, USA.							BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; BELL DJ, 1971, MALE REPRODUCTION PH, V3, P1411; BROWNE LJ, 1988, Patent No. 4728645; GEORGE FW, 1978, NATURE, V274, P172, DOI 10.1038/274172a0; GEORGE FW, 1978, J CLIN ENDOCR METAB, V47, P550, DOI 10.1210/jcem-47-3-550; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; Haffen K., 1970, Adv Morphogen, V8, P285; HUTSON JM, 1985, GEN COMP ENDOCR, V57, P88, DOI 10.1016/0016-6480(85)90204-7; HUTSON JM, 1983, INT REV PHYSIOL, V27, P177; KODAMA H, 1987, CHROMOSOMA, V96, P18, DOI 10.1007/BF00285878; LAKE PE, 1956, Q J MICROSC SCI, V97, P487; Masui K, 1933, SEXING BABY CHICKS; MCPHAUL MJ, 1988, J BIOL CHEM, V263, P16358; MILEWICH L, 1977, ENDOCRINOLOGY, V100, P187, DOI 10.1210/endo-100-1-187; SCHUMACHER M, 1991, J NEUROENDOCRINOL, V3, P221, DOI 10.1111/j.1365-2826.1991.tb00266.x; SCHWARZEL WC, 1973, ENDOCRINOLOGY, V92, P866, DOI 10.1210/endo-92-3-866; SHOZU M, 1991, J CLIN ENDOCR METAB, V72, P560, DOI 10.1210/jcem-72-3-560; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SMITH RE, UNPUB, P54011; STEELE R E, 1987, Steroids, V50, P147, DOI 10.1016/0039-128X(83)90068-5; TENG CS, 1987, DEV BIOL, V123, P255, DOI 10.1016/0012-1606(87)90447-7; VIGIER B, 1989, P NATL ACAD SCI USA, V86, P3684, DOI 10.1073/pnas.86.10.3684; WOUTERS W, 1989, J STEROID BIOCHEM, V32, P781, DOI 10.1016/0022-4731(89)90453-6; YANG Y, COMMUNICATION	24	421	442	2	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					467	470		10.1126/science.1734525	http://dx.doi.org/10.1126/science.1734525			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1734525				2022-12-01	WOS:A1992HA59000042
J	FERGUSON, BM; FANGMAN, WL				FERGUSON, BM; FANGMAN, WL			A POSITION EFFECT ON THE TIME OF REPLICATION ORIGIN ACTIVATION IN YEAST	CELL			English	Article							S-PHASE; DNA-REPLICATION; CELLS	The chromosomes of eukaryotes are characterized by the mosaic nature of their replication - large regions of DNA that replicate early in S phase are interspersed with regions that replicate late. This pattern of early and late synthesis appears to be the consequence of a temporal program that activates replication origins at different times. The basis of this temporal regulation in the yeast S. cerevisiae has been investigated by changing the chromosomal locations of two origins, one activated early in the S phase (ARS1) and one activated late (ARS501). We show that the cis-acting information controlling time of activation can be separated from the element that determines origin function. For the ARS501 origin, late activation appears to be a consequence of its proximity to the telomere.	UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NIGMS NIH HHS [GM18926] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018926, R37GM018926] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; DROUIN R, 1990, CHROMOSOMA, V99, P273, DOI 10.1007/BF01731703; DUBEY DD, 1991, IN PRESS MOL CELL BI; FANGMAN WL, 1983, CELL, V32, P831, DOI 10.1016/0092-8674(83)90069-7; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; GOLDMAN MA, 1988, BIOESSAYS, V9, P50, DOI 10.1002/bies.950090204; HAND R, 1975, J CELL BIOL, V64, P89, DOI 10.1083/jcb.64.1.89; HUBERMAN JA, 1988, NUCLEIC ACIDS RES, V16, P6373, DOI 10.1093/nar/16.14.6373; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KARPEN GH, 1990, CELL, V63, P97; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; REYNOLDS AE, 1989, MOL CELL BIOL, V9, P4488, DOI 10.1128/MCB.9.10.4488; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUNGE KW, 1989, MOL CELL BIOL, V9, P1488, DOI 10.1128/MCB.9.4.1488; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; TAYLOR JH, 1960, J BIOPHYS BIOCHEM CY, V7, P455, DOI 10.1083/jcb.7.3.455; VOLLRATH D, 1988, P NATL ACAD SCI USA, V85, P6027, DOI 10.1073/pnas.85.16.6027; ZAKIAN VA, 1979, CELL, V17, P923, DOI 10.1016/0092-8674(79)90332-5	20	225	227	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1992	68	2					333	339		10.1016/0092-8674(92)90474-Q	http://dx.doi.org/10.1016/0092-8674(92)90474-Q			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1733502				2022-12-01	WOS:A1992HB35300012
J	HARLEY, VR; JACKSON, DI; HEXTALL, PJ; HAWKINS, JR; BERKOVITZ, GD; SOCKANATHAN, S; LOVELLBADGE, R; GOODFELLOW, PN				HARLEY, VR; JACKSON, DI; HEXTALL, PJ; HAWKINS, JR; BERKOVITZ, GD; SOCKANATHAN, S; LOVELLBADGE, R; GOODFELLOW, PN			DNA-BINDING ACTIVITY OF RECOMBINANT SRY FROM NORMAL MALES AND XY FEMALES	SCIENCE			English	Article							TESTIS-DETERMINING FACTOR; SEX-DETERMINING REGION; DETERMINING GENE; PROTEINS; ENCODES; DIFFERENTIATION; EXPRESSION; HOMOLOGY; MUTATION; SEQUENCE	The protein encoded by the human testis determining gene, SRY, contains a high mobility group (HMG) box related to that present in the T cell-specific, DNA-binding protein TCF-1. Recombinant SRY protein was able to bind to the same core sequence AACAAAG recognized by TCF-1 in a sequence dependent manner. In five XY females point mutations were found in the region encoding the HMG box. In four cases DNA binding activity of mutant SRY protein was negligible; in the fifth case DNA binding was reduced. These results imply that the DNA binding activity of SRY is required for sex determination.	IMPERIAL CANC RES FUND,HUMAN MOLEC GENET LAB,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; JOHNS HOPKINS CHILDREN CTR,DIV PEDIAT ENDOCRINOL,BALTIMORE,MD 21205; NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,LONDON NW7 1AA,ENGLAND	Cancer Research UK; Johns Hopkins University; Johns Hopkins Medicine; MRC National Institute for Medical Research			Harley, Vincent/B-8092-2018; Hawkins, Ross/M-7702-2014	Harley, Vincent/0000-0002-2405-1262; Lovell-Badge, Robin/0000-0001-9364-4179	Medical Research Council [MC_U117562207] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER AP, 1985, J BIOL CHEM, V19, P10613; DELACHAPELLE A, 1987, DEVELOPMENT, V101, P33; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; EICHER EM, 1986, ANNU REV GENET, V20, P327, DOI 10.1146/annurev.ge.20.120186.001551; FERGUSONSMITH MA, 1990, HUM GENET, V84, P198; FORD CE, 1959, LANCET, V1, P711; FRIED MG, 1984, J MOL BIOL, V172, P263, DOI 10.1016/S0022-2836(84)80026-1; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUBBAY J, UNPUB; GUELLAEN G, 1984, NATURE, V307, P172, DOI 10.1038/307172a0; HAGGREN W, 1988, MOL CELL BIOL, V8, P1282, DOI 10.1128/MCB.8.3.1282; HARLOW E, 1988, ANTIBODIES LABORATOR; HAWKINS JR, IN PRESS HUM GENET; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; JACOBS PA, 1959, NATURE, V183, P302, DOI 10.1038/183302a0; JAGER RJ, 1990, NATURE, V348, P452, DOI 10.1038/348452a0; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; Jost A., 1973, Recent Progress Hormone Res, V29, P1; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; KOLODRUBETZ D, 1990, J BIOL CHEM, V265, P3234; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; LOVELLBADGE R, 1990, DEVELOPMENT, V109, P635; MOSRIN C, 1990, MOL CELL BIOL, V10, P4737, DOI 10.1128/MCB.10.9.4737; OOSTERWEGEL M, 1991, J EXP MED, V173, P1133, DOI 10.1084/jem.173.5.1133; PALMER MS, 1989, NATURE, V342, P937, DOI 10.1038/342937a0; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; PENTECOST BT, 1985, NUCLEIC ACIDS RES, V13, P4871, DOI 10.1093/nar/13.13.4871; POSSEE RD, 1987, NUCLEIC ACIDS RES, V15, P10233, DOI 10.1093/nar/15.24.10233; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; ROTH SY, 1987, NUCLEIC ACIDS RES, V15, P8112, DOI 10.1093/nar/15.19.8112; SINCLAIR AG, UNPUB; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; STABEN C, 1990, P NATL ACAD SCI USA, V87, P4917, DOI 10.1073/pnas.87.13.4917; SUMMERS M, 1987, TEX ASGR EXP STN B, V1555; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VERGNAUD G, 1986, AM J HUM GENET, V38, P172; WATERMAN M L, 1990, New Biologist, V2, P621; WEN L, 1989, NUCLEIC ACIDS RES, V17, P1197, DOI 10.1093/nar/17.3.1197; [No title captured]	44	392	403	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					453	456		10.1126/science.1734522	http://dx.doi.org/10.1126/science.1734522			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1734522				2022-12-01	WOS:A1992HA59000037
J	HERMANOWSKIVOSATKA, A; VANSTRIJP, JAG; SWIGGARD, WJ; WRIGHT, SD				HERMANOWSKIVOSATKA, A; VANSTRIJP, JAG; SWIGGARD, WJ; WRIGHT, SD			INTEGRIN MODULATING FACTOR-I - A LIPID THAT ALTERS THE FUNCTION OF LEUKOCYTE INTEGRINS	CELL			English	Article							FATTY-ACID DEFICIENCY; INCREASED SURFACE EXPRESSION; MONOCLONAL-ANTIBODIES; HUMAN-NEUTROPHILS; CELL-ADHESION; POLYMORPHONUCLEAR LEUKOCYTES; COMPLEMENT RECEPTORS; TRANSIENT ADHESION; GLYCOPROTEIN-IIIA; HUMAN-MONOCYTES	The avidity of integrin CR3 (also known as alpha(M)beta-2, Mac-1, Mo-1, and CD11b/CD18) may be reversibly altered without changes in the number of cell surface receptors. Here we describe a molecule termed integrin modulating factor (IMF-1), which controls CR3 avidity. Addition of IMF-1 to polymorphonuclear leukocytes (PMNs) or to purified CR3 causes enhanced binding of ligand. IMF-1 is not present in resting PMNs, but stimulation of cells results in a transient rise in IMF-1 content that parallels a transient rise in CR3 activity. We suggest that PMNs control adhesivity by controlling synthesis of IMF-1, which then acts as an allosteric activator of leukocyte integrins. IMF-1 is an acidic, amphiphilic molecule of M(r) 340 +/- 16 that does not contain ester, phosphate, amide, sialic acid, or glycosidic or vicinal hydroxyl functionalities, but does contain a carbon-carbon double bond. These results suggest that IMF-1 is an unsaturated fatty acid or an isoprenoid acid.			HERMANOWSKIVOSATKA, A (corresponding author), ROCKEFELLER UNIV, NEW YORK, NY 10021 USA.		van Strijp, Jos A.G./J-9549-2014	van Strijp, Jos A.G./0000-0001-6253-0830	NIAID NIH HHS [AI24775, AI22003] Funding Source: Medline; NIGMS NIH HHS [GM 07739] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022003, P01AI024775] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BREMER EG, 1986, J BIOL CHEM, V261, P2434; BUYON JP, 1988, J IMMUNOL, V140, P3156; CHAN KFJ, 1989, J BIOL CHEM, V264, P18632; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; COLLER BS, 1986, J CELL BIOL, V103, P451, DOI 10.1083/jcb.103.2.451; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; DANA N, 1986, J IMMUNOL, V137, P3259; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DETMERS PA, 1987, J CELL BIOL, V105, P1137, DOI 10.1083/jcb.105.3.1137; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; Guindon Y, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17A, P554; GYLLENHAMMAR H, 1988, LIPIDS, V23, P89, DOI 10.1007/BF02535286; HARLAN JM, 1985, BLOOD, V66, P167; HENSON PM, 1988, INFLAMMATION BASIC P, P363; HERMANOWSKIVOSATKA A, 1988, J BIOL CHEM, V263, P17822; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KIELCZYNSKI W, 1991, P NATL ACAD SCI USA, V88, P1991, DOI 10.1073/pnas.88.5.1991; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; LANIER LL, 1985, EUR J IMMUNOL, V15, P713, DOI 10.1002/eji.1830150714; LEFKOWITH JB, 1988, J IMMUNOL, V140, P228; LEFKOWITH JB, 1991, J BIOL CHEM, V266, P1071; LINDSTROM P, 1988, J CLIN LAB IMMUNOL, V25, P77; LO SK, 1989, J IMMUNOL, V143, P3325; LO SK, 1989, J EXP MED, V169, P1779, DOI 10.1084/jem.169.5.1779; NEURGEBAUER KM, 1991, NATURE, V350, P68; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PATARROYO M, 1989, SCAND J IMMUNOL, V30, P129, DOI 10.1111/j.1365-3083.1989.tb01197.x; PATARROYO M, 1987, FEBS LETT, V210, P127, DOI 10.1016/0014-5793(87)81321-2; PHILIPS MR, 1988, J CLIN INVEST, V82, P495, DOI 10.1172/JCI113623; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; ROUZER CA, 1990, J BIOL CHEM, V265, P1436; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SCHREINER GF, 1989, J IMMUNOL, V143, P3192; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; Spaethe S.M., 1988, CELLULAR MOL ASPECTS, P153; STALLCUP WB, 1989, DEV BIOL, V132, P212, DOI 10.1016/0012-1606(89)90218-2; TODD RF, 1988, HEMATOL ONCOL CLIN N, V2, P13; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; VEDDER NB, 1988, J CLIN INVEST, V81, P676, DOI 10.1172/JCI113372; WALSH CE, 1981, J BIOL CHEM, V256, P7228; WEBSTER RO, 1980, IMMUNOPHARMACOLOGY, V2, P201, DOI 10.1016/0162-3109(80)90050-8; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; WRIGHT SD, 1986, J IMMUNOL, V136, P1759; WRIGHT SD, 1990, LEUKOCYTE ADHESION MOLECULES, P190; WRIGHT SD, 1989, J EXP MED, V169, P175, DOI 10.1084/jem.169.1.175; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149; WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876	61	155	156	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1992	68	2					341	352		10.1016/0092-8674(92)90475-R	http://dx.doi.org/10.1016/0092-8674(92)90475-R			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1733503				2022-12-01	WOS:A1992HB35300013
J	HEYMAN, RA; MANGELSDORF, DJ; DYCK, JA; STEIN, RB; EICHELE, G; EVANS, RM; THALLER, C				HEYMAN, RA; MANGELSDORF, DJ; DYCK, JA; STEIN, RB; EICHELE, G; EVANS, RM; THALLER, C			9-CIS RETINOIC ACID IS A HIGH-AFFINITY LIGAND FOR THE RETINOID-X RECEPTOR	CELL			English	Article							INTESTINAL RECEPTOR; VITAMIN-A; IDENTIFICATION; GENE; EXPRESSION; ELEMENT; GAMMA	All-trans retinoic acid (RA) has previously been shown to modulate the transcriptional properties of the retinoic acid receptor (RAR) and retinoid X receptor (RXR). The inability of all-trans RA to bind to RXR suggests that it may be metabolized to a more active high affinity ligand. We report here an experimental approach that has identified 9-cis RA as an RXR ligand. It is up to 40-fold more potent than all-trans RA in transfection assays and binds with high affinity. The production of 9-cis RA in cultured cells and the identification of this molecule in liver and kidney demonstrates the existence of this molecule in living organisms. The discovery of this novel hormone points to the key role retinoid metabolism may have in generating new signaling pathways.	SALK INST BIOL STUDIES,LA JOLLA,CA 92037; HOWARD HUGHES MED INST,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,DEPT BIOMED SCI,LA JOLLA,CA 92093; BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030	Salk Institute; Howard Hughes Medical Institute; University of California System; University of California San Diego; Baylor College of Medicine	HEYMAN, RA (corresponding author), LIGAN PHARMACEUT INC,SAN DIEGO,CA 92121, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965; Mangelsdorf, David/0000-0002-4355-0796				Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; ALLEGRETTO EA, 1987, J BIOL CHEM, V262, P1312; BERGER TS, 1992, IN PRESS J STEROID B; BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRIDGES CDB, 1982, METHOD ENZYMOL, V81, P463; BROWN PS, 1959, NATURE, V184, P1377, DOI 10.1038/1841377a0; COREY EJ, 1968, J AM CHEM SOC, V90, P5616, DOI 10.1021/ja01022a059; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; KLIEWER SA, 1992, IN PRESS P NATL ACAD; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MANGELSDORF DJ, 1992, RETINOIDS NORMAL DEV; MATSUI M., 1958, JOUR VITAMINOL, V4, P178; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PIKE JW, 1983, J BIOL CHEM, V258, P1289; PIKE JW, 1979, P NATL ACAD SCI USA, V76, P5485, DOI 10.1073/pnas.76.11.5485; RANDO RR, 1990, ANGEW CHEM INT EDIT, V29, P461, DOI 10.1002/anie.199004611; SUMMERS MD, 1987, TEXAS AGR EXP STAT B, V155; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WECKSLER WR, 1979, ANAL BIOCHEM, V92, P314, DOI 10.1016/0003-2697(79)90664-X; WEDDEN S, 1990, METHOD ENZYMOL, V190, P201; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	30	1697	1795	7	80	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1992	68	2					397	406		10.1016/0092-8674(92)90479-V	http://dx.doi.org/10.1016/0092-8674(92)90479-V			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1310260				2022-12-01	WOS:A1992HB35300017
J	HU, SL; ABRAMS, K; BARBER, GN; MORAN, P; ZARLING, JM; LANGLOIS, AJ; KULLER, L; MORTON, WR; BENVENISTE, RE				HU, SL; ABRAMS, K; BARBER, GN; MORAN, P; ZARLING, JM; LANGLOIS, AJ; KULLER, L; MORTON, WR; BENVENISTE, RE			PROTECTION OF MACAQUES AGAINST SIV INFECTION BY SUBUNIT VACCINES OF SIV ENVELOPE GLYCOPROTEIN GP160	SCIENCE			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; EXPRESSION; LENTIVIRUS	Simian immunodeficiency virus (SIV) is a primate lentivirus related to human immunodeficiency viruses and is an etiologic agent for acquired immunodeficiency syndrome (AIDS)-like diseases in macaques. To date, only inactivated whole virus vaccines have been shown to protect macaques against SIV infection. Protective immunity was elicited by recombinant subunit vaccines. Four Macaca fascicularis were immunized with recombinant vaccinia virus expressing SIVmne gpl60 and were boosted with gpl60 produced in baculovirus-infected cells. All four animals were protected against an intravenous challenge of the homologous virus at one to nine animal-infectious doses. These results indicate that immunization with viral envelope antigens alone is sufficient to elicit protective immunity against a primate immunodeficiency virus. The combination immunization regimen, similar to one now being evaluated in humans as candidate human immunodeficiency virus (HIV)-1 vaccines, appears to be an effective way to elicit such immune responses.	UNIV WASHINGTON,SEATTLE,WA 98195; DUKE UNIV,MED CTR,DURHAM,NC 27710; NCI,FREDERICK,MD 21701	University of Washington; University of Washington Seattle; Duke University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	HU, SL (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121, USA.		Hu, Shiu-Lok/A-3196-2008	Hu, Shiu-Lok/0000-0003-4336-7964	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028065] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00166] Funding Source: Medline; NIAID NIH HHS [R01 AI28065, AI26503] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBER GN, UNPUB; BENVENISTE RE, 1990, J MED PRIMATOL, V19, P351; BENVENISTE RE, 1986, J VIROL, V60, P483, DOI 10.1128/JVI.60.2.483-490.1986; BENVENISTE RE, 1988, J VIROL, V62, P2091, DOI 10.1128/JVI.62.6.2091-2101.1988; BENVENISTE RE, 1989, J MED PRIMATOL, V18, P287; BENVENISTE RE, UNPUB; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; CARLSON JR, 1990, AIDS RES HUM RETROV, V6, P1239, DOI 10.1089/aid.1990.6.1239; CHIN J, 1990, B WORLD HEALTH ORGAN, V68, P1; COONEY EL, 1991, LANCET, V337, P567, DOI 10.1016/0140-6736(91)91636-9; COONEY EL, 1990, 6TH INT C AIDS SAN F; CRANAGE MP, IN PRESS SCIENCE; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; GARDNER MB, IN PRESS AIDS; GRAHAM BS, 1991, 7TH INT C AIDS FLOR; HENDERSON LE, 1988, SCIENCE, V241, P199, DOI 10.1126/science.3388031; HU SL, 1988, J VIROL, V62, P176, DOI 10.1128/JVI.62.1.176-180.1988; HU SL, 1986, NATURE, V320, P537, DOI 10.1038/320537a0; HU SL, 1987, J VIROL, V61, P3617, DOI 10.1128/JVI.61.11.3617-3620.1987; HU SL, 1991, AIDS RES HUM RETROV, V7, P615, DOI 10.1089/aid.1991.7.615; HU SL, IN PRESS AIDS RES HU; HU SL, IN PRESS J MED PRIMA; KOFF WC, 1990, AIDS S1, V4, P179; KULLER LR, UNPUB; LANGLOIS AJ, 1991, AIDS RES HUM RETROV, V7, P713, DOI 10.1089/aid.1991.7.713; LANGLOIS AJ, 1992, SCIENCE, V255, P292, DOI 10.1126/science.1549775; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; MURPHEYCORB M, 1991, AIDS, V5, P655, DOI 10.1097/00002030-199106000-00003; MURPHEYCORB M, 1990, 3RD ANN M NAT COOP V; SHAFFERMAN A, 1991, P NATL ACAD SCI USA, V88, P7126, DOI 10.1073/pnas.88.16.7126; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0	32	327	350	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					456	459		10.1126/science.1531159	http://dx.doi.org/10.1126/science.1531159			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1531159				2022-12-01	WOS:A1992HA59000038
J	JAHR, CE				JAHR, CE			HIGH PROBABILITY OPENING OF NMDA RECEPTOR CHANNELS BY L-GLUTAMATE	SCIENCE			English	Article							MOUSE CENTRAL NEURONS; ANTICONVULSANT MK-801; SYNAPTIC TRANSMISSION; HIPPOCAMPAL-NEURONS; TIME COURSE; CURRENTS; DESENSITIZATION; POTENTIATION; ANTAGONIST; RESPONSES	Synaptic plasticity can be triggered by calcium flux into neurons through synaptically activated N-methyl-D-aspartate (NMDA) receptor channels. The amplitude and time course of the resulting intracellular calcium transient depend on the number of open NMDA receptor channels and the kinetics of their activation. Short applications of L-glutamate to outside-out patches from hippocampal neurons in the presence and absence of MK-801 revealed that about 30 percent of L-glutamate-bound channels are open at the peak of the current. This high probability of opening suggests that very few channels are required to guarantee a large, localized postsynaptic calcium transient.			JAHR, CE (corresponding author), OREGON HLTH SCI UNIV, VOLLUM INST L474, PORTLAND, OR 97201 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021419] Funding Source: NIH RePORTER; NINDS NIH HHS [NS21419] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P207; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; DALE N, 1985, J PHYSIOL-LONDON, V363, P35, DOI 10.1113/jphysiol.1985.sp015694; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FORSYTHE ID, 1988, J PHYSIOL-LONDON, V396, P515, DOI 10.1113/jphysiol.1988.sp016975; GIBB AJ, 1991, P R SOC LONDON, V243, P34; HALLIWELL RF, 1989, BRIT J PHARMACOL, V96, P480, DOI 10.1111/j.1476-5381.1989.tb11841.x; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HOWE JR, 1991, J PHYSIOL-LONDON, V432, P143, DOI 10.1113/jphysiol.1991.sp018381; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JAHR CE, UNPUB; KELLER BU, 1991, J PHYSIOL-LONDON, V435, P275, DOI 10.1113/jphysiol.1991.sp018510; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; LESTER RAJ, IN PRESS J NEUROSCI; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MACDONALD JF, 1991, J PHYSIOL-LONDON, V432, P483, DOI 10.1113/jphysiol.1991.sp018396; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; RANDALL AD, 1990, NEUROSCI LETT, V114, P191, DOI 10.1016/0304-3940(90)90070-P; ROBINSON HPC, 1991, BIOPHYS J, V59, P295, DOI 10.1016/S0006-3495(91)82223-8; ROSENMUND C, 1991, Society for Neuroscience Abstracts, V17, P957; SATHER W, 1990, NEURON, V4, P725, DOI 10.1016/0896-6273(90)90198-O; VYKLICKY L, 1990, J PHYSIOL-LONDON, V428, P313, DOI 10.1113/jphysiol.1990.sp018214; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104	28	124	124	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 24	1992	255	5043					470	472		10.1126/science.1346477	http://dx.doi.org/10.1126/science.1346477			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1346477				2022-12-01	WOS:A1992HA59000043
J	JESSELL, TM; MELTON, DA				JESSELL, TM; MELTON, DA			DIFFUSIBLE FACTORS IN VERTEBRATE EMBRYONIC INDUCTION	CELL			English	Review							TYPE-2 ASTROCYTE DEVELOPMENT; CILIARY NEUROTROPHIC FACTOR; FIBROBLAST GROWTH-FACTOR; RETINOIC ACID RECEPTOR; CHICK LIMB BUD; TYROSINE KINASE RECEPTOR; EARLY XENOPUS EMBRYOS; PROTO-ONCOGENE INT-1; ACTIVIN-A; W-LOCUS		HARVARD UNIV, DEPT BIOCHEM, CAMBRIDGE, MA 02138 USA	Harvard University	JESSELL, TM (corresponding author), COLUMBIA UNIV, HOWARD HUGHES MED INST, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				ALTABA AR, 1989, NATURE, V341, P33; ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; ALTABA ARI, 1991, DEVELOPMENT, V112, P945; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COOKE J, 1989, CIBA F SYMP, V144, P187; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; EICHELE G, 1987, J CELL BIOL, V105, P1917, DOI 10.1083/jcb.105.4.1917; ELLINGERZIEGELBAUER H, 1991, GENE DEV, V5, P94, DOI 10.1101/gad.5.1.94; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ERNSBERGER U, 1989, NEURON, V2, P1275, DOI 10.1016/0896-6273(89)90312-7; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GILLESPIE LL, 1989, DEVELOPMENT, V106, P203; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GODIN I, 1990, DEVELOPMENT, V108, P357; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1991, TRENDS GENET, V7, P245, DOI 10.1016/0168-9525(91)90323-I; GURDON JB, 1985, P NATL ACAD SCI USA, V82, P139, DOI 10.1073/pnas.82.1.139; GURDON JB, 1987, DEVELOPMENT, V99, P285; HALLONET MER, 1990, DEVELOPMENT, V108, P19; HAMA T, 1989, NEUROSCI LETT, V104, P340, DOI 10.1016/0304-3940(89)90600-9; HART IK, 1989, J CELL BIOL, V109, P3411, DOI 10.1083/jcb.109.6.3411; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUANG SS, 1988, J BIOL CHEM, V263, P12608; HUGHES SM, 1988, NATURE, V335, P70, DOI 10.1038/335070a0; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JACOBSON AG, 1966, SCIENCE, V152, P25, DOI 10.1126/science.152.3718.25; JONES CM, 1991, DEVELOPMENT, V111, P531; JONES EA, 1989, DEVELOPMENT, V107, P785; KAMEGAI M, 1990, NEURON, V4, P429, DOI 10.1016/0896-6273(90)90055-K; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LANDIS SC, 1990, TRENDS NEUROSCI, V13, P344, DOI 10.1016/0166-2236(90)90147-3; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LILLIEN LE, 1988, NEURON, V1, P485, DOI 10.1016/0896-6273(88)90179-1; LILLIEN LE, 1990, NEURON, V5, P111, DOI 10.1016/0896-6273(90)90301-U; LILLIEN LE, 1990, J CELL BIOL, V111, P635, DOI 10.1083/jcb.111.2.635; LONDON C, 1988, DEV BIOL, V129, P380, DOI 10.1016/0012-1606(88)90385-5; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MADEN M, 1988, NATURE, V335, P733, DOI 10.1038/335733a0; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MORRIS HR, 1988, BIOCHEM J, V249, P903, DOI 10.1042/bj2490903; MORRISSKAY GM, 1991, EMBO J, V10, P2985, DOI 10.1002/j.1460-2075.1991.tb07849.x; MURPHY M, 1991, P NATL ACAD SCI USA, V88, P3498, DOI 10.1073/pnas.88.8.3498; NAWA H, 1990, NEURON, V4, P269, DOI 10.1016/0896-6273(90)90101-K; NAWA H, 1991, J NEUROCHEM, V56, P2147, DOI 10.1111/j.1471-4159.1991.tb03479.x; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; Nieuwkoop P D, 1973, Adv Morphog, V10, P1; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; NIEUWKOOP PD, 1989, DEV GROWTH DIFFER, V32, P149; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; NOJI S, 1991, NATURE, V350, P83, DOI 10.1038/350083a0; OLSON DJ, 1991, SCIENCE, V252, P1173, DOI 10.1126/science.252.5009.1173; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PATERNO GD, 1989, DEVELOPMENT, V106, P79; PATTERSON PH, 1990, CELL, V62, P1035, DOI 10.1016/0092-8674(90)90379-S; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; RAO MS, 1990, NEURON, V5, P899, DOI 10.1016/0896-6273(90)90350-O; RATHJEN PD, 1990, CELL, V62, P1105, DOI 10.1016/0092-8674(90)90387-T; REPRESA J, 1991, NATURE, V353, P561, DOI 10.1038/353561a0; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SHARPE CR, 1991, NEURON, V7, P239, DOI 10.1016/0896-6273(91)90262-X; SIVE HL, 1991, GENE DEV, V5, P1321, DOI 10.1101/gad.5.8.1321; SIVE HL, 1990, GENE DEV, V4, P932, DOI 10.1101/gad.4.6.932; SLACK JMW, 1989, DEVELOPMENT, V107, P141; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SLACK JMW, 1991, DEVELOPMENT, V113, P661; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH SM, 1991, DEVELOPMENT, V111, P245; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Spemann H., 1938, EMBRYONIC DEV INDUCT; SUMMERBELL D, 1983, LIMB DEV REGENERAT A, P109; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TICKLE C, 1991, DEVELOPMENT, P113; TRAYNOR D, 1991, J BIOL CHEM, V266, P5291; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANOOYEN A, 1985, EMBO J, V4, P2905, DOI 10.1002/j.1460-2075.1985.tb04021.x; WANEK N, 1991, NATURE, V350, P81, DOI 10.1038/350081a0; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; YAMAMORI T, 1991, P NATL ACAD SCI USA, V88, P7298, DOI 10.1073/pnas.88.16.7298; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	142	302	315	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1992	68	2					257	270		10.1016/0092-8674(92)90469-S	http://dx.doi.org/10.1016/0092-8674(92)90469-S			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1310256				2022-12-01	WOS:A1992HB35300007
J	JESSUS, C; BEACH, D				JESSUS, C; BEACH, D			OSCILLATION OF MPF IS ACCOMPANIED BY PERIODIC ASSOCIATION BETWEEN CDC25 AND CDC2-CYCLIN-B	CELL			English	Article							MATURATION-PROMOTING FACTOR; CELL-DIVISION CYCLE; FISSION YEAST CDC25; HISTONE H-1 KINASE; CONTROL GENE CDC2+; SEA-URCHIN EGGS; PROTEIN-KINASE; MEIOTIC MATURATION; SCHIZOSACCHAROMYCES-POMBE; CYTOPLASMIC FACTOR	Activation of maturation-promoting factor at the onset of mitosis requires the tyrosine dephosphorylation of one of its components, the cdc2 protein kinase. cdc25 is the specific tyrosine phosphatase that activates cdc2. We find that Xenopus oocytes contain a relative of cdc25, p72. In Xenopus embryos the abundance of p72 does not oscillate during the cell cycle. However, p72 directly associates with cdc2-cyclin B in a cell cycle-dependent manner, reaching a peak at M phase. The M phase kinase that associates with p72 is catalytically active. These results suggest that the mechanism by which cdc25 triggers cdc2 activation involves a periodic physical association between cdc25 and the cyclin B-cdc2 complex and also that mitotic control can be affected by mechanisms other than transcriptional regulation of the cdc25 gene.			JESSUS, C (corresponding author), COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724, USA.				NIGMS NIH HHS [GM69620] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069620] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLAKHA RC, 1988, J CELL BIOL, V106, P1445, DOI 10.1083/jcb.106.5.1445; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CYERT MS, 1988, CELL, V53, P185, DOI 10.1016/0092-8674(88)90380-7; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL M, 1988, CELL, V54, P739; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HAGAN I, 1988, J CELL SCI, V91, P587; HASHIMOTO N, 1988, DEV BIOL, V126, P242, DOI 10.1016/0012-1606(88)90135-2; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; JESSUS C, 1987, J CELL SCI, V87, P705; JESSUS C, 1991, DEVELOPMENT, V111, P813; JESSUS C, 1990, FEBS LETT, V266, P4, DOI 10.1016/0014-5793(90)90002-C; KISHIMOTO T, 1982, EXP CELL RES, V137, P121, DOI 10.1016/0014-4827(82)90014-3; KISHIMOTO T, 1976, NATURE, V260, P321, DOI 10.1038/260321a0; KOBAYASHI AH, 1991, J CELL BIOL, V114, P755; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LABBE JC, 1988, DEV BIOL, V127, P157, DOI 10.1016/0012-1606(88)90197-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; SOLOMON M, 1988, CELL, V54, P738, DOI 10.1016/S0092-8674(88)90933-6; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; WASSERMAN WJ, 1975, EXP CELL RES, V91, P381, DOI 10.1016/0014-4827(75)90118-4; WEINTRAUB H, 1982, CR ACAD SCI III-VIE, V295, P787; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	64	101	104	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1992	68	2					323	332		10.1016/0092-8674(92)90473-P	http://dx.doi.org/10.1016/0092-8674(92)90473-P			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1310257				2022-12-01	WOS:A1992HB35300011
J	LEID, M; KASTNER, P; LYONS, R; NAKSHATRI, H; SAUNDERS, M; ZACHAREWSKI, T; CHEN, JY; STAUB, A; GARNIER, JM; MADER, S; CHAMBON, P				LEID, M; KASTNER, P; LYONS, R; NAKSHATRI, H; SAUNDERS, M; ZACHAREWSKI, T; CHEN, JY; STAUB, A; GARNIER, JM; MADER, S; CHAMBON, P			PURIFICATION, CLONING, AND RXR IDENTITY OF THE HELA-CELL FACTOR WITH WHICH RAR OR TR HETERODIMERIZES TO BIND TARGET SEQUENCES EFFICIENTLY	CELL			English	Article							RETINOIC-ACID RECEPTOR; THYROID-HORMONE RECEPTORS; MOUSE ESTROGEN-RECEPTOR; VITAMIN-D RECEPTOR; V-ERB-A; RESPONSE ELEMENT; NUCLEAR RECEPTOR; BETA-GENE; EXPRESSION; PROTEIN	We have purified and cloned a HeLa cell nuclear protein that strongly stimulates binding of retinoic acid and thyroid hormone receptors (RARs and TRs) to resPonse elements. The purified protein is a human retinoid X receptor-beta (hRXR-beta). Three murine members of the RXR family (mRXR-alpha, beta, and gamma) have also been cloned, and their interactions with RARs and TRs have been investigated. Under conditions where RAR, RXR, and TR bound poorly as homodimers to various response elements, strongly cooperative RAR-RXR and TR-RXR binding was observed. The binding efficiency was dependent on the sequence, relative orientation, and spacing of the repeated motifs of response elements. We show also that unstable RAR-RXR heterodimers were formed in solution, and that C-terminal sequences and the DNA-binding domains of both receptors were required for efficient formation of stable heterodimers on response elements. These findings suggest a convergence of the signaling pathways of some members of the nuclear receptor superfamily.	FAC MED STRASBOURG,INST CHIM BIOL,INSERM,U184,F-67085 STRASBOURG,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	LEID, M (corresponding author), FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,F-67085 STRASBOURG,FRANCE.			Nakshatri, Harikrishna/0000-0001-8876-0052				Abate C, 1990, Semin Cancer Biol, V1, P19; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BEEBE JS, 1991, MOL ENDOCRINOL, V5, P85, DOI 10.1210/mend-5-1-85; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BROCKES J, 1990, NATURE, V345, P766, DOI 10.1038/345766a0; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; CHAMBON P, 1991, RETINOIDS : 10 YEARS ON, P10; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DESBOIS C, 1991, ONCOGENE, V6, P2129; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1991, GENE, V105, P9, DOI 10.1016/0378-1119(91)90507-8; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUIOCHONMANTEL A, 1988, NATURE, V336, P695, DOI 10.1038/336695a0; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KASTNER P, 1992, IN PRESS EMBO J; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; LINSTEDT AD, 1986, J STEROID BIOCHEM, V24, P677, DOI 10.1016/0022-4731(86)90842-3; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MENDELSOHN C, 1991, DEVELOPMENT, V113, P723; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MONCOLLIN V, 1986, EMBO J, V5, P2577, DOI 10.1002/j.1460-2075.1986.tb04537.x; MUKHERJEE R, 1990, NUCLEIC ACIDS RES, V18, P5713, DOI 10.1093/nar/18.19.5713; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PERLMAN AJ, 1982, J BIOL CHEM, V257, P930; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; ROWE A, 1991, DEVELOPMENT, V111, P771; RUBERTE E, 1991, DEVELOPMENT, V111, P45; Ruberte E., 1991, SEMIN DEV BIOL, V2, P153; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHWABE JWR, 1991, TRENDS BIOCHEM SCI, V16, P291, DOI 10.1016/0968-0004(91)90121-B; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SEGRAVES WA, 1991, CELL, V67, P225, DOI 10.1016/0092-8674(91)90172-U; SELMI S, 1991, J BIOL CHEM, V266, P11589; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SHERMAN MI, 1986, RETINOIDS CELL DIFFE; SKAFAR DF, 1991, BIOCHEMISTRY-US, V30, P6148, DOI 10.1021/bi00239a010; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; SPANJAARD RA, 1991, P NATL ACAD SCI USA, V88, P8587, DOI 10.1073/pnas.88.19.8587; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHITE R, 1987, MOL ENDOCRINOL, V1, P735, DOI 10.1210/mend-1-10-735; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	98	1206	1252	0	40	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1992	68	2					377	395		10.1016/0092-8674(92)90478-U	http://dx.doi.org/10.1016/0092-8674(92)90478-U			19	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1310259				2022-12-01	WOS:A1992HB35300016
J	LEWIS, MJ; PELHAM, HRB				LEWIS, MJ; PELHAM, HRB			LIGAND-INDUCED REDISTRIBUTION OF A HUMAN KDEL RECEPTOR FROM THE GOLGI-COMPLEX TO THE ENDOPLASMIC-RETICULUM	CELL			English	Article							LUMINAL ER PROTEINS; GIANT HELA-CELLS; BREFELDIN-A; THIAMINE PYROPHOSPHATASE; MEMBRANE-PROTEIN; YEAST; ANTIBODIES; IDENTIFICATION; LOCALIZATION; COMPARTMENT	Resident luminal endoplasmic reticulum (ER) proteins carry a targeting signal (usually KDEL in animal cells) that allows their retrieval from later stages of the secretory pathway. In yeast, the receptor that promotes this selective retrograde transport has been identified as the product of the ERD2 gene. We describe here the properties of a human homolog of this protein (hERD2). Overproduction of hERD2 improves retention of a protein with a weakly recognized variant signal (DDEL). Moreover, overexpression of KDEL or DDEL ligands causes a redistribution of hERD2 from the Golgi apparatus to the ER. Mutation of hERD2 alters the ligand specificity of this effect, implying that it interacts directly with the retained proteins. Ligand control of receptor movement may limit retrograde flow and thus minimize fruitless recycling of secretory proteins.			LEWIS, MJ (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.							BRETSCHER MS, 1983, P NATL ACAD SCI-BIOL, V80, P454, DOI 10.1073/pnas.80.2.454; BRETSCHER MS, 1983, EMBO J, V2, P599, DOI 10.1002/j.1460-2075.1983.tb01469.x; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DAILEY L, 1985, J VIROL, V54, P739, DOI 10.1128/JVI.54.3.739-749.1985; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUJIWARA T, 1989, CELL STRUCT FUNCT, V14, P605, DOI 10.1247/csf.14.605; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MARIUZZA RA, 1983, J MOL BIOL, V170, P1055, DOI 10.1016/S0022-2836(83)80206-X; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; POO MM, 1974, NATURE, V247, P438, DOI 10.1038/247438a0; PUDDINGTON L, 1986, J CELL BIOL, V102, P2147, DOI 10.1083/jcb.102.6.2147; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; ROTHMAN JE, 1981, SCIENCE, V213, P1212, DOI 10.1126/science.7268428; SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021; SARASTE J, 1991, IN PRESS J CELL SCI; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; VAN PN, 1989, J BIOL CHEM, V264, P17494; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0	34	340	345	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1992	68	2					353	364		10.1016/0092-8674(92)90476-S	http://dx.doi.org/10.1016/0092-8674(92)90476-S			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1310258				2022-12-01	WOS:A1992HB35300014
J	MAYEDA, A; KRAINER, AR				MAYEDA, A; KRAINER, AR			REGULATION OF ALTERNATIVE PRE-MESSENGER-RNA SPLICING BY HNRNP-A1 AND SPLICING FACTOR-SF2	CELL			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; TRANSFORMED HUMAN-CELLS; SITE SELECTION; BINDING PROTEINS; CORE PROTEINS; HELA-CELLS; PACKAGING PROTEINS; COMPLEX PROTEIN-A1; GENE-EXPRESSION; INVITRO	When messenger RNA precursors (pre-mRNAs) containing alternative 5' splice sites are spliced in vitro, the relative concentrations of the heterogeneous ribonucleoprotein (hnRNP) A1 and the essential splicing factor SF2 precisely determine which 5' splice site is selected. In general, an excess of hnRNP A1 favors distal 5' splice sites, whereas an excess of SF2 results in utilization of proximal 5' splice sites. The regulation of these antagonistic activities may play an important role in the tissue-specific and developmental control of gene expression by alternative splicing.			MAYEDA, A (corresponding author), COLD SPRING HARBOR LAB, POB 100, 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA.		Mayeda, Akila/ABC-1134-2020	Mayeda, Akila/0000-0002-9562-550X; Krainer, Adrian/0000-0001-9024-9501				ACHESON NH, 1980, DNA TUMOR VIRUSES, P125; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; AST G, 1991, EMBO J, V10, P425, DOI 10.1002/j.1460-2075.1991.tb07964.x; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BEYER AL, 1977, CELL, V11, P127, DOI 10.1016/0092-8674(77)90323-3; BIAMONTI G, 1989, J MOL BIOL, V207, P491, DOI 10.1016/0022-2836(89)90459-2; BORSI L, 1987, J CELL BIOL, V104, P595, DOI 10.1083/jcb.104.3.595; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUVOLI M, 1990, NUCLEIC ACIDS RES, V18, P6595, DOI 10.1093/nar/18.22.6595; BUVOLI M, 1990, EMBO J, V9, P1229, DOI 10.1002/j.1460-2075.1990.tb08230.x; BUVOLI M, 1988, NUCLEIC ACIDS RES, V16, P3751, DOI 10.1093/nar/16.9.3751; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CELIS JE, 1986, FEBS LETT, V194, P101, DOI 10.1016/0014-5793(86)80059-X; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; CHOW LT, 1979, J MOL BIOL, V134, P265, DOI 10.1016/0022-2836(79)90036-6; CHUNG S Y, 1986, Proteins Structure Function and Genetics, V1, P195, DOI 10.1002/prot.340010302; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; CONWAY G, 1988, MOL CELL BIOL, V8, P2884, DOI 10.1128/MCB.8.7.2884; CONWAY GC, 1989, MOL CELL BIOL, V9, P5273, DOI 10.1128/MCB.9.12.5273; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; DEKOCH IG, 1981, MECHANISMS LYMPHOCYT, P222; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cb.02.110186.002331; EPERON LP, 1986, NATURE, V324, P280, DOI 10.1038/324280a0; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GATTONI R, 1991, GENE DEV, V5, P1847, DOI 10.1101/gad.5.10.1847; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; GOODWIN LO, 1991, J BIOL CHEM, V266, P8408; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HARPER JE, 1991, MOL CELL BIOL, V11, P5945, DOI 10.1128/MCB.11.12.5945; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; KARN J, 1977, J BIOL CHEM, V252, P7307; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; Krainer AR, 1988, TRANSCRIPTION SPLICI, P131; KRAMER A, 1991, EMBO J, V10, P1503, DOI 10.1002/j.1460-2075.1991.tb07670.x; KUMAR A, 1986, J BIOL CHEM, V261, P1266; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P10717, DOI 10.1021/bi00500a001; KUMAR A, 1987, J BIOL CHEM, V262, P17126; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAR AL, 1990, J MOL BIOL, V211, P103, DOI 10.1016/0022-2836(90)90014-D; LESTOURGEON WM, 1977, COLD SPRING HARB SYM, V42, P885, DOI 10.1101/SQB.1978.042.01.090; LOHMAN TM, 1986, CRIT REV BIOCHEM MOL, V19, P191, DOI 10.3109/10409238609084656; MANLEY JL, 1986, CANCER CELL, V4, P259; MAYEDA A, 1988, MOL CELL BIOL, V8, P4484, DOI 10.1128/MCB.8.10.4484; MAYEDA A, 1992, IN PRESS P NATL ACAD; MAYRAND SH, 1990, NUCLEIC ACIDS RES, V18, P3307, DOI 10.1093/nar/18.11.3307; MERRILL BM, 1990, EUKARYOTIC NUCLEUS M, V2, P579; MUNROE SH, 1992, IN PRESS P NATL ACAD; NADLER SG, 1991, BIOCHEMISTRY-US, V30, P2968, DOI 10.1021/bi00225a034; NELSON KK, 1988, GENE DEV, V2, P319, DOI 10.1101/gad.2.3.319; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PERKINS KK, 1986, P NATL ACAD SCI USA, V83, P887, DOI 10.1073/pnas.83.4.887; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; PLANCK SR, 1988, NUCLEIC ACIDS RES, V16, P11663, DOI 10.1093/nar/16.24.11663; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; RUBY SW, 1991, TRENDS GENET, V7, P79; SCHMITT P, 1987, CELL, V50, P31, DOI 10.1016/0092-8674(87)90659-3; SIERAKOWSKA H, 1986, NUCLEIC ACIDS RES, V14, P5241, DOI 10.1093/nar/14.13.5241; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SPECTOR DJ, 1978, J MOL BIOL, V126, P395, DOI 10.1016/0022-2836(78)90048-7; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SVENSSON C, 1983, J MOL BIOL, V165, P475, DOI 10.1016/S0022-2836(83)80214-9; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; WILK HE, 1985, EUR J BIOCHEM, V146, P71, DOI 10.1111/j.1432-1033.1985.tb08621.x; WILLIAMS KR, 1985, P NATL ACAD SCI USA, V82, P5666, DOI 10.1073/pnas.82.17.5666; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZARDI L, 1987, EMBO J, V6, P2337, DOI 10.1002/j.1460-2075.1987.tb02509.x	84	661	664	1	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1992	68	2					365	375		10.1016/0092-8674(92)90477-T	http://dx.doi.org/10.1016/0092-8674(92)90477-T			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1531115				2022-12-01	WOS:A1992HB35300015
J	SCHELLING, TC				SCHELLING, TC			ADDICTIVE DRUGS - THE CIGARETTE EXPERIENCE	SCIENCE			English	Article								Cigarettes are among the most addictive substances of abuse and by far the most deadly. In this country smokers know it and try to stop. Their success has been dramatic but partial and excruciatingly slow, and until recently quite uncoerced by government. Cigarettes and nicotine have characteristics distinct among addictive drugs, and some of these help explain why efforts to quit smoking are so often frustrated. Nicotine itself is the most interesting chemical in the treatment of addiction and, in some forms, can pose a dilemma: compromise by settling for pure nicotine indefinitely, or stay with cigarettes and keep trying to quit. Nicotine is not alone among addictive drugs in becoming increasingly identified with the poorer classes.	UNIV MARYLAND,SCH PUBL AFFAIRS,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park	SCHELLING, TC (corresponding author), UNIV MARYLAND,DEPT ECON,COLLEGE PK,MD 20742, USA.							JOHNSTON LD, 1984, DRUGS AM HIGH SCH ST, P12; 1983, HLTH CONSEQUENCES SM; 1982, HLTH CONSEQUENCES SM; 1985, NEWS            1205; 1989, REDUCING HLTH CONSEQ, P465; 1982, HLTH CONSEQUENCES SM, P372; 1985, HLTH CONSEQUENCES SM, P25; 1984, HLTH CONSEQUENCES SM	8	45	48	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					430	433		10.1126/science.1734519	http://dx.doi.org/10.1126/science.1734519			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1734519				2022-12-01	WOS:A1992HA59000030
J	TSE, A; HILLE, B				TSE, A; HILLE, B			GNRH-INDUCED CA2+ OSCILLATIONS AND RHYTHMIC HYPERPOLARIZATIONS OF PITUITARY GONADOTROPES	SCIENCE			English	Article							MEMBRANE CURRENTS; CA-2+ TRANSIENTS; K+ CHANNELS; LH-RELEASE; HORMONE; RAT; CELLS	Secretion of gonadotropic hormones from pituitary gonadotropes in response to gonadotropin-releasing hormone (GnRH) is essential for regulation of reproductive potential. Gonadotropes from male rats exhibited an unusual form of cellular excitation that resulted from periodic membrane hyperpolarization. GnRH induced an oscillatory release of intracellular Ca2+ via a guanosine triphosphate (GTP) binding protein-coupled phosphoinositide pathway and hyperpolarized the gonadotrope periodically by opening apamin-sensitive Ca2+-activated K+ (SK) channels. Each hyperpolarization was terminated by firing of a few action potentials that may result from removal of inactivation from voltage-gated Na+ and Ca2+ channels.	UNIV WASHINGTON,SCH MED,DEPT PHYSIOL & BIOPHYS,SJ-40,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Tse, Amy/C-3142-2013	Tse, Amy/0000-0002-0847-7466				BLATZ AL, 1986, NATURE, V323, P718, DOI 10.1038/323718a0; BOSMA MM, UNPUB; CHANG JP, 1986, J BIOL CHEM, V261, P9105; CHEN C, 1989, NEUROCHEM INT, V15, P265, DOI 10.1016/0197-0186(89)90132-0; CROXTON TL, 1988, ENDOCRINOLOGY, V123, P1783, DOI 10.1210/endo-123-4-1783; CROXTON TL, 1989, METHOD ENZYMOL, V168, P145; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORN F, 1991, MOL ENDOCRINOL, V5, P347, DOI 10.1210/mend-5-3-347; IIDA T, 1991, MOL ENDOCRINOL, V5, P949, DOI 10.1210/mend-5-7-949; LEONG DA, 1991, CELL CALCIUM, V12, P255, DOI 10.1016/0143-4160(91)90025-A; MARCHETTI C, 1987, AM J PHYSIOL, V252, pE340, DOI 10.1152/ajpendo.1987.252.3.E340; MASON WT, 1985, NEUROENDOCRINOLOGY, V41, P258, DOI 10.1159/000124186; NAOR Z, 1990, ENDOCR REV, V11, P326, DOI 10.1210/edrv-11-2-326; NUSSINOVITCH I, 1988, J PHYSIOL-LONDON, V395, P303, DOI 10.1113/jphysiol.1988.sp016920; PALADE P, 1989, MOL PHARMACOL, V36, P673; PFAFFINGER P, 1988, J NEUROSCI, V8, P3343; PFAFFINGER PJ, 1988, NEURON, V1, P477, DOI 10.1016/0896-6273(88)90178-X; POLOKOFF MA, 1988, J BIOL CHEM, V263, P11922; POULSEN JH, 1976, NATURE, V263, P156, DOI 10.1038/263156a0; RIVIER JE, 1978, LIFE SCI, V23, P869, DOI 10.1016/0024-3205(78)90522-2; SHANGOLD GA, 1988, P NATL ACAD SCI USA, V85, P6566, DOI 10.1073/pnas.85.17.6566; SIKDAR SK, 1989, BRAIN RES, V496, P113, DOI 10.1016/0006-8993(89)91057-3; SMITH CE, 1987, FEBS LETT, V225, P247, DOI 10.1016/0014-5793(87)81167-5; SMITH PF, 1984, ENDOCRINOLOGY, V115, P2484, DOI 10.1210/endo-115-6-2484; STOJILKOVIC SS, 1990, P NATL ACAD SCI USA, V87, P8855, DOI 10.1073/pnas.87.22.8855; THOMAS P, 1990, NEURON, V5, P723, DOI 10.1016/0896-6273(90)90226-6; TSE A, UNPUB	28	163	164	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					462	464		10.1126/science.1734523	http://dx.doi.org/10.1126/science.1734523			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1734523				2022-12-01	WOS:A1992HA59000040
J	WALSH, C; CEPKO, CL				WALSH, C; CEPKO, CL			WIDESPREAD DISPERSION OF NEURONAL CLONES ACROSS FUNCTIONAL REGIONS OF THE CEREBRAL-CORTEX	SCIENCE			English	Article							MEDIATED GENE-TRANSFER; CELL LINEAGE; SOMATOSENSORY CORTEX; MIGRATION PATTERNS; CORTICAL BARRELS; NERVOUS-SYSTEM; RAT; RETROVIRUS; HINDBRAIN; NEOCORTEX	The cerebral cortex of the mammalian brain has expanded rapidly during the course of evolution and acquired structurally distinguishable areas devoted to separate functions. In some brain regions, topographic restrictions to cell intermixing occur during embryonic development. As a means of examining experimentally whether such restrictions occur during formation of functional subdivisions in the rat neocortex, clonally related neocortical cells were marked by retroviral-mediated transfer of a histochemical marker gene. Clonal boundaries were determined by infection of the developing brain with a library of genetically distinct viruses and amplification of single viral genomes by the polymerase chain reaction. Many clonally related neurons in the cerebral cortex became widely dispersed across functional areas of the cortex. Specification of cortical areas therefore occurs after neurogenesis.	HARVARD UNIV,SCH MED,DEPT GENET,25 SHATTUCK ST,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital				Walsh, Christopher/0000-0002-0156-2238	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023021] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 23021] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1990, EXP NEUROL, V107, P36, DOI 10.1016/0014-4886(90)90061-V; ALTMAN J, 1991, NEOCORTICAL DEV; AUSTIN CP, 1990, DEVELOPMENT, V110, P713; BARBE MF, 1991, J NEUROSCI, V11, P519; BAYER SA, 1991, J COMP NEUROL, V307, P487, DOI 10.1002/cne.903070311; BERRY M, 1965, J ANAT, V99, P691; CEPKO CL, 1990, COLD SH Q B, V55, P265; CEPKO CL, 1989, NEUROMETHODS MOL NEU, V16; COOPER M W, 1989, Society for Neuroscience Abstracts, V15, P808; CRANDELL JE, 1991, EXP NEUROL, V239, P185; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DAWSON DR, 1987, J COMP NEUROL, V256, P246, DOI 10.1002/cne.902560205; FIELDSBERRY S, IN PRESS P NATL ACAD; FISHELL G, 1990, DEV BIOL, V141, P70, DOI 10.1016/0012-1606(90)90102-O; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FROST DO, 1985, NATURE, V317, P162, DOI 10.1038/317162a0; GASSER UE, 1990, P NATL ACAD SCI USA, V87, P4543, DOI 10.1073/pnas.87.12.4543; GOLDOWITZ D, 1987, DEV BRAIN RES, V35, P1, DOI 10.1016/0165-3806(87)90002-2; GROVE E A, 1991, Society for Neuroscience Abstracts, V17, P11; HOGG RV, 1978, INTRO MATH STATISTIC, P96; HUNT P, 1991, CELL, V66, P1075, DOI 10.1016/0092-8674(91)90029-X; Kawasaki E.S., 1990, PCR PROTOCOLS GUIDE, P146; KRUSHEL L A, 1989, Society for Neuroscience Abstracts, V15, P598; LI HH, 1988, NATURE, V335, P414, DOI 10.1038/335414a0; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; Maniatis T., 1982, MOL CLONING; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MCCONNELL SK, 1988, BRAIN RES REV, V13, P1, DOI 10.1016/0165-0173(88)90002-1; Misson JP, 1991, CEREB CORTEX, V1, P221, DOI 10.1093/cercor/1.3.221; MISSON JP, 1988, DEV BRAIN RES, V44, P95, DOI 10.1016/0165-3806(88)90121-6; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OLEARY DDM, 1989, J NEUROSCI, V9, P2230; OLEARY DDM, 1989, TRENDS NEUROSCI, V12, P400, DOI 10.1016/0166-2236(89)90080-5; PARNAVELAS J G, 1990, Society for Neuroscience Abstracts, V16, P1272; PRICE J, 1988, DEVELOPMENT, V104, P473; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAKIC P, 1978, POSTGRAD MED J, V54, P25; RAKIC P, 1974, NATURE, V250, P31, DOI 10.1038/250031a0; RYDER E F, 1988, Society for Neuroscience Abstracts, V14, P892; SCHLAGGAR BL, 1991, SCIENCE, V252, P1556, DOI 10.1126/science.2047863; SUR M, 1988, SCIENCE, V242, P1437, DOI 10.1126/science.2462279; VANDERLO.H, 1973, SCIENCE, V179, P395, DOI 10.1126/science.179.4071.395; WALSH C, 1988, SCIENCE, V241, P1342, DOI 10.1126/science.3137660; WALSH C, UNPUB; WALSH C, 1991, EXPERIENTIA, V46, P940; WELKER C, 1976, J COMP NEUROL, V166, P173, DOI 10.1002/cne.901660205; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WONGRILEY MTT, 1980, P NATL ACAD SCI-BIOL, V77, P2333, DOI 10.1073/pnas.77.4.2333; WOOLSEY TA, 1976, J COMP NEUROL, V170, P53, DOI 10.1002/cne.901700105; 1972, ANAT REC, V166, P257	53	444	452	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					434	440		10.1126/science.1734520	http://dx.doi.org/10.1126/science.1734520			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1734520				2022-12-01	WOS:A1992HA59000031
J	WANG, WD; CAREY, M; GRALLA, JD				WANG, WD; CAREY, M; GRALLA, JD			POLYMERASE-II PROMOTER ACTIVATION - CLOSED COMPLEX-FORMATION AND ATP-DRIVEN START SITE OPENING	SCIENCE			English	Article							RNA-POLYMERASE; TRANSCRIPTION INITIATION; MECHANISM INVIVO; GAL4 DERIVATIVES; DNA; REQUIREMENT; INVITRO; GENE	Studies on bacterial RNA polymerases have divided the initiation pathway into three steps, namely (i) promoter binding to form the closed complex; (ii) DNA melting to form an open complex, and (iii) messenger RNA initiation. Potassium permanganate was used to detect DNA melting by mammalian RNA polymerase II in vitro. Closed complexes formed in a rate-limiting step that was stimulated by the activator GAL4-VP16. Adenosine triphosphate was then hydrolyzed to rapidly melt the DNA within the closed complex to form an open complex. Addition of nucleoside triphosphates resulted in the melted bubble moving away from the start site, completing initiation.	UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, 405 HILGARD AVE, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Wang, Weidong/AAV-2446-2021	Wang, Weidong/0000-0002-0658-7928; Carey, Michael/0000-0003-3899-6280	NIGMS NIH HHS [GM46424, GM35754] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046424, R01GM035754] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER CC, 1981, J MOL BIOL, V149, P189, DOI 10.1016/0022-2836(81)90298-9; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; Carey M, 1991, CURR OPIN CELL BIOL, V3, P452, DOI 10.1016/0955-0674(91)90073-8; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; FIRE A, 1984, J BIOL CHEM, V259, P2509; GRALLA JD, 1991, CELL, V66, P415, DOI 10.1016/0092-8674(81)90001-5; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HAWLEY DK, 1985, J BIOL CHEM, V260, P8618; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; LI Z, 1989, GENE DEV, V3, P1814, DOI 10.1101/gad.3.11.1814; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SHARP PA, 1991, NATURE, V351, P16, DOI 10.1038/351016d0; SIGMAN DS, 1990, BIOCHEMISTRY-US, V29, P9097, DOI 10.1021/bi00491a001; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; VOS JC, 1991, CELL, V65, P105, DOI 10.1016/0092-8674(91)90412-R; WALTER G, 1967, EUR J BIOCHEM, V3, P194, DOI 10.1111/j.1432-1033.1967.tb19515.x; Wang W., UNPUB; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S	34	197	198	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 24	1992	255	5043					450	453		10.1126/science.1310361	http://dx.doi.org/10.1126/science.1310361			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1310361				2022-12-01	WOS:A1992HA59000036
J	WARBURG, A; MILLER, LH				WARBURG, A; MILLER, LH			SPOROGONIC DEVELOPMENT OF A MALARIA PARASITE INVITRO	SCIENCE			English	Article							EXTRACELLULAR-MATRIX; PLASMODIUM; MOSQUITO; CULTURE	The sporogonic cycle of the avian malaria parasite Plasmodium gallinaceum was completed in vitro. Ookinetes (motile zygotes) were seeded onto a murine basement membrane-like gel (Matrigel) in coculture with Drosophila melanogaster cells (Schneider's L2). Transformation into oocysts as well as subsequent growth and differentiation were observed in parasites attached to Matrigel and depended on the presence of L2 cells. Sporozoites were first observed on day 10 in culture. Specific circumsporozoite protein antigenicity was identified in mature oocysts and in sporozoites. It is now possible to follow the entire life cycle of Plasmodium in vitro.			WARBURG, A (corresponding author), NIAID,PARASIT DIS LAB,MALARIA SECT,BLDG 4,ROOM 126,BETHESDA,MD 20892, USA.		Warburg, Alon/ABE-9946-2020	Warburg, Alon/0000-0001-7929-3114				CHAO J, 1964, AM J TROP MED HYG, V13, P181, DOI 10.4269/ajtmh.1964.13.181; FESSLER JH, 1989, ANNU REV CELL BIOL, V5, P309, DOI 10.1146/annurev.cb.05.110189.001521; HOLLINGDALE MR, 1987, IN VITRO METHODS PAR, P180; KAUSHAL DC, 1983, MOL BIOCHEM PARASIT, V8, P53, DOI 10.1016/0166-6851(83)90034-8; KLEINMAN HK, 1987, ANAL BIOCHEM, V166, P1, DOI 10.1016/0003-2697(87)90538-0; KLEINMAN HK, IN PRESS CELLULAR AS; KRETTLI AU, 1988, PARASITE IMMUNOL, V10, P523, DOI 10.1111/j.1365-3024.1988.tb00240.x; LUNSTRUM GP, 1988, J BIOL CHEM, V263, P18318; MELHORN H, 1980, PROTISTOLOGICA, V16, P135; MONS B, 1990, PARASITOL TODAY, V6, P3, DOI 10.1016/0169-4758(90)90377-G; PONNUDURAI T, 1987, IN VITRO METHODS PAR, P153; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHNEIDER I, 1980, MALARIA, V2, P235; SINDEN RE, 1984, EXPERIENTIA, V40, P1330, DOI 10.1007/BF01951886; SINDEN RE, 1985, PARASITOLOGY, V91, P227, DOI 10.1017/S0031182000057334; TERZAKIS JA, 1967, J CELL BIOL, V34, P311, DOI 10.1083/jcb.34.1.311; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VANDERBERG JP, 1977, B WORLD HEALTH ORGAN, V55, P377; WARBURG A, 1991, PARASITOL TODAY, V7, P179, DOI 10.1016/0169-4758(91)90127-A; WARBURG A, UNPUB; 1963, AM TYPE CULTURE COLL	21	59	64	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					448	450		10.1126/science.1734521	http://dx.doi.org/10.1126/science.1734521			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1734521				2022-12-01	WOS:A1992HA59000035
J	AMARENCO, P; DUYCKAERTS, C; TZOURIO, C; HENIN, D; BOUSSER, MG; HAUW, JJ				AMARENCO, P; DUYCKAERTS, C; TZOURIO, C; HENIN, D; BOUSSER, MG; HAUW, JJ			THE PREVALENCE OF ULCERATED PLAQUES IN THE AORTIC-ARCH IN PATIENTS WITH STROKE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSIENT ISCHEMIC ATTACKS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; CHOLESTEROL EMBOLIZATION; INFARCTION; COMPLICATION; EMBOLISM; BYPASS	Background and Methods. The cause of cerebral infarction is obscure in up to 40 percent of patients with this disorder who are studied prospectively. In this investigation, we determined the frequency of ulcerated plaques in the aortic arch and explored the part they may play in the formation of cerebral emboli. Using an autopsy data bank, we studied the prevalence of ulcerated plaques in the aortic arch in 500 consecutive patients with cerebrovascular and other neurologic diseases who were studied at autopsy. Results. Ulcerated plaques were present in 26 percent of the 239 patients with cerebrovascular disease but in only 5 percent of the 261 patients with other neurologic diseases (P < 0.001). After we controlled for age and heart weight, the adjusted rates were 16.9 percent and 5.1 percent, respectively (adjusted odds ratio, 4.0; 95 percent confidence interval, 2.1 to 7.8; P < 0.001). Among the patients with cerebrovascular disease, the prevalence of ulcerated plaques in the aortic arch was 28 percent in the 183 patients with cerebral infarcts and 20 percent in the 56 patients with brain hemorrhage. The prevalence of ulcerated plaques was 61 percent among the 28 patients with no known cause of cerebral infarction, as compared with 22 percent among the 155 patients with a known cause of cerebral infarction (P < 0.001). After adjustment for covariates, the prevalence was 57.8 percent among patients with no known cause of cerebral infarction and 20.2 percent among those with a known cause (adjusted odds ratio, 5.7; 95 percent confidence interval, 2.4 to 13.6; P < 0.001). The presence of ulcerated plaques in the aortic arch was not correlated with the presence of extracranial internal-carotid-artery stenosis, suggesting that these were two independent risk factors for stroke. Conclusions. Ulcerated plaques in the aortic arch may play a part in causing cerebral infarction, especially in patients in whom cerebral infarction has no known cause.	HOP LA PITIE SALPETRIERE, NEUROPATHOL R ESCOUROLLE LAB, F-75651 PARIS 13, FRANCE; UNIV PARIS 06, F-75230 PARIS 05, FRANCE; INSERM, U169, F-94800 VILLEJUIF, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)	AMARENCO, P (corresponding author), HOP ST ANTOINE, SERV NEUROL, 184 RUE FAUBOURG ST ANTOINE, F-75571 PARIS 12, FRANCE.		Tzourio, christophe/B-4015-2009; Tzourio, christophe/L-6344-2019; Tzourio, Christophe I/B-7459-2008	Tzourio, christophe/0000-0002-6517-2984; Tzourio, christophe/0000-0002-6517-2984; 				BEAL MF, 1981, NEUROLOGY, V31, P860, DOI 10.1212/WNL.31.7.860; BRUNS FJ, 1978, AM J MED SCI, V275, P105, DOI 10.1097/00000441-197801000-00013; CAPLAN LR, 1978, NEUROLOGY, V28, P1206, DOI 10.1212/WNL.28.12.1206; CASTLEMA B, 1967, NEW ENGL J MED, V276, P1368, DOI 10.1056/NEJM196706152762410; CHESEBRO JH, 1990, NEW ENGL J MED, V323, P1557, DOI 10.1056/NEJM199011293232209; COGAN DG, 1964, ARCH OPHTHALMOL-CHIC, V71, P308; DAVID NJ, 1963, NEUROLOGY, V13, P708, DOI 10.1212/WNL.13.8.708; ESCOUROLLE R, 1976, J NEUROL SCI, V28, P103, DOI 10.1016/0022-510X(76)90051-4; ESCOUROLLE R, 1966, REV PRATICIEN, V16, P749; FEDER W, 1961, ANN INTERN MED, V55, P911, DOI 10.7326/0003-4819-55-6-911; FISHER CM, 1965, J NEUROPATH EXP NEUR, V24, P455, DOI 10.1097/00005072-196507000-00007; GARDNER TJ, 1985, ANN THORAC SURG, V40, P574, DOI 10.1016/S0003-4975(10)60352-9; GORE I, 1960, AM J CLIN PATHOL, V33, P416; HOLLENHORST RW, 1966, AM J OPHTHALMOL, V61, P1159, DOI 10.1016/0002-9394(66)90238-8; KARALIS DG, 1991, J AM COLL CARDIOL, V17, P73, DOI 10.1016/0735-1097(91)90706-F; LHERMITTE F, 1966, REV NEUROL-FRANCE, V115, P641; LODDER J, 1990, STROKE, V21, P375, DOI 10.1161/01.STR.21.3.375; MCKIBBIN DW, 1976, J THORAC CARDIOV SUR, V71, P741; MILLIKAN C, 1990, STROKE, V21, P1251, DOI 10.1161/01.STR.21.9.1251; MOLDVEEN.M, 1967, CIRCULATION, V35, P946, DOI 10.1161/01.CIR.35.5.946; OSTER P, 1979, JAMA-J AM MED ASSOC, V242, P2070, DOI 10.1001/jama.242.19.2070; PFAFFENBACH DD, 1973, AM J OPHTHALMOL, V75, P66, DOI 10.1016/0002-9394(73)90653-3; POP G, 1990, STROKE, V21, P560, DOI 10.1161/01.STR.21.4.560; PRICE DL, 1970, NEUROLOGY, V20, P1209, DOI 10.1212/WNL.20.12.1209; RAMIREZ G, 1978, ARCH INTERN MED, V138, P1430, DOI 10.1001/archinte.138.9.1430; RUSSELL RWR, 1983, VASCULAR DISEASE CEN, P368; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; SOLOWAY HB, 1964, ARCH NEUROL-CHICAGO, V11, P657, DOI 10.1001/archneur.1964.00460240089012; STURGILL BC, 1963, ARCH PATHOL, V76, P189; TUNICK PA, 1990, AM HEART J, V120, P658, DOI 10.1016/0002-8703(90)90024-R; WINTER WJ, 1957, ARCH PATHOL, V64, P137; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; 1972, NEW ENGL J MED, V286, P1146; 1990, SAS USERS GUIDE STAT, V1	34	449	460	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1992	326	4					221	225		10.1056/NEJM199201233260402	http://dx.doi.org/10.1056/NEJM199201233260402			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA431	1727976				2022-12-01	WOS:A1992HA43100002
J	AMON, A; SURANA, U; MUROFF, I; NASMYTH, K				AMON, A; SURANA, U; MUROFF, I; NASMYTH, K			REGULATION OF P34CDC28 TYROSINE PHOSPHORYLATION IS NOT REQUIRED FOR ENTRY INTO MITOSIS IN SACCHAROMYCES-CEREVISIAE	NATURE			English	Article							CDC2 PROTEIN-KINASE; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; ACTIVATION; DEPHOSPHORYLATION	PROGRESSION from G2 to M phase in eukaryotes requires activation of a protein kinase composed of p34cdc2/CDC28 associated with G1-specific cyclins (reviewed in ref. 1). In some organisms the activation of the kinase at the G2/M boundary is due to dephosphorylation of a highly conserved tyrosine residue at position 15 (Y15) of the cdc2 protein 2-6. Here we report that in the budding yeast Saccharomyces cervisiae, p34CDC28 also undergoes cell-cycle regulated dephosphorylation on an equivalent tyrosine residue (Y19). However, in contrast to previous observations in S. pombe 6, Xenopus 2,3 and mammalian cells 4,5, dephosphorylation of Y19 is not required for the activation of the CDC28/cyclin kinase. Furthermore, mutation of this tyrosine residue does not affect dependence of mitosis on DNA synthesis nor does it abolish G2 arrest induced by DNA damage. Our data imply that regulated phosphorylation of this tyrosine residue is not the 'universal' means by which the onset of mitosis is determined. We propose that there are other unidentified controls that regulate entry into mitosis.	INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Surana, Uttam/H-1142-2011	Amon, Angelika/0000-0001-9837-0314; Nasmyth, Kim/0000-0001-7030-4403; Muroff, Ivor/0000-0003-3721-5278; Surana, Uttam/0000-0002-4785-6514				COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; GAULTIER J, 1991, CELL, V67, P197; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARTWELL LH, 1973, J BACTERIOL, V115, P966, DOI 10.1128/JB.115.3.966-974.1973; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PINES J, 1990, New Biologist, V2, P389; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; Rubin G M, 1975, Methods Cell Biol, V12, P45; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120	23	257	261	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1992	355	6358					368	371		10.1038/355368a0	http://dx.doi.org/10.1038/355368a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1731251				2022-12-01	WOS:A1992HA59100074
J	DALEY, CL; SMALL, PM; SCHECTER, GF; SCHOOLNIK, GK; MCADAM, RA; JACOBS, WR; HOPEWELL, PC				DALEY, CL; SMALL, PM; SCHECTER, GF; SCHOOLNIK, GK; MCADAM, RA; JACOBS, WR; HOPEWELL, PC			AN OUTBREAK OF TUBERCULOSIS WITH ACCELERATED PROGRESSION AMONG PERSONS INFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS - AN ANALYSIS USING RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISMS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; EPIDEMIOLOGY	Background. Tuberculosis typically develops from a reactivation of latent infection. Clinical tuberculosis may also arise from a primary infection, and this is thought to be more likely in persons infected with the human immunodeficiency virus (HIV). However, the relative importance of these two pathogenetic mechanisms in this population is unclear. Methods. Between December 1990 and April 1991, tuberculosis was diagnosed in 12 residents of a housing facility for HIV-infected persons. In the preceding six months, two patients being treated for tuberculosis had been admitted to the facility. We investigated this outbreak using standard procedures plus analysis of the cultured organisms with restriction-fragment-length polymorphisms (RFLPs). Results. Organisms isolated from all 11 of the culture-positive residents had similar RFLP patterns, whereas the isolates from the 2 patients treated for tuberculosis in the previous six months were different strains. This implicated the first of the 12 patients with tuberculosis as the source of this outbreak. Among the 30 residents exposed to possible infection, active tuberculosis developed in 11 (37 percent), and 4 others (13 percent) had newly positive tuberculin skin tests. Of 28 staff members with possible exposure, at least 6 had positive tuberculin-test reactions, but none had tuberculosis. Conclusions. Newly acquired tuberculous infection in HIV-infected patients can spread readily and progress rapidly to active disease. There should be heightened surveillance for tuberculosis in facilities where HIV-infected persons live, and investigation of contacts must be undertaken promptly and be focused more broadly than is usual.	SAN FRANCISCO GEN HOSP,MED CTR,MED SERV,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT MED,DIV GEOG MED,STANFORD,CA 94305; YESHIVA UNIV ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; DEPT PUBL HLTH CITY & CTY SAN FRANCISCO,SAN FRANCISCO,CA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Stanford University; Stanford University; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; San Francisco Department of Public Health			Daley, Charles L./AAC-3231-2021	Jacobs, William/0000-0003-3321-3080	NHLBI NIH HHS [HL 07185] Funding Source: Medline; NIAID NIH HHS [AIZ6170] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; Bloch A B, 1989, Semin Respir Infect, V4, P157; DIPERRI G, 1989, LANCET, V2, P1502; FEREBEE SH, 1970, ADV TUBERC RES, V17, P28; HARRIES AD, 1990, LANCET, V335, P387, DOI 10.1016/0140-6736(90)90216-R; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; MCADAM RA, 1990, MOL MICROBIOL, V4, P1607, DOI 10.1111/j.1365-2958.1990.tb02073.x; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; THEIRRY D, 1990, NUCLEIC ACIDS RES, V18, P188; TOMPKINS LS, 1987, J CLIN MICROBIOL, V25, P1875, DOI 10.1128/JCM.25.10.1875-1880.1987; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991	11	875	884	3	23	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1992	326	4					231	235		10.1056/NEJM199201233260404	http://dx.doi.org/10.1056/NEJM199201233260404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA431	1345800	Bronze			2022-12-01	WOS:A1992HA43100004
J	DAVIDENKO, JM; PERTSOV, AV; SALOMONSZ, R; BAXTER, W; JALIFE, J				DAVIDENKO, JM; PERTSOV, AV; SALOMONSZ, R; BAXTER, W; JALIFE, J			STATIONARY AND DRIFTING SPIRAL WAVES OF EXCITATION IN ISOLATED CARDIAC-MUSCLE	NATURE			English	Article							EXCITABLE MEDIA; CELLULAR AUTOMATON; TACHYCARDIA; MYOCARDIUM; MECHANISM; VORTEX	EXCITABLE media can support spiral waves rotating around an organizing centre 1-7. Spiral waves have been discovered in different types of autocatalytic chemical reactions 8,9 and in biological systems 10-12. The so-called 're-entrant excitation' of myocardial cells 13, causing the most dangerous cardiac arrhythmias, including ventricular tachycardia and fibrillation, could be the result of spiral waves 1,2. Here we use a potentiometric dye 14,15 in combination with CCD (charge-coupled device) imaging technology 16,17 to demonstrate spiral waves in the heart muscle. The spirals were elongated and the rotation period, T(s), was about 180 ms (3-5 times faster than normal heart rate). In most episodes, the spiral was anchored to small arteries or bands of connective tissue, and gave rise to stationary rotations. In some cases, the core drifted away from its site of origin and dissipated at a tissue border. Drift was associated with a Doppler shift in the local excitation period, T, with T ahead of the core being about 20% shorter than T behind the core.			DAVIDENKO, JM (corresponding author), SUNY HLTH SCI CTR,DEPT PHARMACOL,750 E ADAMS ST,SYRACUSE,NY 13210, USA.		Jalife, Jose/AAJ-9156-2021; Jalife, Jose/L-4833-2015	Jalife, Jose/0000-0003-0080-3500; Jalife, Jose/0000-0003-0080-3500				ALLESSIE MA, 1973, CIRC RES, V33, P54, DOI 10.1161/01.RES.33.1.54; BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BURES J, 1983, J NEUROBIOL, V14, P353; CARDINAL R, 1984, CIRCULATION, V70, P136, DOI 10.1161/01.CIR.70.1.136; DAVIDENKO JM, 1990, P NATL ACAD SCI USA, V87, P8785, DOI 10.1073/pnas.87.22.8785; DELGADO C, 1990, CIRC RES, V67, P97, DOI 10.1161/01.RES.67.1.97; DOWNAR E, 1984, J AM COLL CARD, V7, P403; ERMAKOVA EA, 1986, BIOFIZIKA+, V31, P855; FAST VG, 1990, BIOFIZIKA+, V35, P478; FRAZIER DW, 1989, J CLIN INVEST, V83, P1039, DOI 10.1172/JCI113945; GERHARDT M, 1990, SCIENCE, V247, P1563, DOI 10.1126/science.2321017; Gerisch G, 1968, Curr Top Dev Biol, V3, P157; KAUER JS, 1988, NATURE, V331, P166, DOI 10.1038/331166a0; KEENER JP, 1986, SIAM J APPL MATH, V46, P1039, DOI 10.1137/0146062; KRINSKII VI, 1968, PROBL KIBERN, V20, P59; Krinsky V.I., 1984, SPRINGER SERIES SYNE, VVolume 28, P9; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LI T, 1985, J PHARMACOL EXP THER, V232, P688; MARKUS M, 1990, NATURE, V347, P56, DOI 10.1038/347056a0; MULLER SC, 1985, SCIENCE, V230, P661, DOI 10.1126/science.230.4726.661; SALZBERG BM, 1973, NATURE, V246, P508, DOI 10.1038/246508a0; WIENER N, 1946, Arch Inst Cardiol Mex, V16, P205; WINFREE AT, 1972, SCIENCE, V175, P634, DOI 10.1126/science.175.4022.634; WINREE AT, 1989, J THEOR BIOL, V1388, P353; YAMAGUCHI T, 1991, PHYSICA D, V49, P40, DOI 10.1016/0167-2789(91)90191-B; ZHABOTINSKY A. M, 1971, OSCILLATORY PROCESSE, VII, P279; ZYKOV VS, 1987, SIMULATION WAVE PROC, P93	27	986	1014	2	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1992	355	6358					349	351		10.1038/355349a0	http://dx.doi.org/10.1038/355349a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1731248				2022-12-01	WOS:A1992HA59100067
J	ERIKSSON, AE; BAASE, WA; WOZNIAK, JA; MATTHEWS, BW				ERIKSSON, AE; BAASE, WA; WOZNIAK, JA; MATTHEWS, BW			A CAVITY-CONTAINING MUTANT OF T4 LYSOZYME IS STABILIZED BY BURIED BENZENE	NATURE			English	Article							PANCREATIC TRYPSIN-INHIBITOR; PROTEINS; DYNAMICS; PACKING	THE hydrophobic cores of proteins are generally well packed, with few cavities 1,2. Mutations in which a bulky buried residue such as leucine or phenylalanine is replaced with a small residue such as alanine can create cavities in the core of a protein (our unpublished results). The sizes and shapes of such cavities can vary substantially depending on factors such as local geometry, whether or not a cavity already exists at the site of substitution, and the degree to which the protein structure relaxes to occupy the space vacated by the substituted residue. We show by crystallographic and thermodynamic analysis that the cavity created by the replacement Leu 99 --> Ala in T4 lysozyme is large enough to bind benzene and that ligand binding increases the melting temperature of the protein by 6.0-degrees-C at Ph 3.0. Benzene does not, however, bind to the cavity created by the Phe 153 --> Ala replacement. The results show that cavities can be engineered in proteins and suggest that such cavities might be tailored to bind specific ligands. The binding of benzene at an internal site 7 angstrom from the molecular surface also illustrates the dynamic nature of proteins, even in crystals.	UNIV OREGON,HOWARD HUGHES MED INST,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT PHYS,EUGENE,OR 97403	Howard Hughes Medical Institute; University of Oregon; University of Oregon								BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; CAMPBELL ID, 1975, PROC R SOC SER B-BIO, V189, P503, DOI 10.1098/rspb.1975.0070; CONNOLLY ML, 1986, INT J PEPT PROT RES, V28, P360; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DAOPIN S, 1991, J MOL BIOL, V221, P647, DOI 10.1016/0022-2836(91)80079-A; DAOPIN S, 1990, PROTEINS, V7, P198, DOI 10.1002/prot.340070208; Eisenberg H, 1976, Adv Protein Chem, V30, P101, DOI 10.1016/S0065-3233(08)60479-9; FABER HR, 1990, NATURE, V348, P263, DOI 10.1038/348263a0; HERMANS J, 1961, J AM CHEM SOC, V83, P3283, DOI 10.1021/ja01476a025; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; KRETSINGER RH, 1968, J MOL BIOL, V31, P305, DOI 10.1016/0022-2836(68)90446-4; LAKOWICZ JR, 1966, BIOCHEMISTRY-US, V21, P287; LUMRY RW, 1975, C INT CNRS LEAU SYST, V246, P53; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; RINGE D, 1985, PROG BIOPHYS MOL BIO, V45, P197, DOI 10.1016/0079-6107(85)90002-1; SCHELLMAN JA, 1975, BIOPOLYMERS, V14, P999, DOI 10.1002/bip.1975.360140509; SCHOENBORN BP, 1965, NATURE, V207, P28, DOI 10.1038/207028a0; SNYDER GH, 1976, BIOCHEMISTRY-US, V15, P2275, DOI 10.1021/bi00656a005; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WISHNIA A, 1969, BIOCHEMISTRY-US, V8, P5070, DOI 10.1021/bi00840a059; WUTHRICH K, 1975, FEBS LETT, V50, P265, DOI 10.1016/0014-5793(75)80504-7	23	239	241	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1992	355	6358					371	373		10.1038/355371a0	http://dx.doi.org/10.1038/355371a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1731252				2022-12-01	WOS:A1992HA59100075
J	HOTH, M; PENNER, R				HOTH, M; PENNER, R			DEPLETION OF INTRACELLULAR CALCIUM STORES ACTIVATES A CALCIUM CURRENT IN MAST-CELLS	NATURE			English	Article							INOSITOL TRISPHOSPHATE; CA-2+ RELEASE; INFLUX; ENTRY; PHOSPHATES; MESSENGERS; IONOMYCIN; CHANNELS; MN-2+	IN many cell types, receptor-mediated Ca2+ release from internal stores is followed by Ca2+ influx across the plasma membrane 1-3. The sustained entry of Ca2+ is thought to result partly from the depletion of intracellular Ca2+ pools 4,5. Most investigations have characterized Ca2+ influx indirectly by measuring Ca2+-activated currents 6-9 or using Fura-2 quenching by Mn2+, which in some cells enters the cells by the same influx pathway 10,11 But only a few studies have investigated this Ca2+ entry pathway more directly 12-14. We have combined patch-clamp and Fura-2 measurements to monitor membrane currents in mast cells under conditions where intracellular Ca2+ stores were emptied by either inositol 1,4,5-trisphosphate, ionomycin, or excess of the Ca2+ chelator EGTA. The depletion of Ca2+ pools by these independent mechanisms commonly induced activation of a sustained calcium inward current that was highly selective for Ca2+ ions over Ba2+, Sr2+ and Mn2+. This Ca2+ current, which we term I(CRAC) (calcium release-activated calcium), is not voltage-activated and shows a characteristic inward rectification. It may be the mechanism by which electrically nonexcitable cells maintain raised intracellular Ca2+ concentrations and replenish their empty Ca2+ stores after receptor stimulation.			HOTH, M (corresponding author), MAX PLANCK INST BIOPHYS CHEM, W-3400 GOTTINGEN, GERMANY.			Penner, Reinhold/0000-0002-5366-1537; Hoth, Markus/0000-0001-7080-4643				ALBERT PR, 1984, J BIOL CHEM, V259, P5350; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; CASTEELS R, 1981, J PHYSIOL-LONDON, V317, P263, DOI 10.1113/jphysiol.1981.sp013824; CULLEN PJ, 1988, FEBS LETT, V228, P57, DOI 10.1016/0014-5793(88)80584-2; ECKERT R, 1984, PROG BIOPHYS MOL BIO, V44, P215, DOI 10.1016/0079-6107(84)90009-9; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; KASS GEN, 1990, J BIOL CHEM, V265, P17486; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LIU CM, 1978, J BIOL CHEM, V253, P5892; LLANO I, 1987, PFLUG ARCH EUR J PHY, V409, P499, DOI 10.1007/BF00583807; LLOPIS J, 1991, BIOCHEM J, V277, P553, DOI 10.1042/bj2770553; MARTY A, 1989, J PHYSIOL-LONDON, V419, P665, DOI 10.1113/jphysiol.1989.sp017892; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P105, DOI 10.1113/jphysiol.1989.sp017830; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P131, DOI 10.1113/jphysiol.1989.sp017831; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MERTZ LM, 1990, J BIOL CHEM, V265, P15010; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; MUHLEN FV, 1991, P NATL ACAD SCI USA, V88, P926, DOI 10.1073/pnas.88.3.926; NEHER E, 1989, NEUROMUSCULAR JUNCTI, P65; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; SAGE SO, 1989, BIOCHEM J, V258, P923, DOI 10.1042/bj2580923; SNYDER PM, 1988, J BIOL CHEM, V263, P11048; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466	26	1500	1530	3	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 23	1992	355	6358					353	356		10.1038/355353a0	http://dx.doi.org/10.1038/355353a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1309940				2022-12-01	WOS:A1992HA59100069
J	LEVIN, AA; STURZENBECKER, LJ; KAZMER, S; BOSAKOWSKI, T; HUSELTON, C; ALLENBY, G; SPECK, J; KRATZEISEN, C; ROSENBERGER, M; LOVEY, A; GRIPPO, JF				LEVIN, AA; STURZENBECKER, LJ; KAZMER, S; BOSAKOWSKI, T; HUSELTON, C; ALLENBY, G; SPECK, J; KRATZEISEN, C; ROSENBERGER, M; LOVEY, A; GRIPPO, JF			9-CIS RETINOIC ACID STEREOISOMER BINDS AND ACTIVATES THE NUCLEAR RECEPTOR RXR-ALPHA	NATURE			English	Article							THYROID-HORMONE; IDENTIFICATION; TRANSCRIPTION; EXPRESSION; ANALOGS; CELLS	VITAMIN-A (retinol) and its natural derivatives are required for many physiological processes 1-3. The activity of retinoids is thought to be mediated by interactions with two subfamilies of nuclear retinoic acid receptors, RAR and RXR. The RARs bind all-trans retinoic acid (t-RA) with high affinity and alter gene expression as a consequence of this direct ligand interaction 4-10. RXR-alpha is activated by t-RA, yet has little binding affinity for this ligand (ref. 11). t-RA may be converted to a more proximate ligand that directly binds and activates RXR-alpha, and we have developed a method of nuclear receptor-dependent ligand trapping to test this hypothesis. Here we report the identification of a stereoisomer of retinoic acid, 9-cis retinoic acid, which directly binds and activates RXR-alpha. These results suggest a new role for isomerization in the physiology of natural retinoids.	HOFFMANN LA ROCHE INC,DEPT MED CHEM,NUTLEY,NJ 07110; HOFFMANN LA ROCHE INC,DEPT DRUG METAB,NUTLEY,NJ 07110	Roche Holding; Roche Holding	LEVIN, AA (corresponding author), HOFFMANN LA ROCHE INC,DEPT TOXICOL & PATHOL,NUTLEY,NJ 07110, USA.							ALMAN FC, 1991, BIOCHEMISTRY-US, V30, P5605; ASTROM A, 1990, BIOCHEM BIOPH RES CO, V173, P339, DOI 10.1016/S0006-291X(05)81062-9; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CAVEY MT, 1990, ANAL BIOCHEM, V186, P19, DOI 10.1016/0003-2697(90)90565-Q; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COWARD WA, 1969, BRIT J NUTR, V23, P619, DOI 10.1079/BJN19690069; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; DELEENHEER AP, 1990, METHOD ENZYMOL, V189, P104; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; GARLAND WA, 1991, TRAC-TREND ANAL CHEM, V10, P177, DOI 10.1016/0165-9936(91)85018-M; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GRAUPNER G, 1991, BIOCHEM BIOPH RES CO, V179, P1554, DOI 10.1016/0006-291X(91)91750-7; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRIPPO JF, 1987, J BIOL CHEM, V262, P4492; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; HUSELTON CA, 1990, LIQUID CROMATOGRAPHY, P166; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCCLEAN SW, 1982, CLIN CHEM, V28, P693; NAPOLI JL, 1986, METHOD ENZYMOL, V123, P112, DOI 10.1016/S0076-6879(86)23015-3; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROBERTS AB, 1984, RETINOIDS, V2, P209; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHULE R, 1991, P NATL ACAD SCI USA, V88, P6092; THAILER C, 1987, NATURE, V327, P625; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1991, NEW BIOL, V3, P169	35	1231	1290	6	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1992	355	6358					359	361		10.1038/355359a0	http://dx.doi.org/10.1038/355359a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1309942				2022-12-01	WOS:A1992HA59100071
J	LUCKHOFF, A; CLAPHAM, DE				LUCKHOFF, A; CLAPHAM, DE			INOSITOL 1,3,4,5-TETRAKISPHOSPHATE ACTIVATES AN ENDOTHELIAL CA2+-PERMEABLE CHANNEL	NATURE			English	Article							CALCIUM INFLUX; ADENINE-NUCLEOTIDES; CYTOSOLIC CALCIUM; IONIC CURRENTS; MAST-CELLS; 1,4,5-TRISPHOSPHATE; STIMULATION; RELEASE; CA-2+; ENTRY	RECEPTOR-MEDIATED increases in the cytosolic free calcium ion concentration in most mammalian cells result from mobilization of Ca2+ from intracellular stores as well as transmembrane Ca2+ influx. Inositol 1,4,5-trisphosphate (InsP3) releases calcium from intracellular stores 1 by opening a Ca2+-permeable channel in the endoplasmic reticulum 2-4. But the mechanism and regulation of Ca2+ entry into nonexcitable cells has remained elusive because the entry pathway has not been defined. Here we characterize a novel inositol 1,3,4,5-tetrakisphosphate (InsP4) and Ca2+-sensitive Ca2+-permeable channel in endothelial cells. We find that InsP4, which induces Ca2+ influx into acinar cells 5,6, enhances the activity of the Ca2+-permeable channel when exposed to the intracellular surface of endothelial cell inside-out patches. Our results suggest a molecular mechanism which is likely to be important for receptor-mediated Ca2+ entry.			LUCKHOFF, A (corresponding author), MAYO CLIN & MAYO FDN, DEPT PHARMACOL, ROCHESTER, MN 55905 USA.		Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428				ADAMS DJ, 1989, FASEB J, V3, P2389, DOI 10.1096/fasebj.3.12.2477294; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; COLDENSTANFIELD M, 1987, CIRC RES, V61, P632, DOI 10.1161/01.RES.61.5.632; DERIAN CK, 1986, J BIOL CHEM, V261, P3831; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HALLAM TJ, 1988, BIOCHEM J, V255, P179, DOI 10.1042/bj2550179; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LINDAU M, 1986, NATURE, V319, P150, DOI 10.1038/319150a0; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LU CY, 1989, J MEMBRANE BIOL, V109, P85, DOI 10.1007/BF01870793; LUCKHOFF A, 1990, PFLUG ARCH EUR J PHY, V416, P305, DOI 10.1007/BF00392067; LUCKHOFF A, 1986, J CELL PHYSIOL, V126, P414, DOI 10.1002/jcp.1041260312; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; NILIUS B, 1991, NEWS PHYSIOL SCI, V6, P110; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; PIROTTON S, 1987, J BIOL CHEM, V262, P17461; SCHILLING WP, 1989, AM J PHYSIOL, V257, pH778, DOI 10.1152/ajpheart.1989.257.3.H778; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; SCHWARTZ SM, 1978, IN VITRO CELL DEV B, V14, P966, DOI 10.1007/BF02616210; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0	29	413	413	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 23	1992	355	6358					356	358		10.1038/355356a0	http://dx.doi.org/10.1038/355356a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1309941				2022-12-01	WOS:A1992HA59100070
J	MOHANTYHEJMADI, P; DUTTA, SK; MAHAPATRA, P				MOHANTYHEJMADI, P; DUTTA, SK; MAHAPATRA, P			LIMBS GENERATED AT SITE OF TAIL AMPUTATION IN MARBLED BALLOON FROG AFTER VITAMIN-A TREATMENT	NATURE			English	Article							REGENERATING AXOLOTL LIMB; RETINOIC ACID; LOCAL APPLICATION; TADPOLES	NIAZI and Saxena 1 first observed that vitamin A has an inhibitory and modifying influence on tail regeneration in Bufo andersonii tadpoles. A positive relationship was later found between the inhibiting influence of vitamin A and the developmental stage of the regenerating tail in the same species 2. There have been several subsequent reports 3-7 on the effects of vitamin A and its derivatives on limb development and regeneration. Thus in regenerating amphibian limbs, application of retinoids produces pattern duplication in the proximodistal and anteroposterior axes of the limb 3,8,9, and local application of retinoic acid to the anterior side of developing chick limbs causes duplications in the anteroposterior axis of limb 10,11. Here we show that vitamin A can cause limb development when applied to amputated tail stumps of the tadpoles of the marbled balloon frog Uperodon systoma (Anura Microhylidae). This is the first report of homeotic transformation mediated through vitamin A in vertebrates.			MOHANTYHEJMADI, P (corresponding author), UTKAL UNIV, DEPT ZOOL, BHUBANESWAR 751004, ORISSA, INDIA.							DROBERTIS EM, 1990, SCI IT AM, P46; LUDOLPH DC, 1990, DEV BIOL, V140, P41, DOI 10.1016/0012-1606(90)90051-J; MADEN M, 1985, ROUX ARCH DEV BIOL, V194, P228, DOI 10.1007/BF00848251; MADEN M, 1983, J EMBRYOL EXP MORPH, V77, P273; Mohanty-Hejmadi P., 1977, Prakruti Utkal Univ J Sci, V11, P81; NIAZI IA, 1968, EXPERIENTIA, V24, P852, DOI 10.1007/BF02144915; NIAZI IA, 1984, ROUX ARCH DEV BIOL, V193, P111, DOI 10.1007/BF00848639; NIAZI IA, 1979, J EXP BIOL, V17, P866; SCADDING SR, 1986, J EMBRYOL EXP MORPH, V91, P35; SCADDING SR, 1986, J EMBRYOL EXP MORPH, V91, P19; SUMMERBELL D, 1983, J EMBRYOL EXP MORPH, V78, P269; THOMS SD, 1984, DEV BIOL, V103, P319, DOI 10.1016/0012-1606(84)90320-8; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0	13	108	115	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 23	1992	355	6358					352	353		10.1038/355352a0	http://dx.doi.org/10.1038/355352a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1731249				2022-12-01	WOS:A1992HA59100068
J	SCHLAGHECKE, R; KORNELY, E; SANTEN, RT; RIDDERSKAMP, P				SCHLAGHECKE, R; KORNELY, E; SANTEN, RT; RIDDERSKAMP, P			THE EFFECT OF LONG-TERM GLUCOCORTICOID THERAPY ON PITUITARY-ADRENAL RESPONSES TO EXOGENOUS CORTICOTROPIN-RELEASING HORMONE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMA ADRENOCORTICOTROPIN; CORTISOL RESPONSE; DOSE-RESPONSE; DEXAMETHASONE; SECRETION; RECOVERY; AXIS; ACTH; RAT	Background. Suppression of pituitary-adrenal function is a well-known consequence of glucocorticoid therapy, manifested principally by decreased corticotropin secretion. To determine the degree of suppression of pituitary-adrenal function in patients treated with different doses of synthetic glucocorticoid medication for different periods, we measured the pituitary-adrenal response to the administration of exogenous human corticotropin-releasing hormone (CRH). Methods. We studied 279 patients who were receiving daily therapy with 5 to 30 mg of prednisone or its equivalent to treat various chronic diseases, principally collagen vascular disorders, and 50 normal subjects. Therapy ranged in duration from 1 week to 15 years. Stimulation tests using 100-mu-g of CRH as a bolus injection were performed in the morning, 24 hours after the most recent dose of glucocorticoids. In 61 patients an insulin hypoglycemia test, thought by many to be the reference standard, was also performed to assess the reliability of the CRH results. Results. After the administration of CRH, 43 patients had no increase in plasma concentrations of corticotropin and cortisol. The response was blunted in 133 patients and normal in 103. There was poor correlation between the plasma cortisol response after the administration of CRH and the dose or duration of therapy or the basal plasma cortisol concentration. Although plasma cortisol concentrations after stimulation with CRH were generally lower than those after insulin administration, there was a significant correlation between the plasma cortisol responses to the two stimuli (r = 0.82). Conclusions. Pituitary-adrenal function in patients treated with synthetic glucocorticoids cannot be reliably estimated from the dose of glucocorticoid, the duration of therapy, or the basal plasma cortisol concentration. In such patients, testing with CRH is nearly as useful as insulin hypoglycemia testing in the assessment of pituitary-adrenal function.			SCHLAGHECKE, R (corresponding author), UNIV DUSSELDORF,DEPT ENDOCRINOL & RHEUMATOL,MOORENSTR 5,W-4000 DUSSELDORF 1,GERMANY.							BECKER KL, 1990, PRINCIPLES PRACTICE, P1740; BOLT HM, 1980, THERAPIEWOCHE, V30, P6257; BORST GC, 1982, NEW ENGL J MED, V306, P1462, DOI 10.1056/NEJM198206173062405; CARNES M, 1987, NEUROENDOCRINOLOGY, V45, P160, DOI 10.1159/000124718; CHRISTY NP, 1971, HUMAN ADRENAL CORTEX, P395; CUNNINGHAM SK, 1983, ARCH INTERN MED, V143, P2276, DOI 10.1001/archinte.143.12.2276; EBERWINE JH, 1984, J BIOL CHEM, V259, P2166; HAGG E, 1987, CLIN ENDOCRINOL, V26, P221, DOI 10.1111/j.1365-2265.1987.tb00780.x; HARRISON BDW, 1982, CLIN ENDOCRINOL, V17, P109, DOI 10.1111/j.1365-2265.1982.tb01570.x; HASHIMOTO K, 1988, J CLIN INVEST, V82, P13, DOI 10.1172/JCI113561; JINGAMI H, 1985, ENDOCRINOLOGY, V117, P1314, DOI 10.1210/endo-117-4-1314; KELLERWOOD ME, 1984, ENDOCR REV, V51, P1; LIVANOU T, 1967, LANCET, V2, P856; MCEVEN BS, 1986, PHYSIOL REV, V66, P1121; MELBY JC, 1974, ANN INTERN MED, V81, P505, DOI 10.7326/0003-4819-81-4-505; MULLER OA, 1986, PSYCHONEUROENDOCRINO, V11, P49, DOI 10.1016/0306-4530(86)90031-4; NINK M, 1991, KLIN WOCHENSCHR, V69, P185, DOI 10.1007/BF01646939; ORTH DN, 1983, J CLIN INVEST, V71, P587, DOI 10.1172/JCI110804; SCHURMEYER TH, 1985, J CLIN ENDOCR METAB, V61, P22, DOI 10.1210/jcem-61-1-22; SCHURMEYER TH, 1984, J CLIN ENDOCR METAB, V59, P1103, DOI 10.1210/jcem-59-6-1103; STEWART PM, 1988, LANCET, V1, P1208; STRECK WF, 1979, AM J MED, V66, P910, DOI 10.1016/0002-9343(79)90444-3; STREETEN DHP, 1984, ENDOCR REV, V5, P371, DOI 10.1210/edrv-5-3-371; TAYLOR AL, 1988, NEW ENGL J MED, V319, P213, DOI 10.1056/NEJM198807283190405; VALE W, 1983, ENDOCRINOLOGY, V113, P1121, DOI 10.1210/endo-113-3-1121; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VOIGT KH, 1981, THERAPIEWOCHE, V31, P6230; WAND GS, 1985, CLIN ENDOCRINOL META, V14, P33, DOI 10.1016/S0300-595X(85)80064-5; WATSON AC, 1988, CLIN ENDOCRINOL, V28, P471, DOI 10.1111/j.1365-2265.1988.tb03681.x	29	293	298	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1992	326	4					226	230		10.1056/NEJM199201233260403	http://dx.doi.org/10.1056/NEJM199201233260403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA431	1309389				2022-12-01	WOS:A1992HA43100003
J	STORY, RM; WEBER, IT; STEITZ, TA				STORY, RM; WEBER, IT; STEITZ, TA			THE STRUCTURE OF THE ESCHERICHIA-COLI RECA PROTEIN MONOMER AND POLYMER	NATURE			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; DUPLEX DNA; CONSTITUTIVE MUTANTS; ELECTRON-MICROSCOPY; FUNCTIONAL REGIONS; SEQUENCE ANALYSIS; BINDING PROTEIN; TRANSFER-RNA; COMPLEXES	The crystal structure of the recA protein from Escherichia coli at 2.3-angstrom resolution reveals a major domain that binds ADP and probably single- and double-stranded DNA. Two smaller subdomains at the N and C termini protrude from the protein and respectively stabilize a 6(1) helical polymer of protein subunits and interpolymer bundles. This polymer structure closely resembles that of recA/DNA filaments determined by electron microscopy. Mutations in recA protein that enhance coprotease, DNA-binding and/or strand-exchange activity can be explained if the interpolymer interactions in the crystal reflect a regulatory mechanism in vivo.	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06511	Yale University; Howard Hughes Medical Institute; Yale University	STORY, RM (corresponding author), YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511, USA.		Steitz, Thomas A./C-6559-2009					BENEDICT RC, 1988, J BIOL CHEM, V263, P15513; BLANAR MA, 1983, COLD SPRING HARB SYM, V49, P507; BRYANT FR, 1988, J BIOL CHEM, V263, P8716; BRYANT FR, 1986, J BIOL CHEM, V261, P2988; CAZAUX C, 1991, BIOCHIMIE, V73, P281, DOI 10.1016/0300-9084(91)90214-L; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; DASGUPTA C, 1981, CELL, V25, P507, DOI 10.1016/0092-8674(81)90069-6; DEJONG EAM, 1989, J MOL BIOL, V206, P133, DOI 10.1016/0022-2836(89)90529-9; DICAPUA E, 1990, J MOL BIOL, V214, P557, DOI 10.1016/0022-2836(90)90198-U; DICAPUA E, 1990, J STRUCT BIOL, V104, P91, DOI 10.1016/1047-8477(90)90062-H; DICAPUA E, 1982, J MOL BIOL, V157, P87, DOI 10.1016/0022-2836(82)90514-9; DUTREIX M, 1989, J BACTERIOL, V171, P2415, DOI 10.1128/jb.171.5.2415-2423.1989; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; HORII T, 1980, P NATL ACAD SCI-BIOL, V77, P313, DOI 10.1073/pnas.77.1.313; KAWASHIMA H, 1984, MOL GEN GENET, V193, P288, DOI 10.1007/BF00330682; KIRBY EP, 1967, P NATL ACAD SCI USA, V58, P1903, DOI 10.1073/pnas.58.5.1903; KNIGHT KL, 1984, J BIOL CHEM, V259, P1279; KOBAYASHI N, 1987, BIOCHEMISTRY-US, V26, P6801, DOI 10.1021/bi00395a033; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.biophys.20.1.539; LAUDER SD, 1991, J BIOL CHEM, V266, P5450; LAVERY PE, 1988, J MOL BIOL, V203, P861, DOI 10.1016/0022-2836(88)90112-X; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MCKAY DB, 1980, J BIOL CHEM, V255, P6662; MENETSKI JP, 1990, J MOL BIOL, V211, P845, DOI 10.1016/0022-2836(90)90078-Z; MILLER S, 1987, NATURE, V328, P834, DOI 10.1038/328834a0; MORAND P, 1977, J BACTERIOL, V131, P572, DOI 10.1128/JB.131.2.572-582.1977; MORRICAL SW, 1985, BIOCHEMISTRY-US, V24, P760, DOI 10.1021/bi00324a034; MUENCH KA, 1991, J BIOL CHEM, V266, P844; MULLER B, 1990, J MOL BIOL, V212, P97, DOI 10.1016/0022-2836(90)90307-8; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; Ogawa H, 1986, Adv Biophys, V21, P135, DOI 10.1016/0065-227X(86)90019-5; PUGH BF, 1988, J BIOL CHEM, V263, P76; PUGH BF, 1987, J BIOL CHEM, V262, P1326; RADDING CM, 1991, J BIOL CHEM, V266, P5355; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SALLES B, 1983, P NATL ACAD SCI-BIOL, V80, P65, DOI 10.1073/pnas.80.1.65; SANCAR A, 1980, P NATL ACAD SCI-BIOL, V77, P2611, DOI 10.1073/pnas.77.5.2611; STASIAK A, 1988, J MOL BIOL, V202, P659, DOI 10.1016/0022-2836(88)90293-8; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; WANG WB, 1988, J BACTERIOL, V170, P4823, DOI 10.1128/jb.170.10.4823-4827.1988; WANG WB, 1986, J BACTERIOL, V168, P901, DOI 10.1128/jb.168.2.901-910.1986; WEST SC, 1980, P NATL ACAD SCI-BIOL, V77, P2569, DOI 10.1073/pnas.77.5.2569; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WILLIAMS RC, 1986, J MOL BIOL, V187, P109, DOI 10.1016/0022-2836(86)90410-9; WILSON DH, 1990, J BIOL CHEM, V265, P7351; YARRANTON GT, 1982, MOL GEN GENET, V185, P99, DOI 10.1007/BF00333797; ZLOTNICK A, 1990, J BIOL CHEM, V265, P17050; ZLOTNICK A, 1989, J MOL BIOL, V206, P133	57	693	710	0	45	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1992	355	6358					318	325		10.1038/355318a0	http://dx.doi.org/10.1038/355318a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1731246				2022-12-01	WOS:A1992HA59100055
J	BUTTERWORTH, CE; HATCH, KD; MACALUSO, M; COLE, P; SAUBERLICH, HE; SOONG, SJ; BORST, M; BAKER, VV				BUTTERWORTH, CE; HATCH, KD; MACALUSO, M; COLE, P; SAUBERLICH, HE; SOONG, SJ; BORST, M; BAKER, VV			FOLATE-DEFICIENCY AND CERVICAL DYSPLASIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; ORAL-CONTRACEPTIVES; LYMPHOCYTE CULTURE; ASCORBIC-ACID; FRAGILE SITES; FOLIC-ACID; CANCER; RISK; NEOPLASIA; PLASMA	Objective. - To test the hypothesis that nutritional deficiency affects the incidence of cervical dysplasia in young women. Design and Setting. - Case-control study. Participants were derived from community family-planning clinics and referrals to a colposcopy center. Participants. - A total of 726 subjects were screened, yielding 294 cases of dysplasia and 170 controls defined by coexistent cytologic and colposcopic evidence. Main Outcome Measures. - Planned prior to data collection. Odds ratios were computed using logistic regression models to evaluate association between cervical dysplasia and sociodemographic, sexual, and reproductive factors; smoking; oral contraceptive use; human papillomavirus (HPV) infection; and 12 nutritional indices determined by blind analysis of nonfasting blood specimens. Results. - The number of sexual partners, parity, oral contraceptive use, and HPV-16 infection were significantly associated with cervical dysplasia. Plasma nutrient levels were generally not associated with risk. However, red blood cell folate levels at or below 660 nmol/L interacted with HPV-16 infection. The adjusted odds ratio for HPV-16 was 1.1 among women with folate levels above 660 nmol/L but 5.1 (95% confidence interval, 2.3 to 11) among women with lower levels. Interactions of red blood cell folate levels with cigarette smoking and parity were also present but were not statistically significant. Conclusion. - Low red blood cell folate levels enhance the effect of other risk factors for cervical dysplasia and, in particular, that of HPV-16 infection.	UNIV ALABAMA, SCH MED, DEPT OBSTET & GYNECOL, BIRMINGHAM, AL 35233 USA; UNIV ALABAMA, SCH HLTH RELATED PROFESS, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, CTR COMPREHENS CANC, DEPT BIOSTAT & BIOMATH, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH PUBL HLTH, DEPT EPIDEMIOL, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	BUTTERWORTH, CE (corresponding author), UNIV ALABAMA, SCH MED, DEPT NUTR SCI, UAB STN, BIRMINGHAM, AL 35294 USA.		Macaluso, Maurizio/J-2076-2015	Macaluso, Maurizio/0000-0002-2977-9690	NCI NIH HHS [5 P01-CA 28103] Funding Source: Medline; NICHD NIH HHS [N01-HD-5-2927] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD052927] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA028103] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAYOUMI RA, 1976, CLIN CHEM, V22, P327; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; BORST M, 1991, J REPROD MED, V36, P95; BRESLOW NE, 1985, AM J EPIDEMIOL, V122, P149, DOI 10.1093/oxfordjournals.aje.a114074; Breslow NE, 1980, IARC SCI PUBL, V1, P1; BRINTON LA, 1986, JAMA-J AM MED ASSOC, V255, P3265, DOI 10.1001/jama.255.23.3265; BRINTON LA, 1986, J CHRON DIS, V39, P1051, DOI 10.1016/0021-9681(86)90139-6; BRINTON LA, 1989, AM J EPIDEMIOL, V130, P486, DOI 10.1093/oxfordjournals.aje.a115362; BROCK KE, 1988, J NATL CANCER I, V80, P580, DOI 10.1093/jnci/80.8.580; BUTTERWORTH CE, 1982, AM J CLIN NUTR, V35, P73, DOI 10.1093/ajcn/35.1.73; BUTTERWORTH CE, IN PRESS AM J OBSTET; BUTTERWORTH CE, 1991, MICRONUTRIENTS HLTH, P165; CELENTANO DD, 1987, AM J EPIDEMIOL, V126, P592, DOI 10.1093/oxfordjournals.aje.a114699; CRUM CP, 1984, NEW ENGL J MED, V310, P880, DOI 10.1056/NEJM198404053101403; DAS KC, 1980, CLIN CHEM, V26, P72; DEVILLIERS EM, 1987, LANCET, V2, P703; DURST M, 1985, J GEN VIROL, V66, P1515, DOI 10.1099/0022-1317-66-7-1515; Eto I, 1986, Adv Exp Med Biol, V206, P313; FERENCZY A, 1987, BLAUSTEINS PATHOLOGY, P177; GARRY PJ, 1970, CLIN CHEM, V16, P766; HEATH CW, 1966, BLOOD-J HEMATOL, V27, P800, DOI 10.1182/blood.V27.6.800.800; HEIMBURGER DC, 1988, JAMA-J AM MED ASSOC, V259, P1525; IRWIN KL, 1988, JAMA-J AM MED ASSOC, V259, P59, DOI 10.1001/jama.259.1.59; JASKIEWICZ K, 1988, ANTICANCER RES, V8, P711; JENSON AB, 1990, PAPILLOMAVIRUSES HUM, P11; JONES CJ, 1990, CANCER RES, V50, P3657; KUTNINK MA, 1985, J LIQ CHROMATOGR, V8, P31, DOI 10.1080/01483918508067061; LASHNER BA, 1989, GASTROENTEROLOGY, V97, P255, DOI 10.1016/0016-5085(89)90058-9; MACNAB JCM, 1986, NEW ENGL J MED, V315, P1052, DOI 10.1056/NEJM198610233151703; MEANWELL CA, 1987, LANCET, V1, P703; MELCHERS WJG, 1989, J CLIN MICROBIOL, V27, P106, DOI 10.1128/JCM.27.1.106-110.1989; MUIR CS, 1990, CANCER RES, V50, P6441; OLSON AD, 1969, CLIN CHEM, V15, P438; ORR JW, 1985, AM J OBSTET GYNECOL, V151, P632, DOI 10.1016/0002-9378(85)90153-X; PALAN PR, 1991, NUTR CANCER, V15, P13, DOI 10.1080/01635589109514106; PALAN PR, 1988, J NATL CANCER I, V80, P454, DOI 10.1093/jnci/80.6.454; POPESCU NC, 1987, J VIROL, V61, P1682, DOI 10.1128/JVI.61.5.1682-1685.1987; POTISCHMAN N, 1991, CANCER RES, V51, P4785; RAN JY, 1990, BLOOD S, V76, pA114; REEVES WC, 1989, NEW ENGL J MED, V320, P1437, DOI 10.1056/NEJM198906013202201; ROMNEY SL, 1987, ANN NY ACAD SCI, V498, P132, DOI 10.1111/j.1749-6632.1987.tb23757.x; SCHNEIDER A, 1989, ARCH GYNECOL OBSTET, V246, P1, DOI 10.1007/BF00933072; SCOTT JM, 1974, AM J MED TECHNOL, V40, P125; SHOJANIA AM, 1968, LANCET, V1, P1376; SOLOMON D, 1989, JAMA-J AM MED ASSOC, V262, P931; STACEWICZSAPUNTZAKIS M, 1987, J MICRONUTR ANAL, V3, P27; STREIFF RR, 1970, J AMER MED ASSOC, V214, P105, DOI 10.1001/jama.214.1.105; SUNDERMAN FW, 1973, HUM PATHOL, V4, P549, DOI 10.1016/S0046-8177(73)80066-8; SUTHERLAND GR, 1979, AM J HUM GENET, V31, P125; VESSEY MP, 1983, LANCET, V2, P930; WASSERTHEILSMOL.S, 1983, NUTRITIONAL FACTORS, P289; WHITEHEAD N, 1973, JAMA-J AM MED ASSOC, V226, P1421, DOI 10.1001/jama.226.12.1421; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; ZIEGLER RG, 1990, AM J EPIDEMIOL, V132, P432, DOI 10.1093/oxfordjournals.aje.a115678	54	179	184	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					528	533		10.1001/jama.267.4.528	http://dx.doi.org/10.1001/jama.267.4.528			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ439	1729576				2022-12-01	WOS:A1992GZ43900029
J	CONTI, VR; KRONENBERG, MW				CONTI, VR; KRONENBERG, MW			FOLLOW-UP AFTER CORONARY-ARTERY BYPASS-SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											CONTI, VR (corresponding author), UNIV TEXAS,MED BRANCH,GALVESTON,TX 77550, USA.							WEINER DA, 1991, J AM COLL CARDIOL, V18, P343, DOI 10.1016/0735-1097(91)90584-V	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					568	569						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ439	1729582				2022-12-01	WOS:A1992GZ43900038
J	GOODWIN, FK				GOODWIN, FK			ALCOHOLICS KIN DONT LIKE DIAZEPAM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					480	480		10.1001/jama.267.4.480	http://dx.doi.org/10.1001/jama.267.4.480			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ439	1309583				2022-12-01	WOS:A1992GZ43900006
J	GOODWIN, FK				GOODWIN, FK			HICKORY DICKORY DOCK - WHOS INHERITED MOUSIES CLOCK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					480	480		10.1001/jama.267.4.480	http://dx.doi.org/10.1001/jama.267.4.480			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ439	1309583				2022-12-01	WOS:A1992GZ43900005
J	HAMPSON, NB; NORKOOL, DM				HAMPSON, NB; NORKOOL, DM			CARBON-MONOXIDE POISONING IN CHILDREN RIDING IN THE BACK OF PICKUP TRUCKS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective. - To describe the case characteristics of a series of children poisoned with carbon monoxide while traveling in the back of pickup trucks. Design. - Pediatric cases referred for treatment of carbon monoxide poisoning with hyperbaric oxygen between 1986 and 1991 were reviewed. Those cases that occurred during travel in the back of pickup trucks were selected. Clinical follow-up by telephone interview ranged from 2 to 55 months. Setting. - A private, urban, tertiary care center in Seattle, Wash. Patients. - Twenty children ranging from 4 to 16 years of age. Intervention. - All patients were treated with hyperbaric oxygen. Main Outcome Measures. - Characteristics of the poisoning incident and clinical patient outcome. Results. - Of 68 pediatric patients treated for accidental carbon monoxide poisoning, 20 cases occurred as children rode in the back of pickup trucks. In 17 of these, the children were riding under a rigid closed canopy on the rear of the truck, while three episodes occurred as children rode beneath a tarpaulin. Average carboxyhemoglobin level on emergency department presentation was 18.2% +/- 2.4% (mean +/- SEM; range, 1.6% to 37.0%). Loss of consciousness occurred in 15 of the 20 children. One child died of cerebral edema, one had permanent neurologic deficits, and 18 had no recognizable sequelae related to the episode. In all cases, the truck exhaust system had a previously known leak or a tail pipe that exited at the rear rather than at the side of the pickup truck. Conclusions. - Carbon monoxide poisoning is a significant hazard for children who ride in the back of pickup trucks. If possible, this practice should be avoided.	VIRGINIA MASON MED CTR,DEPT HYPERBAR,SEATTLE,WA 98101	Virginia Mason Medical Center	HAMPSON, NB (corresponding author), VIRGINIA MASON CLIN,DEPT MED,1100 9TH AVE,SEATTLE,WA 98111, USA.							ANGRAN PF, 1990, JAMA-J AM MED ASSOC, V264, P712; BARRET L, 1985, CLIN TOXICOL, V23, P309; CHOI IS, 1983, ARCH NEUROL-CHICAGO, V40, P433, DOI 10.1001/archneur.1983.04050070063016; GRACE TW, 1981, JAMA-J AM MED ASSOC, V246, P1698; GUSS DA, 1990, J RESPIR DIS, V11, P773; JOHNSON CJ, 1975, AM J PUBLIC HEALTH, V65, P1327, DOI 10.2105/AJPH.65.12.1327; MYERS RAM, 1983, AM J EMERG MED, V2, P226; PIANTADOSI CA, 1990, UPDATE INTENSIVE CAR, V10, P460; TONG T, 1989, AM J DIS CHILD, V143, P997, DOI 10.1001/archpedi.1989.02150210013004; TURNBULL TL, 1988, ANN EMERG MED, V17, P478, DOI 10.1016/S0196-0644(88)80240-3; 1991, DIGEST MOTOR LAWS; 1982, MMWR, V31, P529	12	39	40	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					538	540		10.1001/jama.267.4.538	http://dx.doi.org/10.1001/jama.267.4.538			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ439	1370334				2022-12-01	WOS:A1992GZ43900031
J	WILLIAMS, RB; BAREFOOT, JC; CALIFF, RM; HANEY, TL; SAUNDERS, WB; PRYOR, DB; HLATKY, MA; SIEGLER, IC; MARK, DB				WILLIAMS, RB; BAREFOOT, JC; CALIFF, RM; HANEY, TL; SAUNDERS, WB; PRYOR, DB; HLATKY, MA; SIEGLER, IC; MARK, DB			PROGNOSTIC IMPORTANCE OF SOCIAL AND ECONOMIC-RESOURCES AMONG MEDICALLY TREATED PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY-ARTERY DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; SMOKING CESSATION; HEART-DISEASE; A BEHAVIOR; SUPPORT; MORTALITY; SURVIVAL; STRESS; DEATH; EDUCATION	Objective. - To evaluate the hypothesis that diminished social and economic resources impact adversely on cardiovascular mortality in patients with coronary artery disease. Design. - Inception cohort study of patients undergoing cardiac catheterization from 1974 through 1980 and followed up through 1989. Setting. - Tertiary care university medical center. Patients. - Consecutive sample of 1965 medically treated patients with stenosis 75% or greater of at least one major coronary artery. Five hundred patients were not enrolled due to logistic problems; 33 refused; 64 had missing data on key medical variables. The final study population included 1368 patients, 82% male, with a median age of 52 years. Main Outcome Measure. - Survival time until cardiovascular death. Results. - Independent of all known baseline invasive and noninvasive medical prognostic factors, patients with annual household incomes of $40 000 or more had an unadjusted 5-year survival of 0.91, compared with 0.76 in patients with incomes of $10 000 or less (Cox model adjusted hazard ratio, 1.9; 95% confidence interval, 1.57 to 2.32; P = .002). Similarly, unmarried patients without a confidant had an unadjusted 5-year survival rate of 0.50, compared with 0.82 in patients who were married, had a confidant, or both (adjusted hazard ratio, 3.34; 95% confidence interval, 1.84 to 6.20; P < .0001). Conclusions. - Low levels of social and economic resources identify an important high-risk group among medically treated patients with coronary artery disease, independent of important medical prognostic factors. Additional study will be required to see if interventions to increase these resources improve prognosis.	DUKE UNIV,MED CTR,DEPT MED,DIV CARDIOL,DURHAM,NC 27710	Duke University	WILLIAMS, RB (corresponding author), DUKE UNIV,MED CTR,DEPT PSYCHIAT,BEHAV MED RES CTR,POB 3926,DURHAM,NC 27710, USA.			Mark, Daniel/0000-0001-6340-8087; Hlatky, Mark/0000-0003-4686-9441	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS005635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036587, P50HL017670] Funding Source: NIH RePORTER; AHRQ HHS [HS-05635] Funding Source: Medline; NHLBI NIH HHS [HL-17670, HL-36587, P01 HL036587] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAREFOOT JC, 1989, AM J CARDIOL, V64, P427, DOI 10.1016/0002-9149(89)90416-5; BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; BLAZER DG, 1982, AM J EPIDEMIOL, V115, P684, DOI 10.1093/oxfordjournals.aje.a113351; BROADHEAD WE, 1983, AM J EPIDEMIOL, V117, P521, DOI 10.1093/oxfordjournals.aje.a113575; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; CHANDRA V, 1983, AM J EPIDEMIOL, V117, P320, DOI 10.1093/oxfordjournals.aje.a113544; Cohen S.E., 1985, SOCIAL SUPPORT HLTH; DEAN A, 1977, J NERV MENT DIS, V165, P403, DOI 10.1097/00005053-197712000-00006; DOLISZNY KM, 1989, CIRCULATION, V80, P410; FLEMING R, 1982, J HUM STRESS, V8, P14, DOI 10.1080/0097840X.1982.9936110; FRASURESMITH N, 1985, PSYCHOSOM MED, V47, P431, DOI 10.1097/00006842-198509000-00003; GIANNETTI VJ, 1985, SOC SCI MED, V20, P241, DOI 10.1016/0277-9536(85)90237-0; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; HARRIS PJ, 1980, CIRCULATION, V62, P718, DOI 10.1161/01.CIR.62.4.718; HARRIS PJ, 1979, CIRCULATION, V60, P1259, DOI 10.1161/01.CIR.60.6.1259; HOUSE JS, 1982, AM J EPIDEMIOL, V116, P123, DOI 10.1093/oxfordjournals.aje.a113387; House JS, 1985, SOCIAL SUPPORT HLTH, P83, DOI DOI 10.1016/0883-0355(88)90010-9; HULKA BS, 1985, MED CARE, V23, P438, DOI 10.1097/00005650-198505000-00009; Kaplan B H, 1977, Med Care, V15, P47, DOI 10.1097/00005650-197705001-00006; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LIU K, 1982, CIRCULATION, V66, P1308, DOI 10.1161/01.CIR.66.6.1308; MERMELSTEIN R, 1986, J CONSULT CLIN PSYCH, V54, P447, DOI 10.1037/0022-006X.54.4.447; PRYOR DB, 1984, J CHRON DIS, V37, P521, DOI 10.1016/0021-9681(84)90003-1; PRYOR DB, 1989, CIRCULATION S2, V80, P409; RUBERMAN W, 1984, NEW ENGL J MED, V311, P552, DOI 10.1056/NEJM198408303110902; RUBERMAN W, 1983, J CHRON DIS, V36, P151, DOI 10.1016/0021-9681(83)90089-9; TAYLOR CB, 1990, ANN INTERN MED, V113, P118, DOI 10.7326/0003-4819-113-2-118; WEINBLATT E, 1978, NEW ENGL J MED, V299, P60, DOI 10.1056/NEJM197807132990202; WIKLUND I, 1988, AM J EPIDEMIOL, V128, P786, DOI 10.1093/oxfordjournals.aje.a115032; WILLIAMS CA, 1985, AM J PUBLIC HEALTH, V75, P483, DOI 10.2105/AJPH.75.5.483; WILLIAMS RB, 1988, PSYCHOSOM MED, V50, P139, DOI 10.1097/00006842-198803000-00004	32	407	412	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					520	524		10.1001/jama.267.4.520	http://dx.doi.org/10.1001/jama.267.4.520			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GZ439	1729574				2022-12-01	WOS:A1992GZ43900027
J	BARKER, DJP; MEADE, TW; FALL, CHD; LEE, A; OSMOND, C; PHIPPS, K; STIRLING, Y				BARKER, DJP; MEADE, TW; FALL, CHD; LEE, A; OSMOND, C; PHIPPS, K; STIRLING, Y			RELATION OF FETAL AND INFANT GROWTH TO PLASMA-FIBRINOGEN AND FACTOR-VII CONCENTRATIONS IN ADULT LIFE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC HEART-DISEASE; RISK	Objective - To determine whether reduced fetal and infant growth are associated with higher plasma fibrinogen and factor VII concentrations in adult life. Design - Follow up study of men born during 1920-30 whose weights at birth and at 1 year had been recorded by health visitors, and men born during 1935-43 whose size at birth had been measured in detail. Setting - Hertfordshire and Preston, England. Subjects - 591 men born in east Hertfordshire who still lived there and 148 men born in Preston who still lived in or close to the city. Main outcome measures - Plasma fibrinogen and factor VII concentrations. Results - Among men in Hertfordshire mean plasma fibrinogen and factor VII concentrations fell with increasing weight at 1 year (from 3.21 g/l in men of less-than-or-equal-to 18 lb to 2-93 g/l in men of greater-than-or-equal-to 27 lb and from 122% of standard to 103%; p < 0.001, p < 0.005 respectively). The trends were independent of cigarette smoking, alcohol consumption, body mass index, and social class. Neither plasma fibrinogen nor factor VII concentration was related to birth weight. In men in Preston, however, fibrinogen concentration fell progressively as the ratio of placental weight to birth weight decreased (p = 0.01). Conclusions - Reduced growth in fetal life and infancy is strongly related to high plasma concentrations of the haemostatic factors fibrinogen and factor VII. This may be a persisting response to impaired liver development during a critical early period.	NORTHWICK PK HOSP & CLIN RES CTR, MRC, EPIDEMIOL & MED CARE UNIT, HARROW HA1 3UJ, MIDDX, ENGLAND	Imperial College London	BARKER, DJP (corresponding author), UNIV SOUTHAMPTON, SOUTHAMPTON GEN HOSP, MRC, ENVIRONM EPIDEMIOL UNIT, SOUTHAMPTON S09 4XY, ENGLAND.			Osmond, Clive/0000-0002-9054-4655				ANDREW M, 1990, AM J PEDIAT HEMATOL, V12, P95; [Anonymous], 1980, CLASSIFICATION OCCUP; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1991, J ROY COLL PHYS LOND, V25, P129; BARKER DJP, 1991, BRIT MED J, V303, P671, DOI 10.1136/bmj.303.6804.671; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BARKER DJP, IN PRESS PAEDIATR PE; BROZOVIC M, 1977, BRIT MED BULL, V33, P231, DOI 10.1093/oxfordjournals.bmb.a071441; BROZOVIC M, 1974, BRIT J HAEMATOL, V28, P381, DOI 10.1111/j.1365-2141.1974.tb00819.x; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; DUBOS R, 1966, PEDIATRICS, V38, P789; GRUENWALD P, 1963, BIOL NEONATORUM, V5, P215; GUREWICH V, 1976, THROMB HAEMOSTASIS, V36, P605; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HOLMES GE, 1977, AM J DIS CHILD, V131, P1078, DOI 10.1001/archpedi.1977.02120230024003; HUMPHRIES SE, 1987, LANCET, V1, P1452, DOI 10.1016/S0140-6736(87)92205-7; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; LEE AJ, 1990, J CLIN EPIDEMIOL, V43, P913, DOI 10.1016/0895-4356(90)90075-Z; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MEADE TW, 1987, THROMB DIATH HAEMO, P37; SWENNE I, 1987, DIABETES, V36, P454, DOI 10.2337/diabetes.36.4.454; VILLAR J, 1984, PEDIATRICS, V74, P783; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WINICK M, 1966, J NUTR, V89, P300, DOI 10.1093/jn/89.3.300	25	197	202	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 18	1992	304	6820					148	152		10.1136/bmj.304.6820.148	http://dx.doi.org/10.1136/bmj.304.6820.148			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA979	1737158	Green Published, Bronze			2022-12-01	WOS:A1992HA97900019
J	BIECHE, I; CHAMPEME, MH; MATIFAS, F; HACENE, K; CALLAHAN, R; LIDEREAU, R				BIECHE, I; CHAMPEME, MH; MATIFAS, F; HACENE, K; CALLAHAN, R; LIDEREAU, R			LOSS OF HETEROZYGOSITY ON CHROMOSOME-7Q AND AGGRESSIVE PRIMARY BREAST-CANCER	LANCET			English	Article							SHORT ARM; CELL CARCINOMA; ALLELE LOSS; GENES; DELETIONS; LUNG; 11P; ADENOCARCINOMA; METASTASIS; ONCOGENE	Genetic alterations are believed to be important in the origin and dissemination of breast cancer. Cytogenetic rearrangements on chromosome 7 are common in breast tumours. We used the c-met proto-oncogene probe, which detects sequences on chromosome 7q31, to analyse tumour and blood leucocyte DNA samples from 245 patients with primary breast cancers. The pmetH polymorphic probe detected a high frequency of allele loss (40.5%) among the 121 informative (heterozygous) patients. This genetic alteration was not significantly associated with standard prognostic features including tumour size, histopathological grade, and lymph-node or steroid receptor status. However, patients with loss of heterozygosity on chromosome 7q31 in primary tumour DNA had significantly shorter metastasis-free survival (p = 0.00022) and overall survival (p = 0.0036) after surgery than patients without this alteration. These findings indicate that this region of chromosome 7 might be the site of a breast tumour or metastasis suppressor gene.	CTR RENE HUGUENIN,ONCOVIROL LAB,5 RUE GASTON LATOUCHE,F-92211 ST CLOUD,FRANCE; CTR RENE HUGUENIN,DEPT MED STAT,F-92211 ST CLOUD,FRANCE; NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892	Rene Huguenin Hospital; Rene Huguenin Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Bièche, Ivan/O-7399-2017	Bièche, Ivan/0000-0002-2430-5429				ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; BIECHE I, 1990, INT J CANCER, V46, P1136, DOI 10.1002/ijc.2910460632; BIECHE I, 1990, HUM GENET, V85, P101; BLOOM HJG, 1957, BRIT J CANCER, V11, P35; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; COLLARD JG, 1987, CANCER RES, V47, P6666; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; EHLEN T, 1990, ONCOGENE, V5, P219; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEY MF, 1989, BRIT J CANCER, V59, P750, DOI 10.1038/bjc.1989.157; GENUARDI M, 1989, AM J HUM GENET, V45, P73; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; LEISTER I, 1990, CANCER RES, V50, P7232; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; LUNBERG C, 1987, P NATL ACAD SCI USA, V84, P2372; MACKAY J, 1988, LANCET, V2, P1384; MACKAY J, 1988, BRIT J CANCER, V58, P710, DOI 10.1038/bjc.1988.295; Maniatis T., 1982, MOL CLONING; MERLO GR, 1989, CANCER RES, V49, P6966; MOTOMURA K, 1988, Genomics, V2, P180, DOI 10.1016/0888-7543(88)90101-2; OLUMI AF, 1990, CANCER RES, V50, P7081; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SKINNER MA, 1990, CANCER RES, V50, P2303; SOBEL ME, 1990, JNCI-J NATL CANCER I, V82, P267, DOI 10.1093/jnci/82.4.267; TRENT JM, 1990, NEW ENGL J MED, V322, P1508, DOI 10.1056/NEJM199005243222107; TRENT JM, 1985, BREAST CANCER RES TR, V5, P221, DOI 10.1007/BF01806017; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WHITE R, 1985, NATURE, V318, P382, DOI 10.1038/318382a0; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1989, CANCER RES, V49, P3598; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; 1989, CYTOGENET CELL GENET, V51, P713; 1980, EUR J CANCER, V16, P1513	40	185	185	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1992	339	8786					139	143		10.1016/0140-6736(92)90208-K	http://dx.doi.org/10.1016/0140-6736(92)90208-K			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ968	1346009				2022-12-01	WOS:A1992GZ96800002
J	DEFIGUEIREDO, CEP; ELLORY, JC; HENDRY, BM				DEFIGUEIREDO, CEP; ELLORY, JC; HENDRY, BM			ERYTHROCYTE CHOLINE UPTAKE AFTER RENAL-TRANSPLANTATION	LANCET			English	Article							TRANSPORT; HEMODIALYSIS; FAILURE; CARRIER; UREMIA; ACIDS; PUMP	Erythrocyte membrane choline transport is abnormally high in chronic renal failure. The aim of this study was to find out whether, and how quickly, this abnormality is reversed by renal transplantation. Ten adults with chronic renal failure were studied before and for up to 6 months after renal transplantation. Plasma creatinine concentration and erythrocyte uptake of radiolabelled choline were measured periodically for up to 6 months. The maximum rate of choline transport (V(max)) was abnormally high before transplantation and fell to normal values during the first week after transplantation. This fall matched that in plasma creatinine. A temporary rise in plasma creatinine in one patient, reversed by methylprednisolone treatment, was accompanied by a rise in choline flux, and graft failure in another patient was accompanied by a return to pretransplant rates of choline transport. Thus, the high rates of choline uptake in uraemia are rapidly reduced on recovery of renal function. The speed of the changes suggests the involvement of a plasma factor.	UNIV OXFORD,PHYSIOL LAB,OXFORD,ENGLAND; JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND	University of Oxford; University of Oxford			Poli=de-Figueiredo, Carlos Eduardo/A-2027-2013	Poli=de-Figueiredo, Carlos Eduardo/0000-0002-7333-8884				ANCELIN ML, 1991, BIOCHEM J, V273, P701, DOI 10.1042/bj2730701; Cole C H, 1968, Trans Assoc Am Physicians, V81, P213; COTTON JR, 1979, J CLIN INVEST, V63, P501, DOI 10.1172/JCI109328; DEVES R, 1986, J MEMBRANE BIOL, V93, P165, DOI 10.1007/BF01870808; DEVES R, 1979, BIOCHIM BIOPHYS ACTA, V557, P469, DOI 10.1016/0005-2736(79)90344-4; EDMONDSON RPS, 1975, CLIN SCI MOL MED, V49, P213, DOI 10.1042/cs0490213; ESTRADA C, 1990, J NEUROCHEM, V54, P1467, DOI 10.1111/j.1471-4159.1990.tb01193.x; FERVENZA FC, 1991, CLIN SCI, V80, P137, DOI 10.1042/cs0800137; FERVENZA FC, 1990, NEPHROL DIAL TRANSPL, V5, P594, DOI 10.1093/ndt/5.8.594; FERVENZA FC, 1989, NEPHRON, V53, P121, DOI 10.1159/000185723; GRAVES SW, 1983, ANN INTERN MED, V99, P604, DOI 10.7326/0003-4819-99-5-604; KAJI D, 1987, AM J PHYSIOL, V252, pF785, DOI 10.1152/ajprenal.1987.252.5.F785; KELLY RA, 1989, KIDNEY INT, V35, P595, DOI 10.1038/ki.1989.28; KIRK K, 1991, BIOCHEM J, V278, P521, DOI 10.1042/bj2780521; MARTIN K, 1977, MEMBRANE TRANSPORT R, P101; RUIZ P, 1990, NEW ENGL J MED, V322, P717, DOI 10.1056/NEJM199003153221102; WELT LG, 1964, T ASSOC AM PHYSICIAN, V77, P169; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061	18	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1992	339	8786					146	148		10.1016/0140-6736(92)90211-K	http://dx.doi.org/10.1016/0140-6736(92)90211-K			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ968	1346011				2022-12-01	WOS:A1992GZ96800004
J	MACFARLANE, IA; GILL, GV; MASSON, E; TUCKER, NH				MACFARLANE, IA; GILL, GV; MASSON, E; TUCKER, NH			DIABETES IN PRISON - CAN GOOD DIABETIC CARE BE ACHIEVED	BRITISH MEDICAL JOURNAL			English	Article								Objective - To investigate the clinical characteristics and metabolic control of diabetic patients given structured diabetic care in prison. Design - Survey of diabetic men serving prison sentences during a 22 month period in a large British prison. Setting - HM Prison, Walton, Liverpool. Subjects - 42 male diabetic prisoners, of whom 23 had insulin dependent and 19 non-insulin dependent diabetes. Main outcome measures - Episodes of diabetic instability, glycated haemoglobin concentrations, body mass index. Results - No serious diabetic instability occurred. Between the initial assessment by the visiting consultant diabetologist and a second assessment 10 weeks later glycated haemoglobin concentrations had fallen from 10.8 (SD 2.9)% to 9.8 (2.4)% (p < 0.05) in prisoners with insulin dependent diabetes and from 8.7 (1.9)% to 7.6 (1.2)% (p < 0.05) in those with non-insulin dependent diabetes. Good glycaemic control continued, a mean glycated haemoglobin concentration of 7.6 (1.5)% being recorded in seven men remaining in prison for six to 18 months. Mean body mass index (weight (kg)/(height (m))2) did not change during the study (insulin dependent prisoners 23.3 (SD 2.1), non-insulin dependent prisoners 27.9 (3.8)). Conclusions - Good diabetic metabolic control is usual in prison, probably due to the rigid dietary regimen, no alcohol, and compliance with treatment. Many younger men had defaulted from their home diabetic clinics, and imprisonment allowed screening for diabetic complications and reassessment of treatment. Structured diabetic care should be offered in all prisons.	HM PRISON,LIVERPOOL,ENGLAND		MACFARLANE, IA (corresponding author), WALTON HOSP,CTR DIABET,LIVERPOOL L9 1AE,MERSEYSIDE,ENGLAND.							BLUGLASS R, 1990, BRIT MED J, V301, P249, DOI 10.1136/bmj.301.6746.249; FISKEN RA, 1990, CLIN CHIM ACTA, V191, P79, DOI 10.1016/0009-8981(90)90060-6; GARROW JS, 1979, BRIT MED J, V2, P1171, DOI 10.1136/bmj.2.6199.1171; GILL GV, 1989, BRIT MED J, V298, P221, DOI 10.1136/bmj.298.6668.221; HOME P, 1984, BRIT MED J, V289, P713, DOI 10.1136/bmj.289.6447.713; SHACKLED, 1988, LANCET, V2, P1402; SMITH R, 1991, BRIT MED J, V302, P550; SMITH R, 1988, BRIT MED J, V297, P89; SMITH R, 1991, BRIT MED J, V302, P64, DOI 10.1136/bmj.302.6768.64; Smith Richard, 1984, PRISON HLTH CARE; 1988, BALANCE, P5; 1985, PRISON MED; 1985, LANCET, V2, P755	13	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1992	304	6820					152	155		10.1136/bmj.304.6820.152	http://dx.doi.org/10.1136/bmj.304.6820.152			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA979	1737159	Green Published, Bronze			2022-12-01	WOS:A1992HA97900020
J	OCONNOR, M				OCONNOR, M			MEDICINE IN EUROPE .7. EUROPE AND NUTRITION - PROSPECTS FOR PUBLIC-HEALTH	BRITISH MEDICAL JOURNAL			English	Article											OCONNOR, M (corresponding author), CORONARY PREVENT GRP,102 GLOUCESTER PL,LONDON W1H 3DA,ENGLAND.							GARROW JS, 1991, OBESITY OVERWEIGHT; JAMES WPT, 1988, HLTH NUTRITION, P9; LANG T, 1990, FINAL REPORT STUDY D; OCONNOR M, 1992, HLTH ED J, V50; RICHARDS T, 1991, BRIT MED J, V303, P1319, DOI 10.1136/bmj.303.6813.1319; 1991, DIETARY REFERENCE VA; 1991, EUROPEAN CITIZEN SEP; 1991, DEV FUTURE COMMON AG; 1991, FOOD ADVISORY COMMIT; 1991, CMND1523; 1990, NUTRITION BANDING SC	11	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1992	304	6820					178	180		10.1136/bmj.304.6820.178	http://dx.doi.org/10.1136/bmj.304.6820.178			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HA979	1737167	Bronze, Green Published			2022-12-01	WOS:A1992HA97900030
J	WROE, SJ; SANDERCOCK, P; BAMFORD, J; DENNIS, M; SLATTERY, J; WARLOW, C				WROE, SJ; SANDERCOCK, P; BAMFORD, J; DENNIS, M; SLATTERY, J; WARLOW, C			DIURNAL-VARIATION IN INCIDENCE OF STROKE - OXFORDSHIRE COMMUNITY STROKE PROJECT	BRITISH MEDICAL JOURNAL			English	Article							SUDDEN CARDIAC DEATH; ACUTE CEREBROVASCULAR-DISEASE; CIRCADIAN VARIATION; MYOCARDIAL-INFARCTION; ISCHEMIC STROKE; MORNING INCREASE; ONSET; FREQUENCY; REGISTRY	Objective - To determine whether diurnal variation occurs in the onset of stroke. Design - Community based study over four years. Setting - Oxfordshire, United Kingdom. Subjects - 105 000 people, of whom 675 had a first ever stroke. 545 had a cerebral infarction, 66 had primary intracerebral haemorrhage, 33 had subarachnoid haemorrhage, and in 31 the type of stroke was not known. Main outcome measures - Time of stroke and degree of activity at onset. Results - In the 578 patients for whom it was known whether onset occurred while asleep or awake, the proportion with onset during sleep was 25% (135/545) for cerebral infarction, 17% (11/66) for primary intracerebral haemorrhage, and 0% (0/33) for subarachnoid haemorrhage. This difference persisted if patients in whom it was not known whether they were asleep or awake at onset were classed as asleep. For all stroke types together there was a significant (chi-2 = 218.7, p < 0.001) diurnal variation with a morning peak between 0800 and 1000, which persisted even after allowing for strokes first noted on waking by redistributing the hour of onset through the preceding eight hours (chi-2 = 47, p < 0.001). A significant diurnal variation was also found in the onset of cerebral infarction (peak 0800-1000, chi-2 = 208.4, p < 0.001). Fewer patients had other forms of stroke and the diurnal variations for primary intracerebral haemorrhage (peak 1000-1200) and subarachnoid haemorrhage (peaks 0800-1000 and 1800-2000) were not significant. There seemed to be a second smaller peak for all types of stroke. Conclusions - All types of stroke are most likely to occur after waking in the morning. The cause of the circadian variation requires further study.	WESTERN GEN HOSP, DEPT CLIN NEUROSCI, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; UCL NATL HOSP NEUROL & NEUROSURG, LONDON WC1N 3BG, ENGLAND; ST JAMES UNIV HOSP, DEPT NEUROL, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND	University of Edinburgh; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Saint James's University Hospital			sandercock, peter/GQI-3167-2022; Bamford, John/ABE-6218-2021	sandercock, peter/0000-0001-8484-0135; 				AGNOLI A, 1975, REV NEUROL, V131, P597; ALLEN CMC, 1983, Q J MED, V52, P515; ANDREOTTI F, 1988, BRIT HEART J, V59, P99; ARBOIX A, 1990, STROKE, V21, P826, DOI 10.1161/str.21.5.826a; ARGENTINO C, 1990, STROKE, V21, P387, DOI 10.1161/01.STR.21.3.387; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; CAPLAN LR, 1983, STROKE, V14, P530, DOI 10.1161/01.STR.14.4.530; COLANTONIO D, 1989, AM J CARDIOL, V64, P403, DOI 10.1016/0002-9149(89)90548-1; FREEDMAN LS, 1979, J EPIDEMIOL COMMUN H, V33, P223, DOI 10.1136/jech.33.3.223; GARDNER MJ, 1989, STATISTICS CONFIDENC; HERDERSCHEE D, 1991, CEREBROVASC DIS, V1, P165, DOI 10.1159/000108835; KUBOTA K, 1987, STROKE, V18, P812, DOI 10.1161/str.18.4.812b; MARLER JR, 1989, STROKE, V20, P473, DOI 10.1161/01.STR.20.4.473; MARSH EE, 1990, ARCH NEUROL-CHICAGO, V47, P1178, DOI 10.1001/archneur.1990.00530110032012; MARSHALL J, 1977, STROKE, V8, P230, DOI 10.1161/01.STR.8.2.230; MOHR JP, 1978, NEUROLOGY, V28, P754, DOI 10.1212/WNL.28.8.754; MULLER JE, 1987, CIRCULATION, V75, P131, DOI 10.1161/01.CIR.75.1.131; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; Olivares L, 1973, STROKE, V4, P773, DOI 10.1161/01.STR.4.5.773; ROCCO MB, 1987, CIRCULATION, V75, P395, DOI 10.1161/01.CIR.75.2.395; TOFLER GH, 1987, NEW ENGL J MED, V316, P1514, DOI 10.1056/NEJM198706113162405; TORVIK A, 1976, STROKE, V7, P255, DOI 10.1161/01.STR.7.3.255; TSEMENTZIS SA, 1985, NEUROSURGERY, V17, P901, DOI 10.1227/00006123-198512000-00005; WILLICH SN, 1987, AM J CARDIOL, V60, P801, DOI 10.1016/0002-9149(87)91027-7; WILLICH SN, 1989, DEUT MED WOCHENSCHR, V114, P613, DOI 10.1055/s-2008-1066644; WINDT C, 1988, J NEUROL NEUROSUR PS, V51, P109	28	117	119	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 18	1992	304	6820					155	157		10.1136/bmj.304.6820.155	http://dx.doi.org/10.1136/bmj.304.6820.155			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA979	1737160	Green Published, Bronze			2022-12-01	WOS:A1992HA97900021
J	CUNNINGHAM, CC; GORLIN, JB; KWIATKOWSKI, DJ; HARTWIG, JH; JANMEY, PA; BYERS, HR; STOSSEL, TP				CUNNINGHAM, CC; GORLIN, JB; KWIATKOWSKI, DJ; HARTWIG, JH; JANMEY, PA; BYERS, HR; STOSSEL, TP			ACTIN-BINDING PROTEIN REQUIREMENT FOR CORTICAL STABILITY AND EFFICIENT LOCOMOTION	SCIENCE			English	Article							DICTYOSTELIUM MUTANT; HUMAN-PLATELETS; ALPHA-ACTININ; MEMBRANE; ASSOCIATION; MACROPHAGES; HEPATOCYTES; GELATION; LINKING; FILAMIN	Three unrelated tumor cell lines derived from human malignant melanomas lack actin-binding protein (ABP), which cross-links actin filaments in vitro and connects these filaments to plasma membrane glycoproteins. The ABP-deficient cells have impaired locomotion and display circumferential blebbing of the plasma membrane. Expression of A.BP in one of the lines after transfection restored translocational motility and reduced membrane blebbing. These findings establish that ABP functions to stabilize cortical actin in vivo and is required for efficient cell locomotion.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,CHILDRENS HOSP,DEPT HEMATOL ONCOL,DIV PEDIAT ONCOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	CUNNINGHAM, CC (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV EXPTL MED,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL019429, R01HL019429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR038910, R01AR038910] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 19429] Funding Source: Medline; NIAID NIH HHS [AI 08051] Funding Source: Medline; NIAMS NIH HHS [AR 38910] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRINK M, 1990, J CELL BIOL, V111, P1477, DOI 10.1083/jcb.111.4.1477; BROTSCHI EA, 1978, J BIOL CHEM, V253, P8988; BYERS HR, 1991, AM J PATHOL, V139, P423; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIES WA, 1977, J CELL BIOL, V75, P941, DOI 10.1083/jcb.75.3.941; Eicke H.-F., 1990, PHYSICAL NETWORKS PO, P169; EZZELL RM, 1988, J BIOL CHEM, V263, P13303; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOX JEB, 1985, J BIOL CHEM, V260, P1970; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARTWIG JH, 1980, J CELL BIOL, V87, P841, DOI 10.1083/jcb.87.3.841; HARTWIG JH, 1989, J CELL BIOL, V109, P1571, DOI 10.1083/jcb.109.4.1571; HARTWIG JH, 1975, J BIOL CHEM, V250, P5696; HARTWIG JH, 1991, LUNG SCI F, P141; JANMEY PA, 1991, J BIOCHEM BIOPH METH, V22, P41, DOI 10.1016/0165-022X(91)90080-G; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P13857; LUBYPHELPS K, 1988, ANNU REV BIOPHYS BIO, V17, P369; MESLAND DAM, 1981, EXP CELL RES, V135, P431, DOI 10.1016/0014-4827(81)90184-1; MORROW J, 1985, BIOCHIM BIOPHYS ACTA, V830, P147; NARVANEN O, 1987, FEBS LETT, V224, P156, DOI 10.1016/0014-5793(87)80440-4; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; OKITA JR, 1985, J CELL BIOL, V100, P317, DOI 10.1083/jcb.100.1.317; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SCHLEICHER M, 1988, J CELL SCI, V90, P59; Stossel T.P., 1987, P131; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; STOSSEL TP, 1984, J CELL BIOL, V99, pS15, DOI 10.1083/jcb.99.1.15s; WANG K, 1975, P NATL ACAD SCI USA, V72, P4483, DOI 10.1073/pnas.72.11.4483; WEISS E, 1973, BEITR PATHOL, V150, P345	30	488	498	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1992	255	5042					325	327		10.1126/science.1549777	http://dx.doi.org/10.1126/science.1549777			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ695	1549777				2022-12-01	WOS:A1992GZ69500040
J	DEVOS, AM; ULTSCH, M; KOSSIAKOFF, AA				DEVOS, AM; ULTSCH, M; KOSSIAKOFF, AA			HUMAN GROWTH-HORMONE AND EXTRACELLULAR DOMAIN OF ITS RECEPTOR - CRYSTAL-STRUCTURE OF THE COMPLEX	SCIENCE			English	Article							X-RAY-DIFFRACTION; MACROMOLECULAR CRYSTALLOGRAPHY; SCANNING MUTAGENESIS; PROLACTIN RECEPTOR; HUMAN CD4; BINDING; SUPERFAMILY; RESOLUTION; FRAGMENT; DETECTOR	Binding of human growth hormone (hGH) to its receptor is required for regulation of normal human growth and development. Examination of the 2.8 angstrom crystal structure of the complex between the hormone and the extracellular domain of its receptor (hGHbp) showed that the complex consists of one molecule of growth hormone per two molecules of receptor. The hormone is a four-helix bundle with an unusual topology. The binding protein contains two distinct domains, similar in some respects to immunoglobulin domains. The relative orientation of these domains differs from that found between constant and variable domains in immunoglobulin Fab fragments. Both hGHbp domains contribute residues that participate in hGH binding. In the complex both receptors donate essentially the same residues to interact with the hormone, even though the two binding sites on hGH have no structural similarity. Generally, the hormone-receptor interfaces match those identified by previous mutational analyses. In addition to the hormone-receptor interfaces, there is also a substantial contact surface between the carboxyl-terminal domains of the receptors. The relative extents of the contact areas support a sequential mechanism for dimerization that may be crucial for signal transduction.			DEVOS, AM (corresponding author), GENENTECH INC, DEPT PROT ENGN, 460 POINT SAN BRUNO BLVD, SAN FRANCISCO, CA 94080 USA.							ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BEWLEY TA, 1984, ARCH BIOCHEM BIOPHYS, V233, P219, DOI 10.1016/0003-9861(84)90620-9; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CLARK RD, UNPUB; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; ELBERG G, 1990, J BIOL CHEM, V265, P14770; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FUH G, 1990, J BIOL CHEM, V265, P3111; GUNTHER N, 1990, J BIOL CHEM, V265, P22082; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; LAMBERT G, 1989, J BIOL CHEM, V264, P12730; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MULKERRIN MG, UNPUB; NICOLL CS, 1986, ENDOCR REV, V7, P169, DOI 10.1210/edrv-7-2-169; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; STEIGEMANN W, 1974, THESIS TU MUNCHEN; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULTSCH M, IN PRESS J MOL BIOL; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	31	2070	2631	2	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 17	1992	255	5042					306	312		10.1126/science.1549776	http://dx.doi.org/10.1126/science.1549776			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ695	1549776				2022-12-01	WOS:A1992GZ69500035
J	LANGLOIS, AJ; WEINHOLD, KJ; MATTHEWS, TJ; GREENBERG, ML; BOLOGNESI, DP				LANGLOIS, AJ; WEINHOLD, KJ; MATTHEWS, TJ; GREENBERG, ML; BOLOGNESI, DP			THE ABILITY OF CERTAIN SIV VACCINES TO PROVOKE REACTIONS AGAINST NORMAL-CELLS	SCIENCE			English	Editorial Material							IMMUNODEFICIENCY VIRUS-INFECTION; PROTECTION; ANTIGENS; MACAQUES		DUKE UNIV,MED CTR,CTR AIDS RES,DEPT SURG,DURHAM,NC 27710	Duke University								ANDERSON C, 1991, NATURE, V353, P287, DOI 10.1038/353287b0; AZOCAR J, 1979, CANCER RES, V39, P3388; BOLOGNESI DP, 1970, COMP LEUKEMIA RES 19, P126; BROWN P, 1991, NEW SCI, V21, P14; CARLSON JR, 1990, AIDS RES HUM RETROV, V6, P1239, DOI 10.1089/aid.1990.6.1239; CELADA F, 1990, J EXP MED, V172, P1143, DOI 10.1084/jem.172.4.1143; DESROSIERS R, COMMUNICATION; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; DESROSIERS RC, 1989, 21ST C AIDS ANN; GARDNER MB, IN PRESS AIDS; GIRARD M P, 1990, AIDS (London), V4, pS143; HENDERSON LE, 1987, J VIROL, V61, P629, DOI 10.1128/JVI.61.2.629-632.1987; HILDRETH JEK, 1989, SCIENCE, V244, P1075, DOI 10.1126/science.2543075; HILLEMAN MR, 1985, J INFECT DIS, V151, P407, DOI 10.1093/infdis/151.3.407; HOXIE JA, 1987, HUM IMMUNOL, V18, P39, DOI 10.1016/0198-8859(87)90111-X; HU SL, IN PRESS SCIENCE; JAVAHERIAN K, UNPUB P NATL ACAD SC; LANGLOIS AJ, 1991, AIDS RES HUM RETROV, V7, P713, DOI 10.1089/aid.1991.7.713; LINDENMANN J, 1977, VIRUS INFECTION CELL, P291; MADDOX J, 1991, NATURE, V353, P297, DOI 10.1038/353297a0; MONTEFIORE DC, IN PRESS NATURE; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; WATANABE M, 1991, P NATL ACAD SCI USA, V88, P4616, DOI 10.1073/pnas.88.11.4616	24	87	89	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1992	255	5042					292	293		10.1126/science.1549775	http://dx.doi.org/10.1126/science.1549775			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ695	1549775				2022-12-01	WOS:A1992GZ69500032
J	LUND, E; DAHLBERG, JE				LUND, E; DAHLBERG, JE			CYCLIC 2',3'-PHOSPHATES AND NONTEMPLATED NUCLEOTIDES AT THE 3' END OF SPLICEOSOMAL U6 SMALL NUCLEAR RNAS	SCIENCE			English	Article							HELA-CELL EXTRACT; LUPUS ANTIGEN-LA; POLYMERASE-III; TRANSCRIPTION TERMINATION; 3'-TERMINAL PHOSPHATE; CAP STRUCTURE; INVITRO; U4; PROTEIN; YEAST	Spliceosomal U6 small nuclear RNA (U6 RNA) in species as diverse as man, frog, fruitfly, and soybean have at their 3' ends a cyclic 2',3'-phosphate (> p) apparently derived from uridylic acid residues that were added post-transcriptionally. The 3' ends of U6 RNA's from various sources may be processed in different ways, or to different extents, depending on the organism or stage of development. The presence of a > p terminus on U6 RNA may influence the activity of U6 RNA either directly during splicing or indirectly by ensuring that the RNA has a defined length or proper conformation (or both).			LUND, E (corresponding author), UNIV WISCONSIN,SCH MED,DEPT BIOMOLEC CHEM,1300 UNIV AVE,MADISON,WI 53706, USA.				NIGMS NIH HHS [GM 30220] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030220, R37GM030220] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS NC, 1986, P NATL ACAD SCI USA, V83, P221, DOI 10.1073/pnas.83.2.221; BARRELL BG, 1971, PROCEDURES NUCLEIC A, V2, P751; BASS BL, 1991, NATURE, V352, P283, DOI 10.1038/352283a0; BINDEREIF A, 1990, EMBO J, V9, P251, DOI 10.1002/j.1460-2075.1990.tb08102.x; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; BRINGMANN P, 1984, EMBO J, V3, P1357, DOI 10.1002/j.1460-2075.1984.tb01977.x; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BROW DA, 1989, NATURE, V337, P14, DOI 10.1038/337014a0; BUZAYAN JM, 1986, NATURE, V323, P349, DOI 10.1038/323349a0; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; CHOUDHURY K, 1988, J CELL PHYSIOL, V137, P529, DOI 10.1002/jcp.1041370319; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; Deutscher M P, 1973, Prog Nucleic Acid Res Mol Biol, V13, P51, DOI 10.1016/S0079-6603(08)60100-2; DEUTSCHER MP, 1990, METHOD ENZYMOL, V181, P434; EPSTEIN P, 1980, J BIOL CHEM, V255, P8901; FABRIZIO P, 1989, GENE DEV, V3, P2137, DOI 10.1101/gad.3.12b.2137; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; FIELD D, COMMUNICATION; FILIPOWICZ W, 1985, P NATL ACAD SCI USA, V82, P1316, DOI 10.1073/pnas.82.5.1316; FILIPOWICZ W, 1983, CELL, V32, P547, DOI 10.1016/0092-8674(83)90474-9; FILIPOWICZ W, 1983, NUCLEIC ACIDS RES, V11, P1405, DOI 10.1093/nar/11.5.1405; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GUPTA S, 1991, NUCLEIC ACIDS RES, V19, P2073, DOI 10.1093/nar/19.suppl.2073; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HARADA F, 1980, BIOCHEM BIOPH RES CO, V95, P1332, DOI 10.1016/0006-291X(80)91620-4; HASHIMOTO C, 1984, NUCLEIC ACIDS RES, V12, P3283, DOI 10.1093/nar/12.7.3283; HIRAI H, 1988, J BIOCH, V164, P991; HUTCHINS CJ, 1986, NUCLEIC ACIDS RES, V14, P3627, DOI 10.1093/nar/14.9.3627; HUTCHINS CJ, 1990, METHOD ENZYMOL, V181, P583; KONARSKA M, 1982, P NATL ACAD SCI-BIOL, V79, P1474, DOI 10.1073/pnas.79.5.1474; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; LUND E, 1987, GENE DEV, V1, P39, DOI 10.1101/gad.1.1.39; LUND E, 1985, SCIENCE, V229, P1271, DOI 10.1126/science.2412294; LUND E, UNPUB; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MATHEWS MB, 1984, MOL CELL BIOL, V4, P1134, DOI 10.1128/MCB.4.6.1134; NEU HC, 1964, J BIOL CHEM, V239, P2927; Nishimura S, 1972, Prog Nucleic Acid Res Mol Biol, V12, P49; OHSHIMA Y, 1981, NUCLEIC ACIDS RES, V9, P5145, DOI 10.1093/nar/9.19.5145; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; REDDY R, 1983, J BIOL CHEM, V258, P8352; REDDY R, 1987, J BIOL CHEM, V262, P75; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; RINKE J, 1985, NUCLEIC ACIDS RES, V13, P2617, DOI 10.1093/nar/13.7.2617; RINKE J, 1982, CELL, V29, P149, DOI 10.1016/0092-8674(82)90099-X; Silberklang M, 1979, Methods Enzymol, V59, P58; SINGH R, 1990, MOL CELL BIOL, V10, P939, DOI 10.1128/MCB.10.3.939; SINGH R, 1989, P NATL ACAD SCI USA, V86, P8280, DOI 10.1073/pnas.86.21.8280; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; STEINBERG TH, 1990, J BIOL CHEM, V265, P499; TERNS MP, UNPUB; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; WOLFF T, IIN PRESS EMBO J; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0	56	120	121	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1992	255	5042					327	330		10.1126/science.1549778	http://dx.doi.org/10.1126/science.1549778			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ695	1549778				2022-12-01	WOS:A1992GZ69500041
J	WONG, YH; CONKLIN, BR; BOURNE, HR				WONG, YH; CONKLIN, BR; BOURNE, HR			GZ-MEDIATED HORMONAL INHIBITION OF CYCLIC-AMP ACCUMULATION	SCIENCE			English	Article							NUCLEOTIDE-BINDING PROTEINS; PERTUSSIS TOXIN; ALPHA-SUBUNIT; ADENYLATE-CYCLASE; MOLECULAR-CLONING; ADP-RIBOSYLATION; PHOSPHOLIPASE-C; GS-ALPHA; RECEPTOR; SITE	Hormones inhibit synthesis of adenosine 3',5' monophosphate (cAMP) in most cells via receptors coupled to pertussis toxin (PTX)-sensitive guanine nucleotide-binding (G) proteins. Mutationally activated alpha-subunits of G(i2) (alpha(i2)) constitutively inhibit cAMP accumulation when transfected into cells. Cells have now been transfected with mutant alpha-subunits of four other G proteins-G(z), a PTX-insensitive G protein of unknown function, and G(i1), G(i3), and G(o), which are PTX-sensitive. Mutant alpha(z), alpha(i1), and alpha(i3) inhibited cAMP accumulation but alpha(o) did not. Moreover, expression of wild-type alpha(z) produced cells in which PTX did not block hormonal inhibition of cAMP accumulation. Thus, G(z) can trigger an effector pathway in response to hormone receptors that ordinarily interact with PTX-sensitive G(i) proteins.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Conklin, Bruce/E-4738-2019	Conklin, Bruce/0000-0003-1463-6061				BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; CANTIELLO HF, 1989, J BIOL CHEM, V264, P20867; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; DIAZLAVIADA I, 1991, J BIOL CHEM, V266, P1170; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GIERSCHIK P, 1987, FEBS LETT, V224, P219, DOI 10.1016/0014-5793(87)80451-9; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HINTON DR, 1990, J NEUROSCI, V10, P2763; HSU WH, 1990, J BIOL CHEM, V265, P11220; JONES DT, 1987, J BIOL CHEM, V262, P14241; JONES SB, 1991, MOL PHARMACOL, V39, P239; KATADA T, 1986, J BIOL CHEM, V261, P5215; KOBAYASHI I, 1990, EUR J BIOCHEM, V191, P499, DOI 10.1111/j.1432-1033.1990.tb19149.x; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LIBERT F, 1991, EMBO J, V10, P1677, DOI 10.1002/j.1460-2075.1991.tb07691.x; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAHAN LC, 1991, MOL PHARMACOL, V440, P1; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; NAMBI P, 1988, BIOCHEM J, V254, P449, DOI 10.1042/bj2540449; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; PARKER EM, 1991, J BIOL CHEM, V266, P519; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0; WONG Y, UNPUB; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0	36	250	254	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1992	255	5042					339	342		10.1126/science.1347957	http://dx.doi.org/10.1126/science.1347957			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ695	1347957				2022-12-01	WOS:A1992GZ69500045
J	BENRUBI, GI				BENRUBI, GI			EUTHANASIA - THE NEED FOR PROCEDURAL SAFEGUARDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							KILL				BENRUBI, GI (corresponding author), UNIV FLORIDA,HLTH SCI CTR,JACKSONVILLE,FL 32209, USA.							ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; COLE JJ, 1989, DEATH STUD, V13, P393, DOI 10.1080/07481188908252317; Hunter S F, 1989, JAMA, V262, P3074, DOI 10.1001/jama.262.21.3074; JONSEN AR, 1988, WESTERN J MED, V149, P195; PARKER M, 1990, J MED ETHICS, V16, P28, DOI 10.1136/jme.16.1.28; REICHEL W, 1989, LANCET, V2, P1321; Schoonheim P L, 1989, J Cancer Educ, V4, P109; SINGER PA, 1988, CAN MED ASSOC J, V138, P1000; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610	10	54	54	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1992	326	3					197	199		10.1056/NEJM199201163260311	http://dx.doi.org/10.1056/NEJM199201163260311			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GZ213	1727551				2022-12-01	WOS:A1992GZ21300011
J	BERMAN, E; LITTLE, C; GEE, T; OREILLY, R; CLARKSON, B				BERMAN, E; LITTLE, C; GEE, T; OREILLY, R; CLARKSON, B			REASONS THAT PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA DO NOT UNDERGO ALLOGENEIC BONE-MARROW TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOCYTIC-LEUKEMIA; 1ST COMPLETE REMISSION; CYTOSINE-ARABINOSIDE; INDUCTION THERAPY; CHEMOTHERAPY; DAUNORUBICIN; ADULTS; TRIAL	Background. Numerous reports suggest that allogeneic bone marrow transplantation prolongs the survival of adult patients with acute myelogenous leukemia (AML) in first remission. However, it is unclear how many such patients actually undergo this procedure. Methods. We reviewed the case records of 350 consecutive adult patients with AML treated with chemotherapy at a single institution from 1979 (when the policy of offering allogeneic transplantation to all such patients in first remission was introduced) through 1990. The criteria for exclusion before transplantation included age greater than 40 and, beginning in 1984, a diagnosis of acute promyelocytic leukemia. Results. One hundred forty-two patients (41 percent of the study population) were 40 years of age or younger. HLA testing was performed for 120 of these patients (85 percent). Sixty-seven patients (47 percent) had an HLA-identical sibling as a potential donor. One hundred three patients (73 percent) entered remission during treatment according to one of five chemotherapy protocols. Of the 52 patients who both entered remission and had an HLA match, 30 underwent transplantation while they were in first remission. These 30 patients constituted 21 percent of all study patients 40 years old or younger, 29 percent of all patients 40 or under who entered remission, 45 percent of all patients with an HLA match, 58 percent of all patients who had both a remission and a match, and 9 percent of all patients treated according to a protocol. Among patients with a match who did not undergo transplantation, those with primary refractory disease were the largest subgroup. Conclusions. These findings suggest that allogeneic bone marrow transplantation is performed in less than 60 percent of adult patients with AML who are potentially eligible for the procedure.	MEM SLOAN KETTERING CANC CTR, BONE MARROW TRANSPLANT SERV, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center	BERMAN, E (corresponding author), MEM SLOAN KETTERING CANC CTR, DEPT MED, LEUKEMIA SERV, 1275 YORK AVE, NEW YORK, NY 10021 USA.							APPELBAUM FR, 1988, BLOOD, V72, P179; ARLIN Z, 1990, LEUKEMIA, V4, P177; BERMAN E, 1991, BLOOD, V77, P1666; BISHOP JF, 1990, BLOOD, V75, P27; BRINCKER H, 1985, CANCER TREAT REP, V69, P5; CASSILETH PA, 1984, BLOOD, V63, P843; CHAMPLIN RE, 1985, ANN INTERN MED, V102, P285, DOI 10.7326/0003-4819-102-3-285; CHAN KW, 1982, TRANSPLANTATION, V33, P613, DOI 10.1097/00007890-198206000-00009; CLARKSON B, 1990, UCLA SYM BI, V108, P231; CUNNINGHAM I, 1989, BLOOD, V73, P1116; FORMAN SJ, 1987, TRANSPLANTATION, V43, P650, DOI 10.1097/00007890-198705000-00009; GELLER RB, 1989, BLOOD, V73, P2209; GRATWOHL A, 1988, LANCET, V1, P1379; HERMANS J, 1989, EUR J CANCER CLIN ON, V25, P545, DOI 10.1016/0277-5379(89)90268-X; KANTARJIAN HM, 1987, CANCER-AM CANCER SOC, V59, P1258, DOI 10.1002/1097-0142(19870401)59:7<1258::AID-CNCR2820590705>3.0.CO;2-G; LOWENBERG B, 1990, J CLIN ONCOL, V8, P287; MCGLAVE PB, 1988, BLOOD, V72, P1512; ORENTLICHER D, 1991, JAMA-J AM MED ASSOC, V266, P559; PREISLER HD, 1979, BLOOD, V53, P455; RAI KR, 1981, BLOOD, V58, P1203; STONE RM, 1988, BLOOD, V71, P690; WEINSTEIN HJ, 1980, NEW ENGL J MED, V303, P473, DOI 10.1056/NEJM198008283030901; YATES J, 1982, BLOOD, V60, P454; YOUNG JW, 1990, BLOOD S, V76, pA575; ZANDER AR, 1988, J CLIN ONCOL, V6, P1548, DOI 10.1200/JCO.1988.6.10.1548	25	54	54	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1992	326	3					156	160		10.1056/NEJM199201163260303	http://dx.doi.org/10.1056/NEJM199201163260303			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ213	1727546				2022-12-01	WOS:A1992GZ21300003
J	DUCHOSAL, MA; EMING, SA; FISCHER, P; LETURCQ, D; BARBAS, CF; MCCONAHEY, PJ; CAOTHIEN, RH; THORNTON, GB; DIXON, FJ; BURTON, DR				DUCHOSAL, MA; EMING, SA; FISCHER, P; LETURCQ, D; BARBAS, CF; MCCONAHEY, PJ; CAOTHIEN, RH; THORNTON, GB; DIXON, FJ; BURTON, DR			IMMUNIZATION OF HU-PBL-SCID MICE AND THE RESCUE OF HUMAN MONOCLONAL FAB FRAGMENTS THROUGH COMBINATORIAL LIBRARIES	NATURE			English	Article							HEPATITIS-B VIRUS; SEVERE COMBINED IMMUNODEFICIENCY; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; ANTIBODY-PRODUCTION; LYMPHOCYTES; ANTIGEN; EXPRESSION; GENERATION; MOUSE	ANTIBODIES are usually prepared from recently boosted animals and reflect ongoing immune responses 1-6. In humans, this is restrictive as ethical constraints generally prevent antigen-boosting. Therefore the rich memory compartment of human antibody responses remains largely untapped 7. Severe combined immune deficiency (SCID) mice 8 populated with human cells 9-11 allow the stimulation of human antibody memory without the usual constraints. Here we show how peripheral blood lymphocytes can be stimulated by antigen to produce large secondary responses after transfer to SCID mice. Specific monoclonal human Fab fragments can then be isolated from the mice by repertoire cloning even when the human donor's last contact with antigen was more than 17 years ago.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; RW JOHNSON PHARMACEUT RES INST, SAN DIEGO, CA 92121 USA; UNIV SHEFFIELD, KREBS INST, DEPT MOLEC BIOL & BIOTECHNOL, SHEFFIELD S10 2TN, S YORKSHIRE, ENGLAND	Scripps Research Institute; Johnson & Johnson; Johnson & Johnson USA; University of Sheffield	DUCHOSAL, MA (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Thornton, George/0000-0002-8744-4987				BANKERT RB, 1989, CURR TOP MICROBIOL, V152, P201; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BOSMA GC, 1988, J EXP MED, V167, P1016, DOI 10.1084/jem.167.3.1016; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BURTON DR, 1991, TRENDS BIOTECHNOL, V9, P169, DOI 10.1016/0167-7799(91)90055-M; CANNON MJ, 1990, J CLIN INVEST, V85, P1333, DOI 10.1172/JCI114573; CATON AJ, 1990, P NATL ACAD SCI USA, V87, P6450, DOI 10.1073/pnas.87.16.6450; CATON AJ, 1991, P NATL ACAD SCI USA, V88, P1590; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; DUCHOSAL MA, 1990, J EXP MED, V172, P985, DOI 10.1084/jem.172.3.985; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; Hansen T. H., 1989, Fundamental immunology., P445; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; JAMES K, 1987, J IMMUNOL METHODS, V100, P5, DOI 10.1016/0022-1759(87)90170-0; KRAMS SM, 1989, J EXP MED, V170, P1919, DOI 10.1084/jem.170.6.1919; LERNER RA, 1991, P NATL ACAD SCI USA, V88, P9705, DOI 10.1073/pnas.88.21.9705; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MILICH DR, 1986, SCIENCE, V234, P1398, DOI 10.1126/science.3491425; MILICH DR, 1987, NATURE, V329, P547, DOI 10.1038/329547a0; MOSIER DE, 1989, NATURE, V338, P211, DOI 10.1038/338211b0; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; PASEK M, 1979, NATURE, V282, P575, DOI 10.1038/282575a0; PERSSON MAA, 1991, P NATL ACAD SCI USA, V88, P2432, DOI 10.1073/pnas.88.6.2432; SEPPALA IJT, 1984, EUR J IMMUNOL, V14, P868, DOI 10.1002/eji.1830140918; STAHL S, 1982, P NATL ACAD SCI-BIOL, V79, P1606, DOI 10.1073/pnas.79.5.1606; TIGHE H, 1990, EUR J IMMUNOL, V20, P1843, DOI 10.1002/eji.1830200832; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; VALENZUELA P, 1979, NATURE, V280, P815, DOI 10.1038/280815a0; WILLIAMSON RA, 1991, BIOCHEM J, V277, P561, DOI 10.1042/bj2770561; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0	30	139	212	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 16	1992	355	6357					258	262		10.1038/355258a0	http://dx.doi.org/10.1038/355258a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1731222				2022-12-01	WOS:A1992GZ69400070
J	JORGENSEN, JL; ESSER, U; FAZEKAS DE ST GROTH, B; REAY, PA; DAVIS, MM				JORGENSEN, JL; ESSER, U; FAZEKAS DE ST GROTH, B; REAY, PA; DAVIS, MM			MAPPING T-CELL RECEPTOR PEPTIDE CONTACTS BY VARIANT PEPTIDE IMMUNIZATION OF SINGLE-CHAIN TRANSGENICS	NATURE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; BETA-CHAIN; ANTIGEN RECEPTOR; JUNCTIONAL REGIONS; MHC MOLECULE; RECOGNITION; GENES; SPECIFICITY; DETERMINANT; USAGE	To test models of T-cell recognition, mice transgenic for T-cell receptor-alpha or beta-chain have been immunized with variant peptides that force changes in the resulting T-cell response. In particular, charge substitutions on the peptide often elicit reciprocal charges in the junctional (CDR3) sequences of T-cell receptor V(alpha) or V(beta) chains, indicating direct T-cell receptor-peptide contact, and allowing derivation of a topology for the T-cell receptor-MHC interaction. At one position on the peptide, variants transformed a homogeneous V(beta) response into a very heterogeneous one.	STANFORD UNIV, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	JORGENSEN, JL (corresponding author), STANFORD UNIV, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA.		de St Groth, Barbara Fazekas/O-3017-2017	de St Groth, Barbara Fazekas/0000-0001-6817-9690; Davis, Mark/0000-0001-6868-657X				ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; AEBISCHER T, 1990, EUR J IMMUNOL, V20, P523, DOI 10.1002/eji.1830200310; AJITKUMAR P, 1988, CELL, V54, P47, DOI 10.1016/0092-8674(88)90178-X; BOTSTEIN D, 1982, ANNU REV GENET, V16, P61, DOI 10.1146/annurev.ge.16.120182.000425; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; CHEN SZ, 1990, BIOTECHNIQUES, V8, P32; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CLAVERIE JM, 1989, IMMUNOL TODAY, V10, P10, DOI 10.1016/0167-5699(89)90058-3; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; DANSKA JS, 1990, J EXP MED, V172, P27, DOI 10.1084/jem.172.1.27; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.biochem.59.1.439; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; ENGEL I, 1988, CELL, V54, P473, DOI 10.1016/0092-8674(88)90068-2; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FINK PJ, 1986, NATURE, V321, P219, DOI 10.1038/321219a0; FOX BS, 1987, J IMMUNOL, V139, P1578; FOX BS, 1988, NATURE, V331, P538, DOI 10.1038/331538a0; GASCOIGNE NRJ, 1984, NATURE, V310, P387, DOI 10.1038/310387a0; HEDRICK SM, 1988, ADV IMMUNOL, V43, P193; HEDRICK SM, 1988, SCIENCE, V239, P1541, DOI 10.1126/science.2832942; HUPPI KE, 1988, IMMUNOGENETICS, V27, P51, DOI 10.1007/BF00404444; JAMESON SC, 1991, J IMMUNOL, V147, P3185; JARVIK J, 1975, P NATL ACAD SCI USA, V72, P2738, DOI 10.1073/pnas.72.7.2738; KANAGAWA O, 1989, CELL IMMUNOL, V119, P412, DOI 10.1016/0008-8749(89)90255-4; KRIEGER JI, 1991, J IMMUNOL, V146, P2331; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; LAI MZ, 1990, J IMMUNOL, V144, P4851; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P742, DOI 10.1073/pnas.83.3.742; PECCOUD J, 1990, EMBO J, V9, P4215, DOI 10.1002/j.1460-2075.1990.tb07869.x; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; ROCK KL, 1985, HYBRIDOMA TECHNOLOGY, P527; RODEWALD HR, 1989, J IMMUNOL, V143, P4238; RONCHESE F, 1987, NATURE, V329, P254, DOI 10.1038/329254a0; SAITO T, 1987, NATURE, V329, P256, DOI 10.1038/329256a0; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCHWARTZ RH, 1985, J IMMUNOL, V135, P2598; SORGER SB, 1990, J IMMUNOL, V144, P1127; STAERZ UD, 1985, J IMMUNOL, V134, P3994; TAYLOR AH, 1990, J EXP MED, V172, P1643, DOI 10.1084/jem.172.6.1643; TJOELKER LW, 1990, P NATL ACAD SCI USA, V87, P7856, DOI 10.1073/pnas.87.20.7856; TOMONARI K, 1990, IMMUNOGENETICS, V32, P60, DOI 10.1007/BF01787331; URBAN JL, 1988, CELL, V54, P577, DOI 10.1016/0092-8674(88)90079-7; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219; WHITE J, 1989, J IMMUNOL, V143, P1822; WITHER J, 1991, J IMMUNOL, V146, P3513; YANAGI Y, 1990, J VIROL, V64, P5919, DOI 10.1128/JVI.64.12.5919-5926.1990; ZINKERNA.RM, 1974, NATURE, V251, P547, DOI 10.1038/251547a0	51	530	534	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 16	1992	355	6357					224	230		10.1038/355224a0	http://dx.doi.org/10.1038/355224a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1309938				2022-12-01	WOS:A1992GZ69400056
J	LASIC, DD				LASIC, DD			MIXED MICELLES IN DRUG DELIVERY	NATURE			English	Article							AMPHOTERICIN-B				LASIC, DD (corresponding author), LIPOSOME TECHNOL INC,1050 HAMILTON COURT,MENLO PK,CA 94025, USA.							BRODIN A, 1982, ACTA PHARM SUEC, V19, P267; CANTU L, 1990, EUROPHYS LETT, V13, P561, DOI 10.1209/0295-5075/13/6/015; FIELDING RM, 1991, ANTIMICROB AGENTS CH, V35, P1208, DOI 10.1128/AAC.35.6.1208; FIELDING RM, IN PRESS ANTIMICROB; GUENTERT TW, 1987, BRIT J CLIN PHARMACO, V23, P569, DOI 10.1111/j.1365-2125.1987.tb03093.x; GUO LSS, 1991, INT J PHARM, V75, P45, DOI 10.1016/0378-5173(91)90249-N; JANOFF AS, 1988, P NATL ACAD SCI USA, V85, P6122, DOI 10.1073/pnas.85.16.6122; LASIC DD, 1982, BIOCHIM BIOPHYS ACTA, V692, P501, DOI 10.1016/0005-2736(82)90404-7; LASIC DD, 1988, BIOCHEM J, V256, P1; LASIC DD, 1991, BIOCHIM BIOPHYS ACTA, V1070, P187, DOI 10.1016/0005-2736(91)90162-2; LASIC DD, 1991, PERIOD BIOL, V93, P287; LOPEZBERESTEIN G, 1985, J INFECT DIS, V151, P704, DOI 10.1093/infdis/151.4.704; PAPAHADJOPOULOS P, 1991, P NATL ACAD SCI USA, V88, P11460; Prescott L.F., 1989, NOVEL DRUG DELIVERY; YOKOYAMA M, 1990, CANCER RES, V50, P1693	15	151	165	1	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1992	355	6357					279	280		10.1038/355279a0	http://dx.doi.org/10.1038/355279a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1731228				2022-12-01	WOS:A1992GZ69400077
J	LIFTON, RP; DLUHY, RG; POWERS, M; RICH, GM; COOK, S; ULICK, S; LALOUEL, JM				LIFTON, RP; DLUHY, RG; POWERS, M; RICH, GM; COOK, S; ULICK, S; LALOUEL, JM			A CHIMERIC 11-BETA-HYDROXYLASE ALDOSTERONE SYNTHASE GENE CAUSES GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM AND HUMAN HYPERTENSION	NATURE			English	Article							POLYMERASE CHAIN-REACTION; DNA; CLONING; IDENTIFICATION; 18-OXOCORTISOL; POLYMORPHISMS; CDNA; RNA	GLUCOCORTICOID-REMEDIABLE aldosteronism (GRA), an autosomal dominant disorder, is characterized by hypertension with variable hyperaldosteronism 1,2 and by high levels of the abnormal adrenal steroids 18-oxocortisol and 18-hydroxycortisol 3-5, which are all under control of adrenocorticotropic hormone and suppressible by glucocorticoids 6. These abnormalities could result from ectopic expression of aldosterone synthase, which is normally expressed only in adrenal glomerulosa, in the adrenal fasciculata. Genes encoding aldosterone synthase 7-9 and steroid 11-beta-hydroxylase 7 (expressed in both adrenal fasciculata and glomerulosa), which are 95% identical 7 and lie on chromosome 8q (refs 7, 10), are therefore candidate genes for GRA. Here we demonstrate complete linkage of GRA in a large kindred to a gene duplication arising from unequal crossing over, fusing the 5' regulatory region of 11-beta-hydroxylase to the coding sequences of aldosterone synthase (maximum lod score 5.23 for complete linkage, odds ratio of 170,000:1). This mutation can account for all the physiological abnormalities of GRA. Our result represents the demonstration of a mutation causing hypertension in otherwise phenotypically normal animals or humans.	BRIGHAM & WOMENS HOSP,DIV ENDOCRINE HYPERTENS,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; VET AFFAIRS HOSP,BRONX,NY 10468	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	LIFTON, RP (corresponding author), UNIV UTAH,ECCLES INST HUMAN GENET,HOWARD HUGHES MED INST,SUITE 6200,SALT LAKE CITY,UT 84132, USA.							BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; CHU MD, 1982, J BIOL CHEM, V257, P2218; CHUA SC, 1987, P NATL ACAD SCI USA, V84, P7193, DOI 10.1073/pnas.84.20.7193; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GOMEZSANCHEZ CE, 1984, J CLIN ENDOCR METAB, V59, P1022, DOI 10.1210/jcem-59-5-1022; KAWAMOTO T, 1990, BIOCHEM BIOPH RES CO, V173, P309, DOI 10.1016/S0006-291X(05)81058-7; LIFTON RP, 1990, GENOMICS, V7, P131, DOI 10.1016/0888-7543(90)90530-8; MORNET E, 1989, J BIOL CHEM, V264, P20961; NEW MI, 1967, J CLIN ENDOCR METAB, V27, P300, DOI 10.1210/jcem-27-2-300; OGISHIMA T, 1991, J BIOL CHEM, V266, P10731; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PICKERING GW, 1990, HYPERTENSION PATHOPH, P18; PLATT ROBERT, 1967, P9; SCHOWALTER DB, 1989, ANAL BIOCHEM, V177, P90, DOI 10.1016/0003-2697(89)90019-5; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; SUTHERLAND DJ, 1966, CAN MED ASSOC J, V95, P1109; ULICK S, 1991, J STEROID BIOCHEM, V38, P59, DOI 10.1016/0960-0760(91)90401-P; ULICK S, 1990, J CLIN ENDOCR METAB, V71, P1151, DOI 10.1210/jcem-71-5-1151; ULICK S, 1983, J BIOL CHEM, V258, P5498; WHITE PC, 1988, P NATL ACAD SCI USA, V85, P4436, DOI 10.1073/pnas.85.12.4436	21	927	941	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1992	355	6357					262	265		10.1038/355262a0	http://dx.doi.org/10.1038/355262a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1731223				2022-12-01	WOS:A1992GZ69400071
J	MAKI, H; SEKIGUCHI, M				MAKI, H; SEKIGUCHI, M			MUTT PROTEIN SPECIFICALLY HYDROLYZES A POTENT MUTAGENIC SUBSTRATE FOR DNA-SYNTHESIS	NATURE			English	Article							ESCHERICHIA-COLI; POLYMERASE SUBUNIT; MOLECULAR-CLONING; FIDELITY; MUTATOR; PURIFICATION; REPLICATION; SITE	ERRORS in the replication of DNA are a major source of spontaneous mutations, and a number of cellular functions are involved in correction of these errors to keep the frequency of spontaneous mutations very low 1. We report here a novel mechanism which prevents replicational errors by degrading a potent mutagenic substrate for DNA synthesis. This error-avoiding process is catalysed by a protein encoded by the mutT gene of Escherichia coli, mutations of which increase the occurrence of A . T --> C . G transversions 100 to 10,000 times the level of the wild type 2. Spontaneous oxidation of dGTP forms 8-oxo-7,8-dihydro-2'-dGTP (8-oxodGTP), which is inserted opposite dA and dC residues of template DNA with almost equal efficiency, and the MutT protein specifically degrades 8-oxodGTP to the monophosphate. This indicates that elimination from the nucleotide pool of the oxidized form of guanine nucleotide is important for the high fidelity of DNA synthesis.			MAKI, H (corresponding author), KYUSHU UNIV,FAC MED,DEPT BIOCHEM,FUKUOKA 812,JAPAN.							AKIYAMA M, 1987, MOL GEN GENET, V206, P9, DOI 10.1007/BF00326530; AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CABRERA M, 1988, J BACTERIOL, V170, P5405, DOI 10.1128/jb.170.11.5405-5407.1988; FERSHT A, 1977, ENZYME STRUCTURE MEC, P91; HORIUCHI T, 1989, B I PASTEUR, V87, P309; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; KASAI H, 1991, OXIDATIVE STRESS OXI, P99; KASAI H, 1984, JPN J CANCER RES, V75, P1037; MAKI H, 1985, J BIOL CHEM, V260, P2987; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SLOANE DL, 1988, NUCLEIC ACIDS RES, V16, P6465, DOI 10.1093/nar/16.14.6465; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274	19	814	834	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1992	355	6357					273	275		10.1038/355273a0	http://dx.doi.org/10.1038/355273a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1309939				2022-12-01	WOS:A1992GZ69400075
J	MOTTONEN, J; STRAND, A; SYMERSKY, J; SWEET, RM; DANLEY, DE; GEOGHEGAN, KF; GERARD, RD; GOLDSMITH, EJ				MOTTONEN, J; STRAND, A; SYMERSKY, J; SWEET, RM; DANLEY, DE; GEOGHEGAN, KF; GERARD, RD; GOLDSMITH, EJ			STRUCTURAL BASIS OF LATENCY IN PLASMINOGEN-ACTIVATOR INHIBITOR-1	NATURE			English	Article							HUMAN ALPHA-1-PROTEINASE INHIBITOR; CRYSTAL-STRUCTURE; SERPINS; ALPHA-1-ANTITRYPSIN; MODEL; ANTITHROMBIN; PLAKALBUMIN; REFINEMENT; OVALBUMIN; MUTANTS	HuMAN plasminogen activator inhibitor-1 (PAI-1) 1,2 is the fast-acting inhibitor of tissue plasminogen activator and urokinase 3 and is a member of the serpin family of protease inhibitors 4. Serpins normally form complexes with their target proteases that dissociate very slowly as cleaved species and then fold into a highly stable inactive state 5 in which the residues that flank the scissile bond (P1 and P1'; ref. 6) are separated by about 70 angstrom (refs 7-9). PAI-1 also spontaneously folds into a stable 10 inactive state without cleavage; this state is termed 'latent' because inhibitory activity can be restored through denaturation and renaturation 2,10. Here we report the structure of intact latent PAI-1 determined by single-crystal X-ray diffraction to 2.6 angstrom resolution. The three-dimensional structure reveals that residues on the N-terminal side of the primary recognition site are inserted as a central strand of the largest beta-sheet, in positions similar to the corresponding residues in the cleaved form of the serpin alpha-1-proteinase inhibitor (alpha-1-PI) 7. Residues C-terminal to the recognition site occupy positions on the surface of the molecule distinct from those of the corresponding residues in cleaved serpins 7-9 or in the intact inactive serpin homologue, ovalbumin 11, and its cleavage product, plakal-bumin 12. The structure of latent PAI-1 is similar to one formed after cleavage in other serpins, and the stability of both latent PAI-1 and cleaved serpins may be derived from the same structural features 13,14.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; BROOKHAVEN NATL LAB, DEPT BIOL, UPTON, NY 11973 USA; PFIZER INC, DIV CENT RES, DEPT MOLEC GENET & PROT CHEM, GROTON, CT 06340 USA; UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; United States Department of Energy (DOE); Brookhaven National Laboratory; Pfizer; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BRUCH M, 1988, J BIOL CHEM, V263, P16626; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; CROWTHER RA, 1969, ACTA CRYSTALL B-STRU, VB 25, P2571, DOI 10.1107/S0567740869006091; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRANKE AE, 1990, BIOCHIM BIOPHYS ACTA, V1037, P16, DOI 10.1016/0167-4838(90)90096-X; GOLDSMITH EJ, 1991, PROTEINS, V9, P225, DOI 10.1002/prot.340090308; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JONES TA, 1991, VERSION 54; KATAGIRI K, 1988, EUR J BIOCHEM, V176, P81, DOI 10.1111/j.1432-1033.1988.tb14253.x; KRESS LF, 1979, J BIOL CHEM, V254, P5317; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MOUREY L, 1990, BIOCHIMIE, V72, P599, DOI 10.1016/0300-9084(90)90123-X; MUNCH M, IN PRESS EMBO J; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; PAPAMOKOS E, 1982, J MOL BIOL, V158, P515, DOI 10.1016/0022-2836(82)90212-1; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2; WRIGHT HT, 1990, J MOL BIOL, V213, P513	33	534	549	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 16	1992	355	6357					270	273		10.1038/355270a0	http://dx.doi.org/10.1038/355270a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1731226				2022-12-01	WOS:A1992GZ69400074
J	SALSER, SJ; KENYON, C				SALSER, SJ; KENYON, C			ACTIVATION OF A C-ELEGANS ANTENNAPEDIA HOMOLOG IN MIGRATING CELLS CONTROLS THEIR DIRECTION OF MIGRATION	NATURE			English	Article							CAENORHABDITIS-ELEGANS; TRANSGENIC MICE; GENE; EXPRESSION; HOMEOBOX; NEMATODE	ANTERIOR-POSTERIOR patterning in insects, vertebrates and nematodes involves members of conserved Antennapedia-class homeobox gene clusters (HOM-C) that are thought to give specific body regions their identities 1-5. The effects of these genes on region-specific body structures have been described extensively, particularly in Drosophila, but little is known about how HOM-C genes affect the behaviours of cells that migrate into their domains of function. In Caenorhabditis elegans, the Antennapedia-like HOM-C gene mab-5 not only specifies postembryonic fates of cells in a posterior body region, but also influences the migration of mesodermal and neural cells that move through this region 5-7. Here we show that as one neuroblast migrates into this posterior region, it switches on mab-5 gene expression; mab-5 then acts as a developmental switch to control the migratory behaviour of the neuroblast descendants. HOM-C genes can therefore not only direct region-specific patterns of cell division and differentiation, but can also act within migrating cells to programme region-specific migratory behaviour.			SALSER, SJ (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; BURGLIN TR, 1991, NATURE, V351, P703, DOI 10.1038/351703a0; CHALFIE M, 1983, SCIENCE, V221, P61, DOI 10.1126/science.6857263; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHO KWY, 1988, EMBO J, V7, P2139, DOI 10.1002/j.1460-2075.1988.tb03053.x; COSTA M, 1988, CELL, V55, P747, DOI 10.1016/0092-8674(88)90131-6; DAMSKY CH, IN PRESS J CLIN INVE; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HUNT P, 1991, DEVELOPMENT, V112, P43; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KENYON C, 1991, SCIENCE, V253, P516, DOI 10.1126/science.1677487; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; MELLO C, IN PRESS EMBO J; REID L, 1990, CELL, V63, P875, DOI 10.1016/0092-8674(90)90491-V; RUSSNAK RH, 1985, MOL CELL BIOL, V5, P1268, DOI 10.1128/MCB.5.6.1268; STRINGHAM EG, IN PRESS MOL BIOL CE; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WOLGEMUTH DJ, 1989, NATURE, V337, P464, DOI 10.1038/337464a0	27	144	147	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1992	355	6357					255	258		10.1038/355255a0	http://dx.doi.org/10.1038/355255a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1346230				2022-12-01	WOS:A1992GZ69400069
J	SELLECK, SB; GONZALEZ, C; GLOVER, DM; WHITE, K				SELLECK, SB; GONZALEZ, C; GLOVER, DM; WHITE, K			REGULATION OF THE G1-S TRANSITION IN POSTEMBRYONIC NEURONAL PRECURSORS BY AXON INGROWTH	NATURE			English	Article							DROSOPHILA CYCLIN-A; OPTIC-LOBES; NERVOUS-SYSTEM; CELL-DIVISION; MELANOGASTER; PATTERNS; NEUROGENESIS	IN the newly cellularized Drosophila embryo, progress through the cell cycle is regulated at the G2-M transition 1,2. We have examined cell-cycle regulation later in Drosophila development, in a group of postembryonic neuronal precursors. The S-phase precursor cells, which generate photoreceptor target neurons (lamina neurons) in the central nervous system, are not present in the absence of photoreceptor innervation 3. Here we report that axons selectively approach G1-phase precursors. Without axon ingrowth, lamina precursors do not enter their final S phase and by several criteria, arrest in the preceding G1 phase. These findings provide evidence that at this stage in development the control of cell division can occur at the G1-S transition.	UNIV DUNDEE,DEPT BIOCHEM,CANC RES CAMPAIGN LABS,CELL CYCLE GENET GRP,DUNDEE DD1 4HN,SCOTLAND	University of Dundee	SELLECK, SB (corresponding author), BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254, USA.		Gonzalez, Cayetano/K-3055-2019; Gonzalez, Cayetano/K-3933-2019	Gonzalez, Cayetano/0000-0002-5259-3608; Glover, David/0000-0003-0956-0103				BAPTISTA CA, 1990, NATURE, V346, P855, DOI 10.1038/346855a0; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; FISCHBACH KF, 1984, DEV BIOL, V104, P219, DOI 10.1016/0012-1606(84)90050-2; FISCHBACH KF, 1983, DEV BIOL, V95, P1, DOI 10.1016/0012-1606(83)90002-7; HOFBAUER A, 1990, ROUX ARCH DEV BIOL, V198, P264, DOI 10.1007/BF00377393; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LINDSLEY DI, 1968, CARNEGIE I PUBL, V627; RATNER N, 1988, P NATL ACAD SCI USA, V85, P6992, DOI 10.1073/pnas.85.18.6992; SELLECK SB, 1991, NEURON, V6, P83, DOI 10.1016/0896-6273(91)90124-I; TRUMAN JW, 1988, DEV BIOL, V125, P145, DOI 10.1016/0012-1606(88)90067-X; WHITE K, 1978, DEV BIOL, V65, P296, DOI 10.1016/0012-1606(78)90029-5; WHITE K, 1986, J COMP NEUROL, V247, P430, DOI 10.1002/cne.902470403; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x	16	90	90	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1992	355	6357					253	255		10.1038/355253a0	http://dx.doi.org/10.1038/355253a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1731221				2022-12-01	WOS:A1992GZ69400068
J	SHAYWITZ, SE; ESCOBAR, MD; SHAYWITZ, BA; FLETCHER, JM; MAKUCH, R				SHAYWITZ, SE; ESCOBAR, MD; SHAYWITZ, BA; FLETCHER, JM; MAKUCH, R			EVIDENCE THAT DYSLEXIA MAY REPRESENT THE LOWER TAIL OF A NORMAL-DISTRIBUTION OF READING-ABILITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RETARDATION; PREVALENCE; BOYS	Background. Dyslexia is now widely believed to be a biologically based disorder that is distinct from other, less specific reading problems. According to this view, reading ability is considered to follow a bimodal distribution, with dyslexia as the lower mode. We hypothesized that, instead, reading ability follows a normal distribution, with dyslexia at the lower end of the continuum. Methods and Results. We used data from the Connecticut Longitudinal Study, a sample survey of 414 Connecticut children who entered kindergarten in 1983 and were followed as a longitudinal cohort. Dyslexia was defined in terms of a discrepancy score, which represents the difference between actual reading achievement and achievement predicted on the basis of measures of intelligence. Data were available from intelligence tests administered in grades 1, 3, and 5 and achievement tests administered yearly in grades 1 through 6. For each child there were 108 possible discrepancy scores ([3 x 3 years] x [2 x 6 years]) based on combinations of the ability scores (full-scale, verbal, and performance 10) in each of three years and two achievement scores (reading and mathematics) in each of six years. We demonstrated that each of the discrepancy scores followed a univariate normal distribution and that the interrelation of two different discrepancy scores followed a bivariate normal distribution. At most, only 9 of 108 discrepancy scores (8.3 percent) and 171 of 3402 pairs of discrepancy scores (5-0 percent) were significantly different (at the 5 percent level) from the expected scores - well within the expected values for data with univariate and bivariate normal distributions, respectively. We also examined the stability of dyslexia over time. The normal-distribution model predicted (and the data indicated) that only 7 of the 25 children (28 percent) classified as having dyslexia in grade 1 would also be classified as having dyslexia in grade 3. Conclusions. Reading difficulties, including dyslexia, occur as part of a continuum that also includes normal reading ability. Dyslexia is not an all-or-none phenomenon, but like hypertension, occurs in degrees. The variability inherent in the diagnosis of dyslexia can be both quantified and predicted with use of the normal-distribution model.	YALE UNIV,SCH MED,DEPT NEUROL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,CTR CHILD STUDY,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DIV BIOSTAT,NEW HAVEN,CT 06510; CARNEGIE MELLON UNIV,DEPT STAT,PITTSBURGH,PA 15213; UNIV TEXAS,DEPT PEDIAT,HOUSTON,TX 77025	Yale University; Yale University; Yale University; Carnegie Mellon University; University of Texas System	SHAYWITZ, SE (corresponding author), YALE UNIV,SCH MED,DEPT PEDIAT,POB 3333,NEW HAVEN,CT 06510, USA.		Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD025802, P01HD021888] Funding Source: NIH RePORTER; NICHD NIH HHS [P50 HD25802, P01 HD21888] Funding Source: Medline; NIMH NIH HHS [MH15758] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BADIAN NA, 1982, J SPEC EDUC, V16, P309, DOI 10.1177/002246698201600306; BADIAN NA, 1988, PRESCHOOL PREVENTION, P78; CONE TE, 1981, LEARN DISABILITY Q, V4, P359, DOI 10.2307/1510737; CRITCHLEY M, 1970, DYSLEXIC CHILD; de Hirsch K., 1966, PREDICTING READING F; HOGG R, 1970, INTRO MATH STAT, P166; JANSKY JJ, 1989, ANN DYSLEXIA, V39, P227, DOI 10.1007/BF02656911; MAKUCH RW, 1989, STATISTICIAN, V38, P61; PRENTICE RL, 1986, J AM STAT ASSOC, V81, P321, DOI 10.2307/2289219; REYNOLDS CR, 1984, J SPEC EDUC, V18, P451, DOI 10.1177/002246698401800403; Reynolds CR, 1990, HDB PSYCHOL ED ASSES, P571; RODGERS B, 1983, BRIT J EDUC PSYCHOL, V53, P369, DOI 10.1111/j.2044-8279.1983.tb02570.x; RUTTER M, 1975, J CHILD PSYCHOL PSYC, V16, P181, DOI 10.1111/j.1469-7610.1975.tb01269.x; RUTTER M, 1981, ED HLTH BEHAVIOR; SATTLER JM, 1988, ASSESSMENT CHILDRENS; SHAYWITZ SE, 1990, JAMA-J AM MED ASSOC, V264, P998, DOI 10.1001/jama.264.8.998; SILVA PA, 1985, J CHILD PSYCHOL PSYC, V26, P407, DOI 10.1111/j.1469-7610.1985.tb01942.x; THORNDIKE RL, 1963, CONCEPTS OVER UNDER; VANDERWISSEL A, 1985, BRIT J DEV PSYCHOL, V3, P3; Wechsler D., 1997, WECHSLER INTELLIGENC; Woodcock R.W., 1977, WOODCOCK JOHNSON PSY; YULE W, 1974, BRIT J EDUC PSYCHOL, V44, P1, DOI 10.1111/j.2044-8279.1974.tb00760.x; YULE W, 1985, CHILD ADOLESCENT PSY, P444; 1977, FED REGISTER, V42, P62082; 1989, JAMA-J AM MED ASSOC, V261, P2236	25	489	490	0	27	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1992	326	3					145	150		10.1056/NEJM199201163260301	http://dx.doi.org/10.1056/NEJM199201163260301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GZ213	1727544				2022-12-01	WOS:A1992GZ21300001
J	SNOWDEN, RJ; HAMMETT, ST				SNOWDEN, RJ; HAMMETT, ST			SUBTRACTIVE AND DIVISIVE ADAPTATION IN THE HUMAN VISUAL-SYSTEM	NATURE			English	Article							SPATIAL-FREQUENCY; CORTICAL-NEURONS; STRIATE CORTEX; INHIBITION; ORIENTATION; CAT; CONTRAST; SPECIFICITY; SELECTIVITY; CELLS	SENSORY systems can adapt to the conditions imposed on them 1. In the visual system, adapting to a pattern increases the threshold of the ability to see that pattern, and reduces the perceived contrast of the pattern above threshold 2-4. Most neurons of the striate cortex reduce their responsiveness after being stimulated for some time by a high-contrast pattern 5-7. Such an effect may lie behind these psychophysical adaptation phenomena 2-4. These adaptation effects have been reported to be confined to patterns of similar orientation, which is understandable in that the visual neurons that adapt are only excited by a small range of orientations 8. Neurophysiological evidence suggests that neurons with different orientation preferences have inhibitory interconnections 9-13. It is therefore of interest to explore the possible effects of these connections on perception. Here we show that adapting to a horizontal pattern can reduce the perceived contrast of a vertical test pattern more than a horizontal test pattern. These 'cross-orientation' effects are modelled by a division-like process, whereas the more normal 'similar-orientation' effects are modelled by a subtractive process.			SNOWDEN, RJ (corresponding author), UNIV WALES COLL CARDIFF,SCH PSYCHOL,POB 901,CARDIFF CF1 3YG,WALES.							ALBRECHT DG, 1982, J NEUROPHYSIOL, V48, P217, DOI 10.1152/jn.1982.48.1.217; BENEVENTO LA, 1972, NATURE-NEW BIOL, V238, P124, DOI 10.1038/newbio238124a0; BLAKEMORE C, 1971, J PHYSIOL-LONDON, V213, P157, DOI 10.1113/jphysiol.1971.sp009374; BLAKEMORE C, 1973, VISION RES, V13, P1915, DOI 10.1016/0042-6989(73)90063-1; BLAKEMORE CB, 1971, SCIENCE, V166, P245; BONDS AB, 1989, VISUAL NEUROSCI, V2, P41, DOI 10.1017/S0952523800004314; DEALY RS, 1974, J PHYSIOL-LONDON, V241, P261, DOI 10.1113/jphysiol.1974.sp010652; DEAN AF, 1980, J PHYSIOL-LONDON, V308, P84; GEORGESON M A, 1985, Spatial Vision, V1, P103, DOI 10.1163/156856885X00125; Gibson JJ, 1937, J EXP PSYCHOL, V20, P453, DOI 10.1037/h0059826; GILINSKY AS, 1968, J OPT SOC AM, V58, P13, DOI 10.1364/JOSA.58.000013; GREENLEE MW, 1988, VISION RES, V28, P1303, DOI 10.1016/0042-6989(88)90061-2; HEELEY DW, 1979, VISION RES, V29, P1229; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; MAFFEI L, 1973, SCIENCE, V182, P1036, DOI 10.1126/science.182.4116.1036; MOLLON J, 1974, New Scientist, V61, P479; MORRONE MC, 1982, PROC R SOC SER B-BIO, V216, P335, DOI 10.1098/rspb.1982.0078; MORRONE MC, 1986, NATURE, V321, P235, DOI 10.1038/321235a0; MOVSHON JA, 1979, NATURE, V278, P850, DOI 10.1038/278850a0; OHZAWA I, 1982, NATURE, V298, P266, DOI 10.1038/298266a0; RAMOA AS, 1986, NATURE, V321, P237, DOI 10.1038/321237a0; SILLITO AM, 1979, TRENDS NEUROSCI, V2, P196, DOI 10.1016/0166-2236(79)90078-X; SNOWDEN RJ, 1991, J NEUROSCI, V11, P2768; TOLHURST DJ, 1981, EXP BRAIN RES, V41, P414	24	49	49	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1992	355	6357					248	250		10.1038/355248a0	http://dx.doi.org/10.1038/355248a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1731220				2022-12-01	WOS:A1992GZ69400066
J	STOUT, JE; YU, VL; MURACA, P; JOLY, J; TROUP, N; TOMPKINS, LS				STOUT, JE; YU, VL; MURACA, P; JOLY, J; TROUP, N; TOMPKINS, LS			POTABLE WATER AS A CAUSE OF SPORADIC CASES OF COMMUNITY-ACQUIRED LEGIONNAIRES-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEGIONELLA-PNEUMOPHILA CONTAMINATION; DISTRIBUTION-SYSTEMS; PNEUMONIA; PREVALENCE	Background. The environmental sources of sporadic, community-acquired legionnaires' disease are largely unknown, and culturing of water sources after identification of a case is currently not recommended. We conducted a prospective study of sporadic cases of community-acquired legionnaires' disease to determine whether the environmental reservoirs could be identified. Methods. We cultured samples of potable water obtained from sources to which each of 20 patients with culture-confirmed, community-acquired legionnaires' disease had been exposed during the two weeks before the onset of symptoms. Monoclonal-antibody subtyping and restriction-endonuclease analysis were performed on the legionella isolates recovered from both the patients and the associated environmental cultures. Results. For 8 of the 20 patients, isolates of Legionella pneumophila with identical subtypes were identified in cultures from both the patient and the potable water to which the patient had been exposed. The environmental reservoirs linked to the infections were the water supplies of two private residences, two nursing homes, two hospital outpatient clinics, and an industrial plant. Conclusions. Potable-water supplies that harbor L. pneumophila are an important source of community-acquired legionnaires' disease. Future studies should include attempts to identify the environmental sources of this infection.	VET AFFAIRS MED CTR, INFECT DIS SECT, UNIV DR C, PITTSBURGH, PA 15240 USA; UNIV PITTSBURGH, PITTSBURGH, PA 15260 USA; UNIV LAVAL, QUEBEC CITY G1K 7P4, QUEBEC, CANADA; STANFORD UNIV, MED CTR, STANFORD, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Laval University; Stanford University								[Anonymous], 1985, CAN MED ASSOC J, V132, P160; ARNOW PM, 1985, J INFECT DIS, V152, P145, DOI 10.1093/infdis/152.1.145; AUBERTIN J, 1987, INFECTION, V15, P328, DOI 10.1007/BF01647732; BATES JH, 1989, CHEST, V95, pS194, DOI 10.1378/chest.95.3_Supplement.194S; BEST M, 1983, LANCET, V2, P307; CHERRY WB, 1978, J CLIN MICROBIOL, V8, P329; EZZEDDINE H, 1989, J HOSP INFECT, V13, P121, DOI 10.1016/0195-6701(89)90018-2; FALCO V, 1991, CHEST, V100, P1007, DOI 10.1378/chest.100.4.1007; FANG GD, 1990, MEDICINE, V69, P307, DOI 10.1097/00005792-199009000-00004; FIELDS BS, 1984, APPL ENVIRON MICROB, V47, P467, DOI 10.1128/AEM.47.3.467-471.1984; FISHERHOCH SP, 1981, LANCET, V1, P932; FRIISMOLLER A, 1986, SCAND J INFECT DIS, V18, P321, DOI 10.3109/00365548609032343; JOLY JR, 1986, J CLIN MICROBIOL, V23, P768, DOI 10.1128/JCM.23.4.768-771.1986; KLIMEK JJ, 1983, AM J INFECT CONTROL, V11, P79, DOI 10.1016/0196-6553(83)90117-7; LEE TC, 1988, ARCH ENVIRON HEALTH, V43, P59, DOI 10.1080/00039896.1988.9934375; MACFARLANE JT, 1982, LANCET, V2, P255; MUDER RR, 1983, JAMA-J AM MED ASSOC, V249, P3184, DOI 10.1001/jama.249.23.3184; MUDER RR, 1986, ARCH INTERN MED, V146, P1607, DOI 10.1001/archinte.146.8.1607; MURACA PW, 1988, AM IND HYG ASSOC J, V49, P584, DOI 10.1202/0002-8894(1988)049&lt;0584:LDITWE&gt;2.0.CO;2; MURACA PW, 1990, INFECT CONT HOSP EP, V11, P79, DOI 10.1086/646126; REDD SC, 1987, JAMA-J AM MED ASSOC, V257, P1221, DOI 10.1001/jama.257.9.1221; REDD SC, 1987, JAMA-J AM MED ASSOC, V2, P274; RUF B, 1989, LUNG, V167, P11, DOI 10.1007/BF02714926; STOUT JE, 1985, APPL ENVIRON MICROB, V49, P221, DOI 10.1128/AEM.49.1.221-228.1985; STOUT JE, 1987, JAMA-J AM MED ASSOC, V257, P2595; SYNDER MB, 1990, J INFECT DIS, V162, P127, DOI 10.1093/infdis/162.1.127; TOMPKINS LS, 1987, J CLIN MICROBIOL, V25, P1875, DOI 10.1128/JCM.25.10.1875-1880.1987; Vickers R M, 1987, Semin Respir Infect, V2, P274; VICKERS RM, 1987, INFECT CONT HOSP EP, V8, P357, DOI 10.1017/S0195941700067412; VICKERS RM, IN PRESS J CLIN MICR; WADOWSKY RM, 1985, APPL ENVIRON MICROB, V49, P1197, DOI 10.1128/AEM.49.5.1197-1205.1985; WITHERELL LE, 1988, J AM WATER WORKS ASS, V80, P87	32	122	127	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1992	326	3					151	155		10.1056/NEJM199201163260302	http://dx.doi.org/10.1056/NEJM199201163260302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ213	1727545				2022-12-01	WOS:A1992GZ21300002
J	WEBER, R; BRYAN, RT; OWEN, RL; WILCOX, CM; GORELKIN, L; VISVESVARA, GS; JURANEK, DD; ADDISS, DG; SPENCER, HC; HIGHTOWER, AW; STEWART, JM; ROBERTS, JM; WAHLQUIST, SP; HORSBURGH, CR; CASTRO, KG; TAUXE, RV; VUGIA, DJ; GLASS, RI; THOMPSON, SE; SCHWARTZ, DA; KOZARSKY, PE; STEINBERG, JP; SHULMAN, JA; DISMUKES, RM; DUPUIS, MH; NICKERSON, JF; RIMLAND, D; HOGAN, SE; JOHNSON, A; ELLIOTT, N				WEBER, R; BRYAN, RT; OWEN, RL; WILCOX, CM; GORELKIN, L; VISVESVARA, GS; JURANEK, DD; ADDISS, DG; SPENCER, HC; HIGHTOWER, AW; STEWART, JM; ROBERTS, JM; WAHLQUIST, SP; HORSBURGH, CR; CASTRO, KG; TAUXE, RV; VUGIA, DJ; GLASS, RI; THOMPSON, SE; SCHWARTZ, DA; KOZARSKY, PE; STEINBERG, JP; SHULMAN, JA; DISMUKES, RM; DUPUIS, MH; NICKERSON, JF; RIMLAND, D; HOGAN, SE; JOHNSON, A; ELLIOTT, N			IMPROVED LIGHT-MICROSCOPIC DETECTION OF MICROSPORIDIA SPORES IN STOOL AND DUODENAL ASPIRATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; AIDS PATIENTS; INTESTINAL MICROSPORIDIOSIS; ENTEROCYTOZOON-BIENEUSI; NOSEMATOSIS; DIAGNOSIS; ENCEPHALITOZOONOSIS; DIARRHEA; CORNEA	Background. The diagnosis of infection with Enterocytozoon bieneusi, a microsporidian organism that causes chronic diarrhea in patients infected with the human immunodeficiency virus (HIV), has depended on invasive procedures. We have developed a new method to detect microsporidia spores in feces and duodenal aspirates. Methods. Stool was obtained from four HIV-infected patients with biopsy-confirmed intestinal microsporidiosis. Slides prepared from unconcentrated, formalin-fixed stool specimens were stained with a new chromotrope-based technique and examined by light microscopy. Methods of stool concentration were also compared. The technique was then evaluated by examining 215 specimens from 134 HIV-infected persons with or without diarrhea. In addition, duodenal aspirates from 10 patients with unexplained chronic diarrhea were examined by light microscopy after staining according to the new and the traditional techniques. Results. E. bieneusi spores were found in all unconcentrated stool specimens from the four patients with microsporidiosis. The use of various methods of stool concentration did not improve the detection of microsporidia spores. In the prospective study, microsporidiosis was detected in samples from 6 of 27 patients with chronic diarrhea, but in none of those from 42 patients with acute diarrhea or 65 patients without diarrhea. The presence of microsporidia spores in stool specimens and duodenal aspirates allowed the successful prediction of the presence of microsporidia in small-bowel biopsy specimens from all four patients who subsequently underwent endoscopy. Conclusions. E. bieneusi is an important cause of chronic diarrhea in HIV-infected persons. This new diagnostic technique serves as a practical, noninvasive means to detect microsporidia spores in stool specimens and is also applicable to the examination of duodenal aspirates.	CTR DIS CONTROL,DIV PARASIT DIS,PARASIT DIS BRANCH,MAILSTOP F13,1600 CLIFTON RD,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR INFECT DIS,SCI RESOURCES PROGRAM,PATHOL BRANCH,ATLANTA,GA 30333; VET AFFAIRS MED CTR,CELL BIOL & AGING SECT,SAN FRANCISCO,CA; EMORY UNIV,GRADY MEM HOSP,SCH MED,DEPT INTERNAL MED,DIV GASTROENTEROL,ATLANTA,GA 30322; EMORY UNIV,CRAWFORD LONG HOSP,SCH MED,ATLANTA,GA 30322; EMORY UNIV,SCH MED,VET AFFAIRS MED CTR,ATLANTA,GA 30322	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; US Department of Veterans Affairs; Veterans Health Administration (VHA); Emory University; Emory University; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System			Schwartz, David A./AAX-7306-2021; Castro, Kenneth G/P-1882-2018; Weber, Rainer/D-5175-2012	Schwartz, David A./0000-0002-7486-8545; Castro, Kenneth G/0000-0001-7964-6354; 				ASHTON N, 1973, BRIT J OPHTHALMOL, V57, P669, DOI 10.1136/bjo.57.9.669; BERGQUIST NR, 1984, BRIT MED J, V288, P902, DOI 10.1136/bmj.288.6421.902; Bryan R. T., 1990, Principles and practice of infectious diseases., P2130; Bryan R T, 1991, Prog Clin Parasitol, V2, P1; CALI A, 1990, J PROTOZOOL, V37, P145, DOI 10.1111/j.1550-7408.1990.tb05885.x; CALI A, 1991, J PROTOZOOL, V38, P215; CANNING E.U., 1986, MICROSPORIDIA VERTEB; CANNING EU, 1990, T ROY SOC TROP MED H, V84, P181, DOI 10.1016/0035-9203(90)90247-C; CONLON CP, 1990, AM J TROP MED HYG, V42, P83, DOI 10.4269/ajtmh.1990.42.83; CURRY A, 1988, J CLIN PATHOL, V41, P477, DOI 10.1136/jcp.41.4.477-b; DAVIS RM, 1990, OPHTHALMOLOGY, V97, P953; DIDIER ES, 1991, J INFECT DIS, V163, P617, DOI 10.1093/infdis/163.3.617; DOBBINS WO, 1985, GASTROENTEROLOGY, V88, P738, DOI 10.1016/0016-5085(85)90145-3; FRIEDBERG DN, 1990, ARCH OPHTHALMOL-CHIC, V108, P504, DOI 10.1001/archopht.1990.01070060052047; GOURLEY WK, 1988, LAB INVEST, V58, pA35; GREENSON JK, 1991, ANN INTERN MED, V114, P366, DOI 10.7326/0003-4819-114-5-366; JOUVENAZ DP, 1981, J INVERTEBR PATHOL, V37, P319, DOI 10.1016/0022-2011(81)90093-8; KOTLER DP, 1990, ANN INTERN MED, V113, P444; LEDFORD DK, 1985, ANN INTERN MED, V102, P628, DOI 10.7326/0003-4819-102-5-628; LUCAS SB, 1989, J CLIN PATHOL, V42, P885, DOI 10.1136/jcp.42.8.885-b; MARGILETH AM, 1973, ARCH PATHOL, V95, P145; MATSUBAYASHI H, 1959, ARCH PATHOL, V67, P181; MODIGLIANI R, 1985, GUT, V26, P179, DOI 10.1136/gut.26.2.179; ORENSTEIN JM, 1990, HUM PATHOL, V21, P475; ORENSTEIN JM, 1990, LANCET, V336, P1127, DOI 10.1016/0140-6736(90)92600-M; Palk G, 1974, MANUAL CLIN MICROBIO, P930; PINNOLIS M, 1981, ARCH OPHTHALMOL-CHIC, V99, P1044, DOI 10.1001/archopht.1981.03930011044012; RIJPSTRA AC, 1988, J INFECT DIS, V157, P827, DOI 10.1093/infdis/157.4.827; RITCHIE LAWRENCE S., 1948, BULL U S ARMY MED DEPT, V8, P326; SCHATTENKERK JKME, 1991, LANCET, V337, P895, DOI 10.1016/0140-6736(91)90215-B; SHADDUCK JA, 1989, REV INFECT DIS, V11, P203; Sheather A. L., 1923, Journal of Comparative Pathology and Therapeutics, V36, P266; TERADA S, 1987, ANN INTERN MED, V107, P61, DOI 10.7326/0003-4819-107-1-61; ULLRICH R, 1989, ANN INTERN MED, V111, P954, DOI 10.7326/0003-4819-111-11-954_1; VANGOOL T, 1990, LANCET, V336, P697, DOI 10.1016/0140-6736(90)92198-Q; YOUNG KH, 1979, J CLIN MICROBIOL, V10, P852, DOI 10.1128/JCM.10.6.852-853.1979; ZENDER HO, 1989, AM J CLIN PATHOL, V92, P352, DOI 10.1093/ajcp/92.3.352; 1990, MMWR, V39, P188	38	468	486	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1992	326	3					161	166		10.1056/NEJM199201163260304	http://dx.doi.org/10.1056/NEJM199201163260304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ213	1370122	Bronze			2022-12-01	WOS:A1992GZ21300004
J	BELL, TA; STAMM, WE; WANG, SP; KUO, CC; HOLMES, KK; GRAYSTON, JT				BELL, TA; STAMM, WE; WANG, SP; KUO, CC; HOLMES, KK; GRAYSTON, JT			CHRONIC CHLAMYDIA-TRACHOMATIS INFECTIONS IN INFANTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							MONOCLONAL-ANTIBODIES; CONJUNCTIVITIS; CELLS	Objective. - To study the natural history of Chlamydia trachomatis infections in infants. Design. - Bacteriologic and serologic study of an inception cohort. Setting. - University of Washington Medical Center, Seattle. Participants. - Twenty-two infants with C trachomatis infections either not treated early in life or recurring after antimicrobial treatment. Main Outcome Measures. - Persistence of infection in various anatomic sites, antibody responses to specific serovars (serologic variants) of C trachomatis, and serovars of isolates from mothers and infants. Results. - The cumulative proportion of infants still infected at the age of 1 year was 35%. Infection persisted in the conjunctiva, nasopharynx, and oropharynx in one child for as long as 866 days (28.5 months), when she was cured by treatment. In none of the infants did serologic tests suggest acquisition of infection other than at birth. Isolates of C trachomatis from mothers and their respective infants were always of the same serovar. Conclusions. - Many infants infected with C trachomatis at birth remain infected for months or years in the absence of specific antimicrobial therapy. Such infections may be confused with those acquired by sexual abuse.	UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	BELL, TA (corresponding author), UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195, USA.		, Holmes/K-6215-2019		NEI NIH HHS [EY-00219] Funding Source: Medline; NIAID NIH HHS [AI-16222, AI-12192] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016222, P01AI012192] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARNES RC, 1985, J CLIN MICROBIOL, V22, P609, DOI 10.1128/JCM.22.4.609-613.1985; Freedman A, 1966, Trans Ophthalmol Soc U K, V86, P313; FUSTER CD, 1987, PEDIATRICS, V79, P235; HAMMERSCHLAG MR, 1982, PEDIATR INFECT DIS J, V1, P395, DOI 10.1097/00006454-198211000-00007; KUO CC, 1972, J INFECT DIS, V125, P665, DOI 10.1093/infdis/125.6.665; LEE ET, 1980, STATISTICAL METHODS, P127; MARDH PA, 1987, LANCET, V1, P804; MCCORMACK WM, 1979, NEW ENGL J MED, V300, P123, DOI 10.1056/NEJM197901183000305; MORDHORST CH, 1978, JAMA-J AM MED ASSOC, V239, P1765, DOI 10.1001/jama.239.17.1765; MORDHORST CH, 1971, AM J OPHTHALMOL, V71, P861, DOI 10.1016/0002-9394(71)90256-X; REES E, 1977, BRIT J VENER DIS, V53, P173; RETTIG PH, 1985, PEDIATR INFECT DIS, V3, P95; SANDSTROM I, 1988, ACTA PAEDIATR SCAND, V77, P207, DOI 10.1111/j.1651-2227.1988.tb10631.x; SCHACHTER J, 1986, JAMA-J AM MED ASSOC, V255, P3374, DOI 10.1001/jama.255.24.3374; SCHACHTER J, 1987, NEW ENGL J MED, V316, P1023; STAMM WE, 1983, J CLIN MICROBIOL, V17, P666, DOI 10.1128/JCM.17.4.666-668.1983; STENBERG K, 1986, LANCET, V2, P1278; Wang S., 1977, NONGONOCOCCAL URETHR, P237; WANG SP, 1985, J INFECT DIS, V152, P791, DOI 10.1093/infdis/152.4.791; WENTWORT.BB, 1974, APPL MICROBIOL, V27, P912, DOI 10.1128/AEM.27.5.912-916.1974; YODER BL, 1981, J CLIN MICROBIOL, V13, P1036, DOI 10.1128/JCM.13.6.1036-1039.1981; 1982, MMWR S2, V31, pS33	22	40	40	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					400	402		10.1001/jama.267.3.400	http://dx.doi.org/10.1001/jama.267.3.400			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727964				2022-12-01	WOS:A1992GY43700039
J	BUCHWALD, D; CHENEY, PR; PETERSON, DL; HENRY, B; WORMSLEY, SB; GEIGER, A; ABLASHI, DV; SALAHUDDIN, SZ; SAXINGER, C; BIDDLE, R; KIKINIS, R; JOLESZ, FA; FOLKS, T; BALACHANDRAN, N; PETER, JB; GALLO, RC; KOMAROFF, AL				BUCHWALD, D; CHENEY, PR; PETERSON, DL; HENRY, B; WORMSLEY, SB; GEIGER, A; ABLASHI, DV; SALAHUDDIN, SZ; SAXINGER, C; BIDDLE, R; KIKINIS, R; JOLESZ, FA; FOLKS, T; BALACHANDRAN, N; PETER, JB; GALLO, RC; KOMAROFF, AL			A CHRONIC ILLNESS CHARACTERIZED BY FATIGUE, NEUROLOGIC AND IMMUNOLOGICAL DISORDERS, AND ACTIVE HUMAN HERPESVIRUS TYPE-6 INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						FATIGUE SYNDROME, CHRONIC; HERPESVIRUS-6, HUMAN; NEUROLOGIC MANIFESTATIONS; FATIGUE; IMMUNOLOGICAL DISEASES	BARR VIRUS-INFECTION; CHRONIC MONONUCLEOSIS SYNDROME; NATURAL-KILLER CELLS; MAGNETIC-RESONANCE; HUMAN-LYMPHOCYTES; SYNDROME AIDS; HUMAN-DISEASE; T-CELLS; HHV-6; HBLV	Objective: To conduct neurologic, immunologic, and virologic studies in patients with a chronic debilitating illness of acute onset. Design: Cohort study with comparison to matched, healthy control subjects. Patients: We studied 259 patients who sought care in one medical practice; 29% of the patients were regularly bedridden or shut-in. Main Outcome Measures: Detailed medical history, physical examination, conventional hematologic and chemistry testing, magnetic resonance imaging (MRI) studies lymphocyte phenotyping studies, and assays for active infection of patients' lymphocytes with human herpesvirus type 6 (HHV-6). Main Results: Patients had a higher mean (+/- SD) CD4/CD8 T-cell ratio than matched healthy controls (3.16 +/- 1.5 compared with 2.3 +/- 1.0, respectively; P < 0.003). Magnetic resonance scans of the brain showed punctate, subcortical areas of high signal intensity consistent with edema or demyelination in 78% of patients (95% Cl, 72% to 86%) and in 21% of controls (Cl, 11% to 36%) (P < 10(-9)). Primary cell culture of lymphocytes showed active replication of HHV-6 in 79 of 113 patients (70%; Cl, 61% to 78%) and in 8 of 40 controls (20%; Cl, 9% to 36%) (P < 10(-8)), a finding confirmed by assays using monoclonal antibodies specific for HHV-6 proteins and by polymerase chain reaction assays specific for HHV-6 DNA. Conclusions: Neurologic symptoms, MRI findings, and lymphocyte phenotyping studies suggest that the patients may have been experiencing a chronic, immunologically mediated inflammatory process of the central nervous system. The active replication of HHV-6 most likely represents reactivation of latent infection, perhaps due to immunologic dysfunction. Our study did not directly address whether HHV-6, a lymphotropic and gliotropic virus, plays a role in producing the symptoms or the immunologic and neurologic dysfunction seen in this illness. Whether the findings in our patients, who came from a relatively small geographic area, will be generalizable to other patients with a similar syndrome remains to be seen.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV GEN MED, 75 FRANCIS ST, BOSTON, MA 02115 USA; UNIV WASHINGTON, HARBORVIEW MED CTR, SEATTLE, WA 98104 USA; WASHOE CTY SHERIFFS DIV, DIV FORENS SCI, RENO, NV 89512 USA; CYTOMETRY ASSOCIATES, SAN DIEGO, CA 92121 USA; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; UNIV SO CALIF, HUNTINGTON MEM HOSP, AIDS RES LAB, PASADENA, CA 91105 USA; NCI, TUMOR CELL BIOL LAB, BETHESDA, MD 20892 USA; STOCKTON RADIOL MED GRP, STOCKTON, CA 95204 USA; CTR DIS CONTROL, DIV VIROL, ATLANTA, GA 30333 USA; UNIV KANSAS, MED CTR, DEPT MICROBIOL, KANSAS CITY, KS 66103 USA; SPECIALTY LABS INC, SANTA MONICA, CA 90009 USA	Harvard University; Brigham & Women's Hospital; Harborview Medical Center; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Southern California; Huntington Memorial Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Centers for Disease Control & Prevention - USA; University of Kansas; University of Kansas Medical Center			Ablashi, Dharam/AAE-8934-2020		NIAID NIH HHS [R01AI26788, R01AI27314, U01AI32246] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026788, R01AI027314, U01AI032246] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABLASHI DV, 1987, NATURE, V329, P207, DOI 10.1038/329207a0; ABLASHI DV, 1991, VIROLOGY, V184, P545, DOI 10.1016/0042-6822(91)90424-A; ACHESON ED, 1959, AM J MED, V26, P569, DOI 10.1016/0002-9343(59)90280-3; AOKI T, 1987, NAT IMMUN CELL GROW, V6, P116; ARCHARD LC, 1988, J ROY SOC MED, V81, P326, DOI 10.1177/014107688808100608; AWAD IA, 1987, NEUROSURGERY, V20, P222, DOI 10.1227/00006123-198702000-00004; BALACHANDRAN N, 1989, J VIROL, V63, P2835, DOI 10.1128/JVI.63.6.2835-2840.1989; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BHAGAVATI S, 1988, NEW ENGL J MED, V318, P1141, DOI 10.1056/NEJM198805053181801; BRADLEY WG, 1984, NONINVASIVE MED IMAG, V1, P35; BUCHWALD D, 1990, J CLIN IMMUNOL, V10, P335, DOI 10.1007/BF00917479; BUCHWALD D, 1991, REV INFECT DIS, V13, pS12; BUCHWALD D, 1987, ARTHRITIS RHEUM, V30, P1132, DOI 10.1002/art.1780301007; BUCHWALD D, 1987, JAMA-J AM MED ASSOC, V257, P2303, DOI 10.1001/jama.257.17.2303; CALIGIURI M, 1987, J IMMUNOL, V139, P3306; CASALI P, 1987, SCIENCE, V236, P77, DOI 10.1126/science.3105056; COYLE PK, 1990, ANN NEUROL, V28, P243; CUNNINGHAM L, 1990, J GEN VIROL, V71, P1399, DOI 10.1099/0022-1317-71-6-1399; DALE JK, 1989, ANN INTERN MED, V110, P92, DOI 10.7326/0003-4819-110-1-92; DEFREITAS E, 1991, P NATL ACAD SCI USA, V88, P2922, DOI 10.1073/pnas.88.7.2922; DUBOIS RE, 1984, SOUTHERN MED J, V77, P1376, DOI 10.1097/00007611-198411000-00007; FOLKS T, 1986, J IMMUNOL, V136, P4049; FRENKEL N, 1990, P NATL ACAD SCI USA, V87, P748, DOI 10.1073/pnas.87.2.748; FRENKEL N, 1990, J VIROL, V64, P4598, DOI 10.1128/JVI.64.9.4598-4602.1990; GOLDENBERG DL, 1987, JAMA-J AM MED ASSOC, V257, P2782, DOI 10.1001/jama.257.20.2782; GOW JW, 1991, BRIT MED J, V302, P692, DOI 10.1136/bmj.302.6778.692; GRANT I, 1987, ANN INTERN MED, V107, P828, DOI 10.7326/0003-4819-107-6-828; GUPTA S, 1991, SCAND J IMMUNOL, V33, P319, DOI 10.1111/j.1365-3083.1991.tb01777.x; HEIER LA, 1989, AM J NEURORADIOL, V10, P929; HENDERSON DA, 1959, NEW ENGL J MED, V260, P757, DOI 10.1056/NEJM195904092601506; HENLE W, 1979, DIAGNOSTIC PROCEDURE, P441; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; JENKINS R, 1991, POST VIRAL FATIGUE S; JONES JF, 1985, ANN INTERN MED, V102, P1, DOI 10.7326/0003-4819-102-1; JOSEPHS SF, 1991, LANCET, V337, P1346, DOI 10.1016/0140-6736(91)93018-5; JOSEPHS SF, 1986, SCIENCE, V234, P601, DOI 10.1126/science.3020691; JUNGREIS CA, 1988, RADIOLOGY, V169, P101, DOI 10.1148/radiology.169.1.3420242; KIBLER R, 1985, J CLIN IMMUNOL, V5, P46, DOI 10.1007/BF00915168; KIRKPATRICK JB, 1987, RADIOLOGY, V162, P509, DOI 10.1148/radiology.162.2.3797666; KLIMAS NG, 1990, J CLIN MICROBIOL, V28, P1403, DOI 10.1128/JCM.28.6.1403-1410.1990; KOMAROFF AL, 1990, AM J CLIN PATHOL, V93, P836; KOMAROFF AL, 1988, CLIN RES, V36, pA743; KOMAROFF AL, 1987, HOSP PRACT, V22, P71; KOMAROFF AL, 1988, J VIROL METHODS, V21, P3, DOI 10.1016/0166-0934(88)90047-X; Krueger G R, 1991, In Vivo, V5, P287; LANDAY AL, 1991, LANCET, V338, P707, DOI 10.1016/0140-6736(91)91440-6; LEVY JA, 1990, VIROLOGY, V178, P113, DOI 10.1016/0042-6822(90)90384-4; LEVY JA, 1990, LANCET, V335, P1047, DOI 10.1016/0140-6736(90)92628-U; LLOYD AR, 1989, MED J AUSTRALIA, V151, P122, DOI 10.5694/j.1326-5377.1989.tb139594.x; LUSSO P, 1991, NATURE, V349, P533, DOI 10.1038/349533a0; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; MURDOCH JC, 1988, NEW ZEAL MED J, V101, P511; POSKANZER DC, 1957, NEW ENGL J MED, V257, P356, DOI 10.1056/NEJM195708222570802; REEDMAN BM, 1973, INT J CANCER, V11, P499, DOI 10.1002/ijc.2910110302; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SALIT IE, 1985, CAN MED ASSOC J, V133, P659; SAXINGER C, 1988, J VIROL METHODS, V21, P199, DOI 10.1016/0166-0934(88)90066-3; SHELOKOV A, 1957, NEW ENGL J MED, V257, P345, DOI 10.1056/NEJM195708222570801; SIGURDSSON B, 1956, LANCET, V270, P766; SIGURDSSON B, 1950, AM J HYG, V52, P222, DOI 10.1093/oxfordjournals.aje.a119421; STRAUS SE, 1988, J INFECT DIS, V157, P405, DOI 10.1093/infdis/157.3.405; STRAUS SE, 1985, ANN INTERN MED, V102, P7, DOI 10.7326/0003-4819-102-1-7; SZE G, 1986, AM J NEURORADIOL, V7, P381; TOBI M, 1982, LANCET, V1, P61; TUKEY JW, 1977, SCIENCE, V198, P679, DOI 10.1126/science.333584; WHITESIDE TL, 1989, CLIN IMMUNOL IMMUNOP, V53, P1, DOI 10.1016/0090-1229(89)90096-2; YOUSEF GE, 1988, LANCET, V1, P146; ZIMMERMAN RD, 1986, AM J ROENTGENOL, V146, P443, DOI 10.2214/ajr.146.3.443; 1957, BRIT MED J, V2, P895	70	279	287	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1992	116	2					103	113		10.7326/0003-4819-116-2-103	http://dx.doi.org/10.7326/0003-4819-116-2-103			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ356	1309285				2022-12-01	WOS:A1992GZ35600002
J	FORBES, GB; PORTA, CR; HERR, BE; GRIGGS, RC				FORBES, GB; PORTA, CR; HERR, BE; GRIGGS, RC			SEQUENCE OF CHANGES IN BODY-COMPOSITION INDUCED BY TESTOSTERONE AND REVERSAL OF CHANGES AFTER DRUG IS STOPPED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							MASS	Objective. -To study the changes in body composition produced by large doses of testosterone and reversal of changes when the drug is discontinued. Design. - Weekly injections of testosterone enanthate were given to young adult male volunteers for 12 weeks. Repeated assays of lean body mass (LBM) by potassium 40 counting were made during this period and at intervals during the ensuing 5 to 6 months. Participants and Setting. - Subjects who were living on their own, who were known to be free of significant disease, and who volunteered as controls for a study of patients with neuromuscular disease. Assays were done in the Clinical Research Center. Main Outcome Measures. - Changes in body weight, LBM, and (by subtraction) body fat. Results. - Testosterone treatment produced a progressive increase in LBM and a progressive decrease in body fat. Body composition reverted slowly toward normal when the injections were stopped; thus, the effects of testosterone lingered for some time. The magnitude of the observed changes in LBM was in keeping with the change in urinary creatinine excretion reported for these same subjects. Conclusion. - Testosterone is a powerful anabolic agent that also serves to reduce body fat content.	UNIV ROCHESTER,SCH MED & DENT,DEPT PEDIAT,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOPHYS,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT NEUROL,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester				Griggs, Robert/0000-0001-7988-4854	NCRR NIH HHS [RR-00044] Funding Source: Medline; NICHD NIH HHS [HD-18454] Funding Source: Medline; NINDS NIH HHS [NS-22099] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K06HD018454] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022099] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALOIA JF, 1981, METABOLISM, V30, P1076, DOI 10.1016/0026-0495(81)90050-0; Forbes G, 1987, HUMAN BODY COMPOSITI; FORBES GB, 1991, J APPL PHYSIOL, V70, P994, DOI 10.1152/jappl.1991.70.3.994; FORBES GB, 1986, BRIT J NUTR, V56, P1, DOI 10.1079/BJN19860080; FORBES GB, 1985, METABOLISM, V34, P571, DOI 10.1016/0026-0495(85)90196-9; FORBES GB, 1985, FED PROC, V44, P343; FORBES GB, 1982, DIET EXERCISE SYNERG, P75; GRIGGS RC, 1989, J APPL PHYSIOL, V66, P498, DOI 10.1152/jappl.1989.66.1.498; HASSAGER C, 1989, MATURITAS, V4, P305; KOCHAKIAN CD, 1976, ANABOLIC ANDROGENIC; WELLE S, IN PRESS J CLIN ENDO; WILMORE JH, 1983, MED SCI SPORT EXER, V15, P21	12	84	85	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					397	399		10.1001/jama.267.3.397	http://dx.doi.org/10.1001/jama.267.3.397			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727963				2022-12-01	WOS:A1992GY43700038
J	GRAHAM, NMH; NELSON, KE; SOLOMON, L; BONDS, M; RIZZO, RT; SCAVOTTO, J; ASTEMBORSKI, J; VLAHOV, D				GRAHAM, NMH; NELSON, KE; SOLOMON, L; BONDS, M; RIZZO, RT; SCAVOTTO, J; ASTEMBORSKI, J; VLAHOV, D			PREVALENCE OF TUBERCULIN POSITIVITY AND SKIN-TEST ANERGY IN HIV-1-SEROPOSITIVE AND HIV-1-SERONEGATIVE INTRAVENOUS-DRUG-USERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRUS-INFECTION; AIDS	Objectives. - To identify differences in purified protein derivative (PPD) tuberculin positivity and skin test anergy rates by human immunodeficiency virus (HIV) serostatus, CD4+ lymphocyte count, and other risk factors in intravenous drug users (IVDUs); and to evaluate the appropriateness of the Centers for Disease Control (CDC)-recommended definition for a positive PPD tuberculin skin test result in HIV-1-seropositive patients. Design. - Nested case-control and cross-sectional analyses. Setting. - Community-based cohort of IVDUs. Patients. - Two hundred sixty HIV-1-seropositive and -seronegative IVDUs, drawn from an unselected cohort, were skin-tested for sensitivity to PPD tuberculin, mumps, and Candida antigens using the Mantoux method. Outcome Measures. - Positivity to PPD tuberculin, skin test anergy. Results. - Even using the CDC definition of an induration 5 mm or greater in diameter in HIV-1 seropositives, this group was substantially less likely to be PPD tuberculin positive than HIV-1 seronegatives (13.8% vs 25.2%; P = .02). In the HIV-1 seropositives the relative odds of being PPD positive varied depending on whether 10 mm or greater (odds ratio [OR], 0.3; 95% confidence interval [CI], 0.2 to 0.7), 5 mm or greater (OR, 0.5; 95% CI, 0.2 to 0.9), or 2 mm or greater (OR, 0.7; 95% CI, 0.4 to 1.3) was used to define a positive test result. The mean diameter induration in the HIV-1-seropositive group was 2.6 mm vs 5.4 mm in the seronegative group (P =.005). Skin test anergy (to mumps and Candida) appeared to explain the differential. Anergy was substantially higher in the HIV-1 seropositive group and increased as the CD4+ lymphocyte count fell (chi-2 for linear trend, 24.5; P < .0001). An inverse linear trend for PPD positivity and CD4+ lymphocyte count was also observed (chi-2 for trend, 6.1; P = .01). In multivariate analyses, being 35 years of age or older and being HIV-1 seronegative were significantly associated with PPD positivity, while history of previous police arrest was of borderline significance. Only HIV-1 seropositivity was significantly associated with anergy. Conclusions. - These findings show that CDC-recommended definition of an induration 5 mm or greater in diameter for PPD tuberculin positivity in HIV-1 seropositives significantly underestimates the "true" infection rate (using the PPD positivity rate in HIV-1 seronegatives as the criterion standard). A definition of 2 mm or greater would appear to be a better cutoff for reducing misclassification in HIV-1 seropositives. This study also confirms that delayed-type hypersensitivity is seriously depressed in HIV-1 seropositive IVDUs and that anergy testing is mandatory to properly assess a negative PPD test result.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; BALTIMORE CITY DEPT HLTH, BALTIMORE, MD USA	Johns Hopkins University	GRAHAM, NMH (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, 624 N BROADWAY, BALTIMORE, MD 21205 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R37DA004334, R56DA004334, R01DA004334] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 04334, DA 05664] Funding Source: Medline; PHS HHS [CCU300466-10] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BIRX D, 1989, 5TH P INT C AIDS MON; CANESSA PA, 1989, CHEST, V96, P1215, DOI 10.1378/chest.96.5.1215; Centers for Disease Control (CDC), 1990, MMWR Morb Mortal Wkly Rep, V39, P638; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; GIORGI JV, 1990, CLIN IMMUNOL IMMUNOP, V55, P173, DOI 10.1016/0090-1229(90)90096-9; JORDAN TJ, 1991, JAMA-J AM MED ASSOC, V265, P2987, DOI 10.1001/jama.265.22.2987; NOLAN CM, 1988, 4TH INT C AIDS STOCK, P313; PITCHENIK AE, 1987, AM REV RESPIR DIS, V135, P875, DOI 10.1164/arrd.1987.135.4.875; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; ROBERT CF, 1989, NEW ENGL J MED, V321, P1268; SELIK RM, 1987, AIDS, V1, P175; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SUNDERAM G, 1986, JAMA-J AM MED ASSOC, V256, P362, DOI 10.1001/jama.256.3.362; THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8; Vlahov D, 1991, NIDA Res Monogr, V109, P75; 1991, MMWR, V40, P27; 1989, MMWR, V34, P236; 1990, MMWR, V39, P153; 1990, MMWR, V39, P1	19	188	191	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					369	373		10.1001/jama.267.3.369	http://dx.doi.org/10.1001/jama.267.3.369			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727959				2022-12-01	WOS:A1992GY43700033
J	HIRSCHMANN, JV				HIRSCHMANN, JV			NORMAL BODY-TEMPERATURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											HIRSCHMANN, JV (corresponding author), UNIV WASHINGTON,SCH MED,SEATTLE,WA 98195, USA.							DINARELLO CA, 1978, NEW ENGL J MED, V298, P607, DOI 10.1056/NEJM197803162981107; DOWNTON JH, 1987, AGE AGEING, V16, P41, DOI 10.1093/ageing/16.1.41; HORVATH STEVEN M., 1950, JOUR AMER MED ASSOC, V144, P1562; IVY AC, 1945, GASTROENTEROLOGY, V5, P326; MELLETTE HC, 1951, J APPL PHYSIOL, V3, P65; WEIZMAN ED, 1982, NEUROBIOL AGING, V3, P299	6	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					414	414						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727969				2022-12-01	WOS:A1992GY43700045
J	HOWSON, CP; FINEBERG, HV				HOWSON, CP; FINEBERG, HV			ADVERSE EVENTS FOLLOWING PERTUSSIS AND RUBELLA VACCINES - SUMMARY OF A REPORT OF THE INSTITUTE-OF-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								In August 1991, the Institute of Medicine released a report entitled Adverse Effects of Pertussis and Rubella Vaccines, which examined 18 adverse events in relation to diphtheria-tetanus-pertussis (DTP) vaccine and four adverse events in relation to the currently used rubella vaccine strain, RA 27/3. The committee spent 20 months reviewing a wide range of information sources, including case series and individual case reports, both published and unpublished, epidemiologic studies, studies in animals, and other laboratory studies. The committee found that the evidence indicates a causal relation between DTP vaccine and anaphylaxis and between the pertussis component of DTP vaccine and extended periods of inconsolable crying or screaming. The committee also reported that the evidence indicates a causal relation between the rubella vaccine and acute arthritis in adult women. The committee found the available evidence weaker but still consistent with a causal relation between DTP vaccine and two conditions-acute encephalopathy and hypotonic, hyporesponsive episodes-and between rubella vaccine and chronic arthritis in adult women. Estimated incidence rates of these adverse events following vaccination are provided, where possible. The committee found that the evidence does not indicate a causal relation between the DTP vaccine and infantile spasms, hypsarrhythmia, Reye's syndrome, and sudden infant death syndrome. The committee found insufficient evidence to indicate either the presence or absence of a causal relation between DTP vaccine and chronic neurologic damage, aseptic meningitis, erythema multiforme or other rash, Guillain-Barre syndrome, hemolytic anemia, juvenile diabetes, learning disabilities and attention-deficit disorder, peripheral mononeuropathy, or thrombocytopenia, and between rubella vaccine and radiculoneuritis and other neuropathies or thrombocytopenic purpura. The committee's evaluative methods are briefly described and a summary of research needs is provided.	NATL ACAD SCI,INST MED,DIV HLTH PROMOT & DIS PREVENT,WASHINGTON,DC 20418; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115	National Academies of Sciences, Engineering & Medicine; Harvard University; Harvard T.H. Chan School of Public Health								ALDERSLADE R, 1981, WHOOPING COUGH, P79; Howson CP, 1991, ADVERSE EFFECTS PERT	2	84	88	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					392	396		10.1001/jama.267.3.392	http://dx.doi.org/10.1001/jama.267.3.392			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727962				2022-12-01	WOS:A1992GY43700037
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FINAL RULE ELIMINATES USE OF 111 WEIGHT-CONTROL INGREDIENTS FROM OVER-THE-COUNTER DRUG PRODUCTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.							1991, FED REG         0808, V56, P37792	1	1	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					339	339		10.1001/jama.267.3.339	http://dx.doi.org/10.1001/jama.267.3.339			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727943				2022-12-01	WOS:A1992GY43700009
J	NIGHTINGALE, ST				NIGHTINGALE, ST			3 ADDITIONAL DRUGS AVAILABLE UNDER TREATMENT IND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, ST (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	1	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					339	339		10.1001/jama.267.3.339	http://dx.doi.org/10.1001/jama.267.3.339			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727943				2022-12-01	WOS:A1992GY43700004
J	SIMONETTI, RG; CAMMA, C; FIORELLO, F; COTTONE, M; RAPICETTA, M; MARINO, L; FIORENTINO, G; CRAXI, A; CICCAGLIONE, A; GIUSEPPETTI, R; STROFFOLINI, T; PAGLIARO, L				SIMONETTI, RG; CAMMA, C; FIORELLO, F; COTTONE, M; RAPICETTA, M; MARINO, L; FIORENTINO, G; CRAXI, A; CICCAGLIONE, A; GIUSEPPETTI, R; STROFFOLINI, T; PAGLIARO, L			HEPATITIS-C VIRUS-INFECTION AS A RISK FACTOR FOR HEPATOCELLULAR-CARCINOMA IN PATIENTS WITH CIRRHOSIS - A CASE-CONTROL STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS-C VIRUS; LIVER NEOPLASMS; HEPATITIS, VIRAL, NON-A, NON-B; HEPATITIS-B; LIVER CIRRHOSIS	POST-TRANSFUSION HEPATITIS; NON-B-HEPATITIS; CHRONIC NON-A; BLOOD-DONORS; ANTIBODIES; PREVALENCE; ETIOLOGY; ALCOHOL	Objective: To determine whether chronic hepatitis C virus (HCV) infection is an independent risk factor for hepatocellular carcinoma and whether it increases the cirrhosis-related risk for hepatocellular carcinoma. Design: Two pair-matched case-control studies. Setting: A referral-based hospital. Patients: In study I, 212 patients with hepatocellular carcinoma (197 of whom had known underlying cirrhosis) were compared with controls who had chronic nonhepatic diseases. In study II, the 197 patients with hepatocellular carcinoma and cirrhosis were compared with 197 pair-matched controls who had cirrhosis but not hepatocellular carcinoma. Measurements: Levels of antibody to HCV (anti-HCV), hepatitis B surface antigen (HBsAg), and antibody to hepatitis B core antigen (anti-HBc) were assayed, and alcohol abuse was assessed by history. Main Results: In study I, 151 patients (71%) with hepatocellular carcinoma were anti-HCV positive compared with 11 controls (5%) with chronic nonhepatic diseases (odds ratio, 42; 95% Cl, 22 to 95). Multivariate analysis showed that anti-HCV was an independent risk factor for hepatocellular carcinoma (odds ratio, 69; Cl, 15 to 308). The analysis also showed that HBsAg (odds ratio, 8.7; Cl, 1.5 to 50) and anti-HBc (odds ratio, 4.2 (Cl, 1.7 to 11) were risk factors for hepatocellular carcinoma. No statistically significant interaction was found between anti-HCV and the markers of HBV infection. In study II, 146 patients (74%) with hepatocellular carcinoma and cirrhosis were anti-HCV positive compared with 122 patients (62%) with cirrhosis alone (odds ratio, 1.8; Cl, 1.1 to 2.8). Multivariate analysis confirmed that anti-HCV (odds ratio, 2.0; Cl, 1.3 to 32) and HBsAg (odds ratio, 2.0; Cl, 1.0 to 4.2) were independent risk factors for hepatocellular carcinoma. Conclusions: Hepatitis C virus infection is a risk factor for hepatocellular carcinoma, apparently by inducing cirrhosis and, to a lesser extent, by enhancing the risk in patients with cirrhosis. Hepatitis C virus infection acts independently of HBV infection (another risk factor) and of alcohol abuse, age, or gender.	UNIV PALERMO, IST MED GEN & PNEUMOL, I-90134 PALERMO, ITALY; IST SUPER SANITA, I-00161 ROME, ITALY	University of Palermo; Istituto Superiore di Sanita (ISS)			Giuseppetti, Roberto/AAA-6508-2021; CICCAGLIONE, ANNA RITA/M-2956-2015; Craxi, Antonio/K-9529-2016	Giuseppetti, Roberto/0000-0001-9958-164X; CICCAGLIONE, ANNA RITA/0000-0002-3791-3781; CAMMA', CALOGERO/0000-0002-9224-1914; Craxi, Antonio/0000-0002-4480-9544; Cottone, Mario/0000-0003-1523-7556				ALTER HJ, 1991, ANN INTERN MED, V115, P644, DOI 10.7326/0003-4819-115-8-644; ALTER HJ, 1990, J GASTROEN HEPATOL, V5, P78, DOI 10.1111/j.1440-1746.1990.tb01783.x; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BOSCH FX, 1989, FALK SYMP, V51, P3; BRESLOW N, 1982, BIOMETRICS, V38, P661, DOI 10.2307/2530047; BRESLOW N. E., 1980, STATISTICAL METHODS; BRUIX J, 1989, LANCET, V2, P1004; CAPORASO N, 1991, J HEPATOL, V12, P367, DOI 10.1016/0168-8278(91)90841-X; CHIARAMONTE M, 1990, ASPETTI EPIDEMIOLOGI, P11; COLOMBO M, 1989, LANCET, V2, P1006; DAZZA MC, 1990, LANCET, V335, P1216, DOI 10.1016/0140-6736(90)92733-X; ESTEBAN JI, 1989, LANCET, V2, P294; GILLIAM JH, 1984, ANN INTERN MED, V101, P794, DOI 10.7326/0003-4819-101-6-794; HASAN F, 1990, HEPATOLOGY, V12, P589, DOI 10.1002/hep.1840120323; JOHNSON PJ, 1987, J HEPATOL, V4, P140, DOI 10.1016/S0168-8278(87)80021-1; KAKLAMANI E, 1991, JAMA-J AM MED ASSOC, V265, P1974, DOI 10.1001/jama.265.15.1974; KEW MC, 1990, LANCET, V335, P873, DOI 10.1016/0140-6736(90)90474-J; KIYOSAWA K, 1987, AM J GASTROENTEROL, V78, P777; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LEVRERO M, 1991, J HEPATOL, V12, P60, DOI 10.1016/0168-8278(91)90910-4; LONDON WT, 1981, HUM PATHOL, V12, P1085, DOI 10.1016/S0046-8177(81)80329-2; MAGRIN S, 1991, J GASTROENTEROL, V23, P312; OKUDA K, 1986, DIGEST DIS SCI, V31, pS133; PAGLIARO L, 1983, HEPATO-GASTROENTEROL, V30, P48; RESNICK RH, 1983, DIGEST DIS SCI, V28, P908, DOI 10.1007/BF01317042; SANCHEZTAPIAS JM, 1990, ANN INTERN MED, V112, P921, DOI 10.7326/0003-4819-112-12-921; SANCHIS J, 1990, 1990 P INT S VIR HEP, P439; SIMONETTI RG, 1989, LANCET, V2, P1338; SIMONETTI RG, 1991, DIGEST DIS SCI, V36, P962, DOI 10.1007/BF01297149; SIRCHIA G, 1990, VOX SANG, V59, P26, DOI 10.1111/j.1423-0410.1990.tb02109.x; STEVENS CE, 1990, JAMA-J AM MED ASSOC, V263, P49, DOI 10.1001/jama.263.1.49; TREMOLADA F, 1990, LANCET, V335, P300, DOI 10.1016/0140-6736(90)90129-S; VARGAS V, 1990, ANN INTERN MED, V112, P232, DOI 10.7326/0003-4819-112-3-232_2; VILLA E, 1988, CANCER-AM CANCER SOC, V62, P611, DOI 10.1002/1097-0142(19880801)62:3<611::AID-CNCR2820620328>3.0.CO;2-0; WEINER AJ, 1990, LANCET, V336, P695, DOI 10.1016/0140-6736(90)92194-M; WEJSTAL R, 1987, SCAND J GASTROENTERO, V22, P1115, DOI 10.3109/00365528708991968; YARRISH RL, 1980, INT J CANCER, V26, P711, DOI 10.1002/ijc.2910260603; YU MC, 1990, JNCI-J NATL CANCER I, V82, P1038, DOI 10.1093/jnci/82.12.1038; ZAMAN SN, 1985, LANCET, V1, P1357; 1988, SAS STAT USERS GUIDE, P189	40	357	360	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1992	116	2					97	102		10.7326/0003-4819-116-2-97	http://dx.doi.org/10.7326/0003-4819-116-2-97			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ356	1309286				2022-12-01	WOS:A1992GZ35600001
J	SUTTER, RW; COCHI, SL				SUTTER, RW; COCHI, SL			PERTUSSIS HOSPITALIZATIONS AND MORTALITY IN THE UNITED-STATES, 1985-1988 - EVALUATION OF THE COMPLETENESS OF NATIONAL REPORTING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WHOOPING-COUGH; SURVEILLANCE; TRANSMISSION; EPIDEMIC	Objective. - To determine the magnitude of hospitalizations for pertussis and pertussis mortality and to estimate the total burden of clinically significant pertussis in the United States. Design. - Capture-recapture methods for estimating population size from independent surveillance systems were used to analyze morbidity and mortality data from case report forms received at the Centers for Disease Control (CDC) from the states, and compared these data with pertussis hospitalizations compiled from a database of US hospitals participating in the Commission on Professional and Hospital Activities-Professional Activities Survey (CPHA-PAS) and death certificate reports compiled by the National Center for Health Statistics (NCHS). Population Studied. - All pertussis hospitalizations and pertussis-related deaths in the United States, 1985 through 1988. Results. - We estimated that 13 557 pertussis hospitalizations (95% confidence interval [CI], 12953 to 14162) and 98 pertussis deaths had occurred during the 4-year study period (an average of more than 3300 hospitalizations and 25 deaths per year). The completeness of reporting hospitalizations to the CDC was 32% and to the CPHA-PAS, 23%, while the completeness of reporting pertussis deaths to the CDC was 33% and to NCHS, 23%. Patients who were hospitalized with per-tussis and reported to CDC were at a higher risk for developing pneumonia (31.0% vs 20.0%, relative risk [RR], 1.6; 95% CI, 1.4 to 1.7), seizures (3.7% vs 2.1 %; RR, 1.9; 95% CI, 1.4 to 2.5) and encephalitis (1.2% vs 0.2%; RR, 5.3; 95% CI, 2.4 to 11.6) compared with patients recorded in the CPHA-PAS system. Conclusions. - Our study suggests that there is substantial underreporting of pertussis, that severe complications of pertussis (including hospitalizations) are reported preferentially to the CDC, and that the national health impact of pertussis based on these indicators is considerably higher than previously published reports have suggested.			SUTTER, RW (corresponding author), CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV IMMUNIZAT,INFORMAT SERV,MAILSTOP E07,ATLANTA,GA 30333, USA.							BIELLIK RJ, 1988, J INFECT DIS, V157, P1134, DOI 10.1093/infdis/157.6.1134; BIELLIK RJ, 1989, 29TH INT C ANT AG CH, P145; BOWIE C, 1990, LANCET, V335, P397, DOI 10.1016/0140-6736(90)90220-Y; BROOME CV, 1981, J INFECT DIS, V144, P187, DOI 10.1093/infdis/144.2.187; Chapman D.G., 1951, U CALIFORNIA PUBLICA, V1, P131; CHERRY JD, 1990, JAMA-J AM MED ASSOC, V263, P1679; COCHI SL, 1989, AM J EPIDEMIOL, V129, P349, DOI 10.1093/oxfordjournals.aje.a115138; Cormack R. M., 1969, Oceanogr. mar. Biol., V6, P455; EDDINS DL, 1985, 20TH IMM C P DALL, P51; GRIFFITH AH, 1989, VACCINE, V7, P199, DOI 10.1016/0264-410X(89)90229-6; HALPERIN SA, 1989, J PEDIATR-US, V115, P686, DOI 10.1016/S0022-3476(89)80643-2; HICKS T, 1987, PERTUSSIS HAWAII COM; JENKINSON D, 1983, BRIT MED J, V287, P185, DOI 10.1136/bmj.287.6386.185; LONG SS, 1990, J INFECT DIS, V161, P480, DOI 10.1093/infdis/161.3.480; MILLER CL, 1976, BRIT MED J, P117; MORTIMER EA, 1990, J INFECT DIS, V161, P473, DOI 10.1093/infdis/161.3.473; NKOWANE BM, 1986, AM J DIS CHILD, V140, P433, DOI 10.1001/archpedi.1986.02140190043021; ONORATO IM, 1987, PEDIATR INFECT DIS J, V6, P145, DOI 10.1097/00006454-198702000-00002; POLLOCK TM, 1984, ARCH DIS CHILD, V59, P162, DOI 10.1136/adc.59.2.162; SACKS JJ, 1985, AM J PUBLIC HEALTH, V75, P1420, DOI 10.2105/AJPH.75.12.1420; SEKAR CC, 1949, J AM STAT ASSOC, V44, P101, DOI 10.2307/2280353; SNEDEOR GW, 1989, STATISTICAL METHODS; SUTTER RW, 1990, AM J EPIDEMIOL, V131, P132, DOI 10.1093/oxfordjournals.aje.a115466; WASSILAK S, 1983, 18TH P IMM C ATL GA, P37; 1987, PEDIATRIC LENGTH STA; 1988, PEDIATRIC LENGTH STA; 1985, MMWR, V34, P399; 1991, REPORT COMMITTEE INF, P358; 1991, MMWR, V40, P1; 1989, STATE IMMUNIZATION R; 1987, VITAL STATISTICS US, V2; 1989, PEDIATRIC LENGTH STA; 1977, INT CLASSIFICATION D; 1985, MMWR, V34, P390; 1983, MMWR, V32, P297; 1987, VERSION 6; 1990, MMWR, V38, P51; 1988, CATALOGUE PUBLIC USE; 1953, REPORTED INCIDENCE S; 1986, PEDIATRIC LENGTH STA	40	139	141	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					386	391		10.1001/jama.267.3.386	http://dx.doi.org/10.1001/jama.267.3.386			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1309387				2022-12-01	WOS:A1992GY43700036
J	WACHTEL, T; PIETTE, J; MOR, V; STEIN, M; FLEISHMAN, J; CARPENTER, C				WACHTEL, T; PIETTE, J; MOR, V; STEIN, M; FLEISHMAN, J; CARPENTER, C			QUALITY-OF-LIFE IN PERSONS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - MEASUREMENT BY THE MEDICAL OUTCOMES STUDY INSTRUMENT	ANNALS OF INTERNAL MEDICINE			English	Article						QUALITY OF LIFE; HIV INFECTIONS; OUTCOME ASSESSMENT (HEALTHY CARE); ACQUIRED IMMUNODEFICIENCY SYNDROME; HEALTH STATUS	AIDS-RELATED COMPLEX; PLACEBO-CONTROLLED TRIAL; CARE	Objective: To assess the reliability and validity of the Medical Outcomes Study (MOS) Short Form Health Survey as an indicator for quality of life in patients infected with the human immunodeficiency virus (HIV). Design: Patient interview survey. Setting: The AIDS Health Services Program in seven sites: Newark and Jersey City, New Jersey; Nassau County, New York; Atlanta, Georgia; Dallas, Texas; Fort Lauderdale and Miami, Florida; New Orleans, Louisiana; and Seattle, Washington. Patients: Patients (520) with HIV infection receiving health services at one of the above sites. Measurements: All components of the MOS Short Form Health Survey were included in the interview. Minor modifications were made to adapt the survey to the particular circumstances of the study. Measured sociodemographic characteristics included age, sex, race, intravenous drug use, and education. Symptoms were assessed by closed-ended questions concerning memory, seizure, weakness or numbness, fever, chills, diaphoreses, dyspnea, diarrhea, and weight loss. Information on the frequency of symptoms was also collected. History of Pneumocystis carinii pneumonia and Kaposi sarcoma was noted. Main Results: The sociodemographic characteristics resemble those of patients with the acquired immunodeficiency syndrome (AIDS) reported to the Centers for Disease Control (CDC): mean age, 36; men, 89%; nonwhite, 31%; intravenous drug use, 34%. Neurologic symptoms (memory trouble, seizures, weakness or numbness) occurred in 71% of patients; constitutional symptoms (fever, chills, night sweats, weight loss) in 69%; dyspnea in 50%; and diarrhea in 47%. Although older age, female sex, nonwhite race, and intravenous drug use were associated with lower MOS scores in several areas, the strongest single or adjusted indicator of lower MOS scores was the presence of symptoms. Finally, patients with HIV infection had significantly lower scores than did previously reported patients with other chronic medical conditions (P < 0.001). Conclusions: The MOS survey is a reliable measure of quality of life for patients with HIV infection. These patients tend to have low scores, suggesting validity of the survey. The MOS survey is extremely sensitive to the effect of symptoms, which suggests that it might be useful as a quality-of-life indicator for AIDS clinical drug trails.			WACHTEL, T (corresponding author), RHODE ISL HOSP, DIV GEN INTERNAL MED, 593 EDDY ST, PROVIDENCE, RI 02903 USA.							BACCHETTI P, 1988, J INFECT DIS, V157, P1044, DOI 10.1093/infdis/157.5.1044; BARKER S, 1990, LANCET, V335, P1045, DOI 10.1016/0140-6736(90)91117-S; BINDMAN AB, 1990, MED CARE, V28, P1142, DOI 10.1097/00005650-199012000-00003; DONABEDIAN A, 1966, MILBANK FUND Q, V44, P166, DOI 10.2307/3348969; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FLEISHMAN J, DHHS PHS893447 PUB; GOSTIN LO, 1990, JAMA-J AM MED ASSOC, V263, P2086, DOI 10.1001/jama.263.15.2086; GREEN J, 1990, JAMA-J AM MED ASSOC, V264, P1261, DOI 10.1001/jama.264.10.1261; GREENFIELD S, 1989, NEW ENGL J MED, V320, P1142, DOI 10.1056/NEJM198904273201710; KAPLAN RM, 1989, MED CARE, V27, pS27, DOI 10.1097/00005650-198903001-00003; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; MOR V, 1989, HEALTH AFFAIR, V8, P139, DOI 10.1377/hlthaff.8.4.139; NAGI SZ, 1976, MILBANK FUND Q, V54, P439, DOI 10.2307/3349677; PIETTE J, 1991, HEALTH SERV RES, V26, P75; RAGNI MV, 1990, J ACQ IMMUN DEF SYND, V3, P708; RAGSDALE D, 1990, NURS RES, V39, P355; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SCHROEDER SA, 1987, NEW ENGL J MED, V316, P160, DOI 10.1056/NEJM198701153160309; STEIN MD, 1991, J GEN INTERN MED, V6, P35, DOI 10.1007/BF02599388; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WU AW, 1990, J ACQ IMMUN DEF SYND, V3, P683; WU AW, 1991, MED CARE, V29, P786, DOI 10.1097/00005650-199108000-00011; 1990, MMWR, V39, P81	26	283	286	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1992	116	2					129	137		10.7326/0003-4819-116-2-129	http://dx.doi.org/10.7326/0003-4819-116-2-129			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ356	1727616				2022-12-01	WOS:A1992GZ35600005
J	AMOS, A; BOSTOCK, Y				AMOS, A; BOSTOCK, Y			FOR DEBATE - POLICY ON CIGARETTE ADVERTISING AND COVERAGE OF SMOKING AND HEALTH IN EUROPEAN WOMENS MAGAZINES	BRITISH MEDICAL JOURNAL			English	Article											AMOS, A (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PUBL HLTH SCI,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							AITKEN PP, 1990, BRIT J ADDICT, V85, P399; AITKEN PP, 1991, BRIT J ADDICT, V86, P383; AITKEN PP, 1987, BRIT J ADDICT, V82, P615; Amos A, 1990, World Health Forum, V11, P416; AMOS A, 1991, LANCET, V337, P93, DOI 10.1016/0140-6736(91)90747-D; AMOS A, 1991, HLTH ED J, V50, P26; AMOS A, 1991, PUTTING WOMEN PICTUR; BAAM R, 1990, ROKEN WELBESCHOUWD; CHAPMAN S, 1982, AM J PUBLIC HEALTH, V72, P491, DOI 10.2105/AJPH.72.5.491; Charlton A., 1986, HLTH ED J, V45, P75; DAVIS RM, 1987, NEW ENGL J MED, V316, P725, DOI 10.1056/NEJM198703193161206; EARNSTER VL, 1985, NY STATE J MED, V85, P335; GODDARD E, 1990, SMOKING SECONDARY SC; GODDARD E, 1987, SMOKING SECONDARY SC; JACOBSON B, 1988, BEATING LADYKILLERS; JACOBSON B, 1985, SMOKE GETS YOUR EYES; LOCK S, 1990, BRIT MED J, V301, P1405, DOI 10.1136/bmj.301.6766.1405; NUTBEAM D, 1988, PLANNING SMOKE FREE; ROGERS D, 1987, TOBACCO REPORTER FEB, P8; WARNER KE, 1985, NEW ENGL J MED, V312, P384, DOI 10.1056/NEJM198502073120627; WARNER KE, 1990, 7TH P WORLD C TOB HL, P765; 1990, IT CAN BE DONE SMOKE; 1983, TOBACCO REPORTER APR, P44; 1989, NATIONAL READERSHIP; 1987, EUROPE CANCER SURVEY; 1987, SMOKE FREE EUROPE 5; 1986, SCOTTISH HLTH STATIS; 1989, HLTH TOBACCO; 1989, SMOKING WISH STOP FI	29	14	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					99	101		10.1136/bmj.304.6819.99	http://dx.doi.org/10.1136/bmj.304.6819.99			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HA171	1737152	Green Published, Bronze			2022-12-01	WOS:A1992HA17100028
J	BRAEGGER, CP; NICHOLLS, S; MURCH, SH; STEPHENS, S; MACDONALD, TT				BRAEGGER, CP; NICHOLLS, S; MURCH, SH; STEPHENS, S; MACDONALD, TT			TUMOR-NECROSIS-FACTOR-ALPHA IN STOOL AS A MARKER OF INTESTINAL INFLAMMATION	LANCET			English	Article							BOWEL-DISEASE	Measurement of disease activity in patients with inflammatory bowel disease is difficult. The best available methods are complex and time consuming, but it may be possible to use tumour necrosis factor alpha (TNF-alpha) concentration in stool as a marker of disease activity. We measured TNF-alpha concentrations in stool samples from normal children, infants with diarrhoea, and children with inflammatory bowel disease in active and inactive phases of the disease. In 10 normal children and 14 children with diarrhoea, median stool TNF-alpha concentrations were 58 and 45 pg/g stool, respectively. Compared with diarrhoeal controls, stool TNF-alpha concentrations were significantly increased in children with active Crohn's disease (n = 13, median 994 pg/g, p < 0.0002) and active ulcerative colitis (n = 4, range 276-5982 pg/g, p < 0.003). In patients with inactive disease, either as a result of surgery or treatment with steroids, the concentration of stool TNF-alpha fell to those of controls. Measurement of stool TNF-alpha concentations may provide a simple way to monitor disease activity in inflammatory bowel disease.	ST BARTHOLOMEWS HOSP,DEPT PAEDIAT GASTROENTEROL,LONDON EC1A 7BE,ENGLAND; CELLTECH LTD,SLOUGH,BERKS,ENGLAND	University of London; Queen Mary University London; Celltech Group Ltd			Braegger, Christian Peter/ABC-9884-2021	Braegger, Christian/0000-0001-8069-9875	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CHONG SKF, 1984, BRIT MED J, V284, P101; DONNELLAN WL, 1966, GASTROENTEROLOGY, V50, P519; DUBRAVEC DB, 1990, P NATL ACAD SCI USA, V87, P6758, DOI 10.1073/pnas.87.17.6758; ELIAKIM R, 1988, GASTROENTEROLOGY, V95, P1176; LAURITSEN K, 1988, GASTROENTEROLOGY, V95, P11, DOI 10.1016/0016-5085(88)90284-3; LIGUMSKY M, 1990, GUT, V31, P686, DOI 10.1136/gut.31.6.686; MACDONALD TT, 1990, CLIN EXP IMMUNOL, V81, P351; MURCH SH, 1991, GUT, V32, P913, DOI 10.1136/gut.32.8.913; SAVERYMUTTU SH, 1983, GASTROENTEROLOGY, V85, P1333; ZIFRONI A, 1983, GUT, V24, P659, DOI 10.1136/gut.24.7.659	10	600	626	1	18	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1992	339	8785					89	91		10.1016/0140-6736(92)90999-J	http://dx.doi.org/10.1016/0140-6736(92)90999-J			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ156	1345871				2022-12-01	WOS:A1992GZ15600003
J	COX, NH; WAGSTAFF, R; POPPLE, AW				COX, NH; WAGSTAFF, R; POPPLE, AW			USING CLINICOPATHOLOGICAL ANALYSIS OF GENERAL-PRACTITIONER SKIN SURGERY TO DETERMINE EDUCATIONAL REQUIREMENTS AND GUIDELINES	BRITISH MEDICAL JOURNAL			English	Article								Objective - To study the impact of skin surgery in general practice on the workload of a pathology laboratory and to identify what further training might be helpful. Design - Analysis of skin biopsy specimens from general practitioners before and after their new contract to determine numbers of specimens, changes in diagnoses, adequacy of treatment of malignant tumours, and areas of low diagnostic accuracy. Setting - District general hospital. Subjects - All 1017 skin biopsy specimens from general practice for 15 months before and 12 months after the new general practitioner contract. Results - The number of pathology specimens received increased from 16 to 65 per month (median = 6 submitted by each general practitioner in the post-contract year). The proportion of the more common pathological diagnoses was unchanged between the two periods, but the proportion of correctly diagnosed naevi, cysts, and seborrhoeic keratoses increased in the second. Although few diagnoses were overtly incorrect, accurate diagnosis of dermatofibromas and malignancies decreased after the contract, and the overall correct diagnosis rate for seborrhoeic keratoses, dermatofibromas, rashes, and malignancies was below 30%. Only nine out of 21 squamous cell carcinomas were adequately excised with tumour free margins, and follow up of malignant tumours may have been inadequate. Conclusions - Skin surgery in general practice has advantages but matters of concern are the increase in laboratory workload, the excision of some benign lesions, and the inappropriateness of biopsy of rashes. Squamous cell carcinoma and other malignant tumours submitted for pathological examination were often unsuspected and inadequately excised, and heightened suspicion is recommended. Pathology request forms may need redesigning to encourage provision of clinical details.			COX, NH (corresponding author), CUMBERLAND INFIRM,CARLISLE CA2 7HY,ENGLAND.							BROWN JS, 1979, BRIT MED J, V1, P1609, DOI 10.1136/bmj.1.6178.1609; DANDO P, 1991, J MED DEFENCE UNION, V1, P12; Godfrey E, 1990, Health Trends, V22, P57; HUNT AC, 1991, BMJ, V301, P495; MORGAN DR, 1991, BMJ, V300, P1379; NIXON RL, 1986, MED J AUSTRALIA, V144, P235, DOI 10.5694/j.1326-5377.1986.tb115884.x; Pitcher R., 1991, BR J DERMATOL S38, V125, P93; PRINGLE M, 1991, BRIT MED J, V302, P830, DOI 10.1136/bmj.302.6780.830; RICHARDS T, 1991, BMJ, V301, P307; SHARMAN J, 1986, PRACTITIONER, V230, P27; SHRANK AB, 1990, HLTH TRENDS, V22, P181; SLATER DN, 1991, BMJ, V300, P1074; STERN RS, 1991, JAMA-J AM MED ASSOC, V265, P74, DOI 10.1001/jama.265.1.74; ZOLTIE N, 1991, BRIT MED J, V302, P941, DOI 10.1136/bmj.302.6782.941; 1989, GENERAL PRACTICE NAT	15	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					93	96		10.1136/bmj.304.6819.93	http://dx.doi.org/10.1136/bmj.304.6819.93			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737150	Green Published, Bronze			2022-12-01	WOS:A1992HA17100026
J	DEMELKER, RA				DEMELKER, RA			DIAGNOSTIC-VALUE OF MICROTYMPANOMETRY IN PRIMARY CARE	BRITISH MEDICAL JOURNAL			English	Article							OTITIS-MEDIA; PRESCHOOL-CHILDREN; EFFUSION; EAR; IDENTIFICATION; TYMPANOMETRY; MANAGEMENT	Objective - To determine the reliability, validity, and feasibility of a new hand held microtympanometer. Design - Comparison of microtympanometry by two independent observations of a general practitioner and a nurse, and against a validated reference instrument. Setting - Primary care health centre of a school for the deaf in the United States. Subjects - 111 schoolchildren receiving a regular check up. Main outcome measures - Tympanometry with the Grason Stadler 28, classified with a slightly modified Jerger's classification. Results - Interobserver reliability was 0.95 (Cohen's X). Results of microtympanometry were highly comparable with results of the reference instrument (likelihood ratio of positive results, 161.2). Conclusions - The microtympanometer could be used in general practice: it is hand held, child friendly, easy to handle, and accurate.			DEMELKER, RA (corresponding author), UNIV UTRECHT,DEPT GEN PRACTICE,3511 ZC UTRECHT,NETHERLANDS.							BLACK NA, 1990, BRIT MED J, V300, P1551, DOI 10.1136/bmj.300.6739.1551; BLUESTONE CD, 1979, ANN OTO RHINOL LARYN, V88, P13, DOI 10.1177/00034894790880S503; Bluestone CD., 2007, OTITIS MEDIA INFANTS, V4th; BURKE P, 1989, J ROY COLL GEN PRACT, V39, P377; CANTEKIN EI, 1977, ANN OTO RHINOL LARYN, V86, P16, DOI 10.1177/00034894770864S202; CANTEKIN EI, 1980, ANN OTO RHINOL LARYN, V89, P190, DOI 10.1177/00034894800890S344; CASSELBRANT ML, 1985, LARYNGOSCOPE, V95, P428; Chalmers D., 1989, OTITIS MEDIA EFFUSIO; DEMELKER RA, 1988, FAM PRACT, V5, P307, DOI 10.1093/fampra/5.4.307; Feinstein A.R., 1985, CLIN EPIDEMIOLOGY; GARDNER MJ, 1989, STATISTICS CONFIDENC; GATES GA, 1986, ANN OTO RHINOL LARYN, V95, P46, DOI 10.1177/000348948609500110; KARMA PH, 1988, RECENT ADV OTITIS ME; KELSEY JL, 1986, METHODS OBSERVATIONA; MARGOLIS RH, 1989, INT J AUDITORY COMMU, V26, P197; REVES R, 1985, BMJ-BRIT MED J, V290, P1953, DOI 10.1136/bmj.290.6486.1953; Sackett D.L., 1985, CLIN EPIDEMIOLOGY BA; VANDELISDONK EH, 1990, ZIEKTEN HUISARTSPRAK; WAZEN JJ, 1988, ANN RHINOL LARY S133, V97, P20; WILMOT JF, 1988, J ROY COLL GEN PRACT, V38, P149; ZIELHUIS G A, 1989, Scandinavian Journal of Primary Health Care, V7, P33, DOI 10.3109/02813438909103668; ZIELHUIS GA, 1990, CLIN OTOLARYNGOL, V15, P147, DOI 10.1111/j.1365-2273.1990.tb00448.x; 1990, LANCET, V336, P23	23	18	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					96	98		10.1136/bmj.304.6819.96	http://dx.doi.org/10.1136/bmj.304.6819.96			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737151	Bronze, Green Published			2022-12-01	WOS:A1992HA17100027
J	HISS, J; ARENSBURG, B				HISS, J; ARENSBURG, B			SUFFOCATION FROM MISUSE OF GAS MASKS DURING THE GULF WAR	BRITISH MEDICAL JOURNAL			English	Article									TEL AVIV UNIV,SACKLER SCH MED,DEPT ANAT & ANTHROPOL,TEL AVIV,ISRAEL; L GREENBERG NATL INST FORENS MED,TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine								Di Maio D.J., 1989, FORENSIC PATHOLOGY, P207; POLSON CJ, 1985, ESSENTIALS FORENSIC, P449	2	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					92	92		10.1136/bmj.304.6819.92	http://dx.doi.org/10.1136/bmj.304.6819.92			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737149	Bronze, Green Published			2022-12-01	WOS:A1992HA17100025
J	JONES, R; LYDEARD, S				JONES, R; LYDEARD, S			IRRITABLE-BOWEL-SYNDROME IN THE GENERAL-POPULATION	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE; PSYCHOSOCIAL FACTORS; SYMPTOMS; DYSFUNCTION; DYSPEPSIA; PREVALENCE; DISORDERS; DIAGNOSIS; BEHAVIOR	Objective - To determine the prevalence of symptoms compatible with a clinical diagnosis of irritable bowel syndrome in the general population. Design - Validated postal questionnaire sent to 2280 subjects randomly selected in 10 year age bands from the lists of eight general practitioners. The Manning criteria were used to define irritable bowel syndrome. Setting - Urban population in Southampton and mixed urban-rural population in Andover, Hampshire. Results - A response of 71% yielded 1620 questionnaires for analysis, of which 412 (25%) reported more than six episodes of abdominal pain in the preceding year, with 350 (22%) reporting symptoms consistent with the diagnosis of irritable bowel syndrome. The male: female ratio was 1:1.38. More subjects with irritable bowel syndrome had constipation and diarrhoea and 35% with the syndrome reported rectal bleeding compared with an overall prevalence of 20%. Other symptoms and conditions including heartburn, dyspepsia, flushing, palpitations, migraine, and urinary symptoms were significantly more common in the group with irritable bowel syndrome. Abdominal pain in childhood was more common in the subjects with irritable bowel syndrome (12%) than without (3%). One third of the group with irritable bowel syndrome had sought medical advice during the study period (male: female ratio 1:1.21); consultation behaviour was influenced by age and the presence of associated symptoms, varied considerably among patients registered with different general practitioners, and was poorly correlated with symptom severity. Conclusion - Symptoms consistent with a diagnosis of irritable bowel syndrome are present in almost one quarter of the general population and tend to be associated with a number of other complaints and conditions, some of which may reflect smooth muscle dysfunction.	UNIV SOUTHAMPTON,PRIMARY MED CARE,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND	University of Southampton								Bordie A K, 1972, J Indian Med Assoc, V58, P451; DENT OF, 1986, DIS COLON RECTUM, V29, P243, DOI 10.1007/BF02553027; DROSSMAN DA, 1988, GASTROENTEROLOGY, V95, P701, DOI 10.1016/S0016-5085(88)80017-9; DROSSMAN DA, 1982, GASTROENTEROLOGY, V83, P529; GOUDY WJ, 1976, 3 IOW AGR HOM EC EXP; HEATON KW, 1991, GUT, V32, P73, DOI 10.1136/gut.32.1.73; INGHAM JG, 1979, J EPIDEMIOL COMMUN H, V33, P191, DOI 10.1136/jech.33.3.191; ISGAR B, 1983, GUT, V24, P190, DOI 10.1136/gut.24.3.190; JONES R, 1989, BRIT MED J, V298, P30, DOI 10.1136/bmj.298.6665.30; LYDEARD S, 1989, J ROY COLL GEN PRACT, V39, P495; MACDONALD L, 1986, FAM PRACT, V3, P80, DOI 10.1093/fampra/3.2.80; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; MENDIS BLJ, 1983, CEYLON MED J, V27, P171; MITCHELL CM, 1987, GASTROENTEROLOGY, V92, P1282, DOI 10.1016/S0016-5085(87)91099-7; SANDLER RS, 1984, GASTROENTEROLOGY, V87, P314; SMITH RC, 1991, GASTROENTEROLOGY, V100, P591, DOI 10.1016/0016-5085(91)80002-Q; SMITH RC, 1990, GASTROENTEROLOGY, V98, P293, DOI 10.1016/0016-5085(90)90817-K; TALLEY NJ, 1990, GUT, V31, P77, DOI 10.1136/gut.31.1.77; TALLEY NJ, 1990, GASTROENTEROLOGY, V99, P327, DOI 10.1016/0016-5085(90)91012-U; Thompson, 1989, INTERPRETATION SYMPT; THOMPSON WG, 1984, GUT, V25, P1089, DOI 10.1136/gut.25.10.1089; THOMPSON WG, 1980, GASTROENTEROLOGY, V79, P283; WHITE AM, 1991, GASTROENTEROLOGY, V100, P68, DOI 10.1016/0016-5085(91)90584-8; WHORWELL PJ, 1986, GUT, V27, P1014, DOI 10.1136/gut.27.9.1014; WHORWELL PJ, 1986, GUT, V27, P37, DOI 10.1136/gut.27.1.37	25	496	513	0	22	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					87	90		10.1136/bmj.304.6819.87	http://dx.doi.org/10.1136/bmj.304.6819.87			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737146	Bronze, Green Published			2022-12-01	WOS:A1992HA17100022
J	JOPLIN, R; LINDSAY, JG; JOHNSON, GD; STRAIN, A; NEUBERGER, J				JOPLIN, R; LINDSAY, JG; JOHNSON, GD; STRAIN, A; NEUBERGER, J			MEMBRANE DIHYDROLIPOAMIDE ACETYLTRANSFERASE (E2) ON HUMAN BILIARY EPITHELIAL-CELLS IN PRIMARY BILIARY-CIRRHOSIS	LANCET			English	Note							CULTURE; LIVER	Primary biliary cirrhosis (PBC) is associated with serum antibodies that react with the dihydrolipoamide acetyltransferase component (E2) of the mitochondrial pyruvate dehydrogenase complex. We have sought the presence of E2 on the surface of human intrahepatic biliary epithelial cells (BEC). Cultured BECs from PBC but not normal liver were found to have E2 on the membrane after three days' culture. Isolated, viable cells examined by laser-scanning confocal microscopy revealed the pattern of E2 staining on the membrane to be similar to that seen with the membrane glycoprotein marker, HEA-125. By contrast, BECs from normal liver showed membrane staining only with HEA-125. When BECs were fixed before incubation with antibody to E2, cytoplasmic staining was observed. Our results suggest that E2 is present on the surface of biliary epithelial cells in PBC, and support the idea of a pathogenetic association between antimitochondrial antibodies and bileduct damage.	QUEEN ELIZABETH HOSP,LIVER UNIT,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT IMMUNOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV GLASGOW,DEPT BIOCHEM,GLASGOW G12 8QQ,SCOTLAND	University of Birmingham; University of Birmingham; University of Glasgow			Neuberger, James/ABG-3010-2020		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		COPPEL RL, 1988, P NATL ACAD SCI USA, V85, P7317, DOI 10.1073/pnas.85.19.7317; GERKEN G, 1988, HEPATOLOGY, V8, P705; GHADIMINEJAD I, 1987, HEPATOLOGY, V7, P743, DOI 10.1002/hep.1840070421; HUNTER A, 1989, EUR J BIOCHEM, V155, P103; JOPLIN R, 1989, IN VITRO CELL DEV B, V25, P1189; JOPLIN R, 1990, J PATHOL, V162, P255, DOI 10.1002/path.1711620312; JOPLIN R, 1991, HEPATOLOGY, V14, P442, DOI 10.1016/0270-9139(91)90181-T; KRAMS SM, 1989, HEPATOLOGY, V9, P414; VANDEWATER R, 1991, J IMMUNOL, V146, P89; YEAMAN SJ, 1986, TRENDS BIOCHEM SCI, V11, P293, DOI 10.1016/0968-0004(86)90033-2	10	94	96	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1992	339	8785					93	94		10.1016/0140-6736(92)91001-O	http://dx.doi.org/10.1016/0140-6736(92)91001-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ156	1370237				2022-12-01	WOS:A1992GZ15600005
J	PELL, ACH; MILLER, HC; ROBERTSON, CE; FOX, KAA				PELL, ACH; MILLER, HC; ROBERTSON, CE; FOX, KAA			EFFECT OF FAST TRACK ADMISSION FOR ACUTE MYOCARDIAL-INFARCTION ON DELAY TO THROMBOLYSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; LEFT-VENTRICULAR FUNCTION; GENERAL-PRACTITIONER; CARE UNIT; STREPTOKINASE; THERAPY; REDUCTION; PATIENT; POLICY; TIME	Objective - To evaluate the impact of a fast track triage system for patients with acute myocardial infarction. Design - Comparison of delays in admission to hospital and in receiving thrombolytic treatment before and after introducing fast track system with delays recorded in 1987-8. Patients fulfilling clinical and electrocardiographic criteria for myocardial infarction were selected for rapid access to the cardiac care team, bypassing evaluation by the medical registrar. Setting - Major accident and emergency, cardiac and trauma centre. Subjects - 359 patients admitted to the cardiac care unit during 1 February to 31 July 1990 with suspected acute infarction. Main outcome measures - Accuracy of diagnosis and delay from arrival at hospital to thrombolytic treatment. Results - 248 of the 359 patients had myocardial infarction confirmed, of whom 127 received thrombolytic treatment. The fast track system correctly identified 79 out of 127 (62%) patients who subsequently required thrombolytic treatment. 95% (79/83) of patients treated with thrombolysis after fast track admission had the diagnosis confirmed by electrocardiography and enzyme analysis. The median delay from hospital admission to thrombolytic treatment fell from 93 minutes in 1987-8 to 49 minutes in fast track patients (p < 0.001). Delay in admission to the cardiac care unit was reduced by 47% for fast track patients (median 60 minutes in 1987-8 v 32 minutes in 1990, p < 0.001) and by 25% for all patients (60 minutes v 45 minutes, p < 0.001). Conclusion - This fast track system requires no additional staff or equipment, and it halves in-hospital delay to thrombolytic treatment without affecting the accuracy of diagnosis among patients requiring thrombolysis.	ROYAL INFIRM, DEPT CARDIOL, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND	Royal Infirmary of Edinburgh				Fox, Keith/0000-0002-0140-2752				[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; BOSSAERT LL, 1988, CRIT CARE MED, V16, P823, DOI 10.1097/00003246-198809000-00001; BURNS JMA, 1989, BRIT HEART J, V61, P322; CASTAIGNE AD, 1989, AM J CARDIOL, V64, pA30, DOI 10.1016/0002-9149(89)90927-2; CHAMBERLAIN DA, 1988, LANCET, V1, P545; FOX KAA, 1990, BMJ-BRIT MED J, V300, P867, DOI 10.1136/bmj.300.6728.867; KNABB RM, 1987, J NUCL MED, V28, P1563; KOREN G, 1985, NEW ENGL J MED, V313, P1384, DOI 10.1056/NEJM198511283132204; LEIZOROVICZ A, 1988, EUR HEART J, V9, P118; MACCALLUM AG, 1990, EUR HEART J, V11, P48, DOI 10.1093/eurheartj/11.suppl_F.48; MCNEILL AJ, 1991, Q J MED, V79, P487; PASSAMANI E, 1987, J AM COLL CARDIOL, V10, pB51, DOI 10.1016/S0735-1097(87)80429-1; PELL A C H, 1990, Health Bulletin (Edinburgh), V48, P225; RAWLES JM, 1988, BRIT MED J, V296, P882, DOI 10.1136/bmj.296.6626.882; RIDKER P, 1990, Journal of the American College of Cardiology, V15, p167A; ROTH A, 1990, J AM COLL CARDIOL, V15, P932, DOI 10.1016/0735-1097(90)90219-F; SHARKEY SW, 1989, JAMA-J AM MED ASSOC, V262, P3171, DOI 10.1001/jama.262.22.3171; SHEEHAN FH, 1983, AM J CARDIOL, V52, P431, DOI 10.1016/0002-9149(83)90002-4; VANDEWERF F, 1988, BMJ-BRIT MED J, V297, P1374, DOI 10.1136/bmj.297.6660.1374; WEAVER WD, 1990, J AM COLL CARDIOL, V15, P925, DOI 10.1016/0735-1097(90)90218-E; WILCOX RG, 1988, LANCET, V2, P525	22	99	97	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 11	1992	304	6819					83	87		10.1136/bmj.304.6819.83	http://dx.doi.org/10.1136/bmj.304.6819.83			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737145	Green Published, Bronze			2022-12-01	WOS:A1992HA17100021
J	PILGRIM, JA; STANSFELD, S; MARMOT, M				PILGRIM, JA; STANSFELD, S; MARMOT, M			LOW BLOOD-PRESSURE, LOW MOOD	BRITISH MEDICAL JOURNAL			English	Article							GENERAL HEALTH QUESTIONNAIRE; HYPERTENSION; DEPRESSION; HOSTILITY	Objective - To determine whether a set of physical symptoms is associated with low blood pressure and to investigate the possible role of psychological factors in their occurrence. Design - Analysis of data collected by questionnaire and physical screening from the first phase of the Whitehall II study, a cohort study of an employed population. Setting - 23 civil service departments in London. Subjects - 10314 male and female London based civil servants aged between 35 and 55. Main outcome measures - Symptoms of dizziness-giddiness and unexplained tiredness; psychological functioning as measured by the 30 item general health questionnaire in which the response "no more than usual" to an item about disease was scored as indicating chronic illness. Results - Dizziness-giddiness in men and unexplained tiredness in both men and women were significantly related to low systolic blood pressure. There was a highly significant inverse relation between general health questionnaire score and systolic blood pressure for both men and women, which persisted after controlling for potentially confounding variables, including age, body mass index, drug treatment, physical illness, and exercise. This association of low blood pressure with physical symptoms was no longer significant when general health questionnaire score was controlled for. Conclusions - There seems a strong relation between low systolic blood pressure and minor psychological dysfunction. Associated physical symptoms seem to be secondary to the primary disturbance in mental state.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND; UNIV COLL & MIDDLESEX SCH MED, ACAD DEPT PSYCHIAT, LONDON, ENGLAND	University of London; London School of Hygiene & Tropical Medicine; University of London; University College London	PILGRIM, JA (corresponding author), UCL, UNIV COLL & MIDDLESEX SCH MED, DEPT COMMUNITY MED, LONDON WC1E 6EA, ENGLAND.		Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline; NHLBI NIH HHS [2 ROI HL36310-04] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036310] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bengtsson C, 1987, Scand J Prim Health Care, V5, P155, DOI 10.3109/02813438709013997; COCHRANE R, 1973, J PSYCHOSOM RES, V17, P215, DOI 10.1016/0022-3999(73)90026-3; Dembroski T M, 1978, J Behav Med, V1, P159, DOI 10.1007/BF00846637; Goldberg DP., 1972, DETECTION PSYCHIATRI; GOLDBERG EL, 1980, PSYCHOL MED, V10, P243, DOI 10.1017/S0033291700044007; GOODCHILD ME, 1985, BRIT J PSYCHIAT, V146, P55, DOI 10.1192/bjp.146.1.55; HUPPERT FA, 1988, PSYCHOL MED, V18, P1001, DOI 10.1017/S0033291700009922; MANN AH, 1977, PSYCHOL MED, V7, P653, DOI 10.1017/S0033291700006309; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; NAKAGAWARA M, 1987, PSYCHIAT RES, V21, P85, DOI 10.1016/0165-1781(87)90065-5; PEMBERTON J, 1989, BRIT MED J, V298, P660, DOI 10.1136/bmj.298.6674.660; RABKIN JG, 1983, AM J PSYCHIAT, V140, P1072; ROBBINS JM, 1982, SOC SCI MED, V16, P27, DOI 10.1016/0277-9536(82)90420-8; STANSFELD S, IN PRESS PSYCHOL MED; WESSELY S, 1990, BMJ-BRIT MED J, V301, P18; 1967, RECOMMENDATIONS HUMA	16	120	121	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					75	78		10.1136/bmj.304.6819.75	http://dx.doi.org/10.1136/bmj.304.6819.75			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737142	Bronze, Green Published			2022-12-01	WOS:A1992HA17100018
J	RAZAY, G; HEATON, KW; BOLTON, CH; HUGHES, AO				RAZAY, G; HEATON, KW; BOLTON, CH; HUGHES, AO			ALCOHOL-CONSUMPTION AND ITS RELATION TO CARDIOVASCULAR RISK-FACTORS IN BRITISH WOMEN	BRITISH MEDICAL JOURNAL			English	Article							DENSITY-LIPOPROTEIN SUBFRACTIONS; CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; CHOLESTEROL; MORTALITY; ETHANOL; SMOKING; GLUCOSE; LIPIDS; MEN	Objective - To examine the relation between alcohol consumption and risk factors for coronary heart disease in women. Design - Cross sectional study of a stratified random sample of the population grouped into five categories of habitual alcohol consumption. Setting - People registered with general practitioners at two large health centres in east Bristol, England. Subjects - 1048 women aged 25-69 years. Main outcome measures - Fasting plasma concentrations of insulin, total cholesterol, total triglycerides, and high density lipoprotein cholesterol, including its subfractions HDL2 and HDL3, and body mass index. Results - Compared with non-drinkers women consuming a moderate amount of alcohol (1-20 g/day) had lower plasma concentrations of triglycerides, by 0.19 mmol/l (95% confidence interval 0.07 to 0.5); cholesterol, by 0.4 mmol/l (0.19 to 0.61); and insulin, by 1.4 mU/l (0.43 to 1.97) and a lower body mass index, by 1.2 kg/m2 (0.43 to 1.97). They also had higher concentrations of high density lipoprotein cholesterol, by 0-09 mmol/l (0.03 to 0.15); HDL2 cholesterol by 0.05 mmol/l (-0.02 to 0.10) and HDL3 cholesterol, by 0.06 mmol/l (0.06 to 0.11). All these were independent of body mass index, smoking habits, and taking oral contraceptives. Conclusions - Moderate alcohol consumption is associated with lower levels of cardiovascular risk factors in women. Insulin may have a central role.	UNIV BRISTOL,DEPT EPIDEMIOL & PUBL HLTH MED,BRISTOL BS8 2PR,ENGLAND	University of Bristol	RAZAY, G (corresponding author), UNIV BRISTOL,BRISTOL ROYAL INFIRM,DEPT MED,BRISTOL BS2 8HW,AVON,ENGLAND.							BALLANTYNE FC, 1982, METABOLISM, V31, P433, DOI 10.1016/0026-0495(82)90230-X; BELFRAGE P, 1977, EUR J CLIN INVEST, V7, P127, DOI 10.1111/j.1365-2362.1977.tb01584.x; CASTELLI WP, 1977, LANCET, V2, P153; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; DIEHL AK, 1988, ATHEROSCLEROSIS, V69, P145, DOI 10.1016/0021-9150(88)90008-1; DIETSCHY JM, 1974, J LIPID RES, V15, P508; DUCIMETIERE P, 1980, DIABETOLOGIA, V19, P205, DOI 10.1007/BF00275270; EVANS SJW, 1991, BRIT MED J, V302, P302, DOI 10.1136/bmj.302.6772.302; FEHILY AM, 1988, EUR J CLIN NUTR, V42, P405; GORDON T, 1983, AM HEART J, V105, P667, DOI 10.1016/0002-8703(83)90492-1; HAFFNER SM, 1985, ARTERIOSCLEROSIS, V5, P169, DOI 10.1161/01.ATV.5.2.169; HASKELL WL, 1984, NEW ENGL J MED, V310, P805, DOI 10.1056/NEJM198403293101301; HEATON KW, 1991, GUT, V32, P316, DOI 10.1136/gut.32.3.316; HENNEKENS CH, 1987, CIRCULATION, V76, P501; JACKSON R, 1991, BRIT MED J, V303, P211, DOI 10.1136/bmj.303.6796.211; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; MARMOT MG, 1981, LANCET, V1, P580; METZ R, 1969, DIABETES, V18, P517, DOI 10.2337/diab.18.8.517; MILLER GJ, 1975, LANCET, V1, P16; MILLER NE, 1981, BRIT MED J, V282, P1741, DOI 10.1136/bmj.282.6278.1741; MILLER NE, 1988, J EPIDEMIOL COMMUN H, V42, P220, DOI 10.1136/jech.42.3.220; OETTLE GJ, 1987, AM J CLIN NUTR, V45, P86, DOI 10.1093/ajcn/45.1.86; OHLER G, 1982, INT J OBES S1, V6, P137; PATEL DG, 1979, METABOLISM, V28, P85, DOI 10.1016/0026-0495(79)90173-2; Pyorala K, 1979, Diabetes Care, V2, P131, DOI 10.2337/diacare.2.2.131; RUSSELL JC, 1989, ARTERIOSCLEROSIS, V9, P121; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STEINER G, 1986, AM J CARDIOL, V57, P27; TASKINEN MR, 1982, METABOLISM, V31, P1168, DOI 10.1016/0026-0495(82)90169-X; THORNTON J, 1983, LANCET, V2, P819; Welborn T A, 1979, Diabetes Care, V2, P154, DOI 10.2337/diacare.2.2.154; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; 1989, REFERENCE MANUAL REL	33	94	95	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					80	83		10.1136/bmj.304.6819.80	http://dx.doi.org/10.1136/bmj.304.6819.80			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737144	Bronze, Green Published			2022-12-01	WOS:A1992HA17100020
J	TURNBULL, PJ; STIMSON, GV; DOLAN, KA				TURNBULL, PJ; STIMSON, GV; DOLAN, KA			PREVALENCE OF HIV-INFECTION AMONG EX-PRISONERS IN ENGLAND	BRITISH MEDICAL JOURNAL			English	Article											TURNBULL, PJ (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,CTR RES DRUGS & HLTH BEHAV,LONDON SW6 1RQ,ENGLAND.		Dolan, Kate/B-1901-2008; Dolan, Kate/G-7859-2017	Dolan, Kate/0000-0002-9848-807X				FARRELL M, 1991, BRIT MED J, V302, P1477, DOI 10.1136/bmj.302.6791.1477; JOHNSON AM, 1988, AIDS, V2, P369, DOI 10.1097/00002030-198810000-00006; MADEN A, 1991, BRIT MED J, V302, P880, DOI 10.1136/bmj.302.6781.880; MADEN A, 1991, BRIT MED J, V301, P1133; TURNBULL PJ, 1991, PRISONS HIV AIDS RIS	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					90	91		10.1136/bmj.304.6819.90	http://dx.doi.org/10.1136/bmj.304.6819.90			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737147	Bronze, Green Published			2022-12-01	WOS:A1992HA17100023
J	BETZ, WJ; BEWICK, GS				BETZ, WJ; BEWICK, GS			OPTICAL ANALYSIS OF SYNAPTIC VESICLE RECYCLING AT THE FROG NEUROMUSCULAR-JUNCTION	SCIENCE			English	Article							SYNAPSIN-I; NEUROTRANSMITTER RELEASE; TRANSMITTER RELEASE; NERVE-TERMINALS; PROTEIN; ACETYLCHOLINE; MEMBRANE; EXOCYTOSIS	The fluorescent dyes FM1-43 and RH414 label motor nerve terminals in an activity-dependent fashion that involves dye uptake by synaptic vesicles that are recycling. This allows optical monitoring of vesicle recycling in living nerve terminals to determine how recycled vesicles reenter the vesicle pool. The results suggest that recycled vesicles mix with the pool morphologically and functionally. One complete cycle of release of transmitter, recycling of a vesicle, and rerelease of transmitter appears to take about 1 minute.			BETZ, WJ (corresponding author), UNIV COLORADO, SCH MED, DEPT PHYSIOL, DENVER, CO 80262 USA.		Bewick, Guy/AAL-8214-2021	Bewick, Guy/0000-0001-8266-7797	NINDS NIH HHS [NS23466, NS10207] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010207, R01NS023466] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARKER LA, 1972, BIOCHEM J, V130, P1063, DOI 10.1042/bj1301063; BETZ W J, 1991, Society for Neuroscience Abstracts, V17, P1157; BETZ W J, 1990, Society for Neuroscience Abstracts, V16, P53; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; CECCARELLI B, 1972, J CELL BIOL, V54, P30, DOI 10.1083/jcb.54.1.30; CECCARELLI B, 1973, J CELL BIOL, V57, P499, DOI 10.1083/jcb.57.2.499; COLLIER B, 1969, CAN J PHYSIOL PHARM, V47, P127, DOI 10.1139/y69-023; HEUSER JE, 1989, Q J EXP PHYSIOL CMS, V74, P1051, DOI 10.1113/expphysiol.1989.sp003333; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HIROKAWA N, 1989, J CELL BIOL, V108, P111, DOI 10.1083/jcb.108.1.111; ISRAEL M, 1990, J NEUROCHEM, V55, P1758, DOI 10.1111/j.1471-4159.1990.tb04966.x; ISRAEL M, 1986, P NATL ACAD SCI USA, V83, P9226, DOI 10.1073/pnas.83.23.9226; KOPIN IJ, 1968, J PHARMACOL EXP THER, V161, P271; LANDIS DMD, 1988, NEURON, V1, P201, DOI 10.1016/0896-6273(88)90140-7; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; NAVONE F, 1984, SCIENCE, V226, P1209, DOI 10.1126/science.6438799; POTTER LT, 1970, J PHYSIOL-LONDON, V206, P145, DOI 10.1113/jphysiol.1970.sp009003; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; TARELLI FT, 1990, PROG BRAIN RES, V84, P83; VALTORTA F, 1990, NEUROSCIENCE, V35, P477, DOI 10.1016/0306-4522(90)90323-V; VALTORTA F, 1988, NEUROSCIENCE, V24, P593, DOI 10.1016/0306-4522(88)90353-3; WHITTAKER VP, 1990, PROG BRAIN RES, V84, P419; WHITTAKER VP, 1987, ANN NY ACAD SCI, V493, P77, DOI 10.1111/j.1749-6632.1987.tb27185.x; ZIMMERMANN H, 1989, CELL BIOL INT REP, V13, P993, DOI 10.1016/0309-1651(89)90015-5; ZIMMERMANN H, 1979, NEUROSCIENCE, V4, P1773, DOI 10.1016/0306-4522(79)90058-7; ZIMMERMANN H, 1988, HDB EXPT PHARM, V86, P349	27	638	646	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 10	1992	255	5041					200	203		10.1126/science.1553547	http://dx.doi.org/10.1126/science.1553547			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY704	1553547				2022-12-01	WOS:A1992GY70400037
J	BODE, J; KOHWI, Y; DICKINSON, L; JOH, T; KLEHR, D; MIELKE, C; KOHWISHIGEMATSU, T				BODE, J; KOHWI, Y; DICKINSON, L; JOH, T; KLEHR, D; MIELKE, C; KOHWISHIGEMATSU, T			BIOLOGICAL SIGNIFICANCE OF UNWINDING CAPABILITY OF NUCLEAR MATRIX ASSOCIATING DNAS	SCIENCE			English	Article							SCAFFOLD-ATTACHED REGIONS; CHROMOSOMAL LOOP ANCHORAGE; DROSOPHILA-MELANOGASTER; TOPOISOMERASE-II; SUPERCOILED DNA; SITES; GENE; TRANSCRIPTION; CHROMATIN; CELLS	Matrix attachment regions (MARs) are thought to separate chromatin into topologically constrained loop domains. A MAR located 5' of the human beta-interferon gene becomes stably base-unpaired under superhelical strain, as do the MARs flanking the immunoglobulin heavy chain gene enhancer; in both cases a nucleation site exists for DNA unwinding. Concatemerized oligonucleotides containing the unwinding nucleation site exhibited a strong affinity for the nuclear scaffold and augmented SV40 promoter activity in stable transformants. Mutated concatemerized oligonucleotides resisted unwinding, showed weak affinity for the nuclear scaffold, and did not enhance promoter activity. These results suggest that the DNA feature capable of relieving superhelical strain is important for MAR functions.	GESELL BIOTECHNOL FORSCH GMBH,MASCHERODER WEG 1,W-3300 BRAUNSCHWEIG,GERMANY; LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	Gesellschaft fur Biotechnologische Forschung mbH; Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [R0I CA51377, R0I CA39681] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039681, R01CA051377] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; BARRIO JR, 1972, BIOCHEM BIOPH RES CO, V46, P597, DOI 10.1016/S0006-291X(72)80181-5; BODE J, 1988, BIOCHEMISTRY-US, V27, P4706, DOI 10.1021/bi00413a019; CLARK P, 1991, EMBO J, V10, P387; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; DIJKWEL PA, 1988, MOL CELL BIOL, V8, P5398, DOI 10.1128/MCB.8.12.5398; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GILMOUR DS, 1986, CELL, V44, P401, DOI 10.1016/0092-8674(86)90461-7; GROSS DS, 1987, TRENDS BIOCHEM SCI, V12, P293, DOI 10.1016/0968-0004(87)90144-7; HIROSE S, 1988, P NATL ACAD SCI USA, V85, P718, DOI 10.1073/pnas.85.3.718; HOMBERGER HP, 1989, CHROMOSOMA, V98, P99, DOI 10.1007/BF00291044; JARMAN AP, 1988, EMBO J, V7, P3337, DOI 10.1002/j.1460-2075.1988.tb03205.x; KAY V, UNPUB; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; KOCHETKOV N K, 1971, Tetrahedron Letters, V22, P1993; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; KOHWISHIGEMATSU T, UNPUB; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; MIELKE C, 1990, BIOCHEMISTRY-US, V29, P7475, DOI 10.1021/bi00484a017; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MIZUTANI M, 1991, P NATL ACAD SCI USA, V88, P718, DOI 10.1073/pnas.88.3.718; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; PHIVAN L, 1990, PROG MOL SUBCELL BIO, V11, P1; PROBST H, 1985, EUR J BIOCHEM, V146, P167, DOI 10.1111/j.1432-1033.1985.tb08634.x; SINDEN RR, 1987, J CHEM EDUC, V64, P294, DOI 10.1021/ed064p294; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; STRATLING WH, 1986, BIOCHEMISTRY-US, V25, P495, DOI 10.1021/bi00350a033; TSUTSUI K, 1988, J BIOL CHEM, V263, P7235; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; UMEK RM, 1988, CELL, V52, P559, DOI 10.1016/0092-8674(88)90469-2; VONKRIES JP, 1990, NUCLEIC ACIDS RES, V18, P3881; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WILLIAMS TM, 1989, ANAL BIOCHEM, V176, P28, DOI 10.1016/0003-2697(89)90267-4; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	42	395	415	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1992	255	5041					195	197		10.1126/science.1553545	http://dx.doi.org/10.1126/science.1553545			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY704	1553545				2022-12-01	WOS:A1992GY70400035
J	CHUCK, SL; LINGAPPA, VR				CHUCK, SL; LINGAPPA, VR			PAUSE TRANSFER - A TOPOGENIC SEQUENCE IN APOLIPOPROTEIN-B MEDIATES STOPPING AND RESTARTING OF TRANSLOCATION	CELL			English	Article							NEWLY SYNTHESIZED PROTEINS; ENDOPLASMIC-RETICULUM; SIGNAL SEQUENCE; MICROSOMAL-MEMBRANES; SECRETORY PROTEINS; MESSENGER-RNA; PRION PROTEIN; HEAT-SHOCK; PRE-GOLGI; DEGRADATION	Previously, we described the stepwise translocation of a large amino-terminal fragment of apolipoprotein B (apo Bl5) in which the nascent secretory chain translocates through a series of distinct, nonintegrated transmembrane intermediates with large domains exposed to the cytoplasm. Thus, apo B15 appears to stop and restart translocation at several points. We have identified a sequence of amino acids in apo B15 that confers this behavior on a heterologous chimeric protein. In addition, we dissect pausing into two distinct steps, stopping and restarting, thereby trapping otherwise transient intermediates. Finally, we demonstrate the function of a second "pause transfer" sequence over 200 amino acids downstream in apo B15 that restarts translocation posttranslationally, suggesting that multiple pause transfer sequences are involved in the biogenesis of apolipoprotein B.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	CHUCK, SL (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143, USA.			Lingappa, Vishwanath R./0000-0003-0962-6571	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045480] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 45480] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELMAN MR, 1973, J CELL BIOL, V56, P206, DOI 10.1083/jcb.56.1.206; AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; ANDREWS DW, 1988, J BIOL CHEM, V263, P15791; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CROSS GAM, 1987, CELL, V48, P179, DOI 10.1016/0092-8674(87)90419-3; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; FISHER WR, 1986, METHOD ENZYMOL, V128, P247; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; LINGAPPA VR, 1984, P NATL ACAD SCI-BIOL, V81, P456, DOI 10.1073/pnas.81.2.456; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PATERSON RG, 1987, CELL, V48, P441, DOI 10.1016/0092-8674(87)90195-4; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; PERARA E, 1985, J CELL BIOL, V101, P2292, DOI 10.1083/jcb.101.6.2292; PESTKA S, 1971, ANNU REV MICROBIOL, V25, P487, DOI 10.1146/annurev.mi.25.100171.002415; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PULLINGER CR, 1989, J LIPID RES, V30, P1065; REDMAN CM, 1966, P NATL ACAD SCI USA, V56, P608, DOI 10.1073/pnas.56.2.608; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; SABATINI DD, 1966, J MOL BIOL, V19, P503, DOI 10.1016/S0022-2836(66)80019-0; SATO R, 1990, J BIOL CHEM, V265, P11880; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SIUTAMANGANO P, 1981, J BIOL CHEM, V256, P2094; SPIESS M, 1989, J BIOL CHEM, V264, P19117; TRAUT RR, 1964, J MOL BIOL, V10, P63, DOI 10.1016/S0022-2836(64)80028-0; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WALTER P, 1983, METHOD ENZYMOL, V96, P84; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0; YOST CS, 1983, CELL, V34, P759; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	53	111	111	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1992	68	1					9	21		10.1016/0092-8674(92)90202-N	http://dx.doi.org/10.1016/0092-8674(92)90202-N			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1370657				2022-12-01	WOS:A1992GZ58300005
J	DEVOTO, SH; MUDRYJ, M; PINES, J; HUNTER, T; NEVINS, JR				DEVOTO, SH; MUDRYJ, M; PINES, J; HUNTER, T; NEVINS, JR			A CYCLIN-A-PROTEIN KINASE COMPLEX POSSESSES SEQUENCE-SPECIFIC DNA-BINDING ACTIVITY - P33CDK2 IS A COMPONENT OF THE E2F-CYCLIN-A COMPLEX	CELL			English	Article							ADENOVIRUS E1A PROTEINS; MATURATION-PROMOTING FACTOR; E2F TRANSCRIPTION FACTOR; CELL-DIVISION CYCLE; LARGE-T-ANTIGEN; SV40 LARGE-T; FISSION YEAST; M-PHASE; CONTROL GENE; SACCHAROMYCES-CEREVISIAE	The E2F transcription factor has been found in association with the cyclin A protein, and this complex accumulates during the S phase of the cell cycle, suggesting that E2F may play a role in cell cycle control. In independent studies, cyclin A has been shown to be associated with two other proteins, the Rb-related p107 protein and the cdc2-related p33 cdk2 protein kinase. Through an analysis of the E2F-cyclin A complex, we now find that both the p107 protein and the cdc2-related p33cdk2 kinase are components of the previously described complex. Moreover, the complex possesses H1 kinase activity. These results thus define a cyclin A-cdk2 kinase complex that possesses sequence-specific DNA binding activity. This suggests that the cdk2 kinase may phosphorylate other DNA-bound substrates, and that one role of the E2F factor may be to localize this protein kinase to the DNA.	SALK INST BIOL STUDIES,LA JOLLA,CA 92037	Salk Institute	DEVOTO, SH (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,GENET SECT,DURHAM,NC 27710, USA.			Devoto, Stephen/0000-0001-9513-3962; Pines, Jonathon/0000-0002-5227-6004				ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURKACZ B, 1986, EMBO J, V5, P369, DOI 10.1002/j.1460-2075.1986.tb04221.x; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EWEN M, 1991, IN PRESS SCIENCE; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAHA B, 1991, IN PRESS SCIENCE; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FORSBURG SL, 1991, NATURE, V351, P245, DOI 10.1038/351245a0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MEYERSON M, 1991, IN PRESS COLD SPRING, V58; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1990, New Biologist, V2, P389; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PINES J, 1991, IN PRESS COLD SPRING, V58; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X	81	367	383	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1992	68	1					167	176		10.1016/0092-8674(92)90215-X	http://dx.doi.org/10.1016/0092-8674(92)90215-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1310073				2022-12-01	WOS:A1992GZ58300018
J	KIM, B; LITTLE, JW				KIM, B; LITTLE, JW			DIMERIZATION OF A SPECIFIC DNA-BINDING PROTEIN ON THE DNA	SCIENCE			English	Article							LEXA REPRESSOR; ESCHERICHIA-COLI; TERMINAL DOMAIN; TRANSCRIPTION; CONTACTS; GCN4; RECA; FOS	Many specific DNA-binding proteins bind to sites with dyad symmetry, and the bound form of the protein is a dimer. For some proteins, dimers form in solution and bind to DNA. LexA repressor of Escherichia coli has been used to test an alternative binding model in which two monomers bind sequentially. This model predicts that a repressor monomer should bind with high specificity to an isolated operator half-site. Monomer binding to a half-site was observed. A second monomer bound to an intact operator far more tightly than the first monomer; this cooperativity arose from protein-protein contacts.	UNIV ARIZONA,DEPT MOLEC & CELLULAR BIOL,TUCSON,AZ 85721	University of Arizona	KIM, B (corresponding author), UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024178] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24178] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG JM, 1989, CELL, V57, P1065, DOI 10.1016/0092-8674(89)90042-1; BERTRANDBURGGRAF E, 1987, J MOL BIOL, V193, P293, DOI 10.1016/0022-2836(87)90220-8; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BRENT RP, UNPUB; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; Fersht A, 1985, ENZYME STRUCTURE MEC, P56; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GOLEMIS EA, COMMUNICATION; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.biochem.59.1.933; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HURSTEL S, 1986, EMBO J, V5, P793, DOI 10.1002/j.1460-2075.1986.tb04283.x; HURSTEL S, 1988, EMBO J, V7, P269, DOI 10.1002/j.1460-2075.1988.tb02809.x; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; KOWNIN P, 1987, CELL, V50, P693, DOI 10.1016/0092-8674(87)90327-8; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LIEBERMAN PM, 1991, MOL CELL BIOL, V11, P63, DOI 10.1128/MCB.11.1.63; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LITTLE JW, 1985, P NATL ACAD SCI USA, V82, P2301, DOI 10.1073/pnas.82.8.2301; LITTLE JW, 1981, P NATL ACAD SCI-BIOL, V78, P4199, DOI 10.1073/pnas.78.7.4199; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LYONS D, UNPUB; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; SAUER RT, 1990, NATURE, V347, P514, DOI 10.1038/347514b0; SCHNARR M, 1988, FEBS LETT, V234, P56, DOI 10.1016/0014-5793(88)81302-4; SCHNARR M, 1985, BIOCHEMISTRY-US, V24, P2812, DOI 10.1021/bi00332a032; THLIVERIS AT, 1991, BIOCHIMIE, V73, P449, DOI 10.1016/0300-9084(91)90112-E; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WERTMAN KF, 1985, J BACTERIOL, V163, P376, DOI 10.1128/JB.163.1.376-384.1985; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030	35	125	129	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1992	255	5041					203	206		10.1126/science.1553548	http://dx.doi.org/10.1126/science.1553548			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY704	1553548				2022-12-01	WOS:A1992GY70400038
J	LOWEL, S; SINGER, W				LOWEL, S; SINGER, W			SELECTION OF INTRINSIC HORIZONTAL CONNECTIONS IN THE VISUAL-CORTEX BY CORRELATED NEURONAL-ACTIVITY	SCIENCE			English	Article							CAT STRIATE CORTEX; FLUORESCENT LATEX MICROSPHERES; OCULAR DOMINANCE; POSTNATAL-DEVELOPMENT; INHIBITION; ASSOCIATION; PROJECTIONS; EXPERIENCE; AREA-18; COLUMNS	In the visual cortex of the brain, long-ranging tangentially oriented axon collaterals interconnect regularly spaced clusters of cells. These connections develop after birth and attain their specificity by pruning. To test whether there is selective stabilization of connections between those cells that exhibit correlated activity, kittens were raised with artificially induced strabismus (eye deviation) to eliminate the correlation between signals from the two eyes. In area 17, cell clusters were driven almost exclusively from either the right or the left eye and tangential intracortical fibers preferentially connected cell groups activated by the same eye. Thus, circuit selection depends on visual experience, and the selection criterion is the correlation of activity.			LOWEL, S (corresponding author), MAX PLANCK INST HIRNFORSCH,DEUTSCHORDEN STR 46,W-6000 FRANKFURT 71,GERMANY.		Singer, Wolf/D-6874-2012					ANDERSON PA, 1988, J NEUROSCI, V8, P2183; BLAKEMORE C, 1972, EXP BRAIN RES, V15, P439; CALLAWAY EM, 1991, P NATL ACAD SCI USA, V88, P745, DOI 10.1073/pnas.88.3.745; CALLAWAY EM, 1990, J NEUROSCI, V10, P1134; Damasio A. R., 1990, SEMIN NEUROSCI, V2, P287; Duke-Elder S, 1973, SYSTEM OPHTHALMOLOGY, V6; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; EYSEL UT, 1987, EXP BRAIN RES, V68, P606; FISKEN RA, 1975, PHILOS T ROY SOC B, V272, P487, DOI 10.1098/rstb.1975.0099; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; GILBERT CD, 1985, VISION RES, V25, P365, DOI 10.1016/0042-6989(85)90061-6; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P1041, DOI 10.1152/jn.1965.28.6.1041; INNOCENTI GM, 1979, NATURE, V280, P231, DOI 10.1038/280231a0; INNOCENTI GM, 1981, SCIENCE, V212, P824, DOI 10.1126/science.7221566; KATZ LC, 1990, NEUROSCIENCE, V34, P511, DOI 10.1016/0306-4522(90)90159-2; KATZ LC, 1984, NATURE, V310, P498, DOI 10.1038/310498a0; KONIG P, 1990, SOC NEUR ABSTR, V16; LOWEL S, 1988, EXP BRAIN RES, V71, P33; LOWEL S, 1987, EXP BRAIN RES, V68, P661; LOWEL S, 1987, J COMP NEUROL, V255, P401, DOI 10.1002/cne.902550307; LOWEL S, 1991, J PHYSIOL-LONDON, V438, pP157; LUHMANN HJ, 1986, EXP BRAIN RES, V63, P443; LUHMANN HJ, 1990, EUR J NEUROSCI, V2, P344, DOI 10.1111/j.1460-9568.1990.tb00426.x; MARTIN KAC, 1984, J PHYSIOL-LONDON, V353, P463, DOI 10.1113/jphysiol.1984.sp015347; MATSUBARA JA, 1987, J NEUROSCI, V7, P1428; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; MORRONE MC, 1982, PROC R SOC SER B-BIO, V216, P335, DOI 10.1098/rspb.1982.0078; NELSON JI, 1975, J THEOR BIOL, V49, P1, DOI 10.1016/S0022-5193(75)80020-8; PRICE DJ, 1986, DEV BRAIN RES, V24, P31, DOI 10.1016/0165-3806(86)90170-7; PRICE DJ, 1985, NATURE, V316, P721, DOI 10.1038/316721a0; ROCKLAND KS, 1982, SCIENCE, V215, P1532, DOI 10.1126/science.7063863; SHATZ CJ, 1977, BRAIN RES, V131, P103, DOI 10.1016/0006-8993(77)90031-2; SINGER W, 1976, EXP BRAIN RES, V26, P171; SINGER W, 1990, CONCEPTS NEUROSCI, V1, P1; SWINDALE NV, 1981, NATURE, V290, P332, DOI 10.1038/290332a0; Von Noorden GK., 1990, BINOCULAR VISION OCU; WIESEL TN, 1982, NATURE, V299, P583, DOI 10.1038/299583a0	40	401	406	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1992	255	5041					209	212		10.1126/science.1372754	http://dx.doi.org/10.1126/science.1372754			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY704	1372754				2022-12-01	WOS:A1992GY70400040
J	MARTIN, GA; YATANI, A; CLARK, R; CONROY, L; POLAKIS, P; BROWN, AM; MCCORMICK, F				MARTIN, GA; YATANI, A; CLARK, R; CONROY, L; POLAKIS, P; BROWN, AM; MCCORMICK, F			GAP DOMAINS RESPONSIBLE FOR RAS P21-DEPENDENT INHIBITION OF MUSCARINIC ATRIAL K+ CHANNEL CURRENTS	SCIENCE			English	Article							GTPASE-ACTIVATING PROTEIN; PHOSPHOLIPASE-C; GENE-PRODUCT; SRC; RECEPTORS; P21; PHOSPHORYLATION; SIMILARITY; BINDING; CLAMP	The interaction between the low molecular weight G protein ras p21 and a guanosine triphosphatase activating protein (GA-P) uncouples a heterotrimeric G protein (G(k)) from muscarinic receptors. Through the use of isolated atrial cell membranes and genetically engineered GAP deletion mutants, the src homology regions (SH2-SH3) at the amino terminus of GAP have been identified as the domains responsible for this effect. Deletion of the domain required to stimulate the guanosine triphosphatase activity of ras p21 relieves the requirement for ras p21 in this system. A model is presented that suggests that ras p21 induces a conformational change in GAP, which allows the SH2-SH3 regions of GAP to function.	BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine	MARTIN, GA (corresponding author), CETUS CORP,DEPT MOLEC BIOL,EMERYVILLE,CA 94608, USA.				NCI NIH HHS [CA51992-01] Funding Source: Medline; NHLBI NIH HHS [HL36930] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA051992] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036930] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKAIKE N, 1986, J PHYSIOL-LONDON, V379, P171, DOI 10.1113/jphysiol.1986.sp016246; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BROWN AM, 1984, NATURE, V311, P570, DOI 10.1038/311570a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FORCE T, 1991, J BIOL CHEM, V266, P6650; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; OKABE K, 1989, Biophysical Journal, V55, p586A; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; RAPP UR, 1991, ONCOGENE, V6, P495; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; YATANI A, 1988, J BIOL CHEM, V263, P9887; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YATANI A, 1990, AM J PHYSIOL, V258, pH1507, DOI 10.1152/ajpheart.1990.258.5.H1507; YATANI A, 1988, SCIENCE, V241, P828, DOI 10.1126/science.2457252; YATANI A, 1991, J BIOL CHEM, V266, P22222; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577	37	143	222	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1992	255	5041					192	194		10.1126/science.1553544	http://dx.doi.org/10.1126/science.1553544			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY704	1553544				2022-12-01	WOS:A1992GY70400034
J	POSADA, J; COOPER, JA				POSADA, J; COOPER, JA			REQUIREMENTS FOR PHOSPHORYLATION OF MAP KINASE DURING MEIOSIS IN XENOPUS OOCYTES	SCIENCE			English	Article							NERVE GROWTH-FACTOR; MICROTUBULE-ASSOCIATED PROTEIN-2; STIMULATED PROTEIN; PHOSPHOTYROSYL PROTEIN; PC12 CELLS; TYROSINE; ACTIVATION; IDENTIFICATION; PURIFICATION; PHOSPHATASES	Mitogen-activated protein (MAP) kinases are activated in response to a variety of extracellular stimuli by phosphorylation on tyrosine and threonine residues. Xp42 is a Xenopus laevis MAP kinase that is activated during oocyte maturation. Modified forms of Xp42 that lacked enzymatic activity or either of the phosphorylation sites were expressed in Xenopus oocytes. When meiotic maturation was induced with progesterone, each mutant Xp42 was phosphorylated, indicating that at least one kinase was activated that can phosphorylate Xp42 on tyrosine and threonine. Phosphorylation of one residue is not strictly dependent on phosphorylation of the other.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Fred Hutchinson Cancer Center				Posada, James/0000-0003-3582-9612	NATIONAL CANCER INSTITUTE [F32CA008860, P01CA028151] Funding Source: NIH RePORTER; NCI NIH HHS [CA-08860, CA-28151] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; COOPER JA, 1989, MOL CELL BIOL, V9, P3143, DOI 10.1128/MCB.9.7.3143; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HACCARD O, 1990, EUR J BIOCHEM, V192, P633, DOI 10.1111/j.1432-1033.1990.tb19270.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HOSHI M, 1989, EUR J BIOCHEM, V184, P477, DOI 10.1111/j.1432-1033.1989.tb15040.x; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1988, DEV BIOL, V130, P28, DOI 10.1016/0012-1606(88)90410-1; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; POSADA J, UNPUB; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; STRATTON KR, 1991, J NEUROCHEM, V56, P147, DOI 10.1111/j.1471-4159.1991.tb02574.x; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TSAO H, 1990, J BIOL CHEM, V265, P15471; TUNG HYL, 1984, EUR J BIOCHEM, V145, P57, DOI 10.1111/j.1432-1033.1984.tb08521.x; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	45	290	297	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1992	255	5041					212	215		10.1126/science.1313186	http://dx.doi.org/10.1126/science.1313186			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY704	1313186				2022-12-01	WOS:A1992GY70400041
J	ROSENFELD, MA; YOSHIMURA, K; TRAPNELL, BC; YONEYAMA, K; ROSENTHAL, ER; DALEMANS, W; FUKAYAMA, M; BARGON, J; STIER, LE; STRATFORDPERRICAUDET, L; PERRICAUDET, M; GUGGINO, WB; PAVIRANI, A; LECOCQ, JP; CRYSTAL, RG				ROSENFELD, MA; YOSHIMURA, K; TRAPNELL, BC; YONEYAMA, K; ROSENTHAL, ER; DALEMANS, W; FUKAYAMA, M; BARGON, J; STIER, LE; STRATFORDPERRICAUDET, L; PERRICAUDET, M; GUGGINO, WB; PAVIRANI, A; LECOCQ, JP; CRYSTAL, RG			INVIVO TRANSFER OF THE HUMAN CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE TO THE AIRWAY EPITHELIUM	CELL			English	Article							DEPENDENT PROTEIN-KINASE; INSITU HYBRIDIZATION; CHLORIDE CHANNELS; ADENOVIRUS TYPE-5; ESCHERICHIA-COLI; MESSENGER-RNAS; CELL-LINE; EXPRESSION; DNA; IDENTIFICATION	Direct transfer of the normal cystic fibrosis (CF) transmembrane conductance regulator (CFTR) gene to airway epithelium was evaluated using a replication-deficient recombinant adenovirus (Ad) vector containing normal human CFTR cDNA (Ad-CFTR). In vitro Ad-CFTR-infected CFPAC-1 CF epithelial cells expressed human CFTR mRNA and protein and demonstrated correction of defective cAMP-mediated Cl-permeability. Two days after in vivo intratracheal introduction of Ad-CFTR in cotton rats, in situ analysis demonstrated human CFTR gene expression in lung epithelium. PCR amplification of reverse transcribed lung RNA demonstrated human CFTR transcripts derived from Ad-CFTR, and Northern analysis of lung RNA revealed human CFTR transcripts for up to 6 weeks. Human CFTR protein was detected in epithelial cells using anti-human CFTR antibody 11-14 days after infection. While the safety and effectiveness remain to be demonstrated, these observations suggest the feasibility of in vivo CFTR gene transfer as therapy for the pulmonary manifestations of CF.	TRANSGENE SA,STRASBOURG,FRANCE; INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205	Transgene SA; UNICANCER; Gustave Roussy; Johns Hopkins University	ROSENFELD, MA (corresponding author), NHLBI,PULM BRANCH,BETHESDA,MD 20892, USA.				NHLBI NIH HHS [HL 40178, HL 47122] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040178, R01HL047122] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; BERNAUDIN JF, 1988, J IMMUNOL, V140, P3822; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU CS, 1991, EMBO J, V10, P1355, DOI 10.1002/j.1460-2075.1991.tb07655.x; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DELEVAL MR, 1991, J THORAC CARDIOV SUR, V101, P633; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; Evans MJ, 1989, LUNG CELL BIOL, P1; FIERS W, 1978, NATURE, V273, P113, DOI 10.1038/273113a0; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAJAHMAD Y, 1986, J VIROL, V57, P267, DOI 10.1128/JVI.57.1.267-274.1986; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HORWITZ MS, 1990, VIROLOGY, P01679; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; JEFFERSON DM, 1990, AM J PHYSIOL, V259, pL496, DOI 10.1152/ajplung.1990.259.6.L496; JETTEN AM, 1989, SCIENCE, V244, P1472, DOI 10.1126/science.2472008; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES M, 1983, J CLIN INVEST, V71, P1410, DOI 10.1172/JCI110894; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MANSOUR SL, 1986, MOL CELL BIOL, V6, P2684, DOI 10.1128/MCB.6.7.2684; MORNEX JF, 1986, J CLIN INVEST, V77, P1952, DOI 10.1172/JCI112524; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; ROSENFELD MA, 1991, CLIN RES, V39, pA311; ROTH MJ, 1985, J BIOL CHEM, V260, P9326; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; Strauss SE, 1984, ADENOVIRUSES, P451; THIMMAPPAYA B, 1982, CELL, V31, P543, DOI 10.1016/0092-8674(82)90310-5; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; TRESIZE AEO, 1991, NATURE, V353, P434; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Weibel E.R., 1991, LUNG SCI F, V1, P711; YOSHIMURA K, 1991, NUCLEIC ACIDS RES, V19, P5417, DOI 10.1093/nar/19.19.5417; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313	53	907	1513	1	50	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1992	68	1					143	155		10.1016/0092-8674(92)90213-V	http://dx.doi.org/10.1016/0092-8674(92)90213-V			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1370653				2022-12-01	WOS:A1992GZ58300016
J	SHIRODKAR, S; EWEN, M; DECAPRIO, JA; MORGAN, J; LIVINGSTON, DM; CHITTENDEN, T				SHIRODKAR, S; EWEN, M; DECAPRIO, JA; MORGAN, J; LIVINGSTON, DM; CHITTENDEN, T			THE TRANSCRIPTION FACTOR E2F INTERACTS WITH THE RETINOBLASTOMA PRODUCT AND A P107-CYCLIN-A COMPLEX IN A CELL CYCLE-REGULATED MANNER	CELL			English	Article							ADENOVIRUS E1A PROTEINS; SV40 LARGE-T; GENE-PRODUCT; SUSCEPTIBILITY GENE; TRANS-ACTIVATION; DNA-REPLICATION; RB GENE; TRANSACTIVATION; PROMOTER; BINDING	E2F is a transcription factor believed to play a role in the activation of genes required for cellular proliferation. Its regulation is likely important for maintenance of G0 and for the initiation of cell growth. The retinoblastoma product (RB) forms a complex with E2F in G1 in primary and established human cells. As these cells enter S, a second E2F-containing complex appears. It contains p107, a nuclear "pocket" protein with similarities in structure and protein-binding properties to RB, and cyclin A, a cyclin believed to play a role in facilitating DNA replication. Hence, the regulation of E2F is carried out differently in G1 or S. The presence of cyclin A and a pocket protein, a possible cell growth regulator, in the same S phase-associated complex suggests a link between the function of E2F and the regulation of the DNA replication process.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	SHIRODKAR, S (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA.							BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; EWEN ME, 1992, IN PRESS SCIENCE; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1988, ANTIBODIES LABORATOR; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEVINS JR, 1989, ADV VIRUS RES, V37, P35; PINES J, 1990, New Biologist, V2, P389; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; REICHEL R, 1988, P NATL ACAD SCI USA, V85, P387, DOI 10.1073/pnas.85.2.387; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x	50	587	603	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 10	1992	68	1					157	166		10.1016/0092-8674(92)90214-W	http://dx.doi.org/10.1016/0092-8674(92)90214-W			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1531040				2022-12-01	WOS:A1992GZ58300017
J	SMITH, DL; JOHNSON, AD				SMITH, DL; JOHNSON, AD			A MOLECULAR MECHANISM FOR COMBINATORIAL CONTROL IN YEAST - MCM1 PROTEIN SETS THE SPACING AND ORIENTATION OF THE HOMEODOMAINS OF AN ALPHA-2 DIMER	CELL			English	Article							REPRESSOR-OPERATOR INTERACTIONS; MATING-TYPE LOCUS; TRANSCRIPTIONAL ACTIVATOR; ANTENNAPEDIA HOMEODOMAIN; DNA; BINDING; IDENTIFICATION; RESOLUTION; COMPLEX; GENES	DNA recognition sequences for dimeric proteins typically contain two types of information. The first is the DNA sequence of each half-site, and the second is the arrangement of these half-sites. We show that dimers of the yeast homeodomain protein alpha-2, although able to read the first type of information, lack the ability to assess the second type. Rather, alpha-2 dimers bind with equal affinity to artificial operators in which the two half-sites are arrayed as inverted repeats, as direct repeats, or as everted (inside-out) repeats. We show that a second protein - MCM1 - sets the exact spacing and orientation of the homeodomains in the alpha-2 dimer so that they accommodate only the geometry of the naturally occurring operators. These experiments show directly how the target specificity of a homeodomain protein is raised by an auxiliary protein, allowing it to distinguish the biologically correct operators from closely related sequences in the cell.			SMITH, DL (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143, USA.							AFFOLTER M, 1990, P NATL ACAD SCI USA, V87, P4093, DOI 10.1073/pnas.87.11.4093; AGGARWAL AK, 1990, ANN REV BIOCH, V59, P933; BENDER A, 1987, CELL, V50, P681, DOI 10.1016/0092-8674(87)90326-6; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; FLORENCE B, 1991, MOL CELL BIOL, V11, P3613, DOI 10.1128/MCB.11.7.3613; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GRINDLEY NDF, 1982, CELL, V30, P19, DOI 10.1016/0092-8674(82)90007-1; GUARENTE L, 1984, P NATL ACAD SCI-BIOL, V81, P7860, DOI 10.1073/pnas.81.24.7860; HALL MN, 1987, SCIENCE, V237, P1007, DOI 10.1126/science.2887035; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HUGHES RE, 1990, CELL, V63, P1331, DOI 10.1016/0092-8674(90)90428-H; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Maniatis T., 1982, MOL CLONING; MILLER AM, 1985, NATURE, V314, P598, DOI 10.1038/314598a0; Miller JH., 1972, EXPT MOL GENETICS; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; PERSIC O, 1989, CELL, V59, P797; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SHERMAN F, 1979, METHODS YEAST GENETI; SILICIANO PG, 1984, CELL, V37, P969, DOI 10.1016/0092-8674(84)90431-8; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; TATCHELL K, 1981, CELL, V27, P25, DOI 10.1016/0092-8674(81)90357-3; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WOLBERGER C, 1991, J MOL BIOL, V217, P11, DOI 10.1016/0022-2836(91)90605-6; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	34	155	159	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1992	68	1					133	142		10.1016/0092-8674(92)90212-U	http://dx.doi.org/10.1016/0092-8674(92)90212-U			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1732062				2022-12-01	WOS:A1992GZ58300015
J	SNYDER, EY; DEITCHER, DL; WALSH, C; ARNOLDALDEA, S; HARTWIEG, EA; CEPKO, CL				SNYDER, EY; DEITCHER, DL; WALSH, C; ARNOLDALDEA, S; HARTWIEG, EA; CEPKO, CL			MULTIPOTENT NEURAL CELL-LINES CAN ENGRAFT AND PARTICIPATE IN DEVELOPMENT OF MOUSE CEREBELLUM	CELL			English	Article							CHICKEN OPTIC TECTUM; CORTICAL-NEURONS; PRECURSOR CELLS; MONOCLONAL-ANTIBODIES; MIGRATION PATTERNS; COMMON PROGENITOR; NERVOUS-SYSTEM; C-MYC; DIFFERENTIATION; CORTEX	Multipotent neural cell lines were generated via retrovirus-mediated v-myc transfer into murine cerebellar progenitor cells. When transplanted back into the cerebellum of newborn mice, these cells integrated into the cerebellum in a nontumorigenic, cytoarchitecturally appropriate manner. Cells from the same clonal line differentiated into neurons or glia in a manner appropriate to their site of engraftment. Engrafted cells, identified by lacZ expression and PCR-mediated detection of a unique sequence arrangement, could be identified in animals up to 22 months postengraftment. Electron microscopic and immunohistochemical analysis demonstrated that some engrafted cells were similar to host neurons and glia. Some transplant-derived neurons received appropriate synapses and formed normal intercellular contacts. These data indicate that generating immortalized cell lines for repair of, or transport of genes into, the CNS may be feasible. Such lines may also provide a model for commitment and differentiation of cerebellar progenitor cells.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT OBSTET GYNECOL,BOSTON,MA 02115; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)			Deitcher, David/K-6538-2019	Deitcher, David/0000-0002-8512-8868	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001403] Funding Source: NIH RePORTER; NINDS NIH HHS [5-K08-NS01403-02] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altman J., 1982, CEREBELLUM NEW VISTA, V47, P8; AUSTIN CP, 1990, DEVELOPMENT, V110, P713; BAROFFIO A, 1988, P NATL ACAD SCI USA, V85, P5325, DOI 10.1073/pnas.85.14.5325; BARRY DI, 1987, P NATL ACAD SCI USA, V84, P8712, DOI 10.1073/pnas.84.23.8712; BARTLETT PF, 1988, P NATL ACAD SCI USA, V85, P3255, DOI 10.1073/pnas.85.9.3255; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BJORKLUND A, 1982, NATURE, V298, P652, DOI 10.1038/298652a0; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BUZSAKI G, 1988, P NATL ACAD SCI USA, V85, P9327, DOI 10.1073/pnas.85.23.9327; CEPKO C, 1988, NEURON, V1, P345, DOI 10.1016/0896-6273(88)90184-5; CEPKO C, 1989, NEUROMETHODS, V16, P177; CEPKO CL, 1989, ANNU REV NEUROSCI, V12, P47, DOI 10.1146/annurev.ne.12.030189.000403; DAVIDSON D, 1988, DEVELOPMENT, V104, P305; DAVIS CA, 1988, GENE DEV, V2, P361, DOI 10.1101/gad.2.3.361; Eccles J. C. M., 1967, CEREBELLUM NEURONAL; EVRARD C, 1990, P NATL ACAD SCI USA, V87, P3062, DOI 10.1073/pnas.87.8.3062; FIELDSBERRY SC, 1992, IN PRESS P NATL ACAD; FISHER LJ, 1991, NEURON, V6, P371, DOI 10.1016/0896-6273(91)90246-V; FREDERIKSEN K, 1988, NEURON, V1, P439, DOI 10.1016/0896-6273(88)90175-4; FREUND TF, 1985, J NEUROSCI, V5, P603; GAGE FH, 1983, SCIENCE, V221, P966, DOI 10.1126/science.6879196; GAGE FH, 1991, NEURON, V6, P1, DOI 10.1016/0896-6273(91)90116-H; GALILEO DS, 1990, P NATL ACAD SCI USA, V87, P458, DOI 10.1073/pnas.87.1.458; GELLER HM, 1988, J CELL BIOL, V107, P1977, DOI 10.1083/jcb.107.5.1977; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; GRAVEL C, 1987, J NEUROSCI METH, V21, P145, DOI 10.1016/0165-0270(87)90112-9; GRAY GE, 1988, P NATL ACAD SCI USA, V85, P7356, DOI 10.1073/pnas.85.19.7356; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; HALLONET MER, 1990, DEVELOPMENT, V108, P19; HATTEN ME, 1986, J NEUROSCI, V6, P2676; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; ISACSON O, 1986, P NATL ACAD SCI USA, V83, P2728, DOI 10.1073/pnas.83.8.2728; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; LABBE R, 1983, SCIENCE, V221, P470, DOI 10.1126/science.6683427; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LEBER SM, 1990, J NEUROSCI, V10, P2451; LUND RD, 1987, ANN NY ACAD SCI, V495, P227, DOI 10.1111/j.1749-6632.1987.tb23678.x; Maniatis T., 1982, MOL CLONING; MCCONNELL SK, 1988, J NEUROSCI, V8, P945; MCCONNELL SK, 1985, SCIENCE, V229, P1268, DOI 10.1126/science.4035355; MIALE IL, 1961, EXP NEUROL, V4, P277, DOI 10.1016/0014-4886(61)90055-3; MORSE HC, 1986, P NATL ACAD SCI USA, V83, P6868, DOI 10.1073/pnas.83.18.6868; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OCHMAN H, 1988, GENETICS, V120, P621; OLEARY DDM, 1989, J NEUROSCI, V9, P2230; Palay S.L., 1974, CEREBELLAR CORTEX CY; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; Peters A., 1978, FINE STRUCTURE NERVO, V4, P588; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; RAFF MC, 1978, NATURE, V274, P813, DOI 10.1038/274813a0; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; ROSENBERG MB, 1988, SCIENCE, V242, P1575, DOI 10.1126/science.3201248; RUPPERT C, 1986, EMBO J, V5, P1897, DOI 10.1002/j.1460-2075.1986.tb04442.x; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; Schaper A, 1897, SCIENCE, V5, P430; SMEYNE RJ, 1989, J NEUROSCI, V9, P1608; SOTELO C, 1986, P NATL ACAD SCI USA, V83, P1135, DOI 10.1073/pnas.83.4.1135; SOTELO C, 1987, NATURE, V327, P421, DOI 10.1038/327421a0; STANFIELD BB, 1985, NATURE, V313, P135, DOI 10.1038/313135a0; TEMPLE S, 1989, NATURE, V340, P471, DOI 10.1038/340471a0; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; WALSH C, 1988, SCIENCE, V241, P1342, DOI 10.1126/science.3137660; WEINSTEIN DE, 1990, GLIA, V3, P130, DOI 10.1002/glia.440030207; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; WOOD JN, 1981, BIOSCIENCE REP, V1, P263, DOI 10.1007/BF01114913	68	735	784	2	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1992	68	1					33	51		10.1016/0092-8674(92)90204-P	http://dx.doi.org/10.1016/0092-8674(92)90204-P			19	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1732063				2022-12-01	WOS:A1992GZ58300007
J	VERRALL, S; HALL, ZW				VERRALL, S; HALL, ZW			THE N-TERMINAL DOMAINS OF ACETYLCHOLINE-RECEPTOR SUBUNITS CONTAIN RECOGNITION SIGNALS FOR THE INITIAL STEPS OF RECEPTOR ASSEMBLY	CELL			English	Article							ENDOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODIES; BINDING-SITES; ALPHA-SUBUNIT; TORPEDO-CALIFORNICA; DELTA-SUBUNIT; ION CHANNELS; MUSCLE; MUTAGENESIS; SELECTION	Ligand-gated ion channels are oligomeric membrane proteins in which homologous subunits specifically recognize one another and assemble around an aqueous pore. To identity domains responsible for the specificity of subunit association, we used a dominant-negative assay in which truncated subunits of the mouse muscle acetylcholine receptor (AChR) were coexpressed with the four wild-type subunits in transfected COS cells. Fragments of the alpha, delta, and gamma-subunits consisting solely of the extracellular N-terminal domain blocked surface expression of the AChR and the formation of alpha-delta-heterodimers, an early step in the assembly pathway of the AChR. Immunoprecipitation and sucrose gradient sedimentation experiments showed that an N-terminal fragment of the alpha-subunit forms a specific complex with the intact delta-subunit. Thus the extracellular N-terminal domain of the alpha, delta, and gamma-subunits contains the information necessary for specific subunit association.			VERRALL, S (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA.							BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; BUONANNO A, 1986, J BIOL CHEM, V261, P6451; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DOWDING AJ, 1987, BIOCHEMISTRY-US, V26, P6372, DOI 10.1021/bi00394a010; FROEHNER SC, 1983, J BIOL CHEM, V258, P7112; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GU Y, 1991, NEURON, V6, P879, DOI 10.1016/0896-6273(91)90228-R; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; GU Y, 1988, J BIOL CHEM, V263, P12878; GU Y, 1990, NEURON, V5, P147, DOI 10.1016/0896-6273(90)90305-Y; GULLICK WJ, 1983, BIOCHEMISTRY-US, V22, P3312, DOI 10.1021/bi00283a003; HAGGERTY JG, 1981, J BIOL CHEM, V256, P8294; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOFFMAN RA, 1980, P NATL ACAD SCI-BIOL, V77, P4914, DOI 10.1073/pnas.77.8.4914; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; ISENBERG KE, 1986, NUCLEIC ACIDS RES, V14, P5111, DOI 10.1093/nar/14.12.5111; KARLIN A, 1980, CELL SURF REV, V6, P191; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPOLLA RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7970, DOI 10.1073/pnas.81.24.7970; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MILLER C, 1989, NEURON, V2, P1195, DOI 10.1016/0896-6273(89)90304-8; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; RALSTON E, 1989, J CELL BIOL, V109, P2345, DOI 10.1083/jcb.109.5.2345; RATNAM M, 1986, BIOCHEMISTRY-US, V25, P2621, DOI 10.1021/bi00357a051; RENAUD KJ, 1991, J BIOL CHEM, V266, P20491; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SINGH I, 1990, EMBO J, V9, P631, DOI 10.1002/j.1460-2075.1990.tb08155.x; SMITH MM, 1987, J BIOL CHEM, V262, P4367; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; YONG G, 1989, J CELL BIOL, V109, P729, DOI 10.1083/jcb.109.2.729; YU L, 1986, NUCLEIC ACIDS RES, V14, P3539, DOI 10.1093/nar/14.8.3539; YU XM, 1991, NATURE, V352, P64, DOI 10.1038/352064a0	43	134	135	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 10	1992	68	1					23	31		10.1016/0092-8674(92)90203-O	http://dx.doi.org/10.1016/0092-8674(92)90203-O			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1370654				2022-12-01	WOS:A1992GZ58300006
J	WEGENER, AMK; LETOURNEUR, F; HOEVELER, A; BROCKER, T; LUTON, F; MALISSEN, B				WEGENER, AMK; LETOURNEUR, F; HOEVELER, A; BROCKER, T; LUTON, F; MALISSEN, B			THE T-CELL RECEPTOR/CD3 COMPLEX IS COMPOSED OF AT LEAST 2 AUTONOMOUS TRANSDUCTION MODULES	CELL			English	Article							MEDIATED SIGNAL TRANSDUCTION; NATURAL-KILLER CELLS; ANTIGEN RECEPTOR; TYROSINE PHOSPHORYLATION; ZETA-CHAIN; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; SUBUNIT INTERACTIONS; TRANSFECTED CELLS; MESSENGER-RNA	Recent studies have demonstrated that the CD3-zeta subunit of the T cell antigen receptor (TCR) complex is involved in signal transduction. However, the function of the remaining invariant subunits, CD3-gamma, -delta, and epsilon, is still poorly understood. To examine their role in TCR function, we have constructed TCR/CD3 complexes devoid of functional zeta-subunit and showed that they are still able to trigger the production of interleukin-2 in response to antigen or superantigen. These data, together with previous results, indicate that the TCR/CD3 complex is composed of at least two parallel transducing units, made of the gamma-delta-epsilon and zeta-chains, respectively, Furthermore, the analysis of partially truncated zeta-chains has led us to individualize a functional domain that may have constituted the building block of most of the transducing subunits associated with antigen receptors and some Fc receptors.			WEGENER, AMK (corresponding author), CNRS MARSEILLE LUMINY, INSERM, CTR IMMUNOL, CASE 906, F-13288 MARSEILLE 9, FRANCE.		Luton, Frederic/N-7673-2017; Malissen, Bernard/AAK-4659-2020	Letourneur, Francois/0000-0003-2232-6127; Malissen, Bernard/0000-0003-1340-9342				ALARCON B, 1991, EMBO J, V10, P903, DOI 10.1002/j.1460-2075.1991.tb08023.x; ANDERSON P, 1989, NATURE, V341, P159, DOI 10.1038/341159a0; BANIYASH M, 1989, J BIOL CHEM, V264, P13252; BAUER A, 1991, P NATL ACAD SCI USA, V88, P3842, DOI 10.1073/pnas.88.9.3842; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BERKHOUT B, 1988, J BIOL CHEM, V263, P8528; BERNOT A, 1991, P NATL ACAD SCI USA, V88, P2550, DOI 10.1073/pnas.88.6.2550; BILL J, 1989, J EXP MED, V169, P115, DOI 10.1084/jem.169.1.115; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BLUMBERG RS, 1990, P NATL ACAD SCI USA, V87, P7220, DOI 10.1073/pnas.87.18.7220; BONIFACINO JS, 1988, P NATL ACAD SCI USA, V85, P6929, DOI 10.1073/pnas.85.18.6929; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAYTON LK, 1991, P NATL ACAD SCI USA, V88, P5202, DOI 10.1073/pnas.88.12.5202; CLEVERS H, 1988, P NATL ACAD SCI USA, V85, P8623, DOI 10.1073/pnas.85.22.8623; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; DELAHERA A, 1991, J EXP MED, V173, P7, DOI 10.1084/jem.173.1.7; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ENGEL I, 1988, CELL, V54, P473, DOI 10.1016/0092-8674(88)90068-2; FINKEL TH, 1991, IMMUNOL TODAY, V12, P79, DOI 10.1016/0167-5699(91)90162-M; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GASCOIGNE NRJ, 1991, P NATL ACAD SCI USA, V88, P613, DOI 10.1073/pnas.88.2.613; GILLIS S, 1978, J IMMUNOL, V120, P2027; GODING JW, 1986, HDB EXPT IMMUNOLOGY, V1; GOLD DP, 1987, P NATL ACAD SCI USA, V84, P7649, DOI 10.1073/pnas.84.21.7649; GREEN NM, 1991, NATURE, V351, P349, DOI 10.1038/351349a0; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; HASER WG, 1987, J EXP MED, V166, P1186, DOI 10.1084/jem.166.4.1186; HERMAN A, 1990, J EXP MED, V172, P709, DOI 10.1084/jem.172.3.709; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HYMAN R, 1974, J NATL CANCER I, V52, P429, DOI 10.1093/jnci/52.2.429; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JACOBSON S, 1989, J VIROL, V63, P1756, DOI 10.1128/JVI.63.4.1756-1762.1989; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; KASHIWAMURA SI, 1990, J IMMUNOL, V145, P337; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KONING F, 1990, EUR J IMMUNOL, V20, P299, DOI 10.1002/eji.1830200211; KRISSANSEN GW, 1987, J IMMUNOL, V138, P3513; KUSTER H, 1990, J BIOL CHEM, V265, P6448; LABIT C, 1984, HYBRIDOMA, V3, P163, DOI 10.1089/hyb.1984.3.163; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1989, EUR J IMMUNOL, V19, P2269, DOI 10.1002/eji.1830191214; LETOURNEUR F, 1989, IMMUNOGENETICS, V29, P265, DOI 10.1007/BF00717911; MALISSEN M, 1988, CELL, V55, P49, DOI 10.1016/0092-8674(88)90008-6; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; MERCEP M, 1988, J IMMUNOL, V140, P324; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; ORTEGA G, 1986, J IMMUNOL, V137, P3240; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P350, DOI 10.1073/pnas.88.2.350; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; RA C, 1989, J BIOL CHEM, V264, P15323; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SAMELSON LE, 1986, NATURE, V324, P674, DOI 10.1038/324674a0; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SUSSMAN JJ, 1988, J IMMUNOL, V140, P2520; VANDENELSEN P, 1986, P NATL ACAD SCI USA, V83, P2944; VIVIER E, 1991, J IMMUNOL, V146, P206; VIVIER E, 1991, J IMMUNOL, V146, P1142; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WHITE J, 1989, J IMMUNOL, V143, P1822; ZAMOYSKA R, 1985, CELL, V43, P153, DOI 10.1016/0092-8674(85)90020-0	81	433	444	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 10	1992	68	1					83	95		10.1016/0092-8674(92)90208-T	http://dx.doi.org/10.1016/0092-8674(92)90208-T			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1531041	Green Published			2022-12-01	WOS:A1992GZ58300011
J	WITKE, W; SCHLEICHER, M; NOEGEL, AA				WITKE, W; SCHLEICHER, M; NOEGEL, AA			REDUNDANCY IN THE MICROFILAMENT SYSTEM - ABNORMAL-DEVELOPMENT OF DICTYOSTELIUM CELLS LACKING 2 F-ACTIN CROSS-LINKING PROTEINS	CELL			English	Article							MYOSIN HEAVY-CHAIN; SITE-A-GLYCOPROTEIN; MONOCLONAL-ANTIBODIES; BINDING PROTEINS; ALPHA-ACTININ; HOMOLOGOUS RECOMBINATION; CHEMOTACTIC STIMULATION; GELATION FACTOR; DISCOIDEUM; AGGREGATION	We generated by gene disruption Dictyostelium cells that lacked both the F-actin cross-linking proteins, alpha-actinin and gelation factor. Several major cell functions, such as growth, chemotaxis, phagocytosis, and pinocytosis, were apparently unaltered. However, in all double mutants, development was greatly impaired. After formation of aggregates, cells were very rarely able to form fruiting bodies. This ability was rescued when mutant and wild-type strains were mixed in a ratio of 70 to 30. The developmental program in the mutant was not arrested, since the expression pattern of early and late genes remained unchanged. Development of the mutant was rendered normal when a functional actin-actinin gene was introduced and expressed, showing the morphogenetic defect to be due to the absence of the two F-actin cross-linking proteins. These findings suggest the existence of a functional network allowing mutual complementation of certain actin-binding proteins.			WITKE, W (corresponding author), MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY.							ANDRE E, 1989, J CELL BIOL, V108, P985, DOI 10.1083/jcb.108.3.985; BERTHOLDT G, 1985, CELL DIFFER DEV, V16, P187, DOI 10.1016/0045-6039(85)90516-0; BEUG H, 1973, J CELL BIOL, V56, P647, DOI 10.1083/jcb.56.3.647; BONNER JT, 1952, AM NAT, V86, P79, DOI 10.1086/281707; BRAY D, 1989, NATURE, V338, P203, DOI 10.1038/338203a0; BRINK M, 1990, J CELL BIOL, V111, P1477, DOI 10.1083/jcb.111.4.1477; CLAVIEZ M, 1982, EMBO J, V1, P1017, DOI 10.1002/j.1460-2075.1982.tb01287.x; CONDEELIS J, 1982, J CELL BIOL, V94, P466, DOI 10.1083/jcb.94.2.466; CONDEELIS J, 1981, NATURE, V292, P161; COUKELL MB, 1975, MOL GEN GENET, V142, P119, DOI 10.1007/BF00266094; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DHARMAWARDHANE S, 1989, CELL MOTIL CYTOSKEL, V13, P57, DOI 10.1002/cm.970130107; DRUBIN DG, 1990, CELL MOTIL CYTOSKEL, V15, P7, DOI 10.1002/cm.970150103; EARLY A, 1988, DEV GENET, V9, P383, DOI 10.1002/dvg.1020090419; EGELHOFF TT, 1989, MOL CELL BIOL, V9, P1965, DOI 10.1128/MCB.9.5.1965; FECHHEIMER M, 1982, CELL MOTIL CYTOSKEL, V2, P287, DOI 10.1002/cm.970020308; GERISCH G, 1991, ANNU REV PHYSIOL, V53, P607, DOI 10.1146/annurev.physiol.53.1.607; GERISCH G, 1981, J CELL SCI, V52, P1; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; GREGG JH, 1982, EXP CELL RES, V142, P229, DOI 10.1016/0014-4827(82)90427-X; HARRINGTON BJ, 1968, APPL MICROBIOL, V16, P106, DOI 10.1128/AEM.16.1.106-113.1968; JERMYN KA, 1991, DEVELOPMENT, V111, P779; KAY RR, 1989, DEVELOPMENT S, P81; KNECHT DA, 1988, DEV BIOL, V128, P178, DOI 10.1016/0012-1606(88)90280-1; KNECHT DA, 1986, MOL CELL BIOL, V6, P3973, DOI 10.1128/MCB.6.11.3973; KNECHT DA, 1987, SCIENCE, V236, P1033; LANGANGER G, 1983, MIKROSKOPIE, V40, P237; LODISH HF, 1982, DEV DICTYOSTELIUM DI, P325; Loomis W F, 1978, Birth Defects Orig Artic Ser, V14, P497; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; MCROBBIE SJ, 1983, BIOCHEM BIOPH RES CO, V115, P351, DOI 10.1016/0006-291X(83)91011-2; MORRISSEY JH, 1984, DEV BIOL, V103, P414, DOI 10.1016/0012-1606(84)90329-4; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; NEWELL PC, 1969, J BACTERIOL, V100, P763, DOI 10.1128/JB.100.2.763-768.1969; NOEGEL A, 1987, FEBS LETT, V221, P391, DOI 10.1016/0014-5793(87)80962-6; NOEGEL A, 1985, EMBO J, V4, P3805, DOI 10.1002/j.1460-2075.1985.tb04151.x; NOEGEL AA, 1989, J CELL BIOL, V109, P607, DOI 10.1083/jcb.109.2.607; Noegel AA, 1991, CURR OPIN CELL BIOL, V3, P18, DOI 10.1016/0955-0674(91)90161-Q; PETERS DJM, 1988, DEV BIOL, V128, P158, DOI 10.1016/0012-1606(88)90278-3; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SCHLEICHER M, 1988, J CELL SCI, V90, P59; SCHLEICHER M, 1988, DEV GENET, V9, P521, DOI 10.1002/dvg.1020090428; SPUDICH JA, 1989, CELL REGUL, V1, P1; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; Vandekerckhove J, 1989, CURR OPIN CELL BIOL, V1, P15, DOI 10.1016/S0955-0674(89)80031-6; VOGEL G, 1987, METHOD CELL BIOL, V28, P129; WALLACE JS, 1984, CELL DIFFER DEV, V14, P205, DOI 10.1016/0045-6039(84)90047-2; WALLRAFF E, 1986, EMBO J, V5, P61, DOI 10.1002/j.1460-2075.1986.tb04178.x; WEBER AT, 1971, DEV BIOL, V26, P606, DOI 10.1016/0012-1606(71)90143-6; WEEDS A, 1982, NATURE, V296, P811, DOI 10.1038/296811a0; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X; WILLIAMS KL, 1976, GENETICS, V82, P287; WITKE W, 1987, EMBO J, V6, P4143, DOI 10.1002/j.1460-2075.1987.tb02760.x; WITKE W, 1991, NOVEL CALCIUM BINDIN, P321; YANAGISAWA K, 1967, EXP CELL RES, V46, P328, DOI 10.1016/0014-4827(67)90070-5	58	135	137	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1992	68	1					53	62		10.1016/0092-8674(92)90205-Q	http://dx.doi.org/10.1016/0092-8674(92)90205-Q			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1732064				2022-12-01	WOS:A1992GZ58300008
J	ATSUMI, T; MCCARTER, L; IMAE, Y				ATSUMI, T; MCCARTER, L; IMAE, Y			POLAR AND LATERAL FLAGELLAR MOTORS OF MARINE VIBRIO ARE DRIVEN BY DIFFERENT ION-MOTIVE FORCES	NATURE			English	Article							SWARMER CELL-DIFFERENTIATION; NA+ PUMP; ALKALOPHILIC BACILLUS; PROTONMOTIVE FORCE; PARAHAEMOLYTICUS; ALGINOLYTICUS; AMILORIDE; MOTILITY	VARIOUS species of marine Vibrio produce two distinct types of flagella, each adapted for a different type of motility 1. A single, sheathed polar flagellum is suited for swimming in liquid medium, and numerous unsheathed lateral flagella, which are produced only under viscous conditions, are suited for swarming over viscous surfaces 2,3. Both types of flagella are driven by reversible motors embedded in the cytoplasmic membrane. Here we report that the energy source for the polar flagellar motor of Vibrio parahaemolyticus is the sodium-motive force, whereas the lateral flagellar motors are driven by the proton-motive force. This is evidence that two distinct types of flagella powered by different energy sources are functionally active in one cell.	NAGOYA UNIV,FAC SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA 46401,JAPAN; THE AGOURON INST,LA JOLLA,CA 92037	Nagoya University								ALLEN RD, 1971, J BACTERIOL, V107, P295, DOI 10.1128/JB.107.1.295-302.1971; ATSUMI T, 1990, J BACTERIOL, V172, P1634, DOI 10.1128/jb.172.3.1634-1639.1990; CHERNYAK BV, 1983, FEBS LETT, V164, P38, DOI 10.1016/0014-5793(83)80014-3; IMAE Y, 1989, J BIOENERG BIOMEMBR, V21, P705, DOI 10.1007/BF00762688; MANSON MD, 1977, P NATL ACAD SCI USA, V74, P3060, DOI 10.1073/pnas.74.7.3060; MATSUURA S, 1977, FEBS LETT, V82, P187, DOI 10.1016/0014-5793(77)80581-4; MCCARTER L, 1988, CELL, V54, P345, DOI 10.1016/0092-8674(88)90197-3; MCCARTER L, 1990, MOL MICROBIOL, V4, P1057, DOI 10.1111/j.1365-2958.1990.tb00678.x; SUGIYAMA S, 1988, J BIOL CHEM, V263, P8215; TOKUDA H, 1988, J BIOCHEM-TOKYO, V103, P650, DOI 10.1093/oxfordjournals.jbchem.a122323; TOKUDA H, 1982, J BIOL CHEM, V257, P7; TSUCHIYA T, 1985, J BACTERIOL, V162, P794, DOI 10.1128/JB.162.2.794-798.1985; YOSHIDA S, 1990, J BIOL CHEM, V265, P20346	13	195	205	2	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1992	355	6356					182	184		10.1038/355182a0	http://dx.doi.org/10.1038/355182a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1309599				2022-12-01	WOS:A1992GY62900065
J	BECKER, S; HINTON, GE				BECKER, S; HINTON, GE			SELF-ORGANIZING NEURAL NETWORK THAT DISCOVERS SURFACES IN RANDOM-DOT STEREOGRAMS	NATURE			English	Article								THE standard form of back-propagation learning 1 is implausible as a model of perceptual learning because it requires an external teacher to specify the desired output of the network. We show how the external teacher can be replaced by internally derived teaching signals. These signals are generated by using the assumption that different parts of the perceptual input have common causes in the external world. Small modules that look at separate but related parts of the perceptual input discover these common causes by striving to produce outputs that agree with each other (Fig. 1a). The modules may look at different modalities (such as vision and touch), or the same modality at different times (for example, the consecutive two-dimensional views of a rotating three-dimensional object), or even spatially adjacent parts of the same image. Our simulations show that when our learning procedure is applied to adjacent patches of two-dimensional images, it allows a neural network that has no prior knowledge of the third dimension to discover depth in random dot stereograms of curved surfaces.			BECKER, S (corresponding author), UNIV TORONTO,DEPT COMP SCI,10 KINGS COLL RD,TORONTO M5S 1A4,ONTARIO,CANADA.		Becker, Suzanna/H-8197-2013	Becker, Suzanna/0000-0002-2645-070X				Hastie T.J., 2017, GEN ADDITIVE MODELS; LEHKY SR, 1990, J NEUROSCI, V10, P2281; RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0; Zemel R.S., 1991, DISCOVERING VIEWPOIN	4	193	194	3	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1992	355	6356					161	163		10.1038/355161a0	http://dx.doi.org/10.1038/355161a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1729650				2022-12-01	WOS:A1992GY62900058
J	CAO, L; FAHA, B; DEMBSKI, M; TSAI, LH; HARLOW, E; DYSON, N				CAO, L; FAHA, B; DEMBSKI, M; TSAI, LH; HARLOW, E; DYSON, N			INDEPENDENT BINDING OF THE RETINOBLASTOMA PROTEIN AND P107 TO THE TRANSCRIPTION FACTOR E2F	NATURE			English	Article							LARGE T-ANTIGEN; ADENOVIRUS E1A PROTEINS; GENE-PRODUCT; POLYACRYLAMIDE GELS; SV40; TRANSFORMATION; REGIONS; CELLS	THE cellular protein p107 and the retinoblastoma protein (pRB) have many features in common. Most strikingly, they contain homologous protein domains that mediate interaction with the oncoproteins of several small DNA tumour viruses, including adenovirus E1A and SV40 large-T antigen 1-9. In cells that do not contain these viral oncoproteins, pRB interacts with the cellular transcription factor E2F (refs 10-12) or a related protein termed DRTF1 (ref. 13). E2F associates with a form of pRB that is found primarily in G1 cells 10. It seems that the E2F-pRB complex dissociates near the G1-S boundary before the initiation of S phase, releasing free E2F and apparently, stimulating the ability of E2F to activate transcription 14. Cells that express E1A have no or little pRB-E2F complex, presumably because of the association of E1A with pRB 10,15. During S phase, E2F forms a second complex that contains cyclin A but apparently lacks pRB 1-5. Here, we report that p107 is found in the cyclin A/E2F complex and that this complex also contains p33cdk2. These observations suggest that p107 and pRB cooperate in the regulation of E2F activity, each affecting different stages of the cell cycle. Thus, by binding to pRB and p107, E1A and large-T antigen target two distinct aspects of E2F regulation.	MASSACHUSETTS GEN HOSP CANC CTR, BLDG 149, 13TH ST, BOSTON, MA 02129 USA	Harvard University; Massachusetts General Hospital			Cao, Liang/K-7806-2017	Cao, Liang/0000-0001-7293-8338				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; EWEN ME, IN PRESS SCIENCE; FAHA B, IN PRESS SCIENCE; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HIEBERT SW, IN PRESS GENES DEV; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEYERSON M, IN PRESS COLD SPRING, V58; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	35	386	394	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 9	1992	355	6356					176	179		10.1038/355176a0	http://dx.doi.org/10.1038/355176a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1530885				2022-12-01	WOS:A1992GY62900063
J	FRANZUSOFF, A; LAUZE, E; HOWELL, KE				FRANZUSOFF, A; LAUZE, E; HOWELL, KE			IMMUNOISOLATION OF SEC7P-COATED TRANSPORT VESICLES FROM THE YEAST SECRETORY PATHWAY	NATURE			English	Article							PROTEIN-TRANSPORT; VESICULAR INTERMEDIATE; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; MEMBRANE; RECONSTITUTION; COMPLEX; EVENTS; STACK	THE transport of proteins destined for post-endoplasmic reticulum locations in the secretory pathway is Mediated by small vesicuLar carriers 1-3. Transport vesicles have been generated in cell-free assays from the yeast Saccharomyces cerevisiae, and mammalian systems 4-14. Yeast genes encoding cytosolic components that participate in vesicular traffic were first identified from the collection of conditional-lethal sec (secretory) mutants 15-17. Mutations in the yeast SEC7 gene disrupt protein transport in the secretory pathway at the nonpermissive temperature 18. The SEC7 gene product is a phosphoprotein of relative molecular mass 230,000 that functions from the cytoplasmic aspect of intracellular membranes 19,20. We report that in a yeast cell-free transport assay, the introduction of antibodies to Sec7 protein (Sec7p) results in the accumulation of transport vesicles. These vesicles are retrieved with Sec7p-specific antibodies by immuno-isolation for biochemical and electron microscopic characterization. Sec7p on the surface of the accumulated transport vesicles, in combination with previous genetic and biochemical studies 18,20, implicate Sec7p as part of a (non-clathrin) vesicle coat. This Sec7p-containing coat structure is proposed to be essential for vesicle budding at multiple stages in the yeast secretory pathway.			FRANZUSOFF, A (corresponding author), UNIV COLORADO, SCH MED, DEPT CELLULAR & STRUCT BIOL, BOX B-111, 4200 E 9TH AVE, DENVER, CO 80262 USA.							ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; DECURTIS I, 1989, CELL, V58, P719, DOI 10.1016/0092-8674(89)90106-2; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GROESCH ME, 1990, J CELL BIOL, V111, P45, DOI 10.1083/jcb.111.1.45; HOWELL KE, 1989, METHOD CELL BIOL, V31, P265; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LODISH HF, 1987, J CELL BIOL, V104, P221, DOI 10.1083/jcb.104.2.221; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1991, TRENDS CELL BIOL, V114, P219; NEWMAN AP, 1987, J CELL BIOL, V105, P1587, DOI 10.1083/jcb.105.4.1587; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PAULIK M, 1988, J BIOL CHEM, V263, P17738; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; SALAMERO J, 1990, P NATL ACAD SCI USA, V87, P7717, DOI 10.1073/pnas.87.19.7717; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; WARREN G, 1990, NATURE, V345, P382, DOI 10.1038/345382a0; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101	27	53	55	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 9	1992	355	6356					173	175		10.1038/355173a0	http://dx.doi.org/10.1038/355173a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1729652				2022-12-01	WOS:A1992GY62900062
J	GORDEUK, V; MUKIIBI, J; HASSTEDT, SJ; SAMOWITZ, W; EDWARDS, CQ; WEST, G; NDAMBIRE, S; EMMANUAL, J; NKANZA, N; CHAPANDUKA, Z; RANDALL, M; BOONE, P; ROMANO, P; MARTELL, RW; YAMASHITA, T; EFFLER, P; BRITTENHAM, G				GORDEUK, V; MUKIIBI, J; HASSTEDT, SJ; SAMOWITZ, W; EDWARDS, CQ; WEST, G; NDAMBIRE, S; EMMANUAL, J; NKANZA, N; CHAPANDUKA, Z; RANDALL, M; BOONE, P; ROMANO, P; MARTELL, RW; YAMASHITA, T; EFFLER, P; BRITTENHAM, G			IRON OVERLOAD IN AFRICA - INTERACTION BETWEEN A GENE AND DIETARY IRON CONTENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IDIOPATHIC HEMOCHROMATOSIS; HEREDITARY HEMOCHROMATOSIS; COMPLEX SEGREGATION; QUANTITATIVE TRAITS; PEDIGREES; MODEL; PREVALENCE; EXPRESSION; PATTERNS; DISEASE	Background and Methods. In contrast to hemochromatosis, which in white populations is inherited through a gene linked to the HLA locus, iron overload in sub-Saharan Africa is believed to result solely from increased dietary iron derived from traditional home-brewed beer. To examine the hypothesis that African iron overload also involves a genetic factor, we used likelihood analysis to test for an interaction between a gene (the hypothesized iron-loading locus) and an environmental factor (increased dietary iron) that determines transferrin saturation and unsaturated iron-binding capacity. We studied 236 members of 36 African families chosen because they contained index subjects with iron overload. Linkage to the HLA region was tested with use of lod scores. Results. In the index subjects, increased iron was present in both hepatocytes and cells of the mononuclear-phagocyte system. Among family members with increased dietary iron due to the consumption of traditional beer, transferrin saturation in serum was distributed bimodally, with 56 normal values (< 60 percent saturation) and 44 elevated values; the mean serum ferritin concentration was five times higher in the subjects with elevated transferrin saturation (P < 0.005). The pedigree analysis provided evidence of both a genetic effect (P < 0.005) and an effect of increased dietary iron (P < 0.005) on transferrin saturation and unsaturated iron-binding capacity. In the most likely model, increased dietary iron raised the mean transferrin saturation from 30 to 81 percent and lowered the mean unsaturated iron-binding capacity from 38 to 13-mu-mol per liter in subjects heterozygous for the iron-loading locus. The hypothesis of tight linkage to HLA was rejected. Conclusions. Iron overload in Africa may be caused by an interaction between the amount of dietary iron and a gene distinct from any HLA-linked gene.	BLOOD TRANSFUS SERV,HARARE,ZIMBABWE; SANYATI BAPTIST HOSP,SANYATI,ZIMBABWE; PROV LAB TISSUE IMMUNOL,CAPE TOWN,SOUTH AFRICA; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH 44106; UNIV ZIMBABWE,SCH MED,HARARE,ZIMBABWE; UNIV UTAH,MED CTR,SALT LAKE CITY,UT 84112; PENN STATE UNIV,MILTON S HERSHEY MED CTR,HERSHEY,PA 17033	Case Western Reserve University; University of Zimbabwe; Utah System of Higher Education; University of Utah; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health			Gordeuk, Victor/AAG-6577-2019; Chapanduka, zivanai/AAE-5631-2022	Chapanduka, zivanai/0000-0002-5489-8392	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R23HD017463, R01HD017463] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 17463] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1978, Br J Haematol, V38, P281, DOI 10.1111/j.1365-2141.1978.tb01044.x; BLOCK M, 1958, IRON CLINICAL MEDICI, P115; BORECKI IB, 1989, AM J MED GENET, V134, P435; Bothwell T.H., 1979, IRON METABOLISM MAN; BOTHWELL TH, 1964, AM J CLIN NUTR, V14, P47, DOI 10.1093/ajcn/14.1.47; BOTHWELL TH, 1984, S AFR MED J, V65, P601; BOTHWELL TH, 1989, METABOLIC BASIS INHE, V1, P1433; BOYLE CR, 1979, BIOMETRICS, V35, P55, DOI 10.2307/2529936; BRINK B, 1976, J LAB CLIN MED, V88, P725; BUCHANAN W M, 1970, South African Medical Journal, V44, P43; BUCHANAN WM, 1967, U COLLEGE RHODESIA F, V1, P5; DADONE MM, 1982, AM J CLIN PATHOL, V78, P196, DOI 10.1093/ajcp/78.2.196; EDWARDS CQ, 1977, NEW ENGL J MED, V297, P7, DOI 10.1056/NEJM197707072970102; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; ELSTON RC, 1971, HUM HERED, V21, P523, DOI 10.1159/000152448; GILL P, 1986, SOL862 STANF U TECH; GORDEUK VR, 1986, LANCET, V1, P1310; HASSTEDT SJ, 1982, COMPUT BIOMED RES, V15, P295, DOI 10.1016/0010-4809(82)90064-7; HENRY RJ, 1960, AM J CLIN PATHOL, V34, P381; IDZERDA RL, 1986, P NATL ACAD SCI USA, V83, P3723, DOI 10.1073/pnas.83.11.3723; ISAACSON C, 1961, J LAB CLIN MED, V58, P845; LALOUEL JM, 1983, AM J HUM GENET, V35, P816; LEGGETT BA, 1990, BRIT J HAEMATOL, V74, P525, DOI 10.1111/j.1365-2141.1990.tb06345.x; LOWE R F, 1981, Central African Journal of Medicine, V27, P1; MACPHAIL AP, 1979, AM J CLIN NUTR, V32, P1272, DOI 10.1093/ajcn/32.6.1272; MORTON NE, 1974, AM J HUM GENET, V26, P489; OTT J, 1978, ANN HUM GENET, V42, P255, DOI 10.1111/j.1469-1809.1978.tb00657.x; Robins-Browne R M, 1979, Contrib Microbiol Immunol, V5, P277; ROSIN IV, 1982, TERAPEVT ARKH, V54, P80; SCHEUER PJ, 1962, J PATHOL BACTERIOL, V84, P53, DOI 10.1002/path.1700840107; SEFTEL HC, 1961, J LAB CLIN MED, V58, P837; SEFTEL HC, 1966, BRIT MED J, V1, P642, DOI 10.1136/bmj.1.5488.642; SIMON M, 1987, AM J HUM GENET, V41, P89; SIMON M, 1977, CLIN GENET, V11, P327; SZASZ G, 1969, CLIN CHEM, V15, P124; YOUNG MR, 1988, AM J HUM GENET, V43, P705; 1978, BRIT J HAEMATOL, V38, P291; [No title captured]	38	241	240	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1992	326	2					95	100		10.1056/NEJM199201093260204	http://dx.doi.org/10.1056/NEJM199201093260204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY045	1727237				2022-12-01	WOS:A1992GY04500004
J	MICHELS, VV; MOLL, PP; MILLER, FA; TAJIK, AJ; CHU, JS; DRISCOLL, DJ; BURNETT, JC; RODEHEFFER, RJ; CHESEBRO, JH; TAZELAAR, HD				MICHELS, VV; MOLL, PP; MILLER, FA; TAJIK, AJ; CHU, JS; DRISCOLL, DJ; BURNETT, JC; RODEHEFFER, RJ; CHESEBRO, JH; TAZELAAR, HD			THE FREQUENCY OF FAMILIAL DILATED CARDIOMYOPATHY IN A SERIES OF PATIENTS WITH IDIOPATHIC DILATED CARDIOMYOPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ECHOCARDIOGRAPHIC MEASUREMENTS; POPULATION; HEART; EPIDEMIOLOGY; FEATURES; HISTORY; ADULT	Background. Dilated cardiomyopathy is characterized by an increase in ventricular size and impairment of ventricular function. Most cases are believed to be sporadic, and familial dilated cardiomyopathy is usually considered to be a rare and distinct disorder. We studied the proportion of cases of idiopathic dilated cardiomyopathy that were familial in a large sequential series of patients whose first-degree relatives were investigated regardless of whether these relatives had cardiac symptoms. Methods. We studied the relatives of 59 index patients with idiopathic dilated cardiomyopathy by obtaining a family history and performing a physical examination, electrocardiography, and two-dimensional, M-mode, and Doppler echocardiography. A total of 315 relatives were examined. Results. Eighteen relatives from 12 families were shown to have dilated cardiomyopathy. Thus, 12 of the 59 index patients (20.3 percent) had familial disease. There was no difference in age, sex, severity of disease, exposure to selected environmental factors, or electrocardiographic or echocardiographic features between the index patients with familial disease and those with nonfamilial disease. A noteworthy finding was that 22 of 240 healthy relatives (9.2 percent) with normal ejection fractions had increased left ventricular diameters during systole or diastole (or both), as compared with 2 of 112 healthy control subjects (1.8 percent) who were studied separately. Conclusions. Dilated cardiomyopathy was found to be familial in at least one in five of the patients in this study, a considerably higher percentage than in previous reports. This finding has important implications for family screening and provides direction for further investigation into the causes and natural history of dilated cardiomyopathy.	MAYO CLIN & MAYO FDN, DEPT PEDIAT, CARDIOL SECT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT INTERNAL MED, CARDIOL SECT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT PATHOL, CARDIOL SECT, ROCHESTER, MN 55905 USA; UNIV MICHIGAN, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT EPIDEMIOL, ANN ARBOR, MI 48109 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	MICHELS, VV (corresponding author), MAYO CLIN & MAYO FDN, DEPT MED GENET, ROCHESTER, MN 55905 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036879] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL36879] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELMANN WH, 1989, J AM COLL CARDIOL, V13, P1219, DOI 10.1016/0735-1097(89)90293-3; ARETZ HT, 1986, MED CLIN N AM, V70, P1215; CODD MB, 1989, CIRCULATION, V80, P564, DOI 10.1161/01.CIR.80.3.564; COUGHLIN SS, 1990, AM J EPIDEMIOL, V131, P48, DOI 10.1093/oxfordjournals.aje.a115484; ELSTON RC, 1971, HUM HERED, V21, P523, DOI 10.1159/000152448; FRAGOLA PV, 1988, AM HEART J, V115, P912, DOI 10.1016/0002-8703(88)90900-3; FUSTER V, 1981, AM J CARDIOL, V47, P525, DOI 10.1016/0002-9149(81)90534-8; GARDIN JM, 1979, J CLIN ULTRASOUND, V7, P439, DOI 10.1002/jcu.1870070606; HENRY WL, 1978, CIRCULATION, V57, P278, DOI 10.1161/01.CIR.57.2.278; HONEY M, 1986, BRIT HEART J, V55, P114; JOHNSON RA, 1982, NEW ENGL J MED, V307, P1051, DOI 10.1056/NEJM198210213071704; KEREN A, 1985, CIRCULATION, V72, P302, DOI 10.1161/01.CIR.72.2.302; KHANDHERIA BK, 1986, MAYO CLIN PROC, V61, P623, DOI 10.1016/S0025-6196(12)62026-6; MARON BJ, 1986, J AM COLL CARDIOL, V7, P190, DOI 10.1016/S0735-1097(86)80282-0; MCKUSICK VA, 1990, MENDELIAN INHERITANC, P165; MESTRONI L, 1990, AM J CARDIOL, V65, P1449, DOI 10.1016/0002-9149(90)91353-8; MICHELS VV, 1985, AM J CARDIOL, V55, P1232, DOI 10.1016/0002-9149(85)90675-7; NISHIMURA RA, 1985, MAYO CLIN PROC, V60, P321, DOI 10.1016/S0025-6196(12)60540-0; PELLICCIA A, 1991, NEW ENGL J MED, V324, P295, DOI 10.1056/NEJM199101313240504; PERRAULT H, 1982, INT J SPORTS MED, V3, P141, DOI 10.1055/s-2008-1026077; QUINONES MA, 1981, CIRCULATION, V64, P744, DOI 10.1161/01.CIR.64.4.744; SCHMITZ A, 1983, CAN J AGR ECON, V31, P135, DOI 10.1111/j.1744-7976.1983.tb01193.x; SUGRUE DD, 1989, BRIT HEART J, V61, P88; TAJIK AJ, 1978, MAYO CLIN PROC, V53, P271; URBANOMARQUEZ A, 1989, NEW ENGL J MED, V320, P409, DOI 10.1056/NEJM198902163200701; URIE PM, 1988, AM J CARDIOL, V62, P325, DOI 10.1016/0002-9149(88)90238-X; VALANTINE HA, 1989, AM J CARDIOL, V63, P959, DOI 10.1016/0002-9149(89)90148-3	27	508	521	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1992	326	2					77	82		10.1056/NEJM199201093260201	http://dx.doi.org/10.1056/NEJM199201093260201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY045	1727235				2022-12-01	WOS:A1992GY04500001
J	NIKONOWICZ, EP; PARDI, A				NIKONOWICZ, EP; PARDI, A			3-DIMENSIONAL HETERONUCLEAR NMR-STUDIES OF RNA	NATURE			English	Article							RIBOSOMAL-RNA; SPECTROSCOPY; PROTEINS; ASSIGNMENT; OLIGORIBONUCLEOTIDE; INTERLEUKIN-1-BETA; RESONANCES; SEQUENCE; C-13; DNA	MULTIDIMENSIONAL heteronuclear NMR has revolutionized solution structure determinations of proteins 1-3. But this technique has not been applied to nucleic acids because of difficulties in the synthesis of isotopically (C-13 and/or N-15) labeLled molecules. Here we report the application of three-dimensional heteronuclear NMR to the study of a uniformly C-13/N-15 or N-15-labelled RNA duplex of defined sequence. These experiments simplify resonance assignment and the analysis of proton-proton nuclear Overhauser effects 4 (and therefore distance information) in the molecule. Our results show that it is now possible to determine the structures of larger and more complex RNAs using multidimensional heteronuclear NMR.			NIKONOWICZ, EP (corresponding author), UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309, USA.							BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; CECH TC, 1989, MOL BIOL RNA; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P12, DOI 10.1021/bi00215a002; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; FERSHT A, 1985, ENZYME STRUCTURE MEC, P389; FESIK SW, 1990, J AM CHEM SOC, V112, P886, DOI 10.1021/ja00158a069; FESIK SW, 1990, Q REV BIOPHYS, V23, P97, DOI 10.1017/S0033583500005515; HALL KB, 1989, BIOCHEMISTRY-US, V28, P5794, DOI 10.1021/bi00440a014; HEUS HA, 1991, J MOL BIOL, V217, P113, DOI 10.1016/0022-2836(91)90615-D; KAY LE, 1990, J AM CHEM SOC, V112, P888, DOI 10.1021/ja00158a070; LORE GM, 1991, SCIENCE, V252, P1390; LUCIA JS, 1991, BIOCHEMISTRY-US, V30, P8242; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PATEL DJ, 1987, Q REV BIOPHYS, V20, P35, DOI 10.1017/S0033583500004224; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SIMON ES, 1990, J ORG CHEM, V55, P1834, DOI 10.1021/jo00293a030; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; VANDEVEN FJM, 1988, EUR J BIOCHEM, V178, P1; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; Wuthrich K., 1986, NMR PROTEINS NUCL AC; [No title captured]	25	107	107	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1992	355	6356					184	186		10.1038/355184a0	http://dx.doi.org/10.1038/355184a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1370345				2022-12-01	WOS:A1992GY62900066
J	RAJFER, J; ARONSON, WJ; BUSH, PA; DOREY, FJ; IGNARRO, LJ				RAJFER, J; ARONSON, WJ; BUSH, PA; DOREY, FJ; IGNARRO, LJ			NITRIC-OXIDE AS A MEDIATOR OF RELAXATION OF THE CORPUS CAVERNOSUM IN RESPONSE TO NONADRENERGIC, NONCHOLINERGIC NEUROTRANSMISSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VASOACTIVE INTESTINAL POLYPEPTIDE; SMOOTH-MUSCLE RELAXATION; INDUCED PENILE ERECTION; RELAXING FACTOR; ENDOTHELIAL-CELLS; IMPOTENT MEN; CYCLIC-GMP; L-ARGININE; ARTERY; HEMODYNAMICS	Background. Nitric oxide has been identified as an endothelium-derived relaxing factor in blood vessels. We tried to determine whether it is involved in the relaxation of the corpus cavernosum that allows penile erection. The relaxation of this smooth muscle is known to occur in response to stimulation by nonadrenergic, noncholinergic neurons. Methods. We studied strips of corpus cavernosum tissue obtained from 21 men in whom penile prostheses were inserted because of impotence. The mounted smooth-muscle specimens were pretreated with guanethidine and atropine and submaximally contracted with phenylephrine. We then studied the smooth-muscle relaxant responses to stimulation by an electrical field and to nitric oxide. Results. Electrical-field stimulation caused a marked, transient, frequency-dependent relaxation of the corpus cavernosum that was inhibited in the presence of N-nitro-L-arginine and N-amino-L-arginine, which selectively inhibit the biosynthesis of nitric oxide from L-arginine. The addition of excess L-arginine, but not D-arginine, largely reversed these inhibitory effects. The specific liberation of nitric oxide (by S-nitroso-N-acetylpenicillamine) caused rapid, complete, and concentration-dependent relaxation of the corpus cavernosum. The relaxation caused by either electrical stimulation or nitric oxide was enhanced by a selective inhibitor of cyclic guanosine monophosphate (GMP) phosphodiesterase (M&B 22,948). Relaxation was inhibited by methylene blue, which inhibits cyclic GMP synthesis. Conclusions. Our findings support the hypothesis that nitric oxide is involved in the nonadrenergic, noncholinergic neurotransmission that leads to the smooth-muscle relaxation in the corpus cavernosum that permits penile erection. Defects in this pathway may cause some forms of impotence.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PHARMACOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT SURG,DIV UROL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,TORRANCE,CA 90509	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center				Bush, Margaret/0000-0003-1937-2640	NHLBI NIH HHS [HL40922, HL35014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035014, R01HL040922] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON PO, 1984, J PHYSIOL-LONDON, V350, P209, DOI 10.1113/jphysiol.1984.sp015197; BARNES CD, 1965, DRUG DOSAGE LABORATO, P261; BUGA GM, 1991, HYPERTENSION, V17, P187, DOI 10.1161/01.HYP.17.2.187; DETEJADA IS, 1989, NEW ENGL J MED, V320, P1025, DOI 10.1056/NEJM198904203201601; DETEJADA IS, 1988, AM J PHYSIOL, V254, pH459, DOI 10.1152/ajpheart.1988.254.3.H459; DIXON WJ, 1990, BMDP STATISTICAL SOF, V2; FOURNIER GR, 1987, J UROLOGY, V137, P163, DOI 10.1016/S0022-5347(17)43911-5; FUCHS AM, 1989, J UROLOGY, V141, P1353, DOI 10.1016/S0022-5347(17)41305-X; FUKUTO JM, 1990, BIOCHEM BIOPH RES CO, V168, P458, DOI 10.1016/0006-291X(90)92343-X; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GRUETTER CA, 1979, J CYCLIC NUCL PROT, V5, P211; IGNARRO LJ, 1985, ANNU REV PHARMACOL, V25, P171, DOI 10.1146/annurev.pharmtox.25.1.171; IGNARRO LJ, 1990, NATURE, V347, P131, DOI 10.1038/347131b0; IGNARRO LJ, 1987, CIRC RES, V60, P82, DOI 10.1161/01.RES.60.1.82; IGNARRO LJ, 1990, BIOCHEM BIOPH RES CO, V170, P843, DOI 10.1016/0006-291X(90)92168-Y; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; JUENEMANN KP, 1986, J UROLOGY, V136, P158, DOI 10.1016/S0022-5347(17)44763-X; JUENEMANN KP, 1987, J UROLOGY, V138, P871, DOI 10.1016/S0022-5347(17)43406-9; KLINGE E, 1977, ACTA PHYSIOL SCAND, V100, P354, DOI 10.1111/j.1748-1716.1977.tb05961.x; KUKOVETZ WR, 1979, N-S ARCH PHARMACOL, V310, P129, DOI 10.1007/BF00500277; LUE TF, 1986, J UROLOGY, V135, P479, DOI 10.1016/S0022-5347(17)45697-7; LUE TF, 1983, J UROLOGY, V130, P1237, DOI 10.1016/S0022-5347(17)51768-1; OTTESEN B, 1984, BRIT MED J, V288, P9, DOI 10.1136/bmj.288.6410.9; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; SHABSIGH R, 1988, UROLOGY, V32, P83, DOI 10.1016/0090-4295(88)90303-2; STACKL W, 1988, J UROLOGY, V140, P66, DOI 10.1016/S0022-5347(17)41488-1; WOOD KS, 1990, BIOCHEM BIOPH RES CO, V170, P80, DOI 10.1016/0006-291X(90)91243-L; 1989, DHHS871751 NAT CTR H; 1988, VITAL HLTH STATIS 13, V93	33	774	817	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1992	326	2					90	94		10.1056/NEJM199201093260203	http://dx.doi.org/10.1056/NEJM199201093260203			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY045	1309211				2022-12-01	WOS:A1992GY04500003
J	SCHWOB, E; MARTIN, RP				SCHWOB, E; MARTIN, RP			NEW YEAST ACTIN-LIKE GENE REQUIRED LATE IN THE CELL-CYCLE	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; SEQUENCE; DISRUPTION; TUBULIN; PROTEIN	ACTIN, a major cytoskeletal component of all eukaryotic cells, is one of the most highly conserved proteins. It is involved in various cellular processes such as motility, cytoplasmic streaming, chromosome segregation and cytokinesis 1,2. The actin from the yeast Saccharomyces cerevisiae, encoded by the essential ACT1 gene 3-5, is 89% identical to mouse cytoplasmic actin and is involved in the organization and polarized growth of the cell surface 6-8. We report here the characterization of ACT2, a previously undescribed yeast split gene encoding a putative protein (391 amino acids, relative molecular mass (M(r)) 44,073) that is 47% identical to yeast actin. The requirement of the ACT2 gene for vegetative growth of yeast cells and the existence of related genes in other eukaryotes indicate an important and conserved role for these actin-like proteins. Superimposition of the Act2 polypeptide onto the three-dimensional structure 9,10 of known actins reveals that most of the divergence occurred in loops involved in actin polymerization, DNase I and myosin binding, leaving the core domain mainly unaffected. To our knowledge, the Act2 protein from S. cerevisiae is the first highly divergent actin molecule described. Structural and physiological data suggest that the Act2 protein might have an important role in cytoskeletal reorganization during the cell cycle.	CNRS,INST BIOL MOLEC & CELLULAIRE,BIOCHIM LAB,15 RUE RENE DESCARTES,F-67084 STRASBOURG,FRANCE; UNIV STRASBOURG 1,F-67084 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Schwob, Etienne/AAC-3050-2020; Schwob, Etienne/H-4678-2015	Schwob, Etienne/0000-0002-9369-6419				ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; AKTORIES K, 1989, J CELL BIOL, V109, P1385, DOI 10.1083/jcb.109.4.1385; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; DALE RMK, 1985, PLASMID, V13, P31, DOI 10.1016/0147-619X(85)90053-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRUBIN DG, 1990, CELL MOTIL CYTOSKEL, V15, P7, DOI 10.1002/cm.970150103; ELZINGA M, 1973, P NATL ACAD SCI USA, V70, P2687, DOI 10.1073/pnas.70.9.2687; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GREER C, 1982, MOL CELL BIOL, V2, P1270, DOI 10.1128/MCB.2.10.1270; HAARER BK, 1987, MOL CELL BIOL, V7, P3678, DOI 10.1128/MCB.7.10.3678; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUFFAKER TC, 1987, ANNU REV GENET, V21, P259; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; LANGFORD CJ, 1983, CELL, V33, P519, DOI 10.1016/0092-8674(83)90433-6; LEGRAIN P, 1991, MOL GEN GENET, V225, P199, DOI 10.1007/BF00269848; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORTIMER RK, 1985, MICROBIOL REV, V49, P181, DOI 10.1128/MMBR.49.3.181-213.1985; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sherman F., 1986, METHODS YEAST GENETI; SHORTLE D, 1982, SCIENCE, V217, P371, DOI 10.1126/science.7046050; SNYDER M, 1987, METHOD ENZYMOL, V154, P107; SOLOMON LR, 1987, J BIOL CHEM, V262, P11382; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; VANDEKERCKHOVE J, 1985, EMBO J, V4, P2815, DOI 10.1002/j.1460-2075.1985.tb04008.x	31	115	116	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1992	355	6356					179	182		10.1038/355179a0	http://dx.doi.org/10.1038/355179a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1729653				2022-12-01	WOS:A1992GY62900064
J	SILVER, RA; TRAYNELIS, SF; CULLCANDY, SG				SILVER, RA; TRAYNELIS, SF; CULLCANDY, SG			RAPID-TIME-COURSE MINIATURE AND EVOKED EXCITATORY CURRENTS AT CEREBELLAR SYNAPSES INSITU	NATURE			English	Article							RAT HIPPOCAMPAL SLICES; PATCH-CLAMP; POSTSYNAPTIC CURRENTS; SYNAPTIC CURRENTS; NEURONS; GLUTAMATE; RECEPTORS; ACTIVATION; CELLS	NEUROTRANSMISSION from mossy fibre terminals onto cerebellar granule cells is almost certainly mediated by L-glutamate 1,2. By taking advantage of the small soma size, limited number of processes and short dendrite length of granule cells, we have obtained high-resolution recordings of spontaneous miniature excitatory postsynaptic currents (m.e.p.s.cs) and evoked currents in thin cerebellar slices 3. Miniature currents have a similar time-course and pharmacology to evoked currents and consist of an exceptionally fast non-NMDA (N-methyl-D-aspartate) component (measured rise-time, 200-mu-s; estimated pre-filtered rise-time < 100-mu-s; decay time constant, tau = 1.0 ms), followed by 50 pS NMDA channel openings that are directly resolvable. We could find no evidence for the recent proposal that miniature currents in granule cells are mediated solely by NMDA channels with a novel time course 4. The non-NMDA receptor component of m.e.p.s.cs has a skewed amplitude distribution, which suggests potential complications for quantal analysis. The difference in time course between the m.e.p.s.cs reported here and other synaptic currents in the brain 5-8 could reflect differences in synaptic function or electrotonic filtering; the relative contribution of these possibilities has vet to be established.			SILVER, RA (corresponding author), UNIV LONDON UNIV COLL,DEPT PHARMACOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.			Cull-Candy, Stuart G/0000-0002-0831-8326; Silver, Robin/0000-0002-5480-6638	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BORNSTEIN JC, 1978, J PHYSIOL-LONDON, V282, P375, DOI 10.1113/jphysiol.1978.sp012470; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; CULLCANDY SG, 1988, J PHYSIOL-LONDON, V400, P189, DOI 10.1113/jphysiol.1988.sp017117; DANGELO E, 1990, NATURE, V346, P467, DOI 10.1038/346467a0; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FINKEL AS, 1983, J PHYSIOL-LONDON, V342, P615, DOI 10.1113/jphysiol.1983.sp014872; FORSYTHE ID, 1988, J PHYSIOL-LONDON, V396, P515, DOI 10.1113/jphysiol.1988.sp016975; GIBB AJ, 1991, P ROY SOC B-BIOL SCI, V243, P39, DOI 10.1098/rspb.1991.0007; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HOWE JR, 1991, J PHYSIOL-LONDON, V432, P143, DOI 10.1113/jphysiol.1991.sp018381; JAKAB RL, 1988, ANAT EMBRYOL, V179, P81, DOI 10.1007/BF00305102; JI ZQ, 1991, J COMP NEUROL, V307, P296, DOI 10.1002/cne.903070210; Katz B., 1969, RELEASE NEURAL TRANS; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KELLER BU, 1991, J PHYSIOL-LONDON, V435, P275, DOI 10.1113/jphysiol.1991.sp018510; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; MACGREGOR RJ, 1987, NEURAL BRAIN MODELLI; NELSON PG, 1986, J PHYSIOL-LONDON, V372, P169, DOI 10.1113/jphysiol.1986.sp016003; RALL W, 1969, BIOPHYS J, V9, P1483, DOI 10.1016/S0006-3495(69)86467-2; ROBINSON HPC, 1991, BIOPHYS J, V59, P295, DOI 10.1016/S0006-3495(91)82223-8; ROPERT N, 1990, J PHYSIOL-LONDON, V428, P707, DOI 10.1113/jphysiol.1990.sp018236; SAH P, 1989, SCIENCE, V246, P815, DOI 10.1126/science.2573153; SOMOGYI P, 1986, NEUROSCIENCE, V19, P1045, DOI 10.1016/0306-4522(86)90121-1; STERN P, IN PRESS J PHYSL; TRAYNELIS SF, 1991, J PHYSIOL-LONDON, V433, P727, DOI 10.1113/jphysiol.1991.sp018453; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A	32	322	322	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1992	355	6356					163	166		10.1038/355163a0	http://dx.doi.org/10.1038/355163a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1370344				2022-12-01	WOS:A1992GY62900059
J	SLATER, AFG; CERAMI, A				SLATER, AFG; CERAMI, A			INHIBITION BY CHLOROQUINE OF A NOVEL HEME POLYMERASE ENZYME-ACTIVITY IN MALARIA TROPHOZOITES	NATURE			English	Article							PARASITE PLASMODIUM-FALCIPARUM; FERRIPROTOPORPHYRIN-IX; ANTIMALARIAL ACTIVITY; MECHANISM; HEMOZOIN; PIGMENT; PH	THE incidence of human malaria has increased during the past 20 years; 270 million people are now estimated to be infected with the parasite 1. An important contribution to this increase has been the appearance of malaria organisms resistant to quinoline-containing antimalarials such as chloroquine and quinine 2. These drugs accumulate in the acid food vacuoles of the intraerythrocytic-stage malaria parasite 3-5, although the mechanism of their specific toxicity in this organelle is uncertain. The primary function of the food vacuole is the proteolysis of ingested red cell haemoglobin 6,7 to provide the growing parasite with essential amino acids. Haemoglobin breakdown in the food vacuole releases haem, which if soluble can damage biological membranes 8 and inhibit a variety of enzymes 9-10. Rather than degrading or excreting the haem, the parasite has evolved a novel pathway for its detoxification by incorporating it into an insoluble crystalline material called haemozoin or malaria pigment 11. These crystals form in the food vacuole of the parasite concomitant with haemoglobin degradation, where they remain until the infected red cell bursts. The structure of haemozoin comprises a polymer of haems linked between the central ferric ion of one haem and a carboxylate side-group oxygen of another 12. This structure does not form spontaneously from either free haem or haemoglobin under physiological conditions 12-14, and the biochemistry of its formation is unclear. Here we report the identification and characterization of a haem polymerase enzyme activity from extracts of Plasmodium falciparum trophozoites, and show that this enzyme is inhibited by quinoline-containing drugs such as chloroquine and quinine. This provides a possible explanation for the highly stage-specific anti-malarial properties of these drugs.			SLATER, AFG (corresponding author), PICOWER INST MED RES, 350 COMMUNITY DR, MANHASSET, NY 11030 USA.							ASHONG JO, 1989, T ROY SOC TROP MED H, V83, P167, DOI 10.1016/0035-9203(89)90631-7; FITCH CD, 1982, ANTIMICROB AGENTS CH, V21, P819, DOI 10.1128/AAC.21.5.819; FITCH CD, 1987, J BIOL CHEM, V262, P15552; FUHRHOP JH, 1975, PORPHYRINS METALLOPO, P757; GINSBURG H, 1987, BIOCHEM PHARMACOL, V36, P1567, DOI 10.1016/0006-2952(87)90038-4; GINSBURG H, 1989, BIOCHEM PHARMACOL, V38, P2645, DOI 10.1016/0006-2952(89)90550-9; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; HOMEWOOD CA, 1972, NATURE, V235, P50, DOI 10.1038/235050a0; KROGSTAD DJ, 1986, BIOCHEM PHARMACOL, V35, P547, DOI 10.1016/0006-2952(86)90345-X; KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302; KROGSTAD DJ, 1987, NEW ENGL J MED, V317, P542, DOI 10.1056/NEJM198708273170905; LEMBERG R, 1949, HEMATIN COMPOUNDS BI; Peters W, 1987, CHEMOTHERAPY DRUG RE; Scheibel L. W., 1988, Malaria: principles and practice of malariology. Volume 1., P219; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; TAPPEL AL, 1953, ARCH BIOCHEM BIOPHYS, V44, P378, DOI 10.1016/0003-9861(53)90056-3; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VANDERJAGT DI, 1986, MOL BIOCHEM PARASIT, V18, P389, DOI 10.1016/0166-6851(86)90095-2; VANDERJAGT DL, 1987, BIOCHEM PHARMACOL, V36, P3285, DOI 10.1016/0006-2952(87)90646-0; WARHURST DC, 1987, ANN TROP MED PARASIT, V81, P65, DOI 10.1080/00034983.1987.11812093; WARHURST DC, 1981, BIOCHEM PHARMACOL, V30, P3323, DOI 10.1016/0006-2952(81)90606-7; WHITE NJ, 1981, LANCET, V2, P1069, DOI 10.1016/S0140-6736(81)91275-7; YA Z, 1986, J PARASITOL, V72, P830, DOI 10.2307/3281830; YAMADA KA, 1979, EXP PARASITOL, V48, P61, DOI 10.1016/0014-4894(79)90055-9; YASUHARA T, 1991, BIOCHEM BIOPH RES CO, V178, P95, DOI 10.1016/0006-291X(91)91784-A; YAYON A, 1984, J PROTOZOOL, V31, P367, DOI 10.1111/j.1550-7408.1984.tb02981.x; YAYON A, 1984, EMBO J, V3, P2695, DOI 10.1002/j.1460-2075.1984.tb02195.x; 1990, WHO TECHNICAL REPORT, V805	28	527	533	1	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 9	1992	355	6356					167	169		10.1038/355167a0	http://dx.doi.org/10.1038/355167a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1729651				2022-12-01	WOS:A1992GY62900060
J	SPEISER, DE; STUBI, U; ZINKERNAGEL, RM				SPEISER, DE; STUBI, U; ZINKERNAGEL, RM			EXTRATHYMIC POSITIVE SELECTION OF ALPHA-BETA-T-CELL PRECURSORS IN NUDE-MICE	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; BONE-MARROW TRANSPLANTATION; CYTOLYTIC LYMPHOCYTE-T; ANTIGEN RECEPTOR; NEGATIVE SELECTION; SELF-RECOGNITION; IMMUNE-RESPONSE; THYMUS GRAFTS; VIRUS; SPECIFICITY	T LYMPHOCYTES expressing alpha-beta-T-cell receptors with sufficient affinity to major histocompatibility complex (MHC) molecules expressed on thymus epithelial cells are positively selected and mature to functional T cells 1-6. But several studies have demonstrated that athymic nude mice 7-9 grafted with MHC-incompatible thymuses developed T cells specific for nude host rather than thymic MHC 10-14. We examined this paradox by analysing the specificity of T lymphocytes derived from nude mice. We report here that nude T lymphocyte precursors transferred to allogeneic SCID (severe combined immunodeficiency) mice with a functioning thymus (but lacking T or B cells 15-17) generated host MHC-restricted effector T cells but also contained T cells restricted to donor MHC. If nude T cells were depleted from nude lymphohaemopoietic donor cells before or after transfer, only host MHC-specific T cells matured. The results may explain the unusual MHC specificities of nude T lymphocytes described in earlier studies 10-14 and demonstrate two separate differentiation steps: in nude mice, T cells may be positively. selected for self-MHC restriction specificity extrathymically; then a functional thymus is required for efficient T cell maturation.			SPEISER, DE (corresponding author), UNIV HOSP ZURICH,INST PATHOL,EXPTL PATHOL LAB,CH-8091 ZURICH,SWITZERLAND.		Speiser, Daniel E./F-2173-2013					ANDO I, 1981, NATURE, V289, P494, DOI 10.1038/289494a0; BEVAN MJ, 1978, IMMUNOL REV, V42, P4; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOYD RL, 1991, IMMUNOL TODAY, V12, P71, DOI 10.1016/0167-5699(91)90161-L; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; CHARAN S, 1986, J IMMUNOL, V136, P3057; FRY AM, 1989, SCIENCE, V246, P1044, DOI 10.1126/science.2511630; GILLIS S, 1979, J EXP MED, V149, P1460, DOI 10.1084/jem.149.6.1460; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; GUYGRAND D, 1991, J EXP MED, V173, P471, DOI 10.1084/jem.173.2.471; HAMAOKA T, 1973, J EXP MED, V137, P1393, DOI 10.1084/jem.137.6.1393; HEDRICK SM, 1979, J EXP MED, V150, P646, DOI 10.1084/jem.150.3.646; HODES RJ, 1989, SCIENCE, V246, P1041, DOI 10.1126/science.2587987; HUNIG T, 1980, J EXP MED, V152, P688, DOI 10.1084/jem.152.3.688; ISHIKAWA H, 1980, J EXP MED, V151, P965, DOI 10.1084/jem.151.4.965; KAST WM, 1984, J EXP MED, V160, P1752, DOI 10.1084/jem.160.6.1752; KEEVER CA, 1989, BLOOD, V73, P1340; Kindred B, 1979, Prog Allergy, V26, P137, DOI 10.1159/000314466; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KLEIN JR, 1986, J EXP MED, V164, P309, DOI 10.1084/jem.164.1.309; KRUISBEEK AM, 1981, J IMMUNOL, V127, P2168; LAKE JP, 1980, J EXP MED, V152, P1805, DOI 10.1084/jem.152.6.1805; LAKE JP, 1991, CELL IMMUNOL, V135, P259, DOI 10.1016/0008-8749(91)90270-L; LONGO DL, 1985, P NATL ACAD SCI USA, V82, P5900, DOI 10.1073/pnas.82.17.5900; LOOR F, 1976, EUR J IMMUNOL, V6, P663, DOI 10.1002/eji.1830060914; MACDONALD HR, 1987, J EXP MED, V166, P195, DOI 10.1084/jem.166.1.195; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MARYANSKI JL, 1981, J IMMUNOL, V126, P871; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; PANTELOURIS EM, 1971, IMMUNOLOGY, V20, P247; RAFF MC, 1973, NATURE, V246, P350, DOI 10.1038/246350a0; ROCHA B, 1990, EUR J IMMUNOL, V20, P919, DOI 10.1002/eji.1830200430; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SCHULZ M, 1989, EUR J IMMUNOL, V19, P1657, DOI 10.1002/eji.1830190921; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; SOIFFER RJ, 1990, BLOOD, V75, P2076; SPRENT J, 1988, IMMUNOL REV, V101, P173, DOI 10.1111/j.1600-065X.1988.tb00737.x; STUTMAN O, 1978, IMMUNOL REV, V42, P138, DOI 10.1111/j.1600-065X.1978.tb00261.x; Wortis H H, 1974, Contemp Top Immunobiol, V3, P243; ZINKERNAGEL RM, 1988, J EXP MED, V168, P1187, DOI 10.1084/jem.168.3.1187; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882; ZINKERNAGEL RM, 1979, J EXP MED, V150, P693, DOI 10.1084/jem.150.3.693; ZINKERNAGEL RM, 1980, J EXP MED, V151, P376, DOI 10.1084/jem.151.2.376	46	40	40	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1992	355	6356					170	172		10.1038/355170a0	http://dx.doi.org/10.1038/355170a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1346064				2022-12-01	WOS:A1992GY62900061
J	WACHTER, RM				WACHTER, RM			AIDS, ACTIVISM, AND THE POLITICS OF HEALTH	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MOVEMENT				WACHTER, RM (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143, USA.							ANGELL M, 1991, NEW ENGL J MED, V324, P1498, DOI 10.1056/NEJM199105233242110; Annas George J, 1989, Villanova Law Rev, V34, P771; [Anonymous], 1987, BAND PLAYED POLITICS; BAYER R, 1991, NEW ENGL J MED, V324, P1500, DOI 10.1056/NEJM199105233242111; Bayer R., 1991, PRIVATE ACTS SOCIAL; BENNETT JT, 1990, HLTH RES CHARITIES I; Blumberg Rhoda Lois, 1984, CIVIL RIGHTS 1960S F; CHASE M, 1989, WALL STREET J   0919, pA3; COLAIACO JA, 1988, ML KING APOSTLE MILI; DELANEY M, 1989, J INFECT DIS, V159, P416, DOI 10.1093/infdis/159.3.416; Dowd Maureen, 1991, NEW YORK TIMES  0302, P7; FINTOR L, 1991, J NATL CANCER I, V83, P528, DOI 10.1093/jnci/83.8.528; FOX P, 1989, MILBANK Q, V67, P58, DOI 10.2307/3350070; Fuchs V., 1974, WHO SHALL LIVE; GROSS J, 1991, NY TIMES        0107, pA12; GROSSMAN H, 1990, NY TIMES        0819, V3, P13; HAMILTON PA, 1982, HLTH CARE CONSUMERIS; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; KOLATA G, 1990, NY TIMES, pA1; KOLATA G, 1991, NY TIMES        0716, pB6; KOLATA G, 1991, NY TIMES        0728, P13; KOLATA G, 1990, NY TIMES        0519, pA8; KRAMER L, 1990, OUTWEEK MAGAZIN 0314, P36; KRAMER L, 1989, REPROTS HOLOCAUST MA; KRAUTHAMMER C, 1990, TIME            0625, P80; LEO J, 1990, US NEWS WORLD R 0205, P18; LITTLE M, 1970, BY ANY MEANS NECESSA; MASTERSONALLEN S, 1990, INT J HEALTH SERV, V20, P485, DOI 10.2190/ATLC-AX39-M5EX-BYHF; McIntosh H, 1990, J Natl Cancer Inst, V82, P730, DOI 10.1093/jnci/82.9.730; ROTHMAN DJ, 1990, HEALTH AFFAIR, V9, P123, DOI 10.1377/hlthaff.9.3.123; Salholz E., 1990, NEWSWEEK        0312, P20; SPIERS HR, 1989, HASTINGS CENT REP, V19, P34, DOI 10.2307/3561987; STALL R, 1990, J ACQ IMMUN DEF SYND, V3, P1181; STRICKAND SP, 1979, POLITICS HLTH, P75; THOMPSON D, 1990, TIME            0122, P24; Wachter Robert M., 1991, FRAGILE COALITION SC; WINKENWERDER W, 1989, NEW ENGL J MED, V320, P1598, DOI 10.1056/NEJM198906153202406; 1991, MMWR, V40, P358; 1990, FED REGISTER, V55, P20856	39	60	61	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1992	326	2					128	133		10.1056/NEJM199201093260209	http://dx.doi.org/10.1056/NEJM199201093260209			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GY045	1727220				2022-12-01	WOS:A1992GY04500009
J	HEALY, B				HEALY, B			RELATIVE TOXICITY OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS EVALUATED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, ARTHRITIS RHEUM, V34, P1353	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1992	267	2					209	209						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY046	1309267				2022-12-01	WOS:A1992GY04600004
J	HEALY, B				HEALY, B			EXERCISE RADIONUCLIDE ANGIOCARDIOGRAPHY PREDICTS CARDIAC DEATH IN PATIENTS WITH CORONARY-ARTERY DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, CIRCULATION S1, V84, P52	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1992	267	2					209	209						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY046	1309267				2022-12-01	WOS:A1992GY04600006
J	HEALY, B				HEALY, B			BETTER TREATMENT FOR CYTOMEGALOVIRUS RETINITIS IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1992	267	2					209	209						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY046	1309267				2022-12-01	WOS:A1992GY04600005
J	VALENZUELA, TD; SPAITE, DW; MEISLIN, HW; CLARK, LL; WRIGHT, AL; EWY, GA				VALENZUELA, TD; SPAITE, DW; MEISLIN, HW; CLARK, LL; WRIGHT, AL; EWY, GA			CASE AND SURVIVAL DEFINITIONS IN OUT-OF-HOSPITAL CARDIAC-ARREST - EFFECT ON SURVIVAL RATE CALCULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							RESUSCITATION; DEATH	Objective. - To determine the effect of different case and survival definitions of out-of-hospital cardiac arrest on survival rate calculations. Design. - A 22-month case series of nontraumatic, out-of-hospital cardiac arrests. Setting. - Southwestern city (population, 400000; area, 390 km2) with a two-tiered emergency response system consisting of emergency medical technicians and paramedics. Patients. - A consecutive sample of 372 patients found without palpable pulse or spontaneous respiration. Main Outcome Measures. - Survival rate after cardiac arrest was calculated using three case definitions of arrest and two definitions of survival. Results. - Twenty percent of all patients survived to hospital admission and 6% survived to hospital discharge. Twenty-six percent of adults whose collapse was witnessed survived to hospital admission, and 10% survived to hospital discharge. Patients whose collapse was witnessed and who experienced initial ventricular fibrillation survived to hospital admission in 38% and to hospital discharge in 15% of cases. Conclusions. - The survival rate after out-of-hospital cardiac arrest varies widely depending on the case and survival definitions selected. To facilitate intersystem comparison and assessment of interventions designed to improve outcome, the Utstein Consensus Conference recommended that case and survival definitions should be adopted by all prehospital emergency systems.	ARIZONA EMERGENCY MED RES CTR,TUCSON,AZ; UNIV ARIZONA,COLL MED,CARDIOL SECT,TUCSON,AZ 85721; UNIV ARIZONA,DEPT MATH,TUCSON,AZ 85721	University of Arizona; University of Arizona				Spaite, Daniel/0000-0003-2601-6476				COBB LA, 1980, MOD CONC CARDIOV DIS, V49, P31; Colton T., 1974, STAT MED, P128; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; DAWSONSAUNDERS E, 1990, BASIC CLIN BIOSTATIS, P148; EISENBERG M, 1979, AM J PUBLIC HEALTH, V69, P30, DOI 10.2105/AJPH.69.1.30; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; EISENBERG MS, 1990, ANN EMERG MED, V19, P1249, DOI 10.1016/S0196-0644(05)82283-8; HUNT RC, 1989, AM J EMERG MED, V7, P68, DOI 10.1016/0735-6757(89)90089-2; PANTRIDG.JF, 1967, LANCET, V2, P271; VALENZUELA TD, 1989, ANN EMERG MED, V18, P573, DOI 10.1016/S0196-0644(89)80847-9; WEAVER WD, 1986, ANN EMERG MED, V15, P1181; WEAVER WD, 1986, J AM COLL CARDIOL, V7, P752, DOI 10.1016/S0735-1097(86)80332-1	12	52	52	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1992	267	2					272	274		10.1001/jama.267.2.272	http://dx.doi.org/10.1001/jama.267.2.272			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY046	1727526				2022-12-01	WOS:A1992GY04600033
J	DESWIET, M; FAYERS, P; SHINEBOURNE, EA				DESWIET, M; FAYERS, P; SHINEBOURNE, EA			BLOOD-PRESSURE IN 1ST 10 YEARS OF LIFE - THE BROMPTON STUDY	BRITISH MEDICAL JOURNAL			English	Article							CHILDREN; INFANTS; CHILDHOOD; AGE	Objectives - To determine the normal range of blood pressure and its pattern of change in the first 10 years of life. To estimate at what age (if any) children consistently appear in one part of the blood pressure distribution and at what age familial correlations in blood pressure become significant. Design - Longitudinal cohort study. Setting - South east England. Subjects - 2088 children of both sexes born consecutively in Farnborough Hospital, Kent, and their parents. Main outcome measure - Blood pressure measured by Doppler ultrasonography and sphygmomanometry. Results - Systolic blood pressure rose from a mean of 88.5 mm Hg at age 6 months to 96-2 mm Hg at 8 years measured with a 8 cm cuff and from 89.1 mm Hg at age 5 years to 94.3 mm Hg at age 10 years measured with a 12 cm cuff. The larger cuff gave blood pressure readings about 6 mm Hg lower. This effect was independent of body weight and arm circumference. Diastolic blood pressure rose from 57.8 mm Hg at 5 years to 61.8 mm Hg at 10 years (12 cm cuff). There was only about 1 mm Hg difference between sexes. Blood pressure was correlated with weight, weight adjusted for height, height, and arm circumference at all ages studied. The correlation coefficient of repeated yearly measurements increased steadily with age from 0.28 at 2 years to 0.59 at 10 years. The correlation coefficients between child's blood pressure and mother's average blood pressure increased from 0.1 at age 1 year to 0.23 at age 10. Conclusions - Blood pressure changes relatively little between the ages of 6 months and 10 years. Yet because of the increasing strength of between occasion and family correlations, children are more consistently occupying a specific part of the blood pressure distribution as they grow older. Studies in children should help determine why some adults have hypertension and others do not.	BROMPTON HOSP,NATL HEART & LUNG INST,DEPT PAEDIAT,LONDON SW3 6LY,ENGLAND	Imperial College London; Royal Brompton Hospital			Fayers, Peter M/A-5999-2010	Fayers, Peter/0000-0003-4778-1513				[Anonymous], 1987, PEDIATRICS, V79, P1; BURKE GL, 1987, PEDIATRICS, V80, P784; CLARKE WR, 1986, AM J EPIDEMIOL, V123, P67, DOI 10.1093/oxfordjournals.aje.a114225; COLE TJ, 1986, ANN HUM BIOL, V13, P433, DOI 10.1080/03014468600008621; de Swiet M, 1984, J Hypertens, V2, P501; DESWIET M, 1989, BRIT MED J, V299, P497, DOI 10.1136/bmj.299.6697.497; DESWIET M, 1980, PEDIATRICS, V65, P1028; DESWIET M, 1980, BMJ-BRIT MED J, V280, P1567, DOI 10.1136/bmj.280.6231.1567; DESWIET M, 1975, CLIN SCI MOL MED, V49, P557, DOI 10.1042/cs0490557; HOFMAN A, 1983, JAMA-J AM MED ASSOC, V250, P370, DOI 10.1001/jama.250.3.370; ROSNER B, 1977, AM J EPIDEMIOL, V106, P306, DOI 10.1093/oxfordjournals.aje.a112466; SHEAR CL, 1986, PEDIATRICS, V77, P862; VERSMOLD HT, 1981, PEDIATRICS, V67, P607; WHINCUP PH, 1989, BMJ-BRIT MED J, V299, P587, DOI 10.1136/bmj.299.6699.587; WILSON PD, 1988, AM J EPIDEMIOL, V127, P946, DOI 10.1093/oxfordjournals.aje.a114898	15	79	79	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1992	304	6818					23	26		10.1136/bmj.304.6818.23	http://dx.doi.org/10.1136/bmj.304.6818.23			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY909	1734987	Green Published, Bronze			2022-12-01	WOS:A1992GY90900028
J	JOHANNES, CB; KAUFMAN, DW; ROSENBERG, L; PALMER, JR; STOLLEY, PD; LEWIS, JL; ZAUBER, AG; WARSHAUER, ME; SHAPIRO, S				JOHANNES, CB; KAUFMAN, DW; ROSENBERG, L; PALMER, JR; STOLLEY, PD; LEWIS, JL; ZAUBER, AG; WARSHAUER, ME; SHAPIRO, S			SIDE OF ORIGIN OF EPITHELIAL OVARIAN-CANCER	BRITISH MEDICAL JOURNAL			English	Article							OVULATION		UNIV PENN,SCH MED,DEPT MED,CLIN EPIDEMIOL UNIT,PHILADELPHIA,PA 19104; MEM SLOAN KETTERING CANC CTR,DEPT SURG,GYNAECOL SERV,NEW YORK,NY 10021; NEW YORK HOSP,CANC CARE & RES PROGRAM,NEW YORK,NY 10021	University of Pennsylvania; Memorial Sloan Kettering Cancer Center; NewYork-Presbyterian Hospital	JOHANNES, CB (corresponding author), BOSTON UNIV,SCH MED,SLONE EPIDEMIOL UNIT,BROOKLINE,MA 02146, USA.			Rosenberg, Lynn/0000-0003-2760-2987; Kaufman, David/0000-0002-2150-5070; Palmer, Julie/0000-0002-6534-335X	NCI NIH HHS [5 R37 CA45762] Funding Source: Medline; FDA HHS [FD-U-000082, UO1 FD01222] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA045762] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FDA HHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CRUICKSHANK DJ, 1990, BMJ-BRIT MED J, V301, P524, DOI 10.1136/bmj.301.6751.524; FATHALLA MF, 1971, LANCET, V2, P163; POTASHNIK G, 1987, BRIT MED J, V294, P219, DOI 10.1136/bmj.294.6566.219; Slone D, 1977, EPIDEMIOLOGICAL EVAL, P59; SNEDECOR GW, 1967, STATISTICAL METHODS, P211	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1992	304	6818					27	28		10.1136/bmj.304.6818.27	http://dx.doi.org/10.1136/bmj.304.6818.27			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY909	1734989	Bronze, Green Published			2022-12-01	WOS:A1992GY90900030
J	MCGIBBEN, L; BALLARD, CG; HANDY, S; SILVEIRA, WR				MCGIBBEN, L; BALLARD, CG; HANDY, S; SILVEIRA, WR			SCHOOL ATTENDANCE AS A FACTOR IN DELIBERATE SELF POISONING BY 12-15 YEAR OLD ADOLESCENTS	BRITISH MEDICAL JOURNAL			English	Article											MCGIBBEN, L (corresponding author), WALSGRAVE GEN HOSP,DEPT PSYCHIAT,COVENTRY CV2 2DX,ENGLAND.			Ballard, Clive/0000-0003-0022-5632				Christoffel K K, 1988, Pediatr Emerg Care, V4, P32, DOI 10.1097/00006565-198803000-00011; Durkheim E., 1952, SUICIDE; MASTERTON G, 1991, BRIT J PSYCHIAT, V158, P155, DOI 10.1192/bjp.158.2.155; PAPATHOMOPOULOS E, 1989, CAN J PSYCHIAT, V34, P205, DOI 10.1177/070674378903400309	4	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1992	304	6818					28	28		10.1136/bmj.304.6818.28	http://dx.doi.org/10.1136/bmj.304.6818.28			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GY909	1734990	Bronze, Green Published			2022-12-01	WOS:A1992GY90900031
J	ONEILL, D				ONEILL, D			PHYSICIANS, ELDERLY DRIVERS, AND DEMENTIA	LANCET			English	Article							AGE; MEDICINE	In western countries, the proportion of drivers who are elderly is increasing rapidly; over a quarter of the driving population will be 55 years of age or older by the year 2000. Although elderly drivers tend to drive less and may avoid night driving, the number of car accidents and the severity of injuries sustained in such accidents by distance driven increases strikingly after the age of 65. But how can doctors identify those elderly drivers who are a danger to themselves and others? And, once they are identified, how should clinicians balance the effects of removing a driving license, which may greatly affect a patient's lifestyle, against public safety and breach of confidentiality if the patient refuses to give up his or her license voluntarily? Medical decisions about illnesses that predispose to loss of consciousness are fairly clear-cut, but normal ageing processes and dementia can be much more difficult to identify and to assess; moreover, there seems little correlation between tests of mental performance and driving ability. Comparisons between practices in different countries may provide some answers, but the introduction of modified driving tests for elderly drivers with some evidence of mild impairment but who wish to retain their driving license should be considered.			ONEILL, D (corresponding author), FRENCHAY HOSP,DEPT CARE ELDERLY,BRISTOL BS16 1LE,AVON,ENGLAND.		O'Neill, Desmond/D-1486-2013	O'Neill, Desmond/0000-0002-5542-9897				[Anonymous], 1990, LANCET, V336, P781; BETTS T, 1988, INT CLIN PSYCHOPH S1, V3, P88; CARR D, 1991, J AM GERIATR SOC, V39, pA62; CARTWRIGHT A, 1990, BRIT MED BULL, V46, P63, DOI 10.1093/oxfordjournals.bmb.a072395; COOPERSMITH HG, 1989, CAN MED ASSOC J, V140, P375; Donnelly R E, 1990, J Geriatr Psychiatry Neurol, V3, P67, DOI 10.1177/089198879000300203; DRACHMAN DA, 1988, ANN NEUROL, V24, P787, DOI 10.1002/ana.410240614; EVANS L, 1988, J GERONTOL, V43, pS186, DOI 10.1093/geronj/43.6.S186; Evans Leonard, 1991, TRAFFIC SAFETY DRIVE; FIFE D, 1984, AM J PUBLIC HEALTH, V74, P473, DOI 10.2105/AJPH.74.5.473; FRIEDLAND RP, 1988, ANN NEUROL, V24, P782, DOI 10.1002/ana.410240613; HANSOTIA P, 1991, NEW ENGL J MED, V324, P22, DOI 10.1056/NEJM199101033240105; HART S, 1991, NEUROPSYCHOLOGY DEME; HOLLAND CA, IN PRESS APPL COGNIT; HUTTON J, 1991, CARERS PROFESSIONALS, P279; KLAMM ER, 1985, DRIVERS 55 PLUS NEED, P87; LUCASBLAUSTEIN MJ, 1988, J AM GERIATR SOC, V36, P1087, DOI 10.1111/j.1532-5415.1988.tb04394.x; MALFETTI JL, 1985, DRIVERS 55 PLUS NEED; MCFARLAND RA, 1964, J GERONTOL, V19, P190, DOI 10.1093/geronj/19.2.190; OCONNOR DW, 1988, BMJ-BRIT MED J, V297, P1107, DOI 10.1136/bmj.297.6656.1107; ODENHEIMER G, 1991, J AM GERIATR SOC, V39, pA9; ONEILL D, IN PRESS J R SOC MED; PFEIFFER RI, 1987, AM J EPIDEMIOL, V125, P420; PONDS RWHM, 1988, J GERONTOL, V43, pP151, DOI 10.1093/geronj/43.6.P151; RAFFLE A, 1985, MED ASPECTS FITNESS, P92; RETCHIN SM, 1988, J AM GERIATR SOC, V36, P813, DOI 10.1111/j.1532-5415.1988.tb04265.x; REUBEN DB, 1988, J AM GERIATR SOC, V36, P1135, DOI 10.1111/j.1532-5415.1988.tb04403.x; SEIB H, 1990, Z GERONTOL, V23, P86; TAIRA ED, 1989, ASSESSING DRIVING AB; WALLER JA, 1967, J CHRON DIS, V20, P615, DOI 10.1016/0021-9681(67)90038-0; WALSH JB, 1980, J IRISH MED ASSOC, V73, P62; WILLIAMS AF, 1989, AM J PUBLIC HEALTH, V79, P326, DOI 10.2105/AJPH.79.3.326; WILLIAMS C, 1991, J AM GERIATR SOC, V39, pA72; 1985, TRAFFIC SAFETY ELDER; 1985, PROFESSIONAL CONDUCT, P19; 1988, MOTORING OLDER DRIVE, P40; 1990, MED ASPECTS FITNESS; 1983, JAMA-J AM MED ASSOC, V249, P3216; 1984, CALDMVRSS8292 CAL ST	39	38	41	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1992	339	8784					41	43		10.1016/0140-6736(92)90155-V	http://dx.doi.org/10.1016/0140-6736(92)90155-V			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GY043	1345962				2022-12-01	WOS:A1992GY04300015
J	PETTOELLOMANTOVANI, M; CASADEVALL, A; KOLLMANN, TR; RUBINSTEIN, A; GOLDSTEIN, H				PETTOELLOMANTOVANI, M; CASADEVALL, A; KOLLMANN, TR; RUBINSTEIN, A; GOLDSTEIN, H			ENHANCEMENT OF HIV-1 INFECTION BY THE CAPSULAR POLYSACCHARIDE OF CRYPTOCOCCUS-NEOFORMANS	LANCET			English	Note							INVITRO	Patients with AIDS who become infected with Cryptococcus neoformans have a poor prognosis. We speculated that the presence of cryptococcal capsular polysaccharide may enhance HIV-1 infection. In an in-vitro study, the presence of cryptococcal polysaccharide significantly increased (p < 0.05) production of p24 antigen after infection of H9 cells with HIV-1 -infected H9 cells. We also found similar results when lymphocytes from an HIV-1 -infected patient were co-cultured with mononuclear cells from an uninfected individual. Our findings suggest a new pathogenic role for the capsular polysaccharide-namely, the capacity to enhance HIV-1 infectivity.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PEDIAT,FORSCHHEIMER BLDG,ROOM 403, 1300 MORRIS PK AVE, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MED, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine			MANTOVANI, Massimo PETTOELLO/AAC-1990-2019	MANTOVANI, Massimo PETTOELLO/0000-0002-0688-1131; Kollmann, Tobias/0000-0003-2403-9762	NATIONAL CANCER INSTITUTE [R35CA039838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI020671, P30AI027741, R01AI020671] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39838] Funding Source: Medline; NIAID NIH HHS [AI-20671, AI-27741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABA M, 1988, P NATL ACAD SCI USA, V85, P6132, DOI 10.1073/pnas.85.16.6132; BHATTACHARJEE AK, 1984, REV INFECT DIS, V6, P619; ENG RHK, 1986, AM J MED, V81, P19, DOI 10.1016/0002-9343(86)90176-2; FRIEDLAND GH, 1991, J ACQ IMMUN DEF SYND, V4, P144; GOLDSTEIN H, 1991, AIDS, V5, P1447, DOI 10.1097/00002030-199112000-00006; KOZEL TR, 1971, INFECT IMMUN, V3, P287, DOI 10.1128/IAI.3.2.287-294.1971; MILLER GPG, 1984, J IMMUNOL, V133, P166; ROSENBERG ZF, 1989, ADV IMMUNOL, V47, P377; Treseler C B, 1990, Infect Dis Clin North Am, V4, P789; WISEMAN G, 1991, AIDS RES HUM RETROV, V7, P839, DOI 10.1089/aid.1991.7.839	10	79	82	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 4	1992	339	8784					21	23		10.1016/0140-6736(92)90142-P	http://dx.doi.org/10.1016/0140-6736(92)90142-P			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY043	1370335				2022-12-01	WOS:A1992GY04300004
J	SHAH, P; DHURJON, L; METCALFE, T; GIBSON, JM				SHAH, P; DHURJON, L; METCALFE, T; GIBSON, JM			LESSON OF THE WEEK - ACUTE ANGLE CLOSURE GLAUCOMA ASSOCIATED WITH NEBULIZED IPRATROPIUM BROMIDE AND SALBUTAMOL	BRITISH MEDICAL JOURNAL			English	Article									E BIRMINGHAM DIST GEN HOSP,DEPT OPHTHALMOL,BIRMINGHAM B9 5ST,W MIDLANDS,ENGLAND; GEN INFIRM,DEPT OPHTHALMOL,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	Leeds General Infirmary				Gibson, Jonathan M/0000-0002-9281-5244				GRAY RH, 1990, HOSPITAL UPDATE, V16, P446; KALRA L, 1988, CHEST, V93, P739, DOI 10.1378/chest.93.4.739; MALANI JT, 1982, NEW ZEAL MED J, V95, P749; PACKE GE, 1984, LANCET, V2, P691	4	35	36	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1992	304	6818					40	41		10.1136/bmj.304.6818.40	http://dx.doi.org/10.1136/bmj.304.6818.40			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY909	1531182	Bronze, Green Published			2022-12-01	WOS:A1992GY90900035
J	SUMNERS, D; KELSEY, M; CHAIT, I				SUMNERS, D; KELSEY, M; CHAIT, I			PSYCHOLOGICAL-ASPECTS OF LOWER URINARY-TRACT INFECTIONS IN WOMEN	BRITISH MEDICAL JOURNAL			English	Article							URETHRAL SYNDROME	Objective - To determine whether women with the urethral syndrome can be distinguished from those with urinary tract infection by case notes, clinical symptoms, or psychiatric state. Design - Longitudinal survey of consecutive women presenting with dysuria and frequency. Setting - General practice and community. Subjects - 58 patients with the urethral syndrome and 44 patients with a urinary tract infection, mean age 39.9 years. Main outcome measures - Results of analysis of serial midstream urine specimens, patients' self rated physical symptoms and responses to 60 item general health questionnaire at presentation and after resolution of symptoms, and results of psychiatric assessment with the clinical psychiatric interview. Results - 4 of 42 patients with a urinary tract infection had recently changed sexual partner compared with none of 58 with the urethral syndrome. Dysuria and nocturia were more common in patients with urinary tract infections than those with the urethral syndrome (mean (SD) score for dysuria 5-37 (2.39) v 4.57 (2.13), p < 0.05; nocturia in 39/44 (88%) patients v 40/58 (69%), chi-2 = 5.5, p < 0.02). Both groups showed transient high levels of distress which resolved with the physical symptoms, but no psychiatric difference distinguished them. Conclusion - The urethral syndrome is not associated with increased psychiatric morbidity.	WHITTINGTON HOSP,LONDON N19 5NF,ENGLAND; ROYAL FREE HOSP,LONDON NW3 2QG,ENGLAND	University of London; University College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	SUMNERS, D (corresponding author), NAPSBURY HOSP,LONDON AL2 1AA,HERTS,ENGLAND.							BORCHAM P, 1984, J R SOC MED, V77, P111; BROOKS D, 1978, BACTERIOLOGICAL EXAM, P39; BRUMFITT W, 1991, BRIT MED J, V303, P1, DOI 10.1136/bmj.303.6793.1; EISENBERG JM, 1979, ANN INTERN MED, V90, P957, DOI 10.7326/0003-4819-90-6-957; FINLAYJONES RA, 1979, BRIT J PSYCHIAT, V134, P609, DOI 10.1192/bjp.134.6.609; FROST D, 1981, BRIT J PSYCHIAT, V138, P292; FRY J, 1980, COMMON DISEASES THEI; GALLAGHER DJ, 1965, BMJ-BRIT MED J, V1, P622, DOI 10.1136/bmj.1.5435.622; GOLDBERG DP, 1970, BRIT J PREV SOC MED, V24, P18; Goldberg DP., 1972, DETECTION PSYCHIATRI; GRAY LA, 1956, JAMA-J AM MED ASSOC, V162, P1361, DOI 10.1001/jama.1956.02970320009003; MASON E, 1977, J IRISH MED ASSOC, V70, P335; ODOWD TC, 1984, BMJ, V288, P208; REES DLP, 1977, BRIT J UROL, V49, P651, DOI 10.1111/j.1464-410X.1977.tb04547.x; SCHMIDT RA, 1985, UROL CLIN N AM, V12, P349; SCOTTI RJ, 1984, CLIN OBSTET GYNECOL, V27, P515, DOI 10.1097/00003081-198406000-00025; WATERS WE, 1969, BR J PREV SOC MED, V23, P293; 1979, BMJ, V2, P717	18	12	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1992	304	6818					17	19		10.1136/bmj.304.6818.17	http://dx.doi.org/10.1136/bmj.304.6818.17			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GY909	1734984	Green Published, Bronze			2022-12-01	WOS:A1992GY90900026
J	THORNTON, HM				THORNTON, HM			BREAST-CANCER TRIALS - A PATIENTS VIEWPOINT	LANCET			English	Editorial Material											THORNTON, HM (corresponding author), SAIONARA,31 REGENT ST,COLCHESTER CO5 7EA,ESSEX,ENGLAND.							Early Breast Cancer Trialists' Collaborative Group, 1990, TREATMENT EARLY BREA, V1; HAMILTON CR, 1990, BRIT MED J, V301, P224, DOI 10.1136/bmj.301.6745.224	2	41	41	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1992	339	8784					44	45		10.1016/0140-6736(92)90157-X	http://dx.doi.org/10.1016/0140-6736(92)90157-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY043	1345963				2022-12-01	WOS:A1992GY04300016
J	DUHAMEL, JR; COLBY, CL; GOLDBERG, ME				DUHAMEL, JR; COLBY, CL; GOLDBERG, ME			THE UPDATING OF THE REPRESENTATION OF VISUAL SPACE IN PARIETAL CORTEX BY INTENDED EYE-MOVEMENTS	SCIENCE			English	Article							MECHANISMS; PRIMATE; MACAQUE; MEMORY	Every eye movement produces a shift in the visual image on the retina. The receptive field, or retinal response area, of an individual visual neuron moves with the eves so that after an eye movement it covers a new portion of visual space. For some parietal neurons, the location of the receptive field is shown to shift transiently before an eve movement. In addition, nearly all parietal neurons respond when an eye movement brings the site of a previously flashed stimulus into the receptive field. Parietal cortex both anticipates the retinal consequences of eye movements and updates the retinal coordinates of remembered stimuli to generate a continuously accurate representation of visual space.	NEI,SENSORIMOTOR RES LAB,BLDG 10,ROOM 10C 101,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)			Duhamel, Jean-René/M-4723-2017	Duhamel, Jean-René/0000-0003-0210-1027				ANDERSEN RA, 1990, J NEUROSCI, V10, P1176; [Anonymous], 1962, TREATISE PHYSL OPTIC; BARASH S, 1991, J NEUROPHYSIOL, V66, P1109, DOI 10.1152/jn.1991.66.3.1109; BUSHNELL MC, 1981, J NEUROPHYSIOL, V46, P755, DOI 10.1152/jn.1981.46.4.755; DROULEZ J, 1990, MOTOR CONTROL CONCEP, P137; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GOLDBERG ME, 1990, COLD SPRING HARB SYM, V55, P729; GOLDBERG ME, 1990, J NEUROPHYSIOL, V64, P489, DOI 10.1152/jn.1990.64.2.489; GOLDENBERG DH, 1983, J FUTURES MARKETS, V3, P225, DOI 10.1002/fut.3990030210; ROBINSON DL, 1978, J NEUROPHYSIOL, V41, P910, DOI 10.1152/jn.1978.41.4.910; WURTZ RH, 1976, J NEUROPHYSIOL, V39, P745, DOI 10.1152/jn.1976.39.4.745; WURTZ RH, 1969, J NEUROPHYSIOL, V32, P727, DOI 10.1152/jn.1969.32.5.727; YIN TCT, 1977, SCIENCE, V197, P1381, DOI 10.1126/science.408924	13	1321	1325	1	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1992	255	5040					90	92						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX791	1553535				2022-12-01	WOS:A1992GX79100045
J	FAHA, B; EWEN, ME; TSAI, LH; LIVINGSTON, DM; HARLOW, E				FAHA, B; EWEN, ME; TSAI, LH; LIVINGSTON, DM; HARLOW, E			INTERACTION BETWEEN HUMAN CYCLIN-A AND ADENOVIRUS E1A-ASSOCIATED P107 PROTEIN	SCIENCE			English	Article							LARGE T-ANTIGEN; CELL-CYCLE; RETINOBLASTOMA PROTEIN; E1A PROTEINS; BINDING; COMPLEXES; REGIONS; PRODUCT; GENE	The products of the adenovirus early region IA (EIA) gene are potent oncoproteins when tested in standard transformation and immortalization assays. Many of the changes induced by EIA may be due to its interaction with cellular proteins. Four of these cellular proteins are the retinoblastoma protein (pRB), p107, cyclin A, and p33cdk2. The pRB and p107 proteins are structurally related and have several characteristics in common, including that they both bind to the SV40 large T oncoprotein as well as to E1A. Cyclin A and p33cdk2 are thought to function in the control of the cell cycle. They bind to one another, forming a kinase that closely resembles the cell cycle-regulating complexes containing p34cdc2. Cyclin A is now shown to bind to p107 in the absence of E1A. The association of p107 with cyclin A suggests a direct link between cell cycle control and the function of p107.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	FAHA, B (corresponding author), MASSACHUSETTS GEN HOSP, CTR CANC, BOSTON, MA 02129 USA.				NATIONAL CANCER INSTITUTE [R01CA055339, P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA 55339, CA 13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DYSON N, UNPUB; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAHA B, UNPUB; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; HU Q, IN PRESS MOL CELL BI; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSAI LH, UNPUB	30	220	223	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 3	1992	255	5040					87	90		10.1126/science.1532458	http://dx.doi.org/10.1126/science.1532458			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX791	1532458				2022-12-01	WOS:A1992GX79100044
J	LETOURNEUR, F; KLAUSNER, RD				LETOURNEUR, F; KLAUSNER, RD			ACTIVATION OF T-CELLS BY A TYROSINE KINASE ACTIVATION DOMAIN IN THE CYTOPLASMIC TAIL OF CD3-EPSILON	SCIENCE			English	Article							MONOCLONAL-ANTIBODY; ANTIGEN RECEPTOR; COMPLEX; PHOSPHORYLATION; IDENTIFICATION; ASSOCIATION; HYBRIDOMAS; PROTEIN	The multichain T cell antigen receptor functions by interacting with and activating one or more nonreceptor tyrosine kinases. The cytoplasmic tail of the zeta-chain can activate T cells independently of the rest of the receptor complex. The function of the remaining invariant CD3 chains remains unknown. A 22-amino acid region of the cytoplasmic tail of CD3-epsilon was also able to independently activate T cells. Stimulation of T cells by means of the cytoplasmic tails of either zeta or CD3-epsilon resulted in quantitatively distinct patterns of tyrosine phosphorylation, suggesting activation of different biochemical pathways.			LETOURNEUR, F (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.			Letourneur, Francois/0000-0003-2232-6127				ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HSI ED, 1989, J BIOL CHEM, V264, P10836; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JUNE CH, 1990, J IMMUNOL, V144, P1591; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KONING F, 1990, EUR J IMMUNOL, V20, P299, DOI 10.1002/eji.1830200211; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LETOURNEUR F, UNPUB; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; REITH M, 1983, NATURE, V338, P383; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SELDIN RF, 1990, CURRENT PROTOCOLS MO, V1, P921; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WHITE J, 1989, J IMMUNOL, V143, P1822	23	425	444	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1992	255	5040					79	82		10.1126/science.1532456	http://dx.doi.org/10.1126/science.1532456			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX791	1532456				2022-12-01	WOS:A1992GX79100041
J	SELVIN, PR; COOK, DN; PON, NG; BAUER, WR; KLEIN, MP; HEARST, JE				SELVIN, PR; COOK, DN; PON, NG; BAUER, WR; KLEIN, MP; HEARST, JE			TORSIONAL RIGIDITY OF POSITIVELY AND NEGATIVELY SUPERCOILED DNA	SCIENCE			English	Article							FLUORESCENCE DEPOLARIZATION; ESCHERICHIA-COLI; DEPENDENCE; PROTEIN; MACROMOLECULES; REQUIREMENT; DYNAMICS; REPEAT	Time-correlated single-photon counting of intercalated ethidium bromide was used to measure the torsion constants of positively supercoiled, relaxed, ana negatively supercoiled pBR322 DNA, which range in superhelix density from +0.042 to -0.123. DNA behaves as coupled, nonlinear torsional pendulums under superhelical stress, and the anharmonic term in the Hamiltonian is approximately 15 percent for root-mean-square fluctuations in twist at room temperature. At the level of secondary structure, positively supercoiled DNA is significantly more flexible than negatively supercoiled DNA. These results exclude certain models that account for differential binding affinity of proteins to positively and negatively supercoiled DNA.	UNIV CALIF BERKELEY,DEPT PHYS,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; SUNY STONY BROOK,SCH MED,DEPT MICROBIOL,STONY BROOK,NY 11794	University of California System; University of California Berkeley; University of California System; University of California Berkeley; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	SELVIN, PR (corresponding author), UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,CHEM BIODYNAM LAB,BERKELEY,CA 94720, USA.				FDA HHS [FD 8R1 GM 41911A-03-NF-03/92] Funding Source: Medline	FDA HHS		ADRIAN M, 1990, EMBO J, V9, P4551, DOI 10.1002/j.1460-2075.1990.tb07907.x; ALLISON SA, 1979, CHEM PHYS, V41, P35, DOI 10.1016/0301-0104(79)80131-7; ANDERSON P, 1978, BIOCHEMISTRY-US, V17, P594, DOI 10.1021/bi00597a006; BARKLEY MD, 1979, J CHEM PHYS, V70, P2991, DOI 10.1063/1.437838; BAUER W, 1970, Journal of Molecular Biology, V47, P419, DOI 10.1016/0022-2836(70)90312-8; BOLES TC, 1990, J MOL BIOL, V213, P931, DOI 10.1016/S0022-2836(05)80272-4; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; FUJIMOTO BS, 1990, NATURE, V344, P175, DOI 10.1038/344175a0; HAHN S, 1986, J MOL BIOL, V188, P355, DOI 10.1016/0022-2836(86)90160-9; HOGAN M, 1979, BIOCHEMISTRY-US, V18, P280, DOI 10.1021/bi00569a007; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; HUNT NG, IN PRESS J CHEM PHYS; HURST JE, IN PRESS J CHEM PHYS; KLENIN KV, 1991, J MOL BIOL, V217, P413, DOI 10.1016/0022-2836(91)90745-R; KRAMER H, 1988, EMBO J, V7, P547, DOI 10.1002/j.1460-2075.1988.tb02844.x; LIDE DR, 1990, CRC HDB CHEM PHYSICS; LILLEY DMJ, 1980, P NATL ACAD SCI-BIOL, V77, P6468, DOI 10.1073/pnas.77.11.6468; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; LOCKSHON D, 1983, NUCLEIC ACIDS RES, V11, P2999, DOI 10.1093/nar/11.10.2999; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MILLAR DP, 1982, J CHEM PHYS, V76, P2080, DOI 10.1063/1.443182; SELVIN PR, 1990, THESIS U CALIFORNIA; SHIBATA JH, 1984, BIOCHEMISTRY-US, V23, P1188, DOI 10.1021/bi00301a025; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; SINGLETON CK, 1982, NATURE, V299, P312, DOI 10.1038/299312a0; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; SONG L, 1990, J MOL BIOL, V214, P307, DOI 10.1016/0022-2836(90)90163-G; TAYLOR WH, 1990, J MOL BIOL, V212, P363, DOI 10.1016/0022-2836(90)90131-5; THOMAS JC, 1983, BIOCHEMISTRY-US, V22, P6194, DOI 10.1021/bi00295a024; WU PG, 1988, BIOCHEMISTRY-US, V27, P8128, DOI 10.1021/bi00421a023	30	59	59	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1992	255	5040					82	85		10.1126/science.1553534	http://dx.doi.org/10.1126/science.1553534			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX791	1553534				2022-12-01	WOS:A1992GX79100042
J	ANSARI, AZ; CHAEL, ML; OHALLORAN, TV				ANSARI, AZ; CHAEL, ML; OHALLORAN, TV			ALLOSTERIC UNDERWINDING OF DNA IS A CRITICAL STEP IN POSITIVE CONTROL OF TRANSCRIPTION BY HG-MERR	NATURE			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; UNWINDING ANGLE; MERCURIC ION; PROTEIN; PROMOTER; COMPLEX; SEQUENCE; BINDING; TN501	POSITIVE control of transcription often involves stimulatory protein-protein interactions between regulatory factors and RNA polymerase 1. Critical steps in the activation process itself are seldom ascribed to protein-DNA distortions. Activator-induced DNA bending is typically assigned a role in binding-site recognition 2, alterations in DNA loop structures 3 or optimal positioning of the activator for interaction with polymerase 4. Here we present a transcriptional activation mechanism that does not require a signal-induced DNA bend but rather a receptor-induced untwisting of duplex DNA. The allosterically modulated transcription factor MerR is a repressor and an Hg(II)-responsive activator of bacterial mercury-resistance genes 5-7. Escherichia coli RNA polymerase binds to the MerR-promoter complex but cannot proceed to a transcriptionally active open complex until Hg(II) binds to MerR (ref. 6). Chemical nuclease studies show that the activator form, but not the repressor, induces a unique alteration of the helical structure localized at the centre of the DNA-binding site 6. Data presented here indicate that this Hg-MerR-induced DNA distortion corresponds to a local underwinding of the spacer region of the promoter by about 33-degrees relative to the MerR-operator complex. The magnitude and the direction of the Hg-MerR-induced change in twist angle are consistent with a positive control mechanism involving reorientation of conserved, but suboptimally phased, promoter elements and are consistent with a role for torsional stress in formation of an open complex.	NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,2145 SHERIDAN RD,EVANSTON,IL 60208; NORTHWESTERN UNIV,DEPT CHEM,EVANSTON,IL 60208	Northwestern University; Northwestern University			O'Halloran, Thomas/ABE-6125-2021; Ansari, Aseem/AAF-4945-2019	O'Halloran, Thomas/0000-0001-8732-5059; 	NIGMS NIH HHS [R01 GM038784] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038784] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOUYAL M, 1987, J MOL BIOL, V195, P795, DOI 10.1016/0022-2836(87)90485-2; AYERS DG, 1989, J MOL BIOL, V207, P749, DOI 10.1016/0022-2836(89)90241-6; BOROWIEC JA, 1985, J MOL BIOL, V184, P587, DOI 10.1016/0022-2836(85)90305-5; BROWN NL, 1986, MOL GEN GENET, V202, P143, DOI 10.1007/BF00330531; BUCH H, 1987, RNA POLYM REGULATION, P115; Cozzarelli N. R., 1990, DNA TOPOLOGY ITS BIO, P139; DEPEW RE, 1975, P NATL ACAD SCI USA, V72, P4275, DOI 10.1073/pnas.72.11.4275; FRANTZ B, 1990, BIOCHEMISTRY-US, V29, P4747, DOI 10.1021/bi00472a001; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HELMANN JD, 1990, SCIENCE, V247, P946, DOI 10.1126/science.2305262; HELTZEL A, 1990, BIOCHEMISTRY-US, V29, P9572, DOI 10.1021/bi00493a011; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KIM R, 1982, COLD SPRING HARB SYM, V47, P451, DOI 10.1101/SQB.1983.047.01.053; KIM R, 1984, NUCLEIC ACIDS RES, V12, P7285, DOI 10.1093/nar/12.19.7285; KOLB A, 1982, NUCLEIC ACIDS RES, V10, P473, DOI 10.1093/nar/10.2.473; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; LUND P, 1989, NUCLEIC ACIDS RES, V17, P5517, DOI 10.1093/nar/17.14.5517; OHALLORAN T, 1987, SCIENCE, V235, P211, DOI 10.1126/science.3798107; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; PARKHILL J, 1990, NUCLEIC ACIDS RES, V18, P5157, DOI 10.1093/nar/18.17.5157; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; Travers A. A., 1990, DNA TOPOLOGY ITS BIO, P57; Travers AA, 1991, CURR OPIN STRUC BIOL, V1, P114, DOI 10.1016/0959-440X(91)90019-P; WANG JC, 1977, NUCLEIC ACIDS RES, V4, P1225, DOI 10.1093/nar/4.5.1225; WATTON SP, 1990, J AM CHEM SOC, V112, P2824, DOI 10.1021/ja00163a067; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZINKEL SS, 1991, J MOL BIOL, V219, P201, DOI 10.1016/0022-2836(91)90562-K	30	157	160	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 2	1992	355	6355					87	89		10.1038/355087a0	http://dx.doi.org/10.1038/355087a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY228	1731201				2022-12-01	WOS:A1992GY22800058
J	EISEMAN, E; BOLEN, JB				EISEMAN, E; BOLEN, JB			ENGAGEMENT OF THE HIGH-AFFINITY IGE RECEPTOR ACTIVATES SRC PROTEIN-RELATED TYROSINE KINASES	NATURE			English	Article							IMMUNOGLOBULIN-E; MONOCLONAL-ANTIBODIES; HISTAMINE-RELEASE; MAST-CELLS; CD4; PHOSPHORYLATION; ASSOCIATION; ANTIGENS; BINDING; SUBUNIT	THE high-affinity IgE receptor (Fc-epsilon RI), which is expressed on the surface of mast cells and basophils, has a central role in immediate allergic responses. In the rat basophilic leukaemia cell line RBL-2H3, which is a model system for the analysis of Fc-epsilon-RI-mediated signal transduction, surface engagement of Fc-epsilon-RI induces histamine release and the tyrosine phosphorylation of several distinct proteins 1. Although the alpha, beta and gamma-subunits of Fc-epsilon-RI lack intrinsic tyrosine protein kinase (TPK) activity, a kinase that copurifies with Fc-epsilon-RI phosphorylates the beta and gamma-subunits of the receptor on tyrosine residues 2,3. We report here that in RBL-2H3 cells, p56lyn and pp60c-src are activated after Fc-epsilon-RI crosslinking, and p56lyn coimmunoprecipitates with Fc-epsilon-RI. In the mouse mast-cell line PT-18, another cell type used to study FC-epsilon-RI-mediated signalling, tyrosine phosphorylation of proteins is also an immediate consequence of receptor crosslinking. Notably, the only detectable src protein-related TPK in PT-18 cells is p62c-yes, and it is this TPK that is activated on Fc-epsilon-RI engagement and coimmunoprecipitates with the receptor. Therefore, it seems that different src protein-related TPKs can associate with the same receptor and become activated after receptor engagement.			EISEMAN, E (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, PRINCETON, NJ 08543 USA.							BANIYASH M, 1987, J IMMUNOL, V138, P2999; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; HEMPSTEAD BL, 1981, BIOCHEM BIOPH RES CO, V98, P815, DOI 10.1016/0006-291X(81)91184-0; HOLOWKA D, 1980, J RECEPTOR RES, V1, P41, DOI 10.3109/10799898009039254; HOLOWKA D, 1982, MOL IMMUNOL, V19, P219, DOI 10.1016/0161-5890(82)90334-0; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUI FT, 1980, J IMMUNOL, V124, P2728; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; PLUZNIK DH, 1982, EXP HEMATOL, V10, P211; QUARTO R, 1986, MOL IMMUNOL, V23, P1215, DOI 10.1016/0161-5890(86)90154-9; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHIMIZU A, 1988, P NATL ACAD SCI USA, V85, P1907, DOI 10.1073/pnas.85.6.1907; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391	22	491	505	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 2	1992	355	6355					78	80						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY228	1370575				2022-12-01	WOS:A1992GY22800055
J	FEINMESSER, R; MIYAZAKI, I; CHEUNG, R; FREEMAN, JL; NOYEK, AM; DOSCH, HM				FEINMESSER, R; MIYAZAKI, I; CHEUNG, R; FREEMAN, JL; NOYEK, AM; DOSCH, HM			DIAGNOSIS OF NASOPHARYNGEAL CARCINOMA BY DNA AMPLIFICATION OF TISSUE OBTAINED BY FINE-NEEDLE ASPIRATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; BURKITTS-LYMPHOMA; CELLS; ANTIBODIES; EXPRESSION; SEROLOGY; GENOMES; NODES	Background. In nasopharyngeal carcinoma the primary lesion is often difficult to find. Metastatic lesions occur frequently but are difficult to distinguish from other head and neck tumors. The viral genome of the Epstein-Barr virus (EBV) can be identified in the cells of this carcinoma. Methods. We used the polymerase chain reaction (PCR) to test for the presence of EBV genomes in 15 samples of metastatic squamous-cell carcinoma of the neck obtained by fine-needle aspiration and in 26 samples obtained by biopsy of lymph nodes. For controls we used disease-free lymph nodes from 10 patients with various head and neck tumors, tonsillar tissue from 46 subjects, blood from 59 EBV-seropositive blood donors, and mononuclear cells from 8 patients with fatal lymphoproliferative lesions. Results. Of the 41 malignant lesions examined, only the nine nasopharyngeal carcinomas (one primary lesion and eight metastases) contained EBV genomes. None of the 20 nodes with other types of cancer, the 10 disease-free nodes, or any of the 105 normal control samples contained detectable EBV. In two patients with suspected metastases from occult primary tumors, the presence of EBV was predictive of nasopharyngeal carcinoma; in both cases overt nasopharyngeal carcinoma developed within one year. Conclusions. In patients with suspected nasopharyngeal carcinoma, fine-needle aspiration can provide tissue for diagnosis by DNA amplification of EBV genomes. The presence of EBV in metastases from an occult primary tumor is predictive of the development of overt nasopharyngeal carcinoma.	HOSP SICK CHILDREN,RES INST,DIV IMMUNOL & CANC,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA; MT SINAI HOSP,DEPT OTOLARYNGOL,TORONTO M5G 1X5,ONTARIO,CANADA; BEILINSON MED CTR,TEL AVIV,ISRAEL	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Rabin Medical Center								AMMATUNA P, 1988, MICROBIOLOGICA, V11, P89; ARRAND JR, 1989, J VIROL, V63, P983, DOI 10.1128/JVI.63.2.983-986.1989; Atichartakarn V, 1985, Southeast Asian J Trop Med Public Health, V16, P619; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; CAI WM, 1983, INT J RADIAT ONCOL, V9, P1763, DOI 10.1016/0360-3016(83)90341-3; CHAN MKM, 1989, ACTA CYTOL, V33, P344; DOSCH HM, 1990, INT IMMUNOL, V2, P833, DOI 10.1093/intimm/2.9.833; DOSCH HM, 1991, INT IMMUNOL, V3, P731, DOI 10.1093/intimm/3.7.731; FEDDER M, 1985, AM J MED, V79, P365, DOI 10.1016/0002-9343(85)90315-8; FRABLE MS, 1982, LARYNGOSCOPE, V92, P1414; GRATAMA JW, 1988, P NATL ACAD SCI USA, V85, P8693, DOI 10.1073/pnas.85.22.8693; HENLE W, 1973, JNCI-J NATL CANCER I, V51, P361; HERBST H, 1990, AM J PATHOL, V137, P13; HO JHC, 1978, INT J RADIAT ONCOL, V4, P182; JESSE RH, 1973, CANCER, V31, P854, DOI 10.1002/1097-0142(197304)31:4<854::AID-CNCR2820310414>3.0.CO;2-D; KLINE TS, 1980, ARCH PATHOL LAB MED, V104, P117; Levine P H, 1981, Cancer Detect Prev, V4, P307; LINZ U, 1990, BIOTECHNIQUES, V9, P286; MACCOMB WS, 1972, AM J SURG, V124, P441, DOI 10.1016/0002-9610(72)90064-5; NEEL HB, 1983, OTOLARYNG HEAD NECK, V91, P255, DOI 10.1177/019459988309100310; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; PEARSON GR, 1983, CANCER, V51, P260, DOI 10.1002/1097-0142(19830115)51:2<260::AID-CNCR2820510216>3.0.CO;2-#; PEIPER SC, 1990, ARCH PATHOL LAB MED, V114, P711; ROBINSON D W, 1959, Plast Reconstr Surg Transplant Bull, V23, P27, DOI 10.1097/00006534-195901000-00004; ROWE DT, 1986, EMBO J, V5, P2599, DOI 10.1002/j.1460-2075.1986.tb04540.x; ROWE M, 1985, INT J CANCER, V35, P435, DOI 10.1002/ijc.2910350404; SMITH PE, 1967, AM J SURG, V113, P633, DOI 10.1016/0002-9610(67)90309-1; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WOLF H, 1973, NATURE-NEW BIOL, V244, P245, DOI 10.1038/newbio244245a0; YAO QY, 1985, INT J CANCER, V35, P35, DOI 10.1002/ijc.2910350107; ZIMBERSTROBL U, 1991, J VIROL, V65, P415, DOI 10.1128/JVI.65.1.415-423.1991	32	128	129	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 2	1992	326	1					17	21		10.1056/NEJM199201023260103	http://dx.doi.org/10.1056/NEJM199201023260103			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX315	1309196				2022-12-01	WOS:A1992GX31500003
J	MANABE, T; RENNER, P; NICOLL, RA				MANABE, T; RENNER, P; NICOLL, RA			POSTSYNAPTIC CONTRIBUTION TO LONG-TERM POTENTIATION REVEALED BY THE ANALYSIS OF MINIATURE SYNAPTIC CURRENTS	NATURE			English	Article							FROG NEUROMUSCULAR JUNCTION; HIPPOCAMPAL SLICES; RAT HIPPOCAMPUS; PERFORANT PATH; NEURONS; TRANSMISSION; INDUCTION; RELEASE; TRANSMITTER	Miniature excitatory synaptic currents were recorded from CA1 pyramidal cells in hippocampal slices to study the site of the persistent change in synaptic efficacy during long-term potentiation. Induction of long-term potentiation produced a large increase in the amplitude of these currents. Such a change in amplitude suggests an increase in postsynaptic transmitter sensitivity.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								ASZTELY F, 1991, BRAIN RES, V558, P153, DOI 10.1016/0006-8993(91)90734-D; BARRETT EF, 1972, J PHYSIOL-LONDON, V227, P691, DOI 10.1113/jphysiol.1972.sp010054; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS T V P, 1988, P3; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; COLEMAN PA, 1989, J NEUROPHYSIOL, V61, P218, DOI 10.1152/jn.1989.61.1.218; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; DOLPHIN AC, 1982, NATURE, V297, P496, DOI 10.1038/297496a0; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; ELMQVIST D, 1965, J PHYSIOL-LONDON, V177, P463, DOI 10.1113/jphysiol.1965.sp007605; FATT P, 1952, J PHYSIOL-LONDON, V117, P109; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; Katz B., 1966, NERVE MUSCLE SYNAPSE; KAUER JA, 1988, NATURE, V334, P250, DOI 10.1038/334250a0; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; RAHAMIMOFF R, 1973, J PHYSIOL-LONDON, V228, P241, DOI 10.1113/jphysiol.1973.sp010084; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; SASTRY BR, 1986, SCIENCE, V232, P988, DOI 10.1126/science.3010459; THIBAULT O, 1989, BRAIN RES, V476, P170, DOI 10.1016/0006-8993(89)91553-9; VANDERKLOOT W, 1991, PROG NEUROBIOL, V36, P93, DOI 10.1016/0301-0082(91)90019-W; VORONIN LL, 1990, NEUROPHYSIOLOGY+, V22, P341; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x	34	301	303	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 2	1992	355	6355					50	55		10.1038/355050a0	http://dx.doi.org/10.1038/355050a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY228	1346229				2022-12-01	WOS:A1992GY22800045
J	MURRAY, RH; RUBEL, AJ				MURRAY, RH; RUBEL, AJ			PHYSICIANS AND HEALERS - UNWITTING PARTNERS IN HEALTH-CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MEDICINE; CANCER; PRACTITIONERS; SURVIVAL; TRIAL		UNIV CALIF IRVINE,IRVINE,CA 92717	University of California System; University of California Irvine	MURRAY, RH (corresponding author), MICHIGAN STATE UNIV,E LANSING,MI 48824, USA.							CASSILETH BR, 1991, NEW ENGL J MED, V324, P1180, DOI 10.1056/NEJM199104253241706; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; CHLEBOWSKI RT, 1990, J CLIN ONCOL, V8, P9, DOI 10.1200/JCO.1990.8.1.9; COOK C, 1986, SOUTH MED J, V79, P1098, DOI 10.1097/00007611-198609000-00014; FISHER P, 1989, BRIT MED J, V299, P365, DOI 10.1136/bmj.299.6695.365; FULDER SJ, 1985, LANCET, V2, P542; GIBSON RG, 1980, BRIT J CLIN PHARMACO, V9, P453, DOI 10.1111/j.1365-2125.1980.tb05840.x; MADDOCKS I, 1985, MED J AUSTRALIA, V142, P547, DOI 10.5694/j.1326-5377.1985.tb113490.x; McGuire Meredith, 1988, RITUAL HEALING SUBUR; SHEKELLE PG, 1991, RAND R40252CCRFLER; SHIPLEY M, 1983, LANCET, V1, P97; SPIEGEL D, 1989, LANCET, V2, P888; WATT J, 1988, TALKING HLTH CONVENT; 1981, ALTERNATIVE MED NETH; 1986, ALTERNATIVE THERAPY; 1987, N Z MED J, V100, P110; 1986, AM MED NEWS     0411, P46; 1990, OTAH405 OFF TECHN AS; 1987, ENCY MED ORG AGENCIE, P93	19	104	105	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 2	1992	326	1					61	64		10.1056/NEJM199201023260113	http://dx.doi.org/10.1056/NEJM199201023260113			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GX315	1727068				2022-12-01	WOS:A1992GX31500013
J	SOLLNER, T; RASSOW, J; WIEDMANN, M; SCHLOSSMANN, J; KEIL, P; NEUPERT, W; PFANNER, N				SOLLNER, T; RASSOW, J; WIEDMANN, M; SCHLOSSMANN, J; KEIL, P; NEUPERT, W; PFANNER, N			MAPPING OF THE PROTEIN IMPORT MACHINERY IN THE MITOCHONDRIAL OUTER-MEMBRANE BY CROSS-LINKING OF TRANSLOCATION INTERMEDIATES	NATURE			English	Article							PRECURSOR PROTEINS; RECEPTOR; IDENTIFICATION; RECOGNITION; INSERTION; CARRIER; SITE	MITOCHONDRIA Contain a complex machinery for the import of nuclear-encoded proteins 1,2. Receptor proteins exposed on the outer membrane surface are required for the specific binding of precursor proteins to mitochondria, either by binding of cytosolic signal recognition factors or by direct recognition of the precursor polypeptides 1-5. Subsequently, the precursors are inserted into the outer membrane at the general insertion site GIP (general insertion protein) 6-10. Here we report the analysis of receptors and GIP by crosslinking of translocation intermediates and by coimmunoprecipitation. Surface-accumulated precursors were crosslinked to the receptors MOM19 and MOM72, suggesting a direct interaction of preproteins with surface receptors. We identified three novel mitochondrial outer membrane proteins, MOM7, MOM8, and MOM30 that, together with the previously identified MOM38, seem to form the GIP site and are present in the mitochondrial receptor com lex.	UNIV MUNICH, INST PHYSIOL CHEM, GOETHESTR 33, W-8000 MUNICH 2, GERMANY; AKAD WISSENSCH DDR, ZENT INST MOLEK BIOL, O-1115 BERLIN, GERMANY	University of Munich			Schlossmann, Jens/I-7743-2016; Pfanner, Nikolaus/AAV-7878-2021	Schlossmann, Jens/0000-0002-2550-6839; 				BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BECKER K, IN PRESS J BIOL CHEM, V267; FONT B, 1991, FEBS LETT, V279, P105, DOI 10.1016/0014-5793(91)80262-2; GILLESPIE LL, 1987, J BIOL CHEM, V262, P7939; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; MARTIN J, 1991, J BIOL CHEM, V266, P18051; ONO H, 1990, J BIOCHEM-TOKYO, V107, P840, DOI 10.1093/oxfordjournals.jbchem.a123135; OSTERMANN J, 1990, FEBS LETT, V277, P281, DOI 10.1016/0014-5793(90)80865-G; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFALLER R, 1989, J BIOL CHEM, V264, P34; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1987, J BIOL CHEM, V262, P7528; PFANNER N, 1991, TRENDS BIOCHEM SCI, V16, P63, DOI 10.1016/0968-0004(91)90026-R; RASSOW J, IN PRESS FEBS LETT; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SOLLNER T, 1988, FEBS LETT, V229, P25, DOI 10.1016/0014-5793(88)80790-7; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0	24	153	156	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 2	1992	355	6355					84	87		10.1038/355084a0	http://dx.doi.org/10.1038/355084a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY228	1530986	Green Published			2022-12-01	WOS:A1992GY22800057
J	KAMB, ML; MURPHY, JJ; JONES, JL; CASTON, JC; NEDERLOF, K; HORNEY, LF; SWYGERT, LA; FALK, H; KILBOURNE, EM				KAMB, ML; MURPHY, JJ; JONES, JL; CASTON, JC; NEDERLOF, K; HORNEY, LF; SWYGERT, LA; FALK, H; KILBOURNE, EM			EOSINOPHILIA-MYALGIA-SYNDROME IN L-TRYPTOPHAN-EXPOSED PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INGESTION	Objectives. - To study the incidence of eosinophilia-myalgia syndrome, the risk factors associated with the syndrome, and the clinical spectrum of illness associated with L-tryptophan use in an exposed population. Design. - Retrospective cohort and nested case-control studies of risk factors for eosinophilia-myalgia syndrome using inpatient and outpatient chart reviews, telephone interviews, and in-person patient interviews. Descriptive study of clinical course of L-tryptophan users. Setting. - Office practice of one psychiatrist based in a small city (population 43 467) in South Carolina. Patients. - Eligible subjects were all patients from the practice who used L-tryptophan during the 1989 study interval. Of these, 418 (87%) were interviewed. Main Outcome Measures. - Clinical spectrum of illness associated with L-tryptophan use, including definite and possible cases of eosinophilia-myalgia syndrome. Results. - Among the 418 interviewed L-tryptophan users, we identified 47 definite cases (11%) and 68 possible cases (16%) of eosinophilia-myalgia syndrome, most of which involved patients who were using one retail brand of L-tryptophan (brand A). Among the 157 brand A users, we identified 45 definite cases (29%) and 36 possible cases (23%) of eosinophilia-myalgia syndrome, and the risk for the syndrome increased as the brand A dose increased. Fifty percent (19 of 38) of those using more than 4000 mg/day developed definite eosinophilia-myalgia syndrome, and 84% (32 of 38) developed either definite or possible eosinophilia-myalgia syndrome. On multivariate analysis, risk for definite eosinophilia-myalgia syndrome was associated with brand A dose and age of the patient; however, gender, race, and use of other medications were not associated with the syndrome. Conclusions. - These results suggest that many people exposed to the agent causing eosinophilia-myalgia syndrome may develop illness, and dose of presumably contaminated L-tryptophan is the single most important predictor of eosinophilia-myalgia syndrome. The broad range of signs and symptoms reported by patients using L-tryptophan illustrates that a strict case definition may identify only about half of those affected.	S CAROLINA DEPT HLTH & ENVIRONM CONTROL, DIV DIS CONTROL & EPIDEMIOL, COLUMBIA, SC USA		KAMB, ML (corresponding author), CTR DIS CONTROL, 1600 CLIFTON RD NE, MAIL STOP E-02, ATLANTA, GA 30333 USA.							BELONGIA EA, 1990, NEW ENGL J MED, V323, P357, DOI 10.1056/NEJM199008093230601; BRESLOW NE, 1980, INT AGENCY RES CANCE, V32; EIDSON M, 1990, LANCET, V335, P645, DOI 10.1016/0140-6736(90)90421-Z; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; KAUFMAN LD, 1991, LANCET, V337, P1071, DOI 10.1016/0140-6736(91)91717-9; KILBOURNE EM, 1983, NEW ENGL J MED, V309, P1408, DOI 10.1056/NEJM198312083092302; MAYENO AN, 1990, SCIENCE, V250, P1707, DOI 10.1126/science.2270484; MIETTINEN OS, 1972, AM J EPIDEMIOL, V96, P168, DOI 10.1093/oxfordjournals.aje.a121443; NORIEGA AR, 1982, LANCET, V2, P697; POOLE L, 1977, SOME COMMON BASIC PR; Rosner B, 1982, FUNDAMENTALS BIOSTAT; SERRANORIOS M, 1984, TOXIC OIL SYNDROME M, P53; SILVER RM, 1990, NEW ENGL J MED, V322, P874, DOI 10.1056/NEJM199003293221302; SLUTSKER L, 1990, JAMA-J AM MED ASSOC, V264, P213, DOI 10.1001/jama.264.2.213; SWYGERT LA, 1990, JAMA-J AM MED ASSOC, V264, P1698, DOI 10.1001/jama.264.13.1698; 1990, PHYSICIANS DESK REFE; 1989, MMWR, V38, P785; 1990, MMWR, V39, P589	19	100	101	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1992	267	1					77	82		10.1001/jama.267.1.77	http://dx.doi.org/10.1001/jama.267.1.77			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW848	1727200				2022-12-01	WOS:A1992GW84800027
J	NISHIGUCHI, S; KUROKI, T; UEDA, T; FUKUDA, K; TAKEDA, T; NAKAJIMA, S; SHIOMI, S; KOBAYASHI, K; OTANI, S; HAYASHI, N; SHIKATA, T				NISHIGUCHI, S; KUROKI, T; UEDA, T; FUKUDA, K; TAKEDA, T; NAKAJIMA, S; SHIOMI, S; KOBAYASHI, K; OTANI, S; HAYASHI, N; SHIKATA, T			DETECTION OF HEPATITIS-C VIRUS-ANTIBODY IN THE ABSENCE OF VIRAL-RNA IN PATIENTS WITH AUTOIMMUNE HEPATITIS	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS-C VIRUS; AUTOIMMUNE DISEASES; RNA, VIRAL; FALSE POSITIVE REACTIONS; RECOMBINANT IMMUNOBLOT ASSAY	NON-A; GENOME; PROTEIN; ASSAY	Objective: To determine whether laboratory findings showing antibodies to hepatitis C virus (HCV) in patients with autoimmune hepatitis represent false-positive results and to identify possible explanations for true-positive results in these patients. Design: Cross-sectional. Setting. University-based hospital. Patients: Fifty-two patients with non-A, non-B chronic hepatitis as a control group and 26 patients with classic chronic active autoimmune hepatitis. Measurements: Comparison of the results of five kinds of assays of HCV antibodies and HCV RNA. Main Results: Of 52 patients with non-A, non-B chronic hepatitis, HCV antibodies (anti-HCV) were detected in 42 patients (81%; 95% Cl, 67% to 90%) by a first-generation enzyme-linked immunosorbent assay (ELISA-I), in 39 patients (75%) by Sp42 ELISA, in 37 patients (71 %) by RIA-I, in 49 patients (94%) by ELISA-II, and in 48 patients (92%) by RIBA-II. We found HCV RNA in 47 patients (90%; Cl, 79% to 97%). Of the 26 patients with autoimmune hepatitis, anti-HCV were detected in 23 patients (88%; Cl, 70% to 98%) by ELISA-I, in 12 (46%) by both RIA-I and Sp42 ELISA, in 20 (77%) by ELISA-II, and in 9 (35%) by RIBA-II. However, HCV RNA was found in only five of these patients (19%; Cl, 7% to 39%). None of our patients, including controls, had antibodies to superoxide dismutase. Of the 21 patients who had autoimmune hepatitis that was completely responsive to steroid therapy, 18 had anti-HCV by ELISA-I, but 13 of these patients had negative results by RIBA-II, and only two patients had HCV RNA. Of the five patients who did not respond to steroid treatment, all had anti-HCV by ELISA-I, four had negative results by RIBA-II, and three had HCV RNA. Conclusions: Testing for HCV antibodies in patients with autoimmune hepatitis frequently elicits positive results when the ELISA-I or ELISA-II tests are used. Most of these appear to represent false-positive results because HCV RNA is usually absent from the serum. Such false positivity may result from previous infection with HCV or from cross-reaction of an epitope of HCV. Other patients with apparent autoimmune hepatitis who fail to respond to corticosteroid therapy may actually have chronic hepatitis C (or other non-A, non-B hepatitis) infection.	NIHON UNIV, SCH MED, TOKYO 101, JAPAN	Nihon University	NISHIGUCHI, S (corresponding author), OSAKA UNIV, SCH MED, DEPT INTERNAL MED 3, 1-5-7 ASAHI MACHI, ABENO KU, OSAKA 545, JAPAN.							BASSETTI D, 1991, LANCET, V337, P912; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; ESTEBAN JI, 1989, LANCET, V2, P294; FUSCONI M, 1990, LANCET, V336, P823, DOI 10.1016/0140-6736(90)93297-3; GARSON JA, 1990, LANCET, V336, P1022, DOI 10.1016/0140-6736(90)92487-3; IKEDA Y, 1990, LANCET, V335, P1345, DOI 10.1016/0140-6736(90)91228-3; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LENZI M, 1990, LANCET, V335, P258, DOI 10.1016/0140-6736(90)90070-L; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MISHIRO S, 1990, LANCET, V336, P1400, DOI 10.1016/0140-6736(90)93101-T; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; OKAMOTO H, 1990, JPN J EXP MED, V60, P223; QUERY CC, 1987, CELL, V51, P211, DOI 10.1016/0092-8674(87)90148-6; ROBERTSON DAF, 1987, LANCET, V2, P9; TAKAHASHI T, 1990, ACTA HEPATOL JPN, V31, P1380; VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I; VENTO S, 1991, LANCET, V337, P1183, DOI 10.1016/0140-6736(91)92858-Y; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q	19	94	110	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1992	116	1					21	25		10.7326/0003-4819-116-1-21	http://dx.doi.org/10.7326/0003-4819-116-1-21			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX157	1309200				2022-12-01	WOS:A1992GX15700004
J	RUTTIMANN, S; CLEMENCON, D; DUBACH, UC				RUTTIMANN, S; CLEMENCON, D; DUBACH, UC			USEFULNESS OF COMPLETE BLOOD COUNTS AS A CASE-FINDING TOOL IN MEDICAL OUTPATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article						BLOOD CELL COUNT; AMBULATORY CARE; DIAGNOSTIC TESTS, ROUTINE; COST-BENEFIT ANALYSIS; PATIENT CARE MANAGEMENT		Objective: To determine the usefulness of routine complete blood counts as a case-finding tool in medical outpatients. Design: Prospective evaluation in a consecutive, unselected cohort. Setting: A university-based outpatient clinic providing primary and referral care in general internal medicine. Patients: A total of 595 patients (mean age [+/- SD], 40 +/- 15 years) making their initial clinic visit. Intervention: A complete blood count was done in all patients. Components of the complete blood count that were not indicated for diagnostic or management purposes at the initial visit were classified as routine tests. Main Outcome Measures: The number and nature of new diagnoses leading to new patient management; the number of additional visits and diagnostic tests precipitated by positive results. Main Results: Of the 2378 tests done, 1540 (65%) were routine tests. The percentages of abnormal test results for the four hematologic test components were as follows: leukocyte count, 7.6%; hemoglobin, 5.8%; mean corpuscular volume (MCV) of red blood cells, 7.9%; and platelet count, 4.5%. In only three patients (0.5%) was a new diagnosis made that led to a new management strategy (treatment of iron deficiency). Further work-up was unprofitable in 14 patients (2.4%). Two additional visits were necessary because of abnormal results on routine tests. No abnormality-associated clinical disease developed during a 15-month follow-up period in patients with unexplained abnormal results on routine hematologic tests. Conclusions: The routine complete blood count has limited usefulness as a case-finding tool and has a minimal effect on care in middle-aged medical outpatients.			RUTTIMANN, S (corresponding author), KANTONSSPITAL,DEPT INTERNAL MED,CH-4031 BASEL,SWITZERLAND.							DELAHUNT B, 1980, NEW ZEAL MED J, V92, P431; FRYE EB, 1987, J GEN INTERN MED, V2, P373, DOI 10.1007/BF02596360; KAPLAN EB, 1985, JAMA-J AM MED ASSOC, V253, P3576, DOI 10.1001/jama.253.24.3576; PANZER RJ, 1987, J GEN INTERN MED, V2, P365, DOI 10.1007/BF02596179; RICH EC, 1983, JAMA-J AM MED ASSOC, V249, P633; SACKETT DL, 1975, LANCET, V2, P357; SCHNEIDERMAN LJ, 1972, ARCH INTERN MED, V129, P88, DOI 10.1001/archinte.129.1.88; SHAPIRO MF, 1987, ANN INTERN MED, V106, P65, DOI 10.7326/0003-4819-106-1-65	8	20	20	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	JAN 1	1992	116	1					44	50						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX157	1727094				2022-12-01	WOS:A1992GX15700007
J	SEHGAL, A; GALBRAITH, A; CHESNEY, M; SCHOENFELD, P; CHARLES, G; LO, B				SEHGAL, A; GALBRAITH, A; CHESNEY, M; SCHOENFELD, P; CHARLES, G; LO, B			HOW STRICTLY DO DIALYSIS PATIENTS WANT THEIR ADVANCE DIRECTIVES FOLLOWED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHOOSING DEATH; RESUSCITATION; WITHDRAWAL; CARE	Objective. - The Cruzan case and the Patient Self-Determination Act will encourage patients to specify in advance which life-sustaining treatments they would want if they become mentally incompetent. However, strictly following such advance directives may not always be in a patient's best interests. We sought to determine whether patients diff er in how strictly they want advance directives followed. Design. - Interview study. Setting. - Seven outpatient chronic dialysis centers. Participants. - One hundred fifty mentally competent dialysis patients. Intervention. - Using a structured questionnaire, we asked the subjects whether they would want dialysis continued or stopped if they developed advanced Alzheimer's disease. We then asked how much leeway their physician and surrogate should have to override that advance directive if overriding were in their best interests, Subjects granting leeway were also asked what factors should be considered in making decisions for them. Results. - Subjects varied greatly in how much leeway they would give surrogates to override their advance directives: "no leeway" (39%), "a little leeway" (19%), "a lot of leeway" (11%), and "complete leeway" (31%). Subjects also varied in how much they wanted various factors considered in making decisions, such as pain or suffering, quality of life, possibility of a new treatment, indignity caused by continued treatment, financial impact of treatment on family members, and religious beliefs. Conclusions. - Strictly following all advance directives may not truly reflect patients' preferences. To improve advance directives, we recommend that physicians explicitly ask patients how strictly they want their advance directives followed and what factors they want considered in making decisions.	DEPT VET AFFAIRS,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV NEPHROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV NEPHROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM MED ETH,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	SEHGAL, A (corresponding author), UNIV CALIF SAN FRANCISCO,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,BOX 0903,SAN FRANCISCO,CA 94143, USA.							ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BOPP J, 1990, HASTINGS CENT REP, V20, P42, DOI 10.2307/3562976; BUCHANAN AE, 1991, ANN INTERN MED, V114, P895; Dresser R S, 1989, Law Med Health Care, V17, P234; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; FULLER, 1941, COL L REV, V41, P799; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; LO B, 1991, JAMA-J AM MED ASSOC, V265, P1874, DOI 10.1001/jama.265.14.1874; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; PORT FK, 1989, AM J NEPHROL, V9, P145, DOI 10.1159/000167954; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; Rhoden N, 1989, Law Med Health Care, V17, P264; ROBERTS JC, 1988, ACTA MED SCAND, V223, P181; SCHNEIDERMAN LJ, 1985, ANN INTERN MED, V102, P693, DOI 10.7326/0003-4819-102-5-693; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; SILVERSTEIN MD, 1991, MAYO CLIN PROC, V66, P906, DOI 10.1016/S0025-6196(12)61577-8; STEINBROOK R, 1984, NEW ENGL J MED, V310, P1598, DOI 10.1056/NEJM198406143102411; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; YOUNGER SJ, 1988, JAMA-J AM MED ASSOC, V260, P2094, DOI 10.1001/jama.260.14.2094; 1989, USRDS1989 NAT I HLTH	23	239	239	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1992	267	1					59	63		10.1001/jama.267.1.59	http://dx.doi.org/10.1001/jama.267.1.59			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW848	1489360				2022-12-01	WOS:A1992GW84800024
J	SENIE, RT; ROSEN, PP; RHODES, P; LESSER, ML; KINNE, DW				SENIE, RT; ROSEN, PP; RHODES, P; LESSER, ML; KINNE, DW			OBESITY AT DIAGNOSIS OF BREAST-CARCINOMA INFLUENCES DURATION OF DISEASE-FREE SURVIVAL	ANNALS OF INTERNAL MEDICINE			English	Article						OBESITY; BREAST NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; BODY MASS INDEX; WOMENS HEALTH	POST-MENOPAUSAL WOMEN; BODY-WEIGHT; ESTROGEN-RECEPTORS; CANCER SURVIVAL; MENSTRUAL STATUS; BOUND ESTRADIOL; RISK-FACTORS; DIETARY-FAT; EPIDEMIOLOGY; ASSOCIATION	Objective: To study disease-free survival at 10 years in relation to obesity at the time of diagnosis. Design: A prospective study of consecutively treated patients with primary breast cancer. Setting: Memorial Sloan-Kettering Cancer Center, New York. Patients: Nine hundred twenty-three women treated by mastectomy and axillary dissection. Main Results: Women who were obese (25% or more over optimal weight for height) at the time of primary breast cancer treatment were at significantly greater risk for recurrence (42%) compared with nonobese patients (32%) 10 years after diagnosis (P < 0.01). In multivariate analyses, obesiTy remained a statistically significant prognostic factor after controLling for measured tumor size, number of positive axillary lymph nodes, age at diagnosis, and adjuvant chemotherapy with a hazard ratio of 1.29 (95% Cl, 1.0 to 1.67). When analyses were restricted to the 557 patients free of lymph node metastases, the hazard ratio of recurrence associated with obesity was 1.59 (CL, 1.06 to 2.39); 32% of obese patients developed recurrent disease compared with 19% of nonobese women. Conclusions: Obesity at the time of diagnosis is a significant prognostic factor that may Limit the reduction in breast cancer mortality attainable through detection at an early stage of disease. Because obesity and the risk for breast cancer increase with age, interventions that encourage weight controL may influence breast cancer survival rates.	MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA; CORNELL UNIV, N SHORE UNIV HOSP, COLL MED, MANHASSET, NY 11030 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Northwell Health; North Shore University Hospital	SENIE, RT (corresponding author), CTR DIS CONTROL, DIV REPROD HLTH, WOMENS HLTH & FERTIL BRANCH, 1600 CLIFTON RD, ATLANTA, GA 30333 USA.							ABE R, 1976, TOHOKU J EXP MED, V120, P351, DOI 10.1620/tjem.120.351; BAIN RP, 1986, J CHRON DIS, V39, P631, DOI 10.1016/0021-9681(86)90188-8; BALLARDBARBASH R, 1990, J NATL CANCER I, V82, P286, DOI 10.1093/jnci/82.4.286; Beatson GT, 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; BOYD NF, 1981, JNCI-J NATL CANCER I, V67, P785; CHANDRA RK, 1981, CANCER RES, V41, P3795; COX DR, 1972, J R STAT SOC B, V34, P187; de Waard F, 1981, Nutr Cancer, V2, P237; DONEGAN WL, 1978, CANCER, V41, P1590, DOI 10.1002/1097-0142(197804)41:4<1590::AID-CNCR2820410449>3.0.CO;2-N; EBERLEIN T, 1985, BREAST CANCER RES TR, V5, P81, DOI 10.1007/BF01807654; GOODWIN PJ, 1988, BREAST CANCER RES TR, V11, P59, DOI 10.1007/BF01807559; GRAY DS, 1991, J CLIN EPIDEMIOL, V44, P545, DOI 10.1016/0895-4356(91)90218-X; GREENBERG ER, 1985, BRIT J CANCER, V51, P691, DOI 10.1038/bjc.1985.104; GREGORIO DI, 1985, JNCI-J NATL CANCER I, V75, P37; GRODIN JM, 1973, J CLIN ENDOCR METAB, V36, P207, DOI 10.1210/jcem-36-2-207; HEASMAN KZ, 1985, BREAST CANCER RES TR, V5, P195, DOI 10.1007/BF01805994; HEMSELL DL, 1974, J CLIN ENDOCR METAB, V38, P476, DOI 10.1210/jcem-38-3-476; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KIRSCHNER MA, 1982, CANCER RES, V42, P3281; LEES AW, 1989, BREAST CANCER RES TR, V13, P143, DOI 10.1007/BF01806526; LESSER ML, 1982, SURGERY, V91, P234; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MASON B, 1982, J SURG ONCOL, V19, P62, DOI 10.1002/jso.2930190116; MCNEE RK, 1987, BREAST CANCER RES TR, V9, P145, DOI 10.1007/BF01807367; MOHLEBOETANI JC, 1988, PREV MED, V17, P634, DOI 10.1016/0091-7435(88)90056-4; NATARAJAN N, 1985, CANCER-AM CANCER SOC, V56, P1704, DOI 10.1002/1097-0142(19851001)56:7<1704::AID-CNCR2820560740>3.0.CO;2-L; NEWBERNE PM, 1983, CANCER RES, V43, P2426; NEWMAN SC, 1986, AM J EPIDEMIOL, V123, P767, DOI 10.1093/oxfordjournals.aje.a114305; NOMURA Y, 1981, GANN, V72, P468; OTA DM, 1986, CANCER, V57, P558, DOI 10.1002/1097-0142(19860201)57:3<558::AID-CNCR2820570326>3.0.CO;2-1; REED MJ, 1983, CANCER RES, V43, P3940; ROSE DP, 1986, DIET NUTRITION CANCE, P151; ROSEN PP, 1982, CANCER, V50, P171, DOI 10.1002/1097-0142(19820701)50:1<171::AID-CNCR2820500132>3.0.CO;2-M; ROSEN PP, 1979, SURGERY, V85, P219; Rowland M L, 1989, Stat Bull Metrop Insur Co, V70, P2; SCHAPIRA DV, 1990, ANN INTERN MED, V112, P182, DOI 10.7326/0003-4819-112-3-182; SENIE RT, 1981, AM J PUBLIC HEALTH, V71, P583, DOI 10.2105/AJPH.71.6.583; SENIE RT, 1980, CANCER, V46, P1705, DOI 10.1002/1097-0142(19801001)46:7<1705::AID-CNCR2820460734>3.0.CO;2-Q; SENIE RT, 1985, BREAST CANCER RES TR, V5, P301, DOI 10.1007/BF01806025; SHERMAN BM, 1974, CANCER, V33, P1306, DOI 10.1002/1097-0142(197405)33:5<1306::AID-CNCR2820330515>3.0.CO;2-#; SOHRABI A, 1980, JAMA-J AM MED ASSOC, V244, P264, DOI 10.1001/jama.244.3.264; TARTTER PI, 1981, CANCER, V47, P2222, DOI 10.1002/1097-0142(19810501)47:9<2222::AID-CNCR2820470919>3.0.CO;2-5; TRETLI S, 1989, INT J CANCER, V44, P23, DOI 10.1002/ijc.2910440105; TRICHOPOULOS D, 1987, INT J CANCER, V40, P721, DOI 10.1002/ijc.2910400602; VERREAULT R, 1989, AM J EPIDEMIOL, V129, P260, DOI 10.1093/oxfordjournals.aje.a115131; WAARD FD, 1975, CANCER RES, V35, P3351; ZUMOFF B, 1983, J SURG ONCOL, V22, P217, DOI 10.1002/jso.2930220402; Zumoff B, 1988, Acta Med Scand Suppl, V723, P153; 1959, STAT B METROP INSUR, V40, P1	51	143	143	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1992	116	1					26	32		10.7326/0003-4819-116-1-26	http://dx.doi.org/10.7326/0003-4819-116-1-26			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX157	1727092				2022-12-01	WOS:A1992GX15700005
J	SMITH, GD; SHIPLEY, MJ; MARMOT, MG; ROSE, G				SMITH, GD; SHIPLEY, MJ; MARMOT, MG; ROSE, G			PLASMA-CHOLESTEROL CONCENTRATION AND MORTALITY - THE WHITEHALL STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; TOTAL SERUM-CHOLESTEROL; FOLLOW-UP; CANCER MORTALITY; RISK-FACTORS; DENSITY-LIPOPROTEIN; COLON CANCER; CARDIOVASCULAR-DISEASE; 7 COUNTRIES; DEATH	Objective. - To examine the relationship between plasma cholesterol concentration and mortality from major causes of death. Design. - Cohort study. Setting. - Civil service offices in London, England. Participants. - There were 17 718 male civil servants aged 40 through 64 years at the time of study entry between 1967 and 1969. Main Outcome Measure. - Mortality from major cause groups. Results. - There were 4022 deaths in the cohort over the 18 years of follow-up. Total mortality increased with cholesterol level, although mortality in the small group with very low cholesterol levels (5% of study population) was nonsignificantly higher (P > .5) than that of the remainder of the lowest quintile cholesterol group. Coronary heart disease mortality increased with increasing cholesterol concentration from the lowest levels (P < .001 for trend). The cancer mortality rate in the group below the fifth centile of the cholesterol distribution was higher than in the remainder of the cohort for lung (P < .001), pancreas (P = .05), liver (P = .09), and all smoking-related cancers (P = .02). Only for lung cancer was there a consistent inverse trend with cholesterol level (P < .01). Rates of mortality due to non-neoplastic respiratory disease were inversely related to cholesterol level (P < .001). Health state at the time of examination and socioeconomic position were related to cholesterol concentration-subjects in lower employment grades, with disease at baseline, with a history of recent unexplained weight loss, or who had been widowed had lower initial cholesterol levels. These associations largely accounted for the relationships between cholesterol level and noncardiovascular mortality. Conclusions. - The inverse associations between plasma cholesterol concentration and mortality from certain causes of death seen in cohort studies could be because the participants with low cholesterol levels possess other characteristics that place them at an elevated risk of death.			SMITH, GD (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		Davey Smith, George/A-7407-2013; Marmot, M G/Y-3920-2019	Davey Smith, George/0000-0002-1407-8314; Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ABRAMSON ZH, 1985, BRIT J CANCER, V52, P93, DOI 10.1038/bjc.1985.154; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; BASU TK, 1974, INT J VITAM NUTR RES, V44, P14; BOTTIGER LE, 1982, ACTA MED SCAND, V211, P437; BUDD D, 1986, CANCER, V58, P1361, DOI 10.1002/1097-0142(19860915)58:6<1361::AID-CNCR2820580630>3.0.CO;2-S; CAMBIEN F, 1980, AM J EPIDEMIOL, V112, P388, DOI 10.1093/oxfordjournals.aje.a113004; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; CLOEY T, 1990, JAMA-J AM MED ASSOC, V263, P2788, DOI 10.1001/jama.263.20.2788; COWAN LD, 1990, AM J EPIDEMIOL, V131, P468, DOI 10.1093/oxfordjournals.aje.a115521; COX DR, 1972, J R STAT SOC B, V34, P187; DAGENAIS GR, 1990, CAN J CARDIOL, V6, P59; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; DYER AR, 1981, J CHRON DIS, V34, P249, DOI 10.1016/0021-9681(81)90030-8; EBIKRYSTON KL, 1988, J CLIN EPIDEMIOL, V41, P251, DOI 10.1016/0895-4356(88)90129-1; FARCHI G, 1987, AM J EPIDEMIOL, V126, P400, DOI 10.1093/oxfordjournals.aje.a114671; FISER RH, 1972, J INFECT DIS, V125, P54, DOI 10.1093/infdis/125.1.54; FOX AJ, 1976, BRIT J PREV SOC MED, V30, P225; GARCIAPALMIERI MR, 1981, AM J EPIDEMIOL, V114, P29, DOI 10.1093/oxfordjournals.aje.a113171; GERHARDSSON M, 1986, INT J EPIDEMIOL, V15, P155, DOI 10.1093/ije/15.2.155; GOLDBOURT U, 1990, ARTERIOSCLEROSIS, V10, P512, DOI 10.1161/01.ATV.10.4.512; HAMMOND EC, 1966, EPIDEMIOLOGICAL APPR, P127; HIATT RA, 1986, J CHRON DIS, V39, P861, DOI 10.1016/0021-9681(86)90034-2; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; JOHANSEN H, 1987, CAN MED ASSOC J, V136, P823; JOHANSSON BW, 1973, EARLY PHASES CORONAR, P314; KAGAN A, 1981, AM J EPIDEMIOL, V114, P11, DOI 10.1093/oxfordjournals.aje.a113157; KARK JD, 1980, J CHRON DIS, V33, P311, DOI 10.1016/0021-9681(80)90026-0; KERTTULA Y, 1988, ANN CLIN RES, V20, P184; KEYS A, 1985, AM J EPIDEMIOL, V121, P870, DOI 10.1093/oxfordjournals.aje.a114057; KNEKT P, 1991, BRIT MED J, V302, P90, DOI 10.1136/bmj.302.6768.90; KNEKT P, 1988, J CLIN EPIDEMIOL, V41, P519, DOI 10.1016/0895-4356(88)90056-X; KOZAREVIC D, 1981, AM J EPIDEMIOL, V114, P21, DOI 10.1093/oxfordjournals.aje.a113170; KROMHOUT D, 1988, ARCH INTERN MED, V148, P1051, DOI 10.1001/archinte.148.5.1051; MARMOT MG, 1984, LANCET, V1, P1003; MORRIS DL, 1983, CANCER-AM CANCER SOC, V52, P1754, DOI 10.1002/1097-0142(19831101)52:9<1754::AID-CNCR2820520933>3.0.CO;2-J; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NEATON JD, 1984, AM HEART J, V108, P759, DOI 10.1016/0002-8703(84)90669-0; NEATON JD, IN PRESS ARCH INTERN; NEUGUT AI, 1989, INT J EPIDEMIOL, V4, P798; PEKKANEN J, 1989, ARCH INTERN MED, V149, P1589, DOI 10.1001/archinte.149.7.1589; PERSSON B, 1984, ACTA MED SCAND, V216, P485; PETERSSON B, 1984, AM J MED, V77, P418, DOI 10.1016/0002-9343(84)90096-2; PETERSSON B, 1983, KLIN WOCHENSCHR, V63, P795; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; REID DD, 1974, LANCET, V1, P469; ROSE G, 1974, LANCET, V1, P181, DOI 10.1016/S0140-6736(74)92492-1; ROSE G, 1986, BRIT MED J, V293, P306, DOI 10.1136/bmj.293.6542.306; ROSE G, 1980, LANCET, V1, P523; SALMOND CE, 1985, BMJ-BRIT MED J, V290, P422, DOI 10.1136/bmj.290.6466.422; SALONEN JT, 1982, AM J EPIDEMIOL, V116, P622, DOI 10.1093/oxfordjournals.aje.a113445; SCHATZKIN A, 1988, CANCER RES, V48, P452; SCHATZKIN A, 1987, LANCET, V2, P298; SHAPER AG, 1989, BRIT MED J, V298, P1381, DOI 10.1136/bmj.298.6684.1381; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P257, DOI 10.1136/jech.44.4.257; SMITH GD, IN PRESS BMJ; SMITH GD, IN PRESS AM J EPIDEM; STEMMERMANN GN, 1981, J NATL CANCER I, V67, P1179; STEMMERMANN GN, 1991, ARCH INTERN MED, V151, P969, DOI 10.1001/archinte.151.5.969; STRACHAN DP, 1991, BMJ-BRIT MED J, V302, P84, DOI 10.1136/bmj.302.6768.84; THOMAS CB, 1982, JOHNS HOPKINS MED J, V150, P89; TORNBERG SA, 1986, NEW ENGL J MED, V315, P1629, DOI 10.1056/NEJM198612253152601; TORNBERG SA, 1989, JNCI-J NATL CANCER I, V81, P1917, DOI 10.1093/jnci/81.24.1917; VITOLS S, 1985, LANCET, V2, P1150; WALD NJ, 1989, BRIT J CANCER, V59, P936, DOI 10.1038/bjc.1989.198; WALLACE RB, 1982, J NATL CANCER I, V68, P915; WESTLUND K, 1972, SCAND J CLIN IN S127, V30, P3; WILLIAMS RR, 1981, JAMA-J AM MED ASSOC, V245, P247, DOI 10.1001/jama.245.3.247; WINAWER SJ, 1990, JAMA-J AM MED ASSOC, V263, P2083, DOI 10.1001/jama.263.15.2083; WINGARD DL, 1984, J CHRON DIS, V37, P401, DOI 10.1016/0021-9681(84)90107-3; YAARI S, 1981, LANCET, V1, P1011; 1982, JAMA-J AM MED ASSOC, V248, P2853	72	255	258	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1992	267	1					70	76		10.1001/jama.267.1.70	http://dx.doi.org/10.1001/jama.267.1.70			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW848	1727199				2022-12-01	WOS:A1992GW84800026
J	STEWART, WF; LIPTON, RB; CELENTANO, DD; REED, ML				STEWART, WF; LIPTON, RB; CELENTANO, DD; REED, ML			PREVALENCE OF MIGRAINE HEADACHE IN THE UNITED-STATES - RELATION TO AGE, INCOME, RACE, AND OTHER SOCIODEMOGRAPHIC FACTORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EPIDEMIOLOGY; SYMPTOMS; WOMEN	Objective. - To describe the magnitude and distribution of the public health problem posed by migraine in the United States by examining migraine prevalence, attack frequency, and attack-related disability by gender, age, race, household income, geographic region, and urban vs rural residence. Design. - In 1989, a self-administered questionnaire was sent to a sample of 15000 households. A designated member of each household initially responded to the questionnaire. Each household member with severe headache was asked to respond to detailed questions about symptoms, frequency, and severity of headaches. Setting. - A sample of households selected from a panel to be representative of the US population in terms of age, gender, household size, and geographic area. Participants. - After a single mailing, 20468 subjects (63.4% response rate) between 12 and 80 years of age responded to the survey. Respondents and nonrespondents did not differ by gender, household income, region of the country, urban vs rural status. Whites and the elderly were more likely to respond. Migraine headache cases were identified on the basis of reported symptoms using established diagnostic criteria. Results. - 17.6% of females and 5.7% of males were found to have one or more migraine headaches per year. The prevalence of migraine varied considerably by age and was highest in both men and women between the ages of 35 to 45 years. Migraine prevalence was strongly associated with household income; prevalence in the lowest income group (< $10 000) was more than 60% higher than in the two highest income groups (greater-than-or-equal-to $30 000). The proportion of migraine sufferers who experienced moderate to severe disability was not related to gender, age, income, urban vs rural residence, or region of the country. In contrast, the frequency of headaches was lower in higher-income groups. Attack frequency was inversely related to disability. Conclusions. - A projection to the US population suggests that 8.7 million females and 2.6 million males suffer from migraine headache with moderate to severe disability. Of these, 3.4 million females and 1.1 million males experience one or more attacks per month. Females between ages 30 to 49 years from lower-income households are at especially high risk of having migraines and are more likely than other groups to use emergency care services for their acute condition.	JOHNS HOPKINS UNIV,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21205; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT NEUROL,BRONX,NY 10461; GLAXO INC,RES TRIANGLE PK,NC	Johns Hopkins University; Yeshiva University; Albert Einstein College of Medicine; GlaxoSmithKline	STEWART, WF (corresponding author), JOHNS HOPKINS UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,615 N WOLFE ST,BALTIMORE,MD 21205, USA.		Lipton, Richard Bruce/AAY-2818-2021; Lipton, Richard B/B-5060-2011		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019381, T32NS007153] Funding Source: NIH RePORTER; NINDS NIH HHS [5-T32 NSO-7153, NS19381] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andersen R, 1979, TOTAL SURVEY ERROR; ANDERSON RJ, 1984, CLIN CHIM ACTA, V138, P185, DOI 10.1016/0009-8981(84)90233-X; BRESLOW NE, 1987, DESIGN ANAL COHORT S, V2, P152; BRUYN GW, 1983, HEADACHE, V23, P127; CELENTANO DD, 1990, SOC SCI MED, V30, P1289, DOI 10.1016/0277-9536(90)90309-G; CELENTANO DD, 1990, J CLIN EPIDEMIOL, V43, P983, DOI 10.1016/0895-4356(90)90082-Z; CHEN TC, 1987, ARCH NEUROL-CHICAGO, V44, P1024, DOI 10.1001/archneur.1987.00520220030011; CLARKE GJR, 1974, EPIDEMIOLOGY MIGRAIN, P14; DALLESANDRO R, 1988, J NEUROL NEUROSUR PS, V51, P21; DEUBNER DC, 1977, HEADACHE, V17, P173, DOI 10.1111/j.1526-4610.1977.hed1704173.x; EATON WW, 1988, HDB SCHIZOPHRENIA, V3, P169; JOHANNES CB, 1989, THESIS J HOPKINS U A; KAPPIUS REK, 1987, HEADACHE, V27, P491, DOI 10.1111/j.1526-4610.1987.hed2709491.x; LIBERATOS P, 1988, EPIDEMIOL REV, V10, P87, DOI 10.1093/oxfordjournals.epirev.a036030; LINET MS, 1989, JAMA-J AM MED ASSOC, V261, P2211, DOI 10.1001/jama.261.15.2211; LIPTON RB, 1991, CEPHALALGIA, V11, P89, DOI 10.1177/0333102491011S1148; MARKUSH RE, 1975, NEUROLOGY, V25, P430, DOI 10.1212/WNL.25.5.430; MCCULLUGH P, 1983, GENERALIZED LINEAR M, P142; MOSS G, 1974, EPIDEMIOLOGY MIGRAIN, P49; SCHNARCH DM, 1980, PSYCHOSOMATICS, V21, P314; SILBERSTEIN SD, 1991, NEUROLOGY, V41, P786, DOI 10.1212/WNL.41.6.786; WATERS W E, 1970, Headache, V9, P178, DOI 10.1111/j.1526-4610.1970.hed0904178.x; ZIEGLER DK, 1990, NEUROL CLIN, V8, P781, DOI 10.1016/S0733-8619(18)30316-5; 1988, NATIONAL DATA BOOK G; 1988, CEPHALALGIA S7, V8, P1	25	1264	1299	2	56	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1992	267	1					64	69		10.1001/jama.267.1.64	http://dx.doi.org/10.1001/jama.267.1.64			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW848	1727198				2022-12-01	WOS:A1992GW84800025
J	SWIFT, M; MORRELL, D; MASSEY, RB; CHASE, CL				SWIFT, M; MORRELL, D; MASSEY, RB; CHASE, CL			INCIDENCE OF CANCER IN 161 FAMILIES AFFECTED BY ATAXIA-TELANGIECTASIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BREAST-CANCER; FLUOROSCOPIC EXAMINATIONS; FEMALE BREAST; HETEROZYGOTES; IRRADIATION; TUBERCULOSIS; MORTALITY; CHEST; WOMEN; RADIOSENSITIVITY	Background. Ataxia-telangiectasia is an autosomal recessive syndrome in which cancers develop in affected homozygotes at a rate approximately 100 times higher than in unaffected age-matched subjects. Retrospective studies have shown that persons heterozygous for the ataxia-telangiectasia gene, who make up about 1 percent of the general population, also have an excess risk of cancer, particularly breast cancer in women. Patients with ataxia-telangiectasia and cells derived from homozygotes and heterozygotes are unusually sensitive to ionizing radiation. Methods. Cancer incidence and mortality, mortality from ischemic heart disease, and mortality from all causes were compared prospectively for a mean of 6.4 years in 1599 adult blood relatives of patients with ataxia-telangiectasia and 821 of their spouses, who served as controls, in 161 families affected by ataxia-telangiectasia. In a case-control substudy, we compared documented occupational and fluoroscopic diagnostic exposures to radiation in the 19 female blood relatives in whom breast cancer was first diagnosed during the period of prospective observation with the exposures in 57 matched blood relatives who did not have breast cancer. Results. Cancer rates were significantly higher in the group of blood relatives than in their spouses, specifically in the subgroup of 294 blood relatives who were known to be heterozygous for the ataxia-telangiectasia gene. The estimated risk of cancer of all types among heterozygotes as compared with noncarriers was 3.8 in men and 3.5 in women, and that for breast cancer in women was 5.1. Among the blood relatives, women with breast cancer were more likely to have been exposed to selected sources of ionizing radiation than controls without cancer (odds ratio = 5.8, P = 0.005). Male and female blood relatives also had 3-fold and 2.6-fold excess mortality from all causes, respectively, from the ages of 20 through 59 years. Conclusions. The ataxia-telangiectasia gene predisposes heterozygotes to cancer, particularly breast cancer in women. There is also excess mortality from all causes in adults under the age of 60. Diagnostic or occupational exposure to ionizing radiation probably increases the risk of breast cancer in women heterozygous for ataxia-telangiectasia.	UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27514; UNIV N CAROLINA,DEPT EPIDEMIOL,CHAPEL HILL,NC 27514	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	SWIFT, M (corresponding author), UNIV N CAROLINA,BIOL SCI RES CTR,CB 7250,CHAPEL HILL,NC 27599, USA.				NCI NIH HHS [CA14235] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014235] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAINES CJ, 1989, CANCER, V63, P1816; BOICE JD, 1978, RADIAT RES, V73, P373, DOI 10.2307/3574828; BOICE JD, 1977, J NATL CANCER I, V59, P823, DOI 10.1093/jnci/59.3.823; BORRESEN AL, 1990, GENE CHROMOSOME CANC, V2, P339, DOI 10.1002/gcc.2870020412; COLE J, 1988, INT J RADIAT BIOL, V54, P929, DOI 10.1080/09553008814552331; CUNLIFFE PN, 1975, BRIT J RADIOL, V48, P374, DOI 10.1259/0007-1285-48-569-374; DELARUE NC, 1975, CAN MED ASSOC J, V112, P1405; GOTOFF SP, 1967, AM J DIS CHILD, V114, P617, DOI 10.1001/archpedi.1967.02090270073006; HEGGIE J C P, 1990, Australasian Physical and Engineering Sciences in Medicine, V13, P71; HENDRICK RE, 1990, RADIOLOGY, V174, P648, DOI 10.1148/radiology.174.3.2305044; HILDRETH NG, 1989, NEW ENGL J MED, V321, P1281, DOI 10.1056/NEJM198911093211901; HOWE GR, 1982, CANCER DETECT PREV, V5, P175; HUDA W, 1990, RADIOLOGY, V177, P813, DOI 10.1148/radiology.177.3.2243994; JANKOWSKI J, 1984, Health Physics, V46, P228; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P336; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCCONVILLE CM, 1990, HUM GENET, V85, P215; MILLER AB, 1989, NEW ENGL J MED, V321, P1285, DOI 10.1056/NEJM198911093211902; MORGAN JL, 1968, AM J DIS CHILD, V116, P557, DOI 10.1001/archpedi.1968.02100020561022; MORRELL D, 1990, CANCER GENET CYTOGEN, V50, P119, DOI 10.1016/0165-4608(90)90245-6; MORRELL D, 1986, J NATL CANCER I, V77, P89; PADOVANI R, 1987, BRIT J RADIOL, V60, P155, DOI 10.1259/0007-1285-60-710-155; PIPPARD EC, 1988, CANCER RES, V48, P2929; ROTHMAN KJ, 1979, NIH DHEW791649 PUBL; SHORE RE, 1977, JNCI-J NATL CANCER I, V59, P813, DOI 10.1093/jnci/59.3.813; SWIFT M, 1976, CANCER RES, V36, P209; SWIFT M, 1983, LANCET, V1, P1049; SWIFT M, 1990, CANCER GENET CYTOGEN, V46, P21, DOI 10.1016/0165-4608(90)90004-T; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SWIFT M, 1986, AM J HUM GENET, V39, P573; SWIFT M, 1974, AM J HUM GENET, V26, P304; SWIFT M, 1990, AM J HUM GENET, V47, P226; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; TOKUNAGA M, 1987, RADIAT RES, V112, P243, DOI 10.2307/3577254; 1967, PHS PUBLICATION, V1693; 1981, GAO EMD811 GEN ACC O	36	746	764	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 26	1991	325	26					1831	1836		10.1056/NEJM199112263252602	http://dx.doi.org/10.1056/NEJM199112263252602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW528	1961222				2022-12-01	WOS:A1991GW52800002
J	VERGE, CF; LAM, A; SIMPSON, JM; COWELL, CT; HOWARD, NJ; SILINK, M				VERGE, CF; LAM, A; SIMPSON, JM; COWELL, CT; HOWARD, NJ; SILINK, M			EFFECTS OF THERAPY IN X-LINKED HYPOPHOSPHATEMIC RICKETS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							D-RESISTANT RICKETS; VITAMIN-D; PRETERM INFANTS; PHOSPHATE; NEPHROCALCINOSIS; HEIGHT; CALCITRIOL; GROWTH	Background. Patients with X-linked hypophosphatemic rickets, which is clinically manifested by growth failure and bowing of the legs, are usually treated with phosphate and a vitamin D preparation. However, the efficacy of this treatment has been disputed, and nephrocalcinosis is a recognized complication of therapy. Methods. We studied 24 patients with X-linked hypophosphatemic rickets (9 boys and 15 girls) ranging in age from 1 to 16 years (median, 5.3). The duration of combination therapy ranged from 0.3 to 11.8 years (median, 3.0). We measured height as a standard-deviation (SD) score (the number of SDs from the mean height for chronologic age). Measurements made before the age of two years or after the onset of puberty were excluded. We compared the results with those reported in 1971 for 16 untreated prepubertal Australian patients. We also determined the severity of nephrocalcinosis (on a scale of 0 to 4, with 0 indicating no abnormalities and 4 stone formation) with renal ultrasonography and whether it could be related to the dosage of phosphate or vitamin D or to other factors. Results. Patients treated for at least two years before the onset of puberty (n = 19) had a mean height SD score of -1.08, as compared with -2.05 in the untreated historical controls. The 13 patients who had been treated with calcitriol and phosphate for at least two years had an increase in the mean height SD score of 0.33, from -1.58 to -1.25 (95 percent confidence interval, 0 to 0.67; P = 0.05). Nineteen of the 24 patients (79 percent) had nephrocalcinosis detected on renal ultrasonography. The grade of nephrocalcinosis was significantly correlated with the mean phosphate dose (r = 0.60, P = 0.002), but not with the dose of vitamin D or the duration of therapy. All patients had normal serum creatinine concentrations. Conclusions. Therapy with calcitriol and phosphate may increase the growth of children with X-linked hypophosphatemic rickets. Nephrocalcinosis in these children represents a complication of therapy and is associated with the dose of phosphate received.	CHILDRENS HOSP, RAY WILLIAMS INST PAEDIAT ENDOCRINOL DIABET & META, SYDNEY, AUSTRALIA; CHILDRENS HOSP, DEPT RADIOL, SYDNEY, AUSTRALIA; UNIV SYDNEY, DEPT PUBL HLTH, SYDNEY, NSW 2006, AUSTRALIA	University of Sydney; University of Sydney; University of Sydney								ALON U, 1985, PEDIATRICS, V75, P754; BALSAN S, 1990, J PEDIATR-US, V116, P365, DOI 10.1016/S0022-3476(05)82822-7; CHAN JCM, 1985, J PEDIATR-US, V106, P533, DOI 10.1016/S0022-3476(85)80068-8; GLORIEUX FH, 1980, NEW ENGL J MED, V303, P1023, DOI 10.1056/NEJM198010303031802; GLORIEUX FH, 1972, NEW ENGL J MED, V287, P481, DOI 10.1056/NEJM197209072871003; GOODYER PR, 1987, J PEDIATR-US, V111, P700, DOI 10.1016/S0022-3476(87)80245-7; HAASE P, 1975, J ANAT, V119, P19; HITCHCOCK NE, 1986, MED J AUSTRALIA, V145, P373, DOI 10.5694/j.1326-5377.1986.tb112388.x; HOWARD CP, 1979, PEDIATR RES, V13, P380; HUFNAGLE KG, 1982, PEDIATRICS, V70, P360; KLEEREKOPER M, 1974, CLIN CHEM, V20, P369; PAK CYC, 1969, J CLIN INVEST, V48, P1914, DOI 10.1172/JCI106158; PATRIQUIN H, 1986, AM J ROENTGENOL, V146, P1253, DOI 10.2214/ajr.146.6.1253; POLISSON RP, 1985, NEW ENGL J MED, V313, P1, DOI 10.1056/NEJM198507043130101; RASMUSSEN H, 1981, J PEDIATR-US, V99, P16, DOI 10.1016/S0022-3476(81)80951-1; REUSZ GS, 1990, LANCET, V335, P1240, DOI 10.1016/0140-6736(90)91304-S; REUSZ GS, 1990, ARCH DIS CHILD, V65, P1125, DOI 10.1136/adc.65.10.1125; STEENDIJK R, 1971, HELV PAEDIATR ACTA, V26, P179; STICKLER GB, 1989, LANCET, V2, P902; STICKLER GB, 1988, AM J DIS CHILD, V142, P14, DOI 10.1001/archpedi.1988.02150010020009; TANNER JM, 1966, ARCH DIS CHILD, V41, P454, DOI 10.1136/adc.41.219.454; TSURU N, 1987, AM J DIS CHILD, V141, P108, DOI 10.1001/archpedi.1987.04460010108039; WOOLFIELD N, 1988, ARCH DIS CHILD, V63, P86, DOI 10.1136/adc.63.1.86; 1976, PHS HRA761120 PUBL	24	169	176	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 26	1991	325	26					1843	1848		10.1056/NEJM199112263252604	http://dx.doi.org/10.1056/NEJM199112263252604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW528	1660098				2022-12-01	WOS:A1991GW52800004
J	ANDERSEN, WK; SILVERS, DN				ANDERSEN, WK; SILVERS, DN			MELANOMA - IT CANT BE MELANOMA - A SUBSET OF MELANOMAS THAT DEFIES CLINICAL RECOGNITION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							MALIGNANT-MELANOMA; DIAGNOSIS	We diagnosed histologically 178 cases of malignant melanoma in 1990. Thirteen cases were recorded in which the diagnosis of malignant melanoma was not considered by the clinician prior to biopsy or, in retrospect, following pathologic diagnosis. Eight of the 13 lesions were amelanotic. The majority were deeply invasive at the time of biopsy, implying poor prognosis. Despite improvements in early detection of malignant melanoma, a significant subcategory of melanomas escapes clinical diagnosis.	COLUMBIA UNIV,COLUMBIA PRESBYTERIAN MED CTR,COLL PHYS & SURG,DEPT DERMATOL,NEW YORK,NY 10032; COLUMBIA UNIV,COLUMBIA PRESBYTERIAN MED CTR,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital	SILVERS, DN (corresponding author), COLUMBIA UNIV,COLUMBIA PRESBYTERIAN MED CTR,COLL PHYS & SURG,DEPT DERMATOL,NEW YORK,NY 10032, USA.							BECKER SW, 1954, AMA ARCH DERM SYPH, V69, P11, DOI 10.1001/archderm.1954.01540130013002; Clark WH., 1967, ADV BIOL SKIN, P621; GRIN CM, 1990, ARCH DERMATOL, V126, P763, DOI 10.1001/archderm.126.6.763; MCMULLAN FH, 1956, ARCH DERMATOL, V74, P618, DOI 10.1001/archderm.1956.01550120038009; MIHM MC, 1971, NEW ENGL J MED, V284, P1078, DOI 10.1056/NEJM197105132841907; STEINER A, 1988, ARCH DERMATOL, V24, P1534; SWERDLOW M, 1952, AM J CLIN PATHOL, V22, P1054; THORN M, 1989, JNCI-J NATL CANCER I, V81, P611, DOI 10.1093/jnci/81.8.611; WICK MM, 1980, CANCER, V45, P2684, DOI 10.1002/1097-0142(19800515)45:10<2684::AID-CNCR2820451033>3.0.CO;2-2	9	56	57	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3463	3465		10.1001/jama.266.24.3463	http://dx.doi.org/10.1001/jama.266.24.3463			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV878	1744961				2022-12-01	WOS:A1991GV87800033
J	CHAMBERLAND, ME; CONLEY, LJ; BUSH, TJ; CIESIELSKI, CA; HAMMETT, TA; JAFFE, HW				CHAMBERLAND, ME; CONLEY, LJ; BUSH, TJ; CIESIELSKI, CA; HAMMETT, TA; JAFFE, HW			HEALTH-CARE WORKERS WITH AIDS - NATIONAL SURVEILLANCE UPDATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-B VIRUS; OCCUPATIONAL RISK; TRANSMISSION; INFECTION; HIV	Objectives. - To characterize health care workers with the acquired immunodeficiency syndrome (AIDS) in the United States and to evaluate the role of occupational transmission of the human immunodeficiency virus (HIV). Data Source. - National AIDS surveillance data. Methods. - Health care workers with AIDS are reported to the Centers for Disease Control by state and local health departments. Health care workers who do not report a nonoccupational risk for HIV infection are termed undetermined risk cases and are investigated by health departments using a standard protocol. Results. - Through June 30, 1990, there were 5425 cases of AIDS in healthcare workers reported in the United States. Three of these workers developed AIDS following well-documented occupational exposure to HIV-infected blood. Of the 539 health care workers initially reported without a nonoccupational risk, follow-up investigations were completed for 303. Nonoccupational risk factors were established for 237 (78.2%) of the 303 investigated health care workers; 66 workers (21.8%) remained in the undetermined category. Follow-up information was incomplete for 236 health care workers who also remained in the undetermined category, resulting in 5120 health care workers (94.4%) with AIDS with nonoccupational risks for HIV infection. Overall, health care workers were more likely than non-health care workers with AIDS to have an undetermined risk for HIV infection (5.6% vs 2.8%; P < .001). While many of the 66 investigated health care workers had jobs involving contact with patients and/or potential contact with blood, none reported percutaneous, mucous membrane, or cutaneous exposures to blood or body fluids known to be infected with HIV. Conclusion. - Surveillance data suggest that most health care workers with AIDS acquired their HIV infection through a nonoccupational route.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333; US PHS,WASHINGTON,DC	Centers for Disease Control & Prevention - USA; United States Public Health Service	CHAMBERLAND, ME (corresponding author), CTR DIS CONTROL,HOSP INFECT PROGRAM,1600 CLIFTON RD NE,MAIL STOP A-07,ATLANTA,GA 30333, USA.							BELL DM, 1991, AM J MED S3B, V91; BUEHLER J, 1989, 5 INT C AIDS MONTR, P124; CASTRO KG, 1988, JAMA-J AM MED ASSOC, V259, P1338, DOI 10.1001/jama.259.9.1338; Centers for Disease Control reports include, 1988, MMWR, V37, P229; CIESIELSKI CA, 1990, NEW ENGL J MED, V322, P1156; COWAN DN, 1991, JAMA-J AM MED ASSOC, V265, P2826, DOI 10.1001/jama.265.21.2826; GERBERDING JL, 1987, J INFECT DIS, V156, P1, DOI 10.1093/infdis/156.1.1; HADLER SC, 1985, INFECT CONT HOSP EP, V6, P24, DOI 10.1017/S0195941700062457; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; KLEIN RS, 1988, NEW ENGL J MED, V318, P86, DOI 10.1056/NEJM198801143180205; LIFSON AR, 1986, JAMA-J AM MED ASSOC, V256, P3231, DOI 10.1001/jama.256.23.3231; MARCUS R, 1989, B WORLD HEALTH ORGAN, V67, P577; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MCCORMICK RD, 1981, AM J MED, V70, P928, DOI 10.1016/0002-9343(81)90558-1; Miller J W, 1989, Conn Med, V53, P457; TURNER SB, 1989, AM J PUBLIC HEALTH, V79, P1425, DOI 10.2105/AJPH.79.10.1425; 1991, MMWR, V40, P309; 1987, MMWR, V36, pS1; 1989, EMPLOY EARN, V36, P13; 1991, HIV AIDS SURVEILLANC, P1; 1988, MMWR, V37, P239; 1989, FED REG         0530, V54, P23042; 1989, MMWR, V38, P1; 1990, MMWR, V39, P1	24	36	36	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3459	3462		10.1001/jama.266.24.3459	http://dx.doi.org/10.1001/jama.266.24.3459			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GV878	1660544				2022-12-01	WOS:A1991GV87800032
J	CRAWSHAW, R				CRAWSHAW, R			REQUIEM FOR AN UNKNOWN LEPER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3411	3412						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV878	1744951				2022-12-01	WOS:A1991GV87800008
J	HAND, R; SENER, S; IMPERATO, J; CHMIEL, JS; SYLVESTER, J; FREMGEN, A				HAND, R; SENER, S; IMPERATO, J; CHMIEL, JS; SYLVESTER, J; FREMGEN, A			HOSPITAL VARIABLES ASSOCIATED WITH QUALITY OF CARE FOR BREAST-CANCER PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPARING TOTAL MASTECTOMY; COMMUNITY HOSPITALS; WOMEN; RECEPTORS; MODALITY; BLACK; AGE	Objective. - To determine the degree of compliance with clinical standards among hospitals for care of breast cancer patients and account for variations in compliance. Design. - Analysis of cancer registry data submitted to the American Cancer Society, Illinois Division, Chicago, for a concurrent prospective descriptive study of breast cancer, supplemented by other hospital data from public sources. Setting. - Ninety-nine Illinois hospitals evenly distributed among rural counties, counties with small cities outside the Chicago metropolitan area, exurban counties in the Chicago metropolitan area, suburban Cook County, and urban Chicago. Patients. - A total of 5766 newly diagnosed patients with histologically confirmed breast cancer in 1988, representing 84% of the estimated 6900 new cases in the state for that year. Main Outcome Measures. - Descriptive statistics and multiple linear regression analyses of five dependent quality variables from clinical indicators related to early diagnosis, hormone receptor determination, adjuvant therapy, radiation therapy, and axillary lymph node dissection. Results. - At the hospitals studied, (1) late stage (IIb through IV) at diagnosis was associated with urban location, higher proportion of poorly insured patients, fewer breast cancer cases treated, and lower oncology charges (proportion of variance explained, R2 = .50, P < .00001). (2) omission of hormone receptor test for stages 11 through IV was associated with urban location and higher proportion of poorly insured patients (R2 = .18, P < .00003); and (3) omission of indicated radiation therapy was associated with urban location and fewer breast cancer cases (R2 = .21, P < .00001). Omission of adjuvant therapy and omission of axillary lymph node dissection were not significantly associated with any of the hospital variables examined. Conclusions. - The findings suggest that there is a group of urban hospitals, generally small and marginally reimbursed, where comprehensive diagnosis and treatment of breast cancer are not obtained.	UNIV ILLINOIS,COLL MED,DEPT MED,CHICAGO,IL 60680; NORTHWESTERN UNIV,SCH MED,DEPT SURG,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT RADIOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,CTR CANC,BIOMETRY SECT,CHICAGO,IL 60611	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Northwestern University; Northwestern University; Northwestern University	HAND, R (corresponding author), AMER CANC SOC,CANC INCIDENCE & END RESULTS COMM,ILLINOIS DIV,77 E MONROE ST,NEW YORK,NY 10017, USA.							ANDERSSON I, 1980, RADIOLOGE, V20, P608; CADY B, 1990, CANCER, V65, P634, DOI 10.1002/1097-0142(19900201)65:3+<634::AID-CNCR2820651306>3.0.CO;2-X; CHU J, 1987, J GERONTOL, V42, P185, DOI 10.1093/geronj/42.2.185; CLARK GM, 1988, SEMIN ONCOL, V15, P20; COL N, 1990, ARCH INTERN MED, V150, P841, DOI 10.1001/archinte.150.4.841; DIEHR P, 1989, MED CARE, V27, P942, DOI 10.1097/00005650-198910000-00005; Eddy D M, 1984, Health Aff (Millwood), V3, P74, DOI 10.1377/hlthaff.3.2.74; EPSTEIN AM, 1990, NEW ENGL J MED, V322, P1122, DOI 10.1056/NEJM199004193221606; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; Fisher E R, 1981, Breast Cancer Res Treat, V1, P37, DOI 10.1007/BF01807890; FORD LG, 1989, CANCER, V64, P219, DOI 10.1002/1097-0142(19890701)64:1+<219::AID-CNCR2820641308>3.0.CO;2-S; Gore S M, 1988, Recent Results Cancer Res, V111, P149; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; GRILLI R, 1991, MED CARE, V29, P50, DOI 10.1097/00005650-199101000-00005; HORM JM, 1984, SEER PROGRAM CANCER; Lazarus E S, 1990, Med Anthropol, V12, P269; MAMON JA, 1990, PREV MED, V19, P363, DOI 10.1016/0091-7435(90)90036-J; MCPHEE S J, 1990, Journal of General Internal Medicine, V5, pS116, DOI 10.1007/BF02600856; MEYER JE, 1990, JAMA-J AM MED ASSOC, V263, P2341, DOI 10.1001/jama.263.17.2341; NEMOTO T, 1980, CANCER, V45, P2917, DOI 10.1002/1097-0142(19800615)45:12<2917::AID-CNCR2820451203>3.0.CO;2-M; OSBORNE CK, 1980, CANCER-AM CANCER SOC, V46, P2884, DOI 10.1002/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U; SAWYER JA, 1990, J GEN INTERN MED, V5, P115, DOI 10.1007/BF02600510; SCANLON EF, 1991, TXB CLIN ONCOLOGY, P177; STOMPER PC, 1989, HEMATOL ONCOL CLIN N, V3, P611, DOI 10.1016/S0889-8588(18)30523-9; 1991, JAMA-J AM MED ASSOC, V265, P391; 1988, COUNTY CITY DATA BOO, pF15; 1988, MANUAL STAGING CANCE; 1989, JAMA-J AM MED ASSOC, V261, P2535; 1988, CANCER FACTS FIGURES; 1987, 1987 SURVEY PUBLIC A; 1985, CONSENSUS DEV C STAT; 1991, JOINT COMMISSION PER, V11, pA1	33	92	92	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3429	3432		10.1001/jama.266.24.3429	http://dx.doi.org/10.1001/jama.266.24.3429			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV878	1744956				2022-12-01	WOS:A1991GV87800026
J	LANDESMAN, S; WEIBLEN, B; MENDEZ, H; WILLOUGHBY, A; GOEDERT, JJ; RUBINSTEIN, A; MINKOFF, H; MOROSO, G; HOFF, R				LANDESMAN, S; WEIBLEN, B; MENDEZ, H; WILLOUGHBY, A; GOEDERT, JJ; RUBINSTEIN, A; MINKOFF, H; MOROSO, G; HOFF, R			CLINICAL UTILITY OF HIV-IGA IMMUNOBLOT ASSAY IN THE EARLY DIAGNOSIS OF PERINATAL HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; INVITRO PRODUCTION; INFANTS BORN; CHILDREN; ANTIBODY; MOTHERS; RISK	Objective. - To ascertain the sensitivity, specificity, predictive value, and clinical use of a human immunodeficiency virus (HIV)-IgA immunoblot assay for diagnosing perinatal HIV infection in infants tested at birth to 1 month, 3 months, and 6 months of age. Design. - Prospective, longitudinal cohort study of children born to HIV-infected and noninfected women. The HIV-IgA immunoblot assays were performed at birth to 1 month, 3 months, and 6 months of age and compared with the Centers for Disease Control's classification system of HIV infection in the children. Children were followed up for at least 15 months to ensure accuracy of infection status. Setting. - Municipal hospital in central Brooklyn, NY, where the prevalence of HIV infection is high. Patients. - Serum samples from 58 children, 22 with documented HIV infection, 18 noninfected children born to seropositive women, and 18 children born to noninfected women, were studied. Main Outcome Measure. - Diagnosis of HIV infection using the Centers for Disease Control's classification scheme was compared with diagnosis using the HIV-IgA immunoblot assay for children 6 months of age or younger. Results. - The HIV-IgA immunoblot assay yielded negative results at 3 and 6 months of age for all 18 infants born to seronegative women; for the 18 seroreverting, noninfected children born to infected women, the assay yielded negative results at 1 month, 3 months, and 6 months of age. The positive predictive value of the assay was 100%-no false-positive results were identified in the 88 serum samples obtained from noninfected infants. For the HIV-infected children, sensitivity was a function of age: one (5.9%) of 17 infants had an assay that yielded positive results at birth to 1 month of age, 13 (62%) of 21 infants had assays that yielded positive results at 3 months of age, and 17 (77%) of 22 infants had assays that yielded positive results at 6 months of age. The presence or absence of symptoms did not affect the sensitivity. Conclusion. - The HIV-IgA immunoblot assay can detect a significant proportion of infected children during an early asymptomatic period of their life. This relatively inexpensive, easily standardized assay may allow for institution of therapy before the onset of clinical symptoms.	NIAID,DIV AIDS,BETHESDA,MD 20892; SUNY HLTH SCI CTR,DEPT OBSTET & GYNECOL,BROOKLYN,NY; THEOBALD SMITH RES INST,BOSTON,MA; NICHHD,PEDIAT ADOLESCENT & MATERNAL AIDS BRANCH,BETHESDA,MD 20892; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PEDIAT,BRONX,NY 10461; NCI,VIRAL EPIDEMIOL BRANCH,BETHESDA,MD 20892; SUNY HLTH SCI CTR,DEPT PEDIAT,BROOKLYN,NY	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Yeshiva University; Albert Einstein College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	LANDESMAN, S (corresponding author), SUNY HLTH SCI CTR,DEPT MED,DIV INFECT DIS,450 CLARKSON AVE,BOX 122,BROOKLYN,NY 11203, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD082917, R01HD025714, N01HD082913] Funding Source: NIH RePORTER; NICHD NIH HHS [N0-1-HD-8-2913, N0-1-HD-8-2917, R0-HD-25714-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMADORI A, 1988, LANCET, V1, P852; AMADORI A, 1990, PEDIATR INFECT DIS J, V9, P26, DOI 10.1097/00006454-199001000-00006; BORKOWSKY W, 1989, J PEDIATR, V114, P942; EDWARDS JR, 1989, J PEDIATR-US, V115, P200, DOI 10.1016/S0022-3476(89)80065-4; ESCAICH S, 1991, J ACQ IMMUN DEF SYND, V4, P130; HUSSON RN, 1990, PEDIATRICS, V86, P1; JOHNSON JP, 1989, AM J DIS CHILD, V143, P1147, DOI 10.1001/archpedi.1989.02150220037017; KATZ SL, 1989, NEW ENGL J MED, V320, P1687, DOI 10.1056/NEJM198906223202509; KOVACS A, 1991, JAMA-J AM MED ASSOC, V265, P1698, DOI 10.1001/jama.265.13.1698; KRIVINE A, 1990, J PEDIATR-US, V116, P372, DOI 10.1016/S0022-3476(05)82823-9; LAURE F, 1988, LANCET, V2, P538; LEE FK, 1989, AIDS RES HUM RETROV, V5, P517, DOI 10.1089/aid.1989.5.517; MARTIN NL, 1991, J PEDIATR-US, V118, P354, DOI 10.1016/S0022-3476(05)82146-8; MCKINNEY RE, 1991, NEW ENGL J MED, V324, P1018, DOI 10.1056/NEJM199104113241503; MOK JQ, 1987, LANCET, V1, P1164; PALOMBA E, 1990, LANCET, V336, P940, DOI 10.1016/0140-6736(90)92310-E; PYUN KH, 1987, NEW ENGL J MED, V317, P611, DOI 10.1056/NEJM198709033171006; RAKUSAN TA, 1991, J ACQ IMMUN DEF SYND, V4, P116; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; WEIBLEN BJ, 1990, LANCET, V335, P988, DOI 10.1016/0140-6736(90)91061-E; WEIBLEN BJ, 1990, J IMMUNOL METHODS, V126, P199, DOI 10.1016/0022-1759(90)90151-K; 1991, MMWR, V40, pRR2; 1991, LANCET, V337, P253; 1987, MMWR, V36, P225; 1991, NEW ENGL J MED, V325, P73	25	67	67	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3443	3446		10.1001/jama.266.24.3443	http://dx.doi.org/10.1001/jama.266.24.3443			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV878	1744958				2022-12-01	WOS:A1991GV87800029
J	LAZOVICH, D; WHITE, E; THOMAS, DB; MOE, RE				LAZOVICH, D; WHITE, E; THOMAS, DB; MOE, RE			UNDERUTILIZATION OF BREAST-CONSERVING SURGERY AND RADIATION-THERAPY AMONG WOMEN WITH STAGE-I OR STAGE-II BREAST-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPARING RADICAL-MASTECTOMY; CONSERVATIVE TREATMENT; AXILLARY DISSECTION; CHOICE; QUADRANTECTOMY; RADIOTHERAPY; LUMPECTOMY; PATIENT; AGE	Objective. - To identify time trends and factors associated with breast-conserving surgery (BCS) and delivery of postoperative radiation therapy among women with stage I or II breast cancer. Design. - Survey. Setting. - Population-based cancer registry in the Seattle-Puget Sound (Wash) region. Participants. - The study included 8095 women diagnosed with stage I or II breast cancer (American Joint Committee on Cancer staging criteria) from 1983 through 1989. Main Outcome Measures. - Breast-conserving surgery with or without radiation therapy vs mastectomy, and, among women with BCS, a comparison of radiation therapy vs no therapy. Results. - In 1985 when results from a US randomized clinical trial of BCS were published, the frequency of BCS peaked (46.3% of stage I; 30.1 % of stage II) followed by a return to levels before 1985 for women with stage II breast cancer and a more moderate decline for stage I breast cancer. The likelihood of BCS decreased with increasing age (P < .001), with stage II disease, and with residence outside the region's major urban center, and it increased with education (P < .001) or median income (P < .001) by census tract. The proportion of women who received radiation therapy after BCS decreased with age (P < .001), was lower for women with stage II than stage I disease, and was lowest in counties without radiation therapy facilities. Conclusions. - Despite scientific evidence of the equivalent efficacy of BCS with radiation therapy and mastectomy, BCS is not performed on the majority of women with stage I or II breast cancer as recommended by the National Institutes of Health, and factors are associated with its use that differ from selection criteria outlined by the National Institutes of Health.	UNIV WASHINGTON,DEPT OCEANOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT SURG,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	LAZOVICH, D (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV PUBL HLTH SCI,1124 COLUMBIA ST,MAILSTOP MP-702,SEATTLE,WA 98104, USA.				NCI NIH HHS [5-P01-CA34847] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA034847] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHCROFT JJ, 1985, J ROY SOC MED, V78, P43; BRESLOW NE, 1980, STATISTICAL METHODS, V2; CAWLEY M, 1990, CANCER NURS, V13, P90; CHU J, 1987, J GERONTOL, V42, P185, DOI 10.1093/geronj/42.2.185; DEBER RB, 1987, ARCH INTERN MED, V147, P1543, DOI 10.1001/archinte.147.9.1543; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; FISHER B, 1985, NEW ENGL J MED, V312, P674, DOI 10.1056/NEJM198503143121102; FISHER B, 1985, WORLD J SURG, V9, P655, DOI 10.1007/BF01655177; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P1766; HELLMAN S, 1987, CANCER RES, V47, P339; KLEINMAN JC, 1983, MED CARE, V21, P1232, DOI 10.1097/00005650-198312000-00010; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; LIBERATI A, 1987, TUMORI J, V73, P601, DOI 10.1177/030089168707300609; LIBERATI A, 1990, AM J PUBLIC HEALTH, V81, P38; MANN BA, 1988, JAMA-J AM MED ASSOC, V259, P3413; MARGOLIS GJ, 1989, PSYCHOSOMATICS, V30, P192, DOI 10.1016/S0033-3182(89)72300-8; MCKINLAY JB, 1981, MILBANK FUND Q, V59, P374, DOI 10.2307/3349685; MORRIS J, 1989, J ROY SOC MED, V82, P12, DOI 10.1177/014107688908200105; MUNOZ E, 1986, ARCH SURG-CHICAGO, V121, P1297, DOI 10.1001/archsurg.121.11.1297; SAMET J, 1986, JAMA-J AM MED ASSOC, V255, P3385, DOI 10.1001/jama.255.24.3385; SARRAZIN D, 1984, CANCER, V53, P1209, DOI 10.1002/1097-0142(19840301)53:5<1209::AID-CNCR2820530531>3.0.CO;2-Y; SARRAZIN D, 1989, RADIOTHER ONCOL, V14, P177, DOI 10.1016/0167-8140(89)90165-5; SILLIMAN RA, 1989, J GERONTOL, V44, pM46, DOI 10.1093/geronj/44.2.M46; Tinker M A, 1987, Surg Annu, V19, P279; Valanis B G, 1985, Cancer Nurs, V8, P167; VERONESI U, 1986, EUR J CANCER CLIN ON, V22, P1085, DOI 10.1016/0277-5379(86)90011-8; VERONESI U, 1981, NEW ENGL J MED, V305, P6, DOI 10.1056/NEJM198107023050102; WARD S, 1989, CANCER NURS, V12, P344; WILSON RE, 1984, SURG GYNECOL OBSTET, V159, P309; WOLBERG WH, 1987, J CLIN ONCOL, V5, P68, DOI 10.1200/JCO.1987.5.1.68; YANCIK R, 1989, CANCER, V63, P976, DOI 10.1002/1097-0142(19890301)63:5<976::AID-CNCR2820630532>3.0.CO;2-A; 1991, JAMA-J AM MED ASSOC, V265, P391; 1983, PHC802329 US DEP COM; 1988, MANUAL STAGING CANCE; 1986, 872789 US DEP HLTH H; 1991, CANCER FACTS FIGURES; 1988, BRIT J CANCER, V57, P630; 1990, MEMBERSHIP DIRECTORY; 1983, PHC802347 US DEP COM	40	315	315	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3433	3438		10.1001/jama.266.24.3433	http://dx.doi.org/10.1001/jama.266.24.3433			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GV878	1688350				2022-12-01	WOS:A1991GV87800027
J	MORRIS, CD; MENASHE, VD				MORRIS, CD; MENASHE, VD			25-YEAR MORTALITY AFTER SURGICAL REPAIR OF CONGENITAL HEART DEFECT IN CHILDHOOD - A POPULATION-BASED COHORT STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VENTRICULAR SEPTAL-DEFECT; TERM FOLLOW-UP; GREAT-ARTERIES; SUDDEN-DEATH; TETRALOGY; FALLOT; TRANSPOSITION; COARCTATION; MUSTARD; DYSRHYTHMIAS	Objective. - To determine long-term survival and the cause of death after repair of one of eight congenital heart defects in childhood. Design. - Cohort study. Setting. - General community. Participants. - All Oregon residents with one of eight congenital heart defects, which was repaired surgically between 1958 and 1989 when the patient was aged 18 years or younger, including (1) tetralogy of Fallot; (2) isolated ventricular septal defect; (3) isolated atrial septal defect; (4) coarctation of the aorta; (5) aortic valvular stenosis; (6) pulmonary valvular stenosis; (7) transposition of the great arteries; and (8) patent ductus arteriosus. Follow-up of this cohort of 2701 individuals was obtained from 94%. Main Outcome Measure. - Mortality from cardiac and noncardiac causes. Results. - Age at surgery and operative mortality have decreased significantly over the last 30 years. Late cardiac mortality at 25 years after surgery was 5% for tetralogy of Fallot and isolated ventricular septal defect, 1 0% for coarctation of the aorta, 17% for aortic stenosis, 5% for pulmonic stenosis,and less than 1% for patent ductus arteriosus; there were no late cardiac deaths after atrial septal defect repair. For transposition, late cardiac mortality was 15% at 15 years after the Mustard operation and was 2% at 10 years after the Senning operation. Conclusion. - Surgical repair of most congenital heart defects is associated with lingering cardiac mortality, particularly for aortic stenosis, coarctation, and transposition.	OREGON HLTH SCI UNIV,DEPT PEDIAT,PORTLAND,OR 97201	Oregon Health & Science University	MORRIS, CD (corresponding author), OREGON HLTH SCI UNIV,DEPT MED,DIV CARDIOL,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL036856, R29HL039052] Funding Source: NIH RePORTER; NHLBI NIH HHS [R23 HL36856, R29 HL39052] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN HD, 1974, CIRCULATION, V50, P465, DOI 10.1161/01.CIR.50.3.465; BEHL PR, 1987, THORAX, V42, P309, DOI 10.1136/thx.42.4.309; BENDER HW, 1989, ANN THORAC SURG, V47, P218, DOI 10.1016/0003-4975(89)90272-5; CARPENTER MA, 1985, J AM COLL CARDIOL, V6, P879, DOI 10.1016/S0735-1097(85)80498-8; CHANDAR JS, 1990, AM J CARDIOL, V65, P655, DOI 10.1016/0002-9149(90)91047-A; CLARKSON PM, 1976, CIRCULATION, V53, P519, DOI 10.1161/01.CIR.53.3.519; DEANFIELD J, 1988, J THORAC CARDIOV SUR, V96, P569; DEANFIELD JE, 1983, CIRCULATION, V67, P626, DOI 10.1161/01.CIR.67.3.626; DUSTER MC, 1985, AM HEART J, V109, P1323, DOI 10.1016/0002-8703(85)90359-X; FRIEDLI B, 1974, AM J CARDIOL, V33, P403, DOI 10.1016/0002-9149(74)90323-3; FUSTER V, 1980, AM J CARDIOL, V46, P635, DOI 10.1016/0002-9149(80)90514-7; HOFFMAN JIE, 1978, AM J CARDIOL, V42, P641, DOI 10.1016/0002-9149(78)90635-5; JAMES FW, 1975, CIRCULATION, V52, P691, DOI 10.1161/01.CIR.52.4.691; KIRKLIN JW, 1977, CIRCULATION, V56, P612, DOI 10.1161/01.CIR.56.4.612; KOPECKY SL, 1988, CIRCULATION, V78, P1150, DOI 10.1161/01.CIR.78.5.1150; LILLEHEI CW, 1986, ANN THORAC SURG, V41, P4, DOI 10.1016/S0003-4975(10)64489-X; LILLEHEI CW, 1986, ANN SURG, V204, P490, DOI 10.1097/00000658-198610000-00017; MANNING JA, 1980, CARDIOVASC CLIN, V11, P117; MARX GR, 1983, J AM COLL CARDIOL, V1, P476, DOI 10.1016/S0735-1097(83)80076-X; MATSUDA H, 1986, JPN CIRC J, V50, P1040, DOI 10.1253/jcj.50.1040; MURPHY JG, 1990, NEW ENGL J MED, V323, P1645, DOI 10.1056/NEJM199012133232401; MURPHY JG, 1989, CIRCULATION S2, V80, P490; PARSONS JM, 1989, BRIT HEART J, V62, P65; QUATTLEBAUM TG, 1976, CIRCULATION, V54, P289, DOI 10.1161/01.CIR.54.2.289; SIMSOLO R, 1988, AM HEART J, V115, P1268, DOI 10.1016/0002-8703(88)90020-8; 1988, PHS881147 DEP HLTH H; 1977, CIRCULATION S1, V55, P87; 1980, PEDIATRICS, V63, P377	28	105	107	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3447	3452		10.1001/jama.266.24.3447	http://dx.doi.org/10.1001/jama.266.24.3447			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV878	1744959				2022-12-01	WOS:A1991GV87800030
J	QUINN, TC; KLINE, RL; HALSEY, N; HUTTON, N; RUFF, A; BUTZ, A; BOULOS, R; MODLIN, JF				QUINN, TC; KLINE, RL; HALSEY, N; HUTTON, N; RUFF, A; BUTZ, A; BOULOS, R; MODLIN, JF			EARLY DIAGNOSIS OF PERINATAL HIV-INFECTION BY DETECTION OF VIRAL-SPECIFIC IGA ANTIBODIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; INFANTS BORN; CHILDREN; WOMEN; MOTHERS; AIDS; TRANSMISSION; TYPE-1; BLOOD	Objectives. - To evaluate the clinical utility of a human immunodeficiency virus (HIV)-IgA serological assay for diagnosis of perinatally acquired HIV infection. Design. - Coded serum samples prospectively collected from children born to HIV-infected mothers and uninfected mothers were analyzed by HIV-IgA immunoblot. Setting. - A university hospital in Baltimore, Md, and an outpatient clinic in Port-au-Prince, Haiti. Population. - Five hundred thirty-nine serum samples were obtained sequentially from 278 children born to HIV-infected women (116 from The Johns Hopkins Hospital and 62 from Port-au-Prince) and from 42 control children born to HIV-seronegative children in Port-au-Prince. Outcome Measures. - Results from the HIV-IgA serological assays were compared with the known infection status of the child at 15 months of age as determined by the standard IgG Western blot and the clinical classification of the Centers for Disease Control. Sensitivity, specificity, and predictive values were calculated at different ages and collectively for children 3 months of age or older. Results. - The HIV-IgA assay was positive in one of six specimens from HIV-infected children under 1 month of age, six of nine specimens from infected children at 3 months of age, and 160 of 161 specimens from 47 HIV-infected children 6 months of age or older. Of 334 specimens from 243 uninfected children, 333 were negative by the HIV-IgA assay. The overall sensitivity and the specificity of the IgA assay for children older than 3 months of age were 97.6% and 99.7%, and the positive and negative predictive values were 99.4% and 98.7%, respectively. Conclusion. - Although the HIV-IgA assay had a low sensitivity within the first months of life, the high sensitivity, specificity, and predictive values of this assay demonstrate its utility for the diagnosis of perinatally acquired HIV infection after the third month of age. Early diagnosis with this relatively simple and inexpensive serological assay should aid in the implementation of antiviral therapy and provide useful information for the care of children born to HIV-infected mothers in both developing and developed countries.	CTR DEV & HLTH,PORT AU PRINCE,HAITI; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH,BALTIMORE,MD 21218; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NURSING,BALTIMORE,MD 21205	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	QUINN, TC (corresponding author), JOHNS HOPKINS UNIV HOSP,BLALOCK 1111,600 N WOLFE ST,BALTIMORE,MD 21205, USA.				PHS HHS [1R01A126521] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMADORI A, 1988, LANCET, V1, P852; BARBACCI M, 1991, LANCET, V337, P709, DOI 10.1016/0140-6736(91)90286-X; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; CHIN J, 1990, LANCET, V336, P221, DOI 10.1016/0140-6736(90)91743-T; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HALSEY NA, 1990, JAMA-J AM MED ASSOC, V264, P2088, DOI 10.1001/jama.264.16.2088; HOFF R, 1988, NEW ENGL J MED, V318, P525, DOI 10.1056/NEJM198803033180901; HUSSON RN, 1990, PEDIATRICS, V86, P1; JOHNSON JP, 1989, AM J DIS CHILD, V143, P1147, DOI 10.1001/archpedi.1989.02150220037017; KRIVINE A, 1990, J PEDIATR-US, V116, P372, DOI 10.1016/S0022-3476(05)82823-9; MARTIN NL, 1991, J PEDIATR-US, V118, P354, DOI 10.1016/S0022-3476(05)82146-8; NEWELL M-L, 1990, AIDS (London), V4, pS111; PAHWA S, 1989, P NATL ACAD SCI USA, V86, P7532, DOI 10.1073/pnas.86.19.7532; PIZZO PA, 1988, NEW ENGL J MED, V319, P889, DOI 10.1056/NEJM198810063191401; QUINN TC, 1990, AIDS, V4, P709, DOI 10.1097/00002030-199008000-00001; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; WEIBLEN BJ, 1990, LANCET, V335, P988, DOI 10.1016/0140-6736(90)91061-E; WEIBLEN BJ, 1990, J IMMUNOL METHODS, V126, P199, DOI 10.1016/0022-1759(90)90151-K; 1990, MMWR, V39, P850; 1989, MMWR, V38, pS1; 1991, MMWR, V40, P195; 1990, MMWR, V39, P845; 1991, HIV AIDS SURVEILLANC, P9; 1991, LANCET, V338, P253; 1990, MMWR, V39, P1	27	81	82	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3439	3442		10.1001/jama.266.24.3439	http://dx.doi.org/10.1001/jama.266.24.3439			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV878	1744957				2022-12-01	WOS:A1991GV87800028
J	WILENSKY, GR				WILENSKY, GR			FINANCING CARE FOR PATIENTS WITH AIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3404	3404						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GV878	1744948				2022-12-01	WOS:A1991GV87800005
J	BURNS, DA				BURNS, DA			A POTPOURRI OF PARASITES IN POETRY AND PROVERB	BRITISH MEDICAL JOURNAL			English	Article											BURNS, DA (corresponding author), LEICESTER ROYAL INFIRM,LEICESTER LE1 5WW,ENGLAND.							BOTTOMLEY G, 1925, POEMS 30 YEARS, P106; DONNE J, 1986, J DONNE POETRY, P48; GUYS PRM, 1972, ST JOHNS HOSPITAL DE, V58, P113; KINGSLEY J, 1968, POEMS SONGS R BURNS, V1, P193; LEHANE B, 1969, COMPLEAT FLEA, P94; Mellanby K, 1941, Br Med J, V2, P405; MELLANBY K, 1945, HUMAN GUINEA PIGS; MILLIGAN S, 1991, PUFFIN BOOK 20TH CEN, P162; SILCOCK A, 1969, VERSE WORSE, P242; STEVENSON B, 1967, STEVENSONS BOOK QUOT, P1171; SWIFT J, 1967, SWIFT POETICAL WORKS, P578; 1964, PLAGUE PHILISTINES, P146	12	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1611	1614		10.1136/bmj.303.6817.1611	http://dx.doi.org/10.1136/bmj.303.6817.1611			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	GX956	1773193	Green Published, Bronze			2022-12-01	WOS:A1991GX95600026
J	DREXLER, H; ZEIHER, AM; MEINZER, K; JUST, H				DREXLER, H; ZEIHER, AM; MEINZER, K; JUST, H			CORRECTION OF ENDOTHELIAL DYSFUNCTION IN CORONARY MICROCIRCULATION OF HYPERCHOLESTEROLEMIC PATIENTS BY L-ARGININE	LANCET			English	Article							CHOLESTEROL-FED RABBITS; DEPENDENT RELAXATION; NITRIC-OXIDE; ARTERIES	Hypercholesterolaemia impairs endothelial function, possibly by interference with the intracellular formation of endothelium-derived relaxing factor from its precursor L-arginine. Whether L-arginine reverses hypercholesterolaemia-induced endothelial dysfunction in the coronary circulation was thus investigated. Epicardial artery cross-sectional area and coronary blood flow velocity were measured in 8 hypercholesterolaemic patients (mean serum cholesterol 7.8 [SE 0.3] mmol/l) and 7 age-matched controls before and after graded intracoronary infusions of the endothelium-dependent agent acetylcholine (0.036, 0.36, 3.6-mu-g/min). The effect of intracoronary infusion of L-arginine (160-mu-mol/min via the guiding catheter) on these measurements was then examined. In controls, acetylcholine induced a moderate dose-dependent constriction of the epicardial artery segment of the left anterior descending artery and increased coronary blood flow (by 239% [SE 57] at the highest dose). In patients with hypercholesterolaemia, the vasoconstrictive effect of acetylcholine on epicardial segments was similar to that in controls, but the increase in coronary blood flow with acetylcholine was significantly attenuated (highest dose: 61% [19), p < 0.02 vs controls). L-arginine restored the acetylcholine-induced increase in blood flow in patients with hypercholesterolaemia (198% [61] vs baseline) but did not affect coronary blood flow in controls. The findings suggest that hypercholesterolaemia impairs endothelium-dependent dilatation of the coronary microcirculation and that this impairment can be restored by short-term administration of L-arginine. The possibility that L-arginine might form the basis of treatment for coronary endothelial abnormalities induced by hypercholesterolaemia could be worth investigating.			DREXLER, H (corresponding author), UNIV FREIBURG, MED KLIN 3, W-7800 FREIBURG, GERMANY.							CALVER A, 1990, LANCET, V336, P1016; COHEN RA, 1988, CIRC RES, V63, P903, DOI 10.1161/01.RES.63.5.903; COOKE JP, 1991, CIRCULATION, V83, P1057, DOI 10.1161/01.CIR.83.3.1057; DREXLER H, 1991, HYPERTENSION, V18, P90, DOI 10.1161/01.HYP.18.4_Suppl.II90; DREXLER H, 1989, CIRCULATION, V80, P466, DOI 10.1161/01.CIR.80.3.466; DREXLER H, IN PRESS CIRCULATION; GALLE J, 1991, ARTERIOSCLER THROMB, V11, P198, DOI 10.1161/01.ATV.11.1.198; GIRERD XJ, 1990, CIRC RES, V67, P1301, DOI 10.1161/01.RES.67.6.1301; GOLINO P, 1991, NEW ENGL J MED, V324, P641, DOI 10.1056/NEJM199103073241001; HENDERSON AH, 1991, BRIT HEART J, V65, P116; HOGAN JC, 1988, BRIT J PHARMACOL, V94, P1020, DOI 10.1111/j.1476-5381.1988.tb11616.x; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MINOR RL, 1990, J CLIN INVEST, V86, P2109, DOI 10.1172/JCI114949; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; OSBORNE JA, 1989, AM J PHYSIOL, V256, pC591, DOI 10.1152/ajpcell.1989.256.3.C591; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; ROSSITCH E, 1991, J CLIN INVEST, V87, P1295, DOI 10.1172/JCI115132; RUBANYI GM, 1991, CIRCULATION, V83, P1118, DOI 10.1161/01.CIR.83.3.1118; SCHMIDT HHHW, 1988, EUR J PHARMACOL, V148, P293, DOI 10.1016/0014-2999(88)90578-X; SCHMIDT HHHW, 1990, BRIT J PHARMACOL, V101, P145, DOI 10.1111/j.1476-5381.1990.tb12104.x; SELLKE FW, 1990, CIRCULATION, V81, P1586, DOI 10.1161/01.CIR.81.5.1586; SHIMOKAWA H, 1989, CIRC RES, V64, P900, DOI 10.1161/01.RES.64.5.900; TAGAWA H, 1991, CIRC RES, V68, P330, DOI 10.1161/01.RES.68.2.330; TANNER FC, 1991, CIRCULATION, V83, P2012, DOI 10.1161/01.CIR.83.6.2012; VERBEUREN TJ, 1986, CIRC RES, V58, P552, DOI 10.1161/01.RES.58.4.552; WERNS SW, 1989, CIRCULATION, V79, P287, DOI 10.1161/01.CIR.79.2.287; WOLLSCHLAGER H, 1986, COMPUT CARDIOL, P483; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; ZEIHER AM, 1991, CIRCULATION, V84, P1984, DOI 10.1161/01.CIR.84.5.1984; ZEIHER AM, 1991, CIRCULATION, V83, P391, DOI 10.1161/01.CIR.83.2.391; ZEIHER AM, 1991, CIRCULATION S, V84, P652	31	719	791	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	1991	338	8782-3					1546	1550		10.1016/0140-6736(91)92372-9	http://dx.doi.org/10.1016/0140-6736(91)92372-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW036	1683971				2022-12-01	WOS:A1991GW03600003
J	ELDER, AT; JYOTHINAGARAM, SG; PADFIELD, PL; SHAW, TRD				ELDER, AT; JYOTHINAGARAM, SG; PADFIELD, PL; SHAW, TRD			HEMODYNAMIC-RESPONSE IN SOCCER SPECTATORS - IS SCOTTISH FOOTBALL EXCITING	BRITISH MEDICAL JOURNAL			English	Article							ELECTROCARDIOGRAM	Objective - To determine the effect of watching a game of Scottish football on heart rate and blood pressure. Design - Prospective study. Setting - Two Scottish Premier League football grounds. Subjects - 10 healthy men, each a supporter of one of two clubs. Main outcome measures - Systolic and diastolic blood pressure and heart rate at home, while walking, and during the match. Results - Systolic blood pressure and heart rate were significantly higher when the men were watching the match than when they were at home. While they were watching the match, heart rate was maximal immediately after a goal had been scored by the supported team. Conclusion - The emotional stress invoked by Scottish football is associated with significant increases in heart rate and systolic blood pressure.	WESTERN GEN HOSP,DEPT MED,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh	ELDER, AT (corresponding author), WESTERN GEN HOSP,DEPT CARDIOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.			Elder, Andrew/0000-0003-3229-9601				CLARK S, 1991, J HUM HYPERTENSION, V5, P7; NORTHCOTE RJ, 1983, BRIT HEART J, V50, P372; PRINGLE SD, 1989, BRIT MED J, V299, P1575, DOI 10.1136/bmj.299.6715.1575; SCHIFFER F, 1976, AM J CARDIOL, V37, P41, DOI 10.1016/0002-9149(76)90497-5; TAGGART P, 1973, LANCET, V2, P341; TAGGART P, 1969, BMJ-BRIT MED J, V4, P130, DOI 10.1136/bmj.4.5676.130	6	4	4	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1609	1610		10.1136/bmj.303.6817.1609	http://dx.doi.org/10.1136/bmj.303.6817.1609			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773191	Green Published, Bronze			2022-12-01	WOS:A1991GX95600024
J	JACK, DB; SOPPITT, AJ				JACK, DB; SOPPITT, AJ			GIVE A DRUG A BAD NAME	BRITISH MEDICAL JOURNAL			English	Article									DUDLEY RD GEN HOSP,DEPT GASTROENTEROL,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND		JACK, DB (corresponding author), FIDIA RES LABS,SCI INFORMAT SERV,I-35031 ABANO TERME,ITALY.							BLAIN J, 1990, REV PRESCRIRE    OCT; Eliot T. S., 1939, OLD POSSUMS BOOK PRA; FABER J, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92954-Z; Heller J., 1962, CATCH 22; HOFFMAN JP, 1990, NEW ENGL J MED, V323, P1428; KURTH MC, 1990, NEW ENGL J MED, V323, P1776; TOLSTOI LN, 1954, ANNA KARENINA; 1990, INDEX NOMINUM; 1991, BRIT NATIONAL FORMUL, V21	9	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1606	1608		10.1136/bmj.303.6817.1606	http://dx.doi.org/10.1136/bmj.303.6817.1606			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773189	Green Published, Bronze			2022-12-01	WOS:A1991GX95600022
J	KAUFMANN, H; ORIBE, E; OLIVER, JA				KAUFMANN, H; ORIBE, E; OLIVER, JA			PLASMA ENDOTHELIN DURING UPRIGHT TILT - RELEVANCE FOR ORTHOSTATIC HYPOTENSION	LANCET			English	Article							VASOVAGAL SYNCOPE; POSTURAL CHANGE; CELLS; VASOPRESSIN	Since plasma endothelin concentration increases with upright posture and decreases with volume expansion, a study was conducted to test whether activation of the baroreceptor reflex releases endothelin into plasma. The effect of passive upright tilt on the plasma concentrations of endothelin and vasopressin was examined in: (1) normal subjects; (2) patients with impaired baroreceptor reflex due to primary autonomic failure; (3) patients with normal afferent baroreceptor function but acute inhibition of vasoconstrictor sympathetic outflow (ie, with vasovagal syncope); and (4) patients with hypophysial diabetes insipidus. In normal subjects, upright tilt did not change arterial pressure and significantly increased the plasma concentrations of endothelin and vasopressin. In patients with autonomic failure, upright tilt induced a considerable fall in arterial pressure, no rise in plasma endothelin, and a slight increase in plasma vasopressin. In subjects with vasovagal syncope, arterial pressure dropped and the plasma concentrations of endothelin and vasopressin rose. In the subjects with diabetes insipidus, arterial pressure fell slightly, without change in plasma concentration of endothelin. The results suggest that activation of the baroreceptor reflex induces the release of endothelin into plasma, probably from the neurohypophysis, and they raise the possibility that impaired endothelin release contributes to the orthostatic hypotension of patients with primary autonomic failure.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University	KAUFMANN, H (corresponding author), CUNY MT SINAI SCH MED,DEPT NEUROL,AUTONOM NERVOUS SYST LAB,BOX 1137,NEW YORK,NY 10029, USA.			Kaufmann, Horacio/0000-0002-1851-9981	NCRR NIH HHS [RR-71] Funding Source: Medline; NINDS NIH HHS [NS-07245] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANNISTER R, 1989, AUTONOMIC FAILURE TX, P1; BRIGDEN W, 1950, CLIN SCI, V9, P75; DAVIES R, 1976, CLIN SCI MOL MED, V51, P267, DOI 10.1042/cs0510267; EMORI T, 1989, BIOCHEM BIOPH RES CO, V160, P93, DOI 10.1016/0006-291X(89)91625-2; KALA R, 1974, SCAND J CLIN LAB INV, V33, P87, DOI 10.3109/00365517409114202; KAUFMANN H, 1990, NEUROLOGY, V40, P1115, DOI 10.1212/WNL.40.7.1115; KAUFMANN H, 1990, Society for Neuroscience Abstracts, V16, P221; KAUFMANN H, 1990, Neurology, V40, P211; MILLER M, 1969, ENDOCRINOLOGY, V84, P557, DOI 10.1210/endo-84-3-557; ROSS CA, 1985, J COMP NEUROL, V242, P511, DOI 10.1002/cne.902420405; SAWCHENKO PE, 1981, SCIENCE, V214, P685, DOI 10.1126/science.7292008; SCHERRER U, 1990, NEW ENGL J MED, V322, P602, DOI 10.1056/NEJM199003013220906; SHICHIRI M, 1990, JAMA-J AM MED ASSOC, V263, P661, DOI 10.1001/jama.1990.03440050055027; TOMITA K, 1990, J CLIN INVEST, V85, P2014, DOI 10.1172/JCI114667; WALLIN BG, 1982, J AUTONOM NERV SYST, V6, P287; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOSHIZAWA T, 1990, SCIENCE, V247, P462, DOI 10.1126/science.2405487; YOSHIZUMI M, 1989, BIOCHEM BIOPH RES CO, V161, P859, DOI 10.1016/0006-291X(89)92679-X; ZEIDEL ML, 1989, AM J PHYSIOL, V257, pC1101, DOI 10.1152/ajpcell.1989.257.6.C1101; ZERBE RL, 1983, AM J MED, V74, P265, DOI 10.1016/0002-9343(83)90625-3	20	135	141	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1991	338	8782-3					1542	1545		10.1016/0140-6736(91)92370-H	http://dx.doi.org/10.1016/0140-6736(91)92370-H			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW036	1683970				2022-12-01	WOS:A1991GW03600002
J	KLEIN, RS; FREEMAN, K; TAYLOR, PE; STEVENS, CE				KLEIN, RS; FREEMAN, K; TAYLOR, PE; STEVENS, CE			OCCUPATIONAL RISK FOR HEPATITIS-C VIRUS-INFECTION AMONG NEW-YORK-CITY DENTISTS	LANCET			English	Article							NON-B-HEPATITIS; NON-A; UNITED-STATES; HEPATOCELLULAR-CARCINOMA; ANTIBODIES; EPIDEMIOLOGY; TRANSMISSION; PREVALENCE	Health-care workers have an occupational risk of infection with hepatitis C virus (HCV). However, neither the magnitude of this risk nor the practices associated with it have been defined. Since dentists have numerous patients and are exposed to blood, they are likely to have the maximum risk. Therefore, we have assessed occupational risk for HCV infection among dentists in the New York City area. Individuals who admitted present or previous intravenous drug use or (men) who were homosexual or bisexual were excluded. Demographic, occupational, and behavioural data were recorded, and sera were tested for antibodies to HCV (anti-HCV). Anti-HCV was found in 8 (1.75%) of 456 dentists compared with 1 (0.14%) of 723 controls (odds ratio [OR] 12.9, 95% confidence interval [Cl] 1.7 to 573). Anti-HCV was found in 4 (9.3%) of 43 oral surgeons compared with 4 (0.97%) of 413 other dentists (OR 10.5, 95% Cl 1.9 to 58). Seropositive dentists claimed to have treated more intravenous drug users in the week (p = 0.04) or month (p = 0.03) before the study than did seronegative dentists. Our findings show that dentists are at increased risk for hepatitis C infection. All health-care workers should regard patients as potentially infected with a communicable bloodborne agent.	MONTEFIORE MED CTR,DEPT BIOSTAT,BRONX,NY 10467; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT EPIDEMIOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT SOCIAL MED,BRONX,NY 10461; NEW YORK BLOOD CTR,WOLF SZMUNESS LAB EPIDEMIOL,NEW YORK,NY 10021	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; New York Blood Center	KLEIN, RS (corresponding author), MONTEFIORE MED CTR,DEPT MED,DIV INFECT DIS,111 E 210TH ST,BRONX,NY 10467, USA.							AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; ABE K, 1987, J INFECT DIS, V155, P1078, DOI 10.1093/infdis/155.5.1078; AHTONE J, 1980, LANCET, V1, P1142; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1978, LANCET, V1, P459; ALTER MJ, 1987, AM J EPIDEMIOL, V125, P133, DOI 10.1093/oxfordjournals.aje.a114496; ALTER MJ, 1982, J INFECT DIS, V145, P886, DOI 10.1093/infdis/145.6.886; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; BRUIX J, 1989, LANCET, V2, P1004; COLOMBO M, 1989, LANCET, V2, P1006; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; ESTEBAN JI, 1989, LANCET, V2, P294; FRANCIS DP, 1984, AM J MED, V76, P69, DOI 10.1016/0002-9343(84)90752-6; KATMITSUKASA H, 1989, LANCET, V2, P987; KEW MC, 1990, LANCET, V335, P873, DOI 10.1016/0140-6736(90)90474-J; KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; KLEIN RS, 1988, NEW ENGL J MED, V318, P86, DOI 10.1056/NEJM198801143180205; MOSLEY JW, 1975, JAMA-J AM MED ASSOC, V9, P967; SCHIFF ER, 1986, J AM DENT ASSOC, V113, P390, DOI 10.14219/jada.archive.1986.0210; STEVENS CE, 1990, JAMA-J AM MED ASSOC, V263, P49, DOI 10.1001/jama.263.1.49; TABOR E, 1978, LANCET, V1, P463, DOI 10.1016/s0140-6736(78)90132-0; TABOR E, 1983, J MED PRIMATOL, V12, P305; TABOR E, 1980, NEW ENGL J MED, V303, P139; WANG JT, 1991, LANCET, V337, P48, DOI 10.1016/0140-6736(91)93365-G; 1987, MMWR S2S, V36; 1988, MMWR, V37, P387; 1988, MMWR, V37, P377	28	148	153	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1991	338	8782-3					1539	1542		10.1016/0140-6736(91)92369-D	http://dx.doi.org/10.1016/0140-6736(91)92369-D			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW036	1683969				2022-12-01	WOS:A1991GW03600001
J	NAVA, E; PALMER, RMJ; MONCADA, S				NAVA, E; PALMER, RMJ; MONCADA, S			INHIBITION OF NITRIC-OXIDE SYNTHESIS IN SEPTIC SHOCK - HOW MUCH IS BENEFICIAL	LANCET			English	Note							HYPOTENSION	Hypotension in septic shock is often resistant to treatment with vasoconstrictors and appears to be mediated by production of nitric oxide (NO). Reversal of endotoxin-induced hypotension in rats was achieved by intravenous injection of 30 mg/kg NG-monomethyl-L-arginine (L-NMMA), an inhibitor of endogenous NO synthesis. A lower dose of 3 mg/kg L-NMMA was ineffective, but 300 mg/kg L-NMMA accelerated and enhanced the fall in blood pressure. NO synthase inhibitors may be helpful in the treatment of hypotension associated with sepsis or therapeutic use of cytokines, but complete inhibition of endogenous NO synthesis may be counterproductive.	WELLCOME RES LABS,LANGLEY COURT,BECKENHAM BR3 3BS,KENT,ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories				nava, eduardo/0000-0003-3259-0511				COHEN J, 1991, LANCET, V338, P736, DOI 10.1016/0140-6736(91)91453-2; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KLABUNDE RE, 1991, BIOCHEM BIOPH RES CO, V178, P1135, DOI 10.1016/0006-291X(91)91010-A; MONCADA S, 1991, PHARMACOL REV, V43, P109; SCOTTBURDEN T, IN PRESS BIOL NITRIC; THIEMERMANN C, 1990, EUR J PHARMACOL, V182, P591, DOI 10.1016/0014-2999(90)90062-B; VALLANCE P, 1989, LANCET, V2, P997; WRIGHT CE, IN PRESS CARDIOVASC	9	389	394	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1991	338	8782-3					1555	1557		10.1016/0140-6736(91)92375-C	http://dx.doi.org/10.1016/0140-6736(91)92375-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW036	1683974				2022-12-01	WOS:A1991GW03600006
J	PETROS, A; BENNETT, D; VALLANCE, P				PETROS, A; BENNETT, D; VALLANCE, P			EFFECT OF NITRIC-OXIDE SYNTHASE INHIBITORS ON HYPOTENSION IN PATIENTS WITH SEPTIC SHOCK	LANCET			English	Note							L-ARGININE; ENDOTOXIN; TONE	Hypotension during septic shock, which may reflect increased synthesis of the potent vasodilator nitric oxide (NO), is often refractory to vasoconstrictors. We describe the effects of NO synthase inhibition in two patients with life-threatening septic shock in whom conventional therapy had failed to restore blood pressure. N(G)-monomethyl-L-arginine (L-NMMA) caused dose-dependent increases in blood pressure and systemic vascular resistance in both patients, and a similar effect was observed in the second patient after treatment with N(G)-nitro-L-arginine methyl ester (L-NAME). These findings indicate that NO synthase induction contributes to the pathogenesis of septic shock, and that inhibition of NO synthase may represent a novel therapeutic option.	ST GEORGE HOSP,SCH MED,DEPT PHARMACOL & CLIN PHARMACOL,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND; ST GEORGE HOSP,SCH MED,INTENS THERAPY UNIT,LONDON SW17 0RE,ENGLAND	St Georges University London; St Georges University London								GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; JOULOUSCHAEFFER G, 1990, AM J PHYSIOL, V259, pH1038; KILBOURN RG, 1990, BIOCHEM BIOPH RES CO, V172, P1132, DOI 10.1016/0006-291X(90)91565-A; MONCADA S, 1991, PHARMACOL REV, V43, P109; REES DD, 1990, BIOCHEM BIOPH RES CO, V173, P541, DOI 10.1016/S0006-291X(05)80068-3; REES DD, 1989, BRIT J PHARMACOL, V96, P418, DOI 10.1111/j.1476-5381.1989.tb11833.x; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; THIEMERMANN C, 1990, EUR J PHARMACOL, V182, P591, DOI 10.1016/0014-2999(90)90062-B; VALLANCE P, 1989, LANCET, V2, P997; WRIGHT CE, IN PRESS CARDIOVASC	10	804	831	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1991	338	8782-3					1557	1558		10.1016/0140-6736(91)92376-D	http://dx.doi.org/10.1016/0140-6736(91)92376-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW036	1720856				2022-12-01	WOS:A1991GW03600007
J	SCOTT, JES; LEE, REJ; HUNTER, EW; COULTHARD, MG; MATTHEWS, JNS				SCOTT, JES; LEE, REJ; HUNTER, EW; COULTHARD, MG; MATTHEWS, JNS			ULTRASOUND SCREENING OF NEWBORN URINARY-TRACT	LANCET			English	Article							REFLUX; INFANTS	A non-invasive method to screen newborn babies for ureteric reflux might allow the possibility of appropriate action to prevent reflux nephropathy. We have tested the sensitivity of ultrasound screening of the urinary tract. 1061 unselected newborn infants born during 1986 were examined by ultrasound and the findings were recorded on videotape. Babies with dilated renal collecting systems underwent further investigations (micturating cystourethrography, intravenous urography, or radioisotope study). With these methods, 11 children were found to have renal disorders. A postal follow-up survey was carried out when the children were 3 years old. 657 (62%) families responded. We searched for non-responders among children born in 1986 who had subsequently had a renal radioisotope investigation: 5 nonresponders were found among these children. Of the total, 24 children had had a urinary-tract infection: 3 more children with ureteric reflux were found; their neonatal ultrasound scans had suggested no abnormality. Thus, mom than half the children of this cohort in whom hydronephrosis or ureteric reflux developed had only slight dilatation (less than 5 mm) on the neonatal scan. On review of the original videotapes there was no difference in internal dimension between left and right kidneys: the internal dimension was 5 mm or less in both kidneys in 96.5% of babies and 4 mm or less in 93.3%. Routine renal ultrasound scanning of newborn babies is of no value in detecting those who may have ureteric reflux: the number of other renal abnormalities likely to be detected is small.	ROYAL VICTORIA INFIRM,DEPT RADIOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; ROYAL VICTORIA INFIRM,DEPT CHILD HLTH,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT SURG,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DIV MED STAT,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK			Matthews, John N S/H-7502-2013	Matthews, John N S/0000-0003-2559-037X				ANDERSON PAM, 1991, BRIT J UROL, V67, P267, DOI 10.1111/j.1464-410X.1991.tb15132.x; DIARD F, 1987, PEDIATR RADIOL, V17, P154, DOI 10.1007/BF02388097; FALKOFF GE, 1987, RADIOLOGY, V162, P343, DOI 10.1148/radiology.162.2.3541028; GORDON AC, 1990, BRIT J UROL, V65, P407, DOI 10.1111/j.1464-410X.1990.tb14766.x; HODSON C J, 1960, Clin Radiol, V11, P219, DOI 10.1016/S0009-9260(60)80047-5; MARSHALL JL, 1990, RADIOLOGY, V175, P355, DOI 10.1148/radiology.175.2.2183279; PLACKETT RL, 1981, ANAL CATEGORICAL DAT, P79; SCOTT JES, 1987, BRIT J UROL, V59, P291, DOI 10.1111/j.1464-410X.1987.tb04634.x; SCOTT JES, 1990, ARCH DIS CHILD-FETAL, V65, P361, DOI 10.1136/adc.65.4_Spec_No.361; STEINHART JM, 1988, PEDIATRICS, V82, P609; 1991, LANCET, V338, P1050	11	39	39	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1991	338	8782-3					1571	1573		10.1016/0140-6736(91)92385-F	http://dx.doi.org/10.1016/0140-6736(91)92385-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW036	1683982				2022-12-01	WOS:A1991GW03600015
J	SZASZ, T				SZASZ, T			DIAGNOSES ARE NOT DISEASES	LANCET			English	Editorial Material											SZASZ, T (corresponding author), SUNY HLTH SCI CTR,SYRACUSE,NY 13210, USA.							FREUDENHEIM M, 1991, WALL STREET J   0924; FREUDENHEIM M, 1991, NY TIMES        0629, pA1; FREUDENHEIM M, 1991, NY TIMES        0923, pD4; GOLDMAN MJ, 1991, AM J PSYCHIAT, V148, P986; KAREL R, 1991, PSYCHIATTRIC NEWS, V26, P16; Polanyi Michael, 1969, KNOWING BEING; ROGERS W, 1982, W ROGERS TREASURY RE, P256; Stigma Shout Survey, 2008, MYTH MENTAL ILLNESS; Szasz T.S., 1987, INSANITY IDEA ITS CO; 1980, DIAGNOSTIC STATISTIC; 1987, DIAGNOSTIC STATISTIC; 1991, LANCET, V338, P785	12	18	18	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1991	338	8782-3					1574	1576		10.1016/0140-6736(91)92387-H	http://dx.doi.org/10.1016/0140-6736(91)92387-H			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW036	1683983				2022-12-01	WOS:A1991GW03600016
J	WONG, D; NYE, K; HOLLIS, P				WONG, D; NYE, K; HOLLIS, P			MICROBIAL-FLORA ON DOCTORS WHITE COATS	BRITISH MEDICAL JOURNAL			English	Article							NURSES	Objective - To determine the level and type of microbial contamination present on the white coats of doctors in order to assess the risk of transmission of pathogenic micro-organisms by this route in a hospital setting. Design - Cross sectional survey of the bacterial contamination of white coats in a general hospital. Setting - East Birmingham Hospital, an urban general hospital with 800 beds. Subjects - 100 doctors of different grades and specialties. Results - The cuffs and pockets of the coats were the most highly contaminated areas. The level of bacterial contamination did not vary with the length of time a coat had been in use, but it increased with the degree of usage by the individual doctor. Staphylococcus aureus was isolated from a quarter of the coats examined, more commonly from those belonging to doctors in surgical specialties than medical specialties. Pathogenic Gram negative bacilli and other pathogenic bacteria were not isolated. Conclusions - White coats are a potential source of cross infection, especially in surgical areas. Scrupulous hand washing should be observed before and after attending patients and it may be advisable to remove the white coat and put on a plastic apron before examining wounds. There is little microbiological reason for recommending a more frequent change of white coat than once a week, nor for excluding the wearing of white coats in non-clinical areas.			WONG, D (corresponding author), E BIRMINGHAM DIST GEN HOSP,PUBL HLTH LAB,BIRMINGHAM B9 5ST,W MIDLANDS,ENGLAND.							AYLIFFE GAJ, 1967, J HYG-CAMB, V65, P515, DOI 10.1017/S0022172400046052; BABB JR, 1983, J HOSP INFECT, V4, P149, DOI 10.1016/0195-6701(83)90044-0; HAMBRAEUS A, 1973, J HYG-CAMBRIDGE, V71, P799, DOI 10.1017/S0022172400023068; LIDWELL OM, 1974, J APPL BACTERIOL, V37, P649, DOI 10.1111/j.1365-2672.1974.tb00489.x; NICOLES PS, 1970, AM J PUBLIC HEALTH, V60, P2175; Nystrom B, 1981, J Hosp Infect, V2, P167, DOI 10.1016/0195-6701(81)90025-6; RANSJO U, 1979, J HYG-CAMBRIDGE, V82, P369, DOI 10.1017/S0022172400053900; ROBINTON ED, 1968, AM J PUBLIC HEALTH N, V58, P1452, DOI 10.2105/AJPH.58.8.1452; SPEERS R, 1969, LANCET, V2, P233	9	115	119	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1602	1604		10.1136/bmj.303.6817.1602	http://dx.doi.org/10.1136/bmj.303.6817.1602			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773186	Green Published, Bronze			2022-12-01	WOS:A1991GX95600019
J	WRIGHT, V				WRIGHT, V			IN DEFENSE OF EPONYMS	BRITISH MEDICAL JOURNAL			English	Article											WRIGHT, V (corresponding author), UNIV LEEDS,RHEUMATOL & REHABIL RES UNIT,LEEDS LS2 9NZ,ENGLAND.							[Anonymous], 1976, SERONEGATIVE POLYART; BECHTEREW VM, 1893, NEUROL ZENTRALBLAT, V12, P426; Brodie BC, 1818, PATHOLOGICAL SURGICA, P54; Crohn BB, 1932, J AMER MED ASSOC, V99, P1323, DOI 10.1001/jama.1932.02740680019005; Felty AR, 1924, B JOHNS HOPKINS HOSP, V35, P16; HUSKISSON EC, 1973, JOINT DISEASE ALL AR; KEAT AC, 1979, Q J MED, V48, P323; MARIE P, 1898, REV MED, V18, P285; MIELANTS H, 1990, Current Opinion in Rheumatology, V2, P570; Paronen I, 1948, ACTA MED SCAND  S212, V212, P1; Reiter H, 1916, DEUT MED WOCHENSCHR, V42, P1535, DOI 10.1055/s-0028-1135542; SCOTT JT, 1986, COPEMANS TXB RHEUMAT, P787; SHARP JT, ARTHRITIS ALLIED CON, P1229; Still G F, 1897, Med Chir Trans, V80, P47; Strumpell A, 1897, DTSCH Z NERVENH, V11, P338, DOI 10.1007/BF01674127; THOMPSON P, 1980, MISTER LEPROSY; Whipple GH, 1907, B JOHNS HOPKINS HOSP, V18, P382	17	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1600	1602		10.1136/bmj.303.6817.1600	http://dx.doi.org/10.1136/bmj.303.6817.1600			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773185	Green Published, Bronze			2022-12-01	WOS:A1991GX95600018
J	YAQOOB, M; MCCLELLAND, P; BELL, GM; AHMAD, R; BAKRAN, A				YAQOOB, M; MCCLELLAND, P; BELL, GM; AHMAD, R; BAKRAN, A			BLADDER-TUMORS IN PARAPLEGIC PATIENTS ON RENAL REPLACEMENT THERAPY	LANCET			English	Note							SPINAL-CORD INJURY; CANCER	Fourteen adult patients with end-stage renal disease due to spina bifida or spinal-cord injury underwent regular haemodialysis for 3-120 (mean 20) months. Seven of these patients received renal transplants. Urinary bladder tumours developed in four of the fourteen patients (three squamous-cell carcinoma in patients still on dialysis, one poorly differentiated transitional-cell carcinoma in a patient after successful transplantation). All four had widespread metastatic disease and died within 8 weeks of the diagnosis of cancer. We recommend regular urological evaluation for patients with neurogenic bladder even after initiation of dialysis treatment. Total cystectomy before transplantation might greatly reduce the risk of these rare tumours.			YAQOOB, M (corresponding author), ROYAL LIVERPOOL UNIV HOSP,RENAL UNIT,PRESCOT ST,LIVERPOOL L7 8XP,ENGLAND.							BROECKER BH, 1981, J UROLOGY, V125, P196, DOI 10.1016/S0022-5347(17)54963-0; ELMASRI WS, 1981, PARAPLEGIA, V19, P265, DOI 10.1038/sc.1981.52; FELDMAN AR, 1986, NEW ENGL J MED, V315, P1394, DOI 10.1056/NEJM198611273152206; GRUBER SA, 1991, TRANSPLANT P, V23, P1104; KAUFMAN JM, 1977, J UROLOGY, V118, P967, DOI 10.1016/S0022-5347(17)58266-X; Melzak J, 1966, Paraplegia, V4, P85; MIRAHMADI MK, 1982, PARAPLEGIA, V20, P43, DOI 10.1038/sc.1982.5; MURALIKRISHNA GS, 1989, BRIT MED J, V299, P1506, DOI 10.1136/bmj.299.6714.1506; PENN I, 1991, TRANSPLANT P, V23, P1101; RAGHAVAN D, 1990, NEW ENGL J MED, V322, P1129, DOI 10.1056/NEJM199004193221607	10	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1991	338	8782-3					1554	1555		10.1016/0140-6736(91)92374-B	http://dx.doi.org/10.1016/0140-6736(91)92374-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW036	1683973				2022-12-01	WOS:A1991GW03600005
J	BANSAL, A; GIERASCH, LM				BANSAL, A; GIERASCH, LM			THE NPXY INTERNALIZATION SIGNAL OF THE LDL RECEPTOR ADOPTS A REVERSE-TURN CONFORMATION	CELL			English	Article							LOW-DENSITY-LIPOPROTEIN; IMMUNOGENIC PEPTIDE-FRAGMENTS; CYTOPLASMIC DOMAIN; AMINO-ACID; INSULIN-RECEPTOR; WATER SOLUTION; COATED PITS; PROTEINS; ENDOCYTOSIS; SPECTROSCOPY	Peptides corresponding to the proposed coated pit internalization signal of the native low density lipoprotein receptor, NPVY, take up in aqueous solution a reverse-turn conformation with the Asn in position i and the Tyr in position i + 3. By contrast, peptides derived from receptors that are defective for endocytosis do not adopt the reverse turn. These internalization-defective receptors include those with a nonaromatic residue substituted for the Tyr and those with Asn --> Ala or Pro --> Ala substitutions. While the tendency of an Asn-Pro sequence to induce a reverse turn was anticipated, the structural importance of an aromatic residue in position i + 3 was not. The sequences associated with the internalization signal thus appear to play a critical conformational role that is required for endocytosis, probably by enabling binding to adaptor molecules. With the results presented in the accompanying paper on lysosomal acid phosphatase, we now have direct evidence for previous proposals of a general correlation of internalization signals with a turn conformational motif.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	BANSAL, A (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235, USA.		Gierasch, Lila M/D-1494-2009		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027616] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 27616] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANSAL A, 1989, CURRENT RES PROTEIN, P331; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BROWN MS, 1976, CELL, V9, P663, DOI 10.1016/0092-8674(76)90130-6; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEHRMAN MA, 1985, CELL, V41, P735, DOI 10.1016/S0092-8674(85)80054-4; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; RICHARDSON JS, 1988, PREDICTION PROTEIN S, P1; Stewart JM, 1984, SOLID PHASE PEPTIDE; THIES RS, 1990, J BIOL CHEM, V265, P10132; WAGNER G, 1981, EUR J BIOCHEM, V114, P375, DOI 10.1111/j.1432-1033.1981.tb05157.x; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WRIGHT PE, 1988, BIOCHEMISTRY-US, V27, P7167, DOI 10.1021/bi00419a001; WUETHRICH K, 1984, J MOL BIOL, V180, P715	36	224	226	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1195	1201		10.1016/0092-8674(91)90295-A	http://dx.doi.org/10.1016/0092-8674(91)90295-A			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760844				2022-12-01	WOS:A1991GX16400017
J	BOKOCH, GM; QUILLIAM, LA; BOHL, BP; JESAITIS, AJ; QUINN, MT				BOKOCH, GM; QUILLIAM, LA; BOHL, BP; JESAITIS, AJ; QUINN, MT			INHIBITION OF RAP1A BINDING TO CYTOCHROME-B558 OF NADPH OXIDASE BY PHOSPHORYLATION OF RAP1A	SCIENCE			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; RAS-RELATED PROTEIN; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE; RAS-P21 GTPASE; COMPONENTS; ACTIVATION; GENE; CELL	Rap1A is a low molecular weight guanosine triphosphate (GTP)-binding protein in human neutrophil membranes whose cellular function is unknown. Rap1A was found to form stoichiometric complexes with the cytochrome b558 component of the phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase system. The (guanosine-5'-O-(3-thiotriphosphate) (GTP-gamma-S)-bound form of Rap1A bound more tightly to cytochrome b558 than did the guanosine diphosphate-bound form. No complex formation was observed between cytochrome b558 and H-Ras-GTP-gamma-S or Rap1A-GTP-gamma-S that had been heat-inactivated, nor between Rap1A-GTP-gamma-S and hydrophobic proteins serving as controls. Complex formation between Rap1A-GTP-gamma-S and cytochrome b558 was inhibited by phosphorylation of Rap1A with cyclic adenosine monophosphate (cAMP)-dependent protein kinase. These observations suggest that Rap1A may participate in the structure or regulation of the NADPH oxidase system and that this function of the Rap1A protein may be altered by phosphorylation.	MONTANA STATE UNIV, DEPT CHEM, BOZEMAN, MT 59717 USA; MONTANA STATE UNIV, DEPT BIOCHEM, BOZEMAN, MT 59717 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; Scripps Research Institute	BOKOCH, GM (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.		Quilliam, Lawrence/B-6447-2015; Quilliam, Lawrence/Q-4987-2019	Jesaitis, Algirdas/0000-0001-9001-5617	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434, R01GM044428] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44428, GM39434] Funding Source: Medline; PHS HHS [5RO126711] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; BOKOCH GM, UNPUB; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CURNUTTE JT, 1988, HEMATOL ONCOL CLIN N, V2, P241, DOI 10.1016/S0889-8588(18)30618-X; DER CJ, 1989, ONCOGENES, P73; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; FISCHER TH, 1990, J BIOL CHEM, V265, P19405; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GABIG TG, 1987, J BIOL CHEM, V262, P1685; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HATA Y, 1991, J BIOL CHEM, V266, P6571; HATA Y, 1990, J BIOL CHEM, V265, P7104; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; IGNARRO LJ, 1974, J EXP MED, V139, P1398; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLEINBERG ME, 1990, J BIOL CHEM, V265, P15577; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; MUELLER H, 1988, MOL PHARMACOL, V34, P347; MUELLER H, 1989, J CELL BIOCHEM, V40, P27; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; PARKOS CA, 1989, BLOOD, V73, P1416; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PEVERI P, 1989, BLOOD, V74, P397; PIZON V, 1988, ONCOGENE, V3, P201; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; QUINN MT, 1989, BIOCHIM BIOPHYS ACTA, V987, P83, DOI 10.1016/0005-2736(89)90458-6; RIVKIR I, 1975, J IMMUNOL, V115, P112; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; SEGAL AW, 1983, NEW ENGL J MED, V308, P245, DOI 10.1056/NEJM198302033080503; SMITH RM, 1989, J BIOL CHEM, V264, P1958; TAKAI Y, IN PRESS SIGNAL TRAN, V3; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138; YATANI Y, 1991, IN PRESS J BIOL CHEM; ZURIER RB, 1973, J CELL BIOL, V58, P27, DOI 10.1083/jcb.58.1.27	42	109	111	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1794	1796		10.1126/science.1763330	http://dx.doi.org/10.1126/science.1763330			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1763330				2022-12-01	WOS:A1991GW31600044
J	CHO, KWY; BLUMBERG, B; STEINBEISSER, H; DEROBERTIS, EM				CHO, KWY; BLUMBERG, B; STEINBEISSER, H; DEROBERTIS, EM			MOLECULAR NATURE OF SPEMANNS ORGANIZER - THE ROLE OF THE XENOPUS HOMEOBOX GENE GOOSECOID	CELL			English	Article							RETINOIC ACID; POSITIONAL INFORMATION; INSITU HYBRIDIZATION; MESODERMAL PATTERN; DORSAL DEVELOPMENT; PROSPECTIVE AREAS; MESSENGER-RNAS; GROWTH-FACTORS; AXIS FORMATION; FROG EMBRYOS	This study analyzes the function of the homeobox gene goosecoid in Xenopus development. First, we find that goosecoid mRNA distribution closely mimics the expected localization of organizer tissue in normal embryos as well as in those treated with LiCl and UV light. Second, goosecoid mRNA accumulation is induced by activin, even in the absence of protein synthesis. it is not affected by bFGF and is repressed by retinoic acid. Lastly, microinjection of goosecoid mRNA into the ventral side of Xenopus embryos, where goosecoid is normally absent, leads to the formation of an additional complete body axis, including head structures and abundant notochordal tissue. The results suggest that the goosecoid homeodomain protein plays a central role in executing Spemann's organizer phenomenon.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles				De Robertis, Edward/0000-0002-7843-1869	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021502, R01HD021502, F32HD007273] Funding Source: NIH RePORTER; NICHD NIH HHS [R37 HD021502-13, R37 HD021502, R01 HD021502, HD 21502-06, HD 07273] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTABA AR, 1989, NATURE, V341, P33; ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BUSA WB, 1989, DEV BIOL, V132, P315, DOI 10.1016/0012-1606(89)90228-5; CHO KWY, 1988, EMBO J, V7, P2139, DOI 10.1002/j.1460-2075.1988.tb03053.x; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; CHO KWY, 1991, CELL, V65, P55, DOI 10.1016/0092-8674(91)90407-P; COOKE J, 1989, DEVELOPMENT, V107, P229; COOKE J, 1987, DEVELOPMENT, V101, P893; COOKE J, 1972, J EMBRYOL EXP MORPH, V28, P27; DENT JA, 1989, DEVELOPMENT, V105, P61; DEROBERTIS EM, 1991, DEVELOPMENT, V112, P669; DEROBERTIS EM, 1990, SCI AM, V263, P46, DOI 10.1038/scientificamerican0790-46; DIXON JE, 1989, DEVELOPMENT, V106, P749; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; ELINSON RP, 1989, DEV GROWTH DIFFER, V31, P423; FRITZ AF, 1989, DEV BIOL, V131, P584, DOI 10.1016/S0012-1606(89)80029-6; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GERHART J, 1989, DEVELOPMENT, V107, P37; GIMLICH RL, 1986, DEV BIOL, V115, P340, DOI 10.1016/0012-1606(86)90254-X; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KELLER RE, 1976, DEV BIOL, V51, P118, DOI 10.1016/0012-1606(76)90127-5; KELLER RE, 1975, DEV BIOL, V42, P222, DOI 10.1016/0012-1606(75)90331-0; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KLEIN SL, 1987, DEV BIOL, V120, P299, DOI 10.1016/0012-1606(87)90127-8; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NIEHRS C, 1991, IN PRESS EMBO J; Nieuwkoop P D, 1973, Adv Morphog, V10, P1; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SAVAGE R, 1989, DEV BIOL, V133, P157, DOI 10.1016/0012-1606(89)90307-2; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIVE HL, 1991, GENE DEV, V5, P1321, DOI 10.1101/gad.5.8.1321; SIVE HL, 1990, GENE DEV, V4, P932, DOI 10.1101/gad.4.6.932; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SLACK JMW, 1989, DEVELOPMENT, V107, P141; SMITH JC, 1985, J EMBRYOL EXP MORPH, V89, P317; SMITH JC, 1989, DEVELOPMENT, V107, P149; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SPEMANN H, 1931, ROUX ARCH ENTW MECH, V123, P389; Spemann H., 1938, EMBRYONIC DEV INDUCT; STEWART RM, 1990, DEVELOPMENT, V109, P363; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; WOLPERT L, 1989, DEVELOPMENT, V107, P3; YUGE M, 1990, DEVELOPMENT, V110, P1051	56	740	749	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 20	1991	67	6					1111	1120		10.1016/0092-8674(91)90288-A	http://dx.doi.org/10.1016/0092-8674(91)90288-A			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1684739	Green Accepted			2022-12-01	WOS:A1991GX16400010
J	CHOWDHURY, JR; GROSSMAN, M; GUPTA, S; CHOWDHURY, NR; BAKER, JR; WILSON, JM				CHOWDHURY, JR; GROSSMAN, M; GUPTA, S; CHOWDHURY, NR; BAKER, JR; WILSON, JM			LONG-TERM IMPROVEMENT OF HYPERCHOLESTEROLEMIA AFTER EXVIVO GENE-THERAPY IN LDLR-DEFICIENT RABBITS	SCIENCE			English	Article							HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; DENSITY-LIPOPROTEIN RECEPTORS; LIVER-TRANSPLANTATION; ALBUMIN	Familial hypercholesterolemia (FH) is an inherited disorder in humans that is caused by a deficiency of low density lipoprotein receptors (LDLRs). An animal model for FH, the Watanabe Heritable Hyperlipidemic rabbit, was used to develop an approach for liver-directed gene therapy based on transplantation of autologous hepatocytes that were genetically corrected ex vivo with recombinant retroviruses. Animals transplanted with LDLR-transduced autologous hepatocytes demonstrated a 30 to 50 percent decrease in total serum cholesterol that persisted for the duration of the experiment (122 days). Recombinant-derived LDLR RNA was harvested from tissues with no diminution for up to 6.5 months after transplantation.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT INTERNAL MED,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,BRONX,NY 10461; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	WILSON, JM (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT INTERNAL MED,BRONX,NY 10461, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042193, R01DK034357, P01DK042718] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01-DK-42718, R01-DK-34357, R01-DK42193-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BILHEIMER DW, 1984, NEW ENGL J MED, V311, P1658, DOI 10.1056/NEJM198412273112603; Cochran WG, 1957, EXPT DESIGNS, P127; DUGAICZYK A, 1982, P NATL ACAD SCI-BIOL, V79, P71, DOI 10.1073/pnas.79.1.71; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GOLDSTEIN JL, 1983, NEW ENGL J MED, V309, P288, DOI 10.1056/NEJM198308043090507; GROSSMAN MI, UNPUB; HOEG JM, 1987, AM J CARDIOL, V59, P705, DOI 10.1016/0002-9149(87)91199-4; KOZARSKY KF, 1986, J CELL BIOL, V102, P1567, DOI 10.1083/jcb.102.5.1567; PANDURO A, 1986, BIOCHEMISTRY-US, V25, P1414, DOI 10.1021/bi00354a034; PINTAR JE, 1987, IN SITU HYBRIDIZATIO, P179; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; STARZL TE, 1984, LANCET, V1, P1382; TRINDER P, 1974, ANN CLIN BIOCHEM, V12, P226; WATANABE Y, 1980, ATHEROSCLEROSIS, V36, P261, DOI 10.1016/0021-9150(80)90234-8; WIEDERKEHR JC, 1990, TRANSPLANTATION, V50, P466, DOI 10.1097/00007890-199009000-00021; WILSON JM, 1988, P NATL ACAD SCI USA, V85, P4421, DOI 10.1073/pnas.85.12.4421; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P843; WILSON JM, 1991, CLIN BIOTECHNOL, V3, P21	18	323	423	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1802	1805						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1722351				2022-12-01	WOS:A1991GW31600047
J	DIEDERICHS, K; BOONE, T; KARPLUS, PA				DIEDERICHS, K; BOONE, T; KARPLUS, PA			NOVEL FOLD AND PUTATIVE RECEPTOR-BINDING SITE OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR	SCIENCE			English	Article							MOLECULAR-CLONING; 3-DIMENSIONAL STRUCTURE; GM-CSF; IDENTIFICATION; PURIFICATION; REGIONS; MOUSE	Granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulates the development of and the cytotoxic activity of white blood cells. Recombinant human GM-CSF has proven useful in the treatment of blood disorders. The structure of GM-CSF, which was determined at 2.4 angstrom resolution by x-ray crystallography, has a novel fold combining a two-stranded antiparallel-beta-sheet with an open bundle of four a helices. Residues implicated in receptor recognition, which are distant in the primary sequence, are on adjacent alpha-helices in the folded protein. A working model for the receptor binding site is presented.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL LAB,ITHACA,NY 14853; AMGEN INC,THOUSAND OAKS,CA 91320	Cornell University; Amgen	KARPLUS, PA (corresponding author), CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL LAB,ITHACA,NY 14853, USA.			Karplus, Paul/0000-0001-8725-6292				ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ALTMANN SW, 1991, J BIOL CHEM, V266, P5333; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRANDHUBER BJ, 1987, SCIENCE, V238, P1707, DOI 10.1126/science.3500515; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURGESS AW, 1987, BLOOD, V69, P43; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CLARKLEWIS I, 1988, J IMMUNOL, V141, P881; CREIGHTON TE, 1984, PROTEIN STRUCTURES M, P226; DIEDERICHS K, 1991, J MOL BIOL, V221, P55, DOI 10.1016/0022-2836(91)90803-E; GASSON JC, 1984, SCIENCE, V226, P1339, DOI 10.1126/science.6390681; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GOUGH NM, 1984, NATURE, V309, P763, DOI 10.1038/309763a0; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; JANIN J, 1976, J MOL BIOL, V100, P197, DOI 10.1016/S0022-2836(76)80148-9; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KAUSHANSKY K, 1989, P NATL ACAD SCI USA, V86, P1213, DOI 10.1073/pnas.86.4.1213; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; MIYATAKE S, 1985, EMBO J, V4, P2561, DOI 10.1002/j.1460-2075.1985.tb03971.x; MOONEN P, 1987, P NATL ACAD SCI USA, V84, P4428, DOI 10.1073/pnas.84.13.4428; MOORE MAS, 1991, ANNU REV IMMUNOL, V9, P159; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; REDFIELD C, 1991, BIOCHEMISTRY-US, V30, P11029, DOI 10.1021/bi00110a004; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SAKAMOTO KM, 1991, J PEDIATR-US, V118, pS17, DOI 10.1016/S0022-3476(05)82185-7; SCHOMBURG D, 1988, J MOL GRAPHICS, V6, P161, DOI 10.1016/0263-7855(88)80069-9; SHANAFELT AB, 1989, P NATL ACAD SCI USA, V86, P4872, DOI 10.1073/pnas.86.13.4872; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	32	194	209	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1779	1782		10.1126/science.1837174	http://dx.doi.org/10.1126/science.1837174			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1837174	Green Submitted			2022-12-01	WOS:A1991GW31600039
J	EBERLE, W; SANDER, C; KLAUS, W; SCHMIDT, B; VONFIGURA, K; PETERS, C				EBERLE, W; SANDER, C; KLAUS, W; SCHMIDT, B; VONFIGURA, K; PETERS, C			THE ESSENTIAL TYROSINE OF THE INTERNALIZATION SIGNAL IN LYSOSOMAL ACID-PHOSPHATASE IS PART OF A BETA-TURN	CELL			English	Article							TRANSFERRIN RECEPTOR INTERNALIZATION; DENSITY-LIPOPROTEIN RECEPTOR; CYTOPLASMIC DOMAIN; CRYSTAL-STRUCTURE; ENDOCYTOSIS; SEQUENCE; LOCALIZATION; RESOLUTION; TRYPSIN; PROTEIN	For rapid endocytosis lysosomal acid phosphatase requires a Tyr-containing signal in its cytoplasmic domain, as do cell surface receptors mediating endocytosis and clustering in coated pits. To determine the structure of the internalization signal an 18 amino acid peptide representing the cytoplasmic tail of lysosomal acid phosphatase was analyzed by two-dimensional nuclear magnetic resonance spectroscopy. Part of the peptide, 5-PPGY-8, forms a well-ordered beta-turn of type I in solution. Our result and data on the structure of the endocytosis signal of the low density lipoprotein receptor reported by Bansal and Gierasch in the accompanying paper represent experimental determinations of the three-dimensional structure of protein transport signals and suggest that the essential aromatic amino acid of internalization signals is recognized by a putative cytoplasmic receptor in the structural context of a tight turn.	GESELL BIOL FORSCH,O-3300 BRAUNSCHWEIG,GERMANY; UNIV GOTTINGEN,W-3400 GOTTINGEN,GERMANY	University of Gottingen	EBERLE, W (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY.		Sander, Chris/H-1452-2011	Sander, Chris/0000-0001-6059-6270				BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BOLOGNESI M, 1982, J MOL BIOL, V162, P839, DOI 10.1016/0022-2836(82)90550-2; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; BRAUN W, 1985, J MOL BIOL, V186, P611, DOI 10.1016/0022-2836(85)90134-2; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; BRUNGER AT, 1987, METHODS CRYSTALLOGRA; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COSTE J, 1990, TETRAHEDRON LETT, V31, P205, DOI 10.1016/S0040-4039(00)94371-5; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GOTTSCHALK S, 1989, EMBO J, V8, P3215, DOI 10.1002/j.1460-2075.1989.tb08480.x; IACOPETTA BJ, 1988, CELL, V54, P485, DOI 10.1016/0092-8674(88)90069-4; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LEHRMAN MA, 1985, CELL, V41, P735, DOI 10.1016/S0092-8674(85)80054-4; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; MOLDAY RS, 1972, BIOCHEMISTRY-US, V11, P150, DOI 10.1021/bi00752a003; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; PEARSE BMF, 1984, EMBO J, V3, P1951, DOI 10.1002/j.1460-2075.1984.tb02075.x; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cellbio.6.1.151; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; POHLMANN R, 1988, EMBO J, V7, P2343, DOI 10.1002/j.1460-2075.1988.tb03078.x; READ RJ, 1988, J MOL BIOL, V200, P523, DOI 10.1016/0022-2836(88)90541-4; SUMNER SCJ, 1990, J BIOMOL STRUCT DYN, V8, P687, DOI 10.1080/07391102.1990.10507836; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WRIGHT CS, 1987, J MOL BIOL, V194, P501, DOI 10.1016/0022-2836(87)90678-4	32	154	155	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1203	1209		10.1016/0092-8674(91)90296-B	http://dx.doi.org/10.1016/0092-8674(91)90296-B			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760845				2022-12-01	WOS:A1991GX16400018
J	ENGELMAN, A; MIZUUCHI, K; CRAIGIE, R				ENGELMAN, A; MIZUUCHI, K; CRAIGIE, R			HIV-1 DNA INTEGRATION - MECHANISM OF VIRAL-DNA CLEAVAGE AND DNA STRAND TRANSFER	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CYCLIC DIGUANYLIC ACID; RETROVIRAL DNA; ACETOBACTER-XYLINUM; CELLULOSE SYNTHESIS; CHEMICAL SYNTHESIS; PROTEIN; INVITRO; RECOMBINATION; SEQUENCES	Retroviral DNA integration involves a coordinated set of DNA cutting and joining reactions. Linear viral DNA is cleaved at each 3' end to generate the precursor ends for integration. The resulting recessed 3' ends are inserted into target DNA by a subsequent DNA strand transfer reaction. Purified HIV-1 integration protein carries out both of these steps in vitro. Two novel forms of the dinucleotide cleaved from HIV-1 DNA were identified and one, a cyclic dinucleotide, was used to analyze the stereochemical course of viral DNA cleavage. Both viral DNA cleavage and DNA strand transfer display inversion at chiral phosphorothioates during the course of the reaction. These results suggest that both reactions occur by a one-step mechanism without involvement of a covalent protein-DNA intermediate.			ENGELMAN, A (corresponding author), NIDDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA.							Berg D. E., 1989, MOBILE DNA; BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BROWN PO, 1990, CURR TOP MICROBIOL, V157, P19; BURGERS PMJ, 1979, BIOCHEMISTRY-US, V18, P592, DOI 10.1021/bi00571a007; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CRAIG NL, 1988, ANNU REV GENET, V22, P77; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; ELLISON V, 1990, J VIROL, V64, P2711, DOI 10.1128/JVI.64.6.2711-2715.1990; FARNET CM, 1991, J VIROL, V65, P1910, DOI 10.1128/JVI.65.4.1910-1915.1991; FARNET CM, 1990, P NATL ACAD SCI USA, V87, P4164, DOI 10.1073/pnas.87.11.4164; FAYET O, 1990, MOL MICROBIOL, V4, P1771, DOI 10.1111/j.1365-2958.1990.tb00555.x; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; FUJIWARA T, 1989, P NATL ACAD SCI USA, V86, P3065, DOI 10.1073/pnas.86.9.3065; GRANDGENETT DP, 1990, CELL, V60, P3, DOI 10.1016/0092-8674(90)90707-L; HONG T, 1991, J VIROL, V65, P551, DOI 10.1128/JVI.65.1.551-555.1991; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KATZMAN M, 1991, P NATL ACAD SCI USA, V88, P4695, DOI 10.1073/pnas.88.11.4695; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KULKOSKY J, 1990, J ACQ IMMUN DEF SYND, V3, P852; LEE YMH, 1990, J VIROL, V64, P5958, DOI 10.1128/JVI.64.12.5958-5965.1990; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1986, ANNU REV GENET, V20, P385; PAUZA CD, 1990, VIROLOGY, V179, P886; POTTER BVL, 1983, BIOCHEMISTRY-US, V22, P1369, DOI 10.1021/bi00275a008; ROMANIUK PJ, 1982, J BIOL CHEM, V257, P7684; ROSS P, 1987, NATURE, V325, P279, DOI 10.1038/325279a0; ROSS P, 1990, J BIOL CHEM, V265, P18933; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; ROWLAND SJ, 1990, MOL MICROBIOL, V4, P961, DOI 10.1111/j.1365-2958.1990.tb00669.x; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; SMITH JS, 1990, J VIROL, V64, P6286, DOI 10.1128/JVI.64.12.6286-6290.1990; VARMUS H, 1989, MOBILE DNA, P53; VORA AC, 1990, J VIROL, V64, P5656, DOI 10.1128/JVI.64.11.5656-5659.1990; WHITCOMB JM, 1990, J VIROL, V64, P4903, DOI 10.1128/JVI.64.10.4903-4906.1990	43	550	568	0	40	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 20	1991	67	6					1211	1221		10.1016/0092-8674(91)90297-C	http://dx.doi.org/10.1016/0092-8674(91)90297-C			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760846				2022-12-01	WOS:A1991GX16400019
J	FAUSTMAN, D; LI, XP; LIN, HY; FU, YE; EISENBARTH, G; AVRUCH, J; GUO, J				FAUSTMAN, D; LI, XP; LIN, HY; FU, YE; EISENBARTH, G; AVRUCH, J; GUO, J			LINKAGE OF FAULTY MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I TO AUTOIMMUNE DIABETES	SCIENCE			English	Article							ISLET-CELL ANTIBODIES; INSULIN-DEPENDENT DIABETICS; VIRAL PEPTIDES; PROTEIN-A; T-CELLS; MELLITUS; GENE; SUSCEPTIBILITY; ASSAY; MICE	Pancreatic islet cells are the targets of an autoimmune response in type I diabetes. In the nonobese diabetic (NOD) mouse model of autoimmune diabetes, expression of major histocompatibility complex (MHC) class I proteins was inversely correlated with diabetes; in this mouse a mutation in the MHC class II-linked gene for the putative MHC class I peptide transporter was also present. Mice deficient in MHC class I expression because they do not produce beta-2-microglobulin also developed late onset autoimmune diabetes. In cells from humans with type I diabetes expression of MHC class I was decreased; subsets of prediabetics categorized as most likely to become hyperglycemic also had low MHC class I. T cell responses to self antigens are faulty in diabetics. In sets of genetically identical twins that are discordant for diabetes, the defect appeared to reside with the antigen presenting cell. Thus, a lack of surface MHC class I protein is associated with autoimmune diabetes; the concomitant defect in antigen presentation may impair the development of self tolerance, which could result in autoimmune disease.	MASSACHUSETTS GEN HOSP,MED SERV,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,DIABET UNIT,IMMUNOBIOL LAB,BOSTON,MA 02129; JOSLIN DIABET CTR,BOSTON,MA 02115; MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02139	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Joslin Diabetes Center, Inc.; Massachusetts Institute of Technology (MIT); Whitehead Institute	FAUSTMAN, D (corresponding author), HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115, USA.							BAEKKESKOV S, 1982, NATURE, V298, P167, DOI 10.1038/298167a0; BAISCH JM, 1990, NEW ENGL J MED, V322, P1836, DOI 10.1056/NEJM199006283222602; BEVAN MJ, 1987, NATURE, V325, P192, DOI 10.1038/325192b0; BOTTAZZO GF, 1974, LANCET, V2, P1279, DOI 10.1016/S0140-6736(74)90140-8; COLMAN PG, 1988, DIABETES CARE, V11, P367, DOI 10.2337/diacare.11.4.367; ERLICH HA, 1990, DIABETES, V39, P96, DOI 10.2337/diabetes.39.1.96; FAUSTMAN D, 1989, DIABETES, V38, P1462, DOI 10.2337/diabetes.38.11.1462; FESTENSTEIN H, 1986, NATURE, V322, P64, DOI 10.1038/322064a0; GANDA OP, 1984, DIABETES, V33, P516, DOI 10.2337/diabetes.33.6.516; GLEICHMANN H, 1987, DIABETES, V36, P578, DOI 10.2337/diabetes.36.5.578; HATTORI M, 1986, SCIENCE, V231, P733, DOI 10.1126/science.3003909; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; LERNMARK A, 1978, NEW ENGL J MED, V299, P375, DOI 10.1056/NEJM197808242990802; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; LIVINGSTONE AM, 1989, J EXP MED, V170, P777, DOI 10.1084/jem.170.3.777; MACCUISH AC, 1974, LANCET, V2, P1529; MAKINO S, 1985, EXP ANIM TOKYO, V34, P425, DOI 10.1538/expanim1978.34.4_425; MIYAZAKI T, 1990, NATURE, V345, P722, DOI 10.1038/345722a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MOREL PA, 1988, P NATL ACAD SCI USA, V85, P8111, DOI 10.1073/pnas.85.21.8111; PALMER JP, 1983, SCIENCE, V222, P1337, DOI 10.1126/science.6362005; ROSSINI AA, 1985, ANNU REV IMMUNOL, V3, P289; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; Sambrook J., 1989, MOL CLONING LAB MANU; SERREZE DV, 1988, J IMMUNOL, V140, P3801; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SRIKANTA S, 1985, DIABETES, V34, P300, DOI 10.2337/diabetes.34.3.300; SRIKANTA S, 1985, NEW ENGL J MED, V313, P461, DOI 10.1056/NEJM198508223130801; STERKERS G, 1988, P NATL ACAD SCI USA, V85, P6473, DOI 10.1073/pnas.85.17.6473; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; TODD JA, 1989, NATURE, V338, P587, DOI 10.1038/338587a0; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VARDI P, 1987, DIABETES, V36, P1286, DOI 10.2337/diabetes.36.11.1286; von Meyenburg H., 1940, SCHWEIZ MED WSCHR, V21, P554; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	37	191	199	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1756	1761		10.1126/science.1763324	http://dx.doi.org/10.1126/science.1763324			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1763324				2022-12-01	WOS:A1991GW31600033
J	FEAVER, WJ; GILEADI, O; LI, Y; KORNBERG, RD				FEAVER, WJ; GILEADI, O; LI, Y; KORNBERG, RD			CTD KINASE ASSOCIATED WITH YEAST RNA POLYMERASE-II INITIATION FACTOR-B	CELL			English	Article							TRANSCRIPTION FACTOR; SUBUNIT COMPOSITION; PURIFICATION; PHOSPHORYLATION; PROMOTER; REQUIREMENT; ELONGATION; INVITRO; SYSTEM; REPEAT	A kinase activity specific for the C-terminal repeat domain (CTD) of RNA polymerase II is associated with nearly homogeneous yeast general initiation factor b by three criteria: cofractionation on the basis of size and charge and coinactivation by mild heat treatment. The kinase phosphorylates the CTD at multiple sites in a processive manner. Factor b may possess a DNA-dependent ATPase activity as well. Both kinase and DNA-dependent ATPase activities exhibit the same nucleotide requirements as previously demonstrated for the initiation of transcription. These results support the idea that phosphorylation of the CTD lies on the pathway of transcription initiation and identify a catalytic activity of a general factor essential for the initiation process.			FEAVER, WJ (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305, USA.		Gileadi, Opher/F-1105-2013	Gileadi, Opher/0000-0001-6886-898X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036659, R01GM036659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FEAVER WJ, 1991, IN PRESS J BIOL CHEM; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; FLORES O, 1990, J BIOL CHEM, V265, P5629; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; KIM WY, 1989, J BIOL CHEM, V264, P3169; KIM WY, 1988, J BIOL CHEM, V263, P18880; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SOPTA M, 1985, J BIOL CHEM, V260, P353; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353; ZHANG J, 1991, J BIOL CHEM, V266, P2290	34	189	193	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1223	1230		10.1016/0092-8674(91)90298-D	http://dx.doi.org/10.1016/0092-8674(91)90298-D			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1836979				2022-12-01	WOS:A1991GX16400020
J	FIETE, D; SRIVASTAVA, V; HINDSGAUL, O; BAENZIGER, JU				FIETE, D; SRIVASTAVA, V; HINDSGAUL, O; BAENZIGER, JU			A HEPATIC RETICULOENDOTHELIAL CELL-RECEPTOR SPECIFIC FOR SO4-4GAINAC-BETA-1,4GLCNAC-BETA-1,2MAN-ALPHA THAT MEDIATES RAPID CLEARANCE OF LUTROPIN	CELL			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; PITUITARY GLYCOPROTEIN HORMONES; LIVER ENDOTHELIAL-CELLS; RAT-LIVER; HYALURONIC-ACID; SIALYLATED OLIGOSACCHARIDES; BOVINE LUTROPIN; STRUCTURAL ELUCIDATION; ENDOCYTOSIS; HEPATOCYTES	We have identified a receptor in hepatic endothelial and Kupffer cells that binds oligosaccharides terminating with the sequence SO4-4GalNAc-beta-1,4GlcNAc-beta-1,2-Man-alpha (S4GGnM). This receptor can account for the rapid removal of the glycoprotein hormone lutropin, which bears unique Asn-linked oligosaccharides terminating in S4GGnM, from the circulation. Hepatic endothelial cells express 579,000 S4GGnM receptors at their surface and bind lutropin with an apparent K(d) of 1.63 x 10(-7) M. Bound ligand is rapidly internalized. Binding does not require divalent cations, is reversed by incubation at pH 5.0 or below, and is inhibited by fucoidin but not by hyaluronate, heparin, chondroitin sulfate, or dextran sulfate. We propose that the S4GGnM-specific receptor represents a major mechanism for clearance of certain sulfated glycoproteins from the blood, including members of the glycoprotein hormone family.	UNIV ALBERTA,DEPT CHEM,EDMONTON T6G 2G2,ALBERTA,CANADA	University of Alberta	FIETE, D (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110, USA.		Baenziger, Jacques U/E-9430-2012		NATIONAL CANCER INSTITUTE [R37CA021923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER; NCI NIH HHS [R37-CA-21923] Funding Source: Medline; NIDDK NIH HHS [R01-DK-41738] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAENZIGER JU, 1980, CELL, V22, P611, DOI 10.1016/0092-8674(80)90371-2; BAENZIGER JU, 1991, IN PRESS P NATL ACAD; BAENZIGER JU, 1991, BIOL CARBOHYDRATES, V3, P1; BREITFELD PP, 1985, INT REV CYTOL, V97, P47, DOI 10.1016/S0074-7696(08)62348-7; DAMM JBL, 1990, EUR J BIOCHEM, V189, P175, DOI 10.1111/j.1432-1033.1990.tb15474.x; ERIKSSON S, 1983, EXP CELL RES, V144, P223, DOI 10.1016/0014-4827(83)90458-5; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; GREEN ED, 1985, P NATL ACAD SCI USA, V82, P7850, DOI 10.1073/pnas.82.23.7850; GREEN ED, 1984, P NATL ACAD SCI-BIOL, V81, P5320, DOI 10.1073/pnas.81.17.5320; GREEN ED, 1986, MOL CELL BIOCHEM, V72, P81; HINDSGAUL V, 1987, CAN J CHEM, V65, P1645; KNOOK DL, 1976, EXP CELL RES, V99, P444, DOI 10.1016/0014-4827(76)90605-4; KNOOK DL, 1977, EXP CELL RES, V109, P317, DOI 10.1016/0014-4827(77)90011-8; LEMIEUX RU, 1975, J AM CHEM SOC, V97, P4076, DOI 10.1021/ja00847a035; MATSUI T, 1991, BIOCHEM BIOPH RES CO, V174, P940, DOI 10.1016/0006-291X(91)91509-B; MCGARY CT, 1989, BIOCHEM J, V257, P875, DOI 10.1042/bj2570875; MIAN AJ, 1973, CARBOHYD RES, V304, P449; MURPHY BD, 1991, ENDOCR REV, V12, P27, DOI 10.1210/edrv-12-1-27; PARSONS TF, 1980, P NATL ACAD SCI-BIOL, V77, P7089, DOI 10.1073/pnas.77.12.7089; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; RAJA RH, 1984, ANAL BIOCHEM, V139, P168, DOI 10.1016/0003-2697(84)90402-0; RAJA RH, 1988, J BIOL CHEM, V263, P16661; SKELTON TP, 1991, J BIOL CHEM, V266, P17142; SMEDSROD B, 1985, J LEUKOCYTE BIOL, V38, P213, DOI 10.1002/jlb.38.2.213; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SMITH PL, 1990, J BIOL CHEM, V265, P874; SMITH PL, 1990, P NATL ACAD SCI USA, V87, P7275, DOI 10.1073/pnas.87.18.7275; SMITH PL, 1991, IN PRESS P NATL ACAD	30	264	270	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1103	1110		10.1016/0092-8674(91)90287-9	http://dx.doi.org/10.1016/0092-8674(91)90287-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1662117				2022-12-01	WOS:A1991GX16400009
J	FU, YH; KUHL, DPA; PIZZUTI, A; PIERETTI, M; SUTCLIFFE, JS; RICHARDS, S; VERKERK, AJMH; HOLDEN, JJA; FENWICK, RG; WARREN, ST; OOSTRA, BA; NELSON, DL; CASKEY, CT				FU, YH; KUHL, DPA; PIZZUTI, A; PIERETTI, M; SUTCLIFFE, JS; RICHARDS, S; VERKERK, AJMH; HOLDEN, JJA; FENWICK, RG; WARREN, ST; OOSTRA, BA; NELSON, DL; CASKEY, CT			VARIATION OF THE CGG REPEAT AT THE FRAGILE-X SITE RESULTS IN GENETIC INSTABILITY - RESOLUTION OF THE SHERMAN PARADOX	CELL			English	Article							HUMAN DNA; EXPRESSION	Fragile X syndrome results from mutations in a (CGG)n repeat found in the coding sequence of the FMR-1 gene. Analysis of length variation in this region in normal individuals shows a range of allele sizes varying from a low of 6 to a high of 54 repeats. Premutations showing no phenotypic effect in fragile X families range in size from 52 to over 200 repeats. All alleles with greater than 52 repeats, including those identified in a normal family, are meiotically unstable with a mutation frequency of one, while 75 meioses of alleles of 46 repeats and below have shown no mutation. Premutation alleles are also mitotically unstable as mosaicism is observed. The risk of expansion during oogenesis to the full mutation associated with mental retardation increases with the number of repeats, and this variation in risk accounts for the Sherman paradox.	EMORY UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT PEDIAT,ATLANTA,GA 30322; ERASMUS UNIV,DEPT CELL BIOL,3000 DR ROTTERDAM,NETHERLANDS; QUEENS UNIV,DEPT CYTOGENET,KINGSTON K7L 3N6,ONTARIO,CANADA	Emory University; Howard Hughes Medical Institute; Emory University; Howard Hughes Medical Institute; Erasmus University Rotterdam; Queens University - Canada	FU, YH (corresponding author), BAYLOR COLL MED,HOWARD HUGHES MED INST,CTR HUMAN GENOME,INST MOLEC GENET,HOUSTON,TX 77030, USA.		Sutcliffe, James S/C-1348-2012; Warren, Stephen T/A-2498-2012	Sutcliffe, James S/0000-0001-5200-6007; Verkerk, Annemieke JMH/0000-0002-7523-3656; PIZZUTI, Antonio/0000-0003-3245-1925	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD020521, R01HD020521] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00038] Funding Source: Medline; NICHD NIH HHS [HD20521] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BROWN WT, 1990, AM J HUM GENET, V47, P175; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; DIETRICH A, 1991, NUCLEIC ACIDS RES, V19, P2567, DOI 10.1093/nar/19.10.2567; DRACOPOLI NC, 1991, GENOMICS, V9, P686, DOI 10.1016/0888-7543(91)90362-I; EDWARDS A, 1991, AM J HUM GENET, V49, P746; GUSTAVSON KH, 1986, AM J MED GENET, V23, P581, DOI 10.1002/ajmg.1320230152; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LAIRD CD, 1987, GENETICS, V117, P587; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; SHERMAN SL, 1985, HUM GENET, V69, P3289; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WEBB TP, 1986, AM J MED GENET, V23, P573, DOI 10.1002/ajmg.1320230151; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	23	1702	1763	0	67	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1047	1058		10.1016/0092-8674(91)90283-5	http://dx.doi.org/10.1016/0092-8674(91)90283-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760838				2022-12-01	WOS:A1991GX16400005
J	GIRARD, F; STRAUSFELD, U; FERNANDEZ, A; LAMB, NJC				GIRARD, F; STRAUSFELD, U; FERNANDEZ, A; LAMB, NJC			CYCLIN-A IS REQUIRED FOR THE ONSET OF DNA-REPLICATION IN MAMMALIAN FIBROBLASTS	CELL			English	Article							DEPENDENT PROTEIN-KINASE; EMBRYONIC-CELL CYCLE; SEA-URCHIN EGGS; MESSENGER-RNA; TYROSINE PHOSPHORYLATION; M-PHASE; P34CDC2; CDC2; DROSOPHILA; EXTRACTS	Cyclin A protein is synthesized and localized into the nucleus at the onset of S phase in nontransformed mammalian fibroblasts. Inhibition of cyclin A synthesis or activity through microinjection of plasmids encoding antisense cyclin A cDNA or affinity-purified anti-cyclin A antibodies during G1 phase was shown to abolish the nuclear staining for cyclin A in plasmid-injected cells, and both procedures led to inhibition of DNA synthesis. No similar effect was observed with injection of other antisense vectors including antisense cyclin B, and reinjection of purified human cyclin A protein into cyclin A antisense-injected cells effectively relieved this inhibition of DNA synthesis. Taken together, these data suggest that cyclin A plays a major role in the control of DNA replication in mammalian cells.			GIRARD, F (corresponding author), CNRS, CRBM, CELL BIOL UNIT, INSERM, BP 5051, F-34033 MONTPELLIER, FRANCE.			Girard, Franck/0000-0003-2587-4495				BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FORSBURG SL, 1991, NATURE, V351, P245, DOI 10.1038/351245a0; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; JENKINS JR, 1988, ONCOGENE HDB, P403; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; LAMB NJC, 1989, J CELL BIOL, V108, P2409, DOI 10.1083/jcb.108.6.2409; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; McClure DB, 1982, COLD SPRING HARBOR C, V9, P345; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURZBECHER HW, 1990, ONCOGENE, V5, P795; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	47	863	875	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 20	1991	67	6					1169	1179		10.1016/0092-8674(91)90293-8	http://dx.doi.org/10.1016/0092-8674(91)90293-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1836977				2022-12-01	WOS:A1991GX16400015
J	HSU, MC; SCHUTT, AD; HOLLY, M; SLICE, LW; SHERMAN, MI; RICHMAN, DD; POTASH, MJ; VOLSKY, DJ				HSU, MC; SCHUTT, AD; HOLLY, M; SLICE, LW; SHERMAN, MI; RICHMAN, DD; POTASH, MJ; VOLSKY, DJ			INHIBITION OF HIV REPLICATION IN ACUTE AND CHRONIC INFECTIONS INVITRO BY A TAT ANTAGONIST	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; TRANS-ACTIVATOR GENE; TRANSCRIPTIONAL REGULATION; QUANTITATIVE-ANALYSIS; ZIDOVUDINE AZT; HTLV-III; SEQUENCE; TYPE-1; PROTEIN	The human immunodeficiency virus-I (HIV-1) trans-activator Tat is an attractive target for the development of antiviral drugs because inhibition of Tat would arrest the virus at an early stage. The drug Ro 5-3335 [7-chloro-S-(2-pyrryl)-3H-1,4-benzodiazepin-2(H)-one], inhibited gene expression by HIV-1 at the level of transcriptional trans-activation by Tat. The compound did not inhibit the basal activity of the promoter. Both Tat and its target sequence TAR were required for the observed inhibitory activity. Ro 5-3335 reduced the amount of cell-associated viral RNA and antigen in acutely, as well as in chronically infected cells in vitro (median inhibition concentration 0.1 to 1 micromolar). Effective inhibition of viral replication was also observed 24 hours after cells were transfected with infectious recombinant HIV-1 DNA. The compound was active against both HIV-1 and HIV-2 and against 3'-azido-3'-deoxythymidine (AZT)-resistant clinical isolates.	UNIV CALIF SAN DIEGO,VET ADM MED CTR,INFECT DIS SECT,SAN DIEGO,CA 92161; COLUMBIA UNIV,ST LUKES ROOSEVELT HOSP CTR,MOLEC VIROL LAB,NEW YORK,NY 10019	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Columbia University; Mount Sinai St. Luke's; Mount Sinai West	HSU, MC (corresponding author), HOFFMANN LA ROCHE INC,DEPT VIROL,NUTLEY,NJ 07110, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029164, U01AI027670, R37AI029164, U01AI027397] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 27397, AI 29164, AI 27670] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; Ausubel F. M, 1987, CURRENT PROTOCOLS MO, V1; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; CASAREALE D, 1987, VIROLOGY, V156, P40, DOI 10.1016/0042-6822(87)90434-X; CONNELL EV, COMMUNICATION; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; HAEFELY WE, COMMUNICATION; HAUBER J, 1988, J VIROL, V62, P673, DOI 10.1128/JVI.62.3.673-679.1988; HAYES T, COMMUNICATION; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2551; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KORNBLUTH RS, 1989, J EXP MED, V169, P1137, DOI 10.1084/jem.169.3.1137; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; NABEL GJ, 1988, SCIENCE, V239, P1299, DOI 10.1126/science.2830675; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; RICE AP, 1988, NATURE, V332, P551, DOI 10.1038/332551a0; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; SADAIE MR, 1988, SCIENCE, V239, P910, DOI 10.1126/science.3277284; SAKAI K, 1988, J VIROL, V62, P4078, DOI 10.1128/JVI.62.11.4078-4085.1988; SELBY MJ, 1989, GENE DEV, V3, P547, DOI 10.1101/gad.3.4.547; SILICIANO RF, 1988, CELL, V54, P561, DOI 10.1016/0092-8674(88)90078-5; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; TANNEAU F, 1990, J INFECT DIS, V162, P837, DOI 10.1093/infdis/162.4.837; TOWN C, COMMUNICATION; TRAUNECKER A, 1989, NATURE, V339, P68, DOI 10.1038/339068a0; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; VOLSKY DJ, 1990, J VIROL METHODS, V28, P257, DOI 10.1016/0166-0934(90)90119-Z	39	228	245	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1799	1802		10.1126/science.1763331	http://dx.doi.org/10.1126/science.1763331			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1763331				2022-12-01	WOS:A1991GW31600046
J	LACY, PE; HEGRE, OD; GERASIMIDIVAZEOU, A; GENTILE, FT; DIONNE, KE				LACY, PE; HEGRE, OD; GERASIMIDIVAZEOU, A; GENTILE, FT; DIONNE, KE			MAINTENANCE OF NORMOGLYCEMIA IN DIABETIC MICE BY SUBCUTANEOUS XENOGRAFTS OF ENCAPSULATED ISLETS	SCIENCE			English	Article							ARTIFICIAL ENDOCRINE PANCREAS; TISSUE REACTION; RATS; TRANSPLANTATION; IMPLANTS; INSULIN; CELLS	The goal of islet transplantation in human diabetes is to maintain the islet grafts in the recipients without the use of immunosuppression. One approach is to encapsulate the donor islets in permselective membranes. Hollow fibers fabricated from an acrylic copolymer were used to encapsulate small numbers of rat islets that were immobilized in an alginate hydrogel for transplantation in diabetic mice. The fibers were biocompatible, prevented rejection, and maintained normoglycemia when transplanted intraperitoneally; hyperglycemia returned when the fibers were removed at 60 days. Normoglycemia was also maintained by subcutaneous implants that had an appropriately constructed outer surface on the fibers.	CELLULAR TRANSPLANTS,PROVIDENCE,RI 02906		LACY, PE (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK001226] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK01226] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTMAN JJ, 1986, DIABETES, V35, P625, DOI 10.2337/diabetes.35.6.625; ARCHER J, 1980, J SURG RES, V28, P77, DOI 10.1016/0022-4804(80)90086-4; CABASSO I, 1980, KIRK OTHMERS ENCY CH, V12, P492; CHICK WL, 1977, SCIENCE, V197, P780, DOI 10.1126/science.407649; CHRISTENSON L, 1989, J BIOMED MATER RES, V23, P705, DOI 10.1002/jbm.820230704; DIONNE KE, 1991, BIOTECHNOL PROGR, V7, P359, DOI 10.1021/bp00010a011; FAN MY, 1990, DIABETES, V39, P519, DOI 10.2337/diabetes.39.4.519; KEMP CB, 1973, DIABETOLOGIA, V9, P486, DOI 10.1007/BF00461694; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LACY PE, 1972, DIABETES, V21, P987, DOI 10.2337/diab.21.10.987; LIM F, 1980, SCIENCE, V210, P908, DOI 10.1126/science.6776628; MAZAHERI R, 1991, TRANSPLANTATION, V51, P750, DOI 10.1097/00007890-199104000-00002; SCHARP DW, 1990, DIABETES, V39, P515, DOI 10.2337/diabetes.39.4.515; SULLIVAN SJ, 1991, SCIENCE, V252, P718, DOI 10.1126/science.2024124; SUN AM, 1977, DIABETES, V26, P1136, DOI 10.2337/diabetes.26.12.1136; TZAKIS AG, 1990, LANCET, V336, P402, DOI 10.1016/0140-6736(90)91946-8; TZE WJ, 1976, NATURE, V264, P466, DOI 10.1038/264466a0; WARNOCK GL, 1989, LANCET, V2, P570; WINN SR, 1989, J BIOMED MATER RES, V23, P31, DOI 10.1002/jbm.820230104	19	296	365	3	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1782	1784		10.1126/science.1763328	http://dx.doi.org/10.1126/science.1763328			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1763328				2022-12-01	WOS:A1991GW31600040
J	LEE, DK; HORIKOSHI, M; ROEDER, RG				LEE, DK; HORIKOSHI, M; ROEDER, RG			INTERACTION OF TFIID IN THE MINOR GROOVE OF THE TATA ELEMENT	CELL			English	Article							RNA POLYMERASE-II; INTEGRATION HOST FACTOR; BOX-BINDING-PROTEIN; B-DNA DODECAMER; TRANSCRIPTION FACTOR; PREINITIATION COMPLEX; FUNCTIONAL DOMAINS; YEAST; GENE; PROMOTER	TFIID binding in the minor groove of DNA at the TATA element was demonstrated by methylation interference and hydroxyl radical footprinting assays, and by binding studies with thymine analog substituted oligonucleotides. These results provide an explanation for TFIID-dependent DNA bending at the TATA element. TFIID binding shows phosphate contacts with the same residues that were found to be essential for TFIID interactions by methylation and thymine-specific modification interference assays. Based on previous studies implicating residues conserved between the direct repeats in DNA binding, as well as models of prokaryotic DNA binding proteins, these results also suggest a model in which the direct repeats of TFIID form two basic antiparallel beta-ribbon arms that could contact DNA through the minor groove.			LEE, DK (corresponding author), ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021, USA.							BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; CHURCHILL MEA, 1990, P NATL ACAD SCI USA, V87, P5528, DOI 10.1073/pnas.87.14.5528; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; DICKERSON RE, 1981, J MOL BIOL, V149, P761, DOI 10.1016/0022-2836(81)90357-0; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FRATINI AV, 1982, J BIOL CHEM, V257, P4686; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; LIEBERMAN PM, 1991, MOL CELL BIOL, V11, P63, DOI 10.1128/MCB.11.1.63; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; Maxam A M, 1980, Methods Enzymol, V65, P499; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MUHICH ML, 1990, P NATL ACAD SCI USA, V87, P9148, DOI 10.1073/pnas.87.23.9148; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; OAKLEY MG, 1990, SCIENCE, V248, P847, DOI 10.1126/science.2111578; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; POON D, 1991, MOL CELL BIOL, V11, P4809, DOI 10.1128/MCB.11.10.4809; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SUN L, 1975, BIOCHEMISTRY-US, V14, P1795, DOI 10.1021/bi00679a036; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; TRAVERS A, 1987, NATURE, V327, P280, DOI 10.1038/327280a0; TRUSS M, 1990, P NATL ACAD SCI USA, V87, P7180, DOI 10.1073/pnas.87.18.7180; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; VANDYKE MW, 1982, P NATL ACAD SCI-BIOL, V79, P5470; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5; ZHOU Q, 1991, EMBO J, V10, P1843, DOI 10.1002/j.1460-2075.1991.tb07710.x	60	150	151	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1241	1250		10.1016/0092-8674(91)90300-N	http://dx.doi.org/10.1016/0092-8674(91)90300-N			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760848				2022-12-01	WOS:A1991GX16400022
J	LONGMORE, GD; LODISH, HF				LONGMORE, GD; LODISH, HF			AN ACTIVATING MUTATION IN THE MURINE ERYTHROPOIETIN RECEPTOR INDUCES ERYTHROLEUKEMIA IN MICE - A CYTOKINE RECEPTOR SUPERFAMILY ONCOGENE	CELL			English	Article							FOCUS-FORMING VIRUS; LEUKEMIA-VIRUS; MEMBRANE GLYCOPROTEIN; GROWTH-FACTOR; FRIEND-VIRUS; MYELOPROLIFERATIVE SYNDROME; EXPRESSION CLONING; CSF-1 RECEPTOR; POINT MUTATION; MULTI-CSF	A point mutation at codon 129 of the murine erythropoietin receptor (cEpoR) results in constitutive activation. We have generated a recombinant spleen focus-forming retrovirus in which the env gene is replaced by the cEpoR cDNA. Mice infected with this virus (but not by viruses expressing the wild-type EpoR) develop erythrocytosis and splenomegaly. From the spleen of infected animals we have isolated clonal, growth factor-independent, proerythroblast cell lines that express cEpoR, do not express the putative oncogene spi-1, and have rearranged and inactivated expression of the p53 suppressor oncogene. These cells induce erythroleukemia upon injection into mice. This demonstrates that oncogenic point mutations exist in a member of the cytokine receptor superfamily. The activated erythropoietin receptor does not transform cultured fibroblasts, suggesting why oncogenic mutations in other members of this receptor superfamily have not been detected.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT MED, BOSTON, MA 02115 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Massachusetts Institute of Technology (MIT)	LONGMORE, GD (corresponding author), NINE CAMBRIDGE CTR, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA.				NHLBI NIH HHS [HL32262] Funding Source: Medline; NIA NIH HHS [AG00294] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K12AG000294] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AIZAWA S, 1990, EMBO J, V9, P2107, DOI 10.1002/j.1460-2075.1990.tb07379.x; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BESTWICK RK, 1988, P NATL ACAD SCI USA, V85, P5404, DOI 10.1073/pnas.85.15.5404; CHANG JM, 1989, BLOOD, V73, P1487; CHATIS PA, 1984, J VIROL, V52, P248, DOI 10.1128/JVI.52.1.248-254.1984; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DAVID YB, 1988, ONCOGENE, V3, P179; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRASER JK, 1989, EXP HEMATOL, V17, P10; FRESHNEY RI, 1987, CULTURE ANIMAL CELLS, P140; FRIEND C, 1957, J EXP MED, V105, P307, DOI 10.1084/jem.105.4.307; GRAHAM FL, 1980, INTRO MACROMOLECULES, P3; GRAU GE, 1986, J IMMUNOL, V136, P686; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HANKINS WD, 1980, CELL, V22, P693; HARLOW E, 1988, ANTIBODIES LABORATOR; HEARD JM, 1987, CELL, V51, P663, DOI 10.1016/0092-8674(87)90135-8; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; HOATLIN ME, 1990, P NATL ACAD SCI USA, V87, P9985, DOI 10.1073/pnas.87.24.9985; ISHIBASHI T, 1987, J CLIN INVEST, V79, P286, DOI 10.1172/JCI112796; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOPITO RR, 1985, J CELL BIOCHEM, V29, P1, DOI 10.1002/jcb.240290102; KOURY MJ, 1986, J CELL PHYSIOL, V126, P259, DOI 10.1002/jcp.1041260216; KRANTZ SB, 1991, BLOOD, V77, P419; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANG RA, 1987, CELL, V51, P675, DOI 10.1016/0092-8674(87)90136-X; LI JP, 1986, J VIROL, V57, P534, DOI 10.1128/JVI.57.2.534-538.1986; LI JP, 1987, J VIROL, V61, P2782, DOI 10.1128/JVI.61.9.2782-2792.1987; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LINEMEYER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1401, DOI 10.1073/pnas.78.3.1401; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; RIDGE SA, 1990, P NATL ACAD SCI USA, V87, P1377, DOI 10.1073/pnas.87.4.1377; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; RUSCETTI SK, 1990, J VIROL, V64, P1057, DOI 10.1128/JVI.64.3.1057-1062.1990; RUTA M, 1983, P NATL ACAD SCI-BIOL, V80, P4704, DOI 10.1073/pnas.80.15.4704; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SEMENZA GL, 1989, P NATL ACAD SCI USA, V86, P2301, DOI 10.1073/pnas.86.7.2301; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SRINIVAS RV, 1983, VIROLOGY, V125, P274, DOI 10.1016/0042-6822(83)90201-5; TROXLER DH, 1977, J VIROL, V22, P361, DOI 10.1128/JVI.22.2.361-372.1977; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; WEINBERG RA, 1989, ONCOGENES MOL ORIGIN, P307; WENDLING F, 1981, P NATL ACAD SCI-BIOL, V78, P3614, DOI 10.1073/pnas.78.6.3614; WOLFF L, 1986, P NATL ACAD SCI USA, V83, P3376, DOI 10.1073/pnas.83.10.3376; WOLFF L, 1982, J VIROL, V43, P472, DOI 10.1128/JVI.43.2.472-481.1982; WOLFF L, 1985, J VIROL, V53, P570, DOI 10.1128/JVI.53.2.570-578.1985; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P3675, DOI 10.1128/MCB.10.7.3675; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	70	135	136	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 20	1991	67	6					1089	1102		10.1016/0092-8674(91)90286-8	http://dx.doi.org/10.1016/0092-8674(91)90286-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1662116				2022-12-01	WOS:A1991GX16400008
J	MATHIAS, SL; SCOTT, AF; KAZAZIAN, HH; BOEKE, JD; GABRIEL, A				MATHIAS, SL; SCOTT, AF; KAZAZIAN, HH; BOEKE, JD; GABRIEL, A			REVERSE-TRANSCRIPTASE ENCODED BY A HUMAN TRANSPOSABLE ELEMENT	SCIENCE			English	Article							SITE-SPECIFIC MUTAGENESIS; VIRUS-LIKE PARTICLES; SACCHAROMYCES-CEREVISIAE; TY1 TRANSPOSITION; EUKARYOTIC GENOME; SPT3 GENE; RETROTRANSPOSONS; SEQUENCES; PROTEIN; DNA	L1 elements are highly repeated mammalian DNA sequences whose structure suggests dispersal by retrotransposition. A consensus L1 clement encodes a protein with sequence similarity to known reverse transcriptases. The second open reading frame from the human L1 element L1.2A was expressed as a fusion protein targeted to Tyl virus-like particles in Saccharomyces cerevisiae and shown to have reverse transcriptase activity. This activity was eliminated by a missense mutation in the highly conserved amino acid motif Y/F-X-D-D. Thus, L1 represents a potential source of the reverse transcriptase activity necessary for dispersion of the many classes of mammalian retroelements.	JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, CTR MED GENET, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, CTR MED GENET, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	GABRIEL, A (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA.			Boeke, Jef/0000-0001-5322-4946	NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028931] Funding Source: NIH RePORTER; NCI NIH HHS [CA16519] Funding Source: Medline; NIAID NIH HHS [AI00803] Funding Source: Medline; NIGMS NIH HHS [GM28931] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SE, 1987, CELL, V49, P111, DOI 10.1016/0092-8674(87)90761-6; BALTIMORE D, 1985, CELL, V40, P481, DOI 10.1016/0092-8674(85)90190-4; BOEKE JD, 1986, MOL CELL BIOL, V6, P3575, DOI 10.1128/MCB.6.11.3575; BOEKE JD, 1989, MOBILE DNA, P335; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; EICHINGER DJ, 1988, CELL, V54, P955, DOI 10.1016/0092-8674(88)90110-9; FANNING TG, 1987, BIOCHIM BIOPHYS ACTA, V910, P203, DOI 10.1016/0167-4781(87)90112-6; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GABRIEL A, 1991, P NATL ACAD SCI USA, V88, P9794, DOI 10.1073/pnas.88.21.9794; GARFINKEL DJ, 1991, J VIROL, V65, P4573, DOI 10.1128/JVI.65.9.4573-4581.1991; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; HATTORI M, 1986, NATURE, V321, P625, DOI 10.1038/321625a0; IVANOV VA, 1991, EMBO J, V10, P2489, DOI 10.1002/j.1460-2075.1991.tb07788.x; JACOBS E, 1988, GENE, V67, P259, DOI 10.1016/0378-1119(88)90402-7; JENSEN S, 1991, EMBO J, V10, P1927, DOI 10.1002/j.1460-2075.1991.tb07719.x; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; KINSEY J, COMMUNICATION; KINSEY JA, 1990, GENETICS, V126, P317; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LAWRENCE W, 1978, METHODS YEAST GENETI; LOEB DD, 1986, MOL CELL BIOL, V6, P168, DOI 10.1128/MCB.6.1.168; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; MATHIAS SL, UNPUB; MULLER F, 1987, MOL GEN GENET, V207, P421, DOI 10.1007/BF00331610; NATSOULIS G, 1989, GENETICS, V123, P269; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PELISSON A, 1991, P NATL ACAD SCI USA, V88, P4907, DOI 10.1073/pnas.88.11.4907; ROSE M, 1984, GENE, V29, P113, DOI 10.1016/0378-1119(84)90172-0; SCOTT A F, 1987, Genomics, V1, P113, DOI 10.1016/0888-7543(87)90003-6; SHEN SH, 1981, CELL, V26, P191, DOI 10.1016/0092-8674(81)90302-0; TEMIN HM, 1985, MOL BIOL EVOL, V2, P455; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.biochem.55.1.631; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WINSTON F, 1984, CELL, V39, P675, DOI 10.1016/0092-8674(84)90474-4; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; XU H, 1991, MOL CELL BIOL, V11, P2736, DOI 10.1128/MCB.11.5.2736; XU H, 1990, Proceedings of the National Academy of Sciences of the United States of America, V87, P8360, DOI 10.1073/pnas.87.21.8360; [No title captured]	41	584	595	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 20	1991	254	5039					1808	1810		10.1126/science.1722352	http://dx.doi.org/10.1126/science.1722352			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1722352				2022-12-01	WOS:A1991GW31600049
J	MATSUI, K; BONIFACE, JJ; REAY, PA; SCHILD, H; FAZEKAS DE ST GROTH, B; DAVIS, MM				MATSUI, K; BONIFACE, JJ; REAY, PA; SCHILD, H; FAZEKAS DE ST GROTH, B; DAVIS, MM			LOW AFFINITY INTERACTION OF PEPTIDE-MHC COMPLEXES WITH T-CELL RECEPTORS	SCIENCE			English	Article							PIGEON CYTOCHROME-C; ANTIGEN RECEPTOR; MONOCLONAL-ANTIBODIES; POSITIVE SELECTION; ADHESION RECEPTORS; RECOGNITION; SPECIFICITY; PROTEINS; BIOLOGY; IA	The interaction of antigen-specific T cell receptors (TCRs) with their ligands, peptides bound to molecules of the major histocompatibility complex (MHC), is central to most immune responses, yet little is known about its chemical characteristics. The binding to T cells of a labeled monoclonal antibody to the TCR was inhibited by soluble class 11 MHC heterodimers complexed to different peptides. Inhibition was both peptide- and TCR-specific and of low affinity, with a K(D) = 4 x 10(-5) to 6 x 10(-5) M, orders of magnitude weaker than comparable antibody-antigen interactions. This finding is consistent with the scanning nature of T cell recognition and suggests that antigen-independent adhesion precedes TCR engagement.	STANFORD UNIV, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA	Stanford University	MATSUI, K (corresponding author), STANFORD UNIV, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA.		de St Groth, Barbara Fazekas/O-3017-2017	de St Groth, Barbara Fazekas/0000-0001-6817-9690; Davis, Mark/0000-0001-6868-657X	NIAID NIH HHS [AI19512] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI019512] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.biochem.59.1.253; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BONIFACE J, UNPUB; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CARBONE FR, 1987, J IMMUNOL, V138, P1838; CHANG TW, 1982, J IMMUNOL, V128, P585; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; DAVIS M, UNPUB; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; ELLIOT EW, UNPUB; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; FINK PJ, 1986, NATURE, V321, P219, DOI 10.1038/321219a0; GOLDSTEIN A, 1987, MOL PHARMACOL, V31, P603; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; JACOBS H, 1990, EUR J IMMUNOL, V20, P2333, DOI 10.1002/eji.1830201024; JACOBS S, 1975, BIOCHEM BIOPH RES CO, V66, P687, DOI 10.1016/0006-291X(75)90564-1; JANEWAY CA, 1989, IMMUNOL REV, V109, P77, DOI 10.1111/j.1600-065X.1989.tb00020.x; JORGENSEN JL, 1991, IN PRESS NATURE; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KRENSKY AM, 1984, J IMMUNOL, V132, P2180; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; MASON DW, 1986, HDB EXPT IMMUNOLOGY, V1, pCH38; MEUER SC, 1983, NATURE, V303, P808, DOI 10.1038/303808a0; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P742, DOI 10.1073/pnas.83.3.742; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; PARHAM P, 1986, HDB EXPT IMMUNOLOGY, V1, pCH14; PATTEN P, 1984, NATURE, V312, P40, DOI 10.1038/312040a0; PECCOUD J, 1990, EMBO J, V9, P4215, DOI 10.1002/j.1460-2075.1990.tb07869.x; PINCUS MR, 1983, P NATL ACAD SCI-BIOL, V80, P3297, DOI 10.1073/pnas.80.11.3297; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; REAY PA, UNPUB; ROBB RJ, 1981, J EXP MED, V154, P1455, DOI 10.1084/jem.154.5.1455; ROCK EP, UNPUB; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHNECK J, 1989, CELL, V56, P47, DOI 10.1016/0092-8674(89)90982-3; SETTE A, 1989, J IMMUNOL, V143, P3289; SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SINGER A, 1986, PROG IMMUNOL, V6, P60; SPITS H, 1986, SCIENCE, V232, P403, DOI 10.1126/science.3485822; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1990, ANNU REV CELL BIOL, V6, P359, DOI 10.1146/annurev.cellbio.6.1.359; TAX WJM, 1983, NATURE, V304, P445, DOI 10.1038/304445a0; WEISS A, 1984, J IMMUNOL, V133, P123; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0	55	348	362	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 20	1991	254	5039					1788	1791		10.1126/science.1763329	http://dx.doi.org/10.1126/science.1763329			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1763329				2022-12-01	WOS:A1991GW31600042
J	MENDEL, DB; KHAVARI, PA; CONLEY, PB; GRAVES, MK; HANSEN, LP; ADMON, A; CRABTREE, GR				MENDEL, DB; KHAVARI, PA; CONLEY, PB; GRAVES, MK; HANSEN, LP; ADMON, A; CRABTREE, GR			CHARACTERIZATION OF A COFACTOR THAT REGULATES DIMERIZATION OF A MAMMALIAN HOMEODOMAIN PROTEIN	SCIENCE			English	Article							NUCLEAR FACTOR-I; DNA-BINDING PROTEINS; ALBUMIN TRANSCRIPTION DIFFERS; POU DOMAIN PROTEINS; RAT HEPATOMA-CELLS; 3 SEQUENCE MOTIFS; CHROMOSOMAL LOCALIZATION; FUNCTIONAL DOMAINS; ACTIVATION DOMAIN; OVERLAP EXTENSION	Dimerization among transcription factors has become a recurrent theme in the regulation of eukaryotic gene expression. Hepatocyte nuclear factor-let (HNF-1-alpha) is a homeodomain-containing protein that functions as a dimer. A dimerization cofactor of HNF-1-alpha (DCoH) was identified that displayed a restricted tissue distribution and did not bind to DNA, but, rather, selectively stabilized HNF-1-alpha-dimers. The formation of a stable tetrameric DCoH-HNF-1-alpha-complex, which required the dimerization domain of HNF-1-alpha did not change the DNA binding characteristics of HNF-1-alpha but enhanced its transcriptional activity. However, DCoH did not confer transcriptional activation to the GAL4 DNA binding domain. These results indicate that DCoH regulates formation of transcriptionally active tetrameric complexes and may contribute to the developmental specificity of the complex.	UNIV CALIF BERKELEY,DEPT MOLEC & CELLULAR BIOL,HOWARD HUGHES MED INST,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley	MENDEL, DB (corresponding author), STANFORD UNIV,BECKMAN CTR MOLEC & GENET MED,HOWARD HUGHES MED INST,STANFORD,CA 94305, USA.			Admon, Arie/0000-0003-0504-3950	NCI NIH HHS [CA 09302] Funding Source: Medline; NHLBI NIH HHS [HL 33942] Funding Source: Medline; NICHD NIH HHS [HD 07201] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033942] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH I, 1990, GENOMICS, V8, P155, DOI 10.1016/0888-7543(90)90238-P; BAUMHEUTER S, UNPUB; BAUMHUETER S, 1988, EMBO J, V7, P2485, DOI 10.1002/j.1460-2075.1988.tb03095.x; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; CONLEY P, UNPUB; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DESCHATRETTE J, 1974, BIOCHIMIE, V56, P1603; DESCHATRETTE J, 1980, CELL, V19, P1043, DOI 10.1016/0092-8674(80)90095-1; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; KUO CJ, 1990, P NATL ACAD SCI USA, V87, P9838, DOI 10.1073/pnas.87.24.9838; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MENDEL D, UNPUB; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; NICOSIA A, 1990, CELL, V61, P1225, DOI 10.1016/0092-8674(90)90687-A; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309	62	215	219	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1762	1767		10.1126/science.1763325	http://dx.doi.org/10.1126/science.1763325			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1763325				2022-12-01	WOS:A1991GW31600034
J	MERCER, AR; EMPTAGE, NJ; CAREW, TJ				MERCER, AR; EMPTAGE, NJ; CAREW, TJ			PHARMACOLOGICAL DISSOCIATION OF MODULATORY EFFECTS OF SEROTONIN IN APLYSIA SENSORY NEURONS	SCIENCE			English	Article							GILL-WITHDRAWAL REFLEX; PRESYNAPTIC FACILITATION; INNERVATING TAIL; DISHABITUATION; MEMORY; LONG; SENSITIZATION; CAMP	In the mollusk Aplysia the neurotransmitter serotonin (5HT) has a fundamental modulatory role in several forms of learning and memory that involve an increase in the efficacy of synaptic transmission between tail sensory neurons (SNs) and motor neurons. The classical 5HT antagonist cyproheptadine (CYP) permits dissociation of three forms of serotonergic modulation in these SNs: (i) CYP reversibly blocks spike-broadening induced either by exogenous application of 5HT or by sensitizing stimulation of a tail nerve. (ii) CYP does not block 5HT-induced or tail input-induced increases in SN somatic excitability. (iii) Concomitant with its block of spike-broadening, CYP reversibly blocks 5HT-induced facilitation of synaptic transmission from SNs. These results suggest that endogenously released 5HT may act at different receptor subtypes that are coupled to different forms of neuromodulation in tail SNs of Aplysia.	YALE UNIV,DEPT PSYCHOL,NEW HAVEN,CT 06520; UNIV OTAGO,DEPT ZOOL,DUNEDIN,NEW ZEALAND	Yale University; University of Otago	CAREW, TJ (corresponding author), YALE UNIV,DEPT PSYCHOL,NEW HAVEN,CT 06520, USA.			Mercer, Alison/0000-0001-8110-4247	NIMH NIH HHS [MH 141083] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAXTER DA, 1990, J NEUROPHYSIOL, V64, P978, DOI 10.1152/jn.1990.64.3.978; BAXTER DA, 1989, J NEUROPHYSIOL, V62, P665, DOI 10.1152/jn.1989.62.3.665; BRAHA O, 1990, P NATL ACAD SCI USA, V87, P2040, DOI 10.1073/pnas.87.5.2040; BYRNE JH, 1987, PHYSIOL REV, V67, P329, DOI 10.1152/physrev.1987.67.2.329; CAREW TJ, 1986, ANNU REV NEUROSCI, V9, P435, DOI 10.1146/annurev.ne.09.030186.002251; CASTELLUCCI V, 1970, SCIENCE, V167, P1745, DOI 10.1126/science.167.3926.1745; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; GINGRICH KJ, 1985, J NEUROPHYSIOL, V53, P652, DOI 10.1152/jn.1985.53.3.652; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GOLDSMITH BA, 1991, P NATL ACAD SCI USA, V88, P9021, DOI 10.1073/pnas.88.20.9021; GREENBERG SM, 1987, J NEUROSCI, V7, P291; HAWKINS RD, 1987, HDB PHYSL 1, V6, P25; HOCHNER B, 1986, P NATL ACAD SCI USA, V83, P8794, DOI 10.1073/pnas.83.22.8794; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; OCCOR KA, 1985, NEUROSCI LETT, V55, P65; OCCOR KA, 1986, BRAIN RES, V371, P190; PEROUTKA SJ, 1981, SCIENCE, V212, P827, DOI 10.1126/science.7221567; POLLOCK JD, 1985, J NEUROSCI, V5, P1862; SCHOLZ KP, 1987, SCIENCE, V235, P685, DOI 10.1126/science.2433766; SIEGELBAUM SA, 1982, NATURE, V299, P413, DOI 10.1038/299413a0; SUGITA S, 1991, Society for Neuroscience Abstracts, V17, P1590; WALTERS ET, 1983, J NEUROPHYSIOL, V50, P1522, DOI 10.1152/jn.1983.50.6.1522; WALTERS ET, 1983, J NEUROPHYSIOL, V50, P1543, DOI 10.1152/jn.1983.50.6.1543	24	100	100	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1811	1813		10.1126/science.1662413	http://dx.doi.org/10.1126/science.1662413			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1662413				2022-12-01	WOS:A1991GW31600050
J	MIAO, VP; COVERT, SF; VANETTEN, HD				MIAO, VP; COVERT, SF; VANETTEN, HD			A FUNGAL GENE FOR ANTIBIOTIC-RESISTANCE ON A DISPENSABLE (B) CHROMOSOME	SCIENCE			English	Article							NECTRIA-HAEMATOCOCCA; PHYTOALEXIN-DETOXIFICATION; ELECTROPHORETIC KARYOTYPE; ASPERGILLUS-NIDULANS; LARGE DNA; PISATIN; PATHOGENICITY; PLANT	A family of cytochrome P-450 (Pda) genes in the pathogenic fungus Nectria haematococca is responsible for the detoxification of the phytoalexin pisatin, an antimicrobial compound produced by garden pea (Pisum sativum L.). The Pda6 gene was mapped by electrophoretic karyotype analysis to a small meiotically unstable chromosome that is dispensable for normal growth. Such traits are typical of B chromosomes. The strains of Nectria studied here have no sequences that are homologous to the Pda family other than Pda6 and therefore demonstrate that unique, functional genes can be found on B chromosomes. Unstable B chromosomes may be one mechanism for generating pathogenic variation in fungi.	UNIV ARIZONA,DEPT PLANT PATHOL,TUCSON,AZ 85721; CORNELL UNIV,DEPT PLANT PATHOL,ITHACA,NY 14853	University of Arizona; Cornell University	VANETTEN, HD (corresponding author), UNIV ARIZONA,DEPT PLANT PATHOL,TUCSON,AZ 85721, USA.							BRODY H, 1989, P NATL ACAD SCI USA, V86, P6260, DOI 10.1073/pnas.86.16.6260; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; Jones RN, 1982, B CHROMOSOMES; KISTLER HC, 1984, J GEN MICROBIOL, V130, P2595; LUCY MC, 1988, PHYSIOL MOL PLANT P, V33, P187, DOI 10.1016/0885-5765(88)90019-7; MACKINTOSH SF, 1989, MOL PLANT MICROBE IN, V2, P354, DOI 10.1094/MPMI-2-354; MATTHEWS DE, 1983, ARCH BIOCHEM BIOPHYS, V224, P494, DOI 10.1016/0003-9861(83)90237-0; MATUO T, 1972, PHYTOPATHOLOGY, V62, P731, DOI 10.1094/Phyto-62-731; MIAO VP, IN PRESS APPL ENV MI; MIAO VPW, 1991, MOL GEN GENET, V226, P214, DOI 10.1007/BF00273606; MILLS D, 1990, MOL PLANT MICROBE IN, V3, P351, DOI 10.1094/MPMI-3-351; ORBACH MJ, 1988, MOL CELL BIOL, V8, P1469, DOI 10.1128/MCB.8.4.1469; Sambrook J., 1989, MOL CLONING; SCHAFER W, 1989, SCIENCE, V246, P247, DOI 10.1126/science.246.4927.247; VANETTEN HD, 1984, PHYSIOL PLANT PATHOL, V25, P149, DOI 10.1016/0048-4059(84)90053-5; VANETTEN HD, 1989, ANNU REV PHYTOPATHOL, V27, P143, DOI 10.1146/annurev.py.27.090189.001043; VANETTEN HD, 1989, NATO ASI SERIES H, V36, P219; VOLLRATH D, 1988, P NATL ACAD SCI USA, V85, P6027, DOI 10.1073/pnas.85.16.6027; WELTRING KM, 1988, GENE, V68, P335, DOI 10.1016/0378-1119(88)90036-4	19	223	231	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1773	1776		10.1126/science.1763326	http://dx.doi.org/10.1126/science.1763326			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1763326				2022-12-01	WOS:A1991GW31600037
J	NERI, A; CHANG, CC; LOMBARDI, L; SALINA, M; CORRADINI, P; MAIOLO, AT; CHAGANTI, RSK; DALLAFAVERA, R				NERI, A; CHANG, CC; LOMBARDI, L; SALINA, M; CORRADINI, P; MAIOLO, AT; CHAGANTI, RSK; DALLAFAVERA, R			B-CELL LYMPHOMA-ASSOCIATED CHROMOSOMAL TRANSLOCATION INVOLVES CANDIDATE ONCOGENE LYT-10, HOMOLOGOUS TO NF-KAPPA-B P50	CELL			English	Article							HEAVY-CHAIN LOCUS; ACUTE LYMPHOBLASTIC-LEUKEMIA; C-MYC ONCOGENE; DISTINCT PATHOGENETIC FORMS; ENHANCER-BINDING-PROTEINS; HUMAN T-CELLS; BURKITT-LYMPHOMA; TRANSCRIPTION FACTOR; PROTO-ONCOGENE; REL ONCOGENE	A B cell lymphoma-associated chromosomal translocation, t(10;14)(q24;q32), juxtaposes the immunoglobulin C-alpha-1 locus to a novel gene, lyt-10. The normal lyt-10 cDNA codes for a 98 kd protein which displays amino-terminal homology with the rel (DNA-binding) domain of the NF-kappa-B-rel family of transcription factors and carboxy-terminal homology with the NF-kappa-B p50 precursor protein, including the putative proteolytic cleavage domain (poly-G) and the ankyrin-like repeat domains. The lyt-10 protein can bind to kappa-B sequences in vitro, although with different specificity from NF-kappa-B p50, and in vitro DNA-binding is activated by removal of the ankyrin domain. Chromosomal translocation generates an lyt-10-C-alpha-1 fusion gene coding for a protein that retains the rel effector domain, lacks the ankyrin regulatory domain, and binds kappa-B sequences in vitro, suggesting its constitutive activation in vivo. Analogous rearrangements of the lyt-10 gene have been found in an additional three cases of lymphoid neoplasia. The lyt-10 gene defines a new subfamily (rel/poly-G/ankyrin) of NF-kappa-B-rel transcription factors with potential for oncogenic activation in human cancer.	COLUMBIA UNIV COLL PHYS & SURG,CTR CANC,NEW YORK,NY 10032; UNIV MILAN,OSPED MAGGIORE,INST RIC & CARATTERE SCI,IST SCI MED,SERV EMATOL,I-20122 MILAN,ITALY; MEM SLOAN KETTERING CANC CTR,CANC GENET LAB,NEW YORK,NY 10021	Columbia University; University of Milan; Memorial Sloan Kettering Cancer Center	NERI, A (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032, USA.		Corradini, Paolo/N-7584-2017; Neri, Antonino/I-9690-2014	Corradini, Paolo/0000-0002-9186-1353; Neri, Antonino/0000-0001-9047-5912; Critelli, Salvatore/0000-0001-7325-0228	NCI NIH HHS [CA-20194, CA-44029, CA-34775] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044029, R01CA034775, P01CA020194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; ARTAVANISTSAKONAS S, 1988, TRENDS GENET, V4, P95, DOI 10.1016/0168-9525(88)90096-0; ATKIN NB, 1985, HUM GENET, V70, P359, DOI 10.1007/BF00295378; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAEUERLE PA, 1990, MOL ASPECTS CELL REG, V6; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BROTHMAN AR, 1990, CANCER RES, V50, P3795; BROWNELL E, 1989, ONCOGENE, V4, P935; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DALLAFAVERA R, 1991, ORIGINS HUMAN CANCER; DUBE ID, 1986, BLOOD, V67, P1181; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLANAGAN JG, 1984, CELL, V36, P681, DOI 10.1016/0092-8674(84)90348-9; FLANAGAN JG, 1982, NATURE, V300, P709, DOI 10.1038/300709a0; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GRUMONT RJ, 1988, ONCOGENE RES, V4, P1; GUNTER KC, 1989, J IMMUNOL, V142, P3286; HAKEM R, 1989, J IMMUNOL, V142, P297; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; KAGAN J, 1989, P NATL ACAD SCI USA, V86, P4161, DOI 10.1073/pnas.86.11.4161; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P3283, DOI 10.1073/pnas.71.8.3283; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; LOWENTHAL JW, 1989, J IMMUNOL, V142, P3121; LU D, 1991, ONCOGENE, V6, P1235; LU M, 1990, GENE CHROMOSOME CANC, V2, P217, DOI 10.1002/gcc.2870020309; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MELLENTIN JD, 1989, SCIENCE, V246, P379, DOI 10.1126/science.2799390; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NERI A, 1988, P NATL ACAD SCI USA, V85, P2748, DOI 10.1073/pnas.85.8.2748; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OFFIT K, 1991, GENE CHROMOSOME CANC, V3, P189, DOI 10.1002/gcc.2870030304; OFFIT K, 1991, BLOOD, V77, P1508; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PESCHLE C, 1984, P NATL ACAD SCI-BIOL, V81, P5514, DOI 10.1073/pnas.81.17.5514; RABBITTS TH, 1981, NUCLEIC ACIDS RES, V9, P4509, DOI 10.1093/nar/9.18.4509; RAIMONDI SC, 1988, BLOOD, V72, P1560; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; SHOWS T, 1984, SOMAT CELL MOLEC GEN, V10, P315, DOI 10.1007/BF01535253; SHOWS TB, 1983, ISOZYMES-CURR T BIOL, V10, P323; SHOWS TB, 1978, CYTOGENET CELL GENET, V21, P99, DOI 10.1159/000130882; SHOWS TB, 1982, ADV HUM GENET, V12, P341; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; ZECH L, 1976, INT J CANCER, V17, P47, DOI 10.1002/ijc.2910170108; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	81	402	406	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1075	1087		10.1016/0092-8674(91)90285-7	http://dx.doi.org/10.1016/0092-8674(91)90285-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760839				2022-12-01	WOS:A1991GX16400007
J	ODIN, JA; EDBERG, JC; PAINTER, CJ; KIMBERLY, RP; UNKELESS, JC				ODIN, JA; EDBERG, JC; PAINTER, CJ; KIMBERLY, RP; UNKELESS, JC			REGULATION OF PHAGOCYTOSIS AND [CA2+]I FLUX BY DISTINCT REGIONS OF AN FC RECEPTOR	SCIENCE			English	Article							MEDIATED PHAGOCYTOSIS; HUMAN NEUTROPHIL; ACTIVATION; EXPRESSION; HETEROGENEITY; FLUORESCENCE; GENERATION; PROTEIN; IGG	The binding of multivalent immunoglobulin G complexes to Fc receptors (Fc-gamma-Rs) on macrophages activates multiple immune functions. A murine macrophage cell fine, but not a fibroblast cell line, that was transfected with human Fc-gamma-RIIA mediated phagocytosis and an intracellular Ca2+ concentration ([Ca2+]i) flux upon cross-linking of human Fc-gamma-RIIA. Transfected macrophages that expressed a truncated receptor lacking 17 carboxy-terminal amino acids phagocytosed small antibody complexes. However, only wild-type transfectants phagocytosed labeled erythrocytes and fluxed [Ca2+]i. Thus, the cytoplasmic domain of human Fc-gamma-RIIA contains distinct functional regions.	MT SINAI MED CTR,DEPT BIOCHEM,NEW YORK,NY 10029; CORNELL UNIV,MED CTR,DEPT MED,NEW YORK,NY 10021	Icahn School of Medicine at Mount Sinai; Cornell University	UNKELESS, JC (corresponding author), MT SINAI MED CTR,DEPT BIOCHEM,NEW YORK,NY 10029, USA.			Kimberly, Robert/0000-0002-5330-3086	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024671, R37AI024322, R01AI024322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033062] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 24322, AI 24671] Funding Source: Medline; NIAMS NIH HHS [AR 33062] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSSON T, 1988, FEBS LETT, V239, P371, DOI 10.1016/0014-5793(88)80954-2; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; CONNELLY PA, 1991, BIOCHEM BIOPH RES CO, V177, P192, DOI 10.1016/0006-291X(91)91967-H; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; EDBERG JC, UNPUB; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GRESHAM HD, 1990, J BIOL CHEM, V265, P7819; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HOLTZMAN E, 1989, LYSOSOMES, pCH2; KIMBERLY RP, 1990, J EXP MED, V171, P1239, DOI 10.1084/jem.171.4.1239; KORCHAK HM, 1988, J BIOL CHEM, V263, P11098; MACINTYRE EA, 1988, J IMMUNOL, V141, P4333; MARTIN MM, 1975, J LUMIN, V10, P381, DOI 10.1016/0022-2313(75)90003-4; MIDOUX P, 1987, CYTOMETRY, V8, P327, DOI 10.1002/cyto.990080314; MILLER J, 1985, J IMMUNOL, V134, P4212; MUNN DH, 1991, CANCER RES, V51, P1117; ODIN JA, 1990, RECEPTORS INFLAMMATO, V1, P1; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; Sambrook J., 1989, MOL CLONING LAB MANU; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; URLAUB G, 1986, SOMAT CELL MOLEC GEN, V12, P216; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	24	158	159	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1785	1788		10.1126/science.1837175	http://dx.doi.org/10.1126/science.1837175			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1837175				2022-12-01	WOS:A1991GW31600041
J	SEGIL, N; ROBERTS, SB; HEINTZ, N				SEGIL, N; ROBERTS, SB; HEINTZ, N			MITOTIC PHOSPHORYLATION OF THE OCT-1 HOMEODOMAIN AND REGULATION OF OCT-1 DNA-BINDING ACTIVITY	SCIENCE			English	Article							HISTONE H2B GENE; GEL-ELECTROPHORESIS; ESCHERICHIA-COLI; POU DOMAIN; CELL; PURIFICATION; PROTEINS	Oct-1 is a transcription factor involved in the cell cycle regulation of histone H2B gene transcription and in the transcription of other cellular housekeeping genes. Oct-1 is hyperphosphorylated as cells enter mitosis, and mitosis-specific phosphorylation is reversed as cells exit mitosis. A mitosis-specific phosphorylation site in the homeodomain of Oct-1 was phosphorylated in vitro by protein kinase A. Phosphorylation of this site correlated with inhibition of Oct-1 DNA binding activity in vivo and in vitro. The inhibition of Oct-1 DNA binding during mitosis suggests a mechanism by which the general inhibition of transcription during mitosis might occur.			SEGIL, N (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MOLEC BIOL LAB,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM 32544, GM 13752] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032544, F32GM013752] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; BRADBURY EM, 1974, NATURE, V247, P257, DOI 10.1038/247257a0; DAVIDSON D, 1964, EXP CELL RES, V35, P317, DOI 10.1016/0014-4827(64)90098-9; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HARLOW E, 1988, ANTIBODIES LABORATOR; HEINTZ N, 1984, P NATL ACAD SCI-BIOL, V81, P2713, DOI 10.1073/pnas.81.9.2713; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4491; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LABELLA F, 1989, GENE DEV, V3, P1982, DOI 10.1101/gad.3.12a.1982; LABELLA F, 1991, MOL CELL BIOL, V11, P5825, DOI 10.1128/MCB.11.12.5825; LAMB NJC, 1991, EMBO J, V10, P1523, DOI 10.1002/j.1460-2075.1991.tb07672.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; ROBERTS SB, 1991, SCIENCE, V253, P1022, DOI 10.1126/science.1887216; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SAHASRABUDDHE CG, 1984, EXP CELL RES, V153, P439, DOI 10.1016/0014-4827(84)90612-8; Schreiber E., 1989, TISSUE SPECIFIC GENE, P33; SEGIL N, 1991, COLD SPRING HARB SYM, V56, P285; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TERASIMA T, 1963, EXP CELL RES, V30, P344, DOI 10.1016/0014-4827(63)90306-9; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	26	222	225	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1814	1816		10.1126/science.1684878	http://dx.doi.org/10.1126/science.1684878			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1684878				2022-12-01	WOS:A1991GW31600051
J	STARR, DB; HAWLEY, DK				STARR, DB; HAWLEY, DK			TFIID BINDS IN THE MINOR GROOVE OF THE TATA BOX	CELL			English	Article							RNA POLYMERASE-II; ECO RI ENDONUCLEASE; TRANSCRIPTION FACTOR; PROMOTER SEQUENCES; FUNCTIONAL DOMAINS; DNA; PROTEIN; YEAST; GENE; INITIATION	We have analyzed the interaction of the general RNA polymerase II transcription factor TFIID with its DNA-binding site, the TATA box (consensus sequence TATAAAA). We have demonstrated that TFIID, unlike most sequence-specific DNA-binding proteins, interacts primarily within the minor groove of the DNA helix. This was established by a novel approach involving complete replacement of the thymines and adenines in the TATA box with cytosines and inosines, respectively. This substitution exchanged the major groove of TATAAAA for that of the sequence CGCGGGG, without altering the surface of the minor groove. The unusual DNA-binding properties of TFIID revealed by this study have important implications for TFIID specificity and function and, more generally, for sequence-specific recognition by DNA-binding proteins.	UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon	STARR, DB (corresponding author), UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403, USA.							ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CHURCH GM, 1977, P NATL ACAD SCI USA, V74, P1458, DOI 10.1073/pnas.74.4.1458; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FIRE A, 1984, J BIOL CHEM, V259, P2509; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GILBERT W, 1976, CONTROL RIBOSOME SYN, P139; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HOEIJMAKERS JHJ, 1990, NATURE, V343, P417, DOI 10.1038/343417b0; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KILPATRICK MW, 1986, J BIOL CHEM, V261, P1350; LU AL, 1981, J BIOL CHEM, V256, P3200; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; Maniatis T., 1982, MOL CLONING; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MAXAM AM, 1980, METHOD ENZYMOL, V65, P497; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MUHICH ML, 1990, P NATL ACAD SCI USA, V87, P9148, DOI 10.1073/pnas.87.23.9148; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NAGAI K, 1990, NATURE, V343, P418, DOI 10.1038/343418a0; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NASH HA, 1991, CELL, V67, P1037, DOI 10.1016/0092-8674(91)90280-C; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; NUSSINOV R, 1990, CRIT REV BIOCHEM MOL, V25, P185, DOI 10.3109/10409239009090609; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PENOTTI FE, 1990, J MOL BIOL, V213, P37, DOI 10.1016/S0022-2836(05)80120-2; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHEIT KH, 1967, BIOCHIM BIOPHYS ACTA, V149, P344, DOI 10.1016/0005-2787(67)90162-1; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SLUKA JP, 1990, BIOCHEMISTRY-US, V29, P6551, DOI 10.1021/bi00480a002; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; STUCKA R, 1990, FEBS LETT, V261, P223, DOI 10.1016/0014-5793(90)80558-Z; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; WHITE SW, 1989, PROTEINS, V5, P281, DOI 10.1002/prot.340050405; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	60	187	188	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1231	1240		10.1016/0092-8674(91)90299-E	http://dx.doi.org/10.1016/0092-8674(91)90299-E			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760847				2022-12-01	WOS:A1991GX16400021
J	VANVACTOR, DL; CAGAN, RL; KRAMER, H; ZIPURSKY, SL				VANVACTOR, DL; CAGAN, RL; KRAMER, H; ZIPURSKY, SL			INDUCTION IN THE DEVELOPING COMPOUND EYE OF DROSOPHILA - MULTIPLE MECHANISMS RESTRICT R7 INDUCTION TO A SINGLE RETINAL PRECURSOR CELL	CELL			English	Article							RECEPTOR TYROSINE KINASE; PATTERN-FORMATION; ECTOPIC EXPRESSION; SEVENLESS PROTEIN; PUTATIVE RECEPTOR; GENE; ENCODES; MELANOGASTER; DOMAIN; ROUGH	The development of the Drosophila R7 photoreceptor cell is determined by a specific inductive interaction between the R8 photoreceptor cell and a single neighboring precursor cell. This process is mediated by bride of sevenless (boss), a cell-surface bound ligand, and the sevenless (sev) tyrosine kinase receptor. The boss ligand is expressed specifically on the surface of the R8 cell, whereas the sev receptor is expressed on 5 cells contacting the developing R8 cell and other cells not in contact with R8. By altering the spatial and temporal expression of boss, we demonstrate that sev-expressing cells that do not contact R8 can assume an R7 cell fate. By contrast, the sev-expressing precursor cells to the R1-R6 photoreceptor cells that do contact R8 are nonresponsive to the inductive cue. Using the rough and N(spl) mutations, we demonstrate that an early commitment to an R1-R6 cell fate blocks the pathway of sev activation in these cells.	UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, HOWARD HUGHES MED INST, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Cagan, Ross Leigh/AAV-9528-2021	Kramer, Helmut/0000-0002-1167-2676; Cagan, Ross/0000-0001-5297-450X; Van Vactor, Jr., David L./0000-0001-8156-9482; Zipursky, Stephen/0000-0001-5630-7181				AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BASLER K, 1990, GENE DEV, V4, P728, DOI 10.1101/gad.4.5.728; BASLER K, 1989, DEVELOPMENT, V107, P723; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BOWTELL DDL, 1989, CELL, V56, P931, DOI 10.1016/0092-8674(89)90626-0; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CAGAN RL, 1992, DETERMINANTS NEURONA; CAMPOSORTEGA JA, 1979, ROUX ARCH DEV BIOL, V186, P27, DOI 10.1007/BF00848106; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HARRIS WA, 1976, J PHYSIOL-LONDON, V256, P415; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HEBERLEIN U, 1991, DEVELOPMENT, V112, P703; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; LIPOSITS Z, 1984, NEUROSCIENCE, V13, P513, DOI 10.1016/0306-4522(84)90245-8; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; RUBIN GM, 1989, CELL, V57, P519, DOI 10.1016/0092-8674(89)90120-7; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; Spemann H., 1938, EMBRYONIC DEV INDUCT; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; WARING DA, 1991, NATURE, V350, P712, DOI 10.1038/350712a0	42	145	145	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 20	1991	67	6					1145	1155		10.1016/0092-8674(91)90291-6	http://dx.doi.org/10.1016/0092-8674(91)90291-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760842				2022-12-01	WOS:A1991GX16400013
J	WILLIAMS, TM; MOOLTEN, D; BURLEIN, J; ROMANO, J; BHAERMAN, R; GODILLOT, A; MELLON, M; RAUSCHER, FJ; KANT, JA				WILLIAMS, TM; MOOLTEN, D; BURLEIN, J; ROMANO, J; BHAERMAN, R; GODILLOT, A; MELLON, M; RAUSCHER, FJ; KANT, JA			IDENTIFICATION OF A ZINC FINGER PROTEIN THAT INHIBITS IL-2 GENE-EXPRESSION	SCIENCE			English	Article							HUMAN INTERLEUKIN-2 GENE; DNA-BINDING PROTEINS; MESSENGER-RNA; LYMPHOCYTES-T; CHLORAMPHENICOL ACETYLTRANSFERASE; FIREFLY LUCIFERASE; ANTIGEN RECEPTOR; MAMMALIAN-CELLS; PROMOTER; ACTIVATION	Transient activation of the interleukin-2 (IL-2) gene after antigen recognition by T lymphocytes is crucial for subsequent T cell proliferation and differentiation. Several IL-2 gene regulatory elements and binding factors necessary for activation of the IL-2 gene have been defined. However, little is known about negative regulation of IL-2 expression, which is likely to be important in the rapid shut-off of IL-2 transcription. A nucleotide sequence element (NRE-A) that negatively regulates IL-2 expression has been identified within the IL-2 gene. T cell nuclear extracts contained an NRE-A binding activity. A complementary DNA was isolated that encodes a zinc finger-containing protein that suppressed IL-2 gene expression. The observation of negative regulation of the immunoglobulin heavy chain gene enhancer by an element similar to NRE-A suggests that related proteins may regulate multiple immune response genes.	WISTAR INST,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	The Wistar Institute; University of Pennsylvania	WILLIAMS, TM (corresponding author), UNIV NEW MEXICO,SCH MED,DEPT PATHOL,ALBUQUERQUE,NM 87131, USA.				NATIONAL CANCER INSTITUTE [R29CA054428, R01CA023413] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023879] Funding Source: NIH RePORTER; NCI NIH HHS [CA23413, CA54428] Funding Source: Medline; NIAID NIH HHS [AI23879] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANGEL P, 1987, CELL, V729; AUSUBEL FM, 1989, CURRENT PROTOCOLS MO, pCH4; BILOFSKY HS, 1988, NUCLEIC ACIDS RES, V16, P1861, DOI 10.1093/nar/16.5.1861; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EFRAT S, 1984, P NATL ACAD SCI-BIOL, V81, P2601, DOI 10.1073/pnas.81.9.2601; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FORTINI ME, 1991, MECH DEVELOP, V34, P113, DOI 10.1016/0925-4773(91)90048-B; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GALSON DL, 1988, MOL CELL BIOL, V8, P381, DOI 10.1128/MCB.8.1.381; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; KAMPS MP, 1990, MOL CELL BIOL, V10, P5464, DOI 10.1128/MCB.10.10.5464; KANT JA, 1989, C INSERM, V179, P53; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; LAI ZC, 1991, MECH DEVELOP, V34, P123, DOI 10.1016/0925-4773(91)90049-C; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHAW J, 1988, J IMMUNOL, V140, P2243; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SIEBENLIST U, 1986, MOL CELL BIOL, V6, P3042, DOI 10.1128/MCB.6.9.3042; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; Williams T. J., UNPUB; WILLIAMS TM, 1989, ANAL BIOCHEM, V176, P28, DOI 10.1016/0003-2697(89)90267-4; WILLIAMS TM, 1988, J IMMUNOL, V141, P662; ZUBIAGA AM, 1991, J IMMUNOL, V146, P3857	43	177	181	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1791	1794		10.1126/science.1840704	http://dx.doi.org/10.1126/science.1840704			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1840704				2022-12-01	WOS:A1991GW31600043
J	YU, VC; DELSERT, C; ANDERSEN, B; HOLLOWAY, JM; DEVARY, OV; NAAR, AM; KIM, SY; BOUTIN, JM; GLASS, CK; ROSENFELD, MG				YU, VC; DELSERT, C; ANDERSEN, B; HOLLOWAY, JM; DEVARY, OV; NAAR, AM; KIM, SY; BOUTIN, JM; GLASS, CK; ROSENFELD, MG			RXR-BETA - A COREGULATOR THAT ENHANCES BINDING OF RETINOIC ACID, THYROID-HORMONE, AND VITAMIN-D RECEPTORS TO THEIR COGNATE RESPONSE ELEMENTS	CELL			English	Article							HUMAN OSTEOCALCIN GENE; DNA-BINDING; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; MOLECULAR-CLONING; MAMMALIAN-CELLS; SEQUENCE; PROTEINS; IDENTIFICATION; TRANSCRIPTION	The retinoic acid receptor (RAR) requires coregulators to bind effectively to response elements in target genes. A strategy of sequential screening of expression libraries with a retinoic acid response element and RAR identified a cDNA encoding a coregulator highly related to RXR-alpha. This protein, termed RXR-beta, forms heterodimers with RAR, preferentially increasing its DNA binding and transcriptional activity on promoters containing retinoic acid, but not thyroid hormone or vitamin D, response elements. Remarkably, RXR-beta also heterodimerizes with the thyroid hormone and vitamin D receptors, increasing both DNA binding and transcriptional function on their respective response elements. RXR-alpha also forms heterodimers with these receptors. These observations suggest that retinoid X receptors meet the criteria for biochemically characterized cellular coregulators and serve to selectively target the high affinity binding of retinoic acid, thyroid hormone, and vitamin D receptors to their cognate DNA response elements.	UNIV CALIF SAN DIEGO,EUKARYOT REGULATORY BIOL PROGRAM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,MOLEC PATHOL GRP,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	YU, VC (corresponding author), UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093, USA.		Glass, Christopher/AAI-3933-2021; Yu, Victor/A-7899-2015	Glass, Christopher/0000-0003-4344-3592; Yu, Victor/0000-0003-3270-4734				AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEEBE JS, 1991, MOL ENDOCRINOL, V5, P85, DOI 10.1210/mend-5-1-85; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DARLING DS, 1989, MOL ENDOCRINOL, V3, P1359, DOI 10.1210/mend-3-9-1359; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLASS CK, 1991, MOL ASPECTS CELLULAR, V6, P299; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HE X, 1989, NATURE, V343, P38; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HOLLOWAY JM, 1990, P NATL ACAD SCI USA, V87, P8160, DOI 10.1073/pnas.87.20.8160; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUROKAWA R, 1991, BIOCHIM BIOPHYS ACTA, V1095, P63; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9781; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; LIPKIN SM, 1991, IN PRESS P NATL ACAD; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; OZONO K, 1990, J BIOL CHEM, V265, P21881; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SPORN MB, 1983, CANCER RES, V43, P3034; STUDIER FW, 1986, J MOL BIOL, V189, P13; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	78	1237	1264	0	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1251	1266		10.1016/0092-8674(91)90301-E	http://dx.doi.org/10.1016/0092-8674(91)90301-E			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1662118				2022-12-01	WOS:A1991GX16400023
J	BAUD, FJ; BARRIOT, P; TOFFIS, V; RIOU, B; VICAUT, E; LECARPENTIER, Y; BOURDON, R; ASTIER, A; BISMUTH, C				BAUD, FJ; BARRIOT, P; TOFFIS, V; RIOU, B; VICAUT, E; LECARPENTIER, Y; BOURDON, R; ASTIER, A; BISMUTH, C			ELEVATED BLOOD CYANIDE CONCENTRATIONS IN VICTIMS OF SMOKE-INHALATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARBON-MONOXIDE; COMBUSTION PRODUCTS; EXPOSURE DURATION; GLASGOW AREA; FIRE DEATHS; INTOXICATION; CARBOXYHEMOGLOBIN; TOXICITY; PYRUVATE; GLUCOSE	Background. The nature of the toxic gases that cause death from smoke inhalation is not known. In addition to carbon monoxide, hydrogen cyanide may be responsible, but its role is uncertain, because blood cyanide concentrations are often measured only long after exposure. Methods. We measured cyanide concentrations in blood samples obtained at the scene of residential fires from 109 fire victims before they received any treatment. We compared the results with those in 114 persons with drug intoxication (40 subjects), carbon monoxide intoxication (29 subjects), or trauma (45 subjects). The metabolic effect of smoke inhalation was assessed by measuring plasma lactate at the time of admission to the hospital in 39 patients who did not have severe burns. Results. The mean (+/- SD) blood cyanide concentrations in the 66 surviving fire victims (21.6 +/- 36.4-mu-mol per liter, P < 0.001) and the 43 victims who died (116.4 +/- 89.6-mu-mol per liter, P < 0.001) were significantly higher than those in the 114 control subjects (5.0 +/- 5.5-mu-mol per liter). Among the 43 victims who died, the blood cyanide concentrations were above 40-mu-mol per liter in 32 (74 percent), and above 100-mu-mol per liter in 20 of these (46 percent). There was a significant correlation between blood cyanide and carbon monoxide concentrations in the fire victims (P < 0.001). Plasma lactate concentrations at the time of hospital admission correlated more closely with blood cyanide concentrations than with blood carbon monoxide concentrations. Plasma lactate concentrations above 10 mmol per liter were a sensitive indicator of cyanide intoxication, as defined by the presence of a blood cyanide concentration above 40-mu-mol per liter. Conclusions. Residential fires may cause cyanide poisoning. At the time of a patient's hospital admission, an elevated plasma lactate concentration is a useful indicator of cyanide toxicity in fire victims who do not have severe burns.	BRIGADE SAPEURS POMPIERS PARIS,SERV MED,PARIS,FRANCE; UNIV PARIS 07,HOP FERNAND WIDAL,TOXIKOL LAB,F-75475 PARIS 10,FRANCE; HOP HENRI MONDOR,TOXIKOL LAB,F-94010 CRETEIL,FRANCE; ECOLE POLYTECH,LOAENSTA,INSERM,U275,F-91128 PALAISEAU,FRANCE; HOP BICETRE,F-94270 LE KREMLIN BICETR,FRANCE; UNIV PARIS 06,HOP PITIE SALPETRIERE,DEPT ANESTHESIE REANIMAT,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Polytechnique de Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	BAUD, FJ (corresponding author), UNIV PARIS 07,HOP FERNAND WIDAL,DEPT BIOPHYS,200 RUE FAUBOURG ST DENIS,F-75010 PARIS,FRANCE.							ALARIE Y, 1985, ANNU REV PHARMACOL, V25, P325, DOI 10.1146/annurev.pa.25.040185.001545; ANDERSON RA, 1982, MED SCI LAW, V22, P35, DOI 10.1177/002580248202200106; ANDERSON RA, 1981, MED SCI LAW, V21, P175, DOI 10.1177/002580248102100305; ANDERSON RC, 1986, ANAL METHODS HUMAN T, P289; Ballantyne B., 1987, CLIN EXPT TOXICOLOGY, P248; BERTOL E, 1983, FORENSIC SCI INT, V22, P111, DOI 10.1016/0379-0738(83)90002-6; BIRKY MM, 1981, B NEW YORK ACAD MED, V57, P997; BRIGHT JE, 1988, HUM TOXICOL, V7, P183, DOI 10.1177/096032718800700214; CLARK CJ, 1981, LANCET, V1, P1332; ELLENHORN MJ, 1988, MED TOXICOLOGY DIAGN, P888; FABRE R, 1960, PRECIS TOXICOLOGIE, V1, P120; FELDSTEIN M, 1954, J LAB CLIN MED, V44, P166; HALL AH, 1989, J TOXICOL CLIN EXPER, V9, P3; HOLLANDER M, 1973, NONPARAMETRIC STATIS; Karter Jr MJ, 1986, FIRE J, V80, P26; Linnell J. L., 1987, CLIN EXPT TOXICOLOGY, P427; Loke J, 1988, PATHOPHYSIOLOGY TREA, P453; MARBACH EP, 1967, CLIN CHEM, V13, P314; Marrs T., 1987, CLIN EXPT TOXICOLOGY, P217; Marrs T. C, 1987, CLIN EXPT TOXICOLOGY, P383; MIERLEY MC, 1983, JAMA-J AM MED ASSOC, V249, P1466, DOI 10.1001/jama.249.11.1466; MOORE SJ, 1987, J PHARMACOL EXP THER, V242, P70; MOUREU H, 1957, Arch Mal Prof, V18, P116; NORRIS JC, 1986, TOXICOLOGY, V40, P121, DOI 10.1016/0300-483X(86)90073-9; PURSER DA, 1984, ARCH ENVIRON HEALTH, V39, P394, DOI 10.1080/00039896.1984.10545871; Rieders F, 1975, METHODOLOGY ANAL TOX, VI, P113; RIOU B, 1990, J NEUROSURG ANESTH, V2, P296, DOI 10.1097/00008506-199012000-00008; RIOU B, 1991, ANESTHESIOLOGY, V74, P552, DOI 10.1097/00000542-199103000-00025; SILVERMAN SH, 1988, J TRAUMA, V28, P171, DOI 10.1097/00005373-198802000-00007; SOKAL JA, 1985, J APPL TOXICOL, V5, P395, DOI 10.1002/jat.2550050611; SOKAL JA, 1985, ARCH TOXICOL, V57, P196, DOI 10.1007/BF00290887; SYMINGTON IS, 1978, LANCET, V2, P91; TERRILL JB, 1978, SCIENCE, V200, P1343, DOI 10.1126/science.208143; Troup C. M., 1987, CLIN EXPT TOXICOLOGY, P22; Vogel S, 1987, CLIN EXPT TOXICOLOGY, P451; YAMAMOTO K, 1975, Z RECHTSMED, V76, P11, DOI 10.1007/BF02116793; ZIKRIA BA, 1972, J TRAUM, V12, P641, DOI 10.1097/00005373-197208000-00001	37	296	305	2	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 19	1991	325	25					1761	1766		10.1056/NEJM199112193252502	http://dx.doi.org/10.1056/NEJM199112193252502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV739	1944484				2022-12-01	WOS:A1991GV73900002
J	BROCHIER, B; KIENY, MP; COSTY, F; COPPENS, P; BAUDUIN, B; LECOCQ, JP; LANGUET, B; CHAPPUIS, G; DESMETTRE, P; AFIADEMANYO, K; LIBOIS, R; PASTORET, PP				BROCHIER, B; KIENY, MP; COSTY, F; COPPENS, P; BAUDUIN, B; LECOCQ, JP; LANGUET, B; CHAPPUIS, G; DESMETTRE, P; AFIADEMANYO, K; LIBOIS, R; PASTORET, PP			LARGE-SCALE ERADICATION OF RABIES USING RECOMBINANT VACCINIA RABIES VACCINE	NATURE			English	Article							ORAL VACCINATION; FIELD TRIAL; VIRUS GLYCOPROTEIN; FOX RABIES; IMMUNIZATION; WILDLIFE; PROTECTION; EXPRESSION; EFFICACY; SAFETY	RABIES infection of domestic and wild animals is a serious problem throughout the world. The major disease vector in Europe is the red fox (Vulpes vulpes) and rabies control has focused on vaccinating and/or culling foxes. Culling has not been effective, and the distribution of live vaccine baits is the only appropriate method for the vaccination of wild foxes 1. Although some European countries have conducted field vaccination campaigns using attenuated rabies virus strains 2-5, their use has not been extensively approved because they retain pathogenicity for rodents and can revert to virulence 6,7. These strains cannot be used in North America because they are pathogenic for the striped skunk (Mephitis mephitis) 8 and are ineffective in the racoon (Procyon lotor) 9. We have constructed a recombinant vaccinia virus 10, VVTGgRAB, expressing the surface glycoprotein (G) of rabies virus (ERA strain) 11-13. The recombinant was a highly effective vaccine in experimental animals 11-13, in captive foxes 14,15 and in racoons 9. We report here the results of a large-scale campaign of fox vaccination in a 2,200 km2 region of southern Belgium, an area in which rabies is prevalent. After distribution, 81% of foxes inspected were positive for tetracycline, a biomarker included in the vaccine bait and, other than one rabid fox detected close to the periphery of the treated area, no case of rabies, either in foxes or in domestic livestock, has been reported in the area.	TRANSGENE SA,F-67000 STRASBOURG,FRANCE; PASTEUR INST BRABANT,DEPT RABIES,B-1180 BRUSSELS,BELGIUM; RHONE MERIEUX LAB IFFA,F-69342 LYONS,FRANCE; STATE UNIV LIEGE,FAC SCI,INST ZOOL,B-4020 LIEGE,BELGIUM	Transgene SA; University of Liege	BROCHIER, B (corresponding author), STATE UNIV LIEGE,FAC VET MED,DEPT VIROL,45 RUE VET,B-1070 BRUSSELS,BELGIUM.		Kieny, Marie-Paule/Q-1238-2019; Kieny, Marie-Paule/N-3914-2017	Kieny, Marie-Paule/0000-0002-5943-6488				ANDERSON RM, 1986, NATURE, V322, P304, DOI 10.1038/322304a0; ANDERSON RM, 1981, NATURE, V289, P765, DOI 10.1038/289765a0; BAER GM, 1975, NATURAL HIST RABIES, V2, P261; BALTAZAR RS, 1987, ANN MED VET, V131, P481; BLANCOU J, 1989, ANN RECH VET, V20, P195; BLANCOU J, 1986, NATURE, V322, P373, DOI 10.1038/322373a0; BROCHIER B, 1990, VACCINE, V8, P101, DOI 10.1016/0264-410X(90)90129-A; BROCHIER B, 1989, J WILDLIFE DIS, V25, P540, DOI 10.7589/0090-3558-25.4.540; BROCHIER B, 1988, VET REC, V123, P618; BROCHIER BM, 1988, VET MICROBIOL, V18, P103, DOI 10.1016/0378-1135(88)90055-7; BROCHIER BM, 1990, VET REC, V127, P165; DEAN DJ, 1974, LABORATORY TECHNIQUE, P75; DESMETTRE P, 1990, VET MICROBIOL, V23, P227, DOI 10.1016/0378-1135(90)90153-M; HARRIS S, 1986, J ANIM ECOL, V55, P575, DOI 10.2307/4740; KAPPELER A, 1988, VACCINATION CONTROL, P55; KIENY MP, 1984, NATURE, V312, P163, DOI 10.1038/312163a0; Leblois H., 1988, EUR Publication, Commission of the European Communities, P101; MOSS B, 1987, ANNU REV IMMUNOL, V5, P305, DOI 10.1146/annurev.iy.05.040187.001513; NEWMARK P, 1988, NATURE, V336, P416, DOI 10.1038/336416a0; PASTORET PP, 1988, VET REC, V123, P481, DOI 10.1136/vr.123.19.481; RUPPRECHT CE, 1986, P NATL ACAD SCI USA, V83, P7947, DOI 10.1073/pnas.83.20.7947; RUPPRECHT CE, 1990, J WILDLIFE DIS, V26, P99, DOI 10.7589/0090-3558-26.1.99; SCHNEIDER LG, 1983, TIERARZTL UMSCHAU, V38, P315; STECK F, 1982, ZBL VET MED B, V29, P372; THOMAS I, 1990, J GEN VIROL, V71, P37, DOI 10.1099/0022-1317-71-1-37; TOLSON ND, 1988, ARCH VIROL, V102, P297, DOI 10.1007/BF01310835; WANDELER AI, 1982, COMP IMMUNOL MICROB, V5, P173, DOI 10.1016/0147-9571(82)90032-7; WIKTOR TJ, 1984, P NATL ACAD SCI-BIOL, V81, P7194, DOI 10.1073/pnas.81.22.7194; WIKTOR TJ, 1985, ANN INST PASTEUR VIR, V136E, P405, DOI 10.1016/S0769-2617(85)80132-5; Wiktor TJ, 1988, APPLIED VIROLOGY RES, V1, P69; 1989, CONSULTATION REQUIRE	31	219	244	1	61	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 19	1991	354	6354					520	522		10.1038/354520a0	http://dx.doi.org/10.1038/354520a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW751	1758494	Green Submitted			2022-12-01	WOS:A1991GW75100013
J	DALEMANS, W; BARBRY, P; CHAMPIGNY, G; JALLAT, S; DOTT, K; DREYER, D; CRYSTAL, RG; PAVIRANI, A; LECOCQ, JP; LAZDUNSKI, M				DALEMANS, W; BARBRY, P; CHAMPIGNY, G; JALLAT, S; DOTT, K; DREYER, D; CRYSTAL, RG; PAVIRANI, A; LECOCQ, JP; LAZDUNSKI, M			ALTERED CHLORIDE-ION CHANNEL KINETICS ASSOCIATED WITH THE DELTA-F508 CYSTIC-FIBROSIS MUTATION	NATURE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL-CELLS; EXPRESSION; GENE; CL; IDENTIFICATION; TRANSPORT; MEMBRANE	CYSTIC fibrosis is associated with a defect in epithelial chloride ion transport (reviewed in refs 1, 2) which is caused by mutations in a membrane protein called CFTR (cystic fibrosis transmembrane conductance regulator) 3. Heterologous expression of CFTR produces cyclicAMP-sensitive Cl--channel activity 4-7. Deletion of phenylalanine at amino-acid position 508 in CFTR (DELTA-F508 CFTR) is the most common mutation in cystic fibrosis 8. It has been proposed that this mutation prevents glycoprotein maturation and its transport to its normal cellular location 9. We have expressed both CFIR and DELTA-F508 CFTR in Vero cells using recombinant vaccinia virus. Although far less DELTA-F508 CFTR reached the plasma membrane than normal CFTR, sufficient DELTA-F508 CFTR was expressed at the plasma membrane to permit functional analysis. DELTA-F508 CFIR expression induced a reduced activity of the cAMP-activated Cl- channel, with conductance, anion selectivity and open-time kinetics similar to those of CFIR, but with much greater closed times, resulting in a large decrease of open probability. The DELTA-F508 mutation thus seems to have two major consequences, an abnormal translocation of the CFTR protein which limits membrane insertion, and an abnormal function in mediating Cl- transport.	INST PHARMACOL MOLEC & CELLULAIRE,660 ROUTE LUCIOLES,SOPHIA ANTIPOLIS,F-06560 VALBONNE,FRANCE; TRANSGENE SA,F-67082 STRASBOURG,FRANCE; NHLBI,PULM BRANCH,BETHESDA,MD 20892	Transgene SA; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Barbry, Pascal/O-5021-2016	Barbry, Pascal/0000-0001-9632-6483				ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BARBRY P, 1990, P NATL ACAD SCI USA, V87, P7347, DOI 10.1073/pnas.87.19.7347; CHAMPIGNY G, 1990, FEBS LETT, V259, P263, DOI 10.1016/0014-5793(90)80024-D; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DREINHOFER J, 1988, BIOCHIM BIOPHYS ACTA, V946, P135, DOI 10.1016/0005-2736(88)90466-X; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; EDWARDS G, 1990, TRENDS PHARMACOL SCI, V11, P417, DOI 10.1016/0165-6147(90)90149-3; GRAY MA, 1990, AM J PHYSIOL, V259, pC752, DOI 10.1152/ajpcell.1990.259.5.C752; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LAZDUNSKI M, 1982, ANNU REV PHYSIOL, V44, P463, DOI 10.1146/annurev.ph.44.030182.002335; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P673; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TRIGGLE DJ, 1987, ANNU REV PHARMACOL, V27, P347; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593	23	594	671	0	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 19	1991	354	6354					526	528		10.1038/354526a0	http://dx.doi.org/10.1038/354526a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW751	1722027				2022-12-01	WOS:A1991GW75100015
J	HILL, RE; FAVOR, J; HOGAN, BLM; TON, CCT; SAUNDERS, GF; HANSON, IM; PROSSER, J; JORDAN, T; HASTIE, ND; VANHEYNINGEN, V				HILL, RE; FAVOR, J; HOGAN, BLM; TON, CCT; SAUNDERS, GF; HANSON, IM; PROSSER, J; JORDAN, T; HASTIE, ND; VANHEYNINGEN, V			MOUSE SMALL EYE RESULTS FROM MUTATIONS IN A PAIRED-LIKE HOMEOBOX-CONTAINING GENE	NATURE			English	Article							DEVELOPING EXCRETORY SYSTEM; BOX; DROSOPHILA; DELETION; DOMAIN; PAX-1; OCT-1; DNA	SMALL eye (Sey) in mouse is a semidominant mutation which in the homozygous condition results in the complete lack of eyes and nasal primordia. On the basis of comparative mapping studies and on phenotypic similarities, Sey bas been suggested to be homologous to congenital aniridia (lack of iris) in human 1,2. A candidate gene for the aniridia (AN) locus at 11p13 bas been isolated by positional cloning 3 and its sequence and that of the mouse homologue has been established (C.T., manuscript in preparation). This gene belongs to the paired-like class of developmental genes first described in Drosophila which contain two highly conserved motifs, the paired box and the homeobox 4,5. In vertebrates, genes which encode the single paired domain as well as those which express both motifs have been described as the Pax multigene family 6-10. A Pax gene recently described as Pax-6 11,12 is identical to the mouse homologue of the candidate aniridia gene. Here we report the analysis of three independent Sey alleles and show that indeed this gene is mutated and that the mutations would predictably interrupt gene function.	GESELL STRAHLEN & UMWELTFORSCH MBH,INST SAUGETIERGENET,W-8042 NEUHERBERG,GERMANY; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	HILL, RE (corresponding author), WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		VAN HEYNINGEN, Veronica/GYE-0531-2022; van Heyningen, Veronica/B-8039-2008	van Heyningen, Veronica/0000-0003-0359-0141; Hanson, Isabel/0000-0002-1878-0530				BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BARTH RK, 1982, P NATL ACAD SCI-BIOL, V79, P500, DOI 10.1073/pnas.79.2.500; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; COTE S, 1987, EMBO J, V6, P2793, DOI 10.1002/j.1460-2075.1987.tb02575.x; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; DILELLA AG, 1986, NATURE, V322, P799, DOI 10.1038/322799a0; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; ESUMI H, 1983, P NATL ACAD SCI-BIOL, V80, P95, DOI 10.1073/pnas.80.1.95; FAVOR J, 1988, MUTAT RES, V198, P269, DOI 10.1016/0027-5107(88)90003-6; FAVOR J, 1982, MUTAT RES, V92, P181; GLASER T, 1990, SCIENCE, V250, P823, DOI 10.1126/science.2173141; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Green MC., 1989, GENETIC VARIANTS STR, P12; HASTIE ND, IN PRESS CURR BIOL; HOGAN BLM, 1988, DEVELOPMENT, V103, P115; HOGAN BLM, 1986, J EMBRYOL EXP MORPH, V97, P95; JOSTES B, 1991, MECH DEVELOP, V33, P27; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KRAUSS S, 1991, NATURE, V353, P267, DOI 10.1038/353267a0; MEYEROWITZ R, 1988, P NATL ACAD SCI USA, V85, P3955; MONAGHAN AP, 1991, DEVELOPMENT, V112, P1053; PLACHOV D, 1990, DEVELOPMENT, V110, P643; PROSSER J, 1990, ONCOGENE, V5, P1573; RESS DJG, 1985, NATURE, V316, P643; ROBERTS RC, 1967, GENET RES, V9, P121, DOI 10.1017/S0016672300010387; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TON CCT, IN PRESS CELL, V67; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; VANDERMEERDEJONG R, 1990, GENOMICS, V7, P270, DOI 10.1016/0888-7543(90)90550-E; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WALTHER C, IN PRESS DEVELOPMENT; [No title captured]	37	1155	1173	1	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 19	1991	354	6354					522	525		10.1038/354522a0	http://dx.doi.org/10.1038/354522a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW751	1684639				2022-12-01	WOS:A1991GW75100014
J	ROSENZWEIG, A; WATKINS, H; HWANG, DS; MIRI, M; MCKENNA, W; TRAILL, TA; SEIDMAN, JG; SEIDMAN, CE				ROSENZWEIG, A; WATKINS, H; HWANG, DS; MIRI, M; MCKENNA, W; TRAILL, TA; SEIDMAN, JG; SEIDMAN, CE			PRECLINICAL DIAGNOSIS OF FAMILIAL HYPERTROPHIC CARDIOMYOPATHY BY GENETIC-ANALYSIS OF BLOOD-LYMPHOCYTES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOSIN HEAVY-CHAIN; LEFT-VENTRICULAR HYPERTROPHY; AMINO-ACID-SEQUENCE; MOLECULAR-BASIS; SUDDEN-DEATH; CLINICAL MANIFESTATIONS; PATHO-PHYSIOLOGY; SKELETAL-MUSCLE; DNA-SEQUENCE; ALPHA	Background. The clinical diagnosis of familial hypertrophic cardiomyopathy is usually made on the basis of the physical examination, electrocardiogram, and echocardiogram. Making an accurate diagnosis can be particularly difficult in children, who may not have cardiac hypertrophy until adulthood. Recently, we demonstrated that mutations in the cardiac myosin heavy-chain genes cause familial hypertrophic cardiomyopathy in some families. We report a diagnostic test for familial hypertrophic cardiomyopathy that relies on the detection of mutations in the beta-myosin heavy-chain gene in circulating lymphocytes that we used to evaluate three generations of a family, including the children. Methods and Results. Using the polymerase chain reaction, we found that normal and mutant beta-cardiac myosin heavy-chain genes are transcribed in circulating lymphocytes. This allowed us to examine beta-cardiac myosin heavy-chain messenger RNA from blood lymphocytes, even though ordinary expression of the gene is virtually restricted to the heart. Base sequences amplified from this messenger RNA were analyzed with a ribonuclease protection assay to identify small deletions, abnormal splicing, or missense mutations. Using this technique we identified a novel missense mutation in a patient with familial hypertrophic cardiomyopathy. We evaluated 15 of the patient' s adult relatives and found perfect agreement with the clinical diagnosis (8 affected and 7 not affected). Clinical analysis of 14 of the children (age, 1 to 20 years) of these affected family members revealed 1 child with echocardiographic findings diagnostic of familial hypertrophic cardiomyopathy. However, genetic analyses showed that six other children had also inherited the missense mutation and might later manifest the disease. Conclusions. Transcripts of beta-cardiac myosin heavy-chain gene can be detected in blood lymphocytes and used to screen for mutations that cause familial hypertrophic cardiomyopathy. This approach makes practical the identification of mutations responsible for this disorder and may be applicable to other diseases in which direct analysis is difficult because the mutated gene is expressed only in certain tissues. Preclinical or prenatal screening in an affected family will make it possible to study the disease longitudinally and to develop preventive interventions.	MASSACHUSETTS GEN HOSP,CARDIAC UNIT,BOSTON,MA 02114; BRIGHAM & WOMENS HOSP,DIV CARDIOL,BOSTON,MA 02115; ST GEORGE HOSP,SCH MED,DEPT CARDIOL SCI,LONDON,ENGLAND; TAICHUNG VET GEN HOSP,DIV CARDIOL,TAICHUNG,TAIWAN; JOHNS HOPKINS UNIV HOSP,DIV CARDIOL,BALTIMORE,MD 21205; HOWARD HUGHES MED INST,BOSTON,MA	Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; St Georges University London; Taichung Veterans General Hospital; Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute	ROSENZWEIG, A (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,25 SHATTUCK ST,BOSTON,MA 02115, USA.		Rosenzweig, Anthony/AAD-7893-2019; McKenna, William J/C-3243-2008	McKenna, William J/0000-0001-7994-2460; Watkins, Hugh/0000-0002-5287-9016	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035877, R01HL046320] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02228, HL35877, HL46320] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONARAKIS SE, 1989, NEW ENGL J MED, V320, P153, DOI 10.1056/NEJM198901193200305; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COTTON RGH, 1989, BIOCHEM J, V263, P1; DIBB NJ, 1989, J MOL BIOL, V205, P603, DOI 10.1016/0022-2836(89)90229-5; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GREGOR P, 1989, INT J CARDIOL, V23, P335, DOI 10.1016/0167-5273(89)90193-9; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HARBARTH P, 1988, DNA-J MOLEC CELL BIO, V7, P297, DOI 10.1089/dna.1988.7.297; HEJTMANCIK JF, 1991, CIRCULATION, V83, P1592, DOI 10.1161/01.CIR.83.5.1592; HOLCOMBE R F, 1987, Genomics, V1, P287, DOI 10.1016/0888-7543(87)90058-9; JAENICKE T, 1990, GENOMICS, V8, P194, DOI 10.1016/0888-7543(90)90272-V; JARCHO JA, 1989, NEW ENGL J MED, V321, P1372, DOI 10.1056/NEJM198911163212005; JUNG G, 1989, GENE, V82, P269, DOI 10.1016/0378-1119(89)90052-8; KARN J, 1983, P NATL ACAD SCI-BIOL, V80, P4253, DOI 10.1073/pnas.80.14.4253; KAUFMAN DL, 1990, GENOMICS, V8, P656, DOI 10.1016/0888-7543(90)90252-P; LICHTER P, 1986, EUR J BIOCHEM, V160, P419, DOI 10.1111/j.1432-1033.1986.tb09989.x; LIEW CC, 1990, NUCLEIC ACIDS RES, V18, P3647, DOI 10.1093/nar/18.12.3647; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; MAHDAVI V, 1982, NATURE, V297, P659, DOI 10.1038/297659a0; MARON BJ, 1976, CIRCULATION, V53, P9, DOI 10.1161/01.CIR.53.1.9; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; MARON BJ, 1987, NEW ENGL J MED, V316, P844, DOI 10.1056/NEJM198704023161405; MARON BJ, 1981, AM J CARDIOL, V48, P418, DOI 10.1016/0002-9149(81)90068-0; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; MARON BJ, 1978, AM J CARDIOL, V41, P803, DOI 10.1016/0002-9149(78)90717-8; MARON BJ, 1986, NEW ENGL J MED, V315, P610, DOI 10.1056/NEJM198609043151003; MCKENNA W, 1981, AM J CARDIOL, V47, P532, DOI 10.1016/0002-9149(81)90535-X; MCKENNA WJ, 1988, J AM COLL CARDIOL, V11, P351, DOI 10.1016/0735-1097(88)90101-5; MCKENNA WJ, 1989, DISEASES HEART, P933; MCKUSICK VA, 1989, NEW ENGL J MED, V320, P910, DOI 10.1056/NEJM198904063201406; MCNALLY EM, 1989, J MOL BIOL, V210, P665, DOI 10.1016/0022-2836(89)90141-1; MOLINA MI, 1987, J BIOL CHEM, V262, P6478; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; PERRY LW, 1980, J PEDIATR-US, V97, P677, DOI 10.1016/S0022-3476(80)80040-0; ROBERTS RG, 1990, LANCET, V336, P1523, DOI 10.1016/0140-6736(90)93305-9; ROZEK CE, 1986, P NATL ACAD SCI USA, V83, P2128, DOI 10.1073/pnas.83.7.2128; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; SHAPIRO LM, 1983, J AM COLL CARDIOL, V2, P437, DOI 10.1016/S0735-1097(83)80269-1; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SMABROOK J, 1989, MOL CLONING LABORATO; SOLOMON SD, 1990, J CLIN INVEST, V86, P993, DOI 10.1172/JCI114802; SOLOMON SD, 1990, AM J HUM GENET, V47, P389; STEDMAN HH, 1990, J BIOL CHEM, V265, P3568; STREHLER EE, 1986, J MOL BIOL, V190, P291, DOI 10.1016/0022-2836(86)90003-3; Surawicz B, 1978, Am J Cardiol, V41, P130, DOI 10.1016/0002-9149(78)90147-9; TANIGAWA G, 1990, CELL, V62, P991, DOI 10.1016/0092-8674(90)90273-H; TONG SW, 1990, J BIOL CHEM, V265, P4893; WIGLE ED, 1985, PROG CARDIOVASC DIS, V28, P1, DOI 10.1016/0033-0620(85)90024-6; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0	54	156	164	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 19	1991	325	25					1753	1760		10.1056/NEJM199112193252501	http://dx.doi.org/10.1056/NEJM199112193252501			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV739	1944483				2022-12-01	WOS:A1991GV73900001
J	WRIGHT, PF; KIMFARLEY, RJ; DEQUADROS, CA; ROBERTSON, SE; SCOTT, RM; WARD, NA; HENDERSON, RH				WRIGHT, PF; KIMFARLEY, RJ; DEQUADROS, CA; ROBERTSON, SE; SCOTT, RM; WARD, NA; HENDERSON, RH			STRATEGIES FOR THE GLOBAL ERADICATION OF POLIOMYELITIS BY THE YEAR 2000	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TYPE-3 POLIOVIRUS; VACCINE STRAIN; VIRUS; EXCRETION; RECEPTOR; WORLD		PAN AMER HLTH ORG, WASHINGTON, DC USA; WHO, EXPANDED PROGRAMME IMMUNIZAT, CH-1211 GENEVA 27, SWITZERLAND; WHO, OFF ASSISTANT DIRECTOR GEN, CH-1211 GENEVA 27, SWITZERLAND	Pan American Health Organization; World Health Organization; World Health Organization	WRIGHT, PF (corresponding author), VANDERBILT UNIV, DEPT PEDIAT, DIV INFECT DIS, NASHVILLE, TN 37232 USA.							ALMOND JW, 1987, ANNU REV MICROBIOL, V41, P153; ALMOND JW, 1990, B WORLD HEALTH ORGAN, V68, P545; [Anonymous], 1990, WKLY EPIDEMIOL REC, V65, P5; [Anonymous], 1990, WHOEPICDSPOLIO901; BURKE KL, 1988, NATURE, V332, P81, DOI 10.1038/332081a0; CHUMAKOV KM, 1991, P NATL ACAD SCI USA, V88, P199, DOI 10.1073/pnas.88.1.199; DEQUADROS CA, 1991, PEDIATR INFECT DIS J, V10, P222, DOI 10.1097/00006454-199103000-00011; DORVAL BL, 1989, BIOCHEM BIOPH RES CO, V159, P1177, DOI 10.1016/0006-291X(89)92234-1; DUNN G, 1990, J MED VIROL, V32, P92, DOI 10.1002/jmv.1890320205; FENNER F, 1988, SMALLPOX ITE ERADICA; HENDERSON RH, 1989, ANN NY ACAD SCI, V569, P69, DOI 10.1111/j.1749-6632.1989.tb27359.x; HOGLE JM, 1985, SCIENCE, V229, P1358, DOI 10.1126/science.2994218; JANSEN RW, 1990, P NATL ACAD SCI USA, V87, P2867, DOI 10.1073/pnas.87.8.2867; KOHARA M, 1988, J VIROL, V62, P2828, DOI 10.1128/JVI.62.8.2828-2835.1988; LEMON SM, 1991, PROG MED VIROL, V38, P42; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; MINOR PD, 1986, J GEN VIROL, V67, P693, DOI 10.1099/0022-1317-67-4-693; NKOWANE BM, 1987, JAMA-J AM MED ASSOC, V257, P1335, DOI 10.1001/jama.257.10.1335; PATRIARCA PA, 1991, REV INFECT DIS, V13, P926; RACANIELLO VR, 1981, SCIENCE, V214, P916, DOI 10.1126/science.6272391; REN R, 1990, CELL, V63, P353, DOI 10.1016/0092-8674(90)90168-E; RICOHESSE R, 1987, VIROLOGY, V160, P311, DOI 10.1016/0042-6822(87)90001-8; SABIN AB, 1985, J INFECT DIS, V151, P420, DOI 10.1093/infdis/151.3.420; SUTTER RW, 1991, LANCET, V338, P715, DOI 10.1016/0140-6736(91)91442-W; TOYODA H, 1984, J MOL BIOL, V174, P561, DOI 10.1016/0022-2836(84)90084-6; 1991, WKLY B, V6, P38; 1988, WHO WHA4128 RES, P26; 1989, WHO WHA4232 RES, P33; 1985, B PAN AM HLTH ORGAN, V19, P213; 1990, MMWR-MORBID MORTAL W, V39, P557	30	89	90	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 19	1991	325	25					1774	1779		10.1056/NEJM199112193252504	http://dx.doi.org/10.1056/NEJM199112193252504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV739	1719418				2022-12-01	WOS:A1991GV73900004
J	BRAVEMAN, PA; EGERTER, S; BENNETT, T; SHOWSTACK, J				BRAVEMAN, PA; EGERTER, S; BENNETT, T; SHOWSTACK, J			DIFFERENCES IN HOSPITAL RESOURCE-ALLOCATION AMONG SICK NEWBORNS ACCORDING TO INSURANCE-COVERAGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective. - To assess whether newborns insurance coverage was associated with differences in the allocation of hospital services. Design. - Retrospective analysis of computerized hospital discharge data, comparing resource allocation among newborns according to insurance status, controlling for race/ethnicity, diagnoses, hospital characteristics (ownership, teaching status, nursery level), and disposition. Setting. - All California civilian acute-care hospitals. Patients. - Population-based sample, excluding out-of-hospital and military hospital births. Resource allocation was studied among all newborns discharged in 1987 with evidence of serious problems (N = 29 751). Main Outcome Measures. - Length of stay, total charges, and charges per day. Results. - Sick newborns without insurance received fewer inpatient services than comparable privately insured newborns with either indemnity or prepaid coverage. This pattern was observed across all hospital ownership types. Mean stay was 15.7 days for all privately insured newborns (15.6 days for those with indemnity and 15.7 days for those with prepaid coverage), 14.8 days for Medicaid-covered newborns, and 13.2 days for uninsured newborns (P < .001). Length of stay, total charges, and charges per day were 16%, 28%, and 10% less, respectively, for the uninsured than for all privately insured newborns (P < .001). Resources for newborns covered by Medicaid were generally greater than for the uninsured and less than for the privately insured. Both uninsured and Medicaid-covered newborns were found to have more severe medical problems than the privately insured. Conclusions. - The findings cannot be explained by differences in medical need or by differences in non-medically indicated services; they constitute prima facie evidence of inequities that need to be addressed by policy changes.	UNIV CALIF SAN FRANCISCO, SCH MED, INST HLTH POLICY STUDIES, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	BRAVEMAN, PA (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT FAMILY & COMMUNITY MED, BOX 0900, SAN FRANCISCO, CA 94143 USA.		Showstack, Jonathan/L-6556-2013	Showstack, Jonathan/0000-0002-1367-419X				ADAY LA, 1978, HEALTH SERV RES, V13, P369; ADAY LA, 1984, AM J PUBLIC HEALTH, V74, P1331, DOI 10.2105/AJPH.74.12.1331; Amler RW, 1987, CLOSING GAP BURDEN U; BAZZOLI GJ, 1986, HEALTH SERV RES, V21, P353; Becker E R, 1983, Inquiry, V20, P248; BRAVEMAN P, 1989, NEW ENGL J MED, V321, P508, DOI 10.1056/NEJM198908243210805; BROWN ER, 1988, CHANGES HLTH INSURAN; CAPER P, 1988, NEW ENGL J MED, V318, P1535, DOI 10.1056/NEJM198806093182310; COHODES DR, 1986, INQUIRY-J HEALTH CAR, V23, P227; DAVIS K, 1983, MILBANK FUND Q, V61, P149, DOI 10.2307/3349903; DAVIS K, 1981, ANNU REV PUBL HEALTH, V2, P159, DOI 10.1146/annurev.pu.02.050181.001111; DOWD BE, 1986, MED CARE, V24, P694, DOI 10.1097/00005650-198608000-00005; EPSTEIN AM, 1990, NEW ENGL J MED, V322, P1122, DOI 10.1056/NEJM199004193221606; FUCHS VR, 1987, NEW ENGL J MED, V316, P1154, DOI 10.1056/NEJM198704303161812; GORDON T, 1986, PEDIATRICS, V77, P29; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; JOHNSON AN, 1989, INQUIRY-J HEALTH CAR, V26, P388; LINCOLN R, 1987, BLESSED EVENTS BOTTO; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; MURRAY JL, 1988, NEW ENGL J MED, V319, P1385, DOI 10.1056/NEJM198811243192105; NUTTER DO, 1987, NEW ENGL J MED, V316, P1156, DOI 10.1056/NEJM198704303161813; SHOWSTACK JA, 1984, AM J PUBLIC HEALTH, V74, P1003, DOI 10.2105/AJPH.74.9.1003; STARFIELD B, 1985, HEALTH SERV RES, V19, P817; STERN RS, 1989, ARCH INTERN MED, V149, P1185, DOI 10.1001/archinte.149.5.1185; WEISFELD VD, 1987, 2 R WOOD JOHNS F SPE; WEISSMAN J, 1989, JAMA-J AM MED ASSOC, V261, P3572, DOI 10.1001/jama.261.24.3572; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; WISE PH, 1985, NEW ENGL J MED, V313, P360, DOI 10.1056/NEJM198508083130605; 1980, PHS801260 US DEP HLT, P1; 1985, SAS USERS GUIDE STAT; 1987, AM HOSPITAL ASS GUID; [No title captured]	32	80	80	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1991	266	23					3300	3308		10.1001/jama.266.23.3300	http://dx.doi.org/10.1001/jama.266.23.3300			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GU964	1960830				2022-12-01	WOS:A1991GU96400029
J	DIRCKX, JH				DIRCKX, JH			SUMMARIZING THE OBSTETRIC HISTORY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter																		CUNNINGHAM FG, 1989, WILLIAMS OBSTETRICS, P258; DANFORTH DN, 1986, OBSTET GYNECOL, P647; HACKER NF, 1986, ESSENTIALS OBSTETRIC, P22; WYNN RM, 1988, OBSTET GYNECOL, P4	4	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1991	266	23					3344	3344		10.1001/jama.266.23.3344	http://dx.doi.org/10.1001/jama.266.23.3344			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU964	1960839				2022-12-01	WOS:A1991GU96400040
J	NIGHTINGALE, SL				NIGHTINGALE, SL			1-PERCENT HYDROCORTISONE PRODUCTS TO BE AVAILABLE OVER-THE-COUNTER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1991	266	23					3263	3263						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU964	1660082				2022-12-01	WOS:A1991GU96400005
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FOOD LABELING REFORM INITIATIVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1991	266	23					3263	3263						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU964	1660082				2022-12-01	WOS:A1991GU96400003
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FOSCARNET APPROVED FOR AIDS PATIENTS WITH CMV RETINITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1991	266	23					3263	3263						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU964	1660082				2022-12-01	WOS:A1991GU96400004
J	BERNAUER, W; GRATWOHL, A; KELLER, A; DAICKER, B				BERNAUER, W; GRATWOHL, A; KELLER, A; DAICKER, B			MICROVASCULOPATHY IN THE OCULAR FUNDUS AFTER BONE-MARROW TRANSPLANTATION	ANNALS OF INTERNAL MEDICINE			English	Article							MALIGNANT ARTERIAL-HYPERTENSION; RADIATION RETINOPATHY; AUTOIMMUNE-DISEASES; CYCLOSPORIN-A; HOST DISEASE; MANIFESTATIONS; RECIPIENTS; GRAFT; IRRADIATION; LEUKEMIA	Objective: To determine the incidence and time course of retinal and optic-disk ischemia after bone marrow transplantation and to describe the clinical, fluorescein-angiographic, and histologic findings in patients with these ischemic fundus lesions. Design: Prospective cohort study; standardized clinical and ophthalmologic evaluation of all patients before bone marrow transplantation and 3, 6, and 12 months after transplantation (and when indicated). Setting: University hospitals in Basel, Switzerland. Patients: Consecutive patients (127) treated with allogeneic or autologous bone marrow grafts. Main Results: Thirteen of the 127 patients (10%; 95% Cl, 5% to 15%) had lesions of the ocular microcirculation. All patients had cotton-wool spots in the fundus of both eyes, and three patients also had bilateral optic-disk edema. Secondary changes included retinal hemorrhages and lipid deposits. The ischemic fundus lesions appeared during the first 6 months after transplantation and were reversible in 9 of the 13 patients. The lesions occurred only in patients who were treated with total body irradiation and were given cyclosporin A as prophylaxis for graft-versus-host disease. Conclusions: Ischemic fundus lesions area frequent complication after bone marrow transplantation. They were only observed in patients treated with total body irradiation and cyclosporin A. This combination of therapy appears to have an additive effect on the development of ocular and possibly generalized microvascular lesions.	KANTONSSPITAL, DEPT INNERE MED & FORSCH, HAEMATOL ABT, PETERSGRABEN 4, CH-4031 BASEL, SWITZERLAND; UNIV BASEL, HOSP EYE, CH-4051 BASEL, SWITZERLAND	Kantonsspital Aarau AG (KSA); University of Basel								BERNAUER W, 1991, KLIN MONATSBL AUGENH, V198, P447, DOI 10.1055/s-2008-1046007; BINAGHI M, 1983, J FR OPHTALMOL, V6, P881; BLOOM JN, 1988, ANN INTERN MED, V109, P963, DOI 10.7326/0003-4819-109-12-963; BROWN GC, 1982, OPHTHALMOLOGY, V89, P1494; COCCIA PF, 1988, BLOOD, V71, P888; COHEN DJ, 1984, ANN INTERN MED, V101, P667, DOI 10.7326/0003-4819-101-5-667; DAICKER B, 1988, OPHTHALMOLOGICA, V197, P169, DOI 10.1159/000309939; DIETERLE A, 1990, TRANSPLANTATION, V49, P1093, DOI 10.1097/00007890-199006000-00013; DUKEELDER S, 1972, SYSTEM OPHTHALMOLOGY, P981; DUKEELDER S, 1967, SYSTEM OPHTHALMOLOGY, V10, P23; FRANKLIN RM, 1983, OPHTHALMOLOGY, V90, P4; FREY FJ, 1990, SCHWEIZ MED WSCHR, V120, P772; GLOOR B, 1985, BRIT J OPHTHALMOL, V69, P320, DOI 10.1136/bjo.69.5.320; GRATWHOL AA, 1977, ANN INTERN MED, V87, P703, DOI 10.7326/0003-4819-87-6-703; GRATWOHL A, 1986, PROG ALLERGY, V38, P404; GRATWOHL A, 1983, NEW ENGL J MED, V308, P1101; HAMILTON DV, 1982, TRANSPLANT P, V14, P597; HAYREH SS, 1989, OPHTHALMOLOGICA, V198, P197, DOI 10.1159/000309999; HAYREH SS, 1989, OPHTHALMOLOGICA, V198, P216, DOI 10.1159/000310000; HAYREH SS, 1986, OPHTHALMOLOGY, V93, P74; HAYREH SS, 1989, OPHTHALMOLOGICA, V198, P230, DOI 10.1159/000310001; HAYREH SS, 1989, OPHTHALMOLOGICA, V198, P178, DOI 10.1159/000309998; HIRST LW, 1983, ARCH OPHTHALMOL-CHIC, V101, P580, DOI 10.1001/archopht.1983.01040010580010; JABS DA, 1983, ARCH OPHTHALMOL-CHIC, V101, P585, DOI 10.1001/archopht.1983.01040010585011; JACK MK, 1983, ARCH OPHTHALMOL-CHIC, V101, P1080; JOSS DV, 1982, LANCET, V1, P906; KINYOUN JL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1473; KINYOUN JL, 1988, AM J OPHTHALMOL, V105, P470, DOI 10.1016/0002-9394(88)90237-1; LEISHMAN R, 1957, Br J Ophthalmol, V41, P641, DOI 10.1136/bjo.41.11.641; LIVESEY SJ, 1989, EYE, V3, P271, DOI 10.1038/eye.1989.37; Merriam GR., 1972, FRONT RAD THER ONCOL, P346; MIHATSCH MJ, 1988, KLIN WOCHENSCHR, V66, P43, DOI 10.1007/BF01713009; NOLL RB, 1984, ARCH NEUROL-CHICAGO, V41, P329, DOI 10.1001/archneur.1984.04050150111026; NUSSENBLATT RB, 1986, SURV OPHTHALMOL, V31, P159, DOI 10.1016/0039-6257(86)90035-4; OECHSLIN M, 1986, TRANSPLANTATION, V41, P60, DOI 10.1097/00007890-198601000-00012; PALESTINE AG, 1984, AM J MED, V77, P652, DOI 10.1016/0002-9343(84)90356-5; PEPOSE JS, 1985, OPHTHALMOLOGY, V92, P472; PILLUNAT LE, 1987, KLIN MONATSBL AUGENH, V190, P131, DOI 10.1055/s-2008-1050344; POMERANTZ RJ, 1987, NEW ENGL J MED, V317, P1643, DOI 10.1056/NEJM198712243172607; SPECK B, 1988, TRANSPLANT P, V20, P505; Speck B, 1989, Clin Transpl, P115; VOGLER WR, 1990, BONE MARROW TRANSPL, V6, P405; WOLFE JA, 1986, TRANSPLANTATION, V41, P541	43	58	59	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1991	115	12					925	930		10.7326/0003-4819-115-12-925	http://dx.doi.org/10.7326/0003-4819-115-12-925			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU417	1952488				2022-12-01	WOS:A1991GU41700002
J	DIMOPOULOS, MA; BARLOGIE, B; SMITH, TL; ALEXANIAN, R				DIMOPOULOS, MA; BARLOGIE, B; SMITH, TL; ALEXANIAN, R			HIGH SERUM LACTATE-DEHYDROGENASE LEVEL AS A MARKER FOR DRUG-RESISTANCE AND SHORT SURVIVAL IN MULTIPLE-MYELOMA	ANNALS OF INTERNAL MEDICINE			English	Article							PROGNOSTIC FACTORS; STAGING SYSTEM; BETA-2-MICROGLOBULIN; MICROGLOBULIN; LYMPHOMA	Objective: To evaluate serum lactate dehydrogenase (LDH) as a prognostic factor in previously untreated patients with multiple myeloma. Design: Study of 391 consecutive patients with uniformly treated multiple myeloma, followed until death in 63% of patients. Setting: Tertiary, referral cancer center. Patients: A total of 391 consecutive, previously untreated, symptomatic patients with various stages of multiple myeloma. Intervention: Various chemotherapy regimens that included doxorubicin or glucocorticoids, or both, with a consistent response rate (53%). Measurements: Outcomes included clinical response based on a 75% reduction of calculated tumor load and survival time from treatment. Univariate and multivariate analyses were used. Main Results: Eleven percent of patients showed a high serum LDH level of more than 5.0-mu-kat/L (300 U/L). An elevated LDH level was seen more frequently with a rise in the tumor load; an increased level was present in 26% of patients with high tumor mass. A high LDH level was associated with plasma cell leukemia or lymphoma-like clinical features (43%) and with plasma cell hypodiploidy (17%). Only 20% of patients with elevated LDH levels responded to chemotherapy compared with a response rate of 57% for patients with low levels of LDH. Using multivariate analysis, LDH was a significant independent predictor of response (P = 0.001), with an odds ratio of 0.25 (95% Cl, 0.11 to 0.57). A high LDH level was associated with a short median survival (9 months) and showed the highest relative risk (2.63; Cl, 1.75 to 3.95; P = 0.001). Conclusions: Elevation of the LDH level suggests the presence of occult extraosseous disease and high tumor mass. The LDH level is a predictor of a poor prognosis in selected patients who should be considered for early intensive treatment.	UNIV TEXAS, MD ANDERSON CANC CTR, BOX 1, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center			Dimopoulos, Meletios Athanasios/AAD-4130-2019	Dimopoulos, Meletios/0000-0001-8990-3254	NCI NIH HHS [CA-16672, CA-37161, CA-28771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037161, R01CA028771, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANIAN R, 1975, CANCER, V36, P1192, DOI 10.1002/1097-0142(197510)36:4<1192::AID-CNCR2820360403>3.0.CO;2-I; ALEXANIAN R, 1990, AM J HEMATOL, V33, P86, DOI 10.1002/ajh.2830330203; ALEXANIAN R, 1985, AM J HEMATOL, V20, P345, DOI 10.1002/ajh.2830200405; BARLOGIE B, 1989, ANN INTERN MED, V110, P521, DOI 10.7326/0003-4819-110-7-521; BARLOGIE B, 1985, BLOOD, V66, P338; BARLOGIE B, 1989, J CLIN ONCOL, V7, P1514, DOI 10.1200/JCO.1989.7.10.1514; Cox, 1970, ANAL BINARY DATA, P87; COX DR, 1972, J R STAT SOC B, V34, P187; DALTON WS, 1989, J CLIN ONCOL, V7, P415, DOI 10.1200/JCO.1989.7.4.415; DURIE BGM, 1990, BLOOD, V75, P823; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; GOLDIE JH, 1983, CANCER TREAT REP, V67, P923; GOULD J, 1988, BLOOD, V71, P453; GREIPP PR, 1988, BLOOD, V72, P219; JAGANNATH S, 1990, BLOOD, V76, P1860; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; SALMON SE, 1978, NEW ENGL J MED, V298, P1321, DOI 10.1056/NEJM197806152982401; SIMONSSON B, 1987, EUR J CLIN INVEST, V17, P336, DOI 10.1111/j.1365-2362.1987.tb02197.x; SWAN F, 1989, J CLIN ONCOL, V7, P1518, DOI 10.1200/JCO.1989.7.10.1518; [No title captured]	20	152	155	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1991	115	12					931	935		10.7326/0003-4819-115-12-931	http://dx.doi.org/10.7326/0003-4819-115-12-931			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU417	1952489				2022-12-01	WOS:A1991GU41700003
J	GASTON, RS; JULIAN, BA; DIETHELM, AG; CURTIS, JJ				GASTON, RS; JULIAN, BA; DIETHELM, AG; CURTIS, JJ			EFFECTS OF ENALAPRIL ON ERYTHROCYTOSIS AFTER RENAL-TRANSPLANTATION	ANNALS OF INTERNAL MEDICINE			English	Note							ERYTHROPOIETIN; HYPERTENSION; RENIN		UNIV ALABAMA, DEPT SURG, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	GASTON, RS (corresponding author), UNIV ALABAMA, MED CTR, DIV NEPHROL, UAB STN, BIRMINGHAM, AL 35294 USA.		Gaston, Robert/AAR-2932-2020					AEBERHARD JM, 1990, TRANSPLANTATION, V50, P613, DOI 10.1097/00007890-199010000-00017; BAKRIS GL, 1990, NEW ENGL J MED, V323, P86, DOI 10.1056/NEJM199007123230203; FRIMAN S, 1990, NEPHROL DIAL TRANSPL, V5, P969, DOI 10.1093/ndt/5.11.969; GOULD AB, 1980, J LAB CLIN MED, V96, P523; ISLAM MS, 1990, TRANSPLANT INT, V3, P222, DOI 10.1111/j.1432-2277.1990.tb01928.x; JACKSON B, 1990, J LAB CLIN MED, V115, P21; MURRAY BM, 1990, AM J KIDNEY DIS, V16, P66, DOI 10.1016/S0272-6386(12)80787-6; THOMAS DJ, 1977, LANCET, V2, P941, DOI 10.1016/S0140-6736(77)90885-6; VLAHAKOS DV, 1991, AM J KIDNEY DIS, V17, P199, DOI 10.1016/S0272-6386(12)81129-2; WICKRE CG, 1983, KIDNEY INT, V23, P731, DOI 10.1038/ki.1983.86; WILLIAMS GH, 1988, NEW ENGL J MED, V319, P1517	11	66	67	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1991	115	12					954	955		10.7326/0003-4819-115-12-954	http://dx.doi.org/10.7326/0003-4819-115-12-954			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU417	1952492				2022-12-01	WOS:A1991GU41700008
J	RIGAU, J; PIQUE, JM; RUBIO, E; PLANAS, R; TARRECH, JM; BORDAS, JM				RIGAU, J; PIQUE, JM; RUBIO, E; PLANAS, R; TARRECH, JM; BORDAS, JM			EFFECTS OF LONG-TERM SULINDAC THERAPY ON COLONIC POLYPOSIS	ANNALS OF INTERNAL MEDICINE			English	Note									BARCELONA UNIV, HOSP CLIN, DEPT GASTROENTEROL, VILLARROEL 170, E-08036 BARCELONA, SPAIN; HOSP GERMANS TRIAS & PUJOL BADALONA, DEPT GASTROENTEROL, BADALONA, SPAIN; HOSP GEN GRANOLLERS, DEPT MED, GRANOLLERS, SPAIN; HOSP GEN GRANOLLERS, DEPT SURG, GRANOLLERS, SPAIN	University of Barcelona; Hospital Germans Trias i Pujol								BENGOECHEA O, 1987, AM J SURG PATHOL, V11, P323, DOI 10.1097/00000478-198704000-00010; CAPPELL MS, 1989, DIS COLON RECTUM, V32, P641, DOI 10.1007/BF02555767; GONZAGA RAF, 1985, LANCET, V1, P751; MOORGHEN M, 1988, J PATHOL, V156, P341, DOI 10.1002/path.1711560411; NICHOLLS RJ, 1988, BRIT MED J, V296, P1707, DOI 10.1136/bmj.296.6638.1707-a; NICHOLSON ML, 1991, GUT, V32, P413, DOI 10.1136/gut.32.4.413; SAPERAS E, 1990, AM J GASTROENTEROL, V85, P138; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119	10	210	218	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1991	115	12					952	954		10.7326/0003-4819-115-12-952	http://dx.doi.org/10.7326/0003-4819-115-12-952			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU417	1659272				2022-12-01	WOS:A1991GU41700007
J	WHEAT, LJ; CONNOLLYSTRINGFIELD, P; BLAIR, R; CONNOLLY, K; GARRINGER, T; KATZ, BP				WHEAT, LJ; CONNOLLYSTRINGFIELD, P; BLAIR, R; CONNOLLY, K; GARRINGER, T; KATZ, BP			HISTOPLASMOSIS RELAPSE IN PATIENTS WITH AIDS - DETECTION USING HISTOPLASMA-CAPSULATUM VARIETY CAPSULATUM ANTIGEN LEVELS	ANNALS OF INTERNAL MEDICINE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; DIAGNOSIS	Objective: To assess the accuracy of Histoplasma capsulatum variety capsulatum polysaccharide antigen testing for the identification of histoplasmosis relapse in patients with the acquired immunodeficiency syndrome (AIDS). Design: A retrospective study using stored specimens. Setting. A referral center and several private hospitals. Patients: Twenty episodes of histoplasmosis relapse were evaluated in 17 patients with AIDS from November 1987 to August 1990. Controls included 30 patients with AIDS and histoplasmosis who did not have a relapse during maintenance therapy and who were initially tested during the same week as the patients with relapse. A second control group included seven patients with AIDS and histoplasmosis who were evaluated for relapse on 23 occasions; relapse, however, was excluded on each occasion. Measurements: To avoid interassay variability, specimens were tested for H.c. var. capsulatum polysaccharide antigen with the same radioimmunoassay. Main Outcome Measure: The change in the Hc. var. capsulatum polysaccharide antigen level during successful as opposed to unsuccessful maintenance therapy for the prevention of histoplasmosis relapse. Main Results: For the 20 episodes of relapse (17 patients), Hc. var. capsulatum antigen levels increased by at least 2 radioimmunoassay units in 12 of 14 serum specimens tested (85.7%; 95% Cl, 57.2% to 98.2%) and in 17 of 18 urine specimens tested (94.4%; Cl, 72.7% to 99.9%). Antigen levels increased in the urine or serum in 1 of 83 specimens (1.2%; Cl, 0.03% to 6.6%) obtained on 56 occasions (1.8%; Cl, 0.04% to 9.6%) from controls (specificity, 98.2%; Cl, 90.4% to 99.96%). In three cases of relapse, antigen levels increased before clinical relapse was suspected. Complement fixation titers increased by at least 2 dilutions in 4 of 11 cases (36.4%; Cl, 10.9% to 69.2%) but in 0 of 9 control patients (Cl, 0% to 28.3%). Conclusion: An increase in Hc. var. capsulatum polysaccharide antigen levels of 2 units or more strongly suggests histoplasmosis relapse. The presence of increasing titers of anti-Hc. var. capsulatum antibodies by complement fixation is less accurate for the diagnosis of relapse.	INDIANA UNIV, SCH MED, DEPT INTERNAL MED, INDIANAPOLIS, IN 46202 USA; REGENSTRIEF INST HLTH CARE, INDIANAPOLIS, IN USA; RICHARD L ROUNDBUSH VET ADM HOSP, INDIANAPOLIS, IN USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc								MCKINSEY DS, 1989, ANN INTERN MED, V111, P655, DOI 10.7326/0003-4819-111-8-655; NETER J, 1974, APPLIED LINEAR STATI, P605; WHEAT J, 1982, ANN INTERN MED, V97, P680, DOI 10.7326/0003-4819-97-5-680; WHEAT LJ, 1986, NEW ENGL J MED, V314, P83, DOI 10.1056/NEJM198601093140205; WHEAT LJ, 1990, MEDICINE, V69, P361, DOI 10.1097/00005792-199011000-00004; WHEAT LJ, 1989, AM J MED, V87, P396, DOI 10.1016/S0002-9343(89)80820-4	6	98	99	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1991	115	12					936	941		10.7326/0003-4819-115-12-936	http://dx.doi.org/10.7326/0003-4819-115-12-936			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU417	1952490				2022-12-01	WOS:A1991GU41700004
J	AARONS, EJ; BEECHING, NJ				AARONS, EJ; BEECHING, NJ			SURVEY OF DO NOT RESUSCITATE ORDERS IN A DISTRICT GENERAL-HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article							CARDIOPULMONARY RESUSCITATION; SURVIVAL	Objective - To evaluate the local use of written "Do not resuscitate" orders to designate inpatients unsuitable for cardiopulmonary resuscitation in the event of cardiac arrest. Design - Point prevalence questionnaire survey of inpatients' medical and nursing records. Setting - 10 acute medical and six acute surgical wards of a district general hospital. Participants - Questionnaires were filled in anonymously by nurses and doctors working on the wards surveyed. Main outcome measures - Responses to questionnaire items concerning details about each patient, written orders not to resuscitate in the medical case notes and nursing records, whether prognosis had been discussed with patients' relatives, whether a "crash call" was perceived as appropriate for each patient, and whether the "crash team" would be called in the event of arrest. Results - Information was obtained on 297 (93.7%) of 317 eligible patients. Prognosis had been discussed with the relatives of 32 of 88 patients perceived by doctors as unsuitable for resuscitation. Of these 88 patients, 24 had orders not to resuscitate in their medical notes, and only eight of these had similar orders in their nursing notes. Conclusions - In the absence of guidelines on decisions about resuscitation, orders not to resuscitate are rarely included in the notes of patients for whom cardiopulmonary resuscitation is thought to be inappropriate. Elective decisions not to resuscitate are not effectively communicated to nurses. There should be more discussion of patients' suitability for resuscitation between doctors, nurses, patients, and patients' relatives. Suitability for resuscitation should be reviewed on every consultant ward round.	FAZAKERLEY DIST GEN HOSP,REG INFECT DIS UNIT,LIVERPOOL L9 7AL,ENGLAND		BEECHING, NJ (corresponding author), FAZAKERLEY DIST GEN HOSP,REG INFECT DIS UNIT,LIVERPOOL L9 7AL,ENGLAND.		Beeching, Nicholas J/L-5363-2017	Beeching, Nicholas/0000-0002-7019-8791				ASPLUND K, 1990, J INTERN MED, V228, P139; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; DENT THS, 1990, BRIT MED J, V300, P713, DOI 10.1136/bmj.300.6726.713; GLEESON K, 1990, ARCH INTERN MED, V150, P1057, DOI 10.1001/archinte.150.5.1057; Halligan M, 1985, Health Prog, V66, P26; HALLIGAN M, 1985, HLTH PROGR, V66, P600; KAMER RS, 1990, AM J MED, V88, P108, DOI 10.1016/0002-9343(90)90457-O; KEATINGE RM, 1989, J ROY SOC MED, V82, P402, DOI 10.1177/014107688908200711; MCCLUNG JA, 1990, NEW ENGL J MED, V323, P270, DOI 10.1056/NEJM199007263230411; PEATFIELD RC, 1977, LANCET, V1, P1223; STOLMAN CJ, 1990, ARCH INTERN MED, V150, P653, DOI 10.1001/archinte.150.3.653; URBURG M, 1987, J FAM PRACTICE, V25, P41; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; 1984, CODE PROFESSIONAL CO	14	45	45	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1504	1506		10.1136/bmj.303.6816.1504	http://dx.doi.org/10.1136/bmj.303.6816.1504			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1782488	Bronze, Green Published			2022-12-01	WOS:A1991GV47600019
J	BUNDRED, NJ; RATCLIFFE, WA; WALKER, RA; COLEY, S; MORRISON, JM; RATCLIFFE, JG				BUNDRED, NJ; RATCLIFFE, WA; WALKER, RA; COLEY, S; MORRISON, JM; RATCLIFFE, JG			PARATHYROID-HORMONE RELATED PROTEIN AND HYPERCALCEMIA IN BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article							MALIGNANT HYPERCALCEMIA; IMMUNOHISTOCHEMICAL LOCALIZATION; REASSESSMENT; MECHANISMS; CARCINOMA	Objective - To see whether parathyroid hormone related protein has a humoral role in breast cancer. Design - Plasma concentrations and tumour expression of parathyroid hormone related protein were determined (by two site immunoradiometric assay and immunohistochemistry respectively) in women with breast cancer and related to the presence of bone metastases and serum calcium concentrations. Subjects - Plasma concentrations of parathyroid hormone related protein were measured in 57 women with early breast cancer without apparent bone metastases, 28 women with bone metastases, and 13 women with bone metastases and hypercalcaemia. Tissue positivity for parathyroid hormone related protein was determined retrospectively in 106 primary breast tumours from women without apparent bone metastases and 72 tumours from women with bone metastases, 25 of whom subsequently developed hypercalcaemia. Results - Plasma parathyroid hormone related protein concentrations were detectable (> 0.23 pmol/l) in 12 (92%) of the 13 hypercalcaemic patients with bone metastases compared with 10 (36%) of the 28 normocalcaemic patients with bone metastases and five (9%) of the 57 normocalcaemic patients without bone metastases. Parathyroid hormone related protein concentrations were significantly higher in hypercalcaemic than normocalcaemic patients with bone metastases. Tumour staining was positive for parathyroid hormone related protein in 22 (88%) of the 25 primary breast cancers from patients with bone metastases who later developed hypercalcaemia compared with 25 (53%) of the 47 from women in this group who remained normocalcaemic and 55 (52%) of the 106 early breast cancers from women without known metastases. Conclusion - Tumour derived parathyroid hormone related protein may have an important humoral role in hypercalcaemia associated with metastatic breast cancer.	SELLY OAK HOSP,DEPT SURG,BIRMINGHAM B29 6JD,ENGLAND; QUEEN ELIZABETH MED CTR,WOLFSON RES LABS,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; ROYAL INFIRM,DEPT PATHOL,LEICESTER LE1 5WW,ENGLAND	Birmingham City University; University of Birmingham	BUNDRED, NJ (corresponding author), UNIV HOSP S MANCHESTER,DEPT SURG,TEACHING & RES BLOCK,MANCHESTER M20 8LR,LANCS,ENGLAND.							BUDAYR AA, 1989, ANN INTERN MED, V111, P807, DOI 10.7326/0003-4819-111-10-807; BURTIS WJ, 1990, NEW ENGL J MED, V322, P1106, DOI 10.1056/NEJM199004193221603; COLEMAN RE, 1988, EUR J SURG ONCOL, V14, P423; DANKS JA, 1989, J BONE MINER RES, V4, P273; GALLACHER SJ, 1990, ANN CLIN BIOCHEM, V27, P551, DOI 10.1177/000456329002700605; HENDERSON JE, 1990, J BONE MINER RES, V5, P105, DOI 10.1002/jbmr.5650050203; ISALES C, 1987, AM J MED, V82, P1143, DOI 10.1016/0002-9343(87)90216-6; KRAMER S, 1991, ENDOCRINOLOGY, V128, P1927, DOI 10.1210/endo-128-4-1927; LEGHA SS, 1981, CANCER, V47, P2803, DOI 10.1002/1097-0142(19810615)47:12<2803::AID-CNCR2820471208>3.0.CO;2-A; MARTIN TJ, 1989, CLIN ENDOCRINOL, V31, P631, DOI 10.1111/j.1365-2265.1989.tb01288.x; MARTIN TJ, 1990, Q J MED, V76, P771; MUNDY GR, 1984, NEW ENGL J MED, V310, P1718; MUNDY GR, 1988, J CLIN INVEST, V82, P1, DOI 10.1172/JCI113555; PERCIVAL RC, 1985, BMJ-BRIT MED J, V291, P776, DOI 10.1136/bmj.291.6498.776; POWELL GJ, 1991, CANCER RES, V51, P3059; RALSTON SH, 1991, J CLIN PATHOL, V44, P472, DOI 10.1136/jcp.44.6.472; RATCLIFFE WA, 1991, CLIN CHEM, V37, P678; SATO K, 1988, J CLIN ENDOCR METAB, V67, P592, DOI 10.1210/jcem-67-3-592; SOUTHBY J, 1990, CANCER RES, V50, P7710; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; VANHOLTENVERZANTVOORT AT, 1987, LANCET, V2, P983	21	75	79	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1506	1509		10.1136/bmj.303.6816.1506	http://dx.doi.org/10.1136/bmj.303.6816.1506			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1782489	Green Published, Bronze			2022-12-01	WOS:A1991GV47600020
J	COUPLAND, RM; KORVER, A				COUPLAND, RM; KORVER, A			INJURIES FROM ANTIPERSONNEL MINES - THE EXPERIENCE OF THE INTERNATIONAL-COMMITTEE OF THE RED-CROSS	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective - To describe and quantify patterns of injury from antipersonnel mines in terms of distribution of injury, drain on surgical resources, and residual disability. Design - Retrospective analysis. Setting - Two hospitals for patients injured in war. Subjects - 757 patients with injuries from antipersonnel mines. Main outcome measures - Distribution and number of injuries; number of blood transfusions; number of operations; disability. Results - Pattern 1 injury results from standing on a buried mine. These patients usually sustain traumatic amputation of the foot or leg; they use most surgical time and blood and invariably require surgical amputation of one or both lower limbs. Pattern 2 injury is a more random collection of penetrating injuries caused by multiple fragments from a mine triggered near the victim. The lower limb is injured but there is less chance of traumatic amputation or subsequent surgical amputation. Injuries to the head, neck, chest, or abdomen are common. Pattern 3 injury results from handling a mine: the victim sustains severe upper limb injuries with associated face injuries. Eye injuries are common in all groups. Conclusions - Patients who survive standing on a buried mine have greatest disability. Non-combatants are at risk from these weapons; in developing countries their social and economic prospects after recovery from amputation are poor.			COUPLAND, RM (corresponding author), RED CROSS, INT COMM, DIV MED, CH-1202 GENEVA, SWITZERLAND.							ADAMS DB, 1988, J TRAUMA, V28, pS159, DOI 10.1097/00005373-198801001-00032; CHENG XM, 1990, J TRAUMA S, V6, P169; COUPLAND RM, 1989, ANN ROY COLL SURG, V71, P404; Jones E L, 1968, Arch Surg, V97, P1; TRAVERSO LW, 1981, MIL MED, V146, P682	5	112	115	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 14	1991	303	6816					1509	1512		10.1136/bmj.303.6816.1509	http://dx.doi.org/10.1136/bmj.303.6816.1509			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1838290	Bronze, Green Published			2022-12-01	WOS:A1991GV47600021
J	FORD, C; ILIFFE, S; FRANKLIN, O				FORD, C; ILIFFE, S; FRANKLIN, O			OUTCOME OF PLANNED HOME BIRTHS IN AN INNER-CITY PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONER OBSTETRICS; PERINATAL-MORTALITY; MATERNITY UNITS; BRADFORD	Objective - To assess the outcome of pregnancy for women booking for home births in an inner London practice between 1977 and 1989. Design - Retrospective review of practice obstetric records. Setting - A general practice in London. Subjects - 285 women registered with the practice or referred by neighbouring general practitioners or local community midwives. Main outcome measures - Place of birth and number of cases transferred to specialist care before, during, and after labour. Results - Of 285 women who booked for home births, eight left the practice area before the onset of labour, giving a study population of 277 women. Six had spontaneous abortions, 26 were transferred to specialist care during pregnancy, another 26 were transferred during labour, and four were transferred in the postpartum period. 215 women (77.6%, 95% confidence interval 72.7 to 82.5) had normal births at home without needing specialist help. Transfer to specialist care during pregnancy was not significantly related to parity, but nulliparous women were significantly more likely to require transfer during labour (p = 0.00002). Postnatal complications requiring specialist attention were uncommon among mothers delivered at home (four cases) and rare among their babies (three cases). Conclusions - Birth at home is practical and safe for a self selected population of multiparous women, but nulliparous women are more likely to require transfer to hospital during labour because of delay in labour. Close cooperation between the general practitioner and both community midwives and hospital obstetricians is important in minimising the risks of trial of labour at home.	WHITTINGTON HOSP,DEPT PRIMARY HLTH CARE,LONDON N19 5NF,ENGLAND	University of London; University College London	FORD, C (corresponding author), 97 BRONDESBURY RD,LONDON NW6 6RY,ENGLAND.		Iliffe, Steve/L-8379-2019	Iliffe, Stephen/0000-0003-2806-3997				BALLA JI, 1989, BRIT MED J, V298, P579, DOI 10.1136/bmj.298.6673.579; BARRETT JFR, 1990, LANCET, V336, P549, DOI 10.1016/0140-6736(90)92097-2; BRYCE FC, 1990, BRIT MED J, V300, P725, DOI 10.1136/bmj.300.6726.725; CAMBELL R, 1984, BMJ, V289, P721; CHAMBERLAIN G, 1988, PRACTITIONER, V232, P771; DIXON EA, 1982, BRIT MED J, V284, P1753, DOI 10.1136/bmj.284.6331.1753; FRANCIS RB, 1984, AM J NEPHROL, V4, P43; JENKINSON S, 1990, BRIT MED J, V301, P664; JEWELL D, 1989, BRIT MED J, V298, P690, DOI 10.1136/bmj.298.6675.690; JEWELL D, 1990, BRIT MED J, V300, P1140, DOI 10.1136/bmj.300.6732.1140; LILFORD RJ, 1987, BRIT MED J, V295, P1298, DOI 10.1136/bmj.295.6609.1298; LOUDON I, 1990, BRIT MED J, V301, P703, DOI 10.1136/bmj.301.6754.703; MARSH GN, 1989, BRIT MED J, V298, P1077, DOI 10.1136/bmj.298.6680.1077; RHODES JD, 1990, BRIT MED J, V300, P1140, DOI 10.1136/bmj.300.6732.1140-a; ROSS M, 1990, BRIT MED J, V300, P1139; RYAN TDR, 1989, BRIT MED J, V299, P1383, DOI 10.1136/bmj.299.6712.1383; SANGALA V, 1990, BRIT MED J, V301, P418, DOI 10.1136/bmj.301.6749.418; TEW M, 1985, J ROY COLL GEN PRACT, V35, P390; ZANDER L, 1984, PREGNANCY CARE 1980S, P126; 1970, DOMICILIARY MEDWIFER; 1980, PERINATAL NEONATAL M; 1984, MATERNITY CARE ACTIO, V2; 1982, REPORT RCOG WORKING	23	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1517	1519		10.1136/bmj.303.6816.1517	http://dx.doi.org/10.1136/bmj.303.6816.1517			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GV476	1782494	Bronze, Green Published			2022-12-01	WOS:A1991GV47600027
J	GODLEE, F				GODLEE, F			HEALTH AND THE ENVIRONMENT - AIR-POLLUTION .2. ROAD TRAFFIC AND MODERN INDUSTRY	BRITISH MEDICAL JOURNAL			English	Article							DIESEL EXHAUST EXPOSURE; PARENTAL OCCUPATION; ASTHMATIC SUBJECTS; RAILROAD WORKERS; CHILDHOOD-CANCER; BLADDER-CANCER; LUNG-CANCER; ASSOCIATION; DIOXIDE											ANDERSON HR, 1987, ARCH DIS CHILD, V53, P295; AVOL EL, 1985, AM REV RESPIR DIS, V132, P619; BERCIANO FA, 1989, ANN ALLERGY, V62, P135; BLUMER M, 1977, ENVIRON SCI TECHNOL, V11, P1082, DOI 10.1021/es60135a002; BROWN LR, 1990, STATE WORLD 1990, P103; FERGUSSON M, 1989, ATMOSPHERIC EMISSION, V1; GARSHICK E, 1987, AM REV RESPIR DIS, V135, P1242; GARSHICK E, 1988, AM REV RESPIR DIS, V137, P820, DOI 10.1164/ajrccm/137.4.820; GILKS JML, 1989, CONCAWE889 REP; GUNNER G, 1991, Journal of Allergy and Clinical Immunology, V87, P185, DOI 10.1016/0091-6749(91)91469-A; HEMMINKI K, 1981, J EPIDEMIOL COMMUN H, V35, P11, DOI 10.1136/jech.35.1.11; HOLMAN C, 1990, ROUTE AHEAD VEHICLE; HOWARD D, 1990, ENERGY TRANSPORT ENV; HUBER TE, 1954, AMA ARCH IND HYG OCC, V10, P399; JENSEN OM, 1987, SCAND J WORK ENV HEA, V13, P129, DOI 10.5271/sjweh.2070; KAPLAN I, 1959, JAMA-J AM MED ASSOC, V171, P97; KOENIG JQ, 1990, AM REV RESPIR DIS, V141, P377, DOI 10.1164/ajrccm/141.2.377; KWA SL, 1980, J OCCUP ENVIRON MED, V22, P792, DOI 10.1097/00043764-198012000-00012; LINN WS, 1983, AM REV RESPIR DIS, V127, P234; MOHSENIN V, 1987, J TOXICOL ENV HEALTH, V22, P371, DOI 10.1080/15287398709531080; OSTRO BD, 1989, ENVIRON RES, V50, P238, DOI 10.1016/S0013-9351(89)80004-0; READ C, 1991, AIR POLLUTION CHILD; SAVITZ DA, 1989, SCAND J WORK ENV HEA, V15, P360, DOI 10.5271/sjweh.1848; STEENLAND K, 1987, AM J EPIDEMIOL, V126, P247, DOI 10.1093/aje/126.2.247; VANDEHOUT KD, 1986, DIESEL EXHAUST AIR P; WILLIAMS RR, 1977, J NATL CANCER I, V59, P1147, DOI 10.1093/jnci/59.4.1147; 1988, TRANSPORT ENV; 1987, AIR QUALITY GUIDELIN; 1988, IARC MONOGRAPHS EVAL, V46; 1991, SOCIAL TRENDS, V20, P147; 1982, IARC MONOGRAPHS EVAL, V29; 1987, ENERGY CLEANER AIR C; 1984, REPORT SCI REV PANEL	33	17	17	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1539	1543		10.1136/bmj.303.6816.1539	http://dx.doi.org/10.1136/bmj.303.6816.1539			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1723637	Green Published, Bronze			2022-12-01	WOS:A1991GV47600035
J	HARRIS, PC; THOMAS, S; RATCLIFFE, PJ; BREUNING, MH; COTO, E; LOPEZLARREA, C				HARRIS, PC; THOMAS, S; RATCLIFFE, PJ; BREUNING, MH; COTO, E; LOPEZLARREA, C			RAPID GENETIC-ANALYSIS OF FAMILIES WITH POLYCYSTIC KIDNEY DISEASE-1 BY MEANS OF A MICROSATELLITE MARKER	LANCET			English	Article							CHROMOSOME-16; MAP; POLYMORPHISMS; DIAGNOSIS; LOCUS; PKD1	Presymptomatic diagnosis of polycystic kidney disease 1 (PKD1) is possible by genetic linkage analysis with markers from both sides of the disease locus. The existing proximal markers are not informative in many families, so such analysis is difficult and time-consuming. We sought more useful length polymorphisms on the proximal side of the locus among simple sequence repeats (microsatellites). We identified two microsatellite polymorphisms that lie closer to the PKD1 locus than any previously described highly variable marker. One, SM7, is especially informative; we have found fourteen alleles and the observed heterozygosity in caucasians is 62.7%. Genetic linkage analysis in PKD1 families suggests that both of the markers lie proximal to the disease gene, closer than existing flanking markers. These polymorphisms can be simply assayed by polymerase chain reaction amplification of the variable regions, which generates DNA fragments that can be separated on non-denaturing acrylamide gels and directly examined after gel staining. This rapid, inexpensive, and non-radioactive method of linkage analysis allows the complete study of DNA samples within 8 h.	HOSP COVADONGA,SERV IMMUNOL,OVIEDO,SPAIN; LEIDEN UNIV,DEPT HUMAN GENET,2300 RA LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC	HARRIS, PC (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND.		Breuning, Martijn H/E-3429-2010	Ratcliffe, Peter/0000-0002-2853-806X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEAR JC, 1984, AM J MED GENET, V18, P45, DOI 10.1002/ajmg.1320180108; BREUNING MH, 1990, J MED GENET, V27, P614, DOI 10.1136/jmg.27.10.614; BREUNING MH, 1990, J MED GENET, V27, P603, DOI 10.1136/jmg.27.10.603; GERMINO GG, 1990, AM J HUM GENET, V46, P925; GILLESPIE GA, 1990, NUCLEIC ACIDS RES, V18, P7071, DOI 10.1093/nar/18.23.7071; GILLESPIE GAJ, 1991, P NATL ACAD SCI USA, V88, P4289, DOI 10.1073/pnas.88.10.4289; HARRIS PC, 1990, GENOMICS, V7, P195, DOI 10.1016/0888-7543(90)90541-2; HIMMELBAUER H, 1991, AM J HUM GENET, V48, P325; LALLOZ MRA, 1991, LANCET, V338, P207, DOI 10.1016/0140-6736(91)90348-S; LITT M, 1989, AM J HUM GENET, V44, P397; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; PARFREY PS, 1990, NEW ENGL J MED, V323, P1085, DOI 10.1056/NEJM199010183231601; RAVINE D, 1991, LANCET, V337, P127, DOI 10.1016/0140-6736(91)90797-S; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; WEBER JL, 1990, GENOMICS, V7, P524, DOI 10.1016/0888-7543(90)90195-Z; WEBER JL, 1989, AM J HUM GENET, V44, P388	16	74	79	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1991	338	8781					1484	1487		10.1016/0140-6736(91)92300-Q	http://dx.doi.org/10.1016/0140-6736(91)92300-Q			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV077	1683919				2022-12-01	WOS:A1991GV07700004
J	KOLARS, JC; AWNI, WM; MERION, RM; WATKINS, PB				KOLARS, JC; AWNI, WM; MERION, RM; WATKINS, PB			1ST-PASS METABOLISM OF CYCLOSPORINE BY THE GUT	LANCET			English	Note							HUMAN-LIVER; IDENTIFICATION	Cyclosporin is thought to be exclusively metabolised in the liver. We instilled cyclosporin into the small bowel of 2 patients during the anhepatic phase of liver transplantation; cyclosporin metabolites were readily detected in portal venous blood. Our findings indicate that the small intestine is a major site of cyclosporin breakdown: such intestinal metabolism might help to explain the poor oral bioavailability and drug interactions of cyclosporin.	UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT SURG, ANN ARBOR, MI 48109 USA; HENNEPIN CTY MED CTR, DRUG EVALUAT UNIT, MINNEAPOLIS, MN 55415 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Hennepin County Medical Center	WATKINS, PB (corresponding author), UNIV MICHIGAN HOSP, KUGHN CLIN RES CTR, A7119 UNIV HOSP, ANN ARBOR, MI 48109 USA.			Kolars, Joseph/0000-0002-2603-188X				AOYAMA T, 1989, J BIOL CHEM, V264, P10388; AWNI WM, 1988, J CHROMATOGR-BIOMED, V425, P233, DOI 10.1016/0378-4347(88)80027-6; GUPTA SK, 1989, BRIT J CLIN PHARMACO, V27, P475, DOI 10.1111/j.1365-2125.1989.tb05396.x; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KOLARS JC, IN PRESS TRANSPLANTA; KRONBACH T, 1988, CLIN PHARMACOL THER, V43, P630, DOI 10.1038/clpt.1988.87; LUCEY MR, 1990, LANCET, V335, P11, DOI 10.1016/0140-6736(90)90137-T; PTACHCINSKI RJ, 1986, CLIN PHARMACOKINET, V11, P107, DOI 10.2165/00003088-198611020-00002; WATKINS PB, 1990, SEMIN LIVER DIS, V10, P235, DOI 10.1055/s-2008-1040480; WATKINS PB, 1987, J CLIN INVEST, V80, P1029, DOI 10.1172/JCI113156	10	387	404	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 14	1991	338	8781					1488	1490		10.1016/0140-6736(91)92302-I	http://dx.doi.org/10.1016/0140-6736(91)92302-I			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV077	1683920	Green Submitted			2022-12-01	WOS:A1991GV07700006
J	NANKHONYA, JM; TURNBULL, CJ; NEWTON, JT				NANKHONYA, JM; TURNBULL, CJ; NEWTON, JT			SOCIAL AND FUNCTIONAL IMPACT OF MINOR FRACTURES IN ELDERLY PEOPLE	BRITISH MEDICAL JOURNAL			English	Article									ARROWE PK HOSP,DEPT GERIATR MED,WIRRAL L49 5PE,ENGLAND; SALFORD UNIV,DEPT BEHAV SCI,SALFORD M6 6PU,ENGLAND	University of Salford	NANKHONYA, JM (corresponding author), 24 COLMORE AVE,WIRRAL L63 9NL,ENGLAND.		Newton, Jonathon T/B-7015-2009					ANDREWS K, 1989, CLIN NEUROLOGY OLD A, P479; Dove A F, 1986, Health Trends, V18, P86; Roberts NA, 1990, CLIN REHABIL, V4, P37; ROWLAND K, 1990, AGE AGEING, V19, P415, DOI 10.1093/ageing/19.6.415; 1989, FRACTURED NECK FEMUR	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1514	1515		10.1136/bmj.303.6816.1514-a	http://dx.doi.org/10.1136/bmj.303.6816.1514-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GV476	1782491	Bronze, Green Published			2022-12-01	WOS:A1991GV47600024
J	RICAURTE, GA; MOLLIVER, ME; MARTELLO, MB; KATZ, JL; WILSON, MA; MARTELLO, AL				RICAURTE, GA; MOLLIVER, ME; MARTELLO, MB; KATZ, JL; WILSON, MA; MARTELLO, AL			DEXFENFLURAMINE NEUROTOXICITY IN BRAINS OF NONHUMAN-PRIMATES	LANCET			English	Note							RAT-BRAIN; FENFLURAMINE	Dexfenfluramine, a drug prescribed for appetite suppression, was evaluated in non-human primates for its potential to produce toxic effects on brain serotonin (5-HT) neurons. Squirrel monkeys received dexfenfluramine subcutaneously twice daily for four days at doses of 1.25 or 5.00 mg/kg. Two weeks later, a dose-related depletion of 5-HT and 5-hydroxyindoleacetic acid was found, together with a reduced number of 5-HT uptake sites. Morphological studies showed acute pathological changes in 5-HT axons, followed by a persistent decrease in 5-HT axon density. Our findings indicate that dexfenfluramine damages central 5-HT neurons in monkeys and raise concern about the potential neurotoxicity of this drug in man.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; NIDA,ADDICT RES CTR,BALTIMORE,MD	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	RICAURTE, GA (corresponding author), JOHNS HOPKINS UNIV,FRANCIS SCOTT KEY MED CTR,SCH MED,DEPT NEUROL,301 BAYVIEW BLVD,BALTIMORE,MD 21224, USA.			Katz, Jonathan/0000-0002-1068-1159	NIDA NIH HHS [DA05707, DA04431] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005707, R29DA005707, R01DA004431] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALPHIN RS, 1969, TOXICOL APPL PHARM, V14, P182, DOI 10.1016/0041-008X(69)90178-1; CACCIA S, 1982, ARCH INT PHARMACOD T, V258, P15; CAMPBELL DB, 1986, DEV DRUGS MODERN MED, P298; GARATTINI S, 1987, BODY WEIGHT CONTROL, P261; GUYGRAND B, 1989, LANCET, V2, P1142; KLEVEN MS, 1989, BRAIN RES, V505, P351, DOI 10.1016/0006-8993(89)91467-4; MOLLIVER DC, 1990, BRAIN RES, V511, P165, DOI 10.1016/0006-8993(90)90237-6; RICAURTE GA, 1988, BRAIN RES, V446, P165, DOI 10.1016/0006-8993(88)91309-1; SANDLER M, 1991, 5 HYDROXYTRYPTAMINE; ZACZEK R, 1990, J PHARMACOL EXP THER, V253, P104	10	76	78	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1991	338	8781					1487	1488		10.1016/0140-6736(91)92301-H	http://dx.doi.org/10.1016/0140-6736(91)92301-H			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV077	1720853				2022-12-01	WOS:A1991GV07700005
J	SANTIBANEZKOREF, MF; BIRCH, JM; HARTLEY, AL; JONES, PHM; CRAFT, AW; EDEN, T; CROWTHER, D; KELSEY, AM; HARRIS, M				SANTIBANEZKOREF, MF; BIRCH, JM; HARTLEY, AL; JONES, PHM; CRAFT, AW; EDEN, T; CROWTHER, D; KELSEY, AM; HARRIS, M			P53 GERMLINE MUTATIONS IN LI-FRAUMENI SYNDROME	LANCET			English	Note							CANCER; FAMILY; GENE	Germline mutations within a defined region of the p53 gene have recently been found in families with the Li-Fraumeni syndrome (LFS). In the present study this region of p53 was sequenced in affected individuals from 8 families with LFS. In only 2 of them were such mutations detected. Our findings suggest that the p53 mutation could be the primary lesion in some but not all families with LFS, and confirm that there is a "hot spot" for these mutations at the CpG dinucleotide moiety of codon 248. Assigning risks and counselling families on the basis of presence of p53 mutations should be approached with caution.	CHRISTIE HOSP & HOLT RADIUM INST,CANC RES CAMPAIGN,PEDIAT & FAMILIAL CANC RES GRP,MANCHESTER M20 9BX,LANCS,ENGLAND; CHRISTIE HOSP & HOLT RADIUM INST,PATERSON INST,CANC RES CAMPAIGN,DEPT CANC GENET,MANCHESTER M20 9BX,LANCS,ENGLAND; CHRISTIE HOSP & HOLT RADIUM INST,CANC RES CAMPAIGN,DEPT MED ONCOL,MANCHESTER M20 9BX,LANCS,ENGLAND; CHRISTIE HOSP & HOLT RADIUM INST,DEPT PATHOL,MANCHESTER M20 9BX,LANCS,ENGLAND; ROYAL MANCHESTER CHILDRENS HOSP,MANCHESTER M27 1HA,LANCS,ENGLAND; ROYAL VICTORIA INFIRM,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; ROYAL HOSP SICK CHILDREN,EDINBURGH EH9 1LF,MIDLOTHIAN,SCOTLAND	Christie NHS Foundation Trust; Christie Hospital; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Christie NHS Foundation Trust; Christie Hospital; Christie NHS Foundation Trust; Christie Hospital; Royal Manchester Children's Hospital; Newcastle University - UK	BIRCH, JM (corresponding author), CHRISTIE HOSP & HOLT RADIUM INST,CANC RES CAMPAIGN,PEDIAT & FAMILIAL CANC RES GRP,MANCHESTER M20 9BX,LANCS,ENGLAND.							BIRCH JM, 1990, CANCER-AM CANCER SOC, V66, P2239, DOI 10.1002/1097-0142(19901115)66:10<2239::AID-CNCR2820661034>3.0.CO;2-Q; DEANE M, 1990, EUR J IMMUNOL, V20, P2209, DOI 10.1002/eji.1830201009; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1988, CANCER RES, V48, P5358; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Sambrook J., 1989, MOL CLONING LAB MANU; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153	10	136	136	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1991	338	8781					1490	1491		10.1016/0140-6736(91)92303-J	http://dx.doi.org/10.1016/0140-6736(91)92303-J			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV077	1683921				2022-12-01	WOS:A1991GV07700007
J	SEERY, JP				SEERY, JP			ACHLORHYDRIA AND GASTRIC CARCINOGENESIS	LANCET			English	Article							HUMAN STOMACH; PATHOGENESIS	The association between achlorhydria and gastric carcinogenesis can be explained by a simple hypothesis based on the known cytological properties of neoplastic cells and the physiology of the stomach. Normal gastric secretions might ensure the rapid elimination of carcinomatous cells. Achlorhydria could be an important permissive factor in the development of gastric carcinoma.			SEERY, JP (corresponding author), ROYAL INFIRM,DEPT CLIN PHARMACOL,LAURISTON PL,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.							BARET MK, 1967, NEOPLASMS STOMACH, P29; FLEMING S, 1991, J PATHOL, V164, P95, DOI 10.1002/path.1711640202; HILL MJ, 1986, MICROBIAL METABOLISM, P221; LEACH SA, 1987, CARCINOGENESIS, V8, P1907, DOI 10.1093/carcin/8.12.1907; LICHT WR, 1988, CARCINOGENESIS, V9, P2227, DOI 10.1093/carcin/9.12.2227; MIRVISH SS, 1975, TOXICOL APPL PHARM, V31, P325, DOI 10.1016/0041-008X(75)90255-0; NEWBOLD KM, 1989, LANCET, V1, P131; NEWBOLD KM, 1988, J PATHOL, V155, P311, DOI 10.1002/path.1711550406; SANDERS MJ, 1985, NATURE, V313, P52, DOI 10.1038/313052a0; SEERY JP, 1991, MED HYPOTHESES, V35, P179, DOI 10.1016/0306-9877(91)90229-R; SOLL AH, 1990, NEW ENGL J MED, V322, P909; SVENDSEN JH, 1986, SCAND J GASTROENTERO, V21, P16, DOI 10.3109/00365528609034615	12	8	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1991	338	8781					1508	1509		10.1016/0140-6736(91)92312-P	http://dx.doi.org/10.1016/0140-6736(91)92312-P			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV077	1683930				2022-12-01	WOS:A1991GV07700016
J	SHEWELL, PC; NANCARROW, JD				SHEWELL, PC; NANCARROW, JD			DOGS THAT BITE	BRITISH MEDICAL JOURNAL			English	Article								Objective - To study the circumstances of dog bites and identify risk factors. Design - Postal questionnaire survey and case note review of victims of dog bites referred between 1982 and 1989. Setting - One referral based regional plastic surgery unit. Patients - 146 consecutive patients referred for primary treatment of dog bites, for whom current addresses were available for 133, 107 (81%) of whom returned the questionnaire. Results - The male to female ratio was 74:72; 79 (54%) patients were aged below 15 years. The commonest dogs producing bites were Staffordshire bull terriers (15 cases), Jack Russell terriers (13), medium sized mongrels (10), and Alsatians (nine). 82 of 96 (85%) dogs were male. 29 of 47 (62%) adults were bitten at home and 45 of 60 (75%) children at a friend's, neighbour's, or relative's house. 91 of 107 (85%) bites occurred in the dog's home. Bites occurred during playing with 13 (12%), petting 14 (13%), or waking 16 (15%) dogs. 45 (42%) bites were judged as unprovoked. 32 bites were identified as severe and 11 attacks as sustained. Conclusions - Most victims are bitten by male dogs which they either own or have had frequent contact with, and the bite occurs in the dog's home.	WORDSLEY HOSP,W MIDLANDS REG PLAST & JAW SURG UNIT,STOURBRIDGE,W MIDLANDS,ENGLAND		SHEWELL, PC (corresponding author), ROYAL ORTHOPAED HOSP,WOODLANDS,BIRMINGHAM B31 2AP,ENGLAND.							BAACK BR, 1989, J TRAUMA, V29, P517, DOI 10.1097/00005373-198904000-00019; BARCLAY T L, 1956, Br J Plast Surg, V9, P34, DOI 10.1016/S0007-1226(56)80006-4; CARITHERS HA, 1958, AMA J DIS CHILD, V95, P150, DOI 10.1001/archpedi.1958.02060050152007; CHUN YT, 1982, PEDIATRICS, V69, P119; HERVEY E, 1977, BRIT MED J, V2, P53; LAUER EA, 1982, AM J DIS CHILD, V136, P202, DOI 10.1001/archpedi.1982.03970390016003; PALMER J, 1983, BRIT J PLAST SURG, V36, P315; THOMAS PR, 1987, MED J AUSTRALIA, V147, P536, DOI 10.5694/j.1326-5377.1987.tb133676.x; ZAKOWSKI D, 1986, PEDIATR EMERG CARE, V2, P85	9	32	33	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1512	1513		10.1136/bmj.303.6816.1512	http://dx.doi.org/10.1136/bmj.303.6816.1512			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1782490	Green Published, Bronze			2022-12-01	WOS:A1991GV47600022
J	VARTY, K; VANDORPE, J; STJOHNSTON, JA; CAMPBELL, WB				VARTY, K; VANDORPE, J; STJOHNSTON, JA; CAMPBELL, WB			WHAT HAPPENS TO PATIENTS WITH NONVASCULAR LEG PAIN	BRITISH MEDICAL JOURNAL			English	Article							NEUROGENIC CLAUDICATION; DIFFERENTIATION		ROYAL DEVON & EXETER HOSP,DEPT SURG,EXETER EX2 5DW,DEVON,ENGLAND	University of Exeter	CAMPBELL, WB (corresponding author), ROYAL DEVON & EXETER HOSP,DEPT SURG,EXETER EX2 5DW,DEVON,ENGLAND.							CARTER SA, 1972, NEW ENGL J MED, V287, P749; GOODREAU JJ, 1978, SURGERY, V84, P749; SMIGIEL M, 1985, GERIATRIC CLIN N AM, V1, P373; STANTON PE, 1987, AM SURGEON, V53, P71; TAIT WF, 1985, BRIT J SURG, V72, P315, DOI 10.1002/bjs.1800720425	5	1	1	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1516	1516		10.1136/bmj.303.6816.1516	http://dx.doi.org/10.1136/bmj.303.6816.1516			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1782493	Bronze, Green Published			2022-12-01	WOS:A1991GV47600026
J	ZWI, AB; CABRAL, AJR				ZWI, AB; CABRAL, AJR			IDENTIFYING HIGH-RISK SITUATIONS FOR PREVENTING AIDS	BRITISH MEDICAL JOURNAL			English	Article							AFRICA		MINIST HLTH MAPUTO,MAPUTO,MOZAMBIQUE		ZWI, AB (corresponding author), LONDON SCH HYG & TROP MED,HLTH POLICY UNIT,LONDON WC1E 7HJ,ENGLAND.		Zwi, Anthony/AAP-7026-2021; Zwi, Anthony/AAP-8731-2020	Zwi, Anthony/0000-0001-6902-6602; 				BALDO M, 1991, ACTION AIDS SO AFRIC, P34; BASSETT MT, 1991, INT J HEALTH SERV, V21, P143, DOI 10.2190/N0NJ-FKXB-CT25-PA09; EISENBERG L, 1984, AM J MED, V77, P524, DOI 10.1016/0002-9343(84)90114-1; FREUDENBERG N, 1990, INT J HEALTH SERV, V20, P589, DOI 10.2190/W70D-28M1-C62K-K60R; Freudenberg N, 1989, AIDS Educ Prev, V1, P12; FREUDENBERG N, 1981, INT J HLTH ED, V24, P1; Green LW, 1988, HLTH PROMOT, V3, P151; HUNT CW, 1989, J HEALTH SOC BEHAV, V30, P353, DOI 10.2307/2136985; JOCHELSON K, 1991, INT J HEALTH SERV, V21, P157, DOI 10.2190/11UE-L88J-46HN-HR0K; KREISS JK, 1986, NEW ENGL J MED, V314, P414, DOI 10.1056/NEJM198602133140704; McKeown Thomas, 1979, ROLE MED; NABARRO D, 1989, AIDS, V3, pS265, DOI 10.1097/00002030-198901001-00037; PACKARD RM, 1991, SOC SCI MED, V33, P771, DOI 10.1016/0277-9536(91)90376-N; PIOT P, 1988, TROPICAL GEOGRAPHICA, P894; ROSENFIELD PL, 1988, TROPICAL GEOGRAPHICA, P197; SANDERS D, 1991, HEALTH POLICY PLANN, V6, P157, DOI 10.1093/heapol/6.2.157; WILSON D, 1990, SOC SCI MED, V31, P609, DOI 10.1016/0277-9536(90)90097-C; Zwi A., 1990, Health Policy and Planning, V5, P316, DOI 10.1093/heapol/5.4.316; 1986, HLTH PROMOTION, V1, P3	19	53	53	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1527	1529		10.1136/bmj.303.6816.1527	http://dx.doi.org/10.1136/bmj.303.6816.1527			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GV476	1782498	Bronze, Green Published			2022-12-01	WOS:A1991GV47600030
J	BUCK, J; DERGUINI, F; LEVI, E; NAKANISHI, K; HAMMERLING, U				BUCK, J; DERGUINI, F; LEVI, E; NAKANISHI, K; HAMMERLING, U			INTRACELLULAR SIGNALING BY 14-HYDROXY-4,14-RETRO-RETINOL	SCIENCE			English	Article							RETINOL-BINDING PROTEIN; RECEPTOR; ACID; PURIFICATION	In mammals, retinol is the precursor for retinoids, which affect various aspects of morphogenesis and development. However, B lymphocytes, although retinol-dependent, do not use retinoic acid as mediator. Retinol is metabolized by B lymphocytes and other cell lines to optically active 14-hydroxy-4,14-retro-retinol; it is this compound that mediates the growth control. Thus another second messenger molecule, in addition to retinoic acid and retinal, is derived from retinol.	COLUMBIA UNIV,DEPT CHEM,NEW YORK,NY 10027	Columbia University	BUCK, J (corresponding author), MEM SLOAN KETTERING CANC CTR,DEPT IMMUNOL,NEW YORK,NY 10021, USA.				NCI NIH HHS [CA49933] Funding Source: Medline; NIAID NIH HHS [AI38351] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049933] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEECHAM AF, 1971, TETRAHEDRON, V27, P5207, DOI 10.1016/S0040-4020(01)90774-4; BEUTEL RH, 1955, J AM CHEM SOC, V77, P5166, DOI 10.1021/ja01624a065; BUCK J, 1990, J EXP MED, V171, P1613, DOI 10.1084/jem.171.5.1613; BUCK J, 1991, J CELL BIOL, V115, P851, DOI 10.1083/jcb.115.3.851; BUCK JD, UNPUB; FEX G, 1977, BIOCHIM BIOPHYS ACTA, V493, P410, DOI 10.1016/0005-2795(77)90197-0; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GONNELLA NC, 1982, J AM CHEM SOC, V104, P3775, DOI 10.1021/ja00377a063; Goodman, 1984, RETINOIDS; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; GOSSWEIN L, 1976, THESIS U WURZBURG; HEILBRON I, 1958, B SOC CHIM FR, P83; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCLEAN SW, 1982, CLIN CHEM, V28, P693; NATORI S, 1974, NATURAL PRODUCTS CHE, V1, P30; ONG DE, 1978, J BIOL CHEM, V253, P828; OROSHNIK W, 1952, J AM CHEM SOC, V74, P295, DOI 10.1021/ja01122a003; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROBERTS AB, 1984, RETINOIDS, V2, P209; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SCHRECKENBACH T, 1977, EUR J BIOCHEM, V76, P499, DOI 10.1111/j.1432-1033.1977.tb11620.x; SCHWIETER U, 1969, Pure and Applied Chemistry, V20, P365, DOI 10.1351/pac196920040365; STRAUB O, 1971, CAROTENOIDS, P772; VETTER W, 1971, CAROTENOIDS, P204; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230	25	169	174	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1654	1656		10.1126/science.1749937	http://dx.doi.org/10.1126/science.1749937			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1749937				2022-12-01	WOS:A1991GV07300048
J	FLOYD, RA				FLOYD, RA			OXIDATIVE DAMAGE TO BEHAVIOR DURING AGING	SCIENCE			English	Editorial Material							GLUTAMINE-SYNTHETASE; FREE-RADICALS; ISCHEMIA; BRAIN				FLOYD, RA (corresponding author), OKLAHOMA MED RES FDN,MOLEC TOXICOL RES PROGRAM,OKLAHOMA CITY,OK 73104, USA.				NIA NIH HHS [AG09690] Funding Source: Medline; NINDS NIH HHS [NS23307] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009690] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOLLI R, 1988, J CLIN INVEST, V82, P476, DOI 10.1172/JCI113621; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; CARNEY JM, NIH AG09690 GRANTS; CARNEY JM, 1985, J BIOL CHEM, V260, P12600; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; JANZEN EG, 1971, ACCOUNTS CHEM RES, V4, P31, DOI 10.1021/ar50037a005; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; OLIVER CN, 1987, J AM GERIATR SOC, V35, P947, DOI 10.1111/j.1532-5415.1987.tb02297.x; RIVETT AJ, 1985, J BIOL CHEM, V260, P300	11	98	103	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1597	1597		10.1126/science.1684251	http://dx.doi.org/10.1126/science.1684251			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1684251				2022-12-01	WOS:A1991GV07300032
J	FRAUENFELDER, H; SLIGAR, SG; WOLYNES, PG				FRAUENFELDER, H; SLIGAR, SG; WOLYNES, PG			THE ENERGY LANDSCAPES AND MOTIONS OF PROTEINS	SCIENCE			English	Article							X-RAY-DIFFRACTION; MOLECULAR-DYNAMICS; CARBON-MONOXIDE; HEME-PROTEINS; SPIN-GLASS; LOW-TEMPERATURES; LIGAND-BINDING; MODEL; MYOGLOBIN; RELAXATION	Recent experiments, advances in theory, and analogies to other complex systems such as glasses and spin glasses yield insight into protein dynamics. The basis of the understanding is the observation that the energy landscape is complex: Proteins can assume a large number of nearly isoenergetic conformations (conformational substates). The concepts that emerge from studies of the conformational substates and the motions between them permit a quantitative discussion of one simple reaction, the binding of small ligands such as carbon monoxide to myoglobin.	UNIV ILLINOIS, BECKMAN INST, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	FRAUENFELDER, H (corresponding author), UNIV ILLINOIS, CTR ADV STUDY, URBANA, IL 61801 USA.							ADAM G, 1965, J CHEM PHYS, V43, P139, DOI 10.1063/1.1696442; AGMON N, 1983, J CHEM PHYS, V79, P2042, DOI 10.1063/1.445988; ANSARI A, 1987, BIOPHYS CHEM, V26, P337, DOI 10.1016/0301-4622(87)80034-0; ANSARI A, 1985, P NATL ACAD SCI USA, V82, P5000, DOI 10.1073/pnas.82.15.5000; Antonini E., 1971, FRONT BIOL, DOI DOI 10.1126/SCIENCE.178.4058.296; Atkins WM, 1991, CURR OPIN STRUC BIOL, V1, P611, DOI 10.1016/S0959-440X(05)80085-5; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BENNETT WS, 1978, P NATL ACAD SCI USA, V75, P4848, DOI 10.1073/pnas.75.10.4848; BINDER K, 1986, REV MOD PHYS, V58, P801, DOI 10.1103/RevModPhys.58.801; BRAWER S, 1985, RELAXATION VISCOUS L; BROOKS CL, 1988, PROTEINS THEORETICAL; BRYNGELSON JD, 1987, P NATL ACAD SCI USA, V84, P7524, DOI 10.1073/pnas.84.21.7524; BRYNGELSON JD, 1989, J PHYS CHEM-US, V93, P6902, DOI 10.1021/j100356a007; CAMPBELL BF, 1988, BIOCHEMISTRY-US, V27, P3507; CARERI G, 1979, ANNU REV BIOPHYS BIO, V8, P69, DOI 10.1146/annurev.bb.08.060179.000441; CASE DA, 1988, PROG BIOPHYS MOL BIO, V52, P39, DOI 10.1016/0079-6107(88)90007-7; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; CHANCE MR, 1986, J BIOL CHEM, V261, P5689; DEDOMINICIS C, 1985, J PHYS LETT-PARIS, V46, pL463, DOI 10.1051/jphyslet:019850046011046300; DERRIDA B, 1981, PHYS REV B, V24, P2613, DOI 10.1103/PhysRevB.24.2613; EATON WA, 1991, P NATL ACAD SCI USA, V88, P4472, DOI 10.1073/pnas.88.10.4472; EIGEN M, 1986, CHEM SCRIPTA, V26B, P13; ELBER R, 1987, SCIENCE, V235, P318, DOI 10.1126/science.3798113; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; ENGLANDER SW, 1979, Q REV BIOPHYS, V8, P521; FABER HR, 1990, NATURE, V348, P263, DOI 10.1038/348263a0; FERRY JD, 1953, J APPL PHYS, V24, P911, DOI 10.1063/1.1721401; Fischer KH., 1991, SPIN GLASSES, DOI [10.1017/CBO9780511628771, DOI 10.1017/CBO9780511628771]; FRAUENFELDER H, 1979, NATURE, V280, P558, DOI 10.1038/280558a0; FRAUENFELDER H, 1988, ANNU REV BIOPHYS BIO, V17, P451; FRAUENFELDER H, 1990, J PHYS CHEM-US, V94, P1024, DOI 10.1021/j100366a002; FRAUENFELDER H, 1989, INT J QUANTUM CHEM, V35, P711, DOI 10.1002/qua.560350606; FRAUENFELDER H, 1989, CHEM SCRIPTA, V29A, P145; FRIEDMAN JM, 1985, SCIENCE, V228, P1273, DOI 10.1126/science.4001941; GAREL T, 1988, EUROPHYS LETT, V6, P307, DOI 10.1209/0295-5075/6/4/005; GO N, 1989, CHEM SCRIPTA, V29A, P151; GOLDANSKII VI, 1983, DOKL AKAD NAUK SSSR+, V272, P978; GROSS DJ, 1984, NUCL PHYS B, V240, P431, DOI 10.1016/0550-3213(84)90237-2; GROSS DJ, 1985, PHYS REV LETT, V55, P304, DOI 10.1103/PhysRevLett.55.304; Gurd F R, 1979, Adv Protein Chem, V33, P73, DOI 10.1016/S0065-3233(08)60459-3; HARTMANN H, 1982, P NATL ACAD SCI-BIOL, V79, P4967, DOI 10.1073/pnas.79.16.4967; HENRY ER, 1985, P NATL ACAD SCI USA, V82, P2034, DOI 10.1073/pnas.82.7.2034; HOFRICHTER J, 1983, P NATL ACAD SCI-BIOL, V80, P2235, DOI 10.1073/pnas.80.8.2235; HOFRICHTER J, 1991, BIOCHEMISTRY-US, V30, P6583, DOI 10.1021/bi00240a031; HONG MK, 1990, BIOPHYS J, V58, P429, DOI 10.1016/S0006-3495(90)82388-2; IBEN IET, 1989, PHYS REV LETT, V62, P1916, DOI 10.1103/PhysRevLett.62.1916; JACKLE J, 1986, REP PROG PHYS, V49, P171, DOI 10.1088/0034-4885/49/2/002; JANKOWIAK R, 1987, SCIENCE, V237, P618, DOI 10.1126/science.237.4815.618; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KIRKPATRICK TR, 1987, PHYS REV B, V36, P8552, DOI 10.1103/PhysRevB.36.8552; KIRKPATRICK TR, 1989, PHYS REV A, V40, P1045, DOI 10.1103/PhysRevA.40.1045; KNOWLES J, 1991, WORKSHOP STRUCTURE F; KOHLER W, 1989, J CHEM PHYS, V90, P1270, DOI 10.1063/1.456131; KOPER GJM, 1987, EUROPHYS LETT, V3, P1213, DOI 10.1209/0295-5075/3/11/010; KUBO R, 1966, REP PROG PHYS, V29, P255, DOI 10.1088/0034-4885/29/1/306; Landau L., 1980, STAT PHYS THEORY CON; LEVINTHAL C, 1968, J CHIM PHYS PCB, V65, P44, DOI 10.1051/jcp/1968650044; Levinthal C., 1969, MOSSB SPECTR BIOL SY, V67, P22; LEVITT M, 1983, J MOL BIOL, V168, P621, DOI 10.1016/S0022-2836(83)80306-4; Linderstrom-Lang K, 1959, ENZYMES, P443; LYONS KB, 1982, HEMOGLOBIN OXYGEN BI, P333; MAKINEN MW, 1979, P NATL ACAD SCI USA, V76, P6042, DOI 10.1073/pnas.76.12.6042; MCCAMMON JA, 1977, NATURE, V267, P585, DOI 10.1038/267585a0; McCammon JA., 1987, DYNAMICS PROTEINS NU; MCCOY S, 1971, PROBES STRUCTURE FUN, V2, P323; MEZARD M, 1987, SPIN GLASS THEORY BE; Moerner W. E., 1988, PERSISTENT SPECTRAL; MOORE JN, 1988, P NATL ACAD SCI USA, V85, P5062, DOI 10.1073/pnas.85.14.5062; MURRAY LP, 1988, P NATL ACAD SCI USA, V85, P2151, DOI 10.1073/pnas.85.7.2151; ORMOS P, 1988, P NATL ACAD SCI USA, V85, P8492, DOI 10.1073/pnas.85.22.8492; ORMOS P, 1990, BIOPHYS J, V57, P191, DOI 10.1016/S0006-3495(90)82522-4; PERUTZ MF, 1966, J MOL BIOL, V21, P199, DOI 10.1016/0022-2836(66)90088-X; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; PETRICH JW, 1991, BIOCHEMISTRY-US, V30, P3975, DOI 10.1021/bi00230a025; PETSKO GA, 1984, ANNU REV BIOPHYS BIO, V13, P331; Phillips W. A., 1981, AMORPHOUS SOLIDS; ROUSSEAU DL, 1986, P NATL ACAD SCI USA, V83, P1310, DOI 10.1073/pnas.83.5.1310; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; SCHER H, 1991, PHYS TODAY, V44, P26, DOI 10.1063/1.881289; SHAKHNOVICH EI, 1989, EUROPHYS LETT, V8, P327, DOI 10.1209/0295-5075/8/4/005; SHAKHNOVICH EI, 1989, EUROPHYS LETT, V9, P569, DOI 10.1209/0295-5075/9/6/013; SINGH GP, 1984, Z PHYS B CON MAT, V55, P23, DOI 10.1007/BF01307496; SRAJER V, 1988, J AM CHEM SOC, V110, P6656, DOI 10.1021/ja00228a009; STEIN DL, 1985, P NATL ACAD SCI USA, V82, P3670, DOI 10.1073/pnas.82.11.3670; STEIN DL, 1989, SCI AM, V261, P52, DOI 10.1038/scientificamerican0789-52; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; STILLINGER FH, 1984, SCIENCE, V225, P983, DOI 10.1126/science.225.4666.983; TOULOUSE G, 1986, P NATL ACAD SCI USA, V83, P1695, DOI 10.1073/pnas.83.6.1695; WAGNER G, 1983, Q REV BIOPHYS, V16, P1, DOI 10.1017/S0033583500004911; Weber G, 1975, Adv Protein Chem, V29, P1, DOI 10.1016/S0065-3233(08)60410-6; WOLYNES PG, IN PRESS SPIN GLASSE; XIE XL, 1991, BIOCHEMISTRY-US, V30, P3682, DOI 10.1021/bi00229a013; ZALLEN R, 1983, PHYSICS AMORPHOUS SO; ZWANZIG R, 1988, P NATL ACAD SCI USA, V85, P2029, DOI 10.1073/pnas.85.7.2029	94	2581	2605	7	388	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 13	1991	254	5038					1598	1603		10.1126/science.1749933	http://dx.doi.org/10.1126/science.1749933			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1749933				2022-12-01	WOS:A1991GV07300033
J	LINDEN, DJ; CONNOR, JA				LINDEN, DJ; CONNOR, JA			PARTICIPATION OF POSTSYNAPTIC PKC IN CEREBELLAR LONG-TERM DEPRESSION IN CULTURE	SCIENCE			English	Article							PROTEIN KINASE-C; PURKINJE-CELL DENDRITES; EXCITATORY AMINO-ACIDS; CLIMBING FIBER; GRANULE CELL; GLUTAMATE SENSITIVITY; CALCIUM; INDUCTION; INVITRO; POTENTIATION	Long-term depression (LTD) in the intact cerebellum is a decrease in the efficacy of the parallel fiber-Purkinje neuron synapse induced by coactivation of climbing fiber and parallel fiber inputs. In cultured Purkinje neurons, a similar depression can be induced by iontophoretic glutamate pulses and Purkinje neuron depolarization. This form of LTD is expressed as a depression of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-mediated current, and its induction is dependent on activation of metabotropic quisqualate receptors. The effect of inhibitors of protein kinase C (PKC) on LTD induction was studied. Inhibitors of PKC blocked LTD induction, while phorbol-12,13-diacetate (PDA), a PKC activator, mimicked LTD. These results suggest that PKC activation is necessary for the induction of cerebellar LTD.			LINDEN, DJ (corresponding author), ROCHE INST MOLEC BIOL,ROCHE RES CTR,DEPT NEUROSCI,NUTLEY,NJ 07110, USA.							AUDINAT E, 1990, J PHYSIOL-LONDON, V430, P297, DOI 10.1113/jphysiol.1990.sp018292; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BROWN TH, 1988, SCIENCE, V242, P724, DOI 10.1126/science.2903551; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CONNOR JA, 1986, P NATL ACAD SCI USA, V83, P6179, DOI 10.1073/pnas.83.16.6179; CREPEL F, 1991, J PHYSIOL-LONDON, V432, P123, DOI 10.1113/jphysiol.1991.sp018380; CREPEL F, 1988, BRAIN RES, V458, P397, DOI 10.1016/0006-8993(88)90486-6; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DUPONT JL, 1987, DEV BRAIN RES, V34, P59, DOI 10.1016/0165-3806(87)90195-7; EKEROT CF, 1985, BRAIN RES, V342, P357, DOI 10.1016/0006-8993(85)91136-9; EKEROT CF, 1981, J PHYSIOL-LONDON, V318, P207; GARTHWAITE G, 1987, DEV BRAIN RES, V36, P288, DOI 10.1016/0165-3806(87)90034-4; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEBB DO, 1949, ORG BEHAVIOR; HIRANO T, 1990, NEUROSCI LETT, V119, P141, DOI 10.1016/0304-3940(90)90818-T; HIRANO T, 1990, NEUROSCI LETT, V119, P145, DOI 10.1016/0304-3940(90)90819-U; HIRANO T, 1991, SYNAPSE, V7, P321, DOI 10.1002/syn.890070408; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; ITO M, 1982, J PHYSIOL-LONDON, V324, P113, DOI 10.1113/jphysiol.1982.sp014103; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.neuro.12.1.85; KANO M, 1987, NATURE, V325, P276, DOI 10.1038/325276a0; KANO M, 1988, NEUROSCI RES, V5, P544, DOI 10.1016/0168-0102(88)90041-7; KNOPFEL T, 1991, EUR J NEUROSCI, V3, P343, DOI 10.1111/j.1460-9568.1991.tb00821.x; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LINDEN DJ, 1991, NEURON, V7, P81, DOI 10.1016/0896-6273(91)90076-C; LINDEN DJ, UNPUB; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P197, DOI 10.1113/jphysiol.1980.sp013358; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ROSS WN, 1987, J PHYSIOL-LONDON, V389, P319, DOI 10.1113/jphysiol.1987.sp016659; SAKURAI M, 1990, P NATL ACAD SCI USA, V87, P3383, DOI 10.1073/pnas.87.9.3383; SANGAMESWARAN L, 1989, P NATL ACAD SCI USA, V86, P5651, DOI 10.1073/pnas.86.14.5651; SCHILLING K, IN PRESS NEURON; TANK DW, 1988, SCIENCE, V242, P773, DOI 10.1126/science.2847315; THOMASSET M, 1984, DEV PHARMACOL THERAP, V7, P6, DOI 10.1159/000457220; THOMPSON RF, 1986, SCIENCE, V233, P941, DOI 10.1126/science.3738519	38	266	272	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1656	1659		10.1126/science.1721243	http://dx.doi.org/10.1126/science.1721243			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1721243				2022-12-01	WOS:A1991GV07300049
J	MILLIGAN, DL; KOSHLAND, DE				MILLIGAN, DL; KOSHLAND, DE			INTRASUBUNIT SIGNAL TRANSDUCTION BY THE ASPARTATE CHEMORECEPTOR	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; DIRECTED CROSS-LINKING; HUMAN INSULIN-RECEPTOR; ESCHERICHIA-COLI; PROTEIN METHYLATION; PHOSPHORYLATION; DIMERIZATION; ADAPTATION; ACTIVATION; FAMILY	Receptors that transmit signals across cell membranes are typically composed of multiple subunits. To test whether subunit interactions are required for transmembrane signaling by the bacterial aspartate receptor, dimers were constructed with (i) two full-length subunits, (ii) one full-length subunit and one subunit lacking the cytoplasmic domain, or (iii) one full-length subunit and one subunit lacking both the cytoplasmic and the transmembrane domains. Methylation of the cytoplasmic domain of all three receptor constructs was stimulated by the binding of aspartate. These findings demonstrate that transmembrane signaling does not require interactions between cytoplasmic or transmembrane domains of adjacent subunits and suggest that signaling occurs via conformational changes transduced through a single subunit.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	MILLIGAN, DL (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.				NIDDK NIH HHS [DK 09765] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009765, R37DK009765] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNARD EA, 1987, TRENDS NEUROSCI, V10, P502, DOI 10.1016/0166-2236(87)90130-5; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BOYD A, 1983, NATURE, V301, P623, DOI 10.1038/301623a0; CHELSKY D, 1984, ANAL BIOCHEM, V141, P143, DOI 10.1016/0003-2697(84)90437-8; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; GOY MF, 1977, P NATL ACAD SCI USA, V74, P4964, DOI 10.1073/pnas.74.11.4964; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Macnab R. M., 1987, ESCHERICHIA COLI SAL, V1, P732; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MILLIGAN DL, UNPUB; MOWBRAY SL, 1985, J BIOL CHEM, V260, P1711; PESSIN JE, 1985, MOL BASIS INSULIN AC, P3; RUSSO AF, 1983, SCIENCE, V220, P1016, DOI 10.1126/science.6302843; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WOLFF C, 1988, J BACTERIOL, V170, P4509, DOI 10.1128/jb.170.10.4509-4515.1988; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	25	82	82	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1651	1654		10.1126/science.1661030	http://dx.doi.org/10.1126/science.1661030			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1661030				2022-12-01	WOS:A1991GV07300047
J	MOLLA, A; PAUL, AV; WIMMER, E				MOLLA, A; PAUL, AV; WIMMER, E			CELL-FREE, DENOVO SYNTHESIS OF POLIOVIRUS	SCIENCE			English	Article							TRANSLATION SYSTEM; INITIATION SITES; RNA-POLYMERASE; POLYPEPTIDE 2C; MESSENGER-RNA; HELA-CELLS; INVITRO; CLEAVAGE; MORPHOGENESIS; INTERMEDIATE	Cell-free translation of poliovirus RNA in an extract of uninfected human (HeLa) cells yielded viral proteins through proteolysis of the polyprotein. In the extract, newly synthesized proteins catalyzed poliovirus-specific RNA synthesis, and formed infectious poliovirus de novo. Newly formed virions were neutralized by type-specific antiserum, and infection of human cells with them was prevented by poliovirus receptor-specific antibodies. Poliovirus synthesis was increased nearly 70-fold when nucleoside triphosphates were added, but it was abolished in the presence of inhibitors of translation or viral genome replication. The ability to conduct cell-free synthesis of poliovirus will aid in the study of picornavirus proliferation and in the search for the control of picornaviral disease.			MOLLA, A (corresponding author), SUNY STONY BROOK,SCH MED,DEPT MICROBIOL,STONY BROOK,NY 11794, USA.				NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015122, R37AI015122] Funding Source: NIH RePORTER; NCI NIH HHS [CA-28146] Funding Source: Medline; NIAID NIH HHS [AI-15122] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALTIMORE D, 1971, BACTERIOL REV, V35, P235, DOI 10.1128/MMBR.35.3.235-241.1971; BROWN BA, 1979, VIROLOGY, V97, P396, DOI 10.1016/0042-6822(79)90350-7; CALIGUIRI LA, 1973, SELECTIVE INHIBITORS, P257; CASJENS S, 1985, VIRUS STRUCTURE ASSE, P76; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DORNER AJ, 1982, J VIROL, V42, P1017, DOI 10.1128/JVI.42.3.1017-1028.1982; DORNER AJ, 1984, J VIROL, V50, P507, DOI 10.1128/JVI.50.2.507-514.1984; FERNANDEZTOMAS CB, 1973, J VIROL, V12, P1181, DOI 10.1128/JVI.12.5.1181-1183.1973; FERNANDEZTOMAS CB, 1973, J VIROL, V12, P1122, DOI 10.1128/JVI.12.5.1122-1130.1973; FLANEGAN JB, 1977, P NATL ACAD SCI USA, V74, P3677, DOI 10.1073/pnas.74.9.3677; GRUBMAN MJ, 1985, J VIROL, V56, P120, DOI 10.1128/JVI.56.1.120-126.1985; HARBER JJ, 1991, J VIROL, V65, P326, DOI 10.1128/JVI.65.1.326-334.1991; HARRISON SC, 1990, VIROLOGY, P37; HOGLE JM, 1985, SCIENCE, V229, P1358, DOI 10.1126/science.2994218; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; KOCH G, 1973, CURR TOP MICROBIOL I, V2, P89; Kuhn R. J., 1987, The molecular biology of the positive strand RNA viruses, P17; LEE KAW, 1982, P NATL ACAD SCI-BIOL, V79, P3447, DOI 10.1073/pnas.79.11.3447; LURIA SE, 1967, GENERAL VIROLOGY, P5; MENDELSOHN C, 1986, P NATL ACAD SCI USA, V83, P7845, DOI 10.1073/pnas.83.20.7845; MOLLA A, UNPUB; NOBIS P, 1985, J GEN VIROL, V66, P2563, DOI 10.1099/0022-1317-66-12-2563; NOVAK JE, 1991, J VIROL, V65, P3384, DOI 10.1128/JVI.65.6.3384-3387.1991; PALMENBERG AC, 1982, J VIROL, V44, P900, DOI 10.1128/JVI.44.3.900-906.1982; PAUL AV, 1987, P NATL ACAD SCI USA, V84, P7827, DOI 10.1073/pnas.84.22.7827; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PEREZBERCOFF R, 1980, PROTEIN BIOSYNTHESIS; PESTOVA TV, 1991, J VIROL, V65, P6194, DOI 10.1128/JVI.65.11.6194-6204.1991; PINCUS SE, 1986, J VIROL, V57, P638, DOI 10.1128/JVI.57.2.638-646.1986; PINCUS SE, 1986, J VIROL, V60, P793, DOI 10.1128/JVI.60.2.793-796.1986; PINCUS SE, 1987, MOL BIOL RNA NEW PER, P175; PUTNAK JR, 1981, MICROBIOL REV, V45, P287, DOI 10.1128/MMBR.45.2.287-315.1981; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROTHBERG PG, 1981, THESIS STATE U NEW Y; RUECKERT RR, 1990, VIROLOGY, P507; SEMLER BL, 1982, CELL, V28, P405, DOI 10.1016/0092-8674(82)90358-0; SEMLER BL, 1988, RNA GENETICS, V1, P23; TAKEDA N, 1986, J VIROL, V60, P43, DOI 10.1128/JVI.60.1.43-53.1986; TAKEGAMI T, 1983, P NATL ACAD SCI-BIOL, V80, P7447, DOI 10.1073/pnas.80.24.7447; VANDERWERF S, 1986, P NATL ACAD SCI USA, V83, P2330; WALKER AI, 1985, THESIS U CAMBRIDGE; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; YPMAWONG MF, 1987, NUCLEIC ACIDS RES, V15, P2069, DOI 10.1093/nar/15.5.2069; YPMAWONG MF, 1987, J VIROL, V61, P3181, DOI 10.1128/JVI.61.10.3181-3189.1987	44	308	325	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1647	1651		10.1126/science.1661029	http://dx.doi.org/10.1126/science.1661029			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1661029				2022-12-01	WOS:A1991GV07300046
J	POWER, RF; MANI, SK; CODINA, J; CONNEELY, OM; OMALLEY, BW				POWER, RF; MANI, SK; CODINA, J; CONNEELY, OM; OMALLEY, BW			DOPAMINERGIC AND LIGAND-INDEPENDENT ACTIVATION OF STEROID-HORMONE RECEPTORS	SCIENCE			English	Article							CHICKEN PROGESTERONE-RECEPTOR; GLUCOCORTICOID RECEPTOR; MOLECULAR-CLONING; RAT-BRAIN; COMPLEMENTARY-DNA; ADENYLATE-CYCLASE; RESPONSE ELEMENT; ESTROGEN; GENE; TRANSCRIPTION	The current view of how steroid hormone receptors affect gene transcription is that these receptors, on binding ligand, change to a state in which they can interact with chromatin and regulate transcription of target genes. Receptor activation is believed to be dependent only on this ligand-binding event. Selected steroid hormone receptors can be activated in a ligand-independent manner by a membrane receptor agonist, the neurotransmitter dopamine. In vitro, dopamine faithfully mimicked the effect of progesterone by causing a translocation of chicken progesterone receptor (cPR) from cytoplasm to nucleus. Dual activation by progesterone and dopamine was dissociable, and a serine residue in the cPR was identified that is not necessary for progesterone-dependent activation of cPR, but is essential for dopamine activation of this receptor.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine	OMALLEY, BW (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030, USA.							APERIA A, 1990, AM J HYPERTENS, V3, pS11, DOI 10.1093/ajh/3.6.11S; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEYER C, 1981, PHYSIOL BEHAV, V26, P249, DOI 10.1016/0031-9384(81)90019-6; BLAUSTEIN JD, 1980, NEUROENDOCRINOLOGY, V31, P403, DOI 10.1159/000123110; BOGIC L, 1988, ENDOCRINOLOGY, V122, P2735, DOI 10.1210/endo-122-6-2735; BRADSHAW MS, 1988, MOL ENDOCRINOL, V2, P1286, DOI 10.1210/mend-2-12-1286; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CONNEELY OM, 1987, BIOCHEM BIOPH RES CO, V149, P493, DOI 10.1016/0006-291X(87)90395-0; CONNEELY OM, 1989, J BIOL CHEM, V264, P14062; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DEKLOFT ER, 1985, EUR J PHARMACOL, V118, P185, DOI 10.1016/0014-2999(85)90679-X; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DENNER LA, UNPUB; DOBSON ADW, 1989, J BIOL CHEM, V264, P4207; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FELDER CC, 1989, J BIOL CHEM, V264, P8739; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gorski J, 1968, Recent Prog Horm Res, V24, P45; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GUICHONMANTEL A, 1989, CELL, V57, P1147; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JENSEN EV, 1968, P NATL ACAD SCI USA, V59, P632, DOI 10.1073/pnas.59.2.632; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; MOBLEY PL, 1983, J PHARMACOL EXP THER, V226, P71; MOBLEY PL, 1980, NATURE, V286, P608, DOI 10.1038/286608a0; NORDEEN SK, 1989, MOL ENDOCRINOL, V3, P1270, DOI 10.1210/mend-3-8-1270; O'Malley B W, 1969, Recent Prog Horm Res, V25, P105; OKULICZ WC, 1989, ENDOCRINOLOGY, V125, P930, DOI 10.1210/endo-125-2-930; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PARSONS B, 1980, ENDOCRINOLOGY, V107, P774, DOI 10.1210/endo-107-3-774; POWER R, UNPUB; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; REKER CE, 1987, J STEROID BIOCHEM, V26, P653, DOI 10.1016/0022-4731(87)91037-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUMACHER M, 1990, TRENDS NEUROSCI, V13, P359, DOI 10.1016/0166-2236(90)90016-4; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHOLL SA, 1986, ENDOCRINOLOGY, V119, P1625, DOI 10.1210/endo-119-4-1625; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; STEIMER T, 1981, NATURE, V292, P345, DOI 10.1038/292345a0; STRALFORS P, 1989, EUR J BIOCHEM, V180, P143, DOI 10.1111/j.1432-1033.1989.tb14624.x; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1549, DOI 10.1210/endo-119-4-1549; SULSER F, 1986, J CLIN PSYCHIAT, V10, P13; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; TORO MJ, 1987, MOL ENDOCRINOL, V1, P669, DOI 10.1210/mend-1-10-669; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WEIGEL N, UNPUB; WILLIAMS KR, 1986, J BIOL CHEM, V261, P1890; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	56	529	539	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1636	1639		10.1126/science.1749936	http://dx.doi.org/10.1126/science.1749936			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1749936				2022-12-01	WOS:A1991GV07300043
J	SCHNEIDER, H; SOLLNER, T; DIETMEIER, K; ECKERSKORN, C; LOTTSPEICH, F; TRULZSCH, B; NEUPERT, W; PFANNER, N				SCHNEIDER, H; SOLLNER, T; DIETMEIER, K; ECKERSKORN, C; LOTTSPEICH, F; TRULZSCH, B; NEUPERT, W; PFANNER, N			TARGETING OF THE MASTER RECEPTOR MOM19 TO MITOCHONDRIA	SCIENCE			English	Article							OUTER-MEMBRANE PROTEIN; PRECURSOR PROTEINS; IMPORT RECEPTOR; MATRIX; INSERTION; CARRIER; SITE	The targeting of proteins to mitochondria involves the recognition of the precursor proteins by receptors on the mitochondrial surface followed by insertion of the precursors into the outer membrane at the general insertion site GIP. Most mitochondrial proteins analyzed so far use a mitochondrial outer membrane protein of 19 kilodaltons (MOM19) as an import receptor. The gene encoding MOM19 has now been isolated. The deduced amino acid sequence predicts that MOM19 is anchored in the outer membrane by an NH2-terminal hydrophobic sequence, while the rest of the protein forms a hydrophilic domain exposed to the cytosol. MOM19 was targeted to the mitochondria via a pathway that is independent of protease-accessible surface receptors and controlled by direct assembly of the MOM19 precursor with GIP.	UNIV MUNICH,INST PHYSIOL CHEM,GOETHESTR 33,W-8000 MUNICH 2,GERMANY; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	University of Munich; Max Planck Society	PFANNER, N (corresponding author), UNIV MUNICH,INST PHYSIOL CHEM,GOETHESTR 33,W-8000 MUNICH 2,GERMANY.		Pfanner, Nikolaus/AAV-7878-2021					BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DOUGLAS MG, 1986, MICROBIOL REV, V50, P166, DOI 10.1128/MMBR.50.2.166-178.1986; ECKERSKORN C, 1989, CHROMATOGRAPHIA, V28, P92, DOI 10.1007/BF02290390; GHISLAIN M, 1987, J BIOL CHEM, V262, P17549; Horwich A, 1990, CURR OPIN CELL BIOL, V2, P625, DOI 10.1016/0955-0674(90)90103-L; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; MILLER BR, 1991, J CELL BIOL, V112, P833, DOI 10.1083/jcb.112.5.833; NOEGEL A, 1987, FEBS LETT, V221, P391, DOI 10.1016/0014-5793(87)80962-6; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFALLER R, 1989, J BIOL CHEM, V264, P34; PFANNER N, 1987, J BIOL CHEM, V262, P7528; PFANNER N, 1988, TRENDS BIOCHEM SCI, V13, P165, DOI 10.1016/0968-0004(88)90140-5; PFANNER N, 1991, TRENDS BIOCHEM SCI, V16, P63, DOI 10.1016/0968-0004(91)90026-R; RIEZMAN H, 1983, EMBO J, V2, P1113, DOI 10.1002/j.1460-2075.1983.tb01554.x; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; SOLLNER T, UNPUB; STEGER HF, 1990, J CELL BIOL, V111, P2355; STUART RA, 1987, EMBO J, V6, P2131, DOI 10.1002/j.1460-2075.1987.tb02480.x; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; YANG M, 1991, J BIOL CHEM, V266, P6416; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359	29	101	103	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1659	1662		10.1126/science.1661031	http://dx.doi.org/10.1126/science.1661031			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1661031	Green Submitted			2022-12-01	WOS:A1991GV07300050
J	STROBEL, SA; DOUCETTESTAMM, LA; RIBA, L; HOUSMAN, DE; DERVAN, PB				STROBEL, SA; DOUCETTESTAMM, LA; RIBA, L; HOUSMAN, DE; DERVAN, PB			SITE-SPECIFIC CLEAVAGE OF HUMAN CHROMOSOME-4 MEDIATED BY TRIPLE-HELIX FORMATION	SCIENCE			English	Article							HUNTINGTONS-DISEASE GENE; LARGE DNA-MOLECULES; GEL-ELECTROPHORESIS; YEAST CHROMOSOME; SINGLE SITE; G8 PROBE; FIELD; MARKERS; D4S10; BINDING	Direct physical isolation of specific DNA segments from the human genome is a necessary goal in human genetics. For testing whether triple-helix mediated enzymatic cleavage can liberate a specific segment of a human chromosome, the tip of human chromosome 4, which contains the entire candidate region for the Huntington's disease gene, was chosen as a target. A 16-base pyrimidine oligodeoxyribonucleotide was able to locate a 16-base pair purine target site within more than 10 gigabase pairs of genomic DNA and mediate the exact enzymatic cleavage at that site in more than 80 percent yield. The recognition motif is sufficiently generalizable that most cosmids should contain a sequence targetable by triple-helix formation. This method may facilitate the orchestrated dissection of human chromosomes from normal and affected individuals into megabase sized fragments and facilitate the isolation of candidate gene loci.	CALTECH,ARNOLD & MABEL BECKMAN LABS CHEM SYNTH,PASADENA,CA 91125; MIT,CTR CANC RES,CAMBRIDGE,MA 02139	California Institute of Technology; Massachusetts Institute of Technology (MIT)	DERVAN, PB (corresponding author), CALTECH,ARNOLD & MABEL BECKMAN LABS CHEM SYNTH,PASADENA,CA 91125, USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000329] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00098, HG00329] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BATES GP, 1991, AM J HUM GENET, V49, P7; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BIRREN BW, 1988, NUCLEIC ACIDS RES, V16, P7563, DOI 10.1093/nar/16.15.7563; BUCAN M, 1990, GENOMICS, V6, P1; CARLE GF, 1986, SCIENCE, V232, P65, DOI 10.1126/science.3952500; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; CLARK SM, 1988, SCIENCE, V241, P1203, DOI 10.1126/science.3045968; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DELOSSANTOS C, 1989, BIOCHEMISTRY-US, V28, P7282, DOI 10.1021/bi00444a021; DERVAN PB, 1988, NUCLEIC ACIDS MOL BI, V2, P49; DOUCETTESTAMM LA, IN PRESS SOMATIC CEL; ERLICH HA, 1991, SCIENCE, V252, P1643, DOI 10.1126/science.2047872; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FOLSTEIN SE, 1985, SCIENCE, V229, P776, DOI 10.1126/science.2992086; GILLIAM TC, 1987, CELL, V50, P565, DOI 10.1016/0092-8674(87)90029-8; GILLIAM TC, 1987, SCIENCE, V238, P950, DOI 10.1126/science.2890209; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; GUSELLA JF, 1986, COLD SPRING HARB SYM, V51, P359, DOI 10.1101/SQB.1986.051.01.043; GUSELLA JF, IN PRESS GENOMICS; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; HORNE DA, 1990, J AM CHEM SOC, V112, P2435, DOI 10.1021/ja00162a063; KOOB M, 1990, SCIENCE, V250, P271, DOI 10.1126/science.2218529; LANDEGENT JE, 1986, HUM GENET, V73, P354, DOI 10.1007/BF00279100; LIPSETT MN, 1964, J BIOL CHEM, V239, P1256; LYAMICHEV VI, 1988, NUCLEIC ACIDS RES, V16, P2165, DOI 10.1093/nar/16.5.2165; MAHER LJ, 1990, BIOCHEMISTRY-US, V29, P8820, DOI 10.1021/bi00489a045; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; POHL TM, 1988, NUCLEIC ACIDS RES, V16, P9185, DOI 10.1093/nar/16.19.9185; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; PRASEUTH D, 1988, P NATL ACAD SCI USA, V85, P1349, DOI 10.1073/pnas.85.5.1349; PRITCHARD CA, 1989, GENOMICS, V4, P408, DOI 10.1016/0888-7543(89)90348-0; RAJAGOPAL P, 1989, BIOCHEMISTRY-US, V28, P7859, DOI 10.1021/bi00445a048; RAJAGOPAL P, 1989, NATURE, V339, P637, DOI 10.1038/339637a0; RICHARDS B, 1991, GENOMICS, V9, P235, DOI 10.1016/0888-7543(91)90247-C; RICHARDS JE, 1988, P NATL ACAD SCI USA, V85, P6437, DOI 10.1073/pnas.85.17.6437; Saiki R.K., 1989, PCR TECHNOLOGY, P7; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SKRAASTAD MI, 1989, AM J HUM GENET, V44, P560; Smith C.L., 1988, P41; STAPLETON PM, 1988, NUCLEIC ACIDS RES, V16, P2735, DOI 10.1093/nar/16.6.2735; STROBEL SA, 1991, NATURE, V350, P172, DOI 10.1038/350172a0; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; STROBEL SA, 1990, SCIENCE, V249, P73, DOI 10.1126/science.2195655; THEUNE S, 1991, GENOMICS, V9, P511, DOI 10.1016/0888-7543(91)90418-E; WASMUTH JJ, 1988, NATURE, V332, P734, DOI 10.1038/332734a0; YOUNGMAN S, 1989, GENOMICS, V5, P802, DOI 10.1016/0888-7543(89)90122-5	48	195	212	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1639	1642		10.1126/science.1836279	http://dx.doi.org/10.1126/science.1836279			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1836279				2022-12-01	WOS:A1991GV07300044
J	VANDERBRUGGEN, P; TRAVERSARI, C; CHOMEZ, P; LURQUIN, C; DEPLAEN, E; VANDENEYNDE, B; KNUTH, A; BOON, T				VANDERBRUGGEN, P; TRAVERSARI, C; CHOMEZ, P; LURQUIN, C; DEPLAEN, E; VANDENEYNDE, B; KNUTH, A; BOON, T			A GENE ENCODING AN ANTIGEN RECOGNIZED BY CYTOLYTIC LYMPHOCYTES-T ON A HUMAN-MELANOMA	SCIENCE			English	Article							IMMUNOGENIC TUM VARIANTS; MOUSE MASTOCYTOMA P815; MUTATED EXON ENCODES; TRANSPLANTATION ANTIGEN-P91A; CELLS; IDENTIFICATION; MUTAGENESIS; TUMOR-P815; CLONING; PEPTIDE	Many human melanoma tumors express antigens that are recognized in vitro by cytolytic T lymphocytes (CTLs) derived from the tumor-bearing patient. A gene was identified that directed the expression of antigen MZ2-E on a human melanoma cell line. This gene shows no similarity to known sequences and belongs to a family of at least three genes. It is expressed by the original melanoma cells, other melanoma cell lines, and by some tumor cells of other histological types. No expression was observed in a panel of normal tissues. Antigen MZ2-E appears to be presented by HLA-A1; anti-MZ2-E CTLs of the original patient recognized two melanoma cell lines of other HLA-A1 patients that expressed the gene. Thus, precisely targeted immunotherapy directed against antigen MZ2-E could be provided to individuals identified by HLA typing and analysis of the RNA of a small tumor sample.	LUDWIG INST CANC RES, B-1200 BRUSSELS, BELGIUM; CATHOLIC UNIV LOUVAIN, CELLULAR GENET UNIT, B-1200 BRUSSELS, BELGIUM; UNIV MAINZ, MED KLIN & POLIKLIN 1, W-6500 MAINZ, GERMANY	Ludwig Institute for Cancer Research; Universite Catholique Louvain; Johannes Gutenberg University of Mainz	BOON, T (corresponding author), LUDWIG INST CANC RES, B-1200 BRUSSELS, BELGIUM.		Bertrand, Mathieu J/P-6465-2016; knuth, alexander/H-2608-2014	Bertrand, Mathieu J/0000-0001-9000-0626; knuth, alexander/0000-0002-9318-2784				ANICHINI A, 1987, IMMUNOL TODAY, V8, P385, DOI 10.1016/0167-5699(87)90215-5; BOON T, 1980, J EXP MED, V152, P1184, DOI 10.1084/jem.152.5.1184; BRUNNER KT, 1981, J EXP MED, V154, P362, DOI 10.1084/jem.154.2.362; CROWLEY NJ, 1990, CANCER RES, V50, P492; DARROW TL, 1989, J IMMUNOL, V142, P3329; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DEPLAEN E, 1988, P NATL ACAD SCI USA, V85, P2274; FEARON ER, 1988, CANCER RES, V48, P2975; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HERIN M, 1987, INT J CANCER, V39, P390, DOI 10.1002/ijc.2910390320; KLEIN G, 1960, CANCER RES, V20, P1561; LAU YF, 1983, P NATL ACAD SCI-BIOL, V80, P5225, DOI 10.1073/pnas.80.17.5225; LUND T, 1982, P NATL ACAD SCI-BIOL, V79, P520, DOI 10.1073/pnas.79.2.520; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MELIEF CJM, 1992, ADV CANCER RES, V58, P143, DOI 10.1016/S0065-230X(08)60294-8; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PREHN RT, 1957, J NATL CANCER I, V18, P769; SIBILLE C, 1990, J EXP MED, V172, P35, DOI 10.1084/jem.172.1.35; SLOVIN SF, 1986, J IMMUNOL, V137, P3042; SZIKORA JP, 1990, EMBO J, V9, P1041, DOI 10.1002/j.1460-2075.1990.tb08208.x; TIWARI JL, 1985, HLA DISEASE ASS, P4; TRAVERSARI C, IN PRESS IMMUNOGENET; UYTTENHOVE C, 1983, J EXP MED, V157, P1040, DOI 10.1084/jem.157.3.1040; VANDENEYNDE B, 1991, J EXP MED, V173, P1373, DOI 10.1084/jem.173.6.1373; VANDENEYNDE B, 1989, INT J CANCER, V44, P634; VANPEL A, 1983, J EXP MED, V157, P1992, DOI 10.1084/jem.157.6.1992; WOLFEL T, 1987, IMMUNOGENETICS, V26, P178, DOI 10.1007/BF00365909	28	2882	3175	9	100	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 13	1991	254	5038					1643	1647		10.1126/science.1840703	http://dx.doi.org/10.1126/science.1840703			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1840703				2022-12-01	WOS:A1991GV07300045
J	WEIS, WI; KAHN, R; FOURME, R; DRICKAMER, K; HENDRICKSON, WA				WEIS, WI; KAHN, R; FOURME, R; DRICKAMER, K; HENDRICKSON, WA			STRUCTURE OF THE CALCIUM-DEPENDENT LECTIN DOMAIN FROM A RAT MANNOSE-BINDING PROTEIN DETERMINED BY MAD PHASING	SCIENCE			English	Article							MULTIWAVELENGTH ANOMALOUS DIFFRACTION; LIVER ASIALOGLYCOPROTEIN RECEPTOR; CARBOHYDRATE-RECOGNITION DOMAINS; PULMONARY SURFACTANT APOPROTEIN; AREA-DETECTOR DIFFRACTOMETER; PROTEOGLYCAN CORE PROTEIN; CARTILAGE PROTEOGLYCAN; SYNCHROTRON RADIATION; CONCANAVALIN-A; MACROMOLECULAR CRYSTALLOGRAPHY	Calcium-dependent (C-type) animal lectins participate in many cell surface recognition events mediated by protein-carbohydrate interactions. The C-type lectin family includes cell adhesion molecules, endocytic receptors, and extracellular matrix proteins. Mammalian mannose-binding proteins are C-type lectins that function in antibody-independent host defense against pathogens. The crystal structure of the carbohydrate-recognition domain of a rat mannose-binding protein, determined as the holmium-substituted complex by multiwavelength anomalous dispersion (MAD) phasing, reveals an unusual fold consisting of two distinct regions, one of which contains extensive nonregular secondary structure stabilized by two holmium ions. The structure explains the conservation of 32 residues in all C-type carbohydrate-recognition domains, suggesting that the fold seen here is common to these domains. The strong anomalous scattering observed at the Ho L(III) edge demonstrates that traditional heavy atom complexes will be generally amenable to the MAD phasing method.	COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA; CNRS, UTILISAT RAYONNEMENT ELECTROMAGNET LAB, F-91405 ORSAY, FRANCE; UNIV PARIS 11, F-91405 ORSAY, FRANCE	Columbia University; Howard Hughes Medical Institute; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	WEIS, WI (corresponding author), COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA.		Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034102, R01GM042628, R37GM034102] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42628, GM34102] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERS EM, 1990, P NATL ACAD SCI USA, V87, P4485, DOI 10.1073/pnas.87.12.4485; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; BREITFELD PP, 1985, INT REV CYTOL, V97, P47, DOI 10.1016/S0074-7696(08)62348-7; BRUNGER AT, 1990, X PLOR MANUAL; CROMER DT, 1983, J APPL CRYSTALLOGR, V16, P437, DOI 10.1107/S0021889883010791; CROMER DT, 1970, J CHEM PHYS, V53, P1891, DOI 10.1063/1.1674266; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; DIPAOLA M, 1984, J BIOL CHEM, V259, P9163; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; EZEKOWITZ R A B, 1991, Current Biology, V1, P60; EZEKOWITZ RAB, 1988, J EXP MED, V167, P1034, DOI 10.1084/jem.167.3.1034; EZEKOWITZ RAB, 1989, J EXP MED, V169, P185, DOI 10.1084/jem.169.1.185; FANCHON E, 1990, ACTA CRYSTALLOGR A, V46, P809, DOI 10.1107/S0108767390005967; FUHLENDORFF J, 1987, BIOCHEMISTRY-US, V26, P6757, DOI 10.1021/bi00395a027; HALBERG DF, 1988, J BIOL CHEM, V263, P9486; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HARDMAN KD, 1972, BIOCHEMISTRY-US, V11, P4910, DOI 10.1021/bi00776a006; Hendrickson W. A., 1985, T AM CRYSTALLOGR ASS, V21, P11; HENDRICKSON WA, 1988, PROTEINS, V4, P77, DOI 10.1002/prot.340040202; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; IKEDA K, 1987, J BIOL CHEM, V262, P7451; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KAHN R, 1985, FEBS LETT, V179, P133, DOI 10.1016/0014-5793(85)80207-6; KAHN R, 1986, NUCL INSTRUM METH A, V246, P596, DOI 10.1016/0168-9002(86)90158-0; KRAULIS P, IN PRESS J APPL CRYS; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LEUNG JO, 1985, J BIOL CHEM, V260, P2523; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; LOEB JA, 1988, J BIOL CHEM, V263, P9752; LOEB JA, 1987, J BIOL CHEM, V262, P3022; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; QUESENBERRY MS, UNPUB; QUESENBERRY MS, IN PRESS GLYCOBIOLOG; REEKE GN, 1975, J BIOL CHEM, V250, P1525; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SANDY JD, 1990, J BIOL CHEM, V265, P21108; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; SUPER M, 1989, LANCET, V2, P1236; SWAIN AL, 1989, J BIOL CHEM, V264, P16620; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1989, BIOCHEM J, V262, P763, DOI 10.1042/bj2620763; TEMPLETON LK, 1982, ACTA CRYSTALLOGR A, V38, P74, DOI 10.1107/S056773948200014X; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0	57	508	530	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 13	1991	254	5038					1608	1615		10.1126/science.1721241	http://dx.doi.org/10.1126/science.1721241			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1721241				2022-12-01	WOS:A1991GV07300035
J	WEISS, MS; ABELE, U; WECKESSER, J; WELTE, W; SCHILTZ, E; SCHULZ, GE				WEISS, MS; ABELE, U; WECKESSER, J; WELTE, W; SCHILTZ, E; SCHULZ, GE			MOLECULAR ARCHITECTURE AND ELECTROSTATIC PROPERTIES OF A BACTERIAL PORIN	SCIENCE			English	Article							INTEGRAL MEMBRANE-PROTEIN; COLI OUTER MEMBRANES; X-RAY-ANALYSIS; ESCHERICHIA-COLI; RHODOBACTER-CAPSULATUS; ALPHA-HELIX; RESOLUTION; CRYSTALLIZATION; DIPOLES; PROGRAM	The integral membrane protein porin from Rhodobacter capsulatus consists of three tightly associated 16-stranded beta-barrels that give rise to three distinct diffusion channels for small solutes through the outer membrane. The x-ray structure of this porin has revealed details of its shape, the residue distributions within the pore and at the membrane-facing surface, and the location of calcium sites. The electrostatic potential has been calculated and related to function. Moreover, potential calculations were found to predict the Ca2+ sites.	INST ORGAN CHEM & BIOCHEM,ALBERTSTR 21,W-7800 FREIBURG,GERMANY; INST BIOL 2,W-7800 FREIBURG,GERMANY; INST BIOPHYS & STRAHLENBIOL,W-7800 FREIBURG,GERMANY		SCHULZ, GE (corresponding author), INST ORGAN CHEM & BIOCHEM,ALBERTSTR 21,W-7800 FREIBURG,GERMANY.		Weiss, Manfred S/B-6857-2013	Weiss, Manfred S/0000-0002-2362-7047				BAUER K, 1989, J BIOL CHEM, V264, P16393; BENSON SA, 1988, J MOL BIOL, V203, P961, DOI 10.1016/0022-2836(88)90121-0; BENZ R, 1988, EUR J BIOCHEM, V176, P1, DOI 10.1111/j.1432-1033.1988.tb14245.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; ENGEL A, 1985, NATURE, V317, P643, DOI 10.1038/317643a0; GARAVITO RM, 1980, J CELL BIOL, V86, P327, DOI 10.1083/jcb.86.1.327; GARAVITO RM, 1983, J MOL BIOL, V164, P313, DOI 10.1016/0022-2836(83)90079-7; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HOL WGJ, 1981, NATURE, V294, P532, DOI 10.1038/294532a0; JAP BK, 1991, NATURE, V350, P167, DOI 10.1038/350167a0; KARSHIKOV A, 1989, PROTEINS, V5, P248, DOI 10.1002/prot.340050308; KLAPPER I, 1986, Proteins Structure Function and Genetics, V1, P47, DOI 10.1002/prot.340010109; KREUSCH A, 1991, J MOL BIOL, V217, P9, DOI 10.1016/0022-2836(91)90604-5; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; NABEDRYK E, 1988, BIOPHYS J, V53, P671, DOI 10.1016/S0006-3495(88)83148-5; NESTEL U, 1989, FEBS LETT, V242, P405, DOI 10.1016/0014-5793(89)80511-3; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; PAUPTIT RA, 1991, J MOL BIOL, V218, P505, DOI 10.1016/0022-2836(91)90696-4; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; SCHILTZ E, 1991, EUR J BIOCHEM, V199, P587, DOI 10.1111/j.1432-1033.1991.tb16158.x; SCHOMBURG D, 1988, J MOL GRAPHICS, V6, P161, DOI 10.1016/0263-7855(88)80069-9; STAUFFER KA, 1990, J MOL BIOL, V211, P297, DOI 10.1016/0022-2836(90)90351-L; TOMMASSEN J, 1988, NATO ASI SER, V16, P351; WARWICKER J, 1982, J MOL BIOL, V157, P671, DOI 10.1016/0022-2836(82)90505-8; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; WELTE W, IN PRESS BIOCH BIOPH; YAMASHITA MM, 1990, P NATL ACAD SCI USA, V87, P5648, DOI 10.1073/pnas.87.15.5648	29	578	594	4	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1627	1630		10.1126/science.1721242	http://dx.doi.org/10.1126/science.1721242			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1721242				2022-12-01	WOS:A1991GV07300040
J	ZHANG, K; PAPAGEORGE, AG; MARTIN, P; VASS, WC; OLAH, Z; POLAKIS, PG; MCCORMICK, F; LOWY, DR				ZHANG, K; PAPAGEORGE, AG; MARTIN, P; VASS, WC; OLAH, Z; POLAKIS, PG; MCCORMICK, F; LOWY, DR			HETEROGENEOUS AMINO-ACIDS IN RAS AND RAP1A SPECIFYING SENSITIVITY TO GAP PROTEINS	SCIENCE			English	Article							GTPASE-ACTIVATING PROTEIN; GENE-PRODUCT; CATALYTIC DOMAIN; EFFECTOR DOMAIN; RAS-P21 GTPASE; P21; IDENTIFICATION; MUTANTS; PURIFICATION; STIMULATION	Guanosine triphosphatase (GTPase) activity of Ras is increased by interaction with Ras-GAP (GTPase-activating protein) or with the GAP-related domain of the type 1 neurofibromatosis protein (NF1-GRD), but Ras is not affected by interaction with cytoplasmic and membrane forms of Rap-GAP; Rap1A, whose effector function can suppress transformation by Ras, is sensitive to both forms of Rap-GAP and resistant to Ras-GAP and NF1-GRD. A series of chimeric proteins composed of portions of Ras and Rap were constructed; some were sensitive to Ras-GAP but resistant to NF1-GRD, and others were sensitive to cytoplasmic Rap-GAP but resistant to membrane Rap-GAP. Sensitivity of chimeras to Ras-GAP and cytoplasmic Rap-GAP was mediated by amino acids that are carboxyl-terminal to the effector region. Residues 61 to 65 of Ras conferred Ras-GAP sensitivity, but a larger number of Rap1A residues were required for sensitivity to cytoplasmic Rap-GAP. Chimeras carrying the Ras effector region that were sensitive only to Ras-GAP or only to cytoplasmic Rap-GAP transformed NIH 3T3 cells poorly. Thus, distinct amino acids of Ras and Rap1A mediate sensitivity to each of the proteins with GAP activity, and transforming potential of Ras and sensitivity of Ras to Ras-GAP are at least partially independent properties.	CETUS CORP,EMERYVILLE,CA 94608		ZHANG, K (corresponding author), NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892, USA.							ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; DECLUE JE, 1991, MOL CELL BIOL, V11, P3132, DOI 10.1128/MCB.11.6.3132; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART PA, 1990, ONCOGENE, V5, P1099; HATA Y, 1990, J BIOL CHEM, V265, P7104; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MCCORMICK F, 1990, MOL CARCINOGEN, V3, P185, DOI 10.1002/mc.2940030404; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SRIVASTAVA SK, 1989, MOL CELL BIOL, V9, P1779, DOI 10.1128/MCB.9.4.1779; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210; Zhang K. Y., UNPUB	43	36	39	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1630	1634		10.1126/science.1749934	http://dx.doi.org/10.1126/science.1749934			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1749934				2022-12-01	WOS:A1991GV07300041
J	FARRAR, GJ; KENNA, P; JORDAN, SA; KUMARSINGH, R; HUMPHRIES, MM; SHARP, EM; SHEILS, DM; HUMPHRIES, P				FARRAR, GJ; KENNA, P; JORDAN, SA; KUMARSINGH, R; HUMPHRIES, MM; SHARP, EM; SHEILS, DM; HUMPHRIES, P			A 3-BASE-PAIR DELETION IN THE PERIPHERIN-RDS GENE IN ONE FORM OF RETINITIS-PIGMENTOSA	NATURE			English	Article							RHODOPSIN GENE; PREVALENCE; MUTATIONS	THE group of retinopathies termed retinitis pigmentosa (RP) greatly contribute to visual dysfunction in man with a frequency of roughly 1 in 4,000 (refs 1, 2). We mapped the first autosomal dominant RP (adRP) gene to chromosome 3q (refs 3, 4), close to the gene encoding rhodopsin, a rod photoreceptor pigment protein. Subsequently, mutations in this gene have been implicated as responsible for some forms of adRP 5-9. Another adRP gene has been mapped to chromosome 8p (ref. 10). A third adRP gene in a large Irish pedigree has been mapped to chromosome 6p (refs 11, 12), showing tight linkage with the gene for peripherin 13,14, a photoreceptor cell-specific glycoprotein, which is thus a strong candidate for the defective gene. We have now identified a three-base-pair deletion which results in the loss of one of a pair of highly conserved cysteine residues in the predicted third transmembrane domain of peripherin. This deletion segregates with the disease phenotype but is not present in unaffected controls, and suggests that mutant peripherin gives rise to retinitis pigmentosa.			FARRAR, GJ (corresponding author), UNIV DUBLIN TRINITY COLL,DEPT GENET,LINCOLN PL GATE,DUBLIN 2,IRELAND.		Farrar, G Jane/B-9832-2011; Bateson, Jane Farrar/AAO-6147-2020	Kumar-Singh, Rajendra/0000-0002-7754-0713	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLANTON SH, IN PRESS GENOMICS; BUNDEY S, 1984, J MED GENET, V21, P417, DOI 10.1136/jmg.21.6.417; BUNKER CH, 1984, AM J OPHTHALMOL, V97, P357, DOI 10.1016/0002-9394(84)90636-6; CONNELL G, 1991, P NATL ACAD SCI USA, V88, P723, DOI 10.1073/pnas.88.3.723; CONNELL GJ, 1990, BIOCHEMISTRY-US, V29, P4691, DOI 10.1021/bi00471a025; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; DRYJA TP, 1990, NEW ENGL J MED, V323, P1302, DOI 10.1056/NEJM199011083231903; FARRAR GJ, 1990, GENOMICS, V8, P35; FARRAR GJ, IN PRESS GENOMICS; INGLEHEARN CF, 1991, AM J HUM GENET, V48, P26; JORDAN SA, IN PRESS AM J HUM GE; MCWILLIAM P, 1989, GENOMICS, V5, P619, DOI 10.1016/0888-7543(89)90031-1; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; TRAVIS GH, 1991, GENOMICS, V10, P733, DOI 10.1016/0888-7543(91)90457-P; TRAVIS GH, 1989, NATURE, V338, P70, DOI 10.1038/338070a0	17	348	364	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1991	354	6353					478	480		10.1038/354478a0	http://dx.doi.org/10.1038/354478a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV078	1749427				2022-12-01	WOS:A1991GV07800060
J	KAJIWARA, K; HAHN, LB; MUKAI, S; TRAVIS, GH; BERSON, EL; DRYJA, TP				KAJIWARA, K; HAHN, LB; MUKAI, S; TRAVIS, GH; BERSON, EL; DRYJA, TP			MUTATIONS IN THE HUMAN RETINAL DEGENERATION SLOW GENE IN AUTOSOMAL DOMINANT RETINITIS-PIGMENTOSA	NATURE			English	Article							RHODOPSIN GENE; RDS; MICE	THE murine retinal degeneration slow (rds) gene is a semidominant mutation with a phenotype having rod and cone photoreceptors that develop abnormally and then slowly degenerate 1-3. The phenotype is a possible model for retinitis pigmentosa, one of the scores of hereditary human retinal degenerations, which is also characterized by photoreceptor degeneration. We report here three mutations of the human homologue of the rds gene (RDS) that cosegregate with autosomal dominant retinitis pigmentosa in separate families. Our results indicate that some cases of autosomal dominant retinitis pigmentosa are due to mutations at the RDS locus.	HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,HOWE LAB OPHTHALMOL,243 CHARLES ST,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BERMAN GUND LAB STUDY RETINAL DEGENERAT,BOSTON,MA 02114; UNIV TEXAS,SW MED CTR,DEPT PSYCHIAT,DALLAS,TX 75237	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	DRYJA, TP (corresponding author), HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,HOWE LAB OPHTHALMOL,243 CHARLES ST,BOSTON,MA 02114, USA.		Travis, Gabriel Harvey/AIF-1062-2022	Travis, Gabriel Harvey/0000-0003-4020-9493				BEGY C, 1990, NUCLEIC ACIDS RES, V18, P3058, DOI 10.1093/nar/18.10.3058; BERSON EL, 1976, T AM ACAD OPHTHALMOL, V81, P659; COHEN AI, 1983, INVEST OPHTH VIS SCI, V24, P832; CONNELL G, 1991, P NATL ACAD SCI USA, V88, P723, DOI 10.1073/pnas.88.3.723; CONNELL GJ, 1990, BIOCHEMISTRY-US, V29, P4691, DOI 10.1021/bi00471a025; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; DRYJA TP, 1990, NEW ENGL J MED, V323, P1302, DOI 10.1056/NEJM199011083231903; INGLEHEARN CF, 1991, AM J HUM GENET, V48, P26; KEEN TJ, 1991, GENOMICS, V11, P199, DOI 10.1016/0888-7543(91)90119-Y; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; REICHEL E, 1989, AM J OPHTHALMOL, V108, P540, DOI 10.1016/0002-9394(89)90431-5; SANYAL S, 1980, J COMP NEUROL, V194, P193, DOI 10.1002/cne.901940110; SHEFFIELD VC, 1991, AM J HUM GENET, V49, P699; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; TRAVIS GH, 1991, GENOMICS, V10, P733, DOI 10.1016/0888-7543(91)90457-P; TRAVIS GH, 1989, NATURE, V338, P70, DOI 10.1038/338070a0; TRAVIS GH, 1991, NEURON, V6, P61, DOI 10.1016/0896-6273(91)90122-G; VANNIE R, 1978, TISSUE ANTIGENS, V12, P106, DOI 10.1111/j.1399-0039.1978.tb01305.x; YANDELL DW, 1989, CANCER CEL, V7, P223	19	376	388	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1991	354	6353					480	483		10.1038/354480a0	http://dx.doi.org/10.1038/354480a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV078	1684223				2022-12-01	WOS:A1991GV07800061
J	KAY, GF; ASHWORTH, A; PENNY, GD; DUNLOP, M; SWIFT, S; BROCKDORFF, N; RASTAN, S				KAY, GF; ASHWORTH, A; PENNY, GD; DUNLOP, M; SWIFT, S; BROCKDORFF, N; RASTAN, S			A CANDIDATE SPERMATOGENESIS GENE ON THE MOUSE Y-CHROMOSOME IS HOMOLOGOUS TO UBIQUITIN-ACTIVATING ENZYME-E1	NATURE			English	Article							L-CELL DEFECT; X-CHROMOSOME; SEX DETERMINATION; DNA-REPLICATION; SHORT ARM; EXPRESSION; DIFFERENTIATION; COMPLEMENTS; CLONING; ANTIGEN	THE human X-linked gene A1S9 (refs 1-3) complements a temperature-sensitive cell-cycle mutation in mouse L cells 4, and encodes the ubiquitin-activating enzyme E1 (refs 5-7). The gene has been reported to escape X-chromosome inactivation 8, but there is some conflicting evidence 9. We have isolated part of the mouse A1s9 gene, mapped it to the proximal portion of the X chromosome and shown that it undergoes normal X-inactivation. We also detected two copies of the gene on the short arm of the mouse Y chromosome (A1s9Y-1 and A1s9Y-2). The functional A1s9Y gene (Als9Y-1) is expressed in testis and is lost in the deletion mutant Sxr(b) (ref. 10). Therefore A1s9Y-1 is a candidate for the spermatogenesis gene, Spy, which maps to this region. A1s9X is similar to the Zfx gene in undergoing X-inactivation 11,12, yet having homologous sequences on the short arm of the Y chromosome 13,14, which are expressed in the testis. These Y-linked genes may form part of a coregulated group of genes which function during spermatogenesis.	MRC,CLIN RES CTR,COMPARAT BIOL SECT,HARROW HA1 3UJ,MIDDX,ENGLAND; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Medical Research Council Clinical Trials Unit; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	RASTAN, S (corresponding author), MRC,CLIN RES CTR,COMPARAT BIOL SECT,HARROW HA1 3UJ,MIDDX,ENGLAND.		Kay, Graham F/A-4130-2011	Brockdorff, Neil/0000-0003-4838-2653				ADLER DA, 1991, P NATL ACAD SCI USA, V88, P4592, DOI 10.1073/pnas.88.11.4592; ASHWORTH A, 1991, NATURE, V351, P406, DOI 10.1038/351406a0; BISHOP CE, 1988, PHILOS T ROY SOC B, V322, P119, DOI 10.1098/rstb.1988.0119; BROCKDORFF N, 1991, GENOMICS, V10, P17, DOI 10.1016/0888-7543(91)90478-W; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROWN CJ, 1989, SOMAT CELL MOLEC GEN, V15, P173, DOI 10.1007/BF01535079; BROWN CJ, 1990, AM J HUM GENET, V46, P273; DAVISSON M T, 1987, Genomics, V1, P213, DOI 10.1016/0888-7543(87)90047-4; EVANS EP, 1982, NATURE, V300, P443, DOI 10.1038/300443a0; GOODFELLOW PN, 1988, DEVELOPMENT, V102, P251; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; KAY G, IN PRESS GENOMICS; KOOPMAN P, 1991, TRENDS GENET, V7, P132, DOI 10.1016/0168-9525(91)90458-3; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; MARDON G, 1989, SCIENCE, V243, P78, DOI 10.1126/science.2563173; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MCLAREN A, 1984, NATURE, V312, P552, DOI 10.1038/312552a0; MCLAREN A, 1988, TRENDS GENET, V4, P153, DOI 10.1016/0168-9525(88)90020-0; MCLAREN A, 1983, BRIT SOC DEV BIOL, P225; MONESI V, 1965, EXP CELL RES, V39, P197, DOI 10.1016/0014-4827(65)90023-6; NAGAMINE CM, 1989, SCIENCE, V243, P80, DOI 10.1126/science.2563174; REICHSTEINER M, 1988, UBUITIN; SIMPSON E, 1984, TRANSPLANTATION, V37, P17, DOI 10.1097/00007890-198401000-00007; SINGH L, 1982, CELL, V28, P205, DOI 10.1016/0092-8674(82)90338-5; SUTCLIFFE MJ, 1989, DEVELOPMENT, V107, P373; THOMPSON LH, 1970, P NATL ACAD SCI USA, V66, P377, DOI 10.1073/pnas.66.2.377; ZACKSENHAUS E, 1988, SOMAT CELL MOLEC GEN, V14, P371, DOI 10.1007/BF01534645; ZACKSENHAUS E, 1990, EMBO J, V9, P2923, DOI 10.1002/j.1460-2075.1990.tb07483.x; ZACKSENHAUS E, 1989, SOMAT CELL MOLEC GEN, V15, P545, DOI 10.1007/BF01534915	30	114	116	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1991	354	6353					486	489		10.1038/354486a0	http://dx.doi.org/10.1038/354486a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV078	1749428				2022-12-01	WOS:A1991GV07800063
J	LINGNER, J; KELLERMANN, J; KELLER, W				LINGNER, J; KELLERMANN, J; KELLER, W			CLONING AND EXPRESSION OF THE ESSENTIAL GENE FOR POLY(A) POLYMERASE FROM SACCHAROMYCES-CEREVISIAE	NATURE			English	Article							BINDING-PROTEIN; YEAST; IDENTIFICATION; SEQUENCE; INVITRO; MOTIFS	POLY(A) polymerase is essential for the maturation of messenger RNA, adding tracts of adenosine residues to the 3' end of precursor RNA generated by endonucleolytic cleavage. This mechanism of MRNA 3' processing seems to be similar in yeast and in higher eucaryotes 1, although there are differences in the recognition signals in the pre-mRNA 2. Here we describe the cloning of the gene for yeast poly(A) polymerase. The enzyme is encoded by a single and essential gene located near the centromere on the left arm of chromosome 11. Poly(A) polymerase purified from recombinant Escherichia coli has the same physical and biochemical properties as the yeast enzyme. The yeast poly(A) polymerase shares features of sequence with its mammalian homologue 3,4.	MAX PLANCK INST BIOCHEM, GENZENTRUM, W-8033 MARTINSRIED, GERMANY	Max Planck Society	LINGNER, J (corresponding author), UNIV BASEL, BIOZENTRUM, DEPT CELL BIOL, CH-4056 BASEL, SWITZERLAND.			Lingner, Joachim/0000-0002-2853-5803				ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BUTLER JS, 1988, SCIENCE, V242, P1270, DOI 10.1126/science.2848317; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Joyce CM, 1991, CURR OPIN STRUC BIOL, V1, P123, DOI 10.1016/0959-440X(91)90020-T; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; LAZCANO A, 1988, J MOL EVOL, V27, P365, DOI 10.1007/BF02101199; LINGNER J, 1991, J BIOL CHEM, V266, P8741; LUNDBLAD V, 1990, CELL, V60, P529; NASMYTH KA, 1980, CELL, V19, P753, DOI 10.1016/S0092-8674(80)80051-1; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1986, METHODS YEAST GENETI; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WAHLE E, IN PRESS EMBO J; YEH E, 1986, MOL CELL BIOL, V6, P158, DOI 10.1128/MCB.6.1.158; YEH E, 1991, NATURE, V349, P713, DOI 10.1038/349713a0	30	113	115	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 12	1991	354	6353					496	498		10.1038/354496a0	http://dx.doi.org/10.1038/354496a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV078	1840648				2022-12-01	WOS:A1991GV07800066
J	MCMURRY, MP; CERQUEIRA, MT; CONNOR, SL; CONNOR, WE				MCMURRY, MP; CERQUEIRA, MT; CONNOR, SL; CONNOR, WE			CHANGES IN LIPID AND LIPOPROTEIN LEVELS AND BODY-WEIGHT IN TARAHUMARA INDIANS AFTER CONSUMPTION OF AN AFFLUENT DIET	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PIMA-INDIANS; HDL CHOLESTEROL; PLASMA-LIPIDS; MEXICO; COUNTRIES; DISEASE; WOMEN; FOOD; FAT	Background. Major new public health problems occur in developing countries as they become more affluent and change their traditional dietary patterns. To study this phenomenon in microcosm, we substituted an "affluent" diet for the traditional diet of a group of Tarahumara Indians, a Mexican people known to consume a low-fat, high-fiber diet and to have a very low incidence of risk factors for coronary heart disease. Methods. Thirteen Tarahumara Indians (five women and eight men [including one adolescent]) consumed their traditional diet (2700 kcal per day) for one week, and were then fed a diet typical of affluent societies, which contained excessive calories (41 00 kcal per day), total fat, saturated fat, and cholesterol, for five weeks. Results. After five weeks of consuming the affluent diet, the subjects' mean (+/- SE) plasma cholesterol level increased by 31 percent, from 121 +/- 5 to 159 +/- 6 mg per deciliter (3.13 +/- 0.13 to 4.11 +/- 0.16 mmol per liter, P < 0.001). The increase in the plasma cholesterol level was primarily in the low-density lipoprotein (LDL) fraction, which rose 39 percent, from 72 +/- 3 to 100 +/- 4 mg per deciliter (1.86 +/- 0.08 to 2.59 +/- 0.10 mmol per liter, P < 0.001). High-density lipoprotein (HDL) cholesterol, usually low in this population, increased by 31 percent, from 32 +/- 2 to 42 +/- 3 mg per deciliter (0.83 +/- 0.05 to 1.09 +/- 0.08 mmol per liter). Consequently, the ratio of LDL to HDL levels changed little (2.25 with the base-line diet and 2.38 with the affluent diet). Plasma triglyceride levels increased by 18 percent, from 91 +/- 8 to 108 +/- 11 mg per deciliter (1.03 +/- 0.09 to 1.22 +/- 0.12 mmol per liter, P < 0.05), with a significant increase in the very-low-density lipoprotein triglyceride fraction. All the subjects gained weight, with a mean increase of 3.8 kg (7 percent). Conclusions. When Tarahumara Indians from a population with virtually no coronary risk factors consumed for a short time a hypercaloric diet typical of a more affluent society, they had dramatic increases in plasma lipid and lipoprotein levels and body weight. If sustained, such changes might increase their risk of coronary heart disease.	OREGON HLTH SCI UNIV, DEPT MED, CLIN NUTR & LIPID METAB SECT, L465, PORTLAND, OR 97201 USA	Oregon Health & Science University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040566] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00334] Funding Source: Medline; NHLBI NIH HHS [HL37940] Funding Source: Medline; NIDDK NIH HHS [DK40566] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOUCHARD C, 1990, NEW ENGL J MED, V322, P1477, DOI 10.1056/NEJM199005243222101; CERQUEIRA MT, 1979, AM J CLIN NUTR, V32, P905, DOI 10.1093/ajcn/32.4.905; CONNOR SE, 1986, NEW AM DIET; CONNOR SL, 1982, CIRCULATION, V65, P1290, DOI 10.1161/01.CIR.65.7.1290; CONNOR SL, 1989, J AM DIET ASSOC, V89, P807; CONNOR SL, 1989, J AM DIET ASSOC, V89, P1236; CONNOR WE, 1978, AM J CLIN NUTR, V31, P1131, DOI 10.1093/ajcn/31.7.1131; DODU SRA, 1988, CARDIOLOGY, V75, P56, DOI 10.1159/000174349; GROOM D, 1971, AM HEART J, V81, P304, DOI 10.1016/0002-8703(71)90099-8; Health. & N.R.C.U.C.o.D.a., 1989, DIET HLTH IMPLICATIO; HOWARD BV, 1983, CIRCULATION, V68, P714, DOI 10.1161/01.CIR.68.4.714; KASHIWAGI A, 1985, METABOLISM, V34, P364, DOI 10.1016/0026-0495(85)90226-4; KNUIMAN JT, 1980, ATHEROSCLEROSIS, V36, P529, DOI 10.1016/0021-9150(80)90245-2; MCMURRY MP, 1985, AM J CLIN NUTR, V41, P1289, DOI 10.1093/ajcn/41.6.1289; MCMURRY MP, 1982, AM J CLIN NUTR, V35, P741, DOI 10.1093/ajcn/35.4.741; MILLER DS, 1967, AM J CLIN NUTR, V20, P1212, DOI 10.1093/ajcn/20.11.1212; MILLER GJ, 1982, LANCET, V2, P1270; NORMAN J, 1976, NATL GEOGR, V149, P702; PISUNYER FX, 1988, MODERN NUTRITION HLT, P797; REID JM, 1971, AM J CLIN NUTR, V24, P1281; SAAD MF, 1988, NEW ENGL J MED, V319, P1500, DOI 10.1056/NEJM198812083192302; Sims E A, 1968, Trans Assoc Am Physicians, V81, P153; SOWERS MF, 1981, J AM DIET ASSOC, V79, P536; Trowell HC, 1981, W DIS THEIR EMERGENC; TROWELL HC, 1981, W DISEASES THEIR EME, P427; WEST KM, 1981, W DISEASES THEIR EME, P129; 1987, CLINFO REFERENCE MAN, V2; 1988, DHHS PHS8850210 DEP, P83; 1988, CIRCULATION, V77, pA721; 1974, DHEW NIH75628 PUBL, P1	30	76	77	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 12	1991	325	24					1704	1708		10.1056/NEJM199112123252405	http://dx.doi.org/10.1056/NEJM199112123252405			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU418	1944471				2022-12-01	WOS:A1991GU41800005
J	MITCHELL, MJ; WOODS, DR; TUCKER, PK; OPP, JS; BISHOP, CE				MITCHELL, MJ; WOODS, DR; TUCKER, PK; OPP, JS; BISHOP, CE			HOMOLOGY OF A CANDIDATE SPERMATOGENIC GENE FROM THE MOUSE Y-CHROMOSOME TO THE UBIQUITIN-ACTIVATING ENZYME-E1	NATURE			English	Article							SEX-DETERMINING REGION; L-CELL DEFECT; INSITU HYBRIDIZATION; DNA-REPLICATION; MICE; LOCALIZATION; EXPRESSION; ANTIGEN; DIFFERENTIATION; SEQUENCES	THE Sxr (sex-reversed) region, a fragment of the Y chromosome short arm, can cause chromosomally female XXSxr or XSxrO mice to develop as sterile males 1-3. The original Sxr region, termed Sxr(a), encodes: Tdy, the primary sex-determining gene; Hya, the controlling or structural locus for the minor transplantation antigen H-Y (ref. 4); gene(s) controlling the expression of the serologically detected male antigen (SDMA) 5; Spy, a gene(s) required for the survival and proliferation of A spermatogonia during spermatogenesis 6,7; Zfy-1/Zfy-2, zinc-finger-containing genes of unknown function 8; and Sry, which is probably identical to Tdy (ref. 9). A deletion variant 10 of Sxr(a), termed Sxr(b), which lacks Hya, SDMA expression, Spy and some Zfy-2 sequences, makes positional cloning of these genes possible. We report here the isolation of a new testis-specific gene, Sby, mapping to the DNA deleted from the Sxr(b) region (the DELTA-Sxr(b) interval). Sby has extensive homology to the X-linked human ubiquitin-activating enzyme E1 (ref. 11). The critical role of this enzyme in nuclear DNA replication 12 together with the testis-specific expression of Sby suggests Sby as a candidate for the spermatogenic gene Spy.	INST PASTEUR,INSERM,U276,UNITE IMMUNOGENET HUMAINE,PARIS 15,FRANCE; UNIV MICHIGAN,MUSEUM ZOOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT BIOL,ANN ARBOR,MI 48109	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	MITCHELL, MJ (corresponding author), UNIV TENNESSEE,DEPT OBSTET GYNECOL,DIV REPROD GENET,MOLEC GENET RES LAB,MEMPHIS,TN 38105, USA.		Mitchell, Michael/I-3987-2016	Mitchell, Michael/0000-0003-2052-7347				AMAR L C, 1988, Genomics, V2, P220, DOI 10.1016/0888-7543(88)90006-7; AVNER P, 1987, P NATL ACAD SCI USA, V84, P5330, DOI 10.1073/pnas.84.15.5330; BISHOP CE, 1987, DEVELOPMENT, V101, P167; BURGOYNE PS, 1986, NATURE, V320, P170, DOI 10.1038/320170a0; CATTANACH BM, 1971, CYTOGENETICS, V10, P318, DOI 10.1159/000130151; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROHMAN MA, 1990, PCR PROTOCOLS; GOLDBERG EH, IN PRESS J REPROD IM; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P7456; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; MARDON G, 1989, SCIENCE, V243, P78, DOI 10.1126/science.2563173; MAYER A, 1989, J BIOL CHEM, V264, P2060; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MCLAREN A, 1988, P NATL ACAD SCI USA, V85, P6442, DOI 10.1073/pnas.85.17.6442; MCLAREN A, 1984, NATURE, V312, P552, DOI 10.1038/312552a0; MITCHELL M, 1989, GENETICS, V121, P803; MITCHELL MJ, IN PRESS GENOMICS; ROBERTS C, 1988, P NATL ACAD SCI USA, V85, P6446, DOI 10.1073/pnas.85.17.6446; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMPSON E, 1984, TRANSPLANTATION, V37, P17, DOI 10.1097/00007890-198401000-00007; SIMPSON EM, 1991, GENOMICS, V11, P601, DOI 10.1016/0888-7543(91)90067-O; SUTCLIFFE MJ, 1989, DEVELOPMENT, V107, P373; TUCKER PK, IN PRESS MAMMALIAN G; ZABEL BU, 1983, P NATL ACAD SCI-BIOL, V80, P6932, DOI 10.1073/pnas.80.22.6932; ZACKSENHAUS E, 1990, CYTOGENET CELL GENET, V53, P20, DOI 10.1159/000132887; ZACKSENHAUS E, 1990, EMBO J, V9, P2923, DOI 10.1002/j.1460-2075.1990.tb07483.x	33	150	156	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1991	354	6353					483	486		10.1038/354483a0	http://dx.doi.org/10.1038/354483a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV078	1684224	Green Published			2022-12-01	WOS:A1991GV07800062
J	PHILLIPS, RE; ROWLANDJONES, S; NIXON, DF; GOTCH, FM; EDWARDS, JP; OGUNLESI, AO; ELVIN, JG; ROTHBARD, JA; BANGHAM, CRM; RIZZA, CR; MCMICHAEL, AJ				PHILLIPS, RE; ROWLANDJONES, S; NIXON, DF; GOTCH, FM; EDWARDS, JP; OGUNLESI, AO; ELVIN, JG; ROTHBARD, JA; BANGHAM, CRM; RIZZA, CR; MCMICHAEL, AJ			HUMAN-IMMUNODEFICIENCY-VIRUS GENETIC-VARIATION THAT CAN ESCAPE CYTOTOXIC T-CELL RECOGNITION	NATURE			English	Article							TOXIC LYMPHOCYTES-T; PERIPHERAL-BLOOD; INFECTED INDIVIDUALS; SEROPOSITIVE INDIVIDUALS; REVERSE-TRANSCRIPTASE; SYNTHETIC PEPTIDES; HOMOSEXUAL MEN; HIV-1; REPLICATION; SELECTION	In a longitudinal study of HIV seropositive patients, there were fluctuations in the specificity of cytotoxic T cells for the virus. This was matched by variability in proviral gag DNA epitope sequences in the lymphocytes of these patients. Some of these viral variants are not recognized by autologous T cells. Accumulation of such mutations in T-cell antigenic targets would provide a mechanism for immune escape.	IMMULOGIC, PALO ALTO, CA 94304 USA; CHURCHILL HOSP, OXFORD HAEMOPHILIA CTR, OXFORD OX3 7LV, ENGLAND		PHILLIPS, RE (corresponding author), UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, MOLEC IMMUNOL GRP, OXFORD OX3 9DU, ENGLAND.		Nixon, Douglas/AAU-5734-2020	Nixon, Douglas/0000-0002-2801-1786; Bangham, Charles/0000-0003-2624-3599	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BASTIN J, 1987, J EXP MED, V165, P1508, DOI 10.1084/jem.165.6.1508; BOLOGNESI DP, 1989, AIDS, V3, pS111, DOI 10.1097/00002030-198901001-00016; BRINCHMANN JE, 1990, J IMMUNOL, V144, P2961; BROLIDEN PA, 1989, CLIN EXP IMMUNOL, V76, P216; CARMAN WF, 1990, LANCET, V336, P325, DOI 10.1016/0140-6736(90)91874-A; CERUNDOLO V, 1991, P ROY SOC B-BIOL SCI, V244, P169, DOI 10.1098/rspb.1991.0066; DELVAL M, 1991, CELL, V66, P1145, DOI 10.1016/0092-8674(91)90037-Y; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; GOTCH FM, 1990, INT IMMUNOL, V2, P707, DOI 10.1093/intimm/2.8.707; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HOFFENBACH A, 1989, J IMMUNOL, V142, P452; HOSMALIN A, 1990, P NATL ACAD SCI USA, V87, P2344, DOI 10.1073/pnas.87.6.2344; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HUET S, 1990, INT IMMUNOL, V2, P311, DOI 10.1093/intimm/2.4.311; JOLY P, 1989, J IMMUNOL, V143, P2193; KABAT E, 1979, NIH802008 DHEW PUBL; KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H; KOENIG S, 1988, P NATL ACAD SCI USA, V85, P8638, DOI 10.1073/pnas.85.22.8638; KOUP RA, 1989, BLOOD, V73, P1909; Maniatis T., 1982, MOL CLONING; MCCUNE JM, 1991, CELL, V64, P351, DOI 10.1016/0092-8674(91)90644-E; MCKEATING JA, 1989, AIDS, V3, P777, DOI 10.1097/00002030-198912000-00001; MEYERHANS A, 1991, EUR J IMMUNOL, V21, P2637, DOI 10.1002/eji.1830211051; MYERS G, 1990, HUMAN RETROVIRUSES A; NIXON DF, 1990, AIDS, V4, P841, DOI 10.1097/00002030-199009000-00002; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; NOWAK MA, 1990, AIDS, V4, P1095, DOI 10.1097/00002030-199011000-00007; PANTALEO G, 1990, P NATL ACAD SCI USA, V87, P4818, DOI 10.1073/pnas.87.12.4818; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; REITZ MS, 1988, CELL, V54, P57, DOI 10.1016/0092-8674(88)90179-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SHEARER GM, 1984, J CLIN INVEST, V74, P496, DOI 10.1172/JCI111447; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; STEEL CM, 1988, LANCET, V1, P1185; TAKAHASHI H, 1989, SCIENCE, V246, P118, DOI 10.1126/science.2789433; TSUBOTA H, 1989, J EXP MED, V169, P1421, DOI 10.1084/jem.169.4.1421; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WALKER BD, 1988, SCIENCE, V240, P64, DOI 10.1126/science.2451288; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WEBER JN, 1987, LANCET, V1, P119, DOI 10.1016/S0140-6736(87)91964-7	43	959	972	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 12	1991	354	6353					453	459		10.1038/354453a0	http://dx.doi.org/10.1038/354453a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV078	1721107				2022-12-01	WOS:A1991GV07800051
J	ROUSSEAU, F; HEITZ, D; BIANCALANA, V; BLUMENFELD, S; KRETZ, C; BOUE, J; TOMMERUP, N; VANDERHAGEN, C; DELOZIERBLANCHET, C; CROQUETTE, MF; GILGENKRANTZ, S; JALBERT, P; VOELCKEL, MA; OBERLE, I; MANDEL, JL				ROUSSEAU, F; HEITZ, D; BIANCALANA, V; BLUMENFELD, S; KRETZ, C; BOUE, J; TOMMERUP, N; VANDERHAGEN, C; DELOZIERBLANCHET, C; CROQUETTE, MF; GILGENKRANTZ, S; JALBERT, P; VOELCKEL, MA; OBERLE, I; MANDEL, JL			DIRECT DIAGNOSIS BY DNA ANALYSIS OF THE FRAGILE X-SYNDROME OF MENTAL-RETARDATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INHERITANCE; EXPRESSION; CHROMOSOME	Background. The fragile X syndrome, the most common form of inherited mental retardation, is caused by mutations that increase the size of a specific DNA fragment of the X chromosome (in Xq27.3). Affected persons have both a full mutation and abnormal DNA methylation. Persons with a smaller increase in the size of this DNA fragment (a premutation) have little or no risk of retardation but are at high risk of having affected children or grandchildren. The passage from premutation to full-mutation status occurs only with transmission from the mother. We have devised a method of identifying carriers of these mutations by direct DNA analysis. Method. We studied 511 persons from 63 families with the fragile X syndrome. Mutations and abnormal methylation were detected by Southern blotting with a probe adjacent to the mutation target. Analysis of EcoRI and Eagl digests of DNA distinguished clearly in a single test between the normal genotype, the premutation, and the full mutation. Results. DNA analysis unambiguously established the genetic status at the fragile X locus for all samples tested. This method was much more powerful and reliable than cytogenetic testing or segregation studies with closely linked polymorphic markers. The frequency of mental retardation in persons with premutations was similar to that in the general population, whereas all 103 males and 31 of 59 females with full mutations had mental retardation. About 15 percent of those with full mutations had some cells carrying only the premutation. All the mothers of affected children were carriers of either a premutation or a full mutation. Conclusions. Direct diagnosis by DNA analysis is now an efficient and reliable primary test for the diagnosis of the fragile X syndrome after birth, as well as for prenatal diagnosis and genetic counseling.	FAC MED STRASBOURG, CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184, 11 RUE HUMANN, F-67085 STRASBOURG, FRANCE; INSERM, U73, F-75005 PARIS, FRANCE; ULLEVAL HOSP, DEPT MED GENET, OSLO 1, NORWAY; JF KENNEDY INST, GLOSTRUP, DENMARK; UNIV GENEVA, INST GENET MED, CH-1211 GENEVA 4, SWITZERLAND; HOP ST ANTOINE, LILLE, FRANCE; CTR TRANSFUS, VANDOEUVRE LES NANCY, FRANCE; CHR UNIV GRENOBLE, GRENOBLE, FRANCE; INSERM, U242, F-13258 MARSEILLE 09, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Oslo; University of Geneva; UDICE-French Research Universities; Sorbonne Universite; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm)			Tommerup, Niels/T-8776-2017	Tommerup, Niels/0000-0003-2304-0112				BUNDEY S, 1974, J MENT DEFIC RES, V18, P115; CRONISTER A, 1991, AM J MED GENET, V38, P503, DOI 10.1002/ajmg.1320380272; FRYNS JP, 1989, FRAGILE X SYNDROME, P1; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; JACKY PB, 1991, AM J MED GENET, V38, P400, DOI 10.1002/ajmg.1320380249; JENKINS EC, 1991, AM J MED GENET, V38, P447, DOI 10.1002/ajmg.1320380262; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LAIRD CD, 1990, AM J HUM GENET, V46, P696; LAIRD CD, 1987, GENETICS, V117, P587; LUBS HA, 1969, AM J HUM GENET, V21, P231; MIGEON BR, 1985, P NATL ACAD SCI USA, V82, P3390, DOI 10.1073/pnas.82.10.3390; NUSSBAUM RL, 1986, AM J MED GENET, V23, P715, DOI 10.1002/ajmg.1320230162; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PEMBREY ME, 1985, AM J MED GENET, V21, P709, DOI 10.1002/ajmg.1320210413; ROUSSEAU F, 1991, AM J HUM GENET, V48, P108; ROUSSEAU F, IN PRESS J MED GENET; SHERMAN SL, 1985, HUM GENET, V71, P184; SHERMAN SL, 1985, HUM GENET, V69, P289, DOI 10.1007/BF00291644; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; SUTHERLAND GR, 1977, SCIENCE, V197, P265, DOI 10.1126/science.877551; SUTHERS GK, 1991, AM J HUM GENET, V48, P460; TONIOLO D, 1988, EMBO J, V7, P401, DOI 10.1002/j.1460-2075.1988.tb02827.x; TURNER G, 1986, NEW ENGL J MED, V315, P607, DOI 10.1056/NEJM198609043151002; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; VOGEL F, 1990, HUM GENET, V86, P25; WEBB T, 1989, FRAGILE X SYNDROME, P40; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	28	572	583	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 12	1991	325	24					1673	1681		10.1056/NEJM199112123252401	http://dx.doi.org/10.1056/NEJM199112123252401			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU418	1944467				2022-12-01	WOS:A1991GU41800001
J	SMEAL, T; BINETRUY, B; MERCOLA, DA; BIRRER, M; KARIN, M				SMEAL, T; BINETRUY, B; MERCOLA, DA; BIRRER, M; KARIN, M			ONCOGENIC AND TRANSCRIPTIONAL COOPERATION WITH HA-RAS REQUIRES PHOSPHORYLATION OF C-JUN ON SERINE-63 AND SERINE-73	NATURE			English	Article							EXPRESSION; GENE; PEA1	RECENT advances indicate a link between tumour promoters, transformation, and AP-1 activity 1. Protein kinase C activation increases AP-1 DNA-binding activity independently of new protein synthesis 2,3. AP-1 is also stimulated by transforming oncoproteins and growth factors 4-6. These proteins are thought to participate in a signalling cascade affecting the nuclear AP-1 complex composed of the Jun and Fos proteins 1,7,8. Because c-Jun is the most potent transactivator in the AP-1 complex 9-12 and is elevated in Ha-ras-transformed cells, in which c-Fos is downregulated 13,14, we focused on it as a potential target. c-Jun could convert input from an oncogenic signalling cascade into changes in gene expression. Indeed, transformation of rat embryo fibroblasts by c-Jun requires an intact transcriptional activation domain 15 and cooperation with oncogenic Ha-ras 16. Expression of oncogenic Ha-ras augments transactivation by c-Jun and stimulates its phosphorylation 14. Here we describe the mapping of the Ha-ras-responsive phosphorylation sites to serines 63 and 73 of c-Jun. Site-directed mutagenesis indicates that phosphorylation of these serines is essential for stimulation of c-Jun activity and for cooperation with Ha-ras in ocogenic transformation.	UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; NCI, DIV CANC PREVENT & CONTROL, BETHESDA, MD 20814 USA; UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT PATHOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Diego; University of California System; University of California San Diego	KARIN, M (corresponding author), UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT PHARMACOL, LA JOLLA, CA 92093 USA.		Binetruy, Bernard/AFL-7188-2022; mercola, dan/L-4182-2013; Binetruy, Bernard/AAG-7139-2022; Binetruy, Bernard/A-6465-2009; Binetruy, Bernard/S-2062-2019	mercola, dan/0000-0002-0281-9840; Binetruy, Bernard/0000-0001-8012-7092				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ALANI R, IN PRESS MOL CELL BI; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BOYLE WJ, IN PRESS METH ENZYM; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KARIN M, 1990, MOL ASPECTS CELLULAR, V6, P143; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WEINBERG RA, 1989, CANCER RES, V49, P3713; YANG-YEN H-F, 1990, New Biologist, V2, P351	26	771	780	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 12	1991	354	6353					494	496		10.1038/354494a0	http://dx.doi.org/10.1038/354494a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV078	1749429				2022-12-01	WOS:A1991GV07800065
J	SUTHERLAND, GR; GEDEON, A; KORNMAN, L; DONNELLY, A; BYARD, RW; MULLEY, JC; KREMER, E; LYNCH, M; PRITCHARD, M; YU, S; RICHARDS, RI				SUTHERLAND, GR; GEDEON, A; KORNMAN, L; DONNELLY, A; BYARD, RW; MULLEY, JC; KREMER, E; LYNCH, M; PRITCHARD, M; YU, S; RICHARDS, RI			PRENATAL-DIAGNOSIS OF FRAGILE X-SYNDROME BY DIRECT DETECTION OF THE UNSTABLE DNA-SEQUENCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									QUEEN VICTORIA HOSP,ADELAIDE,AUSTRALIA; ADELAIDE CHILDRENS HOSP INC,DEPT HISTOPATHOL,ADELAIDE,SA 5006,AUSTRALIA		SUTHERLAND, GR (corresponding author), ADELAIDE CHILDRENS HOSP INC,DEPT CYTOGENET & MOLEC GENET,ADELAIDE,SA 5006,AUSTRALIA.		Sutherland, Grant Robert/D-2606-2012; Kremer, EJ/P-9838-2019; Kremer, Eric J/D-3734-2013; Richards, Robert/ABE-6423-2020; Gedeon, Agi/G-7890-2011	Kremer, EJ/0000-0001-6114-7530; Byard, Roger/0000-0002-0524-5942; Richards, Robert Ian/0000-0002-5978-6453				JENKINS EC, 1991, AM J MED GENET, V38, P447, DOI 10.1002/ajmg.1320380262; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PURVISSMITH SG, 1988, AM J MED GENET, V30, P337, DOI 10.1002/ajmg.1320300134; RICHARDS RI, 1991, AM J HUM GENET, V48, P1051; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; Sutherland G, 1985, FRAGILE SITES HUMAN; SUTHERLAND GR, 1990, CLIN GENET, V37, P2; SUTHERS GK, 1991, AM J HUM GENET, V48, P460; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	11	96	98	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 12	1991	325	24					1720	1722		10.1056/NEJM199112123252407	http://dx.doi.org/10.1056/NEJM199112123252407			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU418	1944473				2022-12-01	WOS:A1991GU41800007
J	TRENT, JD; NIMMESGERN, E; WALL, JS; HARTL, FU; HORWICH, AL				TRENT, JD; NIMMESGERN, E; WALL, JS; HARTL, FU; HORWICH, AL			A MOLECULAR CHAPERONE FROM A THERMOPHILIC ARCHAEBACTERIUM IS RELATED TO THE EUKARYOTIC PROTEIN T-COMPLEX POLYPEPTIDE-1	NATURE			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; HEAT-SHOCK; RIBULOSEBISPHOSPHATE-CARBOXYLASE; MITOCHONDRIAL PROTEIN; ATP HYDROLYSIS; GENE; CLONING; PURIFICATION; SEQUENCE	THERE is evidence to suggest that components of archaebacteria are evolutionarily related to cognates in the eukaryotic cytosol 1-7. We postulated that the major heat-shock protein of the thermophilic archaebacterium, Sulfolobus shibatae, is a molecular chaperone and that it is related to an as-yet unidentified chaperone component in the eukaryotic cytosol. Acquired thermotolerance in S. shibatae correlates with the predominant synthesis of this already abundant protein, referred to as thermophilic factor 55 (TF55; ref. 8). TF55 is a homo-oligomeric complex of two stacked 9-membered rings, closely resembling the 7-membered-ring complexes of the chaperonins, groEL, hsp60 and Rubisco-binding protein 9-15. The TF55 complex binds unfolded polypeptides in vitro and has ATPase activity-features consistent with its being a molecular chaperone 16,17. The primary structure of TF55, however, is not significantly related to the chaperonins. On the other hand, it is highly homologous (36-40% identity) to a ubiquitous eukaryotic protein, t-complex polypeptide-1 (TCP1; refs 18-20). In Saccharomyces cerevisiae, TCP1 is an essential protein that may play a part in mitotic spindle formation 21. We suggest that TF55 in archaebacteria and TCP1 in the eukaryotic cytosol are members of a new class of molecular chaperones.	YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; SLOAN KETTERING MEM CANC CTR,ROCKEFELLER RES LAB,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	Yale University; Memorial Sloan Kettering Cancer Center; United States Department of Energy (DOE); Brookhaven National Laboratory	TRENT, JD (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,333 CEDAR ST,NEW HAVEN,CT 06510, USA.		Hartl, F. Ulrich/Y-8206-2019					AHMAD S, 1990, BIOCHIM BIOPHYS ACTA, V1087, P253, DOI 10.1016/0167-4781(90)90214-M; AUER J, 1989, CAN J MICROBIOL, V35, P200, DOI 10.1139/m89-031; BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; CARAZO JM, 1991, J STRUCT BIOL, V106, P211, DOI 10.1016/1047-8477(91)90071-4; CAVALIERSMITH T, 1987, ANN NY ACAD SCI, V503, P17, DOI 10.1111/j.1749-6632.1987.tb40596.x; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; Dayhoff M., 1978, ATLAS PROTEIN SEQ S3, V5, P345; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; ELLIS RJ, 1991, REV BIOCH, V60, P327; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RJW, 1979, J MOL BIOL, V129, P359; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HORWICH A, 1980, J VIROL, V36, P125, DOI 10.1128/JVI.36.1.125-132.1980; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; LECHNER K, 1987, MOL GEN GENET, V208, P523, DOI 10.1007/BF00328150; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MUSGROVE JE, 1987, EUR J BIOCHEM, V163, P529, DOI 10.1111/j.1432-1033.1987.tb10900.x; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PELHAM HRB, 1989, EMBO J, V8, P3171, DOI 10.1002/j.1460-2075.1989.tb08475.x; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PHIPPS BM, 1991, EMBO J, V10, P1711, DOI 10.1002/j.1460-2075.1991.tb07695.x; PUSHKIN AV, 1982, BIOCHIM BIOPHYS ACTA, V704, P379, DOI 10.1016/0167-4838(82)90169-8; REITER WD, 1990, P NATL ACAD SCI USA, V87, P9509, DOI 10.1073/pnas.87.24.9509; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SEARCY DG, 1991, BIOSYSTEMS, V25, P1, DOI 10.1016/0303-2647(91)90008-9; SHINNICK TM, 1987, J BACTERIOL, V169, P1080, DOI 10.1128/jb.169.3.1080-1088.1987; SILVER LM, 1979, CELL, V17, P275, DOI 10.1016/0092-8674(79)90153-3; SILVER LM, 1987, DEV BIOL, V119, P605, DOI 10.1016/0012-1606(87)90063-7; TRENT JD, 1990, J BACTERIOL, V172, P1478, DOI 10.1128/jb.172.3.1478-1484.1990; URSIC D, 1988, GENE, V68, P267, DOI 10.1016/0378-1119(88)90029-7; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WALL JS, 1986, ANNU REV BIOPHYS BIO, V15, P355; WILLISON K, 1987, EMBO J, V6, P1967, DOI 10.1002/j.1460-2075.1987.tb02459.x; WILLISON K, 1989, CELL, V57, P621, DOI 10.1016/0092-8674(89)90131-1; WILLISON KR, 1986, CELL, V44, P727, DOI 10.1016/0092-8674(86)90839-1; ZILLIG W, 1989, ENDOCYT CELL RES, V6, P1; ZILLIG W, 1987, ANN NY ACAD SCI, V503, P78, DOI 10.1111/j.1749-6632.1987.tb40599.x	43	293	302	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1991	354	6353					490	493		10.1038/354490a0	http://dx.doi.org/10.1038/354490a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV078	1836250				2022-12-01	WOS:A1991GV07800064
J	FEIGHERY, E; ALTMAN, DG; SHAFFER, G				FEIGHERY, E; ALTMAN, DG; SHAFFER, G			THE EFFECTS OF COMBINING EDUCATION AND ENFORCEMENT TO REDUCE TOBACCO SALES TO MINORS - A STUDY OF 4 NORTHERN CALIFORNIA COMMUNITIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							YOUNG ADULTHOOD; DRUG-USE; PROGRESSION; ADOLESCENCE; CIGARETTES; PATTERNS; CHILDREN	Objective. - To examine the effects of a community education and law enforcement intervention on illegal tobacco sales to minors. Design. - A 2-year, before and after trial with retail stores as the unit of analysis. Setting. - Implementation occurred in four suburban California communities with populations of 25000 to 100000. Participants. - All the retail stores in one intervention community and half the retail stores, randomly selected, in the other three intervention communities (n = 169) were visited by minors aged 14 to 16 years with the intent to purchase tobacco. Intervention. - Ongoing community and merchant education and four law enforcement operations were conducted. Main Outcome Measures. - Over-the-counter and vending machine sales of tobacco to minors were the primary outcomes. Results. - Among a cohort of stores visited by minors at the pretest (n = 104) in June 1988, 71% sold tobacco over the counter and 92% sold tobacco through vending machines. At posttest 2 in May 1990, 24% sold tobacco over the counter and 93% sold tobacco through vending machines. Of the 31 stores issued citations, 16 were followed into the courts where the fines were dismissed or reduced. Conclusions. - Education alone had a limited effect on reducing illegal tobacco sales to minors. It did promote community support for more aggressive enforcement strategies. Education plus enforcement decreased significantly over-the-counter sales; vending machine sales were unaffected by these interventions. The lack of support at the judicial level may temper the effectiveness of enforcement. Legislative remedies addressing judicial obstacles and vending machine sales are needed.	N BAY HLTH RESOURCES CTR,PETALUMA,CA		FEIGHERY, E (corresponding author), STANFORD UNIV,MED CTR,SCH MED,CTR RES DIS PREVENT,1000 WELCH RD,STANFORD,CA 94305, USA.							ALTMAN DG, 1991, AM J PUBLIC HEALTH, V81, P891, DOI 10.2105/AJPH.81.7.891; ALTMAN DG, 1989, JAMA-J AM MED ASSOC, V261, P80, DOI 10.1001/jama.261.1.80; ASHLEY MJ, 1988, ANNU REV PUBL HEALTH, V9, P233; DIFRANZA JR, 1987, JAMA-J AM MED ASSOC, V257, P3387, DOI 10.1001/jama.257.24.3387; DIFRANZA JR, 1990, JAMA-J AM MED ASSOC, V263, P2784, DOI 10.1001/jama.263.20.2784; FLEMING R, 1989, ADDICT BEHAV, V14, P261, DOI 10.1016/0306-4603(89)90057-9; GREYDANUS DE, 1989, JAMA-J AM MED ASSOC, V261, P99, DOI 10.1001/jama.261.1.99; HOLDER HD, 1988, JAN I MED PAN OPP RE; HOLDER HD, 1987, ADV SUBST ABUSE S1, V1, P405; KIRN TF, 1987, JAMA-J AM MED ASSOC, V257, P3323; MILGRAM GG, 1986, HDB PREVENTION, P243; YAMAGUCHI K, 1984, AM J PUBLIC HEALTH, V74, P668, DOI 10.2105/AJPH.74.7.668; YAMAGUCHI K, 1984, AM J PUBLIC HEALTH, V74, P673, DOI 10.2105/AJPH.74.7.673; 1989, SURGEON GENERALS WOR; 1990, YOUTH ACCESS CIGARET; 1988, 888406 DEP HLTH HUM; 1990, TOBACCO USE CALIFORN	17	83	83	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 11	1991	266	22					3168	3171						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GT654	1956106				2022-12-01	WOS:A1991GT65400027
J	PIERCE, JP; GILPIN, E; BURNS, DM; WHALEN, E; ROSBROOK, B; SHOPLAND, D; JOHNSON, M				PIERCE, JP; GILPIN, E; BURNS, DM; WHALEN, E; ROSBROOK, B; SHOPLAND, D; JOHNSON, M			DOES TOBACCO ADVERTISING TARGET YOUNG-PEOPLE TO START SMOKING - EVIDENCE FROM CALIFORNIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; CIGARETTE-SMOKING; TRENDS	Objective. - To evaluate whether tobacco advertising encourages teenagers younger than 18 years to start smoking. Design. - Comparison of 1990 California telephone survey data with data from a 1986 national telephone survey (both used a random-digit dialing system); 95% confidence intervals were calculated. To test our hypothesis, we considered whether the perception of advertising was related to age, whether the pattern of market share across age and sex groups followed the pattern of perceived advertising, and whether changes in market share paralleled changes in advertising as perceived by the youngest age group. Participants. - There were 24296 adults and 5040 teenagers. Results. - The most advertised brands of cigarettes were Marlboro, according to 33.6% of adults and 41.8% of teenagers, and Camel, according to 13.7% of adults and 28.5% of teenagers-named most often by 12- to 13-year-olds (34.2%). The brands that were purchased most often were Marlboro and Camel. Together these were the brands of choice of 79.9% of males and 85% of females aged 12 through 17 years. Marlboro's market share increased in youths and young adults up to age 24 years and then decreased gradually with age; Camel's market share decreased abruptly with age: it was the brand of choice of 24.5% +/- 5.8% of males aged 12 through 17 years but was chosen by only 12.7% +/- 3.6% of males aged 18 through 24 years; for females, 21.7% +/- 13.7% aged 12 through 17 years chose Camels, while only 5.5% +/- 3.2% aged 18 through 24 years preferred this brand. Both Marlboro and Camel brands had a higher market share in California in 1990 compared with that for the United States in 1986. Of interest is that the market share for Camel increased among the younger smokers but was more evenly distributed for Marlboro. Conclusions. - Perception of advertising is higher among young smokers; market-share patterns across age and sex groups follow the perceived advertising patterns; and changes in market share resulting from advertising occur mainly in younger smokers. Cigarette advertising encourages youth to smoke and should be banned.	CALIF DEPT HLTH SERV,TOBACCO CONTROL SECT,SACRAMENTO,CA; NCI,BETHESDA,MD 20892	California Department of Health Care Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	PIERCE, JP (corresponding author), UNIV CALIF SAN DIEGO,POPULAT STUDIES CANC PREVENT,2251 SAN DIEGO AVE,SUITE B-111,SAN DIEGO,CA 92110, USA.			Pierce, John/0000-0002-0075-7471				BIRD L, 1991, ADWEEKS MARKETI 0520, P20; BLUM A, 1991, NEW ENGL J MED, V324, P913, DOI 10.1056/NEJM199103283241310; CHAPMAN S, 1989, BRIT J ADDICT, V84, P1267; CHAPMAN S, 1982, AM J PUBLIC HEALTH, V72, P491, DOI 10.2105/AJPH.72.5.491; DAVIS RM, 1987, NEW ENGL J MED, V316, P725, DOI 10.1056/NEJM198703193161206; DOOLITTLE DE, 1991, TOBACCO REP      FEB, P14; Efron B., 1982, JACKKNIFE BOOTSTRAP; FIORE MC, 1989, JAMA-J AM MED ASSOC, V261, P49, DOI 10.1001/jama.261.1.49; GOAD GP, 1991, WALL ST J       0729; GRISOM TE, 1991, WASHINGTON POST 0601, P21; HATZIANDREU EJ, 1990, J NATL CANCER I, V82, P1402, DOI 10.1093/jnci/82.17.1402; KLINTZNER M, 1991, BR J ADDICT, V86, P287; PIERCE JP, 1991, J NATL CANCER I, V83, P1009, DOI 10.1093/jnci/83.14.1009; PIERCE JP, 1990, MED J AUSTRALIA, V152, P113, DOI 10.5694/j.1326-5377.1990.tb125114.x; PIERCE JP, 1989, JAMA-J AM MED ASSOC, V261, P56, DOI 10.1001/jama.261.1.56; PIERCE JP, 1990, SMOKING CESSATION OR; RAFTERY J, 1989, BRIT J ADDICT, V84, P1241; Tye J B, 1987, J Public Health Policy, V8, P492, DOI 10.2307/3342275; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WARNER KE, 1989, AM J PUBLIC HEALTH, V79, P144, DOI 10.2105/AJPH.79.2.144; WATERSON MJ, 1982, ADVERTISING CIGARETT; 1986, TOBACCO USE 1986 MET; 1988, CDC888406 DEP HLTH H; 1989, CDC898411 DEP HLTH H; 1986, NIH862687 DEP HLTH H; 1990, MMWR, V39, P261	26	197	200	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 11	1991	266	22					3154	3158		10.1001/jama.266.22.3154	http://dx.doi.org/10.1001/jama.266.22.3154			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GT654	1956103				2022-12-01	WOS:A1991GT65400024
J	BALARAJAN, R; RALEIGH, VS; YUEN, P; WHEELER, D; MACHIN, D; CARTWRIGHT, R				BALARAJAN, R; RALEIGH, VS; YUEN, P; WHEELER, D; MACHIN, D; CARTWRIGHT, R			HEALTH RISKS ASSOCIATED WITH BATHING IN SEA-WATER	BRITISH MEDICAL JOURNAL			English	Article									PUBL HLTH LAB SERV,GUILDFORD,ENGLAND		BALARAJAN, R (corresponding author), UNIV SURREY,INST PUBL HLTH,GUILDFORD GU2 5XH,SURREY,ENGLAND.			Wheeler, David/0000-0002-4058-7286				EYKIN SJ, 1988, BMJ, V296, P1484; 1990, HLTH RISKS ASS BATHI; 1990, 4TH HOUS COMM ENV CO; 1976, OFFICIAL J EURO 0205	4	48	51	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1991	303	6815					1444	1445		10.1136/bmj.303.6815.1444	http://dx.doi.org/10.1136/bmj.303.6815.1444			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU385	1773151	Bronze, Green Published			2022-12-01	WOS:A1991GU38500026
J	HAUSMANN, N; RICHARD, G				HAUSMANN, N; RICHARD, G			EFFECT OF HIGH-DOSE STEROID BOLUS ON OCCLUSION OF OCULAR CENTRAL ARTERY - ANGIOGRAPHIC STUDY	BRITISH MEDICAL JOURNAL			English	Article									UNIV MAINZ,DEPT OPHTHALMOL,W-6500 MAINZ,GERMANY	Johannes Gutenberg University of Mainz	HAUSMANN, N (corresponding author), LANDESKRANKENHAUS FELDKIRCH,DEPT OPHTHALMOL,A-6807 FELDKIRCH,AUSTRIA.							BRAUGHLER JM, 1985, J NEUROSURG, V62, P805; HAYREH SS, 1980, BRIT J OPHTHALMOL, V64, P818, DOI 10.1136/bjo.64.11.818; MAGARGAL LE, 1977, SURG FORUM, V28, P518; NEUBAUER H, 1962, Klin Monbl Augenheilkd Augenarztl Fortbild, V141, P70; RICHARD G, 1989, FLUORESZENZANGIOGRAP, P19	5	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1991	303	6815					1445	1446		10.1136/bmj.303.6815.1445	http://dx.doi.org/10.1136/bmj.303.6815.1445			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU385	1773152	Bronze, Green Published			2022-12-01	WOS:A1991GU38500027
J	KISERUD, T; EIKNES, SH; BLAAS, HGK; HELLEVIK, LR				KISERUD, T; EIKNES, SH; BLAAS, HGK; HELLEVIK, LR			ULTRASONOGRAPHIC VELOCIMETRY OF THE FETAL DUCTUS VENOSUS	LANCET			English	Article							PHYSIOLOGY; ANATOMY; LIVER; BLOOD; FLOWS; LAMBS	In fetal lambs, the ductus venosus shunts well-oxygenated blood directly to the heart, a pattern expected to be found also in the human fetus. We aimed to describe the human ductus venosus in a longitudinal sonographic study of two-dimensional imaging, colour flow mapping, and pulsed doppler velocimetry every 3-4 weeks during the second half of pregnancy. The fetuses of 29 healthy women were studied. The ductus venosus and its blood flow were identified and recorded for later analysis that included maximum velocity tracing. In the 184 examinations analysed, the ductus venosus appeared as a narrow vessel projecting a high-velocity jet posteriorly to reach the foramen ovale. The mean peak velocity in the ductus venosus increased from 65 cm/s in week 18 to 75 cm/s at term. Low values of the time-averaged maximum velocity were found in 2 fetuses with cardiovascular abnormalities (1 supraventricular tachycardia, 1 congestive heart failure), as a result of reversed flow in the ductus venosus during atrial systole. The high peak velocity in the ductus venosus, which is comparable with arterial velocities, probably gives the blood sufficient momentum to reach the foramen ovale without extensive mixing with deoxygenated blood. Velocimetry of the ductus venosus carries new diagnostic possibilities.			KISERUD, T (corresponding author), TRONDHEIM REG & UNIV HOSP,DEPT GYNECOL & OBSTET,NATL CTR FETAL DIAG & THERAPY,N-7006 TRONDHEIM,NORWAY.			Kiserud, Torvid/0000-0003-1825-1660				BARCLAY AE, 1942, BRIT J RADIOL, V15, P66; Barclay AE, 1944, FOETAL CIRCULATION C; Barcroft J., 1946, RESEARCHES PRENATAL; BEHRMAN RE, 1970, AM J OBSTET GYNECOL, V108, P956, DOI 10.1016/0002-9378(70)90341-8; CHAKO AW, 1953, ANAT REC, V115, P151; CHAMPETIER J, 1989, SURG RADIOL ANAT, V11, P53, DOI 10.1007/BF02102248; CHINN DH, 1982, RADIOLOGY, V144, P153, DOI 10.1148/radiology.144.1.7089248; DAWES GS, 1984, AM J OBSTET GYNECOL, V84, P1634; Dawes GS, 1968, FETAL NEONATAL PHYSL; EDELSTONE D I, 1980, Journal of Developmental Physiology (Eynsham), V2, P219; EDELSTONE DI, 1978, CIRC RES, V42, P426, DOI 10.1161/01.RES.42.3.426; EDELSTONE DI, 1979, AM J PHYSIOL, V237, pH724, DOI 10.1152/ajpheart.1979.237.6.H724; EIKNES SH, 1981, RECENT ADV PRENATAL, P113; GUDMUNDSSON S, 1991, AM J OBSTET GYNECOL, V164, P33, DOI 10.1016/0002-9378(91)90618-2; MEYER WW, 1966, ARCH DIS CHILD, V41, P597, DOI 10.1136/adc.41.220.597; NICOLINI U, 1989, AM J OBSTET GYNECOL, V160, P1139, DOI 10.1016/0002-9378(89)90176-2; REED KL, 1990, CIRCULATION, V81, P498, DOI 10.1161/01.CIR.81.2.498; STAUDACH A, 1987, SECTIONAL FETAL ANAT; WEINER CP, 1989, AM J OBSTET GYNECOL, V161, P714, DOI 10.1016/0002-9378(89)90387-6	19	199	215	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1991	338	8780					1412	1414		10.1016/0140-6736(91)92720-M	http://dx.doi.org/10.1016/0140-6736(91)92720-M			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT904	1683418				2022-12-01	WOS:A1991GT90400002
J	LEE, JA; LEE, HA; SADLER, PJ				LEE, JA; LEE, HA; SADLER, PJ			UREMIA - IS UREA MORE IMPORTANT THAN WE THINK	LANCET			English	Note							TRIMETHYLAMINE; ANTIDIURESIS; OSMOLYTES; KIDNEY; HUMANS	Urea is accumulated as an osmolyte by some groups of animals even though it impairs protein function. These organisms can withstand high internal urea concentrations because they also accumulate other low-molecular-weight osmolytes, the methylamines, which can offset the effects of urea on proteins. Methylamines have also been found in the medulla of the mammalian kidney (where urea concentrations are high) and in the plasma of human subjects with chronic renal failure. These findings suggest that previous investigations of the potential contribution of urea to the syndrome of uraemia may have been confounded because of the presence of variable concentrations of protective substances. That naturally occurring methylamines or related substances may prove to have a useful therapeutic role in uraemia is also possible.	ST MARYS HOSP,DEPT RENAL MED,PORTSMOUTH PO3 6AQ,HANTS,ENGLAND; UNIV LONDON BIRKBECK COLL,DEPT CHEM,CHRISTOPHER INGOLD LABS & GORDON HOUSE,LONDON WC1E 7HX,ENGLAND	University of London; Birkbeck University London	LEE, JA (corresponding author), UNIV NEWCASTLE UPON TYNE,ROYAL VICTORIA INFIRM,DEPT PATHOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							ALWAIZ M, 1987, CLIN PHARMACOL THER, V42, P608, DOI 10.1038/clpt.1987.207; ALWAIZ M, 1987, CLIN PHARMACOL THER, V42, P588, DOI 10.1038/clpt.1987.201; BAGNASCO S, 1986, J BIOL CHEM, V261, P5872; BALABAN RS, 1987, KIDNEY INT, V31, P562, DOI 10.1038/ki.1987.36; BALABAN RS, 1983, AM J PHYSIOL, V245, pC438; BARSOTTI G, 1989, NUTR TREATMENT CHRON, P33; BATES JR, 1986, MAGNETIC RESONANCE M, V3, P849; BECK F, 1984, KIDNEY INT, V25, P397, DOI 10.1038/ki.1984.30; BELL JD, 1991, MAGN RESON MED, V17, P414, DOI 10.1002/mrm.1910170213; BELL JD, 1991, BIOCHIM BIOPHYS ACTA, V1096, P101, DOI 10.1016/0925-4439(91)90046-C; Bollman JL, 1927, P SOC EXP BIOL MED, V24, P923; BONAVENTURA J, 1974, SCIENCE, V186, P57, DOI 10.1126/science.186.4158.57; BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104; BROWN JCC, 1989, MAGNET RESON MED, V11, P193, DOI 10.1002/mrm.1910110207; CHAMBERLIN ME, 1989, AM J PHYSIOL, V257, pC159, DOI 10.1152/ajpcell.1989.257.2.C159; DAVIES SEC, 1988, CLIN CHIM ACTA, V178, P241, DOI 10.1016/0009-8981(88)90232-X; DIAMOND JR, 1990, AM J PHYSIOL, V258, pF1, DOI 10.1152/ajprenal.1990.258.1.F1; GILBOE DD, 1964, P SOC EXP BIOL MED, V115, P633; GUTMAN Y, 1971, BIOCHIM BIOPHYS ACTA, V233, P133, DOI 10.1016/0005-2736(71)90365-8; HUTCHINGS RH, 1966, ANN INTERN MED, V65, P275, DOI 10.7326/0003-4819-65-2-275; KNOCHEL JP, 1976, KIDNEY, P1448; MERRILL JP, 1953, AM J MED, V14, P519; SILIGARDI G, IN PRESS INT J PEPTI; Somero G. N., 1986, NEWS PHYSIOL SCI, V1, P9; SOMERO GN, 1986, AM J PHYSIOL, V251, pR197, DOI 10.1152/ajpregu.1986.251.2.R197; WILLS MR, 1978, METABOLIC CONSEQUENC; YANCEY PH, 1989, AM J PHYSIOL, V257, pF602, DOI 10.1152/ajprenal.1989.257.4.F602; YANCEY PH, 1979, BIOCHEM J, V183, P317, DOI 10.1042/bj1830317; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	29	25	26	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1991	338	8780					1438	1440		10.1016/0140-6736(91)92733-I	http://dx.doi.org/10.1016/0140-6736(91)92733-I			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT904	1683430				2022-12-01	WOS:A1991GT90400014
J	SEAGROATT, V; TAN, HS; GOLDACRE, M; BULSTRODE, C; NUGENT, I; GILL, L				SEAGROATT, V; TAN, HS; GOLDACRE, M; BULSTRODE, C; NUGENT, I; GILL, L			ELECTIVE TOTAL HIP-REPLACEMENT - INCIDENCE, EMERGENCY READMISSION RATE, AND POSTOPERATIVE MORTALITY	BRITISH MEDICAL JOURNAL			English	Article							PRIVATE SECTOR; SURGERY; ENGLAND; WALES	Objectives - To report the incidence of elective total hip replacement and postoperative mortality, emergency readmission rates, and the demographic factors associated with these rates in a large defined population. Design - Analysis of linked, routine abstracts of hospital inpatient records and death certificates. Setting - 10 hospitals in six districts in Oxford Regional Health Authority covered by the Oxford record linkage study. Subjects - Records for 11607 total hip replacements performed electively in 1976-85. Main outcome measures - Incidence of operation, postoperative mortality, relative mortality ratios, and incidence of emergency readmission. Results - NHS operation rates increased over time from 43 to 58 operations/100 000 population. Variation in operation rates between districts reduced over time. Operation rates were on average 25% higher in women than men. There were 93 deaths (11/1000 operations) within 90 days of the operation and 208 emergency readmissions (28/1000 operations) within 28 days of discharge. Postoperative mortality and emergency readmission rates increased with age. No significant trend with time was found. Mortality in the 90 days after the operation was 2.5-fold higher (1.9 to 3.0) than in the rest of the first postoperative year. This represented an estimated excess of 6.5 (4.2 to 8.8) early postoperative deaths/1000 operations. Most deaths were ascribed to cardiovascular events. Thromboembolic disease was the commonest reason for emergency readmission. Conclusions - The pronounced increase in operations in districts with initially low rates suggests a trend towards greater equity in the local provision of NHS hip arthroplasty. The early postoperative clusters of deaths attributed to cardiovascular disease and of readmissions for thromboembolic disease suggest that there is scope for investigating ways of reducing the incidence of major adverse postoperative events.	NUFFIELD ORTHOPAED CTR,NUFFIELD DEPT ORTHOPAED SURG,OXFORD OX3 7LD,ENGLAND	Nuffield Orthopaedic Centre	SEAGROATT, V (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,CLIN EPIDEMIOL UNIT,OXFORD OX3 7LF,ENGLAND.							BAKER RJ, 1978, GLIM SYSTEM; BRADY LP, 1986, CLIN ORTHOP RELAT R, V211, P51; CHANDLER HP, 1981, J BONE JOINT SURG AM, V63, P1426, DOI 10.2106/00004623-198163090-00008; CHARNLEY J, 1975, CLIN ORTHOP RELAT R, V111, P105; CORNELL CN, 1986, J BONE JOINT SURG AM, V68A, P1430, DOI 10.2106/00004623-198668090-00017; DORR LD, 1983, J BONE JOINT SURG AM, V65, P474, DOI 10.2106/00004623-198365040-00007; FRANKEL W, 1991, 2 U BRIST REP; Gustilo R B, 1982, Hip, P27; HENDERSON J, 1989, BRIT MED J, V299, P709, DOI 10.1136/bmj.299.6701.709; LASSEN MR, 1991, LANCET, P618; NICHOLL JP, 1989, BRIT MED J, V298, P243, DOI 10.1136/bmj.298.6668.243; NICHOLL JP, 1984, LANCET, V2, P89; RANAWAT CS, 1984, J BONE JOINT SURG AM, V66A, P745, DOI 10.2106/00004623-198466050-00014; SALVATI EA, 1981, J BONE JOINT SURG AM, V63, P753, DOI 10.2106/00004623-198163050-00010; TERAYAMA K, 1986, CLIN ORTHOP RELAT R, V211, P79; WELCH RB, 1988, ORTHOP CLIN N AM, V19, P551; WROBLEWSKI BM, 1986, CLIN ORTHOP RELAT R, V201, P37; [No title captured]; 1975, CLASSIFICATION SURGI; HOSPITAL PATIENT ENQ; [No title captured]	21	175	179	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1991	303	6815					1431	1435		10.1136/bmj.303.6815.1431	http://dx.doi.org/10.1136/bmj.303.6815.1431			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU385	1773147	Bronze, Green Published			2022-12-01	WOS:A1991GU38500021
J	SZCZEPURA, AK; FLETCHER, J; FITZPATRICK, JD				SZCZEPURA, AK; FLETCHER, J; FITZPATRICK, JD			COST-EFFECTIVENESS OF MAGNETIC-RESONANCE-IMAGING IN THE NEUROSCIENCES	BRITISH MEDICAL JOURNAL			English	Article							TECHNOLOGY	Objectives - To measure, in a service setting, the effect of magnetic resonance imaging on diagnosis, diagnostic certainty, and patient management in the neurosciences; to measure the cost per patient scanned; to estimate the marginal cost of imaging and compare this with its diagnostic impact; to measure changes in patients' quality of life; and to record the diagnostic pathway leading to magnetic resonance imaging. Design - Controlled observational study using questionnaires on diagnosis and patient management before and after imaging. Detailed costing study. Quality of life questionnaires at the time of imaging and six months later. Diagnostic pathways extracted from medical records for a representative sample. Setting - Regional superconducting 1.5 T magnetic resonance service. Subjects - 782 consecutive neuroscience patients referred by consultants for magnetic resonance imaging during June 1988-9; diagnostic pathways recorded for 158 cases. Main outcome measures - Costs of magnetic resonance imaging and preliminary investigations; changes in planned management and resulting savings; changes in principal diagnosis and diagnostic certainty; changes in patients' quality of life. Results - Average cost of magnetic resonance imaging was estimated at 206.20 pounds/patient (throughput 2250 patients/year, 1989-90 prices including contrast and upgrading). Before magnetic resonance imaging diagnostic procedures cost 164.40 pounds/patient (including inpatient stays). Management changed after imaging in 208 (27%) cases; saving an estimated 80.90 pounds/patient. Confidence in planned management increased in a further 226 (29%) referrals. Consultants' principal diagnosis changed in 159 of 782 (20%) referrals; marginal cost Per diagnostic change was 626 pounds. Confidence in diagnosis increased in 236 (30%) referrals. No improvement in patients' quality of life at six month assessment. Conclusions - Any improvement in diagnosis with magnetic resonance imaging is achieved at a higher cost. Techniques for monitoring the cost effectiveness of this technology need to be developed.	WALSGRAVE GEN HOSP,COVENTRY CV2 2DX,ENGLAND		SZCZEPURA, AK (corresponding author), UNIV WARWICK,WARWICK BUSINESS SCH RES BUREAU,HLTH SERV RES UNIT,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND.			Szczepura, Ala/0000-0001-6244-9872				BOGATAY LM, 1987, HOSP TOP, V39, P12; BYDDER GM, 1988, BRIT J RADIOL, V61, P889, DOI 10.1259/0007-1285-61-730-889; CHERRYMAN GR, 1985, BRIT MED J, V291, P1437, DOI 10.1136/bmj.291.6506.1437; COOPER LS, 1988, JAMA-J AM MED ASSOC, V259, P3277, DOI 10.1001/jama.259.22.3277; DIXON AK, 1991, BMJ, V3302, P78; DURICK AA, 1988, RADIOL TECHNOL, V59, P239; EVENS RG, 1988, RADIOLOGY, V166, P27, DOI 10.1148/radiology.166.1.3336692; EVENS RG, 1991, AM J ROENTGENOL, V157, P603, DOI 10.2214/ajr.157.3.1872246; FINEBERG HV, 1977, JAMA-J AM MED ASSOC, V238, P224, DOI 10.1001/jama.238.3.224; GUDEX C, 1988, 38 U YORK CTR HLTH E; KENT DL, 1988, ANN INTERN MED, V108, P759, DOI 10.7326/0003-4819-108-5-759; KENT DL, 1988, ANN INTERN MED, V108, P402, DOI 10.7326/0003-4819-108-3-402; Larson E B, 1989, Int J Technol Assess Health Care, V5, P195; Pribyl S, 1988, Appl Radiol, V17, P29; ROBERTS H, 1990, 33 PUBL FIN F DISC P; ROSSER R, 1983, HLTH INDICATORS; SCHERSTEN T, 1985, INT J TECHNOL ASSESS, V1; SCHUMAN WP, 1988, AJR, V151, P857; STILWELL JA, 1984, BRIT J RADIOL, V57, P647, DOI 10.1259/0007-1285-57-679-647; SZCZEPURA AK, 1988, SOC SCI MED, V26, P715, DOI 10.1016/0277-9536(88)90063-9; SZCZEPURA AK, 1991, 1 BUS SCH HLTH SERV; SZCZEPURA AK, 1990, VALUE USE BACTERIOLO; 1990, MRI ASSESSMENT PROGR; 1988, HLTH TECHNOLOGY, V2, P3; 1990, EC EVALUATION CLIN A; 1988, MRI ASSESSMENT PROGR; 1989, HLTH PERSONAL SOCIAL; 1986, MAGNET RESON MED, V6, P1; 1990, MAGNETIC RESONANCE I; 1989, MRI ASSESSMENT PROGR; 1988, ANN INTERN MED, V108, P474; 1985, DHSS141 DEP HLTH SOC	32	30	30	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1991	303	6815					1435	1439		10.1136/bmj.303.6815.1435	http://dx.doi.org/10.1136/bmj.303.6815.1435			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU385	1819260	Bronze, Green Published			2022-12-01	WOS:A1991GU38500022
J	BARR, E; LEIDEN, JM				BARR, E; LEIDEN, JM			SYSTEMIC DELIVERY OF RECOMBINANT PROTEINS BY GENETICALLY MODIFIED MYOBLASTS	SCIENCE			English	Article							MEDIATED GENE-TRANSFER; HUMAN ADENOSINE-DEAMINASE; TROPONIN-C GENE; HUMAN FACTOR-IX; HEMOPHILIA-B; BONE-MARROW; STEM-CELLS; EXPRESSION; MUSCLE; TRANSPLANTATION	The ability to stably deliver recombinant proteins to the systemic circulation would facilitate the treatment of a variety of acquired and inherited diseases. To explore the feasibility of the use of genetically engineered myoblasts as a recombinant protein delivery system, stable transfectants of the murine C2C12 myoblast cell line were produced that synthesize and secrete high levels of human growth hormone (hGH) in vitro. Mice injected with hGH-transfected myoblasts had significant levels of hGH in both muscle and serum that were stable for at least 3 weeks after injection. Histological examination of muscles injected with beta-galactosidase-expressing C2C12 myoblasts demonstrated that many of the injected cells had fused to form multinucleated myotubes. Thus, genetically engineered myoblasts can bc used for the stable delivery of recombinant proteins into the circulation.	UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042718] Funding Source: NIH RePORTER; NIDDK NIH HHS [1 P01 DK42718-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARMENTANO D, 1990, P NATL ACAD SCI USA, V87, P6141, DOI 10.1073/pnas.87.16.6141; BARR E, UNPUB; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; CULVER K, 1991, P NATL ACAD SCI USA, V88, P3155, DOI 10.1073/pnas.88.8.3155; DZIERZAK EA, 1988, NATURE, V331, P35, DOI 10.1038/331035a0; EVANS WS, 1987, AM J PHYSIOL, V252, pE549, DOI 10.1152/ajpendo.1987.252.4.E549; FAVIA A, 1989, J CLIN ENDOCR METAB, V68, P535; FLOWERS MED, 1990, P NATL ACAD SCI USA, V87, P2349, DOI 10.1073/pnas.87.6.2349; HOLL RW, 1991, J CLIN ENDOCR METAB, V72, P854, DOI 10.1210/jcem-72-4-854; HUGHES SM, 1990, NATURE, V345, P350, DOI 10.1038/345350a0; KALEKO M, 1990, BLOOD, V75, P1733; KARPATI G, 1989, AM J PATHOL, V135, P27; LAW PK, 1988, MUSCLE NERVE, V11, P525, DOI 10.1002/mus.880110602; LIN H, 1990, CIRCULATION, V82, P2217, DOI 10.1161/01.CIR.82.6.2217; Mammen E F, 1983, Semin Thromb Hemost, V9, P1, DOI 10.1055/s-2007-1004999; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; PALMER TD, 1989, BLOOD, V73, P438; PARMACEK MS, 1990, J BIOL CHEM, V265, P15970; PARMACEK MS, 1989, J BIOL CHEM, V264, P13217; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; PONDER KP, 1991, P NATL ACAD SCI USA, V88, P1217, DOI 10.1073/pnas.88.4.1217; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; RUDMAN D, 1981, NEW ENGL J MED, V305, P123, DOI 10.1056/NEJM198107163050302; SCHARFMANN R, 1991, P NATL ACAD SCI USA, V88, P4626, DOI 10.1073/pnas.88.11.4626; SCHIFFRIN A, 1982, DIABETES, V31, P255, DOI 10.2337/diabetes.31.3.255; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P439, DOI 10.1073/pnas.87.1.439; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	29	272	324	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1991	254	5037					1507	1509		10.1126/science.1962212	http://dx.doi.org/10.1126/science.1962212			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT903	1962212				2022-12-01	WOS:A1991GT90300040
J	DHAWAN, J; PAN, LC; PAVLATH, GK; TRAVIS, MA; LANCTOT, AM; BLAU, HM				DHAWAN, J; PAN, LC; PAVLATH, GK; TRAVIS, MA; LANCTOT, AM; BLAU, HM			SYSTEMIC DELIVERY OF HUMAN GROWTH-HORMONE BY INJECTION OF GENETICALLY ENGINEERED MYOBLASTS	SCIENCE			English	Article							DIRECT GENE-TRANSFER; THERAPY; EXPRESSION; INVIVO; CELLS; MICE; DNA; IMPLANTATION; DYSTROPHIN; PROGRESS	A recombinant gene encoding human growth hormone (hGH) was stably introduced into cultured myoblasts with a retroviral vector. After injection of genetically engineered myoblasts into mouse muscle, hGH could be detected in serum for 3 months. The fate of injected myoblasts was assessed by coinfecting the cells with two retroviral vectors, one encoding hGH and the other encoding beta-galactosidase from Escherichia coli. These results provide evidence that myoblasts, which can fuse into preexisting multinucleated myofibers that are vascularized and innervated, may be advantageous as vehicles for systemic delivery of recombinant proteins.	STANFORD UNIV, MED CTR, SCH MED, DEPT PHARMACOL, STANFORD, CA 94305 USA	Stanford University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG009521, R01AG009521] Funding Source: NIH RePORTER; NIA NIH HHS [AG-09521] Funding Source: Medline; NICHD NIH HHS [HD-18179] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACSADI G, 1991, NATURE, V352, P815, DOI 10.1038/352815a0; ALFORD FP, 1973, J CLIN ENDOCR METAB, V37, P515, DOI 10.1210/jcem-37-4-515; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; FAUSTMAN D, 1991, SCIENCE, V252, P1700, DOI 10.1126/science.1710828; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; GARVER RI, 1987, SCIENCE, V237, P762, DOI 10.1126/science.3497452; GUSSONI E, UNPUB; Hughes S., UNPUB; HUGHES SM, 1990, NATURE, V345, P350, DOI 10.1038/345350a0; KAPLAN SL, 1986, LANCET, V1, P697; KARPATI G, 1989, AM J PATHOL, V135, P27; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; LIN H, 1990, CIRCULATION, V82, P2217, DOI 10.1161/01.CIR.82.6.2217; LINDAHL A, 1990, INT CONGR SER, V925, P383; MILLER AD, 1990, BLOOD, V76, P271; MILLER SC, 1988, GENE DEV, V2, P330, DOI 10.1101/gad.2.3.330; MORGAN JE, 1990, J CELL BIOL, V111, P2437, DOI 10.1083/jcb.111.6.2437; MORGAN JR, 1987, SCIENCE, V237, P1476; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; PALMER TD, 1991, P NATL ACAD SCI USA, V88, P1330, DOI 10.1073/pnas.88.4.1330; PAN L, UNPUB; PARTRIDGE TA, 1991, NATURE, V352, P757, DOI 10.1038/352757a0; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; PARTRIDGE TA, 1988, J CELL BIOCHEM     S, V12, P331; PAVLATH GK, UNPUB; PEETERS S, 1977, ENDOCRINOLOGY, V101, P1164, DOI 10.1210/endo-101-4-1164; PETERSON CA, 1990, CELL, V62, P493, DOI 10.1016/0092-8674(90)90014-6; ROEDERER M, 1991, Methods (Orlando), V2, P248, DOI 10.1016/S1046-2023(05)80067-2; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; SCHARFMANN R, 1991, P NATL ACAD SCI USA, V88, P4626, DOI 10.1073/pnas.88.11.4626; SELDEN RF, 1987, SCIENCE, V236, P714, DOI 10.1126/science.3472348; SHIZURU JA, 1987, SCIENCE, V237, P278, DOI 10.1126/science.2955518; STLOUIS D, 1988, P NATL ACAD SCI USA, V85, P3150; TASSIN AM, 1985, J CELL BIOL, V101, P630, DOI 10.1083/jcb.101.2.630; TEUMER J, 1990, FASEB J, V4, P3245, DOI 10.1096/fasebj.4.14.2227214; WEBSTER C, 1988, EXP CELL RES, V174, P252, DOI 10.1016/0014-4827(88)90159-0; WEBSTER C, 1990, SOMAT CELL MOLEC GEN, V16, P557, DOI 10.1007/BF01233096; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0	44	328	382	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 6	1991	254	5037					1509	1512		10.1126/science.1962213	http://dx.doi.org/10.1126/science.1962213			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT903	1962213				2022-12-01	WOS:A1991GT90300041
J	FERRIN, LJ; CAMERINIOTERO, RD				FERRIN, LJ; CAMERINIOTERO, RD			SELECTIVE CLEAVAGE OF HUMAN DNA - RECA-ASSISTED RESTRICTION ENDONUCLEASE (RARE) CLEAVAGE	SCIENCE			English	Article							TRIPLE-HELIX FORMATION; SITE-SPECIFIC CLEAVAGE; CYSTIC-FIBROSIS GENE; ESCHERICHIA-COLI; PROTEIN; SEQUENCES; IDENTIFICATION; PURIFICATION; CHROMOSOME; DUPLEX	Current methods for sequence-specific cleavage of large segments of DNA are severely limited because of the paucity of possible cleavage sites. A method is described whereby any Eco RI site can be targeted for specific cleavage. The technique is based on the ability of RecA protein from Escherichia coli to pair an oligonucleotide to its homologous sequence in duplex DNA and to form a three-stranded complex. This complex is protected from Eco RI methylase; after methylation and RecA protein removal, Eco RI restriction enzyme cleavage was limited to the site previously protected from methylation. When pairs of oligonucleotides are used, a specific fragment can be cleaved out of genomes. The method was tested on lambda-phage, Escherichia coli, and human DNA. Fragments exceeding 500 kilobases in length and yields exceeding 80 percent could be obtained.	NIDDKD,GENET & BIOCHEM BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; COX MM, 1981, J BIOL CHEM, V256, P4676; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; DANIELS DL, 1983, LAMBDA, V2, P519; FERRIN LJ, UNPUB; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; HSIEH P, 1990, GENE DEV, V4, P1951, DOI 10.1101/gad.4.11.1951; HSIEH P, 1989, J BIOL CHEM, V264, P5089; HSIEH PL, UNPUB; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOOB M, 1990, SCIENCE, V250, P271, DOI 10.1126/science.2218529; KOWALCZYKOWSKI SC, UNPUB; MCCLELLAND M, 1987, METHOD ENZYMOL, V155, P22; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; PEI DH, 1990, P NATL ACAD SCI USA, V87, P9858, DOI 10.1073/pnas.87.24.9858; RAO BJ, 1991, P NATL ACAD SCI USA, V88, P2984, DOI 10.1073/pnas.88.8.2984; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; RUDD KE, 1990, NUCLEIC ACIDS RES, V18, P313, DOI 10.1093/nar/18.2.313; STROBEL SA, 1991, NATURE, V350, P172, DOI 10.1038/350172a0; UHLIN BE, 1981, J BACTERIOL, V148, P386, DOI 10.1128/JB.148.1.386-390.1981; WILSON WW, 1990, ANAL BIOCHEM, V191, P370, DOI 10.1016/0003-2697(90)90234-Z; ZIELENSKI J, 1991, GENOMICS, V10, P214, DOI 10.1016/0888-7543(91)90503-7	23	199	232	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1991	254	5037					1494	1497		10.1126/science.1962209	http://dx.doi.org/10.1126/science.1962209			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT903	1962209				2022-12-01	WOS:A1991GT90300036
J	KNAUS, UG; HEYWORTH, PG; EVANS, T; CURNUTTE, JT; BOKOCH, GM				KNAUS, UG; HEYWORTH, PG; EVANS, T; CURNUTTE, JT; BOKOCH, GM			REGULATION OF PHAGOCYTE OXYGEN RADICAL PRODUCTION BY THE GTP-BINDING PROTEIN RAC-2	SCIENCE			English	Article							RESPIRATORY BURST OXIDASE; CELL-FREE SYSTEM; CHRONIC GRANULOMATOUS-DISEASE; NEUTROPHIL NADPH OXIDASE; GUANINE-NUCLEOTIDES; CYTOSOLIC FACTOR; PLASMA-MEMBRANE; ACTIVATION; IDENTIFICATION; ASSOCIATION	A major action of the microbicidal system of human neutrophils is the formation of superoxide anion (O2-) by a multicomponent oxidase that transfers electrons from the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) to molecular oxygen. The mechanism of assembly and activation of the oxidase from its cytosolic and membrane-bound components is unknown, but may require the activity of a guanosine 5'-triphosphate (GTP)-binding component A cytosolic GTP-binding protein (G(ox)) that regulates the NADPH oxidase of neutrophils was identified. G(ox) was purified and shown to augment the rate of O2- production in a cell-free oxidase activation system. Sequence analysis of peptide fragments from G(ox) identified it as Rac 2, a member of the Ras superfamily of GTP-binding proteins. Antibody to a peptide derived from the COOH-terminus of Rac 2 inhibited O2- generation in a concentration-dependent manner. These results suggest that Rac 2 is a regulatory component of the human neutrophil NADPH oxidase, and provide new insights into the mechanism by which this oxygen radical-generating system is regulated.	Scripps Res Inst, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; GENENTECH INC, DEPT CELL BIOL, S SAN FRANCISCO, CA 94080 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Roche Holding; Genentech; Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48008] Funding Source: Medline; NIAID NIH HHS [AI24838] Funding Source: Medline; NIGMS NIH HHS [GM39434] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BADWEY JA, 1982, BIOCHEM BIOPH RES CO, V106, P170, DOI 10.1016/0006-291X(82)92073-3; BOKOCH GM, 1988, FEBS LETT, V227, P66, DOI 10.1016/0014-5793(88)81415-7; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; BOKOCH GM, UNPUB; BOKOCH GM, IN PRESS J CLIN INVE; BOKOCH GM, IN PRESS SCIENCE; BOLSCHER BGJM, 1990, J BIOL CHEM, V265, P15782; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CHESA PG, 1987, P NATL ACAD SCI USA, V84, P3234, DOI 10.1073/pnas.84.10.3234; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CURNUTTE JT, 1989, P NATL ACAD SCI USA, V86, P825, DOI 10.1073/pnas.86.3.825; CURNUTTE JT, 1988, HEMATOL ONCOL CLIN N, V2, P241, DOI 10.1016/S0889-8588(18)30618-X; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; CURNUTTE JT, 1987, J BIOL CHEM, V262, P6450; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; GABIG TG, 1987, J BIOL CHEM, V262, P1685; GABIG TG, 1990, J IMMUNOL, V145, P945; KNAUS UG, UNPUB; LIGETI E, 1988, BIOCHEMISTRY-US, V27, P193, DOI 10.1021/bi00401a029; LIGETI E, 1989, BIOCHEMISTRY-US, V28, P7116, DOI 10.1021/bi00443a050; PEVERI P, 1989, BLOOD, V74, pA107; PEVERI P, UNPUB; POLAKIS PG, 1989, BIOCHEM BIOPH RES CO, V160, P25, DOI 10.1016/0006-291X(89)91615-X; QUILLIAM LA, 1989, FEBS LETT, V247, P221, DOI 10.1016/0014-5793(89)81339-0; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; SEIFERT R, 1986, FEBS LETT, V205, P161, DOI 10.1016/0014-5793(86)80886-9; SMITH RM, 1991, BLOOD, V77, P673	31	608	621	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1991	254	5037					1512	1515		10.1126/science.1660188	http://dx.doi.org/10.1126/science.1660188			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT903	1660188				2022-12-01	WOS:A1991GT90300042
J	LISTERUD, M; BRUSSAARD, AB; DEVAY, P; COLMAN, DR; ROLE, LW				LISTERUD, M; BRUSSAARD, AB; DEVAY, P; COLMAN, DR; ROLE, LW			FUNCTIONAL CONTRIBUTION OF NEURONAL ACHR SUBUNITS REVEALED BY ANTISENSE OLIGONUCLEOTIDES	SCIENCE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS	Although multiple related genes encoding nicotinic acetylcholine receptor (AChR) subunits have been identified, how each of these subunits contributes to AChRs in neurons is not known. Sympathetic neurons express four classes of AChR channels and six AChR subunit genes (alpha-3, alpha-4, alpha-5, alpha-7, beta-2, and beta-4). The contribution of individual subunits to AChR channel subtypes in these neurons was examined by selective deletion with antisense oligonucleotides. An alpha-3 antisense oligonucleotide decreased the number and altered the properties of the normally expressed ACh-activated channels. The remaining AChR channels have distinct biophysical and pharmacological properties that indicate an important functional contribution of the alpha-7 subunit.	COLUMBIA UNIV COLL PHYS & SURG,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University			Role, LW/Q-7371-2018	Role, LW/0000-0001-5851-212X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029071, P01NS027680, P50NS027680] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS029071-16, R01 NS029071, R01 NS029071-14, R01 NS029071-11, R01 NS029071-13, R01 NS029071-10, R01 NS029071-15, R01 NS029071-12, NS 29071, R01 NS029071-17, R01 NS029071-09, R01 NS029071-13S1, NS27680] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BOYD RT, 1988, NEURON, V1, P495; BRUSSAARD A, UNPUB; COUTURIER S, 1990, J BIOL CHEM, V265, P17560; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DENERIS ES, 1991, TRENDS PHARMACOL SCI, V12, P34, DOI 10.1016/0165-6147(91)90486-C; GARDETTE R, 1991, DEV BIOL, V147, P83, DOI 10.1016/S0012-1606(05)80009-0; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; LEPRINCE P, 1983, BIOCHEMISTRY-US, V22, P5551, DOI 10.1021/bi00293a015; LUETJE CW, 1991, J NEUROSCI, V11, P837; MOSS BL, 1989, NEURON, V3, P597, DOI 10.1016/0896-6273(89)90270-5; PAPKE RL, 1989, NEURON, V3, P589, DOI 10.1016/0896-6273(89)90269-9; Sambrook J., 1989, MOL CLONING LAB MANU; SCHOEPFER R, 1989, FEBS LETT, V257, P393, DOI 10.1016/0014-5793(89)81580-7; SILMAN I, 1969, SCIENCE, V164, P1420, DOI 10.1126/science.164.3886.1420; SNEDECOR GW, 1967, STATISTICAL METHODS, P329; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001	17	164	165	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1991	254	5037					1518	1521		10.1126/science.1720573	http://dx.doi.org/10.1126/science.1720573			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT903	1720573	Green Accepted			2022-12-01	WOS:A1991GT90300044
J	MCFALLNGAI, MJ; RUBY, EG				MCFALLNGAI, MJ; RUBY, EG			SYMBIONT RECOGNITION AND SUBSEQUENT MORPHOGENESIS AS EARLY EVENTS IN AN ANIMAL-BACTERIAL MUTUALISM	SCIENCE			English	Article							EUPRYMNA-SCOLOPES; SQUID	Bacterial colonization of the developing tight organ of the squid Euprymna scolopes is shown to be highly specific, with the establishment of a successful association resulting only when the juvenile host is exposed to seawater containing one of a subset of Vibrio fischeri strains. Before a symbiotic infection the organ has elaborate epithelial structures covered with cilia and microvilli that are involved in the transfer of bacteria to the incipient symbiotic tissue. These structures regressed within days following infection; however, they were retained in uninfected animals, suggesting that the initiation of symbiosis influences, and is perhaps a prerequisite for, the normal developmental program of the juvenile host.			MCFALLNGAI, MJ (corresponding author), UNIV SO CALIF,DEPT BIOL SCI,LOS ANGELES,CA 90089, USA.							ARNOLD J M, 1972, Veliger, V14, P361; BLAKE PA, 1980, ANNU REV MICROBIOL, V34, P341, DOI 10.1146/annurev.mi.34.100180.002013; BOETTCHER KJ, 1990, J BACTERIOL, V172, P3701, DOI 10.1128/jb.172.7.3701-3706.1990; FINLAY BB, 1989, MICROBIOL REV, V53, P210, DOI 10.1128/MMBR.53.2.210-230.1989; FUKASAWA S, 1986, AGR BIOL CHEM TOKYO, V50, P1645, DOI 10.1080/00021369.1986.10867623; GILTURNES MS, 1989, SCIENCE, V246, P116, DOI 10.1126/science.2781297; GORDON HA, 1971, BACTERIOL REV, V35, P390, DOI 10.1128/MMBR.35.4.390-429.1971; HACKETT KJ, 1986, SCIENCE, V232, P1253, DOI 10.1126/science.232.4755.1253; HALVERSON LJ, 1986, MICROBIOL REV, V50, P193, DOI 10.1128/MMBR.50.2.193-225.1986; HASTINGS JW, 1987, SYMBIOSIS, V4, P3; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; LEE K-H, 1991, Abstracts of the General Meeting of the American Society for Microbiology, V91, P194; LONG SR, 1989, CELL, V56, P203, DOI 10.1016/0092-8674(89)90893-3; MCFALLNGAI M, 1990, BIOL BULL, V179, P332, DOI 10.2307/1542325; MCFALLNGAI MJ, 1990, ENDOCYTOBIOLOGY, V4, P319; MCFALLNGAI MJ, UNPUB; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; Nealson KH, 1978, METHOD ENZYMOL, V57, P153; NESIS KN, 1982, CEPHALOPODS WORLD, P70; REICHELT JL, 1977, ARCH MICROBIOL, V112, P157, DOI 10.1007/BF00429329; ROLFE BG, 1988, ANNU REV PLANT PHYS, V39, P297, DOI 10.1146/annurev.arplant.39.1.297; SAKAZAKI R, 1981, PROKARYOTES, V2, pCH103; WEI SL, 1989, MAR BIOL, V103, P541, DOI 10.1007/BF00399586	23	249	254	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1991	254	5037					1491	1493		10.1126/science.1962208	http://dx.doi.org/10.1126/science.1962208			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT903	1962208				2022-12-01	WOS:A1991GT90300035
J	NIELSEN, PE; EGHOLM, M; BERG, RH; BUCHARDT, O				NIELSEN, PE; EGHOLM, M; BERG, RH; BUCHARDT, O			SEQUENCE-SELECTIVE RECOGNITION OF DNA BY STRAND DISPLACEMENT WITH A THYMINE-SUBSTITUTED POLYAMIDE	SCIENCE			English	Article							TRIPLE-HELIX FORMATION; SITE-SPECIFIC CLEAVAGE; DUPLEX DNA; INTERCALATING AGENTS; MAJOR GROOVE; BINDING; PROTEIN; MOTIF; INHIBITION; COMPLEX	A polyamide nucleic acid (PNA) was designed by detaching the deoxyribose phosphate backbone of DNA in a computer model and replacing it with an achiral polyamide backbone. On the basis of this model, oligomers consisting of thymine-linked aminoethylglycyl units were prepared. These oligomers recognize their complementary target in double-stranded DNA by strand displacement The displacement is made possible by the extraordinarily high stability of the PNA-DNA hybrids. The results show that the backbone of DNA can be replaced by a polyamide, with the resulting oligomer retaining base-specific hybridization.	HC ORSTED INST,DEPT ORGAN CHEM,DK-2100 COPENHAGEN 0,DENMARK; RISO NATL LAB,DEPT MAT,POLYMER GRP,DK-4000 ROSKILDE,DENMARK	University of Copenhagen; Technical University of Denmark	NIELSEN, PE (corresponding author), PANUM INST,DEPT BIOCHEM B,MED BIOTECHNOL RES CTR,BLEGDAMSVEJ 3C,DK-2200 COPENHAGEN N,DENMARK.		Berg, Rolf H/C-6339-2009	/0000-0001-8771-330X				BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BIRG F, 1990, NUCLEIC ACIDS RES, V18, P2901, DOI 10.1093/nar/18.10.2901; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; DERVAN PB, 1986, SCIENCE, V232, P464, DOI 10.1126/science.2421408; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; EBRIGHT RH, 1990, P NATL ACAD SCI USA, V87, P2882, DOI 10.1073/pnas.87.8.2882; FEDOROVA OS, 1988, FEBS LETT, V228, P273, DOI 10.1016/0014-5793(88)80014-0; FRANCOIS JC, 1988, NUCLEIC ACIDS RES, V16, P11431, DOI 10.1093/nar/16.24.11431; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; GUERON M, 1987, NATURE, V328, P89, DOI 10.1038/328089a0; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HORNE DA, 1990, J AM CHEM SOC, V112, P2435, DOI 10.1021/ja00162a063; JEPPESEN C, 1989, EUR J BIOCHEM, V182, P437, DOI 10.1111/j.1432-1033.1989.tb14850.x; JEPPESEN C, 1989, NUCLEIC ACIDS RES, V17, P4947, DOI 10.1093/nar/17.13.4947; MACK DP, 1990, J AM CHEM SOC, V112, P4604, DOI 10.1021/ja00167a102; MACK DP, 1988, J AM CHEM SOC, V110, P7572, DOI 10.1021/ja00230a067; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; NIELSEN PE, 1991, BIOCONJUGATE CHEM, V2, P1, DOI 10.1021/bc00007a001; NIELSEN PE, 1989, BIOCHEMISTRY-US, V27, P6338; OLLIS DL, 1987, CHEM REV, V87, P981, DOI 10.1021/cr00081a006; PEI D, 1990, J AM CHEM SOC, V112, P4579, DOI 10.1021/ja00167a085; SAUER RT, 1990, NATURE, V347, P514, DOI 10.1038/347514b0; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; SLUKA JP, 1987, SCIENCE, V238, P1129, DOI 10.1126/science.3120311; STROBEL SA, 1990, SCIENCE, V249, P73, DOI 10.1126/science.2195655; SUN JS, 1989, P NATL ACAD SCI USA, V86, P9198, DOI 10.1073/pnas.86.23.9198; WAKELIN LPG, 1990, J MED CHEM, V33, P2039, DOI 10.1021/jm00169a039; [No title captured]	29	2709	3846	16	381	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1991	254	5037					1497	1500		10.1126/science.1962210	http://dx.doi.org/10.1126/science.1962210			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT903	1962210				2022-12-01	WOS:A1991GT90300037
J	OLNEY, JW; LABRUYERE, J; WANG, G; WOZNIAK, DF; PRICE, MT; SESMA, MA				OLNEY, JW; LABRUYERE, J; WANG, G; WOZNIAK, DF; PRICE, MT; SESMA, MA			NMDA ANTAGONIST NEUROTOXICITY - MECHANISM AND PREVENTION	SCIENCE			English	Article							CEREBROCORTICAL NEURONS; KETAMINE; PHENCYCLIDINE; DIAZEPAM	Antagonists of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor, including phencyclidine (PCP) and ketamine, protect against brain damage in neurological disorders such as stroke. However, these agents have psychotomimetic properties in humans and morphologically damage neurons in the cerebral cortex of rats. It is now shown that the morphological damage can be prevented by certain anticholinergic drugs or by diazepam and barbiturates, which act at the gamma-aminobutyric acid (GABA) receptor-channel complex and are known to suppress the psychotomimetic symptoms caused by ketamine. Thus, it may be possible to prevent the unwanted side effects of NMDA antagonists, thereby enhancing their utility as neuroprotective drugs.	UNIV MISSOURI,SCH OPTOMETRY,ST LOUIS,MO 63110	University of Missouri System; University of Missouri Saint Louis	OLNEY, JW (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110, USA.				NIA NIH HHS [AG 05681] Funding Source: Medline; NIDA NIH HHS [DA 53568] Funding Source: Medline; NIMH NIH HHS [MH 38894] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P50AG005681] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKAIKE N, 1987, J PHYSIOL-LONDON, V394, P85, DOI 10.1113/jphysiol.1987.sp016861; ALLEN HL, 1990, SCIENCE, V247, P221, DOI 10.1126/science.2403696; AYIM EN, 1976, E AFR MED J, V53, P377; Burke R E, 1986, Mov Disord, V1, P135, DOI 10.1002/mds.870010208; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COPPEL DL, 1973, ANAESTHESIA, V28, P293, DOI 10.1111/j.1365-2044.1973.tb00449.x; FREEDMAN SB, 1988, EUR J PHARMACOL, V156, P133, DOI 10.1016/0014-2999(88)90155-0; KORTTILA K, 1978, ACTA ANAESTH SCAND, V22, P640, DOI 10.1111/j.1399-6576.1978.tb01348.x; LABRUYERE J, 1989, Society for Neuroscience Abstracts, V15, P761; LEVITAN ES, 1988, NEURON, V1, P773, DOI 10.1016/0896-6273(88)90125-0; MACDONALD RL, 1978, SCIENCE, V200, P775, DOI 10.1126/science.205953; MAGBAGBEOLA JA, 1974, CAN ANAESTH SOC J, V21, P321, DOI 10.1007/BF03005737; MARSHALL BE, 1990, GOODMAN GILMANS PHAR, P307; OLNEY J, UNPUB; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLNEY JW, 1989, BIOL PSYCHIAT, V26, P505, DOI 10.1016/0006-3223(89)90072-3; OLNEY JW, 1986, NEUROSCI LETT, V68, P29, DOI 10.1016/0304-3940(86)90224-7; OLNEY JW, 1988, EXCITATORY AMINO ACI, P337; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th; REICH DL, 1989, CAN J ANAESTH, V36, P186, DOI 10.1007/BF03011442; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; SESMA MA, IN PRESS SOC NEUR AB; SHARP J W, 1990, Society for Neuroscience Abstracts, V16, P1122; STUDY RE, 1981, P NATL ACAD SCI-BIOL, V78, P7180, DOI 10.1073/pnas.78.11.7180; ZORUMSKI CF, 1991, AM J PSYCHIAT, V148, P162	25	759	795	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1991	254	5037					1515	1518		10.1126/science.1835799	http://dx.doi.org/10.1126/science.1835799			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT903	1835799				2022-12-01	WOS:A1991GT90300043
J	SCHUMAN, EM; MADISON, DV				SCHUMAN, EM; MADISON, DV			A REQUIREMENT FOR THE INTERCELLULAR MESSENGER NITRIC-OXIDE IN LONG-TERM POTENTIATION	SCIENCE			English	Article							RELAXING FACTOR; L-ARGININE; SYNAPTIC TRANSMISSION; HIPPOCAMPAL SLICES; DIVALENT-CATIONS; RAT HIPPOCAMPUS; CENTRAL NEURONS; CA1 NEURONS; ENHANCEMENT; ACTIVATION	Long-term potentiation (LTP) of synaptic transmission is a widely studied model of neuronal plasticity. The induction of LTP is known to require processes in the postsynaptic neuron, while experimental evidence suggests that the expression of LTP may occur in the presynaptic terminal. This has led to speculation that a retrograde messenger travels from the post- to the presynaptic cell during induction of LTP. Extracellular application or postsynaptic injection of two inhibitors of nitric oxide synthase, N-nitro-L-arginine or N(G)-methyl-L-arginine, blocks LTP. Extracellular application of hemoglobin, which binds nitric oxide, also attenuates LTP. These findings suggest that nitric oxide liberated from postsynaptic neurons may travel back to presynaptic terminals to cause LTP expression.	STANFORD UNIV, MED CTR,SCH MED,BECKMAN CTR MOLEC & GENET MED, DEPT MOLEC & CELLULAR PHYSIOL, STANFORD, CA 94305 USA	Stanford University			Schuman, Erin M/D-6204-2011					ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; BARINAGA M, 1990, SCIENCE, V248, P1603, DOI 10.1126/science.1973002; BARRIONUEVO G, 1983, P NATL ACAD SCI-BIOL, V80, P7347, DOI 10.1073/pnas.80.23.7347; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1986, J PHYSIOL-LONDON, V377, P391, DOI 10.1113/jphysiol.1986.sp016193; BLISS TVP, 1990, NATURE, V346, P698, DOI 10.1038/346698a0; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRUNE B, 1989, J BIOL CHEM, V264, P8455; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P19, DOI 10.1113/jphysiol.1983.sp014477; DESAI KM, 1991, NATURE, V351, P477, DOI 10.1038/351477a0; DOLPHIN AC, 1982, NEUROSCIENCE, V20, P279; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GIBSON QH, 1957, J PHYSIOL-LONDON, V136, P507, DOI 10.1113/jphysiol.1957.sp005777; GOH JW, 1989, SCIENCE, V244, P980, DOI 10.1126/science.2543072; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; KENNEDY MB, 1988, NATURE, V335, P770, DOI 10.1038/335770a0; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; LARSON J, 1986, SCIENCE, V232, P985, DOI 10.1126/science.3704635; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MADISON DV, 1988, J PHYSIOL-LONDON, V398, P123, DOI 10.1113/jphysiol.1988.sp017033; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; MULLER D, 1988, P NATL ACAD SCI USA, V85, P9346, DOI 10.1073/pnas.85.23.9346; Murad F, 1978, Adv Cyclic Nucleotide Res, V9, P145; NATHAN CF, 1990, J NATL CANCER I, V82, P726, DOI 10.1093/jnci/82.9.726; ODELL TJ, IN PRESS P NATL ACAD; PALMER RMJ, 1988, BIOCHEM BIOPH RES CO, V153, P1251, DOI 10.1016/S0006-291X(88)81362-7; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; SAKUMA I, 1988, P NATL ACAD SCI USA, V85, P8664, DOI 10.1073/pnas.85.22.8664; SASTRY BR, 1986, SCIENCE, V232, P988, DOI 10.1126/science.3010459; SCHUMAN E, UNPUB; SCHUMAN E M, 1991, Society for Neuroscience Abstracts, V17, P2; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; STEVENS CF, 1988, NATURE, V336, P308, DOI 10.1038/336308a0; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; YUI Y, 1991, J BIOL CHEM, V244, P3714	49	978	997	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 6	1991	254	5037					1503	1506		10.1126/science.1720572	http://dx.doi.org/10.1126/science.1720572			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT903	1720572				2022-12-01	WOS:A1991GT90300039
J	SMITH, DP; RANGANATHAN, R; HARDY, RW; MARX, J; TSUCHIDA, T; ZUKER, CS				SMITH, DP; RANGANATHAN, R; HARDY, RW; MARX, J; TSUCHIDA, T; ZUKER, CS			PHOTORECEPTOR DEACTIVATION AND RETINAL DEGENERATION MEDIATED BY A PHOTORECEPTOR-SPECIFIC PROTEIN-KINASE-C	SCIENCE			English	Article							LIMULUS VENTRAL PHOTORECEPTORS; DROSOPHILA-MELANOGASTER; LIGHT ADAPTATION; PHOSPHOLIPASE-C; PHORBOL ESTERS; PHOSPHOINOSITIDE HYDROLYSIS; MOLECULAR HETEROGENEITY; CALCIUM-CONCENTRATION; CYTOPLASMIC CALCIUM; CELLS	The protein kinase C (PKC) family of serine-threonine kinases has been implicated in the regulation of a variety of signaling cascades. One member of this family, eye-PKC, is expressed exclusively in the Drosophila visual system. The inaC (inactivation-no-afterpotential C) locus was shown to be the structural gene for eye-PKC. Analysis of the light response from inaC mutants showed that this kinase is required for the deactivation and rapid desensitization of the visual cascade. Light adaptation was also defective in inaC mutant flies. In flies carrying the retinal degeneration mutation rdgB, absence of eye-PKC suppressed photoreceptor cell degeneration. These results indicate that eye-PKC functions in the light-dependent regulation of the phototransduction cascade in Drosophila.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego				Smith, Dean/0000-0002-4271-0436				BACIGALUPO J, 1991, P NATL ACAD SCI USA, V88, P7938, DOI 10.1073/pnas.88.18.7938; BACILUPO J, 1990, TRANSDUCTION BIOL SY; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BROWN JE, 1984, NATURE, V311, P160, DOI 10.1038/311160a0; COLLEY NJ, 1990, J CELL SCI, V95, P11; DECOUET HG, 1987, EUR J CELL BIOL, V44, P50; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FAIN GL, 1989, J PHYSIOL-LONDON, V416, P215, DOI 10.1113/jphysiol.1989.sp017757; FEIN A, 1984, NATURE, V311, P157, DOI 10.1038/311157a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARRIS WA, 1977, J GEN PHYSIOL, V69, P261, DOI 10.1085/jgp.69.3.261; HILMAN P, 1983, PHYSIOL REV, V63, P668; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KIKKAWA U, 1988, COLD SPRING HARB SYM, V53, P97, DOI 10.1101/SQB.1988.053.01.015; KIKUCHI A, 1986, CANCER RES, V46, P3401; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KORENBROT JI, 1989, VISION RES, V29, P939, DOI 10.1016/0042-6989(89)90108-9; KUHN H, 1987, J RECEPTOR RES, V7, P283, DOI 10.3109/10799898709054990; LABARCA R, 1984, BIOCHEM BIOPH RES CO, V123, P703, DOI 10.1016/0006-291X(84)90286-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE H, 1990, MECH DEVELOP, V33, P19, DOI 10.1016/0925-4773(90)90131-5; LIDSLEY DL, 1990, DROSOPH INFO SER, V68, P125; LISMAN JE, 1972, J GEN PHYSIOL, V59, P701, DOI 10.1085/jgp.59.6.701; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; MCMILLAN M, 1986, BIOCHEM BIOPH RES CO, V134, P970, DOI 10.1016/S0006-291X(86)80515-0; MINKE B, 1975, J COMP PHYSIOL, V98, P345, DOI 10.1007/BF00709805; MINKE B, 1990, P NATL ACAD SCI USA, V87, P113, DOI 10.1073/pnas.87.1.113; MINKE B, 1986, MOL MECHANISM PHOTOR, P241; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OREVI N, UNPUB; Pak W.L., 1979, P67; PAYNE R, 1986, J GEN PHYSIOL, V88, P127, DOI 10.1085/jgp.88.1.127; RANGANATHAN R, IN PRESS NATURE; ROSENTHAL A, 1987, EMBO J, V6, P433, DOI 10.1002/j.1460-2075.1987.tb04773.x; RYU SH, 1990, J BIOL CHEM, V265, P17941; Saibil H., 1990, Seminars in the Neurosciences, V2, P15; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; Smith D, UNPUB; SMITH DP, 1991, ANNU REV CELL BIOL, V7, P161; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STARK WS, 1985, INT J INSECT MORPHOL, V14, P243, DOI 10.1016/0020-7322(85)90057-1; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SVED J, 1986, DROSOPH INFO SERV, V73, P169; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671; YAMAGATA K, 1990, NEURON, V2, P469; YOKOHAMA H, 1988, BIOCHEM J, V255, P957, DOI 10.1042/bj2550957; YOSHIOKA T, 1983, BIOCHEM BIOPH RES CO, V111, P567, DOI 10.1016/0006-291X(83)90344-3; ZICK Y, 1986, P NATL ACAD SCI USA, V83, P9294, DOI 10.1073/pnas.83.24.9294	57	212	213	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1991	254	5037					1478	1484		10.1126/science.1962207	http://dx.doi.org/10.1126/science.1962207			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT903	1962207				2022-12-01	WOS:A1991GT90300031
J	TANG, WJ; GILMAN, AG				TANG, WJ; GILMAN, AG			TYPE-SPECIFIC REGULATION OF ADENYLYL CYCLASE BY G-PROTEIN BETA-GAMMA-SUBUNITS	SCIENCE			English	Article							PIG CEREBRAL-CORTEX; GTP-BINDING PROTEINS; ADENOSINE-3',5'-MONOPHOSPHATE METABOLISM; ALPHA-SUBUNITS; ADENOSINE; PURIFICATION; RESPONSES; HISTAMINE; ONTOGENY; NOREPINEPHRINE	Heterotrimeric guanine nucleotide-binding regulatory proteins (G proteins) dissociate into guanosine triphosphate (GTP)bound alpha-subunits and a complex of beta and gamma-subunits after interaction with receptors. The GTP-alpha subunit complex activates appropriate effectors, such as adenylyl cyclase, retinal phosphodiesterase, phospholipase C, and ion channels. G protein beta-gamma-subunits have been found to have regulatory effects on certain types of adenylyl cyclase. In the presence of G(s-alpha), the alpha-subunit of the G protein that activates adenylyl cyclase, one form of adenylyl cyclase was inhibited by beta-gamma, some forms were activated by beta-gamma and some forms were not affected by beta-gamma. These interactions suggest mechanisms for communication between distinct signal-transducing pathways.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Tang, Wei-Jen/0000-0002-8267-8995	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BLUMER KJ, 1991, ANNU REV PHYSIOL, V53, P37; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; FEINSTEIN P, IN PRESS P NATL ACAD; GAO B, IN PRESS P NATL ACAD; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; GROEBE DR, 1990, NUCLEIC ACIDS RES, V18, P4033, DOI 10.1093/nar/18.13.4033; ITOH H, 1991, J BIOL CHEM, V266, P16226; KATADA T, 1987, J BIOL CHEM, V262, P11897; KATADA T, 1984, J BIOL CHEM, V259, P3586; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KRUPINSKI J, COMMUNICATION; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; POSSEE RD, 1987, NUCLEIC ACIDS RES, V15, P10233, DOI 10.1093/nar/15.24.10233; RALL TW, 1987, MOL CELL BIOCHEM, V73, P157; SATTIN A, 1975, J PHARMACOL EXP THER, V192, P22; SHONK RF, 1987, MOL CELL BIOCHEM, V73, P141; SHONK RF, 1987, MOL CELL BIOCHEM, V73, P169; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; TANG WJ, 1991, J BIOL CHEM, V266, P8595	27	846	857	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1991	254	5037					1500	1503		10.1126/science.1962211	http://dx.doi.org/10.1126/science.1962211			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT903	1962211				2022-12-01	WOS:A1991GT90300038
J	CHAN, HSL; HADDAD, G; THORNER, PS; DEBOER, G; LIN, YP; ONDRUSEK, N; YEGER, H; LING, V				CHAN, HSL; HADDAD, G; THORNER, PS; DEBOER, G; LIN, YP; ONDRUSEK, N; YEGER, H; LING, V			P-GLYCOPROTEIN EXPRESSION AS A PREDICTOR OF THE OUTCOME OF THERAPY FOR NEUROBLASTOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REQUIRING PROLONGED OBSERVATION; MULTIDRUG RESISTANCE GENE; METASTATIC NEURO-BLASTOMA; CARCINOMA CELL-LINES; MONOCLONAL-ANTIBODIES; PROGNOSTIC FACTORS; 30 CHILDREN; IV-S; CHEMOTHERAPY; MDR1	Background and Methods. Multidrug resistance in chemotherapy for cancer is characterized by increased genetic expression of P-glycoprotein, which acts as an ATP-dependent drug-efflux pump. To determine whether P-glycoprotein levels are of prognostic value in such cases, we measured these levels immunohistochemically in a retrospective study of sequential tumor samples from 67 children with neuroblastoma. Results. P-glycoprotein was not detected in pretreatment samples from either of the 2 patients with Stage I disease, any of the 21 with Stage II disease, or any of the 8 with Stage IVS disease, but it was detected in the samples from 1 of the 17 patients with Stage III disease (6 percent) and 12 of the 19 with Stage IV disease (63 percent). Of the 44 patients with nonlocalized neuroblastoma (Stage III, IVS, or IV), 26 of the 31 who were negative for P-glycoprotein had a complete response to primary treatment, as compared with 6 of the 13 who were positive for P-glycoprotein (84 percent vs. 46 percent, P = 0.0232 by Fisher's exact test). Log-rank analysis of outcome, with simultaneous stratification according to tumor stage and age, showed that the group that was negative for P-glycoprotein had significantly longer relapse-free survival (P = 0.0011) and overall survival (P = 0.0373) than the group that was positive. Conclusions. Expression of P-glycoprotein before treatment may predict the success or failure of therapy for nonlocalized neuroblastoma. Neuroblastoma may be a promising tumor to treat with anticancer drug therapy combined with a chemosensitizing agent capable of reversing P-glycoprotein-mediated multidrug resistance.	HOSP SICK CHILDREN,DEPT PEDIAT,DIV IMMUNOL & CANC,TORONTO M5G 1X8,ONTARIO,CANADA; HOSP SICK CHILDREN,DEPT PATHOL,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M5S 1A1,ONTARIO,CANADA; ONTARIO CANC INST,DIV MOLEC & STRUCT BIOL,TORONTO M4X 1K9,ONTARIO,CANADA; ONTARIO CANC INST,DEPT BIOSTAT,TORONTO M4X 1K9,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	CHAN, HSL (corresponding author), HOSP SICK CHILDREN,DEPT PEDIAT,DIV HEMATOL ONCOL,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA.				NATIONAL CANCER INSTITUTE [R01CA037130] Funding Source: NIH RePORTER; NCI NIH HHS [CA-37130] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELL DR, 1985, J CLIN ONCOL, V3, P311, DOI 10.1200/JCO.1985.3.3.311; BOURHIS J, 1989, J NATL CANCER I, V81, P1401, DOI 10.1093/jnci/81.18.1401; BRADLEY G, 1989, CANCER RES, V49, P2790; BRODEUR GM, 1988, J CLIN ONCOL, V6, P1874, DOI 10.1200/JCO.1988.6.12.1874; CHABNER BA, 1989, J NATL CANCER I, V81, P910, DOI 10.1093/jnci/81.12.910; CHAN HSL, 1988, LAB INVEST, V59, P870; CHAN HSL, 1990, J CLIN ONCOL, V8, P689, DOI 10.1200/JCO.1990.8.4.689; CHRISTIANSEN H, 1988, BRIT J CANCER, V57, P121, DOI 10.1038/bjc.1988.24; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; DALTON WS, 1989, J CLIN ONCOL, V7, P415, DOI 10.1200/JCO.1989.7.4.415; Deacon J M, 1985, Prog Clin Biol Res, V175, P525; EVANS AE, 1987, CANCER, V59, P1853, DOI 10.1002/1097-0142(19870601)59:11<1853::AID-CNCR2820591102>3.0.CO;2-F; FINKLESTEIN JZ, 1979, MED PEDIATR ONCOL, V6, P179, DOI 10.1002/mpo.2950060211; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GERLACH JH, 1987, J CLIN ONCOL, V5, P1452, DOI 10.1200/JCO.1987.5.9.1452; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GERLACH JH, 1986, CANCER SURV, V5, P25; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOLDSTEIN LJ, 1990, J CLIN ONCOL, V8, P128, DOI 10.1200/JCO.1990.8.1.128; GREEN AA, 1981, CANCER, V48, P2310, DOI 10.1002/1097-0142(19811115)48:10<2310::AID-CNCR2820481029>3.0.CO;2-W; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; HANN HWL, 1981, NEW ENGL J MED, V305, P425, DOI 10.1056/NEJM198108203050803; HAYES FA, 1981, CANCER, V48, P1715, DOI 10.1002/1097-0142(19811015)48:8<1715::AID-CNCR2820480805>3.0.CO;2-Y; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; LAUG WE, 1978, PEDIATRICS, V62, P77; LING V, 1989, JNCI-J NATL CANCER I, V81, P84, DOI 10.1093/jnci/81.2.84; LOOK AT, 1984, NEW ENGL J MED, V311, P231, DOI 10.1056/NEJM198407263110405; MA DDF, 1987, LANCET, V1, P135; MANCINI AF, 1984, MED PEDIATR ONCOL, V12, P155, DOI 10.1002/mpo.2950120302; NG WF, 1989, MOL CELL BIOL, V9, P1224, DOI 10.1128/MCB.9.3.1224; ONEILL JA, 1985, J PEDIATR SURG, V20, P708, DOI 10.1016/S0022-3468(85)80029-4; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; PHILIP T, 1991, J CLIN ONCOL, V9, P1037, DOI 10.1200/JCO.1991.9.6.1037; POLLARDKNIGHT D, 1990, ANAL BIOCHEM, V185, P353, DOI 10.1016/0003-2697(90)90307-U; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SLATER LM, 1986, J CLIN INVEST, V77, P1405, DOI 10.1172/JCI112450; STERNBER.LA, 1970, J HISTOCHEM CYTOCHEM, V18, P315, DOI 10.1177/18.5.315; TREUNER J, 1984, LANCET, V1, P333; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; ZELTZER PM, 1983, LANCET, V2, P361	43	437	446	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 5	1991	325	23					1608	1614		10.1056/NEJM199112053252304	http://dx.doi.org/10.1056/NEJM199112053252304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR770	1682809				2022-12-01	WOS:A1991GR77000004
J	FAN, CM; MANIATIS, T				FAN, CM; MANIATIS, T			GENERATION OF P50 SUBUNIT OF NF-KAPPA-B BY PROCESSING OF P105 THROUGH AN ATP-DEPENDENT PATHWAY	NATURE			English	Article							INTERFERON GENE-REGULATION; ENHANCER-BINDING-PROTEIN; REL; PURIFICATION; MEDIATOR	THE transcription factor NF-kappa-B is a heterodimer consisting of two proteins encoded by different members of the rel gene family (p50 and p65) 1-7. The p50 subunit is unusual among DNA-binding proteins in that its functional form is encoded in an open reading frame of relative molecular mass 105,000 (p105; ref. 4). The N-terminal region of this open reading frame encodes p50, whereas the remaining C terminus contains ankyrin repeats. Although p50 binds to DNA, full-length p105 translated in vitro does not 4,5. The mechanism by which p50 is generated in vivo, and the fate of the C-terminal region of p105 have not been established. Here we show that functional p50 is produced by ATP-dependent proteolysis of p105. Moreover, we find that the C-terminal half of p 105 is not required for processing in vivo, and is rapidly degraded on processing. We propose that the C-terminal region of p105 is involved in the cytoplasmic assembly of the complex between the p50/p65 heterodimer and the inhibitor I-kappa-B.			FAN, CM (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.							BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HARLOW E, 1988, ANTIBODIES LABORATOR; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RIVIERE Y, 1991, NATURE, V350, P625, DOI 10.1038/350625a0; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7	19	281	291	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 5	1991	354	6352					395	398		10.1038/354395a0	http://dx.doi.org/10.1038/354395a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT761	1956402				2022-12-01	WOS:A1991GT76100052
J	JACOB, J; KELSOE, G; RAJEWSKY, K; WEISS, U				JACOB, J; KELSOE, G; RAJEWSKY, K; WEISS, U			INTRACLONAL GENERATION OF ANTIBODY MUTANTS IN GERMINAL-CENTERS	NATURE			English	Article							B-CELL LINEAGES; IMMUNE-RESPONSE; SOMATIC HYPERMUTATION; PRIMARY IMMUNIZATION; MEMORY; AMPLIFICATION; POLYMERASE; FIDELITY; MICE; NP	THE generation and selection of somatic antibody mutants are key elements of acquired immunity, essential for the affinity maturation of antibody responses dependent on T cells. The mutants are generated through a mechanism that introduces point mutations at high rate into rearranged variable (V) region genes in the course of cell proliferation 1,2. Their appearance coincides with the generation of germinal centres, which are characterized by oligoclonal B-cell proliferation 3,4 and have been suggested to be the microenvironment in which antibody mutants are generated 5,6. We report here direct evidence for this hypothesis. Rearranged V-region genes were amplified from the genomic DNA of cells picked from individual germinal centres. The sequence analysis of these genes revealed that most represent cells of distinct B-cell clones which expanded locally, generating somatic antibody mutants at high rate. By contrast, antigen-induced proliferation of B cells at another site, periarteriolar lymphocyte sheath-associated foci, was not associated with somatic hypermutation.	UNIV COLOGNE,INST GENET,W-5000 COLOGNE 41,GERMANY	University of Cologne	JACOB, J (corresponding author), UNIV MARYLAND,SCH MED,DEPT MICROBIOL & IMMUNOL,BALTIMORE,MD 21201, USA.			Kelsoe, Garnett/0000-0002-8770-040X				ALLEN D, 1987, IMMUNOL REV, V96, P5, DOI 10.1111/j.1600-065X.1987.tb00506.x; APEL M, 1990, INT IMMUNOL, V2, P813, DOI 10.1093/intimm/2.9.813; BLIER PR, 1987, J IMMUNOL, V139, P3996; CUMANO A, 1985, EUR J IMMUNOL, V15, P512, DOI 10.1002/eji.1830150517; CUMANO A, 1986, EMBO J, V5, P2459, DOI 10.1002/j.1460-2075.1986.tb04522.x; DUNNING AM, 1988, NUCLEIC ACIDS RES, V16, P10393, DOI 10.1093/nar/16.21.10393; FOOTE J, 1991, NATURE, V352, P530, DOI 10.1038/352530a0; FRENCH DL, 1989, SCIENCE, V244, P1152, DOI 10.1126/science.2658060; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KEOHAVONG P, 1989, P NATL ACAD SCI USA, V86, P9253, DOI 10.1073/pnas.86.23.9253; KOCKS C, 1989, ANNU REV IMMUNOL, V7, P537, DOI 10.1146/annurev.iy.07.040189.002541; Kroese F G, 1990, Curr Top Pathol, V84 ( Pt 1), P103; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; MANSER T, 1989, J EXP MED, V170, P1211, DOI 10.1084/jem.170.4.1211; MCKEAN D, 1984, P NATL ACAD SCI-BIOL, V81, P3180, DOI 10.1073/pnas.81.10.3180; PAABO S, 1990, J BIOL CHEM, V265, P4718; REYNAUD CA, 1991, CELL, V64, P995, DOI 10.1016/0092-8674(91)90323-Q; ROSE ML, 1980, NATURE, V284, P364, DOI 10.1038/284364a0; SCHITTEK B, 1990, NATURE, V346, P749, DOI 10.1038/346749a0; TAO W, 1990, J IMMUNOL, V145, P3216; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; WEISS U, 1990, J EXP MED, V172, P1681, DOI 10.1084/jem.172.6.1681	23	900	911	0	29	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 5	1991	354	6352					389	392		10.1038/354389a0	http://dx.doi.org/10.1038/354389a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT761	1956400				2022-12-01	WOS:A1991GT76100050
J	KESSLER, DA				KESSLER, DA			COMMUNICATING WITH PATIENTS ABOUT THEIR MEDICATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											KESSLER, DA (corresponding author), US FDA,ROCKVILLE,MD 20857, USA.							JOYCE G, 1988, J PHARM MARK MANAGE, V3, P11; KORSCH BM, 1972, SCI AM, V227, P66, DOI 10.1038/scientificamerican0872-66; LEY P, 1972, J HEALTH SOC BEHAV, V13, P311, DOI 10.2307/2136768; MORRIS LA, 1986, NATIONAL SURVEY PRES; 1990, MED REGIMENS CAUSES, P12; 1984, PRESCRIPTION DRUG AD; 1991, DHHS PHS9150212 PUBL; 1988, MARKET FACTS	8	63	67	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 5	1991	325	23					1650	1652		10.1056/NEJM199112053252312	http://dx.doi.org/10.1056/NEJM199112053252312			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GR770	1944456				2022-12-01	WOS:A1991GR77000012
J	ROCHE, PA; MARKS, MS; CRESSWELL, P				ROCHE, PA; MARKS, MS; CRESSWELL, P			FORMATION OF A NINE-SUBUNIT COMPLEX BY HLA CLASS-II GLYCOPROTEINS AND THE INVARIANT CHAIN	NATURE			English	Article							LYMPHOBLASTOID CELL; BETA-CHAIN; ANTIGENS; PROTEINS; BINDING; GLYCOSYLATION; ASSOCIATION; PEPTIDE	HLA CLASS II molecules are heterodimeric transmembrane glycoproteins that bind and present processed antigenic peptides to CD4-positive T lymphocytes. Intracellularly, class II molecules associate with a third subunit termed the invariant (1) chain. Here we describe the physical characteristics of the intracellular class II alpha-beta-I complex. Chemical crosslinking, size exclusion chromatography and sedimentation velocity studies demonstrate that the alpha-beta-I complex is a nine-subunit transmembrane protein that contains three alpha-beta-dimers associated with an I chain trimer. The organization of class II alpha- and beta-subunits in such a multimer may have a role in the documented ability of the I chain to inhibit peptide binding to class II molecules 1-3. In addition, the formation of the nine-chain complex may induce the structural changes necessary to overcome the cytoplasmic retention signal responsible for the localization of free I chain in the endoplasmic reticulum, releasing class II-I chain complexes for transport to endosomes 4-6.	DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710	Duke University			Marks, Michael S/Q-7223-2019	Marks, Michael S/0000-0001-7435-7262; Roche, Paul/0000-0002-8949-9172				BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; DEKRETSER TA, 1982, EUR J IMMUNOL, V12, P214, DOI 10.1002/eji.1830120309; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; HELENIUS A, 1972, J BIOL CHEM, V247, P3656; KELNER DN, 1986, J IMMUNOL, V137, P2632; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MACHAMER CE, 1984, P NATL ACAD SCI-BIOL, V81, P1287, DOI 10.1073/pnas.81.5.1287; MACHAMER CE, 1982, J IMMUNOL, V129, P2564; MARKS MS, 1990, J CELL BIOL, V111, P839, DOI 10.1083/jcb.111.3.839; MARKS MS, 1989, THESIS DUKE U; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; POLLET RJ, 1981, J BIOL CHEM, V256, P2118; ROCHE PA, 1990, J IMMUNOL, V144, P1849; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; SANT AJ, 1983, J EXP MED, V158, P1979, DOI 10.1084/jem.158.6.1979; SANT AJ, 1985, J EXP MED, V162, P1916, DOI 10.1084/jem.162.6.1916; SOBERS HA, 1968, HDB BIOCH, pJ248; STRUBIN M, 1986, EMBO J, V5, P3483, DOI 10.1002/j.1460-2075.1986.tb04673.x; TANFORD C, 1974, BIOCHEMISTRY-US, V13, P2369, DOI 10.1021/bi00708a021; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0	22	311	315	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 5	1991	354	6352					392	394		10.1038/354392a0	http://dx.doi.org/10.1038/354392a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT761	1956401				2022-12-01	WOS:A1991GT76100051
J	SPRINGER, TA				SPRINGER, TA			THE NEXT CLUSTER OF DIFFERENTIATION (CD) WORKSHOP	NATURE			English	Article											SPRINGER, TA (corresponding author), HARVARD UNIV,SCH MED,CTR BLOOD RES,800 HUNTINGTON AVE,BOSTON,MA 02115, USA.							Bernard A., 1984, LEUCOCYTE TYPING; GILKS WR, 1988, LEUKOCYTE TYPING DIS, V3; GILKS WR, 1990, LEUKOCYTE TYPING DAT, V4; KNAPPD W, 1989, LEUKOCYTE TYPING, V4; MCMICHAEL AJ, 1987, LEUKOCYTE TYPING, V3; REINHERZ EL, 1986, LEUKOCYTE TYPING 2, V2	6	0	1	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 5	1991	354	6352					415	416		10.1038/354415a0	http://dx.doi.org/10.1038/354415a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT761	1956408				2022-12-01	WOS:A1991GT76100058
J	SUMIMOTO, H; OHKUMA, Y; SINN, E; KATO, H; SHIMASAKI, S; HORIKOSHI, M; ROEDER, RG				SUMIMOTO, H; OHKUMA, Y; SINN, E; KATO, H; SHIMASAKI, S; HORIKOSHI, M; ROEDER, RG			CONSERVED SEQUENCE MOTIFS IN THE SMALL SUBUNIT OF HUMAN GENERAL TRANSCRIPTION FACTOR TFIIE	NATURE			English	Article							RNA POLYMERASE-II; SIGMA-FACTORS; INITIATION; PROTEINS; PURIFICATION; SPECIFICITY; EXPRESSION; BINDING; MYOD	A GENERAL initiation factor, TFIIE, is essential for transcription initiation by RNA polymerase II in conjunction with other general factors 1,2 . TFIIE is a heterotetramer containing two subunits of relative molecular mass 57,000 (TFIIE-alpha) and two of 34,000 (TFIIE-beta) 3,4. TFIIE-beta is required in conjunction with TFIIE-alpha for transcription initiation. Here we report the cloning and expression of a complementary DNA encoding a functional human TFIIE-beta. Recombinant TFIIE-beta could replace the natural TFIIE-beta for transcription in conjunction with TFIIE-alpha. Amino-acid sequence comparisons reveal regions with sequence similarities to: subregion 3 of bacterial or factors 6; a region of RAP30 (the small subunit of TFIIF) with sequence similarity to a sigma-factor subregion implicated in binding to RNA polymerase 7; and a portion of the basic region-helix-loop-helix motif found in several enhancer-binding proteins 8-10. These potential homologies have implications for the role of TFIIE in preinitiation complex assembly and function.	WHITTIER INST DIABET & ENDOCRINOL,DEPT MOLEC ENDOCRINOL,LA JOLLA,CA 92037		SUMIMOTO, H (corresponding author), ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021, USA.							CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; FLORES O, 1989, J BIOL CHEM, V264, P8913; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MALIK S, IN PRESS P NATN ACAD; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; REINBERG D, 1987, J BIOL CHEM, V262, P3310; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158	30	79	80	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 5	1991	354	6352					401	404		10.1038/354401a0	http://dx.doi.org/10.1038/354401a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT761	1956404				2022-12-01	WOS:A1991GT76100054
J	THUN, MJ; NAMBOODIRI, MM; HEATH, CW				THUN, MJ; NAMBOODIRI, MM; HEATH, CW			ASPIRIN USE AND REDUCED RISK OF FATAL COLON CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUG; AUTOCHTHONOUS INTESTINAL TUMORS; PROSTAGLANDIN SYNTHESIS; INDOMETHACIN TREATMENT; RATS; INHIBITION; CARCINOGENESIS; PIROXICAM; POLYPOSIS; SULINDAC	Background and Methods. Experiments in animals and two epidemiologic studies in humans suggest that aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs) may be protective against colon cancer. We tested this hypothesis in a prospective mortality study of 662,424 adults who provided information in 1982 on the frequency and duration of their aspirin use. Death rates from colon cancer were measured through 1988. The possible influence of other risk factors for colon cancer was examined in multivariate analyses for 598 case patients and 3058 matched control subjects drawn from the cohort. Results. Death rates from colon cancer decreased with more frequent aspirin use in both men and women. The relative risk among persons who used aspirin 16 or more times per month for at least one year was 0.60 in men (95 percent confidence interval, 0.40 to 0.89) and 0.58 in women (95 percent confidence interval, 0.37 to 0.90). The risk estimates were unaffected when we excluded persons who reported at entry into the study that they had cancer, heart disease, stroke, or another condition that might influence both their aspirin use and their mortality. Adjustment for dietary factors, obesity, physical activity, and family history did not alter the findings significantly. No association was found between the use of acetaminophen and the risk of colon cancer. Conclusions. Regular aspirin use at low doses may reduce the risk of fatal colon cancer. Whether this is due to a direct effect of aspirin, perhaps mediated by the inhibition of prostaglandin synthesis, or to other factors indirectly associated with aspirin use is unclear.			THUN, MJ (corresponding author), AMER CANC SOC, DEPT EPIDEMIOL & STAT, 1599 CLIFTON RD, ATLANTA, GA 30329 USA.							[Anonymous], 1988, BRIT MED J, V296, P320; CRAVEN PA, 1983, J CLIN INVEST, V72, P1365, DOI 10.1172/JCI111093; FLANDERS WD, 1984, J CHRON DIS, V37, P449, DOI 10.1016/0021-9681(84)90028-6; FURUTA Y, 1988, CANCER RES, V48, P3002; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P433; KUDO T, 1980, GANN, V71, P260; Kune GA, 2007, INT J EPIDEMIOL, V36, P951, DOI 10.1093/ije/dym193; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; LUBIN JH, 1984, BIOMETRICS, V40, P63, DOI 10.2307/2530744; LUPULESCU A, 1978, NATURE, V272, P634, DOI 10.1038/272634a0; LYNCH NR, 1978, BRIT J CANCER, V38, P503, DOI 10.1038/bjc.1978.237; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; METZGER U, 1984, DIS COLON RECTUM, V27, P366, DOI 10.1007/BF02553001; Moorghen M, 1990, Acta Histochem Suppl, V39, P195; NARISAWA T, 1983, CARCINOGENESIS, V4, P1225, DOI 10.1093/carcin/4.10.1225; NARISAWA T, 1981, CANCER RES, V41, P1954; NARISAWA T, 1984, J CANCER RES CLIN, V108, P239, DOI 10.1007/BF00402475; PAGANINIHILL A, 1989, BRIT MED J, V299, P1247, DOI 10.1136/bmj.299.6710.1247; PAGANINIHILL A, 1991, J NATL CANCER I, V83, P1182, DOI 10.1093/jnci/83.16.1182-a; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; PLESCIA OJ, 1975, P NATL ACAD SCI USA, V72, P1848, DOI 10.1073/pnas.72.5.1848; POLLARD M, 1983, CANCER LETT, V21, P57, DOI 10.1016/0304-3835(83)90082-4; POLLARD M, 1980, CANCER TREAT REP, V64, P1323; POLLARD M, 1981, SCIENCE, V214, P558, DOI 10.1126/science.7291992; POLLARD M, 1983, J NATL CANCER I, V70, P1103; POLLARD M, 1981, P SOC EXP BIOL MED, V167, P161; REDDY BS, 1990, CANCER RES, V50, P2562; REDDY BS, 1987, CANCER RES, V47, P5340; ROSENBERG L, 1991, J NATL CANCER I, V83, P355, DOI 10.1093/jnci/83.5.355; ROSENBERG L, 1991, J NATL CANCER I, V83, P1183, DOI 10.1093/jnci/83.16.1183; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P230; STELLMAN SD, 1986, JNCI-J NATL CANCER I, V76, P1057; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119	35	1538	1593	1	77	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 5	1991	325	23					1593	1596		10.1056/NEJM199112053252301	http://dx.doi.org/10.1056/NEJM199112053252301			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR770	1669840				2022-12-01	WOS:A1991GR77000001
J	VANDERGOOT, FG; GONZALEZMANAS, JM; LAKEY, JH; PATTUS, F				VANDERGOOT, FG; GONZALEZMANAS, JM; LAKEY, JH; PATTUS, F			A MOLTEN-GLOBULE MEMBRANE-INSERTION INTERMEDIATE OF THE PORE-FORMING DOMAIN OF COLICIN-A	NATURE			English	Article							PHOSPHOLIPID MONOLAYERS; LIPID BILAYERS; PROTEINS; CHANNEL; STATE; PEPTIDE; TRANSLOCATION; MECHANISM; LIPOSOMES; FRAGMENT	THE 'molten' globular conformation of a protein is compact with a native secondary structure but a poorly defined tertiary structure 1,2. Molten globular states are intermediates in protein folding and unfolding 3-5 and they may be involved in the translocation or insertion of proteins into membranes 6. Here we investigate the membrane insertion of the pore-forming domain of colicin A, a bacteriocin that depolarizes the cytoplasmic membrane of sensitive cells 7-9. We find that this pore-forming domain, the insertion of which depends on pH (refs 10, 11), undergoes a native to molten globule transition at acidic pH. The variation of the kinetic constant of membrane insertion of the protein into negatively charged lipid vesicles as a function of the interfacial pH correlates with the appearance of the acidic molten globular state, indicating that this state could be an intermediate formed during the insertion of colicin A into membranes.			VANDERGOOT, FG (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY.		van der Goot, Gisou G/B-2279-2012	van der Goot, Gisou G/0000-0002-8522-274X				BRUNDEN KR, 1984, J BIOL CHEM, V259, P7682; BYCHKOVA VE, 1988, FEBS LETT, V238, P231, DOI 10.1016/0014-5793(88)80485-X; CRAMER WA, 1990, MOL MICROBIOL, V4, P519, DOI 10.1111/j.1365-2958.1990.tb00619.x; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; EAST JM, 1982, BIOCHEMISTRY-US, V21, P4144, DOI 10.1021/bi00260a035; EISENBERG M, 1979, BIOCHEMISTRY-US, V18, P5213, DOI 10.1021/bi00590a028; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; FINK AL, 1990, CURRENT RES PROTEIN, P417; FRENETTE M, 1989, BIOCHEMISTRY-US, V28, P2509, DOI 10.1021/bi00432a024; GOTO Y, 1990, BIOCHEMISTRY-US, V29, P3480, DOI 10.1021/bi00466a009; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; JIANG JX, 1991, BIOCHEMISTRY-US, V30, P3857, DOI 10.1021/bi00230a008; LAKEY JH, 1991, EUR J BIOCHEM, V196, P599, DOI 10.1111/j.1432-1033.1991.tb15855.x; LAKEY JH, 1991, J MOL BIOL, V219, P639; LOHNER K, 1991, BIOCHEMISTRY-US, V30, P6620, DOI 10.1021/bi00240a035; MENESTRINA G, 1989, BIOPHYS J, V55, P393, DOI 10.1016/S0006-3495(89)82833-4; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P5829, DOI 10.1021/bi00476a026; OHGUSHI M, 1983, FEBS LETT, V164, P21, DOI 10.1016/0014-5793(83)80010-6; OLNES S, 1988, TRENDS BIOCHEM SCI, V13, P348; PARKER MW, 1990, TRENDS BIOCHEM SCI, V15, P126, DOI 10.1016/0968-0004(90)90205-P; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PARKER MW, IN PRESS J MOL BIOL; PATTUS F, 1985, EUR J BIOCHEM, V152, P681, DOI 10.1111/j.1432-1033.1985.tb09248.x; PATTUS F, 1990, EXPERIENTIA, V46, P180; PATTUS F, 1983, BIOCHEMISTRY-US, V22, P5698, DOI 10.1021/bi00294a003; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RAMSAY G, 1990, BIOCHEMISTRY-US, V29, P8677, DOI 10.1021/bi00489a024; SCHWARZ G, 1987, BIOPHYS J, V52, P685, DOI 10.1016/S0006-3495(87)83263-0; SLATIN SL, 1988, INT J BIOCHEM, V20, P737, DOI 10.1016/0020-711X(88)90058-4; SONG HY, 1991, J BACTERIOL, V173, P2927, DOI 10.1128/JB.173.9.2927-2934.1991; WINISKI AP, 1986, BIOCHEMISTRY-US, V25, P8206, DOI 10.1021/bi00373a013	31	406	411	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 5	1991	354	6352					408	410		10.1038/354408a0	http://dx.doi.org/10.1038/354408a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT761	1956406				2022-12-01	WOS:A1991GT76100056
J	WANG, J; BEDZYK, MJ; PENNER, TL; CAFFREY, M				WANG, J; BEDZYK, MJ; PENNER, TL; CAFFREY, M			STRUCTURAL STUDIES OF MEMBRANES AND SURFACE-LAYERS UP TO 1,000 A THICK USING X-RAY STANDING WAVES	NATURE			English	Article							BRAGG-DIFFRACTION; INTERFACE; REFLECTION; FIELDS	THE X-ray standing wave (XSW) method, developed in the 1960s, was used originally to determine heavy atom positions in and on silicon and germanium single crystals 1-7. An X-ray standing wave generated by the interference of coherent incident and reflected beams excites X-ray fluorescence from the heavy atom, the intensity of which as a function of incident angle provides an indication of the atom's distance from the X-ray reflecting surface. The availability of X-ray mirrors and the ability to prepare layered synthetic microstructures has made possible the study of biologically relevant structures using the XSW technique on length scales of typically tens to hundreds of angstroms 8-12, allowing heavy atoms in such structures to be located with angstrom or subangstrom resolution. Many model biological systems (such as Langmuir-Blodgett films, which mimic membranes) require access to still larger scales, but it is not obvious that an XSW will remain coherent over such length scales. Here we report studies of a lipid multilayer system using the XSW method, in which we have been able to locate the metal atoms in a zinc arachidate bilayer with angstrom resolution at a distance of almost 1,000 angstrom above the surface of a gold mirror. Our results indicate that the XSW technique should be useful for structural studies of supramolecular aggregates, receptor-ligand interactions and multi-membrane stacks, in which length scales of this order are encountered.	CORNELL UNIV,CORNELL HIGH ENERGY SYNCHROTRON SOURCE,ITHACA,NY 14853; EASTMAN DENT CTR,CORP RES LABS,ROCHESTER,NY 14620	Cornell University; Eastman Chemical Company; University of Rochester	WANG, J (corresponding author), OHIO STATE UNIV,DEPT CHEM,COLUMBUS,OH 43210, USA.		Bedzyk, Michael J/B-7503-2009; Bedzyk, Michael J/K-6903-2013					ANDERSEN SK, 1976, PHYS REV LETT, V37, P1141, DOI 10.1103/PhysRevLett.37.1141; BATTERMAN BW, 1969, PHYS REV LETT, V22, P703, DOI 10.1103/PhysRevLett.22.703; BATTERMAN BW, 1964, PHYS REV A, V133, P759; BECKER RS, 1983, PHYS REV LETT, V50, P153, DOI 10.1103/PhysRevLett.50.153; BEDZYK MJ, 1985, PHYS REV B, V31, P4110, DOI 10.1103/PhysRevB.31.4110; BEDZYK MJ, 1990, SCIENCE, V248, P52, DOI 10.1126/science.2321026; BEDZYK MJ, 1989, PHYS REV LETT, V62, P1376, DOI 10.1103/PhysRevLett.62.1376; BEDZYK MJ, 1988, SCIENCE, V241, P1788, DOI 10.1126/science.3175619; BLOCH JM, 1985, PHYS REV LETT, V54, P1039, DOI 10.1103/PhysRevLett.54.1039; COWAN PL, 1980, PHYS REV LETT, V44, P1680, DOI 10.1103/PhysRevLett.44.1680; DEBOER DKG, 1991, PHYS REV B, V44, P498, DOI 10.1103/PhysRevB.44.498; GOLOVCHENKO JA, 1982, PHYS REV LETT, V49, P560, DOI 10.1103/PhysRevLett.49.560; GOLOVCHENKO JA, 1974, PHYS REV B, V10, P4239, DOI 10.1103/PhysRevB.10.4239; IIDA A, 1985, JPN J APPL PHYS 2, V24, pL675, DOI 10.1143/JJAP.24.L675; MARRA WC, 1979, J APPL PHYS, V50, P6927, DOI 10.1063/1.325845; PARRATT LG, 1954, PHYS REV, V95, P359, DOI 10.1103/PhysRev.95.359; ZHELUDEVA SI, 1990, THIN SOLID FILMS, V193, P395, DOI 10.1016/S0040-6090(05)80049-5	17	62	64	1	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 5	1991	354	6352					377	380		10.1038/354377a0	http://dx.doi.org/10.1038/354377a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT761	1956399				2022-12-01	WOS:A1991GT76100045
J	BUCHOLTZ, GA; LOCKEY, RF				BUCHOLTZ, GA; LOCKEY, RF			SEAWATER-INDUCED ITCHING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											BUCHOLTZ, GA (corresponding author), UNIV S FLORIDA,COLL MED,JAMES A HALEY VET HOSP,TAMPA,FL 33612, USA.							MANDOJANA RM, 1987, CLIN DERMATOLOGY AQU, V5; SHIMODA T, 1988, J ALLERGY CLIN IMMUN, V81, P1187, DOI 10.1016/0091-6749(88)90889-5; WARIN RP, 1974, MAJOR PROBLEMS DERMA, V1, P136	3	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					3040	3040						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1820481				2022-12-01	WOS:A1991GR77500041
J	BUCHWALD, H				BUCHWALD, H			GASTRIC DECONTAMINATION IN PATIENT WITH GASTRIC STAPLING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											BUCHWALD, H (corresponding author), UNIV MINNESOTA,SCH MED,MINNEAPOLIS,MN 55455, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					3040	3040						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1687926				2022-12-01	WOS:A1991GR77500042
J	FACCHINI, F; CHEN, YDI; HOLLENBECK, CB; REAVEN, GM				FACCHINI, F; CHEN, YDI; HOLLENBECK, CB; REAVEN, GM			RELATIONSHIP BETWEEN RESISTANCE TO INSULIN-MEDIATED GLUCOSE-UPTAKE, URINARY URIC-ACID CLEARANCE, AND PLASMA URIC-ACID CONCENTRATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; RISK FACTOR	Objective. - To define the relationship, if any, between insulin-mediated glucose disposal and serum uric acid. Design. - Cross-sectional study of healthy volunteers. Setting. - General Clinical Research Center, Stanford (Calif) University Medical Center. Participants. - Thirty-six presumably healthy individuals, nondiabetic, without a history of gout. Measurements. - Obesity (overall and regional), plasma glucose and insulin responses to a 75-g oral glucose load, fasting uric acid concentrations, plasma triglyceride and high-density lipoprotein-cholesterol concentrations, systolic and diastolic blood pressure, insulin-mediated glucose disposal, and urinary uric acid clearance. Results. - Magnitude of insulin resistance and serum uric acid concentration were significantly related (r = .69; P < .001), and the relationship persisted when differences in age, sex, overall obesity, and abdominal obesity were taken into account (r = .57; P < .001). Insulin resistance was also inversely related to urinary uric acid clearance (r= -.49; P < .002), and, in addition, urinary uric acid clearance was inversely related to serum uric acid concentration (r = -.61; P < .001). Conclusions. - Urinary uric acid clearance appears to decrease in proportion to increases in insulin resistance in normal volunteers, leading to an increase in serum uric acid concentration. Thus, it appears that modulation of serum uric concentration by insulin resistance is exerted at the level of the kidney.	VET AFFAIRS MED CTR,CTR GERIATR RES EDUC & CLIN,3801 MIRANDA AVE,PALO ALTO,CA 94304; STANFORD UNIV,MED CTR,SCH MED,DEPT MED,STANFORD,CA 94305	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University					NCRR NIH HHS [RR-00070] Funding Source: Medline; NHLBI NIH HHS [HL-08506] Funding Source: Medline; NIDDK NIH HHS [DK-07217] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007217] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRAND FN, 1985, AM J EPIDEMIOL, V121, P11, DOI 10.1093/oxfordjournals.aje.a113972; DEFRONZO RA, 1975, J CLIN INVEST, V55, P845, DOI 10.1172/JCI107996; GERTLER MM, 1951, ANN INTERN MED, V34, P1421, DOI 10.7326/0003-4819-34-6-1421; GOLAY A, 1990, J CLIN ENDOCR METAB, V71, P1299, DOI 10.1210/jcem-71-5-1299; GREENFIELD MS, 1981, DIABETES, V30, P387, DOI 10.2337/diabetes.30.5.387; HALES CN, 1963, BIOCHEM J, V88, P137, DOI 10.1042/bj0880137; HOLLENBECK CB, 1984, DIABETES, V33, P460, DOI 10.2337/diabetes.33.5.460; HOLMES EW, 1972, KIDNEY INT, V2, P115, DOI 10.1038/ki.1972.81; KADISH AH, 1968, CLIN CHEM, V14, P116; KAGAN A, 1975, INT J EPIDEMIOL, V4, P271, DOI 10.1093/ije/4.4.271; KAPLAN AL, 1989, CLIN CHEM, P1016; KLEIN R, 1973, ARCH INTERN MED, V132, P401, DOI 10.1001/archinte.132.3.401; MODAN M, 1987, DIABETOLOGIA, V30, P713, DOI 10.1007/BF00296994; MYERS AR, 1968, AM J MED, V45, P520, DOI 10.1016/0002-9343(68)90168-X; PERSKY VW, 1979, CIRCULATION, V59, P969, DOI 10.1161/01.CIR.59.5.969; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Takkunen H, 1977, Adv Exp Med Biol, V76B, P238; TRIVEDI RC, 1978, CLIN CHEM, V24, P1908; WYNGAARDEN JB, 1976, GOUT HYPEURICEMIA; Wyngaarden JB, 1983, METABOLIC BASIS INHE, P1043; 1976, J CHRON DIS, V29, P557	21	619	654	0	36	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					3008	3011		10.1001/jama.266.21.3008	http://dx.doi.org/10.1001/jama.266.21.3008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1820474				2022-12-01	WOS:A1991GR77500033
J	HARRINGTON, C; CASSEL, C; ESTES, CL; WOOLHANDLER, S; HIMMELSTEIN, DU				HARRINGTON, C; CASSEL, C; ESTES, CL; WOOLHANDLER, S; HIMMELSTEIN, DU			A NATIONAL LONG-TERM CARE PROGRAM FOR THE UNITED-STATES - A CARING VISION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH; FUTURE	The financing and delivery of long-term care (LTC) need substantial reform. Many cannot afford essential services; age restrictions often arbitrarily limit access for the nonelderly, although more than a third of those needing care are under 65 years old; Medicaid, the principal third-party payer for LTC, is biased toward nursing home care and discourages independent living; informal care provided by relatives and friends, the only assistance used by 70% of those needing LTC, is neither supported nor encouraged; and insurance coverage often excludes critically important services that fall outside narrow definitions of medically necessary care. We describe an LTC program designed as an integral component of the national health program advanced by Physicians for a National Health Program. Everyone would be covered for all medically and socially necessary services under a single public plan, federally mandated and funded but administered locally. An LTC payment board in each state would contract directly with providers through a network of local public agencies responsible for eligibility determination and care coordination. Nursing homes, home care agencies, and other institutional providers would be paid a global budget to cover all operating costs and would not bill on a per-patient basis. Alternatively, integrated provider organizations could receive a capitation fee to cover a broad range of LTC and acute care services. Individual practitioners could continue to be paid on a fee-for-service basis or could receive salaries from institutional providers. Support for innovation, training of LTC personnel, and monitoring of the quality of care would be greatly augmented. For-profit providers would be compensated for past investments and phased out. Our program would add between $18 billion and $23.5 billion annually to current spending on LTC. Polls indicate that a majority of Americans want such a program and are willing to pay earmarked taxes to support it.	HARVARD UNIV,CAMBRIDGE HOSP,SCH MED,NATL HLTH PROGRAM,1493 CAMBRIDGE ST,CAMBRIDGE,MA 02139	Harvard University; Cambridge Health Alliance; Cambridge Hospital								BALL R, 1989, BECAUSE WERE ALL THI; BARKER WH, 1987, ADDING LIFE YEARS OR; BLENDON RJ, 1988, JAMA-J AM MED ASSOC, V259, P3587, DOI 10.1001/jama.259.24.3587; BLUMENTHAL D, 1988, RENEWING PROMISE MED; BODENHEIMER T, 1990, INT J HEALTH SERV, V20, P199, DOI 10.2190/DAKX-ULL1-R1EF-X5NR; CALLAHAN JJ, 1989, J AGING SOC POLICY, V1, P181; Campbell L J, 1987, Clin Geriatr Med, V3, P99; ESTES CL, 1989, GERONTOLOGIST, V29, P587, DOI 10.1093/geront/29.5.587; ESTES CL, 1990, LONG TERM CARE REQUI; ESTES CL, 1985, INT PERSPECTIVES LON, P315; ESTES CL, 1983, FISCAL AUSTERITY AGI; EVANS RG, 1989, NEW ENGL J MED, V320, P571, DOI 10.1056/NEJM198903023200906; FIRMAN JP, 1988, PRIVATE LONG TERM CA; FREIDSON F, 1970, PROFESSIONAL DOMINAN; HARRINGTON C, 1985, LONG TERM CARE ELDER; HARRINGTON C, 1987, SOCIAL HLTH MAINTENA, pCH4; HARRIS L, 1988, MAJORITIES FAVOR PAS; HAWES C, 1986, FOR PROFIT ENTERPRIS, P492; HAZZARD WR, 1991, ANN INTERN MED, V115, P229, DOI 10.7326/0003-4819-115-3-229; HIMMELSTEIN DU, 1989, NEW ENGL J MED, V320, P102, DOI 10.1056/NEJM198901123200206; HIMMELSTEIN DU, 1991, JAMA-J AM MED ASSOC, V266, P399, DOI 10.1001/jama.266.3.399; HOLAHAN J, 1989, MILBANK Q, V67, P137, DOI 10.2307/3350072; Institute of Medicine report, 1986, IMPROVING QUALITY CA; JUSTICE D, 1988, STATE LONG TERM CARE; KANE R, 1980, NEW ENGL J MED, V302, P1327, DOI 10.1056/NEJM198006123022402; Kane RA, 1987, LONG TERM CARE PRINC; KANE RL, 1991, NEW ENGL J MED, V324, P627, DOI 10.1056/NEJM199102283240910; Kane Robert L., 1985, WILL WAY WHAT US CAN; KUSSEROW RP, 1987, OA1018600010 US DEP; LAPLANTE MP, 1988, DATA DISABILITY NATI; LEVIT KR, 1988, HEALTH AFFAIR, V7, P124, DOI 10.1377/hlthaff.7.5.124; Liu K, 1985, Health Care Financ Rev, V7, P51; NEWCOMER RJ, 1989, 03283 US DEP HLTH HU; PRICE RJ, 1990, LONG TERM CARE ELDER; RIVLIN AM, 1988, CARING DISABLED ELDE; ROWE JW, 1987, NEW ENGL J MED, V316, P1425, DOI 10.1056/NEJM198705283162229; STONE R, 1987, GERONTOLOGIST, V27, P616, DOI 10.1093/geront/27.5.616; STONE R, 1986, NCHS ADV DATA, P124; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; ZAWADSKI RT, 1983, HOME HEALTH CARE SER, V4, P3; 1988, INTERSTUDYS LONG TER, P2; 1987, VITAL HLTH STAT 13, V97; 1987, MEDICARE MEDICAID ST; 1987, AM PUBLIC VIEWS LONG; 1990, CALL ACTION FINAL RE; 1989, ISSUES FINANCING DEL; 1986, HOSPITAL STATISTICS; 1989, DEV AGING 1988 REPOR, P1; 1990, HLTH MED SERVICES US; 1986, MEDIGAP INSURANCE LA; 1987, LONG TERM CARE C; 1987, NATIONAL HLTH EXPEND, V8, P1; 1988, INTERSTUDYS LONG TER, P1; 1989, PRIVATE LONG TERM CA; 1987, VITAL HLTH STAT 10, V166; 1988, SOURCE BOOK HLTH INS	56	25	25	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					3023	3029		10.1001/jama.266.21.3023	http://dx.doi.org/10.1001/jama.266.21.3023			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GR775	1820477				2022-12-01	WOS:A1991GR77500037
J	HEALY, B				HEALY, B			ASPIRIN AND WARFARIN EFFECTIVE IN PREVENTING STROKE AND EMBOLISM IN PATIENTS WITH ATRIAL-FIBRILLATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1991, CIRCULATION, V84, P527	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					2955	2955						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1668176				2022-12-01	WOS:A1991GR77500006
J	HEALY, B				HEALY, B			ORAL-ADMINISTRATION OF ACYCLOVIR APPEARS INEFFECTIVE IN TREATING ACUTE INFECTIOUS-MONONUCLEOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1991, J INFECT DIS, V164, P788	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					2955	2955						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1668176				2022-12-01	WOS:A1991GR77500008
J	HEALY, B				HEALY, B			CURRENTLY LICENSED IMMUNOASSAYS DO NOT ACCURATELY DISTINGUISH ANTIBODIES TO HERPES-SIMPLEX VIRUS SUBTYPES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1991, ANN INTERN MED, V115, P520	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					2955	2955						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1668176				2022-12-01	WOS:A1991GR77500007
J	LAETZ, T; SILBERMAN, G				LAETZ, T; SILBERMAN, G			REIMBURSEMENT POLICIES CONSTRAIN THE PRACTICE OF ONCOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective. -To determine the prevalence of off-label anticancer drug use (ie, using drugs to treat conditions other than those listed on the Food and Drug Administration's approved drug label), the extent of reimbursement denials for these uses, and the effect of denials on the treatment of cancer patients. Design, Setting, and Participants. - A three-part questionnaire was sent to a randomized sample of oncologists taken from the 1990 membership of the American Society of Clinical Oncology in March 1990. A response rate of 56% yielded information from 681 oncologists on the drugs they prescribed to 2018 new cancer patients and on those they frequently use in treating 11 specific types of cancer. Main Outcome Measures. - The labeled uses of the drugs prescribed and frequently used in chemotherapies were checked against the indications treated to determine whether they were prescribed for off-label uses. Three drug compendia were used as cited sources of off-label drug uses. The extent of reimbursement denials over the last 12 months and their effects on treatments were based on respondent opinions. Main Results. - Off-label drug use is prevalent and dominates the chemotherapy regimens of cancers that are more difficult to treat and for which there are no cures or agreements on standardized treatment. Most oncologists reported frustration with shifting reimbursement policies in general and with an increasing rate of denials for some off-label drug uses. Indeed, a surprising number of oncologists claimed that these policies caused them to alter preferred treatments and site of care. Conclusion. - These findings suggest the need for public discussion of off-label drug use issues so that appropriate policies can be developed.	US GEN ACCOUNTING OFF,PROGRAM EVALUAT & METHODOL,441 G ST NW,WASHINGTON,DC 20548									DEVITA VT, 1985, PRINCIPLES PRACTICE, P282; 1991, PEMD9114 US GEN ACC; 1989, FED REG         0130, V54, P4302	3	51	53	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					2996	2999		10.1001/jama.266.21.2996	http://dx.doi.org/10.1001/jama.266.21.2996			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1820471				2022-12-01	WOS:A1991GR77500030
J	MASON, JO				MASON, JO			PROTECTING PHYSICIANS FROM VACCINE LIABILITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											MASON, JO (corresponding author), US PHS,WASHINGTON,DC 20201, USA.							1991, JAMA-J AM MED ASSOC, V266, P2958; 1991, JAMA-J AM MED ASSOC, V266, P2959	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					2951	2951						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GR775	1820459				2022-12-01	WOS:A1991GR77500005
J	ROUBENOFF, R; KLAG, MJ; MEAD, LA; LIANG, KY; SEIDLER, AJ; HOCHBERG, MC				ROUBENOFF, R; KLAG, MJ; MEAD, LA; LIANG, KY; SEIDLER, AJ; HOCHBERG, MC			INCIDENCE AND RISK-FACTORS FOR GOUT IN WHITE MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective. - To identify potentially modifiable risk factors for the development of gout. Design. - Longitudinal cohort study (The Johns Hopkins Precursors Study). Participants. - Of 1337 eligible medical students, 1271 (95%) received a standardized medical examination and questionnaire during medical school. The participants were predominantly male (91%), white (97%), and young (median age, 22 years) at cohort entry. Outcome Measure. - The development of gout. Results. - Sixty cases of gout (47 primary and 13 secondary) were identified among 1216 men; none occurred among 121 women (P = .01). The cumulative incidence of all gout was 8.6% among men (95% confidence interval, 5.9% to 11.3%). Body mass index at age 35 years (P = .01), excessive weight gain (> 1.88 kg/m2) between cohort entry and age 35 years (P = .007), and development of hypertension (P = .004) were significant risk factors for all gout in univariate analysis. Multivariate Cox proportional hazards models confirmed the association of body mass index at age 35 years (relative risk [RR] = 1.12; P = .02), excessive weight gain (RR = 2.07; P = .02), and hypertension (RR = 3.26; P = .002) as risk factors for all gout. Hypertension, however, was not a significant risk factor for primary gout. Conclusions. - Obesity, excessive weight gain in young adulthood, and hypertension are risk factors for the development of gout. Prevention of obesity and hypertension may decrease the incidence of and morbidity from gout; studies of weight reduction in the primary and secondary prevention of gout are indicated.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV MOLEC & CLIN RHEUMATOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV INTERNAL MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,WELCH CTR PREVENT EPIDEMIOL & CLIN RES,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOSTAT,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Liang, Kung-Yee/F-8299-2011	Roubenoff, Ronenn/0000-0002-3959-3179	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG001760] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00722] Funding Source: Medline; NHLBI NIH HHS [HL42734] Funding Source: Medline; NIA NIH HHS [AG01760] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABBOTT RD, 1988, J CLIN EPIDEMIOL, V41, P237, DOI 10.1016/0895-4356(88)90127-8; Campion E W, 1987, Am J Med, V82, P421, DOI 10.1016/0002-9343(87)90441-4; COX DR, 1972, J R STAT SOC B, V34, P187; GLYNN RJ, 1983, ARTHRITIS RHEUM-US, V26, P87, DOI 10.1002/art.1780260115; HALL AP, 1967, AM J MED, V42, P27, DOI 10.1016/0002-9343(67)90004-6; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAWRENCE RC, 1989, J RHEUMATOL, V16, P427; LEE ET, 1980, STATISTICAL METHODS, P122; MANUEL MA, 1974, AM J MED, V57, P741, DOI 10.1016/0002-9343(74)90847-X; ROUBENOFF R, 1990, RHEUM DIS CLIN N AM, V16, P539; WALLACE SL, 1977, ARTHRITIS RHEUM, V20, P895, DOI 10.1002/art.1780200320; [No title captured]; [No title captured]	13	183	193	1	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					3004	3007		10.1001/jama.266.21.3004	http://dx.doi.org/10.1001/jama.266.21.3004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1820473				2022-12-01	WOS:A1991GR77500032
J	SACKS, JJ; HOLMGREEN, P; SMITH, SM; SOSIN, DM				SACKS, JJ; HOLMGREEN, P; SMITH, SM; SOSIN, DM			BICYCLE-ASSOCIATED HEAD-INJURIES AND DEATHS IN THE UNITED-STATES FROM 1984 THROUGH 1988 - HOW MANY ARE PREVENTABLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							HELMET USE; SAFETY HELMETS; CHILDREN; ACCIDENTS; VICTORIA	Objective. - To estimate the potential benefits from more widespread bicycle safety helmet use. Design. - Review of death certificates and emergency department injury data for 1984 through 1988. Categorization of deaths and injuries as related to bicycling and head injury Using relative risks of 3.85 and 6.67 derived from a case-control study and varying helmet usage from 10% to 100%, population attributable risk was calculated to estimate preventable deaths and injuries. Setting. - Entire United States. Main Outcome Measures. - Numbers of US residents coded as dying from bicycle-related head injuries, numbers of persons presenting to emergency departments for bicycle-related head injuries, and numbers of attributable bicycle-related deaths and head injuries. Main Results. - From 1984 through 1988, bicycling accounted for 2985 head injury deaths (62% of all bicycling deaths) and 905 752 head injuries (32% of persons with bicycling injuries treated at an emergency department). Forty-one percent of head injury deaths and 76% of head injuries occurred among children less than 15 years of age. Universal use of helmets by all bicyclists could have prevented as many as 2500 deaths and 757 000 head injuries, ie, one death every day and one head injury every 4 minutes. Conclusions. - Effective community-based education programs and legislated approaches for increasing bicycle safety helmet usage have been developed and await only the resources and commitment to reduce these unnecessary deaths and injuries.	CTR DIS CONTROL,EPIDEMIOL PROGRAM OFF,DIV FIELD EPIDEMIOL,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	SACKS, JJ (corresponding author), CTR DIS CONTROL,NATL CTR ENVIRONM HLTH INJURY CONTROL,DIV INJURY CONTROL F36,ATLANTA,GA 30333, USA.							Bishop P J, 1984, Can J Appl Sport Sci, V9, P94; BUCCINI RV, 1987, OCT AM PUBL HLTH ASS; BUNTAIN WL, 1985, 29TH P ANN M AM ASS, P307; DIGUISEPPI CG, 1989, JAMA-J AM MED ASSOC, V262, P2256, DOI 10.1001/jama.262.16.2256; DORSCH MM, 1987, ACCIDENT ANAL PREV, V19, P183, DOI 10.1016/0001-4575(87)90002-9; FIFE D, 1983, J TRAUMA, V23, P745, DOI 10.1097/00005373-198308000-00011; FLORA JD, 1979, J SAFETY RES, V11, P20; FRIEDE AM, 1985, PEDIATR CLIN N AM, V32, P141; Hodgson V.R., 1990, IMPACT SKID RETENTIO; LUNDAR T, 1985, CHILD NERV SYST, V1, P24, DOI 10.1007/BF00706726; MCDERMOTT FT, 1985, AUST NZ J SURG, V55, P477, DOI 10.1111/j.1445-2197.1985.tb00926.x; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P38; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; THOMPSON DC, 1990, AM J PUBLIC HEALTH, V80, P1471, DOI 10.2105/AJPH.80.12.1471; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; WASSERMAN RC, 1988, AM J PUBLIC HEALTH, V78, P1220, DOI 10.2105/AJPH.78.9.1220; WASSERMAN RC, 1990, AM J SPORT MED, V18, P96, DOI 10.1177/036354659001800116; WEISS BD, 1986, PEDIATRICS, V77, P677; WEISS BD, 1986, AM J PUBLIC HEALTH, V76, P1022, DOI 10.2105/AJPH.76.8.1022; WEISS BD, 1987, AM J DIS CHILD, V141, P135, DOI 10.1001/archpedi.1987.04460020025018; WILLIAMS M, 1991, ACCIDENT ANAL PREV, V23, P119, DOI 10.1016/0001-4575(91)90043-5; WOOD T, 1988, ACCIDENT ANAL PREV, V20, P177, DOI 10.1016/0001-4575(88)90002-4; 1984, VITAL STATISTICS MOR; 1987, MMWR, V36, P269; 1986, INTERCENSAL POPULATI, P38; 1990, CONSUMER REP     MAY, P348; 1977, MANUAL INT CLASSIFIC	29	132	132	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					3016	3018		10.1001/jama.266.21.3016	http://dx.doi.org/10.1001/jama.266.21.3016			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GR775	1820476				2022-12-01	WOS:A1991GR77500035
J	STEIN, HF				STEIN, HF			PUPILS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					2941	2942						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1820456				2022-12-01	WOS:A1991GR77500001
J	BAXT, WG				BAXT, WG			USE OF AN ARTIFICIAL NEURAL NETWORK FOR THE DIAGNOSIS OF MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; ARTIFICIAL INTELLIGENCE; EMERGENCY MEDICINE; MODELS, THEORETICAL; DIAGNOSIS, COMPUTER-AIDED	RECOGNITION; EMERGENCY; PROTOCOL	Objective: To validate prospectively the use of an artificial neural network to identify myocardial infarction in patients presenting to an emergency department with anterior chest pain. Design: Prospective, blinded testing. Setting: Tertiary university teaching center. Patients: A total of 331 consecutive adult patients presenting with anterior chest pain. Measurements: Diagnostic sensitivity and specificity with regard to the diagnosis of acute myocardial infarction. Main Results: An artificial neural network was trained on clinical pattern sets retrospectively derived from the cases of 351 patients hospitalized with a high likelihood of having myocardial infarction. It was prospectively tested on 331 consecutive patients presenting to an emergency department with anterior chest pain. The ability of the network to distinguish patients with from those without acute myocardial infarction was compared with that of physicians caring for the same patients. The physicians had a diagnostic sensitivity of 77.7% (95% CI, 77.0% to 82.9%) and a diagnostic specificity of 84.7% (CI, 84.0% to 86.4%). The artificial neural network had a sensitivity of 97.2% (CI, 97.2% to 97.5%; P = 0.033) and a specificity of 96.2% (CI, 96.2% to 96.4%; P < 0.001). Conclusion: An artificial neural network trained to identify myocardial infarction in adult patients presenting to an emergency department may be a valuable aid to the clinical diagnosis of myocardial infarction; however, this possibility must be confirmed through prospective testing on a larger patient sample.			BAXT, WG (corresponding author), UNIV CALIF SAN DIEGO, MED CTR, DEPT EMERGENCY MED, 225 DICKINSON ST, 8676, SAN DIEGO, CA 92103 USA.							BAILEY BJR, 1980, TECHNOMETRICS, V22, P583, DOI 10.2307/1268196; BAXT WG, 1991, NEURAL COMPUT, V2, P480; BOUNDS DG, 1990, NEURAL NETWORKS, V3, P583, DOI 10.1016/0893-6080(90)90008-9; CIOS KJ, 1990, IEEE ENG MED BIOL, V9, P58, DOI 10.1109/51.59215; EBERHART RC, 1991, 4TH P ANN IEEE S COM, P298; GALLANT SI, 1988, COMMUN ACM, V31, P152, DOI 10.1145/42372.42377; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; HARRISON RF, 1991, P INT JOINT C NEURAL, V1, P1; HIRAIWA A, 1990, IEEE ENG MED BIOL, V9, P39, DOI 10.1109/51.59211; HUDSON DL, 1988, 12TH S COMP APPL MED, V12, P251; KAUFMAN JJ, 1990, IEEE ENG MED BIOL, V9, P23, DOI 10.1109/51.59209; MARCONI L, 1989, P INT JOINT C NEURAL, V2, P577; McClelland J. L., 1988, EXPLORATIONS PARALLE, P121; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MULSANT GH, 1988, 12TH S COMP APPL MED, V12, P245; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; REGGIA JA, 1985, COMPUTERS MED, V2; Rumelhart E., 1986, LEARNING INTERNAL RE, P318, DOI DOI 10.1016/B978-1-4832-1446-7.50035-2; RUSNAK RA, 1989, ANN EMERG MED, V18, P1029, DOI 10.1016/S0196-0644(89)80924-2; SAITO K, 1988, P IEEE INT C NEURAL, V1, P255; SMITH JW, 1988, 12TH S COMP APPL MED, V12, P261; SZOLOVITS P, 1988, ANN INTERN MED, V108, P80, DOI 10.7326/0003-4819-108-1-80; WEIGEND AS, 1990, PREDICTING FUTURE CO; Widrow G, 1960, CONVENTION RECORD 4, P96; Yoon Y. O., 1989, J NEURAL NETWORK SUM, P43	25	337	346	0	59	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1991	115	11					843	848		10.7326/0003-4819-115-11-843	http://dx.doi.org/10.7326/0003-4819-115-11-843			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR171	1952470				2022-12-01	WOS:A1991GR17100002
J	GRUBB, BP; GERARD, G; ROUSH, K; TEMESYARMOS, P; ELLIOTT, L; HAHN, H; SPANN, C				GRUBB, BP; GERARD, G; ROUSH, K; TEMESYARMOS, P; ELLIOTT, L; HAHN, H; SPANN, C			DIFFERENTIATION OF CONVULSIVE SYNCOPE AND EPILEPSY WITH HEAD-UP TILT TESTING	ANNALS OF INTERNAL MEDICINE			English	Article						SYNCOPE; EPILEPSY; HEAD-UP TILT TABLE; CONVULSIONS; ISOPROTERENOL	NEURALLY MEDIATED HYPOTENSION; UNKNOWN ORIGIN; UNEXPLAINED SYNCOPE; HEALTHY-SUBJECTS; BRADYCARDIA; ISOPROTERENOL; DISOPYRAMIDE; PREVENTION; RECURRENT; RESPONSES	Objective: To evaluate the usefulness of head-upright tilt table testing in the differential diagnosis of convulsive syncope from epileptic seizures in patients with recurrent idiopathic seizure-like episodes. Design: Prospective, nonrandomized study. Setting: Electrophysiology laboratory of a university hospital. Patients: Fifteen patients (8 men and 7 women patients; mean age, 29 +/- 20 years) with recurrent unexplained seizure-like episodes, unresponsive to anti-seizure medication. Measurements: Head-upright tilt table testing with or without isoproterenol infusion. Five patients who were initially tilt positive had a second tilt test with continuous electroencephalographic (EEG) recording. Main Results: Syncope associated with tonic-clonic seizure-like activity occurred in six patients (40%) during the baseline tilt and in four patients (27%) during isoproterenol infusion (total positive tests, 67%). The EEG showed diffuse brain wave slowing (not typical of epileptic seizures) in five of five patients during the convulsive episode. All patients who had positive test results eventually become tilt table negative after therapy, and over a mean follow-up period of 21 +/- 2 months, no further seizure-like episodes have occurred. Conclusion: Upright tilt table testing combined with isoproterenol infusion may be useful to distinguish convulsive syncope from epileptic seizures.			GRUBB, BP (corresponding author), MED COLL OHIO, DIV CARDIOL, 3000 ARLINGTON AVE, POB 10008, TOLEDO, OH 43699 USA.							ABISAMRA F, 1988, PACE, V11, P1202, DOI 10.1111/j.1540-8159.1988.tb03973.x; ALMQUIST A, 1989, NEW ENGL J MED, V320, P346, DOI 10.1056/NEJM198902093200603; BRAHAM J, 1981, ANN NEUROL, V10, P277, DOI 10.1002/ana.410100318; CASTAUT H, 1958, ELECTROECEPHALOGR CL, V10, P607; CHEN MY, 1988, CIRCULATION, V78, P239; CHOSY JJ, 1965, J PSYCHOSOM RES, V9, P189, DOI 10.1016/0022-3999(65)90032-2; DEVINSKY O, 1990, SEMIN NEUROL, V10, P321, DOI 10.1055/s-2008-1063976; DUVOISIN RC, 1962, ARCH NEUROL-CHICAGO, V7, P219, DOI 10.1001/archneur.1962.04210030057008; ENGEL J, 1989, SEIZURES EPILEPSY, P340; EPSTEIN SE, 1968, CIRCULATION, V37, P524, DOI 10.1161/01.CIR.37.4.524; FERGUSON DW, 1983, CIRCULATION, V67, P802, DOI 10.1161/01.CIR.67.4.802; GAMACHE C, 1991, PACE, V14, P663; GASTAUT H, 1957, LANCET, V2, P1018; GASTAUT H, 1974, EPILEPSIES, P815; GLICK G, 1963, AM J MED, V34, P42, DOI 10.1016/0002-9343(63)90037-8; GOLDENBERG IF, 1987, CIRCULATION, V76, P133; GROSSI D, 1987, FUNCT NEUROL, V11, P457; GRUBB BP, 1991, AM J MED, V90, P6, DOI 10.1016/0002-9343(91)90499-N; GRUBB BP, 1991, CIRCULATION, V84, P1157, DOI 10.1161/01.CIR.84.3.1157; GURVITCH AM, 1966, ELECTROEN CLIN NEURO, V21, P355, DOI 10.1016/0013-4694(66)90041-1; HAINSWORTH R, 1988, CLIN SCI, V74, P17, DOI 10.1042/cs0740017; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; HAUSER WA, 1990, EPILEPSY FREQUENCY C, P21; JAEGER FJ, 1987, CLIN RES, V35, pA832; KLEIN LJ, 1964, AM J MED, V37, P263, DOI 10.1016/0002-9343(64)90010-5; LATHERS CM, 1990, EPILEPSY SUDDEN DEAT, P485; LIN JTY, 1982, ANN NEUROL, V11, P525, DOI 10.1002/ana.410110513; LLOYDSMITH DL, 1958, ELECTROEN CLIN NEURO, V10, P153, DOI 10.1016/0013-4694(58)90111-1; MALONEY JD, 1988, CLEV CLIN J MED, V55, P542, DOI 10.3949/ccjm.55.6.542; MARK AL, 1983, J AM COLL CARDIOL, V1, P90, DOI 10.1016/S0735-1097(83)80014-X; MCLARAN CJ, 1986, BRIT HEART J, V55, P53; MILSTEIN S, 1989, J AM COLL CARDIOL, V14, P1626, DOI 10.1016/0735-1097(89)90006-5; MILSTEIN S, 1989, PACE, V12, P117, DOI 10.1111/pace.1989.12.p1.117; MILSTEIN S, 1990, AM J CARDIOL, V65, P1339, DOI 10.1016/0002-9149(90)91324-Y; MORADY F, 1982, ANN INTERN MED, V96, P337, DOI 10.7326/0003-4819-96-3-337; PEDLEY TA, 1983, EPILEPSIA, V24, pS31, DOI 10.1111/j.1528-1157.1983.tb04641.x; RAVIELE A, 1990, AM J CARDIOL, V65, P1322, DOI 10.1016/0002-9149(90)91321-V; REA RF, 1989, J AM COLL CARDIOL, V14, P1633, DOI 10.1016/0735-1097(89)90007-7; SAPIRE DW, 1983, AM HEART J, V106, P1406; SCHEUER ML, 1990, NEW ENGL J MED, V323, P1468; SHELDON RS, 1991, PACE, V14, P662; SHVARTZ E, 1968, AEROSPACE MED, V39, P1094; SHVARTZ E, 1970, AEROSPACE MED, V41, P253; STRASBERG B, 1989, AM HEART J, V118, P923, DOI 10.1016/0002-8703(89)90225-1; Thoren P, 1979, Rev Physiol Biochem Pharmacol, V86, P1, DOI 10.1007/BFb0031531; VARGAS E, 1984, GERONTOLOGY, V30, P253, DOI 10.1159/000212640; VOGT FB, 1967, AEROSPACE MED, V38, P564; WAXMAN MB, 1989, AM J CARDIOL, V63, P58, DOI 10.1016/0002-9149(89)91076-X	48	142	144	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1991	115	11					871	876		10.7326/0003-4819-115-11-871	http://dx.doi.org/10.7326/0003-4819-115-11-871			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR171	1952474				2022-12-01	WOS:A1991GR17100006
J	KATKOV, WN; FRIEDMAN, LS; CODY, H; EVANS, A; KUO, G; CHOO, QL; HOUGHTON, M; DIENSTAG, JL				KATKOV, WN; FRIEDMAN, LS; CODY, H; EVANS, A; KUO, G; CHOO, QL; HOUGHTON, M; DIENSTAG, JL			ELEVATED SERUM ALANINE AMINOTRANSFERASE LEVELS IN BLOOD-DONORS - THE CONTRIBUTION OF HEPATITIS-C VIRUS	ANNALS OF INTERNAL MEDICINE			English	Note						BLOOD DONORS; HEPATITIS, VIRAL, NON-A, NON-B; HEPATITIS-C VIRUS; ALANINE AMINOTRANSFERASE; HEPATITIS ANTIBODIES	NON-B-HEPATITIS; TRANSFUSION-TRANSMITTED VIRUSES; NON-A; RECIPIENTS; ANTIBODY; RISK	In 1983, anticipating the introduction of alanine aminotransferase (ALT) screening to limit the frequency of transfusion-associated non-A, non-B hepatitis, we evaluated 100 consecutive blood donors with elevated ALT levels. To assess the role of hepatitis C virus (HCV) in blood donors with ALT elevations, we tested donor sera for antibody to HCV (anti-HCV). Antibody was detected and "confirmed" by a second-generation recombinant immunoblot assay (RIBA-2) in 17% of donors. Aminotransferase levels were higher in donors with anti-HCV. Antibody to HCV was more frequent in donors with persistent ALT elevations and in those who used intravenous drugs; anti-HCV was less frequent in donors who were overweight, who drank alcohol regularly, and who had no alternative explanation for an elevated ALT level. We conclude that asymptomatic ALT elevations are infrequently associated with HCV infection, unless the elevation is substantial, persistent, or associated with intravenous drug use. Hepatitis C virus infection is an unlikely cause of asymptomatic ALT elevations in persons who drink alcohol regularly or who are obese; however, HCV infection is a more likely cause of ALT elevations in thin persons who do not drink alcohol regularly.	HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, GASTROINTESTINAL UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, PHILADELPHIA, PA 19107 USA; CHIRON CORP, EMERYVILLE, CA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Jefferson University; Novartis				Dienstag, Jules/0000-0001-7024-0980; Houghton, Michael/0000-0003-3762-6771	NIDDK NIH HHS [T32-DK07191] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007191] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AACH RD, 1981, NEW ENGL J MED, V304, P989, DOI 10.1056/NEJM198104233041701; ALTER HJ, 1981, JAMA-J AM MED ASSOC, V246, P630, DOI 10.1001/jama.246.6.630; FRIEDMAN LS, 1987, ANN INTERN MED, V107, P137, DOI 10.7326/0003-4819-107-2-137; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MACFARLANE DG, 1990, LANCET, V335, P727, DOI 10.1016/0140-6736(90)90843-T; PALMER M, 1990, GASTROENTEROLOGY, V99, P1408, DOI 10.1016/0016-5085(90)91169-7; SHERMAN KE, 1982, J INFECT DIS, V145, P383, DOI 10.1093/infdis/145.3.383; STEVENS CE, 1984, ANN INTERN MED, V101, P733, DOI 10.7326/0003-4819-101-6-733; VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I	10	39	39	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1991	115	11					882	884		10.7326/0003-4819-115-11-882	http://dx.doi.org/10.7326/0003-4819-115-11-882			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR171	1952477				2022-12-01	WOS:A1991GR17100009
J	SEELEY, DG; BROWNER, WS; NEVITT, MC; GENANT, HK; SCOTT, JC; CUMMINGS, SR				SEELEY, DG; BROWNER, WS; NEVITT, MC; GENANT, HK; SCOTT, JC; CUMMINGS, SR			WHICH FRACTURES ARE ASSOCIATED WITH LOW APPENDICULAR BONE MASS IN ELDERLY WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article						OSTEOPOROSIS, POSTMENOPAUSAL; FRACTURES; BONE DENSITY; GERIATRICS; WOMENS HEALTH	HIP FRACTURE; OSTEOPOROSIS; RISK	Objective: To determine which types of fractures have an increased incidence in elderly women with low appendicular bone mass. Design: Prospective cohort study. Setting: Four clinical centers in the United States (Baltimore, Maryland; Minneapolis, Minnesota; Portland, Oregon; Monangehela Valley, Pennsylvania); and one coordinating center in San Francisco, California. Subjects: Ambulatory, nonblack women (9704) aged 65 years or more who were recruited from population-based listings. Measurements: We measured bone mass at the distal and proximal radius and calcaneus using single-photon absorptiometry. Fractures were verified radiographically. Associations were calculated as age-adjusted hazard ratios (with 95% CIs) per standard deviation decrease in bone mass. Main Results: During a mean follow-up of 2.23 years, 841 nonspinal fractures occurred in 753 women. The risks for fractures of the wrist, foot, humerus, hip, rib, toe, leg, pelvis, hand, and clavicle were significantly related to reduced bone mass (P < 0.05). These fractures represented 74% of nonspinal fractures. The overall hazard ratio for the occurrence of one or more of these fractures was 1.65 (CI, 1.49 to 1.82) at the distal radius. In a subsample of the cohort, vertebral fractures were also related to low bone mass. Fractures of the ankle, elbow, finger, and face, however, were not associated with bone mass at any measurement site; the overall hazard ratio for these fractures was 1.12 (CI, 0.96 to 1.30) at the distal radius. Conclusion: Most types of fractures have an increased incidence in elderly women with low bone mass.	UNIV MARYLAND, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	SEELEY, DG (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL & BIOSTAT, 74 NEW MONTGOMERY, SUITE 600, SAN FRANCISCO, CA 94105 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35582] Funding Source: Medline; NIA NIH HHS [AG05394, AG05407] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		COX DR, 1972, J R STAT SOC B, V34, P187; CUMMINGS SR, 1989, J GERONTOL, V44, pM107; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; ESSES SI, 1989, J BONE MINER RES, V4, P715; GARDSELL P, 1989, CALCIFIED TISSUE INT, V44, P235, DOI 10.1007/BF02553757; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; JENSEN GF, 1983, ACTA MED SCAND, V213, P61; LIPS P, 1987, INT S OSTEOPORSIS, P362; MELTON LJ, 1986, AM J EPIDEMIOL, V124, P254, DOI 10.1093/oxfordjournals.aje.a114383; MELTON LJ, 1982, CLIN ORTHOP RELAT R, V162, P144; MeltonIII L. J., 1988, OSTEOPOROSIS ETIOLOG, P133; OWEN RA, 1982, AM J PUBLIC HEALTH, V72, P605, DOI 10.2105/AJPH.72.6.605; Vega E, 1991, Osteoporos Int, V1, P81, DOI 10.1007/BF01880448; WASNICH RD, 1985, AM J OBSTET GYNECOL, V153, P745, DOI 10.1016/0002-9378(85)90338-2; 1984, JAMA-J AM MED ASSOC, V252, P799	16	495	505	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1991	115	11					837	842		10.7326/0003-4819-115-11-837	http://dx.doi.org/10.7326/0003-4819-115-11-837			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR171	1952469				2022-12-01	WOS:A1991GR17100001
J	VAITKEVICIUS, PV; ESSERWEIN, DM; MAYNARD, AK; OCONNOR, FC; FLEG, JL				VAITKEVICIUS, PV; ESSERWEIN, DM; MAYNARD, AK; OCONNOR, FC; FLEG, JL			FREQUENCY AND IMPORTANCE OF POSTPRANDIAL BLOOD-PRESSURE REDUCTION IN ELDERLY NURSING-HOME PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article						FRAIL ELDERLY; NURSING HOMES; HYPOTENSION; POSTPRANDIAL PERIOD; SYNCOPE	ORTHOSTATIC HYPOTENSION; HEMODYNAMIC-CHANGES; RESPONSES; INGESTION	Objective: To determine the frequency and importance of postprandial reductions in systolic blood pressure in debilitated, elderly patients receiving nursing home care. Design: Cohort study. Setting: Community-based, university-affiliated, teaching nursing home. Patients: A total of 113 volunteer nursing-home residents with a mean (+/- SD) age of 78 +/- 9 years; seven residents who refused the test meal served as controls. Intervention: Participants had sequential blood pressure measurements for 90 minutes after the administration of a standardized meal. Measurements and Main Results: Of 113 patients, 109 (96%) showed a postprandial reduction in systolic blood pressure (mean reduction, 17.9 +/- 15.5 mm Hg) within 75 minutes; 41 patients (36%) had a reduction in systolic blood pressure of more than 20 mm Hg. Twelve patients (11%) had a reduction in systolic blood pressure to less than 100 mm Hg (mean systolic blood pressure, 88 +/- 6.4 mm Hg); two of these patients became acutely symptomatic. Multiple regression analysis showed that higher premeal systolic blood pressure, a history of syncope, treatment with vasodilators, and dependent posture of the lower extremities during the postprandial period were all associated with a more severe postprandial decline in systolic blood pressure. Systolic blood pressure in noneating control subjects did not change during the same observation period. No significant differences in the mean systolic blood pressure nadir were found between the 14 patients who died during the follow-up period (mean follow-up, 6.1 +/- 3.8 months) and those who survived. Conclusion: Postprandial reductions in systolic blood pressure among elderly nursing-home patients are common, often large, and potentially symptomatic, but they do not generally presage subsequent intermediate-term mortality.	NIA, FRANCIS SCOTT KEY MED CTR, GERONTOL RES CTR, CARDIOVASC SCI LAB, BALTIMORE, MD 21224 USA; JOHNS HOPKINS UNIV, SCH MED, DIV GERIATR MED, BALTIMORE, MD 21205 USA; FRANCIS SCOTT KEY MED CTR, BALTIMORE, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University					NATIONAL INSTITUTE ON AGING [T32AG000120] Funding Source: NIH RePORTER; NIA NIH HHS [5T32AG00120-03] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		FAGAN TC, 1986, AM J CARDIOL, V58, P636, DOI 10.1016/0002-9149(86)90291-2; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Heberdeen W., 1772, MED T COLL PHYSICIAN, V2, P59; JANSEN RWMM, 1987, AM J CARDIOL, V60, P1087, DOI 10.1016/0002-9149(87)90358-4; JONSSON PV, 1990, ARCH INTERN MED, V150, P1518, DOI 10.1001/archinte.150.7.1518; KANNEL WB, 1985, HDB BIOL AGING, P859; KELBAEK H, 1989, ARCH INTERN MED, V149, P363, DOI 10.1001/archinte.149.2.363; KELBAEK H, 1987, J APPL PHYSIOL, V63, P1862, DOI 10.1152/jappl.1987.63.5.1862; LAKATTA EG, 1987, CIRCULATION, V75, P69; LIPSITZ LA, 1986, J AM GERIATR SOC, V34, P267, DOI 10.1111/j.1532-5415.1986.tb04222.x; LIPSITZ LA, 1983, NEW ENGL J MED, V309, P81, DOI 10.1056/NEJM198307143090205; LIPSITZ LA, 1986, J CHRON DIS, V39, P619, DOI 10.1016/0021-9681(86)90187-6; LIPSITZ LA, 1989, NEW ENGL J MED, V321, P952; LIU K, 1983, GERONTOLOGIST, V23, P92, DOI 10.1093/geront/23.1.92; LIU K, 1984, GERONTOLOGIST, V24, P70, DOI 10.1093/geront/24.1.70; MICIELI G, 1987, NEUROLOGY, V37, P386, DOI 10.1212/WNL.37.3.386; PEITZMAN SJ, 1989, ARCH INTERN MED, V149, P286, DOI 10.1001/archinte.149.2.286; ROBERTSON D, 1981, AM J CARDIOL, V48, P1048, DOI 10.1016/0002-9149(81)90319-2; ROBINSON BJ, 1985, AGE AGEING, V14, P168, DOI 10.1093/ageing/14.3.168; SHERMAN RA, 1988, AM J KIDNEY DIS, V12, P37, DOI 10.1016/S0272-6386(88)80069-6	20	90	90	1	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1991	115	11					865	870		10.7326/0003-4819-115-11-865	http://dx.doi.org/10.7326/0003-4819-115-11-865			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR171	1952473				2022-12-01	WOS:A1991GR17100005
J	CAIRNS, HS; LEAKER, B; WOODHOUSE, CRJ; RUDGE, CJ; NEILD, GH				CAIRNS, HS; LEAKER, B; WOODHOUSE, CRJ; RUDGE, CJ; NEILD, GH			RENAL-TRANSPLANTATION INTO ABNORMAL LOWER URINARY-TRACT	LANCET			English	Article							ILEAL CONDUITS; DIVERSION; CHILDREN; FATE	Because doubts remain about the safety and efficacy of renal transplantation for patients with primary urological abnormalities, we have studied the outcome of transplantation in a large group of such patients. Between 1977 and 1989, 69 renal transplants were completed in 62 patients with abnormal lower urinary tracts (29 primary vesicoureteric reflux, 13 posterior urethral valves or bladder outflow obstruction, 6 vesicoureteric tuberculosis, 5 neuropathic bladders, and 9 miscellaneous causes). Graft survival in this urological group was similar to that in 150 allograft recipients (157 grafts) with end-stage renal failure of a non-urological cause. No aetiological subgroup had poorer graft survival than the others, although patients with recurrent urinary-tract infections and a history of outflow obstruction tended to have worse graft function. 9 patients (10 transplants) had renal transplantation into a urinary diversion (8 ileal conduits, 1 rectal bladder). These patients had graft survival and renal function comparable with those of the whole urological group. We found no effect of immunosuppressive treatment (cyclosporin or azathioprine), type of kidney donor (living or cadaveric), or donor or recipient age on graft survival time or renal function. Thus, renal transplantation in patients with abnormal lower urinary tracts is safe and effective; patients with ileal conduits do well and have few substantial difficulties. Preoperative assessment of bladder emptying and urodynamics are important in these patients.	UNIV LONDON UNIV COLL,INST UROL & NEPHROL,LONDON WC1E 6BT,ENGLAND	University of London; University College London			Neild, Guy/K-2513-2013					BARNETT M, 1985, J UROLOGY, V134, P654, DOI 10.1016/S0022-5347(17)47370-8; CHURCHILL BM, 1988, J UROLOGY, V140, P1129, DOI 10.1016/S0022-5347(17)41979-3; DUNN M, 1979, BRIT J UROL, V51, P458, DOI 10.1111/j.1464-410X.1979.tb03578.x; GLASS NR, 1985, J UROLOGY, V133, P666, DOI 10.1016/S0022-5347(17)49137-3; MACGREGOR P, 1986, J UROLOGY, V135, P686, DOI 10.1016/S0022-5347(17)45819-8; PITTS WR, 1979, J UROLOGY, V122, P154; REINBERG Y, 1988, J UROLOGY, V140, P1491, DOI 10.1016/S0022-5347(17)42082-9; SCHWARZ GR, 1975, J UROLOGY, V114, P285, DOI 10.1016/S0022-5347(17)67009-5; SHAPIRO SR, 1975, J UROLOGY, V114, P289, DOI 10.1016/S0022-5347(17)67010-1	9	47	47	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1991	338	8779					1376	1379		10.1016/0140-6736(91)92247-Y	http://dx.doi.org/10.1016/0140-6736(91)92247-Y			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR773	1682747				2022-12-01	WOS:A1991GR77300014
J	FISCH, A; SALVANET, A; PRAZUCK, T; FORESTIER, F; GERBAUD, L; COSCAS, G; LAFAIX, C				FISCH, A; SALVANET, A; PRAZUCK, T; FORESTIER, F; GERBAUD, L; COSCAS, G; LAFAIX, C			EPIDEMIOLOGY OF INFECTIVE ENDOPHTHALMITIS IN FRANCE	LANCET			English	Article							POST-OPERATIVE ENDOPHTHALMITIS; HUMAN AQUEOUS-HUMOR; LENS	Data from retrospective studies of endophthalmitis vary widely with respect to incidence and to the pathogens implicated. To see whether we could provide more accurate data, we have done a prospective multicentre national survey of endophthalmitis over one year in France. Records of 36 241 operations and 1148 cases of ocular trauma from 64 centres specialising in eye surgery were analysed. There were 167 cases of endophthalmitis; incidence of postoperative endophthalmitis was 0.31 per 100 operations, and the risk after penetrating ocular trauma was 2.8%. In contrast with most previous studies, Staphylococcus epidermidis was the most frequently isolated organism, with gram-negative organisms accounting for only a small proportion of cases. Patients infected with streptococci had the least favourable outcome. The survey confirms data from retrospective studies showing that the incidence of postoperative or post-injury endophthalmitis is low. The low frequency means that large numbers of patients would be required for a trial of antibiotic efficacy, but such a trial is worthwhile because there are now antibiotics with good ocular bioavailability that are effective against most of the bacteria that cause endophthalmitis.	UNIV HOSP VILLENEUVE ST GEORGES,DEPT OPHTHALMOL,F-94190 VILLENEUVE ST GEO,FRANCE		FISCH, A (corresponding author), UNIV HOSP VILLENEUVE ST GEORGES,ETUD EPIDEMIOL & PROPHYLACT GRP,40 ALLEE SOURCE,F-94190 VILLENEUVE ST GEO,FRANCE.		GERBAUD, Laurent/ABY-4952-2022					ALLEN HF, 1974, ARCH OPHTHALMOL-CHIC, V91, P3, DOI 10.1001/archopht.1974.03900060007002; ALLEN HF, 1978, OPHTHALMOLOGY, V85, P386; ALLEN HF, 1978, OPHTHALMOLOGY, V85, P317; BOHIGIAN GM, 1986, AM J OPHTHALMOL, V101, P323; BRINTON GS, 1984, ARCH OPHTHALMOL-CHIC, V102, P547; CAMERON ME, 1978, OPHTHALMIC SURG LAS, V9, P52; DRIEBE WT, 1986, OPHTHALMOLOGY, V93, P442; FAHMY JA, 1975, ACTA OPHTHALMOL, V53, P522; FISCH A, 1987, J ANTIMICROB CHEMOTH, V20, P453, DOI 10.1093/jac/20.3.453; Forster RK, 1981, CLIN OPHTHALMOL, P1; GLEICHER DA, 1973, AM J OPHTHALMOL, V75, P769, DOI 10.1016/0002-9394(73)90879-9; MELTZER DW, 1981, ARCH OPHTHALMOL-CHIC, V98, P100; OLSON JC, 1983, OPHTHALMOLOGY, V90, P692; PULIAFITO CA, 1982, OPHTHALMOLOGY, V89, P921; ROWSEY JJ, 1982, OPHTHALMOLOGY, V89, P1055; SALVANET A, 1986, J ANTIMICROB CHEMOTH, V18, P199, DOI 10.1093/jac/18.2.199; SHRADER SK, 1990, J INFECT DIS, V162, P115, DOI 10.1093/infdis/162.1.115; WEBER DJ, 1986, REV INFECT DIS, V8, P12	18	108	114	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1991	338	8779					1373	1376						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR773	1682746				2022-12-01	WOS:A1991GR77300013
J	HEDMAN, K; VAHERI, A; BRUMMERKORVENKONTIO, M				HEDMAN, K; VAHERI, A; BRUMMERKORVENKONTIO, M			RAPID DIAGNOSIS OF HANTAVIRUS DISEASE WITH AN IGG-AVIDITY ASSAY	LANCET			English	Article							NEPHROPATHIA EPIDEMICA; HEMORRHAGIC-FEVER; IMMUNOGLOBULIN-M; RENAL SYNDROME; INFECTION; ANTIBODY	Nephropathia epidemica (NE), due to Puumala virus, is endemic in eastern Europe and Scandinavia. Serodiagnosis of NE relies on conventional indirect immunofluorescence to detect IgG against Puumala virus. However, in conventional serology, most patients with acute NE have raised but stable non-diagnostic antibody titres. For better serodiagnosis of NE, we have developed a test that measures the avidity (functional affinity) of IgG antibodies against Puumala virus. This new assay was highly specific and sensitive; a diagnosis of NE could be confirmed or excluded rapidly from an early single serum sample. With this test we have now verified the diagnosis of NE in more than 1300 Finnish patients during 22 months in 1989-91. Our findings point to an incidence of confirmed hantavirus disease much higher than previously shown.			HEDMAN, K (corresponding author), UNIV HELSINKI, DEPT VIROL, HAARTMANINKATU 3, SF-00290 HELSINKI 29, FINLAND.		Hedman, Klaus/D-5379-2009; Vaheri, Antti/AAV-1523-2020					[Anonymous], 1990, LANCET, V336, P407; ANTONIADIS A, 1989, REV INFECT DIS, V11, pS891; AVSICZUPANC T, 1989, ACTA VIROL, V33, P327; BRUMMERKORVENKONTIO M, 1980, J INFECT DIS, V141, P131, DOI 10.1093/infdis/141.2.131; BRUMMERKORVENKONTIO M, 1982, SCAND J INFECT DIS, P88; DESTRIHOU CV, 1989, Q J MED, V73, P941; HEDMAN K, 1989, J INFECT DIS, V159, P736, DOI 10.1093/infdis/159.4.736; KANGRO HO, 1991, J MED VIROL, V33, P100, DOI 10.1002/jmv.1890330207; LEE HW, 1989, PROG MED VIROL, V36, P62; LEE HW, 1978, J INFECT DIS, V137, P298, DOI 10.1093/infdis/137.3.298; LEE HW, 1989, REV INFECT DIS, V11, pS864; LEE PW, 1985, J CLIN MICROBIOL, V22, P940, DOI 10.1128/JCM.22.6.940-944.1985; NIKLASSON B, 1988, J CLIN MICROBIOL, V26, P1519, DOI 10.1128/JCM.26.8.1519-1523.1988; OSTERHAUS ADME, 1989, LANCET, V2, P338; PILASKI J, 1991, LANCET, V337, P111, DOI 10.1016/0140-6736(91)90765-H; PULLEN GR, 1986, J IMMUNOL METHODS, V86, P83, DOI 10.1016/0022-1759(86)90268-1; SCHMALJOHN CS, 1985, SCIENCE, V227, P1041, DOI 10.1126/science.2858126; SETTERGREN B, 1987, J CLIN MICROBIOL, V25, P1134, DOI 10.1128/JCM.25.6.1134-1136.1987; SETTERGREN B, 1989, REV INFECT DIS, V11, P921; THOMAS HIJ, 1991, MED VIROL, V1, P41; YANAGIHARA R, 1990, REV INFECT DIS, V12, P449; ZOLLER L, 1991, LANCET, V338, P183, DOI 10.1016/0140-6736(91)90169-P	22	145	149	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 30	1991	338	8779					1353	1356		10.1016/0140-6736(91)92235-T	http://dx.doi.org/10.1016/0140-6736(91)92235-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR773	1682736				2022-12-01	WOS:A1991GR77300003
J	KINLEN, LJ; HUDSON, C				KINLEN, LJ; HUDSON, C			CHILDHOOD LEUKEMIA AND POLIOMYELITIS IN RELATION TO MILITARY ENCAMPMENTS IN ENGLAND AND WALES IN THE PERIOD OF NATIONAL MILITARY SERVICE, 1950-63	BRITISH MEDICAL JOURNAL			English	Article							LEUKEMIA	Objective - To determine if any excess of childhood leukaemia was associated with the large and increasing numbers of national military servicemen in 1949 and 1950, particularly in rural districts. This would be a further test of the hypothesis that childhood leukaemia can originate in an infection, the transmission of which is facilitated by an increased number of unaccustomed contacts in the community. Design - Rural and urban districts, aggregated by county, were ranked by proportion of servicemen, and five groups containing similar numbers of children were created. In addition, individual local authority districts were ranked and grouped in tenths. Mortality from childhood leukaemia 1950-3 was examined in these groups. Data on infectious diseases were also examined, as well as data on leukaemia in later periods. Setting - England and Wales. Subjects - Children aged under 15 years. Results - In 1950-3 but not subsequently a significant excess of leukaemia in children under 15 was found in the fifth of county groupings with the highest proportions of servicemen. This was due mainly to a significant excess in children under 2 years (and especially in those under 1 year) in rural districts. It was confirmed among the tenth of local authority districts with the highest proportion of servicemen. These rural areas showed significantly more notifications of, and deaths from, poliomyelitis among children than the rural average. Conclusions - The findings support the infection hypothesis. That the excess of leukaemia was greatest in children under 1 year suggests transmission of infection among adults and thence to the fetus. The pattern of spread of poliomyelitis may also have been influenced by the presence of large numbers of servicemen.			KINLEN, LJ (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH MED,CANC RES CAMPAIGN,CANC EPIDEMIOL RES GRP,OXFORD OX2 6HE,ENGLAND.							ANDERSON RM, 1982, SCIENCE, V215, P1053, DOI 10.1126/science.7063839; BRESLOW N, 1987, IARC SCI PUBL, V82, P93; CAMPBELL D, 1984, UNSINKABLE AIRCRAFT; Coburn AFY, 1949, EPIDEMIOLOGY HEMOLYT; GLOVER JA, 1915, CEREBRO SPINAL FEVER; GREAVES MF, 1988, LEUKEMIA, V2, P120; Greaves MF, 1984, PATHOGENESIS LEUKEMI, P129; KINLEN L, 1988, LANCET, V2, P1323; KINLEN LJ, 1991, BRIT J CANCER, V64, P549, DOI 10.1038/bjc.1991.348; KINLEN LJ, 1990, LANCET, V336, P577, DOI 10.1016/0140-6736(90)93389-7; ROBISON LL, 1989, CANCER, V63, P1904; ROYLE T, 1986, BEST YEASTS THEIR LI; TITMUSS RM, 1950, HIST 2ND WORLD WAR, P245; Werner B., 1984, POPULATION TRENDS, V38, P18; 1958, DECENNIAL SUPPLEMENT; 1952, STATISTICAL REV EN 1; 1957, DECENNIAL SUPPLEME 2, V2; 1953, STATISTICAL REV EN 1; 1956, CENSUS 1951 ENGLAND	19	57	57	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1991	303	6814					1357	1362		10.1136/bmj.303.6814.1357	http://dx.doi.org/10.1136/bmj.303.6814.1357			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU384	1760600	Green Published, Bronze			2022-12-01	WOS:A1991GU38400017
J	KOCHEN, MM; HASFORD, JC; JAGER, H; ZIPPEL, S; LAGE, M; ROSENDAHL, C; FUESSL, HS; EICHENLAUB, D				KOCHEN, MM; HASFORD, JC; JAGER, H; ZIPPEL, S; LAGE, M; ROSENDAHL, C; FUESSL, HS; EICHENLAUB, D			HOW DO PATIENTS WITH HIV PERCEIVE THEIR GENERAL-PRACTITIONERS	BRITISH MEDICAL JOURNAL			English	Article							INFECTION; AIDS	Objective - To study the perceptions of patients with HIV of their general practitioners in terms of knowledge, abilities, confidence, and satisfaction. Design - Questionnaire survey of inpatients, outpatients, and members of a self help group. Setting - Two city hospitals, three outpatient clinics, and one AIDS self help group in Munich and Berlin, Germany. Subjects - All 402 patients available between 1 September 1988 and 31 May 1989. Main outcome measures - General practitioners' attitudes towards the patients' HIV status; patients' experience of treatment rejection; reception in the general practitioner's office; the doctor's perceived knowledge about HIV and AIDS. Results - 394 of 402 patients consented to interview; 87% were registered with a general practitioner and 91% of those indicated that the doctor was aware of their HIV diagnosis. The overwhelming majority of patients (94%) had a friendly or at least neutral reception in the general practitioner's surgery and only six patients' general practitioner changed his or her behaviour for the worse because of the HIV diagnosis. Two thirds of patients said they would consult first with their primary care doctor for a physical problem, but only 13% would do so for psychological problems. Over a third of the patients did not routinely inform other doctors or medical staff about their HIV status, but there was no significant correlation between this concealment and ever having been rejected by a doctor (7%) or a dentist (12%). Conclusion - Most patients expressed a high degree of satisfaction with their general practitioners in terms of confidential issues, attitudes, knowledge, and management.	UNIV MUNICH,GEN PRACTICE,W-8000 MUNICH 2,GERMANY; UNIV MUNICH,CHILDRENS HOSP,IMMUNE DEFICIENCY CLIN,W-8000 MUNICH 2,GERMANY; UNIV MUNICH,MED POLICLIN,W-8000 MUNICH 2,GERMANY; SCHWABINGER KRANKENHAUS,IMMUNODEFICIENCY CLIN,MUNICH,GERMANY; SCHWABINGER KRANKENHAUS,DEPT MED 4,MUNICH,GERMANY; AIDS HILFE,MUNICH,GERMANY; AUGUSTE VIKTORIA KRANKENHAUS,DEPT MED 2,BERLIN,GERMANY	University of Munich; University of Munich; University of Munich								BHUGRA D, 1989, J ROY SOC MED, V82, P603, DOI 10.1177/014107688908201013; BUCKNALL A, 1986, J ROY COLL GEN PRACT, V36, P491; GALLAGHER M, 1988, J ROY COLL GEN PRACT, V38, P414; GILLON R, 1987, BRIT MED J, V294, P1332, DOI 10.1136/bmj.294.6583.1332; HODGKIN P, 1988, BRIT MED J, V296, P516, DOI 10.1136/bmj.296.6621.516; KING MB, 1988, BRIT MED J, V297, P182, DOI 10.1136/bmj.297.6642.182; KING MB, 1989, BMJ-BRIT MED J, V299, P713, DOI 10.1136/bmj.299.6701.713; NORTHFELT DW, 1988, ANN INTERN MED, V108, P773; SIBBALD B, 1988, J ROY COLL GEN PRACT, V38, P500; WOFSY CB, 1987, JAMA-J AM MED ASSOC, V257, P2074, DOI 10.1001/jama.257.15.2074; 1990, STATISTICAL YB FEDER, P355; 1988, J R COLL GEN PRACT, V38, P219; 1990, MED J AUSTRALIA, V153, P5	13	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1991	303	6814					1365	1368		10.1136/bmj.303.6814.1365	http://dx.doi.org/10.1136/bmj.303.6814.1365			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU384	1760602	Green Published, Bronze			2022-12-01	WOS:A1991GU38400019
J	OZTURK, M				OZTURK, M			P53 MUTATION IN HEPATOCELLULAR-CARCINOMA AFTER AFLATOXIN EXPOSURE	LANCET			English	Article							HEPATITIS-B VIRUS; EPIDEMIOLOGY; PREVALENCE; CANCER; JAPAN	Mutations of the p53 gene are found in hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Specific mutations might reflect exposure to specific carcinogens and we have screened HCC samples from patients in 14 different countries to determine the frequency of a hotspot mutation at codon 249 of the tumour suppressor p53 gene. We detected mutations in 17% of tumours (12/72) from four countries in south Africa and the southeast coast of Asia. There was no codon 249 mutation in 95 specimens of HCC from other geographical locations including North America, Europe, Middle East, and Japan. Worldwide, the presence of the codon 249 mutation in HCCs correlated with high risk of exposure to aflatoxins and the hepatitis B virus (HBV). Further studies were completed in two groups of HBV-infected patients at different risks of exposure to aflatoxins. 53% of patients (8/15) from Mozambique at high risk of aflatoxin exposure had a tumour with a codon 249 mutation, in contrast with 8% of patients from Transkei (1/12) who were at low risk. HCC is an endemic disease in Mozambique and accounts for up to two thirds of all tumours in men. A codon 249 mutation of the p53 gene identifies an endemic form of HCC strongly associated with dietary aflatoxin intake.			OZTURK, M (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC HEPATOL LAB,BOSTON,MA 02129, USA.		ozturk, mehmet/G-3330-2014; OZTURK, MEHMET/AAS-7241-2021	OZTURK, MEHMET/0000-0002-6092-9706; Kar, Siddhartha/0000-0001-9293-9274; Carr, Brian/0000-0002-6111-5077; PUISIEUX, Alain/0000-0002-9938-3798; Vyas, Girish/0000-0003-1090-4911	NATIONAL CANCER INSTITUTE [R37CA035711, R29CA049832, R01CA035711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K05AA000048] Funding Source: NIH RePORTER; NCI NIH HHS [CA35711, CA49832] Funding Source: Medline; NIAAA NIH HHS [AA00048] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BEASLEY RP, 1982, HEPATOLOGY, V2, pS21; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; DUSHEIKO GM, 1989, AM J EPIDEMIOL, V129, P138, DOI 10.1093/oxfordjournals.aje.a115102; GROOPMAN JD, 1988, CRC CR REV TOXICOL, V19, P113, DOI 10.3109/10408448809014902; HANN HWL, 1982, INT J CANCER, V30, P47, DOI 10.1002/ijc.2910300109; HAYWARD NK, 1991, NATURE, V352, P764, DOI 10.1038/352764a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Kew MC, 1984, ADV HEPATITIS RES, P203; LANGE W, 1987, POSTGRAD MED J, V63, P21; MAYANS MV, 1990, INT J CANCER, V46, P378, DOI 10.1002/ijc.2910460307; MIVECHI NF, 1990, CANCER RES, V50, P2877; MUIR CS, 1990, CANCER RES, V50, P6441; OKUDA K, 1987, CANCER RES, V47, P4967; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PUISIEUX A, IN PRESS CANCER RES; TANAKA T, 1986, AM J EPIDEMIOL, V124, P368, DOI 10.1093/oxfordjournals.aje.a114407; TOWNSEND TR, 1990, JAMA-J AM MED ASSOC, V263, P290; VANRENSBURG SJ, 1985, BRIT J CANCER, V51, P713, DOI 10.1038/bjc.1985.107; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; YEH FS, 1989, CANCER RES, V49, P2506; YU SZ, 1985, SUBCLINICAL HEPATOCE, P189	22	415	424	0	24	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1991	338	8779					1356	1359						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR773	1682737				2022-12-01	WOS:A1991GR77300004
J	PATTERSON, DLH; TREASURE, T				PATTERSON, DLH; TREASURE, T			THE CULPRIT CORONARY-ARTERY LESION	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION; DISEASE		ST GEORGE HOSP,DEPT CARDIOTHORAC,LONDON,ENGLAND	St Georges University London	PATTERSON, DLH (corresponding author), WHITTINGTON HOSP,DEPT CARDIAC,HIGHGATE HILL,LONDON N19 5NF,ENGLAND.							BROWN G, 1990, NEW ENGL J MED, V323, P1989; DETRE K, 1981, CIRCULATION, V63, P1329, DOI 10.1161/01.CIR.63.6.1329; HACKETT D, 1988, EUR HEART J, V9, P1317, DOI 10.1093/oxfordjournals.eurheartj.a062449; HAFT JI, 1988, CHEST, V94, P731, DOI 10.1378/chest.94.4.731; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; MCHENRY PL, 1984, CIRCULATION, V70, P547, DOI 10.1161/01.CIR.70.4.547; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; RENTROP KP, 1988, AM J CARDIOL, V61, P677, DOI 10.1016/0002-9149(88)91048-X; 1980, LANCET, V2, P1173; 1983, CIRCULATION, V68, P939	10	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1991	338	8779					1379	1380		10.1016/0140-6736(91)92248-Z	http://dx.doi.org/10.1016/0140-6736(91)92248-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR773	1682748				2022-12-01	WOS:A1991GR77300015
J	SCHULTZ, R; READ, AW; STRATON, JAY; STANLEY, FJ; MORICH, P				SCHULTZ, R; READ, AW; STRATON, JAY; STANLEY, FJ; MORICH, P			GENITOURINARY TRACT INFECTIONS IN PREGNANCY AND LOW-BIRTH-WEIGHT - CASE-CONTROL STUDY IN AUSTRALIAN ABORIGINAL WOMEN	BRITISH MEDICAL JOURNAL			English	Article							WESTERN-AUSTRALIA; PRETERM BIRTH; HEALTH; MEMBRANES	Objective - To investigate the association between genital and urinary tract infections in pregnant Aboriginal women and low birth weight. Design - Retrospective case-control study controlling for potential confounding variables. Setting - Western Australia from 1985 to 1987. Subjects - All Aboriginal women (n = 269) who had given birth to singleton infants weighing 2250 g or less (cases), and 269 randomly selected Aboriginal women who had given birth to singleton infants weighing 3000 g or more (controls). Main outcome measures - Proportions of women in case and control groups who had had genital and urinary tract infections; odds ratios for low birth weight when genitourinary tract infection was present; population attributable fraction of low birth weight to genitourinary tract infection. Results - At the time of delivery 51% of women in the case group (109/215) had genitourinary tract infections compared with 13% of controls (35/266). After controlling for potential confounding variables the odds ratio for giving birth to infants weighing 2250 g or less when genitourinary tract infection was present was 4.0 (95% confidence interval 2.3 to 7.0). The proportion of infants with low birth weight attributable to genitourinary tract infection in the whole population of Aboriginal women was 32% (95% confidence interval 17% to 49%). Conclusions - There was a strong association between low birth weight and the presence of genitourinary tract infections in Aboriginal women both during pregnancy and at the time of delivery. A community intervention trial of screening and treatment of genitourinary infections in this population is recommended.	WESTERN AUSTRALIAN RES INST CHILD HLTH,PERTH,WA 6001,AUSTRALIA	Telethon Kids Institute; University of Western Australia	SCHULTZ, R (corresponding author), UNIV WESTERN AUSTRALIA,DEPT PUBL HLTH,NEDLANDS,WA 6009,AUSTRALIA.							ARTURO ZC, 1989, THESIS U W AUSTR, P127; BALLARD JL, 1979, J PEDIATR-US, V95, P769, DOI 10.1016/S0022-3476(79)80734-9; BLAND M, 1987, INTRO MED STATISTICS; BOWER C, 1988, REPORT CONGENITAL MA; CHISWICK ML, 1986, BRIT J OBSTET GYNAEC, V93, P1236, DOI 10.1111/j.1471-0528.1986.tb07857.x; CREASY RK, 1980, OBSTET GYNECOL, V55, P692; HILL C, 1987, VALIDATION STUDY W A; HOUSTON S, 1985, MED J AUSTRALIA, V143, pS45; ILLSLEY R, 1963, PERINATAL MORTALITY, P270; KHOURY MJ, 1988, PEDIATRICS, V82, P83; KLIEWER EV, 1989, MED J AUSTRALIA, V151, P493, DOI 10.5694/j.1326-5377.1989.tb128495.x; Lee M L, 1988, J Perinat Neonatal Nurs, V2, P10; LEGER WJ, 1989, AM J PERINAT, V6, P234; MCGREGOR JA, 1988, AM J REPROD IMMUNOL, V16, P123; MOORE D, 1988, PERINATAL STATISTICS; NAEYE RL, 1980, LANCET, V1, P192; ROMERO R, 1989, OBSTET GYNECOL, V73, P576; ROMERO R, 1989, J REPROD MED, V34, P797; ROMERO R, 1989, AM J OBSTET GYNECOL, V161, P817, DOI 10.1016/0002-9378(89)90409-2; Schlesselman J.J., 1982, CASE CONTROL STUDIES; SEWARD JF, 1981, MED J AUSTRALIA, V2, P80, DOI 10.5694/j.1326-5377.1981.tb100804.x; THOMSON N, 1984, AUST NZ J MED, V14, P705, DOI 10.1111/j.1445-5994.1984.tb05038.x; THOMSON N, 1985, MED J AUSTRALIA, V143, pS46; THOMSON N, 1983, AUST ABORIG STUD, V1, P10; TOTH M, 1988, OBSTET GYNECOL, V71, P723; Wang E, 1989, EFFECTIVE CARE PREGN, P534; 1989, AM J EPIDEMIOL, V129, P1247; 1985, SAS PROCEDURES GUIDE	28	26	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1991	303	6814					1369	1373		10.1136/bmj.303.6814.1369	http://dx.doi.org/10.1136/bmj.303.6814.1369			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU384	1760603	Bronze, Green Published			2022-12-01	WOS:A1991GU38400020
J	STONEBRIDGE, PA; BROPHY, CM				STONEBRIDGE, PA; BROPHY, CM			SPIRAL LAMINAR-FLOW IN ARTERIES	LANCET			English	Note							AORTA	Spiral blood-flow patterns in infrainguinal blood-vessels were observed at angioscopy in 54 patients who underwent peripheral vascular reconstruction; the endoluminal surface had spiral folds in 51 of 75 arteries examined. Spiral flow patterns, congruous with inherent endoluminal anatomical features, might more accurately represent blood-flow in infrainguinal arteries than current models of laminar flow.	YALE UNIV,SCH MED,DIV VASC SURG,NEW HAVEN,CT 06510	Yale University	STONEBRIDGE, PA (corresponding author), ROYAL INFIRM,VASC SURG UNIT,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.							FRAZIN L, 1990, CLIN RES, V38, pA331; Fung YC, 1984, BIODYNAMICS CIRCULAT, P77; HUNT TH, 1989, CARDIOVASCULAR SCI T, P124; KARINO T, 1987, ANN NY ACAD SCI, V516, P422; LOGERFO FW, 1985, J VASC SURG, V2, P263, DOI 10.1067/mva.1985.avs0020263; MILLER A, 1991, SURGERY, V109, P286; SEGADAL L, 1987, CIRCULATION, V76, P90, DOI 10.1161/01.CIR.76.1.90; UCHIDA Y, 1987, AM HEART J, V114, P1216, DOI 10.1016/0002-8703(87)90199-2	8	101	113	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1991	338	8779					1360	1361		10.1016/0140-6736(91)92238-W	http://dx.doi.org/10.1016/0140-6736(91)92238-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR773	1682738				2022-12-01	WOS:A1991GR77300005
J	VERITY, CM; GOLDING, J				VERITY, CM; GOLDING, J			RISK OF EPILEPSY AFTER FEBRILE CONVULSIONS - A NATIONAL COHORT STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SEIZURES; CHILDHOOD; BIRTH; FEVER	Objective - To identify children with febrile convulsions, classify their febrile convulsions into simple and complex, and determine the number and type of subsequent afebrile seizures in those children. Design - National population based study. Setting - United Kingdom. Subjects - 16004 neonatal survivors born during one week in April 1970. Main outcome measures - Information about febrile and afebrile seizures obtained from questionnaires at 5 and 10 years of age and from hospital records. Results - Information was available for 14676 of the cohort children. 398 (2.7%) of them had had at least one febrile convulsion. 16 children were known to be neurologically or developmentally abnormal before the first attack. Of the remaining 382 children, 305 had had a simple first febrile convulsion and 77 a complex first febrile convulsion. Thirteen of the 382 had had one or more afebrile seizures, nine of whom had developed epilepsy (recurrent afebrile seizures). A higher proportion of children with complex febrile convulsions (6/95) rather than simple febrile convulsions (3/287) developed epilepsy, the risk being highest for those who had had focal febrile convulsions (5/17; chi-2 = 39.9, p < 0.001). Three of the 32 children who had prolonged febrile convulsions developed afebrile complex partial seizures. Conclusions - The risk of epilepsy after febrile convulsions is much less than reported in many hospital studies, and if febrile convulsions cause brain damage that leads to later epilepsy this is a rare occurrence.	UNIV BRISTOL, INST CHILD HLTH, BRISTOL BS8 1TH, AVON, ENGLAND	University of Bristol	VERITY, CM (corresponding author), ADDENBROOKES HOSP, DEPT PAEDIAT, CAMBRIDGE CB2 2QQ, ENGLAND.			Golding, Jean/0000-0003-2826-3307				ANNEGERS JF, 1987, NEW ENGL J MED, V316, P493, DOI 10.1056/NEJM198702263160901; ANNEGERS JF, 1979, NEUROLOGY, V29, P297, DOI 10.1212/WNL.29.3.297; [Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1980, BMJ, V281, P277; CHAMBERLAIN R, 1975, BRITH BIRTHS 1970, V1; FALCONER MA, 1964, ARCH NEUROL-CHICAGO, V10, P233, DOI 10.1001/archneur.1964.00460150003001; LEE K, 1981, ACTA NEUROL SCAND, V63, P231; LEVITON A, 1981, FEBRILE SEIZURES, P65; MELDRUM B S, 1976, P213; NELSON KB, 1976, NEW ENGL J MED, V295, P1029, DOI 10.1056/NEJM197611042951901; REYNOLDS EH, 1987, EPILEPSIA, V28, P97, DOI 10.1111/j.1528-1157.1987.tb03633.x; ROCCA WA, 1987, NEUROLOGY, V37, P1315, DOI 10.1212/WNL.37.8.1315; ROSS EM, 1980, BRIT MED J, V280, P207, DOI 10.1136/bmj.280.6209.207; TAYLOR DC, 1971, EPILEPSIA, V12, P33, DOI 10.1111/j.1528-1157.1971.tb03913.x; VERITY CM, 1985, BRIT MED J, V290, P1307, DOI 10.1136/bmj.290.6478.1307; VERITY CM, 1985, BMJ-BRIT MED J, V290, P1311, DOI 10.1136/bmj.290.6478.1311; WALLACE SJ, 1975, ARCH DIS CHILD, V50, P943, DOI 10.1136/adc.50.12.943; WALLACE SJ, 1977, ARCH DIS CHILD, V52, P192, DOI 10.1136/adc.52.3.192; Wallace SJ, 1988, CHILD FEBRILE SEIZUR, P109	19	201	205	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 30	1991	303	6814					1373	1376		10.1136/bmj.303.6814.1373	http://dx.doi.org/10.1136/bmj.303.6814.1373			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU384	1760604	Bronze, Green Published			2022-12-01	WOS:A1991GU38400021
J	WALKER, A				WALKER, A			HEALTH AND THE ENVIRONMENT - WASTE-DISPOSAL - FRESH LOOKS AT A ROTTING PROBLEM	BRITISH MEDICAL JOURNAL			English	Article																		CROFT B, 1990, 1990 P HARW WAST MAN; FINGERHUT MA, 1991, NEW ENGL J MED, V324, P212, DOI 10.1056/NEJM199101243240402; GUSTAVSSON P, 1989, AM J IND MED, V15, P245, DOI 10.1002/ajim.4700150302; JAGGER J, 1988, NEW ENGL J MED, V319, P284, DOI 10.1056/NEJM198808043190506; LAGAKOS SW, 1986, J AM STAT ASSOC, V81, P583, DOI 10.2307/2288982; LOWRY S, 1990, BRIT MED J, V300, P177, DOI 10.1136/bmj.300.6718.177; PAIGEN B, 1987, HUM BIOL, V59, P489; WALDRON HA, 1985, BRIT MED J, V290, P1285, DOI 10.1136/bmj.290.6477.1285; 1990, SOCIAL TRENDS, V20; 1991, URBAN SOLID WASTE MA; 1985, 11TH ROYAL COMM ENV; 1988, ASSESSMENT GROUNDWAT; 1989, 2ND REPORT HOUS COMM; 1990, CODE PRACTICE SAFE U; 1991, CLIN WASTE APPRAISAL; 1989, HAZARDOUS WASTE HUMA	16	9	9	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1991	303	6814					1391	1394		10.1136/bmj.303.6814.1391	http://dx.doi.org/10.1136/bmj.303.6814.1391			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU384	1760610	Green Published, Bronze			2022-12-01	WOS:A1991GU38400027
J	WARDROPE, J; RYAN, F; CLARK, G; VENABLES, G; CROSBY, AC; REDGRAVE, P				WARDROPE, J; RYAN, F; CLARK, G; VENABLES, G; CROSBY, AC; REDGRAVE, P			THE HILLSBOROUGH TRAGEDY	BRITISH MEDICAL JOURNAL			English	Article							TRAUMATIC ASPHYXIA		ROYAL HALLAMSHIRE HOSP,ACCID & EMERGENCY MED,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield	WARDROPE, J (corresponding author), NO GEN HOSP,ACCID & EMERGENCY MED,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND.							[Anonymous], 1989, BMJ, V298, P651; CHANNER KS, 1989, BRIT MED J, V299, P1379, DOI 10.1136/bmj.299.6712.1379; FRED HL, 1960, AM J MED, V29, P508, DOI 10.1016/0002-9343(60)90046-2; GORENSTEIN L, 1986, J PEDIATR SURG, V21, P753, DOI 10.1016/S0022-3468(86)80358-X; LANCE JW, 1963, BRAIN, V86, P111, DOI 10.1093/brain/86.1.111; LANDERCASPER J, 1985, J TRAUMA, V25, P838, DOI 10.1097/00005373-198509000-00005; OLLIVIER D, 1837, ANN HYGIENE, V18, P486; PLUM F, 1962, ARCH INTERN MED, V110, P18, DOI 10.1001/archinte.1962.03620190020003; PLUM F, 1981, DIAGNOSIS STUPOR COM; SANDIFORD JA, 1974, J TRAUMA, V14, P805, DOI 10.1097/00005373-197409000-00011; SHAPIRO HM, 1986, ANAESTHESIA, V2, P1573; SHARPE DT, 1985, BRIT MED J, V291, P945, DOI 10.1136/bmj.291.6500.945; Taylor P., 1989, HILLSBOROUGH STADIUM; THOMPSON A, 1989, ANN THORAC SURG, V47, P247, DOI 10.1016/0003-4975(89)90279-8; WILLIAMS JS, 1968, ANN SURG, V167, P384, DOI 10.1097/00000658-196803000-00012; 1990, EMERGENCY PLANNING N	16	33	33	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1991	303	6814					1381	1385		10.1136/bmj.303.6814.1381	http://dx.doi.org/10.1136/bmj.303.6814.1381			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU384	1760607	Green Published, Bronze			2022-12-01	WOS:A1991GU38400024
J	CAMPANELLI, JT; HOCH, W; RUPP, F; KREINER, T; SCHELLER, RH				CAMPANELLI, JT; HOCH, W; RUPP, F; KREINER, T; SCHELLER, RH			AGRIN MEDIATES CELL CONTACT INDUCED ACETYLCHOLINE-RECEPTOR CLUSTERING	CELL			English	Article							TORPEDO ELECTRIC ORGAN; CULTURED MUSCLE-CELLS; GENE-RELATED PEPTIDE; MESSENGER-RNA LEVELS; NEUROMUSCULAR-JUNCTION; BASAL LAMINA; AGGREGATING FACTOR; ALPHA-SUBUNIT; MOTOR NEURONS; PROTEIN	One of the important events in synapse formation is the accumulation of neurotransmitter receptors beneath the presynaptic nerve terminal. Agrin is a component of the synaptic basal lamina that induces the clustering of acetylcholine receptors when bath-applied to muscle fibers in culture. When a cDNA encoding a putative agrin protein is transfected into cells, the molecule is secreted and concentrated on the extracellular surface. Coculture of transfected cells with muscle fibers induces the formation of receptor patches at contact sites. These results demonstrate that expression of a single gene encoding agrin confers receptor clustering that is restricted to specific sites of cell-muscle contact.			CAMPANELLI, JT (corresponding author), STANFORD UNIV, HOWARD HUGHES MED INST, DEPT MOLEC & CELLULAR PHYSIOL, STANFORD, CA 94305 USA.							ANDERSON MJ, 1977, J PHYSIOL-LONDON, V268, P731, DOI 10.1113/jphysiol.1977.sp011879; ANDERSON MJ, 1983, J CELL BIOL, V97, P1396, DOI 10.1083/jcb.97.5.1396; BAYNE EK, 1984, J CELL BIOL, V99, P1486, DOI 10.1083/jcb.99.4.1486; BEVAN S, 1977, J PHYSIOL-LONDON, V267, P195, DOI 10.1113/jphysiol.1977.sp011808; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DENNIS MJ, 1981, ANNU REV NEUROSCI, V4, P43, DOI 10.1146/annurev.ne.04.030181.000355; FALLON JR, 1985, NATURE, V315, P571, DOI 10.1038/315571a0; FERTUCK H C, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1376, DOI 10.1073/pnas.71.4.1376; FONTAINE B, 1987, J CELL BIOL, V105, P1337, DOI 10.1083/jcb.105.3.1337; FROEHNER SC, 1991, J CELL BIOL, V114, P1, DOI 10.1083/jcb.114.1.1; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; GETHING MJ, 1989, METHOD CELL BIOL, V32, P185; GODFREY EW, 1984, J CELL BIOL, V99, P615, DOI 10.1083/jcb.99.2.615; GOLDMAN D, 1988, NEURON, V1, P329, DOI 10.1016/0896-6273(88)90081-5; HALL ZW, 1973, J NEUROBIOL, V4, P343, DOI 10.1002/neu.480040404; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGILLSOLC C, 1990, J EXP BIOL, V153, P1; MAGILLSOLC C, 1988, J CELL BIOL, V107, P1825, DOI 10.1083/jcb.107.5.1825; MCMAHAN UJ, 1978, NATURE, V271, P172, DOI 10.1038/271172a0; NEW HV, 1986, NATURE, V323, P809, DOI 10.1038/323809a0; NITKIN RM, 1990, J CELL BIOL, V111, P1161, DOI 10.1083/jcb.111.3.1161; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; PENG HB, 1991, NEURON, V6, P237; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; QU ZC, 1990, NEURON, V4, P367, DOI 10.1016/0896-6273(90)90049-L; REIST NE, 1987, J CELL BIOL, V105, P2457, DOI 10.1083/jcb.105.6.2457; ROBERTS WM, 1990, J NEUROSCI, V10, P3664; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SCHUETZE SM, 1987, ANNU REV NEUROSCI, V10, P403, DOI 10.1146/annurev.ne.10.030187.002155; STOW JL, 1987, J CELL BIOL, V105, P529, DOI 10.1083/jcb.105.1.529; USDIN TB, 1986, J CELL BIOL, V103, P493, DOI 10.1083/jcb.103.2.493; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WALLACE BG, 1989, J NEUROSCI, V9, P1294; WALLACE BG, 1986, J CELL BIOL, V102, P783, DOI 10.1083/jcb.102.3.783; WEINBERG CB, 1981, DEV BIOL, V84, P255, DOI 10.1016/0012-1606(81)90393-6	39	114	114	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1991	67	5					909	916		10.1016/0092-8674(91)90364-5	http://dx.doi.org/10.1016/0092-8674(91)90364-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1659950				2022-12-01	WOS:A1991GT75500010
J	CHAN, AML; RUBIN, JS; BOTTARO, DP; HIRSCHFIELD, DW; CHEDID, M; AARONSON, SA				CHAN, AML; RUBIN, JS; BOTTARO, DP; HIRSCHFIELD, DW; CHEDID, M; AARONSON, SA			IDENTIFICATION OF A COMPETITIVE HGF ANTAGONIST ENCODED BY AN ALTERNATIVE TRANSCRIPT	SCIENCE			English	Article							INTERLEUKIN-1 RECEPTOR ANTAGONIST; HEPATOCYTE GROWTH-FACTOR; MOLECULAR-CLONING; EPITHELIAL-CELLS; BIOLOGICAL CHARACTERIZATION; SCATTER FACTOR; PURIFICATION; EXPRESSION; PROTEIN; CDNA	We identified a naturally occurring hepatocyte growth factor (HGF) variant, whose predicted sequence extends only through the second kringle domain of this plasminogen-related molecule. This smaller molecule, derived from an alternative HGF transcript, lacked mitogenic activity but specifically inhibited HGF-induced mitogenesis. Cross-linking studies demonstrated that the truncated molecule competes with HGF for binding to the HGF receptor, which has been identified as the c-met proto-oncogene product. Thus, the same gene encodes both a growth factor and its direct antagonist.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Bottaro, Donald P/AAF-3853-2020; Bottaro, Donald P/F-8550-2010; Chan, Andrew/AAC-1145-2020; Chan, Andrew Man-Lok/J-9497-2013	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334; Chan, Andrew/0000-0001-9923-5464; Chan, Andrew Man-Lok/0000-0001-9923-5464				BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CHAN AML, 1988, ONCOGENE, V2, P593; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; Cuatrecasas P, 1976, Adv Protein Chem, V30, P251, DOI 10.1016/S0065-3233(08)60481-7; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOGH J, 1975, HUMAN TUMOR CELLS IN, P115, DOI DOI 10.1007/978-1-4757-1647-4_5; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GOPINATH E, 1989, P NATL ACAD SCI USA, V86, P3045; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; Maniatis T., 1982, MOL CLONING; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PATTHY L, 1984, FEBS LETT, V171, P131, DOI 10.1016/0014-5793(84)80473-1; ROSEN EM, 1990, EXP CELL RES, V186, P22, DOI 10.1016/0014-4827(90)90205-O; RUBIN J, UNPUB; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; ZARNEGAR R, 1989, CANCER RES, V49, P3314	37	209	239	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1991	254	5036					1382	1385		10.1126/science.1720571	http://dx.doi.org/10.1126/science.1720571			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR777	1720571				2022-12-01	WOS:A1991GR77700058
J	CLEM, RJ; FECHHEIMER, M; MILLER, LK				CLEM, RJ; FECHHEIMER, M; MILLER, LK			PREVENTION OF APOPTOSIS BY A BACULOVIRUS GENE DURING INFECTION OF INSECT CELLS	SCIENCE			English	Article							NUCLEAR POLYHEDROSIS-VIRUS; HOMOLOGOUS DNA; DEATH; EXPRESSION; GENOME; VECTORS; INVITRO; PROTEIN; REGION	Programmed cell death is an active process of self destruction that is important in both the development and maintenance of multicellular animals. The molecular mechanisms controlling activation or suppression of programmed cell death are largely unknown. Apoptosis, a morphologically and biochemically defined type of programmed cell death commonly seen in vertebrates, was found to be initiated during baculovirus replication in insect cells. A specific viral gene product, p35, was identified as being responsible for blocking the apoptotic response. Identification of the function of this gene will allow further definition of the molecular pathways involved in the regulation of programmed cell death and may identify the role of apoptosis in invertebrate viral defense systems.	UNIV GEORGIA, DEPT GENET, ATHENS, GA 30602 USA; UNIV GEORGIA, DEPT ENTOMOL, ATHENS, GA 30602 USA; UNIV GEORGIA, DEPT ZOOL, ATHENS, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia			GUO, Zhaoyu/AAS-5699-2020	Clem, Rollie/0000-0002-2368-720X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023719, R01AI023719] Funding Source: NIH RePORTER; NIAID NIH HHS [AI23719] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CHEN LB, 1989, METHOD CELL BIOL, V29, P103; CLEM RJ, UNPUB; CLOUSTON WM, 1985, MED HYPOTHESES, V18, P399, DOI 10.1016/0306-9877(85)90107-0; COCHRAN MA, 1983, J VIROL, V45, P961, DOI 10.1128/JVI.45.3.961-970.1983; DICKSON JA, 1991, J VIROL, V65, P4006, DOI 10.1128/JVI.65.8.4006-4016.1991; FRIESEN PD, 1987, J VIROL, V61, P2264, DOI 10.1128/JVI.61.7.2264-2272.1987; GIORGI F, 1976, J EMBRYOL EXP MORPH, V35, P521; GUARINO LA, 1986, J VIROL, V60, P215, DOI 10.1128/JVI.60.1.215-223.1986; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HINK WF, 1970, NATURE, V226, P466, DOI 10.1038/226466b0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Kerr J.F.R., 1987, P93; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LEE HH, 1978, J VIROL, V27, P754, DOI 10.1128/JVI.27.3.754-767.1978; LIU AF, 1986, J GEN VIROL, V67, P2565, DOI 10.1099/0022-1317-67-11-2565; LOCKSHIN RA, 1985, COMPREHENSIVE INSECT, V2, P301; MARTZ E, 1989, IMMUNOL TODAY, V10, P79, DOI 10.1016/0167-5699(89)90231-4; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; NISSEN MS, 1989, J VIROL, V63, P493, DOI 10.1128/JVI.63.2.493-503.1989; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; PIPAN N, 1980, ZOOMORPHOLOGIE, V94, P217, DOI 10.1007/BF01081936; SMITH WA, 1982, TISSUE CELL, V14, P243, DOI 10.1016/0040-8166(82)90022-2; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213; VOLKMAN LE, 1982, APPL ENVIRON MICROB, V44, P227, DOI 10.1128/AEM.44.1.227-233.1982; Walker N I, 1988, Methods Achiev Exp Pathol, V13, P18; WILSON ME, 1986, VIROLOGY, V151, P315, DOI 10.1016/0042-6822(86)90052-8; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	30	687	767	3	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	1991	254	5036					1388	1390		10.1126/science.1962198	http://dx.doi.org/10.1126/science.1962198			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR777	1962198				2022-12-01	WOS:A1991GR77700060
J	DAVIS, I; ISHHOROWICZ, D				DAVIS, I; ISHHOROWICZ, D			APICAL LOCALIZATION OF PAIR-RULE TRANSCRIPTS REQUIRES 3' SEQUENCES AND LIMITS PROTEIN DIFFUSION IN THE DROSOPHILA BLASTODERM EMBRYO	CELL			English	Article							MATERNAL MESSENGER-RNA; SEGMENT-POLARITY GENE; FUSHI-TARAZU; PATTERN-FORMATION; INSITU HYBRIDIZATION; XENOPUS OOCYTES; BICOID PROTEIN; EXPRESSION; HUNCHBACK; ENCODES	The peripheral cytoplasm (periplasm) of the Drosophila blastoderm embryo is subdivided into apical and basal compartments by a layer of nuclei. We have demonstrated three classes of periplasmic transcript localization: apical, basal, and unlocalized (apical and basal), each of which depends on 3' sequences. We define 3' apical localization signals within the even-skipped, fushi tarazu, and hairy pair-rule segmentation genes and the alpha-1-tubulin and bicoid genes. 3' human alpha-globin sequences direct transcripts basally. Transcript destination depends on transcript structure, not on transcript stability or chromosomal location. Apical transcripts direct apical compartmentalization of cytoplasmic protein. We propose that apical localization of pair-rule transcripts restricts lateral protein diffusion, thereby allowing pair-rule proteins to define sharp boundaries and precise spatial domains.			DAVIS, I (corresponding author), IMPERIAL CANC RES FUND, DEV BIOL UNIT, DEPT ZOOL, OXFORD OX1 3PS, ENGLAND.		Davis, Ilan/F-4975-2010	Ish-Horowicz, David/0000-0001-5684-7129; Davis, Ilan/0000-0002-5385-3053				AKAM ME, 1985, EMBO J, V4, P1689, DOI 10.1002/j.1460-2075.1985.tb03838.x; Alberts B., 1989, MOL BIOL CELL; ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BANERJEE U, 1987, CELL, V49, P281, DOI 10.1016/0092-8674(87)90569-1; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; DAVIS I, 1990, CELL BIOL INT REP, V14, pS9; DAVIS I, 1990, THESIS OXFORD U OXFO; DAVIS L, 1987, NATURE, V330, P477, DOI 10.1038/330477a0; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; EDGAR BA, 1987, GENE DEV, V1, P1226, DOI 10.1101/gad.1.10.1226; EDGAR BA, 1989, DEV GENET, V10, P124, DOI 10.1002/dvg.1020100303; EDGAR BA, 1986, CELL, V47, P747, DOI 10.1016/0092-8674(86)90517-9; Erlich H.A., 1989, PCR TECHNOLOGY; FONTAINE B, 1988, EMBO J, V7, P603, DOI 10.1002/j.1460-2075.1988.tb02853.x; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; GAUL U, 1989, DEVELOPMENT, V107, P651; Gottlieb E, 1990, CURR OPIN CELL BIOL, V2, P1080, DOI 10.1016/0955-0674(90)90159-C; HAENLIN M, 1990, DEVELOPMENT, V110, P905; HARTLEY DA, 1987, EMBO J, V6, P3407, DOI 10.1002/j.1460-2075.1987.tb02664.x; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; Howard K, 1990, Semin Cell Biol, V1, P161; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; INGHAM P, 1988, DEVELOPMENT, V104, P51; INGHAM PW, 1988, NATURE, V331, P73, DOI 10.1038/331073a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; ISHHOROWICZ D, 1987, CELL, V51, P405, DOI 10.1016/0092-8674(87)90636-2; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KELLERMAN KA, 1990, GENE DEV, V4, P1936, DOI 10.1101/gad.4.11.1936; KOPCZYNSKI CC, 1989, DEVELOPMENT, V107, P623; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LAWRENCE JB, 1986, CELL, V45, P407, DOI 10.1016/0092-8674(86)90326-0; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LAWRENCE PA, 1989, DEVELOPMENT, V105, P761; LEHMANN R, 1991, DEVELOPMENT, V112, P679; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MACDONALD PM, 1986, CELL, V47, P721, DOI 10.1016/0092-8674(86)90515-5; Mattaj IW, 1990, CURR OPIN CELL BIOL, V2, P528, DOI 10.1016/0955-0674(90)90138-5; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MITCHISON TJ, 1983, DEV BIOL, V99, P261, DOI 10.1016/0012-1606(83)90275-0; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; PANKRATZ MJ, 1990, CELL, V61, P309, DOI 10.1016/0092-8674(90)90811-R; POLLOCK JA, 1990, GENE DEV, V4, P806, DOI 10.1101/gad.4.5.806; RAFF JW, 1990, DEVELOPMENT, V110, P1249; RALSTON E, 1989, SCIENCE, V244, P1066, DOI 10.1126/science.2543074; RIDDIHOUGH G, 1991, IN PRESS GENES DEV; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEISGUTH F, 1990, GENE DEV, V4, P922, DOI 10.1101/gad.4.6.922; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STELLER H, 1985, EMBO J, V4, P167, DOI 10.1002/j.1460-2075.1985.tb02332.x; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; STRUHL G, 1985, NATURE, V318, P677, DOI 10.1038/318677a0; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; TRAPP BD, 1987, P NATL ACAD SCI USA, V84, P7773, DOI 10.1073/pnas.84.21.7773; WEINER AJ, 1984, CELL, V37, P843, DOI 10.1016/0092-8674(84)90419-7; WEIR MP, 1985, NATURE, V318, P433, DOI 10.1038/318433a0; Wieschaus E., 1986, P199; YISRAELI JK, 1988, NATURE, V336, P592, DOI 10.1038/336592a0	77	134	135	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1991	67	5					927	940		10.1016/0092-8674(91)90366-7	http://dx.doi.org/10.1016/0092-8674(91)90366-7			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1959136				2022-12-01	WOS:A1991GT75500012
J	DROUFFE, JM; MAGGS, AC; LEIBLER, S				DROUFFE, JM; MAGGS, AC; LEIBLER, S			COMPUTER-SIMULATIONS OF SELF-ASSEMBLED MEMBRANES	SCIENCE			English	Article							THERMAL FLUCTUATIONS; STATISTICAL-MECHANICS; MOLECULAR-DYNAMICS; BENDING ELASTICITY; FLUID MEMBRANES; HEXATIC ORDER; IONIC GEL; VESICLES; UNDULATIONS; CURVATURE	Molecular dynamics simulations in three dimensions of particles that self-assemble to form two-dimensional, membrane-like objects are presented. Anisotropic, multibody forces, chosen so as to mimic real interactions between amphiphilic molecules, generate a finite rigidity and compressibility of the assembled membranes, as well as a finite line tension at their free edges. This model and its generalizations can be used to study a large class of phenomena taking place in fluctuating membranes. For instance, both fluid and solid-like phases, separated by a phase transition, are obtained and some of the large-scale properties of these membranes studied. In particular, thermal undulations of quasi-spherical fluid vesicles are analyzed, in a manner similar to recent experiments in lipid systems.	SERV PHYS THEOR SACLAY,F-91191 GIF SUR YVETTE,FRANCE; ECOLE SUPER PHYS & CHIM IND,PHYSICOCHIM THEOR LAB,F-75231 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)								ABRAHAM FF, 1990, SCIENCE, V249, P393, DOI 10.1126/science.249.4967.393; ABRAHAM FF, 1989, PHYS REV LETT, V62, P1757, DOI 10.1103/PhysRevLett.62.1757; Alberts B., 1989, MOL BIOL CELL; BAILLIE CF, 1990, NUCL PHYS B, V335, P469, DOI 10.1016/0550-3213(90)90504-7; BEYSENS D, IN PRESS DYNAMICAL P; BIVAS I, 1987, J PHYS-PARIS, V48, P855, DOI 10.1051/jphys:01987004805085500; CATTERALL SM, 1989, PHYS LETT B, V220, P207, DOI 10.1016/0370-2693(89)90038-5; CICOTTI G, 1987, MOL DYNAMICS MONTE C; DAVID F, 1987, J PHYS-PARIS, V48, P2059, DOI 10.1051/jphys:0198700480120205900; ENGELHARDT H, 1985, J PHYS LETT-PARIS, V46, pL395, DOI 10.1051/jphyslet:01985004608039500; EVANS DJ, 1977, MOL PHYS, V34, P327, DOI 10.1080/00268977700101761; FAUCON JF, 1989, J PHYS-PARIS, V50, P2389, DOI 10.1051/jphys:0198900500170238900; HELFRICH W, 1988, PHYS REV A, V38, P3065, DOI 10.1103/PhysRevA.38.3065; HELFRICH W, 1985, J PHYS-PARIS, V46, P1263, DOI 10.1051/jphys:019850046070126300; HELFRICH W, 1973, Z NATURFORSCH C, VC 28, P693, DOI 10.1515/znc-1973-11-1209; HO JS, 1990, EUROPHYS LETT, V12, P295, DOI 10.1209/0295-5075/12/4/002; HO JS, 1990, PHYS REV A, V41, P5745; HUSE DA, 1988, J PHYS-PARIS, V49, P605, DOI 10.1051/jphys:01988004904060500; Israelachvili J.N., 1985, INTERMOLECULAR SURFA; KANTOR Y, 1986, PHYS REV LETT, V57, P791, DOI 10.1103/PhysRevLett.57.791; KANTOR Y, 1987, PHYS REV A, V38, P4020; LEIBLER S, 1990, NATURE, V348, P586, DOI 10.1038/348586a0; LEIBLER S, 1989, PHYS REP, V184, P265, DOI 10.1016/0370-1573(89)90044-6; LIPOWSKY R, 1990, PHYS REV LETT, V65, P2893, DOI 10.1103/PhysRevLett.65.2893; LIPOWSKY R, 1991, NATURE, V349, P475, DOI 10.1038/349475a0; MEUNIER J, 1987, PHYSICS AMPHIPHILIC; MILNER ST, 1987, PHYS REV A, V36, P4371, DOI 10.1103/PhysRevA.36.4371; Nelson D., 1988, Random Fluctuations and Pattern Growth: Experiments and Models. Proceedings of the NATO Advanced Study Institute, P193; NELSON DR, 1987, J PHYS-PARIS, V48, P1085, DOI 10.1051/jphys:019870048070108500; NELSON DR, 1989, STATISTICAL MECHANIC; PELITI L, 1985, PHYS REV LETT, V54, P1690, DOI 10.1103/PhysRevLett.54.1690; RENKEN RL, 1991, NUCL PHYS B, V354, P328, DOI 10.1016/0550-3213(91)90358-5; SCHNEIDER MB, 1984, J PHYS-PARIS, V45, P1457, DOI 10.1051/jphys:019840045090145700; SMIT B, 1990, NATURE, V348, P624, DOI 10.1038/348624a0; STOKKE BT, 1986, EUR BIOPHYS J BIOPHY, V13, P219, DOI 10.1007/BF00260369; STOKKE BT, 1986, EUR BIOPHYS J BIOPHY, V13, P203, DOI 10.1007/BF00260368	36	146	148	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1991	254	5036					1353	1356		10.1126/science.1962193	http://dx.doi.org/10.1126/science.1962193			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR777	1962193				2022-12-01	WOS:A1991GR77700048
J	EDIDIN, M; KUO, SC; SHEETZ, MP				EDIDIN, M; KUO, SC; SHEETZ, MP			LATERAL MOVEMENTS OF MEMBRANE-GLYCOPROTEINS RESTRICTED BY DYNAMIC CYTOPLASMIC BARRIERS	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEINS; DIFFUSION; MOBILITY; PARTICLES; ANTIGENS; SURFACE	Cell membranes often are patchy, composed of lateral domains. These domains may be formed by barriers within or on either side of the membrane bilayer. Major histocompatibility complex (MHC) class 1 molecules that were either transmembrane- (H-2D(b)) or glycosylphosphatidylinositol (GPI)-anchored (Qa2) were labeled with antibody-coated gold particles and moved across the cell surface with a laser optical tweezers until they encountered a barrier, the barrier-free path length (BFP). At room temperature, the BFPs of Qa2 and H-2D(b) were 1.7 +/- 0.2 and 0.6 +/- 0.1 (micrometers +/- SEM), respectively. Barriers persisted at 34-degrees-C, although the BFP for both MHC molecules was fivefold greater at 34-degrees-C than at 23-degrees-C. This indicates that barriers to lateral movement are primarily on the cytoplasmic half of the membrane and are dynamic.	DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	Duke University; Johns Hopkins University					NIGMS NIH HHS [GM 36277] Funding Source: Medline; PHS HHS [AL14584] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036277] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; BENNETT GV, 1990, CURR OPIN CELL BIOL, V2, P51; Block S, 1990, NONINVASIVE TECHNIQU, V9, P375; DEBRABANDER M, 1991, J CELL BIOL, V112, P111, DOI 10.1083/jcb.112.1.111; EDIDIN M, 1991, J CELL BIOL, V112, P1143, DOI 10.1083/jcb.112.6.1143; EDIDIN M, IN PRESS STRUCTURE C; GHOSH RN, 1990, BIOPHYS J, V57, pA286; JACOBSON K, 1987, ANNU REV PHYSIOL, V49, P163, DOI 10.1146/annurev.ph.49.030187.001115; KUCIK DF, 1991, J CELL BIOL, V114, P1029, DOI 10.1083/jcb.114.5.1029; NIGG EA, 1980, P NATL ACAD SCI-BIOL, V77, P4702, DOI 10.1073/pnas.77.8.4702; OZATO K, 1981, J IMMUNOL, V126, P317; OZATO K, 1980, J IMMUNOL, V125, P2473; PETERS R, 1988, FEBS LETT, V234, P1, DOI 10.1016/0014-5793(88)81290-0; SAXTON MJ, 1990, BIOPHYS J, V58, P1303, DOI 10.1016/S0006-3495(90)82470-X; SHEETZ MP, 1983, SEMIN HEMATOL, V20, P175; SHEETZ MP, 1980, NATURE, V285, P510, DOI 10.1038/285510a0; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; STROYNOWSKI I, 1987, CELL, V50, P759, DOI 10.1016/0092-8674(87)90334-5; STROYNOWSKI I, 1990, ANNU REV IMMUNOL, V8, P501, DOI 10.1146/annurev.iy.08.040190.002441	19	222	222	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1991	254	5036					1379	1382		10.1126/science.1835798	http://dx.doi.org/10.1126/science.1835798			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR777	1835798				2022-12-01	WOS:A1991GR77700057
J	MILBURN, MV; PRIVE, GG; MILLIGAN, DL; SCOTT, WG; YEH, J; JANCARIK, J; KOSHLAND, DE; KIM, SH				MILBURN, MV; PRIVE, GG; MILLIGAN, DL; SCOTT, WG; YEH, J; JANCARIK, J; KOSHLAND, DE; KIM, SH			3-DIMENSIONAL STRUCTURES OF THE LIGAND-BINDING DOMAIN OF THE BACTERIAL ASPARTATE RECEPTOR WITH AND WITHOUT A LIGAND	SCIENCE			English	Article							DIRECTED CROSS-LINKING; EPIDERMAL GROWTH-FACTOR; HUMAN INSULIN-RECEPTOR; ELECTRON-DENSITY MAP; ESCHERICHIA-COLI; MACROMOLECULAR CRYSTALLOGRAPHY; SIGNAL TRANSDUCTION; SECONDARY STRUCTURE; WEISSENBERG CAMERA; TAR CHEMORECEPTOR	The three-dimensional structure of an active, disulfide cross-linked dimer of the ligand-binding domain of the Salmonella typhimurium aspartate receptor and that of an aspartate complex have been determined by x-ray crystallographic methods at 2.4 and 2.0 angstrom (angstrom) resolution, respectively. A single subunit is a four-alpha-helix bundle with two long amino-terminal and carboxyl-terminal helices and two shorter helices that form a cylinder 20 angstrom in diameter and more than 70 angstrom long. The two subunits in the disulfide-bonded dimer are related by a crystallographic twofold axis in the apo structure, but by a noncrystallographic twofold axis in the aspartate complex structure. The latter structure reveals that the ligand binding site is located more than 60 angstrom from the presumed membrane surface and is at the interface of the two subunits. Aspartate binds between two alpha-helices from one subunit and one alpha-helix from the other in a highly charged pocket formed by three arginines. The comparison of the apo and aspartate complex structures shows only small structural changes in the individual subunits, except for one loop region that is disordered, but the subunits appear to change orientation relative to each other. The structures of the two forms of this protein provide a step toward understanding the mechanisms of transmembrane signaling.	UNIV CALIF BERKELEY, DEPT BIOCHEM, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley			Privé, Gilbert G/A-3039-2008	Scott, William/0000-0002-9273-3564; Prive, Gilbert/0000-0002-0712-4319	NIAID NIH HHS [AI 30725] Funding Source: Medline; NIDDK NIH HHS [DK09765] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030725] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK009765, R01DK009765] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN J, 1987, P NATL ACAD SCI USA, V84, P2532, DOI 10.1073/pnas.84.8.2532; ARGOS P, 1977, BIOCHEM BIOPH RES CO, V75, P83, DOI 10.1016/0006-291X(77)91292-X; BANYARD SH, 1978, NATURE, V271, P282, DOI 10.1038/271282a0; BIEMANN HP, UNPUB; BOURRET RB, 1989, J BIOL CHEM, V264, P7085; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; BRUNGER AT, 1990, XPLOR VERSION 21; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DEISENHOFER J, 1984, J MOL BIOL, V180, P385, DOI 10.1016/S0022-2836(84)80011-X; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; HIGASHI T, 1989, J APPL CRYSTALLOGR, V22, P9, DOI 10.1107/S0021889888009562; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; IMAE Y, 1987, J BACTERIOL, V169, P371, DOI 10.1128/jb.169.1.371-379.1987; JANCARIK J, 1991, J MOL BIOL, V221, P31, DOI 10.1016/0022-2836(91)90798-B; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOSHLAND DE, 1988, BIOCHEMISTRY-US, V27, P5829, DOI 10.1021/bi00416a001; KRIKOS A, 1983, CELL, V33, P615, DOI 10.1016/0092-8674(83)90442-7; LEE L, 1990, J BACTERIOL, V172, P377, DOI 10.1128/JB.172.1.377-382.1990; LEE L, 1988, J BACTERIOL, V170, P4769, DOI 10.1128/jb.170.10.4769-4774.1988; LYNCH BA, IN PRESS P NATL ACAD; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MILLIGAN DL, IN PRESS SCIENCE; MILLIGAN DL, UNPUB; MOE GR, 1989, P NATL ACAD SCI USA, V86, P5683, DOI 10.1073/pnas.86.15.5683; MOE GR, 1986, MICROBIAL ENERGY TRA, P163; MOWBRAY SL, 1990, J BIOL CHEM, V265, P15638; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P225, DOI 10.1107/S0021889879012218; RUSSO AF, 1983, SCIENCE, V220, P1016, DOI 10.1126/science.6302843; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAKABE N, 1983, J APPL CRYSTALLOGR, V16, P542, DOI 10.1107/S0021889883010973; STEIGEMANN W, 1982, PROTEIN PACKAGE CRYS; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; TERWILLIGER TC, 1986, P NATL ACAD SCI USA, V83, P6707, DOI 10.1073/pnas.83.18.6707; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WARK KB, 1975, NATURE, V257, P818; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WOLFF C, 1988, J BACTERIOL, V170, P4509, DOI 10.1128/jb.170.10.4509-4515.1988; YAMAMOTO T, 1984, CELL, V33, P615; 1979, SERK4 DAR LAB COLL C	47	394	398	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	1991	254	5036					1342	1347		10.1126/science.1660187	http://dx.doi.org/10.1126/science.1660187			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR777	1660187	Green Submitted			2022-12-01	WOS:A1991GR77700045
J	MILLER, EK; LI, L; DESIMONE, R				MILLER, EK; LI, L; DESIMONE, R			A NEURAL MECHANISM FOR WORKING AND RECOGNITION MEMORY IN INFERIOR TEMPORAL CORTEX	SCIENCE			English	Article							STATE DEPENDENT ACTIVITY; MONKEY VISUAL-CORTEX; SHORT-TERM; RESPONSES; NEURONS; TASKS; V4	Inferior temporal (IT) cortex is critical for visual memory, but it is not known how IT neurons retain memories while new information is streaming into the visual system. Single neurons were therefore recorded from IT cortex of two rhesus monkeys performing tasks that required them to hold items in memory while concurrently viewing other items. The neuronal response to an incoming visual stimulus was attenuated if it matched a stimulus actively held in working memory, even when several other stimuli intervened. The neuronal response to novel stimuli declined as the stimuli became familiar to the animal. IT neurons appear to function as adaptive mnemonic "filters" that preferentially pass information about new, unexpected, or not recently seen stimuli.	NIMH,NEUROPSYCHOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)			Miller, Earl K./AAE-8187-2019; Desimone, Robert/G-1121-2018	Miller, Earl K./0000-0002-0582-6958; 				BAYLIS GC, 1987, EXP BRAIN RES, V65, P614; CARPENTER GA, 1990, NEURAL NETWORKS, V3, P129, DOI 10.1016/0893-6080(90)90085-Y; ESKANDAR EN, 1991, INVEST OPHTH VIS SCI, V32, P1036; FUSTER JM, 1982, J NEUROSCI, V2, P361; GAFFAN D, 1980, BRAIN RES, V196, P373, DOI 10.1016/0006-8993(80)90402-3; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; HAENNY PE, 1988, EXP BRAIN RES, V69, P225, DOI 10.1007/BF00247569; HAENNY PE, 1988, EXP BRAIN RES, V69, P245, DOI 10.1007/BF00247570; HOREL JA, 1984, BEHAV NEUROSCI, V98, P310, DOI 10.1037/0735-7044.98.2.310; Hosmer D, 2013, APPL LOGISTIC REGRES; Kohonen T, 1984, SELF ORG ASS MEMORY; MIKAMI A, 1980, BRAIN RES, V182, P65, DOI 10.1016/0006-8993(80)90830-6; MILLER EK, IN PRESS VIS NEUROSC; MISHKIN M, 1982, PHILOS T R SOC LONDO, V85, P95; MIYASHITA Y, 1988, NATURE, V331, P68, DOI 10.1038/331068a0; RICHES IP, 1991, J NEUROSCI, V11, P1763; ROLLS ET, 1989, EXP BRAIN RES, V76, P153; SQUIRE L, 1991, Society for Neuroscience Abstracts, V17, P4	18	507	514	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1991	254	5036					1377	1379		10.1126/science.1962197	http://dx.doi.org/10.1126/science.1962197			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR777	1962197				2022-12-01	WOS:A1991GR77700056
J	MONTESANO, R; MATSUMOTO, K; NAKAMURA, T; ORCI, L				MONTESANO, R; MATSUMOTO, K; NAKAMURA, T; ORCI, L			IDENTIFICATION OF A FIBROBLAST-DERIVED EPITHELIAL MORPHOGEN AS HEPATOCYTE GROWTH-FACTOR	CELL			English	Article							SCATTER FACTOR; ANGIOGENESIS INVITRO; MOLECULAR-CLONING; HEPATOPOIETIN-A; MESSENGER-RNA; PURIFICATION; CELLS; EXPRESSION; EMBRYOGENESIS; MONOLAYERS	We have previously shown that Madin-Darby canine kidney (MDCK) epithelial cells grown in collagen gels in the presence of fibroblasts or fibroblast-conditioned medium (CM) form branching tubules, instead of the spherical cysts that develop under control conditions. We now report that the fibroblast-derived molecule responsible for epithelial tubulogenesis is hepatocyte growth factor (HGF). First, addition of exogenous HGF to cultures of MDCK cells induces formation of epithelial tubules. Second, the tubulogenic activity of fibroblast CM is completely abrogated by antibodies to HGF. These results demonstrate that HGF, a polypeptide that was identified as a mitogen for cultured hepatocytes, has the properties of a paracrine mediator of epithelial morphogenesis, and suggest that it may play important roles in the formation of parenchymal organs during embryonic development.	KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN	Kyushu University	MONTESANO, R (corresponding author), UNIV GENEVA,MED CTR,INST HISTOL & EMBRYOL,DEPT MORPHOL,CH-1211 GENEVA 4,SWITZERLAND.							ASAMI O, 1991, J BIOCHEM-TOKYO, V109, P8; Bernfield M., 1984, ROLE EXTRACELLULAR M, P545; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAMBARD M, 1981, J CELL BIOL, V91, P157, DOI 10.1083/jcb.91.1.157; COFFER A, 1991, BIOCHEM J, V278, P35, DOI 10.1042/bj2780035; CUNHA GR, 1985, CELL DIFFER DEV, V17, P137, DOI 10.1016/0045-6039(85)90481-6; DOWRICK PG, 1991, CYTOKINE, V3, P299, DOI 10.1016/1043-4666(91)90498-3; FURLONG RA, 1991, J CELL SCI, V100, P173; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GROBSTEIN C, 1956, ADV CANCER RES, V4, P187, DOI 10.1016/S0065-230X(08)60725-3; HALL HG, 1982, P NATL ACAD SCI-BIOL, V79, P4672, DOI 10.1073/pnas.79.15.4672; HIGUCHI O, 1991, BIOCHEM BIOPH RES CO, V176, P599, DOI 10.1016/S0006-291X(05)80226-8; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KINOSHITA T, 1989, BIOCHEM BIOPH RES CO, V165, P1229, DOI 10.1016/0006-291X(89)92733-2; KONISHI T, 1991, IN PRESS BIOCH BIOPH; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P45, DOI 10.1016/0006-291X(91)90887-D; MATSUMOTO K, 1991, IN PRESS CRIT REV ON; MCATEER JA, 1987, ANAT REC, V217, P229, DOI 10.1002/ar.1092170303; MERCOLA M, 1988, DEVELOPMENT, V102, P451; MICHALOPOULOS G, 1984, CANCER RES, V44, P4414; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONTESANO R, 1983, J CELL BIOL, V97, P935, DOI 10.1083/jcb.97.3.935; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; MONTESANO R, 1991, P NATL ACAD SCI USA, V66, P697; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; PRAT PM, 1991, IN PRESS INT J CANCE; ROSEN EM, 1990, P SOC EXP BIOL MED, V195, P34; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Saxen L., 1976, CELL SURFACE ANIMAL, P331; SEKI T, 1990, BIOCHEM BIOPH RES CO, V172, P321, DOI 10.1016/S0006-291X(05)80212-8; SLACK JMW, 1989, LANCET, V1, P1312; SPORN MB, 1990, HDB EXPT PHARM, V1; SPORN MB, 1990, HDB EXPT PHARM, V2; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; UENO N, 1990, Progress in Growth Factor Research, V2, P113, DOI 10.1016/0955-2235(90)90027-H; WARREN SL, 1987, MOL CELL BIOL, V7, P1326, DOI 10.1128/MCB.7.4.1326; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; WOLF HK, 1991, AM J PATHOL, V138, P1035; YANG J, 1979, P NATL ACAD SCI USA, V76, P3401, DOI 10.1073/pnas.76.7.3401; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252; ZARNEGAR R, 1989, CANCER RES, V49, P3314	57	1160	1201	1	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1991	67	5					901	908		10.1016/0092-8674(91)90363-4	http://dx.doi.org/10.1016/0092-8674(91)90363-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1835669				2022-12-01	WOS:A1991GT75500009
J	PAN, T; GUTELL, RR; UHLENBECK, OC				PAN, T; GUTELL, RR; UHLENBECK, OC			FOLDING OF CIRCULARLY PERMUTED TRANSFER-RNAS	SCIENCE			English	Article							PHENYLALANINE TRANSFER-RNA; YEAST TRANSFER RNAPHE; ESCHERICHIA-COLI; CLEAVAGES; SEQUENCE; ENZYME; INVIVO; ACID; GENE	All of the ribose-phosphate linkages in yeast tRNA(Phe) that could be cleaved without affecting the folding of the molecule have been determined in a single experiment. Circular permutation analysis subjects circular tRNA molecules to limited alkaline hydrolysis in order to generate one random break per molecule. Correctly folded tRNAs were identified by lead cleavage at neutral pH, a well-characterized reaction that requires proper folding of tRNA(Phe). Surprisingly, most of the circularly permuted tRNA molecules folded correctly. This result suggests that the tRNA folding motif could occur internally within other RNA sequences, and a computer search of Genbank entries has identified many examples of such motifs.	UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA; UNIV COLORADO, DEPT MOLEC & CELLULAR DEV BIOL, BOULDER, CO 80309 USA	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder					NIGMS NIH HHS [GM37552] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037552] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEHLEN LS, 1990, BIOCHEMISTRY-US, V29, P2515, DOI 10.1021/bi00462a013; BEHLEN LS, UNPUB; BROWN RS, 1985, BIOCHEMISTRY-US, V24, P4785, DOI 10.1021/bi00339a012; BRUCE AG, 1978, NUCLEIC ACIDS RES, V5, P3665, DOI 10.1093/nar/5.10.3665; DARDEL F, 1990, MOL GEN GENET, V223, P121, DOI 10.1007/BF00315804; DREHER TW, 1989, J MOL BIOL, V206, P425, DOI 10.1016/0022-2836(89)90491-9; DREHER TW, 1988, J MOL BIOL, V201, P31, DOI 10.1016/0022-2836(88)90436-6; GAUTHERET D, 1990, COMPUT APPL BIOSCI, V6, P325; GRAY MW, 1990, RIBOSOME, P589; IVANOV VI, 1973, BIOPOLYMERS, V12, P89, DOI 10.1002/bip.1973.360120109; KIM SH, 1978, TRANSFER RNA, P248; KRZYZOSIAK WJ, 1988, BIOCHEMISTRY-US, V27, P5771, DOI 10.1021/bi00415a056; LUGER K, 1989, SCIENCE, V243, P206, DOI 10.1126/science.2643160; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; PAN T, UNPUB; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P368, DOI DOI 10.1007/978-1-4612-5190-3_17; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SAMPSON JR, 1987, COLD SPRING HARB SYM, V52, P267, DOI 10.1101/SQB.1987.052.01.032; SPRINGER M, 1989, EMBO J, V8, P2417, DOI 10.1002/j.1460-2075.1989.tb08372.x; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; WERNER C, 1976, BIOCHIM BIOPHYS ACTA, V432, P161, DOI 10.1016/0005-2787(76)90158-1; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911	24	103	105	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	1991	254	5036					1361	1364		10.1126/science.1720569	http://dx.doi.org/10.1126/science.1720569			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR777	1720569				2022-12-01	WOS:A1991GR77700051
J	RIGAUD, G; ROUX, J; PICTET, R; GRANGE, T				RIGAUD, G; ROUX, J; PICTET, R; GRANGE, T			INVIVO FOOTPRINTING OF RAT TAT GENE - DYNAMIC INTERPLAY BETWEEN THE GLUCOCORTICOID RECEPTOR AND A LIVER-SPECIFIC FACTOR	CELL			English	Article							TYROSINE AMINOTRANSFERASE GENE; STEROID-DEPENDENT INTERACTION; TRANSCRIPTION FACTORS; MMTV PROMOTER; TRYPTOPHAN OXYGENASE; ENHANCER SEQUENCES; NUCLEAR FACTOR; BINDING-SITE; DNA-BINDING; HORMONE	HNF5, a liver-specific DNA-binding protein, interacts with DNA in a manner that allows DNAase I cleavage in the middle of its recognition sequence. Using this property we have identified in vivo HNF5 bound to its sites within two glucocorticoid-responsive units of the rat tyrosine aminotransferase (TAT) gene. One HNF5-binding site is also a glucocorticoid receptor-binding site; glucocorticoid-dependent HNF5 binding could be detected at this site even though it is incompatible with glucocorticoid receptor binding. HNF5 binds within 10 min of hormone addition, indicating that it participates in transcriptional activation. In the TAT gene glucocorticoid-dependent HNF5 binding occurs where there is glucocorticoid-dependent disruption of nucleosomal structure; constitutive binding occurs in constitutively disrupted regions. These results suggest a hit-and-run mechanism of transcriptional activation by glucocorticoid receptor: the activated receptor binds its target sequence, modifies local chromatin structure, then leaves its site accessible to another factor.			RIGAUD, G (corresponding author), UNIV PARIS 07,CNRS,INST JACQUES MONOD,TOUR 43,2 PL JUSSIEU,F-75251 PARIS 05,FRANCE.			Grange, Thierry/0000-0001-8700-3092				ALTSCHMIED J, 1989, NUCLEIC ACIDS RES, V17, P4975, DOI 10.1093/nar/17.13.4975; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BAKKER O, 1988, MOL CELL BIOL, V8, P4557, DOI 10.1128/MCB.8.10.4557; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECKER P, 1984, EMBO J, V3, P2015, DOI 10.1002/j.1460-2075.1984.tb02084.x; BECKER PB, 1986, NATURE, V324, P686, DOI 10.1038/324686a0; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; BURCH JBE, 1983, CELL, V33, P65, DOI 10.1016/0092-8674(83)90335-5; CARR KD, 1990, P NATL ACAD SCI USA, V87, P9300, DOI 10.1073/pnas.87.23.9300; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CORDINGLEY MG, 1988, NUCLEIC ACIDS RES, V16, P609, DOI 10.1093/nar/16.2.609; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DANESCH U, 1987, EMBO J, V6, P625, DOI 10.1002/j.1460-2075.1987.tb04800.x; GRANGE T, 1989, EXP CELL RES, V180, P220, DOI 10.1016/0014-4827(89)90226-7; GRANGE T, 1989, NUCLEIC ACIDS RES, V17, P8695, DOI 10.1093/nar/17.21.8695; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; GRANNER DK, 1983, MOL CELL BIOCHEM, V53-4, P113; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; JACKSON DA, 1988, J CELL SCI, V90, P365; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEMAIGRE FP, 1990, MOL CELL BIOL, V10, P1811, DOI 10.1128/MCB.10.4.1811; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; ODDOS J, 1989, NUCLEIC ACIDS RES, V17, P8877, DOI 10.1093/nar/17.21.8877; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SALUZ H, 1989, P NATL ACAD SCI USA, V86, P2602, DOI 10.1073/pnas.86.8.2602; SCHAUER M, 1989, P NATL ACAD SCI USA, V86, P1123, DOI 10.1073/pnas.86.4.1123; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SCHERER G, 1982, P NATL ACAD SCI-BIOL, V79, P7205, DOI 10.1073/pnas.79.23.7205; SCHMID E, 1987, EUR J BIOCHEM, V165, P499, DOI 10.1111/j.1432-1033.1987.tb11467.x; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; TANGUAY RL, 1990, NUCLEIC ACIDS RES, V18, P5902, DOI 10.1093/nar/18.19.5902; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; WIJNHOLDS J, 1991, NUCLEIC ACIDS RES, V19, P33, DOI 10.1093/nar/19.1.33; WIJNHOLDS J, 1988, EMBO J, V7, P2757, DOI 10.1002/j.1460-2075.1988.tb03130.x; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3	47	243	243	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1991	67	5					977	986		10.1016/0092-8674(91)90370-E	http://dx.doi.org/10.1016/0092-8674(91)90370-E			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1683601				2022-12-01	WOS:A1991GT75500016
J	SENTMAN, CL; SHUTTER, JR; HOCKENBERY, D; KANAGAWA, O; KORSMEYER, SJ				SENTMAN, CL; SHUTTER, JR; HOCKENBERY, D; KANAGAWA, O; KORSMEYER, SJ			BCL-2 INHIBITS MULTIPLE FORMS OF APOPTOSIS BUT NOT NEGATIVE SELECTION IN THYMOCYTES	CELL			English	Article							T-CELL-RECEPTOR; TRANSGENIC MICE; ANTIGEN RECEPTOR; THYMUS; GENE; INVIVO; EXPRESSION; SURVIVAL; PROTEIN; DEATH	The vast majority of cortical thymocytes die during T cell development while those that survive this selective process accumulate in the medulla. bcl-2, an inner mitochondrial membrane protein, has been shown to inhibit apoptosis in certain cell lines. In the thymus, bcl-2 is regionally localized to the mature T cells of the medulla. To assess the role of bcl-2 in the programmed death of thymocytes, we generated transgenic mice that redirected bcl-2 expression to cortical thymocytes. bcl-2 protected immature CD4+8+ thymocytes from glucocorticoid, radiation, and anti-CD3-induced apoptosis. Moreover, bcl-2 altered T cell maturation, resulting in increased percentages of CD3hi and CD4-8+ thymocytes. Despite this, clonal deletion of T cells that recognize endogenous superantigens still occurred. This transgenic model indicates that multiple death pathways operate within the thymus that can be distinguished by their dependence on bcl-2.	WASHINGTON UNIV, DEPT PATHOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	SENTMAN, CL (corresponding author), WASHINGTON UNIV, HOWARD HUGHES MED INST, DEPT MED, ST LOUIS, MO 63110 USA.				NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA49712-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; Blomgren H, 1970, Cell Immunol, V1, P545, DOI 10.1016/0008-8749(70)90041-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COHEN JJ, 1984, J IMMUNOL, V132, P38; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; FINKEL TH, 1989, CELL, V58, P1047, DOI 10.1016/0092-8674(89)90503-5; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LUCKEHUHLE C, 1979, RADIAT RES, V79, P97, DOI 10.2307/3575025; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NETA R, 1988, J IMMUNOL, V140, P108; NUNEZ G, 1991, NATURE, V353, P71, DOI 10.1038/353071a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PENIT C, 1986, J IMMUNOL, V137, P2115; PETRIE HT, 1990, J EXP MED, V172, P1583, DOI 10.1084/jem.172.6.1583; PEZZELLA F, 1990, AM J PATHOL, V137, P225; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHI YF, 1991, J IMMUNOL, V146, P3340; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TURKA LA, 1991, J IMMUNOL, V146, P1428; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	56	1258	1312	1	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1991	67	5					879	888		10.1016/0092-8674(91)90361-2	http://dx.doi.org/10.1016/0092-8674(91)90361-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1835668				2022-12-01	WOS:A1991GT75500007
J	SOMMER, L; HAGENBUCHLE, O; WELLAUER, PK; STRUBIN, M				SOMMER, L; HAGENBUCHLE, O; WELLAUER, PK; STRUBIN, M			NUCLEAR TARGETING OF THE TRANSCRIPTION FACTOR PTF1 IS MEDIATED BY A PROTEIN SUBUNIT THAT DOES NOT BIND TO THE PTF1 COGNATE SEQUENCE	CELL			English	Article							NF-KAPPA-B; DNA-BINDING; GLUCOCORTICOID RECEPTOR; XENOPUS OOCYTES; DORSAL PROTEIN; ACTIVATION; GENES; TRANSACTIVATOR; LOCALIZATION; POLYMERASE	The pancreas-specific transcription factor PTF1 is a heterooligomer that exists as two variants, alpha and beta, both of which bind DNA. The nucleus contains exclusively alpha while the cytoplasm contains both forms. alpha and beta differ in protein composition. Reconstitution of alpha in vitro requires, in addition to the DNA-binding subunits common to both forms, a 75 kd glycosylated protein that apparently does not bind DNA. Here we show that this protein is essential for targeting PTF1 to the nucleus. Upon injection into frog oocytes, alpha is translocated quantitatively to the nucleus while beta remains in the Cytoplasm. However, if beta is coinjected with purified 75 kd protein or a particular size fraction of pancreatic MRNA, it can be converted to alpha and imported into the nucleus.			SOMMER, L (corresponding author), SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND.							BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAILEY JM, 1976, ANAL BIOCHEM, V70, P75, DOI 10.1016/S0003-2697(76)80049-8; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; COCKELL M, 1989, MOL CELL BIOL, V9, P2464, DOI 10.1128/MCB.9.6.2464; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DEROBERTIS EM, 1978, NATURE, V272, P254, DOI 10.1038/272254a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JESSOP NW, 1980, IN VITRO CELL DEV B, V16, P212; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; NAGATA Y, 1974, J BIOL CHEM, V249, P3116; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; PETRUCCO S, 1990, MOL CELL BIOL, V10, P254, DOI 10.1128/MCB.10.1.254; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROUX E, 1989, GENE DEV, V3, P1613, DOI 10.1101/gad.3.10.1613; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SCHIBLER U, 1980, J MOL BIOL, V142, P93, DOI 10.1016/0022-2836(80)90208-9; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SMITH PJ, 1988, ANAL BIOCHEM, V169, P390, DOI 10.1016/0003-2697(88)90301-6; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; TORRES CR, 1984, J BIOL CHEM, V259, P3308; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0	35	51	52	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1991	67	5					987	994		10.1016/0092-8674(91)90371-5	http://dx.doi.org/10.1016/0092-8674(91)90371-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1720355				2022-12-01	WOS:A1991GT75500017
J	STANOJEVIC, D; SMALL, S; LEVINE, M				STANOJEVIC, D; SMALL, S; LEVINE, M			REGULATION OF A SEGMENTATION STRIPE BY OVERLAPPING ACTIVATORS AND REPRESSORS IN THE DROSOPHILA EMBRYO	SCIENCE			English	Article							GENE-EXPRESSION; GAP PROTEINS; HUNCHBACK; MORPHOGEN; PATTERNS; ELEMENTS; PROMOTER; KRUPPEL	Gene expression stripes in Drosophila melanogaster embryos provide a model for how eukaryotic promoters are turned on and off in response to combinations of transcriptional regulators. Genetic studies suggested that even-skipped (eve) stripe 2 is controlled by three gap genes, hunchback (hb), Kruppel (Kr), and giant (gt), and by the maternal morphogen bicoid (bcd). A direct link is established between binding sites for these regulatory proteins in the stripe 2 promoter element and the expression of the stripe during early embryogenesis. The bcd and hb protein binding sites mediate activation, whereas neighboring gt and Kr protein sites repress expression and establish the stripe borders. The stripe 2 clement has the properties of a genetic on-off switch.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT BIOL,BONNER HALL,LA JOLLA,CA 92093; COLUMBIA UNIV,FAIRCHILD CTR,DEPT BIOL SCI,NEW YORK,NY 10027	University of California System; University of California San Diego; Columbia University				Levine, Michael/0000-0001-7629-0081	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034431] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34431] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; FRASCH M, 1987, GENE DEV, V1, P981, DOI 10.1101/gad.1.9.981; GAUL U, 1989, DEVELOPMENT, V107, P651; GOTO T, 1989, CELL, V57, P413, DOI 10.1016/0092-8674(89)90916-1; HARDING K, 1989, EMBO J, V8, P1205, DOI 10.1002/j.1460-2075.1989.tb03493.x; JACKLE H, 1986, NATURE, V324, P668, DOI 10.1038/324668a0; KOSMAN D, 1991, SCIENCE, V254, P118, DOI 10.1126/science.1925551; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MISMER D, 1987, GENETICS, V116, P565; NUSSLEINVOLHARD C, 1985, COLD SPRING HARB SYM, V50, P145, DOI 10.1101/SQB.1985.050.01.020; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STANOJEVIC D, UNPUB; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WARRIOR R, 1990, DEVELOPMENT, V110, P759	17	265	269	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1991	254	5036					1385	1387		10.1126/science.1683715	http://dx.doi.org/10.1126/science.1683715			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR777	1683715				2022-12-01	WOS:A1991GR77700059
J	STRASSER, A; HARRIS, AW; CORY, S				STRASSER, A; HARRIS, AW; CORY, S			BCL-2 TRANSGENE INHIBITS T-CELL DEATH AND PERTURBS THYMIC SELF-CENSORSHIP	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCLONAL-ANTIBODY; DNA FRAGMENTATION; MEMBRANE PROTEIN; BETA-CHAIN; B-CELLS; RECEPTOR; EXPRESSION; ANTIGEN; TRANSLOCATION	Early death is the fate of most developing T lymphocytes. Because bcl-2 can promote cell survival, we tested its impact in mice expressing an E-mu-bcl-2 transgene within the T lymphoid compartment. The T cells showed remarkably sustained viability and some spontaneous differentiation in vitro. They also resisted killing by lymphotoxic agents. Although total T cell numbers and the rate of thymic involution were unaltered, the response to immunization was enhanced, consistent with reduced death of activated T cells. No T cells reactive with self-superantigens appeared in the lymph nodes, but an excess was found in the thymus. These observations, together with previous findings on B cells, suggest that modulated bcl-2 expression is a determinant of life and death in normal lymphocytes.			STRASSER, A (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA.		Cory, Suzanne/E-1642-2013; Strasser, Andreas/C-7581-2013	Cory, Suzanne/0000-0002-6818-3451; Strasser, Andreas/0000-0002-5020-4891	NCI NIH HHS [CA43540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACHAORBEA H, 1985, EUR J IMMUNOL, V15, P31, DOI 10.1002/eji.1830150107; ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BEHLKE MA, 1986, P NATL ACAD SCI USA, V83, P767, DOI 10.1073/pnas.83.3.767; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; DAVIS MM, 1990, ANNU REV BIOCHEM, V59, P475, DOI 10.1146/annurev.biochem.59.1.475; DELLABONA P, 1990, CELL, V62, P1115, DOI 10.1016/0092-8674(90)90388-U; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; GOODMAN T, 1989, J EXP MED, V170, P1569, DOI 10.1084/jem.170.5.1569; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENGARTNER H, 1988, NATURE, V336, P388, DOI 10.1038/336388a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HOUSTON LL, 1980, J IMMUNOL, V125, P837; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KIZAKI H, 1989, J IMMUNOL, V143, P1790; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; MACDONALD HR, 1990, NATURE, V343, P642, DOI 10.1038/343642a0; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MACDONALD HR, 1991, EUR J IMMUNOL, V21, P1963, DOI 10.1002/eji.1830210827; MARRACK P, 1987, SCIENCE, V238, P1073, DOI 10.1126/science.3317824; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; PETRIE HT, 1990, J EXP MED, V172, P1583, DOI 10.1084/jem.172.6.1583; PEZZELLA F, 1990, AM J PATHOL, V137, P225; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; SCOLLAY R, 1984, IMMUNOL REV, V82, P79, DOI 10.1111/j.1600-065X.1984.tb01118.x; SHI YF, 1990, J IMMUNOL, V144, P3326; SHI YF, 1991, J IMMUNOL, V146, P3340; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; STAERZ UD, 1985, J IMMUNOL, V134, P3994; STRASSER A, 1990, CURR TOP MICROBIOL, V166, P175; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TSUJIMOTO Y, 1987, ONCOGENE, V2, P3; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	60	1076	1121	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1991	67	5					889	899		10.1016/0092-8674(91)90362-3	http://dx.doi.org/10.1016/0092-8674(91)90362-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1959134				2022-12-01	WOS:A1991GT75500008
J	SUTER, B; STEWARD, R				SUTER, B; STEWARD, R			REQUIREMENT FOR PHOSPHORYLATION AND LOCALIZATION OF THE BICAUDAL-D PROTEIN IN DROSOPHILA OOCYTE DIFFERENTIATION	CELL			English	Article							GENE; MELANOGASTER; OOGENESIS; EMBRYOS; SEGMENTATION; POLYMERASE; POLARITY; SEQUENCE; ELEGANS; REGION	In the Drosophila female the product of the germline stem cell, the cystoblast, gives rise to 16 interconnected cystocytes. One of them differentiates into the oocyte, while the 15 others become polyploid nurse cells. Bk-D is required for the differentiation of an oocyte and hence for fertility. Recessive mutations in Bic-D block the oocyte-specific accumulation of its own and other RNAs. Based on its properties and distribution, the Bic-D protein appears to be a component of a cytoskeletal transport or anchoring system. Additional results suggest that the phosphorylation of the Bic-D protein is essential for its accumulation in the pro-oocyte and that this process leads to the gradual localization to the pro-oocyte of factors required for oocyte differentiation.			SUTER, B (corresponding author), PRINCETON UNIV,DEPT MOLEC BIOL,MOFFETT LAB A13,PRINCETON,NJ 08544, USA.							BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; BROWN EH, 1964, GROWTH, V28, P41; CARPENTER ATC, 1975, CHROMOSOMA, V1, P157; DAVIDSON EH, 1990, DEVELOPMENT, V108, P365; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; GUTZEIT HO, 1982, J EMBRYOL EXP MORPH, V67, P101; HAENLIN M, 1987, EMBO J, V6, P801, DOI 10.1002/j.1460-2075.1987.tb04822.x; HIGUCHI RG, 1989, NUCLEIC ACIDS RES, V17, P5865, DOI 10.1093/nar/17.14.5865; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; King RC., 1970, OVARIAN DEV DROSOPHI; KOCH EA, 1967, J MORPHOL, V121, P55, DOI 10.1002/jmor.1051210106; KOCH EA, 1966, J MORPHOL, V119, P283, DOI 10.1002/jmor.1051190303; KOCH EA, 1983, CELL TISSUE RES, V228, P21; KOCH EA, 1969, Z ZELLFORSCH MIK ANA, V102, P129, DOI 10.1007/BF00336421; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MAHOWALD AP, 1980, J CELL BIOL, V45, P306; MCKEARIN DM, 1990, GENE DEV, V4, P2242, DOI 10.1101/gad.4.12b.2242; MEYER GF, 1961, Z ZELLFORSCH MIK ANA, V54, P238, DOI 10.1007/BF00338705; MOHLER J, 1986, GENETICS, V112, P803; SCHRIEFER LA, 1989, J MOL BIOL, V207, P451, DOI 10.1016/0022-2836(89)90267-2; SCHUPBACH T, 1991, IN PRESS GENETICS; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SPRADLING A, 1992, IN PRESS DROSOPHILA; STEINHAUER WR, 1989, MOL CELL BIOL, V9, P5726, DOI 10.1128/MCB.9.12.5726; STEWARD R, 1986, GENETICS, V113, P665; Steward R., 1987, UCLA (University of California Los Angeles) Symposia on Molecular and Cellular Biology New Series, V51, P39; STORTO PD, 1989, DEV GENET, V10, P70, DOI 10.1002/dvg.1020100203; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Telfer W. H., 1975, Advances Insect Physiol, V11, P223, DOI 10.1016/S0065-2806(08)60164-2; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WIESCHAUS E, 1979, DEV BIOL, V68, P29, DOI 10.1016/0012-1606(79)90241-0; YISRAELI JK, 1990, DEVELOPMENT, V108, P289; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	37	207	207	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1991	67	5					917	926		10.1016/0092-8674(91)90365-6	http://dx.doi.org/10.1016/0092-8674(91)90365-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1959135				2022-12-01	WOS:A1991GT75500011
J	THOMAS, KR; MUSCI, TS; NEUMANN, PE; CAPECCHI, MR				THOMAS, KR; MUSCI, TS; NEUMANN, PE; CAPECCHI, MR			SWAYING IS A MUTANT ALLELE OF THE PROTOONCOGENE WNT-1	CELL			English	Article							MOUSE MAMMARY ONCOGENE; SEGMENT POLARITY GENE; EMBRYONIC-DEVELOPMENT; NUCLEOTIDE-SEQUENCE; RAT CEREBELLUM; INT-1 PROTOONCOGENE; MOLECULAR-CLONING; WINGLESS GENE; TUMOR VIRUS; EXPRESSION	Mice homozygous for the recessive mutation swaying (sw) am characterized by ataxia and hypertonia, attributed to the malformation of anterior regions of the cerebellum. We show that sw is a deletion of a single base pair from the proto-oncogene Wnt-1. The deletion is Predicted to cause premature termination of translation, eliminating the carboxy-terminal half of the Wnt-1 Protein. Histological examination shows that sw is phenotypically identical to a previously described wnt-1 mutation introduced into mice by gene targeting. Although both mutations in Wnt-1 disrupt primarily the development of the anterior cerebellum, they also exhibit a variability in expressivity such that rostrally adjacent structures in the midbrain and caudally adjacent structures in the posterior cerebellum can also be affected.	CHILDRENS HOSP MED CTR, DEPT NEUROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	THOMAS, KR (corresponding author), UNIV UTAH, MED CTR, COLL MED, HOWARD HUGHES MED INST, ECCLES INST HUMAN GENET, SALT LAKE CITY, UT 84112 USA.			Neumann, Paul/0000-0002-8480-4799				ALTMAN J, 1985, J COMP NEUROL, V231, P1, DOI 10.1002/cne.902310103; ALTMAN J, 1985, J COMP NEUROL, V231, P42, DOI 10.1002/cne.902310105; ALTMAN J, 1985, J COMP NEUROL, V231, P27, DOI 10.1002/cne.902310104; ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; BURGESS AW, 1988, BIOESSAYS, V8, P40, DOI 10.1002/bies.950080111; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; HALLONET MER, 1990, DEVELOPMENT, V108, P19; HERRUP K, 1982, NEUROSCIENCE, V7, P2185, DOI 10.1016/0306-4522(82)90129-4; HESS EJ, 1991, NEURON, V6, P123, DOI 10.1016/0896-6273(91)90127-L; Hogan B., 1986, MANIPULATING MOUSE E; Jacobson M, 1978, DEV NEUROBIOLOGY; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; Lane P. W., 1967, MOUSE NEWS LETT, V36, P40; Lane PW, 1990, MOUSE GENOME, V86, P237; LANE PW, 1970, MOUSE NEWS LETT, V42, P30; Lyon MF, 1989, GENETIC VARIANTS STR; MARTINEZ S, 1989, EUR J NEUROSCI, V1, P549, DOI 10.1111/j.1460-9568.1989.tb00362.x; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MCMAHON JA, 1989, DEVELOPMENT, V107, P643; MERUELO D, 1987, IMMUNOGENETICS, V25, P361, DOI 10.1007/BF00396102; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; Mullen R. J., 1984, Chimeras in developmental biology., P353; NOORDERMEER J, 1989, NUCLEIC ACIDS RES, V17, P11, DOI 10.1093/nar/17.1.11; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; NUSSE R, 1991, CELL, V64, P231, DOI 10.1016/0092-8674(91)90633-A; NUSSE R, 1990, MOL CELL BIOL, V10, P4170, DOI 10.1128/MCB.10.8.4170; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; ROSS ME, 1990, P NATL ACAD SCI USA, V87, P4189, DOI 10.1073/pnas.87.11.4189; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SIDMAN R L, 1968, PHYSIOLOGICAL AND BIOCHEMICAL ASPECTS OF NERVOUS INTEGRATION, P163; Sidman RL., 1965, CATALOG NEUROLOGICAL, DOI [10.4159/harvard.9780674424326, DOI 10.4159/HARVARD.9780674424326]; SIDMAN RL, 1983, GENETICS NEUROLOGICA, P19; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; VANTVEER LJ, 1984, MOL CELL BIOL, V4, P2532, DOI 10.1128/MCB.4.11.2532; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7	53	217	221	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1991	67	5					969	976		10.1016/0092-8674(91)90369-A	http://dx.doi.org/10.1016/0092-8674(91)90369-A			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1835670				2022-12-01	WOS:A1991GT75500015
J	VAESSIN, H; GRELL, E; WOLFF, E; BIER, E; JAN, LY; JAN, YN				VAESSIN, H; GRELL, E; WOLFF, E; BIER, E; JAN, LY; JAN, YN			PROSPERO IS EXPRESSED IN NEURONAL PRECURSORS AND ENCODES A NUCLEAR-PROTEIN THAT IS INVOLVED IN THE CONTROL OF AXONAL OUTGROWTH IN DROSOPHILA	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; SENSORY ORGAN DEVELOPMENT; TRANSCRIPTION FACTOR; ZESTE GENE; ACTIVATION; EMBRYOS; LOCUS; MELANOGASTER; SEQUENCE; PRODUCT	Neurogenesis in Drosophila begins with the formation of neuronal precursors, which give rise to neurons of individual identity. To find out whether there are genes that are expressed in most or all neuronal precursors and are involved in controlling particular aspects of neuronal differentiation, we used the enhancer-trap method to screen for such "neuronal precursor genes." One gene of this group is prospero. Our mutant analysis indicates that prospero regulates other neuronal precursor genes and is essential for the axonal outgrowth and pathfinding of numerous central and peripheral neurons. prospero encodes a large nuclear protein with multiple homopolymeric amino acid stretches and is expressed in neuronal precursors early during their formation. It is probably generally required for proper neuronal differentiation.	UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	VAESSIN, H (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA.			Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498				ARTAVANISTSAKONAS S, 1988, TRENDS GENET, V4, P95, DOI 10.1016/0168-9525(88)90096-0; BENSON M, 1988, EMBO J, V7, P3907, DOI 10.1002/j.1460-2075.1988.tb03277.x; BENSON M, 1987, EMBO J, V6, P1387, DOI 10.1002/j.1460-2075.1987.tb02379.x; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BIER E, 1988, SCIENCE, V240, P913, DOI 10.1126/science.3129785; BIGGIN MD, 1988, CELL, V53, P713, DOI 10.1016/0092-8674(88)90089-X; BLOCHLINGER K, 1990, GENE DEV, V4, P1322, DOI 10.1101/gad.4.8.1322; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BODMER R, 1987, ROUX ARCH DEV BIOL, V196, P69, DOI 10.1007/BF00402027; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CAMPOSORTEGA JA, 1991, INT REV CYTOL, V124, P1; CAMPOSORTEGA JA, 1991, ANNU REV NEUROSCI, V14, P399, DOI 10.1146/annurev.ne.14.030191.002151; CAMPOSORTEGA JA, 1988, TRENDS NEUROSCI, V11, P400, DOI 10.1016/0166-2236(88)90077-X; CAUDY M, 1988, GENE DEV, V2, P843, DOI 10.1101/gad.2.7.843; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; FROHMAN MA, 1990, RACE RAPID AMPLIFICA, P28; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GHYSEN A, 1986, ROUX ARCH DEV BIOL, V195, P281, DOI 10.1007/BF00376060; GHYSEN A, 1989, DEVELOPMENT, V105, P35; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GONZALEZ F, 1989, EMBO J, V8, P3553, DOI 10.1002/j.1460-2075.1989.tb08527.x; HARTENSTEIN V, 1988, DEVELOPMENT, V102, P869; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MANSUKHANI A, 1988, MOL CELL BIOL, V8, P615, DOI 10.1128/MCB.8.2.615; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; PIRROTTA V, 1987, EMBO J, V6, P791, DOI 10.1002/j.1460-2075.1987.tb04821.x; Pirrotta V., 1986, DROSOPHILA PRACTICAL, P83; POLLACK JA, 1985, CAL TECH BIOL ANN RE, V203; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAO Y, 1991, GENE DEV, V5, P1577, DOI 10.1101/gad.5.9.1577; ROBERTSON HM, 1988, GENETICS, V118, P461; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; Sambrook J., 1989, MOL CLONING LAB MANU; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2	57	324	328	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1991	67	5					941	953		10.1016/0092-8674(91)90367-8	http://dx.doi.org/10.1016/0092-8674(91)90367-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1720353				2022-12-01	WOS:A1991GT75500013
J	WHARTON, RP; STRUHL, G				WHARTON, RP; STRUHL, G			RNA REGULATORY ELEMENTS MEDIATE CONTROL OF DROSOPHILA BODY PATTERN BY THE POSTERIOR MORPHOGEN NANOS	CELL			English	Article							SEGMENTATION GENE HUNCHBACK; MATERNAL-EFFECT MUTATIONS; RECEPTOR TYROSINE KINASE; BICOID MESSENGER-RNA; ABDOMINAL SEGMENTATION; UNTRANSLATED REGION; SECONDARY STRUCTURE; ANTERIOR PATTERN; EMBRYO; PROTEIN	In Drosophila embryos, graded activity of the posterior determinant nanos (nos) generates abdominal segmentation by blocking protein expression from maternal transcripts of the hunchback (hb) gene. When active inappropriately at the anterior pole, nos can also block expression of the anterior determinant bicoid (bcd). We show that both regulatory interactions are mediated by similar sequences in the 3' untranslated region of each transcript. These nos response elements (NREs) are both necessary and sufficient to confer nos-dependent regulation, the degree of regulation determined by the number and quality of the elements and the level of nos in vivo. Based on these and other results, we argue that nos acts as a morphogen, controlling hb expression (and hence abdominal pattern) as a function of its concentration-dependent interaction with the NREs.			WHARTON, RP (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA.							BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; ELDON ED, 1991, DEVELOPMENT, V111, P367; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; FROHNHOFER HG, 1986, J EMBRYOL EXP MORPH, V97, P169; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KRAUT R, 1991, DEVELOPMENT, V111, P601; KRAUT R, 1991, DEVELOPMENT, V111, P611; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MACDONALD PM, 1990, DEVELOPMENT, V110, P161; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOHLER J, 1986, GENETICS, V112, P803; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; OLSEN HS, 1990, SCIENCE, V247, P845, DOI 10.1126/science.2406903; PAEK I, 1987, MOL CELL BIOL, V7, P1496, DOI 10.1128/MCB.7.4.1496; PANKRATZ MJ, 1989, NATURE, V341, P337, DOI 10.1038/341337a0; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; STRUHL G, 1989, CIBA F SYMP, V144, P65; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; TREIER M, 1989, EMBO J, V8, P1517, DOI 10.1002/j.1460-2075.1989.tb03536.x; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	46	330	331	1	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1991	67	5					955	967		10.1016/0092-8674(91)90368-9	http://dx.doi.org/10.1016/0092-8674(91)90368-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1720354				2022-12-01	WOS:A1991GT75500014
J	YOUNG, B; HERSCHLAG, D; CECH, TR				YOUNG, B; HERSCHLAG, D; CECH, TR			MUTATIONS IN A NONCONSERVED SEQUENCE OF THE TETRAHYMENA RIBOZYME INCREASE ACTIVITY AND SPECIFICITY	CELL			English	Article							GROUP-I INTRON; SELF-SPLICING RNA; CIRCULARIZED INTERVENING SEQUENCE; THERMOPHILA RIBOZYME; KINETIC DESCRIPTION; RIBONUCLEASE-P; BINDING-SITE; CLEAVAGE; SUBSTRATE; CATALYSIS	The RNA substrate-binding site of the Tetrahymena ribozyme is connected to the catalytic core by the joining region J1/2. Although J1/2 is not conserved among group I introns, small insertions or deletions in this sequence have dramatic effects, enhancing the turnover number and sequence specificity of ribozyme-catalyzed RNA cleavage. Measurements of rate constants for individual steps in the reaction have revealed the basis of these improvements. Ironically, the higher turnover and specificity both result from decreased affinity for RNA, rather than better cleavage. These results provide evidence that the nonconserved J1/2 sequence positions the RNA substrate to optimize tertiary interactions and ensure cleavage at the position corresponding to the 5' splice site. The wild-type RNA is well adapted to its biological function, and its limitations in multiple turnover can be corrected by mutation.	UNIV COLORADO, HOWARD HUGHES MED INST, DEPT MOLEC CELLULAR & DEV, BOULDER, CO 80309 USA; UNIV COLORADO, HOWARD HUGHES MED INST, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder								ALBERY WJ, 1976, BIOCHEMISTRY-US, V15, P5631, DOI 10.1021/bi00670a032; ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; BARFOD ET, 1989, MOL CELL BIOL, V9, P3657, DOI 10.1128/MCB.9.9.3657; BEAUDRY AA, 1990, BIOCHEMISTRY-US, V29, P6534, DOI 10.1021/bi00479a027; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BEEN MD, 1987, COLD SPRING HARB SYM, V52, P147, DOI 10.1101/SQB.1987.052.01.019; BONNEAU PR, 1991, J AM CHEM SOC, V113, P1026, DOI 10.1021/ja00003a043; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; COUTURE S, 1990, J MOL BIOL, V215, P345, DOI 10.1016/S0022-2836(05)80356-0; DANENBERG PV, 1989, BIOCHEMISTRY-US, V28, P6779, DOI 10.1021/bi00442a035; DOUDNA JA, 1989, P NATL ACAD SCI USA, V86, P7402, DOI 10.1073/pnas.86.19.7402; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; DOWNS WD, 1990, BIOCHEMISTRY-US, V29, P5605, DOI 10.1021/bi00475a027; Fersht A., 1985, ENZYME STRUCTURE MEC; FERSHT AR, 1974, PROC R SOC SER B-BIO, V187, P397, DOI 10.1098/rspb.1974.0084; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GOOD NE, 1966, BIOCHEMISTRY-US, V5, P467, DOI 10.1021/bi00866a011; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1991, P NATL ACAD SCI USA, V88, P6921, DOI 10.1073/pnas.88.16.6921; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MCSWIGGEN JA, 1989, SCIENCE, V244, P679, DOI 10.1126/science.2470150; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MURPHY FL, 1989, P NATL ACAD SCI USA, V86, P9218, DOI 10.1073/pnas.86.23.9218; PACE NR, 1990, J BIOL CHEM, V265, P3587; PRICE JV, 1985, NUCLEIC ACIDS RES, V13, P1871, DOI 10.1093/nar/13.6.1871; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; SOLOMON BM, 1990, BIOCHEMISTRY-US, V29, P7303, DOI 10.1021/bi00483a021; SUGIMOTO N, 1989, CHEM LETT, P2223, DOI 10.1246/cl.1989.2223; SUGIMOTO N, 1989, NUCLEIC ACIDS RES, V17, P355, DOI 10.1093/nar/17.1.355; SUGIMOTO N, 1988, BIOCHEMISTRY-US, V27, P6384, DOI 10.1021/bi00417a029; WARING RB, 1986, NATURE, V321, P133, DOI 10.1038/321133a0; WAUGH DS, 1989, SCIENCE, V244, P1569, DOI 10.1126/science.2472671; YOUNG B, 1990, THESIS U COLORADO BO; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008; ZAUG AJ, 1984, SCIENCE, V224, P574, DOI 10.1126/science.6200938	48	77	80	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1991	67	5					1007	1019		10.1016/0092-8674(91)90373-7	http://dx.doi.org/10.1016/0092-8674(91)90373-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1959129				2022-12-01	WOS:A1991GT75500019
J	CHOWRIRA, BM; BERZALHERRANZ, A; BURKE, JM				CHOWRIRA, BM; BERZALHERRANZ, A; BURKE, JM			NOVEL GUANOSINE REQUIREMENT FOR CATALYSIS BY THE HAIRPIN RIBOZYME	NATURE			English	Article							TOBACCO RINGSPOT VIRUS; T7 RNA-POLYMERASE; SATELLITE RNA; SEQUENCE; CLEAVAGE	THERE is much interest in the development of 'designer ribozymes' to target destruction of RNAs in vitro and in vivo 1. Engineering of ribozymes with novel specificities requires detailed knowledge of the ribozyme-substrate interaction, and a rigorous evaluation of sequence specificity. The hairpin ribozyme catalyses an efficient and reversible site-specific cleavage reaction 2-4. We have used mutagenesis and in vitro selection strategies to show that RNA cleavage and ligation has an absolute requirement for guanosine immediately 3' to the cleavage-ligation site. This G is not required for efficient substrate binding, rather, its 2-amino group is an essential component of the active site required for catalysis.	UNIV VERMONT, MARKEY CTR MOLEC GENET, DEPT MICROBIOL & MOLEC GENET, BURLINGTON, VT 05405 USA	University of Vermont			, John/AAB-5945-2021; Berzal-Herranz, Alfredo/K-8614-2014	Berzal-Herranz, Alfredo/0000-0003-3722-7973				BURKARD U, 1988, J BIOL CHEM, V263, P2447; CARTER BJ, 1990, J BIOL CHEM, V265, P7100; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1988, JAMA-J AM MED ASSOC, V260, P3030; CHOWRIRA BM, 1991, BIOCHEMISTRY-US, V30, P8518, DOI 10.1021/bi00099a003; DOUDNA JA, 1990, J ORG CHEM, V55, P5547, DOI 10.1021/jo00308a003; FEDOR MJ, 1990, P NATL ACAD SCI USA, V87, P1668, DOI 10.1073/pnas.87.5.1668; FELDSTEIN PA, 1989, GENE, V82, P53, DOI 10.1016/0378-1119(89)90029-2; GREEN CJ, 1988, J BIOL CHEM, V263, P652; HAMPEL A, 1990, NUCLEIC ACIDS RES, V18, P299, DOI 10.1093/nar/18.2.299; HAMPEL A, 1989, BIOCHEMISTRY-US, V28, P4929, DOI 10.1021/bi00438a002; HASELOFF J, 1989, GENE, V82, P43, DOI 10.1016/0378-1119(89)90028-0; KOIZUMI M, 1991, BIOCHEMISTRY-US, V30, P5145, DOI 10.1021/bi00235a005; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; RUBINO L, 1990, J GEN VIROL, V71, P1897, DOI 10.1099/0022-1317-71-9-1897; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; VANTOL H, 1990, NUCLEIC ACIDS RES, V18, P1971, DOI 10.1093/nar/18.8.1971	18	143	163	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 28	1991	354	6351					320	322		10.1038/354320a0	http://dx.doi.org/10.1038/354320a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT204	1956383				2022-12-01	WOS:A1991GT20400052
J	GILKS, C				GILKS, C			AIDS, MONKEYS AND MALARIA	NATURE			English	Editorial Material							LENTIVIRUSES		KENYA GOVT MED RES CTR, NAIROBI, KENYA	Kenya Medical Research Institute	GILKS, C (corresponding author), JOHN RADCLIFFE HOSP, NUFFIELD DEPT CLIN MED, OXFORD OX3 9DU, ENGLAND.		Gilks, Charles/B-4184-2012	Gilks, Charles/0000-0002-8953-3123				Blacklock B., 1922, Annals of Tropical Medicine and Parasitology, V16, P99; COATNEY GR, 1968, AM J TROP MED HYG, V17, P145; Coatney R., 1971, US GOV PRINTING OFFI, V26, P317; CONTACOS PG, 1970, AM J TROP MED HYG, V19, P190, DOI 10.4269/ajtmh.1970.19.190; DESROSIERS RC, 1989, AIDS RES HUM RETROV, V5, P465, DOI 10.1089/aid.1989.5.465; Garnham P.C.C., 1966, MALARIA PARASITES OT; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; KARPAS A, 1990, NATURE, V348, P578, DOI 10.1038/348578a0; MCLURE M, 1990, NEW SCI         0730, P54; OWUSU SK, 1991, NATURE, V350, P184, DOI 10.1038/350184a0; PEETERS M, 1989, AIDS, V3, P625, DOI 10.1097/00002030-198910000-00001; Rodhain J., 1939, Annales de la Societe Belge de Medecine Tropicale, V19, P563; Rodhain J., 1943, Annales de la Societe Belge de Medecine Tropicale, V23; Rodhain J., 1955, Annales de la Societe Belge de Medecine Tropicale, V35, P757; Rodhain J., 1936, Annales de la Societe Belge de Medecine Tropicale, V16, P521; SCHNEIDER J, 1988, AIDS, V2, P1, DOI 10.1097/00002030-198802000-00001	16	15	15	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 28	1991	354	6351					262	262		10.1038/354262a0	http://dx.doi.org/10.1038/354262a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT204	1956378				2022-12-01	WOS:A1991GT20400021
J	GRIBBEN, JG; FREEDMAN, AS; NEUBERG, D; ROY, DC; BLAKE, KW; WOO, SD; GROSSBARD, ML; RABINOWE, SN; CORAL, F; FREEMAN, GJ; RITZ, J; NADLER, LM				GRIBBEN, JG; FREEDMAN, AS; NEUBERG, D; ROY, DC; BLAKE, KW; WOO, SD; GROSSBARD, ML; RABINOWE, SN; CORAL, F; FREEMAN, GJ; RITZ, J; NADLER, LM			IMMUNOLOGICAL PURGING OF MARROW ASSESSED BY PCR BEFORE AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR B-CELL LYMPHOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-HODGKINS-LYMPHOMA; ACUTE LYMPHOBLASTIC-LEUKEMIA; DOSE COMBINATION CHEMOTHERAPY; BREAKPOINT-CLUSTER REGION; MONOCLONAL-ANTIBODY; FOLLICULAR LYMPHOMAS; CHROMOSOMAL TRANSLOCATION; BREAST-CANCER; T(14-18); ANTIGEN	Background. The use of autologous bone marrow transplantation is increasing in the management of advanced cancers. Many investigators have attempted to "purge" autologous marrow of residual tumor cells because of concern that reinfused tumor cells might contribute to relapse. The efficacy of purging remains unproved. Methods. We performed clonogenic assays in a tumor cell line in culture to determine the efficiency of immunologic purging. Amplification by the polymerase chain reaction (PCR) was used to detect residual lymphoma cells before and after purging of bone marrow from 114 patients with B-cell non-Hodgkin's lymphoma in whom a translocation (t(l4;18)) that could be amplified by PCR was detected at the time of their initial evaluation. Results. Immunologic purging in vitro resulted in a 3-to-6-log destruction of cells in the tumor cell line. Residual lymphoma cells were detected by PCR in the bone marrow of all patients before purging. No lymphoma cells could be detected in the marrow of 57 patients after purging. Disease-free survival was increased in these 57 patients as compared with those whose marrow contained detectable residual lymphoma (P < 0.00001). The ability to purge residual lymphoma cells was not associated with the degree of bone marrow involvement (P = 0.4494) or the previous response to therapy (P = 0.1298). Conclusions. The inability to purge residual lymphoma cells was the most important prognostic indicator in predicting relapse. These results provide evidence of the clinical usefulness of ex vivo purging of autologous bone marrow in the treatment of patients with lymphoma and suggest that the reinfusion of malignant cells in autologous marrow contributes to relapse.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	GRIBBEN, JG (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,44 BINNEY ST,BOSTON,MA 02115, USA.		Freeman, Gordon/AAC-5380-2019; Jones, Jeffrey A/E-9827-2013	Freeman, Gordon/0000-0002-7210-5616; Grossbard, Michael/0000-0002-3919-3028; Roy, Denis-Claude/0000-0002-5921-1692	FIC NIH HHS [TWO4496] Funding Source: Medline; NCI NIH HHS [CA-40216, CA-34183] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA034183, R01CA040216] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AISENBERG AC, 1988, BLOOD, V71, P969; ARMITAGE JO, 1989, BLOOD, V73, P1749; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BALL ED, 1990, BLOOD, V75, P1199; BENJAMIN D, 1983, BLOOD, V61, P1017; BERLINER N, 1986, BLOOD, V67, P80; CLEARY ML, 1986, J EXP MED, V164, P315, DOI 10.1084/jem.164.1.315; CLEARY ML, 1984, P NATL ACAD SCI-BIOL, V81, P593, DOI 10.1073/pnas.81.2.593; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COSSMAN J, 1984, AM J PATHOL, V115, P117; COX DR, 1972, J R STAT SOC B, V34, P187; Cox DR, 2018, ANAL BINARY DATA; CRESCENZI M, 1988, P NATL ACAD SCI USA, V85, P4869, DOI 10.1073/pnas.85.13.4869; FREEDMAN AS, 1987, LEUKEMIA, V1, P9; FREEDMAN AS, 1985, J IMMUNOL, V134, P2228; FREEDMAN AS, 1990, J CLIN ONCOL, V8, P784, DOI 10.1200/JCO.1990.8.5.784; FREI E, 1989, J CLIN ONCOL, V7, P515, DOI 10.1200/JCO.1989.7.4.515; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; GRIBBEN JG, 1989, J CLIN ONCOL, V7, P1621, DOI 10.1200/JCO.1989.7.11.1621; GRIBBEN JG, 1989, BLOOD, V73, P340; GRIBBEN JG, IN PRESS BLOOD; HIGUCHI R, 1986, PCR TECHNOLOGY, P31; HURD DD, 1988, AM J MED, V85, P829; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KWOK S, 1989, NATURE, V339, P490; LEE MS, 1987, BLOOD, V70, P90; LEE MS, 1987, SCIENCE, V237, P175, DOI 10.1126/science.3110950; MEHTA CR, 1984, BIOMETRICS, V40, P819, DOI 10.2307/2530927; NADLER LM, 1984, LANCET, V2, P427; NADLER LM, 1981, J CLIN INVEST, V67, P134, DOI 10.1172/JCI110005; NADLER LM, 1980, J IMMUNOL, V125, P570; NEGRIN RS, 1991, BLOOD, V77, P654; NGAN BY, 1989, BLOOD, V73, P1759; PETERS WP, 1988, J CLIN ONCOL, V6, P1368, DOI 10.1200/JCO.1988.6.9.1368; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; PHILIP T, 1987, NEW ENGL J MED, V316, P1493, DOI 10.1056/NEJM198706113162401; RITZ J, 1981, BLOOD, V58, P648; RITZ J, 1980, NATURE, V283, P583, DOI 10.1038/283583a0; ROY DC, 1990, LEUKEMIA RES, V14, P407, DOI 10.1016/0145-2126(90)90026-6; STEIN RS, 1976, CANCER, V37, P629, DOI 10.1002/1097-0142(197602)37:2<629::AID-CNCR2820370204>3.0.CO;2-K; TAKVORIAN T, 1987, NEW ENGL J MED, V316, P1499, DOI 10.1056/NEJM198706113162402; TASWELL C, 1981, J IMMUNOL, V126, P1614; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; UCKUN FM, 1987, BLOOD, V69, P361; WALLERSTEIN R, 1990, J CLIN ONCOL, V8, P1782, DOI 10.1200/JCO.1990.8.11.1782; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; YUNIS JJ, 1989, NEW ENGL J MED, V320, P1047, DOI 10.1056/NEJM198904203201605; YUNIS JJ, 1982, NEW ENGL J MED, V307, P1231, DOI 10.1056/NEJM198211113072002	49	692	715	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1991	325	22					1525	1533		10.1056/NEJM199111283252201	http://dx.doi.org/10.1056/NEJM199111283252201			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR380	1944436				2022-12-01	WOS:A1991GR38000001
J	HART, MJ; EVA, A; EVANS, T; AARONSON, SA; CERIONE, RA				HART, MJ; EVA, A; EVANS, T; AARONSON, SA; CERIONE, RA			CATALYSIS OF GUANINE-NUCLEOTIDE EXCHANGE ON THE CDC42HS PROTEIN BY THE DBL ONCOGENE PRODUCT	NATURE			English	Article							GTP-BINDING PROTEINS; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; CELL POLARITY; HUMAN HOMOLOG; GENE; PURIFICATION; CYCLE; G25K; IDENTIFICATION	THE superfamily of low molecular mass GTP-binding proteins, for which the ras proteins are prototypes, has been implicated in the regulation of diverse biological activities including protein trafficking, secretion, and cell growth and differentiation 1-3. One member of this family, CDC42Hs (originally referred to as Gp or G25K) 4-5, seems to be the human homologue of the Saccharomyces cerevisiae cell-division-cycle protein, CDC42Sc (refs 6-9). A second S. cerevisiae protein, CDC24 (ref. 10), which is known from complementation studies to act with CDC42Sc to regulate the development of normal cell shape and the selection of nonrandom budding sites in yeast, contains a region with sequence similarity to the dbl oncogene product 11-14. Here we show that dbl specifically catalyses the dissociation of GDP from CDC42Hs and thereby qualifies as a highly selective guanine nucleotide exchange factor for the GTP-binding protein. Although guanine nucleotide exchange activities have been previously described for other members of the Ras-related GTP-binding protein family 15-17, this is the first demonstration, to our knowledge, of the involvement of a human oncogenic protein in catalysing exchange activity.	CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; GENENTECH INC,DEPT CELL BIOL,S SAN FRANCISCO,CA 94080	Cornell University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Roche Holding; Genentech	HART, MJ (corresponding author), CORNELL UNIV,DEPT BIOCHEM CELLULAR & MOLEC BIOL,ITHACA,NY 14853, USA.		Eva, Alessandra/J-8268-2016	Eva, Alessandra/0000-0003-2949-078X; Hart, Matthew/0000-0002-2683-480X				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; EVANS T, 1986, J BIOL CHEM, V261, P7052; Evans T, 1991, CURR OPIN CELL BIOL, V3, P185, DOI 10.1016/0955-0674(91)90137-N; GRAZIANI G, 1989, ONCOGENE, V4, P823; GRAZIANI G, IN PRESS ONCOGENE; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1990, J BIOL CHEM, V265, P5990; HART MJ, IN PRESS J BIOL CHEM; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; POLAKIS PG, 1989, BIOCHEM BIOPH RES CO, V160, P25, DOI 10.1016/0006-291X(89)91615-X; POLAKIS PG, 1989, J BIOL CHEM, V264, P16378; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1991, NEW BIOL, V3, P372; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626	22	389	400	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1991	354	6351					311	314		10.1038/354311a0	http://dx.doi.org/10.1038/354311a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT204	1956381				2022-12-01	WOS:A1991GT20400049
J	KWON, IC; BAE, YH; KIM, SW				KWON, IC; BAE, YH; KIM, SW			ELECTRICALLY ERODIBLE POLYMER GEL FOR CONTROLLED RELEASE OF DRUGS	NATURE			English	Article							INTERMACROMOLECULAR COMPLEXES; SENSITIVE POLYMERS; PHASE-TRANSITION; DELIVERY; MEMBRANE	NEW controlled drug-delivery systems are being explored to overcome the disadvantages of conventional dosage forms 1. For example, stimulated drug-delivery has been used to overcome the tolerance problems that occur with a constant delivery rate, to mimic the physiological pattern of hormonal concentration and to supply drugs on demand 1,2. Stimuli-sensitive polymers, which are potentially useful for pulsed drug delivery, experience changes in either their structure or their chemical properties in response to changes in environmental conditions 2. Environmental stimuli include temperature 3,4, pH 5,6, light (ultraviolet 7 or visible 8), electric field 9-12 or certain chemicals 13. Volume changes of stimuli-sensitive gel networks are particularly responsive to external stimuli, but swelling is slow to occur 14,15. As well as being useful in the controlled release of drugs, such systems also provide insight into intermolecular interactions 16. Here we report on a novel polymeric system, which rapidly changes from a solid state to solution in response to small electric currents, by disintegration of the solid polymer complex into two water-soluble polymers. We show that the modulated release of insulin, and by extension other macromolecules, can be achieved with this polymeric system.			KWON, IC (corresponding author), UNIV UTAH,CTR CONTROLLED CHEM DELIVERY,421 WAKARA WAY,SALT LAKE CITY,UT 84108, USA.		KWON, ICK CHAN/AAS-4776-2020	KWON, ICK CHAN/0000-0003-1272-7074				BAE YH, 1987, MAKROMOL CHEM-RAPID, V8, P481; CHEN FL, 1988, POLYMER, V29, P2285, DOI 10.1016/0032-3861(88)90123-1; EISENBERG SR, 1984, J MEMBRANE SCI, V19, P173, DOI 10.1016/S0376-7388(00)80207-0; HIROKAWA Y, 1984, J CHEM PHYS, V81, P6379, DOI 10.1063/1.447548; HOFFMAN A S, 1986, Journal of Controlled Release, V4, P213; HOPFENBERG HB, 1976, CONTROLLED RELEASE P, pCH3; ILMAIN F, 1991, NATURE, V349, P400, DOI 10.1038/349400a0; ISHIHARA K, 1984, J POLYM SCI POL CHEM, V22, P881, DOI 10.1002/pol.1984.170220341; ISHIHARA K, 1984, J APPL POLYM SCI, V29, P211, DOI 10.1002/app.1984.070290119; Kost J., 1990, PULSED SELF REGULATE; KUHN W, 1950, NATURE, V165, P514, DOI 10.1038/165514a0; KWON IC, 1990, MAKROMOL CHEM-M SYMP, V33, P265, DOI 10.1002/masy.19900330123; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; LICHKUS AM, 1988, MACROMOLECULES, V21, P2636, DOI 10.1021/ma00186a054; OSADA Y, 1981, J POLYM SCI POL LETT, V19, P303, DOI 10.1002/pol.1981.130190605; SIEGEL RA, 1988, MACROMOLECULES, V21, P3254, DOI 10.1021/ma00189a021; SUZUKI A, 1990, NATURE, V346, P345, DOI 10.1038/346345a0; TANAKA T, 1982, SCIENCE, V218, P467, DOI 10.1126/science.218.4571.467; TSUCHIDA E, 1982, ADV POLYM SCI, V45, P1	19	607	683	1	113	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1991	354	6351					291	293		10.1038/354291a0	http://dx.doi.org/10.1038/354291a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT204	1956379				2022-12-01	WOS:A1991GT20400042
J	NASRIN, N; BUGGS, C; KONG, XF; CARNAZZA, J; GOEBL, M; ALEXANDERBRIDGES, M				NASRIN, N; BUGGS, C; KONG, XF; CARNAZZA, J; GOEBL, M; ALEXANDERBRIDGES, M			DNA-BINDING PROPERTIES OF THE PRODUCT OF THE TESTIS-DETERMINING GENE AND A RELATED PROTEIN	NATURE			English	Article							SEX-DETERMINING REGION; MOTIF; EXPRESSION; HOMOLOGY; CLONING; CELLS; SRY	THE upstream region of the human glyceraldehyde-3-phosphate dehydrogenase gene contains an insulin-response element (IRE-A) responsible for insulin-dependent transcription of the gene (ref. 1). The open reading frame of a rat complementary DNA encoding a protein (IRE-ABP) that binds to this sequence contains an HMG box motif 2 that is 67% identical to the mouse candidate gene for the testis-determining factor SRY, and 98% identical to the mouse SRY-like gene, alpha-4(refs 3, 4). Here we report that IRE-ABP and SRY bind to IRE-A DNA with comparable specificity in a DNase-I footprinting assay. Two females with sex reversal were found to have a single amino-acid substitution in the HMG box domain of SRY at position 3 and 7, respectively 5,6. SRY derivatives containing corresponding mutations do not make contact with IRE-A DNA. These results are direct evidence that mouse SRY-like proteins are sequence-specific DNA-binding proteins and identify two amino acids critical to this interaction. Moreover, IRE-A is a candidate SRY-response element.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HOWARD HUGHES MED INST,DIABET UNIT,50 BLOSSOM ST,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,MED SERV,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital								BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; JAGER RJ, 1990, NATURE, V348, P452, DOI 10.1038/348452a0; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JUTTE NHPM, 1982, J REPROD FERTIL, V65, P431, DOI 10.1530/jrf.0.0650431; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; LABRIE F, 1984, ENDOCRINOLOGY, P615; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; ROBINSON R, 1981, BIOL REPROD, V24, P1032, DOI 10.1095/biolreprod24.5.1032; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SKINNER MK, 1991, ENDOCR REV, V12, P45, DOI 10.1210/edrv-12-1-45; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; WATERMAN M L, 1990, New Biologist, V2, P621; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656	17	172	175	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1991	354	6351					317	320		10.1038/354317a0	http://dx.doi.org/10.1038/354317a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT204	1956382				2022-12-01	WOS:A1991GT20400051
J	RUSSELL, DM; DEMBIC, Z; MORAHAN, G; MILLER, JFAP; BURKI, K; NEMAZEE, D				RUSSELL, DM; DEMBIC, Z; MORAHAN, G; MILLER, JFAP; BURKI, K; NEMAZEE, D			PERIPHERAL DELETION OF SELF-REACTIVE B-CELLS	NATURE			English	Article							IMMUNOGLOBULIN-M; TRANSGENIC MICE; CLONAL DELETION; LYMPHOCYTES-B; T-CELL; TOLERANCE; SUSCEPTIBILITY; SUPPRESSION; EXPRESSION; ANTIGENS	B LYMPHOCYTES are key participants in the immune response because of their specificity, their ability to take up and present antigens to T cells, and their capacity to differentiate into antibody-secreting cells. To limit reactivity to self antigens, autospecific B cells can be functionally inactivated or deleted 1-4. Developing B cells that react with membrane antigens expressed in the bone, marrow are deleted from the peripheral lymphocyte pool 4-6. It is important to ascertain the fate of B cells that recognize membrane autoantigens expressed exclusively on peripheral tissues because B cells in the peripheral lymphoid organs are phenotypically and functionally distinct from bone-marrow B cells 7-9. Here we show that in immunoglobulin-transgenic mice, B cells specific for major histocompatibility complex class I antigen can be deleted if they encounter membrane-bound antigen at a post-bone-marrow stage of development. This deletion may be necessary to prevent organ-specific autoimmunity.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DIV BASIC SCI,1400 JACKSON ST,DENVER,CO 80206; HOFFMANN LA ROCHE AG,DEPT MOLEC BIOL,CH-4005 BASEL,SWITZERLAND; ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,PARKVILLE,VIC 3050,AUSTRALIA; SANDOZ LTD,DEPT BIOTECHNOL,CH-4002 BASEL,SWITZERLAND; UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80262	National Jewish Health; Roche Holding; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital; Novartis; Sandoz; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Morahan, Grant/T-7501-2019; Dembic, Zlatko/A-1833-2008	Dembic, Zlatko/0000-0002-9970-6497	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044809] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM044809] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESMARTINEZ JE, 1988, P NATL ACAD SCI USA, V85, P6919, DOI 10.1073/pnas.85.18.6919; CHESTNUT RW, 1981, J IMMUNOL, V115, P1075; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; DEMBIC Z, 1986, NATURE, V320, P232, DOI 10.1038/320232a0; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GROSVELD FG, 1982, NUCLEIC ACIDS RES, V10, P67145; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; Hardy R. R., 1986, HDB EXPT IMMUNOLOGY; JONES DT, 1987, J BIOL CHEM, V262, P13241; LEPTIN M, 1984, EUR J IMMUNOL, V14, P534, DOI 10.1002/eji.1830140610; MORAHAN G, 1989, P NATL ACAD SCI USA, V86, P3782, DOI 10.1073/pnas.86.10.3782; NAKAMURA RM, 1986, HDB EXPT IMMUNOLOGY; NEMAZEE D, 1991, IMMUNOL REV, V122, P117, DOI 10.1111/j.1600-065X.1991.tb00600.x; NEMAZEE D, 1989, P NATL ACAD SCI USA, V86, P8039, DOI 10.1073/pnas.86.20.8039; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NEMAZEE DA, 1987, P EMBO WORKSHOP TOLE, V2, P52; NOSSAL GJV, 1989, SCIENCE, V245, P147, DOI 10.1126/science.2526369; OZATO K, 1980, J IMMUNOL, V124, P533; RAFF MC, 1975, J EXP MED, V142, P1052, DOI 10.1084/jem.142.5.1052; RAMMENSEE HG, 1985, IMMUNOL TODAY, V6, P41, DOI 10.1016/0167-5699(85)90044-1; RON Y, 1987, J IMMUNOL, V138, P2848; SCOTT DW, 1977, J EXP MED, V146, P1473, DOI 10.1084/jem.146.6.1473; SIDMAN CL, 1975, NATURE, V257, P149, DOI 10.1038/257149a0; SIECKMAN D, 1987, FED PROC, V43, P488; STALL AM, 1984, J IMMUNOL, V132, P187; STEINMETZ M, 1981, CELL, V24, P125, DOI 10.1016/0092-8674(81)90508-0; TISCH R, 1988, P NATL ACAD SCI USA, V85, P6914, DOI 10.1073/pnas.85.18.6914; VITETTA ES, 1977, J EXP MED, V146, P1804, DOI 10.1084/jem.146.6.1804	29	325	328	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1991	354	6351					308	311		10.1038/354308a0	http://dx.doi.org/10.1038/354308a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT204	1956380	Green Accepted			2022-12-01	WOS:A1991GT20400048
J	STEINMEYER, K; KLOCKE, R; ORTLAND, C; GRONEMEIER, M; JOCKUSCH, H; GRUNDER, S; JENTSCH, TJ				STEINMEYER, K; KLOCKE, R; ORTLAND, C; GRONEMEIER, M; JOCKUSCH, H; GRUNDER, S; JENTSCH, TJ			INACTIVATION OF MUSCLE CHLORIDE CHANNEL BY TRANSPOSON INSERTION IN MYOTONIC MICE	NATURE			English	Article							RECESSIVE GENERALIZED MYOTONIA; MOUSE MUTANT ADR; SEQUENCE; ETN; CONDUCTANCE; EXPRESSION; PROTEIN; RAT	MYOTONIA (stiffness and impaired relaxation of skeletal muscle) is a symptom of several diseases caused by repetitive firing of action potentials in muscle membranes 1. Purely myotonic human diseases are dominant myotonia congenita (Thomsen) and recessive generalized myotonia (Becker), whereas myotonic dystrophy is a systemic disease. Muscle hyperexcitability was attributed to defects in sodium channels 2,3 and/or to a decrease in chloride conductance (in Becker's myotonia 4 and in genetic animal models 5-10). Experimental blockage of Cl- conductance (normally 70-85% of resting conductance in muscle") in fact elicits myotonia 1,9. ADR (ref. 12) mice are a realistic animal model 5-7,12-18 for recessive autosomal myotonia. In addition to Cl- conductance 5, many other parameters 6,12,16 are changed in muscles of homozygous animals. We have now cloned the major mammalian skeletal muscle chloride channel (ClC-1) 19. Here we report that in ADR mice a transposon of the ETn family 20-23 has inserted into the corresponding gene, destroying its coding potential for several membrane-spanning domains. Together with the lack of recombination between the Clc-1 gene and the adr locus, this strongly suggests a lack of functional chloride channels as the primary cause of mouse myotonia.	UNIV HAMBURG,CTR MOLEC NEUROBIOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY; UNIV BIELEFELD,DEV BIOL UNIT,W-4800 BIELEFELD 1,GERMANY	University of Hamburg; University of Bielefeld			Gründer, Stefan/I-2495-2019	Gründer, Stefan/0000-0002-7635-9883; Jentsch, Thomas/0000-0002-3509-2553				ADRIAN RH, 1974, J PHYSIOL-LONDON, V240, P505, DOI 10.1113/jphysiol.1974.sp010620; BRETAG AH, 1987, PHYSIOL REV, V67, P618, DOI 10.1152/physrev.1987.67.2.618; BRINKMEIER H, 1987, BIOCHEM BIOPH RES CO, V148, P1383, DOI 10.1016/S0006-291X(87)80285-1; BRULET P, 1985, P NATL ACAD SCI USA, V82, P2054, DOI 10.1073/pnas.82.7.2054; BRULET P, 1983, P NATL ACAD SCI-BIOL, V80, P5641, DOI 10.1073/pnas.80.18.5641; BRYANT SH, 1971, J PHYSIOL-LONDON, V219, P367, DOI 10.1113/jphysiol.1971.sp009667; BUCAN M, 1986, EMBO J, V5, P2899, DOI 10.1002/j.1460-2075.1986.tb04585.x; CAMERINO DC, 1989, PFLUG ARCH EUR J PHY, V413, P568, DOI 10.1007/BF00594192; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; FRANKE C, 1991, MUSCLE NERVE, V14, P762, DOI 10.1002/mus.880140811; FRIEDMAN JM, 1991, MAMM GENOME, V1, P130, DOI 10.1007/BF00351059; FUCHTBAUER EM, 1988, P NATL ACAD SCI USA, V85, P3880, DOI 10.1073/pnas.85.11.3880; HELLER AH, 1982, J NEUROSCI, V2, P924; Iaizzo P A, 1991, Neuromuscul Disord, V1, P47, DOI 10.1016/0960-8966(91)90042-Q; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; JOCKUSCH H, 1988, EUR J BIOCHEM, V171, P101, DOI 10.1111/j.1432-1033.1988.tb13764.x; JOCKUSCH H, 1990, DYNAMIC STATE OF MUSCLE FIBERS, P429; JOCKUSCH H, 1990, MOUSE GENOME, V86, P216; KOLTGEN D, 1991, MUSCLE NERVE, V14, P775, DOI 10.1002/mus.880140813; LIPICKY RJ, 1971, J CLIN INVEST, V50, P2091, DOI 10.1172/JCI106703; LIPICKY RJ, 1966, J GEN PHYSIOL, V50, P89, DOI 10.1085/jgp.50.1.89; MEHRKE G, 1988, MUSCLE NERVE, V11, P440, DOI 10.1002/mus.880110505; MEYERS JC, 1981, P NATL ACAD SCI USA, V78, P3516; NEUMANN P, 1989, MOUSE NEWS LETT, V83, P157; QUINTO C, 1982, P NATL ACAD SCI-BIOL, V79, P31, DOI 10.1073/pnas.79.1.31; REININGHAUS J, 1988, MUSCLE NERVE, V11, P433, DOI 10.1002/mus.880110504; RUDEL R, 1990, TRENDS NEUROSCI, V13, P1, DOI 10.1016/0166-2236(90)90049-G; RUDEL R, 1988, MUSCLE NERVE, V11, P202, DOI 10.1002/mus.880110303; RUDEL R, 1985, PHYSIOL REV, V65, P310, DOI 10.1152/physrev.1985.65.2.310; SHELL B, 1987, MOL CELL BIOL, V7, P1364, DOI 10.1128/MCB.7.4.1364; SONIGO P, 1987, P NATL ACAD SCI USA, V84, P3768, DOI 10.1073/pnas.84.11.3768; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; WATKINS WJ, 1984, LAB ANIM, V18, P1, DOI 10.1258/002367784780865036; WILKE TM, 1987, MOL CELL BIOL, V57, P1646; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0	35	319	325	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1991	354	6351					304	308		10.1038/354304a0	http://dx.doi.org/10.1038/354304a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT204	1659665				2022-12-01	WOS:A1991GT20400047
J	WALKER, DH; MALLER, JL				WALKER, DH; MALLER, JL			ROLE FOR CYCLIN-A IN THE DEPENDENCE OF MITOSIS ON COMPLETION OF DNA-REPLICATION	NATURE			English	Article							MATURATION-PROMOTING FACTOR; EMBRYONIC-CELL CYCLE; MESSENGER-RNA; XENOPUS OOCYTES; PROTEIN; INITIATION; EGGS; DEGRADATION; EXTRACTS; ENTRY	THE cyclins were first identified by their cell-cycle-dependent synthesis and destruction 1-3 and have a key role in the control of mitosis in Xenopus embryonic cell cycles 4-6. All higher eukaryotes have at least two types of cyclins, the A- and B-type, which can be distinguished by sequence motifs and the timing of their destruction in the cell cycle 2,7-10. The degradation of both cyclins is required for exit from mitosis 11, but the activation and destruction of cyclin A occur earlier in the cell cycle than with the B-type cyclins 9-11. This suggests that cyclin A has a distinct role in cell-cycle progression. We have used an antisense oligodeoxynucleotide directed against cyclin A to investigate this role. Ablation of cyclin A messenger RNA in cytostatic factor/metaphase-arrested extracts of Xenopus eggs, followed by in vitro progression into interphase, resulted in the premature appearance of cyclin B/cdc2-associated H1 kinase activity and premature entry into mitosis. Although cyclin A-ablated extracts could initiate DNA synthesis during interphase, S phase was not completed before entry into mitosis. The effects of cyclin A ablation were reversed by the addition of cyclin A mRNA or cyclin A protein to the extracts.			WALKER, DH (corresponding author), UNIV COLORADO,SCH MED,HOWARD HUGHES MED INST,DENVER,CO 80262, USA.							BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; COLMAN A, 1990, J CELL SCI, V97, P399; DAGLE JM, 1990, NUCLEIC ACIDS RES, V18, P4751, DOI 10.1093/nar/18.16.4751; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GABRIELLI GB, IN PRESS J BIOL CHEM; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MINSHULL J, 1987, NUCLEIC ACIDS RES, V16, P6343; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9	28	204	215	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1991	354	6351					314	317		10.1038/354314a0	http://dx.doi.org/10.1038/354314a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT204	1659666				2022-12-01	WOS:A1991GT20400050
J	YEUNG, AC; VEKSHTEIN, VI; KRANTZ, DS; VITA, JA; RYAN, TJ; GANZ, P; SELWYN, AP				YEUNG, AC; VEKSHTEIN, VI; KRANTZ, DS; VITA, JA; RYAN, TJ; GANZ, P; SELWYN, AP			THE EFFECT OF ATHEROSCLEROSIS ON THE VASOMOTOR RESPONSE OF CORONARY-ARTERIES TO MENTAL STRESS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDOTHELIUM-DEPENDENT RELAXATION; SILENT MYOCARDIAL ISCHEMIA; BLOOD-FLOW VELOCITY; SUBSELECTIVE MEASUREMENT; VASCULAR RELAXATION; ANGINA-PECTORIS; RELAXING FACTOR; RABBIT AORTA; DISEASE; ACETYLCHOLINE	Background. Mental stress can cause angina in patients with coronary artery disease, but its effects on coronary vasomotion and blood flow are poorly understood. Because atherosclerosis affects the reactivity of coronary arteries to various stimuli, such as exercise, we postulated that atherosclerosis might also influence the vasomotor response of coronary arteries to mental stress. Methods. We studied 26 patients who performed mental arithmetic under stressful conditions during cardiac catheterization. (An additonal four patients who did not perform the mental arithmetic served as controls.) Coronary segments were classified on the basis of angiographic findings as smooth, irregular, or stenosed. In 15 of the patients without focal stenoses in the left anterior descending artery, acetylcholine (10(-8) to 10(-6) Mol per liter) was infused into the artery to test endothelium-dependent vasodilation. Changes in coronary blood flow were measured with an intracoronary Doppler catheter in these 15 patients. Results. The response of the coronary arteries to mental stress varied from 38 percent constriction to 29 percent dilation, whereas the change in coronary blood flow varied from a decrease of 48 percent to an increase of 42 percent. The direction and magnitude of the change in the coronary diameter were not predicted by the changes in the heart rate, blood pressure, or plasma norepinephrine level. Segments with stenoses (n = 7) were constricted by a mean (+/- SE) of 24 +/- 4 percent, and irregular segments (n = 20) by 9 +/- 3 percent, whereas smooth segments (n = 25) did not change significantly (dilation, 3 +/- 3 percent; P < 0.002). Coronary blood flow increased by 10 +/- 10 percent in smooth vessels, whereas the flow in irregular vessels decreased by 27 +/- 5 percent. The degree of constriction or dilation during mental stress correlated with the response to the infusions of acetylcholine (P < 0.0003, r = 0.58). Conclusions. Atherosclerosis disturbs the normal vasomotor response (no change or dilation) of large coronary arteries to mental stress; in patients with atherosclerosis paradoxical constriction occurs during mental stress, particularly at points of stenosis. This vasomotor response correlates with the extent of atherosclerosis in the artery and with the endothelium-dependent response to an infusion of acetylcholine. These data suggest that in atherosclerosis unopposed constriction caused by a local failure of endothelium-dependent dilation causes the coronary arteries to respond abnormally to mental stress.	UNIFORMED SERV UNIV HLTH SCI,DEPT MED PSYCHOL,BETHESDA,MD 20814; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Uniformed Services University of the Health Sciences - USA; Harvard University; Harvard Medical School	YEUNG, AC (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,75 FRANCIS ST,BOSTON,MA 02115, USA.		Krantz, David S./L-5364-2015	Krantz, David/0000-0002-1671-1355; Ganz, Peter/0000-0002-0437-8882; Vita, Joseph/0000-0001-5607-1797				BARRY J, 1988, AM J CARDIOL, V61, P989, DOI 10.1016/0002-9149(88)90112-9; BASSAN MM, 1980, CIRCULATION, V62, P933, DOI 10.1161/01.CIR.62.5.933; BROWN BG, 1981, CIRCULATION, V64, P1089, DOI 10.1161/01.CIR.64.6.1089; COCKS TM, 1983, NATURE, V305, P627, DOI 10.1038/305627a0; COHEN RA, 1984, FED PROC, V43, P2862; COHEN RA, 1988, J PHARMACOL EXP THER, V244, P550; COHEN RA, 1988, AM J PHYSIOL, V254, pH871, DOI 10.1152/ajpheart.1988.254.5.H871; COX DA, 1989, CIRCULATION, V80, P458, DOI 10.1161/01.CIR.80.3.458; DEANFIELD JE, 1984, LANCET, V2, P1001; FISH RD, 1988, J CLIN INVEST, V81, P21, DOI 10.1172/JCI113297; FREYSCHUSS U, 1988, AM J PHYSIOL, V255, pH1443, DOI 10.1152/ajpheart.1988.255.6.H1443; FURCHGOTT RF, 1983, CIRC RES, V53, P557, DOI 10.1161/01.RES.53.5.557; GAGE JE, 1986, CIRCULATION, V73, P865, DOI 10.1161/01.CIR.73.5.865; GANZ W, 1971, CIRCULATION, V44, P181, DOI 10.1161/01.CIR.44.2.181; GORDON JB, 1989, J CLIN INVEST, V83, P1946, DOI 10.1172/JCI114103; HABIB JB, 1986, CIRC RES, V58, P305, DOI 10.1161/01.RES.58.2.305; HEUSCH G, 1990, CIRCULATION, V81, P1, DOI 10.1161/01.CIR.81.1.1; KIRKEEDIE RL, 1982, IEEE T COMPUT SOC CO, P215; LANGE RA, 1989, NEW ENGL J MED, V321, P1557, DOI 10.1056/NEJM198912073212301; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MARTIN W, 1986, J PHARMACOL EXP THER, V237, P529; MEREDITH IT, 1990, CIRCULATION, V82, P516; MINOR RL, 1990, J CLIN INVEST, V86, P2109, DOI 10.1172/JCI114949; NABEL EG, 1988, CIRCULATION, V77, P43, DOI 10.1161/01.CIR.77.1.43; NABEL EG, 1990, CIRCULATION, V81, P850, DOI 10.1161/01.CIR.81.3.850; OSBORNE JA, 1989, AM J PHYSIOL, V256, pC591, DOI 10.1152/ajpcell.1989.256.3.C591; PEULER JD, 1977, LIFE SCI, V21, P625, DOI 10.1016/0024-3205(77)90070-4; ROBERTSON D, 1979, CIRCULATION, V59, P637, DOI 10.1161/01.CIR.59.4.637; ROZANSKI A, 1988, NEW ENGL J MED, V318, P1005, DOI 10.1056/NEJM198804213181601; SANDOR T, 1985, COMPUT BIOMED RES, V18, P531, DOI 10.1016/0010-4809(85)90028-X; SELLKE FW, 1990, CIRCULATION, V81, P1586, DOI 10.1161/01.CIR.81.5.1586; SHIMOKAWA H, 1989, CIRC RES, V64, P900, DOI 10.1161/01.RES.64.5.900; SIBLEY DH, 1986, J AM COLL CARDIOL, V8, P1332, DOI 10.1016/S0735-1097(86)80305-9; SPECCHIA G, 1984, AM HEART J, V108, P56, DOI 10.1016/0002-8703(84)90544-1; SREEHARAN N, 1986, CAN J PHYSIOL PHARM, V64, P1451, DOI 10.1139/y86-246; TAGAWA H, 1991, CIRC RES, V68, P330, DOI 10.1161/01.RES.68.2.330; TODA N, 1986, AM J PHYSIOL, V250, pH718, DOI 10.1152/ajpheart.1986.250.5.H718; TREASURE CB, 1990, CIRCULATION, V81, P772, DOI 10.1161/01.CIR.81.3.772; VANHOUTTE PM, 1989, CIRCULATION, V80, P1, DOI 10.1161/01.CIR.80.1.1; VITA J A, 1990, Journal of the American College of Cardiology, V15, p158A; VITA JA, 1990, CIRCULATION, V81, P491, DOI 10.1161/01.CIR.81.2.491; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; WILSON RF, 1985, CIRCULATION, V72, P82, DOI 10.1161/01.CIR.72.1.82; YAMAMOTO H, 1988, J CLIN INVEST, V81, P1752, DOI 10.1172/JCI113516; YASUE H, 1990, CIRCULATION, V81, P482, DOI 10.1161/01.CIR.81.2.482	45	498	514	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1991	325	22					1551	1556		10.1056/NEJM199111283252205	http://dx.doi.org/10.1056/NEJM199111283252205			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR380	1944439				2022-12-01	WOS:A1991GR38000005
J	BREO, DL				BREO, DL			MD-AIDED SUICIDE VOTED DOWN - BOTH SIDES SAY DEBATE TO CONTINUE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		HUMPHRY, FINAL EXIT; JEANS WAY	2	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1991	266	20					2895	&		10.1001/jama.266.20.2895	http://dx.doi.org/10.1001/jama.266.20.2895			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GQ722	1942460				2022-12-01	WOS:A1991GQ72200041
J	CLASSEN, DC; PESTOTNIK, SL; EVANS, RS; BURKE, JP				CLASSEN, DC; PESTOTNIK, SL; EVANS, RS; BURKE, JP			COMPUTERIZED SURVEILLANCE OF ADVERSE DRUG EVENTS IN HOSPITAL PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL INPATIENTS; INDUCED ILLNESS; PROGRAM	Objective. - To develop a new method to improve the detection and characterization of adverse drug events (ADEs) in hospital patients. Design. - Prospective study of all patients admitted to our hospital over an 18-month period. Setting. - LDS Hospital, Salt Lake City, Utah, a 520-bed tertiary care center affiliated with the University of Utah School of Medicine, Salt Lake City. Patients. - We developed a computerized ADE monitor, and computer programs were written using an integrated hospital information system to allow for multiple source detection of potential ADEs occurring in hospital patients. Signals of potential ADEs, both voluntary and automated, included sudden medication stop orders, antidote ordering, and certain abnormal laboratory values. Each day, a list of all potential ADEs from these sources was generated, and a pharmacist reviewed the medical records of all patients with possible ADEs for accuracy and causality. Verified ADEs were characterized as mild, moderate, or severe and as type A (dose-dependent or predictable) or type B (idiosyncratic or allergic) reactions, and causality was further measured using a standardized scoring method. Outcome Measure. - The number and characterization of ADEs detected. Results. - Over 18 months, we monitored 36 653 hospitalized patients. There were 731 verified ADEs identified in 648 patients, 701 ADEs were characterized as moderate or severe, and 664 were classified as type A reactions. During this same period, only nine ADEs were identified using traditional detection methods. Physicians, pharmacists, and nurses voluntarily reported 92 of the 731 ADEs detected using this automated system. The other 631 ADEs were detected from automated signals, the most common of which were diphenhydramine hydrochloride and naloxone hydrochloride use, high serum drug levels, leukopenia, and the use of phytonadione and antidiarrheals. The most common symptoms and signs were pruritus, nausea and/or vomiting, rash, and confusion-lethargy. The most common drug classes involved were analgesics, anti-infectives, and cardiovascular agents. Conclusion. - We believe that screening for ADEs with a computerized hospital information system offers a potential method for improving the detection and characterization of these events in hospital patients.	UNIV UTAH,SCH MED,DIV INFECT DIS MED,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah	CLASSEN, DC (corresponding author), LATTER DAY ST HOSP,DEPT CLIN EPIDEMIOL,8TH AVE & C ST,SALT LAKE CITY,UT 84143, USA.				AHRQ HHS [HS06028] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1969, World Health Organ Tech Rep Ser, V425, P5; BENNETT BS, 1977, AM J HOSP PHARM, V34, P931, DOI 10.1093/ajhp/34.9.931; BERRY LL, 1988, AM J HOSP PHARM, V45, P1534, DOI 10.1093/ajhp/45.7.1534; CARANASOS GJ, 1974, JAMA-J AM MED ASSOC, V228, P713, DOI 10.1001/jama.228.6.713; CLASSEN DC, 1990, 6TH INT C PHARM AN; CLUFF LE, 1975, MAJOR PROBLEMS INTER, P5; EDLAVITCH SA, 1988, ARCH INTERN MED, V148, P1499, DOI 10.1001/archinte.148.7.1499; GURWITZ JH, 1991, ANN INTERN MED, V114, P956, DOI 10.7326/0003-4819-114-11-956; JACINTO MS, 1983, AM J HOSP PHARM, V40, P444, DOI 10.1093/ajhp/40.3.444; JICK H, 1974, NEW ENGL J MED, V291, P824, DOI 10.1056/NEJM197410172911605; JICK H, 1984, J ALLERGY CLIN IMMUN, V74, P555, DOI 10.1016/0091-6749(84)90106-4; KARCH FE, 1975, JAMA-J AM MED ASSOC, V234, P1236, DOI 10.1001/jama.234.12.1236; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; MALIEKAL J, 1990, HOSP FORMUL, V25, P436; MCCOLLAM A, 1989, INFUSION, V12, P3; MELMON KL, 1971, NEW ENGL J MED, V284, P1361; MICHEL DJ, 1986, AM J HOSP PHARM, V43, P1709, DOI 10.1093/ajhp/43.7.1709; MILLER RR, 1974, ARCH INTERN MED, V134, P219, DOI 10.1001/archinte.134.2.219; MILLER RR, 1977, AM J HOSP PHARM, V34, P753, DOI 10.1093/ajhp/34.7.753; MILLER RR, 1973, AM J HOSP PHARM, V30, P584, DOI 10.1093/ajhp/30.7.584; MIWA LJ, 1989, J PHARM PRACT, V2, P214; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; NELSON RW, 1983, AM J HOSP PHARM, V40, P445, DOI 10.1093/ajhp/40.3.445; OUSLANDER JG, 1981, ANN INTERN MED, V95, P711, DOI 10.7326/0003-4819-95-6-711; PEARSON KC, 1989, J PHARM PRACT, V2, P209; PORTER J, 1977, JAMA-J AM MED ASSOC, V237, P879, DOI 10.1001/jama.237.9.879; PRYOR TA, 1991, INFECT CONT HOSP EP, V12, P239; RAWLINS MD, 1981, BRIT MED J, V282, P974, DOI 10.1136/bmj.282.6268.974; ROGERS AS, 1988, ARCH INTERN MED, V148, P1596, DOI 10.1001/archinte.148.7.1596; ROSSI AC, 1988, JAMA-J AM MED ASSOC, V259, P1203, DOI 10.1001/jama.259.8.1203; SALAZAR TA, 1989, J PHARM P, V2, P245; SANAZARO PJ, 1991, JAMA-J AM MED ASSOC, V265, P1977, DOI 10.1001/jama.265.15.1977; SEIDL LG, 1966, B JOHNS HOPKINS HOSP, V119, P299; SHAPIRO S, 1971, J AMER MED ASSOC, V216, P467, DOI 10.1001/jama.216.3.467; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; TALLEY RB, 1974, JAMA-J AM MED ASSOC, V229, P1043, DOI 10.1001/jama.1974.03230460011003; TATRO DS, 1979, AM J HOSP PHARM, V36, P198, DOI 10.1093/ajhp/36.2.198; 1991, ACCREDITATION MANUAL; 1984, WHO DEMNC84153E PUBL	39	549	567	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1991	266	20					2847	2851		10.1001/jama.266.20.2847	http://dx.doi.org/10.1001/jama.266.20.2847			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ722	1942452	Green Published			2022-12-01	WOS:A1991GQ72200032
J	GARNICK, DW; HENDRICKS, AM; BRENNAN, TA				GARNICK, DW; HENDRICKS, AM; BRENNAN, TA			CAN PRACTICE GUIDELINES REDUCE THE NUMBER AND COSTS OF MALPRACTICE CLAIMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROFESSIONAL LIABILITY; PHYSICIANS; STANDARDS; SYSTEM; CARE	Practice guidelines have the potential to reduce the number of malpractice cases and the costs of settling them. However, for practice guidelines to exert any influence, they must be assumed to be (1) developed for conditions or procedures that frequently lead to events for which negligence claims are filed; (2) widely accepted in the medical profession; (3) fully integrated into clinical practice; and (4) straightforward and readily interpreted in a litigation setting. Because the validity of each of these assumptions can be questioned, the idea that inserting practice guidelines into the existing litigation process will generate large savings in the near future is overly optimistic.	BRIGHAM & WOMENS HOSP, DIV GEN MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	GARNICK, DW (corresponding author), HARVARD UNIV, SCH PUBL HLTH, PROGRAM HLTH CARE FINANCING & INSURANCE, BOSTON, MA 02115 USA.		Garnick, Deborah w/I-9009-2012					ABRAHAM KS, 1988, JAMA-J AM MED ASSOC, V260, P68, DOI 10.1001/jama.260.1.68; [Anonymous], 1986, COSTS COMPENSATION P; BIERIG JR, 1990, MAR CAP CONS C APPR; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1989, U PITT LAW REV, V51, P1; BRENNAN TA, 1991, J HEALTH POLIT POLIC, V16, P67, DOI 10.1215/03616878-16-1-67; CHASSIN MR, 1988, INQUIRY-J HEALTH CAR, V25, P437; DANZON P, 1989, LIABILITY PERSPECTIV; Danzon P.M, 1985, MED MALPRACTICE; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P3077, DOI 10.1001/jama.263.22.3077; EDDY DM, 1988, HEALTH AFFAIR, V7, P19, DOI 10.1377/hlthaff.7.1.19; EICHHORN JH, 1989, ANESTHESIOLOGY, V70, P572, DOI 10.1097/00000542-198904000-00002; FEILD DJ, 1987, J AM COLL CARDIOL, V10, P935, DOI 10.1016/S0735-1097(87)80294-2; Field, 1990, CLIN PRACTICE GUIDEL, DOI DOI 10.17226/1626; FRANKLIN M, 1987, TORT LAW ALTERNATIVE; GRILLI R, 1991, MED CARE, V29, P50, DOI 10.1097/00005650-199101000-00005; HARVEY IM, 1987, LANCET, V1, P145; HAYWARD RSA, 1991, ANN INTERN MED, V114, P758, DOI 10.7326/0003-4819-114-9-758; HENDERSON JA, 1986, LAW CONTEMP PROBL, V49, P243, DOI 10.2307/1191425; HIRSHFELD EB, 1990, JAMA-J AM MED ASSOC, V263, P1556; Holzer J F, 1990, QRB Qual Rev Bull, V16, P71; HUGHES D, 1990, MED PROFESSIONAL LIA, P2; Kelly J T, 1990, QRB Qual Rev Bull, V16, P54; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; Leape L L, 1990, QRB Qual Rev Bull, V16, P42; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MANUEL BM, 1990, NEW ENGL J MED, V322, P627, DOI 10.1056/NEJM199003013220912; PUSEY A, 1991, ANNOTATED DIRECTORY, P2; RELMAN AS, 1990, NEW ENGL J MED, V322, P626, DOI 10.1056/NEJM199003013220911; REYNOLDS RA, 1987, JAMA-J AM MED ASSOC, V257, P2776, DOI 10.1001/jama.257.20.2776; ROBINSON GO, 1986, LAW CONTEMP PROBL, V49, P5, DOI 10.2307/1191413; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; SALES P, 1987, TECH REV, V10, P43; STEPHENSON GM, 1990, REP MED GUIDELINES O, V1, P7; WEILER P, 1990, CALL ACTION, V2; WESSEL, 1988, JURIMETRICS J, V28, P379; 1988, MONITORING HLTH CARE; 1990, GAOTHRD9024 GEN ACC; 1988, PROFESSIONAL LIABILI; 1990, PATIENTS DOCTORS LAW; 1989, LISTING PRACTICE GUI	42	56	57	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1991	266	20					2856	2860		10.1001/jama.266.20.2856	http://dx.doi.org/10.1001/jama.266.20.2856			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ722	1942453				2022-12-01	WOS:A1991GQ72200034
J	GERBERT, B; MAGUIRE, BT; BLEECKER, T; COATES, TJ; MCPHEE, SJ				GERBERT, B; MAGUIRE, BT; BLEECKER, T; COATES, TJ; MCPHEE, SJ			PRIMARY CARE PHYSICIANS AND AIDS - ATTITUDINAL AND STRUCTURAL BARRIERS TO CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIV-INFECTION	Objective. - To explore the extent to which primary care physicians are providing health care for people with human immunodeficiency virus (HIV) infection and to document barriers to HIV care giving. Design. - National random-sample mailed survey Participants. - Population-based random sample of 2004 US general internists, family physicians, and general practitioners in 1990. Response rate was 59%. Main Outcome Measures. - HIV treatment experience, willingness to treat HIV-infected patients, negative attitudes toward homosexuals and intravenous drug users, fear of contagion of the acquired immunodeficiency syndrome (AIDS), perceived lack of information about AIDS, and time demands of HIV care. Results. - Most physicians (75%) had treated one or more patients with HIV infection. A majority (68%) believed that they had a responsibility to treat people with HIV infection, yet half (50%) indicated that they would not, if given a choice. Over 80% of respondents believed that they lacked information about AIDS and that caring for people with AIDS is time consuming. Further, 35% of respondents agreed that they "would feel nervous among a group of homosexuals" and 55% expressed discomfort about having intravenous drug users in their practice. Physicians who had treated 10 or more HIV-infected patients expressed less negativity toward members of these stigmatized groups who are likely to be HIV infected. Conclusions. - These data suggest that many primary care physicians are responding professionally to the AIDS epidemic but that attitudinal barriers may be hindering some physicians from providing treatment to HIV-infected patients.	UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143; UNIV WALES,DEPT PSYCHOL,BANGOR,WALES	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Bangor University	GERBERT, B (corresponding author), UNIV CALIF SAN FRANCISCO,SCH DENT,DIV BEHAV SCI,707 PARNASSUS D1012,SAN FRANCISCO,CA 94143, USA.				NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLEN BL, 1990, NEW ENGL J MED, V323, P755; ARNOW PM, 1989, PUBLIC HEALTH REP, V104, P121; Babbie ER, 1973, SURVEY RES METHODS, P165; BLENDON RJ, 1990, AIDS HLTH CARE SYSTE, P77; COOKE M, 1988, AIDS PUBLIC POLICY J, V3, P59; FREDMAN L, 1989, AM J PREV MED, V5, P188, DOI 10.1016/S0749-3797(18)31079-1; GEMSON DH, 1991, ARCH INTERN MED, V151, P1102, DOI 10.1001/archinte.151.6.1102; GERBERT B, 1991, NEW ENGL J MED, V324, P926; HAYWARD RA, 1991, ANN INTERN MED, V114, P23, DOI 10.7326/0003-4819-114-1-23; KELLY JA, 1987, AM J PUBLIC HEALTH, V77, P789, DOI 10.2105/AJPH.77.7.789; LEWIS CE, 1987, AM J PUBLIC HEALTH, V77, P795, DOI 10.2105/AJPH.77.7.795; LINK RN, 1988, AM J PUBLIC HEALTH, V78, P455, DOI 10.2105/AJPH.78.4.455; MCKUSICK L, 1986, WESTERN J MED, V144, P751; RICHARDSON JL, 1987, MED CARE, V25, P675, DOI 10.1097/00005650-198708000-00001; RIZZO JA, 1990, MED CARE, V28, P251, DOI 10.1097/00005650-199003000-00005; ROTHMAN DJ, 1990, NEW ENGL J MED, V323, P764, DOI 10.1056/NEJM199009133231129; SHULTZ JM, 1988, MINN MED, V71, P277; SMITH MD, 1991, J GEN INTERN MED, V6, pS56, DOI 10.1007/BF02599259; WARTENBERG AA, 1991, J GEN INTERN MED, V6, pS35, DOI 10.1007/BF02599256; 1991, CDC HIV AIDS PRE FEB, P5; 1988, JAMA-J AM MED ASSOC, V259, P1360; 1991, HIV AIDS SURVEILLANC, P7; [No title captured]	23	173	173	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1991	266	20					2837	2842		10.1001/jama.266.20.2837	http://dx.doi.org/10.1001/jama.266.20.2837			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GQ722	1942450				2022-12-01	WOS:A1991GQ72200030
J	HANSENFLASCHEN, JH; BRAZINSKY, S; BASILE, C; LANKEN, PN				HANSENFLASCHEN, JH; BRAZINSKY, S; BASILE, C; LANKEN, PN			USE OF SEDATING DRUGS AND NEUROMUSCULAR BLOCKING-AGENTS IN PATIENTS REQUIRING MECHANICAL VENTILATION FOR RESPIRATORY-FAILURE - A NATIONAL SURVEY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICALLY ILL PATIENTS; ICU; ATRACURIUM; VECURONIUM; INFUSIONS; CARE; ITU	Objective. - To assess current use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation at US hospitals that participate in the training of pulmonary fellows. Design. - Surveys were mailed in September 1990 to the head nurses of medical intensive care units at 265 US hospitals that were listed in an annual guide listing pulmonary fellowship training programs. In the survey, sedating drugs were defined as medications prescribed to treat anxiety, agitation, or sleeplessness. These included opiates, anesthetics, or neuroleptic agents when used for any of these purposes. Survey Respondents. - Surveys were received from nurses at 164 hospitals (62% response rate) representing 93 medical schools and 100 pulmonary fellowship training programs. Nearly half of the respondents worked at university hospitals. Most worked as head nurses in medical (70%) or medical-surgical (21 %) intensive care units (ICUs). Results. - Sedating drugs were given to patients undergoing mechanical ventilation at virtually all the ICUs surveyed, and 36% used these drugs routinely (> 70% of patients). Opiates and benzodiazepines were employed most commonly; haloperidol lactate was widely used as well. Intermittent intravenous injection was the preferred method of administration; 62% of the ICUs also gave these drugs by continuous intravenous infusion. Neuromuscular blocking agents were also used at nearly all the ICUs surveyed; however, most gave these drugs to fewer than 20% of patients experiencing respiratory failure. Orders for the use of sedating drugs and neuromuscular blocking agents were written exclusively by house staff at 65% of the ICUs surveyed. Conclusions. - Sedating drugs and neuromuscular blocking agents are widely used for patients requiring mechanical ventilation in ICUs at US teaching hospitals. There is considerable variation in the choice, frequency, and method of administration. Given the expense (up to $1000 a day) and the potential hazards to patients of prolonged deep sedation and paralysis, more research is warranted to determine optimal use of these drugs during mechanical ventilation.			HANSENFLASCHEN, JH (corresponding author), HOSP UNIV PENN,DEPT MED,DEPT PULM & CRIT CARE,874 MALONEY BLDG,3600 SPRUCE ST,PHILADELPHIA,PA 19104, USA.			Hansen-Flaschen, John/0000-0003-1989-7244				AITKENHEAD AR, 1989, LANCET, V2, P704, DOI 10.1016/S0140-6736(89)90770-8; BEEMER GH, 1987, ANAESTH INTENS CARE, V15, P83, DOI 10.1177/0310057X8701500111; BEVAN DR, 1988, MUSCLE RELAXANTS CLI; BION JF, 1987, INTENS CARE MED, V13, P215; CRIPPEN DW, 1990, CRIT CARE CLIN, V6, P369; DURBIN CG, 1991, CRIT CARE CLIN, V7, P489, DOI 10.1016/S0749-0704(18)30292-6; FARINA ML, 1981, INTENS CARE MED, V7, P125, DOI 10.1007/BF01738615; FIGGE H, 1987, J CRIT CARE, V2, P199, DOI 10.1016/0883-9441(87)90008-6; FISHMAN AP, 1988, PULMONARY DISEASES D; GRAMSTAD L, 1985, BRIT J ANAESTH, V57, P1052, DOI 10.1093/bja/57.11.1052; GRIFFITHS RB, 1986, ANAESTHESIA, V41, P375, DOI 10.1111/j.1365-2044.1986.tb13221.x; HANSENFLASCHEN JH, 1991, PULMONARY DISEASES D, P383; HARRIS CE, 1985, ANAESTHESIA, V45, P366; KENDALL MJ, 1972, BMJ, V2, P354; MARTYN J, 1986, ANESTHESIOLOGY, V65, P67, DOI 10.1097/00000542-198607000-00011; MENZA MA, 1988, HEART LUNG, V17, P238; MERRIMAN HM, 1981, INTENS CARE MED, V7, P217, DOI 10.1007/BF01702623; MILLERJONES CMH, 1980, ANAESTHESIA, V35, P1104, DOI 10.1111/j.1365-2044.1980.tb05052.x; NAGASHIMA H, 1988, CAN J ANAESTH, V35, P134, DOI 10.1007/BF03010652; OLDENHOF H, 1988, CLIN PHARMACOL THER, V43, P263, DOI 10.1038/clpt.1988.31; PARKER CJR, 1988, BRIT J ANAESTH, V61, P531, DOI 10.1093/bja/61.5.531; PARKER MM, 1984, CRIT CARE MED, V12, P69, DOI 10.1097/00003246-198401000-00018; PEAT SJ, 1988, ANAESTHESIA, V43, P962, DOI 10.1111/j.1365-2044.1988.tb05663.x; ROGERS RM, 1990, AM REV RESPIR DIS, V142, P495, DOI 10.1164/ajrccm/142.3.495; SEGREDO V, 1990, ANESTHESIOLOGY, V72, P566, DOI 10.1097/00000542-199003000-00030; SHOEMAKER W, 1989, TXB CRITICAL CARE; SLATER RM, 1988, ANAESTHESIA, V43, P250; Stevens DS, 1990, J INTENSIVE CARE MED, V5, P258; VESELIS RA, 1990, CRIT CARE CLIN, V6, P295; VIBYMOGENSEN J, 1982, BRIT J ANAESTH, V54, P209, DOI 10.1093/bja/54.2.209; WADON AJ, 1986, BRIT J ANAESTH, V58, pS64, DOI 10.1093/bja/58.suppl_1.64S; 1990, AM REV RESPIR DIS, V142, P955; 1989, AM HOSPITAL ASS GUID; 1991, AM BOARD INTERNA SPR	34	218	222	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1991	266	20					2870	2875		10.1001/jama.266.20.2870	http://dx.doi.org/10.1001/jama.266.20.2870			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ722	1942456				2022-12-01	WOS:A1991GQ72200037
J	HIRSHFELD, EB				HIRSHFELD, EB			SHOULD PRACTICE PARAMETERS BE THE STANDARD OF CARE IN MALPRACTICE LITIGATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LIABILITY				HIRSHFELD, EB (corresponding author), AMER MED ASSOC,CHICAGO,IL 60610, USA.							BRENNAN TA, 1991, J HEALTH POLIT POLIC, V16, P67, DOI 10.1215/03616878-16-1-67; CHENEY FW, 1989, JAMA-J AM MED ASSOC, V261, P1599, DOI 10.1001/jama.261.11.1599; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P389, DOI 10.1001/jama.264.3.389; FRYE R L, 1984, Journal of the American College of Cardiology, V4, P434; GARNICK DW, 1991, JAMA-J AM MED ASSOC, V266, P2856, DOI 10.1001/jama.266.20.2856; HIRSHFELD EB, 1990, JAMA-J AM MED ASSOC, V263, P1556; Holzer J F, 1990, QRB Qual Rev Bull, V16, P71; KELLIE SE, 1991, JAMA-J AM MED ASSOC, V265, P1265, DOI 10.1001/jama.265.10.1265; Kelly J T, 1990, QRB Qual Rev Bull, V16, P54; KELLY JT, 1990, ARCH PATHOL LAB MED, V114, P1119; KINNEY ED, 1989, UC DAVIS L REV, V22, P421; Leape L L, 1990, QRB Qual Rev Bull, V16, P42; Pierce E C Jr, 1990, QRB Qual Rev Bull, V16, P61; ROPER W, 1988, NEW ENGL J MED, V319, P1179; [No title captured]; 1990, LEGAL IMPLICATIONS P; 1991, US GAOPEMD9111 GEN A; 1988, 3RD SCOPE WORK CONTR	18	42	42	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1991	266	20					2886	2891		10.1001/jama.266.20.2886	http://dx.doi.org/10.1001/jama.266.20.2886			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ722	1942459				2022-12-01	WOS:A1991GQ72200040
J	NESS, RB; KELLY, JV; KILLIAN, CD				NESS, RB; KELLY, JV; KILLIAN, CD			HOUSE STAFF RECRUITMENT TO MUNICIPAL AND VOLUNTARY NEW-YORK-CITY RESIDENCY PROGRAMS DURING THE AIDS EPIDEMIC	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; MEDICAL-STUDENTS ATTITUDES; INTERNAL MEDICINE	Objective. - To determine the impact on house staff recruitment of large numbers of patients with the acquired immunodeficiency syndrome (AIDS). Design. - Trends in yearly survey data from the National Resident Matching Program from 1983 to 1990 were examined for residency programs in New York City, NY, where AIDS is epidemic, in the four largest US cities with the fewest AIDS cases, and nationally. Within New York City, trends were compared for residency programs serving large numbers of AIDS patients (high AIDS) and for other programs (low AIDS). Main Outcome Measures. - Number of matches in each study year as compared with the baseline year of 1983 and the yearly percentage of positions offered that were filled by matches. Results. - During the study period, New York City experienced a greater decline in US graduate matches than did the four low-AIDS cities or the nation. Within New York City, recruitment to municipal programs, all with large AIDS patient populations, dropped from 241 to 173 matches (28.2%) despite a 3.6% increase in positions. However, recruitment to both high-AIDS and low-AIDS voluntary programs improved in all years except 1990. After controlling for numbers of offered positions, high-AIDS and low-AIDS voluntary programs again showed similar trends until 1990. Conclusions. - These observations cannot be attributed to AIDS alone. Multiple economic and social factors, including AIDS, may have contributed.	ASSOC AMER MED COLL,WASHINGTON,DC 20036	Association of American Medical Colleges	NESS, RB (corresponding author), UNIV PENN,DEPT MED,CEU,ROOM 332R,NEB 6095,420 SERV DR,PHILADELPHIA,PA 19104, USA.				AHRQ HHS [HS06428-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BERNSTEIN CA, 1990, ACAD MED, V65, P458, DOI 10.1097/00001888-199007000-00010; BRENNAN TA, 1987, ANN INTERN MED, V107, P581, DOI 10.7326/0003-4819-107-4-581; COOKE M, 1989, NEW ENGL J MED, V321, P1334, DOI 10.1056/NEJM198911093211911; CURREY CJ, 1990, ACAD MED, V65, P472, DOI 10.1097/00001888-199007000-00015; GRAETTINGER JS, 1988, ANN INTERN MED, V108, P101, DOI 10.7326/0003-4819-108-1-101; IMPERATO PJ, 1988, NEW YORK STATE J MED, V88, P223; KELLY JA, 1987, J MED EDUC, V62, P549; KLUG J, 1988, CLIN PSYCHIATR NEWS, V2, P21; LINK RN, 1988, AM J PUBLIC HEALTH, V78, P455, DOI 10.2105/AJPH.78.4.455; NESS R, 1989, ACAD MED, V64, P588, DOI 10.1097/00001888-198910000-00009; THOMAS RI, 1990, ACAD MED, V65, P482, DOI 10.1097/00001888-199007000-00019; WACHTER RM, 1986, NEW ENGL J MED, V314, P177, DOI 10.1056/NEJM198601163140310; WHALEN JP, 1987, J MED EDUC, V62, P53; YEDIDIA M, 1990, FACTORS INFLUENCING; 1987, ANN SURVEY HOSPITALS; 1988, JAMA-J AM MED ASSOC, V159, P2817; 1987, MMWR, V36, P285; 1988, ANN SURVEY HOSPITALS; 1990, NRMP DATA APRIL 1990; 1989, AIDS DATA COMP ADULT; 1986, MMWR, V35, P757; 1987, NRMP DATA APRIL 1987; 1990, HIV AIDS SURVEILLANC, P1	23	14	14	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1991	266	20					2843	2846						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GQ722	1942451				2022-12-01	WOS:A1991GQ72200031
J	GALE, RP; BUTTURINI, A				GALE, RP; BUTTURINI, A			MAINTENANCE CHEMOTHERAPY AND CURE OF CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA	LANCET			English	Article							LYMPHOCYTIC-LEUKEMIA; PROGNOSTIC FACTOR; DRUG-RESISTANCE; THERAPY; CHILDREN; 6-MERCAPTOPURINE; METHOTREXATE; LYMPHOMA; CELLS	Maintenance chemotherapy with 6-mercapto-purine and methotrexate, widely believed an essential contribution to the high cure rates achieved in children with acute lymphoblastic leukaemia (ALL), is thought to work by killing the leukaemia cells that remain after intensive chemotherapy. We suggest instead that ALL commonly arises in precursor B cells normally programmed to die, and that maintenance chemotherapy does not kill these cells but controls growth of the leukaemia clone so that programmed death can occur. A similar approach may apply to other cancers in which programmed death is intrinsic to the normal counterparts of the neoplastic cells.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV HEMATOL & ONCOL, LOS ANGELES, CA 90024 USA; UNIV PARMA, DEPT PAEDIAT, DIV HEMATOL & ONCOL, I-43100 PARMA, ITALY	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Parma					NATIONAL CANCER INSTITUTE [P01CA023175] Funding Source: NIH RePORTER; NCI NIH HHS [CA 23175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARLOGIE B, 1989, BLOOD, V73, P865; BEISHUIZEN A, 1991, NEW ENGL J MED, V324, P772; BORZY MS, 1989, BLOOD, V73, P1608; CHESSELLS JM, 1986, J CLIN ONCOL, V4, P1758, DOI 10.1200/JCO.1986.4.12.1758; CLAVELL LA, 1986, NEW ENGL J MED, V315, P657, DOI 10.1056/NEJM198609113151101; FREI E, 1961, BLOOD, V18, P431, DOI 10.1182/blood.V18.4.431.431; GALLAGHER RB, 1991, IMMUNOL TODAY, V12, P1, DOI 10.1016/0167-5699(91)90102-Y; GAYNON PS, 1988, LANCET, V2, P921; GOLDIE JH, 1984, CANCER RES, V44, P3643; GREAVES MF, 1988, LEUKEMIA, V2, P120; HANN IM, 1990, BRIT J HAEMATOL, V76, P359, DOI 10.1111/j.1365-2141.1990.tb06368.x; HOROWITZ MM, 1990, BLOOD, V75, P555; JERMY A, 1987, EUR J CANCER CLIN ON, V23, P1365, DOI 10.1016/0277-5379(87)90121-0; KOIZUMI S, 1988, CANCER, V61, P1292, DOI 10.1002/1097-0142(19880401)61:7<1292::AID-CNCR2820610703>3.0.CO;2-O; KOREN G, 1990, NEW ENGL J MED, V323, P17, DOI 10.1056/NEJM199007053230104; LAYWARD L, 1981, BRIT J HAEMATOL, V49, P251, DOI 10.1111/j.1365-2141.1981.tb07221.x; LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V; LONSDALE D, 1975, CANCER, V36, P341, DOI 10.1002/1097-0142(197508)36:2<341::AID-CNCR2820360208>3.0.CO;2-3; MAUER AM, 1980, BLOOD, V56, P1; MOKYR MB, 1987, CANCER INVEST, V5, P31, DOI 10.3109/07357908709020304; Osmond D G, 1990, Semin Immunol, V2, P173; PATTE C, 1986, J CLIN ONCOL, V4, P1219, DOI 10.1200/JCO.1986.4.8.1219; PETO J, 1986, LANCET, V1, P408; PIETERS R, 1991, LANCET, V338, P399, DOI 10.1016/0140-6736(91)91029-T; PINKEL D, 1987, CANCER, V59, P1683, DOI 10.1002/1097-0142(19870515)59:10<1683::AID-CNCR2820591002>3.0.CO;2-G; PINKEL D, 1971, CANCER-AM CANCER SOC, V27, P247, DOI 10.1002/1097-0142(197102)27:2<247::AID-CNCR2820270202>3.0.CO;2-C; POCHEDLY C, 1990, HEMATOL ONCOL CLIN N, V4, P871; RAPSON NT, 1980, BRIT J HAEMATOL, V45, P41, DOI 10.1111/j.1365-2141.1980.tb03809.x; Riehm H, 1987, Haematol Blood Transfus, V30, P139; RIVERA GK, 1991, LANCET, V337, P61, DOI 10.1016/0140-6736(91)90733-6; SCHIMKE RT, 1978, SCIENCE, V202, P1051, DOI 10.1126/science.715457; STRYCKMANS PA, 1983, BLOOD, V62, P606; TERRY WD, 1982, IMMUNOTHERAPY HUMAN; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; WHITEHEAD VM, 1990, BLOOD, V76, P44; YAMADA M, 1990, NEW ENGL J MED, V323, P448, DOI 10.1056/NEJM199008163230705	36	58	59	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 23	1991	338	8778					1315	1318		10.1016/0140-6736(91)92604-Z	http://dx.doi.org/10.1016/0140-6736(91)92604-Z			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR023	1682696				2022-12-01	WOS:A1991GR02300015
J	GODLEE, F				GODLEE, F			HEALTH AND THE ENVIRONMENT - DANGERS OF OZONE DEPLETION	BRITISH MEDICAL JOURNAL			English	Article																		ELWOOD MJ, 1989, OZONE DEPLETION HLTH, P179; GILES GG, 1988, BRIT MED J, V296, P13, DOI 10.1136/bmj.296.6614.13; ISAKSEN ISA, 1989, OZONE DEPLETION HLTH, P24; Jensen O M, 1980, World Health Stat Q, V33, P2; JONES RR, 1989, OZONE DEPLETION HLTH, P214; KAR RA, 1991, SCIENCE, V252, P204; SHIEL AG, 1986, WORLD J SURG, V10, P389; VANDELEUN JC, 1989, OZONE DEPLETION HLTH; WATSON RT, 1989, OZONE DEPLETION HLTH, P51; 1987, ASSESSING RISKS RACE	10	6	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1991	303	6813					1326	1328		10.1136/bmj.303.6813.1326	http://dx.doi.org/10.1136/bmj.303.6813.1326			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT011	1747679	Green Published, Bronze			2022-12-01	WOS:A1991GT01100029
J	ISON, CA; BRANLEY, NS; KIRTLAND, K; EASMON, CSF				ISON, CA; BRANLEY, NS; KIRTLAND, K; EASMON, CSF			SURVEILLANCE OF ANTIBIOTIC-RESISTANCE IN CLINICAL ISOLATES OF NEISSERIA-GONORRHOEAE	BRITISH MEDICAL JOURNAL			English	Article											ISON, CA (corresponding author), ST MARYS HOSP,SCH MED,DEPT MED MICROBIOL,LONDON W2 1PG,ENGLAND.							GILL MJ, 1988, J CLIN PATHOL, V41, P978, DOI 10.1136/jcp.41.9.978; GRANSDEN WR, 1991, J MED MICROBIOL, V34, P23, DOI 10.1099/00222615-34-1-23; JEPHCOTT AE, 1990, LANCET, V335, P165, DOI 10.1016/0140-6736(90)90035-4; LEWIN CS, 1990, J MED MICROBIOL, V31, P153, DOI 10.1099/00222615-31-3-153	4	19	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1991	303	6813					1307	1307		10.1136/bmj.303.6813.1307	http://dx.doi.org/10.1136/bmj.303.6813.1307			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT011	1747674	Bronze, Green Published			2022-12-01	WOS:A1991GT01100023
J	LINDBERG, G; RASTAM, L; GULLBERG, B; EKLUND, GA; TORNBERG, S				LINDBERG, G; RASTAM, L; GULLBERG, B; EKLUND, GA; TORNBERG, S			SERUM SIALIC-ACID CONCENTRATION AND SMOKING - A POPULATION BASED STUDY	BRITISH MEDICAL JOURNAL			English	Article									UNIV LUND,DEPT COMMUNITY HLTH SCI,S-21401 MALMO,SWEDEN; KAROLINSKA HOSP,RADIUM HEMMET,DEPT CANC EPIDEMIOL,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,RADIUM HEMMET,DEPT GEN ONCOL,S-10401 STOCKHOLM,SWEDEN	Lund University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	LINDBERG, G (corresponding author), CTR PUBL HLTH RES,S-65182 KARLSTAD,SWEDEN.							CARSTENSEN JM, 1987, J EPIDEMIOL COMMUN H, V41, P166, DOI 10.1136/jech.41.2.166; HESS EL, 1957, J CLIN INVEST, V36, P449, DOI 10.1172/JCI103442; LINDBERG G, 1991, BRIT MED J, V302, P143, DOI 10.1136/bmj.302.6769.143; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; 1971, VARMLAND SURVEY	5	39	39	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1991	303	6813					1306	1307		10.1136/bmj.303.6813.1306	http://dx.doi.org/10.1136/bmj.303.6813.1306			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT011	1747673	Green Published, Bronze			2022-12-01	WOS:A1991GT01100022
J	MUTTON, DE; ALBERMAN, E; IDE, R; BOBROW, M				MUTTON, DE; ALBERMAN, E; IDE, R; BOBROW, M			RESULTS OF 1ST YEAR (1989) OF A NATIONAL REGISTER OF DOWNS-SYNDROME IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article							PREGNANCY; AGE	Objective - To examine the feasibility of a national register of Down's syndrome and its effectiveness in evaluating prenatal screening for the syndrome. Design - Information for the register was obtained from all eligible cytogenetic laboratories on relevant cytogenetic diagnoses, including date and place of birth or termination, maternal age, indication for karyotyping, and type of diagnostic test used. Setting - Cytogenetic laboratories in England and Wales. Subjects - All fetuses with trisomy 21 diagnosed prenatally and live births with Down's syndrome diagnosed at birth. Main outcome measures - Number of prenatal and postnatal diagnoses of Down's syndrome. National and maternal age specific prevalence of Down's syndrome. Results - For 1989 there were 1060 registrations-323 prenatal diagnoses and 737 postnatal diagnoses -after exclusion of postnatally diagnosed miscarriages and stillbirths. The estimated national rate of affected births for mothers resident in England and Wales was 1-4/1000 live births, assuming no terminations of affected pregnancies and after correction for natural losses which would have occurred in the absence of termination. The corrected maternal age specific rates were close to those found in previous population based studies. The proportion of affected pregnancies diagnosed prenatally in mothers aged 35 to 39 was 44%, and for those aged 40 or more it was 71%. Abnormal findings on ultrasonography played an unexpectedly important part in initiating cytogenetic investigation (13% of the prenatal diagnoses). Conclusions - The findings establish the feasibility of a national Down's syndrome register and its use in evaluating prenatal screening services. Together with information held by the Office of Population Censuses and Surveys on congenital malformations, data from the register will permit studies of environmental variables affecting the prevalence of the syndrome.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DIV MED & MOLEC GENET,PAEDIAT RES UNIT,LONDON SE1 9RT,ENGLAND; ST BARTHOLOMEWS HOSP,COLL MED,WOLFSON INST PREVENT MED,LONDON EC1M 6BQ,ENGLAND	University of London; King's College London; University of London; Queen Mary University London	MUTTON, DE (corresponding author), LONDON HOSP,COLL MED,DEPT EPIDEMIOL & MED STAT,QMW,LONDON E1 4NS,ENGLAND.							BLACK D, 1984, INVESTIGATION POSSIB; CUCKLE H, 1991, PRENATAL DIAG, V11, P29, DOI 10.1002/pd.1970110106; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; CUCKLE HS, 1990, PRENATAL DIAGNOSIS P, P67; HOOK EB, 1988, AM J HUM GENET, V42, P797; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; CONGENITAL MALFORMAT; ABORTION STATISTI AB; 1989, FM1 OFF POP CENS SUR	9	34	35	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1991	303	6813					1295	1297		10.1136/bmj.303.6813.1295	http://dx.doi.org/10.1136/bmj.303.6813.1295			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT011	1836152	Bronze, Green Published			2022-12-01	WOS:A1991GT01100019
J	NOKES, DJ; ANDERSON, RM				NOKES, DJ; ANDERSON, RM			VACCINE SAFETY VERSUS VACCINE EFFICACY IN MASS IMMUNIZATION PROGRAMS	LANCET			English	Article							MUMPS-MEASLES-VACCINES; JERYL-LYNN-MORATEN; RUBELLA VACCINE; YOUNG-CHILDREN; VIRUS-VACCINES; AGE; INFECTION; IMMUNOGENICITY; EPIDEMIOLOGY; IMMUNIZATION	In community-wide immunisation programmes against childhood infections there is a conflict between the interests of the individual (vaccine safety and efficacy) and the interests of the community (vaccine uptake and level of herd immunity). Studies suggesting that the complication rate is greater with the high efficacy Urabe Am 9 mumps vaccine than with the lower efficacy Jeryl Lynn vaccine, have led to concern about whether the higher efficacy mumps vaccine should be introduced or retained in nationwide mass immunisation programmes. We describe the use of a mathematical model to assess benefits and risks to both individual and community, and illustrate this method by reference to immunisation programmes based on these vaccines. On the basis of current epidemiological data on viral transmission and vaccine coverage in England and Wales, data on vaccine-associated and infection-associated complication rates, and vaccine efficacies estimated from clinical trials, our analyses suggest there is little to choose between the two vaccines, but that overall performance depends on the level of vaccine coverage in a defined population. In community-based programmes, the greater apparent safety of the Jeryl Lynn vaccine (fewer vaccine-induced complications) is offset by the greater apparent efficacy of the Urabe Am 9 vaccine (fewer complications due to natural infection). The findings suggest that it may not always be in the interests of the community to use the vaccine with the lowest complication rate.			NOKES, DJ (corresponding author), IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOL, PARASITE EPIDEMIOL RES GRP, LONDON SW7 2BB, ENGLAND.			Anderson, Roy/0000-0002-9528-3175	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON RM, 1985, J HYG-CAMBRIDGE, V94, P365, DOI 10.1017/S002217240006160X; ANDERSON RM, 1987, EPIDEMIOL INFECT, V99, P65, DOI 10.1017/S0950268800066875; ANDERSON RM, 1991, OXFORD TXB PUBLIC HL, V2, P225; BERGER R, 1988, J BIOL STAND, V16, P269, DOI 10.1016/0092-1157(88)90014-5; CAMPBELL AGM, 1990, IMMUNISATION INFECTI, P51; CHRISTENSON B, 1983, J BIOL STAND, V11, P323, DOI 10.1016/S0092-1157(83)80021-3; CHRISTENSON B, 1991, VACCINE, V9, P326, DOI 10.1016/0264-410X(91)90058-E; FARRINGTON CP, 1990, STAT MED, V9, P953, DOI 10.1002/sim.4780090811; FESCHAREK R, 1990, VACCINE, V8, P446, DOI 10.1016/0264-410X(90)90245-H; Furesz J, 1990, Can Dis Wkly Rep, V16, P253; GRENFELL BT, 1985, J HYG-CAMBRIDGE, V95, P419, DOI 10.1017/S0022172400062859; JUST M, 1987, MUNCHEN MED WOCHEN, V129, P446; JUST M, 1987, MUNCHEN MED WOCHEN, V129, P188; KAKAKIOS AM, 1990, MED J AUSTRALIA, V152, P472, DOI 10.5694/j.1326-5377.1990.tb125306.x; KIMFARLEY R, 1985, AM J EPIDEMIOL, V121, P593, DOI 10.1093/oxfordjournals.aje.a114037; LAVERGNE B, 1986, CAN DIS WEEKLY REP, V12, P85; MORGANCAPNER P, 1988, BRIT MED J, V297, P770, DOI 10.1136/bmj.297.6651.770; NALIN DR, 1989, LANCET, V2, P1396; NALIN DR, 1989, BRIT MED J, V299, P1219, DOI 10.1136/bmj.299.6709.1219-b; NOKES DJ, 1988, EPIDEMIOL INFECT, V101, P1, DOI 10.1017/S0950268800029186; NOKES DJ, 1990, EPIDEMIOL INFECT, V105, P175, DOI 10.1017/S0950268800047762; POPOWKRAUPP T, 1986, J MED VIROL, V18, P69, DOI 10.1002/jmv.1890180109; Quast U, 1979, Dev Biol Stand, V43, P269; VESIKARI T, 1983, ACTA PAEDIATR SCAND, V72, P41, DOI 10.1111/j.1651-2227.1983.tb09661.x; VESIKARI T, 1984, AM J DIS CHILD, V138, P843, DOI 10.1001/archpedi.1984.02140470043013; VESIKARI T, 1983, ACTA PAEDIATR SCAND, V72, P37, DOI 10.1111/j.1651-2227.1983.tb09660.x; 1974, J R COLL GEN PRACT, V24, P552; 1958, REGISTRAR GENERALS S; 1958, REPORTS HOSPITAL INP	29	23	23	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 23	1991	338	8778					1309	1312		10.1016/0140-6736(91)92601-W	http://dx.doi.org/10.1016/0140-6736(91)92601-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR023	1682694				2022-12-01	WOS:A1991GR02300013
J	WALD, NJ				WALD, NJ			COUPLE SCREENING FOR CYSTIC-FIBROSIS	LANCET			English	Article											WALD, NJ (corresponding author), ST BARTHOLOMEWS HOSP,COLL MED,WOLFSON INST PREVENT MED,DEPT ENVIRONM & PREVENT MED,LONDON EC1M 6BQ,ENGLAND.		Wald, Nicholas/AAY-8924-2021; Wald, Nicholas/AAY-2814-2021					BROCK DJH, 1991, ANTENATAL DIAGNOSIS, P59; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, 1989, OBSTETRICS, P269; 1988, BRIT MED J, V297, P1599	6	79	79	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 23	1991	338	8778					1318	1320		10.1016/0140-6736(91)92605-2	http://dx.doi.org/10.1016/0140-6736(91)92605-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR023	1682697				2022-12-01	WOS:A1991GR02300016
J	WAWER, MJ; SERWADDA, D; MUSGRAVE, SD; KONDELULE, JK; MUSAGARA, M; SEWANKAMBO, NK				WAWER, MJ; SERWADDA, D; MUSGRAVE, SD; KONDELULE, JK; MUSAGARA, M; SEWANKAMBO, NK			DYNAMICS OF SPREAD OF HIV-I INFECTION IN A RURAL DISTRICT OF UGANDA	BRITISH MEDICAL JOURNAL			English	Article							VIRUS-INFECTION; IVORY-COAST; PREVALENCE; POPULATION; TANZANIA; REGION; AIDS	Objective - To define the geographical distribution of HIV infection and the community characteristics associated with HIV prevalence in a rural population of Uganda. Design - Seroprevalence survey and interviews of the population aged 13 years and older in 21 randomly selected clusters. Setting - Rural population of Rakai district, south west Uganda. Subjects - 1292 adults, of whom 594 men and 698 women gave a blood sample and answered the questionnaire. Main outcome measures - HIV status determined by ELISA and western blotting in relation to community characteristics. Results - The weighted seroprevalence of HIV for the district was 12.6% with prevalence by cluster varying from 1.2% to 52.8%. Seroprevalence was highest in main road trading centres (men 26%, women 47%), intermediate in rural trading villages on secondary roads (men 22%, women 29%), and lowest in rural agricultural villages (men 8%, women 9%). For both men and women, multiple regression showed a strong negative association between cluster seroprevalence and the proportion of the population employed in agriculture (beta = -0.677 for men, -0.807 for women). Among women, cluster seroprevalence increased with a higher proportion of the population reporting multiple sex partners (beta = 0.814), external travel (beta = 0.579), and injections (beta = 0.483). Conclusions - Community characteristics, particularly the proportion of the population in agriculture, are associated with HIV prevalence and can be used for targeting interventions. The seroprevalences of HIV suggest spread of infection from main road trading centres, through intermediate trading villages, to rural agricultural villages.	MULAGO HOSP,DEPT MED,KAMPALA,UGANDA; UGANDAN MINIST HLTH,RAKAI PROJECT,ENTEBBE,UGANDA; MAKERERE UNIV,DEPT MED,KAMPALA,UGANDA; MAKERERE UNIV,INST PUBL HLTH,KAMPALA,UGANDA	Mulago National Referral Hospital; Makerere University; Makerere University	WAWER, MJ (corresponding author), COLUMBIA UNIV,SCH PUBL HLTH,CTR POPULAT & FAMILY HLTH,NEW YORK,NY 10032, USA.			Sewankambo, Nelson/0000-0001-9362-053X	PHS HHS [R01-A129314-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CARSWELL JW, 1989, AIDS, V3, P759, DOI 10.1097/00002030-198911000-00013; CARSWELL JW, 1987, AIDS, V1, P223; Cochran W.G., 1963, SAMPLING TECHNIQUES; DECOCK KM, 1989, LANCET, V2, P408; DELALLA F, 1988, AIDS, V2, P317, DOI 10.1097/00002030-198808000-00013; DENIS F, 1987, LANCET, V1, P408; DOLMANS WMV, 1989, AIDS, V3, P297, DOI 10.1097/00002030-198905000-00008; Hosmer D, 2013, APPL LOGISTIC REGRES; KILLEWO J, 1990, AIDS, V4, P1081, DOI 10.1097/00002030-199011000-00005; KREISS JK, 1986, NEW ENGL J MED, V314, P414, DOI 10.1056/NEJM198602133140704; NAAMARA W, 1988, 2ND P INT C AIDS AFR; NGALY B, 1988, NEW ENGL J MED, V319, P1123, DOI 10.1056/NEJM198810273191704; PIOT P, 1987, J INFECT DIS, V155, P1108, DOI 10.1093/infdis/155.6.1108; PLORDE DS, 1981, BRIT J VENER DIS, V57, P357; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; WILCOX RR, 1980, BR J VENER DIS, V56, P277	16	108	109	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1991	303	6813					1303	1306		10.1136/bmj.303.6813.1303	http://dx.doi.org/10.1136/bmj.303.6813.1303			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT011	1747672	Green Published, Bronze			2022-12-01	WOS:A1991GT01100021
J	ALTIERI, DC; ETINGIN, OR; FAIR, DS; BRUNCK, TK; GELTOSKY, JE; HAJJAR, DP; EDGINGTON, TS				ALTIERI, DC; ETINGIN, OR; FAIR, DS; BRUNCK, TK; GELTOSKY, JE; HAJJAR, DP; EDGINGTON, TS			STRUCTURALLY HOMOLOGOUS LIGAND-BINDING OF INTEGRIN MAC-1 AND VIRAL GLYCOPROTEIN-C RECEPTORS	SCIENCE			English	Article							COAGULATION FACTOR-X; ENDOTHELIAL-CELLS; BLOOD COAGULATION; ALPHA-CHYMOTRYPSIN; FACTOR-VA; ACTIVATION; THROMBIN; CLONING; SUBUNIT; SITE	Three spatially distant surface loops were found to mediate the interaction of the coagulation protein factor X with the leukocyte integrin Mac-1. This interacting region, which by computational modeling defines a three-dimensional macromotif in the catalytic domain, was also recognized by glycoprotein C (gC), a factor X receptor expressed on herpes simplex virus (HSV)-infected endothelial cells. Peptidyl mimicry of each loop inhibited factor X binding to Mac-1 and gC, blocked monocyte generation of thrombin, and prevented monocyte adhesion to HSV-infected endothelium. These data link the ligand recognition of Mac-1 to established mechanisms of receptor-mediated vascular injury.	UNIV TEXAS, CTR HLTH, DEPT BIOCHEM, TYLER, TX 75710 USA; CORVAS INT INC, SAN DIEGO, CA 92121 USA; RW JOHNSON PHARMACEUT RES INST, SAN DIEGO, CA 92121 USA; CORNELL UNIV, MED CTR, COLL MED, DEPT BIOCHEM, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, COLL MED, DEPT PATHOL, NEW YORK, NY 10021 USA	University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT); Johnson & Johnson; Johnson & Johnson USA; Cornell University; Cornell University	ALTIERI, DC (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411, R01HL043773] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 43773, HL 46408, P01 HL 16411] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ALTIERI DC, 1988, P NATL ACAD SCI USA, V85, P7462, DOI 10.1073/pnas.85.20.7462; ARNAOUT MA, 1990, BLOOD, V75, P1037; ARNAOUT MA, 1988, P NATL ACAD SCI USA, V85, P2776, DOI 10.1073/pnas.85.8.2776; BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310; BENDITT EP, 1983, P NATL ACAD SCI-BIOL, V80, P6386, DOI 10.1073/pnas.80.20.6386; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLEVINS RA, 1985, J BIOL CHEM, V260, P4264; BODE W, 1983, J MOL BIOL, V164, P237, DOI 10.1016/0022-2836(83)90077-3; BROZE GJ, 1982, J CLIN INVEST, V70, P526, DOI 10.1172/JCI110644; BRUNCK TK, COMMUNICATION; CHATTOPADHYAY A, 1989, J BIOL CHEM, V264, P11035; CORBI AL, 1988, J BIOL CHEM, V263, P12403; ETINGIN OR, 1990, CELL, V61, P657, DOI 10.1016/0092-8674(90)90477-V; FRIEDMAN HM, 1984, NATURE, V309, P633, DOI 10.1038/309633a0; FRINK RJ, 1983, J VIROL, V45, P634, DOI 10.1128/JVI.45.2.634-647.1983; FUNG MR, 1985, P NATL ACAD SCI USA, V82, P3591, DOI 10.1073/pnas.82.11.3591; GLENN KC, 1979, NATURE, V278, P711, DOI 10.1038/278711a0; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; HAJJAR DP, 1987, J CLIN INVEST, V80, P1317, DOI 10.1172/JCI113208; HANSON SR, 1988, P NATL ACAD SCI USA, V85, P3184, DOI 10.1073/pnas.85.9.3184; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; LAM SCT, 1987, J BIOL CHEM, V262, P947; MARQUART M, 1983, ACTA CRYSTALLOGR B, V39, P480, DOI 10.1107/S010876818300275X; MARUYAMA I, 1984, J CLIN INVEST, V74, P224, DOI 10.1172/JCI111405; NIEMETZ J, 1971, NATURE-NEW BIOL, V232, P247, DOI 10.1038/newbio232247a0; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SAWYER L, 1978, J MOL BIOL, V118, P137, DOI 10.1016/0022-2836(78)90412-6; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STERN DM, 1985, J BIOL CHEM, V260, P6717; TRACY PB, 1979, J BIOL CHEM, V254, P354; VISSER MR, 1988, P NATL ACAD SCI USA, V85, P8227, DOI 10.1073/pnas.85.21.8227; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232; [No title captured]	35	50	50	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1991	254	5035					1200	1202		10.1126/science.1957171	http://dx.doi.org/10.1126/science.1957171			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ834	1957171				2022-12-01	WOS:A1991GQ83400046
J	BONIFAS, JM; ROTHMAN, AL; EPSTEIN, EH				BONIFAS, JM; ROTHMAN, AL; EPSTEIN, EH			EPIDERMOLYSIS-BULLOSA SIMPLEX - EVIDENCE IN 2 FAMILIES FOR KERATIN GENE ABNORMALITIES	SCIENCE			English	Article							HUMAN TYPE-I; INTERMEDIATE FILAMENTS; SEQUENCE; EXPRESSION; LINKAGE; CYTOKERATIN-18; CHROMOSOME-12Q; MARKERS; CELLS	Epidermolysis bullosa simplex (EBS) is characterized by skin blistering due to basal keratinocyte fragility. In one family studied, inheritance of EBS is linked to the gene encoding keratin 14, and a thymine to cytosine mutation in exon 6 of keratin 14 has introduced a proline in the middle of an alpha-helical region. In a second family, inheritance of EBS is linked to loci that map near the keratin 5 gene. These data indicate that abnormalities of either of the components of the keratin intermediate filament heterodipolymer can impair the mechanical stability of these epithelial cells.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT DERMATOL,SAN FRANCISCO,CA 94110	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco					NIAMS NIH HHS [R01-AR39953, R01-AR28069] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR028069] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; BADER BL, 1988, EUR J CELL BIOL, V47, P300; BASAZS I, 1984, HUM GENET, V68, P57; BONIFAS JM, 1991, J INVEST DERMATOL, V96, P550; BONIFAS JM, UNPUB; CHIN S S M, 1990, Journal of Cell Biology, V111, p176A; FINE JD, 1988, ARCH DERMATOL, V124, P523, DOI 10.1001/archderm.124.4.523; HEATH P, 1990, HUM GENET, V85, P669; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HUMPHRIES MM, 1990, GENOMICS, V7, P377, DOI 10.1016/0888-7543(90)90171-P; ITO M, 1991, ARCH DERMATOL, V127, P367, DOI 10.1001/archderm.127.3.367; KITAJIMA Y, 1989, ARCH DERMATOL RES, V281, P5, DOI 10.1007/BF00424265; KUPPUSWAMY MN, 1991, P NATL ACAD SCI USA, V88, P1143, DOI 10.1073/pnas.88.4.1143; LATHROP GM, 1988, GENOMICS, V3, P361; LESSIN SR, 1988, J INVEST DERMATOL, V91, P572, DOI 10.1111/1523-1747.ep12477087; MANN W, 1989, NUCLEIC ACIDS RES, V17, P5410, DOI 10.1093/nar/17.13.5410; MARCHUK D, 1985, P NATL ACAD SCI USA, V82, P1609, DOI 10.1073/pnas.82.6.1609; MARTIN C, 1988, NUCLEIC ACIDS RES, V16, P3596, DOI 10.1093/nar/16.8.3596; MUTHA S, 1991, J INVEST DERMATOL, V97, P383, DOI 10.1111/1523-1747.ep12480948; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P779, DOI 10.1093/nar/16.2.779; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5223, DOI 10.1093/nar/16.11.5223; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P778, DOI 10.1093/nar/16.2.778; O'CONNELL P, 1987, Genomics, V1, P93, DOI 10.1016/0888-7543(87)90110-8; OLAISEN B, 1973, HUM HERED, V23, P189, DOI 10.1159/000152573; OTT J, 1985, ANAL HUMAN GENETIC L; POPESCU NC, 1989, HUM GENET, V82, P109, DOI 10.1007/BF00284039; ROMANO V, 1988, CYTOGENET CELL GENET, V48, P148, DOI 10.1159/000132612; ROSENBERG M, 1988, MOL CELL BIOL, V8, P722, DOI 10.1128/MCB.8.2.722; Sambrook J., 1989, MOL CLONING LAB MANU; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; SYKES B, 1986, LANCET, V2, P69; TSUI LC, 1989, CYTOGENET CELL GENET, V51, P166, DOI 10.1159/000132791; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; WASSEEM A, 1990, GENOMICS, V7, P188; WEAVER EJ, 1989, CYTOGENET CELL GENET, V54, P1103	35	338	347	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1991	254	5035					1202	1205		10.1126/science.1720261	http://dx.doi.org/10.1126/science.1720261			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ834	1720261				2022-12-01	WOS:A1991GQ83400047
J	CHENG, SWC; LYNCH, EC; LEASON, KR; COURT, DL; SHAPIRO, BA; FRIEDMAN, DI				CHENG, SWC; LYNCH, EC; LEASON, KR; COURT, DL; SHAPIRO, BA; FRIEDMAN, DI			FUNCTIONAL IMPORTANCE OF SEQUENCE IN THE STEM-LOOP OF A TRANSCRIPTION TERMINATOR	SCIENCE			English	Article							ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; OPERON ATTENUATOR; GENE-EXPRESSION; RNA-POLYMERASE; NINR REGION; EFFICIENCY; PROMOTERS; PROTEIN; SITES	Intrinsic transcription terminators of prokaryotes are distinguished by a common RNA motif: a stem-loop structure high in guanine and cytosine content, followed by multiple uridine residues. Models explaining intrinsic terminators postulate that the stem-loop sequence is necessary only to form structure. In the tR2 terminator of coliphage lambda, single-nucleotide changes reducing potential RNA stem stability eliminated tR2 activity, and a compensatory change that restored the stem structure restored terminator activity. However, multiple changes in the stem sequence that should have either maintained or increased stability reduced terminator activity. These results suggest that the ability of the stem-loop structure to signal transcription termination depends on sequence specificity and secondary structure.	UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,CHROMOSOME BIOL,FREDERICK,MD 21701; NCI,FREDERICK CANC RES & DEV CTR,MATH BIOL LAB,IMAGING PROC SECT,FREDERICK,MD 21701	University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Friedman, David/G-3198-2015	Friedman, David/0000-0002-2741-4671	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; NIAID NIH HHS [AI1459-10] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADHYA S, 1979, NATURE, V279, P492, DOI 10.1038/279492a0; CARAFA YD, 1991, J MOL BIOL, V21, P835; Cheng S.-F., UNPUB; COSTANTINO N, 1990, J BACTERIOL, V172, P4610, DOI 10.1128/jb.172.8.4610-4615.1990; COURT D, 1969, VIROLOGY, V39, P348, DOI 10.1016/0042-6822(69)90060-9; Daniels D., 1983, LAMBDA, P469; Fiandt M., 1971, BACTERIOPHAGE LAMBDA, P329; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; FRIEDMAN DI, 1987, ANNU REV GENET, V21, P453; FRIEDMAN DI, 1981, P NATL ACAD SCI-BIOL, V78, P1115, DOI 10.1073/pnas.78.2.1115; FRIEDMAN DI, 1988, BACTERIOPHAGES, V2, P263; GOLIGER JA, 1989, J MOL BIOL, V205, P331, DOI 10.1016/0022-2836(89)90344-6; GREENBLATT J, 1981, NATURE, V292, P215, DOI 10.1038/292215a0; JOHNSTON HM, 1981, J MOL BIOL, V145, P725; KRINKE L, 1990, NUCLEIC ACIDS RES, V18, P4809, DOI 10.1093/nar/18.16.4809; KROGER M, 1982, GENE, V20, P25, DOI 10.1016/0378-1119(82)90084-1; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANDICK R, 1987, CELLULAR MOL BIOL, P1276; LEASON KR, 1988, J BACTERIOL, V170, P5051, DOI 10.1128/jb.170.11.5051-5058.1988; LYNN SP, 1988, J BIOL CHEM, V263, P472; LYNN SP, 1985, J MOL BIOL, V183, P529, DOI 10.1016/0022-2836(85)90169-X; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; McKenney K, 1981, Gene Amplif Anal, V2, P383; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; RAY DS, 1981, INITIATION DNA REPLI, P169; REYNOLDS R, IN PRESS J MOL BIOL; REYNOLDS R, IN PRESS J MOL BIOLJ; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; RICHARDSON JP, 1991, CELL, V64, P1047, DOI 10.1016/0092-8674(91)90257-Y; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; ROBERTS JW, 1988, CELL, V52, P5, DOI 10.1016/0092-8674(88)90523-5; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; SALSTROM JS, 1978, J MOL BIOL, V124, P195, DOI 10.1016/0022-2836(78)90156-0; SCHMIDT MC, 1987, J MOL BIOL, V195, P809, DOI 10.1016/0022-2836(87)90486-4; SPENCER CA, 1990, ONCOGENE, V5, P777; TELESNITSKY APW, 1989, J MOL BIOL, V205, P315, DOI 10.1016/0022-2836(89)90343-4; VONHIPPEL PH, 1991, P NATL ACAD SCI USA, V88, P2307, DOI 10.1073/pnas.88.6.2307; YAGER TD, 1987, CELLULAR MOL BIOL, P1241; YANOFSKY C, 1981, NATURE, V289, P751, DOI 10.1038/289751a0; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	41	61	61	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1991	254	5035					1205	1207		10.1126/science.1835546	http://dx.doi.org/10.1126/science.1835546			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ834	1835546				2022-12-01	WOS:A1991GQ83400048
J	CUEVAS, P; CARCELLER, F; ORTEGA, S; ZAZO, M; NIETO, I; GIMENEZGALLEGO, G				CUEVAS, P; CARCELLER, F; ORTEGA, S; ZAZO, M; NIETO, I; GIMENEZGALLEGO, G			HYPOTENSIVE ACTIVITY OF FIBROBLAST GROWTH-FACTOR	SCIENCE			English	Article							PLASMINOGEN-ACTIVATOR PRODUCTION; CAPILLARY ENDOTHELIAL-CELLS; DNA-SYNTHESIS; BLOOD-PRESSURE; NITRIC-OXIDE; K+ CHANNELS; L-ARGININE; BINDING; HEPARIN; GENE	Acidic and basic fibroblast growth factors (FGFs) are members of a family of proteins that are broad-spectrum mitogens, have diverse hormone-like activities, and function in tumorigenesis. FGF's ability to raise the concentration of intracellular calcium ion suggests that FGF could induce the synthesis of endothelium-derived relaxing factor (EDRF) and consequently vasodilation. Systemic administration of FGF decreased arterial blood pressure. This effect was mediated by EDRF and by adenosine triphosphate-sensitive potassium ion channels. The hypotensive effect of FGF was segregated from its mitogenic activity by protein engineering. These results extend the range of FGF autocrine activities and potential therapeutic applications, emphasize the role of endothelium as an arterial blood pressure-regulating organ, and provide insight on the structural basis of FGF functions.	CSIC, CTR INVEST BIOL, VELAZQUEZ 144, E-28006 MADRID, SPAIN; HOSP UNIV RAMON Y CAJAL, E-28034 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consiglio Nazionale delle Ricerche (CNR); Hospital Universitario Ramon y Cajal								AISAKA K, 1989, BIOCHEM BIOPH RES CO, V160, P881, DOI 10.1016/0006-291X(89)92517-5; BAIRD A, 1985, P NATL ACAD SCI USA, V82, P5545, DOI 10.1073/pnas.82.16.5545; BAIRD A, 1986, REGUL PEPTIDES, V16, P243, DOI 10.1016/0167-0115(86)90023-6; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CUEVAS P, UNPUB; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; FUKUTO JM, 1990, BIOCHEM BIOPH RES CO, V168, P458, DOI 10.1016/0006-291X(90)92343-X; GIMENEZGALLEGO G, 1985, SCIENCE, V230, P1385, DOI 10.1126/science.4071057; GIMENEZGALLEGO G, UNPUB; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; LINEMEYER DL, 1987, BIO-TECHNOL, V5, P960, DOI 10.1038/nbt0987-960; MAYER B, 1989, BIOCHEM BIOPH RES CO, V164, P678, DOI 10.1016/0006-291X(89)91513-1; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MOSCATELLI D, 1991, ANN NY ACAD SCI, V638, P177, DOI 10.1111/j.1749-6632.1991.tb49028.x; MOSCATELLI D, 1986, P NATL ACAD SCI USA, V83, P2091, DOI 10.1073/pnas.83.7.2091; NELSON MT, 1990, NATURE, V344, P770, DOI 10.1038/344770a0; PANDIELLA A, 1989, BIOCHEM BIOPH RES CO, V163, P1325, DOI 10.1016/0006-291X(89)91123-6; PRESTA M, 1986, MOL CELL BIOL, V6, P4060, DOI 10.1128/MCB.6.11.4060; QUAST U, 1989, TRENDS PHARMACOL SCI, V10, P431, DOI 10.1016/S0165-6147(89)80003-3; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; ROSENGART TK, 1989, CIRC RES, V64, P227, DOI 10.1161/01.RES.64.2.227; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SANCHEZPUELLES JM, 1990, GENE, V89, P69, DOI 10.1016/0378-1119(90)90207-8; SANZ MJM, 1990, FEBS LETT, V232, P308; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; THOMAS KA, 1986, TRENDS BIOCHEM SCI, V11, P1; VANE J, 1990, NATURE, V348, P673, DOI 10.1038/348673a0	32	226	242	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1991	254	5035					1208	1210		10.1126/science.1957172	http://dx.doi.org/10.1126/science.1957172			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ834	1957172				2022-12-01	WOS:A1991GQ83400049
J	DONALDSON, JG; KAHN, RA; LIPPINCOTTSCHWARTZ, J; KLAUSNER, RD				DONALDSON, JG; KAHN, RA; LIPPINCOTTSCHWARTZ, J; KLAUSNER, RD			BINDING OF ARF AND BETA-COP TO GOLGI MEMBRANES - POSSIBLE REGULATION BY A TRIMERIC G-PROTEIN	SCIENCE			English	Article							ADENYLATE-CYCLASE; ADP-RIBOSYLATION; CHOLERA-TOXIN; BREFELDIN-A; TRANSPORT; SECRETION; COMPONENT; PURIFICATION; APPARATUS; SUGGESTS	The binding of cytosolic coat proteins to organelles may regulate membrane structure and traffic. Evidence is presented that a small guanosine triphosphate (GTP)-binding protein, the adenosine diphosphate ribosylation factor (ARF), reversibly associates with the Golgi apparatus in an energy, GTP, and fungal metabolite brefeldin A (BFA)-sensitive manner similar to, but distinguishable from, the 110-kilodalton cytosolic coat protein beta-COP. Addition of beta-gamma-subunits of G proteins inhibited the association of both ARF and beta-COP with Golgi membranes that occurred upon incubation with guanosine 5'-O-(3-thiotriphosphate) (GTP-gamma-S). Thus, heterotrimeric G proteins may function to regulate the assembly of coat proteins onto the Golgi membrane.	NCI, DIV CANC TREATMENT, BIOL CHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	DONALDSON, JG (corresponding author), NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA.		Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601				ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; COREY EJ, 1976, TETRAHEDRON LETT, P4701; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, UNPUB; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, UNPUB; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; OKABE K, 1990, J BIOL CHEM, V265, P12854; ORCI L, 1991, CELL, V64, P1183; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; ZAHROUI A, 1989, J BIOL CHEM, V264	33	325	328	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 22	1991	254	5035					1197	1199		10.1126/science.1957170	http://dx.doi.org/10.1126/science.1957170			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ834	1957170				2022-12-01	WOS:A1991GQ83400045
J	KERPPOLA, TK; CURRAN, T				KERPPOLA, TK; CURRAN, T			DNA BENDING BY FOS AND JUN - THE FLEXIBLE HINGE MODEL	SCIENCE			English	Article							TRANSCRIPTION FACTOR AP-1; INTEGRATION HOST FACTOR; LEUCINE ZIPPER; BINDING DOMAIN; PROTEIN COMPLEXES; BASIC REGION; PRODUCT; RECOGNITION; ACTIVATION; ONCOGENE	DNA bending is essential for the assembly of multiprotein complexes that contact several DNA sequence elements. An approach based on phasing analysis was developed that allows determination of both the directed DNA bend angle and the orientation of DNA bending. This technique has been applied to the analysis of DNA bending by the transcription regulatory proteins Fos and Jun. Complexes that contained different combinations of full-length and truncated Fos and Jun induced DNA bends of different magnitudes and orientations. The DNA bends induced by the individual proteins were determined on the basis of a quantitative model for DNA bending by dimeric complexes. This information was used to visualize the consequences of DNA bending by Fos and Jun for the structures of Fos-Jun-DNA and Jun-DNA complexes.	ROCHE INST MOLEC BIOL,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110				Curran, Tom/F-5234-2018; Curran, Tom/D-7515-2011; Curran, Tom/C-1164-2008; Kerppola, Tom/AAG-4457-2022; Curran, Thomas/AAE-7631-2019; Kerppola, Tom/AFK-6155-2022	Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Kerppola, Tom/0000-0002-0611-9446; Curran, Thomas/0000-0003-1444-7551; Kerppola, Tom/0000-0002-0611-9446				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COHEN DR, 1990, ONCOGENE, V5, P929; CURRAN T, 1988, CELL, V55, P305; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GOBER JW, 1990, GENE DEV, V4, P1494, DOI 10.1101/gad.4.9.1494; HAGERMAN PJ, 1985, BIOCHEMISTRY-US, V24, P7033, DOI 10.1021/bi00346a001; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; NYE JA, 1990, P NATL ACAD SCI USA, V87, P3992, DOI 10.1073/pnas.87.10.3992; OAKLEY MG, 1990, SCIENCE, V248, P847, DOI 10.1126/science.2111578; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROJO F, 1990, J MOL BIOL, V211, P713, DOI 10.1016/0022-2836(90)90072-T; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0; ZINKEL SS, 1991, J MOL BIOL, V219, P201, DOI 10.1016/0022-2836(91)90562-K	38	186	188	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1991	254	5035					1210	1214		10.1126/science.1957173	http://dx.doi.org/10.1126/science.1957173			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ834	1957173				2022-12-01	WOS:A1991GQ83400050
J	BIKOFF, EK; JAFFE, L; RIBAUDO, RK; OTTEN, GR; GERMAIN, RN; ROBERTSON, EJ				BIKOFF, EK; JAFFE, L; RIBAUDO, RK; OTTEN, GR; GERMAIN, RN; ROBERTSON, EJ			MHC CLASS-I SURFACE EXPRESSION IN EMBRYO-DERIVED CELL-LINES INDUCIBLE WITH PEPTIDE OR INTERFERON	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CARCINOMA-CELLS; GENE-EXPRESSION; MOUSE; ANTIGEN; BETA-2-MICROGLOBULIN; TRANSCRIPTS; MOLECULES; PLACENTA; VECTOR	IT has long been recognized that the absence of expression of products of the major histocompatibility complex (MHC) during early development might allow the fetus to escape recognition by maternal lymphocytes. In addition to the MHC class I heavy chain and beta-2-microglobulin, antigenic peptide is an essential structural component of the class I molecule 1-5. Indeed, there is evidence that MHC-linked genes encoding peptide transporter molecules 6-10 and possibly components of a proteolytic complex 11,12 are necessary for MHC class I assembly and stability at the cell surface. Here we demonstrate that embryonic cells in general show a defect in MHC class I assembly. Surface expression was rescued in the presence of an appropriate antigenic peptide, or by treatment with interferon. Consistent with this, HAM1 (ref. 9) messenger RNA was not constitutively expressed, but was inducible by interferon, and during differentiation in vitro. Thus, tolerance of the fetal allograft may in part be controlled at the level of peptide-dependent MHC class I assembly.	NIAID,IMMUNOL LAB,BETHESDA,MD 20892; COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Columbia University	BIKOFF, EK (corresponding author), CUNY MT SINAI SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,NEW YORK,NY 10029, USA.		Ribaudo, Randall/AAH-7094-2021; Germain, Ronald/ABE-7090-2020; Germain, Ronald N./Z-1945-2019					BERNSTINE EG, 1973, P NATL ACAD SCI USA, V70, P3899, DOI 10.1073/pnas.70.12.3899; BIKOFF EK, 1991, EUR J IMMUNOL, V21, P1997, DOI 10.1002/eji.1830210905; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CROCE CM, 1981, P NATL ACAD SCI-BIOL, V78, P5754, DOI 10.1073/pnas.78.9.5754; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HEDLEY ML, 1989, J IMMUNOL, V142, P4046; JAFFE L, 1990, J IMMUNOL, V145, P3474; JAFFE L, IN PRESS J IMMUN; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MARGULIES DH, 1983, J IMMUNOL, V130, P463; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MONACO JJ, 1982, P NATL ACAD SCI-BIOL, V79, P3001, DOI 10.1073/pnas.79.9.3001; MONACO JJ, 1984, NATURE, V309, P797, DOI 10.1038/309797a0; MORELLO D, 1982, NATURE, V296, P260, DOI 10.1038/296260a0; MORELLO D, 1985, IMMUNOGENETICS, V22, P441, DOI 10.1007/BF00418090; OZATO K, 1985, P NATL ACAD SCI USA, V82, P2427, DOI 10.1073/pnas.82.8.2427; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSENTHAL A, 1984, NATURE, V310, P415, DOI 10.1038/310415a0; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; SILVERMAN T, 1988, J IMMUNOL, V140, P4378; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TAKAHASHI H, 1988, P NATL ACAD SCI USA, V85, P3105, DOI 10.1073/pnas.85.9.3105; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0	30	57	60	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1991	354	6350					235	238		10.1038/354235a0	http://dx.doi.org/10.1038/354235a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ948	1720508				2022-12-01	WOS:A1991GQ94800051
J	HUA, QX; SHOELSON, SE; KOCHOYAN, M; WEISS, MA				HUA, QX; SHOELSON, SE; KOCHOYAN, M; WEISS, MA			RECEPTOR-BINDING REDEFINED BY A STRUCTURAL SWITCH IN A MUTANT HUMAN INSULIN	NATURE			English	Article								CRYSTAL Structures of insulin have been determined in various distinct forms 1-5, the relevance of which to receptor recognition has long been the subject of speculation 2,6,7. Recently the crystal structure of an inactive insulin analogue has been determined and, surprisingly, found to have a conformation identical to native insulin 8,9. On this basis Dodson and colleagues have suggested that the known insulin crystal structures reflect an inactive conformation, and that a change in conformation is required for activity-specifically, the carboxy terminal residues of the B-chain are proposed to separate from the amino terminal residues of the A-chain 8. Here we report the solution structure of an active insulin mutant 7,10, determined by two-dimensional NMR, which supports this hypothesis. In the mutant, the carboxy terminal beta-turn and beta-strand of the B-chain are destabilized and do not pack across the rest of the molecule. We suggest that analogous detachment of the carboxy terminal region of the B-chain occurs in native insulin on binding to its receptor. Our finding that partial unfolding of the B-chain exposes an alternative protein surface rationalizes the receptor-binding properties of a series of anomalous insulin analogues 7,11-13, including a mutant insulin associated with diabetes mellitus in man 14,15.	MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA; CHINESE ACAD SCI, INST BIOPHYS, BEIJING, PEOPLES R CHINA; BRIGHAM & WOMENS HOSP, JOSLIN DIABET CTR, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; CNRS, UA 32, F-91128 PALAISEAU, FRANCE	Harvard University; Massachusetts General Hospital; Chinese Academy of Sciences; Institute of Biophysics, CAS; Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Centre National de la Recherche Scientifique (CNRS)								BADGER J, 1991, ACTA CRYSTALLOGR B, V47, P127, DOI 10.1107/S0108768190009570; BAKER EN, 1988, PHILOS T R SOC LON B, V319, P389; BENTLEY G, 1976, NATURE, V261, P166, DOI 10.1038/261166a0; BI RC, 1984, BIOPOLYMERS, V23, P391, DOI DOI 10.1002/BIP.360230302; BOELENS R, 1990, EUR J BIOCHEM, V191, P147, DOI 10.1111/j.1432-1033.1990.tb19104.x; BRANGE J, 1988, NATURE, V333, P679, DOI 10.1038/333679a0; BROWN H, 1955, BIOCHEM J, V60, P556, DOI 10.1042/bj0600556; CASARETTO M, 1987, BIOL CHEM H-S, V368, P709, DOI 10.1515/bchm3.1987.368.1.709; CHOTHIA C, 1983, NATURE, V302, P500, DOI 10.1038/302500a0; CLORE GM, 1989, CRIT REV BIOCHEM MOL, V24, P479, DOI 10.3109/10409238909086962; DAI JB, 1987, SCI CHINA SER B, V30, P55; DEREWENDA U, 1989, NATURE, V338, P594, DOI 10.1038/338594a0; DEREWENDA U, 1991, J MOL BIOL, V220, P425, DOI 10.1016/0022-2836(91)90022-X; DODSON EJ, 1983, BIOPOLYMERS, V22, P281, DOI 10.1002/bip.360220137; HUA QX, 1991, BIOCHEMISTRY-US, V30, P5505, DOI 10.1021/bi00236a025; HUA QX, UNPUB J MOL BIOL; KLINE AD, 1990, BIOCHEMISTRY-US, V29, P2906, DOI 10.1021/bi00464a003; KOBAYASHI M, 1982, BIOCHEM BIOPH RES CO, V107, P329, DOI 10.1016/0006-291X(82)91708-9; KRISTENSEN SM, 1991, J MOL BIOL, V218, P221, DOI 10.1016/0022-2836(91)90886-B; MARKUSSEN J, 1985, INT J PEPT PROT RES, V26, P70; MIRMIRA RG, 1989, J BIOL CHEM, V264, P6349; NAKAGAWA SH, 1986, J BIOL CHEM, V261, P7332; NANJO K, 1986, J CLIN INVEST, V77, P514, DOI 10.1172/JCI112331; PULLEN RA, 1976, NATURE, V259, P369, DOI 10.1038/259369a0; SHOELSON S, 1983, NATURE, V302, P540, DOI 10.1038/302540a0; SHOELSON SE, UNPUB BIOCHEMISTRY; Steiner D. F., 1990, ENDOCRINOLOGY, P1263; WANG SH, 1991, J PROTEIN CHEM, V10, P313, DOI 10.1007/BF01025630; WEISS MA, 1991, BIOCHEMISTRY-US, V30, P7373, DOI 10.1021/bi00244a004; WUTHRICH K, 1989, METHOD ENZYMOL, V177, P125	30	234	249	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 21	1991	354	6350					238	241		10.1038/354238a0	http://dx.doi.org/10.1038/354238a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ948	1961250				2022-12-01	WOS:A1991GQ94800052
J	JEFFREYS, AJ; MACLEOD, A; TAMAKI, K; NEIL, DL; MONCKTON, DG				JEFFREYS, AJ; MACLEOD, A; TAMAKI, K; NEIL, DL; MONCKTON, DG			MINISATELLITE REPEAT CODING AS A DIGITAL APPROACH TO DNA TYPING	NATURE			English	Article								Most DNA typing systems used in forensic and legal medicine assay allelic length variation at tandem repetitive DNA regions such as minisatellites. A simple alternative approach that displays patterns of variant repeat units along minisatellite alleles is described here. This produces DNA profiles as extraordinarily variable digital sequences appropriate for forensic investigations, including computer databasing, and for analysing allele diversity and the role of recombination in minisatellite instability.			JEFFREYS, AJ (corresponding author), UNIV LEICESTER, DEPT GENET, UNIV RD, LEICESTER LE1 7RH, ENGLAND.		; Monckton, Darren/B-4943-2013	Neil, David/0000-0002-9994-9536; Monckton, Darren/0000-0002-8298-8264				ARMOUR JAL, 1989, GENOMICS, V4, P328, DOI 10.1016/0888-7543(89)90338-8; BAIRD M, 1986, AM J HUM GENET, V39, P489; BALAZS I, 1989, AM J HUM GENET, V44, P182; BOERWINKLE E, 1989, P NATL ACAD SCI USA, V86, P212, DOI 10.1073/pnas.86.1.212; BUDOWLE B, 1991, AM J HUM GENET, V48, P841; CHAKRABORTY R, 1991, EXPER SUPPL, V58, P127; CHANDLEY AC, 1988, CYTOGENET CELL GENET, V48, P152, DOI 10.1159/000132613; DEVLIN B, 1990, SCIENCE, V249, P1416, DOI 10.1126/science.2205919; GRAY IC, 1991, P ROY SOC B-BIOL SCI, V243, P241, DOI 10.1098/rspb.1991.0038; HAGELBERG E, 1991, NATURE, V352, P427, DOI 10.1038/352427a0; JARMAN AP, 1986, EMBO J, V5, P1857, DOI 10.1002/j.1460-2075.1986.tb04437.x; JEFFREYS AJ, 1988, NUCLEIC ACIDS RES, V16, P10953, DOI 10.1093/nar/16.23.10953; JEFFREYS AJ, 1991, EXPER SUPPL, V58, P1; JEFFREYS AJ, 1985, NATURE, V317, P818, DOI 10.1038/317818a0; JEFFREYS AJ, 1990, CELL, V60, P473, DOI 10.1016/0092-8674(90)90598-9; JEFFREYS AJ, 1985, NATURE, V316, P76, DOI 10.1038/316076a0; JEFFREYS AJ, 1991, AM J HUM GENET, V48, P824; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; LANDER ES, 1989, NATURE, V339, P501, DOI 10.1038/339501a0; LITT M, 1989, AM J HUM GENET, V44, P397; NAKAMURA Y, 1987, NUCLEIC ACIDS RES, V15, P2537, DOI 10.1093/nar/15.6.2537; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; ODELBERG SJ, 1989, GENOMICS, V5, P915, DOI 10.1016/0888-7543(89)90134-1; OWERBACH D, 1984, GENE, V32, P475, DOI 10.1016/0378-1119(84)90021-0; PAGE D C, 1987, Genomics, V1, P243, DOI 10.1016/0888-7543(87)90051-6; ROYLE NJ, 1988, GENOMICS, V3, P352, DOI 10.1016/0888-7543(88)90127-9; SIMMLER MC, 1987, EMBO J, V6, P963, DOI 10.1002/j.1460-2075.1987.tb04846.x; SMITH JC, 1990, J FORENSIC SCI SOC, V30, P19, DOI 10.1016/S0015-7368(90)73298-7; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; WEBER JL, 1989, AM J HUM GENET, V44, P388; WOLFF RK, 1989, GENOMICS, V5, P382, DOI 10.1016/0888-7543(89)90076-1; WOLFF RK, 1988, GENOMICS, V3, P347, DOI 10.1016/0888-7543(88)90126-7; WONG Z, 1986, NUCLEIC ACIDS RES, V14, P4605, DOI 10.1093/nar/14.11.4605; WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x	34	364	390	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 21	1991	354	6350					204	209		10.1038/354204a0	http://dx.doi.org/10.1038/354204a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ948	1961248				2022-12-01	WOS:A1991GQ94800040
J	MILNER, PF; KRAUS, AP; SEBES, JI; SLEEPER, LA; DUKES, KA; EMBURY, SH; BELLEVUE, R; KOSHY, M; MOOHR, JW; SMITH, J				MILNER, PF; KRAUS, AP; SEBES, JI; SLEEPER, LA; DUKES, KA; EMBURY, SH; BELLEVUE, R; KOSHY, M; MOOHR, JW; SMITH, J			SICKLE-CELL DISEASE AS A CAUSE OF OSTEONECROSIS OF THE FEMORAL-HEAD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA-THALASSEMIA; AVASCULAR NECROSIS; ANEMIA; SEVERITY; GENE; HIP	Background and Methods. Osteonecrosis of the femoral head is an important complication of sickle cell disease. We studied 2590 patients who were over 5 years of age at entry and followed them for an average of 5.6 years. Patients were examined twice a year, and radiographs of the hips were taken at least twice: at study entry and approximately three years later. Results. At study entry, 9.8 percent of patients were found to have osteonecrosis of one or both femoral heads. On follow-up, patients with the hemoglobin SS genotype and alpha-thalassemia were at the greatest risk for osteonecrosis (age-adjusted incidence rate, 4.5 cases per 100 patient-years, as compared with 2.4 in patients with the hemoglobin SS genotype without alpha-thalassemia and 1.9 in those with the hemoglobin SC genotype). Although the rate of osteonecrosis in patients with the hemoglobin SC genotype did not differ significantly from that in patients with the hemoglobin SS genotype without alpha-thalassemia, osteonecrosis tended to develop in these patients later in life. Intermediate rates of osteonecrosis were observed among patients with the hemoglobin S-beta-0-thalassemia and the hemoglobin S-beta+-thalassemia genotypes (3.6 and 3.3 cases per 100 patient-years, respectively). Osteonecrosis was found in patients as young as five years old (1.8 cases per 100 patient-years for all genotypes). The frequency of painful crises and the hematocrit were positively associated with osteonecrosis. The mean corpuscular volume and serum aspartate aminotransferase level were negatively associated. Twenty-seven patients had hip arthroplasty during the study; 10 were under 25 years of age. Five of the 27 required reoperation 11 to 53 months after the initial operation. Conclusions. Osteonecrosis of the femoral head is common in patients with sickle cell disease, with an incidence ranging from about 2 to 4.5 cases per 100 patient-years. Patients with the hemoglobin SS genotype and alpha-thalassemia and those with frequent painful crises are at highest risk. The overall prevalence is about 10 percent. The results of hip arthroplasty are poor.	UNIV TENNESSEE CTR HLTH SCI, MEMPHIS, TN 38163 USA; NEW ENGLAND RES INST, WATERTOWN, MA USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; INTERFAITH MED CTR, BROOKLYN, NY USA; UNIV ILLINOIS, CHICAGO, IL 60680 USA; UNIV ILLINOIS, CHICAGO, IL 60680 USA; WOODHULL SUNY HLTH SCI CTR, BROOKLYN, NY USA; COLUMBIA UNIV, HARLEM HOSP CTR, NEW YORK, NY 10027 USA	University of Tennessee System; University of Tennessee Health Science Center; HealthCore, Inc; University of California System; University of California San Francisco; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Columbia University	MILNER, PF (corresponding author), MED COLL GEORGIA, ADULT SICKLE CELL CLIN, BLDG FR-100, AUGUSTA, GA 30912 USA.							BALLAS SK, 1989, HEMOGLOBIN, V13, P649, DOI 10.3109/03630268908998842; CHUNG SMK, 1969, J BONE JOINT SURG AM, VA 51, P33, DOI 10.2106/00004623-196951010-00003; CLARKE HJ, 1989, J BONE JOINT SURG BR, V71, P465, DOI 10.1302/0301-620X.71B3.2722941; CNAAN A, 1989, STAT MED, V8, P1255, DOI 10.1002/sim.4780081009; DIGGS LW, 1937, SOUTH MED J, V30, P249; EMBURY SH, 1982, NEW ENGL J MED, V306, P270, DOI 10.1056/NEJM198202043060504; EMBURY SH, 1979, J CLIN INVEST, V63, P1307, DOI 10.1172/JCI109426; EMBURY SH, 1980, J CLIN INVEST, V66, P1319, DOI 10.1172/JCI109984; ENSIGN MF, 1990, SEMIN ULTRASOUND CT, V11, P288; FARBER MD, 1985, J CHRON DIS, V38, P495, DOI 10.1016/0021-9681(85)90033-5; Ficat R P, 1983, Hip, P279; FICAT RP, 1985, J BONE JOINT SURG BR, V67, P3, DOI 10.1302/0301-620X.67B1.3155745; Fleiss JL., 1986, DESIGN ANAL CLIN EXP; GASTON M, 1982, AM J PEDIAT HEMATOL, V4, P197; Glimcher M. J., 1979, CLIN ORTHOP RELAT R, V138, P284; GLIMCHER MJ, 1979, CLIN ORTHOP RELAT R, P273; GLIMCHER MJ, 1979, CLIN ORTHOP RELAT R, P283; Grinnan AG, 1935, AM J ROENTGENOL RADI, V34, P297; HANKER GJ, 1988, J BONE JOINT SURG AM, V70A, P499, DOI 10.2106/00004623-198870040-00004; HERNIGOU P, 1991, J BONE JOINT SURG AM, V73A, P81, DOI 10.2106/00004623-199173010-00011; HIGGS DR, 1982, NEW ENGL J MED, V306, P1441, DOI 10.1056/NEJM198206173062402; HUNGERFORD DS, 1989, ARTHRITIS RHEUM-US, V32, P801, DOI 10.1002/anr.1780320623; IWEGBU CG, 1985, J BONE JOINT SURG BR, V67, P29, DOI 10.1302/0301-620X.67B1.3968138; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; LEE REJ, 1981, CLIN RADIOL, V32, P205, DOI 10.1016/S0009-9260(81)80162-6; LIEINJO LE, 1981, NUCLEIC ACIDS RES, V9, P3707, DOI 10.1093/nar/9.15.3707; LILIENFELD AM, 1980, F EPIDEMIOLOGY; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; RIVER GL, 1961, BLOOD, V18, P385, DOI 10.1182/blood.V18.4.385.385; SAITO S, 1989, CLIN ORTHOP RELAT R, V244, P198; SERJEANT GR, 1989, ANN NY ACAD SCI, V565, P109, DOI 10.1111/j.1749-6632.1989.tb24157.x; SERJEANT GR, 1973, BRIT J RADIOL, V46, P935, DOI 10.1259/0007-1285-46-551-935; SERJEANT GR, 1985, SICKLE CELL DISEASE, P246; STEINBERG MH, 1984, BLOOD, V63, P1353; STEINBERG MH, 1983, BRIT J HAEMATOL, V55, P487, DOI 10.1111/j.1365-2141.1983.tb02164.x; STEINBERG MH, 1986, BLOOD, V68, P985; STULBERG BN, 1990, CLIN ORTHOP RELAT R, V261, P186; SWEET DE, 1981, DIAGNOSIS BONE JOINT, V3, P2780; UEO T, 1985, ARCH ORTHOP TRAUM SU, V104, P145, DOI 10.1007/BF00454690	39	229	232	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 21	1991	325	21					1476	1481		10.1056/NEJM199111213252104	http://dx.doi.org/10.1056/NEJM199111213252104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ406	1944426				2022-12-01	WOS:A1991GQ40600004
J	RANGANATHAN, R; HARRIS, GL; STEVENS, CF; ZUKER, CS				RANGANATHAN, R; HARRIS, GL; STEVENS, CF; ZUKER, CS			A DROSOPHILA MUTANT DEFECTIVE IN EXTRACELLULAR CALCIUM-DEPENDENT PHOTORECEPTOR DEACTIVATION AND RAPID DESENSITIZATION	NATURE			English	Article								CALCIUM is involved in the adaptation of vertebrate photoreceptors to light 1,2 and may have a similar role in invertebrate phototransduction 3,4. But the molecular mechanisms mediating this stimulus-dependent regulation are not well understood in any G protein-coupled transduction system. We have developed a preparation of isolated Drosophila photoreceptors that has allowed us to carry out an electrophysiological characterization of the light-activated response in these sensory neurons using patch-clamp techniques. We report here that extracellular calcium entering through the light-activated conductance is a key regulator of both the activation and deactivation phases of the phototransduction cascade, and that inaC mutant photoreceptors 5 are specifically defective in the calcium-dependent deactivation mechanism. These data suggest that the light-dependent calcium influx inactivates this cascade through a biochemical pathway that requires the inaC gene product, and that this mechanism represents a molecular basis for stimulus-dependent regulation of visual transduction in Drosophila photoreceptors.	UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA; SALK INST BIOL STUDIES, LA JOLLA, CA 92093 USA; SAN DIEGO STATE UNIV, DEPT BIOL, SAN DIEGO, CA 92182 USA; SAN DIEGO STATE UNIV, INST MOLEC BIOL, SAN DIEGO, CA 92182 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Salk Institute; California State University System; San Diego State University; California State University System; San Diego State University								BAINBRIDGE SP, 1981, J EMBRYOL EXP MORPH, V66, P57; BROWN JE, 1974, J GEN PHYSIOL, V64, P643, DOI 10.1085/jgp.64.6.643; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FAIN GL, 1990, TRENDS NEUROSCI, V13, P378, DOI 10.1016/0166-2236(90)90023-4; FEIN A, 1975, SCIENCE, V187, P1094, DOI 10.1126/science.1114339; Fein A., 1989, P173; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARDIE RC, 1991, NEURON, V6, P477, DOI 10.1016/0896-6273(91)90255-X; HARDIE RC, 1983, PROGR SENSORY PHYSL, P1; HENGSTEN, 1967, KYBERNETIK, V3, P276; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOENIG JH, 1977, DROSOPHILA INFORMATI, V52, P50; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; LISMAN JE, 1972, J GEN PHYSIOL, V59, P701, DOI 10.1085/jgp.59.6.701; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; Pak W.L., 1979, P67; PAK WL, 1975, HDB GENETICS, P703; PAYNE R, 1986, PHOTOBIOCH PHOTOBIOP, V13, P373; PAYNE R, 1986, J GEN PHYSIOL, V88, P127, DOI 10.1085/jgp.88.1.127; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; RUBIN LJ, 1985, BIOPHYS J, V47, P38; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	28	163	164	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 21	1991	354	6350					230	232		10.1038/354230a0	http://dx.doi.org/10.1038/354230a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ948	1961249				2022-12-01	WOS:A1991GQ94800049
J	ROSENSTEIN, Y; PARK, JK; HAHN, WC; ROSEN, FS; BIERER, BE; BURAKOFF, SJ				ROSENSTEIN, Y; PARK, JK; HAHN, WC; ROSEN, FS; BIERER, BE; BURAKOFF, SJ			CD43, A MOLECULE DEFECTIVE IN WISKOTT-ALDRICH SYNDROME, BINDS ICAM-1	NATURE			English	Article								THE protein CD43 (also known as sialophorin, leukosialin, large sialoglycoprotein or gp115) is expressed on the surface of T lymphocytes, monocytes, neutrophils, platelets and some B lymphocytes 1-6. Expression of CD43 is deficient and/or defective in the X-chromosome-linked immunodeficiency disorder Wiscott-Aldrich syndrome 7, suggesting that CD43 might have a role in T-cell activation. We have shown that expression of human CD43 in an HLA-DR-specific murine T-cell hybridoma enhances the antigen-specific response to stimulation by the human lymphoblastoid cell line Daudi, and that Daudi cells bind specifically to purified immobilized CD43 (ref. 8). These data indicate that the specific interaction of CD43 with a ligand on the surface of Daudi cells might contribute to T-cell activation. Here we report evidence that intercellular adhesion molecule-1 (ICAM-1, or CD54), is a ligand for CD43.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, CTR BLOOD RES, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	ROSENSTEIN, Y (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV PEDIAT ONCOL, BOSTON, MA 02115 USA.			Bierer, Barbara/0000-0001-6448-8170				ARDMAN B, 1990, J EXP MED, V172, P1151, DOI 10.1084/jem.172.4.1151; AXELSSON B, 1988, J IMMUNOL, V141, P2912; BEYERS AD, 1989, IMMUNOL REV, V111, P59, DOI 10.1111/j.1600-065X.1989.tb00542.x; BIERER BE, 1988, P NATL ACAD SCI USA, V85, P1154; BORCHE L, 1987, EUR J IMMUNOL, V17, P1523, DOI 10.1002/eji.1830171023; BROWN WRA, 1981, NATURE, V289, P456, DOI 10.1038/289456a0; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; CLARK EA, 1986, HUM IMMUNOL, V16, P100, DOI 10.1016/0198-8859(86)90039-X; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DORKEN B, 1989, LEUCOCYTE TYPING 4, P3; GAHMBERG CG, 1976, J CELL BIOL, V68, P642, DOI 10.1083/jcb.68.3.642; GOLDSTEIN SAN, 1986, J IMMUNOL, V137, P3383; GORGA JC, 1986, CELL IMMUNOL, V103, P160, DOI 10.1016/0008-8749(86)90077-8; HAHN WC, 1991, J IMMUNOL, V147, P14; JOHNSTON SC, 1990, J IMMUNOL, V145, P1181; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; MENTZER SJ, 1987, J EXP MED, V165, P1383, DOI 10.1084/jem.165.5.1383; NONG YH, 1989, J EXP MED, V170, P259, DOI 10.1084/jem.170.1.259; PARK JK, 1991, NATURE, V350, P706, DOI 10.1038/350706a0; PARKMAN R, 1981, LANCET, V2, P1387; REMOLDODONNELL E, 1987, BLOOD, V70, P104; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SANCHEZMADRID F, 1982, CELL IMMUNOL, V73, P1, DOI 10.1016/0008-8749(82)90431-2; SILVERMAN LB, 1989, J IMMUNOL, V142, P4194; SPRINGER TA, 1987, REV IMMUNOL, P223; STAUNTON DE, 1990, CELL, V61, P242; STOLL M, 1989, LEUCOCYTE TYPING 4, P605; TAKAI Y, 1987, P NATL ACAD SCI USA, V84, P6864, DOI 10.1073/pnas.84.19.6864; WICKEN M, 1988, SCAND J IMMUNOL, V28, P457	33	258	264	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1991	354	6350					233	235		10.1038/354233a0	http://dx.doi.org/10.1038/354233a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ948	1683685				2022-12-01	WOS:A1991GQ94800050
J	ROY, AL; MEISTERERNST, M; POGNONEC, P; ROEDER, RG				ROY, AL; MEISTERERNST, M; POGNONEC, P; ROEDER, RG			COOPERATIVE INTERACTION OF AN INITIATOR-BINDING TRANSCRIPTION INITIATION-FACTOR AND THE HELIX LOOP HELIX ACTIVATOR USF	NATURE			English	Article							RNA POLYMERASE-II; MAJOR LATE PROMOTER; GENETIC SPECIFICITY; UPSTREAM ELEMENT; DNA-BINDING; TATA; PROTEINS; IDENTIFICATION; PURIFICATION; EXPRESSION	TRANSCRIPTION initiation by mammalian RNA polymerase II is effected by multiple common factors 1,2 interacting through minimal promoter elements and regulated by gene-specific factors 3 interacting with distal control elements. Minimal promoter elements that can function independently or together, depending on the specific promoter, include the upstream TATA box 4,5 and a pyrimidine-rich initiator 6-8 (Inr) overlapping the transcription start site. The binding of TFIID to the TATA element 4,9 promotes the assembly of other factors into a preinitiation complex 10-12 but factors which function at the Inr have not been defined. We show here that a novel factor (TFII-I) binds specifically to Inr elements, supports basal transcription from the adenovirus major late promoter and is immunologically related to the helix-loop-helix activator USF (ref. 13). We further show that TFII-I also binds to the upstream high-affinity USF site (E box), that USF also binds to the Inr, and that TFII-I and USF interact cooperatively at both Inr and E box sites. Thus, TFII-I represents a novel type of transcription initiation factor whose interactions at multiple promoter elements may aid novel communication mechanisms between upstream regulatory factors and the general transcriptional machinery.			ROY, AL (corresponding author), ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021, USA.							BLACKWOOD EM, 1991, SCIENCE, V251, P1149; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GROSSCHEDL R, 1980, P NATL ACAD SCI-BIOL, V77, P1432, DOI 10.1073/pnas.77.3.1432; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MEISTERENST M, 1991, CELL, V66, P1; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495	24	439	444	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1991	354	6350					245	248		10.1038/354245a0	http://dx.doi.org/10.1038/354245a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ948	1961251				2022-12-01	WOS:A1991GQ94800054
J	SETO, E; SHI, Y; SHENK, T				SETO, E; SHI, Y; SHENK, T			YY1 IS AN INITIATOR SEQUENCE-BINDING PROTEIN THAT DIRECTS AND ACTIVATES TRANSCRIPTION INVITRO	NATURE			English	Article							MAMMARY-TUMOR VIRUS; MAJOR LATE PROMOTER; LONG-TERMINAL REPEAT; RNA POLYMERASE-II; CONTROL REGION; GENE; BOX; TATA; IDENTIFICATION; PURIFICATION	REGULATION of eukaryotic messenger RNA transcription is governed by DNA sequence elements that serve as binding sites for sequence-specific transcription factors 1-3. These include upstream and downstream promoter-proximal elements, enhancers, repressors, and silencers, which modulate the rate of specific initiation by RNA polymerase II. In addition, the promoter-proximal region between -45 and +30 (relative to the start of initiation) contains two highly conserved motifs, the TATA sequence at around -30 and CA at +1 (ref. 4). Although the TATA element-binding factor TFIID has been purified and cloned from several organisms and has provided invaluable insight into the process of transcription initiation and its regulation, little is known about factors that interact at the +1 region. We have recently shown that the adeno-associated virus type 2 P5 promoter +1 region (P5 + 1 element) binds transcription factor YY1 (ref. 5). We report here that this sequence is necessary and sufficient for accurate basal transcription. Further, partially purified YY1 can restore basal level transcription from a P5 + 1 element in a HeLa extract depleted for YY1 or a Drosophila embryo extract devoid of YY1 activity, whereas a YY1-specific antibody can block the reactivation. Finally, using electrophoretic mobility shift assay, we have identified YY1-related factors that bind to two other transcription initiators in cellular genes.	PRINCETON UNIV,DEPT MOLEC BIOL,HOWARD HUGHES MED INST,PRINCETON,NJ 08544	Howard Hughes Medical Institute; Princeton University								BOYER TG, 1990, J BIOL CHEM, V265, P20524; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; BUETTI E, 1983, EMBO J, V2, P1423, DOI 10.1002/j.1460-2075.1983.tb01601.x; CHANG LS, 1989, J VIROL, V63, P3479, DOI 10.1128/JVI.63.8.3479-3488.1989; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FLANAGAN JR, IN PRESS P NATN ACAD; GARFINKEL S, 1990, J BIOL CHEM, V265, P10309; HARIHARAN N, IN PRESS P NATN ACAD; HARLOW E, 1988, ANTIBODIES LABORATOR; HEIERMANN R, 1985, NUCLEIC ACIDS RES, V13, P2709, DOI 10.1093/nar/13.8.2709; HEN R, 1982, P NATL ACAD SCI-BIOL, V79, P7132, DOI 10.1073/pnas.79.23.7132; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; LEE F, 1984, NUCLEIC ACIDS RES, V12, P4191, DOI 10.1093/nar/12.10.4191; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; MAJORS J, 1983, P NATL ACAD SCI-BIOL, V80, P5866, DOI 10.1073/pnas.80.19.5866; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; OKAMOTO T, 1990, VIROLOGY, V177, P606, DOI 10.1016/0042-6822(90)90526-W; PARK K, IN PRESS P NATN ACAD; PARKS CL, 1988, J VIROL, V62, P54, DOI 10.1128/JVI.62.1.54-67.1988; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; STENLUND A, 1987, SCIENCE, V236, P1666, DOI 10.1126/science.3037693; ULLRICH A, 1982, J MOL BIOL, V156, P467, DOI 10.1016/0022-2836(82)90261-3; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495	34	393	402	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1991	354	6350					241	245		10.1038/354241a0	http://dx.doi.org/10.1038/354241a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ948	1720509				2022-12-01	WOS:A1991GQ94800053
J	SOUDAH, HC; HASLER, WL; OWYANG, C				SOUDAH, HC; HASLER, WL; OWYANG, C			EFFECT OF OCTREOTIDE ON INTESTINAL MOTILITY AND BACTERIAL OVERGROWTH IN SCLERODERMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROGRESSIVE SYSTEMIC-SCLEROSIS; ANALOG SMS 201-995; MIGRATING MOTOR COMPLEX; ESOPHAGEAL DYSFUNCTION; MYOELECTRIC ACTIVITY; TRANSIT-TIME; SOMATOSTATIN; CISAPRIDE; PSEUDOOBSTRUCTION; ABSORPTION	Background. Patients with scleroderma may have abnormal motility of the small intestine, with pseudoobstruction and bacterial overgrowth. Standard stimulatory agents are often ineffective in such patients. Because the somatostatin analogue octreotide evokes intestinal motor activity in normal subjects, we hypothesized that it might increase motility in patients with scleroderma. Methods. We studied the effects of octreotide on intestinal motility and plasma motilin concentrations in five fasting patients with scleroderma who had bacterial overgrowth and in six fasting normal subjects. The motor effects of octreotide were correlated with its effects on abdominal symptoms and bacterial overgrowth as determined by the level of breath hydrogen excretion. Results. In the normal subjects, octreotide (l0-mu-g subcutaneously) increased the mean (+/- SD) frequency of intestinal migrating complexes, which reflect intestinal motility, from 1.5 +/- 1.0 to 4.1 +/- 1.1 every three hours. In the patients with scleroderma, who had no spontaneous migrating complexes, octreotide (100-mu-g) induced 3.6 +/- 2.3 complexes every three hours. These complexes propagated at the same velocity and had two-thirds the amplitude of the spontaneous complexes in normal subjects. Plasma motilin concentrations, which were higher in the patients with scleroderma (229 +/- 74 pmol per liter) than in the normal subjects (112 +/- 37 pmol per liter), were inhibited by octreotide, suggesting that intestinal activity evoked by octreotide is independent of motilin. Treatment of the patients with scleroderma with octreotide (50-mu-g every evening) for three weeks reduced breath hydrogen excretion while they were fasting from 25 +/- 5 to 4 +/- 2 ppm (P = 0.001) and breath hydrogen excretion after they ingested 50 g of glucose from 46 +/- 24 to 8 +/- 7 ppm (P = 0.015); these reductions were accompanied by a significant decrease in nausea, bloating, and abdominal pain and by less frequent emesis. Conclusions. Octreotide stimulates intestinal motility in normal subjects and in patients with scleroderma. In such patients, the short-term administration of octreotide reduces bacterial overgrowth and improves abdominal symptoms. This agent may be useful for the treatment of intestinal dysmotility in patients with scleroderma.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,GASTROENTEROL RES UNIT,3912 TAUBMAN CTR,BOX 0362,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIDDK NIH HHS [R01 DK35783, P30 DK34933] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933, R01DK035783] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKESSON A, 1987, SCAND J RHEUMATOL, V16, P291, DOI 10.3109/03009748709102931; ANDERSON IH, 1981, NEW ENGL J MED, V304, P891, DOI 10.1056/NEJM198104093041507; BAUER W, 1982, LIFE SCI, V31, P1133, DOI 10.1016/0024-3205(82)90087-X; BUENO L, 1975, J PHYSIOL-LONDON, V249, P69, DOI 10.1113/jphysiol.1975.sp011003; CAMILLERI M, 1989, GASTROENTEROLOGY, V96, P704; CAMILLERI M, 1986, GASTROENTEROLOGY, V91, P619, DOI 10.1016/0016-5085(86)90631-1; CLARK M, 1967, BRIT J DERMATOL, V79, P449, DOI 10.1111/j.1365-2133.1967.tb11531.x; COHEN S, 1972, J CLIN INVEST, V51, P2663, DOI 10.1172/JCI107084; CORAZZA GR, 1990, GASTROENTEROLOGY, V98, P302, DOI 10.1016/0016-5085(90)90818-L; DIMARINO AJ, 1973, NEW ENGL J MED, V289, P1220, DOI 10.1056/NEJM197312062892304; FUESSL HS, 1987, DIGESTION, V36, P101, DOI 10.1159/000199407; Goetz Robert H., 1945, CLIN PROCEED, V4, P337; GORDEN P, 1989, ANN INTERN MED, V110, P35, DOI 10.7326/0003-4819-110-1-35; GREYDANUS MP, 1989, GASTROENTEROLOGY, V96, P110, DOI 10.1016/0016-5085(89)90770-1; Hale CH, 1944, AM J ROENTGENOL RADI, V51, P407; HAMELROY J, 1985, GASTROENTEROLOGY, V88, P1; HOROWITZ M, 1987, GASTROENTEROLOGY, V93, P311, DOI 10.1016/0016-5085(87)91020-1; HORSWELL RR, 1961, GASTROENTEROLOGY, V40, P580; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KAHN IJ, 1966, NEW ENGL J MED, V274, P1339, DOI 10.1056/NEJM196606162742402; KERLIN P, 1982, GASTROENTEROLOGY, V82, P701; KERLIN P, 1988, GASTROENTEROLOGY, V95, P982, DOI 10.1016/0016-5085(88)90173-4; KING CE, 1986, GASTROENTEROLOGY, V91, P1447, DOI 10.1016/0016-5085(86)90199-X; KREJS GJ, 1984, DIABETES, V33, P548, DOI 10.2337/diabetes.33.6.548; METZ G, 1976, LANCET, V1, P668; PEACHEY RDG, 1969, GUT, V10, P285, DOI 10.1136/gut.10.4.285; PEETERS TL, 1983, REGUL PEPTIDES, V5, P209, DOI 10.1016/0167-0115(83)90252-5; PEETERS TL, 1988, SCAND J GASTROENTERO, V23, P769, DOI 10.3109/00365528809090758; POITRAS P, 1980, AM J PHYSIOL, V239, pG215, DOI 10.1152/ajpgi.1980.239.3.G215; Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, 1980, ARTHRITIS RHEUM, V23, P581; REES WDW, 1982, GASTROENTEROLOGY, V83, P575; REINHARDT JF, 1962, AMER J ROENTGENOL RA, V88, P687; ROHRMANN CA, 1981, AM J ROENTGENOL, V143, P933; SCHEMANN M, 1986, GASTROENTEROLOGY, V90, P1950, DOI 10.1016/0016-5085(86)90266-0; SCHUFFLER MD, 1981, MEDICINE, V60, P173, DOI 10.1097/00005792-198105000-00002; TREACY WL, 1962, MAYO CLIN PROC, V37, P607; VANTRAPPEN G, 1979, DIGEST DIS SCI, V24, P497, DOI 10.1007/BF01489315; VANTRAPPEN G, 1978, GASTROINTESTINAL MOT, P3; WHITEHEAD WE, 1989, GASTROENTEROLOGY, V96, P428, DOI 10.1016/0016-5085(89)91567-9; WITT K, 1989, SCAND J GASTROENTERO, V24, P1248, DOI 10.3109/00365528909090795	40	307	311	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 21	1991	325	21					1461	1467		10.1056/NEJM199111213252102	http://dx.doi.org/10.1056/NEJM199111213252102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ406	1944424				2022-12-01	WOS:A1991GQ40600002
J	EASTERBROOK, PJ; KERULY, JC; CREAGHKIRK, T; RICHMAN, DD; CHAISSON, RE; MOORE, RD				EASTERBROOK, PJ; KERULY, JC; CREAGHKIRK, T; RICHMAN, DD; CHAISSON, RE; MOORE, RD			RACIAL AND ETHNIC-DIFFERENCES IN OUTCOME IN ZIDOVUDINE-TREATED PATIENTS WITH ADVANCED HIV DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AIDS-RELATED COMPLEX; PLACEBO-CONTROLLED TRIAL; PNEUMOCYSTIS-CARINII PNEUMONIA; RECEIVING ZIDOVUDINE; AZIDOTHYMIDINE AZT; DOUBLE-BLIND; EXPERIENCE; EFFICACY; SURVIVAL	Objectives. - To determine if racial-ethnic differences exist in survival, disease progression, and development of myelosuppression in zidovudine-treated patients with advanced human immunodeficiency virus (HIV) disease. Design. - Prospective observational study. Setting. - Hospital and private clinics in 12 metropolitan centers. Patients. - The study included 754 non-Hispanic white, 165 black, and 106 Hispanic- patients with the acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex (ARC) who received up to 2 years of zidovudine therapy. Outcome Measures. - Survival, development of Pneumocystis carinii pneumonia (PCP), other opportunistic infections, and myelosuppression. Results. - At initiation of zidovudine therapy, Hispanic and particularly black patients had more advanced HIV disease than white patients, as indicated by lower baseline CD4+ counts, hematocrits, and AIDS-defining diagnoses. Black patients with AIDS also had a worse prognosis compared with white and Hispanic patients with AIDS. The product-limit survival rates at 2 years for white, black, and Hispanic patients with AIDS were 40%, 27%, and 39%, respectively (black vs white, P = .01; Hispanic vs white, P = .32, by the log-rank test). The respective proportions of patients who developed PCP at 2 years were 46%, 66%, and 44% (black vs white, P = .0001; Hispanic vs white, P = .86) and for other opportunistic infections the proportions were 56%, 63%, and 63%, respectively (black vs white, P = .03; Hispanic vs white, P = .09). There were no significant racial-ethnic differences in survival or in the development of opportunistic infections for patients with ARC, and there were no differences in the incidence of myelosuppression or dose reduction or suspension for patients with either ARC or AIDS. After adjusting for more advanced HIV disease (mainly low CD4+ counts and hematocrits), black race was no longer a significant independent predictor of survival. Adjustment for racial differences in the use of PCP prophylaxis accounted for most of the excess risk for the development of PCP in black patients compared with white patients with AIDS. Conclusions. - Racial differences in survival and the development of opportunistic infections are mainly due to the more advanced HIV disease in black patients when zidovudine therapy is started and to their less frequent use of PCP prophylaxis. Innovative approaches are needed to ensure more widespread use of and earlier access to zidovudine therapy and PCP prophylaxis.	BURROUGHS WELLCOME CO,RES TRIANGLE PK,NC 27709; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT PATHOL,LA JOLLA,CA 92093	Burroughs Wellcome Fund; University of California System; University of California San Diego; University of California System; University of California San Diego	EASTERBROOK, PJ (corresponding author), JOHNS HOPKINS UNIV HOSP,SCH MED,DEPT MED,1830 MONUMENT ST,ROOM 8059,BALTIMORE,MD 21205, USA.		Easterbrook, Philippa J/A-3937-2009	Easterbrook, Philippa/0000-0002-2603-5418				BACCHETTI P, 1988, J INFECT DIS, V157, P1044, DOI 10.1093/infdis/157.5.1044; BAKEMAN R, 1987, J NATL MED ASSOC, V79, P921; COX DR, 1972, J R STAT SOC B, V34, P187; CREAGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009, DOI 10.1001/jama.260.20.3009; DOURNON E, 1988, LANCET, V2, P1297; FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FRIEDLAND GH, 1991, J ACQ IMMUN DEF SYND, V4, P144; GOLDEN JA, 1989, LANCET, V1, P654; HAMILTON JD, 1991, CLIN RES, V39, pA216; JACKSON L, 1990, 6TH INT C AIDS SAN F; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; MOORE RD, 1991, ARCH INTERN MED, V151, P981, DOI 10.1001/archinte.151.5.981; PINCHING AJ, 1989, J INFECTION, V18, P33, DOI 10.1016/S0163-4453(89)80078-7; RICHMAN DD, 1988, AM J MED, V85, P208; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SELIK RM, 1988, AM J PUBLIC HEALTH, V78, P1539, DOI 10.2105/AJPH.78.12.1539; SELTZER R, 1988, AIDS PUBLIC POLICY J, V3, P31; STAMBUK D, 1989, Q J MED, V262, P161; STEINBERG JP, 1989, J ACQ IMMUN DEF SYND, V2, P229; WILLIAMS I, 1989, J INFECTION, V18, P23, DOI 10.1016/S0163-4453(89)80077-5; 1987, MMWR, V36, pS1; 1988, MMWR, V37, P1	25	87	88	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1991	266	19					2713	2718		10.1001/jama.266.19.2713	http://dx.doi.org/10.1001/jama.266.19.2713			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GP691	1942423				2022-12-01	WOS:A1991GP69100026
J	HENKIN, R				HENKIN, R			COOLING THE BURN FROM HOT PEPPERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											HENKIN, R (corresponding author), TASTE & SMELL CLIN,WASHINGTON,DC, USA.								0	10	10	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1991	266	19					2766	2766						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP691	1942431				2022-12-01	WOS:A1991GP69100037
J	KELLEY, PW; PETRUCCELLI, BP; STEHRGREEN, P; ERICKSON, RL; MASON, CJ				KELLEY, PW; PETRUCCELLI, BP; STEHRGREEN, P; ERICKSON, RL; MASON, CJ			THE SUSCEPTIBILITY OF YOUNG-ADULT AMERICANS TO VACCINE-PREVENTABLE INFECTIONS - A NATIONAL SEROSURVEY OF UNITED-STATES-ARMY RECRUITS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LINKED IMMUNOSORBENT-ASSAY; VARICELLA-ZOSTER VIRUS; EPIDEMIC MEASLES; RUBELLA; POPULATION; IMMUNIZATION; ANTIBODY; MUMPS	Objective. - Due to recent resurgences of measles, mumps, and rubella among young US adults, we sought to generate antibody prevalence data for national and military immunization policy evaluations. Design. - We used a questionnaire and serological survey of Army recruits to assess antibody status to measles, mumps, rubella, and varicella by enzyme-linked immunosorbent assay and to poliovirus types 1, 2, and 3 by microneutralization assay. Setting. - Basic training reception centers at Fort Benning, Ga, and Fort Jackson, SC. Patients. - The study included 1547 US Army recruits who were inducted during September and October 1989. Outcome Measures. - Seronegativity by various demographic factors. Results. - Seronegativity rates, directly adjusted to the 15- to 24-year-old US population in 1980, were 20.7% for measles, 15.6% for mumps, 17.5% for rubella, and 6.9% for varicella. For measles, mumps, and rubella, susceptibility was less in females, blacks, and college-educated recruits, and varicella susceptibility was greater in females and blacks. Recruits who were born after 1969 lacked measles, mumps, and rubella antibodies more often than older recruits. The adjusted seronegativity rates for poliovirus types 1, 2, and 3 were 2.3%, 0.6%, and 14.6%, respectively; trends by age, sex, and race-ethnicity were generally unremarkable. Conclusions. - Among young adult Americans, susceptibility to measles, mumps, and rubella is unevenly distributed and may be substantial. Our findings support national objectives to further improve immunization coverage in school-age and adult populations and provide further impetus for legislation requiring college entrants to present evidence of having received at least two doses of measles vaccine, with one on or after entry into elementary school.	CTR DIS CONTROL,CTR PREVENT SERV,DIV IMMUNIZAT,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	KELLEY, PW (corresponding author), WALTER REED ARMY MED CTR,DIV PREVENT MED,ADV PREVENT MED STUDIES BRANCH,WASHINGTON,DC 20307, USA.		Mason, Carl J/F-3538-2010; Mason, Carl/ABH-3298-2021	Mason, Carl J/0000-0002-3676-2811; Mason, Carl/0000-0002-3676-2811				ARDAY DR, 1989, AM J PUBLIC HEALTH, V79, P471, DOI 10.2105/AJPH.79.4.471; ARMITAGE P, 1987, STATISTICAL METHODS, P400; BURKE DS, 1979, J INFECT DIS, V139, P225, DOI 10.1093/infdis/139.2.225; BURKE DS, 1987, NEW ENGL J MED, V317, P131, DOI 10.1056/NEJM198707163170302; CHEN RT, 1990, J INFECT DIS, V162, P1036, DOI 10.1093/infdis/162.5.1036; COCHI SL, 1988, AM J DIS CHILD, V142, P499, DOI 10.1001/archpedi.1988.02150050037025; COCHI SL, 1988, AM J DIS CHILD, V142, P1021, DOI 10.1001/archpedi.1988.02150100015006; COHEN ZB, 1985, CLIN PEDIATR, V24, P387, DOI 10.1177/000992288502400705; CRAWFORD GE, 1981, J INFECT DIS, V144, P403, DOI 10.1093/infdis/144.5.403; DEFOREST A, 1989, 89TH ANN M AM SOC MI, P136; DEMMLER GJ, 1988, J INFECT DIS, V157, P2211; DORFMAN SF, 1985, MT SINAI J MED, V52, P248; Fleiss JL, 1981, STAT METHODS RATES P, P218; GERSHON AA, 1976, PEDIATRICS, V58, P692; Hardy I R, 1990, Infect Dis Clin North Am, V4, P159; LIAO SJ, 1954, AM J HYG, V59, P273, DOI 10.1093/oxfordjournals.aje.a119640; LONGFIELD JN, 1990, ARCH INTERN MED, V150, P970, DOI 10.1001/archinte.150.5.970; MARKOWITZ LE, 1990, NEW ENGL J MED, V322, P580, DOI 10.1056/NEJM199003013220903; MARKOWITZ LE, 1990, PEDIATR INFECT DIS J, V9, P101, DOI 10.1097/00006454-199002000-00008; MCKINNEY WP, 1989, AM J INFECT CONTROL, V17, P26, DOI 10.1016/S0196-6553(89)80009-4; Melnick JL, 1979, DIAGNOSTIC PROCEDURE, V5th, P471; MUMM AH, 1990, PROGRAM ABSTRACTS PR; MURRAY DL, 1988, AM J PUBLIC HEALTH, V78, P836, DOI 10.2105/AJPH.78.7.836; NEUMANN PW, 1985, J CLIN MICROBIOL, V22, P296, DOI 10.1128/JCM.22.2.296-298.1985; NKOWANE BM, 1987, JAMA-J AM MED ASSOC, V257, P1335, DOI 10.1001/jama.257.10.1335; Orenstein W A, 1986, Dev Biol Stand, V65, P75; PAUL JR, 1964, AM J HYG, V80, P286, DOI 10.1093/oxfordjournals.aje.a120477; SHASBY DM, 1977, NEW ENGL J MED, V296, P585, DOI 10.1056/NEJM197703172961102; SHEHAB Z, 1983, J INFECT DIS, V148, P472; STRASSBURG MA, 1984, INFECT CONT HOSP EP, V5, P123, DOI 10.1017/S019594170005997X; Wharton M, 1990, Infect Dis Clin North Am, V4, P47; 1989, PEDIATRICS, V84, P1110; 1990, GUIDE ADULT IMMUNIZA; 1988, MMWR, V37, P527; 1989, MMWR, V38, P101; 1985, REV INFECT IDS, V7, pS177; 1990, MMWR, V38, P35; 1983, 1980 CENSUS POPULATI; 1988, IOM8804 NAT AC SCI I; 1989, MMWR, V38, P1; 1990, MMWR, V39, P353; 1991, MMWR, V40, P93	42	119	121	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1991	266	19					2724	2729		10.1001/jama.266.19.2724	http://dx.doi.org/10.1001/jama.266.19.2724			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP691	1942425				2022-12-01	WOS:A1991GP69100028
J	MIRKIN, G				MIRKIN, G			SIDE-EFFECTS OF RAW HONEY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											MIRKIN, G (corresponding author), GEORGETOWN UNIV HOSP,SCH MED,WASHINGTON,DC 20007, USA.							BEATY HN, 1987, PRINCIPLES INTERNAL, P561; BIBEROGLU S, 1988, JAMA-J AM MED ASSOC, V259, P1943, DOI 10.1001/jama.1988.03720130021010; LAMPE KF, 1988, JAMA-J AM MED ASSOC, V259, P2009; MCGEE MD, 1974, HOSP FORMUL MANAG, V9, P41; PATWARDHAN VN, 1973, TOXICANTS OCCURRING, P495; SEYAMA I, 1985, JPN J PHYSIOL, V35, P401, DOI 10.2170/jjphysiol.35.401	6	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1991	266	19					2766	2766						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP691	1942432				2022-12-01	WOS:A1991GP69100036
J	CROSS, SJ; LEE, HS; RAWLES, JM; JENNINGS, K				CROSS, SJ; LEE, HS; RAWLES, JM; JENNINGS, K			SAFETY OF THROMBOLYSIS IN ASSOCIATION WITH CARDIOPULMONARY-RESUSCITATION	BMJ-BRITISH MEDICAL JOURNAL			English	Article									UNIV ABERDEEN, DEPT MED & THERAPEUT, ABERDEEN AB9 1FX, SCOTLAND	University of Aberdeen	CROSS, SJ (corresponding author), ABERDEEN ROYAL INFIRM, DEPT CARDIAC, ABERDEEN AB9 2ZD, SCOTLAND.							[Anonymous], 1988, LANCET, V2, P349; DEBONO D, 1990, PRACTICAL CORONARY T, P28; DUBOIS C, 1986, EUR HEART J, V7, P945, DOI 10.1093/oxfordjournals.eurheartj.a061999; PASTERNAK RC, 1988, HEART DISEASE TXB CA, P1222; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465	5	24	25	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 16	1991	303	6812					1242	1242		10.1136/bmj.303.6812.1242	http://dx.doi.org/10.1136/bmj.303.6812.1242			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ342	1747647	Bronze, Green Published			2022-12-01	WOS:A1991GQ34200026
J	FANNING, A; EDWARDS, S				FANNING, A; EDWARDS, S			MYCOBACTERIUM-BOVIS INFECTION IN HUMAN-BEINGS IN CONTACT WITH ELK (CERVUS-ELAPHUS) IN ALBERTA, CANADA	LANCET			English	Article								Human infection with Mycobacterium bovis is rare in developed countries because of milk pasteurisation and the slaughter of infected cattle. An epizootic of M bovis infection in domesticated elk (Cervus elaphus) in Alberta, Canada, which started in April, 1990, prompted us to seek human contacts of elk herds. There were 446 identified contacts, in 394 of whom tuberculin skin tests were done. Of 81 contacts who were skin-test positive, 50 had been in contact with culture-positive animals. 6 of 106 subjects tested a second time became tuberculin positive. 1 case of active M bovis infection was diagnosed by sputum culture. The mode of transmission of M bovis from these farm animals to man is likely to be aerosolisation of infected particles. Because of the apparent susceptibility of farmed Cervidae (deer) to M bovis infection, and the evidence of spread to man, control measures to prevent human infection should be developed.			FANNING, A (corresponding author), UNIV ALBERTA,DEPT MED,DIV INFECT DIS,2E4 11 WALTER MACKENZIE HLTH SCI CTR,EDMONTON T6G 2J3,ALBERTA,CANADA.							COLLINS CH, 1957, IRISH VET J, V41, P363; FANNING A, 1991, American Review of Respiratory Disease, V143, pA284; GEORGHIOU P, 1989, AUST NZ J MED, V19, P409, DOI 10.1111/j.1445-5994.1989.tb00289.x; KARLSON AG, 1970, ANN INTERN MED, V73, P979, DOI 10.7326/0003-4819-73-6-979; ROBINSON P, 1988, NZ J MED, V18, P701; Stumpff C. D., 1982, Proceedings of the American Animal Health Association, V86, P524; WIGLE WD, 1973, AM REV RESPIR DIS, V106, P528; YATES MD, 1986, J EPIDEMIOL COMMUN H, V40, P295, DOI 10.1136/jech.40.4.295	8	74	76	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 16	1991	338	8777					1253	1255		10.1016/0140-6736(91)92113-G	http://dx.doi.org/10.1016/0140-6736(91)92113-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ166	1682654				2022-12-01	WOS:A1991GQ16600014
J	GODLEE, F				GODLEE, F			HEALTH IMPLICATIONS OF CLIMATIC-CHANGE	BRITISH MEDICAL JOURNAL			English	Editorial Material																		[Anonymous], 1990, POLICYMAKERS SUMMARY; BROWN L, 1989, STATE WORLD 1989 WOR; Brown L.R., 1990, STATE WORLD 1990 WOR; BROWN LR, 1991, STATE WORLD 1991 WOR; HAINES A, 1991, J PUBLIC HEALTH MED, V13, P69; HANSEN J, 1988, 1ST P N AM C PREP CL, P35; Houghton J.T., 1990, CLIMATE CHANGE IPCC; LEAF A, 1989, NEW ENGL J MED, V321, P1577, DOI 10.1056/NEJM198912073212305; LONGSTRETH JA, 1989, POTENTIAL EFFECTS GL; MacKenzie J. J., 1988, ILL WINDS AIRBORNE P; MCELROY MB, 1989, B AM ACADEMY ARTS SC, V42, P25; OESCHLI FW, 1970, ENVIRON RES, V3, P277; PEARCE F, 1991, NEW SCI         1122, P20; ROGOT E, 1976, AM J EPIDEMIOL, V103, P565, DOI 10.1093/oxfordjournals.aje.a112261; TITUS JG, 1989, POTENTIAL EFFECTS GL; WARRICK R, 1986, GREENHOUSE EFFECT CL; 1991, POLICY IMPLICATIONS; 1990, WORLD RESOURCES 1990, P14; 1988, 1988 POL OPT C STAT	19	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1991	303	6812					1254	1256		10.1136/bmj.303.6812.1254	http://dx.doi.org/10.1136/bmj.303.6812.1254			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ342	1747652	Green Published, Bronze			2022-12-01	WOS:A1991GQ34200033
J	HEALY, JMS; HEFFRON, JJA; LEHANE, M; BRADLEY, DG; JOHNSON, K; MCCARTHY, TV				HEALY, JMS; HEFFRON, JJA; LEHANE, M; BRADLEY, DG; JOHNSON, K; MCCARTHY, TV			DIAGNOSIS OF SUSCEPTIBILITY TO MALIGNANT HYPERTHERMIA WITH FLANKING DNA MARKERS	BRITISH MEDICAL JOURNAL			English	Article							RYANODINE RECEPTOR GENE; MYOTONIC-DYSTROPHY GENE; SARCOPLASMIC-RETICULUM; LINKAGE GROUP; CHROMOSOME-19; CALCIUM; PIGS; LOCALIZATION; CANDIDATE; RELEASE	Objective - To define the region on human chromosome 19 carrying the gene for malignant hyperthermia susceptibility and to evaluate the use of flanking DNA markers in diagnosing susceptibility. Design - Prospective molecular genetic linkage studies in a large malignant hyperthermia pedigree. Setting - Irish malignant hyperthermia testing centre. Subjects - A large Irish malignant hyperthermia pedigree. Main outcome measures - Routine diagnosis of susceptibility to malignant hyperthermia with in vitro contracture test on muscle biopsy specimens and genetic linkage between susceptibility and polymorphic DNA markers in a malignant hyperthermia family. Results - Genetic typing of polymorphic DNA markers in a large Irish malignant hyperthermia pedigree generated a lod score of > 3 for the marker D19S9 and showed that the gene for susceptibility is flanked by the markers D19S9 and D19S16. These tightly linked flanking markers allowed non-invasive presymptomatic diagnosis of susceptibility in five untested subjects in the large pedigree with an accuracy of > 99.7%. Conclusions - DNA markers flanking the gene for susceptibility to malignant hyperthermia can be used with high accuracy to diagnose susceptibility in subjects in large known malignant hyperthermia pedigrees and may replace the previous in vitro contracture test for diagnosing this inherited disorder in large families with malignant hyperthermia.	NATL UNIV IRELAND UNIV COLL CORK,DEPT BIOCHEM,CORK,IRELAND; UNIV DUBLIN TRINITY COLL,DEPT GENET,DUBLIN 2,IRELAND; CHARING CROSS & WESTMINSTER MED SCH,DEPT ANAT,LONDON W6 8RF,ENGLAND	University College Cork; Trinity College Dublin; Imperial College London			Bradley, Daniel G/A-3240-2012; Healy, Sandra J/D-5256-2013	McCarthy, Tommie/0000-0003-4884-6972; Bradley, Daniel G/0000-0001-7335-7092				BRITT BA, 1969, CAN ANAESTH SOC J, V16, P89, DOI 10.1007/BF03005788; BRITT BA, 1970, CAN ANAESTH SOC J, V17, P293, DOI 10.1007/BF03004694; BRITT BA, 1987, MALIGNANT HYPERTHERM, P325; BROOK JD, 1984, HUM GENET, V68, P282, DOI 10.1007/BF00292584; BRUNNER HG, 1989, GENOMICS, V5, P589, DOI 10.1016/0888-7543(89)90027-X; DAVIES KE, 1988, MOL BASIS INHERITED; ELLIS FR, 1985, RECENT ADV ANAESTHES, P173; ENGEL AG, 1986, MYOLOGY, V2, pR4; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRONERT GA, 1986, MYOLOGY, V2, P1763; HARLEY HG, 1989, CYTOGENET CELL GENET, V51, P1011; HEFFRON JJA, 1988, BRIT J ANAESTH, V60, P274, DOI 10.1093/bja/60.3.274; Humphries S E, 1983, Mol Biol Med, V1, P463; IAIZZO PA, 1988, PFLUG ARCH EUR J PHY, V411, P648, DOI 10.1007/BF00580861; KALOW W, 1987, MALIGNANT HYPERTHERM, P155; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEVITT RC, 1990, NATURE, V345, P297, DOI 10.1038/345297b0; LEVITT RC, 1990, J NEUROL SCI S, P513; LOPEZ JR, 1985, MUSCLE NERVE, V8, P355, DOI 10.1002/mus.880080502; MACKENZIE AE, 1990, AM J HUM GENET, V46, P1082; MACLENNAN DH, 1990, NATURE, V343, P559, DOI 10.1038/343559a0; McCarthy T V, 1990, Acta Anaesthesiol Belg, V41, P107; MCCARTHY TV, 1990, NATURE, V343, P562, DOI 10.1038/343562a0; MICKELSON JR, 1988, J BIOL CHEM, V263, P9310; NAKAMURA Y, 1988, Genomics, V3, P67, DOI 10.1016/0888-7543(88)90161-9; NELSON TE, 1983, J CLIN INVEST, V72, P862, DOI 10.1172/JCI111057; OHNISHI ST, 1983, FEBS LETT, V161, P103; ORDING H, 1987, MALIGNANT HYPERTHERM, P267; OTT J, 1985, ANAL HUMAN GENETIC L; ROPERS HH, 1990, CYTOGENET CELL GENET, V55, P218, DOI 10.1159/000133015; Sambrook J., 1989, MOL CLONING LAB MANU; SCHEPENS J, 1987, NUCLEIC ACIDS RES, V15, P3192, DOI 10.1093/nar/15.7.3192; SCHONK D, 1989, GENOMICS, V4, P384, DOI 10.1016/0888-7543(89)90346-7; SCHONK D, 1990, HUMAN CYTOGENET CELL, V55, P1075; WAINWRIGHT BJ, 1985, NUCLEIC ACIDS RES, V13, P4610, DOI 10.1093/nar/13.12.4610; 1984, BRIT J ANAESTH, V56, P1267	36	21	21	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1991	303	6812					1225	1228		10.1136/bmj.303.6812.1225	http://dx.doi.org/10.1136/bmj.303.6812.1225			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ342	1684123	Bronze, Green Published			2022-12-01	WOS:A1991GQ34200019
J	PEREIRA, JH; PALANDE, DD; SUBRAMANIAN, A; NARAYANAKUMAR, TS; CURTIS, J; TURK, JL				PEREIRA, JH; PALANDE, DD; SUBRAMANIAN, A; NARAYANAKUMAR, TS; CURTIS, J; TURK, JL			DENATURED AUTOLOGOUS MUSCLE GRAFT IN LEPROSY	LANCET			English	Note							PERIPHERAL-NERVE REPAIR	Autologous muscle grafts were used to repair 12 mixed peripheral nerves (9 posterior tibial, 3 median) in 10 patients with leprosy who had total anaesthesia and analgesia of the area supplied by the nerve. Postoperatively, 7 patients reported improved sensation in the foot or hand, with a return of vibration sense and joint position sense in 11 and of perception of a 10 g pin in 5; the ability to sweat in the affected area was also restored in 7.	ROYAL COLL SURG ENGLAND,DEPT PATHOL,35-43 LINCOLNS INN FIELDS,LONDON WC2A 3PN,ENGLAND; SACRED HEART LEPROSY CTR,TAMIL NADU 612401,INDIA	Royal College of Surgeons of England								ANTIA JH, 1970, INT J LEPROSY, V38, P12; FAWCETT JW, 1986, J NEUROSURG, V65, P354, DOI 10.3171/jns.1986.65.3.0354; GLASBY MA, 1986, NEURO-ORTHOPEDICS, V2, P21; GSCHMEISSNER SE, 1991, J BONE JOINT SURG BR, V73, P688, DOI 10.1302/0301-620X.73B4.2071663; NAPIER JR, 1949, BRAIN, V72, P63, DOI 10.1093/brain/72.1.63; NORRIS RW, 1988, J BONE JOINT SURG BR, V70, P530, DOI 10.1302/0301-620X.70B4.3403592; PEREIRA JH, 1990, J BONE JOINT SURG BR, V72, P874, DOI 10.1302/0301-620X.72B5.2170419; PEREIRA JH, IN PRESS J HAND SURG; Rao K S, 1987, Indian J Lepr, V59, P442	9	43	43	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 16	1991	338	8777					1239	1240		10.1016/0140-6736(91)92105-B	http://dx.doi.org/10.1016/0140-6736(91)92105-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ166	1682647				2022-12-01	WOS:A1991GQ16600007
J	SMITH, B; SELBY, P; SOUTHGATE, J; PITTMAN, K; BRADLEY, C; BLAIR, GE				SMITH, B; SELBY, P; SOUTHGATE, J; PITTMAN, K; BRADLEY, C; BLAIR, GE			DETECTION OF MELANOMA-CELLS IN PERIPHERAL-BLOOD BY MEANS OF REVERSE-TRANSCRIPTASE AND POLYMERASE CHAIN-REACTION	LANCET			English	Article							HUMAN MALIGNANT-MELANOMA; GENE; AMPLIFICATION; TYROSINASE; INSERTION; SEQUENCE; DNA	Only small numbers of cells from solid tumours are needed for haematogenous metastasis. Detection is difficult because existing techniques are not sensitive enough. We have used reverse transcriptase to make complementary DNA from peripheral blood messenger RNA, and the polymerase chain reaction (PCR) to amplify cDNA specific for a gene actively transcribed only in the tumour tissue type. We prepared cDNA from peripheral blood of seven patients with malignant melanoma, four patients with other metastatic cancers, and four healthy subjects, as well as from several melanoma-derived cell lines. PCR was used to amplify the gene for tyrosinase, a tissue-specific gene in melanocytes. Since normal melanocytes are not thought to circulate in peripheral blood, detection of tyrosinase transcription in peripheral blood should indicate the presence of circulating cancer cells. The method was highly sensitive and could detect a single melanoma cell from a cell line in 2 ml normal blood. Blood samples from four of the seven patients with malignant melanoma gave positive results, whereas all eight control subjects gave negative results. This method does not depend on the characterisation of cancer-specific genetic abnormalities and can be applied to any cancer for which tissue-specific genes can be identified, including epithelial cancers. It could prove useful in the diagnosis of primary or metastatic cancers, in assessing prognosis, and in detecting residual disease after treatment.	ST JAMES UNIV HOSP,INST CANC STUDIES,YORKSHIRE CANC RES CAMPAIGN,BECKETT ST,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND; UNIV LEEDS,DEPT BIOCHEM & MOLEC BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	Saint James's University Hospital; University of Leeds			Southgate, Jennifer/AAJ-9089-2021	Southgate, Jennifer/0000-0002-0135-480X				CAREY TE, 1976, P NATL ACAD SCI USA, V73, P3278, DOI 10.1073/pnas.73.9.3278; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; LAWN RM, 1980, CELL, V21, P647, DOI 10.1016/0092-8674(80)90428-6; LIAO SK, 1975, J NATL CANCER I, V54, P1037; LO YMD, 1989, LANCET, V2, P1363; LYONS J, 1990, PCR PROTOCOLS GUIDE, P386; MOSS TJ, 1990, J CLIN ONCOL, V8, P736, DOI 10.1200/JCO.1990.8.4.736; NAITO H, 1991, EUR J CANCER, V27, P762, DOI 10.1016/0277-5379(91)90184-F; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SAWYERS CL, 1990, P NATL ACAD SCI USA, V87, P563, DOI 10.1073/pnas.87.2.563; TARIN D, 1984, BRIT MED J, V288, P749, DOI 10.1136/bmj.288.6419.749; TOMITA Y, 1989, BIOCHEM BIOPH RES CO, V164, P990, DOI 10.1016/0006-291X(89)91767-1; WILSON JT, 1978, NUCLEIC ACIDS RES, V5, P563, DOI 10.1093/nar/5.2.563	15	583	629	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 16	1991	338	8777					1227	1229		10.1016/0140-6736(91)92100-G	http://dx.doi.org/10.1016/0140-6736(91)92100-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ166	1719320				2022-12-01	WOS:A1991GQ16600002
